<SEC-DOCUMENT>0000950170-24-022226.txt : 20240228
<SEC-HEADER>0000950170-24-022226.hdr.sgml : 20240228
<ACCEPTANCE-DATETIME>20240228170038
ACCESSION NUMBER:		0000950170-24-022226
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240228
DATE AS OF CHANGE:		20240228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Atea Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001593899
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				460574869
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39661
		FILM NUMBER:		24696550

	BUSINESS ADDRESS:	
		STREET 1:		225 FRANKLIN STREET
		STREET 2:		SUITE 2100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		857-204-8109

	MAIL ADDRESS:	
		STREET 1:		225 FRANKLIN STREET
		STREET 2:		SUITE 2100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>avir-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:avir="http://www.ateapharma.com/20231231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_af2fe959-cc5a-41f6-8bc5-501c3a9350e7" name="dei:AmendmentFlag" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363">false</ix:nonNumeric><ix:nonNumeric id="F_06d6cb9f-bf12-44b5-ac0d-66e699fd1470" name="dei:DocumentFiscalPeriodFocus" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363">FY</ix:nonNumeric><ix:nonNumeric id="F_fdbd8ee8-add0-48b3-9606-fbe2d8518a2b" name="dei:EntityCentralIndexKey" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363">0001593899</ix:nonNumeric><ix:nonFraction id="F_8825678c-5618-4fdf-86f5-25beefdc3d5d" name="us-gaap:CommitmentsAndContingencies" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_f13f86af-3f04-4fdb-a9a7-d85157377ef3" name="us-gaap:CommitmentsAndContingencies" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_6a58375c-3c73-45b9-96be-2164642efd86" name="us-gaap:PreferredStockValue" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_3f67c47a-74e2-4ce2-b416-6f7418743d08" name="us-gaap:PreferredStockValue" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_3be2bd17-90cb-4ad6-9f95-d622754a93f7" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_bb842308-4e24-47f1-9016-a28f5d33ba86">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonFraction id="F_26675b1d-cb04-4da6-8149-4bb408ad51ca" name="us-gaap:NumberOfOperatingSegments" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonNumeric id="F_09624d57-9bf3-4359-9740-b83c401c942c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="C_74f3bf0b-5c43-436d-86d9-f0ad7bbfae47" format="ixt-sec:durwordsen">three years</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="avir-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_e6ae33ec-eab3-42a1-9844-29f7c68d4027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec7ec460-3701-487b-868d-61c2b3b9856f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6082deea-8f3f-4b55-a38d-ea31916b467f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e263b72f-5f38-4b91-b56a-46d57583ec9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17b49d78-dae5-461d-9aa2-8c05ca6e3b14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90c6d8d7-56c9-490c-bdcc-72c602e51c09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bf67e90-3bf5-437f-9149-e6de45de31f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff6f76c6-f05a-4d88-acf9-a3905001881d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avir:OfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99cf4023-d6e5-48bb-8b91-c16c96320d2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2120fa2-8eb2-4101-8a98-bf8dc964d235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2df95855-8dda-4f54-99a2-64899a2d8236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_741e6762-6491-44e9-9d3f-00660692cfff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7289ade-105d-4563-a9d4-f2ae3de82763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avir:OfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c0e66ec-bf40-4f31-a93c-62669833f34d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_648185c1-cde8-40e2-9c2e-3faf51913ced"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a0ce532-9b29-4fdb-8d7c-26fffea11b48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avir:ResearchAndDevelopmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4dc26114-0dcd-4d93-aff6-f3d487ca3445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7cf00f8c-9982-454f-9f70-f11345935575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_134ce635-cd15-4e3a-bce0-502a40422357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b18b1fcf-b3ac-4d66-bbfb-5bd569b10abc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avir:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e7810ba-ac14-4633-950d-17f455aae7a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb12c3db-f2bf-4359-9b84-6e55943ac2cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95e99b78-705a-4c5a-8427-757b8ec386de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6e3b279-caec-40bb-8720-9d81118a4e31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avir:EntityControlledByDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avir:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_839b2d04-8e9a-4f78-802e-358d03925bc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9efbbc1b-078b-4f87-947b-73866d7dde2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">avir:JefferiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avir:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c22f1db1-902d-4c7a-b09a-45671bb979be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f773dd53-698b-4d30-a6b5-df061f6a5858"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_159d6d12-6162-484a-9282-0ea77a622978"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_641d1e37-afd3-4641-8d1a-05bebb533e59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5182e60-9be2-448b-a355-f35129b377d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c968b4c-959e-4b16-a465-e034a657083f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb842308-4e24-47f1-9016-a28f5d33ba86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4858b4b-fada-48fa-9ad8-39d05a6e7b50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6399a783-fb32-4189-8185-57a59a53f325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f911c61-390f-464f-b142-8191cfb56974"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4121b4df-602e-41a1-a327-97cd041787d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avir:SharesReservedUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdd23298-c96b-461d-b614-f7ff7d9f6a55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avir:RocheLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08a2ebd0-8a41-4aeb-aeaf-b254fd869fe7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c947d34f-cb72-4ce4-a2e2-5cd07b77a75b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76b14b33-56a4-4cf1-80df-723f41684b40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ee4d578-76e6-43b0-9c50-08cb7a6fb76d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avir:MerckLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d9ddc2b-fdf7-4243-aa54-0ba461e33dd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1ccbc8d-fccc-4ef6-b237-b3060720a1f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53e1a418-db9d-4b78-8fda-8cf250f5882f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9b4d51c-a9e8-4986-afd4-c57dce1daa35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avir:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ba33c50-6a8d-4f09-b491-7da8f49a8f50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avir:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_790b7edc-c301-4076-b9d2-20c39e9f87b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78f030a1-a021-4e69-b8c8-b89c33ca2f1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c1df01c-45d9-4b82-b0a8-9c4a4df04fae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34dd0c12-849b-4618-af9e-a655ab282d18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_975884e8-2fb7-4e8c-a0e2-9c732451f66c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7c74a74-1bf5-49eb-9231-e2e57e9cec94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b416c72d-54aa-4b09-b126-d3012f0dd986"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_677d6563-424e-4877-8d04-062f7a6292c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be71de03-d103-4906-b856-69607d3bce32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avir:RocheLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b6262d6-cb17-47e6-a290-98609c2cd44a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be3c9676-01ad-494a-ba2a-56772d6be054"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avir:OutstandingOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b14283c-1b14-4a23-bceb-fe0448f96bd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29ced885-cd6c-4728-afb5-8721d3d3a564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38c339a5-7c33-4fe4-88f1-30dc3c9078f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avir:OfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bdc446e2-c3c8-45df-b44f-251b2b84015d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avir:OutstandingRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a00419f3-633d-4353-a505-f066bdea810a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e51f2865-c244-4aee-985f-6b147207f1c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avir:OutstandingPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ac4181a-51cc-4958-ac53-7166a997b2a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avir:RocheLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24439972-d677-48cc-8863-848995b1b44c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e97f5628-4e13-4a16-80cb-1a647ed32f3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14ac9cbe-603c-4063-874a-18ef17519699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd4755f2-8af0-43f4-b924-629b18b55def"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_492b70ed-33a9-48ec-91b4-5bf4e27baa9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">avir:JefferiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avir:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e76c0f9-bba5-44a0-93ae-345a4101d6c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d2d29de-6d0b-4b53-b56c-521ea942b78d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avir:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1430c916-1a16-453a-bad9-54788ee5a480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">avir:JefferiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avir:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_74f3bf0b-5c43-436d-86d9-f0ad7bbfae47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7a5ba3b-2c98-40aa-a0e2-a6986cac7344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avir:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f732af4-d836-404e-a933-0b892aefa2ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">avir:BusinessDevelopmentConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9feada43-9600-4ad4-8a75-de79be8486b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avir:EntityControlledByDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avir:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac643507-3356-46e0-b8b6-3ce7ebaa7b58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81ef7f57-de18-4346-8a86-4f826a99b8fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avir:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d94cdb2-afb4-4c89-bda1-0c555813396a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62b17805-037e-4608-865a-45eafd3e8444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fc9ee26-6947-4538-b0a8-2c3589305d62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04aa3fcc-acfa-4ce1-806a-36590f240e92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avir:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa0a55b5-ae8d-454b-abaa-c3998b787bed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avir:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d744964-680d-40b2-ba6f-5c4572c15939"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c710aa45-dbe9-4f74-a306-1b6b7afa6554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ced1b9b-cadf-4b52-b730-507c4215184a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b71efb31-3b73-4d78-88bd-0522c7021985"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31dd3b4f-faf9-41d7-b2d8-342548a15e74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24dbddef-dc7c-4756-ab44-6dbdef0b512c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avir:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13f35122-e303-4b3d-a59e-14c0c552587f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2379ff73-5bee-4de8-86f9-afedc9100f71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avir:RocheLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20998f02-abbf-48fb-8f95-9b2494effbb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_504aa066-1c9a-4526-b64e-13d9e2393363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43bf2db5-6e41-408f-92b7-55c92bcb1e87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ae7bd15-ab3e-4d2d-98a8-359e5079ac8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e35146f5-20fa-4ec8-a345-92d23314956f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2be2f376-615a-4108-a6a0-9913d287e512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7618177-dbbf-4f5e-963a-5fa2381e45b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_302fd01a-656a-4ecd-a50f-578a8254ff85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e82bec19-1afd-4f24-a813-5e90d1f66925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_436595f0-3519-4a55-81e8-9e4c814063e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ba65c73-8524-40e6-ae35-92adc4ada4bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c43a7923-c261-4651-bc39-5f0700559de8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa816b49-5422-4e75-80e8-d75787e65427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfb5c27a-df03-47f9-a4cd-6d0ff368feee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f28b0360-b9b7-4972-a2a7-9ed9288fa68a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avir:EntityControlledByDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avir:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35620468-f729-48e1-8999-2b9f79ad7f7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be5035eb-e660-4560-be97-44cb8c0f9a0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_154ac387-b035-4286-8b39-36a8ea30d163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_979c91bd-5edb-4472-af3c-4aa5b8c738a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86685938-2c65-4dd3-9449-fcecbd25ce2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b64973ad-fef2-423f-96bd-ad36857f2986"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avir:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a68f75ab-379f-4790-b7da-2cc14623e5e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3c8ea54-34b8-4665-bdf3-a8dcf0a0cfef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5dd8525-8aef-4672-9fb8-129bfa24627c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c5aa2e0-6ee2-47c4-83c0-bcebcd1b5028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79bea9f4-f71d-40b2-9f73-0182a669f7ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avir:SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da444999-94ef-4fbd-9372-2cec9051adf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d0f79dd-b812-4c0e-ae93-dd31e490b53c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6cc6cbb-fa79-4362-b951-fdcabe1d05f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f787167a-61d9-4235-9630-d8d7035b8ce9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e5a6e9b-41ce-4bde-b88a-39f1e3b103e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_101c9929-49f6-4ecd-b591-e27524e394d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6080656-f365-4660-9a2e-1abe8d881a2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eea6202c-efed-4922-944f-49a05b0bd392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58bb1f1f-c269-4b19-b52e-f3998d06a8a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74e7c620-e2ac-4ca1-a2bd-90153b3ef496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001593899</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Security"><xbrli:measure>avir:Security</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>avir:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Installment"><xbrli:measure>avir:Installment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Arial;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Arial;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Arial;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Arial;"><ix:nonNumeric id="F_7e76f69d-733c-4ce0-8dbd-9efb5743f2cd" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Arial;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;"> (Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_9e6a0c89-7c16-4364-8096-fbcacc1de314" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">For the fiscal year ended</span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_010cedad-5907-4995-8ed1-f00b32a2572a" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_02165538-e213-4989-9c45-27ab64888c80" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_1d40a94c-5fc5-473b-869f-41e2c06479be" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_4d3a8dd2-dcd1-4c7d-a74d-bdbbca40f74a" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_6dba3b0e-bf8e-4ebc-8108-c627991a72b1" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_b692983c-38de-4f75-9684-8d7f8e793523" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">001-39661</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:22pt;font-family:Arial;"><ix:nonNumeric id="F_2f94d124-8623-4489-a694-11c2598f8b72" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:22pt;font-family:Arial;min-width:fit-content;">ATEA PHARMACEUTICALS, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">(Exact name of registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:Arial;"><ix:nonNumeric id="F_db6e71c0-2ccf-4428-8033-9eeca0fd090e" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:Arial;"><ix:nonNumeric id="F_234fb03e-f4ae-4494-a4b0-b0f42222751f" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">46-0574869</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-family:Arial;"><ix:nonNumeric id="F_7de1cef4-ab0f-4571-aa38-b47e1d2cb03a" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">225 Franklin Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">, </span><span style="font-family:Arial;"><ix:nonNumeric id="F_270a5e85-fefb-4191-853b-332d0bd280a7" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 2100</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-family:Arial;"><ix:nonNumeric id="F_1c445d20-9904-44b7-974e-75b841246f66" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">, </span><span style="font-family:Arial;"><ix:nonNumeric id="F_bc0144ef-16ff-41b0-b2c5-3d93a722e453" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-family:Arial;"><ix:nonNumeric id="F_b8d1ed41-e605-4f94-9aed-d58065e34061" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02110</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_527f7923-5728-4380-92c9-d168d966eaf6" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_c9f04e2b-8978-434d-8baa-33737ba619fe" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">284-8891</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Arial;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Arial;"><ix:nonNumeric id="F_70cafdd2-0e22-4eb1-b780-9daa709c32b6" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Arial;"><ix:nonNumeric id="F_f3ca983b-41c1-4c86-a4d3-6c4fab64ff0a" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">AVIR</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Arial;"><ix:nonNumeric id="F_d675e656-86d6-44f4-821b-9376e7a48a25" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:7pt;font-family:Arial;"><ix:nonNumeric id="F_e152c967-a513-4f1b-9826-306f9931f9e1" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:7pt;font-family:Arial;"><ix:nonNumeric id="F_ebf0c9e0-f12b-4a69-a594-67227fa65634" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:7pt;font-family:Arial;"><ix:nonNumeric id="F_6d792ec6-a488-43ee-bc48-0703cae62b01" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"> NO </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="font-size:7pt;font-family:Arial;"><ix:nonNumeric id="F_d1f7a1ea-8c13-4a43-b36b-c1fc0785655e" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"> NO </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.9%;"/>
    <td style="width:1%;"/>
    <td style="width:55.84%;"/>
    <td style="width:1.06%;"/>
    <td style="width:20.1%;"/>
    <td style="width:1%;"/>
    <td style="width:2.1%;"/>
   </tr>
   <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7pt;font-family:Arial;"><ix:nonNumeric id="F_17dd4ce6-8ec9-420b-8429-48dd2ad06661" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_4ae1f6d6-4a92-4686-bb02-dbeda0d52dc6" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_8e005d9a-0684-405b-b6b7-570ab25b3343" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_755c4a59-1f09-4cce-a56d-8d2945761673" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_7a9e17d2-1d8b-4299-8ae9-df1d84af304a" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  YES </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"> NO </span><span style="font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_1857773f-6e3c-4449-b4be-08b5b0d6607a" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">As of June 30, 2023, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the last reported sales price for the registrant&#8217;s common stock, par value $0.001 per share, on the Nasdaq Global Select Market on such date, was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">$</span><span style="font-size:7pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b76fe62-ccf3-48d1-92a0-8beca8e85e10" contextRef="C_648185c1-cde8-40e2-9c2e-3faf51913ced" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">283.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"> million.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">The number of shares of Registrant&#8217;s Common Stock outstanding as of February 25, 2024 was </span><span style="font-size:7pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe0c9ba6-3eb5-4cb8-9b1f-a84dd50d79bc" contextRef="C_0bf67e90-3bf5-437f-9149-e6de45de31f3" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">84,164,545</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="font-size:7pt;font-family:Arial;"><ix:nonNumeric id="F_6676b9ec-316b-4729-a5b2-f19eea26a2bf" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">Portions of the registrant&#8217;s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12%;"/>
    <td style="width:80.92%;"/>
    <td style="width:7.08%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#forward_looking"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">ii</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#summary_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">SUMMARY RISK FACTORS</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">iv</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">PART I</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">50</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Cybersecurity</span></a><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">PART II</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">125</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">139</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_foreign_jurisdictions"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">139</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">PART III</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">PART IV</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0563c1;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">141</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Item 16</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">143</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="forward_looking"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKI</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">NG STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical development timelines and results and other future conditions. The words &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; "objective," "on track," &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">These forward-looking statements include, among other things, statements about:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our expectations relating to clinical trials for our product candidates, including projected costs, study designs and the timing for initiation, recruitment, completion, and reporting interim, top-line and final data;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the potential therapeutic benefits of our product candidates and the potential indications and market opportunities therefor;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the potential of bemnifosbuvir to retain antiviral activity against circulating COVID-19 variants of concern and to treat Coronavirus disease 2019 ("COVID-19");</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the safety profile and related adverse events of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our plans to research, develop and commercialize our current and future product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the potential benefits of any future collaboration we may enter into;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the rate and degree of market acceptance and clinical utility of any products for which we may receive marketing approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our manufacturing and commercialization capabilities and strategy;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our estimates regarding future revenue, expenses and results of operations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the progress of, timing of and amount of expenses associated with our research, development and commercialization activities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our future financial position, capital requirements, cash runway, needs for additional financing and the availability of such financing;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our business strategy;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">developments relating to our industry and our competitors, including competing treatments and vaccines for diseases we are treating;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our expectations regarding federal, state and foreign laws and regulations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to attract, motivate, and retain key personnel; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the impact on our business as COVID-19 continues to evolve.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">These forward-looking statements are based on management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause actual results to differ materially from current expectations include the initiation, execution</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and completion of clinical trials, uncertainties surrounding the timing of availability of data from our clinical trials, ongoing discussions with and actions by regulatory authorities, our development activities and those other factors we discuss in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Part I, Item 1A. &#8220;Risk Factors.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> You should read these risk factors and the other cautionary statements made in this report as being applicable to all related forward-looking statements wherever they appear in this report. The risk factors are not exhaustive and other sections of this report may include additional factors which could adversely impact our business and financial performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Preliminary and interim results from any trial and results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Given these uncertainties, you should not rely on these forward-looking statements as predictions of future events. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#2e2e2e;white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As used in this Annual Report on Form 10-K, unless otherwise specified or the context otherwise requires, the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and the &#8220;Company&#8221; refer to Atea Pharmaceuticals, Inc. and its subsidiary.  All brand names or trademarks appearing in this Annual Report on Form 10-K are the property of their respective owners.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">iii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="summary_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">SUMMARY RISK F</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ACTORS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. The principal risks and uncertainties affecting our business include the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">There is significant uncertainty around our development of bemnifosbuvir as a potential treatment for COVID-19. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are expending significant resources to develop bemnifosbuvir for the treatment of COVID-19 and to develop the combination of bemnifosbuvir and ruzasvir for the treatment of Hepatitis C virus ("HCV") and in anticipation of potential commercialization of these product candidates.  We  may not be able to recover these resources if these product candidates are not approved for the treatment of the respective indication for which they are being developed, we are not successful at commercializing these product candidates or in the case of the development of bemnifosbuvir for the treatment of COVID-19, bemnifosbuvir is rendered inferior or obsolete due to rapid changes in COVID-19 epidemiology as a result of the emergence of new SARS-CoV-2 variants or subvariants.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If approved, each of our product candidates will face significant competition from other treatments, including direct acting antivirals, that are currently marketed and in the case of COVID-19, are in development. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our business, operations and financial results may be materially and adversely affected by the continuing evolution of COVID-19. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have a limited operating history and no history of successfully developing or commercializing any approved antiviral products, which may make it difficult to evaluate the success of our business to date and to assess the prospects for our future viability. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have incurred significant operating expenses since inception. We expect our expenditures will increase for the foreseeable future. We have no products that have generated any commercial revenue and we may not again achieve or maintain profitability. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We will require substantial additional financing, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our ability to use our net operating loss carryforwards and other tax attributes to offset taxable income may be subject to certain limitations. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our business is highly dependent on the success of our most advanced product candidates. If we fail to successfully develop bemnifosbuvir for the treatment of COVID-19 or the combination of bemnifosbuvir and ruzasvir for the treatment of HCV or we are unable to obtain regulatory approval or successfully commercialize any of our product candidates, or are significantly delayed in doing so, our business will be harmed. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The regulatory approval processes of the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We intend to develop certain of our product candidates in combination with other product candidates that we discover or acquire, which exposes us to additional risks.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">iv</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">regulatory approval, limit their commercial potential or result in significant negative consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We currently conduct and may in the future conduct clinical trials of our product candidates in sites outside the United States ("US").  The FDA may not accept data from trials conducted in foreign locations. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may not be successful in our efforts to identify and successfully develop additional product candidates. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks related to healthcare laws and other legal compliance matters may materially and adversely affect our business and financial results.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks related to commercialization may materially and adversely affect our business and financial results.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks related to manufacturing and our dependence on third parties may materially and adversely affect our business and financial results.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks related to intellectual property may materially and adversely affect our business and financial results.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are highly dependent on our management, directors and other key personnel.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have only a limited number of employees, which may be inadequate to manage and operate our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our business and operations may suffer in the event of system failures, security breaches, deficiencies or intrusions which could materially affect our results. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may engage in acquisitions or strategic collaborations that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We or the third parties whom we depend upon may be adversely affected by natural disasters or other unforeseen events resulting in business interruptions and our business continuity and disaster recovery plans may not adequately protect us from such business interruptions. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Increased attention to, and evolving expectations for, environmental, social, and governance (&#8220;ESG&#8221;) initiatives could increase our costs, harm our reputation, or otherwise adversely impact our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Litigation against us could be costly and time-consuming to defend and could result in additional liabilities.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks related to our common stock may materially and adversely affect our stock price. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we fail to maintain effective internal control over financial reporting and effective disclosure controls and procedures, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which may adversely affect investor confidence in our company.  </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">v</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are a clinical-stage biopharmaceutical company leveraging our deep understanding of antiviral drug development, medicinal chemistry, biology, biochemistry and virology to discover and develop novel orally administered product candidates to treat serious viral diseases. Currently, we are developing our lead product candidate, bemnifosbuvir, in a global Phase 3 clinical trial as a monotherapy for the treatment of COVID-19, and in a global Phase 2 clinical trial as part of a combination therapy with ruzasvir, an NS5A inhibitor, for the treatment of HCV infection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Bemnifosbuvir</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Derived from our internal discovery program, bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. We believe that utilizing this double prodrug moiety approach allows us to maximize formation of the active metabolite potentially resulting in an oral antiviral product candidate that is selective for and highly effective at preventing replication and transcription of SARS-CoV-2, the causative agent of COVID-19, HCV and other single stranded RNA (&#8220;ssRNA&#8221;) viruses while avoiding toxicity to host cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">COVID-19 &#8211; Our Strategy and Objective</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">More than four years after emerging as a global pandemic and public health crisis, COVID-19 remains a persistent and serious health threat because of continued variant fueled surges of infection.  The SARS-CoV-2 virus is accumulating mutations with amino acid substitutions faster than any other endemic ssRNA virus and the constant evolution of new variants has resulted in continued waves of infections globally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our COVID-19 strategy is focused on the development of bemnifosbuvir for the treatment of COVID-19.  We believe that oral antivirals protecting against the development of severe infection and transmission remain urgently needed particularly for high-risk patients who currently have few or no treatment options due to limitations of currently available vaccines and therapeutics. High-risk patients include those who are unvaccinated, patients who fail to respond to available vaccines, vaccinated patients with waning efficacy, which can occur between three to six months after immunization, and patients for whom current treatments are contraindicated.   Without suitable treatments, high-risk patients remain vulnerable to severe COVID-19 and associated hospitalization and death.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As COVID-19 continues to persist as a global endemic disease, we believe that the global COVID-19 therapeutic market, and in particular the US market, will remain a multi-billion-dollar commercial opportunity for many years to come.  Further, as the commercialization of COVID-19 therapeutics enters more fully into traditional distribution and reimbursement channels in 2024 and after, we anticipate that a major consideration for third-party payers will be a cost/value analysis that is driven in part by the economic burden of hospitalization, especially for high-risk populations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The objective of our COVID-19 development program is to address the current unmet medical needs of high-risk patients who remain vulnerable to hospitalization and death from COVID-19 by developing bemnifosbuvir, as a safe, effective, convenient, oral antiviral without the key limitations of current treatment options, including drug-drug interactions, tolerability and other safety concerns.  The FDA has granted Fast Track designation for the investigation of bemnifosbuvir to treat COVID-19.  Currently, we are evaluating bemnifosbuvir in SUNRISE-3, a global Phase 3 clinical trial that is enrolling high-risk patients with mild to moderate COVID-19.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For COVID-19, bemnifosbuvir targets the SARS-CoV-2 RNA polymerase (Nsp12), a highly conserved enzyme that is unlikely to change as the virus mutates and new variants continue to emerge. The RNA polymerase complex is responsible for both replication and transcription of SARS-CoV-2.   Bemnifosbuvir</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">has a unique dual mechanism of action at both the RNA-dependent RNA polymerase ("RdRp") and nidovirus RdRp associated nucleotidyltransferase ("NiRAN") active sites on the highly conserved SARS-CoV-2 RNA polymerase, which has the potential to create a high barrier to resistance. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">In vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> data have shown that bemnifosbuvir was active with similar activity against all SARS-CoV-2 variants of concern ("VOC") and variants of interest ("VOI") that have been tested to date, including Omicron subvariants BA.4, BA.5 and XBB and EG.5.1.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">HCV &#8211; Our Strategy and Objective</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Despite the availability of direct acting antiviral oral combination treatment regimens, HCV continues to be a serious viral disease in the US and globally. Approximately 58 million people globally are living with chronic HCV infection.  The World Health Organization ("WHO") estimates a global incidence of 1.5 million new infections and 290,000 deaths per year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the US, HCV is recognized as a health crisis with approximately 2.4 million individuals estimated to be infected.  Prevalence of HCV in the US is expected to remain constant over the coming years as rising HCV incidence is largely attributable to the opioid crisis, IV drug use, and HCV reinfection, especially among younger adults, offsets the number of new patients treated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our HCV strategy focuses on the development of bemnifosbuvir in combination with ruzasvir, an HCV NS5A inhibitor, a product candidate which we have exclusively licensed from MSD International GmbH, an affiliate of Merck &amp; Co, Inc. ("Merck").  Combination therapy utilizing two or more direct acting antivirals with different mechanisms of action is a scientifically and clinically well-established approach that is utilized by currently available human immunodeficiency virus, hepatitis B virus and HCV treatment regimens.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The objective of our HCV development program is to improve upon the current standard of care ("SOC") by offering, if successfully developed, the combination of bemnifosbuvir and ruzasvir, as a potentially differentiated eight-week duration, pan-genotypic protease inhibitor-free regimen for HCV-infected patients with or without cirrhosis.  Currently, we are conducting a Phase 2 clinical trial of bemnifosbuvir in combination with ruzasvir in treatment na&#239;ve HCV infected patients, either without cirrhosis or with compensated cirrhosis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For HCV, the combination of bemnifosbuvir and ruzasvir targets the HCV non-structural protein 5B (&#8220;NS5B&#8221;) and the HCV non-structural protein 5A (&#8220;NS5A&#8221;), respectively, and is designed to inhibit these enzymes which are essential for HCV replication.  Both bemnifosbuvir and ruzasvir have individually demonstrated potent, pan-genotypic, antiviral activity against HCV and the combination of bemnifosbuvir and ruzasvir has exhibited synergistic activity against HCV </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vitro.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Key Clinical Trials</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">COVID-19 &#8211; SUNRISE-3: Global Phase 3 Clinical Trial of Bemnifosbuvir</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">SUNRISE-3, is a currently ongoing global, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial that is evaluating bemnifosbuvir (550 mg twice-daily ("BID") for five days) in high-risk non-hospitalized patients with mild or moderate COVID-19.  SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy (primary analysis) but it is also exploring the effect of combination therapy in a smaller sub-set of patients who receive a compatible antiviral drug along with bemnifosbuvir (secondary analysis).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The trial consists of two study populations derived from the type of SOC received: 1) a &#8220;supportive care population&#8221; (those patients who do not qualify for another antiviral treatment or where other antivirals are not locally available) which is assessing bemnifosbuvir given as monotherapy (primary analysis) and 2) a &#8220;combination antiviral population&#8221; which is assessing combination therapy if the SOC includes treatment with other compatible antiviral drugs against COVID-19 (secondary analysis). Patients are being randomized 1:1 to receive either bemnifosbuvir 550 mg BID plus locally available SOC or placebo BID plus locally available SOC for five days.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The primary endpoint of the SUNRISE-3 study is all-cause hospitalization or death through Day 29 in approximately 2,200 patients in the supportive care monotherapy population. Secondary endpoints in each of the supportive care monotherapy patient population and the combination antiviral population</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">include COVID-19 related hospitalization or death, COVID-19 complications, medically attended visits, symptom rebound/relapse and viral load rebound.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The trial is enrolling patients who are &#8805;70 years old (regardless of other risk factors), patients &#8805;55 years old with one or more risk factors, patients &#8805;50 years old with two or more risk factors and patients &#8805;18 years old with certain risk factors including immunocompromised conditions, all regardless of COVID-19 vaccination status.  We believe that this population encompasses those patients who currently remain at high-risk for progression of COVID-19 to severe disease and associated hospitalization and death.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In January and February 2024, we announced the enrollment of more than 650 patients and more than 1,350 patients, respectively, in the supportive care monotherapy cohort.  Each of these patient enrollment milestones triggers an interim analysis by an independent data safety monitoring board (&#8220;DSMB&#8221;) principally for safety and futility after the respective patient group has completed Day 29 post treatment.   As a result, we currently anticipate that the first interim analysis by the DSMB will occur in March of 2024 and the second interim analysis by the DSMB will occur in the second quarter of 2024.  Patient enrollment in the SUNRISE-3 trial, which has currently surpassed 1,400 patients in the supportive care monotherapy population, continues and topline data from the trial are anticipated in the second half of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">HCV &#8211; Global Phase 2 Clinical Trial of the Combination of Bemnifosbuvir and Ruzasvir</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Currently, we are conducting a global Phase 2 clinical trial of bemnifosbuvir in combination with ruzasvir in treatment-na&#239;ve, HCV-infected patients either without cirrhosis or with compensated cirrhosis.  This study is designed to evaluate the safety and efficacy of eight weeks of treatment with the combination consisting of once daily bemnifosbuvir 550 mg and ruzasvir 180 mg.  Up to approximately 280 HCV-infected, treatment-na&#239;ve patients across HCV genotypes (&#8220;GT&#8221;), including a lead-in cohort of 60 patients without cirrhosis, are expected to be enrolled in this Phase 2 clinical trial. The primary endpoints of the study are safety and sustained virologic response ("SVR") at Week 12 post-treatment (&#8220;SVR12&#8221;). Other virologic endpoints include virologic failure, SVR at Week 24 post-treatment (&#8220;SVR24&#8221;) and resistance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In February 2024, we announced final results from the full lead-in cohort in which a 98% SVR at Week 4 post-treatment ("SVR4") rate was observed [58 of 59 subjects achieved SVR4 with one patient who did not return for post-treatment follow-up].  The one patient who did not achieve SVR4 had poor adherence, and was infected with HCV GT-2. These results are consistent with the initial results announced in January 2024. The SVR4 rate exceeded the protocol-defined efficacy criterion of &#8805;90% SVR4 for continuing the study.  As a result, in January 2024 we commenced enrolling up to an additional 220 patients in the study, including patients with cirrhosis. In the lead-in cohort, very rapid kinetics were observed with viral load for each patient near or below the lower limit of quantification ("LLOQ") at four weeks of treatment, which we believe is supportive of an eight-week treatment regimen for the combination of bemnifosbuvir and ruzasvir. All 60 patients in the lead-in cohort achieved viral load below the LLOQ by the end of the eight-week treatment regimen.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The combination of bemnifosbuvir and ruzasvir in the lead-in cohort was generally safe and well tolerated and there were no drug related serious adverse events ("SAEs"), no treatment discontinuations and adverse events ("AEs") were mostly mild.  Final SVR12 results from all 280 patients enrolled in the global Phase 2 study are anticipated in the second half of 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If the Phase 2 study is successfully completed, subject to discussion and alignment with regulatory authorities, we anticipate initiating a Phase 3 clinical development program in the second half of 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Our Corporate Strategy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our corporate goal is to become a global leader in the discovery, development, and commercialization of novel oral antiviral therapies for serious viral infections. We intend to achieve this goal by pursuing the following strategies:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Deploy our expertise and experience, particularly our depth of knowledge with respect to nucleos(t)ide analogs, to discover, in-license and develop novel or differentiated direct acting antivirals that have the potential to meet unmet medical needs or improve the current SOC.    </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Develop and commercialize bemnifosbuvir for the treatment of high-risk patients who face the greatest threat of progression to severe COVID-19 as a result of the limitations of current therapies. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Explore combination therapy for specific COVID-19 patient populations. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Improve the existing SOC for the treatment of HCV with a pan-genotypic eight-week, protease inhibitor-free regimen combining bemnifosbuvir and ruzasvir. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Maximize the value of our product candidates by selectively seeking advantageous collaborations to strengthen our commercialization capabilities in the US and enhance our global commercialization reach.   </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Our Development Pipeline</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table summarizes our orally administered antiviral product candidate pipeline. We have full global rights to commercialize all our product candidates in all indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57592461_0.jpg" alt="img57592461_0.jpg" style="width:624px;height:388px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Antiviral Therapy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Viral Polymerase as an Antiviral Target</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The viral polymerase, which is the single protein present in all RNA viruses, is a key enzyme in the replication of viruses making it an attractive target for antiviral therapeutics. Among other things, the core structural features of viral polymerase are highly conserved, making drugs targeted to the polymerase less susceptible to the effects of viral mutation and resistance. Among RNA viruses, there are two types of viral polymerase:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">RdRp: All ssRNA viruses, including SARS-CoV-2 and HCV, depend on the RdRp, encoded in the viral genome, for replication and transcription. Since these enzymes are not present in the host cell, this facilitates the design of selective inhibitors of viral replication, which target viral but not host cell polymerases.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:center;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">RNA-dependent DNA polymerase (&#8220;RdDp" or "reverse transcriptase&#8221;): Reverse transcriptase is used by certain DNA or RNA viruses, such as HBV and HIV-1, to replicate their genomes.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Advances in technology have enabled intensive structural and functional studies of viral RNA polymerase including the identification, in the case of SARS-CoV-2, of NiRAN and have opened avenues for the development of new and more effective antiviral therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Viral Resistance and Variants &#8211; Challenges to the Development of Antiviral Therapeutics</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A major challenge to the development of direct acting antivirals is the emergence of viral resistance. Resistance is a function of a virus&#8217; ability to genetically mutate which can make them less susceptible to certain antiviral therapies over time. In the case of RNA viruses, which generally lack proofreading abilities, the rate of mutation is substantially higher than DNA viruses and can occur at six orders of magnitude greater than the rate of mutation of host cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Another anticipated and naturally recurring consequence of viral mutations is the emergence of new variants.  Variants are new strains of the original virus with genetic codes that are unique from the original virus.  As a result of the unique genetic code, variants may have more or less transmissibility or virulence and may result in more severe disease than the original virus. Additionally, because of the changes in the genetic code of the variant, the effectiveness of vaccines and therapeutics may be reduced to the point of obsolescence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Our Lead Antiviral Candidate - Bemnifosbuvir</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Bemnifosbuvir is an investigational, novel, proprietary, orally administered double prodrug of a guanosine nucleotide analog which has been derived from our internal discovery program.  More specifically, bemnifosbuvir is the hemisulfate salt of a phosphoramidate protide, AT-511, that is metabolized after multistep activation to the active 5&#8217;-triphosphate metabolite, AT-9010, which is an inhibitor of SARS-CoV-2 and HCV replication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our medicinal chemists designed bemnifosbuvir with the following critical elements to achieve the objectives noted below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">specific modifications at the 6-position of the purine base, acting as a prodrug, were designed to prevent the toxic effects of other such modifications and enhance cell membrane permeability, resulting in an intermediate metabolite that maximizes formation of the triphosphate active metabolite in cells;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the stereospecific phosphoramidate, acting as a prodrug, was designed to bypass the first rate-limiting phosphorylation enzyme in the intracellular activation pathway;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">specific modifications in the sugar moiety of the purine nucleotide scaffold, to produce potent antiviral activity with a high degree of selectivity; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">highly specific salt form to enhance solubility and drug bioavailability.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We believe that these modifications together with the double prodrug approach impart the following potentially advantageous characteristics and features to bemnifosbuvir:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">enhanced antiviral activity and selectivity, as well as well-established pharmacology and animal models to predict clinical activity;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">favorable safety profile;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">convenience of oral administration; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">efficient, predictable, scalable, and reproducible manufacturing, as well as long shelf life for potential stockpiling.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Our Development Programs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Bemnifosbuvir for the Treatment of COVID-19</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">COVID-19 &#8211; Disease Overview and Limitation of Current Standard of Care</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">COVID-19, the disease caused by infection with SARS-CoV-2 and its variants, gave rise to a global pandemic that swept rapidly throughout the world beginning in 2020.  In 2023, public health emergencies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">declared by each of the WHO and Centers for Disease Control and Prevention ("CDC") ended, however, SARS-CoV-2 continues to cause vast rates of infection and in many cases serious COVID-19 disease due to waning immunity and continued emergence of SARS-CoV-2 variants. The COVID-19 surge in the US and globally during the winter of 2023 / 2024 demonstrates that newly emerged variants such as JN.1 continue to thrive and become dominant despite the availability of treatments and updated vaccines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the US, COVID-19 remains a major cause of respiratory virus-associated hospitalizations and is a continuing threat, particularly for those most vulnerable to severe disease. Older adults and individuals who have risk factors or who are immunocompromised are at a higher risk for developing more serious complications from COVID-19, leading to hospitalization and death.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">At the outset of the pandemic, unprecedented progress was made with both COVID-19 vaccines and treatment options.  Despite this progress, substantial limitations remain to currently available vaccines and therapies, including waning immunity to both naturally acquired and vaccine generated immunity, failure of certain populations to mount an adequate immune response to vaccines and lack of efficacy of currently available monoclonal antibodies to currently circulating SARS-CoV-2 subvariants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Limitations of current oral antivirals include drug-drug interactions with many commonly prescribed medications including anti-seizure medications, anti-psychotics, anti-coagulants  and other safety concerns.  As a result, many high-risk patients currently do not have suitable outpatient therapies and as a result, are also more likely to be hospitalized because of severe disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">With the ongoing evolution of the SARS-CoV-2 virus and the continuing emergence of new variants, there remains an urgent need to develop new oral therapies that are safe, efficacious, convenient and with low risk of drug-drug interactions for the treatment of COVID-19 that can be utilized as monotherapy and potentially as part of a combination therapy.  We believe that oral therapies protecting against the development of severe infection and transmission remain urgently needed particularly for vulnerable patients who currently have limited or no treatment options. This includes patients who are unvaccinated, patients who fail to respond to available vaccines, vaccinated patients with waning efficacy, which can occur between three to six months after immunization, and patients for whom vaccines and existing treatments are contraindicated.  As COVID-19 remains endemic with continued variant fueled pandemic surges, we believe that this need will continue for years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Vaccines for Prevention</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Several vaccines are either approved or authorized under an emergency use authorization ("EUA") and additional vaccines are in development to prevent COVID-19 infection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The ability of vaccines to produce durable immunity protection against disease and transmission is currently limited due to multiple factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">limited efficacy against certain viral variants;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">limited durability of response impacting the ability to achieve long term immunity;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">failure of certain patient populations to mount immune response to vaccines;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delayed onset of protection; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">vaccine hesitancy.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Monoclonal Antibodies ("mAbs") for the treatment and prevention of COVID-19</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Starting in November 2020 and into 2022, the FDA granted EUAs to several mAbs for the prophylaxis and/or treatment of COVID-19.  The use of mAbs for the treatment of COVID-19 was subsequently limited and is currently not authorized in the US for the following reasons:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">limited or no efficacy against currently circulating variants has led to the recission of all previously granted EUAs; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">inconvenience of intravenous administration such as the need to administer in specialized facilities that were properly equipped to accommodate IV infusions in actively infected patients. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Even if future mAbs are developed, the continued emergence of new SARS-CoV-2 variants may make even these new mAbs ineffective for the treatment of COVID-19.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Project NextGen</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In 2023, the US federal government announced the Project NextGen initiative with the purpose to accelerate and streamline the rapid development of the next generation of vaccines and treatments through public-private collaborations.  Based at the Department of Health and Human Services (&#8220;HHS&#8221;) and seeded with an initial investment of $5 billion, Project NextGen is coordinating across the US federal government and the private sector to fund and advance a pipeline of new, innovative vaccines and mAbs into clinical trials and potential review by the FDA. Project NextGen is focusing on:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">mucosal vaccines;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">vaccines that provide broader protection against variants of concern and a longer duration of protection;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">pan-coronavirus vaccines;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">new and more durable monoclonal antibodies that are resilient against new variants as they arise; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">advancing new technologies that will improve access and enable faster, cheaper, rapid and more flexible production of vaccines and therapeutics.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Antivirals for the treatment of COVID-19</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Antiviral therapies, which are complementary to vaccines, have been approved or authorized for the treatment of COVID-19.  In the US, Veklury</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(remdesivir), an RdRp inhibitor, is approved for the treatment of COVID-19 in adults and certain pediatric patients who are hospitalized or outpatients at high-risk of progression to severe COVID-19. Lagevrio&#153; (molnupiravir), an orally administered direct-acting antiviral for the treatment of adults with mild to moderate COVID-19 in the outpatient setting is authorized for use under an EUA in the US. Paxlovid&#153; is approved in the US for adults with mild to moderate COVID-19 in the outpatient setting and is available under EUA for pediatric patients 12 years and older weighing at least 40 kg.  All three antiviral therapies are approved or authorized for use in many additional countries globally.  Other oral antiviral therapies are approved in other countries including Xocova</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> (enstirelvir), a protease inhibitor which is approved in Japan.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Limitations of currently authorized or approved antiviral therapies include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Drug-Drug interactions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Due to the potentially serious drug-drug interactions associated with Paxlovid (ritonavir-boosted nirmatrelvir) and many commonly prescribed medications, including strong CYP3A4 inducers and certain other anti-coagulant, anti-convulsant, anti-arrhythmic, chemotherapeutic, and neuropsychiatric medications, the Paxlovid prescribing information includes a boxed warning and many patients with COVID-19 may be ineligible for treatment with Paxlovid or if eligible, require careful management including close monitoring of the patient by the prescriber. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Safety.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Lagevrio (molnupiravir) is a mutagenic ribonucleoside agent that is recommended by the NIH COVID-19 Treatment Guidelines Panel (&#8220;NIH Panel&#8221;) for use only when Paxlovid is not available, not feasible to use or clinically inappropriate.  Additionally, the NIH Panel recommends against the use of Lagevrio in pregnant patients unless there are no other options and COVID-19 therapy is clearly indicated.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">IV infusion. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Veklury is administered via intravenous infusion which minimizes the convenience of administration. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our Development of COVID-19 Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are developing bemnifosbuvir, an investigational, orally administered, novel antiviral product candidate, for the treatment of COVID-19.  We believe bemnifosbuvir as a monotherapy has the potential</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">to address the key limitations of current therapies and the continued unmet medical need particularly for high-risk patients with limited treatment options. SUNRISE-3 is a global Phase 3 randomized, double-blind, placebo-controlled clinical trial that is currently evaluating bemnifosbuvir (550 mg BID for 5 days) in high-risk non-hospitalized patients with mild or moderate COVID-19.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">While SUNRISE-3 is principally designed to evaluate bemnifosbuvir as monotherapy (primary analysis) in approximately 2,200 patients, it is also designed to explore the effect of combination therapy in a smaller sub-set of patients who receive a compatible antiviral drug along with bemnifosbuvir (secondary analysis).  We intend to use data from the smaller subset of patients who receive combination therapy to inform our development plans to evaluate bemnifosbuvir as combination therapy for the treatment of COVID-19.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In parallel with conducting SUNRISE-3, we are engaging in efforts to identify and advance a protease inhibitor product candidate for the treatment of COVID-19.  We are seeking a protease inhibitor that is highly potent, well tolerated with limited drug-drug interactions and does not require a pharmacokinetic ("PK") booster (e.g., ritonavir). The optimization of lead compounds is ongoing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Targeting SARS-COV-2 NiRAN/RdRp to treat COVID-19</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The RNA polymerase complex of SARS-CoV and SARS-CoV-2 supports the transcription and replication of their approximately 30,000-nucleotide viral RNA genomes. It is the largest and most complex RNA synthesis machinery among RNA viruses. As shown in the illustration below, the multi-subunit SARS-CoV polymerase complex is composed of a number of non-structural proteins ("Nsp") including viral RdRp ("Nsp12"), processivity factors ("Nsp7", "Nsp8"), a proofreading exonuclease, a N7-methyl transferase ("Nsp14"), and a helicase ("Nsp13"). The Nsp12 protein contains two domains, an RdRp core, which is the catalytic subunit incorporating ribonucleotides into RNA templates, and an N-terminal NiRAN domain, the function of which was previously unknown.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57592461_1.jpg" alt="img57592461_1.jpg" style="width:611px;height:224px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have investigated the mechanism by which SARS-CoV initiates viral RNA synthesis and have discovered that there are two distinct pathways: one protein-primed and mediated by the NiRAN through the UMPylation of Nsp8, and the other through de novo synthesis of dinucleotide primers in a NiRAN-independent manner. Importantly, both functions can be inhibited by AT-9010, the active triphosphate metabolite of bemnifosbuvir. Furthermore, we have obtained a 2.98 &#197; cryo-EM quaternary structure of Nsp12/7/8/RNA/AT-9100, which confirms that AT-9010 not only bound to the NiRAN active site but also was incorporated by the RdRp and functions as a chain terminator. We believe this unique dual mechanism of bemnifosbuvir creates a potentially higher barrier to resistance compared to other direct acting antiviral inhibitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">SARS-CoV-2 Variants</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">SARS-CoV-2 has proven to be able to mutate quickly with more than seven million variants identified since fall 2020 and more than one million identified in 2023 alone. A number of these variants have been designated by the WHO and CDC as VOI because there is evidence of increased transmissibility, more</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">severe disease, reduced effectiveness of vaccines or antibodies, or diagnostic detection failures. The WHO and CDC have also identified several VOCs which express similar attributes to VOIs but are more likely to be responsible for greater disease severity across the globe. Previously identified VOCs included Alpha, Beta, Gamma, and Delta while the currently circulating VOC is Omicron, which includes BA.1, BA.2, BA.3 BA.4, BA.5, XBB, EG.5.1, JN.1 and descendent lineages.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the US, as of February 17, 2024, JN.1 is estimated to account for over 90% of all currently circulating SARS-CoV-2 variants.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Given the mutagenic nature of SARS-CoV-2, we expect that the evolution of the virus will continue with more variants emerging and presenting new and varied health challenges.  The continued emergence of dominant SARS-CoV-2 variants is a key contributor to COVID-19 remaining as an endemic threat where the virus will still be circulating, with surges from time to time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Potent in vitro inhibition of SARS-CoV-2 replication across variants</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since bemnifosbuvir targets viral RNA polymerase, a highly conserved enzyme critical to viral replication and transcription, we expect it will maintain its antiviral activity even against the recently emerged variants with mutations in the spike (S) protein responsible for the receptor recognition and host cell membrane fusion process.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have assessed the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> potency of AT-511 (free base of bemnifosbuvir) against SARS-CoV-2 VOC and VOI. The data from these studies are summarized in the table below showing that AT-511 maintained its potency against all major VOC and VOI tested. These data support the key mechanistic advantage of the compound, which targets the highly conserved viral RNA polymerase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57592461_2.jpg" alt="img57592461_2.jpg" style="width:616px;height:302px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Non-mutagenic</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Results from non-clinical studies indicated that bemnifosbuvir was non-mutagenic and non-teratogenic and it has shown no reproductive toxicity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">More specifically, analysis of SARS-CoV-2 infected Huh7.5 cells treated with AT-511 (the free base of bemnifosbuvir) by next generation sequencing ("NGS") showed that bemnifosbuvir was not a mutagen (which is consistent with the lack of genotoxicity observed in the preclinical </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">studies) and did not introduce mutations in the viral genome.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57592461_3.jpg" alt="img57592461_3.jpg" style="width:617px;height:220px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition to the standard battery of preclinical safety, pharmacology and repeat dose toxicity studies, which showed no adverse effects of bemnifosbuvir treatment in rats and non-human primates at respective doses up to 650 and 1000 mg/kg/day for 13 weeks, completed preclinical studies have demonstrated that bemnifosbuvir did not affect male or female fertility in treated rats, did not affect early embryo-fetal development in treated pregnant rats or rabbits, and did not affect the pre- or post-natal development, reproductive capability, or behavioral assessments of the offspring of rats treated prior to and during mating (males) and prior to mating through pregnancy and lactation (females).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Clinical Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Summary</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">At the outset of the COVID-19 pandemic, we initiated our COVID-19 program with a global Phase 2 clinical trial of bemnifosbuvir in hospitalized patients.  This was followed by the initiation, together with our former collaborator, F. Hoffmann-LaRoche Ltd. and Genentech, Inc. (together, &#8220;Roche&#8221;), of MOONSONG, a Phase 2 outpatient clinical trial, MORNINGSKY, a Phase 3 outpatient clinical trial and MEADOWSPRING, a Phase 3 six-month follow-up study for patients who had been enrolled in MORNINGSKY.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Together with Roche, we completed the Phase 2 outpatient MOONSONG clinical trial in October 2021 and, due to the complexities and time required to effect the transfer of study sponsorship from Roche to us following the termination of the collaboration, the very dynamic COVID-19 landscape in which SARS-CoV-2 was rapidly evolving and the introduction of the original vaccines and antivirals, after careful consideration, each of the Phase 3 MORNINGSKY and MEADOWSPRING clinical trials were discontinued after careful consideration prior to completion in December 2021 and March 2022, respectively.  We leveraged the key clinical data obtained from these patient studies, including clinical efficacy data from MORNINGSKY, with additional supporting Phase 1 and clinical pharmacology studies conducted in healthy subjects, to support the design of SUNRISE-3, the currently ongoing Phase 3 clinical trial of bemnifosbuvir for the treatment of COVID-19.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">SUNRISE-3 &#8211; Global Phase 3 clinical trial</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In 2023, the FDA granted Fast Track designation for the investigation of bemnifosbuvir for the treatment of COVID-19.  In SUNRISE-3, we are targeting the patient population whom we believe are at the greatest risk for disease progression to severe COVID-19 or mortality, and for whom there are currently the fewest treatment options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57592461_4.jpg" alt="img57592461_4.jpg" style="width:624px;height:351px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In January and February 2024, we announced the enrollment of more than 650 patients and more than 1,350 patients, respectively, in the supportive care monotherapy cohort of the trial.  As a result, we currently anticipate that the first interim analysis by the DSMB will occur in March of 2024 and the second interim analysis by the DSMB will occur in the second quarter of 2024.  At each interim analysis, we anticipate the DSMB will evaluate the data principally for safety and futility. Patient enrollment in the SUNRISE-3 trial, which has currently surpassed 1,400 patients in the supportive care monotherapy population, continues and topline data from the trial are anticipated in the second half of 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">MORNINGSKY - Global Phase 3 clinical trial</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Phase 3 MORNINGSKY study was a global, randomized, placebo-controlled study across 50 centers globally in non-hospitalized adult and adolescent patients with mild or moderate COVID-19 who were at high-risk or standard risk for disease progression regardless of vaccination. Due to the complexities and time required to effect the transfer of study sponsorship from Roche to us following the termination of the collaboration, and the very dynamic COVID-19 landscape including the rapid evolution of SARS-CoV-2 and the introduction and availability of the original vaccines and antivirals, after careful consideration, MORNINGSKY was discontinued prior to completion in December 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Patients were randomized (2:1; active:placebo) to receive bemnifosbuvir 550 mg BID or placebo for five days. The primary endpoint was time to alleviation/improvement of COVID-19 symptoms.  Secondary endpoints included the proportion of patients requiring hospitalization, all-cause mortality, and change in viral load. At the time of discontinuation, 216 patients had been randomized, with 207 patients included in efficacy analyses. The study enrolled a broad outpatient population, including 47% with high-risk factors, 28% who received &#8805;1 doses of vaccine against COVID-19, and 56% who were seropositive for SARS-CoV-2 at baseline. Because the study was prematurely discontinued, no formal statistical comparisons were made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">While the primary endpoint of the MORNINGSKY study, time to symptom alleviation, was not achieved, the results from MORNINGSKY showed that non-hospitalized adult and adolescent patients who received bemnifosbuvir (n=137) experienced a 71% relative reduction in risk of hospitalization (2.9% versus 10%) (p=0.047, unadjusted, exploratory; secondary endpoint) versus placebo (n=70), regardless of vaccination status. In an exploratory analysis, an 82% reduction in risk of hospitalization was seen in a subset of patients greater than 40 years of age in the bemnifosbuvir arm. In another ad hoc analysis, the proportion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">of patients who were considered standard risk experienced a similar relative reduction in risk of hospitalization as those who were considered high-risk (75% versus 69%).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57592461_5.jpg" alt="img57592461_5.jpg" style="width:556px;height:244px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">Error bars denote the 97.5% Confidence Interval</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">No deaths were observed during the study.  No clear differences in any of the virology end points between the bemnifosbuvir and placebo arms were observed.  Overall, bemnifosbuvir was well tolerated.  There were no drug-related SAEs reported, and proportions of patients with AEs leading to study drug discontinuation were low (2.8% in the bemnifosbuvir arm vs 7.0% in the placebo arm).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The MEADOWSPRING trial, originally designed as a six-month follow-up study of patients previously enrolled in MORNINGSKY, was closed out in March 2022 after enrolling only 72 patients. As a result, firm conclusions about the long-term symptoms of COVID-19 could not be drawn from this study.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Hospitalized Patients - Global Phase 2 clinical trial</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Phase 2 study was a randomized, double-blind, placebo-controlled, study that evaluated bemnifosbuvir in hospitalized/confined patients with moderate COVID-19 versus placebo.  The study was initially designed to assess the treatment effect of bemnifosbuvir (550 mg BID; Part A) on a primary endpoint of proportion of subjects with Progressive Respiratory Insufficiency ("PRI"). However, low background rates of disease progression precluded completion of the study as initially planned. The protocol was amended to explore higher doses of bemnifosbuvir (1100 mg BID; Part B), however the study was prematurely discontinued in January 2022. Only two subjects (both receiving placebo) had been enrolled in Part B.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Rates for reduction of PRI were low in 550 mg BID patients and no difference was seen between treatment groups (Intent To Treat [ITT] population: 3/41 7.3% bemnifosbuvir patients and 4/40 10.0% placebo patients).  The all-cause mortality for the Part A 550 mg BID subjects was 0/41 in the bemnifosbuvir group and 5.0% (2/40) in the placebo group. In addition, one placebo patient in the Part B 1100 mg BID group died.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Virology results indicated that treatment with bemnifosbuvir rapidly reduced the SARS-CoV-2 viral load from baseline, as measured by PCR of nasopharyngeal swabs. Compared with placebo, participants on bemnifosbuvir had a 0.61 log</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> (95% CI: -1.38&#8211;0.16) greater mean reduction from baseline viral load on Day 2, and this trend was sustained through Day 8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57592461_6.jpg" alt="img57592461_6.jpg" style="width:624px;height:463px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Bemnifosbuvir&#8217;s SARS-CoV-2 antiviral activity was also observed in patients with baseline viral loads above the median of 5.36 log</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> as compared to placebo. In this subset, those in the bemnifosbuvir arm achieved SARS-CoV-2 clearance as early as Day 2 (in 6% of patients), Day 8 (in 13% of patients) Day 10 (in 33% of patients), and Day 12 (in 31% of patients) compared to 0% of patients in the placebo arm at the same timepoints. By Day 14 (last viral sampling study day), 50% of patients in the bemnifosbuvir arm and 23% in the placebo arm had no detectable RNA virus.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span><img src="img57592461_7.jpg" alt="img57592461_7.jpg" style="width:624px;height:377px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">After dosing with 550 mg BID for five days, bemnifosbuvir was generally well tolerated and there were no drug-related SAEs. AEs were equally distributed across treatment arms. Most were mild-to-moderate in severity and assessed as not related to bemnifosbuvir.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">MOONSONG </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">- </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Global Phase 2 clinical trial</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Phase 2 study was a randomized, double-blind, multi-center, placebo-controlled trial, that evaluated the antiviral activity, safety, efficacy and PK of bemnifosbuvir in adult outpatients with mild or moderate COVID-19. Patients were randomized 1:1 to bemnifosbuvir 550 mg or placebo (Cohort A) and 3:1 to bemnifosbuvir 1,100 mg or placebo (Cohort B); all doses were given BID for 5 days. The modified intent-to-treat infected population comprised 100 patients (bemnifosbuvir 550 mg, n = 30; bemnifosbuvir 1,100 mg, n = 30; cohort A placebo, n = 30; cohort B placebo, n = 10). Treatment with bemnifosbuvir in this study did not meet the primary endpoint of showing a reduction in SARS-CoV-2 viral load in the overall population of patients compared to placebo, of whom approximately two thirds were low-risk with mild symptoms.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">However, in high-risk patients with underlying health conditions, a reduction of viral load of approximately 0.5 log</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> at Day 7 was observed with administration of 550 mg BID as compared to placebo (prespecified subgroup analysis Cohort A n=7; placebo n=10) and with administration of 1,100 mg BID as compared to placebo (exploratory subgroup analysis Cohort B; n=14; placebo n=7).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57592461_8.jpg" alt="img57592461_8.jpg" style="width:624px;height:401px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Bemnifosbuvir was generally well tolerated in this study. The proportion of patients experiencing any AE was 28% in the placebo group, 20% in the bemnifosbuvir 550 mg BID group and 33% in the bemnifosbuvir 1100 mg BID group. There were three non-drug related SAEs in each of the treatment groups and all other AEs were grade 1 or 2. Gastrointestinal ("GI")-related AEs were the most commonly reported AEs: 8% in the placebo group; 7% in the bemnifosbuvir 550 mg BID group; 20% in the bemnifosbuvir 1100 mg BID group, with mild to moderate nausea/vomiting resulting in premature study drug discontinuation of 3% in the placebo group, 0% in the bemnifosbuvir 550 mg BID group and 17% in the bemnifosbuvir 1100 mg BID group. No clinically significant differences in laboratory abnormalities were observed in the treatment arms as compared to placebo.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Other Studies</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Supporting Phase 1 and clinical pharmacology studies, including a bronchoalveolar lavage ("BAL") study, multiple drug-drug interaction studies and a mass balance study, have been conducted and completed since we initiated our COVID-19 program.  In these studies, the safety and PK of bemnifosbuvir has been evaluated at doses up to 1100 mg BID for five days in healthy subjects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Results from the BAL study in healthy subjects demonstrated that bemnifosbuvir was efficiently delivered to the lungs (epithelial lining fluid), the primary site of SARS-CoV-2 infection. Five clinical drug-drug interaction studies were completed with results demonstrating an overall low drug-drug interaction potential associated with bemnifosbuvir.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Phase 1 &#8211; Drug-Drug Interaction Studies</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A series of Phase 1 studies demonstrated an overall low drug-drug interaction potential associated with bemnifosbuvir, including no dosage adjustment needed for co-administration of bemnifosbuvir with drugs that are CYP3A substrates or for drugs that are sensitive substrates of efflux and hepatic uptake transporters. CYP3A is an enzyme that metabolizes many classes of medicines and supplements, and the sensitive substrates of efflux and hepatic uptake transporters regulate cellular trafficking of drugs that are commonly prescribed among high-risk COVID-19 patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In these studies, bemnifosbuvir was administered with index drugs for CYP3A4 (midazolam), P-glycoprotein (digoxin, cyclosporine, carbamazepine), breast cancer resistance protein and organic anion transporter polypeptide 1B1 (rosuvastatin). Based on low potential for drug interaction, we believe bemnifosbuvir has the potential to be co-administered with commonly prescribed therapeutics that are often taken for other conditions, especially in vulnerable patient populations who are at high-risk for disease progression to severe COVID-19.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Bemnifosbuvir has been generally well tolerated in healthy subjects.  Consistent with the results from the MOONSONG Phase 2 outpatient clinical trial, an increased incidence of mild to moderate GI-related adverse events, specifically nausea and vomiting, were observed at doses greater than 550 mg BID in healthy subjects.  As 550 mg BID has been well tolerated for up to ten days, the 550 mg BID dose for five days was selected for the Phase 3 SUNRISE-3 study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, other completed clinical pharmacology studies supporting a potentially favorable PK and safety profile for bemnifosbuvir include a study in healthy Japanese subjects as well as a study assessing the effects of bemnifosbuvir on cardiac repolarization in healthy adult subjects. Other supporting clinical pharmacology studies in special populations (e.g., subjects with hepatic and renal impairment) are ongoing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Bemnifosbuvir and Ruzasvir for the Treatment of HCV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">HCV &#8211; Disease Overview and Current Standard of Care</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">HCV is a blood-borne, positive sense, ssRNA virus, primarily infecting cells of the liver. HCV is a leading cause of chronic liver disease and liver transplants and spreads via blood transfusion, hemodialysis, and needle sticks. In the US, injection drug use accounts for approximately 60% of all new cases of HCV. Diagnosis of HCV is made through blood tests, including molecular tests that allow for the detection, quantification and analysis of viral genomes and the classification of an infection into specific viral GTs. Hepatitis C becomes chronic Hepatitis C in 55% to 85% of acute cases, with an incubation period lasting from two to 26 weeks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">HCV is classified into seven GTs (GT-1 through GT-7) and 67 subtypes, with HCV GT-1 being responsible for more than 70% of HCV cases in the US. Patients with HCV are also classified by liver function status: compensated cirrhosis (liver scarring) denotes those patients that do not yet have impaired liver function, while decompensated cirrhosis describes patients with moderate to severe liver function impairment.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">According to the WHO, an estimated 58 million people globally have chronic HCV infection, with about 1.5 million new infections occurring per year. The most recently published CDC HCV surveillance report showed a continuing increase in HCV infections in the US. The WHO estimated that approximately 290,000 people died in 2019 from HCV related liver diseases, with the majority of deaths related to cirrhosis and hepatocellular carcinoma.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The CDC HCV surveillance report also showed a continuing increase in HCV infections in the US and new and reinfection rates exceeding cures on a yearly basis with the number of reported cases of acute HCV in the US more than doubling between 2014 and 2021 (129% increase). However, there is a wide gap between the number of reported cases versus estimated cases. Most individuals who become infected with HCV remain unaware that they are infected because HCV can go undetected until the condition progresses to symptomatic disease or until specific clinical tests are performed to confirm diagnosis. Consequently, cases are unreported, skewing actual disease prevalence rates. The burden of underreporting is realized when high medical expenditures (comorbid treatment costs, liver transplants) and mortality rates from advanced chronic liver disease do not proportionally align with reported prevalence rates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Increasing Incidence of HCV in the US</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57592461_9.jpg" alt="img57592461_9.jpg" style="width:591px;height:265px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Source: CDC.  2021 Viral Hepatitis Published September 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Despite significant advances in treatment beginning in 2013, there remains a large, underserved, HCV patient population in the US. The US HCV prevalence is expected to continue to remain steady over the coming years as rising HCV incidence offsets the number of new patients treated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">It is estimated that a substantial global market for HCV therapeutics will exist for the foreseeable future.  The HCV commercial market is expected to remain large. Reported global net sales exceeded $3.0 billion in 2023, with the US contributing about 50% of these sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The US HCV prevalence is expected to continue to remain steady over the coming years as rising HCV incidence offsets the number of new patients treated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">It is estimated that a substantial global market for HCV therapeutics will exist to 2050 and beyond. The HCV commercial market is large and expected to remain large. Reported global net sales exceeded $3.0 billion in 2023, with about 50% attributable to the US.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Antivirals for the treatment of HCV</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">No vaccine exists for the prevention of HCV but beginning in 2013 several sequentially introduced and improved oral antiviral therapeutics have boosted SVR rates to over 95% in a majority of patients, with treatment durations of eight to 12 weeks depending upon the regimen and patient population. The leading HCV products are combination therapies comprised of agents with differing mechanisms of action and therapeutic targets: NS3/4A protease inhibitors, NS5A inhibitors, and NS5B nucleos(t)ide polymerase inhibitors. A patient&#8217;s GT, cirrhotic status, and prior treatment failures determine the appropriate antiviral therapeutic used in treatment. In the US, currently the two leading therapeutics for treatment of chronic HCV are:</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Epclusa&#174; (sofosbuvir and velpatasvir): an orally administered, fixed dose combination regimen consisting of an HCV nucleotide analog NS5B polymerase inhibitor and an HCV NS5A inhibitor, was first approved by the FDA in 2016. It is indicated for the treatment of adults and pediatric patients &#8805;3 years with chronic HCV GT-1, -2, -3, -4, -5 or -6 infection, either without cirrhosis or with compensated cirrhosis. For patients with decompensated cirrhosis, Epclusa is approved for use in combination with ribavirin. Patients on Epclusa require 12 weeks of treatment.</span></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Mavyret&#174; (glecaprevir and pibrentasvir): an orally administered, fixed dose combination regimen consisting of an HCV NS3/4A protease inhibitor and an HCV NS5A inhibitor was first approved by the FDA in 2017. It is indicated for the treatment of adults and pediatric patients &#8805;3 years with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">chronic HCV  GT-1, -2, -3, -4, -5 or -6 infection, without cirrhosis or with compensated cirrhosis. Mavyret is also approved for HCV patients with GT-1 infection who have been previously treated with a regimen either containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (but not both). Mavyret was the first eight-week treatment approved for HCV GT-1, -2, -3, -4, -5 or -6 in adult patients without cirrhosis and with compensated cirrhosis who have not been previously treated. Longer treatment durations (up to 16 weeks) are indicated for some treatment-experienced populations. Mavyret is not approved for use in patients with decompensated cirrhosis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Even with the presence and availability of these currently approved direct acting antivirals, only 6% of the prescribers of HCV therapeutic products who participated in quantitative market research we recently conducted indicated that there are no unmet medical needs with current treatments. The key unmet medical needs identified in this market research included the need for treatments with fewer contradictions than exist with current options, including in particular fewer drug-drug interactions, and the need for treatments with shorter treatment durations given that respondents estimated approximately 17% of patients fail to complete current regimens.   This research was conducted by an independent market research consulting firm who surveyed 157 US healthcare providers including hepatologists, infectious disease specialists, gastroenterologists and primary care physicians each of whom, within the 12 months prior to the participation in the project, had  treated at least 25 HCV patients, initiated more than 15 patients on direct acting antivirals and prescribed Epclusa or Mavyret to at least 50% of their eligible patients.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our Development of HCV Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are developing bemnifosbuvir in combination with ruzasvir for the treatment of HCV.  Bemnifosbuvir is an investigational oral, potent inhibitor of HCV NS5B RdRp. Ruzasvir is an investigational oral, potent, pan&#8209;genotypic NS5A inhibitor that we licensed from Merck in December 2021. Based on our preclinical and clinical data to date, we believe that this combination, if approved, could offer the following potential benefits:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">convenient and short duration (eight weeks) protease inhibitor-free treatment in HCV&#8209;infected patients with or without cirrhosis;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">equivalent antiviral potency across all GTs, regardless of cirrhosis status, including the difficult to treat HCV GT-3 population;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">obviate the need for extensive pretreatment assessments, including genotyping, procedures to assess cirrhosis, and liver function assessment; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">well tolerated regimen, with low potential for drug-drug interactions.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Rationale supporting the combination of bemnifosbuvir and ruzasvir for HCV</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">With the antiviral potency observed with bemnifosbuvir, especially in more difficult to treat GT-3 infected patients, we believe that the combination of bemnifosbuvir and ruzasvir has the potential to improve on the SVR12 rates observed in the prior studies conducted by Merck.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To further support our clinical development of the combination of bemnifosbuvir and ruzasvir, we have conducted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> synergy experiments in HCV GT-1b replicon assays.  As shown in the figure below, these experiments demonstrated that the combination resulted in substantially greater inhibition of HCV replication than with either agent alone, suggesting a synergistic antiviral effect between the two inhibitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">In vitro </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Synergy: Assay performed in HCV GT1b replicon</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57592461_10.jpg" alt="img57592461_10.jpg" style="width:525px;height:373px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Viral resistance has emerged as an important consideration since it may impact the effectiveness of antiviral treatments for HCV infection. We profiled the antiviral activity of AT-511, the free base of bemnifosbuvir, and ruzasvir against major HCV NS5A and NS5B </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">R</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">esistance-</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ssociated  </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ariants ("RAVs") selected </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">or identified in HCV patients with hard-to-treat sub-genotypes who have failed treatment with currently available direct acting antivirals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In these </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> studies, AT-511 was approximately 10-fold more active than sofosbuvir against a panel of laboratory strains and clinical isolates of HCV GTs tested (GT-1, -2, -3, -4, -5)) and bemnifosbuvir was not resistant to known sofosbuvir RAVs such as S282T and L159F/S282T.  AT-511 also retained antiviral activity against all HCV GT-1a and HCV GT-3a NS5A RAVs tested. In GT-1a, ruzasvir was 10 times more active than velpatasvir, a direct acting antiviral, and retained single-digit picomolar potency against a panel of RAVs selected by previous NS5A inhibitors and was 10 times more potent than velpatasvir against selected double mutants. In HCV GT-3a, one of the most difficult to treat HCV GTs, ruzasvir was six times more active than velpatasvir and retained sub-nanomolar potency against select NS5A RAVs which were treatment-emergent in HCV GT-3 patients failing direct acting antivirals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Ruzasvir and a panel of other NS5A inhibitors were profiled for antiviral activity against seven difficult-to-treat HCV sub-genotypes using the HCV GT-1b replicon backbone.  Both ruzasvir and velpatasvir maintained picomolar potency over the majority of these difficult-to-treat sub-genotypes such as HCV GT-1l, -4r, and -6v. All tested NS5A inhibitors exhibited 100- to 1000-fold EC</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shifts for HCV GT-3b and GT-3g.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In a 13-week combination toxicity study in rats, bemnifosbuvir and ruzasvir were well tolerated when administered orally at 500 mg/kg/day alone or in combination. No test article-related adverse effects were noted for any of the three dose groups. Systemic exposures of bemnifosbuvir, its metabolites, and ruzasvir were similar when dosed alone or in combination, suggesting no significant drug-drug interactions between the two drugs.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Clinical Development</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Summary</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To date, we have completed two clinical trials of bemnifosbuvir in HCV infected patients to support the treatment of chronic HCV infection and have one on-going, global Phase 2 clinical study.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Open Label Study &#8211; Ongoing Global Phase 2 clinical trial</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In June 2023, we initiated enrollment of a Phase 2 clinical trial of bemnifosbuvir in combination with ruzasvir in treatment-na&#239;ve, HCV-infected patients either without cirrhosis or with compensated cirrhosis.  This study is designed to evaluate the safety and efficacy of eight weeks of treatment with the pan-genotypic combination consisting of once daily bemnifosbuvir 550 mg and ruzasvir 180 mg.   Up to 280 HCV-infected, treatment-naive patients across all GTs, including a lead-in cohort of approximately 60 patients are expected to be enrolled in this Phase 2 clinical trial. The primary endpoints of the study are safety and SVR12. Other virologic endpoints include virologic failure, SVR24 and resistance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Phase 2 Open Label Study of Bemnifosbuvir + Ruzasvir in HCV Patients</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57592461_11.jpg" alt="img57592461_11.jpg" style="width:624px;height:290px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In February 2024, we announced final results from the full lead-in cohort in which a 98% SVR4 rate was observed [58 of 59 subjects achieved SVR4 with one patient who did not return for post-treatment follow-up].  The one patient who did not achieve SVR4 had poor adherence, and was infected with HCV GT-2. These results are consistent with the initial results announced in January 2024. The SVR4 rate exceeded the protocol-defined efficacy criterion of &#8805;90% SVR4 for continuing the study.  As a result, in January 2024 we commenced enrolling up to an additional 220 patients in the study, including patients with cirrhosis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Proportion of Patients with HCV RNA &lt;LLOQ by Study Visit with Eight Weeks of Treatment with the Combination of Bemnifosbuvir and Ruzasvir</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57592461_12.jpg" alt="img57592461_12.jpg" style="width:624px;height:446px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the lead-in cohort, very rapid kinetics were observed with viral load for each patient near or below the LLOQ at four weeks of treatment, which we believe is supportive of an eight-week treatment regimen for the combination of bemnifosbuvir and ruzasvir.  All 60 patients in the lead-in cohort achieved viral load below the LLOQ by the end of the eight-week treatment regimen.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">On-Treatment Viral Kinetics &#8211; Individual HCV RNA Levels in Patients Receiving Combination of Bemnifosbuvir and Ruzasvir for Eight Weeks</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57592461_13.jpg" alt="img57592461_13.jpg" style="width:579px;height:347px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the lead in cohort, the combination treatment was generally safe and well tolerated. There were no drug related SAEs, no treatment discontinuations and AEs were mostly mild.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If the Phase 2 study is successfully completed, subject to discussion and alignment with regulatory authorities, we anticipate initiating a Phase 3 clinical development program in the second half of 2024.  Currently, we expect these initial Phase 3 studies will target a population of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">HCV-infected patients either without cirrhosis or with compensated cirrhosis that is similar to the patients being enrolled in the Phase 2 clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Bemnifosbuvir in combination with daclatasvir - Phase 2 clinical trial</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We conducted a Phase 2, open-label clinical trial to evaluate bemnifosbuvir in combination with daclatasvir, an approved commercially available HCV NS5A inhibitor, in HCV-infected subjects. Ten treatment-na&#239;ve, non-cirrhotic HCV GT-1 infected subjects received 553 mg free base bemnifosbuvir and 60 mg daclatasvir once daily for a period of eight or 12 weeks. The primary efficacy endpoint of the study was SVR12 (a sustained viral response, defined as HCV RNA &lt; LLOQ at 12 weeks after end of treatment (&#8220;EOT&#8221;)).  Secondary efficacy endpoints included HCV RNA&lt; LLOQ, and Target Not Detected (&#8220;TND&#8221;) (an assessment of virologic response that is more rigorous than LLOQ), by study visit, virologic failure, and appearance of RAVs to either of the study drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Despite the use of a less potent first-generation HCV NS5A inhibitor, daclatasvir, all subjects achieved HCV RNA &lt; LLOQ and TND at the EOT and nine of the ten subjects achieved SVR12. One subject who was TND by week two received eight weeks of treatment, achieved SVR4, and then experienced likely virologic relapse at post-treatment week 12. The single subject who relapsed with GT 1b virus had the following multiple RAVs/variants both at baseline and at the SVR12 timepoint: NS5A: R30Q; NS5B: L159F/A218S/C316N. Phenotypic analysis demonstrated that bemnifosbuvir retained the same potency against clinical isolates obtained from this relapsed subject at baseline and SVR12 (only a 1.1 and 0.8-fold shift, respectively, in EC</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">50 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">compared to reference). Compared to sofosbuvir, the EC</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and EC</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">90m </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">values for bemnifosbuvir were ~10-fold lower. Thus, the significance of the RAVs in this case is unclear.  No other subjects had pre-existing NS5A RAVs at baseline.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As shown in the graph below, viral load decreased rapidly after initiation of study drugs, with 70% of subjects achieving plasma HCV RNA &lt; LLOQ by week two (and 50% achieving TND by week 2).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Proportion (%) of subjects achieving HCV RNA &lt;LLOQ and TND by study visit with bemnifosbuvir in combination with daclatasvir</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57592461_14.jpg" alt="img57592461_14.jpg" style="width:580px;height:365px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We believe that the rapid early clearance of HCV RNA observed in the Phase 2 clinical trial evaluating bemnifosbuvir in combination with daclatasvir supported continued evaluation of bemnifosbuvir in shortened treatment regimens, ideally with a more potent, next-generation HCV NS5A inhibitor. This has led us to conduct the currently ongoing Phase 2 clinical trial evaluating bemnifosbuvir in combination with ruzasvir.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Bemnifosbuvir in combination with ruzasvir &#8211; Phase 1 clinical trial</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A Phase 1 clinical study in healthy subjects was conducted in first quarter of 2023 to evaluate the potential drug-drug interaction between bemnifosbuvir and ruzasvir and the effect of food on the PK of the agents.  The study drugs were well-tolerated and plasma PK profiles were not substantially affected by food nor concomitant dosing, the latter indicating lack of drug-drug interaction between bemnifosbuvir and ruzasvir.  These data supported the evaluation of the combination in HCV-infected patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Bemnifosbuvir as a single agent &#8211; Phase 1 clinical trial</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We conducted a Phase 1 trial to evaluate single and multiple doses of bemnifosbuvir as a single agent in healthy and HCV-infected subjects for up to seven days. All HCV-infected subjects were treatment-na&#239;ve with HCV RNA &#8805;5 log10 IU/mL. The objectives of the trial were to assess safety, tolerability, PK and antiviral activity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The trial evaluated single oral doses of bemnifosbuvir up to 400 mg salt form (369 mg free base) in healthy subjects (Part A), single doses up to 600 mg salt form (553 mg free base) in non-cirrhotic HCV-infected subjects (Part B), and multiple doses up to 600 mg salt form (553 mg free base) once daily for seven days in non-cirrhotic HCV GT-1b infected subjects (Part C). Additional cohorts evaluated 600 mg salt form (553 mg free base) once daily for seven days in non-cirrhotic GT-3, (Part D) and Child-Pugh A cirrhotic GT -1, -2, -3, HCV-infected subjects (Part E). The tables below show the dosage and mean maximum HCV RNA reductions for each treatment cohort.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A total of 88 subjects were dosed across all parts of the trial, with 72 subjects who received active drug and 16 subjects who received placebo. In this trial, bemnifosbuvir showed equivalent pan-genotypic antiviral activity in both cirrhotic and non-cirrhotic HCV infected patients. The mean maximum HCV reduction after a single dose (Part B) was 2.3 log</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">IU/mL, and the mean maximum HCV RNA reduction after seven days of dosing with bemnifosbuvir at 553 mg free base was 4.6 log</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">IU/mL. Data also showed a mean maximum HCV RNA reduction of 4.4 log</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">IU/mL after seven days of dosing of bemnifosbuvir at 553 mg free base in non-cirrhotic GT-1b HCV-infected subjects, and a mean reduction of 4.5 log</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">IU/mL after seven days of dosing in non-cirrhotic GT-3 HCV-infected subjects. The PK data in cirrhotic subjects was similar to non-cirrhotic subjects. E</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">max</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> modeling predicted that a dose of 553 mg free base of bemnifosbuvir once daily would result in maximum viral load reduction.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Maximum HCV RNA change in Part B (single dose in non-cirrhotic, HCV GT-1 infected subjects)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.252%;"/>
    <td style="width:2.06%;"/>
    <td style="width:12.378%;"/>
    <td style="width:2.06%;"/>
    <td style="width:12.378%;"/>
    <td style="width:2.06%;"/>
    <td style="width:12.378%;"/>
    <td style="width:2.06%;"/>
    <td style="width:12.378%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.75pt solid #000000;border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;Maximum Reduction (log</span><span style="color:#000000;top:1pt;white-space:pre-wrap;font-size:6.7pt;font-family:Arial;position:relative;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;IU/mL)<br/>bemnifosbuvir dosage (free base equivalent)</span></p></td>
    <td style="border-top:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">100 mg (92 mg)<br/>N=3</span></p></td>
    <td style="border-top:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">300 mg (277 mg)<br/>N=3</span></p></td>
    <td style="border-top:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">400 mg (369 mg)<br/>N=3</span></p></td>
    <td style="border-top:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">600 mg (553 mg)<br/>N=3</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Mean &#177;SD*</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">0.8<br/>&#177;0.153</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1.7<br/>&#177;0.564</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2.2<br/>&#177;0.391</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2.3<br/>&#177;0.255</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Individual</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">0.6, 0.8, 0.9</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1.1, 1.8, 2.2</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1.8, 2.2, 2.5</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2.1, 2.3, 2.6</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Maximum HCV RNA change in Part C (multiple dose in non-cirrhotic, HCV GT-1 infected subjects)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.631%;"/>
    <td style="width:1.04%;"/>
    <td style="width:18.553%;"/>
    <td style="width:1.04%;"/>
    <td style="width:18.553%;"/>
    <td style="width:1.04%;"/>
    <td style="width:18.553%;"/>
    <td style="width:1.04%;"/>
    <td style="width:18.553%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;Maximum Reduction (log</span><span style="color:#000000;top:1pt;white-space:pre-wrap;font-size:6.7pt;font-family:Arial;position:relative;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;IU/mL)</span></p></td>
    <td style="border-top:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Placebo<br/>QD** x 7 days<br/>(N=6)</span></p></td>
    <td style="border-top:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">150 mg (138 mg)<br/>QD x 7 days<br/>(N=6)</span></p></td>
    <td style="border-top:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">300 mg (277 mg)<br/>QD x 7 days<br/>(N=6)</span></p></td>
    <td style="border-top:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">600 mg (553 mg)<br/>QD x 7 days<br/>(N=6)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Mean &#177;SD</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">0.4&#177;0.109</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2.6&#177;1.073</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4.0&#177;0.415</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4.4&#177;0.712</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Individual</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">0.3, 0.3, 0.4, 0.4, 0.5, 0.6</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1.7, 1.8, 1.8, 2.7, 3.0, 4.5</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3.4, 3.7, 3.9, 4.2, 4.2, 4.5</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3.5, 4.0, 4.1, 4.3, 5.2, 5.3</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Maximum HCV RNA change in Part D (multiple dose in non-cirrhotic, HCV GT-3 infected subjects) and Part E (multiple dose in cirrhotic HCV-infected subjects)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.772%;"/>
    <td style="width:1.02%;"/>
    <td style="width:31.634%;"/>
    <td style="width:1.02%;"/>
    <td style="width:27.554%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td rowspan="2" style="border-top:0.5pt solid #000000;border-right:0.75pt solid #000000;border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;Maximum Reduction<br/>(log</span><span style="color:#000000;top:1pt;white-space:pre-wrap;font-size:6.7pt;font-family:Arial;position:relative;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;IU/mL)</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Part D &#8211; GT-3</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Part E &#8211; Cirrhotic</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">600 mg (553 mg)<br/>QD x 7 days<br/>(N=6)</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">600 mg (553 mg)<br/>QD x 7 days<br/>(N=6)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Mean &#177;SD</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4.5&#177;0.262</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4.6&#177;0.485</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Individual</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4.2, 4,4, 4.4, 4.5, 4.5, 5.0</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">GT1b: 4.0, 4.0, 4.5<br/>GT2: 5.0<br/>GT3: 4.8, 5.2</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">*           SD = standard deviation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">**         QD = once daily</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Bemnifosbuvir HCV safety</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">No SAEs, dose-limiting toxicities or AEs leading to trial discontinuation were observed in the HCV Phase 1 or Phase 2 clinical trials of bemnifosbuvir that we have completed to date. The most common side effects observed were headache and small increases in blood lipid levels, with no consistent patterns in other reported effects. Most side effects were not severe and were not thought to be related to bemnifosbuvir.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Ruzasvir</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Ruzasvir is an investigational oral, pan-genotypic NS5A inhibitor that we licensed from Merck in December 2021.  In studies conducted by Merck, ruzasvir demonstrated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> potent antiviral activity with an EC</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">50 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">in the sub- to low picomolar range against all GTs (&lt;10 pM against GTs 1-7).  The antiviral activity of ruzasvir was evaluated in a proof-of-concept ("POC") study in HCV-infected patients, where viral load reductions &gt;3 log</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> were observed in HCV GT-1, GT-2 and GT-3 infected patients after treatment with monotherapy.  This clinical antiviral activity is on par with what was achieved, as single</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">agents, with pibrentasvir and velpatasvir, the NS5A inhibitor components of Mavyret and Epclusa, respectively. These POC data supported evaluation of ruzasvir in larger phase 2 multiple drug combination studies (including two and three drug regimens) previously conducted by Merck. These studies included treatment-na&#239;ve and interferon-experienced patients with or without compensated cirrhosis.  In general, high SVR12 rates (&gt;90%) were observed in two-drug combination studies (ruzasvir plus uprifosbuvir, a pyrimidine nucleotide prodrug, for 12 weeks) conducted by Merck in GT-1, -2, -4 and -6-infected patients (C-Breeze 1 and 2). A lower SVR12 rate was observed in GT-3 subjects with compensated cirrhosis (40% SVR12; C-Breeze 1).  We believe this lower rate is attributed to the reduced antiviral activity associated with the nucleotide uprifosbuvir in GT-3 cirrhotic subjects as an increase in ruzasvir dose to 180 mg substantially increased the SVR12 rate in this population (68% SVR12; C-Breeze 2), highlighting the observed dose-related clinical antiviral activity of ruzasvir in GT-3 subjects with cirrhosis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In studies conducted by Merck, over 1,200 HCV-infected participants received ruzasvir at daily doses up to 180 mg for durations up to 12 weeks as part of 2-drug and 3-drug regimens with or without ribavirin. The overall safety data indicates that ruzasvir was generally well-tolerated with no consistent treatment-related changes in laboratory, vital signs, or electrocardiogram parameter values.  SAEs and discontinuations due to AEs were rare in all studies conducted by Merck.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">       </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Dengue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In February 2023, after advancing AT-752 into a Phase 2 clinical trial, we decided not to pursue further clinical development of AT-752 for the treatment and prophylaxis of dengue.  This action was taken due to the long timelines anticipated for patient enrollment, expected clinical operational challenges, including the challenge of successfully administering an antiviral very shortly after infection which is not feasible with the current diagnostic tests, and the estimated resource burdens, including substantial costs, associated with the further clinical development of an antiviral for each of the treatment and prophylaxis of dengue.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Roche License Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In October 2020, we entered into a license agreement (&#8220;Roche License Agreement&#8221;) with Roche in connection with the global development, manufacture and commercialization of bemnifosbuvir, products containing bemnifosbuvir or AT-511, the free base of bemnifosbuvir, and related companion diagnostics.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As partial consideration for the rights we granted to Roche under the Roche License Agreement, Roche paid us an upfront payment of $350 million in November 2020. Additionally, upon realization of a development milestone in June 2021, we received an additional $50 million from Roche.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the term of the Roche License Agreement, Roche and we jointly developed bemnifosbuvir for COVID-19 on a worldwide-basis and equally shared the costs associated with such development activities. On February 10, 2022, the Roche License Agreement terminated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a result of the Roche License Agreement termination, we regained worldwide exclusive rights from Roche to research, develop, manufacture and commercialize bemnifosbuvir, products containing bemnifosbuvir or AT-511, the free base of bemnifosbuvir and related companion diagnostics in all fields of use.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Merck License Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In December 2021, we entered into a license agreement with Merck (&#8220;Merck License Agreement&#8221;) for the development, manufacture and commercialization of ruzasvir.  Ruzasvir is the NS5A inhibitor we are developing in combination with bemnifosbuvir for the treatment of HCV.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pursuant to the terms of the Merck License Agreement, we obtained from Merck an exclusive (subject to certain reserved rights to conduct internal research), sublicensable, and worldwide license under certain Merck patents and know-how to research, develop, manufacture, have manufactured, use, import, export, sell, offer for sale, and otherwise commercialize ruzasvir (&#8220;Compound"), or products containing the Compound (each a &#8220;Product&#8221;) for all therapeutic or prophylactic uses in humans (&#8220;Field&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In consideration for the rights we acquired under the Merck License Agreement, we paid Merck an upfront payment in the amount of $25 million and we will be required to pay Merck milestone payments up to $135 million in the aggregate upon our achievement of certain development and regulatory milestones</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and up to $300 million in the aggregate upon our achievement of certain sales-based milestones.  The first potential milestone, in the amount of $5.0 million, would be payable upon the commencement of a Phase 3 clinical trial. Additionally, we have agreed to pay Merck tiered royalties based on annual net sales of Products ranging from high single digit to mid-teens percentages, subject to certain adjustments. Our royalty payment obligations will continue on a country-by-country and Product-by-Product basis until the later of (i) the expiration of the last to expire valid claim of a licensed Merck patent claiming such Product and (ii) a period of years after the first commercial sale of such Product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Under the terms of the Merck License Agreement, we are obligated to use commercially reasonable efforts to develop and commercialize at least one Product in the Field in certain countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The term of the Merck License Agreement will continue, on a Product-by-Product and country-by-country basis, until expiration of all royalty payment obligations arising under the Merck License Agreement. We may terminate the Merck License Agreement for convenience upon 90 days prior written notice. Each party has the right to terminate the Merck License Agreement in the event of the other party&#8217;s material breach of the terms of the Merck License Agreement subject to a 60-day cure period and in the event of the other party&#8217;s bankruptcy or insolvency.  Merck has the right to terminate the Merck License Agreement immediately if we commence any interference or opposition proceeding or other challenge to the validity or enforceability of any Merck patent licensed to us under the Merck License Agreement or if we otherwise oppose any extension of, or the grant of any supplementary protection certificate with respect to, any such Merck patent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Upon any termination of the Merck License Agreement, the license granted to us by Merck will terminate. Upon termination of the Merck License Agreement by us for convenience other than as a result of a safety issue, or upon any termination by Merck, Merck will have an exclusive, fully paid, perpetual, sublicensable license to certain of our patents and know-how that are reasonably necessary to develop, manufacture or commercialize a Product that contains ruzasvir as the sole active agent, as such Product exists at termination. Additionally, if requested by Merck, during a period of time after delivery of the notice of termination of the Merck License Agreement by Merck or by us for convenience other than as a result of a safety issue, we will have the obligation to negotiate with Merck for the grant to Merck of a non-exclusive, royalty bearing license to certain of our patents and know-how that are reasonably necessary to develop, manufacture or commercialize a Product that is comprised of the combination of ruzasvir and bemnifosbuvir, as such Product exists at termination, with certain license terms pre-specified in the Merck License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Manufacturing</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We do not currently own or operate manufacturing facilities for the production of preclinical or clinical product candidates, nor do we have plans to develop or operate our own manufacturing operations in the future. We currently rely upon third-party contract manufacturing organizations (&#8220;CMOs&#8221;) to produce our product candidates for both preclinical and clinical use and anticipate to rely upon these or other CMOs or other third parties for commercial supply if any of our product candidates is successfully developed and approved for sale. While we expect that we will be able to enter into such arrangements, we do not currently have long term agreements in place for manufacture of product at commercial scale quantities. As a result, there are no assurances that our manufacturing and supply chain infrastructure will remain uninterrupted and reliable or that our CMOs or other third parties will be able to satisfy demand in a timely manner.  While there are a limited number of companies that can produce raw materials and active pharmaceutical ingredients  in the quantities and with the quality and purity that we require for our product candidates, based on our diligence to date, we believe our current network of manufacturing partners are able to fulfill these requirements, and are capable of continuing to expand capacity as needed. Additionally, we have, and will continue to evaluate further relationships with additional suppliers to increase overall capacity as well as further reduce risks associated with reliance on a limited number of suppliers for manufacturing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our employees who have extensive manufacturing and supply chain experience oversee the relationships with our CMOs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Competition</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a clinical-stage biopharmaceutical company, we face competition from a wide array of companies in the pharmaceutical and biotechnology industries. These include both small companies and large</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">companies with much greater financial and technical resources and far longer operating histories than our own. We may also compete with the intellectual property, technology, and product development efforts of academic, governmental, and private research institutions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our competitors may have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing, and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The key competitive factors affecting the success of any product candidates that we develop, if approved, are likely to be their efficacy, safety, convenience, price, and the availability of reimbursement from government and other third-party payors. The commercial opportunity for any product candidate we develop, if any are approved, could be reduced or eliminated if such product fails to achieve market acceptance from patients, prescribers and payors, our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may commercialize products more quickly than we are able to.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">SARS-CoV-2</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Many therapies and vaccines are approved or authorized for emergency use for the treatment and prevention, respectively of COVID-19 in the US and multiple additional countries.  In addition to approved or authorized products, there are other agents in development for the treatment of COVID-19 both within and outside the US.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Direct acting antiviral therapies for the treatment of COVID-19 that are currently approved or authorized by the FDA for use include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Paxlovid&#153; (nirmatrelvir tablets; ritonavir tablets) (Pfizer Inc.), which includes nirmatrelvir, a SARS-CoV-2 main protease inhibitor, and ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor, approved for the treatment of mild-to-moderate COVID-19 in adults who are at high-risk for progression to severe COVID-19, including hospitalization or death; and authorized for emergency use in pediatric patients (12 years of age and older weighing at least 40 kg) at high-risk for progression to severe COVID-19, including hospitalization or death. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Lagevrio&#153; (molnupiravir) (Ridgeback Biotherapeutics LP/Merck &amp; Co., Inc.), a ribonucleoside analog authorized for emergency use for the treatment of adults with mild-to-moderate COVID-19 who are at high-risk for progression to severe COVID, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Veklury</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> (remdesivir) (Gilead Sciences, Inc.), a SARS-CoV-2 nucleotide analog RdRp inhibitor approved for the treatment of COVID-19 in adults and pediatric patients (28 days of age and older and weighing at least 3 kg) who are (i) hospitalized, or (ii) not hospitalized and have mild-to-moderate COVID-19, and are at high-risk for progression to severe COVID-19, including hospitalization and death.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">These antiviral therapies are also approved or authorized for use in many countries outside the US.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition to bemnifosbuvir, other orally administered antiviral agents that are currently in later stage development in the US for the treatment of COVID-19 include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:29.28%;"/>
    <td style="width:29.3%;"/>
    <td style="width:25.26%;"/>
    <td style="width:16.16%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Investigational Therapy</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Company</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Mechanism of Action</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Phase of Development</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Ensitrelvir (S-217622)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shionogi</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Protease inhibitor</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Phase 3</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Ibuzatrelvir (PF-07817883)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Pfizer</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Protease Inhibitor</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Phase 2</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition to the antivirals listed above, both within and outside the US, several monoclonal antibodies were previously authorized for emergency use for the prophylaxis or treatment of COVID-19. While these authorizations were rescinded in the US, it is possible that monoclonal antibodies which have effectiveness against future SARS-CoV-2 variants may be developed and authorized or approved for the treatment of COVID-19.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Vaccines that are approved or authorized for emergency use for the prevention of COVID-19 in the US include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Comirnaty</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> (COVID-19 Vaccine, mRNA) (Pfizer-BioNTech), 2023-2024 formula FDA-approved vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pfizer-BioNTech (COVID-19 Vaccine, monovalent), 2023-2024 formula vaccine authorized for all doses administered to individuals 6 months through 11 years of age to prevent COVID-19.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Spikevax</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> (COVID-19 Vaccine, mRNA) (Moderna), 2023-2024 formula FDA-approved vaccine for active immunization to prevent COVID-19 in individuals 12 years of age and older.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moderna (COVID-19 Vaccine, monovalent), 2023-2024 formula vaccine authorized for all doses administered to individuals 6 months through 11 years of age to prevent COVID-19.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Novavax COVID-19 Vaccine, Adjuvanted, 2023-2024 formula monovalent vaccine authorized to prevent COVID-19 for individuals 12 years of age and older.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The potential treatments and vaccines for COVID-19 continue to evolve and the lists above are not comprehensive lists of every or all treatments and vaccines that are in development for COVID-19. These lists include the products or product candidates approved or authorized for emergency use and the direct acting antivirals in late stage clinical development in the US as of the date of this Annual Report on Form 10-K that we believe would be the most competitive with bemnifosbuvir.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">HCV</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since 2014, many direct-acting antiviral therapies have been approved for use for the treatment of HCV in the US and globally.  Orally administered, FDA-approved treatments for patients with chronic HCV include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Sovaldi</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> (sofosbuvir) (Gilead Sciences, Inc.), an HCV nucleotide analog NS5B polymerase inhibitor approved for the treatment of adult patients with GT-1, -2, -3, -4, -5, -6 chronic HCV infection without cirrhosis or with compensated cirrhosis as a component of a combination antiviral treatment regimen; pediatric patients &#8805;3 years old with HCV GT-2 or -3 infection without cirrhosis or with compensated cirrhosis in combination with ribavirin.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Epclusa&#174; (sofosbuvir and velpatasvir) (Gilead Sciences, Inc.) fixed dose combination regimen of sofosbuvir and velpatasvir, an HCV NS5A inhibitor, approved for the treatment of adults and pediatric patients &#8805;3 years old with chronic HCV GT-1, -2, -3, -4, -5, or -6 infection without cirrhosis or with compensated cirrhosis, or for use in combination with ribavirin with decompensated cirrhosis. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Harvoni&#174; (ledipasvir and sofosbuvir) (Gilead Sciences, Inc.) a fixed dose combination of ledipasvir, an HCV NS5A inhibitor, and sofosbuvir approved for the treatment of adult and pediatric patients &#8805;3 years old with HCV GT-1, -4, -5 or -6 infection without cirrhosis or with compensated cirrhosis. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Vosevi&#174; (sofosbuvir, velpatasivir, and voxilaprevir) (Gilead Sciences, Inc.) a fixed dose triple combination of  sofosbuvir, velpatasvir and voxilaprevir, an HCV NS3/4A protease inhibitor </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">approved for the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis who have HCV GT-1, -2, -3, -4, -5, or -6 infection and have previously been treated with an HCV regimen containing an HCV NS5A inhibitor; HCV GT-1a or -3 infection who have previously been treated with an HCV regimen containing sofosbuvir without an HCV NS5A inhibitor.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Mavyret</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> (glecaprevir and pibrentasvir) (AbbVie, Inc.) a fixed-dose combination of glecaprevir, an HCV NS3/4A protease inhibitor and pibrentasvir, an HCV NS5A inhibitor, approved for the treatment of adult and pediatric patients &#8805;3 years old with chronic HCV GT-1, -2, -3, -4, -5, or -6 infection without cirrhosis or with compensated cirrhosis. Mavyret as an eight-week treatment is approved for patients who have not been previously treated. Longer treatment durations (up to 16 weeks) are indicated for some treatment-experienced populations. Mavyret is not approved for use in patients with decompensated cirrhosis.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Zepatier</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(elbasvir and grazoprevir) (Merck &amp; Co., Inc.) a fixed-dose combination of elbasvir, an HCV NS5A inhibitor and grazoprevir, an HCV NS3/4A protease inhibitor approved for the treatment of chronic HCV GT-1 or -4 infection in adult and pediatric patients &#8805;12 years old or weighing at least 30 kg.  Zepatier is indicated for use with ribavirin in certain patient populations.  </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition to the branded products, Gilead Sciences, Inc. markets authorized generic copies of Epclusa and Harvoni through its subsidiary, Asegua Therapeutics, LLC.  We are not aware of any investigational agents in late-stage development in the US although there may be other investigational agents for HCV in various stages of clinical development in other parts of the world.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Commercialization</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We currently believe that we can maximize the value of our product portfolio by retaining global development rights to our product candidates.  However, to further maximize the value of product candidates that are authorized or approved for sale, we may seek collaborations that allow us to access and leverage commercialization expertise and resources of collaborators in certain markets.  To assist in the commercialization in the US of any product candidates we successfully develop, we may enter into arrangements with third parties that have existing commercial infrastructure including primary care sales force and expertise in managed care.  Outside the US, we anticipate that commercialization of our products, if approved or authorized for use, would be undertaken by third party collaborators.  Currently, we do not have any sales, marketing or commercial product distribution infrastructure and we do not have any existing arrangements with third parties to commercialize our product candidates in the US or elsewhere.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our nucleotide therapeutic products for viral diseases, including our purine nucleotide compounds for SARS-CoV-2 and HCV. We seek to protect our proprietary compounds and methods of treatment for viral diseases using our nucleotide compounds, alone and in combination with other therapeutic agents, in addition to dosage forms, dosing regimens and formulations for their administration. We also seek protection on the manufacturing process for the production of our nucleotide compounds. Our success also depends on our ability to operate without infringing, misappropriating or otherwise violating the proprietary rights of others and to prevent others from infringing, misappropriating or otherwise violating our proprietary rights.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our policy is to seek to protect our proprietary position by filing US and foreign patent applications covering our proprietary technologies, inventions, and improvements that are important to the development and implementation of our business. In addition, we currently plan to seek patent term adjustments, restorations, and/or patent term extensions where applicable in the US, Europe and other jurisdictions. We also rely on trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position. Additionally, we expect to benefit, where appropriate, from statutory frameworks in the US, Europe and other countries that provide a period of regulatory data exclusivity to compensate for the time required for regulatory approval of our drug products.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of February 1, 2024, we are the sole owner of fourteen patent families covering our product candidates and proprietary nucleotide compounds, which include composition of matter, pharmaceutical compositions, methods of use, and processes of manufacture as described in more detail below. Our owned patent estate as of February 1, 2024, on a worldwide basis, includes more than 300 pending, granted, or allowed patent applications with eighteen issued US patents, nine pending US non-provisional applications, two pending international patent applications filed under the Patent Cooperation Treaty (&#8220;PCT&#8221;), and more than 250 pending or granted patent applications that have entered the national phase of prosecution in countries outside the US.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of February 1, 2024, we are the exclusive licensee of three patent families from Merck covering composition of matter, process of preparation, and formulations of the NS5A inhibitor ruzasvir (MK-8408), which collectively include two issued US patents, granted patents in France, Great Britain, and Germany and one pending US patent application and one pending patent application in the European Patent Office ("EPO").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The exclusivity terms of our patents depend upon the laws of the countries in which they are obtained. In the countries in which we currently file, the patent term is 20 years from the earliest date of filing of a non-provisional patent application. The term of a US patent may be extended to compensate for the time required to obtain regulatory approval to sell a drug (a patent term extension) or by delays encountered during patent prosecution that are caused by the US Patent and Trademark Office (referred to as patent term adjustment). For example, the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act, permits a patent term extension for FDA-approved new chemical entity drugs of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review and diligence during the review process. Patent term extensions in the US cannot extend the term of a patent beyond a total of 14 years from the date of product approval, only one patent covering an approved drug, or its method of use may be extended, and only those claims covering the approved drug, or an approved method for using it may be extended. A similar kind of patent extension, referred to as a Supplementary Protection Certificate, is available in the European Union ("EU"). Legal frameworks are also available in certain other jurisdictions to extend the term of a patent. We currently intend to seek patent term extensions on any of our issued patents in any jurisdiction where we have a qualifying patent and the extension is available; however, there is no guarantee that the applicable regulatory authorities, including the FDA in the US, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. Further, even if our patent is extended, the patent, including the extended portion of the patent, may be held invalid or unenforceable by a court of final jurisdiction in the US or a foreign country.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Current issued patents and patent applications covering the composition of matter for our present clinical candidates AT-511 and bemnifosbuvir will expire on dates ranging from 2036 to 2038, if the applications are issued and held valid by a court of final jurisdiction if challenged, and without regard to any possible patent term adjustments or extensions. Current patent applications covering the use of AT-511 and bemnifosbuvir for the treatment of SARS-CoV-2 will expire on dates ranging from 2040 to 2041, if the applications are issued and held valid by a court of final jurisdiction if challenged, and without regard to any possible patent term adjustments or extensions. Current issued patents and patent applications covering the use of AT-511 and bemnifosbuvir for the treatment of HCV will expire on dates ranging from 2036 to 2042, if the applications are issued and held valid by a court of final jurisdiction if challenged, and without regard to any possible patent term adjustments or extensions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">However, any of our patents, including patents that we may rely on to protect our market for approved products, may be held invalid or unenforceable by a court of final jurisdiction. Alternatively, we may decide that it is in our interest to settle a litigation in a manner that affects the term or enforceability of our patent. Changes in either the patent laws or in interpretations of patent laws in the US and other jurisdictions may diminish our ability to protect our inventions and enforce our intellectual property rights. Accordingly, we cannot predict the breadth or enforceability of claims that have been or may be granted on our patents or on third-party patents. The pharmaceutical and biotechnology industries are characterized by extensive litigation regarding patents and other intellectual property rights. Our ability to obtain and maintain our proprietary position for our nucleotide compounds and the use of these compounds will depend on our success in enforcing patent claims that have been granted or may grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We do not know whether any of the pending patent applications that we have filed or may file or license from third parties will result in the issuance of any additional patents. The issued patents that we own or may receive in the future may be challenged, invalidated, or circumvented, and the rights granted under any issued patents may not provide us with sufficient protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may be able to independently develop and commercialize drugs with similar mechanisms of action and/or duplicate our methods of treatments or strategies without infringing our patents. Because of the extensive time required for clinical development and regulatory review of a drug we may develop, it is possible that, before any of our drugs can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent. For more information regarding risks relating to intellectual property, see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Part I, Item 1A. &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our patent families, as of February 1, 2024, are further described below.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">AT-511 and bemnifosbuvir</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We own a first patent family that describes AT-511 or a pharmaceutically acceptable salt thereof (for example, bemnifosbuvir), pharmaceutical compositions of AT-511 or the pharmaceutical salts thereof, and methods to treat HCV using AT-511 or a salt thereof. This family consists of seven issued US patents (US Pat. Nos. 9,828,410; 10,000,523; 10,005,811; 10,239,911; 10,815,266; 10,870,672; 10,870,673) covering AT-511 or a pharmaceutically acceptable salt thereof, related compounds and their pharmaceutical compositions. This patent family is now also in the national stage of prosecution or granted in the African Regional Intellectual Property Organization (&#8220;ARIPO&#8221;), Australia, Brazil, Canada, China, Colombia, the Eurasian Patent Office (&#8220;EAPO&#8221;), Egypt, the EPO, Georgia, Hong Kong, Indonesia, Israel, India, Japan, Korea, Mexico, Macao, Malaysia, Nigeria, New Zealand, the Philippines, Russia, Saudi Arabia, Singapore, Thailand, Vietnam, Ukraine, South Africa, and the United Arab Emirates. We have more than 30 foreign patents granted or allowed, and more than 20 pending patent applications. The expected year of expiration for this patent family, where issued, valid and enforceable, is 2036, without regard to any extensions, adjustments, or restorations of term that may be available under national law.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We also own a second patent family that specifically covers bemnifosbuvir (the hemisulfate salt for AT-511), pharmaceutical compositions, process of preparation, and methods to treat HCV using bemnifosbuvir. This family includes two issued US patents (US Pat. No. 10,519,186, and US Patent No. 10,906,938,) and one allowed US application covering bemnifosbuvir. This family is currently in the national phase of prosecution in Argentina, ARIPO, Australia, Brazil, Canada, China, Colombia, the EAPO, the EPO, Georgia, Hong Kong, Indonesia, Israel, India, Japan, Korea, Mexico, Malaysia, Nigeria, New Zealand, the Philippines, Russia, Singapore, Taiwan, Thailand, Vietnam, Ukraine, Uzbekistan, and South Africa. We have over 25 granted foreign patents and over 25 pending applications. The expected year of expiration for this patent family, if issued, valid and enforceable, is 2038, without regard to any extensions, adjustments, or restorations of term that may be available under US or other national laws.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We own two patent families that disclose methods for the treatment of SARS-CoV-2 using AT-511 or bemnifosbuvir. These families include four granted US patents (US Patent Nos. 10,874,687, 11,707,480, 11,783,038, and 11,813,278) and two pending US applications. A patent application in this family has been allowed in Japan and applications are pending in Argentina, ARIPO, Australia, Bahrain, Brazil, Canada, Chile, China, Columbia, Ecuador, Egypt, the EPO, the EAPO, Georgia, India, Israel, Japan, Jordan, Kuwait, Libya, Malaysia, Mexico, Morocco, New Zealand, Nicaragua, Nigeria, Oman, Philippines, Russia, Saudi Arabia, Singapore, South Africa, South Korea,  Taiwan, Thailand, Tunisia, Uzbekistan, and Vietnam. The expected year of expiration for patents issued from these families, if valid and enforceable, is 2040 or 2041, without regard to any extensions, adjustments, or restorations of term that may be available under US or other national laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We own a fifth patent family that discloses the use of AT-511 or a pharmaceutically acceptable salt thereof for the treatment or prevention of a positive-stranded RNA virus infection, including a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Flaviviridae </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">viral infection such as dengue, West Nile, or yellow fever. This family consists of one allowed application and one issued patent (US Patent No. 10,946,033) and is currently pending or granted in Australia, Brazil, Canada, China, the EAPO, the EPO, Hong Kong, Indonesia, Japan, Korea, Malaysia, Nigeria, Russia,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Singapore, Thailand, Vietnam, and South Africa. We have over 30 foreign patents granted and over 20 pending patent applications. The expected year of expiration for this patent family, if issued, valid and enforceable, is 2037, without regard to any extensions, adjustments, or restorations of term that may be available under US or other national laws.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We own a sixth patent family that discloses the use of AT-511 and bemnifosbuvir for the treatment of HCV in patients with cirrhosis of the liver. This family includes one granted US application (US Patent No. 11,690,860). The expected year of expiration for this patent family, if issued, valid and enforceable, is 2039, without regard to any extensions, adjustments, or restorations of term that may be available under US or other national laws.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We own a seventh patent family that describes methods to treat mutant or resistant forms of the SARS-CoV-2 virus. This family consists of pending applications in the US, the EPO, Japan, Canada and Hong Kong, as well as one application in Argentina and one application in Taiwan. The expected year of expiration for patents issued from non-provisional patent applications filed on the basis of this patent application, if valid and enforceable, is 2041, without regard to adjustments of term that may be available under US or other national laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We also own an eighth patent family that discloses methods for manufacturing AT-511 and bemnifosbuvir. This family consists of one pending US application. The expected year of expiration for patents issued from non-provisional patent applications filed on the basis of these provisional patent applications, if valid and enforceable, is 2041, without regard to adjustments of term that may be available under US or other national laws.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We also own a ninth patent family that discloses additional processes for the manufacture of AT-511 and bemnifosbuvir. This family consists of one pending patent application in the US in addition to pending applications in Argentina, Australia, Canada, China, the EPO Hong Kong, India, Japan, Korea, Mexico, New Zealand, and Taiwan. The expected year of expiration for patents issuing from these non-provisional patent applications, if valid and enforceable, is 2041, without regard to any adjustments of term that may be available under US or other national law.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We also own a tenth patent family that discloses new morphic forms of bemnifosbuvir. This family consists of one pending patent application in the US, as well as pending applications in Australia, Brazil, Canada, China, the EAPO, the EPO, Israel, India, Japan, Korea, Mexico, Russia, and Taiwan. The expected year of expiration for patents issued from non-provisional patent applications filed on the basis of this patent application, if valid and enforceable, is 2042, without regard to adjustments of term that may be available under US or other national laws.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Ruzasvir</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have exclusively licensed three patent families from Merck covering composition of matter, process of preparation, and formulations of ruzasvir (MK-8408), a pan-genotype NS5A inhibitor to treat HCV. The family covering the composition of matter includes one granted US patent (US Patent No. 9,555,038), and granted patents in France, Great Britain, and Germany. The expected expiration date is in 2034. The family describing a process of preparation includes one granted US patent (US Patent No. 10,457,690), with an expected expiration date in 2036. The family describing formulations includes one pending US patent application and one pending patent application in the EPO, which if granted, is expected to expire in 2039.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We also solely own a patent family covering the combination of bemnifosbuvir and ruzasvir. This family consists of one patent application in the US, in addition to patent applications in the United Arab Emirates, Argentina, Australia, Brazil, Canada, China, Colombia, the EAPO, the EPO, Indonesia, Israel, India, Japan, Korea, Mexico, Malaysia, New Zealand, the Philippines, Qatar, Russia, Saudi Arabia, Singapore, Thailand, Taiwan, and South Africa. These patent applications, if granted, will have an expiration date in 2042.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Government Regulation and Product Approval</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Government authorities in the US, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the new drug application (&#8220;NDA&#8221;), process before it may be legally marketed in the US.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">US Drug Development Process</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the US, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The process required by the FDA before a drug may be marketed in the US generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with FDA&#8217;s good laboratory practice requirements and other applicable regulations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">approval by an independent institutional review board (&#8220;IRB&#8221;), or ethics committee at each clinical site before each trial may be initiated;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice requirements (&#8220;GCPs&#8221;) to establish the safety and efficacy of the proposed drug for its intended use;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">submission to the FDA of an NDA after completion of all pivotal trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practice (&#8220;cGMP&#8221;), requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity, and satisfactory completion of potential inspections of selected clinical investigation sites to assess compliance with GCPs; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the US.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Prior to beginning the first clinical trial with a product candidate in the US, a sponsor must submit an IND to the FDA. An IND is a request for allowance from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the investigational product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. Once submitted, the IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30- day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA allowance to begin a clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which among other things include the requirement that all research subjects provide their informed consent for their participation in any clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Furthermore, an independent IRB or ethics committee for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the investigational product has been associated with unexpected serious harm to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Phase 1: The product candidate is initially introduced into healthy human subjects, and in some cases, patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Phase 2: The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Phase 3: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product labeling.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach alignment on the next phase of development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">US Review and Approval Process</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, including results from preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, the Pediatric Research Equity Act (&#8220;PREA&#8221;), requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and certain supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is deemed safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once filed, the FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after it the application is submitted.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving a NDA, the FDA may inspect one or more clinical sites to assure compliance with GCPs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter ("CRL"). An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL usually describes the specific deficiencies in the NDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">identified by the FDA and may require additional clinical data, such as an additional clinical trials or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a CRL is issued, the sponsor must resubmit the NDA addressing all of the deficiencies identified in the letter or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations or restrictions on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;), to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. The FDA may also require one or more post-approval studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-approval studies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Emergency Use Authorization</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Commissioner of the FDA, under delegated authority from the Secretary of HHS may, under certain circumstances in connection with a declared public health emergency, allow for the marketing of a product that does not otherwise comply with FDA regulations by issuing an EUA for such product. Before an EUA may be issued by HHS, the Secretary must declare an emergency based a determination that public health emergency exists that effects or has the significant potential to affect, national security, and that involves a specified biological, chemical, radiological, or nuclear agent or agents (&#8220;CBRN&#8221;), or a specified disease or condition that may be attributable to such CBRN. On February 4, 2020, the HHS Secretary determined that there is such a public health emergency that involves SARS-CoV-2, the virus that causes the COVID-19 infection. Once the determination of the threat or emergency has been made, the Secretary of HHS must then declare that an emergency exists justifying the issuance of EUAs for certain types of products (referred to as EUA declarations). On March 27, 2020, the Secretary of HHS declared on the basis of his determination of a public health emergency that has the potential to affect national security or the health and security of US citizens living abroad that involves SARS-CoV-2 that circumstances exist justifying authorization of drugs and biologics during the COVID-19 pandemic, subject to the terms of any EUA that is issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Once an EUA declaration has been issued, the FDA can issue EUAs for products that fall within the scope of that declaration. To issue an EUA, the FDA Commissioner must conclude that (1) the CBRN that is referred to in the EUA declaration can cause serious or life-threatening diseases or conditions; (2) based on the totality of scientific evidence available, it is reasonable to believe that the product may be effective in diagnosing, treating, or preventing the disease or condition attributable to the CBRN and that the product&#8217;s known and potential benefits outweigh its known and potential risks; and (3) there is no adequate, approved, and available alternative to the product. Products subject to an EUA must still comply with the conditions of the EUA, including labeling and marketing requirements. Moreover, the authorization to market products under an EUA is limited to the period of time the EUA declaration is in effect, and the FDA can revoke an EUA in certain circumstances.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA offers a number of expedited development and review programs for qualifying product candidates. For example, the FDA Fast Track program is intended to expedite or facilitate the process for reviewing product candidates that meet certain criteria. Specifically, investigational drugs are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the application may be eligible for priority review. With regard to a Fast Track product candidate, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any marketing application for a drug submitted to the FDA for approval, including a product with a Fast Track designation or Breakthrough Therapy designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review. An NDA is eligible for priority review if the product candidate is designed to treat a serious condition, and if approved, would provide a significant improvement in safety or effectiveness compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an NDA designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, depending on the design of the applicable clinical trials, a product candidate may be eligible for accelerated approval. Product candidates intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA generally requires that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled confirmatory clinical trials to verify and describe the predicted clinical benefit and may require that such confirmatory trials be underway prior to granting any accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required clinical trials in a timely manner, or if such trials fail to verify the predicted clinical benefit. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fast Track designation, Breakthrough Therapy designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Post-approval Requirements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon drug manufacturers. Changes to the manufacturing process are strictly regulated,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon NDA holders and any third-party manufacturers that NDA holders may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">fines, warning letters, or untitled letters;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">clinical holds on clinical studies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict marketers&#8217; communications on the subject of off-label use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labelling.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Marketing Exclusivity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Marketing exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent data exclusivity within the US to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application (&#8220;ANDA&#8221;), or an NDA submitted under Section 505(b)(2) (&#8220;505(b)(2) NDA&#8221;), submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDCA alternatively provides three years of non-patent exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pediatric exclusivity is another type of marketing exclusivity available in the US. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to any existing periods of regulatory exclusivity or patent terms if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials, and a grant of pediatric exclusivity does not require the sponsor to obtain approval for the product candidate for pediatric use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Other Healthcare Laws</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, US federal and state anti-kickback, fraud and abuse, false claims, pricing reporting, and physician payment transparency laws and regulations regarding drug pricing and payments or other transfers of value made to physicians and other licensed healthcare professionals as well as similar foreign laws in the jurisdictions outside the US. Such foreign laws and regulations may be broader in scope than the provisions described above and may apply regardless of payor. These laws and regulations may differ from one another in significant ways, thus further complicating compliance efforts. For instance, in the EU, many EU member states have adopted specific anti-gift statutes that further limit commercial practices for medicinal products, in particular vis-&#224;-vis healthcare professionals and organizations. Additionally, there has been a recent trend of increased regulation of payments and transfers of value provided to healthcare professionals or entities and many EU member states have adopted national &#8220;Sunshine Acts&#8221; which impose reporting and transparency requirements (often on an annual basis), similar to the requirements in the US, on pharmaceutical companies. Certain countries also mandate implementation of commercial compliance programs, or require disclosure of marketing expenditures and pricing information.  Violation of any of such laws or any other governmental regulations that apply may result in significant penalties, including, without limitation, administrative civil and criminal penalties, damages, disgorgement fines, additional reporting requirements and oversight obligations, contractual damages, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs and/ or imprisonment.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidate for which we may seek regulatory approval. Sales in the US and in foreign jurisdictions will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by third-party payors.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. In the US, there is no uniform policy among payors for coverage or reimbursement. Decisions regarding whether to cover any of a product, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that can require manufacturers to provide scientific and clinical support for the use of a product to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Third-party payors may not consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Additionally, decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the US and in foreign jurisdictions, there has been, and continues to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the profitable sale of product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Among policy makers and payors in the US, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the US, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;) was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since its enactment, there have been judicial and political challenges to certain aspects of the ACA. On June 17, 2021, the US Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2032, with the exception of a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. In addition, on January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. On August 16, 2022, the Inflation Reduction Act of 2022, or ("IRA"), was enacted into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations.  HHS has issued and will continue to issue guidance implementing the IRA, although the Medicare drug price negotiation program is currently subject to legal challenges. While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Individual states in the US have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, certain individual states as well as regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs. The states of Louisiana and Washington used bidding procedures in 2019 and more recently Minnesota did so in 2021 to secure contracts with suppliers of HCV antiviral therapeutics for certain populations including those covered by Medicare and those in correctional institutions. Other states are currently engaged in similar discussions.  Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the EU, on December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment (&#8220;HTA&#8221;) was adopted. While the Regulation entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once applicable, it will have a phased implementation depending on the concerned products. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We expect that additional state, federal and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for drug products and healthcare services, which could result in reduced demand for our product candidates once approved or additional pricing pressures.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Data Privacy and Security</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Numerous state and federal laws, regulations and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information and could apply now or in the future to our operations or the operations of our partners. In the US, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. Further, certain foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. For additional information, see Part I, Item 1A, &#8220;Risk Factors&#8221;.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Government Regulation Outside of the US</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition to regulations in the US, we are subject to a variety of regulations in other jurisdictions, such as the EU, governing, among other things, clinical trials, marketing authorization and any commercial sales and distribution of our products once approved. Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. The requirements and processes governing the conduct of clinical trials, approval process, product licensing, pricing and reimbursement vary from country to country. Failure to comply with applicable foreign regulatory requirements may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Non-clinical studies and clinical trials</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Similar to the US, the various phases of non-clinical and clinical research in the EU are subject to significant regulatory controls.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical (pharmaco-toxicological) studies must be conducted in compliance with the principles of good laboratory practice (&#8220;GLP&#8221;) as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products &#8211; e.g., radio-pharmaceutical precursors for radio-labelling purposes). In particular, non-clinical studies, both </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (&#8220;ICH&#8221;) guidelines on Good Clinical Practices (&#8220;GCP&#8221;) as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation (&#8220;CTR&#8221;) which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">While the EU Clinical Trials Directive required a separate clinical trial application (&#8220;CTA&#8221;) to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application for multi-center</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the EU Clinical Trials Directive, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the EU Clinical Trials Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Medicines used in clinical trials must be manufactured in accordance with Good Manufacturing Practice (&#8220;GMP&#8221;). Other national and EU-wide regulatory requirements may also apply.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Marketing Authorization</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In order to market our future product candidates in the EU and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EU, medicinal product candidates can only be commercialized after obtaining a marketing authorization (&#8220;MA&#8221;). To obtain regulatory approval of a product candidate under EU regulatory systems, we must submit a MA application (&#8220;MAA&#8221;). The process for doing this depends, among other things, on the nature of the medicinal product. There are two types of MAs:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8220;Centralized MA&#8221; are issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) of the European Medicines Agency (&#8220;EMA&#8221;) and are valid throughout the EU. The centralized procedure is mandatory for certain types of product candidates, such as: (i) medicinal products derived from biotechnology processes, such as genetic engineering, (ii) designated orphan medicines, (iii) medicinal products containing a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases and (iv) advanced therapy medicinal products (&#8220;ATMPs&#8221;) such as gene therapy, somatic cell therapy or tissue-engineered medicines. The centralized procedure is optional for product candidates containing a new active substance not yet authorized in the EU, or for product candidates that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8220;National MAs&#8221; are issued by the competent authorities of the EU member states, only cover their respective territory, and are available for product candidates not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU member state, this national MA can be recognized in another member state through the mutual recognition procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member states through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the reference member state. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Under the centralized procedure the maximum timeframe for the evaluation of a MAA by the EMA is 210 days.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the EU, innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">PRIority MEdicines (&#8220;PRIME&#8221;) scheme, which provides incentives similar to the breakthrough therapy designation in the US. In March 2016, the EMA launched an initiative, the PRIME scheme, a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment, but this is not guaranteed. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the CHMP is appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s committee level. An initial meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, in the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and has to be renewed annually until fulfillment of all the conditions. Once the pending studies are provided, it can become a &#8220;standard&#8221; MA. However, if the conditions are not fulfilled within the timeframe set by the EMA, the MA ceases to be renewed. Furthermore, MA may also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. This may arise in particular when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This MA is close to the conditional MA as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a MA. However, unlike the conditional MA, the applicant does not have to provide the missing data and will never have to. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually, and the MA is withdrawn in case the risk-benefit ratio is no longer favorable.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Under the above-described procedures, in order to grant the MA, the EMA or the competent authorities of the EU member states make an assessment of the risk benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. MAs have an initial duration of five years. After these five years, the authorization may be renewed for an unlimited period on the basis of a reevaluation of the risk-benefit balance.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Data and Marketing Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The EU also provides opportunities for data and market exclusivity. Upon receiving MA, reference products generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, the data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial MA of the reference product in the EU. The overall 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Pediatric Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the EU, MAAs for new medicinal products have to include the results of studies conducted in the pediatric population, in compliance with a pediatric investigational plan ("PIP") agreed with the EMA&#8217;s Pediatric Committee ("PDCO"). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all the EU member states and study results are included in the product information, even when negative, the product is eligible for six months&#8217; supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a two-year extension of the orphan market exclusivity is granted.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The aforementioned EU rules are generally applicable in the European Economic Area (&#8220;EEA&#8221;) which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Brexit and the Regulatory Framework in the United Kingdom</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since the end of the Brexit transition period on January 1,2021, Great Britain (England, Scotland and Wales) has not been directly subject to EU laws, however under the terms of the Ireland/Northern Ireland Protocol, EU laws generally apply to Northern Ireland. The EU laws that have been transposed into United Kingdom (&#8220;UK&#8221;) law through secondary legislation remain applicable in Great Britain, however, new legislation such as the EU CTR is not applicable in Great Britain (&#8220;GB&#8221;). Under the Medicines and Medical Devices Act 2021, the Secretary of State or an &#8216;appropriate authority&#8217; has delegated powers to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials and medical devices.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since January 1, 2021, the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) has been the UK&#8217;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules will apply in Northern Ireland than in GB; broadly, Northern Ireland will continue to follow the EU regulatory regime, but its national competent authority will remain the MHRA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). On January 17, 2022, the MHRA launched an eight-week consultation on reframing the UK legislation for clinical trials which aimed to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The MHRA responded to the consultation on March 21, 2023 and confirmed that it would bring forward changes to the legislation. The final legal texts introduced by the UK Government will ultimately determine the extent to which the UK clinical trials framework aligns with or diverges from the EU CTR.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment and a rolling review procedure. All existing EU MAs for centrally authorized products were automatically converted or grandfathered into UK MAs, effective in GB (only), free of charge on January 1, 2021, unless the MA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">holder opted out. In order to use the centralized procedure to obtain a MA that will be valid throughout the EEA, companies must be established in the EEA. Therefore, since Brexit, companies established in the UK can no longer use the EU centralized procedure and instead an EEA entity must hold any centralized MAs. In order to obtain a UK MA to commercialize products in the UK, an applicant must be established in the UK and must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to obtain an MA to commercialize products in the UK. A new international recognition framework has been in place from January 1, 2024, whereby the MHRA will have regard to decisions on the approval of MAs made by the EMA and certain other regulators when determining an application for a new GB MA.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">There is no pre-MA orphan designation. Instead, the MHRA will review applications for orphan designation in parallel to the corresponding MA application. The criteria are essentially the same, but have been tailored for the market, i.e., the prevalence of the condition in GB, rather than the EU, must not be more than five in 10,000. Should an orphan designation be granted, the period of market exclusivity will be set from the date of first approval of the product in GB.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Human Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of February 28, 2024, we had 75 full-time employees, including 22 employees with M.D., Ph.D. or Pharm.D. degrees. Of these full-time employees, 53 employees are engaged in research and development activities. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our human capital resource priorities include attracting, recruiting, retaining, incentivizing and integrating our existing and new employees. The principal purpose of our competitive equity and cash compensation and benefits programs is to promote and support these priorities. We consider our human capital resources strategy to be comprehensive and built to foster our core way of working which is grounded on the principles of scientific rigor in a collaborative, entrepreneurial, and results-oriented manner. We plan to continue to evaluate our suite of human capital resources as we grow.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Organization</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Atea Pharmaceuticals, Inc. was incorporated in July 2012 and began principal operations in March 2014. Our principal office facilities are in Boston, Massachusetts. Atea Pharmaceuticals Securities Corporation, a Massachusetts corporation incorporated in 2016, is a wholly owned subsidiary of Atea Pharmaceuticals, Inc.  Our website is www.ateapharma.com. Information that is contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report on Form 10-K, and you should not consider information on our website to be part of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Available Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We make available free of charge on the investor relations portion of our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements for our annual meetings of stockholders, and amendments to those reports, as soon as reasonably practicable after we file such material with, or furnish it to, the Securities and Exchange Commission (&#8220;SEC&#8221;). These filings are available for download free of charge on the investor relations portion of our website located at https://ir.ateapharma.com. The SEC also maintains a website that contains reports, proxy statements and other information that we and other issuers file electronically with the SEC. The address of that website is https://www.sec.gov.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Information about our Executive Officers and Directors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table sets forth the name, age and position of each of our executive officers and directors as of the date of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.326%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1.02%;"/>
    <td style="width:4.038%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1.02%;"/>
    <td style="width:57.557%;"/>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:1.5pt solid #000000;vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td colspan="4" style="border-top:1.5pt solid #000000;vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="border-top:1.5pt solid #000000;vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Name</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Age</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Position</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Executive Officers</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Jean-Pierre Sommadossi, Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">67</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">President and Chief Executive Officer and Chairman of the Board of Directors</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Andrea Corcoran</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">61</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Chief Financial Officer, Executive Vice President, Legal and Secretary</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Janet Hammond, M.D., Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">63</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Chief Development Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Maria Arantxa Horga, M.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">55</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Chief Medical Officer</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">John Vavricka</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">60</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Chief Commercial Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Wayne Foster</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">55</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Executive Vice President and Chief Accounting Officer</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Directors</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Franklin Berger (1)(2)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">74</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Director (Lead Director)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Jerome Adams, M.D. (3)(4)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">49</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Director</span></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Barbara Duncan (1)(3)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">59</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Director</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Bruno Lucidi (1)(2)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">64</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Director</span></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Polly A. Murphy, D.V.M., Ph.D. (3)(4)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">59</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Director</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Bruce Polsky, M.D. (2)(4)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">69</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Director</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(1) Member of the Audit Committee.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(2) Member of the Compensation Committee.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(3) Member of the Nominating and Corporate Governance Committee.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(4) Member of the Strategy and Public Policy Committee.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Executive Officers</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Jean-Pierre Sommadossi, Ph.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, is the founder of our company and has served as our President and Chief Executive Officer and as Chairman of our Board since July 2012. Prior to that, he co-founded and held several roles at Idenix Pharmaceuticals, Inc., a biopharmaceutical company, from 1998 to 2010, including Principal Founder and Chief Executive Officer and Chairman. Dr. Sommadossi also co-founded Pharmasset, Inc., a biopharmaceutical company, in 1998. Dr. Sommadossi has also served on the board of directors of ABG Acquisition Corporation since February 2021, as Chairman of the board of directors of Panchrest, Inc., a marketing authorized representative in healthcare, since 2013, and Chairman of the board of directors of Biothea Pharma, Inc., a biotechnology company since 2021. Dr. Sommadossi has also served as a member of the board of directors of The BioExec Institute since 2004. Previously, Dr. Sommadossi served as Chairman of the board of directors of Kezar Life Sciences, Inc., a biopharmaceutical company, from June 2015 to May 2022, Vice Chairman of the board of directors of Rafael Pharmaceuticals, Inc., a biopharmaceutical company, from October 2016 to November 2020 and as Chair of the board of directors of PegaOne, Inc., a biopharmaceutical company from September 2020 to January 2021. Dr. Sommadossi also served as a member of the Harvard Medical School Discovery Council from 2010 to 2021 Dr. Sommadossi received his Ph.D. and Pharm.D. degrees from the University of Marseilles in France. We believe that Dr. Sommadossi&#8217;s extensive scientific, operational, strategic and management experience in the biotech industry qualifies him to serve on our Board.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Andrea Corcoran </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">has served as our Chief Financial Officer since October 2020, our Secretary since September 2014 and our Executive Vice President, Legal since December 2013. Ms. Corcoran also served as Executive Vice President, Administration from September 2014 to October 2020. Prior to joining us, Ms. Corcoran served as Senior Vice President, Strategy and Finance at iBio, Inc., a biotechnology company, from 2011 to 2012, as General Counsel and Secretary at Tolerx, Inc., a biopharmaceutical company, from 2007 to 2011, and as Executive Vice President of Idenix Pharmaceuticals, Inc. from 1998 to 2007. Ms. Corcoran received her J.D. from Boston College Law School and her B.S. from Providence College.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Janet Hammond, M.D., Ph.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, has served as our Chief Development Officer since August 2020. Prior to joining us, Dr. Hammond served at AbbVie, Inc., a biopharmaceutical company, from November 2016 to August 2020 as Vice President and Therapeutic Area Head for General Medicine and Infectious Disease Development and at F. Hoffmann-La Roche from March 2011 to November 2016 as Senior Vice President, Global Head of Infectious Diseases and Head of Pharmaceutical Research and Early Development China. Dr. Hammond received her M.D. and Ph.D. from the University of Cape Town, South Africa, and her Sc.M. in Clinical Investigation from Johns Hopkins University School of Hygiene and Public Health.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Maria Arantxa Horga, M.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, has served as our Chief Medical Officer since January 2021 and previously served as our Acting Chief Medical Officer since October 2020 and as Executive Vice President, Clinical Sciences since August 2020. Prior to joining us, Dr. Horga served as Vice President, Pharmacovigilance and Medical Affairs at Biohaven Pharmaceuticals from October 2019 to August 2020. Prior to that, Dr. Horga served as Vice President, Global Head of Clinical Program Execution, Site Head of the Roche NY Innovation Center from July 2017 to August 2019, and as Global Head of Translational Medicine, Infectious Diseases at F. Hoffmann-La Roche from 2012 to 2016. Dr. Horga received her M.D. from the Santander School of Medicine and completed her residency in Pediatrics and a fellowship in Pediatric Infectious Diseases at the Mount Sinai School of Medicine.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">John Vavricka </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">has served as our Chief Commercial Officer since October 2018. Prior to joining us, Mr. Vavricka co-founded and served as the Chief Executive Officer of Biothea Pharma, Inc., a biotechnology company, from March 2018 to June 2021. Prior to that Mr. Vavricka founded and served as the Chief Executive Officer and President of Iroko Pharmaceuticals, Inc., a global pharmaceuticals company, from 2007 to 2015. Mr. Vavricka received his B.S. from Northwestern University.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Wayne Foster </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">has served as our Executive Vice President, Finance and Chief Accounting Officer since January 2022 and previously served as Senior Vice President, Finance and Administration from December 2019 to January 2022. Prior to joining us, Mr. Foster served as Vice President of Finance at Mersana Therapeutics, Inc., a biopharmaceutical company, from January 2012 to September 2019. Mr. Foster received his B.B.A. from the University of Massachusetts Amherst.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Directors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Franklin Berger </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">has served as a member and the Lead Director of our Board since September 2019. Mr. Berger has served as Founder and Managing Director at FMB Research LLC, a consulting firm, since June 2005. Mr. Berger also has served on the boards of directors of ESSA Pharma Inc. since March 2015, Kezar Life Sciences, Inc. since January 2016, Atreca Inc. since October 2014, Rain Therapeutics Inc. since May 2020 and as lead director of Rain Therapeutics Inc. since April 2021. Mr. Berger previously served on the boards of directors of BELLUS Health, Inc. from May 2010 to June 2023, Tocagen, Inc. from October 2014 to December 2020, of Proteostasis Therapeutics, Inc. from February 2016 to December 2020, and of Five Prime Therapeutics, Inc. from October 2014 to April 2021. Mr. Berger received his B.A. and M.A. from Johns Hopkins University and his M.B.A. from Harvard Business School. We believe that Mr. Berger&#8217;s financial background and experience as an equity analyst in the biotechnology industry combined with his experience serving on the boards of directors of multiple public companies qualifies him to serve on our Board.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Jerome Adams, M.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, has served as a member of our Board since May 2021. Dr. Adams also has served as Director of Health Equity Initiatives at Purdue University since October 2021. Dr. Adams served as the 20</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> Surgeon General of the US from September 2017 to January 2021, where he focused on the opioid epidemic and was a member of the COVID-19 Task Force. Prior to that, Dr. Adams served as the State Health Commissioner for the State of Indiana from November 2014 to September 2017, where he presided over Indiana&#8217;s efforts to deal with state-wide, unprecedented HIV outbreak. Before beginning his public service in 2014, Dr. Adams was a practicing anesthesiologist and Associate Professor in the Department of Anesthesiology at Indiana University from January 2008 to September 2017. Earlier in his career, Dr. Adams was a Clinical Research Assistant at Eli Lilly and Company. He has served in leadership positions at a number of professional organizations, including the American Medical Association, the Indiana State Medical Association, and the Indiana Society of Anesthesiologists. Dr. Adams received his B.S. in Biochemistry and B.A. in Psychology from the University of Maryland, Baltimore County, his M.D. from the Indiana University School of Medicine and his M.P.H. from the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">University of California, Berkeley. We believe that Dr. Adams&#8217; extensive public sector experience, including his work on the COVID-19 Task Force, qualifies him to serve on our board.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Barbara Duncan </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">has served as a member of our Board since October 2020. Ms. Duncan served at Intercept Pharmaceuticals, Inc. as Chief Financial Officer and Treasurer from May 2009 to June 2016. Ms. Duncan also has served as Chair of the board of directors of Fusion Pharmaceuticals Inc. since November 2020, and on the boards of directors of Ovid Therapeutics, Inc. since June 2017, and Halozyme, Inc. since February 2023. Previously, Ms. Duncan served on the boards of directors of Jounce Therapeutics, Inc. from June 2016 to May 2023, Adaptimmune Therapeutics plc from June 2016 to June 2023, Immunomedics, Inc. from March 2019 to October 2020, Innoviva, Inc., from November 2016 through April 2018, Aevi Genomic Medicine, Inc., from June 2015 through January 2020, and ObsEva S.A. from November 2016 to May 2021. Ms. Duncan received her B.A. from Louisiana State University and her M.B.A. from the Wharton School, University of Pennsylvania. We believe Ms. Duncan is qualified to serve on our Board due to her experience in the biotechnology industry and with public companies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Bruno Lucidi </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">has served as a member of our Board since September 2014. Mr. Lucidi has served as an independent consultant to biotechnology companies since July 2013. Mr. Lucidi served as a Life Sciences Expert at Wallonia Trade and Foreign Investment Agency, an economic development agency, from January 2017 to June 2020. From October 2017 to September 2019, Mr. Lucidi was Chief Executive Officer at AgenTus Therapeutics, a pre-clinical stage biopharmaceutical company. Mr. Lucidi has more than 35 years of experience in the pharmaceutical industry. He held Senior Executive positions at Bristol-Myers Squibb, Johnson and Johnson and GSK and he has been CEO and Chairman of the board of several biopharmaceutical companies in Europe and the US. Mr. Lucidi was trained in Oncology at the Gustave Roussy Institute, Villejuif, France, in Marketing and Strategic Management of Companies at the Ecole Superieure de Commerce, Paris, France, and in Finance, Merger and Acquisitions at the Investment Banking Institute in New York. We believe Mr. Lucidi is qualified to serve on our Board due to his extensive experience in the life sciences industry.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Polly A. Murphy, D.V.M., Ph.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">has served as a member of our Board since August 2020. Dr. Murphy has served as Chief Business Officer at UroGen Pharma, Inc. since August 2020. Prior to that, Dr. Murphy served in various leadership roles at Pfizer, Inc. from September 2008 to August 2020, including as Vice President and Head of Commercial Development Pfizer Oncology Business Unit from January 2019 to August 2020, Vice President and Head of Global Marketing and Commercial Development Pfizer Oncology Business Unit from June 2017 to December 2018, and as Vice President and Head of Strategy and Business Development for Pfizer China from November 2013 to May 2018. Dr. Murphy has served on the board of directors of Celcuity Inc. since September 2022. Dr. Murphy received her D.V.M. and Ph.D. from Iowa State University. We believe Dr. Murphy is qualified to serve on our Board due to her experience in the pharmaceutical industry in business development and commercialization.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Bruce Polsky, M.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, has served as a member of our Board since November 2014. Dr. Polsky is the chair of the Department of Medicine at NYU Langone Hospital &#8211; Long Island in Mineola, New York, where he has practiced since May 2015. He also has served as professor and Chair of the Department of Medicine at NYU Long Island School of Medicine and as an Associate Dean at NYU Long Island School of Medicine since February 2019. Dr. Polsky is a leading clinical virologist who played an active role in clinical investigations of HIV/AIDS, HBV, HCV and other viral infections. From December 1998 to May 2015, Dr. Polsky was at Mount Sinai St. Luke&#8217;s and Mount Sinai Roosevelt Hospitals, where he served as Chair of the Department of Medicine and as Chief of the Division of Infectious Diseases, among other positions. Dr. Polsky received his M.D. from Wayne State University. We believe Dr. Polsky is qualified to serve on our Board due to his extensive clinical experience in the life sciences industry.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">1A. Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">You should carefully consider the risks and uncertainties described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition.&#8221; Our business, financial condition, results of operations or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common stock could decline and you could lose all or part of your investment. Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors, including those set forth below as well as other events that we do not currently anticipate or other events that we currently deem immaterial.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Related to the Development of Product Candidates for the Treatment of COVID-19</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">There is significant uncertainty around our development of bemnifosbuvir as a potential treatment for COVID-19.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since the start of the COVID-19 pandemic, we have focused substantive efforts on the development of bemnifosbuvir for the treatment of COVID-19. We may not succeed in developing, securing market authorization or approval, or commercializing bemnifosbuvir as a potential treatment for COVID-19.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In October 2020, we entered into the Roche License Agreement with Roche under which we granted to Roche an exclusive license to development and commercialization rights related to certain of our compounds, including bemnifosbuvir, outside of the US (other than for certain HCV uses). In November 2021, Roche notified us that it was terminating the Roche License Agreement effective February 10, 2022. In December 2021, due to the changing COVID-19 treatment landscape, including the availability of new oral antiviral treatment regimens, and the termination of the collaboration with Roche, we determined to discontinue each of the Phase 3 MORNINGSKY and MEADOWSPRING clinical trials. We did not enroll a sufficient number of patients in either Phase 3 study to conduct prespecified statistical analyses. In January 2022 we determined to close out the Phase 2 clinical trial in hospitalized patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Nonetheless, we are advancing the development of bemnifosbuvir for the treatment of COVID-19 in high-risk non-hospitalized patients pursuing both a mono- and combination therapy strategy. We do not know if either monotherapy or combination therapy approach will be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Currently, we are conducting SUNRISE-3, a global, multicenter, randomized, double blind, placebo-controlled Phase 3 clinical trial evaluating bemnifosbuvir (550 mg BID for 5 days) in high-risk non-hospitalized patients with mild or moderate COVID-19. For the description of this trial, please see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Part 1, Item 1, "Business"</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. There are two interim analyses for review by the DSMB principally for safety and futility after approximately 650 and 1,350 patients in the supportive care monotherapy cohort have completed Day 29.  We currently anticipate that the first interim analysis by the DSMB will occur in March of 2024 and that the second interim analysis by the DSMB will occur in the second quarter of 2024.  At either interim analysis, the DSMB may determine that there are safety concerns or that the study as currently designed is futile.  In this instance, we would be required to either discontinue the study or if recommended by the DSMB make amendments to the study.  If feasible to implement, it is possible that such amendments, would make the trial more difficult to complete, if possible at all, and the time and cost for completion of the trial would be expected to increase.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In parallel with the conduct of SUNRISE-3, we are also engaging in efforts to identify a proprietary protease inhibitor product candidate that could potentially be combined with bemnifosbuvir for the treatment of COVID-19.  Our efforts to develop a potential protease inhibitor to evaluate in combination with bemnifosbuvir are at a very early stage and we do not know if such efforts will be successful, or if successful, when such a protease inhibitor product candidate we identify may be permitted to enter clinical development. Before we can begin clinical development of a newly identified protease inhibitor product candidate, or any other product candidate, we will need to complete extensive preclinical studies to support the submission of an IND to the FDA or CTA to a comparable regulatory authority outside the US.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Alternatively, we may in-license or acquire the rights to develop and commercialize a protease inhibitor drug candidate from a third-party. Proposing, negotiating and implementing acquisition or in-license of a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">protease inhibitor or any other product candidate that may be combined with bemnifosbuvir for the potential treatment of COVID-19 may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing and sales resources, may compete with us for the acquisition of such product candidates. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, if at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, clinical trials evaluating combination regimens are subject to additional costs, time and risks, including the requirement to sufficiently demonstrate the effect, if any, of each constituent component of the combination regimen to the satisfaction of the FDA or other regulatory authorities.  For example, we expect that we will be required to conduct early-stage clinical trials evaluating the safety of any newly discovered protease inhibitor candidate before we can conduct later stage clinical trials evaluating the combination of bemnifosbuvir with such protease inhibitor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have committed and plan to continue to commit significant financial and personnel resources to the development of bemnifosbuvir as a monotherapy, to the discovery of a protease inhibitor candidate to combine with bemnifosbuvir and to the combination of bemnifosbuvir and a protease inhibitor candidate for the treatment for COVID-19 (each, a &#8220;bemnifosbuvir COV19 product candidate&#8221;). If we are unable to successfully develop one or more bemnifosbuvir COV19 product candidates, we will have taken resources away from other development programs and may not be able to recuperate the resources dedicated to developing bemnifosbuvir COV19 product candidates, which could have a material adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we are unable to complete the SUNRISE-3 clinical trial in the manner or on the timeline we anticipate or if data from our Phase 3 SUNRISE-3 clinical trial and other clinical trials are not supportive of further development or commercialization of one or more bemnifosbuvir COV19 product candidates, or the investor community otherwise has a negative reaction to any of the design of our clinical trial, expected time to complete our clinical trial or the clinical trial data, the demand for our common stock could decrease significantly, and the price of our common stock could decline substantially, which could result in significant losses for our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Further, while we believe there is currently an urgent need for additional oral antiviral treatments for COVID-19, the longevity and extent of future market demand for new oral antiviral treatments is uncertain. If the serious health consequences associated with COVID-19 and infection with SARS-CoV-2 variants or subvariants were to dissipate for all persons, including those currently at high-risk for severe disease, the need for new treatments could decrease significantly.   This reduction in incidence of serious health consequences could occur as a result of multiple factors including a significant and sustained decrease in the number or severity of new infections, an increase in the uptake and effectiveness of current and future vaccines and the introduction of other treatment options.   If the need for a new treatment decreases before or soon after commercialization of a bemnifosbuvir COV19 product candidate, if successfully developed and approved, our business would be adversely impacted.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">A bemnifosbuvir COV19 product candidate, even if successfully developed and approved, is expected to face significant competition from other treatments and vaccines for COVID-19 which have been authorized or approved for use or are in development.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Many biotechnology and pharmaceutical companies have and are continuing to develop treatments for COVID-19 or vaccines against SARS-CoV-2, the virus that causes COVID-19. Many of these companies, which include large pharmaceutical companies, have greater resources for development and established commercialization capabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Currently in the US and elsewhere, there are therapeutics available for the treatment of COVID-19 including two oral antiviral therapies, Paxlovid&#153; developed by Pfizer which has been approved by the FDA, and Lagevrio&#153; developed by Merck and Ridgeback Therapeutics, which is authorized by FDA for emergency use for the treatment of high-risk COVID-19 patients. Additionally, Veklury&#174;, a nucleotide prodrug developed by Gilead Sciences, is approved for the treatment of COVID-19 in adults and pediatric patients who are hospitalized or if not hospitalized have mild to moderate COVID-19 and are at high-risk for progression to severe COVID-19, including hospitalization and death. In Japan, the oral protease inhibitor, ensitrelvir, branded Xocova&#174; developed and marketed by Shionogi, has been granted special approval for emergency use in patients with mild to moderate SARS-CoV-2 infection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">        </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the US and other territories outside Japan, Shionogi continues to develop ensitrelvir and is currently conducting a global development program including four Phase 3 trials evaluating ensitrelvir for the treatment of COVID-19.  Additionally, Pfizer is conducting development of a second generation oral protease inhibitor. Other companies developing oral direct acting antivirals for treatment of COVID-19 include Junshi Biosciences, Jiangsu Simcere Pharmaceuticals, and SyneuRx.   Efforts to develop new mAbs for the treatment of COVID-19 are also ongoing and being conducted by Regeneron Pharmaceuticals Inc. and Invivyd, Inc. among others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition to therapeutics, in the US and elsewhere, vaccines indicated for active immunization to prevent COVID-19 and associated vaccine updates which are intended to extend the immunizing effect initiated with the administration of the initial vaccine have been approved or authorized for emergency use.  Vaccine manufacturers, including Pfizer and BioNTech SE and Moderna, Inc., are continuing to develop new vaccines and vaccine updates that may have greater and longer immunizing effects against current and future variants of SARS-CoV-2.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In 2023, the US federal government announced the Project NextGen initiative with the purpose to accelerate and streamline the rapid development of the next generation of vaccines and treatments through public-private collaborations.  Based at HHS and seeded with an initial investment of $5 billion, Project NextGen is coordinating across the US federal government and the private sector to fund and advance a pipeline of new, innovative vaccines and mAbs into clinical trials and potential review by the FDA.  Project NextGen is focusing on mucosal vaccines, vaccines that provide broader protection against variants of concern and a longer duration of protection, pan-coronavirus vaccines, new mAbs that are more durable and resilient against new variants, and advancing new technologies that will improve access and enable faster, cheaper, rapid and more flexible production of vaccines and therapeutics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Given the products currently approved or authorized for use as well as those in development by others, any treatment we may develop could face significant competition. If we are unable to develop a treatment that can be distinguished based on efficacy, safety, cost or other factors from the growing number of treatments for COVID-19 or if any treatment becomes the standard of care, can be administered more conveniently or at a lower cost, or any entity is more successful at commercializing an authorized or approved treatment, even if a bemnifosbuvir COV19 product candidate is approved, we may not be able to successfully commercialize such a product for the treatment of COVID-19, or compete with other treatments or vaccines, which would adversely impact our business and operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our business, operations and financial results may be adversely affected by the continuing evolution of COVID-19.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The evolving and constantly changing impact of COVID-19, which was declared a global pandemic by the WHO in March 2020, will directly affect the potential commercial prospects of our product candidates for the treatment of COVID-19. In May 2023, three years into the pandemic, the WHO determined that COVID-19 no longer fit the definition of the public health emergency of international concern. While noting that this determination did not mean that the pandemic itself is ended, the WHO concluded that the global emergency COVID-19 has caused is ended for the time being. In reaching this conclusion, the WHO considered evidence of reducing risks to human health driven mainly by high population-level immunity from infection, vaccination or both; consistent virulence of currently circulating SARS-CoV-2 Omicron sub-lineages and improved clinical case management.  Further, the WHO considered that these factors have contributed to a decline in the weekly number of COVID-19 related deaths and hospitalizations since the beginning of the pandemic and that while SARS-CoV-2 continues to evolve, the currently circulating variants do not appear to be associated with increased severity.  The WHO currently classifies COVID-19 as an established and ongoing health issue.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The rates of infection, severity of the disease, the availability, administration and acceptance of vaccines, monoclonal antibodies, antiviral agents and other therapies, potential vaccine mandate policies, and &#8220;herd immunity&#8221; by the global population if achieved and sustained may materially affect the design and will impact the enrollment of our clinical trials, the potential regulatory authorization or approval of our bemnifosbuvir COV19 product candidates and the commercialization of our bemnifosbuvir COV19 product candidates, if authorized or approved.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Pandemics, epidemics or outbreaks of an infectious disease may materially and adversely impact our business, including our preclinical studies and clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If other pandemics, epidemics or outbreaks of infectious disease occur in the future, we may experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delays or difficulties in enrolling patients in our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">diversion of health care resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">interruptions in preclinical studies due to restricted or limited operations resulting from restrictions on our on-site activities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">interruption or delays to activities we outsource to third parties.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we or any of the third parties with whom we engage were to experience shutdowns or other business disruptions due to pandemics, epidemics or outbreaks of infectious disease, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Related to Our Financial Condition and Capital Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We have a limited operating history and no history of successfully developing or commercializing any approved antiviral products, which may make it difficult to evaluate the success of our business to date and to assess the prospects for our future viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are a clinical-stage biopharmaceutical company. Our operations to date have been limited to financing and staffing our company, developing our technology, and identifying and developing our product candidates. Our prospects must be considered in light of the uncertainties, risks, expenses and difficulties frequently encountered by biopharmaceutical companies in their early stages of operations. We have not yet demonstrated an ability to complete any late-stage or pivotal clinical trials, obtain marketing approval, manufacture a product at commercial-scale, or conduct sales and marketing activities necessary for successful product commercialization, or have third parties to do these activities on our behalf. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing, obtaining marketing approval for and commercializing antiviral therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown obstacles in developing or commercializing our products. For example, in November 2022, we initiated SUNRISE-3, the Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of high risk outpatients with mild or moderate COVID-19. Our initial SUNRISE-3 study design and sample size</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">contemplated that the rate of hospitalization in the placebo cohort would be at least 4%.  Since the initiation of the study, there has been a decline in the observed rate of hospitalization in the general population to below 4%. To address this, in August 2023, we amended the SUNRISE-3 clinical trial protocol to, among other things, take into account this lower rate of hospitalization with the effect that the study sample size was increased to approximately 2,200 patients in the supportive care monotherapy population in comparison to our initial target sample size of 1,300 patients in the supportive care monotherapy population.  With the current sample size of 2,200 patients in the supportive care monotherapy population, we believe that the study is adequately powered for target rates of hospitalization and death of approximately 2 to 3% in patients who are at high-risk for disease progression.  If the actual rate of hospitalization in the placebo cohort of patients is less, the DSMB evaluating the data at either of two interim analyses may determine that the study as currently designed is futile.  In this instance, we would be required to either discontinue the study or if recommended by the DSMB make amendments to the study.  If feasible to implement, it is possible that such amendments, would make the trial more difficult to complete, if possible at all, and the time and cost for completion of the trial would be expected to increase.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As the COVID-19 landscape has evolved, rates of testing, diagnosis and hospitalization for COVID-19 have varied and continue to vary substantially.  Reported rates of hospitalization in many geographic regions have and may continue to fluctuate significantly.  Additionally, we believe that the current rate of testing is substantially lower than the rate of testing occurring throughout earlier phases of the COVID-19 pandemic.  Further, it is uncertain what effect the migration of government provided therapeutics, testing kits and other related items to more traditional health channels will have on rates of testing and diagnoses among other things. Even the perception that patients will now incur costs associated with the testing for and treatment of COVID-19 may result in rates of testing and treatment to further decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we successfully develop and obtain approval of any product candidate, we will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in this transition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results included in this report or reports for any other particular prior quarterly or annual period as indications of future operating performance.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We have incurred significant operating expenses since inception and expect to incur significant additional operating expenses for the foreseeable future. We have no products that have generated any commercial revenue.  We expect to incur operating losses in 2024 and for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have incurred significant operating expenses since our inception. For the years ended December 31, 2023 and 2022, our operating expenses were $164.2 million and $130.7 million, respectively. As of December 31, 2023, we had an accumulated deficit of $195.8 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have not commercialized any products and have never generated any revenue from product sales. We have devoted almost all of our financial resources to research and development, including our clinical trials and preclinical development activities. We expect to continue to incur significant additional operating expenses and to incur operating losses for the foreseeable future as we seek to advance product candidates through clinical development, continue preclinical development, expand our research and development activities, discover or acquire and develop product candidates, including any product candidate we may seek to combine with bemnifosbuvir for the potential treatment of COVID-19, complete preclinical studies and clinical trials, seek regulatory approval and, if we receive regulatory approval, commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In order to obtain the FDA&#8217;s or a foreign regulatory authority&#8217;s approval to market any product candidate in the US or abroad, respectively, we must submit to the FDA an NDA or similar application to the foreign regulatory authority demonstrating to the FDA&#8217;s or foreign regulatory authority&#8217;s satisfaction that the product candidate is safe and effective for its intended use(s). This demonstration requires significant research and extensive data from animal tests, which are referred to as nonclinical or preclinical studies, as well as human tests, which are referred to as clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Furthermore, the costs of advancing product candidates into each succeeding clinical phase tend to increase substantially over time. The total costs to advance any of our product candidates to marketing approval in even a single jurisdiction would be substantial and difficult to accurately predict. Because of the numerous risks and uncertainties associated with the development of drug products, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of products or again achieve profitability. As we advance clinical development activities, particularly our Phase 3 SUNRISE-3 clinical trial for the treatment of high-risk outpatients with mild or moderate COVID-19 and our Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of HCV, our expenses have increased and we expect will continue to increase substantially. Additionally, our expenses will also increase substantially if or as we:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">initiate clinical trials of a potential bemnifosbuvir combination regimen for the treatment of patients with COVID-19; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">continue to discover and develop additional product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">seek regulatory and marketing approvals for product candidates that successfully complete clinical trials, if any; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">establish manufacturing and supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain marketing approval, if any; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">establish a sales, marketing, internal systems and distribution infrastructure to commercialize any products for which we may obtain regulatory approval, if any, in geographies in which we plan to commercialize our products ourselves or with co-promotion collaborators;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">maintain, expand, protect and enforce our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">hire additional staff, including clinical, scientific, technical, regulatory, operational, financial, commercial and support personnel, to execute our business plan and support our product development and potential future commercialization efforts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">more extensively utilize external vendors for support with respect to research, development, manufacturing, commercialization, regulatory, pharmacovigilance and other functions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">acquire or in-license commercial products or additional product candidates and technologies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">make milestone, royalty or other payments under the Merck License Agreement with respect to the development and commercialization of ruzasvir in combination with bemnifosbuvir for the treatment of HCV;   </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">make upfront, milestone, royalty or other payments in connection with any future in-license agreements relating to other product candidates; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">incur continuing and increasing legal, accounting and other expenses in operating our business as a public company. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Furthermore, our ability to successfully develop, commercialize and license any products and generate product revenue is subject to substantial additional risks and uncertainties. Each of our product candidates and any future product candidate we may discover, license or otherwise acquire, will require additional preclinical and/or clinical development, regulatory approval in not less than one jurisdiction, the securing of manufacturing supply, capacity, distribution channels and expertise, the use of external vendors, the building of or other access to a commercial organization, substantial investment and significant marketing efforts before we generate any revenue from product sales. As a result, we expect to continue to use cash for operating activities and incur operating expenses and operating losses for the foreseeable future. The use of cash and incurrence of operating expenses and operating losses has had, and we expect will continue to have, an adverse effect on our working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The amount of future expenses or losses and our ability to achieve or maintain profitability in future years, if ever, are uncertain. We have no products that have generated any commercial revenue, do not expect to generate revenues from the commercial sale of products in the near term, and might never generate revenues from the sale of products. Our ability to generate product revenue and maintain profitability will</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">depend on, among other things, successful completion of the clinical development of our product candidates; obtaining necessary regulatory approvals from the FDA and foreign regulatory authorities; establishing manufacturing and sales capabilities; market acceptance of our products, if approved, and establishing marketing infrastructure or otherwise arranging to commercialize our product candidates for which we obtain approval; and raising sufficient funds to finance our activities. We might not succeed at any of these undertakings. If we are unsuccessful at some or all of these undertakings, our business, prospects, and results of operations may be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We maintain our cash at financial institutions, often in balances that exceed federally insured limits.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The majority of our cash is held in accounts at US banking institutions. Cash held in depository accounts may exceed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) standard deposit insurance limit of $250,000. If such banking institutions were to fail, such as Silicon Valley Bank when the FDIC took control in March 2023, we could lose all or a portion of those amounts held in excess of such insured amounts. In the future, our access to our cash in amounts adequate to finance our operations could be significantly impaired if the financial institutions with which we have arrangements encounter liquidity constraints or failures. Any future limitation on timely access to our funds or any material loss that we may experience in the future could have a material adverse effect on our financial condition and could materially impact our ability to pay our operating expenses or make other payments.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We will require substantial additional financing, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since inception, we have incurred substantial operating expenses. We expect to incur substantial expenses in connection with our current and planned business activities, particularly the conduct of the Phase 3 SUNRISE-3 clinical trial for the treatment of high-risk outpatients with mild or moderate COVID-19, our Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of HCV, and if the Phase 2 clinical trial is successful, Phase 3 clinical development of this HCV combination product candidate.  Additionally, we anticipate that we will incur substantial expenses in connection with the discovery, license or other acquisition and potential development of a combination bemnifosbuvir COV19 product candidate and in connection with the discovery, acquisition and development of other product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We will continue to need additional capital to fund future clinical trials and preclinical development, which we may raise through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. Additional sources of financing might not be available on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we might be unable to initiate or complete planned clinical trials or seek regulatory approvals of any of our product candidates from the FDA, or any foreign regulatory authorities, and could be forced to discontinue product development. In addition, attempting to secure additional financing could divert the time and attention of our management from day-to-day activities and may harm our product candidate development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Based on our current operating plan, we believe that our cash and cash equivalents as of December 31, 2023 will be sufficient to fund our operating expenses and capital expenditure requirements through 2026. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We will require significant additional funds in order to launch and commercialize our current and any future product candidates to the extent that such launch and commercialization are not the responsibility of a collaborator. In addition, other unanticipated costs may arise in the course of our development efforts. Because the design and outcome of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and, if approved, commercialization of any product candidate we develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The timing and amount of our future capital requirements will depend on many factors, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the scope, progress, results and costs of our preclinical studies and clinical trials, in particular our Phase 3 SUNRISE-3 clinical trial for the treatment of COVID-19 and our current Phase 2 and any potential Phase 3 clinical development of the combination of bemnifosbuvir and ruzasvir for the treatment of HCV;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the timing of and costs associated with discovery, license or acquisition of a protease inhibitor or another direct acting antiviral product candidate to combine with bemnifosbuvir and develop for the treatment of patients with COVID-19;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the timing of, and the costs involved in, obtaining marketing approvals for our current and future product candidates in regions where we choose to commercialize any products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the number of future product candidates and potential additional indications that we may pursue and their development requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the stability, scale, yield and cost of manufacturing our product candidates for clinical trials, in preparation for regulatory approval and in preparation for commercialization; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the costs of manufacturing and commercialization activities for any approved product candidate to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of manufacturing commercial supply at a scale to meet demand and the costs and timing of establishing capabilities for and conducting product sales, marketing, distribution activities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the costs, timing and changes in pharmaceutical pricing and reimbursement infrastructure resulting from, among other things, the enactment of the IRA and other legislation and regulations that may be subsequently enacted; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to compete with other therapies in the indications we target; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the extent to which we in-license or acquire rights to products, product candidates or technologies in addition to ruzasvir; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the continued growth of our headcount and associated costs as we expand our research and development capabilities and establish a commercial infrastructure; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications and maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property-related claims; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the continued costs of operating as a public company. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Currently, we do not have any committed external source of funds or other support and we cannot be certain that additional funding will be available on acceptable terms, or at all.   Our ability to access potential sources of future liquidity and raise funds will depend upon financial, economic and geopolitical conditions and other factors, many of which are beyond our control. These external factors, including high rates of interest and inflation, will also impact and may increase substantially costs we incur in connection with any potential fundraising.  If we are unable to raise additional capital in sufficient amounts, on terms acceptable to us, or on a timely basis, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We have not generated any revenue from product sales and may not be able to achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We incurred a net loss of $136.0 million and $115.9 million for the years ended December 31, 2023 and 2022, respectively. Our ability to achieve and sustain future profitability depends upon our ability to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">generate revenue from product sales.  We have not generated product revenue and we do not expect to generate product revenue unless or until we successfully complete clinical development and obtain regulatory approval of, and then successfully commercialize, at least one of our product candidates. Our product candidates are in varying stages of development, which is expected to necessitate additional preclinical studies in some cases and in all cases will require additional clinical development as well as regulatory review and approval, substantial investment in and access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. Currently, we do not anticipate generating revenue from product sales for at least the next few years. Our ability to generate revenue depends on a number of factors, including, but not limited to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">timely completion of our clinical trials, including our Phase 3 SUNRISE-3 clinical trial for the treatment of high-risk outpatients with mild to moderate COVID-19 on the timeline we anticipate, the ongoing Phase 2 trial and any subsequent Phase 3 trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of HCV, potential clinical trials evaluating a bemnifosbuvir combination regimen for the treatment of COVID-19, preclinical studies and other future clinical trials of other product candidates, each of which may be significantly slower or more costly than we currently anticipate and will depend substantially upon the performance of third-party contractors;  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to complete additional IND enabling studies and successfully submit INDs, CTAs or comparable applications to allow us to initiate clinical trials for any other product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">whether we are required by the FDA or similar foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to demonstrate to the satisfaction of the FDA or similar foreign regulatory authorities the safety and efficacy of our product candidates or any future product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future product candidates, if any; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the timely receipt of necessary marketing approvals from the FDA or similar foreign regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the availability, actual and perceived advantages and relative cost, convenience, safety and efficacy of any bemnifosbuvir COV19 product candidate or HCV product candidate we may be able to commercialize, compared to other COVID-19 and HCV therapies, as well as the accuracy and sufficiency of clinical evidence supporting any such advantages of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the willingness of physicians, operators of clinics and patients to conduct or participate in clinical trials evaluating our product candidates and, if successfully developed, to utilize or adopt any of our product candidates or future product candidates that may be approved as antiviral therapies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability and the ability of third parties with whom we contract to manufacture adequate clinical and commercial supplies of our current or future product candidates, remain in good standing with regulatory authorities and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices (&#8220;cGMP&#8221;) or similar requirements outside the US; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to successfully establish a commercial strategy and thereafter commercialize our current or future product candidates, in the US and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to establish, maintain, protect and enforce intellectual property rights in and to our product candidates or any future product candidates. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Many of the factors listed above are beyond our control, and could cause us to experience significant delays, incur substantially greater expenses than anticipated or prevent us from obtaining regulatory approvals or commercializing our product candidates. Even if we are able to commercialize our product candidates, we may not be able to achieve and maintain profitability after generating product sales or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our profitability, the value of our common stock will be materially adversely affected. In addition, if we are unable to generate sufficient revenue through the sale of any products, we may be unable to continue operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss carryforwards and other tax attributes to offset taxable income may be subject to certain limitations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, we had US federal net operating loss carryforwards (&#8220;NOLs&#8221;), of $31.4 million, which may be available to offset future taxable income, if any, of which $0.4 million begin to expire in 2034 and of which $31.0 million do not expire but are limited in their usage in future tax years to an annual deduction equal to 80% of annual taxable income. In addition, as of December 31, 2023, we had state NOLs of $55.3 million, which may be available to offset future taxable income, if any, and begin to expire in 2042.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (&#8220;Code&#8221;), a corporation that undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change by value in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and its research and development credit carryforwards to offset future taxable income. Our NOLs and research and development credit carryforwards may be subject to limitations arising from previous ownership changes, and if we undergo an ownership change, our ability to utilize NOLs (to the extent not previously utilized) and research and development credit carryforwards could be further limited by Sections 382 and 383 of the Code.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For each of the years ended December 31, 2023 and 2022, we have completed a Section 382 study, the results of which indicated that no ownership shift occurred during such respective period. However, this conclusion could be challenged by tax authorities. In addition, future changes in our stock ownership, some of which might be beyond our control, could result in an ownership change under Sections 382 and 383 of the Code. For these reasons, we may not be able to utilize existing NOLs or research and development credit carryforwards or net operating losses and research and development credits that may be generated in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may delay, suspend or terminate the development of a product candidate at any time if we believe the perceived market or commercial opportunity does not justify further investment or for other strategic business, financial or other reasons, which could materially harm our business and adversely affect our stock price.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Even if the results of preclinical studies and clinical trials that we have conducted or may conduct in the future may support further development of one or more of our product candidates, we may delay, suspend or terminate the future development of a product candidate at any time for strategic, business, financial or other reasons, including the determination or belief that the emerging profile of the product candidate is such that it may not receive regulatory approvals in key markets, gain meaningful market acceptance, otherwise provide any competitive advantages in its intended indication or market or generate a significant return to stockholders. For example, in February 2023, after advancing AT-752 into a Phase 2 clinical trial, we decided not to pursue further clinical development of AT-752 for the treatment and prophylaxis of dengue.  This action was taken due to the anticipated long timelines and other challenges associated with the clinical development of an antiviral for the treatment of dengue. This action and any other similar delays, suspensions or terminations of other clinical programs or product candidates could materially harm our business, results of operations or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Related to the Discovery, Development, Preclinical and Clinical Testing, Manufacturing and Regulatory Approval of Our Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our business is highly dependent on our ability to develop one or more bemnifosbuvir COV19 product candidates. If we are not successful in developing a bemnifosbuvir COV19 product candidate, our business will be harmed.  Our business is also highly dependent on the success of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">our other most advanced product candidates, including the combination of bemnifosbuvir and ruzasvir for the treatment of HCV, which will require significant additional clinical testing, including Phase 3 clinical testing, before we can seek regulatory approval and potentially launch commercial sales. If these product candidates fail in clinical development, do not receive regulatory approval or are not successfully commercialized, or are significantly delayed in doing so, our business will be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A substantial portion of our business and future success depends on our ability to develop, obtain regulatory approval for and successfully commercialize one or more bemnifosbuvir COV19 product candidates and the combination of bemnifosbuvir and ruzasvir for the treatment of HCV. We currently have no products that are approved for commercial sale and have not completed the development of any of our product candidates, and we may never be able to develop marketable products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the near term we expect that a substantial portion of our efforts and expenditures will continue to be devoted to developing a potential bemnifosbuvir COV19 product candidate. Among other things, this effort will require the successful completion of our Phase 3 SUNRISE-3 clinical trial for the treatment of high-risk outpatients with mild to moderate COVID-19 and additional nonclinical and clinical development and the incurrence of expenses related to discovering, acquiring or in-licensing and then developing a drug or drug candidate to combine with bemnifosbuvir for the treatment of COVID-19.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">There have been a large number of programs developing therapeutics for COVID-19 that have not succeeded. This includes the development of obeldesivir (GS-5245), an oral nucleoside prodrug, that was being developed by Gilead Sciences in two Phase 3 clinical trials.  In February 2024, Gilead Sciences announced that its Phase 3 clinical trial of obeldesivir which had enrolled standard risk patients failed to meet its primary endpoint of alleviation of symptoms. Previously, in September 2023, Gilead Sciences announced that, based upon lower-than-expected COVID-19 incidence rates and related hospitalizations or all cause deaths, it was discontinuing enrollment in its Phase 3 clinical trial in non-hospitalized patients at high-risk of progression.  These or similar factors may also adversely impact our SUNRISE-3 Phase 3 clinical trial, our ability to submit an NDA or other marketing authorization for or obtain marketing approval of bemnifosbuvir for the treatment of high-risk patients with COVID-19 or any other bemnifosbuvir COV19 product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">COVID-19 is unpredictable and therapies, including any bemnifosbuvir COV19 product candidate, may be adversely impacted up to the point of obsolescence by the emergence of new variants or subvariants as well as by the development and authorization and approval of new vaccines, vaccine updates and therapeutics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Additionally, we expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to developing the combination of bemnifosbuvir and ruzasvir for the treatment of HCV which will require additional clinical development, management of clinical, medical affairs and manufacturing activities, obtaining regulatory approvals in multiple jurisdictions, securing of manufacturing supply, building of or otherwise accessing a commercial organization, substantial investment and significant marketing efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We can not be certain that any of our current or future product candidates will be successful in clinical trials, receive regulatory approval or be successfully commercialized even if we receive regulatory approval. Further, our development of any product candidate may be delayed or suspended, which may affect our ability to successfully commercialize such product candidate.  Additionally, our ability to successfully commercialize a product will also be dependent upon our ability to timely manufacture at commercial scale the quantities of product that will satisfy market demand.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If our competitors develop products to treat diseases and, if applicable, specified patient populations which our current or future product candidates are being developed to treat, before we are able to successfully develop a product candidate, or if our competitors develop any products that are superior to our product candidates, our potential market share could become smaller or non-existent. Even if we receive approval to market any product candidate, we cannot be certain that our product candidates will be as or more effective than other commercially available alternatives, successfully commercialized or widely accepted in the marketplace.  For each of COVID-19 and HCV, there are currently approved and marketed oral antiviral products against which we would be required to compete.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">   </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We can not be certain that, if approved, the safety and efficacy profile of any product will be consistent with the results observed in clinical trials, or in the case of a bemnifosbuvir COV19 product candidate, that it will demonstrate efficacy against continuing mutations of the SARS-COV-2 virus, the causative agent of COVID-19. If we are not successful in the clinical development of a bemnifosbuvir COV19 product candidate or our other most advanced product candidates, the required regulatory approvals for these product candidates are not obtained, there are significant delays in the development or approval of these product candidates, supplying on an uninterrupted basis commercial quantities of approved products or any approved products are otherwise  not commercially successful, our business, financial condition and results of operations may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, expensive, time-consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be seriously harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are not permitted to commercialize, market, promote or sell any product candidate in the US without obtaining marketing approval from the FDA. Foreign regulatory authorities impose similar requirements. The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved and the disease or condition for which the product candidate is intended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development particularly with respect to COVID-19, which continues to evolve rapidly, and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the early stages of the COVID-19 pandemic when there were no available countermeasures, initial COVID-19 vaccines, therapeutic antibodies and other therapeutics that demonstrated positive clinical trial results moved rapidly through the regulatory review and EUA process of the FDA and regulatory authorities in other jurisdictions, including the EU.  The speed at which all parties acted to create, develop and review these countermeasures, including therapeutics for COVID-19, was exceptional.  With COVID-19 countermeasures, including oral antivirals, now available and COVID-19 moving from pandemic to endemic status, these exceptional and extraordinary dynamics have lessened and evolving priorities within the FDA and the regulatory authorities in other jurisdictions, including changes based on new data regarding potential therapeutics of others, new variants of the virus, preferred clinical development pathways and clinical trial endpoints may significantly affect the regulatory timeline for further authorizations or approvals for additional COVID-19 therapeutics including bemnifosbuvir.  Even with Fast Track designation, and the conduct of SUNRISE-3 under a US IND, uncertainty remains regarding the timelines and regulatory processes required for the authorization or approval of new treatments for COVID-19, including bemnifosbuvir.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies.  Approval by any one regulatory authority does not ensure approval by any other regulatory authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have not submitted an NDA for, or obtained regulatory approval of, any product candidate. We must complete additional clinical development in each case and in some cases additional preclinical or nonclinical development to demonstrate the safety and efficacy of our product candidates in humans to the satisfaction of the regulatory authorities before we will be able to obtain these approvals, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design, implementation or interpretation of results of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use of our products;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the US or elsewhere; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would seriously harm our business. In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a REMS or similar risk management measures. Regulatory authorities may not approve the price we intend to charge for products we may develop, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could seriously harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Before obtaining marketing approval from the FDA or other comparable foreign regulatory authorities for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, time-consuming and subject to uncertainty. A failure of one or more clinical trials can occur at any stage of the process, such as the failure in October 2021 of bemnifosbuvir to meet the primary endpoint in the overall patient population in the Phase 2 MOONSONG clinical trial. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials.  This may be particularly true in the development of therapeutics for the treatment of COVID-19, including our development of bemnifosbuvir COV19 product candidates, where the evolution of the virus and disease have occurred at such a rapid rate that product candidates in development have the potential to become obsolete before clinical development is completed. Moreover, preclinical and clinical data, particularly the analysis of exploratory endpoints and analysis of data derived from patient subgroups, such as the data from the MORNINGSKY study upon which we have relied to initiate the Phase 3 SUNRISE-3 clinical trial and continue clinical development of bemnifosbuvir for the treatment of COVID-19, as well as the data from the lead-in cohort in our HCV Phase 2 clinical trial of the combination of bemnifosbuvir and ruzasvir, are often susceptible to varying interpretations, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To date, we have not completed any late-stage or pivotal clinical trials for any of our product candidates. We cannot guarantee that any of our planned or ongoing clinical trials will be initiated or conducted as planned or completed on schedule, if at all. We also cannot be sure that submission of any future IND or similar application will result in the FDA or other regulatory authority, as applicable, allowing future clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">cause regulatory authorities to suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Events that may prevent successful or timely initiation or completion of clinical trials include but are not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">inability to generate sufficient preclinical, toxicology, or other </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> data to support the initiation or continuation of clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delays or failure in obtaining regulatory allowance to commence or amend a clinical trial; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective clinical research organizations ("CROs") and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among CROs and clinical trial sites; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delays in identifying, recruiting and training suitable clinical investigators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delays in obtaining required institutional review board (&#8220;IRB&#8221;) or ethics committee approval or positive opinion at each clinical trial site; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delays in recruiting, screening and enrolling a suitable number and diversity of patients to participate in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">subjects enrolled in our clinical trials or clinical sites deviating from the clinical trial protocol or dropping out of a trial; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">insufficient or inadequate supply or quality of product candidates or other materials necessary for use in clinical trials, or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">imposition of a temporary or permanent clinical hold by regulatory authorities for a number of reasons, including after review of an IND or amendment or equivalent foreign application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; or a negative finding from an inspection of our clinical trial operations or study sites; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">developments on trials conducted by competitors for related technology that raises FDA or foreign regulatory authority concerns about risk to patients of the technology broadly, </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">developments during the course of a clinical trial that cause the FDA, a foreign regulatory authority or the clinical trial DSMB to find that the investigational protocol or plan is clearly deficient to meet its stated objectives; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">difficulty collaborating with patient groups and investigators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">failure by our CROs, other third parties or us to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s GCPs, or applicable regulatory guidelines in other countries; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits, or occurrence of adverse events in trial of the same class of agents conducted by other companies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">changes to the clinical trial protocols; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">delays caused by patients withdrawing from clinical trials or failing to return for post-treatment follow-up;  </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols or otherwise impact the conduct of the clinical trial; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">changes in the standard of care or rate of event occurrence upon which a clinical development plan was based, which may require discontinuation of current trials or new or additional trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the cost of clinical trials of our product candidates being greater than we anticipate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development of such product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">transfer of manufacturing processes to larger-scale facilities operated by a CMO and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">third parties being unwilling or unable to satisfy their contractual obligations to us. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, events, occurrences and disruptions caused by the continuing evolution of COVID-19 may increase the likelihood that we encounter difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. In particular, the rate of incidence, testing and diagnosis of COVID-19, rates of hospitalization and death, changes in the SOC for the treatment of COVID-19, which continues to evolve due to the mutation of the virus and increasing knowledge being obtained by healthcare providers, rates and durability of vaccines and population immunity, and availability of therapeutic options, may impact the successful completion of our Phase 3 SUNRISE-3 clinical trial and other COVID-19-related clinical trials we may initiate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any inability to successfully complete our Phase 3 SUNRISE-3 clinical trial, our Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of HCV or the completion of any other planned clinical trials we may initiate could result in additional costs to us or impair our ability to generate revenue from product sales. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which any approved products have patent protection and may allow our competitors to further strengthen the market position of their current products or bring new products to market before we do, which could impair our ability to successfully commercialize our product candidates and may seriously harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the DSMB for such trial, or by the FDA or any other regulatory authority, or if the IRBs of the institutions at which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Further, conducting clinical trials in foreign countries, as we are currently doing and otherwise expect to continue doing for other product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate product revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to further strengthen the market position of their current products or bring new or additional products to market before we do, which could significantly reduce the commercial viability of our product candidates. Any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU CTR which was adopted in April 2014 and repeals the EU Clinical Trials Directive (&#8220;Clinical Trial Directive&#8221;), became applicable on January 31, 2022. While the EU Clinical Trials Directive required a separate CTA to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the EU Clinical Trials Directive, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the EU Clinical Trials Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR. Through January 31, 2023, submissions of CTAs that we made in connection with each of our SUNRISE-3 Phase 3 clinical trial and our Phase 2 HCV clinical trial were made using the EU Clinical Trial Directive. We have submitted CTAs under the CTR since February 1, 2023. Our experience with submissions under the CTR is limited. Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our developments plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">It is currently unclear to what extent the UK will seek to align its regulations with the EU. While the MHRA has confirmed that it will bring forward changes to the legislation post-Brexit, the final legislation has not yet been introduced by the UK Government and it therefore remains uncertain as to the extent to which the UK clinical trials framework will align with or diverge from the EU CTR. A decision by the UK not to closely align its regulations with the new approach that has been adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may also be impacted.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We are developing certain of our product candidates in combination with other therapies, which exposes us to additional risks.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Combination therapies are commonly used for the treatment of viral infections.  Developing combination therapies exposes us to additional clinical risks, such as the requirement that we demonstrate the safety and efficacy of each active component of any combination regimen we may develop.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For the treatment of HCV, we are currently developing bemnifosbuvir in combination with ruzasvir, a product candidate that has not yet been approved for marketing by the FDA or similar foreign regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If the FDA or similar foreign regulatory authorities do not approve the combination agents or revoke their approval thereof, or if safety, efficacy, manufacturing, or supply issues arise with the drugs we choose to evaluate in combination with our product candidates, we may be unable to obtain approval of or market our product candidates for combination therapy regimens.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Additionally, if the third-party manufacturers of therapies or therapies in development used in combination with our product candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our product candidates, or if the cost of combination therapies are prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Adverse events or other undesirable side effects caused by our product candidates could cause us, our collaborators, any DSMB for a trial, or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in previous trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational products are tested in large-scale clinical trials or, in some cases, after they are made available to patients on a commercial scale following approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If any serious adverse events occur, clinical trials or commercial distribution of any product candidates or products we develop could be suspended or terminated, and our business could be seriously harmed. Treatment-related side effects could also affect patient recruitment and the ability of enrolled patients to complete the trial or result in potential liability claims. Regulatory authorities could order us to cease further development of, deny approval of, or require us to cease selling any product candidates or products for any or all targeted indications. If we are required to delay, suspend or terminate any clinical trial or commercialization efforts, the commercial prospects of such product candidates or products may be harmed, and our ability to generate product revenues from them or other product candidates that we develop may be delayed or eliminated. Additionally, if one or more of our product candidates receives marketing approval and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against its manufacture or distribution; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">regulatory authorities may require additional warnings on the label, including &#8220;boxed&#8221; warnings, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we may be required to change the way the product is administered or conduct additional clinical trials or post-approval studies; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we may be required to create a REMS or similar risk management measures which could include a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we may be subject to fines, injunctions or the imposition of criminal penalties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could seriously harm our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the patient eligibility criteria defined in the protocol; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the size of the target disease population and rates of diagnostic testing among the target disease population;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the proximity of patients to trial sites; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the design of the trial; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any products that may be approved for the indications we are investigating; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to obtain and maintain patient consents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before trial completion; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">other factors outside of our control, such as the occurrence of a global health crisis similar to COVID-19 which, among other things, created substantial burdens on healthcare providers who were required to prioritize immediate critical patient care over clinical research, political unrest, war and terrorism. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Particularly with respect to our COVID-19 clinical trials and most notably with respect to SUNRISE-3, we have observed that the rate of enrollment varies significantly based upon the rate of transmissibility and severity of disease associated with newly emerged SARS-CoV-2 variants.  To the extent waves of infection with variants causing severe disease decline prior to the time we complete enrollment of the study we anticipate that the rate of enrollment in the SUNRISE-3 clinical trial is also likely to lessen.   This occurrence could have the effect of delaying the completion of the trial which currently requires the enrollment of approximately 2,200 patients in the supportive care monotherapy cohort. A delay in the completion of the study would also delay our ability to seek regulatory approval to commercialize bemnifosbuvir.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, our clinical trials will compete with other clinical trials sponsored by third parties, including potential competitors, that are in the same or substantially similar therapeutic areas as our product candidates, and this competition may reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. For example, we are aware of other clinical trials sponsored by our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">potential competitors, including Shionogi, that are recruiting patients in clinical trials evaluating oral antivirals for the treatment of high-risk outpatients with mild to moderate COVID-19, the same patient population that we are seeking to enroll in SUNRISE-3.  Since the number of qualified clinical investigators is limited, it is possible that we will conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Delays in patient enrollment as a result of competition, or in the case of COVID-19 in particular, evolution of the disease and treatment paradigms as well as rates of infection, testing, diagnoses, hospitalizations and deaths, or for other reasons, may result in increased costs or may affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion or commencement of these trials and adversely affect our ability to advance the development of our product candidates.  For example, we are aware that Gilead Sciences in September 2023 discontinued the enrollment of high-risk outpatients in the COVID-19 Phase 3 clinical trial of its product candidate, obeldesivir, an oral nucleoside prodrug. The stated reasons for the discontinuation of enrollment prior to completion of the trial was the observation by Gilead Sciences of lower-than-expected COVID-19 incidence rates and related hospitalizations or all cause deaths in countries where patients were being enrolled. These or similar factors may also impact our SUNRISE-3 Phase 3 clinical trial of bemnifosbuvir for the treatment of high-risk patients with COVID-19.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">A Fast Track designation by the FDA may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If a product candidate is intended for the treatment of a serious or life-threatening condition and the product candidate demonstrates the potential to address unmet medical needs for such condition, the product candidate sponsor may apply for Fast Track designation. In April 2023, the FDA granted Fast Track designation for the investigation of bemnifosbuvir for the treatment of COVID-19. As the sponsor of a product candidate that has received Fast Track designation, we may have opportunities for more frequent interactions with the FDA review team during product development and, once a NDA is submitted, the NDA may be eligible for priority review. An NDA for a Fast Track designated product candidate may also be eligible for rolling review, where the FDA may consider review of sections of the NDA on a rolling basis before the complete NDA is submitted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA has broad discretion whether or not to grant Fast Track designation to any particular product candidate.  As a result, we may seek such Fast Track designation for other product candidates, but cannot assure you that the FDA would decide to grant it. Even though a Fast Track designation has been received for the investigation of bemnifosbuvir to treat COVID-19, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Many product candidates that have received Fast Track designation have nevertheless failed to obtain approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We currently conduct clinical trials, and may in the future choose to conduct additional clinical trials, of our product candidates in sites outside the US, and the FDA may not accept data from trials conducted in foreign locations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We currently conduct, and expect in the future to conduct, clinical trials outside the US for our product candidates. The acceptance of study data from clinical trials conducted outside the US or another jurisdiction by the FDA or comparable foreign regulatory authorities may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the US, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the US population and US medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, if the study was not otherwise subject to an IND, the FDA will not accept the data as support for an application for marketing approval unless the study was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the US or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, there are risks inherent in conducting clinical trials in multiple jurisdictions, inside and outside of the US, such as:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">regulatory and administrative requirements of the jurisdiction where the trial is conducted that could burden or limit our ability to conduct our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">foreign exchange fluctuations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">manufacturing, customs, shipment and storage requirements for clinical trial materials and supplies as well as shipment and storage of biological samples; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">cultural differences in medical practice and clinical research; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the risk that the patient populations in such trials are not considered representative as compared to the patient population in the target markets where approval is being sought. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Interim, &#8220;topline&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">From time to time, we may publicly disclose preliminary or top-line data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data.  For example, in January and February 2024, we have announced preliminary, then-available data from the 60 patients lead-in cohort in our Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of HCV.  Similar to all preliminary and then-available data, these results and related findings and conclusions are subject to change as additional data becomes available or following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Consequently, the top-line or preliminary data that we report may differ from final results reported from the same studies, or different conclusions or considerations may qualify such preliminary or topline data, once additional data have been received and fully evaluated. Top-line and preliminary data also remain subject to audit and verification procedures that may result in the final results being materially different from the preliminary or topline data we previously published. As a result, top-line data should be viewed with caution until the final data are available.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may subsequently complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final results could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to identify and successfully develop additional product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Part of our strategy involves identifying novel product candidates. For example, we are currently engaged in internal efforts to identify a protease inhibitor product candidate that we may be able to combine with bemnifosbuvir for the treatment of COVID-19. These efforts and any subsequent discovery efforts we initiate to identify other novel product candidates may fail to yield product candidates for clinical development for a number of reasons, including those discussed in these risk factors and also:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we may not be able to assemble sufficient resources to acquire or discover additional product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">competitors may develop alternatives that render our potential product candidates obsolete or less attractive; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">potential product candidates we develop may nevertheless be covered by third-parties&#8217; patent or other intellectual property or exclusive rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">potential product candidates may, on further study, be shown to have harmful side effects, toxicities or other characteristics that indicate that they are unlikely to be products that will receive marketing approval or achieve market acceptance, if approved; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">potential product candidates may not be effective in treating their targeted diseases or symptoms; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the market for a potential product candidate may change so that the continued development of that product candidate is no longer reasonable; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a potential product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the regulatory pathway for a potential product candidate is highly complex and difficult to navigate successfully or economically. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we are unable to identify and successfully develop and commercialize additional suitable product candidates, this would adversely impact our business strategy and our financial position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may focus on potential product candidates that may prove to be unsuccessful and we may have to forego opportunities to develop other product candidates that may prove to be more successful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may choose to focus our efforts and resources on one or more potential product candidates that ultimately prove to be unsuccessful, or to license or purchase a marketed product that does not meet our financial expectations. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Furthermore, we have limited financial and personnel resources and are placing significant focus on the development of our lead product candidates, particularly our bemnifosbuvir COV19 product candidate and bemnifosbuvir in combination with ruzasvir for the treatment of HCV, and as such, we may forgo or delay pursuit of opportunities with other future product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and other future product candidates for specific indications may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular future product candidate, we may relinquish valuable rights to those future product candidates through collaboration, licensing or other royalty arrangements in cases in which it</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">would have been more advantageous for us to retain sole development and commercialization rights to such future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may attempt to secure FDA approval of certain product candidates through the use of the accelerated approval pathway or similar expedited approval pathways outside the US. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA or similar expedited approval by foreign regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA or foreign regulatory authorities may seek to withdraw accelerated approval or similar conditional approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are developing our product candidates for the treatment of serious</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">conditions, and therefore may decide to seek approval of such product candidates under the FDA&#8217;s accelerated approval pathway. A product candidate may be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease or condition and generally provides a meaningful advantage over available therapies, upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, confirmatory studies to verify and describe the drug&#8217;s clinical benefit. If the sponsor fails to conduct such studies in a timely manner, or if such confirmatory studies fail to verify the drug&#8217;s predicted clinical benefit, the FDA may withdraw its approval of the drug on an expedited basis. In addition, in December 2022, President Biden signed an omnibus appropriations bill to fund the U.S. government through fiscal year 2023. Included in the omnibus bill is the Food and Drug Omnibus Reform Act of 2022, which among other things, provided FDA new statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval. Under these provisions, the FDA may require a sponsor of a product seeking accelerated approval to have a confirmatory trial underway prior to such approval being granted</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the EU, a &#8220;conditional&#8221; marketing authorization may be granted in cases where all the required safety and efficacy data are not yet available. A conditional marketing authorization is subject to conditions to be fulfilled for generating missing data or ensuring increased safety measures. A conditional marketing authorization is valid for one year and has to be renewed annually until fulfillment of all relevant conditions. Once the applicable pending studies are provided, a conditional marketing authorization can become a &#8220;standard&#8221; marketing authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA, the marketing authorization will cease to be renewed. Furthermore, marketing authorizations may also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to the introduction of specific procedures. This may arise when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This type of marketing authorization is close to a conditional marketing authorization as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a marketing authorization. However, unlike a conditional marketing authorization, the applicant does not have to provide the missing data and will never have to. Although a marketing authorization &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">annually and the marketing authorization may be withdrawn where the risk-benefit ratio is no longer favorable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The competent regulatory authorities in the EU have broad discretion whether to grant such a conditional marketing authorization or marketing authorization under exceptional circumstances, and, even if such assessment or authorization is granted, we may not experience a faster development process, review or authorization compared to conventional procedures. Moreover, the removal or threat of removal of such marketing authorizations may create uncertainty or delay in the clinical development of our product candidates and threaten the commercialization prospects of our products and product candidates, if approved. Such an occurrence could materially impact our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we decide to submit an NDA seeking accelerated approval or receive an expedited regulatory designation for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. Failure to obtain accelerated approval or any other form of expedited development, review or approval for a product candidate would result in a longer time period prior to commercialization of such product candidate, if any, and could increase the cost of development of such product candidate, which could harm our competitive position in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us or any future collaboration partners from obtaining approvals for the commercialization of any product candidate we develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any product candidates we may develop and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the US and by comparable authorities in other countries. Any product candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction. It is possible that none of the product candidates we are developing or that we may seek to develop in the future will ever obtain regulatory approval. We, as a company, have no experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs, suppliers, vendors or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The process of obtaining marketing approvals, both in the US and abroad, is expensive, may take many years if numerous clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission's proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April 26, 2023. The proposed revisions have yet to be agreed and adopted by the European Parliament and European Council and the proposal may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may however have a significant impact on the pharmaceutical industry and our business in the long term.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we may develop, the commercial prospects for those product candidates may be harmed, and our ability to generate product revenue will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may seek an EUA from the FDA or comparable emergency use authorizations from foreign regulatory authorities with respect to our bemnifosbuvir COV19 product candidates in development for the treatment of COVID-19, and if we fail to obtain or maintain such authorizations, we may be required to pursue a more lengthy clinical development process than we expect, and our business may be harmed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If available at the time we have sufficient data from our Phase 3 SUNRISE-3 clinical trial, we may seek an EUA from the FDA or comparable emergency use authorizations from foreign regulatory authorities with respect to our bemnifosbuvir COV19 product candidates. The FDA has the authority to issue an EUA, pursuant to the Federal FDCA and a declaration by the HHS Secretary, that circumstances exist justifying the issuance of EUAs for certain types of products (referred to as EUA declarations).  On March 27, 2020, the Secretary of HHS declared that circumstances then existed that justified authorization of drugs and biologics during the COVID-19 pandemic, subject to the terms of any EUA that subsequently issued for a specific product. Once an EUA declaration has been issued and remains in place, the FDA can issue EUAs for products that fall within the scope of that declaration. To issue an EUA, the FDA Commissioner must conclude that (1) the CBRN, that is referred to in the EUA declaration can cause serious or life-threatening diseases or conditions; (2) based on the totality of scientific evidence available, it is reasonable to believe that the product may be effective in diagnosing, treating, or preventing the disease or condition attributable to the CBRN and that the product&#8217;s known and potential benefits outweigh its known and potential risks; and (3) there is no adequate, approved, and available alternative to the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since December 2021, in the US two oral direct acting antivirals Paxlovid</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#153; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(nirmatrelvir and ritonavir) and </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Lagevrio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#153;</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> (molnupiravir)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> have been authorized for emergency use for high-risk COVID-19 patients.  While Lagevrio remains available under the emergency use authorization, following the submission of a NDA, Paxlovid has been approved for use for the treatment of mild-to-moderate COVID-19 in adults at high-risk for progression to severe COVID-19.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA&#8217;s standards for granting an EUA are lower than for approving NDAs in accordance with traditional review procedures, and even if we seek and obtain an EUA for one or more of our product candidates, we cannot assure you that the FDA would approve a NDA for such product candidate, if such approval is required. Accordingly, even if we obtain an EUA for a bemnifosbuvir COV19 product candidate, we may be required to conduct additional clinical trials before we are able to submit an NDA or comparable marketing applications for such product candidate.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The authorization to market products under an EUA is limited to the period of time the EUA declaration is in effect. If the Secretary of HHS determines that the circumstances justifying the issuance of EUAs have also lapsed, the HHS Secretary will provide advance notice that the EUA declaration will be terminated. After an EUA declaration is terminated, all EUAs issued under that declaration also terminate and therefore emergency use of all products under the EUA declaration is no longer authorized. The FDA can also revoke an EUA in certain circumstances even if the EUA declaration has not been terminated.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FDA&#8217;s policies regarding an EUA can change unexpectedly. We cannot predict how long any authorization, if obtained, will remain in place. The FDA&#8217;s policies regarding vaccines and other products used to diagnose, treat or mitigate COVID-19 remain in flux as the FDA responds to new and evolving public health information and clinical evidence. Moreover, the federal government has taken steps to terminate distinct emergency authorizations related to COVID-19.  For example, following the expiration on May 11, 2023 of the COVID-19 public health emergency under the Public Health Service Act, although</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the FDA has maintained its authority to grant EUAs to qualifying products, certain FDA policies and operational procedures related to COVID-19 expired, and the FDA has continued to return to normal operations, including a potential transition of products marketed under EUAs, to the conventional FDA requirements, including premarket authorization requirements. Changes in COVID-19 pandemic related policies and procedures and resumption of pre-pandemic operations are also occurring at regulatory agencies outside the US.  Among other things, these changes include a return to longer periods for review of CTAs than was occurring during the pandemic.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Therefore, even if we believe the data from our Phase 3 SUNRISE-3 clinical trial and any other COVID-19 clinical trials we may initiate are positive, we may be unable to obtain an EUA or other emergency authorizations for a bemnifosbuvir COV19 product candidate at all or in a timely manner. Moreover, even if we do obtain an EUA or comparable emergency authorization, it is possible that such EUA or other authorizations may be revoked and we may be required to cease any commercialization activities, until, if ever, we receive NDA approval for such product.  Any cessation of commercialization activities would adversely impact our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the US, which would limit our ability to realize their full market potential.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In order to market any products outside of the US, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and as an organization we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If any current or future product candidate we develop receives marketing approval, whether as a single agent or in combination with other therapies, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current approved antiviral products are well established in the medical community for the treatment of HCV and in the US, two oral antivirals, Paxlovid and Lagevrio, are currently approved and authorized, respectively, for the treatment of COVID-19, and doctors may continue to rely on these therapies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If the product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the continued longevity of any market for which we develop a product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">efficacy and potential advantages, including convenience and ease of administration, of our product compared to alternative treatments; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the prevalence and severity of any side effects associated with our product relative to any alternative treatment;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the strength and effectiveness of sales, marketing and distribution support; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the cost to patients of treatment regimens with our product in relation to alternative treatments; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the ability to obtain sufficient adequate reimbursement from third-parties as well as the impact of any agreements among any competitor and any third party payor limiting access to our product.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If the market opportunities for our product candidates are smaller than we believe they are or any approval we obtain is based on a narrower definition of the patient population, our business may suffer.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We currently focus on the discovery and development of product candidates for the treatment of serious viral diseases. Our eligible patient population, pricing estimates and available coverage and reimbursement may differ significantly from the actual market addressable by our product candidates. Our estimates of the number of people who have these diseases, the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, and the market demand for our product candidates are based on our beliefs and analyses. These estimates have been derived from a variety of sources, including the scientific literature, current third-party data regarding prescriptions dispensed, and market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of the diseases we are targeting. The number of patients may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be receptive to treatment with our product candidates, and new patients may become increasingly difficult to identify or access. Additionally, the availability of superior or competitive therapies from our competitors could negatively impact or eliminate market demand for our product candidates. If the market opportunities for our product candidates are smaller than we estimate, it could have an adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Disruptions at the FDA and foreign regulatory authorities caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The ability of the FDA and foreign regulatory authorities to review or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform routine functions including a rapid substantial influx of applications from numerous sponsors as occurred with COVID-19. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the US government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, any reoccurrence of a public health emergency may lead to further administrative or inspectional delays.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Though we have insurance coverage for clinical trial product liability, we do not carry insurance for all categories of risk that our business may encounter. Some of the additional policies we currently maintain include general liability, property, auto, workers&#8217; compensation, cybersecurity, umbrella, and directors&#8217; and officers&#8217; insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a part of the clinical trial regulatory submission process, in many countries, we are required to provide local insurance coverage covering claims that persons associated with the clinical trial may assert if they are or believe they are injured as a result of participation in the clinical trial or contact with the investigational product candidate being studied in the clinical trial.  These local insurance policies can be time consuming to obtain which may delay the anticipated start of a clinical trial in a particular country.  Additionally, these local insurance policies may not cover all the claims an injured party may assert and may be insufficient to cover the losses associated with our defense of the claim and any judgment against us that may result.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any additional product liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for any of our product candidates, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments are for claims not covered by or are in amounts that exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the development and commercialization of any product candidates we develop. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury from biological or hazardous waste, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Operating as a public company has in the past and may in the future make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash and cash equivalents position and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our business and operations may suffer in the event of information technology system failures, cyberattacks, or deficiencies, which could materially affect our results.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our information technology systems, as well as those of our CROs and other contractors and consultants, are vulnerable to attack, failure and damage from computer viruses and other malware (e.g., ransomware), unauthorized access or other cybersecurity attacks, malfeasance by external or internal parties, human error (e.g., social engineering, phishing), natural disasters (including hurricanes), terrorism, war, fire and telecommunication or electrical failures. In the ordinary course of our business, we directly or indirectly collect, store and transmit sensitive data, including intellectual property, confidential information, preclinical and clinical trial data, proprietary business information, personal data and personally identifiable health information of our clinical trial subjects and employees, in our data centers and on our networks, or on those of third parties. The secure processing, maintenance and transmission of this information is critical to our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Despite security measures that we and our critical third parties (e.g., collaborators) implement, our information technology systems may be vulnerable to attacks by hackers or internal bad actors, or breached due to human error, a technical vulnerability, malfeasance or other disruptions. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, level of persistence, intensity and sophistication of attempted attacks and intrusions from around the world have increased. We also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. We may not be able to anticipate all types of security threats, nor may we be able to implement preventive measures effective against all such security threats. The techniques used by cybercriminals change frequently, may not be recognized until launched and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. Because of this, we may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attacks increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.  We cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages or breaches in our systems or those of our CROs and other contractors and consultants or that any such significant breakdowns, data leakages or breaches will be timely discovered, disclosed (if applicable) and remediated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product candidate development programs. For example, the loss data from completed, ongoing or planned preclinical studies or clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If a security breach or other incident were to result in the unauthorized access to or unauthorized use, disclosure, release or other processing of personal information, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media and other parties pursuant to privacy and security laws. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information and significant regulatory penalties, and such an event could disrupt our operations, damage our reputation and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay our clinical development of our product candidates. Further, our insurance coverage may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Related to Healthcare Laws and Other Legal Compliance Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We are subject to extensive and costly government regulation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our product candidates will be subject to extensive and rigorous domestic government regulation, including regulation and oversight by the FDA, the CMS, other divisions of HHS, the US Department of Justice, state and local governments, and their respective equivalents outside of the US. The FDA regulates the research, development, preclinical and clinical testing, manufacture, safety, effectiveness, record-keeping, reporting, labeling, packaging, storage, approval, advertising, promotion, sale, distribution, import and export of pharmaceutical products. If our products are marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not they have obtained FDA approval. Such foreign regulation may be equally or more demanding than corresponding US regulation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Government regulation substantially increases the cost and risk of researching, developing, manufacturing and, if approved, selling our products. The regulatory review and approval process, which includes preclinical testing and clinical trials of each product candidate, is lengthy, expensive and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">uncertain. We must obtain and maintain regulatory authorization to conduct clinical trials. We must obtain regulatory approval for each product we intend to market, and the manufacturing facilities used for the products must be inspected and meet legal requirements. Securing regulatory approval requires the submission of extensive preclinical and clinical data and other supporting information for each proposed therapeutic indication in order to establish the product&#8217;s safety and efficacy, potency and purity, for each intended use. The development and approval process takes many years, requires substantial resources, and may never lead to the approval of a product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Even if we are able to obtain regulatory approval for a particular product, the approval may limit the indicated medical uses for the product, may otherwise limit our ability to promote, sell and distribute the product, may require that we conduct costly post-marketing surveillance, and/or may require that we conduct ongoing post-marketing studies. Material changes to an approved product, such as, for example, manufacturing changes or revised labeling, may require further regulatory review and approval. Once obtained, any approvals may be withdrawn, including, for example, if there is a later discovery of previously unknown problems with the product, such as a previously unknown safety issue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we, our consultants, CMOs, CROs or other vendors, fail to comply with applicable regulatory requirements at any stage during the regulatory process, such noncompliance could result in, among other things, delays in the approval of applications or supplements to approved applications; refusal of a regulatory authority, including the FDA, to review pending market approval applications or supplements to approved applications; warning letters; fines; import and/or export restrictions; product recalls or seizures; injunctions; total or partial suspension of production; civil penalties; withdrawals of previously approved marketing applications or licenses; recommendations by the FDA or other regulatory authorities against governmental contracts; and/or criminal prosecutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Enacted and future healthcare legislation and policies may increase the difficulty and cost for us to commercialize our product candidates and could adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the US, the EU and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities involving any product candidates for which we obtain marketing approval, impact pricing and reimbursement and impact our ability to sell any such products profitably. In particular, there have been and continue to be a number of initiatives at the US federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. In addition, new regulations and interpretations of existing healthcare statutes and regulations are frequently adopted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In March 2010, the Patient Protection and ACA, was enacted, which substantially changed the way healthcare is financed in the US by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a Medicare Part D coverage gap discount program, requiring manufacturers to agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">increases and changes in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">extension of a manufacturer&#8217;s Medicaid rebate liability to covered outpatient drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">establishment of the Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Since its enactment, there have been judicial, Congressional and executive challenges to certain aspects of the ACA. On June 17, 2021, the US Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the US since the ACA was enacted. In August 2011, the Budget Control Act of 2011 imposed aggregate reductions of Medicare payments to providers, effective April 1, 2013 which, due to subsequent legislative amendments, will stay in effect through 2032. Further, on March 11, 2021 the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, payment methodologies may be subject to other changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as outcomes-based reimbursement. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several US Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. Most recently, on August 16, 2022, the IRA was signed into law.  Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).  The IRA permits the HHS Secretary to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. For that and other reasons, it is currently unclear how the IRA will be effectuated. We expect that additional US federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the US federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Individual states in the US have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, states and other regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In markets outside of the US and the EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Enacted and future legislation and policies may increase the difficulty and cost for us to obtain marketing approval of our product candidates and could adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the US, legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA&#8217;s regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the US, the EU or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny and post-marketing requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for groups specified by, among other things, age or medical condition, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if any of our product candidates is approved, it will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the US and requirements of comparable foreign regulatory authorities. Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP and similar regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and similar requirements and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If the FDA or another regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory authorities may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory authority or enforcement authority may, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">issue warning letters; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">impose civil or criminal penalties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">suspend or withdraw regulatory approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">suspend any of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">refuse to approve pending applications or supplements to approved applications submitted by us; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">impose restrictions on our operations, including closing our CMOs facilities; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">seize or detain products, or require a product recall. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if any regulatory approval is withdrawn, our business will be seriously harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, the policies of the FDA and of other regulatory authorities may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the US or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action, and we may not achieve or sustain profitability.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The US federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our business operations and current and future relationships with clinical trial investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our business operations and current and future arrangements with clinical trial investigators, other healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, and if approved, market, sell and distribute our product candidates. Such laws include but are not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the US federal Anti-Kickback Statute, which makes it illegal for any person to knowingly and willfully solicit, offer, receive, pay or provide any remuneration (including any kickback, bribe or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under US federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the US federal civil and criminal false claims laws, including the civil False Claims Act (&#8220;FCA&#8221;), which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the US federal government, claims for payment or approval that are false, fictitious or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the US federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The government may deem manufacturers to have &#8220;caused&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. Companies that submit claims directly to payors may also be liable under the FCA for the direct submission of such claims. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the US federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the US federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and its implementing regulations, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the US federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the US federal Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives), and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">US federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where reported prices may be used in the calculation of reimbursement and/or discounts on approved products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">US federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">analogous US state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the US federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws that require the registration of pharmaceutical sales representatives; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock or stock options for services provided to us and may be in the position to influence the ordering of or use of our product candidates, if approved, may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We are subject to governmental regulation and other legal obligations, particularly related to privacy, data protection and information security, and we are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our actual or perceived failure to comply with such obligations could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are subject to diverse laws and regulations relating to data privacy and security. New privacy rules are being enacted in the US and globally, and existing ones are being updated and strengthened. For example, the California Consumer Privacy Act (&#8220;CCPA&#8221;) went into effect on January 1, 2020 and creates individual privacy rights for California consumers, increases the privacy and security obligations of entities handling certain personal information, requires new disclosures to California individuals and affording such individuals new abilities to opt out of certain sales of personal information, and provides for civil penalties for violations as well as a private right of action for data breaches that has increased the likelihood of, and risks associated with data breach litigation. Further, the California Privacy Rights Act (&#8220;CPRA&#8221;), which generally went into effect on January 1, 2023, significantly amends the CCPA and imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">certain uses of sensitive data. It has also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement, additional compliance investment and potential business process changes may be required. Similar laws have passed in other states, and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the US. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. Any liability from failure to comply with the requirements of applicable data privacy and data protection laws could adversely affect our financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Complying with these numerous, complex and often changing regulations is expensive and difficult, and failure to comply with any privacy laws or data security laws or any security incident or breach involving the misappropriation, loss or other unauthorized processing, use or disclosure of sensitive or confidential patient, consumer or other personal information, whether by us, one of our CROs or business associates or another third-party, could adversely affect our business, our operations abroad, financial condition and results of operations.  Such adverse effects may include, but are not limited to: investigation costs; material fines and penalties; compensatory, special, punitive and statutory damages; litigation; consent orders regarding our privacy and security practices; requirements that we provide notices, credit monitoring services and/or credit restoration services or other relevant services to impacted individuals; adverse actions against our licenses to do business; reputational damage; and injunctive relief.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. For example, the EU General Data Protection Regulation ("GDPR") went into effect in May 2018, and imposes strict requirements for processing the personal data of individuals within the EEA or in the context of our activities in the EEA. The GDPR and related implementing laws in individual EU member states govern the collection and use of health data and other personal data in the EU including the personal data processed by companies outside the EU in connection with the offering of goods or services to individuals in the EU or the monitoring of their behavior (including in the context of clinical trials). Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. In addition to the foregoing, a breach of the GDPR could result in regulatory investigations, reputational damage, orders to cease / change our processing of our data, enforcement notices, and/ or assessment notices (for a compulsory audit). Companies may also face civil claims including representative actions and other class action type litigation (where individuals have suffered harm), potentially amounting to significant compensation or damages liabilities, as well as associated costs, diversion of internal resources, and reputational harm.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the US, and the efficacy and longevity of current transfer mechanisms between the EEA, and the US remains uncertain.  On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework (&#8220;DPF&#8221;), rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we conduct our business, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, since January 1, 2021, after the end of the transition period following the UK&#8217;s departure from the EU, we are also subject to the UK data protection regime (the UK GDPR and UK Data Protection Act 2018), which imposes separate but similar obligations to those under the GDPR and comparable penalties, including fines of up to &#163;17.5 million or 4% of a noncompliant company&#8217;s global annual revenue for the preceding financial year, whichever is greater. On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a data transfer mechanism from the UK to US entities self-certified under the DPF. As we continue to expand into other foreign countries and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We cannot assure you that our CROs or other third-party service providers with access to our or our suppliers&#8217;, trial patients&#8217;, investigators and clinical site employees&#8217; personally identifiable and other sensitive or confidential information in relation to which we are responsible will not breach contractual obligations imposed by us, or that they will not experience data security breaches or attempts thereof, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, results of operations and financial condition. We cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, use, storage and transmission of such information. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Most healthcare providers in the US, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act. We do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. Even when HIPAA does not apply, according to the Federal Trade Commission (&#8220;FTC&#8221;), failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We, our CROs and third-party service providers receive and maintain sensitive information, including health-related information, that we receive throughout the clinical trial process, in the course of our research collaborations. As such, we may also be subject to state laws, requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. Our clinical trial programs outside the US may implicate international data protection laws, including the UK GDPR, GDPR and legislation of the EU member states implementing it. In addition, the EU imposes obligations on the use of data generated from clinical trials and enables European patients to have the opportunity to access their personal data processed in the context of clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our activities outside the US impose additional compliance requirements and generate additional risks of enforcement for noncompliance. Failure by our CROs and other third-party contractors to comply with the strict rules on the transfer of personal data outside of the EU into the US may result in the imposition of criminal and administrative sanctions on such collaborators, which could adversely affect our business. Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#8217; health information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, patients about whom we or our collaborators obtain health information, as well as the providers who share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we or third-party CMOs, CROs or other contractors or consultants fail to comply with applicable federal, state or foreign regulatory privacy requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217; ability to develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security or reputational damage. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. Moreover, certain environmental laws may impose liability without regard to fault or legality of the action at the time of its occurrence.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the use of social media by us or our employees to communicate about our product candidates or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with applicable laws and regulations, our policies and other legal or contractual requirements, which may give rise to regulatory enforcement action, liability, lead to the loss of trade secrets or other intellectual property or result in public exposure of personal information of our employees, clinical trial patients, customers and others. Furthermore, negative posts or comments about us or our product candidates in social media could seriously damage our reputation, brand image and goodwill. Any of these events could have a material adverse effect on our business, prospects, operating results and financial condition and could adversely affect the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Related to Commercialization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Developments by competitors may render our products or technologies obsolete or non-competitive or may reduce the size of our markets.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our industry is characterized by extensive research and development efforts, rapid developments in technologies, intense competition and a strong emphasis on proprietary products. We expect our product candidates to face intense competition with existing products and increasing competition as new products enter the relevant markets and advanced technologies become available. We face potential competition from many different sources, including pharmaceutical, biotechnology and specialty pharmaceutical companies. Academic research institutions, governmental agencies and public and private institutions are also potential sources of competitive products and technologies. Our competitors may have or may develop superior technologies or approaches, which may provide them with competitive advantages. Many of these competitors have products already approved or in development in the therapeutic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">categories that we are targeting with our product candidates. Either alone or together with their collaborative partners, many of these competitors operate larger research and development programs and have substantially greater financial resources and access to larger pools of capital, including in some cases US government funding, than we do.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Additionally, many of these competitors have greater experience in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">developing product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">undertaking preclinical testing and clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">obtaining NDA approval by the FDA and comparable approvals of product candidates from foreign regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">formulating and manufacturing products; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">launching, marketing and selling products. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If these competitors access the marketplace before we do with safer, more effective, or less expensive therapeutics or vaccines, our product candidates, if approved for commercialization, may not be profitable to sell or worthwhile to continue to develop. Technology in the pharmaceutical industry has undergone rapid and significant change, and we expect that it will continue to do so. Any compounds, products or processes that we develop may become obsolete or uneconomical before we recover any expenses incurred in connection with their development. The success of our product candidates will depend upon factors such as product efficacy, safety, reliability, availability, timing, scope of regulatory approval, acceptance and price, among other things. Other important factors to our success include speed in developing product candidates, completing clinical development and laboratory testing, obtaining regulatory approvals and manufacturing and selling commercial quantities of potential products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For the diseases that we are targeting, significant competition exists from approved and authorized oral treatments as well as other treatments in development. The approved drugs, particularly for HCV and increasingly for COVID-19, are well-established products and are widely accepted by physicians, patients and third-party payors. For a description of approved and authorized vaccines and therapeutics, as well as competing treatments in clinical development, please see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Part I, Item1 "Business"</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our product candidates, if approved, are expected to compete directly or indirectly with existing products and products currently in development. Even if approved and commercialized, our product candidates may fail to achieve market acceptance with hospitals, physicians, patients or third-party payors. Hospitals, physicians, patients or third-party payors may conclude that our products are less safe or effective or otherwise less attractive than existing drugs. If our product candidates do not receive market acceptance for any reason, our revenue potential would be diminished, which would materially adversely affect our ability to become profitable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Many of our competitors have substantially greater capital resources, access to larger pools of capital, robust product candidate pipelines, established presence in the market, deep and broad commercial infrastructures and greater expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. As a result, our competitors may achieve product commercialization or patent or other intellectual property protection earlier than we can.  For example, in May 2023, Gilead Sciences was granted a patent in the US that may cover our compound bemnifosbuvir.  If Gilead Sciences asserts this patent, we may not be successful in invalidating it.  If we are not successful, we will need to obtain a license from Gilead, which may not be available on reasonable terms, if at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales, marketing and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">any products that we may develop or that would render any products that we may develop obsolete or noncompetitive, which would have a material adverse effect on our business and operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs and biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the US, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered and reimbursed. The Medicare program is increasingly used as a model for how private and other governmental payors develop their coverage and reimbursement policies for new drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors in the US. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Some third-party payors may require pre-approval of coverage for new or innovative drug therapies before they will reimburse healthcare providers who use such therapies. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Outside the US, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in the EU and other jurisdictions have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the US, the reimbursement for our product candidates may be reduced compared with the US and may be insufficient to generate commercially reasonable revenue and profits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the US and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates.  For example, the future value of the US HCV market may be impacted by payors obtaining additional discounts from manufacturers and by payor contracting dynamics. Individual state Medicaid agencies may enact HCV treatment subscription models where manufacturers provide unrestricted access to their antiviral medication for a capitated total price. Contract duration and restrictions of such agreements could impact the ability of the non-awarded HCV oral antivirals to compete.  In addition, future US government sponsored HCV eradication initiatives could impact the HCV market opportunity.  While future US government sponsored HCV programs could significantly expand the number of HCV infected patients being treated, it also could negatively impact market value and access to many HCV oral antivirals.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We expect to experience pricing pressures in connection with the sale of our product candidates due to the presence of approved, and in the case of HCV, authorized generic, products already in many marketplaces, the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes resulting from legislative actions, including the recently enacted IRA. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, beginning in March 2020, the US federal government has been the primary purchaser of COVID-19 therapeutics, vaccines and diagnostics. In October 2023, the Administration for Strategic Preparedness &amp; Response, an agency of the US Public Health Service within HHS released new guidance sunsetting the US federal government COVID-19 Therapeutics Distribution Program. The guidance effectively ended the distribution of US federal government procured oral antivirals through the Federal Retail Pharmacy Therapeutics Program. As a result of the guidance, Paxlovid and Lagevrio officially entered the commercial market in November 2023 ending the role of the US federal government as the single payer for COVID-19 oral antivirals. Patients insured through federally funded programs such as Medicaid and Medicare may continue to access Paxlovid free of charge through 2028.  Beginning in 2025, we expect that US patient reimbursement for COVID-19 oral antivirals will become subject to traditional payer dynamics for commercial, Medicare and Medicaid patients.   We anticipate a major consideration for determining reimbursement by these third-party payers will be a cost/value analysis that is driven in part by the economic burden of hospitalization, especially for at-risk populations. The effect of third-party payers managing patient access to COVID-19 oral antivirals and patient&#8217;s co-insurance amounts may impact future demand and patient uptake of COVID-19 oral antiviral medications</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing any of our product candidates, if approved, and we may not be able to generate any product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have limited personnel and limited infrastructure for the sales, marketing or distribution of products, and no experience as a company in commercializing a product candidate. The cost of building and maintaining such an organization may exceed the cost-effectiveness of doing so.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Currently, we anticipate to establish our own commercial organization in the US to commercialize, together with a collaborator, our COVID-19 and HCV product candidates, if approved.  Outside the US, we anticipate to rely on a collaborator to commercialize our COVID-19 and HCV products candidates if approved.   We do not currently have any commercialization arrangements in place with any collaborator either within or outside the US  and we may be unable to enter into acceptable arrangements to do so.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">There are significant expenses and risks involved with building our own sales, marketing and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could delay the product launch, and adversely impact the commercialization of our product candidates, if approved. Additionally, if the commercial launch of our product candidates for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Factors that may inhibit our efforts to commercialize our product candidates on our own include but are not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe our future products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our inability to equip medical and sales personnel with effective materials, including medical and sales literature to help them educate physicians and other healthcare providers regarding applicable diseases and our future products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our inability to develop or obtain sufficient operational functions to support our commercial activities; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In those territories where we engage a collaborator to commercialize our products in whole or in part our sales will depend on the collaborator&#8217;s strategic interest in the product and such collaborator&#8217;s ability to successfully commercialize the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we are unable to build our own sales force or access a collaborative relationship for the commercialization of any of our product candidates, we may be forced to delay the potential commercialization of our product candidates or reduce the scope of our sales or marketing activities for such product candidates. If we elect to increase our expenditures to fund additional commercialization activities ourselves, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We could enter into arrangements with collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to any of our product candidates or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we are unable to establish adequate sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates and may not become profitable and may incur significant additional losses. We will be competing with many companies, including large pharmaceutical companies, including Pfizer in COVID-19 and Gilead Sciences and AbbVie in HCV, that have extensive and well-funded marketing and sales operations. Without a robust internal team or the support of third-parties to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, even if we do establish adequate sales, marketing and distribution capabilities, the progress of general industry trends with respect to pricing models, supply chains and delivery mechanisms, among other things, could deviate from our expectations. If these or other industry trends change in a manner which we do not anticipate or for which we are not prepared, we may not be successful in commercializing our product candidates or become profitable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our future profitability may depend, in part, on our ability to commercialize our product candidates in foreign markets for which we currently anticipate to rely on collaboration with third parties. We do not currently have any collaborator for the commercialization of any of our product candidates in foreign markets. We are evaluating the opportunities for the commercialization of our product candidates in foreign markets. Neither we or any third party with which we may collaborate is permitted to market or promote any of our product candidates before regulatory approval of such product candidate is received from the applicable regulatory authority in that foreign market, and such regulatory approval for any of our product candidates may never result. To obtain regulatory approvals in countries outside the US, it will be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">necessary to comply with numerous and varying regulatory requirements of such countries regarding the safety and efficacy of our product candidates and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to additional risks and uncertainties, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our customers&#8217; ability to obtain reimbursement for our product candidates in foreign markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our inability to directly control commercial activities of any third parties upon which we are relying; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">import or export licensing requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability, or the ability of our collaborators, to supply our product candidates on a timely and large-scale basis in local markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">longer lead times for shipping which may necessitate local manufacture of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">language barriers for technical training and the need for language translations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">reduced protection of patent and other intellectual property rights in some foreign countries; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the existence of additional potentially relevant third-party intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">longer accounts receivable collection times; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">foreign currency exchange rate fluctuations; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Foreign sales of any product for which we obtain approval could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If any of our product candidates is approved for commercialization, we currently anticipate to selectively partner with third parties to market such product candidate both within and outside the US.   If we or a collaborator market a product candidate outside the US, we expect that we will be subject to additional risks related to international pharmaceutical operations, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">different regulatory requirements for drug approvals and rules governing drug commercialization in foreign countries; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">reduced protection for patent and other intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">foreign reimbursement, pricing and insurance regimes; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">potential noncompliance with the US Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery and anticorruption laws in other jurisdictions; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As an organization, we have no prior experience in these areas. In addition, we will need to comply with complex regulatory, tax, labor and other legal requirements imposed by both the EU and many of the individual member states in the EU as well as in other global territories.  Many US-based biotechnology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and biopharmaceutical companies have found the process of marketing products outside of North America to be very challenging.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Certain legal and political risks are also inherent in foreign operations without regard to whether these activities are conducted by us in whole or in part or by a collaborator. There is a risk that foreign governments may nationalize private enterprises in certain countries where we or any collaborator with which we are collaborating may operate. In certain countries or regions, terrorist activities and the response to such activities may threaten our operations more than in the US. Social and cultural norms in certain countries may not support compliance with our corporate policies, including those that require compliance with substantive laws and regulations. Also, changes in general economic and political conditions in countries where we may operate are a risk to our financial performance and future growth.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Additionally, the need to identify financially and commercially strong partners for commercialization outside the US who will comply with the high manufacturing and legal and regulatory compliance standards we require is a risk to our financial performance. As we operate our business globally, our success will depend, in part, on our ability to anticipate and effectively manage these and other related risks. There can be no assurance that the consequences of these and other factors relating to our international operations will not have an adverse effect on our business, financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In many countries outside the US, particularly in the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we may be required to conduct clinical trials that compare the cost-effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Currently, we face an inherent risk of product liability claims as a result of the testing our product candidates and we will face product liability risks if we, or a collaborator, commercialize any of our product candidates that are approved.  Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs, which may not be covered by insurance. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">injury and impairment of our business reputation and significant negative media attention; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">withdrawal of participants from our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">initiation of investigations by regulators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">significant costs to defend the claims and related litigation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">distraction of management&#8217;s attention from our primary business; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">substantial monetary awards to patients or other claimants; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">inability to commercialize a product candidate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">exhaustion of any available insurance and our capital resources; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">decreased demand for a product candidate, if approved for commercial sale; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">loss of revenue. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Failure to obtain or retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with commercial collaborators. To date, we have not sought and do not yet have any experience securing product liability insurance for a product that is being commercialized.  Currently, we have clinical trial insurance to cover the use of our product candidates in the clinical trials we are conducting. However, these insurance policies have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future commercial collaborators entitle us to indemnification against product liability claims and associated losses, such indemnification may not be available or adequate should any claim or loss arise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Related to Manufacturing and our Dependence on Third Parties</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We rely and expect to continue to rely on third parties for the manufacture of materials for our research programs, preclinical studies and clinical trials and we do not have long-term contracts with any of these parties. This reliance on third parties increases the risk that we will not have sufficient quantities of such materials or any product candidates that we may develop and, if approved, commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We rely and expect to continue to rely on third parties for the manufacture of materials for our clinical trials, research activities and preclinical development. We expect to rely on third parties for commercial manufacture if any of our product candidates receive marketing approval.  We do not currently have long-term agreements with any of the third-party manufacturers we currently use to provide preclinical and clinical trial materials, and we purchase any required materials on a purchase order basis. Certain of these manufacturers are critical to our production and the loss of these manufacturers, or an inability to obtain quantities at an acceptable cost or quality, could delay, prevent or impair our ability to timely conduct preclinical studies or clinical trials, and would materially and adversely affect our development and commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the failure of the third-party to manufacture our product candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them as a result of accidents, fire, loss of personnel, business decisions at or by the third-party manufacturer or otherwise; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the breach by the third-party contractors of our agreements with them; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the failure of third-party contractors to comply with applicable regulatory requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the failure of the third-party to manufacture our product candidates according to our specifications; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">improper handling of clinical supplies, whether during transit or otherwise, impacting the quality of such clinical supplies leading to loss of GMP status and the resulting inability to use such clinical supplies in clinical trials which may result in clinical interruptions and delays in the commencement of planned clinical trials;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">clinical supplies not being delivered to clinical sites on time, leading to delays in the commencement of planned clinical trials or interruptions in ongoing clinical trials, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the misappropriation or unauthorized disclosure of our intellectual property or other proprietary information, including our trade secrets and know-how. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For ruzasvir, we have a sole supplier located in China for our active pharmaceutical ingredient, and for all our product candidates, including bemnifosbuvir, all suppliers of the regulatory starting materials for the respective manufacturing processes are located in China. We expect to continue to use such third-party manufacturers. Any disruption in production or inability of our manufacturers in China to produce adequate quantities to meet our needs, including as a result of COVID-19, a natural disaster, other public health crises, trade disruptions, changes in the US trade policies, could impair our ability to operate our business on a day-to-day basis and adversely impact our ability to continue the  research and development of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations and similar regulatory requirements for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the US. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA and other applicable regulatory authorities, they will not be able to secure and/or maintain authorization for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not authorize these facilities for the manufacture of our product candidates or if it withdraws any such authorization in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or, if approved, market our product candidates. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our third-party manufacturers may be unable to successfully scale up manufacturing of our product candidates in sufficient quality and quantity in a timely manner, if at all, which may impair the clinical advancement and commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In order to conduct clinical trials of our product candidates and commercialize any approved product, our manufacturers need to manufacture them in large quantities. However, they may be unable to successfully increase the manufacturing capacity for any of our product candidates or products in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we, or any manufacturers are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity in a timely manner, the development, testing and clinical trials of these product candidates may be delayed or infeasible, and regulatory approval or commercial launch and sustained commercialization of any resulting products may be delayed or not obtained, which could significantly harm our business. Supply sources could be interrupted from time to time and, if interrupted, would disrupt our manufacturers&#8217; ability to manufacture our product candidates at the scale required. If we are unable to meet the clinical or commercial supply need for our product candidates, or to do so on commercially reasonable terms, we may not be able to develop our product candidates and commercialize our products successfully.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We do not have multiple sources of supply for all of the components used in our product candidates, nor long-term supply contracts, and certain of our suppliers are critical to our production. If we were to lose a critical supplier, it could have a material adverse effect on our ability to complete the development of our product candidates. If we obtain regulatory approval</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">for any of our product candidates, we would need to expand the supply of their components in order to commercialize them.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We do not have multiple sources of supply for all of the components used in the manufacture of bemnifosbuvir or ruzasvir. For ruzasvir, we have a sole supplier located in China for our active pharmaceutical ingredient, and for all our product candidates, including bemnifosbuvir, all suppliers of the regulatory starting materials for the respective manufacturing processes are located in China.  We do not have long-term supply agreements with any of our component suppliers. We may not be able to establish additional sources of supply for our product candidates, or may be unable to do so on acceptable terms. Manufacturing suppliers are subject to cGMP and comparable foreign quality standards and requirements covering manufacturing, testing, quality control and record keeping relating to our product candidates and subject to ongoing inspections by applicable regulatory authorities. Manufacturing suppliers are also subject to local, state and federal regulations and licensing requirements. Failure by any of our suppliers to comply with all applicable regulations and requirements may result in long delays and interruptions in supply.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The number of suppliers of the components of our product candidates is limited. In the event it is necessary or desirable to acquire supplies from alternative suppliers, we might not be able to obtain them on commercially reasonable terms, if at all. It could also require significant time and expense to redesign our manufacturing processes to work with another manufacturer and redesign of processes can trigger the need for conducting additional clinical studies such as comparability or bridging studies. Additionally, certain of our suppliers are critical to our production, and the loss of these suppliers to one of our competitors or otherwise would materially and adversely affect our development and commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As part of any application for marketing approval, regulatory authorities generally conduct inspections that must be satisfactory prior to the approval of the product. Failure of manufacturing suppliers to successfully complete these regulatory inspections could result in delays or prevent the approval of our product candidates. In addition, if supply from the supplier of an approved product is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified through a NDA amendment or supplement, which could result in further delay. The FDA or other regulatory authorities outside of the US may also require additional studies if a new supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we are unable to obtain the supplies we need at a reasonable price or on a timely basis, it could have a material adverse effect on our ability to complete the development of our product candidates or, if we obtain regulatory approval for our product candidates, to commercialize them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We rely on third parties to conduct our preclinical studies and clinical trials. Any failure by a third-party to conduct the clinical trials according to GCPs and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are dependent on third parties to conduct critical aspects of our Phase 3 SUNRISE-3 clinical trial, our Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir, our preclinical studies and our other clinical trials and we expect to rely on third parties to conduct future clinical trials and preclinical studies for our product candidates. Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials or research activities complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP or similar regulations outside the US. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any third parties conducting our clinical trials or preclinical studies are not and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot guarantee that any such CROs, investigators or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash and cash equivalents or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or foreign regulatory authorities conclude that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned, and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any NDA or similar applications we submit to the FDA or foreign regulatory authorities. Any such delay or rejection could prevent us from commercializing our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs and substantially all our clinical trial sites have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which could materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We currently expect that we may collaborate with third parties in connection with the commercialization of our product candidates, if approved. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and commercialize our product candidates successfully, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For commercialization of any of our product candidates that may be approved, our current strategy includes the potential establishment of collaborative relationships with third parties.  As a result of entering into collaborative arrangements with third parties, we become dependent on the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of any product candidates we may seek to develop or commercialize with them. Our ability to generate product revenue from any collaborations will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them. We cannot predict the success of any collaboration that we enter into.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Collaborations involving our product candidates involve many risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators may not properly obtain, maintain, enforce or defend intellectual property or proprietary rights relating to our product candidates or may use our proprietary information inappropriately or in such a way as to expose us to potential litigation or other intellectual property-related proceedings, including proceedings challenging the scope, ownership, validity and enforceability of our intellectual property; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators may own or co-own intellectual property rights covering our product candidates that result from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">disputes may arise with respect to the ownership of intellectual property developed pursuant to collaborations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators may terminate the collaboration, and, as a result, we may not be able to develop a product candidate or we will have to use our own clinical resources and capital to continue development of the product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators may decide not to pursue development and commercialization of any product candidates we develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors, such as an acquisition that diverts resources or creates competing priorities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators with marketing and distribution rights to one or more product candidates may not commit sufficient resources to the marketing and distribution of such product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators may undergo a change of control and the new owners may decide to take the collaboration in a direction that is not in our best interest; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators may become party to a business combination transaction and the continued pursuit and emphasis on our development or commercialization program by the resulting entity under our existing collaboration could be delayed, diminished or terminated; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborators may become bankrupt, which may significantly delay our research or development programs, or may cause us to lose access to valuable technology, devices, materials, know-how or intellectual property of the collaborator relating to our product candidates; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">key personnel at our collaborators may leave, which could negatively impact our ability to productively work with our collaborators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborations may require us to incur short- and long-term expenditures, issue securities that dilute our stockholders, or disrupt our management and business; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaborations may be terminated which may result in a need for additional capital to pursue further development or commercialization or result in delays to development or commercialization of the applicable product candidates; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For example, in February 2022, the Roche License Agreement, under which we exclusively granted to Roche certain rights to develop bemnifosbuvir and certain rights to commercialize bemnifosbuvir outside of the US, terminated. As a result, substantially all activities that Roche was conducting in connection with the development and manufacture of bemnifosbuvir, including global manufacture of clinical trial material and certain operations necessary for the conduct of clinical trials, ceased. Substantially all of these activities are necessary for the continued and ongoing global development of a bemnifosbuvir COV19 product candidate and since February 2022, we have been and remain solely responsible for the conduct and cost of such activities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may face significant competition in seeking appropriate collaborations. Business combinations among biotechnology and pharmaceutical companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate or delay its potential commercialization or reduce the scope of any sales, marketing or distribution activities, or increase our expenditures and undertake development, manufacture or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacture or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we enter into collaborations to develop, manufacture and potentially commercialize any product candidates, we may not be able to realize the benefit of such transactions if we or our collaborator elect not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations. In addition, if our agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator&#8217;s technology or intellectual property or require us to stop development of those product candidates completely. For example, if the license agreement with Merck was terminated, we would be required to discontinue the development, manufacture and commercialization of ruzasvir in combination with bemnifosbuvir, our lead product candidate for the treatment of HCV, unless we could enter into another agreement with Merck potentially on terms less favorable to us. We may also find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Any collaborator may also be subject to many of the risks relating to product development, regulatory approval, and commercialization described in this &#8220;Risk Factors&#8221; section, and any negative impact on our collaborators may adversely affect us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Data provided by collaborators and others upon which we rely that have not been independently verified could turn out to be false, misleading or incomplete.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We rely on third-party vendors, such as CROs, CMOs, investigators, scientists and other service providers to provide us with significant data and other information related to our programs, preclinical studies or clinical trials and our business. If such third parties provide inaccurate, misleading or incomplete data, our business, prospects and results of operations could be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Misconduct by our employees and independent contractors, including principal investigators, CROs, consultants, vendors and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and commercialization, could include intentional, reckless or negligent conduct or unauthorized activities that violate: (i) the laws and regulations of the FDA, and other similar regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii) manufacturing standards; (iii) data privacy, security, anti-corruption, fraud and abuse and other healthcare laws and regulations; or (iv) laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of preclinical studies or clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other US federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If our CMOs and CROs use hazardous materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical materials by our CMOs and medical and biological materials by our CROs. Our CMOs and CROs are subject to federal, state and local laws and regulations in the US and in the countries in which they operate governing the use, manufacture, storage, handling and disposal of hazardous materials. Although we believe that our CMOs&#8217; and CROs&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from chemical, medical, biological or other potentially hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. Generally, we do not have any insurance for liabilities arising from the improper handling of chemical, medical, biological or other potentially hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If we are unable to obtain, maintain, enforce and adequately protect our intellectual property rights with respect to our technology and product candidates, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect our intellectual property and prevent others from duplicating AT-511 (the free base of bemnifosbuvir), bemnifosbuvir and our in-licensed compound ruzasvir and their use or manufacture, or any of our other pipeline product candidates and any future product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the US and other countries with respect to such product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patents or patent applications at a reasonable cost or in a timely manner. Although we enter into confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, CROs, consultants, scientific advisors and other contractors, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the US and other jurisdictions are typically not published until 18 months after filing, and some remain so until issued. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file any patent application related to an invention or product candidate. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The strength of patents in the pharmaceutical field involves complex legal, factual and scientific questions and can be uncertain. It is possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own may fail to result in issued patents with claims that cover our product candidates in the US or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may challenge the inventorship, ownership, validity, enforceability or scope of such patents, which may result in such patents being narrowed or invalidated, or being held unenforceable. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates. Additionally, any US provisional patent application that we file is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of filing the related provisional patent application. If we do not timely file any non-provisional patent application, we may lose our priority date with respect to the provisional patent application and any patent protection on the inventions disclosed in the provisional patent application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. In addition, no assurances can be given that third parties will not create similar or alternative products or methods that achieve similar results without infringing upon our patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If the patent applications we hold with respect to our programs or product candidates fail to issue, if the breadth or strength of protection of our current or future issued patents is threatened, or if they fail to provide meaningful exclusivity for our product candidates, it could dissuade companies from collaborating with us to develop product candidates, or threaten our ability to commercialize our current or future product candidates. Several patent applications covering our product candidates have been filed recently</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">by us. We cannot offer any assurances about which, if any, will result in issued patents, the breadth of any such patents or whether any issued patents will be found invalid or unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, ownership, scope, validity or enforceability, and our patents may be challenged in courts or patent offices in the US and abroad. In addition, the issuance of a patent does not give us the right to practice the patented invention, as third parties may have blocking patents that could prevent us from marketing our product candidate, if approved, or practicing our own patented technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Wide-ranging patent reform legislation in the US, including the Leahy-Smith America Invents Act of 2011 (&#8220;Leahy-Smith Act&#8221;), may increase the uncertainty of the strength or enforceability of our intellectual property and the cost to defend it. The Leahy-Smith Act includes a number of significant changes to US patent law, including provisions that affect the way patent applications are prosecuted and also affect patent litigation. Under the Leahy-Smith Act, the US transitioned from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. This will require us to be prompt going forward during the time from invention to filing of a patent application and to be diligent in filing patent applications, but circumstances could prevent us from promptly filing or prosecuting patent applications on our inventions. The Leahy-Smith Act also enlarged the scope of disclosures that qualify as prior art. Furthermore, if a third-party filed a patent application before effectiveness of applicable provisions of the Leahy-Smith Act, on March 16, 2013, an interference proceeding in the US can be initiated by a third-party to determine if it was the first to invent any of the subject matter covered by the claims of our patent applications. We may also be subject to a third-party preissuance submission of prior art to the US Patent and Trademark Office (&#8220;USPTO&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Leahy-Smith Act created for the first time new procedures to challenge issued patents in the US, including post-grant review, inter partes review and derivation proceedings, which are adversarial proceedings conducted at the USPTO, which some third parties have been using to cause the cancellation of selected or all claims of issued patents of competitors. For a patent with a priority date of March 16, 2013 or later, which all of our patent filings have, a petition for post-grant review can be filed by a third-party in a nine-month window from issuance of the patent. A petition for inter partes review can be filed immediately following the issuance of a patent if the patent was filed prior to March 16, 2013. A petition for inter partes review can be filed after the nine-month period for filing a post-grant review petition has expired for a patent with a priority date of March 16, 2013 or later. Post-grant review proceedings can be brought on any ground of challenge, whereas inter partes review proceedings can only be brought to raise a challenge based on published prior art. These adversarial actions at the USPTO include review of patent claims without the presumption of validity afforded to US patents in lawsuits in US federal courts. The USPTO issued a final rule effective November 13, 2018 announcing that it will now use the same claim construction standard currently used in the US federal courts to interpret patent claims in USPTO proceedings, which is the plain and ordinary meaning of words used. If any of our patents are challenged by a third-party in such a USPTO proceeding, there is no guarantee that we will be successful in defending the patent, which would result in a loss of the challenged patent right to us, including loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a result of all of the foregoing, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement, misappropriation or other violation may result in substantial costs or prevent or delay our development and commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">101</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our commercial success depends in part on our avoiding actual and allegations of infringement, misappropriation or other violation of the patents and other proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the US, involving patent and other intellectual property rights in the pharmaceutical industry, including patent infringement lawsuits, interferences, oppositions, re-examination, and post-grant and inter partes review proceedings before the USPTO and similar proceedings in foreign jurisdictions, such as oppositions before the EPO. Numerous US and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. Many companies in intellectual property-dependent industries, including the pharmaceutical industry, have employed intellectual property litigation as a means to gain an advantage over their competitors. As the pharmaceutical industry expands and more patents are issued, and as third parties become more aware of our product pipeline, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For example, in March 2021, Gilead Sciences first presented a patent claim to the USPTO that purports to cover bemnifosbuvir.  On May 9, 2023, the USPTO issued US Patent No. 11,642,361 (&#8220; &#8216;361 patent&#8221;) with an amended claim (&#8220;Claim&#8221;) to Gilead Sciences that still purports to cover bemnifosbuvir.  We believe that the &#8216;361 patent, if valid and enforceable, will expire in mid-2028.  On August 7, 2023, we filed a Post Grant Review Petition with the USPTO Patent Trial and Appeal Board (&#8220;PTAB&#8221;), challenging the issuance of the Claim to Gilead, on the basis that the Claim is not supported by the written description of the &#8216;361 patent and that the &#8216;361 patent does not have an enabling disclosure for the Claim. In February 2024, the PTAB denied to exercise its discretion to institute the post grant proceeding. This denial does not stop us from making the same or similar arguments, or additional arguments, nor from bringing the same or new evidence of invalidity or unenforceability in court if Gilead Sciences files an infringement suit.  However, while we believe this Claim is invalid and unenforceable, a trial court or an appellate court may disagree and uphold the Claim of the '361 patent, which would require us, prior to commercialization of a bemnifosbuvir product candidate to obtain a license from Gilead Sciences to the &#8216;361 patent.  Such a license may not be available on reasonable terms or at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Third party claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to composition of matter, drug delivery, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. We cannot guarantee that our technologies, products, compositions and their uses do not or will not infringe, misappropriate or otherwise violate third-party patent or other intellectual property rights. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Pending patent applications that have been published can, or subject to certain limitations, later present claims in a manner that could cover our product candidates or the use of our product candidates. After issuance, the scope of patent claims remains subject to construction as determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. In order to successfully challenge the validity of a US patent, we would need to initiate an action either in federal court or at the PTAB as we have done against the '361 patent.  An action brought before the PTAB must be timely submitted within nine months of the issuance of the patent we are seeking to challenge.  In either a PTAB or federal court proceeding, there is no assurance that the PTAB or a court of competent jurisdiction would invalidate the claims of any such US patent or, if a PTAB decision is appealed, that a federal court would uphold a PTAB determination of invalidity.  If any third-party patents were held by a court of competent jurisdiction to cover the composition of matter of any of our product candidates, the manufacturing process of any of our product candidates or the method of use for any of our product candidates, the holders of any such patents may be able to block our ability to commercialize such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">102</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">product candidate unless we obtain a license under the applicable patents, which may not be available at all or on commercially reasonable terms, or until such patents expire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Litigation and contested proceedings can be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate greater resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of the merit of such claims. We may not be aware of all intellectual property rights potentially relating to our technology and product candidates and their uses, or we may incorrectly conclude that third-party intellectual property is invalid or that our activities and product candidates do not infringe, misappropriate or otherwise violate such intellectual property. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third-party&#8217;s intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Parties making claims against us may obtain injunctive or other equitable relief, which could if granted effectively block our ability to further develop and commercialize one or more of our product candidates and/or harm our reputation and financial results. Defense of these claims, regardless of their merit, could involve substantial litigation expense and could be a substantial diversion of management and employee resources from our business. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, in the case of claims concerning registered trademarks, rename our product candidates, or obtain one or more licenses from third parties, which may require substantial time and monetary expenditure, and which might be impossible or technically infeasible. Furthermore, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us; alternatively or additionally it might include terms that impede or destroy our ability to compete successfully in the commercial marketplace. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">A number of companies and universities file and obtain patents in the same area as our products, which are nucleotide prodrugs, and these patent filings could be asserted against us, which may affect our business, and if successful, could lead to expensive litigation, affect the profitability of our products and/or prohibit the sale of a product or its use.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our product candidates are predominantly nucleotide prodrugs, or nucleotide phosphoramidates. A number of companies and universities have patent applications and issued patents in this general area, including for viral indications, such as, for example, Gilead Pharmasset, LLC; Gilead Sciences; Merck &amp; Co.; Bristol Myers Squibb; Roche; University of Cardiff; University College Cardiff Consultants; NuCana, plc; Janssen Pharmaceutical Companies; Medivir AB; and others. If any of these companies or universities, or others, assert that a patent it holds is infringed by any of our product candidates or their use or manufacture, we may be drawn into expensive litigation, which may affect our business, take the time of and distract the attention of our employees, and if the litigation is successful, could affect the profitability of our products or prohibit their sale.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For example, we note that Gilead Sciences has obtained the U.S. '361 patent that includes a Claim that purportedly covers bemnifosbuvir.  We requested the PTAB Board to institute a post grant review of this patent and it declined to exercise its discretion to do so. This denial does not stop us from making the same or similar arguments, or additional arguments, nor from bringing the same or new evidence of invalidity or unenforceability in court if Gilead files an infringement suit.  While we believe this Claim is invalid and unenforceable, a trial court or an appellate court may disagree and uphold the Claim of the '361 patent, which would require us, prior to commercialization of a bemnifosbuvir product candidate to obtain a license from Gilead Sciences to the &#8216;361 patent.  Such a license may not be available on reasonable terms or at all.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">103</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our products are subject to The Drug Price Competition and Patent Term Restoration Act of 1984, as amended (also referred to as the Hatch-Waxman Act), in the US, that can increase the risk of litigation with generic companies trying to sell our products, and may cause us to lose patent protection.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Because our clinical candidates are pharmaceutical molecules reviewed by the Center for Drug Evaluation and Research of the FDA, after commercialization they will be subject in the US to the patent litigation process of the Hatch-Waxman Act, as currently amended, which allows a generic company to submit an Abbreviated New Drug Application ("ANDA") to the FDA to obtain approval to sell our drug using bioequivalence data only. Under the Hatch-Waxman Act, we will have the opportunity to list our patents that cover our drug product or its method of use in the FDA&#8217;s compendium of &#8220;Approved Drug Products with Therapeutic Equivalence Evaluation,&#8221; sometimes referred to as the FDA&#8217;s Orange Book.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Currently, in the US, the FDA may grant five years of exclusivity for new chemical entities (&#8220;NCEs&#8221;) for which all of our products may qualify. An NCE is a drug that contains no active moiety that has been approved by the FDA in any other NDA. A generic company can submit an ANDA to the FDA four years after approval of our product. The submission of an ANDA by a generic company is considered a technical act of patent infringement. The generic company can certify that it will wait until the natural expiration date of our listed patents to sell a generic version of our product or can certify that one or more of our listed patents are invalid, unenforceable or not infringed. If the latter, we will have 45 days to bring a patent infringement lawsuit against the generic company. This will initiate a challenge to one or more of our Orange Book-listed patents based on arguments from the generic company that our listed patents are invalid, unenforceable or not infringed. Under the Hatch-Waxman Act, if a lawsuit is brought, the FDA is prevented from issuing a final approval on the generic drug until 30 months after the end of our data exclusivity period, or a final decision of a court holding that our asserted patent claims are invalid, unenforceable or not infringed. If we do not properly list our relevant patents in the Orange Book, do not timely file a lawsuit in response to a certification from a generic company under an ANDA, or if we do not prevail in the resulting patent litigation, we can lose our proprietary protection, and our product can rapidly become generic. Further, even if we do correctly list our relevant patents in the Orange Book, bring a lawsuit in a timely manner and prevail in that lawsuit, the generic litigation may be at a very significant cost to us of attorneys&#8217; fees and employee time and distraction over a long period. Further, it is common for more than one generic company to try to sell an innovator drug at the same time, and so we may be faced with the cost and distraction of multiple lawsuits. We may also determine it is necessary to settle the lawsuit in a manner that allows the generic company to enter our market prior to the expiration of our patent or otherwise in a manner that adversely affects the strength, validity or enforceability of our patent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">A number of pharmaceutical companies have been the subject of intense review by the FTC or a corresponding agency in another country based on how they have conducted or settled drug patent litigation, and certain reviews have led to an allegation of an antitrust violation, sometimes resulting in a fine or loss of rights. We cannot be sure that we would not also be subject to such a review or that the result of the review would be favorable to us, which could result in a fine or penalty.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The FTC has brought a number of lawsuits in federal court in the past few years to challenge Hatch-Waxman Act ANDA litigation settlements between innovator companies and generic companies as anti-competitive. As an example, the FTC has taken an aggressive position that anything of value is a payment, whether money is paid or not. Under its approach, if an innovator as part of a patent settlement agrees not to launch or delay launch of an authorized generic during the 180-day period granted to the first generic company to challenge an Orange Book-listed patent covering an innovator drug, or negotiates a delay in entry without payment, the FTC may consider it an unacceptable reverse payment. The pharmaceutical industry argues that such agreements are rational business decisions to dismiss risk and are immune from antitrust attack if the terms of the settlement are within the scope of the exclusionary potential of the patent. In 2013, the US Supreme Court, in a five-to-three decision in FTC v. Actavis, Inc., rejected both the pharmaceutical industry&#8217;s and FTC&#8217;s arguments with regard to so-called reverse payments, and held that whether a &#8220;reverse payment&#8221; settlement involving the exchange of consideration for a delay in entry is subject to an anticompetitive analysis depends on five considerations: (a) the potential for genuine adverse effects on competition; (b) the justification of payment; (c) the patentee&#8217;s ability to bring about anticompetitive harm; (d) whether the size of the payment is a workable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">surrogate for the patent&#8217;s weakness; and (e) that antitrust liability for large unjustified payments does not prevent litigating parties from settling their lawsuits, for example, by allowing the generic to enter the market before the patent expires without the patentee&#8217;s paying the generic. Furthermore, whether a reverse payment is justified depends upon its size, its scale in relation to the patentee&#8217;s anticipated future litigation costs, its independence from other services for which it might represent payment, as was the case in Actavis, and the lack of any other convincing justification. The Court held that reverse payment settlements can potentially violate antitrust laws and are subject to the standard antitrust rule-of-reason analysis, with the burden of proving that an agreement is unlawful on the FTC, leaving to lower courts the structuring of such rule of reason analysis. If we are faced with drug patent litigation, including Hatch-Waxman Act litigation with a generic company, we could be faced with such an FTC challenge based on that activity, including how or whether we settle the case, and even if we strongly disagree with the FTC&#8217;s position, we could face a significant expense or penalty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The term of any individual patent depends on applicable law in the country where the patent is granted. In the US, provided all maintenance fees are timely paid, a patent generally has a term of 20 years from its application filing date or earliest claimed non-provisional filing date. Extensions may be available under certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. For patents that are eligible for extension of patent term, we expect to seek extensions of patent terms in the US and, if available, in other countries, however there can be no assurance that we will be granted any patent term extension we seek, or that any such patent term extension will provide us with any competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The Hatch-Waxman Act in the US provides for the opportunity to seek a patent term extension on one selected patent for each of our products, and the length of that patent term extension, if at all, is subject to review and approval by the USPTO and the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the US, the Hatch-Waxman Act permits one patent term extension of up to five years beyond the normal expiration of one patent per product, which if a method of treatment patent, is limited to the approved indication (or any additional indications approved during the period of extension). The length of the patent term extension is typically calculated as one half of the clinical trial period plus the entire period of time during the review of the NDA by the FDA, minus any time of delay by us during these periods. There is also a limit on the patent term extension to a term that is no greater than fourteen years from drug approval. Therefore, if we select and are granted a patent term extension on a recently filed and issued patent, we may not receive the full benefit of a possible patent term extension, if at all. We might also not be granted a patent term extension at all, because of, for example, failure to apply within the applicable period, failure to apply prior to the expiration of relevant patents or otherwise failure to satisfy any of the numerous applicable requirements. Moreover, the applicable authorities, including the FDA and the USPTO in the US, and any equivalent regulatory authorities in other countries, may not agree with our assessment of whether such extensions are available, may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to obtain approval of competing products following our patent expiration by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. If this were to occur, it could have a material adverse effect on our ability to generate product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In 1997, as part of the Food &amp; Drug Administration Modernization Act, (&#8220;FDAMA&#8221;), Congress enacted a law that provides incentives to drug manufacturers who conduct studies of drugs in children. The law, which provides six months of exclusivity in return for conducting pediatric studies, is referred to as the pediatric exclusivity provision. If clinical studies are carried out by us that comply with the FDAMA, we may receive an additional six-month term added to our regulatory data exclusivity period and our patent term extension period, if received, on our product. However, if we choose not to carry out pediatric studies that comply with the FDAMA, or are not accepted by the FDA for this purpose, we would not receive this additional six-month exclusivity extension to our data exclusivity or our patent term extension.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">105</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In Europe, supplementary protection certificates are available to extend a patent term up to five years to compensate for patent term lost during regulatory review, and can be extended for an additional six months if data from clinical trials is obtained in accordance with an agreed-upon pediatric investigation plan. Although all countries in Europe must provide supplementary protection certificates, there is no unified legislation among European countries and so supplementary protection certificates must be applied for and granted on a country-by-country basis. This can lead to a substantial cost to apply for and receive these certificates, which may vary among countries or not be provided at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If we are unable to obtain licenses from third parties on commercially reasonable terms or at all, or fail to comply with our obligations under such agreements, our business could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">It may be necessary for us to use the patented or other proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning or otherwise controlling such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Additionally, if we fail to comply with our obligations under any future license agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, or impede, or delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Litigation and adversarial proceedings are expensive, time-consuming and if unsuccessful, can adversely affect our ability to sell our products when commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Competitors and other third parties may infringe, misappropriate or otherwise violate our or our future licensors&#8217; patents, trademarks, copyrights or other intellectual property. As a result, we may need to file infringement, misappropriation or other intellectual property-related claims against third parties. To counter infringement or other unauthorized use, we may be required to file claims on a country-by-country basis, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such claims, which often last for years before they are concluded.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">106</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any claims we assert against third parties could also provoke these parties to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property. In addition, in a patent infringement proceeding, such parties could counterclaim that the patents we have asserted are invalid or unenforceable, or both. In patent litigation in the US, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the US or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). The outcome following legal assertions of invalidity and unenforceability is unpredictable.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In any such proceeding, a court may decide that a patent of ours, or a patent that we in-license, is not valid, is unenforceable and/or is not infringed, or may construe such patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, interpreted narrowly or held unenforceable in whole or in part, could put our patent applications at risk of not issuing, and could limit our ability to assert those patents against those parties or other competitors and curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks, which could materially harm our business and negatively affect our position in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Even if we establish infringement, misappropriation or other violation of our intellectual property, the court may decide not to grant an injunction against further such activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On June 3, 2019, we received an anonymous third-party Observation filed in connection with our international Patent Cooperation Treaty patent application for our second patent family, which covers the hemisulfate salt form of AT-511, or bemnifosbuvir. The Observation generally challenges the patentability of the hemisulfate salt bemnifosbuvir over the free base AT-511 described in our first patent family. On August 1, 2019, we filed a response to the Observation describing that the bemnifosbuvir hemisulfate salt of AT-511 is not obvious in view of the AT-511 free base because bemnifosbuvir disproportionately concentrates in the liver over the heart, as shown in vivo in a dog model, which can provide an increased therapeutic effect to treat HCV, and decreased toxicity because HCV is a disease of the liver. Further, while not raised in the response to the Observation, we have now also shown that bemnifosbuvir has a longer half-life and higher concentration in the lung than in the liver </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> in monkeys, which is relevant to our COVID-19 indication. The Observations by anonymous third parties as well as our responses are placed in the file and available to be read and considered by any country examining our respective patent applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In December 2019, the US Patent Office issued a patent to us covering the composition of matter of bemnifosbuvir.  Our composition of matter patent on bemnifosbuvir has also been granted in China, Japan, Korea, Australia, Brazil, Eurasia, Canada, Israel, New Zealand, South Africa, Russia and Mexico, and is pending in certain other countries and regions, including Europe.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our patent on AT-511 or its pharmaceutically acceptable salt, which includes bemnifosbuvir, has been granted in United States, China, Japan, Korea, Australia, Eurasia, Canada, Israel, Singapore, Malaysia,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">107</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Indonesia, Georgia, Russia, Ukraine, Columbia and Mexico, and is also pending in certain other countries and regions, including Europe.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may not be aware of patent claims that are currently or may in the future be pending that affect our business by the competitors working in this area. Patent applications are typically published between six and eighteen months from filing, and the presentation of new claims in already pending applications can sometimes not be visible to the public, including to us, for a period of time, or if publicly available, not yet seen by us. We cannot provide any assurance that a third-party practicing in the general area of our technology will not present a patent claim that covers one or more of our products or their methods of use or manufacture at any time, including before or during this registration period. If that does occur, we may have to take steps to try to invalidate such patent or application, and we may either choose not to or may not be successful in such attempt. A license to the patent or application may not be available on commercially reasonable terms or at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On April 12, 2022, we received notification of a Pre-Grant Opposition from the Controller General of Patents, Designs, and Trademarks at the Indian Patent Office. The Opposition was filed by Sankalp Rehabilitation Trust and challenges our pending patent claims to AT-511 or a pharmaceutically acceptable salt thereof. In February 2023, we responded to this Pre-Grant Opposition.  We are currently awaiting further action on this matter by the Indian Patent Office.  In addition to the Pre-Grant Opposition related to AT-511, we have received notification of a second Pre-Grant Opposition filed by the Sankalp Rehabilitation Trust.  This second Pre-Grant Opposition challenges our pending patent claims to bemnifosbuvir.  In October 2023,  we responded to this second Pre-Grant Opposition.  While we intend to vigorously defend our patent claims on AT-511 and bemnifosbuvir and their use to treat HCV in India, we cannot guarantee that the Indian Patent Office will decide in our favor with respect to either or both Pre-Grant Oppositions and allow our patent claims to either AT-511 or bemnifosbuvir to grant. In addition, Pre-Grant Oppositions in India can proceed very slowly, and therefore these proceedings may not be resolved for several years. Our patent applications will not issue as a patent on AT-511 or bemnifosbuvir or their use to treat HCV in India unless and until these Pre-Grant Oppositions are resolved in our favor. If it is not resolved in our favor, we may not receive patents on AT-511, bemnifosbuvir or their use to treat HCV in India.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Changes in patent laws and enforcement by courts and other authorities in the US and other jurisdictions may impact our ability to protect our patents.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The US Supreme Court and lower courts have issued opinions in patent cases in the last few years that many consider may weaken patent protection in the US, either by narrowing the scope of patent protection available in certain circumstances, holding that certain kinds of innovations are not patentable or generally otherwise making it easier to invalidate patents in court. Additionally, there have been recent proposals for additional changes to the patent laws of the US and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our ability to enforce our proprietary technology. Depending on future actions by the US Congress, the US courts, the USPTO and the relevant law-making and other bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce and defend our existing patents and patents that we might obtain in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In June 2023, the European Unitary Patent system and the European Unified Patent Court (&#8220;UPC&#8221;) were launched. European patent applications now have the option, upon grant of a patent, of becoming a Unitary Patent which is subject to the jurisdiction of the UPC. In addition, conventional European patents, both already granted at the time the new system began and granted thereafter, are subject to the jurisdiction of the UPC, unless actively opted out. This was a significant change in European patent practice and deciding whether to opt-in or opt-out of Unitary Patent practice entail strategic and cost considerations. The UPC provides our competitors with a new forum to centrally revoke our European patents and makes it possible for a competitor to obtain pan-European injunctions against us. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. While we have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, doing so may preclude us from realizing the benefits of the UPC. Moreover, the decision whether to opt-in or opt-out of Unitary Patent status will require coordinating with co-applicants, if any, adding complexity to any such decision.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">108</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as in the US and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property rights in foreign jurisdictions, our ability to compete and our business prospects in such marketplaces could be substantially harmed. For example, we have been notified that two Pre-Grant Opposition have been filed with the Controller General of Patents, Designs and Trademarks at the Indian Patent Office relating to our pending patent claims to AT-511, bemnifosbuvir and their use to treat HCV in India. While we intend to defend our patent claims for AT-511, bemnifosbuvir and their use to treat HCV, we cannot provide any assurance that we will succeed or that the Indian patent office will allow the patent claims to grant. The cost of foreign adversarial proceedings can also be substantial, and in many foreign jurisdictions, the losing party must pay the attorney fees of the winning party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">    </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The USPTO, EPO and other patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the US in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay such fees due to non-US patent agencies. While, in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors or other third parties might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may not be able to enforce our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive.  Therefore, we may choose not to pursue or maintain protection for certain intellectual property in certain jurisdictions.  The requirements for patentability may differ in certain countries, particularly in developing countries. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the US.  These products may compete with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by changes in foreign intellectual property laws. Additionally, laws of some countries outside of the US and Europe do not afford intellectual property protection to the same extent as the laws of the US and Europe. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, including India, China and other developing countries, may not favor the enforcement of our patents and other intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This could make it difficult for us to stop the infringement of our patents or the misappropriation or other violation of our other intellectual property rights. A number of foreign countries have stated that they are willing to issue compulsory licenses to patents held by innovator companies on approved drugs to allow the government or one or more third-party companies to sell the approved drug without the permission of the innovator patentee where the foreign government concludes it is in the public interest. India, for example, has used such a procedure to allow domestic companies to make and sell patented drugs without innovator approval. There is no guarantee that patents covering any of our drugs will not be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">109</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">subject to a compulsory license in a foreign country, or that we will have any influence over if or how such a compulsory license is granted. Further, Brazil allows its regulatory agency ANVISA to participate in deciding whether to grant a drug patent in Brazil, and patent grant decisions are made based on several factors, including whether the patent meets the requirements for a patent and whether such a patent is deemed in the country&#8217;s interest. In addition, several other countries have created laws that make it more difficult to enforce drug patents than patents on other kinds of technologies. Further, under the treaty on the Trade-Related Aspects of Intellectual Property, as interpreted by the Doha Declaration, countries in which drugs are manufactured are required to allow exportation of the drug to a developing country that lacks adequate manufacturing capability. Therefore, our drug markets in the US or foreign countries may be affected by the influence of current public policy on patent issuance, enforcement or involuntary licensing in the healthcare area.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The WTO is currently considering a waiver of intellectual property rights for COVID-19 vaccines and the US government has taken a stance in support of the waiver. The current proposal is for a temporary waiver of intellectual property rights that cover COVID-19 vaccines, however, the ultimate timing and scope of the waiver, if approved, is unknown. The scope and timing of such waiver will likely be subject to extensive negotiations given the complexity of the matter, which may result in prolonged uncertainty and therefore could adversely affect our business. If a waiver is approved and covers COVID-19 treatments, such as bemnifosbuvir, our ability to successfully commercialize bemnifosbuvir and protect our related technology could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We rely on our ability to stop others from competing by enforcing our patents, however some jurisdictions may require us to grant licenses to third parties. Such compulsory licenses could be extended to include some of our product candidates, which may limit our potential revenue opportunities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties, in certain circumstances. For example, compulsory licensing, or the threat of compulsory licensing, of life-saving products and expensive products is becoming increasingly popular in developing countries, either through direct legislation or international initiatives. Compulsory licenses could be extended to include some of our product candidates, if they receive marketing approval, which may limit our potential revenue opportunities. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the US and Europe. Competitors may also use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in major markets for our products where such patent rights exist, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may be limited to monetary relief and may be unable to enjoin infringement if a government is the infringer, which could materially diminish the value of the patent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is either not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with parties who have access to them, such as our employees, CROs, consultants, scientific advisors and other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">110</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">contractors. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and our trade secrets could be disclosed, and we may not have adequate remedies for any such breach. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the US are less willing or unwilling to protect trade secrets. Misappropriation or unauthorized disclosure of our trade secrets or other confidential proprietary information could cause us to lose trade secret protection, impair our competitive position and have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets or other confidential proprietary information are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret or other confidential proprietary information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Further, we cannot provide any assurances that competitors or other third parties will not otherwise gain access to our trade secrets and other confidential proprietary information or independently discover or develop substantially equivalent technology and processes. If we are unable to prevent disclosure of the trade secrets and other non-patented intellectual property related to our product candidates and technologies to third parties, there is no guarantee that we will have any such enforceable trade secret protection and we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, that our employees have wrongfully used or disclosed alleged trade secrets of their former employers, or asserting ownership of what we regard as our own intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have employed, and may in the future employ, individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of such individuals&#8217; former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or our ability to hire personnel, which, in any case of the foregoing, could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Although it is our policy to require all of our employees and consultants to assign their inventions to us, to the extent that employees or consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. We may also be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our proprietary rights may not adequately protect our technologies and product candidates, and intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">111</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">others may be able to make products that are the same as or similar to our product candidates but that are not covered by the claims of our patents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">others, including inventors or developers of our patented technologies who may become involved with competitors, may independently develop similar technologies that function as alternatives or replacements for any of our technologies without infringing, misappropriating or otherwise violating our intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we might not have been the first to conceive and reduce to practice the inventions covered by our patents or patent applications; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we might not have been the first to file patent applications covering certain of our inventions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third-party may subsequently file a patent covering such intellectual property; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our pending patent applications might not result in issued patents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">there might be prior public disclosures that could invalidate our patents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our issued patents may not provide us with any commercially viable products or competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors or other third parties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the Supreme Court of the US, other US federal courts, Congress, the USPTO or similar foreign authorities may change the standards of patentability and any such changes could narrow or invalidate, or change the scope of, our patents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ownership, validity or enforceability of our patents or patent applications may be challenged by third parties; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the patents or pending or future applications of third parties, if issued, may have an adverse effect on our business. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We expect to experience significant growth over time in the number of our employees and the scope of our operations, particularly in the areas of product candidate development, regulatory and clinical affairs and sales, marketing and distribution. To manage our growth activities, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team, as a group, in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. As we expand our company, we may have difficulty identifying, hiring and integrating new personnel. Future growth would impose significant additional responsibilities on our management, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors; and</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">112</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">maintaining our operational, financial and management controls, reporting systems and procedures. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth, including the potential establishment of a commercial infrastructure and commercialization of product candidates, if any, that are approved for sale will require significant capital expenditures and may divert financial resources from other projects, such as the development of other product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow product revenues, if any, could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize any approved products and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including substantially all aspects of clinical trial conduct and execution, international regulatory affairs activities and manufacturing. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by independent organizations, advisors or consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing independent organizations, advisors or consultants or find other competent outside independent organizations, advisors and consultants on economically reasonable terms, or at all. If we are not able to effectively expand our organization by hiring new employees and expanding our groups of advisors and consultants, or we are not able to effectively maintain or obtain facilities to accommodate this expansion, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Many of the biotechnology and pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we do. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can discover and develop product candidates and operate our business will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We only have a limited number of employees to manage and operate our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of February 25, 2024, we had 75 full-time employees. Our focus on the clinical development of product candidates in two distinct disease indications requires us to manage and operate our business in a highly efficient manner. We cannot assure you that we will be able to hire and/or retain adequate staffing levels to develop our product candidates or run our operations and/or to accomplish all of the objectives that we otherwise would seek to accomplish.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If we lose key management or scientific personnel, cannot recruit qualified employees, directors, officers or other significant personnel or experience increases in our compensation costs, our business may materially suffer.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are highly dependent on our officers, directors and key employees. Due to the specialized knowledge each of our officers, directors and key employees possesses with respect to our product candidates and our operations, the loss of service of any of one or more of our officers, directors or key employees could seriously delay, harm or prevent the planning and execution of clinical trials and other key activities required for the successful advancement of our business. Although we have employment agreements with our executive officers, in general, these agreements do not prevent our executive officers from terminating their employment with us at any time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">113</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We do not carry key person life insurance on any officers or directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition to retaining the continued service of our officers, directors and key employees, our future success and growth will depend in part on our ability to identify, hire and retain additional personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our ability to identify, hire and retain additional personnel and, if necessary, replace departed executive officers and key employees may be difficult or costly and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to discover or otherwise identify and develop product candidates and gain regulatory approval of and commercialize products successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or effectively incentivize these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to develop and commercialize product candidates will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Many of our key officers, directors and employees are vested in a substantial amount of our common stock or options to purchase our common stock. Our employees, including many of our officers and key employees, may be more likely to leave us if the shares they own have significantly fluctuated in value relative to the original purchase prices of the shares, or if the exercise prices of the options that they hold are significantly below or above the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The global economy, including credit and financial markets, has recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in interest rates, increases in inflation rates and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. Similarly, international conflicts, terrorism and political instability have created extreme volatility in the capital markets.  These conditions may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. In addition, there is a risk that one or more of our CROs, suppliers, CMOs or other third-party providers may not survive an economic downturn. As a result, our business, results of operations and price of our common stock may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Our business could face adverse consequences as a result of the actions of activist shareholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have in the past and may in the future be subject to unsolicited attempts to gain control of our company, proxy contests, and other forms of shareholder activism. For example, in May 2023, our board of directors received an unsolicited proposal from a stockholder to acquire all outstanding shares of our common stock. Our Board of Directors carefully reviewed and evaluated the proposal in consultation with our independent financial and legal advisors and decided not to approve the proposal.  If in the future, a stockholder, by itself or in conjunction with other stockholders or as part of a group, engages in activist activities with respect to us, our business could be adversely affected because responding to an unsolicited offer, proxy contest or other actions by activist stockholders can be costly and time-consuming, disruptive to our operations and divert the attention of management and our employees from the execution of our strategy. In addition, actual or perceived uncertainties as to our future direction caused by activist activities may cause or appear to cause instability, potentially making it more difficult to attract and retain qualified personnel and collaborators or leading to the loss of collaboration opportunities, and if individuals are elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively and timely implement our strategic plans. Activist stockholder activities may also cause significant fluctuations in our stock price based on temporary or speculative market perceptions, or other factors that do not necessarily reflect the fundamental underlying value of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">114</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our business. Finally, we might experience a significant increase in legal fees and administrative and associated costs incurred in connection with responding to an unsolicited offer, proxy contest or related action. These actions could also negatively affect the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Risks Related to Our Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline, even if our business is doing well.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. We currently have limited research coverage by securities and industry analysts.  If any of the analysts who cover us, or may cover us, downgrades our common stock or issues an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our preclinical studies or clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions may also limit the price that investors are willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from filling vacancies on our board of directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the ability of our board of directors to alter our bylaws without obtaining stockholder approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">115</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our restated certificate of incorporation designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our restated certificate of incorporation, specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving claims brought against us by stockholders, other than suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction and any action that the Court of Chancery of the State of Delaware has dismissed for lack of subject matter jurisdiction, which may be brought in another state or federal court sitting in the State of Delaware. Our restated certificate of incorporation also specifies that unless we consent in writing to the selection of an alternate forum, the federal district courts of the US shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our restated certificate of incorporation described above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We believe this provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes or federal judges experienced in resolving Securities Act disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors, officers, employees and agents as it may limit any stockholder&#8217;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees or agents. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">General Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Raising additional capital may cause additional dilution to our stockholders, restrict our operations, require us to relinquish rights to our technologies or product candidates, and could cause our share price to fall.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Until such time, if ever, as we can generate substantial revenue from product sales, we may finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">116</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">operations, our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, redeeming our stock, making certain investments and engaging in certain merger, consolidation or asset sale transactions, among other restrictions. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We may engage in acquisitions or strategic collaborations that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the future, we may enter into transactions to acquire other businesses, products or technologies or enter into strategic collaborations, including licensing transactions. If we do identify suitable acquisition or collaboration candidates, we may not be able to complete such acquisitions or collaborations on favorable terms, or at all. Any acquisitions or collaborations may not strengthen our competitive position, and these transactions may be viewed negatively by stock research analysts or investors, and we may never realize the anticipated benefits of such acquisitions or collaborations. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business or collaboration that are not covered by the indemnification we may obtain from the seller or our collaborator. In addition, we may not be able to successfully integrate any acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions or collaborations may also divert management attention from day-to-day responsibilities, lead to a loss of key personnel, increase our expenses and reduce our cash and cash equivalents available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or collaborations or the effect that any such transactions might have on our operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by natural disasters or pandemics and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Natural disasters (including, but not limited to earthquakes, fires, storms, floods, droughts, and extreme temperatures) or pandemics, other than or in addition to COVID-19, could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. Climate change has increased, and is expected to continue to increase the frequency or intensity of such events. Moreover, climate change may result in various chronic changes in the physical environment, such as changes in temperature or precipitation patterns or sea-level rise, as well as changes to the availability of certain natural resources, that may also have an adverse impact on our operations. If a natural disaster, power outage, pandemic, such as the COVID-19 pandemic, or other event occurred that prevented us from using all or a significant portion of our headquarters or the virtual network capabilities upon which our employees depend to collaborate and access critical business records, that damaged critical infrastructure, such as the manufacturing facilities on which we rely, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Increased attention to, and evolving expectations for ESG initiatives could increase our costs, harm our reputation, or otherwise adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Companies across industries are facing increasing scrutiny from a variety of stakeholders related to their ESG and sustainability practices. Expectations regarding voluntary ESG initiatives and disclosures may result in increased costs (including but not limited to increased costs related to compliance, stakeholder</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">117</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">engagement, contracting and insurance), enhanced compliance or disclosure obligations, or other adverse impacts to our business, financial condition, or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">While we may at times engage in voluntary initiatives (such as voluntary disclosures, certifications, or goals, among others) to improve the ESG profile of our Company and/or product candidates and if approved, our products, such initiatives may be costly and may not have the desired effect. Moreover, we may not be able to successfully complete such initiatives due to factors that are within or outside of our control. Even if this is not the case, our actions may subsequently be determined to be insufficient by various stakeholders, and we may be subject to investor or regulator engagement on our ESG efforts, even if such initiatives are currently voluntary.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Certain market participants, including major institutional investors and capital providers, use third-party benchmarks and scores to assess companies&#8217; ESG profiles in making investment or voting decisions. Unfavorable ESG ratings or other reputational issues could result in various negative impacts, including negative investor sentiment, decreased interest in our shares, changes in the availability or cost of capital, or our ability to attract/retain employees, customers, or business partners. Simultaneously, some parties are seeking to restrict or eliminate companies&#8217; attention to ESG matters. Both advocates and opponents to certain ESG matters are increasingly resorting to a range of activism forms, including media campaigns and litigation, to advance their perspectives. To the extent we are subject to such activism, it may require us to incur costs or otherwise adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition, we expect there will likely be increasing levels of regulation, disclosure-related and otherwise, with respect to ESG matters. For example, various policymakers, including the SEC and the State of California, have adopted or are considering adopting requirements for significantly expanded climate-related disclosures, which may require us to incur significant additional costs to comply, including the implementation of significant additional internal controls processes and procedures regarding matters that have not been subject to such controls in the past, and impose increased oversight obligations on our management and board of directors. These and other changes in stakeholder expectations will likely lead to increased costs as well as scrutiny that could heighten all of the risks identified in this risk factor. Additionally, many of our customers and suppliers may be subject to similar expectations, which may augment or create additional risks, including risks that may not be known to us.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Litigation against us could be costly and time-consuming to defend and could result in additional liabilities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We may from time to time be subject to legal proceedings and claims that arise in the ordinary course of business or otherwise, such as claims brought by third parties in connection with commercial disputes and employment claims made by our current or former employees. Claims may also be asserted by or on behalf of a variety of other parties, including government agencies, patients or vendors of our customers, or stockholders. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any litigation involving us may result in substantial costs, operationally restrict our business, and may divert management&#8217;s attention and resources, which may seriously harm our business, overall financial condition and results of operations. Insurance may not cover existing or future claims, be sufficient to fully compensate us for one or more of such claims, or continue to be available on terms acceptable to us. A claim brought against us that is uninsured or underinsured could result in unanticipated costs, thereby adversely impacting our results of operations and resulting in a reduction in the trading price of our stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The market price of our common stock has been volatile and may fluctuate substantially.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our stock price has been and is likely to remain volatile. Extreme fluctuations have occurred in our stock price. Additionally, the stock market in general, and The Nasdaq Global Select Market-listed companies and biopharmaceutical companies in particular have experienced extreme volatility in trading volume that exacerbates, is disproportionate to or in some cases has been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at a profit. The market price for our common stock may be influenced by many factors, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the success of competitive products or technologies; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">118</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">actual or expected changes in our growth rate relative to our competitors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">results of our ongoing, planned or any future preclinical studies, clinical trials or clinical development of our product candidates or those of our competitors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">unanticipated serious safety concerns related to the use of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">developments related to our existing or any future collaborations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">developments concerning our manufacturers or our manufacturing plans; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">regulatory actions with respect to our product candidates or our competitors&#8217; products and product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">regulatory or legal developments in the US and other countries; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">development of third-party product candidates that may address our markets and make our product candidates less attractive; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">changes in physician, hospital or healthcare provider practices that may make our product candidates less useful;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our failure to commercialize our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">announcements by us, our partners or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the recruitment or departure of key scientific or management personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the level of expenses related to any of our product candidates or clinical development programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">changes in accounting practices; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the trading volume of our common stock; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our cash, cash equivalents and marketable securities position; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to effectively manage our growth; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">sales of our common stock by us or our stockholders in the future; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">publication of research reports about us or our industry, or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ineffectiveness of our internal controls; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">significant lawsuits, including intellectual property or stockholder litigation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">actual or expected changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">119</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">general economic, industry and market conditions, including rising inflation and interest rates; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the other factors described in this &#8220;Risk Factors&#8221; section. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">If we fail to maintain effective internal control over financial reporting and effective disclosure controls and procedures, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which may adversely affect investor confidence in our company.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are required to comply with the SEC&#8217;s rules implementing Sections 302 and 404 of the Sarbanes-Oxley Act, which require management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of controls over financial reporting. In addition, we have in the past and may for future fiscal years beginning January 1, 2024 and after be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm and our independent registered public accounting firm has in the past and may be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 for future fiscal years beginning January 1, 2024 and after. Our independent registered public accounting firm may issue a report that is adverse in the event material weaknesses have been identified in our internal control over financial reporting. For the year ended December 31, 2023, our independent registered public accounting firm was not required to issue an attestation report on internal control over financial reporting or attest to the effectiveness of our internal control over financial reporting pursuant to Section 404.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To comply with the requirements of Section 404, we may need to undertake additional actions, such as implementing new internal controls and procedures and hiring additional accounting or internal audit staff. We will need to continue to dedicate internal resources, engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing whether such controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Testing and maintaining internal control can divert our management&#8217;s attention from other matters that are also important to the operation of our business. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. When evaluating our internal control over financial reporting, we may identify material weaknesses that we may not be able to remediate in time to meet the applicable deadline imposed upon us for compliance with the requirements of Section 404. If we identify any material weaknesses in our internal controls over financial reporting or we are unable to comply with the requirements of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm, if required, is unable to express an opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports. As a result, the market price of our common stock could be materially adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We are continuing to refine our disclosure controls and procedures to provide reasonable assurance that information we must</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">120</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, is likely to be your sole source of gain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain all available funds and future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common stock is likely to be your sole source of gain on an investment in our common stock for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">121</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 1B. Unresolve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">d Staff Comments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 1C. Cybers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">e</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">curity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF).  This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our cybersecurity risk management program includes:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology (&#8220;IT&#8221;) environment; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">cybersecurity awareness training of our employees, incident response personnel, and senior management;  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">a third-party risk management process for certain service providers, suppliers, and vendors that have access to our critical systems and information. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. For more information, see the section titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Risk Factors &#8212; Our business and operations may suffer in the event of information technology system failures, cyberattacks, or deficiencies, which could materially affect our results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cybersecurity Governance</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#8220;Audit Committee&#8221;) oversight of cybersecurity and other IT risks. The Committee oversees management&#8217;s implementation of our cybersecurity risk management program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Audit Committee receives periodic reports from management on our cybersecurity risks and would be notified between such regular updates regarding any significant cybersecurity threat or incident, if applicable. The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">122</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our IT team, which includes both our internal staff and retained consultants with IT and cybersecurity expertise, is led by our executive director of IT.  The IT team has responsibility for, among other things, developing and implementing practices, procedures and controls designed to identify, assess and manage cybersecurity programs and risks.  The IT team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the IT environment.  Our IT team is supplemented by a security committee, comprised of representatives from key functional areas of our business and includes both our CFO and our Sr. VP of Human Resources to whom the executive director of IT reports.   Combined, members of our security committee and our internal IT team have more than 25 years of risk management experience, including with respect to IT and cybersecurity systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 2. Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">perties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our principal office is located at 225 Franklin Street, Boston, Massachusetts, where we lease 17,544 square feet of office space. We lease this space under a sublease agreement, with the term January 1, 2022 through December 31, 2026.  We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are not subject to any material legal proceedings.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 4. Mine Safe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ty Disclosures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">123</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">PART II	</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stoc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">kholder Matters and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Certain Information Regarding the Trading of Our Common Stock</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our common stock has been listed on The Nasdaq Global Select Market under the symbol &#8220;AVIR&#8221; since October 30, 2020.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Holders of Our Common Stock</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of February 28, 2024 there were 18 stockholders of record of our common stock, which does not reflect stockholders whose shares were held in nominee or street name by brokers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Dividends</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to fund the development and expansion of our business, and therefore do not anticipate paying cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, business prospects, contractual arrangements, any limitations on payment of dividends present in any future debt agreements and other factors that our board of directors may deem relevant, and will be subject to the restrictions contained in any future financing instruments.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Use of Proceeds</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On November 3, 2020, we completed the initial public offering (&#8220;IPO&#8221;) of our common stock pursuant to which we issued and sold 14,375,000 shares of our common stock at a price to the public of $24.00 per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">All shares issued and sold in the initial public offering were registered under the Securities Act pursuant to a Registration Statement on Form S-1 (File No.333-249404), as amended (&#8220;Registration Statement&#8221;), declared effective by the SEC on October 29, 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We received net proceeds of approximately $317.6 million after deducting underwriting discounts and commissions and offering expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The net proceeds from our IPO have been invested primarily in money market accounts and marketable securities.  There has been no material change in the expected use of the net proceeds from our IPO as described in our Prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on October 29, 2020.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 6.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> Reserved</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">124</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes to those statements included elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are a clinical-stage biopharmaceutical company leveraging our deep understanding of antiviral drug development, medicinal chemistry, biology, biochemistry and virology to discover and develop novel orally administered product candidates to treat serious viral diseases. Currently, we are developing our lead product candidate, bemnifosbuvir, in a global Phase 3 clinical trial as a monotherapy for the treatment of COVID-19, and in a global Phase 2 clinical trial as part of a combination therapy with ruzasvir, an NS5A inhibitor, for the treatment of HCV infection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Bemnifosbuvir</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Derived from our internal discovery program, bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. We believe that utilizing this double prodrug moiety approach allows us to maximize formation of the active metabolite potentially resulting in an oral antiviral product candidate that is selective for and highly effective at preventing replication and transcription of SARS-CoV-2, the causative agent of COVID-19, HCV and other single ssRNA viruses while avoiding toxicity to host cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">COVID-19 &#8211; Our Strategy and Objective</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">More than four years after emerging as a global pandemic and public health crisis, COVID-19 remains a persistent and serious health threat because of continued variant fueled surges of infection.  The SARS-CoV-2 virus is accumulating mutations with amino acid substitutions faster than any other endemic ssRNA virus and the constant evolution of new variants has resulted in continued waves of infections globally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our COVID-19 strategy is focused on the development of bemnifosbuvir for the treatment of COVID-19.  We believe that oral antivirals protecting against the development of severe infection and transmission remain urgently needed particularly for high-risk patients who currently have few or no treatment options due to limitations of currently available vaccines and therapeutics. High-risk patients include those who are unvaccinated, patients who fail to respond to available vaccines, vaccinated patients with waning efficacy, which can occur between three to six months after immunization, and patients for whom current treatments are contraindicated.   Without suitable treatments, high-risk patients remain vulnerable to severe COVID-19 and associated hospitalization and death.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As COVID-19 continues to persist as a global endemic disease, we believe that the global COVID-19 therapeutic market, and in particular the US market, will remain a multi-billion-dollar commercial opportunity for many years to come.  Further, as the commercialization of COVID-19 therapeutics enters more fully into traditional distribution and reimbursement channels in 2024 and after, we anticipate that a major consideration for third-party payers will be a cost/value analysis that is driven in part by the economic burden of hospitalization, especially for high-risk populations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The objective of our COVID-19 development program is to address the current unmet medical needs of high-risk patients who remain vulnerable to hospitalization and death from COVID-19 by developing bemnifosbuvir, as a safe, effective, convenient, oral antiviral without the key limitations of current treatment options, including drug-drug interactions, tolerability and other safety concerns.  The FDA has granted Fast Track designation for the investigation of bemnifosbuvir to treat COVID-19.  Currently, we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">125</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">are evaluating bemnifosbuvir in SUNRISE-3, a global Phase 3 clinical trial that is enrolling high-risk patients with mild to moderate COVID-19.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For COVID-19, bemnifosbuvir targets the SARS-CoV-2 RNA polymerase (Nsp12), a highly conserved enzyme that is unlikely to change as the virus mutates and new variants continue to emerge. The RNA polymerase complex is responsible for both replication and transcription of SARS-CoV-2.   Bemnifosbuvir has a unique dual mechanism of action at both the RdRp and nidovirus RdRp associated NiRAN active sites on the highly conserved SARS-CoV-2 RNA polymerase, which has the potential to create a high barrier to resistance. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">In vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> data have shown that bemnifosbuvir was active with similar activity against all SARS-CoV-2 VOC and VOI that have been tested to date, including Omicron subvariants BA.4, BA.5 and XBB and EG.5.1.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">HCV &#8211; Our Strategy and Objective</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Despite the availability of direct acting antiviral oral combination treatment regimens, HCV continues to be a serious viral disease in the US and globally. Approximately 58 million people globally are living with chronic HCV infection.  The WHO estimates a global incidence of 1.5 million new infections and 290,000 deaths per year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In the US, HCV is recognized as a health crisis with approximately 2.4 million individuals estimated to be infected.  Prevalence of HCV in the US is expected to remain constant over the coming years as rising HCV is incidence largely attributable to the opioid crisis, IV drug use, and HCV reinfection, especially among younger adults, offsets the number of new patients treated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our HCV strategy focuses on the development of bemnifosbuvir in combination with ruzasvir, an HCV NS5A inhibitor, a product candidate which we have exclusively licensed from Merck.  Combination therapy utilizing two or more direct acting antivirals with different mechanisms of action is a scientifically and clinically well-established approach that is utilized by currently available human immunodeficiency virus, hepatitis B virus and HCV treatment regimens.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The objective of our HCV development program is to improve upon the current SOC by offering, if successfully developed, the combination of bemnifosbuvir and ruzasvir, as a potentially differentiated eight-week duration, pan-genotypic protease inhibitor-free regimen for HCV-infected patients with or without cirrhosis.  Currently, we are conducting a Phase 2 clinical trial of bemnifosbuvir in combination with ruzasvir in treatment na&#239;ve HCV infected patients, either without cirrhosis or with compensated cirrhosis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For HCV, the combination of bemnifosbuvir and ruzasvir targets the HCV NS5B and the HCV NS5A, respectively, and is designed to inhibit these enzymes which are essential for HCV replication.  Both bemnifosbuvir and ruzasvir have individually demonstrated potent, pan-genotypic, antiviral activity against HCV and the combination of bemnifosbuvir and ruzasvir has exhibited synergistic activity against HCV </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">in vitro.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Key Clinical Trials</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">COVID-19 &#8211; SUNRISE-3: Global Phase 3 Clinical Trial of Bemnifosbuvir</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">SUNRISE-3, is a currently ongoing global, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial that is evaluating bemnifosbuvir (550 mg BID) for five days) in high-risk non-hospitalized patients with mild or moderate COVID-19.  SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy (primary analysis) but it is also exploring the effect of combination therapy in a smaller sub-set of patients who receive a compatible antiviral drug along with bemnifosbuvir (secondary analysis).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The trial consists of two study populations derived from the type of SOC received: 1) a &#8220;supportive care population&#8221; (those patients who do not qualify for another antiviral treatment or where other antivirals are not locally available) which is assessing bemnifosbuvir given as monotherapy (primary analysis) and 2) a &#8220;combination antiviral population&#8221; which is assessing combination therapy if the SOC includes treatment with other compatible antiviral drugs against COVID-19 (secondary analysis). Patients are being randomized 1:1 to receive either bemnifosbuvir 550 mg BID plus locally available SOC or placebo BID plus locally available SOC for five days.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">126</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The primary endpoint of the SUNRISE-3 study is all-cause hospitalization or death through Day 29 in approximately 2,200 patients in the supportive care monotherapy population. Secondary endpoints in each of the supportive care monotherapy patient population and the combination antiviral population include COVID-19 related hospitalization or death, COVID-19 complications, medically attended visits, symptom rebound/relapse and viral load rebound.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The trial is enrolling patients who are &#8805;70 years old (regardless of other risk factors), patients &#8805;55 years old with one or more risk factors, patients &#8805;50 years old with two or more risk factors and patients &#8805;18 years old with certain risk factors including immunocompromised conditions, all regardless of COVID-19 vaccination status.  We believe that this population encompasses those patients who currently remain at high-risk for progression of COVID-19 to severe disease and associated hospitalization and death.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In January and February 2024, we announced the enrollment of more than 650 patients and more than 1,350 patients, respectively, in the supportive care monotherapy cohort.  Each of these patient enrollment milestones triggers an interim analysis by an independent DSMB principally for safety and futility after the respective patient group has completed Day 29 post treatment.   As a result, we currently anticipate that the first interim analysis by the DSMB will occur in March of 2024 and the second interim analysis by the DSMB will occur in the second quarter of 2024.  Patient enrollment in the SUNRISE-3 trial, which has currently surpassed 1,400 patients in the supportive care monotherapy population, continues and topline data from the trial are anticipated in the second half of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">HCV &#8211; Global Phase 2 Clinical Trial of the Combination of Bemnifosbuvir and Ruzasvir</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Currently, we are conducting a global Phase 2 clinical trial of bemnifosbuvir in combination with ruzasvir in treatment-na&#239;ve, HCV-infected patients either without cirrhosis or with compensated cirrhosis.  This study is designed to evaluate the safety and efficacy of eight weeks of treatment with the combination consisting of once daily bemnifosbuvir 550 mg and ruzasvir 180 mg.  Up to approximately 280 HCV-infected, treatment-na&#239;ve patients across HCV GTs, including a lead-in cohort of 60 patients without cirrhosis, are expected to be enrolled in this Phase 2 clinical trial. The primary endpoints of the study are safety and SVR12. Other virologic endpoints include virologic failure, SVR24 and resistance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In February 2024, we announced final results from the full lead-in cohort in which a 98% SVR4 rate was observed [58 of 59 subjects achieved SVR4 with one patient who did not return for post-treatment follow-up].  The one patient who did not achieve SVR4 had poor adherence, and was infected with HCV GT-2. These results are consistent with the initial results announced in January 2024. The SVR4 rate exceeded the protocol-defined efficacy criterion of &#8805;90% SVR4 for continuing the study.  As a result, in January 2024 we commenced enrolling up to an additional 220 patients in the study, including patients with cirrhosis. In the lead-in cohort, very rapid kinetics were observed with viral load for each patient near or below the LLOQ at four weeks of treatment, which we believe is supportive of an eight-week treatment regimen for the combination of bemnifosbuvir and ruzasvir. All 60 patients in the lead-in cohort achieved viral load below the LLOQ by the end of the eight-week treatment regimen.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The combination of bemnifosbuvir and ruzasvir in the lead-in cohort was generally safe and well tolerated and there were no drug related SAEs, no treatment discontinuations and adverse events AEs were mostly mild.  Final SVR12 results from all 280 patients enrolled in the global Phase 2 study are anticipated in the second half of 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If the Phase 2 study is successfully completed, subject to discussion and alignment with regulatory authorities, we anticipate initiating a Phase 3 clinical development program in the second half of 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Dengue</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">After conducting a Phase 2 clinical trial, in February 2023, we decided not to pursue further clinical development of AT-752 for the treatment and prophylaxis of dengue. This action was taken due to the long timelines anticipated for patient enrollment, expected clinical operational challenges, including the challenge of successfully identifying patients shortly after infection which is not feasible with the diagnostic tests that are currently readily available in endemic countries, and the estimated resource burdens, including substantial costs, associated with the further clinical development of an antiviral for each of the treatment and prophylaxis of dengue.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">127</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Financial Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We believe we are well capitalized to advance our current programs.  We had $578.1 million in cash, cash equivalents and marketable securities at December 31, 2023.  Based on our current plans, we anticipate these financial resources will allow us to advance our current and planned clinical programs to and through key inflection points and to fund our activities through 2026. We have based this estimate on assumptions that may prove to be wrong and we could exhaust our available capital resources sooner than we expect.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Roche License Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In October 2020, with Roche, we entered into the Roche License Agreement in connection with the global development, manufacture and commercialization of bemnifosbuvir, products containing bemnifosbuvir or AT-511, the free base of bemnifosbuvir, and related companion diagnostics. During the term of the Roche License Agreement, Roche and we jointly developed bemnifosbuvir for COVID-19 on a worldwide-basis and equally shared the costs associated with such development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Roche License Agreement terminated on February 10, 2022, and, accordingly, our obligations to share costs with Roche also ended. As a result of the termination of the Roche License Agreement, we regained worldwide exclusive rights from Roche to research, develop, manufacture and commercialize bemnifosbuvir, products containing bemnifosbuvir and related companion diagnostics in all fields of use.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Merck License Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In December 2021, we entered into the Merck License Agreement for the development, manufacture and commercialization of ruzasvir.  Ruzasvir is an investigational NS5A inhibitor we are developing in combination with bemnifosbuvir for the treatment of HCV.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pursuant to the terms of the Merck License Agreement, we obtained from Merck an exclusive (subject to certain reserved rights to conduct internal research), sublicensable, and worldwide license under certain Merck patents and know-how to research, develop, manufacture, have manufactured, use, import, export, sell, offer for sale, and otherwise commercialize a Product for all therapeutic or prophylactic uses in humans.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition to a non-refundable upfront payment that we made in February 2022, we will be required to pay Merck milestone payments upon our achievement of certain development, regulatory and sales-based milestones.  Additionally, we will pay Merck tiered royalties based on annual net sales of Products ranging from high single digits to mid-teens percentages. Our royalty payment obligations will continue until the later of (i) the expiration of the last to expire valid claim of a licensed Merck patent claiming such Product and (ii) a period of years after the first commercial sale of such Product in such country. We may terminate the Merck License Agreement for convenience upon prior written notice. The first potential milestone, in the amount of $5.0 million, would be payable upon the commencement of a Phase 3 clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Financial Operations Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, we had cash, cash equivalents and marketable securities of $578.1 million. Net cash used in operating activities was $85.4 million for the year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We expect that our net cash used in operating activities will increase significantly as we advance our product candidates through preclinical and clinical development, seek regulatory approval, and prepare for and, if approved, proceed to commercialization; acquire, discover, validate and develop additional product candidates; obtain, maintain, protect and enforce our intellectual property portfolio; and hire additional personnel. In addition, we may incur additional costs as we continue to operate as a public company.  We believe that our available cash and cash equivalents will be sufficient to fund our planned operations through 2026. We have based this estimate on assumptions that may prove to be wrong and we could exhaust our available capital resources sooner than we expect.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We do not have any products approved for sale and have not generated any product revenue since inception. We do not anticipate generating any revenue from product sales for the foreseeable future. Our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">128</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ability to generate product revenue will depend on the successful development, regulatory approval and eventual commercialization of one or more of our product candidates. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through private or public equity or debt financings, collaborative or other arrangements with third parties, or through other sources of financing. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We plan to continue to use third-party service providers, including CROs to carry out our preclinical and clinical development, and CMOs to manufacture and supply the materials used during the development of our product candidates. Additionally, we expect to rely on CMOs for the manufacture of commercial supply of any product candidate we may successfully develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As we continue to advance our programs, we expect to incur significantly higher expenses over the next several years. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">continue Phase 3 clinical development of bemnifosbuvir as a monotherapy for the treatment of COVID-19;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">continue the clinical development of the combination of bemnifosbuvir and ruzasvir for the treatment of HCV which is expected to include later stage Phase 3 development if the Phase 2 clinical trial we are currently conducting is successful;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">continue discovery and IND-enabling activities in anticipation of nominating a protease inhibitor product candidate for the treatment of COVID-19;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">initiate clinical development of a protease inhibitor for the treatment of COVID-19;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">manufacture increasing quantities of bemnifosbuvir drug substance and drug product in anticipation of potential commercialization;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">seek market approval and prepare for potential commercialization of product candidates we may successfully develop; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">acquire or in-license clinical stage drug candidates, form strategic alliances or establish collaborations with third parties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">maintain, expand, protect and enforce our intellectual property portfolio;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">hire additional research, development and administrative personnel; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">establish commercialization capabilities if we are successful in developing our product candidates.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Components of Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We do not have any products approved for sale and we have not generated any revenue in the periods presented.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If our development efforts for our product candidates are successful and result in commercialization, we may generate revenue in the future from product sales.  Additionally, we may generate revenue from collaboration or license agreements that we may enter into with third parties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Substantially all of our research and development expenses consist of expenses incurred in connection with the discovery and development of our product candidates. These expenses include external costs consisting of fees paid to third parties, including CROs and CMOs, to conduct certain research and development activities on our behalf and consulting costs, as well as internal costs consisting of payroll</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">129</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and personnel-related expenses, including salaries and bonuses, employee benefit costs and stock-based compensation expenses for our research and product development employees and allocated overhead, including rent, equipment, depreciation, information technology costs and utilities attributable to our research and development personnel. We expense both internal and external research and development expenses as they are incurred. In circumstances where amounts have been paid in advance or in excess of costs incurred, we record a prepaid expense, which is expensed as services are performed or goods are delivered.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A significant portion of our research and development costs have been external costs, which we track by therapeutic area. We have not historically tracked our internal research and development expenses by therapeutic area as they are deployed across multiple programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As discussed in Note 3 to our consolidated financial statements, during the term of the Roche License Agreement which terminated in February 2022, we and Roche shared certain manufacturing and clinical development costs on a 50/50 basis. Billings to us by Roche for our percentage share of such expenses were recorded in research and development expenses.  During the year ended December 31, 2023, we recorded a net reduction to research and development expenses of $18.6 million related to credits received from Roche. During the year ended December 31, 2022, we recorded a net reduction to research and development expenses of $6.9 million related to credits received from Roche. These credits were the result, following the termination of the Roche License Agreement, of changes and adjustments by Roche in estimated amounts of expenses reported by Roche during the period in which we and Roche shared costs associated with the development of bemnifosbuvir.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table summarizes our external research and development expenses by indication and internal research and development expenses:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">COVID-19 external costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">44,153</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">19,546</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">HCV external costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">16,874</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5,817</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Dengue external costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5,550</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">11,150</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">RSV external costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2,135</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Internal research and development costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">47,666</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">43,288</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">114,243</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">81,936</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We are focusing substantially all of our resources on the development of our product candidates, particularly bemnifosbuvir for the treatment of COVID-19 and the combination of bemnifosbuvir and ruzasvir for the treatment of HCV. We expect our research and development expenses to continue to increase substantially for at least the next few years, as we seek to complete our current clinical programs which in the case of HCV, is expected to include a Phase 3 clinical trial if our Phase 2 clinical trial is successful, pursue regulatory approval of our product candidates and prepare for the possible commercialization of these product candidates. Predicting the timing or cost to complete our clinical programs, validate our commercial manufacturing and supply processes and manufacture of product at commercial scale is difficult and delays may occur because of many factors, including factors outside of our control. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate or the time to complete planned clinical trials is extended due to delays in enrollment or otherwise, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict with any certainty when our product candidates, if ever, will receive regulatory approval with any certainty, if ever.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">General and administrative expenses consist principally of payroll and personnel expenses, including salaries and bonuses, benefits and stock-based compensation expenses, professional fees for legal, consulting, accounting and tax services, allocated overhead, including rent, equipment, depreciation,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">130</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">information technology costs and utilities, and other general operating expenses not otherwise classified as research and development expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We anticipate that our general and administrative expenses may increase, including in connection with any future expansion of our organization for potential commercialization of our product candidates, as a result of increased personnel costs, expanded infrastructure, increased consulting, legal and accounting services costs associated with complying with Nasdaq and SEC requirements and increased investor relations costs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Interest Income and Other, Net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Interest income and other, net, consists primarily of interest income earned on our cash, cash equivalents and marketable securities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Income Taxes</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Income taxes consists primarily of federal and state current income taxes.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table summarizes our results of operations for the periods indicated:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">114,243</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">81,936</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">32,307</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">49,919</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">48,714</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,205</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">164,162</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">130,650</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">33,512</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(164,162</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(130,650</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(33,512</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Interest income and other, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">29,224</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">11,151</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">18,073</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(134,938</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(119,499</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(15,439</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Income tax benefit (expense)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(1,018</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3,590</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(4,608</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(135,956</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(115,909</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(20,047</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Research and development expenses increased by $32.3 million from $81.9 million for the year ended December 31, 2022 to $114.2 million for the year ended December 31, 2023. The increase was primarily driven by higher external spend related to our Phase 3 COVID-19 SUNRISE-3 clinical trial and our Phase 2 clinical trial of the combination of bemnifosbuvir and ruzasvir for the treatment of HCV offset by a larger reduction related to credits received from Roche. We also had an increase of $4.4 million in internal costs primarily due to an increase of $2.8 million in personnel-related expenses, including salaries and bonuses, benefits and increased stock-based compensation expense of $0.8 million for our research and product development employees and $1.6 million in consulting and other research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">General and administrative expenses increased by $1.2 million from $48.7 million for the year ended December 31, 2022 to $49.9 million for the year ended December 31, 2023. The increase in general and administrative expenses reflected an increase of $2.4 million in personnel-related expenses, including salaries, benefits and increased stock-based compensation expense of $1.9 million; partially offset by a decrease in professional fees and other expenses of $1.3 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Interest Income and Other, Net</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Interest income and other, net, increased by $18.1 million for the year ended December 31, 2023 compared to the year ended December 31, 2022, primarily due to investing in higher yield marketable securities and higher interest rates for the entire year.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">131</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Income Taxes</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We recorded an income tax expense of $1.0 million for the year ended December 31, 2023 as compared to a net income tax benefit of $3.6 million for the year ended December 31, 2022.  The net income tax benefit recorded for the year ended December 31, 2022 was primarily the result of changes in estimates between our original provision for 2021 income taxes and the actual amounts reflected in the income tax returns as filed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, we had cash, cash equivalents and marketable securities of $578.1 million.  We believe that our available cash, cash equivalents and marketable securities will be sufficient to fund our planned operations through 2026. We have based this estimate on assumptions that may prove to be wrong and we could exhaust our available capital resources sooner than we expect.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We entered into an open market sales agreement ("Sales Agreement") with Jefferies LLC ("Jefferies"), in 2021 pursuant to which we may from time to time offer and sell shares of our common stock for an aggregate offering price of up to $200.0 million, through or to Jefferies, acting as sales agent or principal. We have agreed to pay Jefferies a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Jefferies with customary indemnification and contribution rights. As of December 31, 2023, no shares have been issued under the Sales Agreement. The shares will be offered and sold under the Company's shelf registration statement on Form S-3 and related prospectus filed with the SEC on November 24, 2021, as amended.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Future Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To date, we have not generated any product revenue. We do not expect to generate any product revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates and we do not know when, or if, this will occur. We expect to continue to incur increased expenditures for the foreseeable future, and we expect our expenses to increase as we continue the development of, and seek regulatory approvals for, our product candidates and begin to commercialize any approved products. We are subject to all of the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. Moreover, we expect to incur additional general and administrative costs as we continue to operate as a public company and expand our organization to support more advanced clinical development of our product candidates and the initiation of activities in preparation for potential commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We may seek to raise capital through public or private equity or debt financings, collaborative arrangements with third parties, or through other sources of financing. We anticipate that we may need to raise substantial additional capital, the requirements for which will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the scope, timing, rate of progress and costs of our drug discovery efforts, preclinical development activities, laboratory testing and clinical trials for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the number and scope of clinical programs we decide to pursue; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the cost, timing and outcome of preparing for and undergoing regulatory review of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the scope and costs of development and commercial manufacturing activities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the cost and timing associated with commercializing our product candidates, if they receive marketing approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the extent to which we acquire or in-license other product candidates and technologies; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">132</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our ability to establish and maintain collaborations on favorable terms, if at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following regulatory approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">our implementation of operational, financial and management systems; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the costs associated with being a public company. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of one or more of our product candidates. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing that we enter into may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Adequate funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials or we may also be required to sell or license to others rights to our product candidates in certain territories or indications that we would prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements to supplement our funds, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which could materially affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Market volatility, inflation, interest rate fluctuations and concerns associated with the evolution of COVID-19, macroeconomic trends and geopolitical events, including civil or political unrest and terrorism, may have a significant impact on the availability of funding sources and the terms on which any funding may be available.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">See </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Part I, Item 1A,&#8220;Risk Factors&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for additional risks associated with our substantial capital requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Summary Statement of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table sets forth the primary sources and uses of cash, cash equivalents, and restricted cash for each of the periods presented below:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(85,395</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(120,982</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">40,303</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(455,410</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">257</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">370</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net decrease in cash, cash equivalents and<br/>&#160;&#160;&#160;restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(44,835</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(576,022</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cash Flows from Operating Activities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2023 was $85.4 million. Cash used in operating activities was primarily due to a net loss of $136.0 million, accretion of premium and discounts on marketable securities of $15.4 million, an increase in prepaid expenses and other assets of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">133</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">$1.9 million, partially offset by and a decrease in accounts payable and accrued expenses of $14.4 million and stock-based compensation of $49.4 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2022 was $121.0 million. Cash used in operating activities was primarily due to a net loss of $115.9 million, accretion of premium and discounts on marketable securities of $5.5 million, an increase in prepaid expenses and other assets of $7.7 million, partially offset by a decrease in accounts payable and accrued expenses of $39.6 million and stock-based compensation of $46.7 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cash Flows from Investing Activities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Net cash used in investing activities for the year ended December 31, 2023 was $40.3 million and consisted of purchases of marketable securities of $562.4 million offset by sales and maturities of marketable securities of $602.7 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Net cash used in investing activities for the year ended December 31, 2022 was $455.4 million and consisted of purchases of fixed assets of $1.9 million and purchases of marketable securities of $545.4 million offset by sales and maturities of marketable securities of $91.9 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cash Flows from Financing Activities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2023 was $0.3 million and consisted of proceeds from the issuance of common stock under our Employee Stock Purchase Plan.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2022 was $0.4 million and consisted of proceeds from the exercise of stock options and proceeds from the issuance of common stock under our Employee Stock Purchase Plan.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Contractual Obligations and Commitments</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We lease our office space in Boston, Massachusetts under a non-cancelable operating sublease . The term of the sublease commenced on January 1, 2022 and will expire on December 31, 2026.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table summarizes our contractual obligations as of December 31, 2023:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:43.186%;"/>
    <td style="width:1.041%;"/>
    <td style="width:1%;"/>
    <td style="width:9.428%;"/>
    <td style="width:1%;"/>
    <td style="width:1.041%;"/>
    <td style="width:1%;"/>
    <td style="width:7.586%;"/>
    <td style="width:1%;"/>
    <td style="width:1.041%;"/>
    <td style="width:1%;"/>
    <td style="width:7.586%;"/>
    <td style="width:1%;"/>
    <td style="width:1.041%;"/>
    <td style="width:1%;"/>
    <td style="width:9.428%;"/>
    <td style="width:1%;"/>
    <td style="width:1.041%;"/>
    <td style="width:1%;"/>
    <td style="width:7.586%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Payments Due by Period</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Less than<br/>1 year</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">1 to<br/>3 years</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">3 to<br/>5 years</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">More than<br/>5 years</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="18" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease obligations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">821</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,693</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2,514</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We enter into contracts in the normal course of business with CROs for preclinical and clinical studies and testing, CMOs for manufacture and supply of our clinical trial materials and other third parties for other services and products used for operating purposes. These contracts do not contain any minimum purchase commitments and generally provide for termination following a certain period after notice, and therefore we believe that our non-cancelable obligations under these agreements are not material. Payments due upon cancelation principally consist only of payments for services provided and expenses incurred up to the date of cancelation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In December 2021, we entered into a license agreement with Merck for the development, manufacture and commercialization of ruzasvir.  Ruzasvir is the NS5A inhibitor we are developing in combination with bemnifosbuvir for the treatment of HCV.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pursuant to the terms of the Merck License Agreement, we obtained from Merck an exclusive (subject to certain reserved rights to conduct internal research), sublicensable, and worldwide license under certain Merck patents and know-how to research, develop, manufacture, have manufactured, use, import, export, sell, offer for sale, and otherwise commercialize ruzasvir, or products containing ruzasvir for all therapeutic or prophylactic uses in humans.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In consideration for the rights we acquired under the Merck License Agreement, we paid Merck a non-refundable upfront payment in the amount of $25 million.  We are obligated to pay Merck milestone payments of $135 million in the aggregate upon its achievement of certain development and regulatory milestones and up to $300 million in the aggregate upon its achievement of certain sales-based</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">134</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">milestones.  Additionally, we will pay Merck tiered royalties based on annual net sales of Products ranging from high single digits to mid-teens percentages. Our royalty payment obligations will continue until the later of (i) the expiration of the last to expire valid claim of a licensed Merck patent claiming such Product and (ii) a period of years after the first commercial sale of such Product in such country. We may terminate the Merck License Agreement for convenience upon prior written notice. The first potential milestone would be payable upon the commencement of a Phase 3 clinical trial in the amount of $5.0 million. The table above does not include the potential milestones or royalties that we may be obligated to pay under the Merck License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The table above also does not include potential milestone and success fees that we may be required to pay under agreements we have entered into with certain consultants. We have an agreement with a consultant that requires payment of a success fee calculated as a percentage of certain product sales, subject to a cumulative maximum payout of $5.0 million. This success payment is contingent upon the occurrence of future events and the timing and likelihood of such payment is neither probable nor estimable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our financial statements have been prepared in accordance with US generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The effects of material revisions in estimates, if any, will be reflected in the consolidated financial statements prospectively from the date of change in estimates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our critical accounting policies are those policies that require the most significant judgments and estimates in the preparation of the financial statements. Management has determined that our most critical accounting policies are those relating to revenue recognition, accrued research and development expenses and stock based compensation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Accrued Research and Development</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have entered into various agreements with CMOs and CROs. Our research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We use a fair value-based method to account for all stock-based compensation arrangements with employees and non-employees, including stock options and stock awards. The fair value of the option granted is recognized on a straight-line basis over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period, which usually is the vesting period. In determining fair value of the stock options granted, we use the Black&#8211;Scholes model, which requires the input of subjective assumptions. These assumptions include: estimating the fair market value of the common stock, estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of our common stock price over the expected term (expected volatility), risk-free interest rate and expected dividends. See Note 11 to our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">135</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted during the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We consider all highly-liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. Our cash equivalents include money market funds and commercial paper, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Marketable Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy. Marketable securities consist of investments with maturities greater than three months. Marketable securities include US treasury obligations, US agency obligations, corporate debt and commercial paper. We classify all of our marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Unrealized gains and losses are recorded as a component of other comprehensive income within stockholders&#8217; equity. Amortization and accretion of discounts and premiums are recorded as interest income.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair Value Measurement,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Level 1&#8212;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Level 2&#8212;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Level 3&#8212;Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Off-balance Sheet Risk</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Financial instruments that potentially subject us to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the US government. We do not believe that we are subject to any significant concentrations of credit risk from these financial instruments. We have no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Indemnification Agreements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We enter into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, we indemnify, hold harmless and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, including in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments we could be required to make under these arrangements is not determinable. We have never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, we believe the fair value of these agreements is minimal.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have also agreed to indemnify our directors and officers for certain events or occurrences while the director or officer is, or was serving, at our request in such capacity. The indemnification period covers all</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">136</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">pertinent events and occurrences during the director&#8217;s or officer&#8217;s service. The maximum potential amount of future payments we could be required to make under these indemnification agreements is not specified in the agreements; however, we have director and officer insurance coverage that reduces our exposure and enables us to recover a portion of any future amounts paid. We believe the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">137</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item7a"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span id="item_7a_quantitative_qualitative_disclos"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ve Disclosures About Market Risk</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Interest Rate Sensitivity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates or exchange rates. As of December 31, 2023, we had cash, cash equivalents and marketable securities of $578.1 million, consisting of interest-bearing money market funds, US treasury obligations, US agency obligations, corporate debt and commercial paper for which the fair value would be affected by changes in the general level of US interest rates. However, due to the short-term maturities and the low-risk profile of our cash equivalents, an immediate 10% relative change in interest rates would not have a material effect on the fair value of our cash equivalents or on our future interest income.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We do not believe that inflation, interest rate changes or foreign currency exchange rate fluctuations have had a significant impact on our results of operations for any periods presented herein.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 8. Financial Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">s and Supplementary Data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The financial statements required to be filed pursuant to this Item 8 are appended to this Annual Report on Form 10-K. An index of those financial statements is found in Item 15 of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 9A. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023. Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of December 31, 2023, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Under the supervision of and with the participation of our principal executive officer and principal financial officer, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023 based on the criteria set forth in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This report does not include an attestation report of our registered public accounting firm regarding our internal control over financial reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">because we do not qualify as an accelerated or a large accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">138</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_foreign_jurisdictions"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 9C. Disclosu</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">re Regarding Foreign Jurisdictions That Prevent Inspections</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">139</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">PART III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Code of Ethics</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our board of directors has adopted a written Code of Business Conduct and Ethics applicable to all officers, directors and employees, including our principal executive officer, principal financial officer, principal accounting officer and controller, or persons performing similar functions. We have posted a current copy of our Code of Business Conduct and Ethics on our website at </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">www.ateapharma.com</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> in the &#8220;Investors&#8221; section under &#8220;Corporate Governance.&#8221; We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendments to, or waivers from, a provision of our Code of Business Conduct and Ethics, as well as Nasdaq&#8217;s requirement to disclose waivers with respect to directors and executive officers, by posting such information on our website at the address and location specified above. The information contained on our website is not incorporated by reference into this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Executive Officers and Directors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The information concerning our executive offers and directors required by this Item 10 is contained under the caption &#8220;Information About our Executive Officers and Directors&#8221; at the end of Part I, Item I, "Business", of this Annual Report on Form 10-K. The remainder of the information required to be disclosed by this Item 10 will be included in our definitive Proxy Statement for the 2024 Annual Meeting of Stockholders under the headings &#8220;Corporate Governance,&#8221; &#8220;Delinquent Section 16(a) Reports&#8221; (if applicable) and &#8220;Committees of the Board&#8221; and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">e Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The information required by this Item 11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The information required by this Item 12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> Transactions, and Director Independence.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The information required by this Item 13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">tant Fees and Services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The information required by this Item 14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our independent registered public accounting firm is KPMG LLP, Boston, MA, Auditor Firm ID: </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_cee3200d-27fa-4986-b569-c947750402c3" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">185</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">140</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">PART IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ial Statement Schedules.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(1)        Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following documents are included on pages F-1 through F-22 attached hereto and are filed as part of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:91.28%;"/>
    <td style="width:1.46%;"/>
    <td style="width:7.26%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_accounting_firm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Report of Independent Registered Accounting Firm</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(2)        Financial Statement Schedules</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Schedules have been omitted since they are either not required or not applicable or the information is otherwise included herein.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(3)        Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.538%;"/>
    <td style="width:1%;"/>
    <td style="width:40.552%;"/>
    <td style="width:1%;"/>
    <td style="width:5.979%;"/>
    <td style="width:1%;"/>
    <td style="width:10.998%;"/>
    <td style="width:1%;"/>
    <td style="width:6.459%;"/>
    <td style="width:1%;"/>
    <td style="width:11.598%;"/>
    <td style="width:1%;"/>
    <td style="width:8.878%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Filed/</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Exhibit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Filing</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Date</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Furnished</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;3.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000119312520286850/d97355dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Restated Certificate of Incorporation.</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">11/5/2020</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;3.2</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000119312520286850/d97355dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Amended and Restated Bylaws.</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">6/21/2023</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;4.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000119312520267199/d913778dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Specimen Stock Certificate evidencing the shares of common stock</span></a><span style="color:#0000ee;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-249404</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4.2</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10/9/2020</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;4.2</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001593899/000156459021016724/avir-ex42_366.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Description of Capital Stock</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4.2</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3/30/2021</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;4.3</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000119312520274635/d913778dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Fourth Amended and Restated Stockholders Agreement, as amended</span></a><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-249404</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10/23/2020</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000119312520275997/d913778dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">2020 Incentive Award Plan and form of agreements thereunder</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-249404</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10/26/2020</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1-1#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000156459022007672/avir-ex1011_322.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Form of 2022 Performance-Based Restricted Stock Unit Award Agreement (CEO) under the 2020 Incentive Award Plan</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2/28/2022</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1-2#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000156459022007672/avir-ex1012_323.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Form of 2022 Performance-Based Restricted Stock Unit Award Agreement (Non-CEO Executive) under the 2020 Incentive Award Plan</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1.2</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2/28/2022</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1(3)#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="avir-ex10_13.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Form of 2024 Performance-Based Restricted Stock Unit Award Agreement (CEO) under the 2020 Incentive Award Plan</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">*</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1(4)#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="avir-ex10_14.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Form of 2024 Performance-Based Restricted Stock Unit Award Agreement (Non-CEO Executive) under the 2020 Incentive Award Plan</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">*</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.2#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000119312520275997/d913778dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-249404</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.3</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10/26/2020</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.3#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000095017023039920/avir-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Non-Employee Director Compensation Program</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8/8/2023</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">141</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.538%;"/>
    <td style="width:1%;"/>
    <td style="width:40.552%;"/>
    <td style="width:1%;"/>
    <td style="width:5.979%;"/>
    <td style="width:1%;"/>
    <td style="width:10.998%;"/>
    <td style="width:1%;"/>
    <td style="width:6.459%;"/>
    <td style="width:1%;"/>
    <td style="width:11.598%;"/>
    <td style="width:1%;"/>
    <td style="width:8.878%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Filed/</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Exhibit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Filing</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Date</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Furnished</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.3-1#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000095017023039920/avir-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Form of Non-Employee Director Stock Option Award Agreement</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8/8/2023</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.3-2#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000095017023039920/avir-ex10_3.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Form of Non-Employee Director Restricted Stock Unit Award Agreement</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.3</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8/8/2023</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.4#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000119312520275997/d913778dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Form of Indemnification Agreement for Directors and Officers</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-249404</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.5</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10/26/2020</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.5&#x5E;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000156459022007672/avir-ex105_908.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">License Agreement, dated as of December 23, 2021, by and between the Registrant and MSD International GMBH</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.5</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2/28/2022</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.6#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000119312520275997/d913778dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Employment Agreement between the Company and Jean-Pierre Sommadossi, Ph.D., dated October 25, 2020</span></a><span style="color:#0000ee;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-249404</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.9</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10/26/2020</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.7#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000119312520275997/d913778dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Employment Agreement between the Company and Andrea Corcoran, dated October 25, 2020</span></a><span style="color:#0000ee;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1/A</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-249404</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.10</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10/26/2020</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.8#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001593899/000156459021016724/avir-ex108_178.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Employment Agreement between the Company and Janet Hammond, MD, PhD, dated November 3, 2020</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.8</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3/30/2021</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.9#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001593899/000156459021016724/avir-ex109_177.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Employment Agreement between the Company and Arantxa Horga, MD, dated November 3, 2020</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.9</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3/30/2021</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.10#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001593899/000156459021016724/avir-ex1010_175.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Employment Agreement between the Company and John Vavricka, dated November 3, 2020</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.10</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3/30/2021</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.11#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001593899/000156459021016724/avir-ex1011_176.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Employment Agreement between the Company and Wayne Foster, dated November 3, 2020</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.11</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3/30/2021</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.12#</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001593899/000119312520267199/d913778dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">2013 Stock Incentive Plan, as amended, and form of agreements thereunder</span></a><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">333-249404</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10/9/2020</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.13</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000119312521223025/d69975dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Sublease Agreement, dated as of July 19, 2021, by and between the Company and DataRobot, Inc.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">7/23/2021</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.13-1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000095017022015570/avir-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Amendment to Sublease Agreement dated April 11, 2022 between the Company and DataRobot, Inc.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8/8/2022</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.14#</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000119312521167921/d185451dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Consulting Agreement, dated May 18, 2021, by and between the Company and Upstream Wellness and Health LLC.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5/20/2021</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.15</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1593899/000095017022015570/avir-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Consulting Agreement dated June 10, 2022, by and between the Company and Bruce Polsky, M.D.	</span></a><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">001-39661</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8/8/2022</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">21.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="avir-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">List of Subsidiaries of the Registrant</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">*</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">23.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="avir-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">*</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">31.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="avir-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">*</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">31.2</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="avir-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">*</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">32.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="avir-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">**</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">32.2</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="avir-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">**</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">142</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.538%;"/>
    <td style="width:1%;"/>
    <td style="width:40.552%;"/>
    <td style="width:1%;"/>
    <td style="width:5.979%;"/>
    <td style="width:1%;"/>
    <td style="width:10.998%;"/>
    <td style="width:1%;"/>
    <td style="width:6.459%;"/>
    <td style="width:1%;"/>
    <td style="width:11.598%;"/>
    <td style="width:1%;"/>
    <td style="width:8.878%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="7" style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Filed/</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Exhibit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Filing</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Date</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Furnished</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">97.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="avir-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Policy for Recovery of Erroneously Awarded Compensation</span></a></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">*</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">101.INS</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Inline XBRL Instance Document - - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">*</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">101.SCH</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">*</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">*</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">** Furnished herewith.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x5E; Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"># </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Indicates management contract or compensatory plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Item 16. Form </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">10-K Summary</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">143</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="exhibit_index"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">SIGNAT</span><span id="signatures"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">URES</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.36%;"/>
    <td style="width:1%;"/>
    <td style="width:4%;"/>
    <td style="width:45.64%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">ATEA PHARMACEUTICALS, INC.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Date: February 28, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Jean-Pierre Sommadossi</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Jean-Pierre Sommadossi, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.98%;"/>
    <td style="width:1.04%;"/>
    <td style="width:43.3%;"/>
    <td style="width:1.04%;"/>
    <td style="width:21.64%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Jean-Pierre Sommadossi</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">President, Chief Executive Officer and Chairman of the Board of Directors (principal executive officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Jean-Pierre Sommadossi, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Andrea Corcoran</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Chief Financial Officer and Executive Vice President, Legal and Secretary (principal financial officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Andrea Corcoran</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Wayne Foster</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Executive Vice President, Chief Accounting Officer (principal accounting officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Wayne Foster</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Franklin Berger</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;Director (Lead Director)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Franklin Berger</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Jerome Adams</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Jerome Adams, M.D., M.P.H</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Barbara Duncan</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Barbara Duncan</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Bruno Lucidi</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Bruno Lucidi</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Polly A. Murphy</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Polly A. Murphy, D.V.M., Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.98%;"/>
    <td style="width:1.04%;"/>
    <td style="width:43.3%;"/>
    <td style="width:1.04%;"/>
    <td style="width:21.64%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Bruce Polsky</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Bruce Polsky, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">144</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.92%;"/>
    <td style="width:7.08%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_accounting_firm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Consolidated Statements of Cash Flows</span><span style="color:#0000ff;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_of_independent_accounting_firm"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Report of Independent </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Registered</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To the Stockholders and Board of Directors<br/>Atea Pharmaceuticals, Inc.:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Atea Pharmaceuticals, Inc. and subsidiary (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Critical Audit Matters</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_ea180156-234c-4532-9c9f-6c7daf2c461f" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2014.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_5328b805-d278-4521-b2ee-a89a29f81b00" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Boston, Massachusetts</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"><br/>February 28, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Arial;min-width:fit-content;">ATEA PHARMACEUTICALS, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">Consolidated B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">alance Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current assets</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_493d5898-a6cc-414e-8cfd-51d796082465" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,823</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15b271e7-7ae2-4368-9a85-3ec03d5f07ec" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,460</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cd49ddb-d4d9-49c2-828b-8755f9bfbec0" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">434,283</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b64ca75-bc14-43b2-9da4-42820325fc1e" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">458,249</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbbd58dc-d724-476f-b222-c5f5ec27ed51" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,349</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01a7fada-a0cc-4ae5-a88d-a46a609a967e" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,213</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7f22d16-c598-4f76-a14a-e0281c99448b" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">590,455</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fac0ecd1-a551-4a7e-ba83-59dee3df63e4" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">660,922</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21867c07-8f26-495a-939e-856908ea5781" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,289</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10483874-5b55-4a1f-ad2a-343ec0dd7ffb" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,705</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc057eb1-4aa8-4868-b730-882ddc02d607" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe5641e5-f5d8-4c4e-845b-42b201ee9bf7" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,396</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45a9bea3-6e3d-4bcd-abf0-fb084cc72ac3" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,494</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease right-of-use assets, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_383813e3-46ca-471b-b514-031830af9b88" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,828</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74144d64-1645-49f8-9d95-e41b80483305" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,389</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a57788fc-fb7b-4644-aa2a-7c1b67165bbb" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">594,968</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb9d2932-fa36-4522-8cc2-d9f2e8f15f03" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">666,708</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current liabilities</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2cb9782-5b83-467c-9494-2d9661e5aa28" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,252</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6147103-aaf1-46c4-a0fa-3dcde5316b95" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,551</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5b204ce-00a0-4eb4-b78b-29c57b53c14c" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,364</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57f8ac48-1ad3-4de9-9d78-a6309715870f" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,206</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b220e97-34a1-43d8-9ae0-bd58f12a5500" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">760</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8dc579e-4d13-4d63-b397-79b825514e3c" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">721</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f394fdda-43c7-4687-875a-c22da7c3d88e" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,376</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a868df0-ef0d-4e99-b4b4-5fab67c03778" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,478</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cdc1ffd-42fb-4598-958c-20941ada85c3" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,642</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b213c86-6c9f-4b56-be22-96f1b8bb757c" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,403</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Income taxes payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b42b52b0-d597-4fe7-a75d-ca136b12b87e" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AccruedIncomeTaxesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,758</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9437567a-1e82-4a1d-8c40-244f1f34cba2" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AccruedIncomeTaxesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,255</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5815bc31-34bd-4eea-9dc3-f538c5cccd45" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,776</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6aad8978-7bdd-4c3a-bb52-4e4da61071bb" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,136</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="-sec-ix-hidden:F_8825678c-5618-4fdf-86f5-25beefdc3d5d;"><span style="-sec-ix-hidden:F_f13f86af-3f04-4fdb-a9a7-d85157377ef3;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (see Note 8)</span></span></span></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Preferred stock, $</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b975b12f-de89-41a5-961d-cbc2a73e71e4" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_0c08feb2-dd9e-4f22-aae3-df8cd75e49b5" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;par value per share; </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae46d2f0-57ba-481c-aedb-41de21add9aa" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_da3cdf45-217a-4632-83dd-ef137dd8dae6" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;shares authorized; </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf205be5-b98d-49d9-9483-b691eaa51b97" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0fbc097a-f012-416c-bbb6-21428349d163" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_fa0d4975-e7c2-46fe-8db8-24eefa52ffde" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_17c35954-4cf5-426a-8bc5-29a2a46a6a5b" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;shares issued and outstanding as of December 31, 2023 and 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="-sec-ix-hidden:F_6a58375c-3c73-45b9-96be-2164642efd86;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="-sec-ix-hidden:F_3f67c47a-74e2-4ce2-b416-6f7418743d08;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Common stock, $</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5ad8dbe-c964-4020-9461-f9f0898be8cc" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_55d54fc2-f912-4b98-af2c-1b9508e9a82d" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;par value; </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f76b4c1e-3515-44cc-82c0-ec07fbac0607" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ace7fab3-d416-4d02-9515-5c2dc755bb6c" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;shares authorized; </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d41bdfc-682d-4c14-b861-d304feb14197" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4b1ae773-daa2-4514-8cff-29537551dbf1" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">83,435,513</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;and </span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ff2b742-b5a3-4257-ae90-0cfb7c7debc6" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_05ab1ff7-6d6c-4638-870c-109785d35441" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">83,287,639</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;shares issued and outstanding as of December 31, 2023 and 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_242d6043-9f12-4b30-8894-01e5d1579592" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6476e01-fa2a-4af6-a914-59840a86d84d" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac03d363-19d1-4512-9366-affb7dcbb67f" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">750,737</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02c74ec3-55b3-4684-98f4-12619ab73ba0" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">701,052</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accumulated other comprehensive gain (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ca3e754-d252-4db2-b34d-df7905692997" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4abc1cbe-9829-4639-ad32-8058bff4a92d" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">684</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87db8f52-03a7-4964-a102-810b5392f24d" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">195,835</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4535a14-f4e5-4c5f-b969-a663a4da71b9" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,879</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffc63291-9adf-4f6c-9203-946ad2a43727" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">555,192</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f9e3018-4537-4155-9425-7b6bc72ee653" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">640,572</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77dc6a4d-5812-4a5a-abe8-9bfcedcdd44a" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">594,968</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1b2110d-c778-4eb9-81bf-2c838f2eae62" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">666,708</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Arial;min-width:fit-content;">ATEA PHARMACEUTICALS, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="consolidated_statements_operations_compr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">Consolidated Statements of Oper</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">ations and Comprehensive Loss</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.814%;"/>
    <td style="width:1.64%;"/>
    <td style="width:1%;"/>
    <td style="width:13.062999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.64%;"/>
    <td style="width:1%;"/>
    <td style="width:11.842%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b8c53c0-bb0e-40e5-ae3f-07d1453d706a" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,243</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35e05a89-30e0-4f45-b40c-ab18775e732a" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,936</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef338337-a717-4e12-a091-14a8b5a6e3bf" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,919</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2276ef3-6209-4dfb-9b3e-ab8733fb6aff" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,714</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9df55c55-748c-49ad-9eae-76ab2193c9aa" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,162</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9dd9b75-ac71-4df8-84a9-440a552e0e5e" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,650</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d7dbd3d-1512-46ff-bc62-cc8f9936b13c" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">164,162</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a5ce441-91d5-42b8-b22b-e7d584615973" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">130,650</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Interest income and other, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c033f947-c6a2-4add-ab6b-c95d4a69e0aa" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,224</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5638fad-2cf1-41eb-88b5-6fc152944f4b" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,151</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_542bfef9-8c20-43ed-b75e-a3605a7978fb" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">134,938</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_371474a9-0211-434a-b03b-73472a8d1701" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">119,499</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Income tax benefit (expense)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05afaf18-52bb-4fac-b8ff-b6f88baa7ac3" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,018</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e3c5964-18fe-4d34-8b46-14467ecbf04d" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,590</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41e85c9e-d0be-4230-99da-31960b99ed4a" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">135,956</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cbb88ed-3b97-4678-bd4f-e95bf25c18f5" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,909</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unrealized gain (loss) on available-for-sale investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06740dcf-af38-44fd-86ca-53888df9d8cb" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">891</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf22d0f6-d7c9-4ad5-a9bf-1b8abe8d74be" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">684</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2be1ac0-d5be-42d4-8636-2266fcfa2ac5" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">135,065</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f763d6b4-c0d9-48a9-beac-2240b5d2c854" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,593</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss per share - basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3a8eb4c-9c6b-4c23-af5e-626c5e5f6a82" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f5df8c41-bb12-41c9-8f80-f666a5f4e2fb" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.63</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6a7fec8-ddd2-4819-b0c6-ca259d5707b9" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1c6677b3-6da2-4749-911e-c6138529f7f7" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.39</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted-average number of common shares - basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cfeefbb-acdc-4644-9c2e-4c5b9d1081f4" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0b9e9f31-aba3-47e3-98bf-af281de02f47" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">83,389,750</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9f11904-5c98-45cc-a83b-50e74ad9e1b8" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_12b109ec-aa3e-4866-bb88-c6b2aa9bc554" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">83,245,385</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="stockholders_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Arial;min-width:fit-content;">ATEA PHARMACEUTICALS, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="consolidated_statements_convertible_pref"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">Consolidated Statements of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">Stockholders&#8217; Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">(in thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.04%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.78%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:4.1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.22%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.68%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.82%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.36%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Common Stock</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Additional<br/>Paid-in</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Accumulated Other Comprehensive</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Retained Earnings (Accumulated</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Gain (Loss)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance &#8211; January 1, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c50e140-8a46-4b51-bdba-57b1b0cd90cf" contextRef="C_7cf00f8c-9982-454f-9f70-f11345935575" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">83,102,730</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a0b9dc9-e1e0-46a3-8aaf-7b42b5221537" contextRef="C_7cf00f8c-9982-454f-9f70-f11345935575" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7387203e-186b-4545-a4d0-88c936a768b6" contextRef="C_741e6762-6491-44e9-9d3f-00660692cfff" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">653,964</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_378d654e-4829-40de-8732-a3623ff9be3a" contextRef="C_14ac9cbe-603c-4063-874a-18ef17519699" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,030</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7f27968-1a22-4a60-9869-83903f40af8c" contextRef="C_7f911c61-390f-464f-b142-8191cfb56974" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">710,077</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Issuance of common stock for exercise<br/>&#160;&#160;&#160;of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_418e7bd1-a460-491c-989f-bdb5aea259ca" contextRef="C_839b2d04-8e9a-4f78-802e-358d03925bc9" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">155,873</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32b0e8dd-e127-4e16-88c8-2fd23c5d2ffa" contextRef="C_6c968b4c-959e-4b16-a465-e034a657083f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aaff2ac5-6bb7-4684-aa85-df78d76e42a3" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Issuance of common stock under ESPP</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4b36534-c861-463e-9de7-156e57a5e05c" contextRef="C_839b2d04-8e9a-4f78-802e-358d03925bc9" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,036</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d240cfc8-6395-43b1-ae3a-595e0f720cf5" contextRef="C_6c968b4c-959e-4b16-a465-e034a657083f" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_feb999ea-75ec-4ae6-adf9-22074f266574" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c1ab249-b3a8-40c4-82f9-0202851a9cc9" contextRef="C_6c968b4c-959e-4b16-a465-e034a657083f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,718</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_093e06ab-f721-4715-9fcd-b793ab0e577b" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,718</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_020834b9-21e2-4e70-b6f4-c2190a244774" contextRef="C_be5035eb-e660-4560-be97-44cb8c0f9a0e" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">684</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e275dea4-a6bd-4ff1-98f2-106c03b3ff16" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">684</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_831724cb-8973-4555-98fe-9ce7a0ed61f7" contextRef="C_e97f5628-4e13-4a16-80cb-1a647ed32f3f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,909</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f016fb28-598d-4a52-882d-c07dead1e2c4" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,909</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance &#8211; December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ab08175-e730-48b5-bd52-bbd13a528241" contextRef="C_1c5aa2e0-6ee2-47c4-83c0-bcebcd1b5028" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">83,287,639</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cd49f1f-9402-4b50-af0a-ff956f49ffe5" contextRef="C_1c5aa2e0-6ee2-47c4-83c0-bcebcd1b5028" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35f441bb-cd3d-4167-9532-fafba8f39724" contextRef="C_b416c72d-54aa-4b09-b126-d3012f0dd986" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">701,052</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5563abf2-4080-4eb8-b7fc-ad94e87df78f" contextRef="C_53e1a418-db9d-4b78-8fda-8cf250f5882f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">684</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_159346e0-aa56-4dbe-bea4-6a762683fb85" contextRef="C_a00419f3-633d-4353-a505-f066bdea810a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,879</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b15e495-4ff1-4973-8568-e6a175ec8582" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">640,572</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Issuance of common stock upon release of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95f5b781-b662-43ba-a1b9-b69874c6902f" contextRef="C_2df95855-8dda-4f54-99a2-64899a2d8236" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">53,935</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Issuance of common stock under ESPP</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ca1652c-c1e8-411d-9a09-77b2663679d1" contextRef="C_2df95855-8dda-4f54-99a2-64899a2d8236" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">93,939</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2f4ed2b-8c38-4a7e-8139-6b6a70c750f3" contextRef="C_35620468-f729-48e1-8999-2b9f79ad7f7e" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbf82f17-afb5-4de5-944e-5bec7ddea3ac" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d6f88ed-8d6d-4e04-8a06-baf27cf3311f" contextRef="C_35620468-f729-48e1-8999-2b9f79ad7f7e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,428</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_892d5baf-b854-4ac5-b93e-cb861ee6cb74" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,428</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other comprehensive income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54616155-a900-4705-8a7b-878f2445d979" contextRef="C_b71efb31-3b73-4d78-88bd-0522c7021985" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">891</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0b9fbf0-8c0a-4a61-b94e-0e40ea9cbd40" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">891</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e0eea35-c377-4bbd-a70c-d84ea2a8dfa2" contextRef="C_e35146f5-20fa-4ec8-a345-92d23314956f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">135,956</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_353d0383-a39f-4d7e-835d-f169c289da41" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">135,956</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance &#8211; December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb1e376a-7a87-4d96-8139-b3de4e145852" contextRef="C_2d9ddc2b-fdf7-4243-aa54-0ba461e33dd8" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">83,435,513</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbcda4b7-d4ae-4f1b-8dd8-f9e684be4c2d" contextRef="C_2d9ddc2b-fdf7-4243-aa54-0ba461e33dd8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bea33680-8adc-401a-9373-919df0a0e3c8" contextRef="C_677d6563-424e-4877-8d04-062f7a6292c3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">750,737</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f4a2257-9692-4245-9f93-0e898591113e" contextRef="C_cb12c3db-f2bf-4359-9b84-6e55943ac2cb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19d114d3-09f2-437d-b316-206917a87ca9" contextRef="C_2be2f376-615a-4108-a6a0-9913d287e512" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">195,835</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fb959ff-c1dc-4e9b-99f5-cc11fd1976e3" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">555,192</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Arial;min-width:fit-content;">ATEA PHARMACEUTICALS, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">Consolidated Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">ents of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47eba798-1c1f-4243-b9e6-0681d08c36d0" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">135,956</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84302aa6-f2f4-4bac-9652-19d17b04084f" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,909</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in<br/>operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bfbc2fd-cc4c-477b-82fe-7d4e32374fad" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,428</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62845f9c-52f2-4a5b-b2a9-7bf5ae3b6993" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,718</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c373a56-4f7d-4710-be76-ae1eb82efa3f" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">416</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58be84c1-fe09-47f2-a4d7-8d062e542807" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">260</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accretion of premium and discounts on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34203c09-3cb4-43b7-b42b-fc6ab6a4558a" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,446</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_866d6a0e-878d-4a23-89b9-86e3e47fe307" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,465</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Changes in operating assets and liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f780722c-2a63-436c-8110-79f84ead86c1" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,864</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1a5319e-e6a7-4972-b0f4-73027840887a" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0c0e3af-9603-4421-ba0a-d5daf7765126" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6497342a-191a-456a-937a-a05708b5da1b" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,494</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91c49669-1c5c-4614-8034-5af8e341bbf1" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,701</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dd7d299-53f2-4885-8778-904351781f49" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,983</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d782fa82-4046-4992-a1af-a096f264649e" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,661</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_169479cc-d910-45b0-8665-7b6feb085929" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">37,623</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3314d59-844d-49d6-a074-46215caa7a6c" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">161</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50df42fa-dd67-4c65-9999-089e79895355" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">765</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d006ca88-f5ef-4913-b8d4-73698b9c968e" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,395</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3473c2e4-0b53-4575-af45-73d131e7d232" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">120,982</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Additions to property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28c4d06a-f76d-413f-a040-db4f5b4752f7" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,943</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f681871-788e-4242-a0dc-3987ef3a0656" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">562,362</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_692cbf98-faa3-4f02-aad5-0821f0692e8a" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">545,352</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Sales and maturities of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48cd7418-cb47-4ab3-934f-036e13e59baa" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">602,665</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3120846-1400-42fc-9e53-90a6507db653" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,885</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_771b2417-de0e-427e-8970-e2a05c356edd" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,303</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1087b577-c830-4124-83a9-8a0340c0736b" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">455,410</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Proceeds from issuance of common stock for exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_861e118e-945c-4056-aef9-bcfa47108f98" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:7pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Proceeds from issuance of common stock under ESPP</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa9718f6-e7ba-4140-ac62-93948a0af173" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36bc7799-ed39-4bbd-adb0-5c7943bc1844" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3605a064-83ac-4b73-970a-da240f5c4479" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4424b719-71c5-4e3e-bacc-d01ce0e77877" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">370</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4fe1fc4-ef72-427b-9af0-10328f1434e9" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,835</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4aced5e-a648-490b-8006-771279e4d928" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">576,022</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash, cash equivalents and restricted cash at the<br/>&#160;&#160;&#160;beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9b032aa-f5ad-4fbc-a90d-b52bc3c04b4a" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_454bd732-b280-4c0b-b6c0-e236b10fc62c" contextRef="C_7f911c61-390f-464f-b142-8191cfb56974" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">764,680</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash, cash equivalents and restricted cash at the end<br/>&#160;&#160;&#160;of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40df466a-24ed-4a36-b7d8-55bb9b30ca2a" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,823</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f75e0c7-e1c1-4ca6-8490-e1ac4f00571f" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash, cash equivalents and restricted cash at the end<br/>&#160;&#160;&#160;of period</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c48dca6-986e-413e-888c-874af992ddd3" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,823</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb93d1f6-b262-46c4-8990-b0af42e30f23" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,460</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5451e91a-ebe4-41a0-9e25-3346dff49b31" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3">198</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d38594e-a9df-4229-8a28-e93bbf24d0d9" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,823</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cd981e9-2ad9-4ff2-8339-1e23dc8c10bf" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Supplemental disclosure of non-cash financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Right of use assets obtained in exchange for operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27722673-de92-42f2-a24a-e75781e67917" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,938</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="notes"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Arial;min-width:fit-content;">ATEA PHARMACEUTICALS, INC.</span><span id="bkmk_323"></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="bkmk_306"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_e8917e00-4cf9-4d16-839a-bf8e9f3f29fd" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:NatureOfOperations" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">1. Nature of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Business Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Atea Pharmaceuticals, Inc., ("Atea" or the "Company") is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from severe viral infections.  Currently, Atea is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 ("COVID-19"). Atea is also currently conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus ("HCV").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, the Company had $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3861d90-eb9e-45d0-886a-602bfd61507b" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">578.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million in cash, cash equivalents and marketable securities, which the Company believes will be sufficient to fund its operations for a period through at least twelve months from the issuance date of these consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In November 2021, the Company entered into an open market sales agreement (&#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), under which the Company may from time to time offer and sell shares of its common stock for an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4b3001a-4eaf-4212-b9fd-2e47a60e4434" contextRef="C_9efbbc1b-078b-4f87-947b-73866d7dde2f" name="avir:StockIssuanceProgramAuthorizedAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, through or to Jefferies, acting as sales agent or principal. The shares will be offered and sold under the Company&#8217;s shelf registration statement on Form S-3 and a related prospectus filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on November 24, 2021, as amended. The Company has agreed to pay Jefferies a commission of </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b854eb19-01cf-40b5-b7d7-3542ef447492" contextRef="C_1430c916-1a16-453a-bad9-54788ee5a480" name="avir:CommissionRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Jefferies with customary indemnification and contribution rights. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27c6b011-b254-4b3e-a9ae-547fc7d2411b" contextRef="C_492b70ed-33a9-48ec-91b4-5bf4e27baa9d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares have been issued under the Sales Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company is subject to risks and uncertainties common to clinical-stage biopharmaceutical companies. These risks include, but are not limited to, potential failure of preclinical and clinical studies, uncertainties associated with research and development activities generally, competition from technical innovations of others, dependence upon key personnel, compliance with governmental regulations, the need to obtain marketing approval for any product candidate that the Company may develop, the need to gain broad acceptance among patients, payers and health care providers to successfully commercialize any product for which marketing approval is obtained and the need to secure and maintain adequate intellectual property protection for the Company&#8217;s proprietary technology and products. Further, the Company is currently dependent on third-party service providers for much of its preclinical research, clinical development and manufacturing activities. Product candidates currently under development will require significant amounts of additional capital, and additional research and development efforts, including further additional clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company may seek additional capital through one or more of a combination of financing through the sale of additional equity securities, debt financing, or funding in connection with any new collaborative relationships it may enter into or other arrangements. There can be no assurance that the Company will be able to obtain such additional funding, on terms acceptable to the Company, on a timely basis or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s existing stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Company is also subject to risks associated with the continued evolution of COVID-19 and its consequences, including actual and potential delays associated with certain of its ongoing and anticipated trials, and potential negative impacts on the Company&#8217;s business operations and its ability to raise</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">7</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">additional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">capital to finance its operations. Geopolitical events, including civil or political unrest and terrorism, have resulted in a significant disruption of global business and financial markets. In addition, recent or future market volatility, increased inflation and higher interest rates, if sustained, may increase our cost of financing and may restrict our access to potential sources of future liquidity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_41846b16-4cfb-440a-a2db-45a7683d2aad" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_3a84f2d5-1a80-444b-9035-d6fc072c5b05" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="avir:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Basis of Presentation and Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and in these accompanying notes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors and assumptions that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, which include but are not limited to estimates of accrued research and development expenses, valuation of marketable securities, valuation of stock-based awards, valuation of operating lease right-of-use assets and lease liabilities and income taxes. Changes in estimates are recorded in the period in which they become known.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_40524708-b4e7-4218-b7f4-fe3bce0d953a" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The consolidated financial statements include the accounts of Atea Pharmaceuticals, Inc. and its wholly- owned subsidiary, Atea Pharmaceuticals Securities Corporation. All intercompany amounts have been eliminated in consolidation.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_9275e258-3a1b-4acd-839b-d2057348e2b6" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company considers all highly-liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company&#8217;s cash equivalents include money market funds and commercial paper, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_b7c1870e-0844-456d-bff0-551ef8900c13" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company&#8217;s investment strategy is principally focused on capital preservation. The Company invests in financial instruments that among other things meet the credit quality standards outlined in the Company&#8217;s investment policy. Marketable securities consist of investments with maturities greater than three months. Investments not classified as cash equivalents with maturities of less than twelve months are classified as current assets on the consolidated balance sheet.  Investments with maturities greater than twelve months for which the Company has the intent and ability to hold the investment for greater than twelve months are classified as non-current on the consolidated balance sheet. Marketable securities include US treasury obligations, US agency obligations, corporate debt, commercial paper and asset-backed securities.  The Company classifies all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Unrealized gains and losses are recorded as a component of accumulated other comprehensive gain (loss) within stockholders&#8217; equity. Interest, dividends and amortization and accretion of discounts and premiums are recorded as interest income and other, net.  The Company periodically reviews its marketable securities for impairment and adjusts these investments to their fair value when a decline in market value is deemed to be other than temporary.  Declines in fair value judged to be other than temporary on marketable securities, if any, are included in interest income and other, net.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_bbc4d059-49e5-4970-b72b-6c68e4345879" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="avir:ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Significant Suppliers</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the US government. The Company does not believe that it is subject to any significant concentrations of credit risk from these financial instruments. The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">8</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company is dependent on third-party manufacturers for the supply of products for its research and development activities including its development programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs for preclinical and clinical development activities. The Company also currently anticipates to rely on this small number of manufacturers for commercial supply if any of the current product candidates are approved for sale. The Company's research and development programs, including any potential commercialization efforts, could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_19685318-c7a1-4d51-93d0-0582449b52d5" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair Value Measurement,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Level 1&#8212;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Level 2&#8212;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Level 3&#8212;Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the assets and liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The carrying amounts of prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value due to short-term nature of these assets and liabilities.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_868e0ae3-4f9c-4dec-b568-1e83896e96bd" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the asset. </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_db694ea3-8c60-4991-a698-671a647dc97d" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="avir:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" escape="true" continuedAt="F_db694ea3-8c60-4991-a698-671a647dc97d_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company estimates the useful life of its assets as follows:</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><ix:continuation id="F_db694ea3-8c60-4991-a698-671a647dc97d_1">
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.17%;"/>
          <td style="width:1.66%;"/>
          <td style="width:49.17%;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Asset</span></p></td>
          <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><ix:nonNumeric id="F_9f019bb8-31ed-40da-920c-870389ee1c09" contextRef="C_7d2d29de-6d0b-4b53-b56c-521ea942b78d" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Five years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Office furniture and fixtures</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><ix:nonNumeric id="F_13b4648e-cde4-467b-8bca-8a1d2cd4be0f" contextRef="C_6399a783-fb32-4189-8185-57a59a53f325" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Five years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Computer hardware</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><ix:nonNumeric id="F_66a82b5e-07cf-48dc-ad56-e885692aab8a" contextRef="C_c7618177-dbbf-4f5e-963a-5fa2381e45b8" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Two years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="-sec-ix-hidden:F_3be2bd17-90cb-4ad6-9f95-d622754a93f7;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of useful life or remaining lease term</span></span></span></p></td>
         </tr>
        </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Maintenance and repairs that do not improve or extend the life of the respective asset are expensed to operations as incurred. Upon disposal of an asset, the related cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the consolidated statements of operations.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_2d62b0a1-fd30-4b55-8c38-c6121730ce6d" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="avir:OtherAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Other Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Other assets consist of vendor deposits related to research and development activities and a security deposit related to our facility lease.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_afa1035c-5c7a-4ea1-9eb6-08afd613cae3" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Impairment of Long-lived Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Company reviews long-lived assets, including property and equipment and right-of-use assets ("ROU") when events or changes in circumstances indicate the carrying value of the assets may not be fully recoverable. Recoverability is measured by comparing the book value of the assets to the estimated undiscounted future net cash flows that the asset is expected to generate. If the estimated undiscounted future net cash flows are less than the book value, the asset is impaired, and the impairment loss to be recognized in income is measured as the amount by which the book value of the asset exceeds its fair value, which is measured based on the estimated discounted future net cash flows that the asset is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">9</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">expected </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">to generate. </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01b7dfe1-ba91-4334-a880-00f6f90d5a1b" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c1598cc6-957e-4790-a0d9-7406d28b67a1" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> impairment losses were recorded during the years ended December 31, 2023 and 2022.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_1779adb0-43ae-4c8f-8555-ceadec631298" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company accounts for leases in accordance with ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Lease Accounting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.   At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. Leases with a term greater than one year are recognized on the consolidated balance sheet as a ROU asset and current and non-current lease liabilities, as applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense.  The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company estimates it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_db496878-b06c-49c0-85ce-7b2b774124b3" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses consist principally of costs associated with outsourced research and development activities, including drug discovery, preclinical and clinical development, manufacturing and research conducted by contract research organizations and academic institutions, employee compensation, including stock-based compensation and consulting expenses together with related expenses, professional fees and facility and overhead costs. Facility and overhead costs primarily include the allocation of rent, utility and office-related expenses attributable to research and development personnel. In circumstances where amounts have been paid in advance or in excess of costs incurred, the Company records a prepaid expense, which is expensed as services are performed or goods are delivered.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has entered into various research and development contracts with third parties. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase of completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_93a34553-46ad-45a4-ab3f-d6cca5774206" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Costs to secure and maintain the Company&#8217;s patents are expensed as incurred and are classified as general and administrative expenses in the Company&#8217;s consolidated statements of operations.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_bdbd4410-ddde-43ad-80d8-d4339d1b1016" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock-based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock-based compensation expense is classified in the consolidated statement of operations and comprehensive loss in the same manner as the award recipient&#8217;s payroll costs or service payments are classified. Stock-based awards granted to employees and non-employees are measured based on the estimated fair value of the awards using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;). Stock-based compensation expense with respect to awards with service conditions is recognized using the straight-line method over the service period. Stock-based compensation with respect to awards with performance conditions is recognized when satisfaction of the performance conditions is probable. Stock-based compensation is based on awards ultimately expected to vest and, as such, it is reduced by forfeitures. The Company accounts for forfeitures as they occur.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair value of common stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The fair value of its common stock is based on the daily closing quoted market price of its common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Risk-free interest rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The risk-free interest rate is based on the US Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">10</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. Given the Company&#8217;s lack of specific history, the expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;Since the Company was privately held through October 29, 2020 and did not have any trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. During the fiscal year ended December 31, 2022 the Company began to incorporate the historical volatility of its own stock price in its calculation of its expected volatility.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected dividend yield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> &#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company uses an expected dividend yield of </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cf8aea2-c382-419f-bbbb-4a9a77e45caf" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company also accounts for any modifications to share based payments in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Compensation &#8211; Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> (ASC 718).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The purchase price of the Company's common stock under the Company&#8217;s 2020 Employee Stock Purchase Plan ("ESPP") is equal to </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a727901d-c3dd-47d1-b30b-adc7a9794ca2" contextRef="C_b18b1fcf-b3ac-4d66-bbfb-5bd569b10abc" name="avir:ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the lesser of (i) the fair market value per share of its common stock on the first business day of an offering period and (ii) the fair market value per share of its common stock on the purchase date. The fair value of the discounted purchases made under ESPP is calculated using the Black-Scholes valuation model. The fair value of the look-back provision plus the </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97a14069-3f8f-4eee-8540-4c28dcf700bb" contextRef="C_b18b1fcf-b3ac-4d66-bbfb-5bd569b10abc" name="avir:ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% discount is recognized as compensation expense over the 180-day purchase period.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_a04dd871-cdfc-4c02-822a-097137132445" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_853d48f4-49ba-4afb-8c38-23a3a3036177" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with equity holders.  For the years ended December 31, 2023 and 2022, the only components of comprehensive loss other than net loss were unrealized gains and losses on available for sale investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_c80eddcf-5d17-49a1-85bd-7351ac6143d1" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Basic net income loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of shares of common stock outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding common stock equivalents except where such securities would be antidilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_3ebf7fa3-6484-4bb3-9911-53f524cc6971" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="avir:InProcessResearchAndDevelopmentAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">In-process Research and Development Assets</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">11</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In-process research and development assets that are acquired in a transaction that does not qualify as a business combination under GAAP and that do not have an alternative future use are expensed in the period in which the assets are acquired.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_aff6a027-bfc0-4cea-9338-c384cca7d978" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Segments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its chief executive officer, who manages and allocates resources to the operations on a total company basis. Accordingly, there is a </span><span style="font-size:10pt;font-family:Arial;"><span style="-sec-ix-hidden:F_26675b1d-cb04-4da6-8149-4bb408ad51ca;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> operating segment and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7897746-16f1-48bf-b7d0-edb4c1a0aa9f" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> reportable segment.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_6e23ad47-7204-4135-b8f6-348c9b32576e" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Other accounting standards that have been issued or proposed by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s consolidated financial statements upon adoption.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company did not adopt any accounting pronouncements during the year ended December 31, 2023.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_9825d672-5418-4394-a99a-ddcf2e7c49d6" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">3. Collaboration Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In October 2020, the Company entered into a License Agreement (&#8220;Roche License Agreement&#8221;) with F. Hoffmann-LaRoche Ltd. and Genentech, Inc. (together, &#8220;Roche&#8221;) under which the Company granted an exclusive license for certain development and commercialization rights related to bemnifosbuvir outside of the United States (other than for certain HCV uses) to Roche.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In November 2021, Roche provided the Company with a notice of termination of the Roche License Agreement which became effective in February 2022.  Upon termination, the rights and licenses granted by the Company to Roche under the Roche License Agreement were returned to the Company, resulting in the Company having all rights to continue the clinical development and future commercialization of bemnifosbuvir worldwide. Global development plan activities and related cost sharing between the parties continued through the effective date of the termination.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The activities to complete the global development plan were accounted for under ASC 808.  Expenses incurred and reimbursements made or received from Roche were accounted for pursuant to ASC 730, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  As such, the Company was expensing costs as incurred, including any reimbursements made to Roche, and recognizing reimbursement received from Roche as a reduction of research and development expense through the effective date of the termination.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For the year ended December 31, 2022, the Company recorded a net credit of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d44c40f-0b40-4997-922e-db1f69c323e9" contextRef="C_9ac4181a-51cc-4958-ac53-7166a997b2a6" name="avir:ResearchAndDevelopmentCreditAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,898</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> from Roche. The credit recorded during the year ended December 31, 2022 represents a change in estimate as a result of close out activities and related reporting of amounts incurred by Roche associated with the global development plan. Included in prepaid expenses and other current assets as of December 31, 2022 is a net balance due from Roche of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df0c6607-ebfb-4973-b313-327e9f8c2af6" contextRef="C_be71de03-d103-4906-b856-69607d3bce32" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,060</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  For the year ended December 31, 2023, the Company recorded a net credit of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67d05e87-825b-4001-afef-4655fad4fee6" contextRef="C_2379ff73-5bee-4de8-86f9-afedc9100f71" name="avir:ResearchAndDevelopmentCreditAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,576</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> from Roche. The credit recorded during the year ended December 31, 2023 represents a change in estimate as a result of close out activities and related reporting of amounts incurred by Roche associated with the global development plan. Included in prepaid expenses and other current assets as of December 31, 2023 is a net balance due from Roche of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1668040d-46fe-4839-ab3c-1ab6f34ef11c" contextRef="C_bdd23298-c96b-461d-b614-f7ff7d9f6a55" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,904</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Payment for this amount due was received in February 2024.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_45dbd4a4-09e7-4e0f-9034-5d75eecce2b6" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">4. Fair Value Measurements</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_d4c25d84-4ed0-4425-a953-6b3aacb0e4bf" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.331%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:10.618%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:10.618%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:10.618%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:10.618%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a19d7ae5-c2d4-4775-9c8b-9fa2276596be" contextRef="C_e263b72f-5f38-4b91-b56a-46d57583ec9d" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,740</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51583379-27c2-40b9-8296-569c00512902" contextRef="C_5d94cdb2-afb4-4c89-bda1-0c555813396a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,740</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Marketable Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Treasury obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48900372-e880-4bbd-abf4-ef07f299a8b1" contextRef="C_74e7c620-e2ac-4ca1-a2bd-90153b3ef496" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155,938</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_055d5be7-57f1-4357-a47d-6d525d58f257" contextRef="C_1d0f79dd-b812-4c0e-ae93-dd31e490b53c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155,938</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb3e9615-ac7d-420f-bfe9-5439fe86c672" contextRef="C_76b14b33-56a4-4cf1-80df-723f41684b40" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,160</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68024c13-b568-4e13-a658-a323b111bd61" contextRef="C_154ac387-b035-4286-8b39-36a8ea30d163" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,160</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90fa081f-6313-4faf-9ee3-f0757ab8611c" contextRef="C_f787167a-61d9-4235-9630-d8d7035b8ce9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,448</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d4b757b-5dd5-4028-87e4-84b546e81055" contextRef="C_31dd3b4f-faf9-41d7-b2d8-342548a15e74" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,448</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c11b37a7-a19b-4b73-b8cc-f63264214947" contextRef="C_58bb1f1f-c269-4b19-b52e-f3998d06a8a6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,737</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0678ebf7-9f2b-4ca2-a8ed-8e01d4344a6e" contextRef="C_43bf2db5-6e41-408f-92b7-55c92bcb1e87" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,737</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c9b011a-d240-4e33-8126-c8e94621152e" contextRef="C_975884e8-2fb7-4e8c-a0e2-9c732451f66c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,740</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1422ee9f-59b8-495f-8f4d-15562a5466a3" contextRef="C_78f030a1-a021-4e69-b8c8-b89c33ca2f1e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">434,283</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9aa6794-69f4-438f-bc33-fbf3172a097f" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">578,023</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.331%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:10.618%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:10.618%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:10.618%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:10.618%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d582f54a-671e-4f10-b003-7c0ba2385ecc" contextRef="C_134ce635-cd15-4e3a-bce0-502a40422357" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167,584</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cee30605-3e16-45f7-818f-b4b6ca651a32" contextRef="C_f773dd53-698b-4d30-a6b5-df061f6a5858" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167,584</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Marketable Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Treasury obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c7acdb1-cf35-4841-b1b1-8886bbe1dcf9" contextRef="C_3e7810ba-ac14-4633-950d-17f455aae7a6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,118</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c50b786-25c2-4d6d-9907-7de9b2114193" contextRef="C_13f35122-e303-4b3d-a59e-14c0c552587f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,118</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9635793e-fd07-44ca-8c5b-578c42cf83eb" contextRef="C_6b14283c-1b14-4a23-bceb-fe0448f96bd1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,941</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63f20b88-e50a-4799-a2c5-1f35ec982ad7" contextRef="C_302fd01a-656a-4ecd-a50f-578a8254ff85" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,941</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cef563cd-fb5c-439b-b34b-50242a62343a" contextRef="C_5c1df01c-45d9-4b82-b0a8-9c4a4df04fae" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">310,433</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8d77b20-3ee8-4520-b479-9ffd314dc2ce" contextRef="C_aa816b49-5422-4e75-80e8-d75787e65427" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">310,433</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_796a3ad6-7f6f-4664-94f4-c7cffa16c818" contextRef="C_0ced1b9b-cadf-4b52-b730-507c4215184a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,249</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abad9b16-8132-4aa7-9bb5-90e11aceeb8b" contextRef="C_641d1e37-afd3-4641-8d1a-05bebb533e59" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,249</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f6524ac-168c-43c9-803d-5f7af846c03a" contextRef="C_101c9929-49f6-4ecd-b591-e27524e394d7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,508</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40b9e9a5-8359-47b3-8b0b-230a5387089a" contextRef="C_20998f02-abbf-48fb-8f95-9b2494effbb9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,508</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f82e5da3-8ed5-4825-8601-a878ad1baf73" contextRef="C_790b7edc-c301-4076-b9d2-20c39e9f87b1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167,584</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49e33220-f7ca-47df-9be9-87977ffcdd07" contextRef="C_08a2ebd0-8a41-4aeb-aeaf-b254fd869fe7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">458,249</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5f5fe23-e7f7-492a-a9ae-904c0fd9f12c" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">625,833</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company&#8217;s assets with fair value categorized as Level 1 within the fair value hierarchy include money market accounts which invest in money market funds that are publicly traded mutual funds and are presented as cash equivalents on the consolidated balance sheets as of December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">There were no transfers among Level 1, Level 2 or Level 3 categories in the years ended December 31, 2023 and 2022.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_80bd91a1-3741-48c1-a663-1849567cd2b0" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">5. Marketable Securities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_9c6670ca-ed92-425e-82c8-e7d9d9fc2c9b" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.57%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.081999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.081999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.081999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.982%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Marketable Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Treasury obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29440dee-35a4-4e07-963b-1098b21baffd" contextRef="C_1d0f79dd-b812-4c0e-ae93-dd31e490b53c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155,816</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_372a3e09-777c-4456-be38-2d85968e8588" contextRef="C_1d0f79dd-b812-4c0e-ae93-dd31e490b53c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8062e00a-f0bb-4a6a-9aec-d7b04059b1bf" contextRef="C_1d0f79dd-b812-4c0e-ae93-dd31e490b53c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_741d333e-5a8c-452f-8215-ecb98177dc14" contextRef="C_1d0f79dd-b812-4c0e-ae93-dd31e490b53c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155,938</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0cfd4e7-f886-43d3-b7e1-7069a608f877" contextRef="C_154ac387-b035-4286-8b39-36a8ea30d163" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,115</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b5bab4b-41fe-466e-ba47-f9e30ce36a27" contextRef="C_154ac387-b035-4286-8b39-36a8ea30d163" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23ae1d7c-77f3-4ecd-aada-c6d78f7cf21b" contextRef="C_154ac387-b035-4286-8b39-36a8ea30d163" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_784438ff-a456-42b0-a655-72ffb2ed0f74" contextRef="C_154ac387-b035-4286-8b39-36a8ea30d163" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,160</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01592796-b6dd-4e9a-9dc0-e38753cec242" contextRef="C_31dd3b4f-faf9-41d7-b2d8-342548a15e74" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,461</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28d85787-715f-44d3-ad0f-13fd2b560732" contextRef="C_31dd3b4f-faf9-41d7-b2d8-342548a15e74" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_189c7b2e-bf48-4cbb-abd1-aa0c18e36511" contextRef="C_31dd3b4f-faf9-41d7-b2d8-342548a15e74" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_089620e8-9bb6-4cc5-a9ca-dca117d3a11f" contextRef="C_31dd3b4f-faf9-41d7-b2d8-342548a15e74" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,448</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e06bd5b-5303-401f-9b43-5209c4b21e1c" contextRef="C_43bf2db5-6e41-408f-92b7-55c92bcb1e87" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,684</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a75d11a-6ed4-4fff-b5fb-db8263fe7f93" contextRef="C_43bf2db5-6e41-408f-92b7-55c92bcb1e87" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_957dee73-40fb-4918-884d-fe4c7d4918c7" contextRef="C_43bf2db5-6e41-408f-92b7-55c92bcb1e87" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b86a5644-19a3-4015-9169-6b77fc11b011" contextRef="C_43bf2db5-6e41-408f-92b7-55c92bcb1e87" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,737</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f10212a-59e7-4cc1-b7ca-64e915bcad67" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">434,076</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e361cae-5b54-40d9-8c37-23d347381554" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">320</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e06aafcf-a610-4e1d-a433-f55ec967f569" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccdc3607-8726-4ca4-8ee8-cce56d351c02" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">434,283</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">13</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.57%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.081999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.081999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.081999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.982%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Marketable Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Treasury obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c4e3306-f9a4-4537-bed9-453fcf923ef8" contextRef="C_13f35122-e303-4b3d-a59e-14c0c552587f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,422</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09bf4e85-01d4-425b-b9ad-fe9d86866c1f" contextRef="C_13f35122-e303-4b3d-a59e-14c0c552587f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f391b32e-8ce8-433e-8241-32850c0ecd44" contextRef="C_13f35122-e303-4b3d-a59e-14c0c552587f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,118</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac5d4c53-9a0c-44f2-bf53-2ea58a20d35d" contextRef="C_302fd01a-656a-4ecd-a50f-578a8254ff85" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28ace0ac-d43a-42ba-9db1-35c5d78dd2de" contextRef="C_302fd01a-656a-4ecd-a50f-578a8254ff85" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b877bc69-aede-45c7-8a7f-22510a3001ea" contextRef="C_302fd01a-656a-4ecd-a50f-578a8254ff85" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,941</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cd4cba0-7d2f-4e20-8e7b-653703fd5381" contextRef="C_aa816b49-5422-4e75-80e8-d75787e65427" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">310,433</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce868b20-3ab3-4784-9f0b-9f7b8bb1fc2a" contextRef="C_aa816b49-5422-4e75-80e8-d75787e65427" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">310,433</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab8ae984-d521-4d3c-9bc0-aa70fef4755c" contextRef="C_641d1e37-afd3-4641-8d1a-05bebb533e59" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,504</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16ed42be-d641-48aa-90dd-307b69581901" contextRef="C_641d1e37-afd3-4641-8d1a-05bebb533e59" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">255</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e28cf1b0-b1b2-4309-b5c2-937d0ac12825" contextRef="C_641d1e37-afd3-4641-8d1a-05bebb533e59" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,249</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9cd0d34-f3c8-49b6-96af-fe0e2ba44103" contextRef="C_20998f02-abbf-48fb-8f95-9b2494effbb9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,574</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd62fb67-47ac-4053-aa67-e2a388823133" contextRef="C_20998f02-abbf-48fb-8f95-9b2494effbb9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec7e05d3-9bfb-47b1-810c-37ce1fdfb06e" contextRef="C_20998f02-abbf-48fb-8f95-9b2494effbb9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,508</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e15687f-8d95-4287-89b6-a9cb2799f7ec" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">458,933</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e82c3a9-fbc3-4fdf-89d6-81dc3aface3c" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">684</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2e6f1b7-6254-4fa4-a538-ee9afaf09f72" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">458,249</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023 and 2022, respectively the Company held</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_337147ef-fee3-403c-9751-283f6725a803" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Security" decimals="INF" format="ixt:num-dot-decimal">26</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c646730d-0309-4dfb-b2a8-078a313648a9" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Security" decimals="INF" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ecurities, respectively that were in an unrealized loss position of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36d211b0-d4fc-4edd-8c41-5fdbe4951613" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a670b0e-1de6-4f20-bd40-82b8040d56b2" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">684</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> with an aggregate fair value of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1978598-3d36-4886-8730-4641a8f2357a" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,003</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9802e92f-057f-4432-b606-6329d1f6ceed" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,221</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  The Company has the intent and ability to hold such securities until recovery. As a result, the Company did </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6547aab6-b7d0-4f22-94d8-fa5ee2f05107" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_49c904b4-53c7-416d-821f-c6af0c805c88" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> record any charges for credit-related impairments for its marketable debt securities for the year ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_788c52eb-af13-447a-b9f1-cad197d4870d" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c28a0383-01b3-4753-903b-0b9465245dbe" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> of the securities had remaining maturities longer than one year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company received proceeds of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea4b506b-f26c-43a3-bce7-e85e235d703d" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">602,665</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b32b84a0-ea1c-46f2-9018-34075803e316" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,885</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> from sales and maturities of marketable securities during the year ended December 31, 2023 and 2022.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_0aa81bf8-6c1d-48a6-9923-0dcdbb9218d1" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">6. Property and Equipment, net</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_e7218537-a89a-454c-8599-1f1e2097f0e0" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Property and equipment, net, consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.84%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1%;"/>
        <td style="width:13.04%;"/>
        <td style="width:1%;"/>
        <td style="width:1.54%;"/>
        <td style="width:1%;"/>
        <td style="width:13.04%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_645dc7f3-c85a-47b7-b69c-007299a6f8f5" contextRef="C_7d2d29de-6d0b-4b53-b56c-521ea942b78d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81e41b3d-a0d5-4a67-9a8c-89d12b723975" contextRef="C_24dbddef-dc7c-4756-ab44-6dbdef0b512c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Office furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_332c40e9-3597-40b8-b139-57db2e7a8e72" contextRef="C_6399a783-fb32-4189-8185-57a59a53f325" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">396</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a810d70-7588-4da4-9cb4-d182a0b7902c" contextRef="C_e3c8ea54-34b8-4665-bdf3-a8dcf0a0cfef" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">396</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Computer hardware</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01c4747c-84b2-410d-83fb-7e208dc233d6" contextRef="C_c7618177-dbbf-4f5e-963a-5fa2381e45b8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e14d9c9-f177-4abb-a0fd-8346f28a6a92" contextRef="C_436595f0-3519-4a55-81e8-9e4c814063e3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41edcc89-3e1d-46f0-8da3-2df89bd2a8df" contextRef="C_bb842308-4e24-47f1-9016-a28f5d33ba86" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,475</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_889d67a0-09a6-454e-b228-5bbb70bf5277" contextRef="C_34dd0c12-849b-4618-af9e-a655ab282d18" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,475</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total property and equipment, at cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdd08849-d96f-4c65-a29f-59ad66aca71f" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,978</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_528cba5a-35ce-4c0b-a688-9b0ac014eae3" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,978</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d32d811-8405-49eb-9294-ca013a20b046" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">689</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e8639b5-e065-4b55-97d9-1c19d85b34b2" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_373d3c98-bd91-4e1c-a721-98840319d260" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,289</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_435f0b0c-0d49-41ae-bdc7-2d10fc34065e" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,705</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Depreciation and amortization expense was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d7325de-2290-4c9b-a393-a9b1edd564d0" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">416</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f49397e1-fcbf-4ee5-935e-101e40ebbf49" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">260</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for the years ended December 31, 2023 and 2022, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_a8834a68-0c1c-4680-8fba-916445061516" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">7. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_31da7853-9221-4700-804e-2f51524c499d" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development, including manufacturing and clinical expenditures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1f79f1e-8268-416f-a123-03b569da9eaa" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="avir:AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,999</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_424c8a1c-1453-4a03-8011-b9d43c1538b6" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="avir:AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,667</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_500d9147-8504-4b95-8588-355a7ba3c0a5" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Payroll and payroll related</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9212bb2-4085-497b-8674-145087e75b36" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,696</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b440ab4-c7d6-4207-ac41-7c34adb7b3f2" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,459</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Professional fees and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_132a72f7-19f4-4baf-8eb1-f1f57b960f3a" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="avir:AccruedProfessionalFeesAndOtherCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">669</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b03825e3-eb74-4a53-8dfc-6550c5bd19c6" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="avir:AccruedProfessionalFeesAndOtherCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">981</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_090b69a2-4654-4783-896b-d240cabc2aa8" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,364</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0eb74c8e-97b6-4ae9-ab2d-46b530fdf0d7" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,206</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_97315cdd-a20d-420e-ac7b-29b5e8f97cc6" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">8. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Operating Lease Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In July 2021, the Company entered into a non-cancelable operating lease agreement pursuant to which the Company leased its principal office facility in </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_c83a68e4-3b60-43f3-8b2a-e562c48315f9" contextRef="C_ff6f76c6-f05a-4d88-acf9-a3905001881d" name="avir:LocationOfOfficeSpace"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Boston, Massachusetts at 225 Franklin Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> ("225 Lease"). The 225 Lease commencement date was </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_cd22c577-a2f7-4c31-8f8c-918a0978e9d8" contextRef="C_38c339a5-7c33-4fe4-88f1-30dc3c9078f4" name="avir:LeaseCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">January 1, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and runs through </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_7a0aa768-5dac-481b-8e09-fc1dc731f62c" contextRef="C_38c339a5-7c33-4fe4-88f1-30dc3c9078f4" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">December 31, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The 225 Lease does </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_7ff9d6db-140f-430b-8c09-864e90dd9fd1" contextRef="C_ff6f76c6-f05a-4d88-acf9-a3905001881d" name="us-gaap:LessorOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">no</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">t contain any options for renewal or extension.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In connection with the 225 Lease commencement, the Company recorded a ROU asset and operating lease liability of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9655c65-409b-4a39-9ba4-4c93f6cb224f" contextRef="C_c7289ade-105d-4563-a9d4-f2ae3de82763" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,938</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ba12abf-38b9-464f-b08e-196d559a8476" contextRef="C_c7289ade-105d-4563-a9d4-f2ae3de82763" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,873</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> as of January 1, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_ee02be4a-5c7c-4ef2-b546-0837ad4e8194" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="avir:SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following assets and liabilities are recorded on the Company&#8217;s consolidated balance sheet as of December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.78%;"/>
        <td style="width:1.52%;"/>
        <td style="width:1%;"/>
        <td style="width:14.9%;"/>
        <td style="width:1%;"/>
        <td style="width:1.52%;"/>
        <td style="width:1%;"/>
        <td style="width:15.28%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fd1603e-ec2d-4aa4-ae1f-6af84539257e" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,828</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fd5b578-6d61-45b0-9d8e-3c772063c0fc" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,389</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_544740b0-f0e4-4735-bc2e-4a7eadec589d" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">760</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4c7fa78-dc01-437a-9c7d-3e7b791564b5" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">721</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-current operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30170752-252e-40a8-91e9-65db8e57bc68" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,642</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ee54d4a-a05b-4324-8d54-65b65bb21139" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,403</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_d98fffe2-7c36-4d95-82ee-40d8e37fff97" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The components of the lease expense which are allocated between the general and administrative expenses and the research and development expenses on the consolidated statement of operations for the years ended December 31, 2023 and 2022 were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.16%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:14.36%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:14.36%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_235a16e6-c916-45aa-bd8d-dd8c7e303793" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">646</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7f9256f-8f7e-4b59-a418-bca17db769ae" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3">811</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_635a4c6b-7ba6-470c-9a57-7accbb47fa6c" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7fe933a-3a08-42e6-9f4f-7f8aff5b000a" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3">78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e07d2dd-3b14-4f5b-82b0-7d8ccf585e2a" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">686</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51b4b68e-a679-44f7-b7bc-1437f7c6c340" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3">889</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_17e24753-680b-4bee-9f53-29edbc6682c2" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="avir:SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The variable lease costs for the years ended December 31, 2023 and 2022 include common area maintenance and other operating charges associated with the 225 Lease. As the 225 Lease does not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company estimates it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.16%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:14%;"/>
        <td style="width:1%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:11.52%;"/>
        <td style="width:1%;"/>
        <td style="width:2.2%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of   December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Remaining lease term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_891ea9ad-03c6-4043-b4df-1107880165cc" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_63a0d799-75d8-4d6c-826e-da6d48cb3340" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Discount rate</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3608b87-d906-47e2-aac9-5bce7f03f071" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f203e1df-7dd6-4ce7-b819-ade617ac524a" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">15</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_f9a332a5-c22b-4ff8-8edf-d482850b49f4" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Future minimum payments under the 225 Lease, currently the Company&#8217;s only operating lease as of December 31, 2023 were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc5bf564-b256-4c97-a1b0-4de2c3954baa" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3">821</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5ef9423-d6f0-4b88-a93b-b2f32d13a626" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">838</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b959a39-8490-4539-b8c0-b59eb193819e" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">855</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9ff65ee-d2c6-4194-850b-17a3f33190ea" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,514</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less amount representing implied interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14ba5738-a687-4a3a-b1a9-b696b630fb0d" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6fa84ca-ef27-44de-858c-656c5e7da4ae" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,402</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea9aa31e-9ac9-4719-ba99-ee07e976f907" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">760</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Noncurrent portion of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8335e7f8-83f4-421a-920b-6dfbfb9b95e2" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,642</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Rent expense recognized was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d62d8e6-9014-4556-b47f-a4c2f4ec9842" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">646</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eddbb8a5-9d18-4e69-b14a-3c7ee730fac5" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">811</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for the years ended December 31, 2023 and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company maintains a deposit of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15fa4d4f-a6f8-489f-99f7-620121534ff9" contextRef="C_8e5a6e9b-41ce-4bde-b88a-39f1e3b103e8" name="avir:BankDepositRestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> with the landlord, which is included in other assets in the consolidated balance sheet as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">      </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">License Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In December 2021, the Company entered into a license agreement (&#8220;Merck License Agreement&#8221;) with MSD International GmbH, an affiliate of Merck &amp; Co, Inc. (&#8220;Merck&#8221;) for the development, manufacture and commercialization of ruzasvir. Ruzasvir is the NS5A inhibitor the Company is developing in combination with bemnifosbuvir for the treatment of HCV.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pursuant to the terms of the Merck License Agreement, the Company obtained from Merck a worldwide exclusive (subject to certain reserved rights to conduct internal research) and, sublicensable license under certain Merck patents and know-how to research, develop, manufacture, have manufactured, use, import, export, sell, offer for sale, and otherwise commercialize ruzasvir or products containing ruzasvir (each a &#8220;Product&#8221;) for all therapeutic or prophylactic uses in humans.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition to a non-refundable upfront payment that the Company made in February 2022, the Company will be required to pay Merck milestone payments upon its achievement of certain development, regulatory and sales-based milestones.  Additionally, the Company will pay Merck tiered royalties based on annual net sales of Products ranging from high single digits to mid-teens percentages. The Company&#8217;s royalty payment obligations will continue until the later of (i) the expiration of the last to expire valid claim of a licensed Merck patent claiming such Product and (ii) a period of years after the first commercial sale of such Product in such country. The Company may terminate the Merck License Agreement for convenience upon prior written notice. The first potential milestone in the amount of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cb00ab7-6a19-4afe-92e4-618ff9ff5cba" contextRef="C_6ee4d578-76e6-43b0-9c50-08cb7a6fb76d" name="avir:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million would be payable upon the commencement of a Phase 3 clinical trial.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Contingent Consulting Fee</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has an agreement with a consultant that requires payment of a success fee calculated as a percentage of certain product sales, subject to a cumulative maximum payout of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b906fc6-1eb9-4d4d-b4c3-dbde60fd6f51" contextRef="C_2f732af4-d836-404e-a933-0b892aefa2ad" name="avir:ConsultingAgreementSuccessFeePayout" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million. This success payment is contingent upon the occurrence of future events and the timing and likelihood of such payment is neither probable nor estimable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Indemnification</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company enters into certain types of contracts that contingently requires the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i) the Company&#8217;s bylaws, under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship with the Company, (ii) contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship with the Company, and (iii) procurement, service or license agreements under which the Company may be required to indemnify vendors, service providers or licensees for certain claims, including claims that may be brought against them arising from the Company&#8217;s acts or omissions with respect to the Company&#8217;s products, technology, intellectual property or services.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">16</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on the Company&#8217;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount payable under these contracts since the Company has no history of prior indemnification claims and the unique facts and circumstances involved in each particular claim will be determinative.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_21923dfc-2fdf-4758-9ee0-4976251b679b" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:PreferredStockTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">9. Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023 the Company has </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71731f46-27a7-41f9-9f5d-2c744f784c8c" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of preferred stock authorized.  </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa2cb6f8-0676-4a58-9cbb-a39373701cdf" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">None</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> of these shares of preferred stock have been issued.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_3a5f30d2-b49c-4305-be05-4f4e706ccf56" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="avir:CommonStockTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">10. Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, the authorized capital of the Company included </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_347f12f0-4b0e-4db3-9162-75389acf18ab" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock, of which </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e5999c8-cc4b-4a38-a8a9-827ecd483250" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c1ee40bf-7900-401f-ae3e-ac829b39006d" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">83,435,513</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock were issued and outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_41fc8f81-3942-4553-9c91-e88b6e38bd5d" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On all matters to be voted upon by the holders of common stock, holders of common stock are entitled to one vote per share.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> The holders of common stock are entitled to receive dividends, when declared by the board, and to share ratably in the Company&#8217;s assets legally available for distribution to the holders of the Company&#8217;s stock in the event of liquidation. The holders of common stock have no preemptive, redemption or conversion rights.</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_cdce23d6-bff9-4a90-af02-9f1a8958e198" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ScheduleOfStockByClassTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, the Company had the following reserved shares of common stock:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.18%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1%;"/>
        <td style="width:19.14%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding options</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_016a7eff-ebae-495a-900a-29b7e353d06b" contextRef="C_be3c9676-01ad-494a-ba2a-56772d6be054" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,017,319</ix:nonFraction></span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b5c03a3-fae7-4265-87e8-6dc1eb31e9ae" contextRef="C_bdc446e2-c3c8-45df-b44f-251b2b84015d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,337,517</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding performance-based restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89943ec7-a8ed-4d1b-93d3-77e6cafeb1bb" contextRef="C_e51f2865-c244-4aee-985f-6b147207f1c6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">724,970</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares reserved for future grant under 2020 Incentive Award Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f350e034-c7ba-4293-a07c-c635b7223435" contextRef="C_79bea9f4-f71d-40b2-9f73-0182a669f7ed" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,510,704</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares reserved under Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81fdf336-08a5-4c27-aae5-c3b175c22e6e" contextRef="C_4121b4df-602e-41a1-a327-97cd041787d0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,896,901</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3da47908-6c12-4700-80e0-5e8662a1252b" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,487,411</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_5daed8b8-9947-48e7-b930-5c6ded755ed4" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">11. Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In October 2020, the Company&#8217;s shareholders approved the Company&#8217;s 2020 Incentive Award Plan (&#8220;2020 Plan&#8221;). The 2020 Plan initially provided for the issuance of up to </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef6f1b7d-d27b-4ce6-badf-2dca06f20e4c" contextRef="C_8ba33c50-6a8d-4f09-b491-7da8f49a8f50" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,924,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock and for the grant of incentive stock options or other incentive awards to employees, officers, directors and consultants of the Company. The number of shares of common stock that may be issued under the 2020 Plan is also subject to increase on the first day of each calendar year equal to the lesser of i) </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21c08040-e926-452f-936d-444a3afa433e" contextRef="C_c9b4d51c-a9e8-4986-afd4-c57dce1daa35" name="avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year or ii) such smaller number of shares as is determined by the board of directors. Through December 31, 2023, the shares available under the plan were increased by </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d5aaff5-9488-4fd5-b6a8-27433101ad1f" contextRef="C_81ef7f57-de18-4346-8a86-4f826a99b8fb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,450,364</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares.  As of December 31, 2023, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52c6614a-7ec4-4b52-bc1e-0cdf562e5bf2" contextRef="C_aa0a55b5-ae8d-454b-abaa-c3998b787bed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,510,704</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock were available for future issuance under the 2020 Plan. In January 2024, the shares of the Company's common stock available under the 2020 Plan were increased by </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a57c7a47-3bde-418a-9e56-9d8b7dd94107" contextRef="C_b7a5ba3b-2c98-40aa-a0e2-a6986cac7344" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,171,775</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The 2020 Plan replaced and is the successor of the Company&#8217;s 2013 Equity Incentive Plan, as amended (&#8220;2013 Plan&#8221;).  In the event of any cancellation of an outstanding option award under the 2013 Plan, the shares underlying the cancelled option award will be made available for grant under the 2020 Plan.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">17</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2023 and 2022, respectively, the Company granted </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1169695-8488-4773-bd08-b802bd5736c3" contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,264,700</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c40f25c4-1f95-40ef-8475-1c7b37e67555" contextRef="C_ac643507-3356-46e0-b8b6-3ce7ebaa7b58" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">182,350</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> restricted stock units to employees with an aggregate grant date fair market value of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_084e27f3-7af4-4123-9e79-5e3e2938ca13" contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21" name="avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,384</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d5241a8-714c-45e6-95f7-df576425a4b4" contextRef="C_ac643507-3356-46e0-b8b6-3ce7ebaa7b58" name="avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,302</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The restricted stock unit awards vest in </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8ac369d-9c78-4d9d-baf2-04bb3a3e042b" contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21" name="avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> annual installments. In January 2023, the Company issued </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_888dc4b7-dd80-4c66-a9d3-2ccf85af7636" contextRef="C_ec7ec460-3701-487b-868d-61c2b3b9856f" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,935</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock upon the vesting and settlement of restricted stock units. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a976076-baf7-441c-a2be-667ad4c0e1a8" contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,998</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f98af60e-c30b-4f2f-9097-2132ea40c233" contextRef="C_ac643507-3356-46e0-b8b6-3ce7ebaa7b58" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,600</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> restricted stock units were cancelled due to employee terminations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:12pt;font-family:Arial;"><ix:nonNumeric id="F_5d705137-b457-4b58-ac6d-10633dc7e6a3" contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.8%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:12.8%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:15.66%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding at January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6135a72-103d-4b23-bd73-5484ae055e40" contextRef="C_c43a7923-c261-4651-bc39-5f0700559de8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">161,750</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec361541-4dc3-43df-bb9c-756aa6ee4102" contextRef="C_c43a7923-c261-4651-bc39-5f0700559de8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_987f43ec-a5ad-4e9d-b3f4-5b8f263e4a5a" contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,264,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_449da4b3-9705-47ff-8821-9717466ed52b" contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.59</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Released</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a15d298a-16c8-4429-8eee-1ba0379dcbce" contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21" name="avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,935</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fd96214-874d-431f-9364-eef539989241" contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21" name="avir:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b5badcd-139a-47cf-9c70-fa4fc1f1af25" contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,998</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbf4b843-ac78-4598-8c3f-1ed4b4872f34" contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.42</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unvested shares at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67f96eca-4ac6-4c88-8845-1114350ab643" contextRef="C_bfb5c27a-df03-47f9-a4cd-6d0ff368feee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,337,517</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f47007d-6830-4381-8697-8c7ad546d7e9" contextRef="C_bfb5c27a-df03-47f9-a4cd-6d0ff368feee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.69</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Performance-based Restricted Stock Units</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_568ca551-8c37-4561-867b-2cab028342e7" contextRef="C_8d744964-680d-40b2-ba6f-5c4572c15939" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> performance-based restricted stock units were granted during the year ended December 31, 2023. During the year ended December 31, 2022, the Company granted </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_281b87f3-3da2-4641-8920-6a1ed8a85915" contextRef="C_2b6262d6-cb17-47e6-a290-98609c2cd44a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">742,070</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> performance-based restricted stock units to employees with an aggregate grant date fair value of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5250af10-5001-4948-8f5e-ca9a148bec67" contextRef="C_2b6262d6-cb17-47e6-a290-98609c2cd44a" name="avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,298</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b19c8d4-da9f-486b-8fce-797f92fc3a7c" contextRef="C_8d744964-680d-40b2-ba6f-5c4572c15939" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> performance-based restricted stock units were granted during the year ended December 31, 2023.  </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_0a641f7e-3594-4fd7-b674-b21de84760f3" contextRef="C_8d744964-680d-40b2-ba6f-5c4572c15939" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The performance stock unit awards provide for a performance period from February 1, 2022 through January 31, 2025 to achieve up to six defined performance metrics.  The percentage of each award eligible to vest will be determined based on the number of metrics achieved during the performance period and may range from </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_480535c5-3aba-469a-8b35-82db724f90c2" contextRef="C_86685938-2c65-4dd3-9449-fcecbd25ce2f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b97190e4-ae89-4822-ad40-ff636079eac9" contextRef="C_c6080656-f365-4660-9a2e-1abe8d881a2c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">%. The Company has not recognized any compensation expense through December 31, 2023, as the minimum performance criteria had not been deemed probable. The vesting of any eligible awards will occur in equal installments on January 31, 2025 and January 31, 2026.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2023, there were </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d43ac76-ce91-4bb1-9c66-e94277b8838a" contextRef="C_8d744964-680d-40b2-ba6f-5c4572c15939" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> cancellations of performance-based restricted stock units.  During the year ended December 31, 2022, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_766884b5-87ab-4741-b5ec-a6abe40ade10" contextRef="C_2b6262d6-cb17-47e6-a290-98609c2cd44a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> performance-based restricted stock units were cancelled due to employee terminations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_742a15a0-5e57-4e84-9c0a-2a11425fd180" contextRef="C_8d744964-680d-40b2-ba6f-5c4572c15939" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.8%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:12.8%;"/>
        <td style="width:1%;"/>
        <td style="width:1.58%;"/>
        <td style="width:1%;"/>
        <td style="width:15.66%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding at January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ddb148c-9be0-4228-9d2f-728bb5176be8" contextRef="C_95e99b78-705a-4c5a-8427-757b8ec386de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">724,970</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f14f87ca-f4be-4cbb-9127-fcd578f335b1" contextRef="C_95e99b78-705a-4c5a-8427-757b8ec386de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">7.14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Release</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unvested shares at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b432a0eb-4ca1-4389-b62c-eba4e40272cc" contextRef="C_90c6d8d7-56c9-490c-bdcc-72c602e51c09" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">724,970</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_988f0267-b9c2-48a3-828d-c706fa9b4041" contextRef="C_90c6d8d7-56c9-490c-bdcc-72c602e51c09" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_4eb9567f-d765-4fd4-9005-cb96787e2c20" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following summarizes stock option activity:</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">18</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.17%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.602%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.001999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.602%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price<br/>Per Share</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>($000s)</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding at January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_268703fe-f553-4a87-a963-4f1fe07c6126" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,632,278</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f409b425-9099-4294-8e06-64f4e5e75f8a" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">18.48</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_55b60e90-e45b-4dab-ab14-34ef029a7d7e" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7496ff91-b19a-4aa3-9c0f-3b6e555d7b41" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,937</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32a63067-9fa3-46b9-b2f0-e1d0b72ad5d2" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,777,550</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c38d44cc-4f1f-4bea-842d-9fe685dc91c9" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.48</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a83172f1-aad0-4d38-bbc3-a8afd84aca0f" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">392,509</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34f2c0cb-adba-4508-8cf8-4b5edb851115" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">21.46</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_802e455b-7e2c-4628-8437-adafb1b95bcb" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,017,319</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c322908d-8153-495c-84b4-a189afacf78a" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">15.30</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_416123cc-9df7-4e05-9030-0efdee8812e8" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b8c845b-c560-4ede-b1bf-043b810fee51" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Vested and expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fa1b95b-39a3-43e3-8558-90edbf53c1ce" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,017,319</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bf32d73-c9c5-461a-ac96-6acc85b28e25" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">15.30</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_2af66fce-fb59-4734-bbd4-8c2dae1c83f9" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1dce0a29-385e-41ec-ab61-a845f3a010a8" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Vested and exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1cb5c913-aeaa-4026-9c67-5df13ab747ae" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,084,169</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1ad1562-bc15-4df6-ad3f-c78212fe1eb6" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">16.46</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_4a322891-fa7c-47a0-9842-44a090116781" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.4</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98383de0-0728-4d69-8ba2-5f79226bed19" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,078</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of the options and the estimated fair value of the Company&#8217;s common stock for those options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Option grants generally vest over a service period of </span><span style="font-size:10pt;font-family:Arial;"><span style="-sec-ix-hidden:F_09624d57-9bf3-4359-9740-b83c401c942c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_34609155-c74e-425f-bba2-fc88069fb58c" contextRef="C_a5182e60-9be2-448b-a355-f35129b377d3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and have a contractual term of </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_5e7556cc-1c26-4baf-b054-4a8d09d02a28" contextRef="C_d1ccbc8d-fccc-4ef6-b237-b3060720a1f5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. As of December 31, 2023, total unrecognized compensation expense related to stock option awards was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cb3e5f8-1568-45ff-88b0-811477648230" contextRef="C_2fc9ee26-6947-4538-b0a8-2c3589305d62" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,157</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, which amount is being recognized over a remaining weighted average period of </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_faa5a7da-0886-4fd0-956d-9f583ca2926e" contextRef="C_d1ccbc8d-fccc-4ef6-b237-b3060720a1f5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">2.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The weighted average grant date fair value per option granted during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffc9e753-b480-42d2-83b4-26cd409d27d2" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.27</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64cd1ffe-0a6c-4ff3-a378-1a599df777ce" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.09</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, respectively. </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_19741941-6264-4419-bc82-ec30daefac84" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_19741941-6264-4419-bc82-ec30daefac84_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The fair value of each award was estimated using </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_9cb157ed-0ee3-4b3d-8506-b2ecf7705be9" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Black-Scholes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> based on the following assumptions:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Arial;"><ix:continuation id="F_19741941-6264-4419-bc82-ec30daefac84_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.04%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:22.86%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:22.86%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfda20d6-378d-4fea-bcbe-a6f33766da89" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">3.65</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d33f3f8-324e-493b-b9ea-c62b9c8715e8" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">2.10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected term</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_a82c31d6-e852-460a-a607-47b443b463e3" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.97</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><ix:nonNumeric id="F_d31ff8e8-9f0a-4a37-9c83-1e2d338b8c6e" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.96</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d003bb1-31ef-408b-ad3c-f75678d96396" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">85.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57375a6a-0434-4d66-918b-84f535040406" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">85.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bff06fc-074c-4605-9925-381c5b81b6e6" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="INF">0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21bff24d-439d-4e46-bd04-cae1072c9571" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="INF">0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In October 2020, the Company&#8217;s shareholders approved the ESPP, which became effective upon the closing of the Company&#8217;s IPO in November 2020. The Company initially reserved a total of </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71a070f8-f0dc-4ba4-89ef-a322aa114ab5" contextRef="C_e6ae33ec-eab3-42a1-9844-29f7c68d4027" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,187,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of its common stock for issuance under the ESPP. The ESPP provides that the number of shares reserved and available for issuance under the ESPP will be increased on January 1 of each calendar year by </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fdb002e-92ca-413e-87d5-024c535fb7f0" contextRef="C_f2120fa2-8eb2-4101-8a98-bf8dc964d235" name="avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding December 31 or such lesser amount as specified by the board of directors. Through December 31, 2022, there was no increase in the number of shares reserved for issuance under the ESPP.  In January 2024 and 2023, the number of shares of the Company's common stock available for issuance under the ESPP was increased by </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2425f36e-e766-4783-91c3-f0568f011db7" contextRef="C_4dc26114-0dcd-4d93-aff6-f3d487ca3445" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">834,355</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c118f4e9-33c2-4081-b52a-2ca507d8bc0a" contextRef="C_2ba65c73-8524-40e6-ae35-92adc4ada4bb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">832,876</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company issued </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85838b62-63ca-4645-8cd4-c5a86d8869f9" contextRef="C_6082deea-8f3f-4b55-a38d-ea31916b467f" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">93,939</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8693717f-faed-4dfa-b14e-3ff43f48818c" contextRef="C_c710aa45-dbe9-4f74-a306-1b6b7afa6554" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,036</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares for proceeds of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc867951-5122-4c68-9108-28b06a6e097b" contextRef="C_6082deea-8f3f-4b55-a38d-ea31916b467f" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58568b5f-451a-4b10-8e3d-0385d627ab6e" contextRef="C_c710aa45-dbe9-4f74-a306-1b6b7afa6554" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> during the years ended December 31, 2023 and 2022, respectively.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">19</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock-based Compensation Expense</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_fae5f473-aa6e-4b79-bb75-af161969c555" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock-based compensation expense is classified as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.32%;"/>
        <td style="width:2.2%;"/>
        <td style="width:1%;"/>
        <td style="width:18.14%;"/>
        <td style="width:1%;"/>
        <td style="width:2.2%;"/>
        <td style="width:1%;"/>
        <td style="width:18.14%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be74cf38-d18d-4247-bd02-71e645f2f76f" contextRef="C_2e76c0f9-bba5-44a0-93ae-345a4101d6c8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,666</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16e9596a-b463-4c72-bb4c-a2c706750b09" contextRef="C_979c91bd-5edb-4472-af3c-4aa5b8c738a4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,870</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_217a835a-256b-4b29-9da3-50b2c5b995b5" contextRef="C_d7c74a74-1bf5-49eb-9231-e2e57e9cec94" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,762</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39aac41a-1a77-4eb3-af78-f2464ee20569" contextRef="C_24439972-d677-48cc-8863-848995b1b44c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,848</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9e0fd2f-cf60-49e4-95d9-ddf65fec9629" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,428</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f42ef4e3-1888-4510-b2a5-c3b9f8e6a414" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,718</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_a2a373a8-20b6-45a4-a6f9-6f0dead484d3" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The components of stock-based compensation expense were:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.32%;"/>
        <td style="width:2.2%;"/>
        <td style="width:1%;"/>
        <td style="width:18.14%;"/>
        <td style="width:1%;"/>
        <td style="width:2.2%;"/>
        <td style="width:1%;"/>
        <td style="width:18.14%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c55cb8d-fbfa-4740-8d04-1a25df2e2fee" contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,679</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86398563-4c86-4538-b5c3-a2a1dfcaf52b" contextRef="C_ac643507-3356-46e0-b8b6-3ce7ebaa7b58" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Performance-based restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_242f2753-fb49-495d-a23a-f32b901ccc02" contextRef="C_d1ccbc8d-fccc-4ef6-b237-b3060720a1f5" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,626</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_565f86cc-e2e4-49dd-abea-1924d3479ecb" contextRef="C_d5dd8525-8aef-4672-9fb8-129bfa24627c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,220</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3994a77-ad2b-439b-b461-354ce91b330f" contextRef="C_dd4755f2-8af0-43f4-b924-629b18b55def" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_beb8798d-5937-485b-804d-fbc854ec0f70" contextRef="C_c947d34f-cb72-4ce4-a2e2-5cd07b77a75b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5e86dfb-329c-4cbf-9d50-bc4787ebca04" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,428</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9384bcb4-2a2d-4e23-9645-a30d92594202" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,718</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_ee1f20d2-7eed-4798-881d-610137d04431" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">12.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For the year ended December 31, 2023, the Company recorded income tax expense of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3940df0f-940a-419d-82d4-e93654214e0d" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,018</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  The Company recorded a net benefit for income taxes of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3421182b-ff11-4959-812d-76571b24b55e" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,590</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for the year ended December 31, 2022.  The benefit for income taxes was primarily the result of changes in estimates between the Company&#8217;s initial provision for 2021 income taxes and the actual amounts reflected in the income tax returns as filed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_09ce2c94-1220-44e5-94d5-886ff6372f2a" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.62%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1%;"/>
        <td style="width:10.36%;"/>
        <td style="width:1%;"/>
        <td style="width:1.98%;"/>
        <td style="width:1%;"/>
        <td style="width:10.36%;"/>
        <td style="width:1%;"/>
        <td style="width:2.4%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected income tax benefit at the federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_376543e4-7adb-47c6-a4bd-e3a97ea71693" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bb013fb-2d95-402b-a4d2-1c96a11af9eb" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">State and local taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3855d7ae-0ba7-4d8f-98a7-7a238bfa91f0" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_566b80f6-3663-4c18-9b68-c332b3aafa9f" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Return to provision adjustments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78daa2b8-2b5c-4bd7-a059-03736b3ded5f" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fa063ef-1f64-437a-bd9d-60950bcba98d" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">3.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55b0af0f-33bd-4ab4-b5ee-f235212f69bc" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bc17a15-9c87-4755-9968-986da00a9d7c" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52b4f86c-23be-44e4-a261-fa78925c8b8f" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_180f0bd6-cc33-49e4-a5a3-a5adbdfb0874" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="avir:EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04833203-72e1-4397-8b3a-597a46a98ded" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="avir:EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0903227-a9ce-4a2d-9732-cd9e2f95d1f3" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_976e880a-28e3-435d-8dee-152987fea0ce" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7a64e45-ee35-42a0-812a-a77059f5bf7b" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">24.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d1abc9f-d154-461c-84e2-180006dd2ce4" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">25.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19e79204-2169-4dc4-954f-a1b116956155" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6874a068-accb-4a8c-8075-98cd54700087" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">20</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_93090447-041f-41d4-915d-f95b755af505" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_93090447-041f-41d4-915d-f95b755af505_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets consisted of the following:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Arial;"><ix:continuation id="F_93090447-041f-41d4-915d-f95b755af505_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Deferred tax assets (liabilities)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7145b1d-24fe-4b17-bb2c-0d660852ac83" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="avir:DeferredTaxAssetsInProcessResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,692</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_627fab8e-d029-429e-a633-7520f019b73e" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="avir:DeferredTaxAssetsInProcessResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,305</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb20c252-5e33-4b36-98ba-6a82a34269fa" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,385</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ae4b4bc-7ba5-4c96-bf88-de96f57b2cac" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,590</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">License agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_213b2d25-9332-490e-8198-d8193b271a69" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="avir:DeferredTaxAssetsLicenseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,609</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_333adf71-cc47-4e6d-b704-898500c22f71" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="avir:DeferredTaxAssetsLicenseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,043</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3f234e0-50b9-4562-9d8a-238cf072579f" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,884</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f425f51-69dc-4a10-836f-8498e6653dc4" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,215</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5fb27e5-d936-4267-a7d4-18475bf01464" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,155</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a4ce8dd-db70-4206-9da8-d17f91eca0c5" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,826</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0be47c8c-d54f-45dc-b5da-ed3d4e9a0147" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eed0f3e8-c73f-4d11-8e44-49dec98521a1" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a822788-1a45-46c5-9ce0-248a10c38c76" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="avir:DeferredTaxAssetsPrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">695</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9023b261-97e3-45a5-a8e2-1b1bb08c102e" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="avir:DeferredTaxAssetsPrepaidExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">893</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Deferred tax assets (liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb68145b-d6bc-411e-b168-ddb96c36db8c" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,173</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30822690-d2a1-4a67-ac68-c2df85519ecc" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,156</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d3be8a0-d92f-418f-bb29-5fd2e11f72c3" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,173</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cab9988c-f578-4679-9b76-5ab5a958d179" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,156</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7c1694b-489f-4a95-9941-1bea1fc0d031" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52c7e9aa-c87c-4f8e-89ba-6768bfadd8a8" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As required by the 2017 Tax Cut and Jobs Act, effective January 1, 2022, taxpayers can no longer immediately expense qualified research and development expenditures. Taxpayers are now required to capitalize and amortize these costs over </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_2b92c13d-09a5-4618-af15-e43ea5fb9d99" contextRef="C_e82bec19-1afd-4f24-a813-5e90d1f66925" name="avir:ResearchAndDevelopmentCostsAmortizationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for research conducted in the US or </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_5e6a1df3-944b-4039-affc-9046d64fe7e9" contextRef="C_17b49d78-dae5-461d-9aa2-8c05ca6e3b14" name="avir:ResearchAndDevelopmentCostsAmortizationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">15 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for research conducted abroad.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, the Company had federal net operating losses of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecc946f6-24a6-4664-9b58-3f3f6d4eab66" contextRef="C_2ae7bd15-ab3e-4d2d-98a8-359e5079ac8a" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,378</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and state net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16fd84cb-e37d-468a-a20b-c03bc882f5d5" contextRef="C_b4858b4b-fada-48fa-9ad8-39d05a6e7b50" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,305</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, which may be used to offset future tax liabilities.  The Company has federal and state credit carryforwards of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b464e4e8-2193-4506-9fd1-2900a854145d" contextRef="C_2ae7bd15-ab3e-4d2d-98a8-359e5079ac8a" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,944</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a434d586-19b6-4373-b5f2-059856ad387e" contextRef="C_b4858b4b-fada-48fa-9ad8-39d05a6e7b50" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,210</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, respectively. The federal net operating losses and research and development tax credits begin to expire in </span><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_f92c64e9-95ac-424b-bbfc-0558be7af7c7" contextRef="C_5a0ce532-9b29-4fdb-8d7c-26fffea11b48" name="avir:TaxCreditCarryforwardExpirationYear"><ix:nonNumeric id="F_40828361-7420-4212-a89b-4aaaa77039aa" contextRef="C_e82bec19-1afd-4f24-a813-5e90d1f66925" name="avir:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">2034</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Management has evaluated the positive and negative evidence bearing upon the realizability of the Company&#8217;s deferred tax assets. Based on the Company&#8217;s projected net operating losses, for 2024 and beyond, the Company determined that it is more likely than not that it will not recognize the benefits of the deferred tax assets. As a result, the Company has recorded a full valuation allowance of approximately $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c6b93b2-e7cf-45e3-a33d-78e3b76dc689" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,173</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> at December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Under the provisions of Sections 382 and 383 of the Internal Revenue Code (&#8220;IRC&#8221;), net operating loss and credit carryforwards and other tax attributes may be subject to limitation if there has been a significant change in ownership of the Company, as defined by the IRC.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company performed an analysis through December 31, 2023 pursuant to Section 382 of the IRC to determine whether any limitations might exist on the utilization of net operating losses and other tax attributes. Based on this analysis, the Company has determined that there was no impact on the Company's ability to utilize net operating losses or credit carryforwards in 2023.  To the extent that the Company raises additional equity financing or other changes in the ownership interest of significant stockholders occurs, additional tax attributes may become subject to an annual limitation. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company files federal and various state income tax returns. The statute of limitations for assessment by the Internal Revenue Service (&#8220;IRS&#8221;), and state tax authorities remains open for all tax years ended since the inception of the Company. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the IRS or state tax authorities to the extent utilized in a future period. No federal or state tax audits are currently in process.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_6b06a1d6-89c4-425f-80a0-fc7b959ffd4d" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:IncomeTaxExaminationDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">21</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_9e40e273-13af-4a7e-887f-621d18521d07" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table summarizes the reconciliation of the beginning and ending amount of total unrecognized tax benefits for the year ended December 31, 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.32%;"/>
        <td style="width:1.9%;"/>
        <td style="width:1%;"/>
        <td style="width:17.78%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance beginning of year</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87b757f6-a6e4-4f3b-898c-909c75ec5e0c" contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,255</ix:nonFraction></span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Decrease related to current year provision to return adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Increase related to accrued interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e242e3d4-ba62-4a8b-a07e-b811c548dd0d" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="avir:UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">503</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance at end of period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29fd9259-f41c-4a36-a63c-eead8d1284a6" contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,758</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_37b5af23-e531-4cbe-8a71-ced5fc3eae2b" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">13. Net Loss Per Share</span></p><div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_0ca38a2a-02ad-417d-be01-466e174fcb95" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Basic and diluted earnings per share are calculated as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.211%;"/>
        <td style="width:9.142%;"/>
        <td style="width:1%;"/>
        <td style="width:14.903%;"/>
        <td style="width:1%;"/>
        <td style="width:2.06%;"/>
        <td style="width:1%;"/>
        <td style="width:13.683%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:3.75pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="border-top:3.75pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="6" style="border-top:3.75pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
        <td style="border-top:3.75pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b93362f7-449d-48a0-b897-60ff64396c8f" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">135,956</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc6dd83f-aaef-4b74-b9ae-91d8399ef2a0" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,909</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebf84c7c-3c11-461c-a21c-6694d05a43fe" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8a86520c-aec6-4ac3-b728-e046c42f12d0" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">83,389,750</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87265ac5-5805-44b3-9a2d-1626732fc9c1" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3c3841e6-d656-4b28-8ac3-ad5596e72c60" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">83,245,385</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss per share - basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_602f2bea-d10f-4d2a-b820-82bcacfebdb8" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_64eedcda-0f95-4f59-877c-459c83cf92c2" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.63</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7811c10-3c2c-48be-9eff-73292a3d97bb" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_555ca420-de14-4153-b63b-265f43477fac" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.39</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock options for the purchase of </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20298725-1df6-4b49-a855-1f60cf36c266" contextRef="C_eea6202c-efed-4922-944f-49a05b0bd392" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,017,319</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_278e311e-e083-4a42-a3f4-5edac0a3fe92" contextRef="C_0c0e66ec-bf40-4f31-a93c-62669833f34d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,337,517</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> restricted stock units, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_382f8c7a-7458-45c7-9f82-60372138a1c0" contextRef="C_159d6d12-6162-484a-9282-0ea77a622978" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">724,970</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> performance-based restricted stock units and </span><span style="font-size:10pt;font-family:Arial;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_d65e820f-eff2-4c8c-86b0-6a0e7dac813a" contextRef="C_99cf4023-d6e5-48bb-8b91-c16c96320d2f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">30,254</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> ESPP shares w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ere excluded from the computation of the net loss per share for the year ended December 31, 2023, due to the net loss during the periods as their effect is antidilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock options for the purchase of </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_745cba9c-80b3-4dee-ae2c-0ae75ccbd035" contextRef="C_a68f75ab-379f-4790-b7da-2cc14623e5e5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,632,278</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f1a1ac4-e868-452d-bb7e-8865e905ebde" contextRef="C_c22f1db1-902d-4c7a-b09a-45671bb979be" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">161,750</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> restricted stock units, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0baee6e6-04dd-4683-976c-d5e85976eb03" contextRef="C_da444999-94ef-4fbd-9372-2cec9051adf7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">724,970</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> performance-based restricted stock units and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_689262df-e175-41f8-9f43-a1f7cf77cd8f" contextRef="C_62b17805-037e-4608-865a-45eafd3e8444" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">24,743</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> ESPP shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">were excluded from the computation of the net loss per share for the year ended December 31, 2022, due to the net loss during the periods as their effect is antidilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_1212487c-303c-4387-b044-817f640bb927" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">14. Benefit Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2021, the Company implemented a defined contribution plan under Section 401(k) of the Internal Revenue Code (&#8220;401(k) Plan&#8221;). The 401(k) Plan covers substantially all employees who meet minimum age and service requirements.  Under the terms of the 401(k) Plan, the Company records matching contributions up to </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1213abbc-71cd-443e-92e7-ec74105658a6" contextRef="C_e6cc6cbb-fa79-4362-b951-fdcabe1d05f1" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the participant&#8217;s eligible compensation. During the years ended December 31, 2023 and 2022, the Company recognized expense of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c82edaa5-9b30-4688-83b3-a3312eb471aa" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">708</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_726261e8-f954-4e16-8e59-3daa496c47cc" contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">541</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, respectively, relating to matching contributions to the 401(k) Plan.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Arial;"><ix:nonNumeric id="F_c22067b4-06c6-40af-ba1f-213ba26ea3a3" contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">15. Related Party Transactions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2021, the Company entered into a consulting agreement with an entity controlled by one of its directors.  The agreement provides for an annual retainer of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90306642-a3fb-40ec-b6bf-6f03de4a4dc3" contextRef="C_f28b0360-b9b7-4972-a2a7-9ed9288fa68a" name="us-gaap:RetainageDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  The Company recognized expense in the amount of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0f0e6b3-15db-4305-802e-2687af0056a7" contextRef="C_9feada43-9600-4ad4-8a75-de79be8486b3" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8637fb82-4a69-40db-9291-754df0abce90" contextRef="C_f6e3b279-caec-40bb-8720-9d81118a4e31" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> in each of the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In May 2022, the Company entered into a consulting agreement with one of its directors.  The Company recognized expense of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e7b2626-0381-431a-b504-d141f425dee4" contextRef="C_04aa3fcc-acfa-4ce1-806a-36590f240e92" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> in connection with this consulting agreement for the year ended December 31, 2022.  </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52474e67-8d77-4ccc-b09a-b5ded834f032" contextRef="C_b64973ad-fef2-423f-96bd-ad36857f2986" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> expense related to this agreement was recognized during the year ended December 31, 2023.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">               </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">      </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1(3)
<SEQUENCE>2
<FILENAME>avir-ex10_13.htm
<DESCRIPTION>EX-10.1(3)
<TEXT>
<html>
 <head>
  <title>EX-10.1(3)</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1(3)</font></p></div>
  <p style="border-top:0.5pt solid;padding-top:6pt;border-right:0.5pt solid;padding-left:1.107%;padding-bottom:6pt;font-size:10pt;border-bottom:0.5pt solid;border-left:0.5pt solid;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;padding-right:1.107%;text-align:center;"><font style="text-transform:uppercase;font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">atea pharmaceuticals, INC.<br>2020 INCENTIVE AWARD PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance-based restricted STOCK Unit Grant Notice</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Capitalized terms not specifically defined in this Performance-Based Restricted Stock Unit Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Atea Pharmaceuticals, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company has granted to the participant listed below (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) the performance-based Restricted Stock Units described in this Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PSUs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), subject to the terms and conditions of the Plan and the Performance-Based Restricted Stock Unit Agreement attached as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), both of which are incorporated into this Grant Notice by reference.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <table style="margin-left:1.167%;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.94%;"></td>
    <td style="width:61.06%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Participant:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Grant Date:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 31, 2024</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Target Number of PSUs:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Performance Period:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 1, 2024 through January 31, 2027</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Vesting Schedule:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The PSUs will vest based on the achievement of vesting conditions set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to this Grant Notice.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By Participant&#x2019;s signature below, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement.  Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.7%;"></td>
    <td style="width:42.3%;"></td>
    <td style="width:13.78%;"></td>
    <td style="width:36.22%;"></td>
   </tr>
   <tr style="height:33.1pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:36pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ATEA PHARMACEUTICALS, INC.</font></p></td>
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:36pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PARTICIPANT</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1(3)</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance-BASED RESTRICTED STOCK UNIT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Article I.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>general</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Award of PSUs and Dividend Equivalents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company has granted the PSUs to Participant effective as of the grant date set forth in the Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Grant Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Each PSU represents the right to receive one Share or, at the option of the Company, an amount of cash, in either case, as set forth in this Agreement.  Participant will have no right to the distribution of any Shares or payment of any cash until the time (if ever) the PSUs have vested.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company hereby grants to Participant, with respect to each PSU, a Dividend Equivalent for ordinary cash dividends paid to substantially all holders of outstanding Shares with a record date after the Grant Date and prior to the date the applicable PSU is settled, forfeited or otherwise expires.  Each Dividend Equivalent entitles Participant to receive the equivalent value of any such ordinary cash dividends paid on a single Share.  The Company will establish a separate Dividend Equivalent bookkeeping account (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividend Equivalent Account</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) for each Dividend Equivalent and credit the Dividend Equivalent Account (without interest) on the applicable dividend payment date with the amount of any such cash paid.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incorporation of Terms of Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The PSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference.  In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unsecured Promise</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The PSUs and Dividend Equivalents will at all times prior to settlement represent an unsecured Company obligation payable only from the Company&#x2019;s general assets.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Article II.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>VESTING; forfeiture AND SETTLEMENT</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Vesting; Forfeiture</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to Sections 2.1(b), (c) and (d) below, the PSUs will become eligible to vest based on the Company&#x2019;s achievement of the performance metrics set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Metrics</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and such PSUs that become eligible to vest, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Eligible PSUs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), upon and subject to the determination by the Administrator of the extent to which the Metrics were achieved during the Performance Period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Determination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The number of PSUs that become Eligible PSUs on the Determination will equal (i) the Target Number of PSUs set forth in the Grant Notice multiplied by (ii) the Percentage of PSUs Eligible to Vest as set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Grant Notice based on the Company&#x2019;s achievement of the Metrics.  The Administrator will make the Determination reasonably promptly following expiration of the Performance Period or, if earlier, a reasonable period of time before the occurrence of a Change in Control during the Performance Period.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to Section 2.1(d) below, in the event of a Change in Control during the Performance Period, a number of PSUs will become Eligible PSUs and vest upon such Change in Control equal to the greater of (i) the Target Number of PSUs set forth in the Grant Notice and (ii) the actual number </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1(3)</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of PSUs that would become Eligible PSUs based upon the Administrator&#x2019;s Determination, in each case, subject to the Participant remaining a Service Provider until such Change in Control and provided, for the avoidance of doubt, that in the case of the foregoing clause (ii), the Administrator&#x2019;s Determination may in the Administrator&#x2019;s discretion include any PSUs that the Administrator determines were, as of the date of such Determination, reasonably likely to become Eligible PSUs absent such Change in Control.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise provided in Section 2.1(b), to the extent any PSUs become Eligible PSUs, such Eligible PSUs will vest in accordance with the schedule set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> under the heading &#x201c;Vesting Schedule&#x201d;.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Any PSUs that do not become Eligible PSUs as of the Determination will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator.  In the event of Participant&#x2019;s Termination of Service for any reason, all unvested PSUs (including Eligible PSUs) will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company and provided that if Participant&#x2019;s employment is terminated by the Company without Cause or by Participant for Good Reason (as such terms are defined in Participant&#x2019;s employment agreement with the Company) during the three months prior to a Change in Control and Participant executes a separation and release agreement in substantially the form attached to such employment agreement during the time periods set forth therein, the PSUs will remain outstanding and eligible to vest under Section 2(b) as if Participant had remained employed until the applicable Change in Control (and, for the avoidance of doubt, will be forfeited upon such Change in Control to the extent they do not become vested or upon expiration of such three month period if no Change in Control occurs).  Dividend Equivalents (including any Dividend Equivalent Account balance) will vest or be forfeited, as applicable, upon the vesting or forfeiture of the PSU with respect to which the Dividend Equivalent (including the Dividend Equivalent Account) relates.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Settlement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">PSUs and Dividend Equivalents (including any Dividend Equivalent Account balance) will be paid in Shares or cash at the Company&#x2019;s option as soon as administratively practicable after the vesting of the applicable PSU, but in no event more than sixty (60) days after the PSU&#x2019;s vesting date.  Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Law until the earliest date the Company reasonably determines the making of the payment will not cause such a violation (in accordance with Treasury Regulation Section 1.409A-2(b)(7)(ii)), provided the Company reasonably believes the delay will not result in the imposition of excise taxes under Section 409A.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If an PSU is paid in cash, the amount of cash paid with respect to the PSU will equal the Fair Market Value of a Share on the day immediately preceding the payment date.  If a Dividend Equivalent is paid in Shares, the number of Shares paid with respect to the Dividend Equivalent will equal the quotient, rounded down to the nearest whole Share, of the Dividend Equivalent Account balance divided by the Fair Market Value of a Share on the day immediately preceding the payment date.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Article III.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>TAXATION AND TAX WITHHOLDING</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Representation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Participant represents to the Company that Participant has reviewed with Participant&#x2019;s own tax advisors the tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement.  Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1(3)</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tax Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company has the right and option, but not the obligation, to treat Participant&#x2019;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the PSUs or Dividend Equivalents as Participant&#x2019;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Award.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the PSUs and the Dividend Equivalents, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the PSUs or Dividend Equivalents.  Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the PSUs or the Dividend Equivalents or the subsequent sale of Shares.  The Company and the Subsidiaries do not commit and are under no obligation to structure the PSUs or Dividend Equivalents to reduce or eliminate Participant&#x2019;s tax liability.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By accepting this Award, Participant understands and agrees, to (1) sell that number of Shares determined in accordance with this Section 3.2(c) as may be necessary to satisfy all the minimum statutory withholding obligations with respect to any taxable event arising in connection with the PSUs (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sell to Cover Election</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and (2) allow the transfer agent (together with any other party the Company determines necessary to execute the Sell to Cover Election, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to remit the cash proceeds of any such sale(s) to the Company.  Furthermore, Participant directs the Company to make a cash payment equal to the minimum statutory tax withholding from the cash proceeds of such sale(s) directly to the appropriate taxing authorities.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Participant hereby appoints the Agent as Participant&#x2019;s agent and authorizes the Agent to (1) sell on the open market at the then prevailing market price(s), on the Participant&#x2019;s behalf, as soon as practicable on or after the date the Shares are issued upon the vesting of the PSUs, that number (rounded up to the next whole number) of the Shares so issued necessary to generate proceeds to cover (A) the minimum statutory tax withholding obligations incurred with respect to such vesting or issuance and (B) all applicable fees and commissions due to, or required to be collected by, the Agent with respect thereto and (2) apply any remaining funds to Participant&#x2019;s tax withholding obligations hereunder.  Participant hereby authorizes the Company and the Agent to cooperate and communicate with one another to determine the number of Shares that must be sold pursuant to this Section 3.2(d).  Participant understands that the Agent may effect sales as provided in this Section 3.2(d) in one or more sales and that the average price for executions resulting from bunched orders will be assigned to Participant&#x2019;s account.  In addition, Participant acknowledges that it may not be possible to sell Shares as provided by this Section 3.2(d) due to a legal or contractual restriction applicable to Participant or the Agent, a market disruption, or rules governing order execution priority on the national exchange where the Shares may be traded.  Participant further agrees and acknowledges that in the event the sale of Shares would result in material adverse harm to the Company, as determined by the Company in its sole discretion, the Company may instruct the Agent not to sell Shares as provided by this Section 3.2(d).  In the event of the Agent&#x2019;s inability to sell Shares, Participant will continue to be responsible for the timely payment to the Company and/or its affiliates of all federal, state, local and foreign taxes that are required by applicable laws and regulations to be withheld.  Participant acknowledges that regardless of any other term or condition of this Section 3.2(d), the Agent will not be liable to Participant for special, indirect, punitive, exemplary, or consequential damages, or incidental losses or damages of any kind, or any failure to perform or for any delay in performance that results from a cause or circumstance that is beyond its reasonable control.  Participant hereby agrees to execute and deliver to the Agent any other agreements or documents as the Agent reasonably deems necessary or appropriate to carry out the purposes and intent of Sections 3.2(c) and (d). The Agent is a third-party beneficiary of this </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1(3)</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 3.2(d).  Sections 3.2(c) and (d) shall terminate on the date on which all tax withholding obligations arising in connection with the Award have been satisfied.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Article IV.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>other provisions</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Participant acknowledges that the PSUs, the Shares subject to the PSUs and the Dividend Equivalents are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan. In addition, if the Board determines that due to an unusual, extraordinary or nonrecurring transaction or event materially affecting the PSUs, an adjustment in the Metrics is necessary or appropriate to avoid the dilution or enlargement of the benefits or potential benefits intended to be made available under the PSUs, the Board may adjust the Metrics in such a manner as the Board determines in good faith to be equitable to reflect such transactions or events.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#x2019;s Secretary at the Company&#x2019;s principal office or the Secretary&#x2019;s then-current email address or facsimile number.  Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#x2019;s last known mailing address, email address or facsimile number in the Company&#x2019;s personnel files.  By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party.  Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Titles</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Conformity to Securities Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Limitations Applicable to Section 16 Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement, the PSUs and the Dividend Equivalents will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule.  To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1(3)</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agreement Severable</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Limitation on Participant&#x2019;s Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets.  Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the PSUs and Dividend Equivalents, and rights no greater than the right to receive cash or the Shares as a general unsecured creditor with respect to the PSUs and Dividend Equivalents, as and when settled pursuant to the terms of this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Not a Contract of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">* * * *</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1(4)
<SEQUENCE>3
<FILENAME>avir-ex10_14.htm
<DESCRIPTION>EX-10.1(4)
<TEXT>
<html>
 <head>
  <title>EX-10.1(4)</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1(4)</font></p></div>
  <p style="border-top:0.5pt solid;padding-top:6pt;border-right:0.5pt solid;padding-left:1.107%;padding-bottom:6pt;font-size:10pt;border-bottom:0.5pt solid;border-left:0.5pt solid;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;padding-right:1.107%;text-align:center;"><font style="text-transform:uppercase;font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">atea pharmaceuticals, INC.<br>2020 INCENTIVE AWARD PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance-based restricted STOCK Unit Grant Notice</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Capitalized terms not specifically defined in this Performance-Based Restricted Stock Unit Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Atea Pharmaceuticals, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company has granted to the participant listed below (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) the performance-based Restricted Stock Units described in this Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PSUs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), subject to the terms and conditions of the Plan and the Performance-Based Restricted Stock Unit Agreement attached as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), both of which are incorporated into this Grant Notice by reference.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <table style="margin-left:1.167%;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.94%;"></td>
    <td style="width:61.06%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Participant:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Grant Date:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 31, 2024</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Target Number of PSUs:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Performance Period:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 1, 2024 through January 31, 2027</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Vesting Schedule:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The PSUs will vest based on the achievement of vesting conditions set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to this Grant Notice.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By Participant&#x2019;s signature below, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement.  Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.7%;"></td>
    <td style="width:42.3%;"></td>
    <td style="width:13.78%;"></td>
    <td style="width:36.22%;"></td>
   </tr>
   <tr style="height:33.1pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:36pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ATEA PHARMACEUTICALS, INC.</font></p></td>
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:36pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PARTICIPANT</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance-BASED RESTRICTED STOCK UNIT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Article I.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>general</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Award of PSUs and Dividend Equivalents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="ole_link5"><font id="ole_link6"></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company has granted the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">PSUs to Participant effective as of the grant date set forth in the Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Grant Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Each PSU represents the right to receive one Share or, at the option of the Company, an amount of cash, in either case, as set forth in this Agreement.  Participant will have no right to the distribution of any Shares or payment of any cash until the time (if ever) the PSUs have vested.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company hereby grants to Participant, with respect to each PSU, a Dividend Equivalent for ordinary cash dividends paid to substantially all holders of outstanding Shares with a record date after the Grant Date and prior to the date the applicable PSU is settled, forfeited or otherwise expires.  Each Dividend Equivalent entitles Participant to receive the equivalent value of any such ordinary cash dividends paid on a single Share.  The Company will establish a separate Dividend Equivalent bookkeeping account (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividend Equivalent Account</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) for each Dividend Equivalent and credit the Dividend Equivalent Account (without interest) on the applicable dividend payment date with the amount of any such cash paid.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incorporation of Terms of Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The PSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference.  In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unsecured Promise</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The PSUs and Dividend Equivalents will at all times prior to settlement represent an unsecured Company obligation payable only from the Company&#x2019;s general assets.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Article II.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>VESTING; forfeiture AND SETTLEMENT</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Vesting; Forfeiture</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to Sections 2.1(b), (c) and (d) below, the PSUs will become eligible to vest based on the Company&#x2019;s achievement of the performance metrics set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Metrics</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and such PSUs that become eligible to vest, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Eligible PSUs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), upon and subject to the determination by the Administrator of the extent to which the Metrics were achieved during the Performance Period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Determination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The number of PSUs that become Eligible PSUs on the Determination will equal (i) the Target Number of PSUs set forth in the Grant Notice multiplied by (ii) the Percentage of PSUs Eligible to Vest as set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Grant Notice based on the Company&#x2019;s achievement of the Metrics.  The Administrator will make the Determination reasonably promptly following expiration of the Performance Period or, if earlier, a reasonable period of time before the occurrence of a Change in Control during the Performance Period.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to Section 2.1(d) below, in the event of a Change in Control during the Performance Period, a number of PSUs will become Eligible PSUs and vest upon such Change in Control equal to the greater of (i) the Target Number of PSUs set forth in the Grant Notice and (ii) the actual number </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of PSUs that would become Eligible PSUs based upon the Administrator&#x2019;s Determination, in each case, subject to the Participant remaining a Service Provider until such Change in Control and provided, for the avoidance of doubt, that in the case of the foregoing clause (ii), the Administrator&#x2019;s Determination may in the Administrator&#x2019;s discretion include any PSUs that the Administrator determines were, as of the date of such Determination, reasonably likely to become Eligible PSUs absent such Change in Control.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise provided in Section 2.1(b), to the extent any PSUs become Eligible PSUs, such Eligible PSUs will vest in accordance with the schedule set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> under the heading &#x201c;Vesting Schedule&#x201d;.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Any PSUs that do not become Eligible PSUs as of the Determination will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator.  In the event of Participant&#x2019;s Termination of Service for any reason, all unvested PSUs (including Eligible PSUs) will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company.  Dividend Equivalents (including any Dividend Equivalent Account balance) will vest or be forfeited, as applicable, upon the vesting or forfeiture of the PSU with respect to which the Dividend Equivalent (including the Dividend Equivalent Account) relates.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Settlement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">PSUs and Dividend Equivalents (including any Dividend Equivalent Account balance) will be paid in Shares or cash at the Company&#x2019;s option as soon as administratively practicable after the vesting of the applicable PSU, but in no event more than sixty (60) days after the PSU&#x2019;s vesting date.  Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Law until the earliest date the Company reasonably determines the making of the payment will not cause such a violation (in accordance with Treasury Regulation Section 1.409A-2(b)(7)(ii)), provided the Company reasonably believes the delay will not result in the imposition of excise taxes under Section 409A.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If an PSU is paid in cash, the amount of cash paid with respect to the PSU will equal the Fair Market Value of a Share on the day immediately preceding the payment date.  If a Dividend Equivalent is paid in Shares, the number of Shares paid with respect to the Dividend Equivalent will equal the quotient, rounded down to the nearest whole Share, of the Dividend Equivalent Account balance divided by the Fair Market Value of a Share on the day immediately preceding the payment date.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Article III.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>TAXATION AND TAX WITHHOLDING</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Representation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Participant represents to the Company that Participant has reviewed with Participant&#x2019;s own tax advisors the tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement.  Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tax Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company has the right and option, but not the obligation, to treat Participant&#x2019;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the PSUs or Dividend Equivalents as Participant&#x2019;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Award.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the PSUs and the Dividend Equivalents, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the PSUs or Dividend Equivalents.  Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the PSUs or the Dividend Equivalents or the subsequent sale of Shares.  The Company and the Subsidiaries do not commit and are under no obligation to structure the PSUs or Dividend Equivalents to reduce or eliminate Participant&#x2019;s tax liability.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By accepting this Award, Participant understands and agrees, to (1) sell that number of Shares determined in accordance with this Section 3.2(c) as may be necessary to satisfy all the minimum statutory withholding obligations with respect to any taxable event arising in connection with the PSUs (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sell to Cover Election</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and (2) allow the transfer agent (together with any other party the Company determines necessary to execute the Sell to Cover Election, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to remit the cash proceeds of any such sale(s) to the Company.  Furthermore, Participant directs the Company to make a cash payment equal to the minimum statutory tax withholding from the cash proceeds of such sale(s) directly to the appropriate taxing authorities.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Participant hereby appoints the Agent as Participant&#x2019;s agent and authorizes the Agent to (1) sell on the open market at the then prevailing market price(s), on the Participant&#x2019;s behalf, as soon as practicable on or after the date the Shares are issued upon the vesting of the PSUs, that number (rounded up to the next whole number) of the Shares so issued necessary to generate proceeds to cover (A) the minimum statutory tax withholding obligations incurred with respect to such vesting or issuance and (B) all applicable fees and commissions due to, or required to be collected by, the Agent with respect thereto and (2) apply any remaining funds to Participant&#x2019;s tax withholding obligations hereunder.  Participant hereby authorizes the Company and the Agent to cooperate and communicate with one another to determine the number of Shares that must be sold pursuant to this Section 3.2(d).  Participant understands that the Agent may effect sales as provided in this Section 3.2(d) in one or more sales and that the average price for executions resulting from bunched orders will be assigned to Participant&#x2019;s account.  In addition, Participant acknowledges that it may not be possible to sell Shares as provided by this Section 3.2(d) due to a legal or contractual restriction applicable to Participant or the Agent, a market disruption, or rules governing order execution priority on the national exchange where the Shares may be traded.  Participant further agrees and acknowledges that in the event the sale of Shares would result in material adverse harm to the Company, as determined by the Company in its sole discretion, the Company may instruct the Agent not to sell Shares as provided by this Section 3.2(d).  In the event of the Agent&#x2019;s inability to sell Shares, Participant will continue to be responsible for the timely payment to the Company and/or its affiliates of all federal, state, local and foreign taxes that are required by applicable laws and regulations to be withheld.  Participant acknowledges that regardless of any other term or condition of this Section 3.2(d), the Agent will not be liable to Participant for special, indirect, punitive, exemplary, or consequential damages, or incidental losses or damages of any kind, or any failure to perform or for any delay in performance that results from a cause or circumstance that is beyond its reasonable control.  Participant hereby agrees to execute and deliver to the Agent any other agreements or documents as the Agent reasonably deems necessary or appropriate to carry out the purposes and intent of Sections 3.2(c) and (d). The Agent is a third-party beneficiary of this Section 3.2(d).  Sections 3.2(c) and (d) shall terminate on the date on which all tax withholding obligations arising in connection with the Award have been satisfied.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Article IV.</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>other provisions</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Participant acknowledges that the PSUs, the Shares subject to the PSUs and the Dividend Equivalents are subject to adjustment, modification and termination in certain events as </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">provided in this Agreement and the Plan. In addition, if the Board determines that due to an unusual, extraordinary or nonrecurring transaction or event materially affecting the PSUs, an adjustment in the Metrics is necessary or appropriate to avoid the dilution or enlargement of the benefits or potential benefits intended to be made available under the PSUs, the Board may adjust the Metrics in such a manner as the Board determines in good faith to be equitable to reflect such transactions or events.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#x2019;s Secretary at the Company&#x2019;s principal office or the Secretary&#x2019;s then-current email address or facsimile number.  Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#x2019;s last known mailing address, email address or facsimile number in the Company&#x2019;s personnel files.  By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party.  Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Titles</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Conformity to Securities Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Limitations Applicable to Section 16 Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement, the PSUs and the Dividend Equivalents will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule.  To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agreement Severable</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Limitation on Participant&#x2019;s Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets.  Participant will have only the rights of a general </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the PSUs and Dividend Equivalents, and rights no greater than the right to receive cash or the Shares as a general unsecured creditor with respect to the PSUs and Dividend Equivalents, as and when settled pursuant to the terms of this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Not a Contract of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">* * * *</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>avir-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:79.424%;"></td>
    <td style="width:2.48%;"></td>
    <td style="width:1%;"></td>
    <td style="width:16.097%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Legal Name</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </font></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">State of Organization</font></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Atea Pharmaceuticals Securities Corporation</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">  </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Massachusetts</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>avir-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We consent to the incorporation by reference in the registration statements (No. 333-249780) on Form S-8 and (No. 333-261344) on Form S-3 of our report dated February 28, 2024, with respect to the consolidated financial statements of Atea Pharmaceuticals, Inc. and subsidiary.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">/s/ KPMG LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Boston, Massachusetts<br>February 28, 2024</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>avir-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">CERTIFICATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">I, Jean-Pierre Sommadossi, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Atea Pharmaceuticals, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.4%;"></td>
    <td style="width:3%;"></td>
    <td style="width:5.2%;"></td>
    <td style="width:46.4%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Date:  February 28, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Jean-Pierre Sommadossi</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Jean-Pierre Sommadossi, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(principal executive officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>avir-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">CERTIFICATION</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">I, Andrea Corcoran, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Atea Pharmaceuticals, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.4%;"></td>
    <td style="width:3%;"></td>
    <td style="width:5.2%;"></td>
    <td style="width:46.4%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Date:  February 28, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Andrea Corcoran</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Andrea Corcoran</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Chief Financial Officer, Executive Vice President, Legal, and Secretary</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(principal financial officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>avir-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In connection with this Annual Report on Form 10-K of Atea Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned officer hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44%;"></td>
    <td style="width:3.88%;"></td>
    <td style="width:2%;"></td>
    <td style="width:4%;"></td>
    <td style="width:46.12%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Date: February 28, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Jean-Pierre Sommadossi</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Jean-Pierre Sommadossi, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(principal executive officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>avir-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In connection with this Annual Report on Form 10-K of Atea Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned officer hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44%;"></td>
    <td style="width:3.88%;"></td>
    <td style="width:2%;"></td>
    <td style="width:4%;"></td>
    <td style="width:46.12%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Date: February 28, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">/s/ Andrea Corcoran</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Andrea Corcoran</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Chief Financial Officer, Executive Vice President, Legal, and Secretary</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(principal financial officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>10
<FILENAME>avir-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ATEA PHARMACEUTICALS, INC.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Atea Pharmaceuticals, Inc.  (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), effective as of October 2, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Persons Subject to Policy</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall apply to current and former Officers of the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation Subject to Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall apply to Incentive-Based Compensation received on or after the Effective Date. For purposes of this Policy, the date on which Incentive-Based Compensation is &#x201c;received&#x201d; shall be determined under the Applicable Rules, which generally provide that Incentive-Based Compensation is &#x201c;received&#x201d; in the Company&#x2019;s fiscal period during which the relevant Financial Reporting Measure is attained or satisfied, without regard to whether the grant, vesting or payment of the Incentive-Based Compensation occurs after the end of that period.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recovery of Compensation</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event that the Company is required to prepare a Restatement, the Company shall recover, reasonably promptly, the portion of any Incentive-Based Compensation that is Erroneously Awarded Compensation, unless the Committee has determined that recovery would be Impracticable. Recovery shall be required in accordance with the preceding sentence regardless of whether the applicable Officer engaged in misconduct or otherwise caused or contributed to the requirement for the Restatement and regardless of whether or when restated financial statements are filed by the Company.  For clarity, the recovery of Erroneously Awarded Compensation under this Policy will not give rise to any person&#x2019;s right to voluntarily terminate employment for &#x201c;good reason,&#x201d; or due to a &#x201c;constructive termination&#x201d; (or any similar term of like effect) under any plan, program or policy of or agreement with the Company or any of its affiliates.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Manner of Recovery; Limitation on Duplicative Recovery</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Committee shall, in its sole discretion, determine the manner of recovery of any Erroneously Awarded Compensation, which may include, without limitation, reduction or cancellation by the Company or an affiliate of the Company of Incentive-Based Compensation or Erroneously Awarded Compensation, reimbursement or repayment by any person subject to this Policy of the Erroneously Awarded Compensation, and, to the extent permitted by law, an offset of the Erroneously Awarded Compensation against other compensation payable by the Company or an affiliate of the Company to such person. Notwithstanding the foregoing, unless otherwise prohibited by the Applicable Rules, to the extent this Policy provides for recovery of Erroneously Awarded Compensation already recovered by the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 or Other Recovery Arrangements, the amount of Erroneously</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1.06in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Awarded Compensation already recovered by the Company from the recipient of such Erroneously Awarded Compensation may be credited to the amount of Erroneously Awarded Compensation required to be recovered pursuant to this Policy from such person.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administration</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be administered, interpreted and construed by the Committee, which is authorized to make all determinations necessary, appropriate or advisable for such purpose. The Board of Directors of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) may re-vest in itself the authority to administer, interpret and construe this Policy in accordance with applicable law, and in such event references herein to the &#x201c;Committee&#x201d; shall be deemed to be references to the Board.  Subject to any permitted review by the applicable national securities exchange or association pursuant to the Applicable Rules, all determinations and decisions made by the Committee pursuant to the provisions of this Policy shall be final, conclusive and binding on all persons, including the Company and its affiliates, equityholders and employees. The Committee may delegate administrative duties with respect to this Policy to one or more directors or employees of the Company, as permitted under applicable law, including any Applicable Rules.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Interpretation</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy will be interpreted and applied in a manner that is consistent with the requirements of the Applicable Rules, and to the extent this Policy is inconsistent with such Applicable Rules, it shall be deemed amended to the minimum extent necessary to ensure compliance therewith.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Indemnification; No Liability</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company shall not indemnify or insure any person against the loss of any Erroneously Awarded Compensation pursuant to this Policy, nor shall the Company directly or indirectly pay or reimburse any person for any premiums for third-party insurance policies that such person may elect to purchase to fund such person&#x2019;s potential obligations under this Policy.  None of the Company, an affiliate of the Company or any member of the Committee or the Board shall have any liability to any person as a result of actions taken under this Policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Application; Enforceability</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise determined by the Committee or the Board, the adoption of this Policy does not limit, and is intended to apply in addition to, any other clawback, recoupment, forfeiture or similar policies or provisions of the Company or its affiliates, including any such policies or provisions of such effect contained in any employment agreement, bonus plan, incentive plan, equity-based plan or award agreement thereunder or similar plan, program or agreement of the Company or an affiliate or required under applicable law (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Recovery Arrangements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The remedy specified in this Policy shall not be exclusive and shall be in addition to every other right or remedy at law or in equity that may be available to the Company or an affiliate of the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1.06in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severability</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The provisions in this Policy are intended to be applied to the fullest extent of the law; provided, however, to the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment and Termination</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Board or the Committee may amend, modify or terminate this Policy in whole or in part at any time and from time to time in its sole discretion. This Policy will terminate automatically when the Company does not have a class of securities listed on a national securities exchange or association.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">11.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Applicable Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder, the listing rules of the national securities exchange or association on which the Company&#x2019;s securities are listed, and any applicable rules, standards or other guidance adopted by the Securities and Exchange Commission or any national securities exchange or association on which the Company&#x2019;s securities are listed.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the committee of the Board responsible for executive compensation decisions comprised solely of independent directors (as determined under the Applicable Rules), or in the absence of such a committee, a majority of the independent directors serving on the Board.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Erroneously Awarded Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the amount of Incentive-Based Compensation received by a current or former Officer that exceeds the amount of Incentive-Based Compensation that would have been received by such current or former Officer based on a restated Financial Reporting Measure, as determined on a pre-tax basis in accordance with the Applicable Rules.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Exchange Act of 1934, as amended.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Reporting Measure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any measure determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and any measures derived wholly or in part from such measures, including GAAP, IFRS and non-GAAP/IFRS financial measures, as well as stock or share price and total equityholder return.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means United States generally accepted accounting principles.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IFRS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means international financial reporting standards as adopted by the International Accounting Standards Board.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impracticable</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (a) the direct costs paid to third parties to assist in enforcing recovery would exceed the Erroneously Awarded Compensation; provided that the Company has (i) made reasonable attempts to recover the Erroneously Awarded Compensation, (ii) documented</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1.06in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">such attempt(s), and (iii) provided such documentation to the relevant listing exchange or association, (b) to the extent permitted by the Applicable Rules, the recovery would violate the Company&#x2019;s home country laws pursuant to an opinion of home country counsel; provided that the Company has (i) obtained an opinion of home country counsel, acceptable to the relevant listing exchange or association, that recovery would result in such violation, and (ii) provided such opinion to the relevant listing exchange or association, or (c) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to a Restatement, any compensation that is granted, earned, or vested based wholly or in part upon the attainment of one or more Financial Reporting Measures and received by a person: (a) after beginning service as an Officer; (b) who served as an Officer at any time during the performance period for that compensation; (c) while the Company has a class of its securities listed on a national securities exchange or association; and (d) during the applicable Three-Year Period.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each person who serves as an executive officer of the Company, as defined in Rule 10D&#x2011;1(d) under the Exchange Act.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an accounting restatement to correct the Company&#x2019;s material noncompliance with any financial reporting requirement under securities laws, including restatements that correct an error in previously issued financial statements (a) that is material to the previously issued financial statements or (b) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Three-Year Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to a Restatement, the three completed fiscal years immediately preceding the date that the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare such Restatement, or, if earlier, the date on which a court, regulator or other legally authorized body directs the Company to prepare such Restatement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The &#x201c;Three-Year Period&#x201d; also includes any transition period (that results from a change in the Company&#x2019;s fiscal year) within or immediately following the three completed fiscal years identified in the preceding sentence.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">However, a transition period between the last day of the Company&#x2019;s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to 12 months shall be deemed a completed fiscal year.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1.06in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img57592461_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )Z _L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *\X\>ZA?6.OQ):7UU CVZNRQSLHSN89P#@< 5Z/7E_P 1_P#D8;?_
M *]%_P#0WH Y_P#M[6/^@M??^!#_ .-']O:Q_P!!:^_\"'_QK/HIB-#^WM8_
MZ"U]_P"!#_XT?V]K'_06OO\ P(?_ !K/HH T/[>UC_H+7W_@0_\ C1_;VL?]
M!:^_\"'_ ,:SZ* -#^WM8_Z"U]_X$/\ XT?V]K'_ $%K[_P(?_&L^B@#0_M[
M6/\ H+7W_@0_^-']O:Q_T%K[_P "'_QK/HH T/[>UC_H+7W_ ($/_C1_;VL?
M]!:^_P# A_\ &L^B@#0_M[6/^@M??^!#_P"-']O:Q_T%K[_P(?\ QK/HH T/
M[>UC_H+7W_@0_P#C6SI6I:A<:'K4\NHWK2P1QF)OM+_*2V#WKEJZ#1/^1<\0
M_P#7*+_T.@#/_M[6/^@M??\ @0_^-']O:Q_T%K[_ ,"'_P :SZ* -#^WM8_Z
M"U]_X$/_ (T?V]K'_06OO_ A_P#&L^B@#0_M[6/^@M??^!#_ .-']O:Q_P!!
M:^_\"'_QK/HH T/[>UC_ *"U]_X$/_C1_;VL?]!:^_\  A_\:SZ* -#^WM8_
MZ"U]_P"!#_XT?V]K'_06OO\ P(?_ !K/HH T/[>UC_H+7W_@0_\ C1_;VL?]
M!:^_\"'_ ,:SZ* -#^WM8_Z"U]_X$/\ XT?V]K'_ $%K[_P(?_&L^B@#0_M[
M6/\ H+7W_@0_^-']O:Q_T%K[_P "'_QK/HH T/[>UC_H+7W_ ($/_C1_;VL?
M]!:^_P# A_\ &L^B@#0_M[6/^@M??^!#_P"-']O:Q_T%K[_P(?\ QK/HH T/
M[>UC_H+7W_@0_P#C1_;VL?\ 06OO_ A_\:SZ* -#^WM8_P"@M??^!#_XT?V]
MK'_06OO_  (?_&L^B@#0_M[6/^@M??\ @0_^-']O:Q_T%K[_ ,"'_P :SZ*
M-#^WM8_Z"U]_X$/_ (T?V]K'_06OO_ A_P#&L^B@#0_M[6/^@M??^!#_ .-7
M=7U34H?!EE>QZG?I<O>/&T@NI 2H7..M85:>M_\ )/M/_P"O^3_T&@# _P"$
MEU[_ *#>I?\ @4_^-'_"2Z]_T&]2_P# I_\ &LNBD,U/^$EU[_H-ZE_X%/\
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M (GT^UNM7U&2"64*Z&[D&1CV-4+[Q#K<6H7,::UJ2HDK*H^UR< $^].\%?\
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M  DNO?\ 0;U+_P "G_QK4OO^2<:3_P!?LW\A7+T :G_"2Z]_T&]2_P# I_\
M&C_A)=>_Z#>I?^!3_P"-9=% &I_PDNO?]!O4O_ I_P#&C_A)=>_Z#>I?^!3_
M .-9=% &I_PDNO?]!O4O_ I_\:/^$EU[_H-ZE_X%/_C6710!J?\ "2Z]_P!!
MO4O_  *?_&C_ (277O\ H-ZE_P"!3_XUET4 :G_"2Z]_T&]2_P# I_\ &C_A
M)=>_Z#>I?^!3_P"-9=% &I_PDNO?]!O4O_ I_P#&C_A)=>_Z#>I?^!3_ .-9
M=% &I_PDNO?]!O4O_ I_\:/^$EU[_H-ZE_X%/_C6710!J?\ "2Z]_P!!O4O_
M  *?_&MGPGK.K:AXIT^TNM6U&6"60AT-W(,C!]&KDJZ#P-_R.NE_]=3_ .@F
M@"&[\1:Y'>3HFM:D%61@!]KDX&?K4/\ PDNO?]!O4O\ P*?_ !JE??\ (0N?
M^NK?S-04 :G_  DNO?\ 0;U+_P "G_QH_P"$EU[_ *#>I?\ @4_^-9=% &I_
MPDNO?]!O4O\ P*?_ !H_X277O^@WJ7_@4_\ C6710!J?\)+KW_0;U+_P*?\
MQH_X277O^@WJ7_@4_P#C6710!J?\)+KW_0;U+_P*?_&C_A)=>_Z#>I?^!3_X
MUET4 :G_  DNO?\ 0;U+_P "G_QH_P"$EU[_ *#>I?\ @4_^-9=% &I_PDNO
M?]!O4O\ P*?_ !H_X277O^@WJ7_@4_\ C6710!J?\)+KW_0;U+_P*?\ QH_X
M277O^@WJ7_@4_P#C6710!J?\)+KW_0;U+_P*?_&O8_A[<7%WX0M[BZN)IYGD
MDW232,Y.&(')/H*\(KW/X:_\B1:?[\G_ *&: .MHHHH **** "BBB@ HHHH
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MO;.]1"LP#QF"WC3$@/4[0,@C([TS6=:GU&=ECN+D6>U ('<[054 _+G'4$T
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MMLR@?(7'S \]#@'\* ,&BBB@ K3UO_DGVG_]?\G_ *#696GK?_)/M/\ ^O\
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M3'#H!U.3S%#NS2;(U/\ N$;<\_,Q(XZ<&H];FTJ]O+N]M+F\,L\S2"*6U5%
M8YQN$AZ?2H+(:485-W<7T$ZOG=!"LBLO&.K*5(Y]>W3'( W68+2VUF\AL)?-
MM4E98GSG*_7O]:HUHZ[J8UC6;B^6,QB0C 8Y;@ 9)]3C)^M9U !1110 5[G\
M-?\ D2+3_?D_]#->&5[G\-?^1(M/]^3_ -#- '6T444 %%%% !1110 4444
M%%%% !7E_P 1_P#D8;?_ *]%_P#0WKU"O*?B:NKGQ);_ &#0KZ_B^QKF6WB=
ME#;W^7(4\XP?QH0'*T55V>)?^A1U;_P'D_\ B*-GB7_H4=6_\!Y/_B*=A7+5
M%5=GB7_H4=6_\!Y/_B*-GB7_ *%'5O\ P'D_^(HL%RU1579XE_Z%'5O_  'D
M_P#B*-GB7_H4=6_\!Y/_ (BBP7+5%5=GB7_H4=6_\!Y/_B*-GB7_ *%'5O\
MP'D_^(HL%RU1579XE_Z%'5O_  'D_P#B*-GB7_H4=6_\!Y/_ (BBP7+5%5=G
MB7_H4=6_\!Y/_B*-GB7_ *%'5O\ P'D_^(HL%RU1579XE_Z%'5O_  'D_P#B
M*-GB7_H4=6_\!Y/_ (BBP7+5=!HG_(N>(?\ KE%_Z'7*[/$O_0HZM_X#R?\
MQ%:%EJ'B6RTW4+/_ (0S5G^V(B[O)D&S:<]/+YHL%R&BJNSQ+_T*.K?^ \G_
M ,11L\2_]"CJW_@/)_\ $46"Y:HJKL\2_P#0HZM_X#R?_$4;/$O_ $*.K?\
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M -"SJO\ X#2?_$T?V7XC_P"A9U7_ ,!I/_B:+!<CHJ3^R_$?_0LZK_X#2?\
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M]E^(_P#H6=5_\!I/_B:/[+\1_P#0LZK_ . TG_Q-%@N1T5)_9?B/_H6=5_\
M :3_ .)H_LOQ'_T+.J_^ TG_ ,318+D=%2?V7XC_ .A9U7_P&D_^)H_LOQ'_
M -"SJO\ X#2?_$T6"Y'14G]E^(_^A9U7_P !I/\ XFC^R_$?_0LZK_X#2?\
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MQ'_T+.J_^ TG_P 318+D=%2?V7XC_P"A9U7_ ,!I/_B:/[+\1_\ 0LZK_P"
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M% !1110 4444 2M_Q[K]:BJ5O^/=?K45 !1110 4444 %%%% !1110 4444
M%%%% !1110 5)#_K14=20_ZT4 ,?[[?6DI7^^WUI* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ JU%_JEJK5J+_ %2T /HHHH **** "BBB@ HHHH *
M*** "BBB@!LCB.-G;HH)->=^%['5_%MA'XGG\2:C:RS3LT%K;N!;QHKE=K(?
MOYP>>.M>C$ @@C(-<3:> [_2YY(-)\47=EH\DIE:R6!69<G)"2'E1]!^=,0R
M]^(DUO-?7%MX?N+K1M/G-O=7ZSJI5@0&VQGE@,CG/Y5;7QI<7/BF?1['17N8
M;?R9)KP7"JB1.H;>01U&?NC).#TJG=_#R>>>^MX/$%Q;Z+?W!N+JP6!268D%
M@).J@D#C'YUN:;X9CT[Q#JVIK.&BOXH8A;B/ C$:[>N><_04:!J85O\ $:29
M[6\DT"XBT&ZN/L\.HF=22Q) )CZA<@\Y_P *CO/B3<6LFHRCPY/+I^FWK6MU
M=K<KA/F"A@I&6)ST[<<\U):?#J6W>TLYM?GGT*TN/M$&G-;J"&!+ -(#EADG
MC%6KCP'Y^A^(--_M+;_:]Z;OS/(SY665MN-WS?=ZY'7I1H&I#XF^(#^&M4,$
MVDQR6:["TYU"))"&QDK"?F8#/Z&K5UXYBL5\0BYLBDVD;&2/S<_:%<?(0=O&
M3QWQ65KWPN76]6O[P:N(4O A9'LDE=&4  K(3N5>.@Q]:U-;\"PZUXEL=7-Z
MT*0JBW%N(\BX"-N4$YXY]C1H&IF2^+)-&NO%.H3VUY+)9QV3O:R7NZ)#( "(
MQL^3&>>NXCM5@Z_>7/B+PV]_I]_IGVE[G9 +Y=CQK&&#2H%.3SPN05([U9UC
MP+_:S>(C_:/E?VRMN/\ 4;O)\K'^T-V<>V/>M2_\."_UG1-0:YVKIBRJ8O+S
MYN]-O7/&.O0T <#K?BFZ\2R>')QHLUMICZW";6\>96\X*Q4Y0<J?SZ'FNCNO
MB ]CXKBT>ZTF-(9;H6R3KJ$3R9)PK&$?,%)[GM^55[?X;7,#6$'_  D<[Z=I
M]ZMW:6C6RX3#%BI;.6ZX![<\4Q?A<JZ]_:(U<&-=0%\D;62&3._<5,N=Q';T
M'7!HT#4-2^*MI8:O<V\=@DUE:3>1/<&^B23<#AMD)^9P/4>]>@JP90RG((R#
M7G][\,!)J]U>6&I6D$-S,9WAN=)ANB&/+8=^0/;M7H"@*H4   8XH!"TUOO)
M]?Z&G4UOO)]?Z&D,)'$<;.W102:\[\+V.K^+;"/Q//XDU&UEFG9H+6W<"WC1
M7*[60_?S@\\=:]&(!!!&0:XFT\!W^ESR0:3XHN[+1Y)3*UDL"LRY.2$D/*CZ
M#\Z8BC96VI>.-7UN:;7M2TVSL;MK.V@T^;RCE>K.<<YSTK&.NZ[!X=EO9]0G
MGE\.ZSY%Q+&Q474&0#O X)Y'7_Z]=9=>"M0AU>]O] \23Z2M\_F7,'V9)D9^
M[+N(VD^M7[#P=86'A:[T-9)9EO!(;B>4[GD=Q@N??I^5 &7<:A<ZIXSO/L=[
M,NGZ9I9=EBD*J\TH)4G!P<*,CTKEUN]2U/P]X$M7UG4X&U"65+B>"Y997 )Q
MEN<_CFNW\,>$!X=T*[L'OVO)[HDR7+1[21M"J,9/0#UK-F^'UR-%T"SLM=^S
M76C,[1W/V0/O+'^X6P/S- #-,O+OPMXRDT/4-;DO=+DL3>1SW\@\RWVM@AGX
MR#SR?TYSH^*KPZGX.O[W1-=6.*WAD=IK%U<N57(4.#\O.,XY^E/TCP9%:WEW
M?ZU>MK6H747DR2W$*J@CZ[%C&0 >_P#^NI-<\*O>Z&VDZ)=P:);2EA.D%DC+
M*K#!&.,'W'- '.:YJ^HVWPV\.W(O+N&*X%LNH7T.6ECB*99\\D'/?_&IOAWK
M)N]8UK3K?5KW5=,A$4MI<WNXR88'<"6 )&1QQVK7L?#6NV'AB+2H/%++<0.H
M@NA81_)$JA1&4)(;USG-7?#OAPZ(UY<W-_+J&HWKJ]S=2($W;1A0%'"@>GO0
M!NT444AC6^\GU_H:=36^\GU_H:=0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %5I_\ 7?\  1_,U9JM/_KO^ C^9H CHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** 'P_P"M%(_WV^II8?\ 6BD?[[?4T -HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** )6_X]U^M15*W_'NOUJ*@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *DA_UHJ.I(?\ 6B@!C_?;ZTE*_P!]OK24
M %%%% !1110 4444 %%%% !1110 4444 %%%% !5J+_5+56K47^J6@!]%%%
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M4 %%%% !1110 4444 %%%% !4D/^M%1U)#_K10 Q_OM]:2E?[[?6DH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "K47^J6JM6HO]4M #Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BD()4@'![&J$.J1_:&M;H"&=3CG[K>X-9
M5*T*;2F[7_JQ48.2;70MQSK)-+%T>,\CV/0U#?7/V983G&Z4*?IWK+U>=[#5
M8;E/XDP1ZX/2H-;ODN?LQA;<NS?QV)__ %5Y&)S)TZ56#^.+T\TWH_NW.JGA
MN:47T9TQ.!DU%;SK<1F1/N9(4^H'>L35-7!LXH8F^>5 SD=@1TK3@DAL-,A,
MSA%"#KZUV4\="I7<8OW8J[?F]C*5"48)M:MZ%VBJ=E=O>AIE0I!T3/5O?Z5<
MKLIU(U(\\=F92BXNS"BBBM"0HHHH *:WWD^O]#3J:WWD^O\ 0T .HHHH ***
M* "BBB@ HHHH **** "BBB@!K?>3Z_T-.IK?>3Z_T-.H RO$FC?\)#X=OM)^
MT?9_M4>SS=F_;R#G&1GIZUS^E>!+R+5;"^UWQ#+JW]G1M'9Q"U2W2,,NTYVD
M[N*[6B@#SG3/A7_9&K03VFJ69L8;@2K;SZ/!)+C=G;YY^;Z'J*U+WP%]KT/Q
M%IO]I;/[8O/M7F>1GR>5.W&[YON]<CK795F:OKEMHSV$<\<TLE]<K;0I" 26
M.>3DC@ 9)I6 R]5\'_VGK-WJ'V[ROM&CR:7Y?D[MNXD[\[AG&>GZTRV\&?9Y
M?"S_ &_=_8,,D6/)QY^Z,)G[WRXQGO6IJ7B71](U2QTV^O5AO+YMMO&48[SD
M#J!@<G'.*Q[WXG>#].OI[*ZUCR[BWD:.5/LTQVL#@C(3!Y]*- (M,\!?V=9^
M';?^TO,_L:XFGW>1CSM^[C[WRXW=>>E5+SX;SSSW]M;^([BVT/4+DW-UIZVZ
M$NQ(+ 2YRH) XQ^==G#J5I/I2:I%+NLWA$ZR;2,QXW9QC/3MC-8NB^/_  QX
MAU$6&EZG]HN2I<)Y$B<#KRR@4: 9VK?#^35M=M[J36G73H)8Y8K,6J%XBF,!
M)C\RKQT'O5.[^&=U<R:G$/$T\6G:I>M=7EHEJN'!8,%#$Y4\8)[\<5T%AX[\
M,:GK/]DV6L0S7N2 BJV&(ZA6(VM^!-4;GXI>#+.[FM9]9V30NT<B_99CA@<$
M9"8ZT: 5]9^'L^H:IJ%S8:_/IUMJ5NMO>6R6ZOY@5=JX8GY1CKCKSSS3-;^&
MR:QH^AV(U5[>33+?[*\R0Y,\14*RXW<9QZG&:Z>RU^TOM;O=)C29+BTCCE)=
M0%D1QD,O.2.QR!S6I18#EM3\&)?ZM<WL=X($FT=]*6(0YV!CD/G<,XZ8Q^-;
M.A:9_8N@V&F>=YWV2!8?,V[=VT8SC)Q^=:%%, KQKXZ_Z_0O]V?_ -DKV6O&
MOCK_ *_0O]V?_P!DH1S8S^#+^NIY#2BDI15'A,<*6D%+02QU**2E%!+%%.IH
MIU!+'"E%(*44Q#A2BD%**!,44ZFBG4$L44X4T4X4$BBG"FBG"@EBBG4T4Z@D
M6G"FTX4$L44HI!2B@ECJ<*;3A02Q12BD%**"6.%**04HH$.%**04HH$.I124
MHIDCA2T@I:"6.%**04HH)%I124HH)%HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** .P\%^)O[.G&G7C_Z)(W[MV/^K8_T/^>]
M>FUX%7H_@CQ/]JC72KV3]^@_<.Q^^H_A/N/Y5+1]'D^8VMAZK]'^G^1VU%%%
M2?2A1110 5:B_P!4M5:M1?ZI: 'T444 %%%% !1110 4444 %%%% !1110 4
M444 9UQK$-G*([N*6'/1MN5/T(K-U=['4[<2VUQ&UQ&.%S@L/3!K6O;G3O*:
M*\F@V'JKL*YVRMM-_MDS6EP9H($:9D*GY<=.3UKQ<<ZDG[%N,HR^4EY^=O0]
M##QBE[2S37W,DD>*PM(5U(FYN -T<!/W ?[QJL?$-V.(D@B7LJQC%8LUW)>7
M$D[$L\C9..:!'.>D,I_X :\">*JWM1;2_%^KW_1=#U(X6-OWFK_#Y(W$UB"Y
M(34+6-E_YZQC:P_QJ:ZLY)]0BDN+M7LY!N6<L  OH/0US;"1/O1NOU4BM?29
M/MNEWU@YSY:>?&3_  D=:THU95W[.LKO==+M:V?=/[T14HJFN>&B_P ^J.D;
M7=+MD6-)@P48"QJ35^VG:XC\PPO$IZ"3@G\.U<[HK:%;!7^UQR7']Z4;<?0&
MNE26.49CD5QZJ<U]+@JM6JN:<H^D?U>OX'D8BG&#M%/U8^BBBO0.4**** "F
MM]Y/K_0TZFM]Y/K_ $- #J*** "BBB@ HHHH **** "BBB@ HHHH :WWD^O]
M#3J:WWD^O]#3J "BBB@ KB/%&UOB3X+23/EYNV4=MXC&*[>L77O#XUFZTJZC
MN!;W&G70N$?R]^Y<$,G48R._M0!Y7XD;6_$^I>)-1TO0VO+>W=+6VOEN40V_
MD-O8JC<MEO2N@O-6CUWQ;\.M4B(VW,=PY /W6\L;A^!R/PKT:VL;2RMS;VMK
M!! 228XHPJY/7@<<U##HNE6_V;R-,LHOLN[[/L@5?)W?>V8'RY[XZTK#,34]
M5U8W&I6=]H@M-#6WE#:N;M'PNP_-Y0&ZN1\,:M?:+XGT3P[:>*+'Q%I4UNZL
M(($4VBHN5)9"?8?,:]690RE6 *D8(/>J=EHVEZ:TC6&FV=J9?]88(%3?]<#F
M@1YY;ZMH/BKQMIDMO?Z=9:;HLC1VD9FCCENYFP,(F<A!QCCD]/;5\6LOB7Q7
MI7A%/GMD(O\ 4AGCRU/R(?\ >;&1]*Z2+PIX<MYTGAT#2HYHV#I(EG&&5AR"
M"!P:OQV-I#>37D5K EU, )9EC >0#H&;J<>] '(N$3XTP^4<,^AMYH'3 EXK
MMJQ;3P^+?Q7J&O2W EEN88[>*/R]ODHO)&<G.2<]JVJ8!1110 5XU\=?]?H7
M^[/_ .R5[+7C7QU_U^A?[L__ +)0CFQG\&7]=3R&E%)2BJ/"8X4M(*6@ECJ4
M4E**"6**=313J"6.%**04HIB'"E%(*44"8HIU-%.H)8HIPIHIPH)%%.%-%.%
M!+%%.IHIU!(M.%-IPH)8HI12"E%!+'4X4VG"@EBBE%(*44$L<*44@I10(<*4
M4@I10(=2BDI13)'"EI!2T$L<*44@I102+2BDI102+1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %/A,HGC,!82AALV==V>,>
M],KT3P1X8\E$U:]3]XPS;HP^Z/[Q]SVI-G5@\+/$U5"'S?8Z_33=G3;<WX47
M6P>:%Z9JU114'WL5RI(****!A5J+_5+56K47^J6@!]%%% !1110 4444 %%%
M% !1110 4444 %073VRPD7)38?X6YS^'>IZH:S??V7I5SJ"P^:\*9"^OX^E1
M4=HMETXN4U%;LQ;K2[.Z)^QZ),2?^6A?R5_7G]*+70]3@#?9_L5GO7:Q ,C$
M>A)JQHVKZC=6IU#4&T]-/\K?O@<DJ?0Y]*UQJ-FTL40N8]\L7G(,_>3^]]*\
M^&#H3?M-GY6C^6OXG?4K5Z=Z=KV]7_P/P,9?#E\1\^L2)[11A1^AI?\ A%I#
MUU>[)^O_ ->M&UU[2KUY$MK^&1HU+.%;H!U/O5.\\01.MN=,N[*4M/&DGF.?
MNMGIC^(XZ53PF$2OO\V_U$JF+<N6UODE^A%_PC-POW-:NA]>?ZT+HFK0%C#J
M44FX;3YL(Y'H36K'K&G37S64=Y"]RN<QJV2,=:9;Z[I=W=FUM[^"2<9&Q6Y/
MT]:KZGAOLNW_ &\_\R/;8GJK]?A6WW'/GP]-&X:?2X9E'7[-.4S^!K7T]-+M
M74)9-9R]O.0@_P#?70_G5_4'NX[&5[(0FX ROG$A/?./:L+PYKVHZQ?W4%Q!
M:O;0C!N+<DH6]!GK40PM*A42CN^Z3_%69?/5KTI3>RWU?Y,Z?J,BBD"A1A0
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M/% '3V44\%C!%=7/VFX2-5EGV!/,8#EMHX&3S@5/113$%>-?'7_7Z%_NS_\
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M5^/:W?73N<1#H=W$VCLEEL,>GRQS%0!ARF #[YH30KJ+PUH<,=CMN8[N.6X
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M HHHH **** "BBB@ HHHH **** "K47^J6JM6HO]4M #Z*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FM]Y/K
M_0TZFM]Y/K_0T .HHHH **** "BBB@ HHHH **** "BBB@!K?>3Z_P!#3J:W
MWD^O]#3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM/\ Z[_@(_F:
MLU6G_P!=_P !'\S0!'1110 4444 %%%% !1110 4444 %%%% !1110 4444
M/A_UHI'^^WU-+#_K12/]]OJ: &T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% $K?\>Z_6HJE;_CW7ZU%0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %20_ZT5'4D/^M% #'^^WUI*5_OM]:2@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *M1?ZI:JU:B_U2T /HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:WWD^O]#3J:WWD^O\
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M(WA?1MQ_T/O_ ,]7_P : -:BLC_A%]&_Y\__ "*_^-'_  B^C?\ /G_Y%?\
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M61_PB^C?\^?_ )%?_&C_ (1?1O\ GS_\BO\ XT :]%9'_"+Z-_SY_P#D5_\
M&C_A%]&_Y\__ "*_^- &O161_P (OHW_ #Y_^17_ ,:/^$7T;_GS_P#(K_XT
M :]%9'_"+Z-_SY_^17_QH_X1?1O^?/\ \BO_ (T :]6HO]4M<]_PB^C?\^?_
M )%?_&MJQLX+2VCB@0JD8(4;B< GW- %JBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK?>3Z_P!#3J:WWD^O
M]#0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *K3_Z[_@(_F:LU6G_ -=_P$?S- $=%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 ^/_6+]::WWC]:='_K%^M-;[Q^M "44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% #S_J5^M,IY_U*_6F4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !3XO]8M,I\7^L6@!IZFDI3U-)
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %68?]4*K59A_U0H DHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *:WWD^O]#3J:WWD^O\ 0T .HHHH **** "BBB@ HHHH **** "BBB@
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M^3$O_P 52CP!X8'_ ##/_(\O_P 51<S>3UWU7X_Y'BRU,M>RCP'X:'_,-_\
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M36^\?K3H_P#6+]::WWC]:"A**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!Y_U*_6F4\_ZE?K3* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M I\7^L6F4^+_ %BT -/4TE*>II* "BBB@ HHHH **** "BBB@ HHHH ****
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M  '-'_"XO"7_ #VN_P#P'-%@N=]17 _\+B\)?\]KO_P'-'_"XO"7_/:[_P#
M<T6"YWU%<#_PN+PE_P ]KO\ \!S1_P +B\)?\]KO_P !S18+G?45P/\ PN+P
ME_SVN_\ P'-'_"XO"7_/:[_\!S18+G?45P/_  N+PE_SVN__  '-'_"XO"7_
M #VN_P#P'-%@N=]17 _\+B\)?\]KO_P'-'_"XO"7_/:[_P# <T6"YWU5I_\
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M%M^%?^>MU_WX-'_"V_"O_/6Z_P"_!HL%SO3_ *E?K3*X<_%WPKY87S;O(/\
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MX7_"C^R-,_Z!UI_WX7_"KE% %/\ LC3/^@=:?]^%_P */[(TS_H'6G_?A?\
M"KE% %/^R-,_Z!UI_P!^%_PJM-I.FB;C3[3[H_Y8K[^U:M5I_P#7?\!'\S0!
MG_V3IW_0/M?^_*_X4?V3IW_0/M?^_*_X5<HH I_V3IW_ $#[7_ORO^%']DZ=
M_P! ^U_[\K_A5RB@"G_9.G?] ^U_[\K_ (4?V3IW_0/M?^_*_P"%7** *?\
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M81VBE"2Z$ @DC &.?6L[3/"7B.2]T@:W>Z:;/1D(M!9H^^1MNU6?=P,#G H
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MFLB372'.%E7.PXSU SQGK6[XN\./XDTN**WNOLM[:SK<VL^W(21>F1Z?Y]J
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M #YV_P#WZ7_"OF_]6JO\Z^YGH?VC'^4\_HKT#^SK'_GSM_\ OTO^%']G6/\
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MH6UNI!6"($<@A!Q4M>IE>01PE7VM5\S6WEYG/B,8ZD>6*L@HHHKZ,X0HHHH
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M5KBVFD@GCARDD3E64Y'0CD5Q?@O4Y+GQ391Z+K^K:O9&U9M3%^[.L#X^7:6
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MT[_GW_\ 'V_QI?ZLXO\ FC][_P @_M"EV?\ 7S.2%**ZW^Q=/_Y]_P#Q]O\
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M%>(_\+(\=?\ /KIG_?!_^*H_X61XZ_Y]=,_[X/\ \518+GMU%>(_\+(\=?\
M/KIG_?!_^*H_X61XZ_Y]=,_[X/\ \518+GMU%>(_\+(\=?\ /KIG_?!_^*H_
MX61XZ_Y]=,_[X/\ \518+GMU%>(_\+(\=?\ /KIG_?!_^*H_X61XZ_Y]=,_[
MX/\ \518+GMU%>(_\+(\=?\ /KIG_?!_^*H_X61XZ_Y]=,_[X/\ \518+GMU
M%>(_\+(\=?\ /KIG_?!_^*H_X61XZ_Y]=,_[X/\ \518+GMU%>(_\+(\=?\
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M_/MIW_?'_P!E1_PL'QO_ ,^VG?\ ?'_V5%@N>S45XS_PL'QO_P ^VG?]\?\
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M_P#S[:=_WQ_]E18+GLU%>,_\+!\;_P#/MIW_ 'Q_]E1_PL'QO_S[:=_WQ_\
M946"Y[-17C/_  L'QO\ \^VG?]\?_94?\+!\;_\ /MIW_?'_ -E18+GM)_U*
M_6F5XV?B%XWV ?9]-Z]-AS_Z%3?^%@^-_P#GVT[_ +X_^RHL%SV:BO&?^%@^
M-_\ GVT[_OC_ .RH_P"%@^-_^?;3O^^/_LJ+!<]FHKQG_A8/C?\ Y]M._P"^
M/_LJ/^%@^-_^?;3O^^/_ +*BP7/9J*\9_P"%@^-_^?;3O^^/_LJ/^%@^-_\
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M%@N>S45XS_PL'QO_ ,^VG?\ ?'_V5'_"P?&__/MIW_?'_P!E18+GLU%>,_\
M"P?&_P#S[:=_WQ_]E1_PL'QO_P ^VG?]\?\ V5%@N>S45XS_ ,+!\;_\^VG?
M]\?_ &5'_"P?&_\ S[:=_P!\?_946"Y[-17C/_"P?&__ #[:=_WQ_P#94?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *]0^''_(O7'_7VW_H"5Y?7J'PX_Y%ZX_Z^V_]
M 2@#L****0PHHHH **** "BBB@ HHHH *\?\;_\ (WWW_;/_ -%K7L%>/^-_
M^1OOO^V?_HM: .?HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?V#K'_0)OO\ P'?_  H SZ*T/[!UC_H$WW_@._\ A1_8.L?] F^_\!W_ ,*
M,^BM#^P=8_Z!-]_X#O\ X4?V#K'_ $";[_P'?_"@#/HK0_L'6/\ H$WW_@._
M^%']@ZQ_T";[_P !W_PH SZ*T/[!UC_H$WW_ (#O_A1_8.L?] F^_P# =_\
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M\!W_ ,* ,^BM#^P=8_Z!-]_X#O\ X4?V#K'_ $";[_P'?_"@#/HK0_L'6/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R::*WB,LTB1QKU=V
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M3T'7.,<5&F@:;'J+7R0R+,TAE*B=_+WD8+^7NV;L=\9K2HH RCX;TDI"GV3
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img57592461_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &J!(D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "DI:2@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA]:H_P QU-%1P3Q7,"302+)$XW*Z'(8>H-25F= 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EI* %HHHH **** "BBB@ H
MHHH **** "BB@D 9)P!0 R5_+A=_[JDUYKIQ":3;N[ #R@[$]L\DUU6K>*]-
MCBGL[9GO;ED*>7;#<%)&/F;H/SKC+?3[F:WABOW40QJH^SQ]&Q_>/?Z=*Z*2
M:3N4BQIV95FNV!'VA]R@_P!P#"_IS^-7:.E%:C"J^H+OTVZ7UB;^56*CN/\
MCUFS_P \V_E0!WMA)YVG6LI_CB1OS JQ7*:!XLTTZ=96EVSV4ZPH@^T#:KX4
M#(;I75 A@"""#R"*XY)IZD"T444@"BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1)ZJ?3MVKC[V>XLK]&NH'@O;<%9[?.1)$>KH?X@#SZ]:]<JCJFCV.LVWD7T
MD .48<,A]58<@U%.LT_>U-:^#C)?N]&<.CI)&LD;!D895@>"*9<7,-I"99Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUU% '(_\(UXI_P"A[NO_  70?X4?\(UXI_Z'NZ_\%T'^%==10!R/_"->*?\
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MB"?[/AVC,V.H4A<_3.: ):*C@$XB'VAHS)W,8('ZFI* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HKG-<\4RZ3K-KI5KH]SJ-U<0M,%AD1=JJ0
M#G<1ZTW3/%QNM:32-1TB\TN\EC,D*SE664#KAE)&1Z4 =+165KFNP:'ILEY*
MAE".BF-&&[YF"C^=9%WXRN4UV\TK3_#]YJ$EHB-*\4L:@;AD?>(H ZRBN?T+
MQ5%K%Y>6$]C<Z?J%H%:6VN<9VMT8$$@C@UNK+&S%5=2PZ@')% #Z*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EI* %HHHH **** "BBB
M@ ) &3P*\\ENSJVJ3ZFQS&<Q6P](P>O_  (\_3%==XFG>V\-:A+&</Y)4'TS
MQG]:Y&.-88DB085%"@>PK:DNHT.JE_K=:]H(/U8_X+5VJ5C\]Q?3?WIM@^B@
M#^>:W*+M%%<_XFUVYT.?2WBB62WEF?[4",LL2KEF7W'7Z"DW8#H**YFP\6I*
ML<<\32S.+B8M%M"B*.1E!Y.2<+VSZ\57O/&R?V=YMO!+:2-Y#A[R+<!#*2!(
M%4Y;D8V]:7,A'745GZ'?R:IH=E?3+&LD\0=A&<K^'^';I6A3&0W<XM;26?J4
M4D#U/8?G6?:Z5<?98X;R[;8HYB@^4$]3N;J?TJQ>_O[NTM.Q;SG_ -U>GZX_
M*KU,"*"WAM8_+@B2-?11C-2T44 %%%%( K5\(7A@EGT:0_+&/.ML_P#/,GE?
MP/Z$5E5']LBTS5-.OYI5BCCF*.[' V,I!_H?PJ9J\7<+7T1Z+17%7OQ"AR5T
MNPEN?268^4GX=S^59$GC7Q!(V5-A$/[HB9OU)KA=6*-HX6H]]#TRBO.[3QYJ
ML#C[=:6]U%_$8,HX_ D@_I5JZ\47.O;X]*E:TLE.UYL8F8]P!_!]>OI6E-JH
M[(RK4ITE>2.LO]9TW3!_IM[#"3T5F^8_0=360_C6P/\ Q[6=_<^C)!M!_%B*
MYZ"QMK9BT<0\P_>D;YG;ZL>:L5TJE%'+S29J'QE+G(T.\V^\D8/Y9IZ^-(Q_
MK=(U%?=51OY-7*ZSKEOH8LFN4<QW5RMN77I'D$[C[#'-1P>)=->#?/.MN^V1
MRCG)5$9E+''0?*:.6'8+R[G:)XTT<G$S7-M_UVMW4?GC%:=GK&FZA_QZ7]O,
M?1) 3^76O-Y?$MD([26UWW<-Q=+:&2'&V)R<#=G![TB76FZGKEYIALP\MHBN
MTQ4 $DD%01SD=Z3IP>P^:1ZO17GMO)J6G8.GZC+L'_+"Y)E3Z9/S#\#6Y8>,
M(2ZP:M";&9C@2$[H7/LW;Z'%1*DUMJ-5%UT.FHI P90RD$'D$=Z6LC0****
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M 'R/\:YWQ'JD&IO 8%<>6"#N&.M<M9^+]/U"RO;LPW-K':0+<N)T )B92RL
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M\5YC8SR:_P"%H;B:)89;J'>%5LA6_A(/X U<T353I+P:F.+*Z5?ML8Z(W3S
M/8\'V^E;4ZTHOEEL,])HI%8,H92"I&01WI:[ "BBB@"&[N[>QM9+J[GC@MXA
MN>61@JJ/4DUS$V@ZJMY=:CH>KV;P7L@N#!=6^]"2JC*R(P(!"CL:/&X97TJ:
M\7=HD5SNO !G:_\ RR9_6,-U]]I/ -5%T2YTF5KCPW=K8ECN>RE!>UD/^[UC
M/NF/<&@#B/B,^LZCJ'AGPKJ.GVT$M_J22>9;7/FJZ)][Y2H(^]GGTKV^O'?!
M$]SX_P#BG?\ BR[@6*ST:+[#:HK^8GFG.\JV!GJQSCHPKV*@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** .7\>9_P"$?7&@#7/](C_T4]N?O?A72QG]RGR[/E'R
M^GM7,^/MO_"/KNU\Z(/M$?\ I0&<\_=X]:M^)V=/"\Q25LD1C>IP2"PSR/6A
M@<G=?:K+2KS2QIS2:F]S)(1)9-,EV&8E"'' XP,D\8KT:'=Y2;P VT9 [&O-
M?LZ=-TW_ '^?_&NT\*LS>'K<LS,06&6))P&/<UG"HI;%R@XFU1116A 5S'BZ
MSGOI=&CM\!A>@EVA\Q5&QN2*Z<UXM\4M0OK;Q<L4%[<0QBU0[8Y2HR2>PK2E
M2=67*B9R45=GKNGVSVEFD,KQO(.6:.(1J?\ @(Z5<KSCX1W=S=Z5J7VFXEF*
MW"A3(Y;'R]LUZ/2J0<)N+Z#3NKA1114##-<?XNM;S7+RUTBVMUDA5&N)VE8J
MF?NH,@'D$DX]A77UQSVD=U?WSS&1B+AE'[Q@  !@8!KBQV.A@Z7M9JZO8N$'
M-V1M>&;NZNM#M_M\;1WD0,,X(/+J<$CU!QG/O6QUKF-%A6VUMXXBX1K;<5+E
MAG=[FNF'2M,)B8XJC&M%63%*/*[,6F.048>QIYZ5Y[\6+JXM= LFMIY82UU@
MF-RI(VGTKHD[*Y5&DZM2--=78S/#D4O]H:&BAY9+>:3S8?L)B,(.[YC)CGZ=
M\UZH#Q7S'_:^I_\ 02O/^_[?XU[?\-YYKGP5:R3RO*Y>0;G8L?O'N:SIUE-V
M1VXS+JF%@IR:=WYG6DC'-<+))8V-SK=OJVFS7=S=7!>%1 7,\9 V!6QQC&.H
MQUKN:\4UJZNO[7U+_2K@8N)  LS #!..].K55-79X]?$1HQ4I=3V> @01Y0I
M\H^4G.WCI7G+_9YM.U#3([&5M7?47>!A;,"A\S(??C  'O7;Z:[OX:M9&<ES
M:J2Q/).WK7ATE_>M&[&^NLX)_P!>W^-;TZ;GL=E&BZNQ]"*?D )R<<UYW+.E
MGXKU@SW MUDND95?33-O&Q1D-CCTKL-+D>3PQ:RL[&0VBDL3R3MZUP,$?F01
ML\DY+ $GSGY/YTZ=)SND<5?$QH6YEN>I(04!!XQ3JQ_"[,_ART9V9FVGECD]
M3WK8J&K.QO%\R3"BBBD,**** $/2N4T7(\<ZYGPX+,83_B9?\_7'3\/:NK/2
MN2T7:/'6NX\1&\.U,Z;C_CU__70!UPHH'2B@ HHHH *2EI* %HHHH **** "
MBBB@ HHHH YSQE)_Q++6W'_+>[C!'LN6/_H-8-:WBY]VH:5#Z&64_@H'_LU9
M-=-/X2D%%%%6,**** "DM8?MFNV<&,I!FYD_#A1^9S^%!(52S$  9)/:M'PS
M;M]DEU"12)+QMR ]1&.$'\S^-<F-J^SHON] 1N448-%?-E!5/4[$:A9M%G;*
MIW1/_=8=/\*N8([44 <A%(9(\LNUP2KK_=8=16/K<OF7=O; _*@,S_7HO]37
M1ZI"+?6"RC"7*;_^!+P?TQ7)7+^;JEY)Z.(Q]%'^)->]'$.KAE)[[,WPT;U+
M]AM%%%<QZ 4444 %%%% ",H92K $$8(-:&D3)<VTNEW8$FQ, /SYD1XY^G3\
MJH4QFDBDCN(?]="=RC^\.Z_B*THU/9RN8UJ2JPY?N-BYU?2=/O9K:=TCN(;;
M[4X\OGRP<;@>_/XU);:K87.I2:?&LBW,:%BKV[("@.#@D8(R>U<]KWAZ?Q&9
M]1L98D>2UB2W9CCG+B16XX!5\?4>U;<6EW$E]J%U/<O!),8XH'@8%DA0=.00
M,L6)_"O43;/$:MHQ'\2Z/$)&-P,QW8L& C)/G=E]_P"5)9>(-+OIS!##<(PE
M^SGS;1HU#XSLR1UP.GTKGY/!NH/?2W0F@.^;[1Y98_ZSS]P;./\ GF2/K6P-
M*NHII%*AA/K/VP,A^Y& #S[Y7&/>B[#0Z *H;<%4,>^.:6BN>U;6)))GLK!]
MFP[9K@?PG^ZOOZGM6=>O"A#GF53IRJ2Y8FE>:SI]C)Y4UP/-[QH"[#Z@=*;;
M:[IMW((H[D+(>B2 H3],]:YN*&.!=L:XSR3W)]2>]$D23(4D0.I[$5XW]L5.
M:_*K'H?48VWU.WTR].CZTDI.+2\813CLK]%?^A_"N\KQ2UOVMHS8WTC26$HV
M+*QRT)/3)[K[]J]4\-:@^HZ)"\QS<0DPS?[Z\9_'@_C7IPKPQ$/:0^9Q2IRI
M2Y)&O1110 $X&3TK#US0K+Q3:64GVVXB^S3"YM[BRE4$-@C(."",$UJWT'VK
M3[FWY_>Q,G#;3R".HZ5X]X?\/>(K'2;8)I^JH=/T%T2SENF2.6\WNIZ-R-IR
MO3MTH [&X^'6@O9):;+K8D,L3-YQ+R>8ZN[,Q!)8LHYIEYX.TN?5KK47$^Z\
M0QW,(8>5-\FS)&,YV\<$5PD'A[Q=<Z2EK.-;BAC%^\(\YHGYCC, .')QOW8!
M)J2^LO%CWFIO%;ZI+YUK;&:0N8W7!C\V*'YMIR YS@$'(SS0!NZCX3TFTT^W
M-[J&I&*UC>U222;<WE2@)Y9PO*_=QZ>M03>#=&M93<N]PD*+DQO/B(,(_+\P
M@_Q;>,].^*RKW1]6FGU&YL(=8AA5;);"WEG8$+N'FY!8_, .<FN:.G:QKVF:
MJMM'J4J217L<K33DQS.)OW*Q@GMA@>GIWIB.RM]"T=3?V4(DES:Q6=Q&[$CR
MU0[!TZ[6/(JK%X6L+5XI=]U--%.LXEFEW,65"B@G'0*<8K$O;#5VED;[)JS:
M49(2;9)B)BHM\ #YL\28SSU]:KII?B);NUN;I[UIX6L@=LQV$8(FR,X/&,F@
M#L):I2]ZNR]ZA@LY[^Z2VMHS)*YP /YGT%,!VA7VHV.KQ'3%:2:0[3#VD'H?
M\>U>Q(6**77:Q R <X-8WA[PY;Z';YXDNW'[R7'Z#T%;=2QA1110 5F>(;I[
M/P_?31Y\P1%8\?WFX'ZD5IURGQ#NWM?"LXBSYT@?R\=<K&S#_P!!%3-VBP.?
M>RAFT9]/\P+$]N8"RD< KMS61/X3LTN+B[CNC \]DEG*9(T=&"X&XJW!)  K
MD]5CO([/Q"E@UJ-/2VL1('#%\;!C81Q^=3:QJ^K:A'K,$[PBUCE,9MS(F^/;
M,@0A1\_(Y)/!R,5QJ#6S$:^G^#W@U.XAEO9AIT;VK1Q%E8W!B08+'J,,.G?%
M;ITPPRZA-::D;:XO9EF+[4?:54+@ ]00*Y36(;J]U>QU*Q8_:VO+F>V /#K"
M@54/LVUO^^JKZ58:=JH\)W<]C%(;FZNMYE3+%1O90?H:&F]6_P"OZ0'>:/IT
M.DZ9#86\C2)#G+,022222<=.2>*;I2K]@DA8 JDTL9!Z8W'C]:X#1H9]+T9]
M?W):1GS;8/;D&2=WN,*\F\;5VXQDYP"3[5<T_P 3ZB(=*FDEC?[1YZ/#;["\
M\RNX5F&,["$^\G?VJ73;=P/5?"E^]KNTBY8F.,_Z)(Q^\A_@^J_RQ75UX)I&
MKZI?0:=>W,T,TBW]L\!25&=2RMYB$)]T8S@'GUZ5[;I^IQZGH\=_;H6WH6\O
M/(8=5^N1BNJC+3E8R]7(^*'N[[6K/0FN9+/3KFW>:22!RLLY4@&(,/N## DC
MD]!CFLJUUS7S;V_BJ:X$UE(FZ;2H$R(H#U93C<TJ]3V(R .E;GBK9=^'K?7;
M!A,U@RWT+1\^9%CYP/K&6_'%; 0Z/J,D<Q\,Z^RW#2HRVMS(HVWD6.5;MY@'
M4=QR.^. \:ZUJ?AJ-O NDE[S4]0VQ:;(K@O% ^05?N&7D!NZ\]C5WXA^,M.M
MK.'1=/B;4]=NRCV4%N3NA<\I+D<@CJ!W[\5N?#KX?3Z%+-XB\1SF^\3WPS-,
MYW>0#_ OOZD?0<=0#H_!7A>W\'^%++1H,,T2[II /]9(>6;\_P! *Z"BB@ H
MHHH **** "BBB@ HIKDA&(Z@5Y_X2\::AJ>EWL.J;(]02&6XM7"X6:($@$#U
M4C!% 'H.:YO5-=U&WUF2QLH+5A'$DC-.S#.XD8&!_LU:T+5S<>$K'5=2GBC,
MELLLTK$(H)')] *YZ34K'4_$]]-87D%U$+:%2\$@< Y?C(KSLSQ$\/AI5:>Z
MM^9=-)RLR]_;NO?\^^F_]]R?X4?V[KW_ #PTW_ON3_"HZ*^4_M[&_P R^Y'3
M[&!5'C'6S<W$(L]/S ^PGS'Y. <]/>G?\);KG_/IIW_?Q_\ "L5/^0GJ?_7P
M/_0%JEJNH/;SZ@#J<NGP6-M$Z&&)7,TL@9ANRIXX QP/>OO<*U+"TZL]6TKG
MA.I6GB)4X.R3['17/C/6[:UEG-GIY$:%B!(_./PJ^FOZ\\:OY&F_, ?OR?X5
MR^IF1M#E>5$65[0/(J'*ABF3CVS71P_ZB+_<7^5>-Q!C:N#]G[!VYK[Z]CKR
M^4JO.JCO8L?V[KW_ #PTW_ON3_"D_MW7O^>&F_\ ?<G^%1U2UFZELM!U.[MV
MV30VLDD;8SM8+P:\"AG.-JU8TU):M+9=3T94H)7-'^W=>_YX:;_WW)_A1_;V
MO?\ /#3?^^Y/\*X]/$6H_P#"'WTESMM]=L8HC-A1M<.5VRJ#V93^!S5WQ1K;
MV>G:R;74)+:2WOK2%I&B0"!) N[:2#G@YR:]VG3S25^:HEKV_$Q;I]CH_P"W
M=>_YX:;_ -]R?X4?V[KW_/#3?^^Y/\*Y"VU8KK^GVFF>)7UY)YBEU"R1MY,6
MTGS-R*-N"!P>N:L:GKE[:ZXTD#@:-ICQ0ZE\@.YY>^>VP%#^-9R_M+VG)&HK
M6O?E[=+>8U[.VQU']NZ]_P \--_[[D_PI/[=U[_GAIO_ 'W)_A7+:]K>I:/X
MJMXT DT>&Q\Z^0+EE!DV^8#UXXS[5K6][+-XAU&T\U7M8K6VEAV@8RX8D@]\
M\5A.MF4*7M7-6Y;[?@-*FW:QI_V[KW_/OIO_ 'W)_A1_;NO?\\--_P"^Y/\
M"HZ*\C^WL;_,ON1K[&!4N?&.MVU_]E-GIY/E"3=YCXP21CI[4W_A--;_ .?+
M3_\ OX_^%4+@ ^+8P0"/LJG!Z?>:LRWU(3:=HK7$5U=:A?VC3!+:-0&VG#$D
MD =17M8;$X[$4?:4VO30UC##QLIK<Z+_ (336_\ GST__OX_^%+_ ,)IK7_/
MGI__ '\?_"N?34\MHXL;&>=-0NY+6<2(H>$H"&0@GJ",Y'84XWEJ%:41W9L5
MG^SF_P#+'D[\[?7=MSQNQBMI/,TDUK?T&OJ3?_#F]_PFFM?\^>G_ /?Q_P#"
MC_A--:_Y\]/_ ._C_P"%<U?ZG]BBU@V-A?74VFK(CS>6GDI(J^YRP&<U=0W
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M;^AR:L]@!K,<*7:.R%H3\L@!X<#MD=NU;GJFI12"EH *2EI* %HHHH ****
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MYUBC)\F2))H@3G:&ZK^!%>)G%*<DJM]%I_P3T,#.*;A;4?17,P>)YO/:.YA
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M91B]6CHPJ]G7A.6R:.3K2LOLKV]LUQ+"/LER\_E2IN\S,3*,#!!.XCK71_\
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M$T<$FE1RZA8+:V%S'*9%:0R3(F[:-NW"M\W/)S6I_P *IUW_ )_-/_\ '_\
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M3/,@[Q"BBBH*"BBB@ HHHH *,<Y[T44 %%%% !1110 4444 %<9XB_Y&I/\
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M*** $HI:*8#6SM.W&<<9KRUM"FN[FT%]I&I?;XIF>^O))R(I$P?N$,.2=NT
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M;OY;GQ9=6]CM$JQI=*A@.>001]WIBM[2;:--*VQ:I/?1R9*W+RAVP?0@8XH
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MB#TD1T_D?Z5T85_O+/J<F-5Z5^UC/NK>32)?)N23 3B*X/0CT;T/\ZB>[@3
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MC3H<#Z_XUCZO:(FK6]FLLYM5B\]H7E9E9@V%X)[<G\JYL/BI5JBARVOY_P#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$ @\$'O6M&JZ4U-= .25@RAE(*D9!'<4M0K;?V=?7.G#/EQ$/!G_ )YMG _
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M5-1>[E5PRH5VX7'?\/RKN** *.G:-IVD^;]@LXH#,<R%!RV.F3Z#T[5>HHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E
M+24 +1110 4444 %%%% !1110!PFJIY?BC45_OK%(/Q7;_[+4-7_ !-'Y?B2
MWDQQ/:%?Q1L_R:LN6X@@'[V:./\ WF KKAK%%(O:3/\ 9]6,;'"7*8'^^O\
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M[O(R-WIQZTU4FMO(3C%F'JG@_3+O2S;V5K:V5RA1H;F.!=R,I!!XP3T]:WC
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M"3*WR1@#W/7\*DCTN$N);IWNY1T:7H/HO04:G^\ABM!_R\2!#C^Z.6_0?K0
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MN*E&HPSP>,]1MEAN(7@AE02IN1QY.>0>OTKLK?2HK?6+[4@[-)=I&C(<;5"
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M*9&+$%SNV\]  0,>U4/$?AFYUC5[2XMYHDMG58;]')S+$KAP!QR<@CGLQKJ
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M4\CT%+VVDO9;-)T:YB57DC!Y4'H3]<5'>ZI;6%S9V\[,)+R7RH@%SEL$\^G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !24M)0 M%%% !1110 4444 %%%% !1110 4444
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B** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img57592461_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '$ YH# 2(  A$! Q$!_\0
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MR_Z!MS_WVM'_  M&R_Z!MS_WVM9>H>&XX?"3QC3FCO+2".Y>ZV']X3DNF?\
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M'IO_  M&R_Z!MS_WVM'_  M&R_Z!MS_WVM>94460?VSC/YOP1Z;_ ,+1LO\
MH&W/_?:T?\+1LO\ H&W/_?:UYE119!_;.,_F_!'IO_"T;+_H&W/_ 'VM'_"T
M;+_H&W/_ 'VM>94460?VSC/YOP1Z;_PM&R_Z!MS_ -]K1_PM&R_Z!MS_ -]K
M7F5=QX>\.1W?A]5FT]I9M0$IBN=F1 %'R\]LMFBR-\/F&.KRY8R_!?Y&K_PM
M&R_Z!MS_ -]K1_PM&R_Z!MS_ -]K6'-<VP\(I>_V'IBW;W36A A/ V]1S][-
M5M)TV/1;V=/$%O:P-);$VWVQ?,0ON')"G/3-%D:O&XWF2516?6VBOM?0Z7_A
M:-E_T#;G_OM:/^%HV7_0-N?^^UK!BL8(/&]O:ZAIUE*EUY?E+;$K#M;^(+U/
M /![U5T*&P?QF]E<V*3QR7+QQJS86, GMWX&!19"^NXWF47-:NVW_ .H_P"%
MHV7_ $#;G_OM:/\ A:-E_P! VY_[[6O.V1/[3:,*-GG[=O;&[I7:ZQIVF3^(
M8-&@32XD>Z5&6WA99T7&3EC\O/MZBBR%2Q^-J1;4UHTMEJV7_P#A:-E_T#;G
M_OM:/^%HV7_0-N?^^UKDM3GBU"]ETG3M$M87CF*1/$"),+G.XDX/ R<]*H-H
M6J*EPQLI MO_ *PY''&>.>>"#QGBBR(GF6.3M"7,NZC_ , [S_A:-E_T#;G_
M +[6C_A:-E_T#;G_ +[6N T6P35=9M;%Y#&L[[2ZC)'%:VEZ';E],NI7,JS:
MI]E>)@-I4=_QHL@I9ACZBO&2MZ+R_P SJ?\ A:-E_P! VY_[[6C_ (6C9?\
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MZ*\*R((Y9(; I)(H[,P'-5-,M_$>D7#36NF7GSJ4D22U9E=?0@CFL?[5<_\
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M$WW_ (#M_A43G48H5FD-VD3?=D;<%/T-.D35(81-*MZD1QAV#A>>G- <M/\
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M$W_?PT?:KG_GXF_[^&@RO1[/[U_D6_[!UC_H$WW_ (#M_A1_8.L?] F^_P#
M=O\ "JGVJY_Y^)O^_AH^U7/_ #\3?]_#0%Z/9_>O\BW_ &#K'_0)OO\ P';_
M  H_L'6/^@3??^ [?X54^U7/_/Q-_P!_#1]JN?\ GXF_[^&@+T>S^]?Y%O\
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MI9%GOWD:4<8CB4X+?7@U%JFCV5AJULBWK_V;<Q+-'<%-S%2.1@=\C%:,WB^
M:I<7UK9&-A:_9[1'PRQY.6)'?.352Z\06NK6=C%JMJY>VD;+6H6,&,C[H&,
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M9!_8N)\OO//O$7_(QZC_ -=V_G697K=[X*T2[OI[B87?F2N6;;* ,G\*K_\
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MWUO9ZQ)JHU">%BOVFY66"0K@MLV_=(XX/:NAM=+BM'O'C$IDO)3+*['YB<
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M)/[[?G1YDG]]OSIM% #O,D_OM^='F2?WV_.FT4 .\R3^^WYT>9)_?;\Z;10
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M,D_OM^='F2?WV_.FT4 .\R3^^WYT>9)_?;\Z;10 [S)/[[?G1YDG]]OSIM%
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MZ_\ K4?9K?\ NR?]]?\ UJDHH"R(_LUO_=D_[Z_^M1]FM_[LG_?7_P!:I**
MLB/[-;_W9/\ OK_ZU'V:W_NR?]]?_6J2B@+(C%M;Y'$G_?7_ -:GRV\#2N2'
MR3S\W_UJ4=:=)_K&^M 61#]FM_[LG_?7_P!:C[-;_P!V3_OK_P"M4E% 61']
MFM_[LG_?7_UJ/LUO_=D_[Z_^M4E% 61']E@_NR?]]?\ UJ/LUO\ W9/^^O\
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M/^^O_K4?9K?^[)_WU_\ 6J2B@+(C^S6_]V3_ +Z_^M1]FM_23_OK_P"M4E%
M60DUO TSDA\D\X;_ .M3/LUO_=D_[Z_^M4\O^M;ZTR@+(C^S6_\ =D_[Z_\
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MK_\ %4?V+K__ $,-O_X+U_\ BJ+!RLOT50_L77_^AAM__!>O_P 51_8NO_\
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M?V)X@(S_ ,)!!CU_LX?_ !5,+,Q=1M99[SQ/91)OGO+")X5SC?\ *R$<^_\
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M#;_^"]?_ (JC^Q=?_P"AAM__  7K_P#%46%RLOT50_L77_\ H8;?_P %Z_\
MQ5']BZ__ -##;_\ @O7_ .*HL'*R_15#^Q=?_P"AAM__  7K_P#%4?V+K_\
MT,-O_P""]?\ XJBP<K+]%4/[%U__ *&&W_\ !>O_ ,51_8NO_P#0PV__ (+U
M_P#BJ+!RLOT50_L77_\ H8;?_P %Z_\ Q5']BZ__ -##;_\ @O7_ .*HL'*R
M_534WE73;@06TMQ)(C1B.(J#R",_,0,5'_8NO_\ 0PV__@O7_P"*H_L77_\
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MM2\[4IW@21WC!),8^4$@;F3V^4UH:O=/KGPWDU'S[F"5;4O(D3&,^:O#!N^
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M(L3XZB%1ND/_ 'R,?\"JG=Z=9W?BRR&F6RI>6MP+B^NTS^[CVD"(GN6R/E[
M9XXH"R+?_".3YQ_PD.JYZXS%_P#$4?\ ".3_ /0PZKGZQ?\ Q%<^L49TR'6<
M#^V3KGE&;/SD>>4\K_=V?P],<UK+I]I/XRAGTBW6,V3R-J%TF<2LRX$)/\1R
M0Q_NX'K0%D6O^$<GSC_A(=5SZ9B_^(ID.A-<0K-!XEU*2)QE71HB#]#LK#TN
M*)++PQJT8_XFEY?%;F8'YY0=_F*WJ!@<=MHKH?#9VQZK;K_JK?4ITC]@2&Q^
M!8T!9#?^$<G_ .AAU7_R%_\ $4?\(Y/_ -##JO\ Y"_^(K=HI!9&%_PCD_\
MT,.J_P#D+_XBC_A')_\ H8=5_P#(7_Q%;M% 61A?\(Y/_P!##JO_ )"_^(H_
MX1R?_H8=5_\ (7_Q%;M% 61A?\(Y/_T,.J_^0O\ XBC_ (1R?_H8=5_\A?\
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MM% 61A?\(Y/_ -##JO\ Y"_^(H_X1R?_ *&'5?\ R%_\16[10%D87_".3_\
M0PZK_P"0O_B*/^$<G_Z&'5?_ "%_\16[10%D87_".3_]##JO_D+_ .(H_P"$
M<G_Z&'5?_(7_ ,16[10%D87_  CD_P#T,.J_^0O_ (BC_A')_P#H8=5_\A?_
M !%;M% 61A?\(Y/_ -##JO\ Y"_^(H_X1R?_ *&'5?\ R%_\16[10%D80\.3
MY_Y&'5?_ "%_\13I/#MP96)\0ZJ3GK^Z_P#B*VQUITG^L;ZT!9&!_P (Y/\
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MC^RW8AN-C>8DD88*S(W&1\V<^Q% <S.T)0G/FQ?]]BDRG_/6+_OL5F$8.**
MYS3RG_/6+_OL493_ )ZQ?]]BLRB@.<T\I_SUB_[[%&4_YZQ?]]BLRB@.8UI"
MGFMF6,<]"PIF4_YZQ?\ ?8JC<_\ 'U+_ +QJ*@'(T\I_SUB_[[%&4_YZQ?\
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M*A_X19/^@WK?_@6/_B:/^$63_H-ZW_X%C_XFCVT0]A(FHJ'_ (19/^@WK?\
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MJ65Q93QP0P7-HR.RN69)#Q@< %<=^#5S_A%D_P"@WK?_ (%C_P")H_X19/\
MH-ZW_P"!8_\ B:/;1#V,C$TO2+NTOOMK6=A;21VGV<16K$+.V0=SG:,=.."1
MDU8T2VU.R6_%W;6RF:XDN(_+G+\M_"?E&.G6M/\ X19/^@WK?_@6/_B:/^$6
M3_H-ZW_X%C_XFCVT1^QD4-/L;S3-$,<7D3:B[&:5I&(1Y6.6Y SCL/H*JWMI
MK$VO)<_9;2XLK?!MHWN2FU\?-(PV'+=0.>/J:V?^$63_ *#>M_\ @6/_ (FC
M_A%D_P"@WK?_ (%C_P")H]M$/8R)J*A_X19/^@WK?_@6/_B:/^$63_H-ZW_X
M%C_XFCVT1>PD345#_P (LG_0;UO_ ,"Q_P#$T?\ "+)_T&];_P# L?\ Q-'M
MHA["1-14/_"+)_T&];_\"Q_\31_PBR?]!O6__ L?_$T>VB'L)$U%0_\ "+)_
MT&];_P# L?\ Q-'_  BR?]!O6_\ P+'_ ,31[:(>PD345#_PBR?]!O6__ L?
M_$T?\(LG_0;UO_P+'_Q-'MHA["1..H^M27'_ !\R_P"\:J?\(LF?^0WK?_@6
M/_B:5_"REVSKFMDYZ_:Q_P#$T>UB'L9$M%0_\(LG_0;UO_P+'_Q-'_"+)_T&
M];_\"Q_\31[:(>PD345#_P (LG_0;UO_ ,"Q_P#$T?\ "+)_T&];_P# L?\
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MW_X%C_XFC_A%D_Z#>M_^!8_^)H]M$/82)J*A_P"$63_H-ZW_ .!8_P#B:/\
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M$E%0_P#"+)_T&];_ / L?_$T?\(LG_0;UO\ \"Q_\31[:(>PD345#_PBR?\
M0;UO_P "Q_\ $T?\(LG_ $&];_\  L?_ !-'MHA["1-14/\ PBR?]!O6_P#P
M+'_Q-'_"+)_T&];_ / L?_$T>VB'L)$U%0_\(LG_ $&];_\  L?_ !-'_"+)
M_P!!O6__  +'_P 31[:(>PD345#_ ,(LG_0;UO\ \"Q_\31_PBR?]!O6_P#P
M+'_Q-'MHA["1-574EN7T^:.TBCEED4H!))L !!&<X-2?\(LG_0;UO_P+'_Q-
M'_"+)_T&];_\"Q_\31[:(>QD4-*AU.STK3K26"U#PA89B)BP\M5QN7@<YQP?
MSJ**VU0>*)+Y[6V%J\ M\BX)< ,6W8V]\],_C6I_PBR?]!O6_P#P+'_Q-'_"
M+)_T&];_ / L?_$T>VB'L9$U%0_\(LG_ $&];_\  L?_ !-'_"+)_P!!O6__
M  +'_P 31[:(>PD345#_ ,(LG_0;UO\ \"Q_\31_PBR?]!O6_P#P+'_Q-'MH
MA["1-14/_"+)_P!!O6__  +'_P 31_PBR?\ 0;UO_P "Q_\ $T>VB'L)$U%0
M_P#"+)_T&];_ / L?_$T?\(LG_0;UO\ \"Q_\31[:(>PD345#_PBR?\ 0;UO
M_P "Q_\ $T?\(LG_ $&];_\  L?_ !-'MHA["1-4]E_Q^Q?7^E4O^$63_H-Z
MW_X%C_XFI[+PXMM>PS#5]7D*-G9+<AE;V(V\BA58MA[&2U.DHHHK8T"BBB@
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MM?$UN;"Q>037=S<PF;;9VS'"9QO*]5&>.318>'[BTAT%'FC8Z:TID(!^?>K
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M8/I0 448/I1@^E !11@^E&#Z4 '>G/\ ?;ZTF#FE<?.WUI] &T48/I1@^E(
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M,PLC"_X1:'_H+:W_ .#!Z/\ A%H?^@MK?_@P>MVBCF861A?\(M#_ -!;6_\
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M6A_Z"VM_^#!Z5/"L)<#^U];_ /!@];E.C_UB_6FI.Z!I&!_PBT/_ $%M;_\
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MH53<1N8%L#G@ $DX-/7:P:'0F&)L[A&=R[3E<Y'H?;VIB6MO&H5(X%4$$!4
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MWUI74;S\PZTSO3G^^WUIW5MA!M']]:-H_OK3:*5UV&.VC^^M&T?WUIM%%UV
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MO?Z@LLF3'&VIRAGQUP-V3BG?S"Q'J6B:UJ!TXOJ-DXM1OFBEM6,<TPZ.0''
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M_"+V'_/SJG_@PF_^*HL@U-O!]*,'TK$_X1>P_P"?G5/_  83?_%4?\(O8?\
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M3?\ Q5)V;&KFW@^E&#Z5B?\ "+V'_/SJG_@PF_\ BJ/^$7L/^?G5/_!A-_\
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MFC:)J",]EJMY<HAPS0:K(X!]#AJ=] L=)@^E&#Z5B?\ "+V'_/SJG_@PF_\
MBJ/^$7L/^?G5/_!A-_\ %5-D/4V\'THP?2L3_A%[#_GYU3_P83?_ !5'_"+V
M'_/SJG_@PF_^*HL@U-O!]*6,'S%XK#_X1>P_Y^=4_P#!A-_\52IX6L"X_P!)
MU3_P8S?_ !5-6N@=S:P?2C!]*Q/^$7L/^?G5/_!A-_\ %4?\(O8?\_.J?^#"
M;_XJIL@U-O!]*,'TK$_X1>P_Y^=4_P#!A-_\51_PB]A_S\ZI_P"#";_XJG9!
MJ;>#Z48/I6)_PB]A_P _.J?^#";_ .*H_P"$7L/^?G5/_!A-_P#%460:FW@^
ME&#Z5B?\(O8?\_.J?^#";_XJC_A%[#_GYU3_ ,&$W_Q5%D&IMX/I1@^E8G_"
M+V'_ #\ZI_X,)O\ XJC_ (1>P_Y^=4_\&$W_ ,519!J;>#Z5@ZCH5[/?7EQ8
M7\=LM_ L%TLD)<X4$!D.1AL,1SD=*?\ \(O8?\_.J?\ @PF_^*H_X1>P_P"?
MG5/_  83?_%4)I=0=V68["\M;=K:SN(%MH[>.&VCEA+;"O!+$$;@1CCBL]?#
M]_%9ZB]OJ$,&J7J+&)XK?;' BYP$3.>[').<GVJ?_A%[#_GYU3_P83?_ !5'
M_"+V'_/SJG_@PF_^*IW7<5B?0M.N]+L1:3M9F*, 1"VA=,>I8LS%B3SGZUJ8
M/I6)_P (O8?\_.J?^#";_P"*H_X1>P_Y^=4_\&$W_P 52=GK<:N;>#Z48/I6
M)_PB]A_S\ZI_X,)O_BJ/^$7L/^?G5/\ P83?_%460:FW@^E&#Z5B?\(O8?\
M/SJG_@PF_P#BJ/\ A%[#_GYU3_P83?\ Q5%D&IMX/I1@^E8G_"+V'_/SJG_@
MPF_^*H_X1>P_Y^=4_P#!A-_\519!J;>#Z48/I6)_PB]A_P _.J?^#";_ .*H
M_P"$7L/^?G5/_!A-_P#%460:FW@^E.B!\Q>*PO\ A%[#_GYU3_P83?\ Q53V
M?AVSM[R*9+C42R-D![Z5E/U!;!IQM="=['04445W&04444 %5Y_OCZ58J"8
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M2K."_%Y$%218?(15&$1=VXX4#@DXS]!3VTRP:?SVM;4S9W>88%+9]<XSFDM
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MW@GV:GR^0KEK^T]9X_XIF3CI_ID7%5C-JK:HNH-X;G,RPF%0;Z+:JDY.!ZG
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M8JGL]1U:2\B270)(8V;#2&[C;:/7 Y-:=/B_UJTXM76@FM"U1117<9!1110
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M'N:EN7>XM_$TL%W-JD,NF &\>#8RNI;$2X ##!+<#///6NF_M/Q(/^9<A_\
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M2\1_]"W#_P"#%?\ XFC^TO$?_0MP_P#@Q7_XFCE871NT5A?VEXC_ .A;A_\
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M1110 4Z/_6+]:;3H_P#6+]:<=T#&T444@"BBB@ HHHH **** "BBB@ HHHH
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M_P"#9_\ XQ74T4>QAV#F9RWVGQA_T+^D_P#@V?\ ^,4?:O&'_0 TK_P;/_\
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MGC_J+/\ _&*ZFBCV4.P<S.6-SXOSG_A'])_\&S__ !B@W7C ]= TK_P;/_\
M&*ZFBCV4.P<S.6^U>,#_ ,P#2O\ P;/_ /&*7[5XQ_Z &E?^#9__ (Q7444>
MQAV#F9RWVGQ?_P!"_I/_ (-G_P#C% NO& Z:!I7_ (-G_P#C%=311[&'8.9G
M+"Z\8#IH&E?^#9__ (Q1]J\8?]"_I7_@V?\ ^,5U-%'L8=@YF<M]J\89S_8&
ME?\ @V?_ .,4?:?%_P#T+^D_^#9__C%=311[&'8.9G+?:?%__0OZ3_X-G_\
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M$DDGR/4U8^T^+_\ H7])_P#!L_\ \8KJ:*/90[!S,Y;[3XO_ .A?TG_P;/\
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M'_0OZ3_X-G_^,4?:O&'_ $+^E?\ @V?_ .,5U-%'L8=@YF<L;KQ@>N@:4?\
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MT\E;)K?9SNW%PV?I@5S^G^"S8:DC&UT^XMTNFN$GE:3SERY<#;]W()X;V'%
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M_F%=/2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img57592461_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &7!'0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)=+;58Q;.3:)&)#)][^$\''7\*K^#M';Q!I?BZXTPQZ9!J1^SP6B-S RYSN
M^[G/0=B:+!<]*MO$6BWMZ;.UU6SFN>1Y4<REN.O&:TZ\E\,S6GAO5-)T;Q)X
M5@L;]7\NTU.%01,_0$L.<G/J>O05U3^/+2[BU&WLK/4%N[>VFD5IK<JA**3U
MS[46"YO77B#1K&[6TNM4LX;AC@123*K?D36D"" 0<@]#7FGPZ\,:+K'@Q=0U
M*R@O[R^DD:>:=0[@[B, GD=,\>M6+JXUG4?%K^$]"U(:39:9:(SS>4)9'X&
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M-::79;(H H*RW!&0<]3CGC/85#X!UV_U+53%J'B-Y[DQ$SZ9<V8A>)N.4/\
M$!S18+GH]%%<?I.KWUQ\2]>TR6Y9K.WMXFAB(&%) R?7O2&=A17D<OBS74^'
MFMZD+]_M=OJAABD*KE4W+\O3W-:0U+Q3HOB?P^=1UB*]MM88K);+ $6$X!^4
M]3C(YIV%<]&6>)Y7B25&D3[R!@2OU':I*\E\)Z7JG_"T=>!UR0FVDC:X/D+_
M *2IZ*>?EQZBKOA/4_$>K2:CJ=WK6W3M,NI@;<0J6G !.TMV &,46"YZ;17A
MB>/_ !)<P_VM!J%V9S)E=/CT[=;E<XQYF<]/:NE\8>)[N/4((K;Q#<6#M:K-
M]BM;#SY%)&<N3C Y'^%%@N>ERS10)OFE2-,XW.P S^-/KP_Q)JFJ>)?A3IVK
M7=]M9+HPS1+& )CN(5SZ$ =/>NC\5:]K/A33-(T?^UY;B\O'<RWXM0TBH.RQ
M@X)YQ^%%@N>FUEZ_KUEX;TMM0O\ S/(#JG[M=QR>G%>?^'?&VK6\6MB\DNM0
MMK.S-S!<W5IY#%AQM(!QC)_0U@^)E\37OPZ@UK4M:CN;:]E21K0P!?*!)VE6
M'ZBBP7/<58.BLO0C(I:YCQA+J=MX(N+K2+EH+NWC64,J@Y4?>'/MG\JP_P#A
M*[W7-?\ "MEI=SY:W%O]LOM@!^3'W3D<<@C\:5@N=;H?B*P\0I=-8&4BUF,,
MGF)M^8>GM6M7D#^+-;B\"Z]J"7I%U;ZMY43A%&$R..E:FNWGB;0/#^G75SKG
MGW-]J,(;RX518D8'<@ZY'3GK3L%STNBN/U?5[^W^)&@Z;%<,MG<6\K2Q8&'(
M!Q[]A7-:/XBUN?Q<+?6==?3;G[4573)[,"*6//1)/6BP7/5:*Y?Q[XAN?#GA
MHW-D$^US3)!$7&0I;//Y UEWDWB+P9X<U+5=2UM=6VPKY2/;A/+E)QVZKS2L
M,[RBO++_ %#Q?X9TO3?$5YKL=_!<21BXLC;JJHK\_*PY./P_&KES>^)=7^(6
MK:'INM+8VD5O'*',(D9/E7A1[D\YIV%<]$DECAC,DLBQHO5F. /QIRL&4,I!
M4C(([UXUJ>I:SK_PKU1K[4<3:=>-!,R1C_25!7 /3')SD>E:&I7GB'PQX"T*
M2UUDW%S=7,(C,D*J$C:/B,]<@$=>M%@N>K4UV"(SMT49->>:Q?>)=&.D>'DU
ME)]3U6=R;Y[<*(4 &55>A[\FGV.HZ]HGB\^'-6U-=4M[NS>>&<Q"-T(!R"!V
MX/Z46"YUV@:]9>)-+74+#S/(9V0>8NTY!P>*9/XETVVUR3299&6>*V-S*Y'[
MN)/5F[5S7PA_Y$.'_KXE_P#0J@\)PQZKXS\:2W*[P\BVI!_N8(Q^0H [VUN[
M:^M4NK6>.:!QE9(V!4CV-,L=0L]2@,]C=17,08J7B<,,CJ,BO*-(UR3POX+\
M4:)+)BZTR9HK?U(D.%(_')_&IM'@UN*_LO!>DZDNE"SLENKRX6$2.\CX) ![
M?,/RHL%ST:]\065AK=CI-QYB3WH8PMM^0D=1GUK4KS7QY#>Z=H7AJZO;I;G4
M;348U:=$V[\YSQVS@5Z4.@I#"BBB@ HHHH **** "BBB@##UCPXNKZ[HNIFZ
M,1TR1W$83/F;@!C.>.GO69K/@*WU;Q;8Z^EX]N\$D<LL*Q[EF9#\ISD8..,\
MUU]% '&ZGX#>Z\27&L:?K=WIK7B".[CA0'S0 !PQ/RG ZX-5_P#A6T0\'/X>
M34W$9O?M0F,.2!G[N-W/US^%=U13N%CG[[PNM[XGT?6OM90Z;&Z"+R\^9N&.
MN>/R-4G\$*][XEN?M[#^W(1$5\K_ %/RD9Z_-U]JZVBD!YZGPM)MK+3[CQ%>
MSZ1;,LALF0 ,XZX;/"DYXYQDUK:QX*>[UK^V-'UBXTB^:(0RM%&'21!TRI(Y
MX'Y5UE%.X6.0U'P1/JGAA=(O-=N;B;[4MRUU-&&)(_A"Y&!^/%=<J[5"^@Q2
MT4@.'N_AY,M]?2Z/XAN]+MM0<O<VT<88,3U*G(VYYJU?^ ;*?PK8Z!9W#6L%
MI.DPD*;V<@DG/(Y.>M==11<+$5Q#]HM98=VWS$*9QTR,5QX^'J#X?_\ "*_V
MDV-^_P"T^3_M[ON[OPZUVM% '.:CX474-9T'43>%#I.<)Y>?-R .N>.GO65=
M?#LR:SJ5W::[>65GJ9W7=K"H_>'G.&[ Y/;N:[BBBX6.+D^'D$O@:V\--J$@
M-M(98KI8P"&W$CY<_P"UCK1?^!+R^_LN['B.YCUBP5T^W^0I,BL2<%,X&,XZ
MUVE%.X6..TKP!#8:1KFG7.I7%XFK$F2610)%)')SDY.3FJS?#RXF\)+H%SK\
ML\<4\<D,C6X_=(G 0#=^N:[JBBX6.2UGP2][K2ZSI6LW&E:@8A#+)'&'611T
MRI(YX'Y5$OP]MH_"FI:.M_,]UJ3"2YOIEWN[@@YQD<<=,]Z[*BE<+',:GX/7
M4K+0+;[:8QI$T4H;RL^;L &.O&<>]4M:\"7FN7-Q'=>);PZ5/+YKV)C4XYSA
M7/('X5VE%%PL8OB'P]'KOAB?1%G-M'(B(LFW?M"D$<9&>GK5-?""CQ#HVK?;
M3G3+3[*(O+_UG!&[.>.O3!KIJ* ,'2O#0TOQ-K.LBZ,AU+R\Q>7CR]HQUSSG
MZ"FZ_H.IZI=0W.F^(KK2W1-C(D8D1^<Y*DCGWKH** .%D^&T<FAWUB=7N'NM
M1G26^O)(PS2A3G:!D8&?K6AK'P^T#4M#ET^#3K.SE9 J7,5LF]",<Y&">G//
M-=511<+'*Q^#7_MO0M4FU-I9=*M?LY'DX\XX(W$YXZ].:C7P0UOJFN7=CJ]Q
M9QZJJDQP)@Q2 @[U;/?G(Q_$:ZZBBX'&6G@2YDU6SOM=\0W6K?8G\RVB>)8T
M5O4X)R>!^5=DZJZ,C@,K#!![BEHH X2'X=W>ERS)H/B>]TVQF<NUJ(ED"D_W
M22,?E5K4? DDVHP:GIFNW>GZDENMO-<;!+YZ@8RP..>!S78T4[A8PO#'A>W\
M-6LZK<37=U=2>;<W,Q^:5OZ#_&L?0?AS:Z%XKGUI+UY48R&"V:/ A+GG!SSQ
MQT%=K12N 5Y^?AUJD.OWVL67BN:WN;MB68V:NRKG(4$MT' XQT%>@44 8-_:
M:A:^";RU:235;X6DB;L>6TS$'L.AY[5Y#X:;6]-N=-314NI-0++'<6\VDI&B
M)_$#+]X@>IQ7OE%.XK''ZEX(GDUVYU?1-=N=(N+L#[2J1"1)".AP2,&GZEX)
M?4](TJRN=9N9I+&[%TUQ,N]Y2"3MZC YX],5UM%*X[&%=>&ENO&-EX@-T5-M
M;M!Y'EY#[L\[L\=?2N>E^&LJ?:[33O$=[9:3=N7FLDC#=>H5L\ ].GYUWU%%
MPL<M=>"+62X\.M:W!MX-$8M'%LW>8..IR,'CKSUJY:^&Q;>,K[Q"+HL;JW6
MP;,;<8YW9YZ=,5NT4 <5!\.;-?#-YHMU>22K/=FZ29$V-$_;')Z?UJ]HOAK5
M]/U".YU#Q3>ZC'$I"0-&(U.1C+8)W?C73T47"Q@WGAI;OQC8>(?M14VD#0^1
MY>=^<\[L\=?2J.F^"$T[PWK.C_;VD&I/*YE\K'E[QCIGG'U%=910!G:%I8T3
M0K+3!-YPMHA'YFW;NQWQDXK/\+^%E\-0:A$+LW'VRY>X),>W9N[=3GZUT-%
M'%V_P[M4\&7?ARXO7ECGN&N%G6/:48D$<9.<8_&HK3X>SQZMI6I7WB&ZOKC3
MW^7S8@%*8P% !X]SSFNYHIW%8YS2?"BZ5>:]<"\,O]K2F0KY>/*SGCKSU]JJ
M6_@J6T\ MX7M]5*%PRM=>1SM9B2-N[T..M==12&9NCZ/#HF@VVE6K$1P1; X
M&"3W;ZDDFLFW\+:E!X;&FGQ/J#7:SF9;X\N/]D@DY7VS7444 <GHG@IK#7/[
M;U75[C5M16/RXI)4"+&OLHSS_C5[Q5X6@\464$;W$MK<VTHFM[F+[T;C^8Z?
MD*WJ* .1D\#R:CH-UIVN:Y=ZC),ZR).5$9A*]"BC('7GUJ?1?#6L:?J$5SJ'
MBJ]U&*)2$@:,1J<C'S8)W?C73T47"QPC?#9&\+7>B?VHV+B^^V>=Y'W?]G&[
MGZYJYKO@W4-9FF1/$MW;:?<(J368B5U(  .TD_+G'YUU]%.X6*FF:?!I.F6V
MGVV[R;>-8TW')P!CFN<T_P $OI>O:C>VNL3)97Y=Y;(Q KO8$9W9SQGIC\:Z
MZBD!SFA>$+;2?"#>'+B8WENXD5W*;-P<D],G'6LS3? VJ:8UO;Q>+M0_LRW<
M&.U$:AMH.0I?.<=L8Z5VU%%P.&U+X=/=ZIJ=S9:_=V%MJ?-W;QQ@[SCLV>!R
M<CW-2WOP_2[\*Z3I"ZG)#<:6ZR07:1#.X=]N?IW[5VE%.XK'(ZGX(FU Z=>Q
MZY<V^M647E?;TC&90>NY.G<]_P ZFC\'R7.@ZAIFM:S=ZF;T#=*X">7CIL7D
M#GGWKJ**0SS[_A6ES,-.^W>)KR[_ +/GCDMU>(!%13G;C/). -V>W2NSUG2X
MM:T:\TV9BL=S$8RP&=N>A_ \U>HH"QY^OPMMU\'MH9U-S.;H70O?)^8,!@<;
MO3CK6C>^ X+GP+;>&(KTPI 4;S_*R6(.2=N1U)/>NOHIW"QR>N^"WU36+#5K
M+5YM.O;2+R?,CC#[T],$\'D^M7=/\,+8>+M3U_[69&OHDC,)CQLV@#.<\YQZ
M5OT4@,+PMX;'AFRNK871N//N7N-QCV;=V..I].M4-9\):KJ=W<M;^*[ZTL[G
M_66PC5P 1@A6R"HKK** ,[0M$L_#VCP:98JP@A!P6.68DY)/N36!JW@5[WQ+
M)K>GZW=:9-<1"*Z6% ?,48'!)^4X YYZ5V%% '"K\-HH_!][X=34Y/+N;O[0
M)FBR5&0=I&>>G6K.O_#ZSU_6-)U"6Y*&P"K(GE@^>JD$ G/'?UZUV-%.XK&#
M%X:6+QM/XC^U$F6T%MY'E],$'=NS[=,5%XJ\)IXD-E<17TMA?V3[[>YB4,5S
MU!'&1QZUT=%(9QVE>!&T[7YM8N-:N;VZN+1K>9ID&221\PP>   -OZU?\.^$
MX=#\*-H$MP;N%Q(KOLV9#YR,9/K71447 \W?X4R2:1_94GB:]>RB??;0F(;8
MCG)R,_-W],9KF_&%I.OCN_FNHKRUA,42V\L>G+>+-M7K\W"_A7ME%.XK'-^!
M;G6KOPQ#+KL1CNBS!-T81C'_  EE'0]?TJ2P\+16?B/6M6>X\Y=45$> QX"!
M1CKGG/T%=!12&>??\*QD2V?3(?$M_'H3N7:P"#."<E=^>F?:MV7PA ?$FCZK
M!/Y,6F6Y@CMA'D,""!\V>.OH:Z2BG<+#)H8[B%X9HTDB=2KHXR&!Z@@]:Y/7
M/AWHNK&Q^S6EE8BVN%FD$-FG[Y1_ <8X/XUU]%(#CM5\"O/KIUC1=9FT>Z>%
M89!%$KHR*   I(QP!^55G^&EL?"EYHZZE,9[V=;BXO)$#,[ Y^[D?S[UW5%%
MPL<]JGA9=2U'0KO[68_[)?<%\O/F\ 8SGCI[U>\0Z+%XAT&[TN9_+6=<!PN[
M80<@X^HK3HH Y/P_X(70/#=[I<.J3FYNV+O?(NR0'  QR>F/7UIND^"9[375
MUG5-<N-3O8HFB@=HEC"*?89R>377447"QD>'-'NM$TQK6\U:XU.0RLXGN/O
M'^'DG@?7O6-J_@:2^\2OK>G:W=:9//$(;D0H&\Q1@<$GY3@#GGI7844 <(/A
MI"GA"^\/QZI)Y=U=_:1,T6YDY'RD9YZ=>*V=4\++J6H:#=_;#'_9+[POEY\W
M@#&<\=/>NBHHN%CE1X-D@\9R^(++5YK9+DJ;JU$899=HQC=G@?A5GPUX5C\/
M6>H6S7/VI+VX>9@T>W 88V]3FNAHH X2V^'U_IRM::7XLU"STLN6%JD:EDR<
MD*^<C\JM:OX%EOM?DU?3]=NM-FGA$%SY2!C(HP."?NG '/-=C13N%CB5^'-M
M_P (*?#$FH2,HF,R7(C *MG(XSSUQU_*I[WP/+J.DV$=WKETVJV#EX-25 K@
MGL5[CIW[5U]%*X6.:T[PM>);WL.M:]=:LEW"861T$:*I[A1GGGK7.R_"N:XT
M?^RIO%%[)91,&M86B&V+GOS\W&0.F,UZ/13N*Q$UNCVAMI!OC9/+8'N,8-<C
MX-^'T'A&_NKL7[WDDJ"*/?'M\I,YP.3GMZ=*[.BD,X63X;H_AK4]'_M1@+Z]
M^U^;Y'W.0=N-W/3KFMOQ+X5M_$OA]-+FN)(6B97BG0<HZC ./Q-;]%%PL<7I
M_@.>V\16.MWVOW5_>6R,C&6, ,"" % /RXR3WS3/^%?W-UJ-I+JWB2\U"TLY
MA/!;R1J"&!XR_4UV]%.X6,CQ)X>M/$^BRZ;=LZ*Q#)(GWD8="*R;3P7<OIMY
M8ZYK]WJT%Q"(55T$8C .0PY.6SCDUUM%(#A+;X<RM+91:KXBO-0TVR</;V;Q
MA5!'W=Q!^;%;EGX96T\9:AXA%T6-Y"D7D>7C9MQSNSST]*WZ*+A8Y"U\!6\/
MAS6-&FO7ECU*X><R+'M,9." .3G!%5Y? %S=>'[#2[S7I;@V5VEQ'*]N!A%&
M!&!GI[Y-=O11<+'/^)_"L/B2.UD%W-97UF_F6]U",E#[CN.!531?!1L-3GU;
M4]6N-4U*2(PK/*@01H>RJ,XKJZ* ,+PEX;7PKH2:8MT;D+(S^84V=3G&,FL/
M1+:;1_B=KENT3_9M2B2ZAD"G;N'##/3.2>*[FB@#BM:^'-KK/BZ'76O7B0-&
MTUL(\K,4Z$G/';L:LZ]X+?4M<CUO2]7GTK41'Y,DL<8<2)Z$$C_(%=911<+'
MG7B72;NZO_"OAPS7-Z(Y_M5U=RC.0G/)Z#.2,?2O1:** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;>6U=88X82^ZYW#:&(^Z,9Y/'6CPZ=7@U"[LM2O'O0D,4AF:(($E;.Y%( !
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ'97TB!'N(5D91T!(J_6+X0_Y$_2/^O6/^5;5 !1110 4444 %%%% !1110
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MXN]+N;>TNFM;EXR(IE )1NQYKGK'PUJLUC#)>>)-;@N2H\V(2P,%;O@B/D4
M=#IRM'8HCWOVPH2OGD#+8)&#CC(Z'W%6ZQ/">F7.D:"MG=EFF6>9BS,"6#2,
MP)QQD@@UMTAB&L<^&=+:Y\YXI7'F>;Y+S.8@_7.PG;UYZ5LT4 9-_P"'--U*
MZ-Q<0OO=0DFR1D$JCH' .&'UIU_H-AJ/DM-$Z/"A1'@D:)@I_ARI''M6I10!
MESZ!IL]A;V9MO+AMR##Y3%&C/JK#D59T_3K73+;[/:1;$R68DDLS'J23R3[F
MK=% !7(>(_\ D>O"W^]/_P"@UU]<AXC_ .1Z\+?[T_\ Z#0!U]%%% !1110
M4444 %%%% !1110 4444 %%%% !2$@ DD #J32U7OO\ D'W7_7)OY&@3=E<9
M_:FG_P#/];?]_5_QH_M33_\ G^MO^_J_XU\_!1@<#\J7:OH/RJK'S7^L$OY/
MQ/H#^U-/_P"?ZV_[^K_C3DU"RE<)'=P,[' 59 2:^?=J^@_*MCPJH_X2O3.!
M_KQ_(T6+I9[*=2,.3=VW/<Z***D^C"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6/\ E6U0 4444 %%%% !1110 4444 %%%% !1110 444F: %HI,TM !1110
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MRPK7\*_\C7IG_7<?R-9%:_A7_D:],_Z[C^1H-\-_'AZK\SW.BBBH/T$****
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MC_KU3^5;58OA'_D3](_Z]4_E6U0 4444 %%%% !1110 4444 %%%% !1110
M4E+1B@#C/'^L:AH]O8M87)A,CL'(4'. ,=:X?_A-O$7_ $$F_P"^%_PKJOBE
M_P >NF?]='_D*\VJD?(YKB:T,5*,)M+3KY&__P )MXB_Z"3?]\+_ (4?\)MX
MB_Z"3?\ ?"_X5@44['G?7,1_._O9Z]X!U:^U?3+J6_G,SI-M4D 8&!Z5UE<+
M\+_^0->_]?'_ +**[JI>Y]GE\I3PL)2=W8****1V!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGA_4IM7T6"\N(HX9W++)$C;@C*Q4KGU&*TZ "BBB@ HHHH **** "N0\1_\
M(]>%O]Z?_P!!KKZY#Q'_ ,CUX6_WI_\ T&@#KZ*** "BBB@ HHHH **** "B
MBB@ HHHH **** "J]]_R#[K_ *Y-_(U8JO??\@^Z_P"N3?R-!,OA9\^#H*6D
M'04M6?G+"M?PK_R->F?]=Q_(UD5K^%?^1KTS_KN/Y&@WPW\>'JOS/<Z***@_
M00HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZJ+:+3#IOD/@NS>9MV\^V: -SPA_R)^D?]>L?\JVJQ?"/_(H:3_UZI_*MJ@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \^^*7_'KIG_ %T?^0KS:O2?
MBE_QZZ9_UT?^0KS:K6Q\7G'^^2^7Y!1113/+/4/A?_R!KW_KX_\ 917=5POP
MO_Y U[_U\?\ LHKNJA[GW66?[I#T"BBBD=P4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444C*
M'4J>A&#0!CZKH%AK\UK=2W%T&@!\E[6Y:/&>I!4U-I6B0:0TK0W5],9  ?M5
MT\H&/3<>.M<;?Z0WA>_M93XJN;:V^SFVMHA:K--C<&VA0I+ #OC/2NC\*W?V
MV.XE77YM3"D(T<UL(7A;W7 (S[TQ'15QES#JOB+5KY8TT:**PG\E%O+,SR]
M=_48!SQBNIU#3K35;-K2^A$T#$$H21G'(Z5P-UIGA=!+'9^'(IM0:^:QA@:X
M93(5&2Y.>% R>_;UH0'?:?'>164:7TT,MP,[GAC**>>, DXXQWJU6-X6>V;P
M_ +2S^QQHSHUOOW;'5R& /<9!YK9I#"BBB@ HHHH **** "N0\1_\CUX6_WI
M_P#T&NOKD/$?_(]>%O\ >G_]!H Z^BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JO??\ (/NO^N3?R-6*KWW_ "#[K_KDW\C03+X6?/@Z"EI!T%+5GYRP
MK7\*_P#(UZ9_UW'\C616OX5_Y&O3/^NX_D:#?#?QX>J_,]SHHHJ#]!"BBB@
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M%%%%([@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%%% !7(>(_\ D>O"W^]/_P"@UU]<AXC_ .1Z\+?[T_\ Z#0!U]%%% !1110
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M#\ZX'GU/YT^+_71\G[P[^]1'B6[2]G^/_ &\OLK\WX'>TM(.U+7U1YP4444
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M!>K*\3?\BOJG_7K)_P"@FM6LKQ-_R*^J?]>LG_H)H B\(?\ (GZ1_P!>L?\
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MC_WA_.FTZ+_71_[P_G2)I_&CZ%B_U2?04^F1?ZI/H*?4'Z)'8****!A1110
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M!1110,**** "BBB@#BM5_P"0I<?[U4ZN:K_R%+C_ 'JIU^98S_>)^K/H*/\
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MN]_Z[-5&@ H/2B@]* /3=)_Y!%G_ -<5_E5RJ>D_\@BS_P"N*_RJY0 4444
M%%%% !111F@#S[XI?\>NF?\ 71_Y"O-J])^*7_'KIG_71_Y"O-JM;'Q><?[Y
M+Y?D%%%%,\L]0^%__(&O?^OC_P!E%=U7"_"__D#7O_7Q_P"RBNZJ'N?=99_N
MD/0****1W!1110 4444 4M6_Y ][_P!<'_\ 037@*_='TKW[5O\ D#WO_7!_
M_037@*_='TJD?,Y_\4/F+1115'SIM^$/^1MTW_KH?Y&O;Z\0\(?\C;IO_70_
MR->WU,CZS(OX#]0HHHJ3W HHHH **** $;[I^E<"_P#K'_WC7?-]T_2N!?\
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MO3/^NX_D:R*V/"O_ "->F?\ 7<?R-!OA?X\/5?F>Y44E+69^@A1110 4444
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M 8>L@_VU>\'_ %S52P?2N@?X8:=(Y=]5U5F8Y)-QU_2F_P#"K=+_ .@GJO\
MX$?_ %J ,'!]*0@XZ5O_ /"K=+_Z">J_^!'_ -:C_A5NE_\ 03U7_P "/_K4
M ==I/_((L_\ KBO\JN5QR?#Z"- B:[K2JHP +KH/RIW_  @,7_0?UO\ \"C_
M (4 =?17(?\ " Q?]!_6_P#P*/\ A1_P@,7_ $'M;_\  H_X4 =?17FN@^$[
MF_N=6CO-9UN-+:[,4!^T$;DQU]ZV_P#A 8O^@_K?_@4?\* .OI*Y'_A 8O\
MH/ZW_P"!1_PH_P"$!B_Z#^M?^!1_PH S?BC_ ,>NF?\ 71_Y"O-N?2O4[KX9
MZ?>A1=:MJTP3E0]SG'Z57_X5'H?_ #^:C_W_ /\ ZU4F>#CLIGB:SJJ5KGFG
M/I1SZ5Z7_P *CT/_ )_-1_[_ /\ ]:C_ (5'H?\ S^:C_P!__P#ZU/F.3^P*
MG\Z)OAA_R!KW_KX_]E%=S7$VWPUL;)"EKJ^KPHQR0ES@$_E4_P#P@,7_ $']
M;_\  H_X5+/H<+1="C&F];'7T5R'_" Q?]!_6_\ P*/^%'_" Q?]!_6__ H_
MX4CH.OHKS;5_"=S9ZSHUK;:SK;P74K)<-]H)VJ%R#G''-;7_  @,7_0?UO\
M\"C_ (4 =?17(?\ " Q?]!_6_P#P*/\ A1_P@,7_ $'];_\  H_X4 =%JW_(
M'O<?\\'_ /037@(!VCZ5ZVWP_@="C:[K3*PP0;KJ/RK/_P"%1Z'_ ,_FH_\
M?_\ ^M5)GDYCE\\6XN+M8\UY]*,'TKTO_A4>A_\ /YJ/_?\ _P#K4?\ "H]#
M_P"?S4?^_P#_ /6I\QYG]@5/YT<?X0'_ !5NG?\ 70_R->WUP</PITBWF6:'
M4-3CD7E66?!'Z5=_X0&+_H/ZW_X%'_"I;N>SEV#EA:;A)WNSKZ*Y#_A 8O\
MH/ZW_P"!1_PH_P"$!B_Z#^M_^!1_PI'H'7T5YMXD\)7.FVMG)8:SK<KRW<<4
M@^T%L(QY/2MK_A 8O^@]K?\ X%'_  H Z^BN0_X0&+_H/ZW_ .!1_P */^$!
MB_Z#^M_^!1_PH ZYNA^E<$X/F/P?O'^=7_\ A 8O^@]K?_@4?\*K_P#"L[ G
M)U;5O_ G_P"M7D9KELL:HJ,K6.G#5U1;NBM@^AHP?0U9_P"%9Z?_ -!;5O\
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M\<H+KSETEMUR[)YTDAPO8+@?=],\T =)IEW:WNG0S6<;1VY&U$:$Q$ '&-I
M(Z>E6ZK6!O39Q_V@+<77.\6Y)3KQC//3%6:0PHHHH **** .6UUTLO&.AW]P
MZQVOES0-(YPJ.P!&3VS@T[PR?M6M^(-0A.ZTGN$2)Q]U]B %@>XSQGVKHY88
MYT*2QI(AZJZ@@_@:5(TB14C141> JC 'X4 $H=HG$;!7*D*2,@'M7F&MV'BE
M/%F@)/K5F]R[2^1(+; 3Y><COD5ZE43VT,LT<TD2-)%G8Q&2N>N* .5_LKQO
M_P!#%8?^ ?\ ]>C^RO&__0Q6'_@'_P#7KKZ* .0_LKQO_P!#%8?^ ?\ ]>H;
MK0?&=Y;/;R^(;$QN,'%I_P#7KM:* /-O^$ \2?\ 0?M/_ :C_A /$G_0?M/_
M  &KTFB@#S;_ (0#Q)_T'[3_ ,!JLV/@_P 5Z=<&>W\068<KMYM<\5Z!10!R
M']E>-_\ H8K#_P  _P#Z]']E>-_^ABL/_ /_ .O77T4 <A_97C?_ *&*P_\
M /\ ^O65K\WC70;*&Y?7+&42W$<&T6N,;CC/6O1*BGMH;E D\22*K!@'&<$=
M#0!RO]E>-_\ H8K#_P  _P#Z]']E>./^ABL/_ /_ .O77T4 <A_97C?_ *&*
MP_\  /\ ^O39-&\;2Q/&_B&PVNI4C['V/XUV-&:!-7/)Q\*-8'_,=M_^_!H_
MX51K'_0=M_\ OP:]8HIW.7ZAAOY$>3_\*HUC_H.V_P#WX-3V7PTUZPO8;N#7
MK42PMN3-N2,UZC11<:P.'3NH(Y#^RO''_0Q6'_@'_P#7H_LKQO\ ]#%8?^ ?
M_P!>NOHI'4<A_97C?_H8K#_P#_\ KU1UB/QMI&CW>HMKUC(MO&9"@M,;L=NM
M=[3)88YXFBE17C8896&010!Q=A:>-K[3[>[7Q!8*)HUD"FTZ9&<=:L?V5XW_
M .ABL/\ P#_^O76QHL<:HBA548 '0"G4 <A_97C?_H8K#_P#_P#KT?V5XW_Z
M&*P_\ __ *]=?10!Y7<?"_7+FYEN)->MM\K%VQ;D#)ZU'_PJC6?^@[;_ /?@
MUZQ13N<CP.';NX(\G_X51K'_ $';?_OP:!\*=95@1KMOD'(_<&O5\YI:+L%@
M<,MH(X\:3XW  'B*P_\  /\ ^O2_V5XW_P"ABL/_  #_ /KUU]%(ZK'(?V5X
MW_Z&*P_\ _\ Z]17-AXWM[6:<^(; B-&<C[)UP,^M=I364.I5@"I&"#WH&<%
MH?\ PFNMZ+:ZDFNV,2W";PAM,X_6M#^RO''_ $,5A_X!_P#UZZN&"*VA6*&-
M8XU&%51@"I* .0_LKQO_ -#%8?\ @'_]>C^RO''_ $,5A_X!_P#UZZ^B@#@9
MO"7BRXF:5_$%EN8Y.+6H_P#A#/%/_0P6?_@+7H5%<<L!A9/FE!7]#55JB5DS
MSW_A#/%/_0P6?_@+2KX-\5*P8>(+/(.1_HM>@T4++L*M537W![>I_,<A_97C
M?_H8K#_P#_\ KT?V5XW_ .ABL/\ P#_^O77T5V&1R']E>-_^ABL/_ /_ .O1
M_97CC_H8K#_P#_\ KUU]% '.^#-7O-8T5Y;]HVN8;B2!WC7 ;:<9QVKHJB@M
MH;9"D$21J6+$(, D]34M !1110 4444 %%%% !1110 4444 %<WXLT_Q%J$=
MK'H5Y#;Q M]I#2F)G'&T*X5B.^<8KI** .&TG0O$&CS>9:Z+X=21C^\N&NII
M)F'?+LA)_.NYHHH P+R'Q/!=/)92:;?0%RT<=TK1/$/0,H(/IR ?>H5/C*\^
M1UTC34/61&>X<?0$*/SS]*Z6B@!J!EC56;<P !8C&3ZTZBB@ HHHH **** "
MBBB@ HHHH **** "BBL#1M:GEFUBVU$HLVG3MEE& 82-RMCZ?RH WZ*YO3/$
MJKH5K?ZQ*D4EX[-!%'&Q8ID[?E&2?EP2?>MZVN8KRWCN('#Q2#<K#N* )J**
M* "BBB@ HK#\6ZE>:5X;N;O3S&+M2BQF5=R@LP'(_&J]GXF+>#GU:Y51<P(T
M<T:_\]E.W:![MC\Z .DHKE_#7B&YE\.3WVOS6\,L%P\4C(NU1@X  ZD]JT#K
MMG?:=?M87'[Z"%F*LA1U.TD':P!Q[T :X/-+7,Z5XFLXM#TXZE>@WLMHD[+L
M)=P>K!5'//I6NFM:<]O9SK=QM%>.$@8?QL>WUX- %^BL^YUO3;)[E+F[CB-L
MBO-NS\BL< GVIEIKVG:A/);VETKS*I8 J1N'JN1\P]Q0!IT5SMEXFLX-/M3J
M6J6TUQ.'9&@C8"0!L?*O).*N7?B32K&0)<W6PD D[&(3/3<0,+^.* -:BJD6
MI6DUU<6T<Z--;JK2K_=!&0?IBLO_ (2"W>_AN(]3M?[-:T><H8VWL%."X/3:
M* -_%%4M/U:RU5'>RF\Z-<?.JG:<^A(P1]*EOYGMM.N9X\;XXF=<],@$T 6*
M*XO3]<U>./0+FZO+>[35"$>!(=C1Y7=N4@G(&.<^M=!<>(M*M;XV<UXJS*P5
MOE)5">@9L8!^IH U**R;SQ)I-A<2V]S>*LT0#2(%+%5/1B .GO3K?Q#I5W>I
M:07L<DSC<FW.UQWVMT)'H#0!IDXI:Y;Q/XIL[+2=3BM;X)?P1D*P4D*^.%W8
MV[O:KY\2:;91V\5[=A9VA1W^4G;D=6(&%_'% &U16==Z[IUE/'#/<@/(H90J
MEL*>C' .![FJC:W%:Z_-;76I6HB81)# $(=7;.,MT(..* -RBL;6M8CM;:[A
M@O[>VO88EE9IT++&I; + >O2I9M?TZTNDLKB[7[855O*1&+$'H< =/Y4 :E&
M*0&EH ***0D*"2< 4 +17)^'O$EYJ6M3078C6UN8VFL"JX)17*G)[GH?H:-0
MN-=M_$=AI\6K0B*]$K9-H"4V@$#[W/6@#K**H7T]Q8Z'<S^8LMQ! S[RF S
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M!0!W*W$+RM$LJ-(O50P)'U%25QWA$Z']CL%18O[9$9\_C]\'_CW]^OK[5V-
M!1110 4'BBD/0T <[X7\5KXC>]B:S:UEMI"%5G#>8F2 X]L@TMAXJ74/%=YH
ML=HPCMXRPN=_#L" P ]B:XV":XT+1--\06MN\KB2XLY8T'+!Y&\LX]F_G6K:
MZ;<Z7K45I;9-X-%D8/C[TS/DG_OHTQ'="YA:4Q+-&91U0,-P_"LS3=6DO-6U
M:TE6-$LYDCC8'ELJ&Y_.N+7^SI-!TF+2U'_"1":(OM'[]7!_>F0]<?>SGBI-
M3@6XU#5XI$8H^M6@8#(R-H[B@9Z(D\4JEHY4=5X)5@0*=YB84[EPWW3GK]*X
MNXL$MO$VJV6GVZQ1W&D%C%&NU6DRP!P.^.*SXM2M+JP\'VD$A>XAN8A,BJ<Q
M%48$-Z'/K2 ]!^T0AU0RQ[V^ZNX9/TJNEY.=3GMY+81VT:*R3F4?.3U&WJ*\
MUB_LAO"E_%&@.NO=RBWX/F^9YIVF,_W?IQUJWXFADDN->24,7:TLE<KG)._G
M!% 'H_VJ 1M(9HPBG!;>, ^F:431,%*R(P?[I##YOIZURFO_ &#2(].L8]/L
M4AE9CYUTO[B,@?Q =6/;-86G6\C^'KR]C5-VEZHUS (D94$8QN" \A2I- '?
MZC>S6EL7M;=;F8,H,7FA" 3C.35GSXMX0R('/ 7<,DUYY?+]N\.ZAKI5LZA?
MP>5D<B%)%"_U/XUM>%M/M6U?7KV2!6N1J#JLCC)4;5^[GI^% CK17)MXNO$M
MKV_.E*=.L[AH976X_>84X+!<8]\9KJ^E>8MI\QT+5M166YEBM]4EEFL6;,4T
M8?YAMQG/?KVH&>DM=0)&DCRHBN,J78#/YT]YHXQEW51C/S,!Q7GVK2"?Q1+/
M=OIPT^:SC^Q-J*,8\$?-LP<!NGOTJ2WTM)-6\+6E[)]N1+:X.]E8*_3&0>HQ
MZT =W]HAR@\Z/+_<^8?-]/6EDGBB($DB(S?=#,!GZ5YM_9EK'X5UVY2WQ/;:
MBXMWP<Q .N G]T<GI6I.VG#Q1J1\0(K;[>(61E4G<F/F$?\ M;O3GI0!T&@:
MR=2T*'4+SR8&=F4@-A1AB._TK5>>*./S'D14_O,P _.O)M*62.VT5KD6B::+
M:41?VDC&,2^8>"/[VWU]ZV);&"'0K S:Q98BN)9H%N(F-K(I_@^;L,\'/TH$
M=O<7TT-[:QI;J]M*&,EP9541X''!ZY]JM22A$R,%B#M4G&X^E>?M''KY\-QS
M6/V6*YMKI&AY*KE<9'MW'X5/HC3:O?6Z7*O_ ,2.U>*3<.#.<KGW^49_&@9V
M%C>R3Z?%<7L*VDK@EHC*&"X_VAP:N*RNH92&4\@@Y!KS73[**]L?!,%S$7BS
M,60@X.%/!'I[&O2(HTAB6.-%1%&%51@ >U #Z*** "L ^)XQXK&B_9SY9&W[
M3NX\W;NV8_W>:VKJXCM+66YE.(XD+L?8#->8R6^NMX6;51IR>=]L_M43>?\
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MA1202H)'3(Z4ZB@!I16&"H(]"*#&A4*5! [$4ZB@!-HXX''2@*!G '/6EHH
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MO:/J-W):6.K6%U<Q?ZR&"Y1W3Z@'(J74=5T[2+<3ZG?VME"3@27,RQKGTRQ
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M[;3K&66WM-%33IXY(+V I;NC!AM!D(YR<#!SDGUK(@NX/ _Q3U]+I_*TO6+
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M"G_"%>%+?0_MOVSR7=O.\KR\[F+?=R>F?6G^+/"</BBVM&6[FL-1L9O/LKV
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M=1Q+*LD1.=CHW##//4?RPWP_X*DT[7I?$&M:S-K6M/#]G2X>%88X8LYVI&O
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M3['].*=:_#^ZNM9LM5\3>)KW6KBQE\ZUB6%+:"-^S;$ZD>Y^N: *>I>']/\
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M#;R0D,,?*I+G/'\^U=KJ%E;>)OC;#IVL0I<V6F:/]JMK68!D:5Y K2%3P<#
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M22?<DD_C6I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6L=/LM,M_L]A
M9V]I#N+^7!$L:[CU. ,9-6:** "BBB@ HHHH *J1:5IT&HS:C#86L=]. LMR
MD*B20#H&8#)Z#K5NB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "JTFGV4M_#?26=N]Y"I6*X:)3)&
MIZA6QD ^U6:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img57592461_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HK.N;O[%J4>\_N9EP?8CO6C6-*
MO&I*45O%V?Z?>5*#BD^XSS5\_P G^+;N_#-/K%%U_P 5$5S\N/+_ $_QK:/
MR:RPN)5?G_NR:^XJI3Y+>:"BLZUN_MNHRE#^YB7 ]R>]:-:T*\:T7.&UVO6Q
M,X.+LPHHHK8D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_%+Q+J?AWP]976CW2PRSW 0R>6KY7:3QN!'85?M_%;V/PT@\2ZB/.F%HDCA
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M"K8#9ZYQCGKWI6'<[@S1+((VD0.>BEAD_A3Z\1U?X=^%=.TR[:Z\7*VKI&S
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MTG[/<30[IGW>6Y7.%&,XKA]12Q\#^,]/F\+:[]MMV*F39,K_ ,6"C%>""/\
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M70!@^V6T11^A4*G'X\_G7OE/86YRFC>+)O\ A!6U[7[8V<MN'$\>PJ2RMM
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M\8+6T.HR%FC4;FA$=NS!>OW ,_ES76?#SX@_\)?'-9WL,<&I0('(0_+*O0L
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M&JK*ZE?3S17L;35=7P\UQ*D']]B1GZ"NFL]/M[%-L*?,?O.W+-]361!XNL'
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M>SV^C:7:7CWEMIMG#=29WSQ0*KMDY.6 R<FI+[3;#4XEBU"RMKN-3N5+B)9
M#Z@$'FBX6/+_ (OW\.J>!=%O[<YAN+A94^AC8UM6/B3_ (13X4:+JC6C72+%
M$CHK;2%/?.#793:)I5Q9164^F64MI"<QP/;JR)]%(P.IJPEI;1V@M$MXEME7
M8(50! OIMZ8]J+A8\O\ $/Q6\+:MX7O;3[+<S37$+(D$L( 5R."3D@8/.1Z<
M5'\'='N[/P[K&HSQO'#>JJP!N-X0-EA[9;'X&O0%\(>&TG\]=!TT29SG[,G!
M]>E;0  P!@"BX6/G;X9>,=,\(W&I2:DMP1<)&$\E WW2V<Y(]:]>\-?$+1/%
M>I/8:>+I9DB,I\Z,*"H(!Y!/J*TSX3\-LQ9O#^E$DY)-E'S^E6;'0](TR9IK
M#2K&TE9=I>WMTC8CKC('3@4-@D<_+\+_  ;/,\LFC N[%F(N90,GD\!\"CQ!
MXNTKP -*T^:RG%C)&R1M#\WE!-H P3D]?7/UKKZKWEC::A 8+VUAN83UCFC#
MK^1I#/%_B1\0M#\3>'X]-TV&:6;SED\V6/:(P >G?)SCZ9KLOAY:W7A?X:R7
M6H0R!E$M[Y)X8)MR![$A<_C73V?A7P_I\ZSVFBV$,RG*R+;KN4^QQD5K,JNI
M5E#*PP01D$4[BL<CX$\=)XVBOF&GM9O:,@(\WS P;..=H_NFNEU.PBU32[NP
MFR(KF%XF(Z@,",_K3=/TK3M)C>/3K&VM$=MS+!$$#'U.*N4AGS[H&K:K\)_$
MMS9ZK9226=QP^S@. >)(R>#U/''7G%:/Q%^(FB>*/#,6GZ<EWYYG65O-C"A0
M PP3D\\CI7M5W8VE_#Y-Y:P7,6<[)HPZY^AK,A\(>&X)O.BT'35DSD$6R<?3
MCBG<5C@[=2O[/!# @_9G//\ UV-1?#C37UCX1ZUIT6/-N)ITCW' W>6FW/XX
MKU::UM[FV:VG@BEMW7:T4B!E(]"#QBF66GV6FP>18VD%K#DMY<$81<^N ,9H
MN%CQ+X;>-;'P;%J&CZ['/;$S>8&\HDJV K*PZCH/UIL,\GQ%^+=M?V-O(NGV
MCQ,7=>D<9W?-Z%CD >_UKV74/#VC:M+YNH:59W,N,>9+"K-CTR1FK5G86>G0
M>18VD%K%G.R",(N?H*+A8\,^(5W-I_Q>COH+<W$EKY$XB&?F"*&/3V!JS\0/
MB3IWBGPW#I>EV]R)9I5>7S4 VXZ*,$Y).*]G?2].DU!=0>PM6O5&%N3"ID Q
MC ;&>YJM#X:T*VOOML.CV$=UNW"5;=0P/J#C@^]%PL>5>*M-U7P[\&='T\"2
M,-+NO@N00'+,%;VR0#[@5A3S> 4\!I%9VLMQXAD@ 8E9-R28RS$_=VCGIGC\
M:^@Y88KB%XIHTDC<89'4$,/0@UG6GAK0K R&TT>PA,BE'*6ZC<IZ@\=#Z=*+
MA8X#X:?\DEU;_>N?_18JE\"?]1KO^]!_)Z]6M=-L;&U:UM+*VM[=LDQ0Q*B'
M/7@#'-)8:5IVEJZZ?86MHLA!<6\*Q[L=,X S1<+%NO!/!-A9ZC\6]5@OK2"Z
MAWW3>7/&'7(?K@\5[W5&WT;2[2\>\MM-LX;J3.^>*!5=LG)RP&3DT T36EC9
MV$9CL[6"W0]5AC"#\A7C'QL_Y&?2/^O?_P!G->WU2O='TS4I8Y;[3K2ZDC^X
M\\"N5^A(XH3!G-_%7_DFVK?]L?\ T<E<1IDU_!\ +A]/:19/-<2-'G<(_,^;
M&/;K[9KV*ZM+:^MGMKNWBN('^_%*@=6YSR#P>:;:V-G8VHM;2U@M[<9Q%%&$
M09Z\#BBX6/ = F\ 0>#'_M&VENM?8.HBVR$EB2$VXPN,8Z\]?:NF^"4HM]*\
M03,K$1M&Q51R<*YP/>O3+;PUH5E>?:[71["&YSD2QVZA@?8XX_"K-EIFGZ:)
M!86-M:^8=TGD0JF\^IP.:+A8\<\5ZU\./$VD76H*);76FC9HU2!E=I,<!\ H
M>>ISG'>D\-Z/JVM_!?5K4))(!/YMDC9^8(5+!?4'# #US7JTOA+PY/<FXET+
M3GE)R6:V3D^IXYK71$C14C5411A548 'M1<+'@G@K5/ 4.B_9/$^GQI?PNP,
MTD+OY@)R/NY((Z<CL*]&\"WW@_4+[4#X8T[R'@1%EF\K8'5B< 9.?X>X':NA
MO?"^@ZC.T]YHUC/,QRTCP*6;ZG&35VRTZRTV'R;&SM[6+KL@C"#\A0V%BS7G
M[?%W0+6_O;+4(+RVFM9WA/[L.&VL1D8.1TZ$?G7H%9FH>'-%U67S;_2;*YE_
MYZ2PJS?GC-(9X)JMP?'_ ,2TFT.TEC65XQN( 8!<9D;'3I^@[U]'54L-*T_2
MHS'I]C;6B-]X01*F?K@<U;IMB2"O"? '_)9M1_ZZ77_H1KW:J,&C:7:WKWMO
MIMG#=R9WSQP*KMGDY8#)S0!YG\=/^09H_P#UVD_]!%>B>%_^12T;_KQ@_P#1
M:U;OM+T_5(TCU"QMKM$.56XA60*?4 @XJS'&D,211(J1H JJHP% Z #L* /$
MM#_Y."N?^OBX_P#1;53\8S6TGQ>9/%;3_P!D1E=JKNP(]G&,<X+=<<]:]N31
M],CU!M033K1;ULYN5@42'(P?FQGI2:CHNEZNJKJ.GVUV$^[YT08K],]*+A8^
M>/%TWAF;7['_ (1:U:.S0A9)=KA9'W \;N>!CTKN_CI_R#-'_P"NTG_H(KTD
M^']%:WA@;2+ PP$M%&;9"L9/4J,<'@=*FOM+T_5(TCU"QMKM$.56XA60*?4
M@XHN%BIX7_Y%+1O^O&#_ -%K7DVA_P#)P5S_ -?%Q_Z+:O;8XTAB2*)%2- %
M55& H'0 =A51-'TR/4&U!-.M%O6SFY6!1(<C!^;&>E%PL>.^+/\ DO&F?]?%
MI_-:Z7XW_P#(EV?_ &$4_P#1<E=[+H^F3WZ7\VG6DEXF-EP\"F1<=,,1D8J2
M]T^RU* 07]G;W4(;<(YXE=0?7!'7DT7"QC> _P#D0]$_Z]4I_C?_ )$;6_\
MKSD_]!-;<$$-K D%O$D4,:A4CC4*J@=@!T%$T$5S \$\22PR*5>.10RL#U!!
MZBD,\O\ @;_R+^I_]?0_] %9OQV_U^A?[L_\TKURQTVPTR)HM/LK:TC8[F2W
MB6,$^I  YIM_I&F:KY?]HZ=:7GEYV?:(%DVYZXW XZ"G?45M#S[XG?\ )*;'
M_>M__035!);R+]GJ(V2!BT;K+D [8S,VX\^W^->IW6GV5]:_9;NSM[BWX_=2
MQ!TXZ<$8KC/B3X:O=0\%1Z?X?MD1()UD:T@4(&0 \*!@<$@X_K0!Y#I1\ M;
MVQU5=?6Y5/WXA,1B9O;^+%>UZ9JWA_4O =]%X==1:6MI)'Y(4JT?R$\@\\\G
M/?GFN%T_Q1J-EX6BT)OAY=33Q0>3EK=BKMC[S+LSD]3SU[BN@^%'@W4- L+^
MYU>$1/?!%6V;!(0;N6'3G=T[8]Z;$C(^!/\ J-=_WH/Y/5.__P"3BD_Z[1?^
MDZU[#8:5IVEJZZ?86MHLA!<6\*Q[L=,X S36TC3&U$:BVG6AOATN3 OFCC'W
ML9Z<4KCL8FH?#KPIJE_-?7FDB2YG;?(XGE7<?7 8"L/XC:38Z)\*KG3].@$%
MK%)'LC#%L9D!/)))Y->B5!=V=K?VS6]Y;0W,#8W131AU..1D'BE<+'GOPXTJ
MVUOX4?V==H&AG>9#D9VG<<,/<'D5R_PIU2X\.^,K[PQ?-M$SL@4G@3)GI]0#
M]<"O:K2RM=/MUM[*VAMH%R5CAC"*,]< <57.B:2VH?V@=+LC>YW?:3;IYF<8
MSNQG.*=PL>/Z'_R<%<_]?%Q_Z+:NG\4^(O .J:E=Z3XFA>&YLV\M9FA?=T!^
M1DR<<]#Q7=IH^F1Z@VH)IUHMZV<W*P*)#D8/S8STJ'4/#NBZM*)=0TJSN90,
M>9+"K-CTSC-%PL>1?"%)5\<:H-+DG?1EC<%I!C<-W[O=VW8S^M8_@GP];>)_
M$/B+3+C"E[:5HI,<QR"5=K?X^Q(KZ LK"STZW%O8VL%M"#D1PQA%S]!45IH^
MF6%Q)<6>G6EM/+GS)(8%1GR<\D#)YYHN%CR;X7>(;G0-<N/!NL9C/FL(-Q^Y
M+W7Z-U'O]:]FJC+HNE3WZW\VF64EXI!6X>!3(".A#$9X[5>H8(\0^+.AWVD>
M*;?Q79*QC=HV:0+D12I@+GV( Q[@UT-K\;=">P5[JQOH[H+\T4:JR[O9MPX^
MH%>F.B2QM'(BNC##*PR"/>LC_A$?#GV@3_V#IOF@Y#?94Z^O2BX6..UM;KXE
M_"YKV"R:WN5F:>W@SN+["RX!P,DJ6_&N<\!?$RT\-:/_ &'KMM=(;9V$;HF2
MH))*LIP002?7KVQ7MBJ%4*H 4#  ' %9U_X=T75)#)?Z397,AZR2P*S?GC-%
MPL>+>-/%\WQ&OK'0] L;@PK)O D #2/C&2 2 H!/.>_:O9-'T"WTSPM;Z$_[
MV%+<PR$_QY!W?F2:M:?I&FZ3&4TZPMK16^\(8@F?KCK5VBX6/EFXN[[PO_PD
M'AO)V7$BPRGI_JWR"/J,_@:^@O 6C?V%X+TVT9=LS1^=-Z[W^8@_3('X5I7/
MA[1+RZ:ZNM'T^>X8@F:6V1G..G)&:TJ&P2/#9?\ DX4?]?2_^BA5GXZ_\?NB
M?]<YOYK7K?\ 8VE_VC_:/]FV?V[.?M/D+YF<8^]C/3BG7^E:=JBHNH:?:W@C
M)*"XA63;GKC(.*+A8\ZG^-6A6VFJMG97L]RL8"JZJB9 [G)./H#63\-?#6JZ
MMXLE\7ZQ \2%GEB+KM\V1\C(!_A )Y^F*]3@\-Z%:OOM]%TZ%P<[H[5%/Z"M
M2BX6.7U#X=>%-4OYKZ\TD27,[;Y'$\J[CZX# 5:N)=&\!>%FD2!X--M,8CCR
M[99O]HY/+=S6]4-U:6U];/;7=O%<0/C=%,@=6P<C(/!Y I#/G;QEXLT[7O'=
MCK-FLXM8!"'$B -\KDG SZ&O:=#\=:1X@TO4-0LEN?*L%+S+)& V-I;CG!Z'
MO5W_ (1'PU_T+VD_^ 4?_P 35VQTK3M,CDCL-/M;1)#EU@A6,-]0!S3N)(X.
MY^+/@V2W^UF"::Y492)[8;P?3<>!^=8_POTR^USQ7J/C*^A,44K.(<]&=CSC
MU"KQGW]C7HQ\'^&C.9CH&FF0G))M4Z^N,8K91%C1410J*,*H& !Z47"PM>#>
M*[74/ /Q-_X2.&W>6SGG:=7QA6WYWQD] >6Q^!KWFHY[>&ZA:&XACFB;[R2*
M&4_4&A,&CS>[^-F@)I[26EI>RW14[(I$50&_VFR>/IFL?X3:!?7^NW?B[45=
M1(7,+,,>:[D[F'L.1^/M7I2>#_#4<XF30=-60'((MDX/TQ6R      .@%%PL
M>#:IJ(\&?&JYU.^@D:V:1I/D'+)(F,KZX)_0UG_$KQ=%XPN;.>QM)TT^TWQK
M/*N/,=L$CT'"CWKWS4=&TS5U1=2T^VNPGW/.B#E?H3TILF@Z/-9Q6<NDV+VL
M1W1PM;H40^H7&!1<+'$?%FUEN/AO!)&I8030RO@=%VE<_FPJ/X7^--+N='TO
MPX!,-1CC<$;/DP"6SGZ5Z0\4<D1B>-6C8;2A&01Z8]*S[#P[HNEW+7%AI5E:
MS,,&2&!5;'ID#@>U 6/ O!WBF+PEXTO[ZYMI)K63S(93'RR N"&'8\@#\:N^
M+M9'Q*\::=9:-#,8%40JSKSRV6<CLH&/RK;^&6A72>,];&IZ5,+26WD0BYMS
MY;YE4X^88/3]*]8T[0])T@L=.TVUM"PPS0Q*I(]R!DTVQ)'D'Q:D8>-](MM3
M,ZZ&L<9VQYQMW$2$?[6,?I7/^.YO!DEO:1^$K5LH<SW 60+@CA?GYSP3TKZ%
MO],L-5@\C4+."ZBSD)-&' /J,U67PYH:6/V)='L/LI8.83;(4+#H2,8)]Z5Q
MV.8\1VLMY\&&BA4LXTV"3 &>%",?T!KE?A/XTTO3]+@\/W(F%[/>$1;4RI#
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MZQMK1&.6$$03<??'6KE#8)!1112&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 (0&&" 1Z&L;4CH,>5NX[=G_N(N6_(5J3VRW'$COLQRBM
M@'ZXK&_M[PUITK1"ZM8G0X;:I//U KEQ&JL^5+SU_#_@G3AXR;O!-OR_K]#&
M>SMYI=UAH5U(.QE8JGY?_7JW#8>(%0I;16MBC=0F,_GS750RQSPI-$P:-U#*
MP[@T^N:&603YN9KTLOR5_P 3:6.G\/+]]W^?^1RA\.ZS./W^K$>P+?TQ3?\
MA#IF_P!9J3,?]T_XUUM%7_9>&?Q)OU;_ ,R?K]=;-+Y(Y+_A"A_S_-_WQ_\
M7H_X0Z9?]7J3+_P$_P"-="-6L3JATT7"_; N[RL'..OTJY4K+,&]H_B_\RI8
M[%1MS/?R7^1R@\.ZS!_J=6)]F9OZYIL]AX@9 ES#:7R+T#XS^?%=;15/+:5K
M1<E\_P#.Y/UZI>[2?R_R.(2SMH)=U_H=U&.YB8L@_#_Z];VFG0I,+:1VX?\
MN,N&_(\UH7VH6FF6_P!HO)EABW!=Q!ZGZ5EKK7AS5)T@%S;32N<*&4@D^Q(J
M*>%A0E:+BWYI)_>O\C252I7CS<LK=U=K\?\ ,W  !@  >@I:@AMEMSB-WV?W
M&;('TS4]>E&]M4>>[7T"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTHN^[]Y>BU1WU%( %4 = ,4M>B>&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M -]&CF#VZ[&Q16/YTO\ SU?_ +Z-'G2_\]7_ .^C1S![==C8HK'\Z7_GJ_\
MWT:/.E_YZO\ ]]&CF#VZ[&Q16/YTO_/5_P#OHT>=+_SU?_OHT<P>W78V**R/
M.E_YZO\ ]]&GI=S(?O;AZ&CF&JZ-2BH8+E9QCHPZBIJHU335T%%%% PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@! 0PR"",XXI:AMO]4W
M_71__0C4K,%4DG@4 *3BN>U3QKHNE.T3W!FF7@QP#<1^/3]:XKQ=XTFU":2Q
MT^4I9K\K2(>9?7G^[_.N+JDCY[&YWR2<*"OY_P"1Z5-\48 ?W.ER./\ ;E"_
MR!J+_A:?_4&_\FO_ +"O.J*=D>6\XQG\_P""_P CT7_A:?\ U!O_ ":_^PH_
MX6G_ -0;_P FO_L*\ZHHLA?VOC/Y_P %_D>B_P#"T_\ J#?^37_V%'_"T_\
MJ#?^37_V%>=4460?VOC/Y_P7^1Z+_P +3_Z@W_DU_P#84?\ "T_^H-_Y-?\
MV%>=4460?VOC/Y_P7^1Z+_PM/_J#?^37_P!A1_PM/_J#?^37_P!A7G5%%D']
MKXS^?\%_D>B_\+3_ .H-_P"37_V%'_"T_P#J#?\ DU_]A7G5%%D']KXS^?\
M!?Y'HO\ PM/_ *@W_DU_]A1_PM/_ *@W_DU_]A7G5%%D']KXS^?\%_D>B_\
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MI8[^!)6@?<%W!L?,.#WZ5U5[HVKZE"(;ZZT*ZB!R$GTAW7/K@SU%_P (Y?\
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MR11VQ\1R"Y>>,O$J><^"XR,KNVYY';FO29=-L)[Z*]ELK:2[B&(YWB4R(.>
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M2D_M*WR_I'7S>*K&3Q9INJB*X\BU@$;J57<2 PX&<=QWKHM%N]N@WFI6\6H
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M_@##_P#$T^8\S^P*G\Z/,:*]._L>7_GRL/\ P!A_^)H_L>7_ )\K#_P!A_\
MB:.87]@5/YT>8T5Z=_8\O_/E8?\ @##_ /$T?V/+_P ^5A_X P__ !-',']@
M5/YT>8T5Z=_8\O\ SY6'_@##_P#$T?V/+_SY6'_@##_\31S!_8%3^='F-%>G
M?V/+_P ^5A_X P__ !-']CR_\^5A_P" ,/\ \31S!_8%3^='F-%>G?V/+_SY
M6'_@##_\31_8\O\ SY6'_@##_P#$T<P?V!4_G1YC17IW]CR_\^5A_P" ,/\
M\31_8\O_ #Y6'_@##_\ $T<P?V!4_G1YC17IW]CR_P#/E8?^ ,/_ ,31_8\O
M_/E8?^ ,/_Q-',']@5/YT>8T5Z=_8\O_ #Y6'_@##_\ $T?V/+_SY6'_ ( P
M_P#Q-',']@5/YT>8T5Z=_8\O_/E8?^ ,/_Q-']CR_P#/E8?^ ,/_ ,31S!_8
M%3^='F-%>G?V/+_SY6'_ ( P_P#Q-']CR_\ /E8?^ ,/_P 31S!_8%3^='F-
M%>G?V/+_ ,^5A_X P_\ Q-']CR_\^5A_X P__$T<P?V!4_G1YC17IW]CR_\
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MZ7J%A+9PQP.MY#Y>\A0"5SR1[\5T=%%PL%%%%(84444 %%%% !1110 4444
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MCTZZ9W:SCD41JS=2IV[NO.TL5SV[5TE%%D%C'N?#EO-)93P7-U:7=I%Y,=S
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M /'_ /ZU9U% &C_:B_\ /O\ ^/\ _P!:C^U%_P"??_Q__P"M6=10!H_VHO\
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M#5HFF6-E'-<1M8MNM[A67S$/?J,'()!!&* ,7#Z)XEUF=9Y;A8-)$T0G8N5
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MGI</A3Q!KFM:>Q/]H-J!9XXU^K*,' ].N.>2*]>HIW%8****0PHHHH ****
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MOBQPD@\P^JGAOT)II'CYCCO85J44^MWZ;?YGO%% ((R.112/8"BBB@ HHHH
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M=/\ A43ZA:_:HCYO\+?PGV]J +]%5?[1M?\ GK_XZ?\ "C^T;7_GK_XZ?\*
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MA9=+L5MQ=%VSN<E>,^W/ JUX?\/VV@67EQX>=QF68CECZ#T'M6Q2&9G]C_\
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M&S]>:ZUK.V>S-FUO"UJ4\OR2@*;<8V[>F,=J@L](T_3%E_LRPL[)I!\Q@@5
MQ&<9VXSC-3RBL3V]W;78D-M<13"-S&_EN&VL.JG'0CTKE-?MY;GX@Z#'%>3V
MC_9+D^;"$+?P<?.K#]*W]"T>/1--%LLAFF=VFN)RNTRRL<LV.V3V[# J6^T?
M3-49#J&G6EV8\A#<0+)MSUQD'%-IM <_XOADL_#5J9[R:Y$.H6TDD\X0$+YJ
M\G8JC ^E+>74$OQ.TJW256FBT^X:1 >5#%,9^N#6_;Z/IEI:2VEMIUI#;39\
MR&.!51\C!RH&#QQ2VNDZ;8^7]DT^UM_+W!/*A5-N[&[&!QG SZXHL%CDO#4#
MP>!-9GL(L7TLMZRLGWF<.X7G\!BJU^+$_"&R%CL,AB@^Q[?O_:=PQM[[]V[/
MXY[UWL%M!:Q^7;PQPQ[BVV-0HR3DG [D\U7CT?2X;]K^+3;-+QB2UPL"B0D]
M<MC/-+ET"QR]F;7_ (6O>BZ,7VW^S8?)#'G.6W[??'XXS[US\[.=#E-M+"FD
MMXFX>6/? L6>I (S'YON![UV;>&H[KQ1J%_J$%I=6-S;0Q+#*F\AD+')4C'?
MBMP6EL+/[&+>+[+L\OR=@V;,8V[>F,<8I<MPL8=EI5S!XI;4[W5;*2=[,Q-;
MV]L82ZA@0[9D8G'(_P"!5NVUU;WMNMQ:SQ3PO]V2)PRMVX(XJC_8EK::==VV
MC06FF2SH5\V"V4 -C 8J,;L9[U/I6FVVCZ7;Z?:+M@@0(N>I]2?<GD_6J2L!
MS_CB6.:RTZ&.1'E75[5"BL"0VX-@CL<'/TYIVIZL'O=;LK/3+%_L]NIOY[R<
M0JRLA*]$8L N?O8 Z5T+Z=8R7\=^]E;M>1KM2X:)3(HYX#8R!R?S-,N-)TV\
MNXKNYT^TGN8L>7-+"K.F#D88C(P>:&F!YJLEJ_A?X?-J;H;;SPKF8_+@(P4'
MVZ#GBNEN[FWMO'FHW&TR6\&C%K^-%#;B&R@([MMWX![&M'5O#HO+K0_LD5K%
M9V%PTDD)7:I0HRX50,=^G%:]EIUCIL+0V%G;VL3-N*01*BD],X Z\"I46%CA
M+_4I[O5/!MP;&QLX9;H-:B*ZWR^4T9X*[ %&"N<,1G K1\/6EO+KGC&22"-G
M>[\IF*@DIY2_+].3Q71VV@Z/9MNM=)L8&WB3,5NBG<,X;@=1D\^YJU%:V\+S
M/%;Q1M,VZ5D0 R'&,MZG'K34>X6,3P*[/X'T<LQ)%N%!/H.!^@KGO%.K"]\+
M>)H[33+&.Q@>2">:XG$;M.,?,J!"&.=N"6!)Q[5WUO;PVL"06\,<,*#"1QJ%
M51[ =*J3:)I-Q=O=S:7927+J5:9[="[ C:06(R1CCZ<4-.U@MH<MY:7?CCPQ
M)<(LKKI4DH+C.'^3YOKR:S]8\V+3?'L=J&5!/$[JF1\K1IYAX]5SFO019VHF
MBF%M")8D,<;B,;D7^Z#V' X]J<EM;Q2321P1)),0965 #(0,#<>_''-'*%CC
M?$2Z2-9\'_9EMQ<"Z3R/+ R(-C=,?PYVXKL;O_CSG_ZYM_*JUOHFDV8 MM+L
MH )!*!%;HN' (#<#K@D9]ZO$!E((!!X(/>FD"/+;2WEL?!7AC5+V\EN](B:%
MKFTF"JD0) 212@4D*Q'#E@<^U=1IK)8_$36HKAU5]1@@FM=QQYBHI5@/4@\X
M'8YKH_L%G]A^P_9(/L>S9]G\L>7M]-N,8]J;=Z;87]LMO>65M<P(05BFB5U!
M P" 1CI24;!8Y_4F34/B#HL%N=[Z;'/-=%#GR@Z!45O0MG./09KG[\"'Q!?>
M$^ FJ:E!>1J!UB(WR_K$1_P*O0K.PL].@\BQM(+6'.[RX(PBY]<"E:RM'O4O
M'M86NHU*).8P753U ;J!0XW"QYU=IY>N7G@]2 M_JD5XJ_\ 3NP\R3_QZ,C_
M (%7IE0-96C7JWK6L)NU38LYC&\+Z!NN/:IZ:5@2"BBBJ&%%%% !1110 5HV
M'^H;_>_H*SJTK$8M\^K$TX[FM'XBS1115G6%%%% !1110 5'/!%<P/!/&LD3
MC:RL,@BI** /(_%/A:70YS/ &DL7/RMU*'^ZW]#7-U[Y/!%<P/!/&LD3C:RL
M,@BO,-:\#WMKJD<>G1M-;3MA&/\ RS]F/I[T".<T_3[G5+V.TM(R\KG\ /4^
M@KU[P_X?MM LO+CP\[C,LQ'+'T'H/:CP_P"'[;0++RX\/.XS+,1RQ]!Z#VK8
MH&%%%% !1110 4444 %%%% $-M_JF_ZZ/_Z$:FJ&V_U3?]='_P#0C4U !111
M0 4444 %%%% %'6;>6[T2^MX%WRRP.B+D#)(('6LG31INGW-E!/H@T^\D39'
M.T$6'<#D!T)P2,]<9K?N//\ L[_9O+\['R>9G:3[XYK+EL+_ %*^LY;Y+:""
MTD\Y4AE:0R/@@9)5< 9]\^U,Y:T/?4XJ[TZ:;_A]_P!Y=U74%TO3)[UD,GE+
MP@.-Q)P!GZD5@ZD=4%]H0OOLKJUXK%H%9-C;6^7!)W#WXZ=*W=7T]=5TJXLF
M?9YJX#XSM(.0<?4"LZ;3]7OKC39;IK.);2=9'2)V;S/E()R5&.OW<=^M!&(C
M.4K*]M+6]=;_ "M^A-K%WJEA9W-_$;/R;==_DNC%G4=?GR IQGC:?K3HM6D.
MN16DBH+>ZMO.MW (8D?>4\^A!_.LK4/#-U>#4HVAT^=[IF:&\N"S2PJ1P@&T
MX .0"&&,YP>A7Q3:RPZ#8M!($OX)$AA8?Q,XV$#\#G\*#.=2K'FG9I*S]=7?
M\.VFQ*WB*Z&D-J!2!();SR()6!VQQ;MOF/SSR#Z=16Y8R32VJO--;S;N4EMP
M0CKV."3C\SZ]\"!;2>QTNVM+".WD6%!&8YV*AU QU .#WZ'^M1:%I;Z7!<!Q
M#&9YVE$,&?+B!P J\#TST')Z4&U-58S2EKIK_6S_ #7H1)?:EJ4UZ-.-K#%:
MRF%3/&SF5P.>C#:,G'>LG4+ZXUB#0;J!H80]Z%,4D9DV2J'!R0PR!@]AZYK6
MAL-2TVXO?L M9H+J4SCSY&0Q.WWNBG<,\]1Z5&OA][>TTFWAE5_LEUY\KO\
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M"HVC//?T]ZVJ1U4>:[WMTOOY_P!?H%%%%!N%%%% !4+_ /'W%_N-_2IJA?\
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M **** "BBB@ J%_^/N+_ '&_I4U-* R*_.5! _''^% #J*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **@:[C5BI6;(..(7(_/%)]MB_N3_ /?A_P#"@"Q15?[;%_<G_P"_#_X4
M?;8O[D__ 'X?_"@"Q15?[;%_<G_[\/\ X4?;8O[D_P#WX?\ PH L457^VQ?W
M)_\ OP_^%'VV+^Y/_P!^'_PH L457^VQ?W)_^_#_ .%'VV+^Y/\ ]^'_ ,*
M+%%5_ML7]R?_ +\/_A1]MB_N3_\ ?A_\* +%%5_ML7]R?_OP_P#A1]MB_N3_
M /?A_P#"@"Q15?[;%_<G_P"_#_X4?;8O[D__ 'X?_"@"Q15?[;%_<G_[\/\
MX4?;8O[D_P#WX?\ PH L457^VQ?W)_\ OP_^%'VV+^Y/_P!^'_PH L457^VQ
M?W)_^_#_ .%'VV+^Y/\ ]^'_ ,* +%%5_ML7]R?_ +\/_A1]MB_N3_\ ?A_\
M* +%%5_ML7]R?_OP_P#A1]MB_N3_ /?A_P#"@"Q15?[;%_<G_P"_#_X4?;8O
M[D__ 'X?_"@"Q15?[;%_<G_[\/\ X4?;8O[D_P#WX?\ PH L457^VQ?W)_\
MOP_^%'VV+^Y/_P!^'_PH L457^VQ?W)_^_#_ .%'VV+^Y/\ ]^'_ ,* +%%5
M_ML7]R?_ +\/_A1]MB_N3_\ ?A_\* +%%5_ML7]R?_OP_P#A1]MB_N3_ /?A
M_P#"@"Q15?[;%_<G_P"_#_X4?;8O[D__ 'X?_"@"Q15?[;%_<G_[\/\ X4?;
M8O[D_P#WX?\ PH L457^VQ?W)_\ OP_^%'VV+^Y/_P!^'_PH L457^VQ?W)_
M^_#_ .%'VV+^Y/\ ]^'_ ,* +%%5_ML7]R?_ +\/_A1]MB_N3_\ ?A_\* +%
M%5_ML7]R?_OP_P#A1]MB_N3_ /?A_P#"@"Q15?[;%_<G_P"_#_X4?;8O[D__
M 'X?_"@"Q15?[;%_<G_[\/\ X4?;8O[D_P#WX?\ PH L457^VQ?W)_\ OP_^
M%'VV+^Y/_P!^'_PH L457^VQ?W)_^_#_ .%'VV+^Y/\ ]^'_ ,* +%%5_ML7
M]R?_ +\/_A1]MB_N3_\ ?A_\* +%%5_ML7]R?_OP_P#A1]MB_N3_ /?A_P#"
M@"Q15?[;%_<G_P"_#_X4?;8O[D__ 'X?_"@"Q15?[;%_<G_[\/\ X4?;8O[D
M_P#WX?\ PH L457^VQ?W)_\ OP_^%'VV+^Y/_P!^'_PH L457^VQ?W)_^_#_
M .%'VV+^Y/\ ]^'_ ,* +%%5_ML7]R?_ +\/_A1]MB_N3_\ ?A_\* +%%5_M
ML7]R?_OP_P#A1]MB_N3_ /?A_P#"@"Q15?[;%_<G_P"_#_X4?;8O[D__ 'X?
M_"@"Q15?[;%_<G_[\/\ X4?;8O[D_P#WX?\ PH L457^VQ?W)_\ OP_^%'VV
M+^Y/_P!^'_PH L457^VQ?W)_^_#_ .%'VV+^Y/\ ]^'_ ,* +%%5_ML7]R?_
M +\/_A1]MB_N3_\ ?A_\* +%%5_ML7]R?_OP_P#A1]MB_N3_ /?A_P#"@"Q1
M5?[;%_<G_P"_#_X4?;8O[D__ 'X?_"@"Q15?[;%_<G_[\/\ X4?;8O[D_P#W
MX?\ PH L457^VQ?W)_\ OP_^%'VV+^Y/_P!^'_PH L457^VQ?W)_^_#_ .%'
MVV+^Y/\ ]^'_ ,* +%%5_ML7]R?_ +\/_A1]MB_N3_\ ?A_\* +%%5_ML7]R
M?_OP_P#A1]MB_N3_ /?A_P#"@"Q15?[;%_<G_P"_#_X4?;8O[D__ 'X?_"@"
MQ15?[;%_<G_[\/\ X4?;8O[D_P#WX?\ PH L457^VQ?W)_\ OP_^%'VV+^Y/
M_P!^'_PH L457^VQ?W)_^_#_ .%'VV+^Y/\ ]^'_ ,* +%%5_ML7]R?_ +\/
M_A1]MB_N3_\ ?A_\* +%%5_ML7]R?_OP_P#A1]MB_N3_ /?A_P#"@"Q15?[;
M%_<G_P"_#_X4?;8O[D__ 'X?_"@"Q15?[;%_<G_[\/\ X4?;8O[D_P#WX?\
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M457^VQ?W)_\ OP_^%'VV+^Y/_P!^'_PH L457^VQ?W)_^_#_ .%'VV+^Y/\
M]^'_ ,* +%%5_ML7]R?_ +\/_A1]MB_N3_\ ?A_\* +%%5_ML7]R?_OP_P#A
M1]MB_N3_ /?A_P#"@"Q14"W<;,%"S9)QS"X'YXJ>@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M')/)(YQCFN]KY_\ ';^(]/\ %GA?5_B+!I\VCVUSB+^Q79527(;+B0;C]T'
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M1&^]!-$'V-ZC(X/O1<+'F_BK[-IOBK4==T7Q186.K11+'=V-Z!B8!00%SSR
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M[OK@#-%PL><_#>UMYH_&+2P1NS7<D;,R@DK\WRY]/:L#31+-^S_J:@%O+NN
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MY)&32 JRSGPGX1EGO;R6]:TB9C+*?FD;LHR2>I &23TR3UKF=2TB?2_A>3<
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M,.K=5.T<?ATJ[<:-I=W>QWMSIMG-=QXV3R0*SK@Y&&(R,&KM(84444 %%%%
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ML9DA2Y$9$P'WMK([#(XR"0>:ST\<V4EE/?1Z=J365M*T5S<")0L.UMI)!;+
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M4H5'EB4*1\I#;\!N-VW;GOWKJ-+=I-(LG=BSM A9F.23M')H MT444 %%%%
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M;UPS@$$>G/;!]"*AU&XU'2+OP_:_VG-<_:[\QSR31Q@NGEL=HVJ !E0?7WH
MZ:J&GZM!J5S?P0I(K6,_D2%P "VT-D8/3##TKGDU>]@\32V^K7]SIX>[$=E$
MULK6ES&1P/-VY$AP>"XYQ@'H<:SU.]'BW6M$L9?L4M[J3/\ ;I%5E4+%&2B
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MN8\E.PY)_P!D9.,D XJI?6-[J6F^--3BL+E%O[58+2%X66641HPW>61N&2>
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MLH+I8Y(UFC60)(,,H(S@CL:Y#7KPV'Q(T6?[-/.@L)Q(($WLB[E^;:.6QQP
M3[&NUK/ET>WFUZVUAGE%Q;PO B@C858@G(QG/ [TAG'7UC>ZEIOC34XK"Y1;
M^U6"TA>%EEE$:,-WED;ADG@$9('2M+4;S5;:\T^U+ZA9Z;]B#-/867VB4S#
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MJZP(&5A@@[1P:MT4AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY\00@ MM*X.1TPQZ8J_10!B7'AJ.[NHWNM2U">UCN!<I9R.AC#@Y'.W>0#R
M6QP!T&*9<^$=-NH=0CD:XW7ET+OS%<!X)0 %:,X^4C:.N>_;BMZB@"G?:='J
M.CSZ;<2RM'/ 89)!@.01@GIC/X8]JIWGAVWNETYH[FYMKC3U*V]S"5WJ"NT@
MAE*D$ =1VXQ6Q10!@Q^$=.%KJ<%Q)<W0U(JUR\\F6+*  P( VG@'C@8& !Q5
MB'0L03P7VIWVHQ30F I<L@ 0\'B-5R3ZG)],9.=:B@##'ABW;0ETFYO;RYBC
M*&"60HLD!3&PHR*O((!!.??(XJ:TT%(-234+N^N]0NHT,<+W/E@0J?O;515&
M3QDD$X&,XK6HH S+#0[;3M)FTZ":X$4KRN7\S:ZF1BQPRXQ@GBJ3Z'+8O<ZJ
MES>ZKJB6K06PN'B3:#S@;%11D@9)R>/SZ"B@#)L-(EB\,1:5?7DEU*;?RIKB
M3$C.Q')^<$'KT((]J2'1KV*2-CXBU-T0@^6T=L%8#L<0@X^A%:]% &%JGAIM
M5OX+N36M1A-M+YT$<2P;8FVE<C=&2>">I/6GW/AU)[V"_CU&]MM0C@^SO=0^
M7NF3.<.K(4Z\\*.OI6U10!0TG2+?2+>6.%I9'FE::>:5@7ED/5C@ =AP  ,=
M*IW'A:QN;;6H'EN FKMNG(9<K\H7Y>..%'7-;=% &=/HUO<:AIMZ[RB33PXB
M (PVY=IW<>GIBJUYX8LKV'68Y);@+JP43[6'R[5"C;QQP.^:VJ* ,Z?1K>XU
M#3;UWE$FGAQ$ 1AMR[3NX]/3%,;P_8R/JQF#RIJH N(V;Y<!-F%QR.!Z]:U*
M* .>B\(P+<:=/<ZIJ5V^G.&MO/D3"C:5P0J -P>IRW'7KG3M-)@LKC4)HWD+
M7TOG2AB, [%3Y>.F%'7-7J* ,%/"=C%H^G:?#/=1-IQW6MTC+YL9YSU7:<@D
M$%2"#TJ>V\.VL4EW-=S3ZA<7<7D2S7>TDQ?\\P%55"\D\ 9)YS6O10!C6'AY
M;%$A;4[^YLXXS'':SLAC52,8)5 S8' W$_G@U7C\(6JP06<FH7\^F0.&CL)7
M0Q *<JI(0.RJ<8#,1P,YKH:* *$.DP0:U=ZJKR&>ZBCB=21M 3.,#&<_,>]4
ME\+6*>&UT(2W'V57$@?<N_(D\SKC'7VZ5N44 <G)HUQ=^/+^\2>^L@+&!([F
M #:WS2;EPZLC?PGD$CCIFK__  BFG_V3%I_F7&Q+I;QY2X,DLH<.6<D<Y(YP
M![8K=HH S]5T>#51;L\DT%Q;2>;;W$! >)L8.,@@@C(((((/2H+7P_!!+=W$
M]U<WEY=1>2]S<%=XC[*H5551DD\#DGG-:]% &*/#-D-)TK3?-N/)TR2*2%MP
MW,8_N[N,'WP!5MM(MWU>;4B\OG2VHM67(VA Q;(XSG+'O5^B@#GD\)I!I<&G
M6FL:I:V\5L+8K&\9WJ,\G<A ;D\KMSQZ#$TGABS5;(V$UQITUE#]GAFMF4MY
M6/N,'#!AT/()!&0>M;=% &1<^'K>^TDV%Y=7<[&03"Y:0"5) <JZX 52"!@
M >W)S%;^&88]:M]7N+^^N[Z"-XUDG= "K8XVJJJ,8Z@ G/.>,;E% &5J&A1W
MNH1:A#>75C>QQF+S[;9EXR<[6#JRD9Y'&144_AR*5K2=+^^AOK9&C%ZCHTKJ
MW+*P92I!.#C;Q@8P.*VJ* ,3_A%K)M)U*QEFN97U(,+JZ=E\Z3(P.<;1@<
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M:2R>6A&0SA5)0$<_-CC/I2ZA?H\VBR6VL+;PW4XV*D E%VI0L%#?P\#.[VH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRW(C2:=C&8_E!P%,:*I.#SC)Z9Q2^)M>FT>?3H$DM+6.[D='O[P$PP;5W $
MKDMR!EAT[]*Z&BD,\UTH66IP>,5UF]5K*>ZA+W=O&T28*+MD4$MM7(4[B2N!
MG.*Z#PEJE[>7>HV<FHQ:O96I3R-2B0*)"V24)7Y6*C;RN.O/-=513$<OJ/\
MR4?1?^O"Z_\ 0HZP](U.QTSP'<Z'J#I'JZ+<0O8$9FGD9FP43JX;<""!@YKT
M2B@9Y_8AO#6NZ'/KTB00C1%L_M,K 1QSJ0S*7/ ) XR>=IK7UGQ8ENNFM87-
MG%:7LLD9U.[#&WBVC/JH;=@@'<!QU-=312 \K2>2Y\/?$*:2XCN-Z[A+%$T:
M2#R!AE5B3@C&#D@]0<$5TG_,Z^&O^P7/_P"TJ["BG<5CS&WM91XG3P4T9-G#
MJ#:IG'R_9OOJGT\TX_"O1[ZXDM;"XN(H&N)(HF=84ZR$#(4>YZ50M-%,'B34
M-9FN!-)<Q1PQ)Y>WR8UR2,Y.<DY[5K4#/,9M>FUS4_"<YU/3K@-?)(]O90ON
MMBT;861]Y&>HP54G!XX-6=9C:SUO4O#4(*IX@FAECV\ *V1<_P#CJ9_X%7HM
M%%Q6.,U;Q%-;:K>Z-'<Z=I<=M GD+<PM+)=[@<"%%=,X(VX&XD]O7&TG/_".
M?#S=G(NL<_\ 7*2O3** .$CU2717\;ZC!;&YDM[R-A'DCCRH\DX!. ,D^P-0
M6>HRZC\1-%D.JV&HHMI<KYMA R1J?D)4L7<,>AP"".,CD5Z%10!YAHNL:98^
M"=:L;@A;NXN+M8K<KA[LN[*OECJ_/R\9QCFM6QM9[/Q%X3M)R1<0Z+-&Y/)#
M 1 _K7=447"QY;H]I93>%_\ A'];\2WUI=*[0W&F 0"0MOW#8IB,C!LA@03G
M/6O40, #TI:*0PHHHH **** "BBB@ J.X0O;2HHRS(0![XJ2B@#S[X<^"1I&
MAL->T6S&HK<L\<DB1RN%P,889QSGO5SXD:!J?B#3]+ATRW\YX;Y99 75=J $
M$_,1GKVKM:* .3^(VC7^O>#Y[#38//N6EC94WJN0&YY8@5FZKX;U:Y\4^#[V
M&UW6^GQ!;IO,4>6<#L3D_AFN^HH XV70M2;XLP:V+;.G+8&$S;UX?+<;<Y[C
MM5.W\,:NWB[Q?=;/LUOJ5J(;6Y\Q?O; ,X!W#!]J[ZB@#Q";P+XC?PE_8L7A
M'3H[N%]S:C]HC,MP-W1>Z\'N0,#H#Q78ZUX;U:\\0^#+J"UW0:<!]J?S%'EX
MV=LY/0],UWU% '+_ !#TB+6/!&HQ2%5>",W$;M_"R#/X9&1^-8'PBL+E](O=
M?OV:2ZU*4 2-U9$X!_//Y"N\U/3;36-/EL+Z,RVTPQ(@=DW#.>JD&GV%C;:9
M8PV5G$(K:! D: D[0/<\F@#BO'VBZU?:[X=U+2--^W?V=*TLD?GI%GE2!ECW
MP>QK9L-0\0ZK#>V^I^&O[,4V[>6_VZ.;>QXVX4#'U-=)10!YUX?\,:Q8_"?4
M=$N+/9J,R3A(?-0Y+#CY@<?K5&Z\$Z]_PB'A>2TAC&LZ*YD-L\BX?+;L;@<9
MX'?')YKU.B@#S6YTCQ9KGC70-<O](@L[6TD(:!+I)'B'=F/ .>P7.,<UF:?<
MZW:?%3Q3/HVGP:@RA1+;23")F!Q@JQXX/7/:O7:SK30M-L=6O-4MK8)>WF!/
M+O8[\=."<#\ * .$TSX?ZE?:!XD?66BM]3UM_,$:OO6$JQ902/\ :/8G@"HK
MC2_&^I^%(O"4VC6MO$JI!)J1O%96C0C!"#YLG _P%>HT4 >?ZEX1OX_$_@Y[
M"#SK#28_*FE+JI4   X)R<X[9JWX=T'4['XB>(]5N;;997@402^8IWXQG@'(
M_$5VM% 'G?AWPCJL-GXRM;V%;8:K-)]F<NK95M^&.TG ^8=>:M^"[7Q-I/A:
M;1KO28[66T@D%K<BY203.2Q'RC[N,CK7<T4 8OA3^W?^$>M_^$CV_P!IY;S-
MNWIDXSL^7./2MJBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)+];C4(OL-O:"4VXB;?'TRQ.WD=> 3]*FL/%6BZG,\5I?!W1#(V8W4!1U.2
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M,]0ID8[<X&<8SQFH?">ESZ3H$45X%%].[W-UM.1YKL689'IG'X5MT4 %%%%
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M.:#2%6$[6>_]?@1ZOI<6LZ<]C/+-'%(1N,3 $X.<<@\5;BC6&)(D&$10JCT
MKC-=U'Q#H,UG=RZC;SI<3B,V:0  #V8_,?TKLYO-\A_)V>;M.S?]W=VSCM08
MTJL)U)>ZU)6O?MNNK'T5QDVHZYH_B?3+.[U"*]BOCAHU@$?E\XXQS^?H:CGU
M?7-075]0TZ]BMK739&18#"'\[9RQ+'D?A_\ 7IV,WCX*ZY7==-+[7[VV\SMZ
M*XX:_J.NWFGV&F7"6+S6GVJ>8QB0KVV@'CK6EX6U6[U&VNX+\JUW93M!(ZC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%0OWLX&[=+Z?>YKT"BBX6.,?PSJ">$M)CA$;:I97::C)&[X664LS2)N[9WL
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MM/4CJ.<8YJEX?T6:S\2SWEEI4VC:9) ?-M'F0K+.2,.J(S*N%7&>,YZ5U]%
M&7H,^L7%@[ZY:06MT)G"I"VX&,'Y3U/)^OY5J444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*(:I'F5]BL4<(&YPK-C"DX. Q&1S5O2_$>DZS<RV]A=B6:)0[*8V3*DX#+N
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M5"WUK3KNZ@MK>Z626>W^U1!0</%D#<#C'4CCK4MEJ-IJ!N!:R^9]FF:"4[2
MKKC(R1SC/:@"U17.Z;>R7OBG6YGFD%I8+':I&&.S=MWNV.Y^91^!]:E@\8Z#
M="!X+XO#,RJDX@D\G<W13)MVJW(^4D')QC- &[165<^(]+M-2;39)Y&O556-
MO%!)(^ULX;"J<CCD]!QG&15:'5X+*37;F]UCS[:RE&^/[,5^R#8#MR!E^H.>
M>N* -ZBL/_A+]"\S8;[!9=\1,,@$XR!^Z)7$O)  3<3D8JW:Z[IEY8SWD=T%
MAMV*3F9&B:)AU#*X!4].H[T :-%9ECK^G:A>FSA>=+D1^8(KBUE@9ESC($BK
MD9]*JCQCH;Q7$L=U+)%;!S/)':RNL6TD,&(4A3P>#R1@]"* -VBJ<^JV5L+,
MRS@?;9!%;X4MYC$$C&!TP"<GBFW^KV>G.D<[3-*X)6*""29\#J=J*3CMG&.1
M0!>HK+/B32%T=-6:^C6P=PGG," K%MN&R,KSP<XQWQ2V&OZ;J5XUI;S2?:%C
M\T1RP21%DSC<N]1N7/<9'(]: -.BLAO$^D)=) UQ(-\ODI,;>3R6?IM$NW83
MGC[W7CK69)JXT_QGK,EY=3+I]MID$S)\SJGSON8*,\X R0.U '5453GU6RMA
M9F6<#[;((K?"EO,8@D8P.F 3D\5!:>(--OKO[-;S2,Q9E5S!(L<A7J$D*A6(
MP>%)Z'T- &G16!IVLV]KI$UW>ZP;Y!=R0K*MJ4;=OVB)4498@\9 )/6H?$&I
MFY\*76I:7-.DMBPG*%7A?]V0S(Z, 0"N>".00?2@#I:*9#*L\$<R'*2*&4^Q
M&:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%(P#*5/0C!H \HU?PYK_ ,/$OM;\,ZFCZ7YGG3V%PN0!G''KUZC:< =:I^*-
M?OO%&L>&[&+3Y;FTO;(7<FFK=B 3L=WRF3T&W_)KL&^&6DR*+>74M:ET\,#_
M &>]Z3!@'(&W&<?C6IKG@S2-=AM%E26UELP%MI[1_+DB Z!3Z<>G% '%>'[+
MQ'X5;7[S^QI-+T<6$DT%H]ZMRL<R@$8.<\_,3Q_(5-X"\)Z?KF@6?B._N+R;
M699FE-X+EPZE7("]<8PO.0>M=EHWA2ST=YY&N[_49YX_*>74+@S,4_N]AC\*
MS+3X;Z38W6^UOM6BM/.$WV!+LBW+9!Y7&3T'4T <WIFEVWCOQQXD7Q#YL\&G
M2B&UM/-9%098;L*1S\OKW^E9FGW%U#X7\?:&;B2XL-.W);-(Q8H,L-N3V^4?
MKZUWVJ^ ],U/5I-4AN]1TV]E&V:73[CRC*/]K@^G:I[?P5H]IX:N]#MDEBM[
MM2)Y0^97)ZL6(//X8]J /,-2\/VUM\*=/\3QW%Y_;$2Q&.Y-PV8UW;0BC.%
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M5Z->?#?2+B]N;FVO=4TX79)N(;&Z\N.8GKN7!]3QTJ[>>"-&N_"H\.)'+:V
M96_<, ^0<Y)8')/?- '$>*+?[9XK\#6WGSP+-;>6SP/L<*5 (![9&1^-2Z=I
M5KX=^++:!IXECTJ_T]FEMC*Q7)!YY.<_+UZ\FNVNO".GWFJZ/J,DUR)M*7;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*-JM@?, I&3\W.<CCCG!/Q$W:?+JZ:CHBVZ2';ICR?Z4\8;;G=OX8\L%V'C
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M[FEFC+1Q1_=55164DDY_B  '>L^\\6:II\=_9R6UI-J=E=6L>Y=R13QS. I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1@GD8Y QD?2IYYI;?Q7:>();&^-A/8-:X6V>26!M^\%HU!8!A[<8 ;%=;12
MX"_L+S4-.\9:G#8W"1ZC:K#;0/$RRRF-&!?9C<,DX (S@=.E;&O6EQ)+X7,-
MO*_D7\;2%$)\M?+<$G'0<@5T]% '&V$MQHL^O6-SIE[<37=Y)<6S0VY=+A9
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M5QFLV(L8?!FCPG>\%_"%R>JQ1-N/Y5V=(84444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,.;PTIO+RXL]6U&P^VD-/';-&59L;=PWHQ4D8'RD=!6GI]A;:780V-G$
M(K>%=J("3@?4\GZU9HH *;(BRQM&XW(P*L/4&G44 <Y%X.MDM8+&74M1N-,@
M8-'8RO&8\*<JI8('95., L>@SFNCHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** *,NE03ZS;:I(SM-;1/%$A(V+O(W-C&=W &<]*O444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %5[V&XGM62UNOLT^05D,8
M<<'."IZ@]#@@XZ$'FK%13W5O:B,W$\4(D<1H9'"[G/11GJ3Z4 9-GHEU_;8U
M?5+Z.ZN8X3! D%N88XU8@L<%F)8X'.<8'2L/P/I,46LZ_J,3N]LMW):V8;I&
M@8O(%]O,9A_P&NRN+F"T@:>YFCAA3[TDC!5';DFDAN[:XEFB@N(I9(6VRJCA
MC&<9PP'0X]: .?;PAN\(76@_;O\ CXF>7S_*^[NE\S&W=SZ=:U+G2?M.N:;J
M7G[?L4<J>7LSOWA1G.>,;?0]:TJ1W5$9V.%49)]J ."\/Z1J>H:#J$$&L"WL
M[J]NTE1K??(@\YPWEON&W(]0V"<CTKH+WPV3)H\VEW$=I+I2-% )83*AC9 I
M!4,ISP.<]JU+/4;74--BU"UE\RUEC\Q)-I&5]<$9IUA?6VIV$%]9R>9;3H'C
M?:1N![X/(IB,N;1+R+6)]3TJ_AMIKJ-4NHY[8S1R%>%8 .I5L$CJ01CCBJK^
M$$;2$L_MKFX:_2_N;EXP3-('#'@$!0<  =@!UKIJ*0S,.D9\4#6O/Z69M?)V
M?[>[=NS^&,4NC:5_9,5VGG>;]HNY;G.S;MWMG;U.<>M:+$*I8] ,FJ^GW]MJ
MEA#?6<OFVTR[HWVE<CZ$ T 9^E>'HK#0;C29Y?M,,[SM(=NS*R,Q*]3V;&:;
MINDZMI\=M:'6(I+"WPJ+]DQ,R#[JL^\J>, D("<=CS6W10!S8\/:G::CJEYI
MNM1PG4)?,:.>T\U8\(J@KAU.[CJ21TXXR5_X1&*VL-+BTZZ:WN],9F@N)4\S
M>7_U@D7(W!LDG!'.".E;5C?VVHP-/:2^9&LCQ$[2/F5BK#D=B#5F@#%L]"D&
MI7&I:I=)>7DL'V9?+A,4<<6<E54LQR3R22>@Z8K)/@R^?1[71WUP?8+.6-X%
M6T D*HX95D;<0V ,94+S@\]#V%% &;!I7D^(;S5O.S]HMXH/*V?=V%SG.><[
M_3M64?!ZG29[07S+<'4'U&WN%C&89"Q9>"3N S@],@GI73T4 <_%X?OI/$5G
MK-_JJSRVT4D0@AMO+BP^.0"S$'CG).>, 8Y3[-/?^.?M$L4JVFF6VV$NA"R3
M2_>*D\':H R/[QK774;5M3?31+F[2(3-'M/"$D YQCJ#WJU0!G:]I?\ ;>@W
MNF>=Y/VF(Q^9MW;<]\9&?SJ/5M$35--@M_/:&>V=)K>X503'*GW6VG@CKD=P
M3TZUJT4 9MM::F1-_:&HP3!XRB);VIB49[G<[DG\0/:LB/PA+;:?H,=KJ*"[
MT92L<DUOOCDW+M)*!@0?0AN/?-=310!Q&N:)-I?A/Q;=W%]]JGO[=I)"(A&%
M*Q[<*,GCCC.3ZD]:T8?#U[>?V9_:6JK=65DZSQ1"WV2.ZCY#(^XAL=>%7)P:
MZ:B@#G=0\.WNJW5L+[4X9+*VO%NXT%IMF!4DJOF;L8!XR$!(&,YR:>FA7]A>
M7CZ1J4%O;WDIGDAN+0S%)#]YD8.N,\'!#<_E6_10 V-2D:(SM(R@ NV,M[G
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M9&LWDDC0X\PPNJ/UY1F #CCJI(K,UG4]3B\1:7I6G26D/VN*:1Y;B!I<;-N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img57592461_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_5.jpg
M_]C_X  02D9)1@ ! @$"6 )8  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M      #VU@ !     -,M2% @(
M                            $6-P<G0   %0    ,V1E<V,   &$
M;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960
M  -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E
M8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (
M#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#
M;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M    $G-21T(@245#-C$Y-C8M,BXQ
M                                  !865H@        \U$  0    $6
MS%A96B                      6%E:(        &^B   X]0   Y!865H@
M        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M   6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z
M+R]W=W<N:65C+F-H
M                 &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L
M="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                  !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#
M;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E
M(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                    =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #
M7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M               "CP    )S:6<@     $-25"!C=7)V        !      %
M  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '(
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M6 5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP;
M!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(
M;@B"")8(J@B^"-((YPC["1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]
M"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,
M7 QU#(X,IPS #-D,\PT-#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;
M#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1
M,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E
M% 84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86
M^A<=%T$791>)%ZX7TA?W&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ
M&E$:=QJ>&L4:[!L4&SL;8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=
MPQWL'A8>0!YJ'I0>OA[I'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U
M(:$ASB'[(B<B52*"(J\BW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@E
MER7')?<F)R97)H<FMR;H)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0
M*@(J-2IH*ILJSRL"*S8K:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN
M@BZW+NXO)"]:+Y$OQR_^,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&
M,W\SN#/Q-"LT932>--@U$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% X
MC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@
M/B ^8#Z@/N _(3]A/Z(_XD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#
MP$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI
M2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0
M)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I
M5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=
MR5X:7FQ>O5\/7V%?LV %8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I
M93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=L
MKVT(;6!MN6X2;FMNQ&\>;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P
M=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\
MX7U!?:%^ 7YB?L)_(W^$?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'
MA:N&#H9RAM>'.X>?B 2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.
M9H[.CS:/GI &D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=U
ME^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA
M1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"
MJW6KZ:Q<K-"M1*VXKBVNH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.U
MBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_U
MP'# [,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+
M-LNVS#7,M<TUS;7.-LZVSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95
MUMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB
M4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH
M[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?Z
MY_MW_ ?\F/TI_;K^2_[<_VW____N  Y!9&]B90!DP     '_VP"$  $! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @("
M @(" @,# P,# P,# P,! 0$! 0$! @$! @(" 0(" P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __  !$(!.T+-@,!
M$0 "$0$#$0'_Q $+  $  P$! 0$! 0$         "0H+" <&!00# @$!  $$
M P$!              4#! <)!@@* @$0  $#! $! P,-"@<)"P0!)0 #! 4!
M @8'" D1$@H3%!4A%K875W>W.%AXF!D:(M35=C>7&+@Y.C'2([66UM=!,C96
MB*C866DSLR1UA\=(R.A)>5$TM"55)F%"DM,U)Z>I*E)#4Y4H\'%BLD149)3G
M:"F)R8)C=(1EA49F2A$!  $" @,)!A$*!0,#!0    $" P0%$08'(9$24A24
M5@@8,5'2$]-507&QP>$B,G(SM-05=18W"1GP8:&R([-T-39V@4(D-!?18I/Q
M@CA#4R65*?_:  P# 0 "$0,1 #\ O\
M
M
M
M
M
M
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MXPC(5XUPC>V<WKNX=ZE5LNJM9>U=.@G/
M
M
M
M
M
M
M                     .=>6?*?3?"GCMM3E!OW)+<7U;J3&U9^?>666KR4
MF[6<-XS'\6QYC<HEZ3RC+\B?-8R,;=^RB[YVE;==9;6Z^T,HG=J/+WKS[1ZA
MO4UV51WAFDN*.D\FS9"OFR\ABV#8Y 5>6Z1XT84\NM9-I+)'OI!:4F7M++*7
MVV2$@M8DN]:-U0F-\$)\9OG/[Q&LOA DP-',#*M\6/R<S'E-U<%.-.+.G^0X
MQQ=Q+ M*X)BL=6JK1_M/9\= Y[GLA'(75[UV03$GDT1 .J]MMMU<>0MI3[BM
M]X:(G3"Z=>ENF7Q*UKQWU3C&/L\F9XW 2&[-B1\>DG/[>VW=%I5R[-<AEE;*
MRD@T4F5W"<0U7543B8JB+-#NIIT[0]JYD\.-!\\>/N><;>1V#QF::_S>,<(H
MJN6R/I[#<CL;KIP>=X1+W65=X[F.,NUO+M':%UM:_=(JT4;JK(J!EV]%?8V?
M=*+K]X=H+.)OS=FMO_/N!&Z?).%HF&R=ME68.=<XO,WTHJ[;VPK?:T7CT^WN
M5JJE5LWI_*V6W^6M#6V
M
M
M
M
M
M
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MW5NN;.+V+VRMZ=:UK9=VT_N ?4
M
M                                 >=SFWM38QED5@62[0UWCV<SJD8C
M!X7.9KC43EDRK-/+HZ&2BL<?R;>8D5):0MJ@VM11OJNM2MEG>N]0#T0
M
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M8E6P^MNJF+OT87"9GE]W$W*HIIHHQ-FJJJJ>Y%-,5S,S/H1$:9?=GRY"
M
M
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M<Q?YMMR/>9!-KHH-U9!PR@]A1<2V4O1;V6]U!NDG]S_>]O:!Y7]F\Z)7R",
M_.%O'^U$!]F\Z)7R", _.%O'^U$"HIXL3IE\%^G[K_A1+\/>/F/:1DMG9CO"
M-SMU!Y'GD[=D+'%X36;J ;N;,RRO)$FUL<O-NKK:M[4KKJK5[];J4M[ T*N)
MOQ6.-'S?]-?!UC@'0
M
M                        &>'UPOWKWI8>^!TTOUP)@#0\
M
M                                                    "#OKM_%W
MU![]"7L'RPOL!\+/O?7AT"^\*^S/)/IV/BF(5:R6:C@     .K>"WQR.,OOT
MX#_/[0HXCX"KWLLP]7W[<-5/IW!_OJ5ZL@7H-   "GCU,_%B_5T\XM[\,OT!
MO;B]I.1PIA[9'Z4WM?>N;UX:TPO8GE?6?^CEF_H;T=Z[_,^[Z4=^6\W\KVV>
M4\E8'"/VYS_9=_Y[/_9' ?;G/]EW_GL_]D<"6O@_XM7IJ\L\^B-5;09;&X?Y
MIDLNTA\7F=TVXX^U',/)'R23%F\VAC4JY;8>[O>=^Q1:?8142E95*[SZMRER
M:06C45D7"*3ANJFN@NG8L@NC?:JBLBK;2]-5)2RMUBB:EEU*VW4K6E:5[: ?
MZ                  #X3:>;>UIK'8VQO1GIKU@8'E^;>AO/?1OI;UJX_(3
MOHSTCYH_\P\_\P\EY;R"WDN_WO)W]G=J%8KH^>)P^M?YA-N)_P"A)[0GG&LL
MXV+Z_OTDO;2[GK-NAK?0_K6]H/7/>])>E_\ SCTE3R/D_P#<K^]Z@6L *4_5
MJ\71CW$[=^=\:."FGL&WSF.L).1Q7/=W[0FYE34;'/8E=1G,XQAF(X1)0L_G
M[#'GUES9[*73L.A<]062;)N$*6/+PY;Z7GBN.H/S3YU<<^*.S>._$2_'-Z[(
MQ_"7TUK/']SX;D>*PU[GTMEN2(JY1N'9D;,*1>'QC]1!K<U;6U<T3OO6\G;=
M9>%_P        !YGNK8OM/Z;VUMOT/ZXO:MUEGFQ?6_Z0]$>G?63BTKDWH?T
MKYC)^C/2?HSR'G'FSCR/?[_DE.SNU"LWT?/$X?6O\PFW$_\ 0D]H3SC66<;%
M]?WZ27MI=SUFW0UOH?UK>T'KGO>DO2__ )QZ2IY'R?\ N5_>]0+6
M      *HW5\\3Q]5-S'E.)?Z$/M\^C-=X+GWK_\ TE/:N\OZ]&S]QZ)]:OM
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MA4JG)1USIK6RU_$R2%UJ,C!9!%J7T3>1K]%L_9*U[BZ*=_W('M@
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M.VH:](     40O'%_DMZ=GX_\C_8[IX"Y[Q-^*QQH^;_ *:^#K' .@
M
M
M ,\/KA?O7O2P]\#II?K@3 &AX
M
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MCI2*DFR3V/D6#M"Z]!TR>M%K%4E++JV7V74NI6M*@?H@
M #/A\<G_ (6=-7\7>6/\Y<=@/;_#V]"OI6\XNESIKD7RCXM^VAN3*\SW+$S^
M8^W=R,PKS^/Q3:&38[ -_6]KO;N)8JU\PAH]%'OHL4[U>YWU*WWUNNJ$V/V7
M'H4?(9_SF>8?^D$!";U@_":\4L)XN;AY&]/7VR->[+TSC.6[1?:1R#,)#8^$
M9[A&.HN\CR+&<6?99>\SN$RN!QQNO=$7+2DGZ1\UL:+)7N7%'EH1]>#2YS[
MU_S"V'P,FIM_):=W_@.5;-P_''"ZBS3%=T:W8Q\B_F8=&^ER;!'+];LWR,I2
MSN^<K14=6O\ N/JAI:@8V'4D_;[\H?\ Q(9KX:&@&R>!F3>-?_:0\:/F18I\
M/&^@)P^D;X>GH_<GNFKPWW_O+B)Z^-N;6TS"Y9GV6^W[R?QKT]/NWLBBX?\
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M8X!T
M
M           !YW.:AU-D^616>Y+J_7>0YS!*1BT'FDYA6-2V60RL*\ND896*
MR-_&.)B.4B9"ZJ[:Y%:RJ"U:WV=V[U0/1
M
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M1^XL+TSZ^8!>/@LWG\1Q" S9DP:X_G:R='][9VDJZ1N<WMUUW?DO.EPUZP
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MK'?\HL&T(C%676W^6LN_1XS]DP[;J]O?[;O[VM* 7J0
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M9^/_ "/]CNG@+GO$WXK'&CYO^FO@ZQP#H
M
M
M
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MM-Z[>NVEZGK4QIUJ^7P_.,KD815SY-Y+N9FC-\NA95NR01I?YP'L7,#P@?3
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M&M5WB-$':\;D#KSBU%-DZN;M'07/0,;#J2?M]^4/_B0S7PT- -D\#,F\:_\
MM(>-'S(L4^'C?0%V/H(_L<>GI\W?'/YQEP)=@ %#;QQRL=;KSIQH*W)TEU,S
MY.JL;:TO\M='(P>CK)2ZRZE.Y1.URX9TNI6O;6M;>S^"O8'!O&E*53\%QU";
MI#_S1;E_A2L%]RK;V15.1G!Y%;U5++;+_P#UVD\]5.MUG]SM[U+J4#2[
M%>KKH=?+5O2&QG&->8EB<9NKEYLV#NR7#-72,HXC,3PC":O7D4CL?:#Z-_\
M6](B0EXYRVBHMG5%U++,W/\ PAHDC56X*JC+JU^+AY1,F^T-"Z:WGBFNYOOR
M<$MJ3@#BDEKZ5CI*M+V=<8R/<NJ=D2F0Q3*UO?:DNWE7=:>4KY96^M;.P/1-
M0^*"ZQ? [:F,8=U7>*F199@LTXM;RJ.?:&E.+F[KXUC<FWD\BUX\M@,3USEG
MF=KM-S>U4A:-7W\FFF^8V*T7H&@AQOY#ZFY9:*U=R/T9DZ.8:GW!B4?F.&3R
M2=S995@]\HBZCI1BI6J\5D$!*-UV$DR5[%V,@U6;JTHHG=2@>V
M              %$+QQ?Y+>G9^/_ "/]CNG@+GO$WXK'&CYO^FO@ZQP#H
M
M
M    "C9U?.<?,/4/B4.G)QLU=R6W-@.@=C9MP!99YI[%<\GH;7N7,\_Y12F+
MYLVR#&&;M*,DT<JQQ*UD^M53NHX;6T3O[;?4 O)@
M
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M(UP&[$=4.9&K#U:]K3VT7&24K_!_+T4_^K4+6X
M !1"\<7^2WIV?C_R/]CNG@+GO$WXK'&CYO\ IKX.L< Z
M
M                                                    SP^N%^]>
M]+#WP.FE^N!, :'@
M
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MOWYE4?/S36+S&[&I*QM)Q;G)9?,$8B*;O;47E8J.9WN4FRUZC=$-/_+]4O\
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M31^ZONJUCY'9<YVP$,VI52ZQ5[Y2U*YLT<53#8Z QL.I)^WWY0_^)#-?#0T
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MY)LD@L&N]ZT<6]:?K#];L+ZR?6[ZT?6GZ.:>M[UK>C?0WK=]$>2\Q]"^B?\
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M/Q_Y'^QW3P%SWB;\5CC1\W_37P=8X!T
M
M                                      !GA]<+]Z]Z6'O@=-+]<"8
MT/
M
M       @[Z[?Q=]0>_0E[!\L+[ ?"S[WUX= OO"OLSR3Z=CXIB%6LEFHX
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MSB+8QDZ_ADUV[Q;$M?XNS<2+/6^!NI)HDZ78IO)!\]<))5>OW=K9I:W":T
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MM1GA^U&SY-K8O(M\50<.;X/9;!G7OW><0#M]?8A;Y1RBVK6J=H3$@
M                  !1"\<7^2WIV?C_ ,C_ &.Z> N>\3?BL<:/F_Z:^#K'
M .@
M
M          ,\/KA?O7O2P]\#II?K@3 &AX
M
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M#X?.,'>HO6;L7L5,T7*)X5-415?JIF8F-.BJ)COP[.*#.8
M
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MT?-_TU\'6. =
M
M                    0C\M^AAQZY@=1WCOU*\WV[N;&=K<<)K0LWBV!XJI
MA%NO9UQQ^V<ZVEC24_9+XI)9)5&:F'56[[S=\A=5M2GDJIW_ '8$W
M
M
M
M                                           ?XN6S=XW79O$$731T
MBJV=-7*5B[=RW7LN270705MN26162NK;?9=2MMUM:TK3L A^WGT .CER+R%[
ME6S.!>H49^3E5IR3?ZOD,_T-Z2E7+9)L[>R+71.9:W9OE'ODO++T53OM7=WJ
M.5*7.%5%;@_YT?X?WHW\>)YID^M^!.GW4VPDTYE@\VF^S[?EK"21:JM&[IBS
MWOF6R6+.YI17RR-J:5MB+NQ-S92UPDFK:$P+-FTCVC5@P:MF+!BV09LF3-!)
MLT9M&R5J+9JU;(VV(MVS=&RVRRRRVEMEM*4I2E* ?T
M   S1.ESM?3'$WQ2O-F3YXS4#@V49-M[F7AVK,^V&I9&X_C^ZMG[L83.$Y*I
M/OD6\;CL=GNI74S'Q;YQ5JTO2G6Z5+DZ+V6@:6Z*R+A%)PW537073L6071OM
M51615MI>FJDI96ZQ1-2RZE;;J5K2M*]M *@GC%^0/%V'Z>,/QTS/(,.G>3N9
M;@UWF>G<&15C93.\+B\;</[LRV2\9V^5D,5QM[BCIW!V.5:H5D5Y.B2-%K$G
M-40E+\.3BFP,,Z*7 B&V6D[0R5QKG-\E8I/:*47MP7-=S;*S+5OW*B+>^U&[
M6,]#U2IW>RB5;:4NNIV75";0#RK=&C--<C=>S>IM]ZNP/<.M<C3[DQA.Q<8B
M<LQYTI:DLD@^LCYAJZ2:2K&B]US5XCY-VT5KY1%1.^E+J!S5P%Z=?&SIJ:ZV
MIJ'BK#Y-B^K]I;SR3?5^&9#DKK*V>%9%E&$Z\P5_C>(2LJFID?K0;Q^MVBS=
M*4>2;Y-==?M=7)5232#NH                        HA>.+_);T[/Q_Y'
M^QW3P%SWB;\5CC1\W_37P=8X!T
M
M
M
M
M
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MZ=GX_P#(_P!CNG@+GO$WXK'&CYO^FO@ZQP#H
M
M                                           "O#SAZ]?Z&?5>XK],
M']%/VR/TF,@XTP7MW^WGZS_65^D1N!YJCSKVM/:=RGUR>L_S3S_N>N!AZ0[W
MD.\V[/+5"P\
M
M
M
M                                          'C^_\ ?&K.+^EME\@]
MVY2TPO5.I,2E,SS;)'=BJ]&,1%I4KY%FS;VWNY.7DW=Z;1BS0MO</7JZ2"-M
MRBEEM0S'N??BJNI)S&VL^PCA1*9!Q/TS)3E<=UYA>M(2)R7D!GR;E[YG!OLL
MSBL5.3$=ELU??;<G$XGYB@TN6HUJO)7I4>+!Q4[Y'>)7XX0Z>\\TV+UDL%P>
M&8*OU,YW?9R[E=3HQKR+<NZR$I[<3*6UNZ:5BDU'*2SI)2U--.JR=UO<[] L
MQ=#3Q6&<[\V[@'#WJ3)8I=F6S)J(PO4O*+%86,PIE-9Q+7MXZ#Q3<N&PZ33%
M(Q[F,RK1NRFX-M&1Z#Q9!NO')I7WOD@O: <*]1?J$:$Z9G%_,>3^_P"2<W0T
M,HC X3A$,HV]=VT]B2K=TKCN XBW<WVI72,E1FJNY<*?R$?'MW#M;^31NI4,
MTSDAXBKK5]1S;<A@W&G+-HZ;@\H46CL&X\<*<8GGFP4F+QPC&M;JY_BD(_WA
ME&5N;G3=)5TR>,&E7E]+F;%E52B8'.\UST\17P*EH;8.X-Y]4/2]91PV9P:_
M+UKOB<PN8=MW-))%JQQ?E)#9%@TLYOOC+O*66LE;EF]BJ5]+D;E;*A>.\/GX
MAUKU2U)GC3R4Q_%-<\QL*QE3*(AWB5KF-P3?.%P]K1K.SV-Q,D]?N,<V!CJB
M]CB6AK%UF[AHI<_84L;I.VK +2X     40O'%_DMZ=GX_P#(_P!CNG@+GO$W
MXK'&CYO^FO@ZQP#H
M
M                       #/#ZX7[U[TL/? Z:7ZX$P!H>
M
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MW);2^3[%E,ACZ.JOX&.PF$S5]DKZ:8T8K>6:I-KETO(W]ZVG<N[ Z_
M
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MO="_$     %$+QQ?Y+>G9^/_ "/]CNG@+GO$WXK'&CYO^FO@ZQP#H
M
M
M#/#ZX7[U[TL/? Z:7ZX$P!H>
M
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M>[E?P#Z% N/@               ,@7H[_O$O'7YYFW/]XV<!K]
M
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M.L< Z
M
M             SP^N%^]>]+#WP.FE^N!, :'@
M
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MHP.!;#NC<?>1.6R]Z=%&L)-,&M55%DV;)]).JTI>%H0
M
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MX@V\C5[(/:7IQB\PZN3[M+>RJUW;V@:!'$WXK'&CYO\ IKX.L< Z
M
M
MII=5'I2<^N2'B#N G.'2^A?7GQ=TIF'!V5V;L_VT=+X[ZV6&G^2$EGVQE_65
ME>Q8+8<SZW<3<6.^['Q+N]WV^2:T66I5.@7+0
M
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M;+,&80LG YI*4JW;>4D\QP#)(AZ^7LI<BM*7N^[=VVWV6!.:
M
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MWVW5[;*4M"F=U:,'<<&.O-R1FYZ D;X3$^:L7REBHM!&Q"LSAVQ,T@^1#!I
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M:^#K' .@
M
M
M
M                     (8NME^0/5'OOI^PS* *T@      .GN%7QM^.7OP
M8-_/C0"ZT    ,B?Q5'[<7EM^+O&_P#5HU*!-!JSP3/MEZQUSL;ZS+T+Z_\
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MZO\ =IW?_(!>6
M                                   #\'*<HQW",8R/-,OFH[&\3Q"!
ME\HRC(IATFRB8''8"/<2TW-2CQ:MJ+2.BXUHJNNK?6EJ:2=UU?4H!G8<^_&;
M\@YS8^0X?T\-4:YP+44%+O8^(V]N?'Y;-=D;":,72R+7)(O#:RD!B^O8.81_
ME+(^0;3,CY+R=ZBS52Y1M8$6WVL/K9?*'UW]'C2O]30'VL/K9?*'UW]'C2O]
M30'VL/K9?*'UW]'C2O\ 4T#3.Z9&\-B\ENGMPVY ;<EFD[L_</'G6>P<\F6,
M5'03.3RC)<<9R,L\;0\0W:1D8BNZ6NNM102L2LIZEM*4 [H        AVZXW
M2\8=5K@SE>C81Y$0.\,%ET-J\><IFZJ(13+94#'2+#UL3[YO;>Y9XOG\#).H
MIXM2U:QDJNW?517N9V)7!FH<&NHOU&?#Z\F=H:Y6U\[QIVYDVL-OGBQOF'G6
MN+9$YA7"B$;ED,I%2,>XB\@MCKEO0N3Q#EW&23)=-6ZV39>1MJ%@G*?'';#=
MX@NRPGIQX9CV?7,FZ;7)<IY.SF8X@C(VV64=.E\'B='8+-.62RE+JIH6Y"E>
ME;6E*K*5IWJA7]P;7W4V\2CSYNGIIQ(YSE<JI#Q6:[)5A'T/H/B_J9!XZ7:1
M[=!O<M&XQCL4BL[6C8=-=:9R"1N64K<[>+.G-0UB>$G$;6'!'BMI7B=J!"ZF
M$Z:PYKCR,HNU0:2.5Y Z<.9G,<XFD&]UZ-DYFV6R3V4=VVW766+N[K+*]RVV
ME K4>*0Z'^?<],/Q3FGQ-Q-;+>3FE,24P[86KX5OW\@W7I]B]D)N*OQ%HC9W
MIG96O9.4>7-6/9YS-1CQ1LC=>Y9L&C@*K?2L\2IS3Z56$V\9LSUS!\D- 87)
MR+7']4;'F)G7FQ=3/_3M[K(L9Q#8#>'R!Q"P:SU9]Y:)EX24M8OE+;VWFUEB
M[=P'=W,3QH7*_=>K)W7G%CC'A7$C(,HC%X:3VM*[4D=ZYYCS-XDZ2=O]<]NO
M-3XUB^25LO2M0?/V$U1K;16])*UQ<@NV#][PL/1>VWN?D9B'4^Y1X;.0NDM6
M/ULZX_I9\T?IS6^=ROZ.5(3:4:A)VTD)#!M=.U[Y=":4NM3DLCM95:7N;&S_
M ,F&DN     %$+QQ?Y+>G9^/_(_V.Z> N>\3?BL<:/F_Z:^#K' .@
M
M
M.5MC<Y.'FH-W87QLVCR6TS@._MCNL098'I[*L[@H;867/,_GE,7PEM 8R\=I
MR<DME61I7,F-J=EU7#FVJ=G;=Z@'5(
M
M                                  0Q=;+\@>J/??3]AF4 5I
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MHHDHG5_KW6D+$:W8RO>4[O>\XSR*R-*VEMM;:I-[+Z77=_LM"W(
M
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M1;HI-VZ2:"""=B*""-EJ2***5M+$TDD[*6V)IIV6TI;;2E*4I3LH!_H
M%$+QQ?Y+>G9^/_(_V.Z> N>\3?BL<:/F_P"FO@ZQP#H
M
M                                                  #/#ZX7[U[T
ML/? Z:7ZX$P!H>
M
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M#8G#I7)QT#C..1Z$9$QZ%5+E%U[DFK>WRBRMZBZZM;E%;[U+[KJAZ$
M
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M_(_V.Z> N>\3?BL<:/F_Z:^#K' .@
M
M                                    ,\/KA?O7O2P]\#II?K@3 &AX
M
M
M    $?O4/XI;#Y;:QPG"]<3.%PLIC>=VY0^<9M(SD;'JQ]N/S,35%HK!8[DC
MA1YYQ(V7=V]).SN4NKW^VE*5"(;ZE;E-_C]H#^E.Q?[*P'U*W*;_ !^T!_2G
M8O\ 96 ^I6Y3?X_: _I3L7^RL!]2MRF_Q^T!_2G8O]E8#ZE;E-_C]H#^E.Q?
M[*P'U*W*;_'[0']*=B_V5@>Q\>NDQR,U-O+4^S,CS32CV!P3/,<RB7:0F1YT
MYEW,?#R2#QRC&H/M<1K-9Y>DG6B=JKA&RMW\-]M/5 L,
M
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M/EI/+F.;1V-LV\^VR.17=OUGLND_LOHNK<NK6^_MKWJ_P@=X
M            %$+QQ?Y+>G9^/_(_V.Z> N>\3?BL<:/F_P"FO@ZQP#H
M
M
M  #/#ZX7[U[TL/? Z:7ZX$P!H>
M
M
M
M                                           !YSM?<&J-$8+-[/W7
MLG!M2ZZQM'R\[G&QLIA<.Q:*LK2ZJ=KR;GWK"/267K96U)/RGE%;_N;+;KJT
MH! YL_Q4_16UM.+P#/DGE>SG+12J#U]K#2NU)F#;KVW+4O30GIW&,:B)A.VB
M=MWEH]9VWNHK;W5+JTOI8']>K?%.]%79TTS@'')W(-9/Y!:K=DMM+3.U\>A;
MUNVWNT>9-%XI/XU"HJ65NNHL_=M4*=RM+K[;JV6W!.YJS;6K-XX/";-TQL?!
MMLZZR5&YQC^=:XRN#S3$IE).^J:U8[(,=?2,6[N;JVUL4ML5K<DI2MMU*74K
M0#T(                         40O'%_DMZ=GX_\ (_V.Z> N>\3?BL<:
M/F_Z:^#K' .@
M
M                   ,\/KA?O7O2P]\#II?K@3 &AX
M
M
M
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M?-_TU\'6. =
M
M                   >,Y5QRX]9WL+']MYOH?3.9;6Q-:#<8ML[*M7X1D.P
ML:<8Q)73.-+X_FDO!O,DAEL>F+ZNV-S9RG<T<UJJE6R^O> ]F
M
M
M
M
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M"\<7^2WIV?C_ ,C_ &.Z> N>\3?BL<:/F_Z:^#K' .@
M
M
M
M
M
M
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MMZ=GX_\ (_V.Z> N>\3?BL<:/F_Z:^#K' .@
M
M                                           *-G5\YQ\P]0^)0Z<G
M&S5W);<V Z!V-FW %EGFGL5SR>AM>Y<SS_E%*8OFS;(,89NTHR31RK'$K63Z
MU5.ZCAM;1._MM]0"\F
M
M
M
M                                   %:/K#>&AXN=3G)YS?VN,G4XQ<
MLY1DG;.Y["0*,]KG:[MBA8BP<;4P=%U%.;LB\W1L:^GXQT@^\CW:NT9'R*"=
M@4^-G>#^ZP.#2CAGAT/QUW/'6.[4FLO@>ZFL%8NT4HYOL=KLMJP&NG;:Y&U&
MRU9.E%:VJ+6T3JK92]2T/[]3>#VZNF>R[1KGR''/1L/<YNM?R^;[@MRA=NT3
M\G=>NRB]58_GMSYRM;==1%)19M;=?;V**)6UI>!<?Z._AON*W2RFV6[\GR-Q
MR7Y:)QSEE'[8R7'F^/8CK)"4:6MI=MJ3 ZOYRL/*NT%%6J\\^>.Y19I?>FWH
MP1<.6ZH6-0                        !1"\<7^2WIV?C_ ,C_ &.Z> N>
M\3?BL<:/F_Z:^#K' .@
M
M                          ,\/KA?O7O2P]\#II?K@3 &AX
M
M
M
M
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MXF_%8XT?-_TU\'6. =
M
M                          9X?7"_>O>EA[X'32_7 F -#P
M
M
M
M
M     @!Y.^&BZ6_+O?NT>2FY\-W%)[2W!DRV6YH^@]PST!$.)=9JU95NCX=F
MU\V8-K&S-.VEEO;_  =M:UK6M0)9^1O&W2^_.+6PN+^Y5'[;1N<:]0UWF-S?
M)*8W(68@UL8(4LID]]*5C5KDV"=MSCU+O5KV5I6O:! 1!^$WZ(^3M%'^-8[M
M[(6"+F]FJ]@^1LU+-$G::2*RC51RPL<(V.;$7"=];*W4NI;?;7L[*T[0_9^R
M*=&CW/\ >_Y^,H^]0'V13HT>Y_O?\_&4?>H'P.PO"T]!C4D19D&UG&<ZR@%+
MEK$YO87*E;"XB^]LC<Y<6V262+QK*ZYNWMJI?2E_;992MU>RGJ@6(N'^#:$U
MCQ?T;K;B[E<+F_'K7^NX'"=1Y5CV;1NQX>8PS%F]8.,6:9S#NGT;DWD:,;DE
M'22M]+E4[J5KWJ5H!TB       !"/UU>E7MGJX\9M><?M:\C8/0K#"]KL]I9
M%'9%@\KE4-L5W&0$OCD#'R<I"Y-"OX)IC:.2/WEB56<DB]=U0K=:A<A8M0/B
MN@;T9T^D/Q_V3CFQW^LM@\D-K[(FY3,=M:_2F7+9WK"&N08:QPEB_P FQ['9
MR/9,6J+B5?L:)7H)R\FO9:X=)HH+ 3V@9+'BQL8TYC'61VS34K3'X^5R#5FH
M\GW0RQWS--NGN.7A7MTN[DF3&EB#+()K#48.0?\ ;;19TZ=WNEN\LX4ON#4J
MXHM\X:\6^-C79MK^S9+;06G&^PK)5-=*3MSA'7>.)Y9;(I.4TG*3^V>M<46M
M4MMOM4[:74I7MH!11ZH7AO>IUS4ZK>S>4,RSU=GW';=_(C6J$E+X5MR+89]@
M7'!M(XKKZKQSC>QHW"6_KBUYJ>"M=/&,<O(>5<)7)L:OE+J4O"_IK36V!:<U
M[A6J-6XI"X+KC76,PV&X1AV.M+6,)C>,8^Q1C8>(C6UM:]QLS9M[;*5NK=??
M6E;K[KKJUNJ'TDW"0V2PTMCF1Q,9/X]/QC^$G8*;8-96&FH:5:JL92)EHM\D
MNQDHR28KWHN&ZUEZ2R5]UE]M;:UH!CL<C]8Q' /Q ,W@/'"CF&@]$=0?7$QJ
M:*:.>ST#'.MDXAFD%A*"W=NJO%0:$U2&I8M16JS1'N+^4K=?W@V.@     HA
M>.+_ "6].S\?^1_L=T\!<]XF_%8XT?-_TU\'6. =
M
M                                                9X?7"_>O>EA[
MX'32_7 F -#P
M
M
M
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MZ:^#K' .@
M
M                ()>8O0GU/S$ZF?&SJ99+O?8F&YSQMG./<Y":R@\;QI_B
M>2J\?-J.]J0Z$K+OU+9AHGD,@ZJT<U1I6J2-.]9]T!.T
M
M
M
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M@6-0"TVWBEI%Q>VL<U5M0N74K92VM]W:%\3B;\5CC1\W_37P=8X!T
M
M
M
M
M
M
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MCC1\W_37P=8X!T
M
M                     !7AYP]>O]#/JO<5^F#^BG[9'Z3&0<:8+V[_ &\_
M6?ZROTB-P/-4>=>UI[3N4^N3UG^:>?\ <]<##TAWO(=YMV>6J%AX
M
M
M
M
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MO3L_'_D?['=/ 7/>)OQ6.-'S?]-?!UC@'0
M
M                                         &>'UPOWKWI8>^!TTOUP
M)@#0\
M
M
M
M                     %=;Q5L!)S?1#Y3.HY#RZ>-Y7QXGY2VVM:JIQE.0
M&MX91=).VVZY7R+J91N4_@I8C2^^M>RVH'AO@]I7&9#H^M&D"JR4E8+D[NZ*
MS6QK;91=#)EFN$3;5*2K;ZMSVN&S,3?;6[U?-[TJ?P4H!Y=XSK5R.7=+[5>Q
MD&W>E-1\M\ >JO*(6JW(8SFNOMGXI*M:J5NLO;IN\A<0U];J=ZE;D+;:VUK=
M2ZP)#/#/[@4W)T5N&#]Z\\[FM?P.PM/R]E5K5[F*>LMJ9KC6*L[KJ4MNL[N
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M"+5HU12;-6K9*Q!NV;H66I(((()6VI(HHI6TMLLMI2VVVE*4IV ?[
M    "B%XXO\ );T[/Q_Y'^QW3P%SWB;\5CC1\W_37P=8X!T
M
M                                                      !GA]<+
M]Z]Z6'O@=-+]<"8 T/
M
M
M
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M_P EO3L_'_D?['=/ 7/>)OQ6.-'S?]-?!UC@'0
M
M                                             &>'UPOWKWI8>^!T
MTOUP)@#0\
M
M
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M_P EO3L_'_D?['=/ 7/>)OQ6.-'S?]-?!UC@'0
M
M                                             %+#JP=,SG1R \1)
MT^>8^G^/F19OQIU!F7!22V1M5CD6",8G%F.JN2TGF^P'#N)F<JC<F=VXWBR]
MCQ6C9BO<K97NI444^X NG@
M
M
M                                                 !GA^)-_>1^E
M%[W_  6_7QWJ!H>
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MP=8X!T
M
M
M
M
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M^QW3P%SWB;\5CC1\W_37P=8X!T
M
M                                 !RML;G)P\U!N["^-FT>2VF<!W]L
M=UB#+ ]/95G<%#;"RYYG\\IB^$MH#&7CM.3DELJR-*YDQM3LNJX<VU3L[;O4
M ZI
M
M
M                               #/#\2;^\C]*+WO^"WZ^.]0-#P
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M'S?]-?!UC@'0
M
M                   &>'UPOWKWI8>^!TTOUP)@#0\
M
M
M
M           #/#\2;^\C]*+WO^"WZ^.]0-#P
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M'_D?['=/ 7/>)OQ6.-'S?]-?!UC@'0
M
M                                     &>'UPOWKWI8>^!TTOUP)@#0
M\
M
M
M                             #/#\2;^\C]*+WO^"WZ^.]0-#P
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MIS?>E\$VE*XK"O'4A$X^^RZ$;2SB*CWSZQ-X[:,[U^Y8HI;2^ZE.VM* =:@
M                      %$+QQ?Y+>G9^/_ "/]CNG@+GO$WXK'&CYO^FO@
MZQP#H
M
M            #/#ZX7[U[TL/? Z:7ZX$P!H>
M
M
M
M    !GA^)-_>1^E%[W_!;]?'>H&AX
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M=GX_\C_8[IX"Y[Q-^*QQH^;_ *:^#K' .@
M
M                                         ,\/KA?O7O2P]\#II?K@
M3 &AX
M
M
M                                 &>'XDW]Y'Z47O?\%OU\=Z@:'@
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MZ> N>\3?BL<:/F_Z:^#K' .@
M
M                               .>,XXA\3MG;8Q7?6R>,''?86\L%<8
MR[PC<^<:5UMEFV,.=87,7Y#ASG%=BSV-2&7X\XQ.?4N?1E[1XC<P>7560K8I
M6MP'0X
M
M
M                                  9X?B3?WD?I1>]_P6_7QWJ!H>
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MGB;\5CC1\W_37P=8X!T
M
M
M
M
M                                                        !GA^
M)-_>1^E%[W_!;]?'>H&AX
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M3464LLN#,DZTG7UY"=8/9+/@MP1Q38D1QARK,X_$8'#,:BI-3<?+C**RC:R
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M9X_J2]FE(J0$9'WODVM[A2J=JM;J654NK;V=ZO:%X'B;\5CC1\W_ $U\'6.
M=
M
M         4CNK=U"^:VD/$==._BEJ;D;L3!>.NT\TX%1^PM20;U@EB>6,ME<
MG)3$,[;RK=:/7=*)Y/C*-K-SW5;>\C;2E.ROJ@7<0
M
M
M
M         SP_$F_O(_2B][_@M^OCO4#0\
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MS\?^1_L=T\!<]XF_%8XT?-_TU\'6. =
M
M                                       9X?7"_>O>EA[X'32_7 F
M-#P
M
M
M                               ,\/Q)O[R/THO>_P""WZ^.]0-#P
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MG5+;WY<[.]MK:K7D9LS T,J]9>O,#[F*8]C6O)"(BO0>LL3PS'+O-'<ZZO\
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MO@ZQP#H
M
M              #/#ZX7[U[TL/? Z:7ZX$P!H>
M
M
M
M      !GA^)-_>1^E%[W_!;]?'>H&AX
M                 /YWC-I(-'3!^U;/F#YLNS>LGB"3EH\:.4KD7+5TV6MO
M1<-G"-]UE]E]M;;[:UI6E:5 SCNK9X13D%B^T<SW1TPX[']IZ;RJ3D,B_1KE
M\JA\1V5JQ=Y6KY]!X),YB^B,2SK!F:WEO1Z+B29S;1"J+.B,BI;<ZO"\!QZX
MHPLMTQ]'\+>14$_R2+DN%&M./V\8.??.5IJ6>.],0N%['M?RMRRSQ#('$K>\
M5\[34\LW>=BJ5UMUEE:!FG\V>A-U:>D[R-G,UXC07)G9.LVKV3NU/RAX?TS[
MVPF>(O5O*IQ6PX_3J_K_ -<9$P;6(I2-ZB2<([7I2YHZ6IVV)!\[P^Z'75ZZ
ML'(F#RGDQBO)G!,(D9&.1VIRJYE([%3R9#$&#BESQ+#4MQ.$,]VG/>0461CF
M[*BL:F]K6UVZ:)T54M#5XT=IK7_'73>K=#:JAK<?UOIW <5UOA$12J:BK3&\
M/AF<'%^>N$TD?/I-PV9T5=N;K:*.G-ZBM_;??=6H>I@              >#;
MGXK\8>1Z35#D/QQT-OI!E:SL9([GU!KW:*32R/4D%F%K5/.,>G;&]K%:6=WH
MTLI2B5SI6MO952_M#Y_3G"OAOQVEE9[C]Q+XS:+G5U*++36G-#ZLUE+++48O
MHRBJLCA6*PCQ12D;)N6_>K?6OD'"J?\ >J7TJ'3(      *(7CB_R6].S\?^
M1_L=T\!<]XF_%8XT?-_TU\'6. =
M
M                                   9X?7"_>O>EA[X'32_7 F -#P
M
M
M
M                           ,\/Q)O[R/THO>_P""WZ^.]0-#P
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M+>G9^/\ R/\ 8[IX"Y[Q-^*QQH^;_IKX.L< Z
M
M                                             @#YI]!W$^9'5)XQ
M=3B2Y)9%@4YQJGN.4XRU"QUG&Y!$Y;?QYVT[VLS;.LQ<9G%/(>W*7#OS)6ZR
M.<5:66^5MHK6O< G\
M
M
M                                             #/#\2;^\C]*+WO^
M"WZ^.]0-#P                                             J4>)Q
MOZL.@X+47+7IT<A.0D)KWRB&J-Y:2U)&69-6%FG2\C)X3MN*A48*>F:LIJBB
ML+,T2MM;MET(U2VSO.7*E I%\@>H5UW-G:8V+@'(_:G-"8T;E>.N(G9D7GVL
MYR'PU]C*RR%[EOD,FXP.,19QUZR:?>ON72IV]E.WU0/&^$7,OJV\=]4Y!A7
MK8')_%-02FPI7*<DCM*8)*Y1BJVR7N-XG$S#V0D&.(SZ*.0*8O"0]BJ-5K;K
M6R:%W<I2^EUP=C?6B^)(]V;G_P#F@R+^S4!]:+XDCW9N?_YH,B_LU YWS?2'
M6]ZK>W</IM#4O.'D]GS9._%L6F-C8#L!EA."QZU[!203NG\DA\?UAK&%76O;
M*R#I=:-;K+WI7N%+E;TZW!JZ=+3ANXZ?O3\XN\0Y*583F0Z@UZHAF<I$V7VQ
M#O8.:Y)/;'V)=#W*U\LXB$\YS"0L:K7VIJ+M[;%+K$[KJV6AWZ
M              40O'%_DMZ=GX_\C_8[IX"Y[Q-^*QQH^;_IKX.L< Z
M
M
M
M
M
M                                 SP_$F_O(_2B][_@M^OCO4#0\
M                                           ')_.GBPQYN<1-^<3I
M/,W>O(_>V OL#>9LQA$<D>8XW?NV;A61;0;B3AD)%:RUIW;;+W*-O;=VUK7L
M[*AR5T<>E7CW2$XR9UQKQK<TUO%AF^]\GWBKEDYAC'!G<>[R77^L,"4QU.)8
M9%DR+ALT1UHFYHYJO9=?<[NL\G2B=+K@EE
M   HA>.+_);T[/Q_Y'^QW3P%SWB;\5CC1\W_ $U\'6. =
M
M                                                     0!\T^O%
MB?#?JD\8NF/)<;<BSV<Y*SW'*#9;>8[,C<?B<2OY#;:=ZI9N76'.,,E7DQ;B
MSAIYZK;9(MZN[+O)6U2K3O@3^
M
M
M                                                     !GA^)-_
M>1^E%[W_  6_7QWJ!H>
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MV;2.-LW$^YR..7:,%F4NJ_OOJNE<@E6R_MIW:?P =X
M      %$+QQ?Y+>G9^/_ "/]CNG@+GO$WXK'&CYO^FO@ZQP#H
M
M                                                        #/#Z
MX7[U[TL/? Z:7ZX$P!H>
M
M
M                                                !GA^)-_>1^E%
M[W_!;]?'>H&AX
M'^:RR+=%5PX530003O6776OM21112MK>HJJI?6VQ--.RVM;KJUI2E*=M0(XM
MJ=83I9Z5FW.-;'Y^\587(V+FC.2Q^.W%B&63<0[K:K?5K-Q6'R$\_A7-MJ5:
MW6.TT;K:76=M*>4L[P?LZ;ZL?3.Y S*.-ZAYV<7<PR9SV^9XNGN##X7*)#L4
MN3N]&XWD<E#SDEW+K?NO(-U.[2ZVM>REUM:A(0
M    %$+QQ?Y+>G9^/_(_V.Z> N>\3?BL<:/F_P"FO@ZQP#H
M
M                                                      #/#ZX7
M[U[TL/? Z:7ZX$P!H>
M
M
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MCNG@+GO$WXK'&CYO^FO@ZQP#H
M
M                                #/#ZX7[U[TL/? Z:7ZX$P!H>
M
M
M
M                        !GA^)-_>1^E%[W_!;]?'>H&AX
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MS$FSA(B"BN7/'^0F969D'2;%A$QT6TV"L^?2;Y\M8BBW2LN555NI9;;6ZM*
M=LPLW#9)$Q\]CTM&3T'+M$7\5-0K]K*1,FQ<64O;O(^18JKLWK1>RO;8HG?=
M9=3U:5J!^F           *(7CB_R6].S\?\ D?['=/ 7/>)OQ6.-'S?]-?!U
MC@'0
M
M           %+#JP=,SG1R \1)T^>8^G^/F19OQIU!F7!22V1M5CD6",8G%F
M.JN2TGF^P'#N)F<JC<F=VXWBR]CQ6C9BO<K97NI444^X NG@
M
M
M
M               !GA^)-_>1^E%[W_!;]?'>H&AX
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MIV?C_P C_8[IX"Y[Q-^*QQH^;_IKX.L< Z
M
M
M
M
M
M            SP_$F_O(_2B][_@M^OCO4#0\
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M$NP     40O'%_DMZ=GX_P#(_P!CNG@+GO$WXK'&CYO^FO@ZQP#H
M
M                                                           #
MGC..7G$[6.V,5T+LGD_QWU[O+.G&,M,(TQG&ZM;8GMC,76:3%^/8<VQ774]D
ML?E^0N,LGT[F,98T9K7/WEM44*7J4K:!T.
M
M
M
M  &>'XDW]Y'Z47O?\%OU\=Z@:'@
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M
M
M       ,\/KA?O7O2P]\#II?K@3 &AX
M
M
M                                                           &
M>'XDW]Y'Z47O?\%OU\=Z@:'@
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MW[1J^:*>5:O6R#MLKW+T_*-W*5JR*G<5ML4L[Z=]*]EU*74[?5I2H']
MHA>.+_);T[/Q_P"1_L=T\!<]XF_%8XT?-_TU\'6. =
M
M                                                  9X?7"_>O>E
MA[X'32_7 F -#P
M
M
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M'8>BHF+B_*^<>C8YDP\OY/R7EO,VR3?RODN^IY/RGD^WN]Z[L[>SMK_"!^B
M   *(7CB_P EO3L_'_D?['=/ 7/>)OQ6.-'S?]-?!UC@'0
M
M                                                     &>'UPOW
MKWI8>^!TTOUP)@#0\
M
M
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MTR*112BV$>K1=K<\432:*!J88GBN.8)BN-81AT,PQS$<-Q^&Q7%L>BD+6T9
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M%_DMZ=GX_P#(_P!CNG@+GO$WXK'&CYO^FO@ZQP#H
M
M                                               #/#ZX7[U[TL/?
M Z:7ZX$P!H>
M
M
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M"38M;W"5OE4?*)=E]0ZR                         %$+QQ?Y+>G9^/\
MR/\ 8[IX"Y[Q-^*QQH^;_IKX.L< Z
M
M                                     YXSCB'Q.V=MC%=];)XP<=]A
M;RP5QC+O"-SYQI76V6;8PYUA<Q?D.'.<5V+/8U(9?CSC$Y]2Y]&7M'B-S!Y=
M59"MBE:W =#@
M
M
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MT?-_TU\'6. =
M
M
M
M
M                                                  9X?B3?WD?I
M1>]_P6_7QWJ!H>
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M_(_V.Z> N>\3?BL<:/F_Z:^#K' .@
M
M                                    *6'5@ZF?.CC_ .(DZ?/#C3_(
M/(L(XT[?S+@I&[(U4QQW!'T3E+':O):3PC8#=W+3.*R63-+<DQ9"QFK5L^0N
M2LIWDJIJ?=@73P
M
M
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M]CNG@+GO$WXK'&CYO^FO@ZQP#H
M
M                                 #/#ZX7[U[TL/? Z:7ZX$P!H>
M
M
M
M                         !GA^)-_>1^E%[W_  6_7QWJ!H>
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M3?BL<:/F_P"FO@ZQP#H
M
M                          #/#ZX7[U[TL/? Z:7ZX$P!H>
M
M
M
M                  !GA^)-_>1^E%[W_!;]?'>H&AX
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MQH^;_IKX.L< Z
M
M                     SP^N%^]>]+#WP.FE^N!, :'@
M
M
M
M             9X?B3?WD?I1>]_P6_7QWJ!H>
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M[$-[&D9"PL8TL3;,(Y@V3ML22LMI;9;3LH!]F
M 40O'%_DMZ=GX_\ (_V.Z> N>\3?BL<:/F_Z:^#K' .@
M
M                                                   ( ^:?0=Q/
MF1U2>,74XDN2618%.<:I[CE.,M0L=9QN01.6W\>=M.]K,VSK,7&9Q3R'MREP
M[\R5NLCG%6EEOE;:*UKW )_
M
M
M                                                    SP_$F_O(
M_2B][_@M^OCO4#0\
M  $8'6;X;3_/CIF\K^,F%M6[S8N78(QRC6#5Q>FA5]L?5^3P6S,0A$7BE/)L
M%,JEL2LB+EKJTLL2?W]^M+.]4"L!X-OG;@>'8/O[ID[>E$=?;JB-P9!N35>-
M9BW2QB7RA*4@<9PS9VNF2,DJR=N,UP2<PE)^I%*H4DJMW[J^WRB+):UL%[X
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ML_'_ )'^QW3P%SWB;\5CC1\W_37P=8X!T
M
M
M
M
M
M          !GA^)-_>1^E%[W_!;]?'>H&AX
M                    9FO5YZ@_76U=U+.8>ON-&U>9T1HG%=MO8S6L9K_6
ML[.88Q@+8:&6JWQZ50P651=L$WZRW96UPK;;=WK:5IV=E C@^M%\21[LW/\
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MH
M
M        ""7F+UV-3\.^IGQLZ9N2Z(V)F6<\DISCW!PFS8/),:88GC2O(/:C
MO5<.O*Q#].Z8=IX](-:NW-$:TJJC7NV?= 3M
M
M
M
M    !GA^)-_>1^E%[W_!;]?'>H&AX
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M1\HXL?N;M19^B]NM6ONKYXG8I:K:K98M:&O*     %$+QQ?Y+>G9^/\ R/\
M8[IX"Y[Q-^*QQH^;_IKX.L< Z
M
M                                 SP^N%^]>]+#WP.FE^N!, :'@
M
M
M
M                         9X?B3?WD?I1>]_P6_7QWJ!H>
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MM5Z][LIW0-7WB;\5CC1\W_37P=8X!T
M
M                                     !GA]<+]Z]Z6'O@=-+]<"8 T
M/
M
M
M                              SP_$F_O(_2B][_ (+?KX[U T/
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M%XXO\EO3L_'_ )'^QW3P%SWB;\5CC1\W_37P=8X!T
M
M                                                !GA]<+]Z]Z6'
MO@=-+]<"8 T/
M
M
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MO!KN     !1"\<7^2WIV?C_R/]CNG@+GO$WXK'&CYO\ IKX.L< Z
M
M
MI'=6[IZ<UMW^(ZZ=_*W4W'+8F=<==69IP*D-A;;@V3!7$\39:UY.2F7YVXE7
M"T@@Z33QC&5K7CGNI7=U&ZE:=M?4 NX@
M
M
M                                                           !
MGA^)-_>1^E%[W_!;]?'>H&AX
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MZ> N>\3?BL<:/F_Z:^#K' .@
M
M
M
M
M
M ,\/Q)O[R/THO>_X+?KX[U T/
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ML<:/F_Z:^#K' .@
M
M                      /&<JY&\>L$V%C^I,WWQIG#=K98M!M\6UCE6T,(
MQ[862N,GDKH;&D,?PN7G&>23*V0S%E6C&ULV4N=N:522I??3N@>S
M
M
M
M                    !GA^)-_>1^E%[W_!;]?'>H&AX
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M?8[13(KKIN=Q3#K)IW+*Y M_)R&0WLZ-%754)"K<-(
M     !1"\<7^2WIV?C_R/]CNG@+GO$WXK'&CYO\ IKX.L< Z
M
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M4@                                !GA]<+]Z]Z6'O@=-+]<"8 T/
M
M
M
M                           SP_$F_O(_2B][_@M^OCO4#0\
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M<&QC)I[%T9!9JX?I8[,3<6^D(1-ZX8H7K6ME$J*7HV77=M;+:T#T@
M                 HA>.+_);T[/Q_Y'^QW3P%SWB;\5CC1\W_37P=8X!T
M
M                       !Y_MG\E>R_>_S+V.20%$/P,?_ 'HG^1-_UN +
M_@                                       SP^N%^]>]+#WP.FE^N!
M, :'@
M
M
M                                 9X?B3?WD?I1>]_P6_7QWJ!H>
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MB,PA\:9-)MA)RC!_*,G[UL]3NM452<KV7W4[:7W?P@=Y
M        %$+QQ?Y+>G9^/_(_V.Z> N>\3?BL<:/F_P"FO@ZQP#H
M
M                #S_;/Y*]E^]_F7L<D@*(?@8_^]$_R)O^MP!?\
M                                &>'UPOWKWI8>^!TTOUP)@#0\
M
M
M
M                        #/#\2;^\C]*+WO\ @M^OCO4#0\
M                                    %>?Q3WKK^H_Y<^MGSCS3TUQ[
M]=_FOF_E?6I^D9JOR_>\K_PKS?TWYCY;S?\ E/(][O\ _!_+ 1T^"QT;J^ X
M#[^Y#Q;",?;>V3R7G]8Y;D5+&JTI$87K/ M>SF*8516VY5RP1])9^_EE[.U*
MKFCYO=?9=:BC?4+EP                            %$+QQ?Y+>G9^/\
MR/\ 8[IX"Y[Q-^*QQH^;_IKX.L< Z
M                                                       \_P!L
M_DKV7[W^9>QR2 HA^!C_ .]$_P B;_K< 7_
M              !GA]<+]Z]Z6'O@=-+]<"8 T/
M
M
M
M       SP_$F_O(_2B][_@M^OCO4#0\
M                 '*_.#6W'[<?$3D1JOE1EF+X%Q]S_5F48KM#.\SR>$PO
M'L(@)=G5JEF+K+,D>,(''G>+RM[=\S=NUK$47J"5UW;V=E0SG^E!U0HOP\G+
MG?/$S<>S=9\PN$NUIZ-R9GN'B#L_7.YH2)G63=:*Q[;V*ML5RV39(N,EQQ%"
M/RK%Y%\TF&56#59"J]K9*DB%U_!?$3]%W8$&WGHGGMJJ%1732O4CLZAMAZ^G
M&BJEM:WMW$+FF&0;^JB%]M;;[D[%$:UIVVWW6W6W5#[/Z^[HX_ZPOCO_ $CD
M?P0 ^ONZ./\ K"^._P#2.1_! $G>K]G8!NG7>&;:U5E45G.M]B8[&9;A&802
MMZ\-DN-S+:QW%S,8LHFE>JR?-E+;T[JVVUK;7^ #[L
M      HA>.+_ "6].S\?^1_L=T\!<]XF_%8XT?-_TU\'6. =
M
M              >?[9_)7LOWO\R]CDD!1#\#'_WHG^1-_P!;@"_X
M                               .5MC<&^'FW]W87R3VCQITSGV_M<.L
M0>X'N'*L$@IG86(O, GE,HPES 9,\:*2<:MBN1JW/6-R=]M6[FZJEG9=ZH'5
M(
M
M
M                             9X?B3?WD?I1>]_P6_7QWJ!H>
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M%XXO\EO3L_'_ )'^QW3P%SWB;\5CC1\W_37P=8X!T
M
M      !Y_MG\E>R_>_S+V.20%$/P,?\ WHG^1-_UN +_ (
M
M
M
M                                                       ,\/Q)
MO[R/THO>_P""WZ^.]0-#P
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M
M                         #S_ &S^2O9?O?YE[')("B'X&/\ [T3_ ")O
M^MP!?\                                       %-+JH]5OGUQO\0=
MP$X/:7WUZS.+NZ\PX.Q6S=8>U=I?(O7,PW!R0DL!V,AZ]<KUU.[#AO7%B;>Q
MIWH^6:7M.SRK6J*U:J5"Y:
M
M
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M\EO3L_'_ )'^QW3P%SWB;\5CC1\W_37P=8X!T
M
M  !Y_MG\E>R_>_S+V.20%$/P,?\ WHG^1-_UN +_ (
M                     ,\/KA?O7O2P]\#II?K@3 &AX
M
M
M
M             &>'XDW]Y'Z47O?\%OU\=Z@:'@
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MNUM"RB     %$+QQ?Y+>G9^/_(_V.Z> N>\3?BL<:/F_Z:^#K' .@
M
M                  //]L_DKV7[W^9>QR2 HA^!C_[T3_(F_P"MP!?\
M                                   &>'UPOWKWI8>^!TTOUP)@#0\
M
M
M
M                           #/#\2;^\C]*+WO^"WZ^.]0-#P
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MZ\^S1K/VP[6#8WVIQ]K=1O5Q6JU;Z*)TM#5\XF_%8XT?-_TU\'6. =
M
M                    >?[9_)7LOWO\R]CDD!1#\#'_ -Z)_D3?];@"_P"
M                                      #/#ZX7[U[TL/? Z:7ZX$P!
MH>
M
M
M                              !GA^)-_>1^E%[W_!;]?'>H&AX
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M#"M7:OQ]M"0D:T22H]DWGJKS64Y&^L3L5FLMRJ646?R;Y;M6=O%U%+J^K2E
M][?L&,HQ>1DFS:2,;(M'#"0CW[=%XQ?L7B-[=VS>-'%BC=TT=-U+K%$[[;K+
M[+JVW4K2M: 8\/5.U5'])7KG;22X_-%,1QC0_(34_(S3D/ J+Q[7'(')X["-
MY1F%PEU:)7)P.,NIU>!02NN4LJS:42ON4IWJU#8A9NV[]HU?-%/*M7K9!VV5
M[EZ?E&[E*U9%3N*VV*6=].^E>RZE+J=OJTI4#^@    40O'%_DMZ=GX_\C_8
M[IX"Y[Q-^*QQH^;_ *:^#K' .@
M                                                   //]L_DKV7
M[W^9>QR2 HA^!C_[T3_(F_ZW %_P
M       5X></04_3,ZKW%?J??I6>UO\ HSY!QIG?:0]HSUX>O7]'?<#S:_FO
MME^W%BWK;]>'G?F'?];[_P!']WR_=<]OD:!8>
M
M
M
M     #/#\2;^\C]*+WO^"WZ^.]0-#P
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MDF48\TDY2^,BDU%K(]E<Y6N\FE2^ZEEOJ=M0.W0         "@'XYS_NN_\
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M    HA>.+_);T[/Q_P"1_L=T\!<]XF_%8XT?-_TU\'6. =
M
M            >?[9_)7LOWO\R]CDD!1#\#'_ -Z)_D3?];@"_P"
M
M
M
M
M#/#\2;^\C]*+WO\ @M^OCO4#0\
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M+Q1\IYH%O\     *(7CB_P EO3L_'_D?['=/ 7/>)OQ6.-'S?]-?!UC@'0
M
M                       'G^V?R5[+][_,O8Y) 40_ Q_]Z)_D3?\ 6X O
M^                                       "$?EOUS^/7#_ *CO'?IJ
M9OJ+<V3;6Y'S6A83%L\Q5/"+M>P3CD#LYUJW&E9^^7RN-R2B,+,-:N'WF[%>
MZC:M/)44O^X FX
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MI?Y>UG5LIY7LL4NNMOI:'5X
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M;0](>V)[8GK>:>N?UY^E?_67KB])=_SKR_\ *>4[>]ZH';H
M          !1"\<7^2WIV?C_ ,C_ &.Z> N>\3?BL<:/F_Z:^#K' .@
M
M                    //\ ;/Y*]E^]_F7L<D@*(?@8_P#O1/\ (F_ZW %_
MP                                       9X?7"_>O>EA[X'32_7 F
M -#P
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M%=GCS6VU&BM$K*V5K;;2MUU:AV*
M
M >/\A?R!;Q]Y_9?L+F@*,X
M  6>^BM\5G/O?_RGX.M5@2^@                            ?\WV6*67
M)J6VWIWVW67V7VTNLOLNI6VZVZVZE;;K;K:]E:5]2M ,\[Q27!.)Z<&^>*?5
MKX'LF7'3+IG;MF)9ZAK:.;8YC\?O>+C9?8&";!BX)BE;")N=B8Q 3S')8_R"
M<;*)1MMR[=>]](7*A=IZ>G+*/YT<)>-'+1A&(PBN[=6064ST$U6\Y9P.:-JN
M('/8%BXK==>X80N;0\@U04O[JEZ*5M;[;;ZW6T#LH
M     HA>.+_);T[/Q_Y'^QW3P%SWB;\5CC1\W_37P=8X!T
M
M           !Y_MG\E>R_>_S+V.20%$/P,?_ 'HG^1-_UN +_@
M                             SP^N%^]>]+#WP.FE^N!, :'@
M
M                  #/"X;_ +Z/OOWP>4'ZN4V!H>@
M
M                      /'^0OY MX^\_LOV%S0%&<
M                       +/?16^*SGWO\ ^4_!UJL"7T
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M_%8XT?-_TU\'6. =
M                                          >?[9_)7LOWO\R]CDD!
M1#\#'_WHG^1-_P!;@"_X                                       ,
M\/KA?O7O2P]\#II?K@3 &AX
M                                                 SPN&_[Z/OOW
MP>4'ZN4V!H>@
M                                                   /'^0OY MX
M^\_LOV%S0%&<              #VS4/'3=&^6^7O-3X.[RQE@48G+Y:^ME8"
M%8PS%>QXJA55[D<M$-7+M=*/7O3;(7JN;[$;[K4ZTMK6@>)@?;:YUSF>VLV@
M-=:]A+\BS+*'2S.#ADWL;'7/7#=FYD%[:OI=Y'QC6Q%DT54NO663LMMLKVU
M[(^JZYU^X;_\,S3W]H('^:W2_P"<[=%5=71_<213O55N]LO3]W=33MK??=W;
M=@777=VVVM>RE*UJ!P*   =4ZMX1<K=S1"&0:]TIE4E O&U7D?-S*L+A<1*M
M*>;]UU#R6;RN.LYANIYS;W+VMZUJG=O[M:^34[H?Q[8X9<H-(1:T[LO3>40<
M"U326>S\??$99 1R2U5+4[Y.;P^3GXJ,MK>GW:^<+)]VZZVE>RM]O:',0
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ML&+9!FR9,T$FS1FT;)6HMFK5LC;8BW;-T;+;++++:6V6TI2E*4H!_0
M                  40O'%_DMZ=GX_\C_8[IX"Y[Q-^*QQH^;_IKX.L< Z
M
M                         \_VS^2O9?O?YE[')("B'X&/_O1/\B;_ *W
M%_P                                       4;.KYP<YA[>\2ATY.2
M>KN-.YL^T#KG-N +W/-PXK@<],Z]Q%G@'**4RC-G.09.S:*QD8CBN.*VO7UR
MJEM&[:ZBE_9;ZH%Y,
M                                          !GA<-_WT???O@\H/U<
MIL#0]
M                                             >/\A?R!;Q]Y_9?L
M+F@*,X             .X^)? C<_*YTVFH=JGAVJD9%1E,;*G;*59UO:WV4>
MLL8AZ+(R&3R:5+JV_P GY-DDK;6Q9RE?V6U"R;J;6^B],:(VCI_2#Z-DD]?0
M^4Q6P'K=VC)S;C.G&+*.Y%3+I-M9:@ID=S91+RC:VMM&*7DT*)I666)T"F>!
M*[T=<$KDW*YUEBJ'>;:WUSD\VBXK6ZEJ,M/J,,0:HT[M*TJHO%SCZM*5[*=U
M.ZO\-*4J'[_*?J6<J,9Y%;BQ;56UJ8Y@.)YQ+XG 0]N":VE[6],74M@)-:R2
MG\.E99W8_F(YPXMN5<*=E%>RSNV4MMH'/JW5 YSN$54%=X=])9.])6WVM-/V
M]Y-2VME]O>MU_;=;WK;JT[:5I6@' H "3KI5<=L8WIR"?SF=1:$WA^I8!++%
M81\WL=1<SE#V0288NQF&RM*I.8UO6QT^N2N[;%E62::EEZ5ZEM0Z5YI=5+<$
M#MC+M7\>'T/A6.:_FGV+/LQ6@8;(Y[(9V$=^93:C-OD3.6Q^/@FS]LJV;VVM
M%5EK+:K55M\I8FD'UO SJ8;/VIM*#T3R)]!9HQV'Y]"P68IX_&0LDC-+-'2[
M>&R&)A&;3'92%FDDJL[/)LFZB2JEM5;E$[KJV!'SU(./6/<=.3$SC^&,DXO"
M<VQ^+V)B\.A2[S:";3+V5BI2%;5NNNI8U9S\&[O;I4[/(-%44_X+:5J'!(
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MG@+GO$WXK'&CYO\ IKX.L< Z
M                                                  \_VS^2O9?O
M?YE[')("B'X&/_O1/\B;_K< 7_
M
M                                 ,\+AO\ OH^^_?!Y0?JY38&AZ
M
M                                     \?Y"_D"WC[S^R_87- 49P
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M7NW6TH$>H            6>^BM\5G/O?_P I^#K58$OH
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M[ 0S5YA,=I&>QQ[D:*45)QM8]M-N=D2Z$:I6LA2_RES9:GW'9W?5[:!=P
M                    40O'%_DMZ=GX_P#(_P!CNG@+GO$WXK'&CYO^FO@Z
MQP#H
M                             #S_ &S^2O9?O?YE[')("B'X&/\ [T3_
M ")O^MP!?\                                       'G<YM[4V,99
M%8%DNT-=X]G,ZI&(P>%SF:XU$Y9,JS3RZ.ADHK''\FWF)%26D+:H-K44;ZKK
M4K99WKO4 ]$
M                                     9X7#?\ ?1]]^^#R@_5RFP-#
MT
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M+G"(04              L]]%;XK.?>__ )3\'6JP)?0
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MBN+ZCW#L?4^"WU7?4HXO;5P?"H[R%/5LM0[E$ZULI;6H36@
M          %$+QQ?Y+>G9^/_ "/]CNG@+GO$WXK'&CYO^FO@ZQP#H
M
M                  #S_;/Y*]E^]_F7L<D@*(?@8_\ O1/\B;_K< 7_
M                                     9X?7"_>O>EA[X'32_7 F -#
MP
M                          !GA<-_WT???O@\H/U<IL#0]
M
M                             >/\A?R!;Q]Y_9?L+F@*,X
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MYVUM[MUM:AXV            %GOHK?%9S[W_ /*?@ZU6!+Z
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MD8V1:-W\?(,'"+QB_8O$;'#1XS=M[U&[IHZ;J6WIJ67767V74NMK6E:5 _K
M    "B%XXO\ );T[/Q_Y'^QW3P%SWB;\5CC1\W_37P=8X!T
M
M            !Y_MG\E>R_>_S+V.20%$/P,?_>B?Y$W_ %N +_@
M                              SP^N%^]>]+#WP.FE^N!, :'@
M
M                   #/"X;_OH^^_?!Y0?JY38&AZ
M
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MJQJ<<H6H(KWTI8E?99VW5K6E:U[0/<OK1>=?NY?_  L]/?V? /K1>=?NY?\
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MVU!M(NTGS=-):U[8]#3[     "B%XXO\EO3L_'_D?['=/ 7/>)OQ6.-'S?\
M37P=8X!T
M                                 !Y_MG\E>R_>_P R]CDD!1#\#'_W
MHG^1-_UN +_@                                       SP^N%^]>]
M+#WP.FE^N!, :'@
M                                        #/"X;_OH^^_?!Y0?JY38
M&AZ
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MO;V@;"(     40O'%_DMZ=GX_P#(_P!CNG@+GO$WXK'&CYO^FO@ZQP#H
M
M                     #S_ &S^2O9?O?YE[')("B'X&/\ [T3_ ")O^MP!
M?\                                       &>'UPOWKWI8>^!TTOUP
M)@#0\
M                               9X7#?]]'WW[X/*#]7*; T/0
M
M                                 'C_ "%_(%O'WG]E^PN: HS@
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MY2            %GOHK?%9S[W_\ *?@ZU6!+Z
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MMH$H8         !0#\<Y_P!UW_EL_P#5' G^\+C^PHX,_P"4S^N'R" G^
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MH^-NN3M_\WHK2M?]T U?>)OQ6.-'S?\ 37P=8X!T
M
M     !Y_MG\E>R_>_P R]CDD!1#\#'_WHG^1-_UN +_@
M                       XTVIT\^%.[^0F <K=L\<M=YUR*U8\P:0U[MN<
M9OU<LQ1[K7)%<PP1Q%.$9!!JFIC&3+7/&W>2O[JUW;7MIZ@'98
M
M               #/"X;_OH^^_?!Y0?JY38&AZ
M
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M.L< Z
M                               \_P!L_DKV7[W^9>QR2 HA^!C_ .]$
M_P B;_K< 7_
M
M                  ,\+AO^^C[[]\'E!^KE-@:'H
M
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M=I@O-#<S2.0M089'(PN<(V6T[.^[S#'8N:G5[J=M?NG&2.7E]?\ R]X#A(
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MP#H
M                            #S_;/Y*]E^]_F7L<D@*(?@8_^]$_R)O^
MMP!?\                                       %/3JB=7;G1QDZ_'
M[@;I_9>.P'&G>F7<)XG9&'/M;X'/2TNQW1R*D=>[ 3:Y?,P+S)XFZ5Q9O8@E
M<V=)7-;Z>41K8I7O 7"P
M                                             &>%PW_?1]]^^#R@
M_5RFP-#T
M                 $6'(_K9]+?B+N?,N//(SESB&L-RZ^];OKQP:4P[:LJ_
M@_79BD%F^/>7?XW@<U"K^D\5R5B\M\BY5[MCBEM_=4I=9:'A_P!I#Z)7R]\
M_-[O'^RX!]I#Z)7R]\ _-[O'^RX!]I#Z)7R]\ _-[O'^RX!]I#Z)7R]\ _-[
MO'^RX!]I#Z)7R]\ _-[O'^RX!]I#Z)7R]\ _-[O'^RX!]I#Z)7R]\ _-[O'^
MRX!]I#Z)7R]\ _-[O'^RX!]I#Z)7R]\ _-[O'^RX":/&,DA,RQK'LOQF03EL
M;RN#B<DQ^413712DH2=8-Y2)D$DG22#E)-XP=)J6VJ66*6TN[+K:5[: ?N
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M$=X           L]]%;XK.?>_P#Y3\'6JP)?0
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M'L&Z+-BP8LT;&[1FS:-[$V[5HU;IVV)IV6VV666TMMI2E*4 _K
M %0+Q6O2XYV=2C] S]"K1GMT>TO^E'[9?_P3=.ZZ];7MB_HZ^LW\K&P<$],>
MF/6)*_\ OO\ .O-_-?Y?R7E4?*!+_P!!7BYO;A=TGN*?&CDO@WM:[MUK[>?K
MUPKUS8=F/H7UX\DMQ9_CG_M1X!D.58E(^D<2RI@[_P""/U_(^7\DKW%K%$[
ME^ R7M]>'4\0/R'W=MW?&?\ "IS*YKN/9&:;+RA\ZY/\/UE59G-,AD,@>IVW
M*<A;ZV-FRK^J2*=*]Q)&RVRVE+;:4H'DWV7'KK_(9_SF>'G^D$ ^RX]=?Y#/
M^<SP\_T@@/L]<>&'ZX\#L/ YR6X0^:14+F>+RTDZ_24XA+^;1\=.,7CQQY!M
MOY9PMY%LC==W$[+[[NSLMI6O90#7'     "B%XXO\EO3L_'_ )'^QW3P%SWB
M;\5CC1\W_37P=8X!T
M                                          !Y_MG\E>R_>_S+V.20
M%$/P,?\ WHG^1-_UN +_ (
M ,\/KA?O7O2P]\#II?K@3 &AX
M                                                   SPN&_[Z/O
MOWP>4'ZN4V!H>@
M                       @AYF>')Z:7/+DGLCE=R!QC<$CMW:OK/\ 7:\Q
M;;,KC,"MZQL"Q;6\#YC"-F"R++R>,X>RM5[MU?*+6WJ5[*WUH!R_]D-Z-O\
MB7R _/M.?@L!]D-Z-O\ B7R _/M.?@L!]D-Z-O\ B7R _/M.?@L#E#GGX6OI
M/\?.#7,[?>N<2W@VV%I#BAR*V]@CB6W/,2D4WS+6NH,PS/&%I.,5C4TI&/2F
MX5"Y9"ZZEJR=*V5K2E0(=/#4=#_@AU0N*F^-N<K(#9DMF.O^0:NN,=6PC8TC
MAL>GC-FN,'R:U)VQ9LW-CIYZ4GG%?+5K2O<K;;V?<@6.OLAO1M_Q+Y ?GVG/
MP6 ^R&]&W_$OD!^?:<_!8#[(;T;?\2^0'Y]IS\%@/LAO1M_Q+Y ?GVG/P6!9
M6PC$(;7N%XA@..6.$L>P?%X#$(%-VO<Z=)PV-1+2%B['+JZEMSEQ8Q964O4K
M2E;[NVO]T#Z@                 \?Y"_D"WC[S^R_87- 49P
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M)S-LFFLHDZTNK=8F[FI!=^HW1K6EO8W:^7\FE;2E*6IV6TI2E*=@'Q@
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M-?!UC@'0
M                                 'G^V?R5[+][_,O8Y) 40_ Q_P#>
MB?Y$W_6X O\ @                                       SP^N%^]>
M]+#WP.FE^N!, :'@
M                                         #/"X;_OH^^_?!Y0?JY3
M8&AZ
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M*-T.X')(            6>^BM\5G/O?_ ,I^#K58$OH
M        X)ZHNA-L<H^GWRMX^:+O9)[>VOJJ2Q37ZLC/5Q=DCD3J0C5VB[G(
M*4K=$IH6MKK_ "UM*W6]GW-*U[* 9T,]X3#K:92L@XR='2N1KM4[D6J\]R+I
M+K-D;[N_>D@I(13B]%.^_P!6MMM:4K7U0/P?L@_6._Q6X[_GTCOP" ^R#]8[
M_%;CO^?2._ (#[(/UCO\5N._Y]([\ @:2O36T/G_ !>X!</^.NU4(IMLC2W'
M_6^N<W;P4E9,PR.28OCS2,E+(R5331LD&5KE&[R:M++:7V^KV4 [=
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M/KA?O7O2P]\#II?K@3 &AX
M                                                SPN&_P"^C[[]
M\'E!^KE-@:'H
M                          X ZL7[++J6?, YD?JZ[& K@^"7^(+RN^=^
MX^!C5P%ST                      !X_R%_(%O'WG]E^PN: HS@
M                                !9[Z*WQ6<^]__*?@ZU6!+Z
M                                                  !1"\<7^2WI
MV?C_ ,C_ &.Z> N>\3?BL<:/F_Z:^#K' .@
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M)("B'X&/_O1/\B;_ *W %_P
M  5O^=_0=RSF1U=.)O4XC>26.X'!<:LBXOSC[4+[6DE/RV6V<>=S/=K/&S3,
M6^9Q3.(NRAN[\R2NOCW%&M]OE+J*TKW +(
M
M#/"X;_OH^^_?!Y0?JY38&AZ
M                                     . .K%^RRZEGS .9'ZNNQ@*X
M/@E_B"\KOG?N/@8U<!<]                       >/\A?R!;Q]Y_9?L+F
M@*,X                                        6>^BM\5G/O?_ ,I^
M#K58$OH
M   %$+QQ?Y+>G9^/_(_V.Z> N>\3?BL<:/F_Z:^#K' .@
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M<XRAO2WHCS'TGYAYXJGYSYAZ3;^5[O;W/+6=O]]0#R_]-;B1\HW4']-X3[Z
M?IK<2/E&Z@_IO"??0#]-;B1\HW4']-X3[Z ?IK<2/E&Z@_IO"??0#]-;B1\H
MW4']-X3[Z ?IK<2/E&Z@_IO"??0#]-;B1\HW4']-X3[Z ?IK<2/E&Z@_IO"?
M?0#]-;B1\HW4']-X3[Z ?IK<2/E&Z@_IO"??0#]-;B1\HW4']-X3[Z ?IK<2
M/E&Z@_IO"??0#]-;B1\HW4']-X3[Z ?IK<2/E&Z@_IO"??0#]-;B1\HW4']-
MX3[Z ?IK<2/E&Z@_IO"??0'Q&S.97%.1UOL&/8<@]3O7S[",K9LF;7,H==R[
M=NH%^@V;-T4W%RBRZZU]MMEMM*W775I2GJ@4RO!RR3?B=]8O^D^E(\>_7]^B
M+ZQ_;EB)77'KN]:OZ3WKE];GKL91?IGT!ZXX_P \\W\IYOYZAW^[Y6SM"[9^
MFMQ(^4;J#^F\)]] /TUN)'RC=0?TWA/OH!^FMQ(^4;J#^F\)]] /TUN)'RC=
M0?TWA/OH!^FMQ(^4;J#^F\)]] /TUN)'RC=0?TWA/OH!^FMQ(^4;J#^F\)]]
M /TUN)'RC=0?TWA/OH!^FMQ(^4;J#^F\)]] /TUN)'RC=0?TWA/OH!^FMQ(^
M4;J#^F\)]] /TUN)'RC=0?TWA/OH!^FMQ(^4;J#^F\)]] /TUN)'RC=0?TWA
M/OH!^FMQ(^4;J#^F\)]] /TUN)'RC=0?TWA/OH#_ %0YG\37*R+9OR(U&LNX
M530013S:%N4565OHFFG9;1UVW7WWW4I2G]VM0.F@
M
M                          &>%PW_ 'T???O@\H/U<IL#0]
M
M    ' '5B_99=2SY@',C]778P%<'P2_Q!>5WSOW'P,:N N>@
M          /'^0OY MX^\_LOV%S0%&<
M           +/?16^*SGWO\ ^4_!UJL"7T
M  #P#=?+'BQQJNC+>1G);C_H&Z;3HM#6[KW)KK5=TNC51=*BL93.LC@:OTZJ
MM5;>\EWZ=Y.ZG\-M>P/0=;;5U=N;%FV<:?V1@.UL*>+*-F>8:VS#'LZQ9VX1
M31560;9!B\C*1*ZR23A.ZZRU:MUMM]M:T[+J=H??
M     "B%XXO\EO3L_'_D?['=/ 7/>)OQ6.-'S?\ 37P=8X!T
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M))@A1.J;>U)M1.RP-2$                   ( ^N9_T7?^6S_FC @#
M                                   '[^*?X48W_P ?P_\ .+8"^R
M                 $-/*GKC<3N(?4'T#TVMDZ]Y$3>\N1DQHZ$PC*\'Q/6T
MEJ>+=;^V0YU=ARF53L]MK&LO8MXV?:W+2=6D$^N19UI>A:X4[4J!,L
M
M                    SPN&_P"^C[[]\'E!^KE-@:'H
M                                                          X
MZL7[++J6?, YD?JZ[& K@^"7^(+RN^=^X^!C5P%ST
M   !X_R%_(%O'WG]E^PN: HS@
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MO\EO3L_'_D?['=/ 7/>)OQ6.-'S?]-?!UC@'0
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MVM%'$O>U0N[\<Z22"_P                   $ ?7,_Z+O_ "V?\T8$ 8
M                                     _?Q3_"C&_\ C^'_ )Q; 7V0
M                   SP^N%^]>]+#WP.FE^N!, :'@
M
M        #/"X;_OH^^_?!Y0?JY38&AZ
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M3B>,MK:K77W^198W"-$4Z4KW:)IV]VE+>RE G>
M  *(7CB_R6].S\?^1_L=T\!<]XF_%8XT?-_TU\'6. =
M                   C$ZI'2DT%U;=3:[TOR,V)O?!<)UML2NT(I#1V48+C
M3N8RFS&IG%&2V179YK;93%XWBXG(7UK:B"#95.YRIVJ76W5M @]^Q4]++W?.
M?_YT^.O^BJ ^Q4]++W?.?_YT^.O^BJ!+ETJ.B-Q3Z0$CO"3XU; Y"9POOUEK
MUCF-F\LKUQDJ,:CK5?,W$%=C5N ZGUG>S4=WYR[H[JZN>44HFCY.B7=OJH'S
M_5.Z$7$7JZYUJC8/)+8O(["9G3V)3N&XRVTAEVLL;C'T9D$PA-O5YU'/-0;*
M=N7Z3MO;:E<W6:IVIUK2ZRZOW5 E^P'#8S76"X7KZ$7?NH;!,2QS#8AS*JMU
MY-S&8Q#LX1@O(K-&K%HL_6:,;+EKDD44[E*UK;993LMH$:G42Z+?3[ZGZD?/
M<G=1N?;0A87UO06[M:SBV";9C(1.U_<RB7,ZU;O8C*HJ)=R*KADTG8^5:M%[
M[[DD[:*K6J!&!H[P?W2(T_F;/+\JLY,\B6L>Y:/&N%;QVUC-N&><LKEE$KGC
M'3.M-.S$LV47OLO5;/'R[1>B-J:B5R5RR:H6;\)P?#-:8CCFO]=8GC>"8+A\
M0RQ_$\-P^$C<;Q;&8*-1M;Q\/ P,.V9Q<3&,D+*6)(())IV6T[*4H!]0
M               $ ?7,_P"B[_RV?\T8$ 8
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MP-#T
M                  < =6+]EEU+/F <R/U==C 5P?!+_$%Y7?._<? QJX"Y
MZ                       \?Y"_D"WC[S^R_87- 49P
M                         L]]%;XK.?>__E/P=:K E]
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M.F\4QO,7L?=WXY[L!VVOG]AO(R_^&^,=9Q,2"C:ZOW54+K:U]7M [;
M         BVY1];#I6<,\GE,'Y"\U]28OG,"_1BLBP;$O75N+-\8DU_.JTCL
MJP_2^-["R3%WZ-C2MRR,@U;*(6*(W*4LM71JH'Q.@^OIT>N2^2,L0U5SPU%Z
MY9.5:P43$[-99YH9Q-3+^EM(^,A+M[X?K9&:>R*U]J#=-K<M<X=7V()]Y:^U
M.H2_@      HA>.+_);T[/Q_Y'^QW3P%SWB;\5CC1\W_ $U\'6. =
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M                   9X?7"_>O>EA[X'32_7 F -#P
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M#_\ %ZYZ>_-I[V$96!>6
M#/"X;_OH^^_?!Y0?JY38&AZ
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MH&@>     %$+QQ?Y+>G9^/\ R/\ 8[IX"Y[Q-^*QQH^;_IKX.L< Z
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MH^^_?!Y0?JY38&AZ
M                              . .K%^RRZEGS .9'ZNNQ@*X/@E_B"\
MKOG?N/@8U<!<]                       >/\ (7\@6\?>?V7["YH"C.
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M$+QQ?Y+>G9^/_(_V.Z> N>\3?BL<:/F_Z:^#K' .@
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M-]RBCB4A;WBUU+GUMH%B8              " /KF?]%W_EL_YHP( P
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MOXI_A1C?_'\/_.+8"^R
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M33SV'FF*$E&._-7R#9ZV\Y9.;+_)K)IJV=[LOMMNI6E _9
M                         &>%PW_?1]]^^#R@_5RFP-#T
M
M  < =6+]EEU+/F <R/U==C 5P?!+_$%Y7?._<? QJX"YZ
M        \?Y"_D"WC[S^R_87- 49P
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M>N,DBJ7J6LK9K,=+M]I+2*J'>1;KRLIN_3#F]%?N7J))S*R=*_RBE:A>2
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MY!*UE(N(>,Q]&%U__(.;DU4'6492]4M96+4LHJDY04M^X5MNJ%;\
M    /W\4_P *,;_X_A_YQ; 7V0                   ^=?9?B<7+-(&2RC
M'8Z=?W-K&,*^FXUI+/+WJU6[.UI'.'*;QQ<[<4\FE2RRM5+_ +FWMKZ@'T0
M                                   #.N\6W^UZZ:OO5:L_6<R\#11
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M3:RSRBRBBM_=[;[KKJUK4/V0
M  !GA<-_WT???O@\H/U<IL#0]
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M_C^'_G%L!?9                   #/#ZX7[U[TL/? Z:7ZX$P!H>
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M4.-X9+@.22+"1Q:*D(B/1@%<"UGK5LU9+-I*^Y:UPBZONOI;6V^RE*VU"5@
M                                       ,\+AO^^C[[]\'E!^KE-@:
M'H
M                X ZL7[++J6?, YD?JZ[& K@^"7^(+RN^=^X^!C5P%ST
M                     !X_R%_(%O'WG]E^PN: HS@
M                      !9[Z*WQ6<^]_\ RGX.M5@2^@
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MRQ&[NAL8L&2$<Q9Q[:EU&S!HW9-Z7W=^^B#5&Q!*EU]?5NNHG93MK_=J!_6
M   *(7CB_P EO3L_'_D?['=/ 7/>)OQ6.-'S?]-?!UC@'0
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M_G%L!?9                   #/#ZX7[U[TL/? Z:7ZX$P!H>
M
M                ,\+AO^^C[[]\'E!^KE-@:'H
M                                                     X ZL7[+
M+J6?, YD?JZ[& K@^"7^(+RN^=^X^!C5P%ST                      !X
M_P A?R!;Q]Y_9?L+F@*,X
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M\EO3L_'_ )'^QW3P%SWB;\5CC1\W_37P=8X!T
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MO!-7BR2:<IE$ZY66E,MS?(+DJUL6R+-<G?.Y-[=;7R=J[JZQ.EJ5MEEH=1
M             0!]<S_HN_\ +9_S1@0!@
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M!Y0?JY38&AZ
M                         . .K%^RRZEGS .9'ZNNQ@*X/@E_B"\KOG?N
M/@8U<!<]                       >/\A?R!;Q]Y_9?L+F@*,X
M                                6>^BM\5G/O?_ ,I^#K58$OH
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MT[/Q_P"1_L=T\!<]XF_%8XT?-_TU\'6. =
M                                        ( ^N9_T7?^6S_FC @#
M          "4=YJW!N*?"-OGVQ,.Q;*>07*I*UEK:-S"!B)^_5^M4V]CM]ET
M7&S;%VFPR5]&/D;[7B7=<M59%EY.MER#BV\/YN%7)SAAI?5D_BW(OCW[;&;/
M\_E9^+R+VI]4YWYEBSK'<5CF4+Z7SJ?BI9MYM+13Y?S9-.YM9YSW[;JWJ*4H
M'8:'/+I=.ET6K7A,JY<N54T&[=#C=QX67776OHFDBBDGF%RBJJJEU+;;;:5K
M=6O93U0/5.?K?B-JKBPX7IQVUOK+;&X()%IKO&TM4ZR@]CXX\JK&O9:1E'>,
M(ODH'UNLEJ)NE&SU:MKA=-"VZMU]U;0K7(HK.%DF[=)1===2Q%!!&RY59996
MZEB:22=E+KU%%+[J4MMI2M:UKV4 G-WY7C+PYV7PFUYL+2^$Y<QP'5\YE.^[
M(C6N"3V5Y],Y%A$MA>-J3=)ZZ-CIY)KF[=Y)>1?OE:H6V(JI_=I(^4#ZO]/G
MI9_(L_S<N.W]<0.O=!Y)P,Y X'G.TX?B#@V :TU^BZ6F\ZV=HC2,%CZ]8YG?
M(S"<6K"/LE=O+H1C;:HZNJC8E9Y6RRV^Y2M;*! 7;@4!RYYF/\,T;"M,)PG9
M>Q)&N,M&L"RAV&*X,Q35>R,O;CL31%@P38P,<N[L9V53MJI6U+O6W7=X"7K8
M&0=+O@L_3U!D.F6VW<Z8LXJ[*?.L#Q3:V3L%%V:CYF\R"6V'(1&/P[Z2;.[5
MKV<7<E6B:J-US>Q/R5:!Y1R.XM\4>2/&C+.4?#:,:X[-8+24E\HQB#:/H>.>
MLX>Q.4RN"D\-<77ML8GX.%=5?M/1Z:;5PA;1.VU1-5%5((M.(FPM;:_W;C=^
MY,)P[.=5Y9Y3"LX9YA 1,TG Q&0WI-+<NAW4DU<.8&3QEY5-U<[9W)._-+%D
MT[[;KZ74#^WF3QKD>+>[Y[7WE5Y#$9!)/)]=SRU:*5F,,E55Z1_EW":::*TE
M$KH*LG5;;;;;UD*J6VT34L[0Y5           '[^*?X48W_Q_#_SBV OL@
M                !GA]<+]Z]Z6'O@=-+]<"8 T/
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M>[Q#,8YZQ\I=;95PDC8O;;2Q6WM#L8
M      !GA<-_WT???O@\H/U<IL#0]
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MZO3CO_1R1_"X#ZA'HX_ZO3CO_1R1_"X#ZA'HX_ZO3CO_ $<D?PN ^H1Z./\
MJ].._P#1R1_"X$G>K]8X!I;7>&:EU5BL5@VM]=X[&8EA&'P25Z$-C6-PS:QI
M%PT8BHHK>DR8MD[;$[:W75I;3^$#[L                        HA>.+_
M "6].S\?^1_L=T\!<]XF_%8XT?-_TU\'6. =
M          !X/RAY#87Q+XZ[JY-;&C,HFL#T3K?*MH9=$X2RB9'+I& Q"+7E
MY)GCC"=F\;AG<PNV;W6H)NG[-&Z^M*7JV4^ZH%7K[:MTLO<#Y_\ YK..O^E4
M ^VK=++W ^?_ .:SCK_I5 /MJW2R]P/G_P#FLXZ_Z50#[:MTLO<#Y_\ YK..
MO^E4 ^VK=++W ^?_ .:SCK_I5 /MJW2R]P/G_P#FLXZ_Z50#[:MTLO<#Y_\
MYK..O^E4 ^VK=++W ^?_ .:SCK_I5 /MJW2R]P/G_P#FLXZ_Z50$@_32\1AP
MDZJ'(I[QEX^:NY3X=GC#6^3;06EMR83J3'L1N@,5E,<B)!FF_P )W?L.9K,+
M.<G;W(IU841NLL4K<K96EMMX3[                  " /KF?\ 1=_Y;/\
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M
M             #@#JQ?LLNI9\P#F1^KKL8"N#X)?X@O*[YW[CX&-7 7/0
M                   'C_(7\@6\?>?V7["YH"C.
M                    %GOHK?%9S[W_ /*?@ZU6!+Z
M         &?3UIO%7[?7VWE/$/I22+*+CH">5P/*.4;''H_-LNV!E]7%\-(8
MYQ_@I1G,PC7';'ZU6:4^JQ=R4F[M\K$^:HV-WCP*PW,_#>M-AF"8[R,YZO\
MG-C.&;3RMI!8UD_(O8&RHMW-9,M%3<['1+'#<QR1'(8=-G"1KQ1LCZ-:M6;:
MVEB=$[+TK;@OPX.OR*R'PF>&?HY06T]B<A<DX48W&X?':N6G'^UY%]D&P&49
MDDSC"D0Z2R5_.0F+O7\C6UG?>^6L:WVHV*JUM3N" /HM^)\Y,<<-T8OQ-ZG^
M7Y-LS2$ODS77ZVY=IV.T=W<=,B5D;8BQ_L>>F:-IG,]?Q4C?6V=MFJ+3T2A2
MYPBX5L;5CUPTID5D7"*3ANJFN@NG8L@NC?:JBLBK;2]-5)2RMUBB:EEU*VW4
MK6E:5[: ?Z                        %$+QQ?Y+>G9^/_ "/]CNG@+GO$
MWXK'&CYO^FO@ZQP#H                                  /C=AZ\P7;
M6"Y9K+9N)P.=Z]SN!D<7S/#,HCFTOCN3X[+MKVDI"S46[L4:OXU^U4N3524M
MK9?96M*T CR^I2Z1_P#JY>('YC\)_!8#ZE+I'_ZN7B!^8_"?P6 ^I2Z1_P#J
MY>('YC\)_!8#ZE+I'_ZN7B!^8_"?P6!1L\7[PVXI\0-C\&(WBYQ[U+H)AG6$
M[W>YBSU5A<-AK?)GD#.ZO0A7,TE#MFUK]:+1E'-J%RG;5.U>^E/[ZH%Y/ZE+
MI'_ZN7B!^8_"?P6 ^I2Z1_\ JY>('YC\)_!8#ZE+I'_ZN7B!^8_"?P6 ^I2Z
M1_\ JY>('YC\)_!8'MV@>G+P.XK9TMLWC=Q&T%I#82\#(8NMF>M-;8WB>1*X
M[*N6#N2A;Y2*9-W5T:^=1;915+O=R^]"RM:?<T [1                  $
M ?7,_P"B[_RV?\T8$ 8           DHZ3'FOZ:F#^<>3\KZU=@^9=_L[WG7
MK5?]_P C_P#O/,O+=O\ ]9W@/!><_G/Z7_(GSO\ W7VT<C[G_P##><6^9?P_
M_>?DP.40)^.2B]>(W3#U)I",K;'YMO!-A?EBB%;K'-49=-+.<]K>I=?2]2YO
M5S'P:GW/=N:*UIZGJ 0#@3!=-2Q+3VG^7?+E^DW36U_KQ;",(<N4*WV+95)(
M6S%6-JMU.XG5S-4@4+N[VW=UUZO92O9<$0"BBBRBBRREZJJM]RBJJEUUZBBE
M]U;KU%+[JUNOOONK6M:UK6M:U FOZ.VOH:*E-X<F,LM32@]6X@O!1SQ2E;JM
M%7C)QD>722-*W6)6+QF.PZ27;=7U4WU]/4]6H$2>WMDS6X=H9[M#(+KJRN<Y
M1+Y"NC=?6^UB@^=7WL(M"ZO;7S2(CZ)-4:>KW4D;:?W ),^B_D3>+Y/9A!N;
M^Y=D^GI]!C3ML_E9"*RC$)2B79=2E]?_ %:BZO\ N:_^X>K;6GJVA'1R'QMY
MB&^]TXP^0O;.(3:>>Q]4[[;[>\BCE$G1JNGY2MU][=TUK8JE?VU[Z=]MU*UI
M7M ELZ*<9?&3/(S8TC11KCF/8ABT8\D+[*^;TO6=3LZ]I9V6UN648L82EZE+
M.VMEJMO;3[NT"$&6?UE)63D[K*)W2,@\?W)V]O995VY4<5LIVUNKV6U4[/X:
M@3C:._8V;[])^3\U]<V2>C_*_P![_A%@7FG9V^IY3TSWNY_]?V 04@
M    #]_%/\*,;_X_A_YQ; 7V0
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M]'WW[X/*#]7*; T/0
M                              !P!U8OV674L^8!S(_5UV,!7!\$O\07
ME=\[]Q\#&K@+GH                      #Q_D+^0+>/O/[+]A<T!1G
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MD9-Y]T]D;]$YQEVBT7SU6MEE[IZ[;:XL467O[RCA2ZY2^Z^ZZM]P2_@
M                  %$+QQ?Y+>G9^/_ "/]CNG@+GO$WXK'&CYO^FO@ZQP#
MH                                        9X?CB_RJ=.WWO\ D=[(
M]0 :'@                       ! 'US/^B[_RV?\ -&! &
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M.$8=G92EU4+NVO;9=2H0A           #]_%/\*,;_X_A_YQ; 7V0
M            IZ=43J[<Z.,G7XX'<#=/[+QV XT[TR[A/$[(PY]K? YZ6EV.
MZ.14CKW8";7+YF!>9/$W2N+-[$$KFSI*YK?3RB-;%*]X"X6
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M!)F%C(;4,*Z1510N;W.,*C[)NJ5U*J(JSBB=]>]9W;0LF@
M                      ,\+AO^^C[[]\'E!^KE-@:'H
M                                                           X
M ZL7[++J6?, YD?JZ[& K@^"7^(+RN^=^X^!C5P%ST
M    !X_R%_(%O'WG]E^PN: HS@
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M&^RME]B=]MR=H2^                        %$+QQ?Y+>G9^/_(_V.Z>
MN>\3?BL<:/F_Z:^#K' .@
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M^'_G%L!?9                   #/#ZX7[U[TL/? Z:7ZX$P!H>
M                        #^=XS:2#1TP?M6SY@^;+LWK)X@DY:/&CE*Y%
MRU=-EK;T7#9PC?=9?9?;6V^VM:5I6E0(0NF'TQ]U=,7DSS&Q#5^8ZPE^FEO_
M "BS=FEM5*3^9-MN\?=QR5(UAE6)1.,JX6ZPJ5UA+P:5K9)_ZXTY%%"%C$[F
M2E]7+BX)Q0          !!MU..F+N[J=\G^'^)[5S;6$+TS>/N27;JW!J1M.
M9B]V[R'W/'U>L<8Q>?QVW#&6&0NL(6!54:7/K,C5D54)F33\RMON:N$0G#;-
MF[-N@S9H(M6C5%)LU:MDK$&[9NA9:D@@@@E;:DBBBE;2VRRVE+;;:4I2G8!_
ML                                     SPN&_[Z/OOWP>4'ZN4V!H>
M@
M              #@#JQ?LLNI9\P#F1^KKL8"N#X)?X@O*[YW[CX&-7 7/0
M                    'C_(7\@6\?>?V7["YH"C.
M                     %GOHK?%9S[W_P#*?@ZU6!+Z
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M\!<]XF_%8XT?-_TU\'6. =
M  #/#\<7^53IV^]_R.]D>H -#P                        @#ZYG_ $7?
M^6S_ )HP( P                                      !^_BG^%&-_\
M?P_\XM@+[(                   9X?7"_>O>EA[X'32_7 F -#P
M                                                         !Y?
MN/<>!:&P*4V7LN4<P^(P[F,:/W[2,D)==)>7D&\8QMM8QC=R\5HJ\<V6UK;9
M6EM*]M>RE .,?K7^$WNC9!^;O-_P( ^M?X3>Z-D'YN\W_ @#ZU_A-[HV0?F[
MS?\  @#ZU_A-[HV0?F[S?\" /K7^$WNC9!^;O-_P( ^M?X3>Z-D'YN\W_ @#
MZU_A-[HV0?F[S?\  @#ZU_A-[HV0?F[S?\" /K7^$WNC9!^;O-_P( ^M?X3>
MZ-D'YN\W_ @#ZU_A-[HV0?F[S?\  @#ZU_A-[HV0?F[S?\" /K7^$WNC9!^;
MO-_P( ^M?X3>Z-D'YN\W_ @#ZU_A-[HV0?F[S?\  @#ZU_A-[HV0?F[S?\"
M/K7^$WNC9!^;O-_P(!3BXV-9C7GB:-M=1?+()_&\1,IS#>TM";,L<PKYZ[8Y
MKIB4Q#&UKL$82SG/VU7\^YL1K:K&67(TKWU*6ITK<!<=^M?X3>Z-D'YN\W_
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M\:V+A+U:1Q3+8VR6@WSADZCEG+)111*U11D^20=MKJWI74[JEEMWJ?P ?;
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MIX"Y[Q-^*QQH^;_IKX.L< Z
M   &>'XXO\JG3M][_D=[(]0 :'@                       ! 'US/^B[_
M ,MG_-&! &                                       /W\4_PHQO\
MX_A_YQ; 7V0                   SP^N%^]>]+#WP.FE^N!, :'@
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M[7SR P./G)-HS0H[=1\2[G['"R:5:*7IIUMM^ZK0"X:
M (X>J_\ $FV-^,&N_9O" 5)0
M    N<\!/B;<>_Q :?\ I[\#K\
M                   < =6+]EEU+/F <R/U==C 5P?!+_$%Y7?._<? QJX"
MYZ                       \?Y"_D"WC[S^R_87- 49P
M                          L]]%;XK.?>_P#Y3\'6JP)?0
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M_P EO3L_'_D?['=/ 7/>)OQ6.-'S?]-?!UC@'0
M                  SP_'%_E4Z=OO?\CO9'J #0\
M     ( ^N9_T7?\ EL_YHP( P
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M-/\ T]^!U^
M   . .K%^RRZEGS .9'ZNNQ@*X/@E_B"\KOG?N/@8U<!<]
M         >/\A?R!;Q]Y_9?L+F@*,X
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MFI;7^\=FZRLDDX+%X^*@(VUVQPQ&_P FV;(V>KVUMI=6H$KX
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MJ #0\                        ( ^N9_T7?\ EL_YHP( P
M                           !^_BG^%&-_P#'\/\ SBV OL@
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MZQP#H                                        9X?CB_RJ=.WWO\
MD=[(]0 :'@                       ! 'US/^B[_RV?\ -&! &
M                                /W\4_P *,;_X_A_YQ; 7V0
M             AIY4]<;B=Q#Z@^@>FULG7O(B;WER,F-'0F$97@^)ZVDM3Q;
MK?VR'.KL.4RJ=GMM8UE[%O&S[6Y:3JT@GUR+.M+T+7"G:E0)E@
M                            !6!\7E^QMS3YP&B?Y\E .O\ PWG[$K@1
M^(&POAQVB!-^                       CAZK_ ,2;8WXP:[]F\(!4E
M            ZIX08'39'+30F+J(^<-?;"B<CD$*IWJ)KQF%46S.206MLK2M
M$7#& 43OKVTI2V[M GUY?=4"/XL;B<ZB9Z>IL=Q'8Y!3,M,4V-;BE6$A.6.7
M:</=&4P;)JJ51B_-G'EJKV5NHY[/)TI;2Z\.7?KS/_R7?_AV?_BC @ZV9F7M
MB[(V#L'T=Z']?>;Y7F7HCSSTAZ*]<\\_F_1WG_FK'S[S'S[R7EO(H^5[O>[E
MG;W:!\0  ],T]J3--Y['Q;5^ QUTCDF4R*;-"MU%*,HQE;_*R4Y++)V*5:Q$
M,QMO<.5.[==1.RM+;;KZVVW!:.W/H_"..W3GW'JG Z>6C,?U?D59.65HEZ0R
M'(W%$+IR>E:I77VVOW[NW_<^]6UNC:FA9V6)VTH%24               !<Y
MX"?$VX]_B T_]/?@=?@                                !6-Z\GY6]
M"^]SDGLFL)3+_<5>FU0_>'_UEJ[]&7_W\(&20:[P
M                  Z+X??&VXN?.+TE\)>,E.]\#7[V?49.V)_;-JC_ '/E
M?QZPOFG'WH@  'C_ "%_(%O'WG]E^PN: HS@
M               !9[Z*WQ6<^]__ "GX.M5@2^@
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M<!,L%%F$M$2"/8HW<H7WHKI74O3NNLNI6H?8@             I8^*RZU'M
MZ[E^F5QDR113?NZ\9;M^1>4X\X\L]U=I_+6U;$M9LE6E]ZC?8&X8E;N.TKJ>
M68XNYK=2SRDHT71#MGPT'1E1Z;_&BN_]XXSYIS,Y,8[&2&7LY1M;;)Z6U2XO
M;S.,:>0M4[ZS#(GZUJ,KE/9Y*ZLC1LQOLKZ+M66"!+QP'QA>!?O,[A]F^* 6
M[.@C^QQZ>GS=\<_G&7 EV  4CNH7@7BXI/FMR-?\'WV:)\3'6Q'JNB;(_9'
M:)96X-5A'T:4;QVS,I9YXS3\\HO]Q*)6.J?W:=G8!QI[6GCC/_9+8'YV>F9_
M7(![6GCC/_9+8'YV>F9_7("#_K4XOUXL>QCC]?UDW.1.,:=3VP[="TG,OXN9
M/9;.)1^)5V!5LGQWFY9XSNJP4B>]65I8E?3LHA6MU%>P-7SB;\5CC1\W_37P
M=8X!T                                        ,\/QQ?Y5.G;[W_(
M[V1Z@ T/                        " /KF?\ 1=_Y;/\ FC @#
M                                '[^*?X48W_Q_#_SBV OL@
M           !GA]<+]Z]Z6'O@=-+]<"8 T/
M              !6!\7E^QMS3YP&B?Y\E .O_#>?L2N!'X@;"^'':($WX
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MPK==7LI2E.WLI2E.R@%:X               !<YX"?$VX]_B T_]/?@=?@
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M@+[(                   9X?7"_>O>EA[X'32_7 F -#P
M                          5@?%Y?L;<T^<!HG^?)0#K_ ,-Y^Q*X$?B!
ML+X<=H@3?@                      (X>J_P#$FV-^,&N_9O" 5)0
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M5_'K"^:<?>B   >/\A?R!;Q]Y_9?L+F@*,X
M               6>^BM\5G/O?\ \I^#K58$OH
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MN'#,QB'<#D<-Z:QF2ALBB?2,2^52\X8NVSM'O=Y)6R^E+J!"3]EQZ%'R&?\
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MG;[W_([V1Z@ T/                        " /KF?]%W_ );/^:," ,
M                                     ?OXI_A1C?\ Q_#_ ,XM@+[(
M                   9X?7"_>O>EA[X'32_7 F -#P
M                      5@?%Y?L;<T^<!HG^?)0#K_ ,-Y^Q*X$?B!L+X<
M=H@3?@                      (X>J_P#$FV-^,&N_9O" 5)0
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M#19M43%/#MTQ'=:;XZCGWK,"_P#LYLO,#\!_C+IAU[/MVK^B,)ZMU$J7CIJ
M /:./.D,JY&[CP;3N'V^3E,PE[&KF3O05<-("$;67O)[(7]B5.]5G#12"J];
M>VVJMUMJ=M>]?:?%RY%JB:ZNY#G6S34'.-I^N^7ZD9)N8O'7HIJKF)FFS:IB
M:KUZN(_RVK<553&YPIB*8G35"='J@[RQ3BOH?!.!&@KZ0B;_ !1JGGJC56Q1
M]'Z_OO5K;$OW:=UJOI_8\O19Y)J5I;>JT\I2ZVJ;WU+#"VYNW)Q%SO[GI^PV
M"=;3:!D^R'9YE_5UV<SR>FY@Z8Q<TS$UT8.9G]G75&[X[&W.%<OSN35;X43'
M!OJXQ)-8(             #HOA]\;;BY\XO27PEXR4[WP-?O9]1D[8G]LVJ/
M]SY7\>L+YIQ]Z(  !X_R%_(%O'WG]E^PN: HS@
M                 !9[Z*WQ6<^]_P#RGX.M5@2^@
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MZ?9=3O0>R^0VW=CXPO\ =4I7_A6-96T5_P#)7O\ J=M.RH$YX
M    "J%XC#H4\M^KOM/C-G'&W8G'/"(G3.O\]Q3*&^\,NV9C<B_D<IR.$EX]
M: 2P+46RFSIDBVC;[5KG"S6^V^MM+;+Z5K=0)T^F5QBSWAAP'XL<6=HR^(3V
MP='ZJB<&RR8P%_,RF&R$LP=OUUG&/2&0P&+3;N.NL=6TMO<QS16M:5[4Z>IV
MAW4     %$+QQ?Y+>G9^/_(_V.Z> N>\3?BL<:/F_P"FO@ZQP#H
M                               9X?CB_P JG3M][_D=[(]0 :'@
M                   ! 'US/^B[_P MG_-&! &
M                  /W\4_PHQO_ (_A_P"<6P%]D
M*%/68XY<A<Z\3WTS]MX1HC<V9:IQ/.NG<XRG9N*ZOS?(=>XTWQCE=+3.2KS^
M:1$&\QN&1QZ'OH[?7.'*=K1M6BJM;+*]X"^L
M               *P/B\OV-N:?. T3_/DH!U_P"&\_8E<"/Q V%\..T0)OP
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MOE>YW^]9V]V@1Q@               +G/ 3XFW'O\0&G_I[\#K\
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MQV@ZZ9IM$UTS+73.9F<=F&*JNZ-.F+='N;5JG3_DLVHHM4?]M$/)S[<.
M          =%\/OC;<7/G%Z2^$O&2G>^!K][/J,G;$_MFU1_N?*_CUA?-./O
M1   /'^0OY MX^\_LOV%S0%&<
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M'Y$^M_YW>Z=COYM<!_  Y%A^]._)VUNL+YVPO,<'Y$^M_P"=WNG8[^;7 ?P
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M'Y$^M_YW>Z=COYM<!_  Y%A^]._)VUNL+YVPO,<'Y$^M_P"=WNG8[^;7 ?P
M.18?O3OR=M;K"^=L+S'!^134])SEIO#E5C^['^ZLDC\B=87,X.SQ^]ACD%CU
M&J$VRR9:1M5LA&+&QU552-1K2JE+JV=VO9V=M2QQ=FW9FF*(T:=+O;U.-LNO
M^U_+<^Q.O>*M8J[@;^%ILS19M6>#%VF_->F+5%'"TS13[K3HT;G=E+N6;ND
M ( ^N9_T7?\ EL_YHP( P                                      !
M^_BG^%&-_P#'\/\ SBV OL@
M                      "L#XO+]C;FGS@-$_SY* =?^&\_8E<"/Q V%\..
MT0)OP                      $</5?^)-L;\8-=^S>$ J2@
M                            !<YX"?$VX]_B T_]/?@=?@
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M4?[GROX]87S3C[T0  #Q_D+^0+>/O/[+]A<T!1G
M                   "SWT5OBLY][_^4_!UJL"7T
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MT/+QRSF/DXR0:+6*H.$%+TE4[J76W5MK2H'ZX
M    *(7CB_R6].S\?^1_L=T\!<]XF_%8XT?-_P!-?!UC@'0
M       9TYR1YD0                                       63N@C_
M ()<EOQBUC_-F:D9F'NJ?2GUFTK[NK^3:U?Q6 _4Q2P41S9(  ( ^N9_T7?^
M6S_FC @#                                       '[^*?X48W_P ?
MP_\ .+8"^R                   'SK[+\3BY9I R648['3K^YM8QA7TW&M
M)9Y>]6JW9VM(YPY3>.+G;BGDTJ665JI?]S;VU]0#Z(
M                     5@?%Y?L;<T^<!HG^?)0#K_PWG[$K@1^(&POAQVB
M!-^                       CAZK_Q)MC?C!KOV;P@%24
M                           +G/ 3XFW'O\0&G_I[\#K\
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ML+F@*,X                                        6>^BM\5G/O?\
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MX=.E[6L#+W90RG6,>BFD@V<MY5?MK>ZK0#0%
M   !1"\<7^2WIV?C_P C_8[IX"Y[Q-^*QQH^;_IKX.L< Z
M      #.G.2/,B                                       "R=T$?\
M$N2WXQ:Q_FS-2,S#W5/I3ZS:5]W5_)M:OXK ?J8I8*(YLD  $ ?7,_Z+O_+9
M_P T8$ 8                                       _?Q3_  HQO_C^
M'_G%L!?9                   #/#ZX7[U[TL/? Z:7ZX$P!H>
M                              "L#XO+]C;FGS@-$_SY* =?^&\_8E<"
M/Q V%\..T0)OP                      $</5?^)-L;\8-=^S>$ J2@
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M>E[%Q6ERCI6^H11            !<YX"?$VX]_B T_\ 3WX'7X
M                       5C>O)^5O0OO<Y)[)K"4R_W%7IM4/WA_\ 66KO
MT9?_ '\(&20:[P                                      Z+X??&VX
MN?.+TE\)>,E.]\#7[V?49.V)_;-JC_<^5_'K"^:<?>B   >/\A?R!;Q]Y_9?
ML+F@*,X                                        6>^BM\5G/O?\
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MZ> N>\3?BL<:/F_Z:^#K' .@                    SISDCS(@
M                               LG=!'_!+DM^,6L?YLS4C,P]U3Z4^L
MVE?=U?R;6K^*P'ZF*6"B.;)  ! 'US/^B[_RV?\ -&! &
M                        /W\4_P *,;_X_A_YQ; 7V0
M     SP^N%^]>]+#WP.FE^N!, :'@
M        K ^+R_8VYI\X#1/\^2@'7_AO/V)7 C\0-A?#CM$";\
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MI7U:767VUI6G_E _S           %SG@)\3;CW^(#3_T]^!U^
M                      %8WKR?E;T+[W.2>R:PE,O]Q5Z;5#]X?_66KOT9
M?_?P@9)!KO                                      #HOA]\;;BY\X
MO27PEXR4[WP-?O9]1D[8G]LVJ/\ <^5_'K"^:<?>B   >/\ (7\@6\?>?V7[
M"YH"C.                                        %GOHK?%9S[W_\
M*?@ZU6!+Z                        9)//[]Z+RK_ ,3+CQ[/M3@:VP #
M))\.A^\8<:??$YG_ *L/)4#6V                           !1"\<7^2
MWIV?C_R/]CNG@+GO$WXK'&CYO^FO@ZQP#H                    ,Z<Y(\
MR(                                       +)W01_P2Y+?C%K'^;,U
M(S,/=4^E/K-I7W=7\FUJ_BL!^IBE@HCFR0  0!]<S_HN_P#+9_S1@0!@
M                                  #]_%/\*,;_ ./X?^<6P%]D
M               ,\/KA?O7O2P]\#II?K@3 &AX
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M0"'G.';5_FF7OF5]JC)YE&0.VE]E*4LO:N)9VLWOMI3U*6W)7TK3_P!L!\N
M          +G/ 3XFW'O\0&G_I[\#K\
M    *QO7D_*WH7WN<D]DUA*9?[BKTVJ'[P_^LM7?HR_^_A R2#7>
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M27PEXR4[WP-?O9]1D[8G]LVJ/]SY7\>L+YIQ]Z(  !X_R%_(%O'WG]E^PN:
MHS@                                       !9[Z*WQ6<^]_\ RGX.
MM5@2^@                       &.'UN-@Y1J7KN<R-JX0\1CLTUGRL@=@
MXA(.6;61;L<HPQIAF1P#Q>/>IK,WR+66C4K[T5K+TE;;:VWTK;6M .AOM8?6
MR^4/KOZ/&E?ZF@/M8?6R^4/KOZ/&E?ZF@0P\8.9&^^'O)[%.86B,GC,:WOA<
MGG4OC^2R>,P.2QK5_LC$LJPC+%5<:G6+Z"=6OL=S202LM40NM0O5MO3I;?99
M6@3/?:P^ME\H?7?T>-*_U- ?:P^ME\H?7?T>-*_U- TSNF1O#8O);I[<-N0&
MW)9I.[/W#QYUGL'/)EC%1T$SD\HR7'&<C+/&T/$-VD9&(KNEKKK44$K$K*>I
M;2E .Z                        "B%XXO\EO3L_'_ )'^QW3P%SWB;\5C
MC1\W_37P=8X!T                    &=.<D>9$
M                    %D[H(_X)<EOQBUC_ #9FI&9A[JGTI]9M*^[J_DVM
M7\5@/U,4L%$<V2  " /KF?\ 1=_Y;/\ FC @#
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MM.Y2M A)            "YSP$^)MQ[_$!I_Z>_ Z_
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ML+F@*,X                                        6>^BM\5G/O?\
M\I^#K58$OH                       !X[.<=^/^3R\AD&2Z,T[D,]+.;W
MDK-SFLL*EI>2=J=GE'4A)/X1P\>.;^RG;>I?==7L]6H'Y7Z+7&3Y.>B/S1:_
M_J\ _1:XR?)ST1^:+7_]7@'Z+7&3Y.>B/S1:_P#ZO /T6N,GR<]$?FBU_P#U
M> ?HM<9/DYZ(_-%K_P#J\![)"PD-C<3'P./1,9 P<0T1814+"L&L7$QC%O92
MQNSCXYBD@S9-$+*=EB:=EMEM/4I2@'Z8                       !1"\<
M7^2WIV?C_P C_8[IX"Y[Q-^*QQH^;_IKX.L< Z                    #.
MG.2/,B                                       "R=T$?\$N2WXQ:Q
M_FS-2,S#W5/I3ZS:5]W5_)M:OXK ?J8I8*(YLD  $ ?7,_Z+O_+9_P T8$ 8
M                                       _?Q3_  HQO_C^'_G%L!?9
M                   "/#>'2DX"\D.5^J^<.Z-"^O/E%I20UI*ZRV?[:.Z,
M=];+_3^8+9]KE?UE8IL6"UY,^MW+'%[ONR$2[L=]ODG5%D:43H$AX
M            4FNIW\>[D/\ C'C?L"Q,G,+_ +>G\O1EH9ZV'_R%UF_BK'Q3
M#N#"X==P                                      E;Z,GQVX+WNM@?
MS>U+3&_ ?XP[A]1G[>L/]%XS]2E;](9NK  $</5?^)-L;\8-=^S>$ J2@
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M %;%]GE,8OJ#ZRV<7&FS;QE^:-/_ &8C!7:9_P +O<_/"O\ $BUP
M  !T7P^^-MQ<^<7I+X2\9*=[X&OWL^HR=L3^V;5'^Y\K^/6%\TX^]$   \?Y
M"_D"WC[S^R_87- 49P                                        L]
M]%;XK.?>_P#Y3\'6JP)?0
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M/>)OQ6.-'S?]-?!UC@'0                    9TYR1YD0
M                           63N@C_@ER6_&+6/\ -F:D9F'NJ?2GUFTK
M[NK^3:U?Q6 _4Q2P41S9(  ( ^N9_P!%W_EL_P":," ,
M                       ?OXI_A1C?_'\/_.+8"^R
M                       %)KJ=_'NY#_C'C?L"Q,G,+_MZ?R]&6AGK8?\
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M*7!HW@    !1"\<7^2WIV?C_ ,C_ &.Z> N>\3?BL<:/F_Z:^#K' .@
M               SISDCS(@
M  LG=!'_  2Y+?C%K'^;,U(S,/=4^E/K-I7W=7\FUJ_BL!^IBE@HCFR0  0!
M]<S_ *+O_+9_S1@0!@                                      #]_%
M/\*,;_X_A_YQ; 7V0                   J+=37K(<UN+/7BX,=/S4TYKM
MGQUWYEG#"'V%&SF ,)K+'++=_(21UQG=L5E*SI-U&*.,9;6V-KK;+O-EOY2G
M;7U +=(                   4FNIW\>[D/^,>-^P+$R<PO^WI_+T9:&>MA
M_P#(76;^*L?%,.X,+AUW                                      "5
MOHR?';@O>ZV!_-[4M,;\!_C#N'U&?MZP_P!%XS]2E;](9NK  $</5?\ B3;&
M_&#7?LWA *DH                                        7.> GQ-N
M/?X@-/\ T]^!U^                                 %8WKR?E;T+[W.
M2>R:PE,O]Q5Z;5#]X?\ UEJ[]&7_ -_"!DD&N\           $T.RIE'G]P-
MQW.VE?2')?A;'^C-A,.]:O.9KIQ=JB@OF":25+73^V/1C&[URK?WZ-EVDC=V
M6^=)UOLJ8Y/B)I_^E7W/S3WG>G6G'4=8[J[X76&S^TVJ:B6O%XRCNW<5ELTQ
M$XF(CVU? BW1=KJG3P*[>)G1'CJ=,+Q>NBP          =6\,..CODSOG%L&
M<WTC\%AZWYGM;(W"E&L?CFM\;42>9$[>2-];4(Y222[K%LLI6EB;EU9??_)V
MWUI1OW?%6YJ_S=R/39@V%[,;VU;:'A-7[L^*U>L:<5F%^9X-%C!6)BJ]557.
MY1-<:+5%4[D5W*:JO:Q5,>E]17E*QY.[Z<KX==:WU!J^/IK[5,>V3M;L586-
M4I9(Y&W:ITL30MR1\C2]"E+;+K8Y!HG=;2Y.I\X:UXJW[;W<[LN5]9O:Y8VL
M;1*[F1Z*=2LIM<CR^BF-%$VJ)T5WZ:8W(\?7&FC<B8LT6:9B)IEP.7#KH
M       '1?#[XVW%SYQ>DOA+QDIWO@:_>SZC)VQ/[9M4?[GROX]87S3C[T0
M #Q_D+^0+>/O/[+]A<T!1G
M  "SWT5OBLY][_\ E/P=:K E]
M           &1'U9;W_/'Q'>W-2RSYPZ:;"YPZ>X>QR2:][:D;$8]D> <>+F
M4?=;;?YEVO(YPO=?9;]TY645K2MU]:U#7-BHN-@XR.A89BTBXB'8,XN*C&""
M;5C'1L>W3:,6+-LC;8DW:-&J-J::=M*6V66TI2G90#^\#(:Y&-FW3F\2QDLG
MA5C;&\;U)U'<+V/'QJ-E$HV,UQL_/,:V+(XLE9;?2Y*%MP'/EHVVE+Z7VM:_
MWU+J=M UY0     HA>.+_);T[/Q_Y'^QW3P%SWB;\5CC1\W_ $U\'6. =
M                 !G3G)'F1
M    !9.Z"/\ @ER6_&+6/\V9J1F8>ZI]*?6;2ONZOY-K5_%8#]3%+!1'-D@
M @#ZYG_1=_Y;/^:," ,                                       ?O
MXI_A1C?_ !_#_P XM@+[(                   9X?7"_>O>EA[X'32_7 F
M -#P                   *374[^/=R'_&/&_8%B9.87_;T_EZ,M#/6P_\
MD+K-_%6/BF'<&%PZ[@                                     !*WT9
M/CMP7O=; _F]J6F-^ _QAW#ZC/V]8?Z+QGZE*WZ0S=6  (X>J_\ $FV-^,&N
M_9O" 5)0                                        N<\!/B;<>_Q
M:?\ I[\#K\                                 *QO7D_*WH7WN<D]DU
MA*9?[BKTVJ'[P_\ K+5WZ,O_ +^$#)(-=X
M            =%\/OC;<7/G%Z2^$O&2G>^!K][/J,G;$_MFU1_N?*_CUA?-.
M/O1   /'^0OY MX^\_LOV%S0%&<
M       +/?16^*SGWO\ ^4_!UJL"7T
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M'U7/C OER[!^G/-_Q@'U7/C OER[!^G/-_Q@'U7/C OER[!^G/-_Q@'U7/C
MOER[!^G/-_Q@'U7/C OER[!^G/-_Q@'U7/C OER[!^G/-_Q@'U7/C OER[!^
MG/-_Q@'U7/C OER[!^G/-_Q@'U7/C OER[!^G/-_Q@'U7/C OER[!^G/-_Q@
M'U7/C OER[!^G/-_Q@'U7/C OER[!^G/-_Q@.4OLZ'B.O=+Q?Z52?WJ5N47^
M-5OL/=GW8?T4R+F=GP3[.AXCKW2\7^E4G]ZCE%_C5;YV?=A_13(N9V?!/LZ'
MB.O=+Q?Z52?WJ.47^-5OG9]V']%,BYG9\$^SH>(Z]TO%_I5)_>HY1?XU6^=G
MW8?T4R+F=GP3[.AXCKW2\7^E4G]ZCE%_C5;YV?=A_13(N9V?!/LZ'B.O=+Q?
MZ52?WJ.47^-5OG9]V']%,BYG9\$^SH>(Z]TO%_I5)_>HY1?XU6^=GW8?T4R+
MF=GP3[.AXCKW2\7^E4G]ZCE%_C5;YV?=A_13(N9V?!/LZ'B.O=+Q?Z52?WJ.
M47^-5OG9]V']%,BYG9\$^SH>(Z]TO%_I5)_>HY1?XU6^=GW8?T4R+F=GP3[.
MAXCKW2\7^E4G]ZCE%_C5;YV?=A_13(N9V?!/LZ'B.O=+Q?Z52?WJ.47^-5OG
M9]V']%,BYG9\$^SH>(Z]TO%_I5)_>HY1?XU6^=GW8?T4R+F=GP3[.AXCKW2\
M7^E4G]ZCE%_C5;YV?=A_13(N9V?!/LZ'B.O=+Q?Z52?WJ.47^-5OG9]V']%,
MBYG9\$^SH>(Z]TO%_I5)_>HY1?XU6^=GW8?T4R+F=GP3[.AXCKW2\7^E4G]Z
MCE%_C5;YV?=A_13(N9V?!/LZ'B.O=+Q?Z52?WJ.47^-5OG9]V']%,BYG9\$^
MSH>(Z]TO%_I5)_>HY1?XU6^=GW8?T4R+F=GP3[.AXCKW2\7^E4G]ZCE%_C5;
MYV?=A_13(N9V?!/LZ'B.O=+Q?Z52?WJ.47^-5OG9]V']%,BYG9\$^SH>(Z]T
MO%_I5)_>HY1?XU6^=GW8?T4R+F=GP3[.AXCKW2\7^E4G]ZCE%_C5;YV?=A_1
M3(N9V?!/LZ'B.O=+Q?Z52?WJ.47^-5OG9]V']%,BYG9\$^SH>(Z]TO%_I5)_
M>HY1?XU6^=GW8?T4R+F=GP3[.AXCKW2\7^E4G]ZCE%_C5;YV?=A_13(N9V?!
M/LZ'B.O=+Q?Z52?WJ.47^-5OG9]V']%,BYG9\$^SH>(Z]TO%_I5)_>HY1?XU
M6^=GW8?T4R+F=GP3[.AXCKW2\7^E4G]ZCE%_C5;YV?=A_13(N9V?!/LZ'B.O
M=+Q?Z52?WJ.47^-5OG9]V']%,BYG9\$^SH>(Z]TO%_I5)_>HY1?XU6^=GW8?
MT4R+F=GP3[.AXCKW2\7^E4G]ZCE%_C5;YV?=A_13(N9V?!/LZ'B.O=+Q?Z52
M?WJ.47^-5OG9]V']%,BYG9\$^SH>(Z]TO%_I5)_>HY1?XU6^=GW8?T4R+F=G
MP3[.AXCKW2\7^E4G]ZCE%_C5;YV?=A_13(N9V?!>N:RZ)GBI-+H2[;4W)V0U
MVWGU6:\VCB',IY")RJT?8X38JOK&*:5'%[2QVK1.MW;W:*7=G\)\5W*Z_=S,
MN::J:A:E:BV[]K4W*\#EEK$S3-V,-:HM1<FB*HHFO@1'"FF*JM&GN:9[[U'Z
MKGQ@7RY=@_3GF_XQ\.6GU7/C OER[!^G/-_Q@'U7/C OER[!^G/-_P 8#S#9
M'1/\5-N#T-[:?)^1V!ZW?2/H+UU\RWDUZ)]+^8^D_,//4U?-O/\ T8W\KW>S
MO^1L[?[V@'F'V>7Q)?NL0'TKK?O8!]GE\27[K$!]*ZW[V ?9Y?$E^ZQ ?2NM
M^]@'V>7Q)?NL0'TKK?O8!]GE\27[K$!]*ZW[V ?9Y?$E^ZQ ?2NM^]@'V>7Q
M)?NL0'TKK?O8!]GE\27[K$!]*ZW[V ?9Y?$E^ZQ ?2NM^]@'V>7Q)?NL0'TK
MK?O8!]GE\27[K$!]*ZW[V ?9Y?$E^ZQ ?2NM^]@'V>7Q)?NL0'TKK?O8!]GE
M\27[K$!]*ZW[V ?9Y?$E^ZQ ?2NM^]@'V>7Q)?NL0'TKK?O8!]GE\27[K$!]
M*ZW[V ?9Y?$E^ZQ ?2NM^]@'V>7Q)?NL0'TKK?O8!]GE\27[K$!]*ZW[V ?9
MY?$E^ZQ ?2NM^]@'V>7Q)?NL0'TKK?O8!]GE\27[K$!]*ZW[V ?9Y?$E^ZQ
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M_P 8!]5SXP+Y<NP?ISS?\8!]5SXP+Y<NP?ISS?\ & ?5<^,"^7+L'Z<\W_&
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M/Z*9%S.SX)]G0\1U[I>+_2J3^]1RB_QJM\[/NP_HID7,[/@GV=#Q'7NEXO\
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M9T/$=>Z7B_TJD_O4<HO\:K?.S[L/Z*9%S.SX)]G0\1U[I>+_ $JD_O4<HO\
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M-'S?]-?!UC@'0
M
M
M
M
M
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M?&2H(N48QKG5^4266X*V:K7JW6)O9?=\[&K-VEZM5+XYD[OMI?8W4[ UE
M   HA>.+_);T[/Q_Y'^QW3P%SWB;\5CC1\W_ $U\'6. =
M
M
M
M
M
M
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M *:^#K' .@
M
M
M
M
M
M
M      #X/.=6:QV>E'(;*UQ@>PT(=1RM$HYSB&/Y:E%JO+4;'BL<G/QTA8Q4
M=6-TZ*7)4MK?1.VEW;W:=@?:-&C5@U;,6+9NR8LFZ+1FS:(IMFK1JV3M1;MF
MS=&VQ%!N@C92RRRRE+;;:4I2E*4 _H
M
M
M
M
M
M
M
M
M                                                       #QW;O
M(CC_ ,?HFZ>WUO/3ND8*QM:\OFMN[-PK6T3:TO?-HRQU=(YE-PK.UM=)/$6]
M+ZW]VJZMB?;WKK:5#PK#NI5TY]ASB.,8!S\X49SDKE%PY;X]AW*G1>33CANS
M2JL[71B87.WK]5%JC;6]2^U.MMEM.VZM* =IHK(N$4G#=5-=!=.Q9!=&^U5%
M9%6VEZ:J2EE;K%$U++J5MNI6M*TKVT _T
M
M
M
M
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MKA"M[=9%2\.MP
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M%<O>*IK8SF6*/GE^QN/:+I_6SR\+->:N<DQ*ZVVU%6OI!)-52UY&H6A?)
M                                        QL.FW^WWXO?^)#"_#0[
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MS8GMX<<(CSG ,<R#!'TS/^M&=V_&9TCYFUAG-WFJD98]4\GV6(W5NLI<&C$
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M5KA"M[=9%2\.MP
M
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MO5+#^1^J&:S386-M+*NZ-TG.<:_QYQ5W5*Y?RCK%FEB=O\K??4-(
M                                                  !C7<H5,2R+
MQ"&X$N8#A&S53OJSS41O9;*;[4XMIHQMRJ]$9*E(*6453LQMAJ9"J:=UO?L\
MP3MK;6ZG96H;(S"QBFQ9IQEK2R-L:-[(^QA:C:QL8VHV6M+6=K>E&]K2UO2V
MB=+/N*6=G=]3L _K @'\05T=I_JZ\9]<XEIQWJ3$.2NH-E-<CP#8NV7V204&
MWP*=C7D9L?!WL]AV$Y[D23"?52BY!-"R/42O?1*%;KTZ=ZM0^=\.WTL^7_29
MT!OK1'*#8^CL]A,ZVW$[3UHAI++-A91'P3U_B++%\[I-4S_5VM%HY:3LQB&N
M0M:VO$U/)*77U2NI3R@1_>(TZZW$C6.L.=?2;GM=\C'?(O(].X_BC'-(C$=9
MN-*I2.R\1P_8T$L[R-[MV/SJQDTA)Q))W=9CBEZ;NV^U.Q5.EJMP58/#G]8#
MC3TB-I\F<XY)8/O/-XG<VO\  L4Q=OH_&L!R2182.+9'-R\@M/I9[LS6K9JR
M6;25EJ-S=9U?=?2ZEUEE*4NJ&G#T]N>6H>I1Q<PSEMHS'-D8IKC.9K,H.)A=
ML0^,06;-W>#Y1)XG+*2,;A^89W!)-G$C%*7MZI22UUZ%UM;[4[JULH'(W4GZ
M[W3RZ74C7"-\[&G,VWBHP:2B/'S2L,TS?:+.-?MD7;"2ROSZ6Q_"M?M'K5VW
M7;ISLQ'OGS1>CADV=)6WW6A6[R_QR6&LIURWP+ILY-DN,V)MJLY?+^5D5A$Z
MNM<@G<\L<X[#<?-@Q[1-!U6ZQ*ZR47JJG2E]UJ=:ULM#KOB=XSG@IN#(\=Q/
MDWHK;W$]Y/.4&3C,VLS$[RU7CCEQ).&UBV0S\)#X1GR$58Q\W6O<ML6=>34O
M5LOLM31M75"WOAV8XGL/$\;SS \D@\QPK,8.,R7$\LQJ39S6/9'CTTS2D(F:
MA9:/578R49),5[%45DK[DU$[J5I6M*@1E]5#K <:>D1ANH\XY)8/O/-XG<V3
M9)BF+M]'XU@.22+"1Q:*CY>06GTL]V9K5LU9+-I*RU&YNLZONOI=2ZRRE*75
M#Q#8_B%NG5J#@MHOGGLW(MD8AB'):%RB9TAHIYC&-2?)//4\.R66Q:>198-C
M^;2^(1K9C(Q%:J23[(6L(CYPV26>IN%TT+@KY9'XY'"FN4.&F)=-K*)O"[5F
M%K6?R/E3$XME"S=1JUOE%7&(1G'_ #");+,WEZZ;=.V<5M<I)V*7WH7*7)I!
M/QTO/$-<!^J/DZ6IM?R>7Z4Y$*LGK]CI#<K.*CI;,&D8@J\E'6MLK@I.7Q?-
M/1K%.JZS*JS*9M0357HQJV057M"=P#D;FESJXM=/K3C_ 'GROVO!ZQPE%96-
M@FSJBTEEF=9):S7>M\1P#$HZQQ.99DCM%O==Y%LE<FW1I<NY40;)JK6!4(VO
MXX;3L-E*[+2'3XV1L;"[/+T0R+:/('&M.9(O=8[7L;UNQ'%M6;QCD4UF5J:E
MU?3-UUBE]R?=NI;12\)8>(OB">$W5=X]<E]8X)ZYM'\CX[CONZ9OT3M9>&I*
M97"QFOLF<2$QJW*HAVK$9\VB8RVUP^:>38S#1.Q=:K*YFA<[J%.WP?/[82.^
M;-N__?<- U80*_\ U'/$F]-SISYCD&G\@RO+>0G(#&%G<=DNH]!QL7D'K&FV
M]54:1&Q\_GI:!P3&9-!\@H@]C6KR4GHR^S_A4<EWD_*! Q.^.6@V\S)H8UTR
MY66Q])ZNG#2<[S 9X[,OXZU2M&KJ3@F'&3*&42]62[*J()2+VQ.ZO91:^E.]
M4)+.#_B\>G=RBS7&-8[QQ+8W#C,\J6C(YAD6Q7V/YCI).<?M&]MT4_VA WQ<
MI (UF;U&Z,A+8_&QE4:)KN7#7OWII!:W161<(I.&ZJ:Z"Z=BR"Z-]JJ*R*MM
M+TU4E+*W6*)J674K;=2M:5I7MH!!]U1^OSPZZ26W->:9Y'ZVY+YKE&RM<TV=
M!/\ 26':MR. :0%<FG,5\TEG6=[DUM(H2_I& 6O\FBU71\C=97RO>K=9:'-'
M4V\3MQ#Z>D+JR$QG6^9\BM\[6U=@6Y$=-QN3X_K]OK3!]D8O'Y=B*6X<YL;9
M^GB>7S<++MW#>)CXR95JUN\Y4O2;JLU'8?@=(WQ/&A^J-OJ!XLRG&7:_'_>>
M61&53N,(,<BCMTZM=Q^'14MD$PG,9_'8[@$_C3NL''6J(J/,=LCU'-]6U7=J
MM6U'06$>0O(W1O%#4N5;UY&[/Q34.IL*;I.,BS3+WU6D>V4<JVMV$:Q;().9
M.<GI9W?:@QCF"#E^^<7VI-T5%+K;:A3JY >-PXU8=E;F'XV<*=K[TQEF_>,U
M,PV9M?'M )R3=M:C8WE8&!BL$W?*+L)!?RM4[9#T8ZM0HG>HC8I?>BD$E'2Q
M\3[PFZD6Q<?T%E>+9-Q.Y%Y<HV9X3A&Q<BALIU]L2<<-4+_6I@.U6#/';7V7
MJO\ RR+2/EH>%6D^Q"UEYPZ6JT2"C]TIOWE+3OS[M[_^F;7 UV   " %AXCG
MA#(]1Q3IA(:LY56[\3Y 27'&[+E<(U';J"N<1<HZB'$K2?LWC?F?K4O<M+KK
M%_6_YY6RM*U;4KVTH$;G._QCO%SC+N_)],\:>-^0<PV>!R[[&\MVG;N.)T]K
M=_/QBZS:12UO)M==[=DL[@V3E/R/I)1K%M7*MM][6KAMY)PL$O'3$ZX?'3J?
M<>M^;VUWJ_<VMG/&**I*[?PS,8:&?V436Q_)LI8IZ]S.,EK,;S%1U#XJXI<B
MYNB7C5Q6RBZ":"J#A8/).F[XD#@]U1.22/%S0.J^5F(9^O@V5; LF-PX/J*
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M'961=IL,)SK8<-6(6;Y,A1%2K^BUU]BE+DK*4MK<%&_QN7QR.&?S9LE^%.<
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M.*NZI7+^4=8LTL3M_E;[ZAI
M
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M:,A%2[!G*1C]M=WV[V/D&Z;MD[0O]3OHN6RMM]E?[MMU /[P
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M=HR$5+L&<I&/VUW?;O8^0;INV3M"_P!3OHN6RMM]E?[MMU /[P
M
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MP[[\<3^5GIX>]WR)]DNI0+,GAF?V'7!#\7=U?K+[G X\ZR'B8/JE.7+#BO\
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M77]VE]SN<TWADFXNNI9]Q2ZJSJO;V>IV_P  '7(
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M6SEYJO0&\\_QV]PG<I<TFWL1#ZTO=-NRZVVQS2#V*]LI==2ZE+%+NRE+NRM
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M,[KJU^[[UJ.9+]G9ZG96O;_< TM0
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M,=2UAJ-T]1240IN':,:YIE$Y&W7I*5MD<-UA:LS4^ZLK;9E*=U.]6GW(:3(
M !EC>,E@FD1U;\8D&]+:+93P^TW.O^[9=;6KMOG6X<9LK?6Y52BEWF..HT[:
M4LIV4I3N]M*W7!I =/\ R1WF7 WA-E[^ZZY]E7$;C=DCRZ_NTON=SFF\,DW%
MUU+/N*756=5[>SU.W^ #KD
M
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MY5#^15\BM&76]ZS[F[L[:>H![F
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MSN]S>P[4H$$?C<OCD<,_FS9+\*<X!<PZ$O['OIW_ #9L$_WIT!+*!D"]=_\
M>"^5'SB-'_!UJ #7Z   ,TCQM/Q].)OS1+/AEV6!=TZ)O[(WIS?-$TK[#HX"
M4,#(GZEO[R_M+_Q$-)^RO6 &J_R>Y+:>X>:&V/R5W]D3_$]0ZHB&DUFD_&8S
MDV8OV#.1F8S'H[S?'<0B9N??7.YJ8;(5N3;W(M[5*K.+T6Z:JR81\].+K@\&
M.J9M+;FHN+$OLA;*-089C&?25^Q<.884URW&L@E7<')/L)97Y')9)()X1,6L
M6\S>]CX]%%298T;WN:*J51#]SDWT,NDYRYOD7^X.$>FT,FDK>^YS?5D9(:.S
M19_8W=-FLM)9#IV1PAWD;]I:Y[;?2OGZ"M$4;%DU4TD[+0H?^(\Z O'GI4:^
MU+R/XQ;3SY_KW:^UW.K);3VTY&!R.?Q>:>8ODN:1LUA>51<?CTE)X<SC\969
M.&\@S>/&JRK:]206JO2RT+5'A%=K9YLSH^8Q#YM(2<FTT]OW;VJ<"=2JZKI:
MW VC?$<[CX]JY7NO6OC(:;SV09-4ZW5L;(-[4$Z6I)666A1>ZFN)X]GOB(.0
MF"Y=&IS6*9IU$,<Q/)X=99RW1EL>R/8N*0\U&JKLEFSQ!-]&O%4KKTE$U;:7
M]MMUMU*5H&G-U'.F!HGGSP%RO@_?C&*:]A83&8Q7CF^A89&*@]'[%P6&=1NL
M9K'XF';IIQ^.Q+=>^+?,VR=/+03QTWLI;52VZT,V/HY\_P#<G0>ZEV9:EY*1
M608AJF9S6_0O,K6[A"YZIC2^/3#R/@-KPB+>M]DJ[UU)/U)!LZ9U<)3&-/G=
MK7RWG356T-;^$FHC)(:)R+'Y-A-P$_&,)J$F8ITB^C)>(E&J3Z-DXY\VO4;O
M&#]DO8JBJG==8HG?2ZVM:5I4#], !6$\7?K1YGG1NS7)6C99PGIK?NC-EOKD
M4KE:-F<A-2NI:N5JVVW>11M<[23MK?7LI2M]*=OJ^J'!G@BMA,Y+B+S5U38Z
M1OD,+Y'8=L)TRMK;YPW9[-UDRQMBZ5I1.EU$7:^I'%B?;?=2MR%_92WU:W!=
MN S:O&Y?'(X9_-FR7X4YP"YAT)?V/?3O^;-@G^].@)90,B?K8?O''(#YU7'3
MV&:6 UQYB)CYZ)E(.6;^=Q4U'/8F2:^570\YCY%LJS>-_+ME$7"/EFRUUO?3
MOLOM[>VVM*]E0($OLN/0H^0S_G,\P_\ 2" ?9<>A1\AG_.9YA_Z00#[+CT*/
MD,_YS/,/_2" ^FPKPT71+UWF6); P[A7Z'R[!<F@<QQ66_2.Y:2'HO(\8E6D
MW!R/F$IOA]&/O,9-BDKY%RBL@KW>ZI9?96MM0ETY$;K@>-FA=S<A<JQS,<NQ
M71VL,WVSE&-:]CXF6SB8QK7^.R&4S[3%8N=G,:B)*<K$1:US=!=^UL6OMI9Y
M2E:T B4Z7_B#>#W5BW'FNB./V*\@->;$PO7ZVRO1N^,6UEBR&4XVRG(J E_6
MBK@NW=DKR4C".YQHHZ162;5M;K^4LK?2Q3N!.>!6R\5)S4QWBMTJ-H:O1FD6
MNU.8;MMH; H5->ZV0=8JX=QTSN2=JW2OL5O@X[ $%(MRKV^3L>3K.R^E:*]V
MH1 ^"2XKST/A/,KF=D$6LTA<WE\'X]:S?KH41K))X;8]SK:CIM<LG19U&>?Y
M!C3=-9&OD+G31TE6MRB-U$@OE@9YWC=>2+A[L3A1Q#CGK2UECN'9QR,RY@FM
M>H\7?9=,W:VU^X=(>3M2;(L&N&Y)1*ZE]]ZU7=_;;91.VJ@64?#5\7V7%_H[
M<46ET?YGD^^8&1Y09FXJ@V0NEGNZ5D9O"I"ZB"=JBOD]0M,::VJ*WJJ7V-J5
M[;;.XDF$\   !E#^+OS]IG'65S+&&+RY^[U1H+0^NG[2RMRM\=(2D))[41CK
M4Z5NK;<M'[.;N:6TI3MJY[>SMKZH:@O&#73S3_&GCQJ20;^:/]7:,U+KI\U\
MHDMYL\PG <?QERW\JA_(J^16C+K>]9]S=V=M/4 ]S
M
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MN76NY5&B=$Z=G<#6C
M               4;_$8>&MV+R?V9E'//I]8[&3NV,L1NE>0O'BU_'0#W8,W
M'M+;%-HZL=2:S*%7S649-[:34*NNVNEG"7G;2Y60760=!5(XO]8OK!=)5R^X
M]XWLS9NO(+#U'<>[XS\G=>.IV,P-S=59.YC#X9M"*;9IK!-J^\HO<PB7$4T5
M=U4O705NN4[P2:S_ (T3JM3$._C([4?!?%7KQ'R3?(8#4V['$Q%7]^R[SE@A
ME'([)(!1;NVUM['3%RGW;J_<]O96@1JN'76A\1#O6"3D+MP<H',/+UAF+^V'
M;8)QCT2B^\SND'3VL'%X_J#7:R<2LWO>.;D[LCF6Z"-+ZR#BB-MP:8'1:Z36
MO^D;Q,;:;C)EAGFZ=A2;3.^0^U&+-9HRRS.;8^UBQQ_%TWMEDFAKW F%][*(
ML<435<**NI!1%LL_5;I!T5U1>/F6<J^G7S0X]8 V\_S_ &CQWV7 8#&>63;6
MS.=(X\ZE<.@[W*U]B+5.<R2.:M+E;ZTL2M6K==ZE*@9'W3RZD_,KHP\C-CYG
MIK&L7B\^?P<MJ7;^G-_X1DSN!=*1,M1>D;EF-1>0X#FT#E&'9"RJHA<WD6*Z
M*OE45[5$5%4;POQZ6S/9GB?^@7O"'VDWU)K/D5*[/RS%,;5UQ&99":UQ[:VF
M)7$-D:WL>QV3YAG^21K#*,?G&<=++7OGER+:35<H(=MJ:0%"O0W)GJ8="7E/
MGD5B:69\9]U(,J8KM35&S<3:2V)9Y L7S^D.XF<<ETW6/YA HOK5W$%D,2XO
MLO3444CG]S9RKY8)>,\\9?U:,OQI]!8_@_#'5DH[MNM;YG@>G]E2&2Q=:I*I
MTO8M=G;PV-AZEUMZE%*><Q+BG?3MI6E;>];<'(F=]*_K!<[./'*;JS<Q_;*2
MB=7:P=;$2G>03>;8[6VYCV+/(Q>5::XUNLS8/L/U9A6$OG\S9(7LHR M:M+D
MXU)>VYPHV"<OP0.]\<991SQXS23]%#+,D@]/[QPZ.N5MHO)0.'O<MP38CJQ&
MZM*UMB7V:8S;VVTKV^=U[W9V4[0Z&\<!\7K@7[\VX?81B@$F7A(?V+^I_?FW
M[[/G0%F0#+ \9!^UR@?FB:9]F.V@-*;A7\3?B7\V;0_P68J!2Q\3SX?3:FS=
MDY1U'^#&O978LKEC9!]RCT5A<?=(YHM/1K-%BGN;6^+L$:O\L],,&J2>1Q3&
MQ>3H\LI)(HN+%W]S4((^&?B@NJ_P5UM':(1R#5V_,.P-EZU<2A.5.$9AEN3Z
M^C(JY!HWQIEE6&9]K#.7K* L:7-6K6:?25&#>OFR-$T44$D0]DP7..KAXI3D
MAC6$;@RE_!<3M49 MF>SU=:8FM@O'?1N/)VW/)3T4@\6FELYW!)0:BC+&6T]
M)SDQ;1>Z^JB,?:_7M#_GP?/[82.^;-N__?<- NU^(RZ7N<=4#@0OA^ED6SWD
M+H;,TMT:AQYT[;1Z6P5V4!,0.6:QLDY!TTBXJ1RR#E/*QR[F]-O668-45E6[
M=99=,,W?@MU3NI%T5=D[&U]JET]U]>YR9BKN+C)R$U]+N,77RV%M9V46R3!Y
M5;%LUPK)G$0DFS=.HM]$2#IA5*Q16ZB+6Y$).=G^+XZQ&\(-/76NX3C1IK)\
MF6I 1D_H;2V:3&PWK^;50CV+" :[9V;N2)K+KKJ42:>;1?G7EEON*U4HG6T.
M%^4O1\ZG$'PNV5U:N;C',X-UD^S<#3G8/<[O();D/E,?L>2>XZIM38\=*U6E
MM?0K3)_1$2T:3M6\FYND4NZU;MK&USD+B'@M-[XYF?3WWYH"U^C7-]'\EY+*
MY"*M5MN71P/<>$XPMB,K>E6O?LM?95@>2(>I3N?\$I7M[:UI0(9?&T_'TXF_
M-$L^&798%W3HF_LC>G-\T32OL.C@)0P*?WB<.@QF7/F(B^;'#_&TYWE3K3%$
ML:V5JUHHS9/M[ZT@_.74.\QB]>K=N\VK@J:ZR3=JLK:I-Q5;6B-U731BV<A3
MWX-=?3JK])>'D>-6/R,1D>"X#)R46CQTY:Z^RR91U1,77N?2L)#-V>1:YVI@
MR*<@XJX4A*2J,:@\I<K:TL46<U6#HS+NH'UK?$K;6Q?A?C5V/P6LYR7@97.]
M=Z*P_(,!T'A<.QO1L6V+O#+)B<SG-'F+Q*K2]ZBQEYUXU<REJ:<:QO?5:I4#
MQGI+Z?C./7B1-(Z"A)=_D,-H[G'N[3\1/RJ+=O)SD9K1;:N%L)>1;M*4:(/Y
M)I"V++6)?R=JE]:6^I2@&O&   9 O*[]YFSW_P 7;%OUEL< U^@/".4OQ9.1
MGO$;=^#_ "$#,5\'S^V$COFS;O\ ]]PT"^]UPNF SZK?!;+-"0DA"X[NG"YY
MCMGC[E4]15&'8;-QR-EHRS'<A?-$5WS/%,ZQ^:>Q3Q6RQ>UFJX0?50<7LDTK
M@S$=$<N>K!T#M];!UQCBF=\:<XDE&Z.SM([8PZ.R/7F=VL$ETH;(_04TA(8]
M.)HV.._&Y+CKRR]PVN[B+Y5HJHFH$JF6>,[ZL&1X])0L/K+A%@4D^31L:Y=B
M>H]O/,AAKDW**]ZT:VSKD%FF**J.$DKD;Z/(QW91)2ZMMMJE+%+ YUZ;/2MY
M_=>CF2CRBY4J;*DM"Y-FL9EG(KE-L=HXQ]'8,+"W1Z2^M--^09Q#*7G)*%:)
M13)*";IP>*1]+;KO(6I,V;D-92$A8G&X:)QZ!CVD1!P,8PA86*8(V-V,9$Q;
M5)C'1[-O92EB#1DS0L33LIZEMEM*4_@ R&.CO^\2\=?GF;<_WC9P&OT!FW>+
MJZ1=VE-M(]371F->2U7O;(FD!R7AH=FIYMA.[WZ5UL1LM9%M;<BR@=O(M:I2
M"]UJ:5F3H^454O<3"=M G^\+_P!8.WJ!<6;>,^[<H3>\M^*N.Q,/).I-XLK-
M[?THT\UA</V?<J\OO<2N18^I5&%R12EZRESJC1\M=2^3I98%I, !5?\ %V</
MI'D9TOO;IQ6.4?Y?P[V;#;9=V(4LO<K:MR=JK@6RD$4[JVU\G&JRT1-.+Z5[
M;&D,K7LK_<#Q7P9G*IEM/I\;5XMOW:=<IXJ;F?R,<R\XK<I36>];9#,H!S:W
MOMI5/_X(,1E5M_<K=92E4ZU[MUWW07"@,FOQ;W[:#;'O,Z"]@+4#4NXY?%ZT
M/[S.K_81!@>S 9$_"G]YYPO_ ,53;'PU9Z!KL        5 O&K?LLM!_/_U9
M^KKRJ >"I_99;\^?_M/]77BJ!;]   ,@7Q1W[=?G-_DS?J><?0-?H !G9>*3
MZ$.[U]]YEU).(&MI[:.O=H,F$QR6US@L:^R#-M?["B6-L=*;5B\6C6ZTE+Z_
MRV'8-G$O<S3<+Q4JF[>N*49N>^U"*'A_XK#JO<0]4PNG:3^E^2>+XJP:P^'R
M?)W"LSS'-<9@F5E$VD*GFVO]E:PR3)VC6RG=25GW$N\22[J-BUJ*:2:8<B;[
MY<]5KQ '([ ]=S:>8\@\V;K+)ZPT-J'%K,>U9K5H_O:M)G)K8-HI2(Q]A;<K
M965RK)I!=9NVK:FYD+&B2*20:='1(Z6T!TG^$N,Z,=OXK)MV9O*J;.Y$9O$6
MJ7Q<ULJ8CV3&F/XVZ=-V[]7#,#A&+>+C[E;4JNE$G#^J+=1\HC8$OP%.3QGW
M*%EK?@'I?B]&RJ:.6<E]YLL@EXJUQ7RSK5VD8M3()N]=LG=2[R==C9%BUR5R
MG:G=5!3NTK=;WK Z-\)#PW?\:>EPQW#ED,I%YUS&V)+;GIYU2]-^GJN'9M\)
MU0T61HI<AYE)-(F2R%FI2E%%&N0V5NKV4MML"T<
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M?H   S2/&T_'TXF_-$L^&798%W3HF_LC>G-\T32OL.C@)0P,B?J6_O+^TO\
MQ$-)^RO6 &K_ +ZTK@7)#2>VM ;1C/3&NMSZ[R_669Q]M;4W"N/9G!/8&268
M.+K+ZL95F@^JLS<V4\JU=)IJIUI?9;6@9#W++A3U*_#X\RFNP<2F-@:[]:V3
M3%G'_ESK^+\OKK:&*.J=U%F_N?LYG%;95_#.+$,APV?2<VVJ]^RY%ZQN;NW
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M3#GRB;ENTR7"<3@<:M42[EUKN51HG1.G9W UHP
M
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MGN/*;+9>ZR^RMCB)BH9TG=W5J]H7$@
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MBO9=1*RE?[VG8'O>#X#@NL<8B\)UMA>):]PR#1HVA<1P?'(?$\8AV]/X$(N
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M6Z-M;JUM33I3MJ!]0
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ME]E;'$3%0SI.[NK5[0N)
M
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MQD5&1[=-HPCHY@T31:,6#%HC8DBBE9:FDG;2VVE*4I0#^\
M
M                                            %?\ Z^G1'ANKWH_$
M'.N)O"M<<N-,O[JZGV+FWI9CB,_A\V\0]=NL]B2F-062Y$AC:W9Z3C7+>.?K
M1\HWK:FE:B^>5N"2'IS:ZY@:>X>:;U'SGRO5&P>0NK\?LP.<V+IW),OR;&L^
MQG&^['X5DTN[S? -=3;?-5L;20;S%*LUDG3UM>\M7K5U<B@';X
M                <*]276?,3=7#?<6G."N7ZJUSO_:L"I@$=LC;N4YIB4'@
M.(9,DM'9ODF/26!8#L3(/7Y9CZJK6'NL:-K63IU1]1S8HU326"/;H'=%&&Z0
M6A,O2V!.8=L;EANJ3;.]Q[%PRLL]Q&(QO'5WR>%ZUUU(9'"8Y/J8O&V.U9%^
MZ<1[!S)2CNOEDZHLV-$@GS
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MG;;8G9;;9999;2VRRRVE+;;;;;:4MMMMMIV4I3U*4 _Z
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M%@Q:(V)(HI66II)VTMMI2E*4 _O
M
M
M
M
M
M
M                                                           '
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img57592461_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (  K(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_%;6T,;A+Z=I+B[+#)$<<1RF.F9  >H.*V-.^(<TFOVZ:G!!;:1J&A+J]G(
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M]:EJ"#_77/\ UT'_ * M3T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% $$'^NN?^N@_] 6IZ@@_UUS_UT'_H"U/0 4444 %%%% !1110
M 4444 %%%% !1110!1CUG2Y9EBCU*S>5CM5%G4DGT S5ZL^'_D8[W_KTM_\
MT.:M"A@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_A56( ^(;X$9!M+?(/\ OS5(=U@V>6MC^:?_ %J )OM<?]V;_OR_^%'VN/\
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MX_[LW_?E_P#"C[7'_=F_[\O_ (5/10!!]KC_ +LW_?E_\*/M<?\ =F_[\O\
MX5/10!!]KC_NS?\ ?E_\*/M<?]V;_OR_^%3T4 0?:X_[LW_?E_\ "C[7'_=F
M_P"_+_X5/10!!]KC_NS?]^7_ ,*/M<?]V;_OR_\ A4]% $'VN/\ NS?]^7_P
MH^UQ_P!V;_OR_P#A4]% $'VN/^[-_P!^7_PH^UQ_W9O^_+_X5/10!!]KC_NS
M?]^7_P */M<?]V;_ +\O_A4]% $'VN/^[-_WY?\ PH^UQ_W9O^_+_P"%3T4
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M)G;+YM]HHZ2=9;8>_P#>7^7Z'I+>YAN[=)[>598G&5=3D&AH$R6BBBD,*0G
M)QGV%+39&9(V94+L 2%! +'TYH \5E\0^/\ 0/%>F7VM7-IYNJ7D-H^A1PHQ
M6%GE 99%))*XW9S_ ,M!GIBO:R 001D'J#7@_AJ]\5/\1IM<UWPS::EJ4S)#
M:R#6K=5L(6+ K&@9MS8)S@[O^^CGWFA@4B&L7R,M;D].I2KBL&4,I!!Z$4$
M@@C(/4&J9#6+;ERUN3R.Z?\ UJ +M%(K!U#*<@]"*6@ HHHH *\\^+/BRZ\,
M:=H\=EJ_]D27M\(Y;TVRSB*$*2YV$')Y7@<FO0ZX_P ;67B'[;HNL>']/LM3
MDT^9S-8W B1Y%9=N8Y7!\LCV(S[]" 2_#^^EU+PZUW)XLB\2K),2EVEFML8Q
M@?NV1>A!R>0#\WTKJZXGX<>&]2T2TU>^U:W@M+W5[][UK.!]RVX/1,C@GKDC
MBNVH **** "BBB@ HHHH *\/T3Q]XMNO$.ERS:O:3RWVJM97'AH6JK-91 G,
MI8?/\H&<MQ_3VYP61@K;6((# 9P?6O"M'^'?BN#4-&L9M"LK6>PU4WMQXGBN
MD::ZCW,2A7[YW!L?-QQR!S0![O1110 4444 %%%% !4-W<?9+*>Y\F6;RHVD
M\J%=SO@9VJ.Y/0"IJ* /-?!WB_Q'J_Q!U^QURV_L^TMK.*>#3SL9X0W.6<#)
M8CDC.!G':N?TOQUXL>'0_%]WJ=N^@ZSJW]GC2_LJK]G1G9%<2CYB1L).>/TQ
MV>F>'M2A^*WB/6+BVVZ9?6,$,,N]3O90 PVYR,<]1BN-TSP)XK2/0_"-WIUN
MN@:+JQU!=5^THQN$#,RIY0^96)<@GI^7(![31110 4444 %%%% !7GOQ4\6>
M(/#F@W)T#3I?,C@$TVIN%\JW4OMP V=[GTQP"":]"KEOB/H]_K_P^U?2],@\
M^]N(E6*/>J[B'4]6( X!ZF@"EK,GC/5-,\.P>';F&S^V1B34-4>*.1K<; PV
MQL0&W'(X'''3J$^&7B+5?$&CZDFK3Q7LNGZA+9IJ$,81+M5QAP!QW[<=/>LG
MQ]8^-KGPGI&A>'=+EEBD@1-3DBNXH9 BJH,2LYXW?-E@#T[@FNE\!QWUKX?7
M3[KPJOAR&T/EV]LMZESO7&2VY>^2<YY)Y[T =11110 4444 %%%% %'6-0ET
MO2;B\@L+B_EC V6UL,O(Q(  STZ\GL,FN,^&GB77]?N_$Z>(3'%+8W_DI;)M
M*VXP24W ?-C^\<YKT&O-M*\%ZS+%X_L[B1M,77+UVM;I2LA\I@06VAN,@XP2
M#S0!7\.>/M3\2?%R;3[=]GAO[!)):?(I%R4D"&8-C=@G<!SC SBO4:\@T+X=
M>+]#^(NDW1U]+G2[+35MOM2V$,0,8DS]FV!LC(^;S.37K] !1110 4444 %%
M%% !1110 4444 %%%% !1110!0UJTU"^TB>VTO4SIEZ^/+N_(6;R\$$_(W!R
M,C\:\RO9O$&GZP=(NOC1:QZ@(VD: Z';ED54+DM@_+\H+<XXKUROGKQMX2N]
M.\27^IQ:]X=CL9[^Z1[B]F998I+J (T3A0?NJ<J.P.3UH ]AUN"\D^&VHVXN
MFU*^?29$%Q!$ ;F0Q$;E1<CYCR ,]>*\4NT74H/!%G>_#[Q6UGH]JT.II'I3
M(;D[%P%((++YB[CDCJ>YKW[0+&/2_#FF6$5S]ICMK2*%9\Y\T*@&[J>N,_C6
M=K?C?0= 6_%[=,9;$0^=#%$SOF4D1J !R3M/'YXH O>'+Z'4=!M;FWTJ[TJ$
M@JEE=VX@DB"DJ 4'"CC(]B*U*H:+K-CX@T>VU739O.M+E=T;[2#Z$$'H0015
M^@ HHHH **** ((/]=<_]=!_Z M3U!!_KKG_ *Z#_P! 6IZ "BBB@ HHHH *
M***  @$$$9![5S5SI%YHMP]]H"AHF.Z?3V.$?U*?W6]NG\JZ6BFF)HH:5K%K
MJ]N9+=BKH=LL+C#QMZ,*OUBZKH(NK@:AI\WV/4T'$RCB0?W7'<4FE:_]HN#I
MVI1?8]30<Q'[LH_O(>XHMV"_<VZ***0S/CUFSENOLR+=>;QE6LY5P"2 22N
M.#R>.#6A6?#_ ,C'>_\ 7I;_ /H<U:%-@@I" 001D'J#2T4@*3!K%BZ@M;GE
ME[I[CVJXK!U#*<@]"*4C(P:I,&L&+H";<_>4?P>X]J +M%(K*ZAE((/0BEH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P *_P#DEWA[G/\ HH_F:["@""#_ %US_P!=!_Z M3U!!_KKG_KH/_0%J>@
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M!:GJ"#_77/\ UT'_ * M3T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:UN5W+O&&4@D%6'8@@@_2M.N=\#:5IVA^#['3-*OEOK:VWH;E2"))-[;R,9
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MTJ73=-L]'TVWT[3[=+>TMT"11)T4#^?U/)JU0!S5EX3-EXZU?Q,M]N;4;:*
M0>5_J]@ W;L\YQTP*I:IX)OM>\(V^EZOXBEN-5M;D75OJL5JD+)*K$H?+4X(
M .,9&<9X-=E10!ROA+P=+X>O=1U34M8EUC6=1*"XNWA6%=B#"JJ+D* /SKJJ
M** ((/\ 77/_ %T'_H"U/4$'^NN?^N@_] 6IZ "BBB@ HHHH **** "BBB@
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M8 *6\D@R3@#*J1DGC'O5B"9;B%94#A6Z"2-D;\0P!% $E%%% !1110 4444
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M2*3+:B42;.2!R/48..V<=JU* "BBB@ HHHH @@_UUS_UT'_H"U/4$'^NN?\
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ME+5;6O\ CQB_Z^[;_P!'I6A0!!]CMO\ GBOY4AL;8G_5#\":L44 5CI]J?\
MEE_X\:3^S[;M'CZ,:M44 5?[/@[!@?4-1]@B_O2#_@9JU10!5^P)_P ]IO\
MONAK$,"/M%Q@C&-_%6J:[B.-G(8A02=JDG\ .30!D65LS75R$EV/;2>63MSD
ME%;\L,*AU;P_)J++<+(D5]%_J[J+*N/8^H]JETC4(9M2U-%2Y!DN0RE[:10
M(8QR2H /'0X[>HK:I["W.6@\17NDRQV7B"W".QVQWB']W+]?0_YXK?&H0\;A
M(@/3<AJ2YM8+VW>WN84EB<89'&0:YPVNI>%\M9"34-('WK5CF6$?[![CV_\
MUT;AL=&EU _W94_/%2@@C(.15"PN]-UFU%Q:F.5#]X8PRGT(ZBIC809)3>A/
M=6-(9:HJK]FG7)CNW'LXW4?Z<G_/&0?B#0!:K/UK_CQB_P"ONV_]'I4WVJ93
MB2U?ZH=U4M2N4N+9(U#JPFBE.Y<<(ZO^NW%" UZ*9%*LT2R+G#>M/H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O'?&>I7^FIK=Y9?%O3XI[<RNFE-
M!;,XVY(@ZELC[O()]J])\5WUYIOAJ[O+"\TRSN8]FR?5'*6Z9< [R.>A('N1
M7CNK7D5UK5Y=6UU\'WADG>2.2Z7=,P+$@N<<MZGUH ]F\,7<M_X4T>\GFDFE
MGLH97ED0(SED!)*C@$YZ"N*\933KK%\D?Q6T[0\(N--N(;9S'\H/.XACNZ]/
MXN];?@?5?%&H&]B\16NEF&-(9+*_TMF-O=(ZDG;N.3CCG@<_B>,\16VJ:_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M] 6IZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q/$VF6>H64#74"R,MS
M JMD@@-*BL,CU!-;=9^M?\>,7_7W;?\ H]*:W$]B[##';PI#"BI&@VJJC  I
M]%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!!!_KKG_ *Z#_P! 6IZ@@_UUS_UT'_H"U/0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !6;JT-_<QQQ6L-LR"2*4M+.R'*2!\8"'KMQG/?I6E1
M0!'"9FA4SHB2_P 2QN74?0D#/Y5)110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %<MXZTF_P!4TE'MM9U:PMK3?/<PZ.G^E70"
MY"1MG*G/;!SG%=!J%A;:IIUSI][%YMK<QM%+'N(W*PP1D<CCTKB+WX?7>@VE
M@?A[=QZ4]I</,]C=SS/:W6]0I\SDMP ,?T/( )OA+J=]JG@A'U'4#>SPW,L.
M97W3Q*#PDV1_K .OL17=5RO@3PM=^&=-OFU*[BNM3U.]DOKMX%*QK(^,J@/.
M!CJ>>:ZJ@""#_77/_70?^@+4](  20 ">3[TM !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img57592461_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (! U$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1F"*
M68X4#))[4M(ZAT9&&0PP: /+/#OC?4==\0V4@\1:;$ES,P;1I("I2+) Q-M.
MZ0X!VY&<_A3]1\6^(MNM>(K.]A32M(OQ:'3S K>>H959C)U!^88Q_P#K;9>#
MO$$2:/X>DL+9--TO4A>KJJS M(H8L%"?>#'=C/3@>G+M2\)>(L:UX=L[*&32
M=8OQ>-J!G53 I9692G4G*@#']>*T)U/3T=9(U=3E6 (/L:=38T6*-8T&%4!0
M/84I&X8.?P.*DH6BH_)7U?\ [[;_ !H\E?5_^^V_QH DHJ/R5]7_ .^V_P :
M/)7U?_OMO\: )**C\E?5_P#OMO\ &CR5]7_[[;_&@"2BH_)7U?\ [[;_ !H\
ME?5_^^V_QH DHJ/R5]7_ .^V_P :/)7U?_OMO\: )**C\E?5_P#OMO\ &CR5
M]7_[[;_&@"2BH_)7U?\ [[;_ !H\E?5_^^V_QH DHJ/R5]7_ .^V_P :/)7U
M?_OMO\: )**C\E?5_P#OMO\ &CR5]7_[[;_&@"2BH_)7U?\ [[;_ !H\E?5_
M^^V_QH DHJ/R5]7_ .^V_P :/)7U?_OMO\: )**C\E?5_P#OMO\ &CR5]7_[
M[;_&@"2BH_)7U?\ [[;_ !H\E?5_^^V_QH DHJ/R5]7_ .^V_P :/)7U?_OM
MO\: )**C\E?5_P#OMO\ &CR5]7_[[;_&@"2BH_)7U?\ [[;_ !H\E?5_^^V_
MQH DHJ/R5]7_ .^V_P :/)7U?_OMO\: )**C\E?5_P#OMO\ &CR5]7_[[;_&
M@"2BH_)7U?\ [[;_ !H\E?5_^^V_QH DHJ/R5]7_ .^V_P :/)7U?_OMO\:
M)**C\E?5_P#OMO\ &CR5]7_[[;_&@"2BH_)7U?\ [[;_ !H\E?5_^^V_QH D
MHJ/R5]7_ .^V_P :/)7U?_OMO\: )**C\E?5_P#OMO\ &CR5]7_[[;_&@"2B
MH_)7U?\ [[;_ !H\E?5_^^V_QH DHJ/R5]7_ .^V_P :/)7U?_OMO\: )**C
M\E?5_P#OMO\ &CR5]7_[[;_&@"2BH_)7U?\ [[;_ !H\E?5_^^V_QH DHJ/R
M5]7_ .^V_P :/)7U?_OMO\: )**C\E?5_P#OMO\ &CR5]7_[[;_&@"2BH_)7
MU?\ [[;_ !H\E?5_^^V_QH DHJ/R5]7_ .^V_P :/)7U?_OMO\: )**C\E?5
M_P#OMO\ &CR5]7_[[;_&@"2BH_)7U?\ [[;_ !H\E?5_^^V_QH DHJ/R5]7_
M .^V_P :/)7U?_OMO\: )**C\E?5_P#OMO\ &CR5]7_[[;_&@"2BH_)7U?\
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=-_SSC_[[/\ A7!?##_F*_\ ;'_V>O0:SDK,TB[HCW3?\\X_^^S_ (4;IO\
MGG'_ -]G_"I**DHCW3?\\X_^^S_A1NF_YYQ_]]G_  J2B@!BF4M\R(!ZAR?Z
M4^BB@ HHHH **** "BBB@ HHHH **** "BBB@#-URVU:[LDAT>_BL)VD&^XD
MA$I5,'.U3P3G'7MFLOP[X(TWP]J$^IK+/=:G<*1-<RL!G)!("J H!(!Z$^]-
M\>ZG?:5X>2:RF>V5[F**YNTCWFVA8X9\8/L/QKF/ACXEU36;R.VFNI[RWBL&
M:YEEYV3^>^T;CW,9'&>@]J?01T.JW]])\1M'TI;]K*R6V>Z(7'^E.&V^6<]@
M.?S]B$OKV^L?B9I=K!?O/::A;R^?9-@BW\M<K(.XW$X]^?;%+QY<6^I:E:^'
MT\-#6[P0M>;3<>1Y* XR''.21C&1VZU=\ :9X=_L2#6]&TS[+)>1XD:20R2
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MG_?MO\* )**C\]/23_OVW^%'GIZ2?]^V_P * )**C\]/23_OVW^%'GIZ2?\
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M\* )**C\]/23_OVW^%'GIZ2?]^V_PH DHJ/ST])/^_;?X4>>GI)_W[;_  H
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M^V/_ +/7H-8SW-H;!1114E!1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHHH ]!^&'_,5_[8_P#L]>@UY]\,/^8K_P!L?_9Z]!K&>YM'8****DH****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@/'VG7YO;"YTKPMINIO+.@
MN9I+:.21@.-C%E.%(Q\W;%6/"FDZM!XCFO;KP[I.BV8M?*6.T2(N[E@<[U4'
M&!T)QT_"#XA>&]$DTNXU"YN;6QFGN8I9I;HR,EPT:.J(0K C@G[O/'0UE_#*
MVM8]8GDA\+_8R+<@:I#)<>1."R_*JS<]LYZ\4^@NIT/B#4M>NO%\'A[1+VWL
M2+%KV2>6'S"WS[0@';G'/_ZJK>$=<\2^+6L=3ECM[#2H01*%&Y[R0 J=O]U
MWXY'?M#XVMM%/B&WN9=2\01:R;3RXK71"?-DBWDYX4\9/<@<>U8?P\T;56U[
M[197E_::+IEQ+;3:?>7QD9I-IS\BJJ#E@3UY!ZT= ZGKE%%%(84444 %%%%
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M (]TW_/./_OL_P"%&Z;_ )YQ_P#?9_PJ2B@"/=-_SSC_ .^S_A1NF_YYQ_\
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M-3'CC_37B$!E.DQ'Y <[0"V ,G/'6F(ZW6M8M= T>YU2]+_9[==S! "QR<
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M1110 4444 %%%% !7S[7T%7SZ.@QTK2F9U HHHK0S"BBB@#V+P/_ ,B?8?\
M;3_T8U=!7/\ @?\ Y$^P_P"VG_HQJZ"L'N;K8****0PHHHH *\-U[_D8M3_Z
M^Y?_ $,U[E7ANO?\C%J?_7W+_P"AFKAN9U#/HHHK4S"BBB@#U'X;?\B[<?\
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M_0#7AM>Y:]_R+NI_]>DO_H!KPVM8;&=0****LS"BBB@#W+0?^1=TS_KTB_\
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MD:233;9W<EF9HP2Q/4DU478F2N>4R>*=2FM([>:02A(I(M\C,S'?P6.3R<9
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M+U(+27;Y;E6);(R,*!D\<]*L:7JECK6GQW^G7"7%M)]UUR/P(/(/L:X?4O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (KBV@N[=[>
MYACFA<8>.10RL/0@\&H;'2]/TN-TT^QM;1'.66WA6,,?4X S5NB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img57592461_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .2!8L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;7/]T_I6UX2^)9UF>]M;^V"SVA5&,$>%+?,&QER<97BBV_D)Z?D>BT5Y;/\
M$76=4U6[L-#MK!3:S/&YOD<9P3C&QC_=.?PK1\,_$&XOM531]4MXQ>>8Z%K5
M#Y?RJ2>6;/4'MZ413EH*;Y-ST&BBBD,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^L_@Y_R*-W_U_O\ ^BXZ /0J*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** *6KVT]YI-U;VTSPSR1.J2(<%6*D CD=SZUPF@?#F_M]8;4=9U62^
M=98I(A<Q^84V]<$N<9P/R%>D44XOEES+<)>]'E>P@ 4  8 X %+112 ****
M.7\7^%)/$-B1:W?V2Z602I,D>6#!2!@Y&#D@YSVKAT^&GBV=D@N_%FHR6N<.
MDCLRNI^\"OF],<8[U[!12BN78;;9F:'HL&B:?#;1+'E(DC9TC";MHQDXK3HH
MJFVW=DI)*R"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E?%OCC3/"UNGGW2)<2EA&
MCQ.P;:5W?=';->?S>)_'GBF<C2+6$6,A(CFMYC"Q ^8'YI!@D8[=Z[7QK\.K
M/Q>L#R7,\4T!<IM<*IWE<Y^4G^&N2:P\4^ XP+9M'FLH "OF&5I"#\@S@*,\
M#/XU$;6O4W_ N5]/9F'X6\*W>O\ B*2T\0WVI2A+0RHKW0DZ.H!YW#NU>T:-
MX:TK0(E33[.&':I7<L2J<$Y(X [UXEX1^($5GXEEO-1MW(-F8@+=!_?4_P 3
M>QKW33=6@U6!98$D56!(#@ \''8FMHW5./IJ8?\ +R5^^A?HHHJ#0**** "B
MBB@ HHHH **** "BBB@ HHHH \EU4C_A96EC_IO>?^@FO4[9@EC"S' $:_RK
M)G\*6-QK$.IO+<":%I&50R[27&#GC/ZUL- K6X@R=H &>_%*%XT5#JK_ )L)
M+FK.?1V*1U.POWDLXI]TNXH5V$<KR1DC':O+/A9(OA_4[G3[UO)9X6G"GYC@
ME%SE>.QKT#3?!.G:9K<FJPSW33R323%7=2N7!!X"@XY]:K>,/ &G^,/*:ZN+
MF)H\ >4ZJ,#=ZJ?[QII\K375:C>L7'ST.6\=ZE#JOB"PTB"3?(NI6[,@4@@%
M<=3Q_$*]'T2T^PZ1!;8(V;N"1W8GM]:Y[PK\.M-\+3+/;7-W)*$*8D=2N"P;
MLH]!78U2M"'(GN[D2O*?,]+*P5S.K^ ?#VN3^=?V$,LFYGRT,;<L<GJIKIJ*
MDH^4?C9X;TKPWXHM[72[=(8FL4D9515&XR.#]T#L!7MGP<_Y%&[_ .O]_P#T
M7'7E'[1'_(Z6W_8.C_\ 1TE>K_!S_D4;O_K_ '_]%QT >A4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?X.?\BC=_P#7^_\ Z+CH ]"HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **P-;\:Z
M!X>V?VG?>27QM_<R-G.?[JGT-3P>*='N/*\N[SYSA$_=ORQ.,=*%KL#TW-BB
MD5@ZAE.0:6@#@/B5X^C\(Z2-D:R3RDA +KRF^5D!QP2>&KS'P[J%AXGOSJVN
MZW;)$TK@V=].L@VE=P&78< MQQU%>O\ C/2/#LUHE[KR6?D0ECOGLQ/C<5'
MP3UQ7%:=:?#G5;P65A<Z<TQ9E$8TAE!*C)ZJ!T%*C?F;W?Y%5;<J2T1UUKXW
M\)V*%+2[T6W4G)$-W$@)_#Z"M[2/$>GZT<6=U:S?*6_<SK)P#CM7(7_@#PSI
M<2RWB:?&C-M!_LY6YY/;/H:?X!U'P]<W;1:&EN4$#,'BMS%E=XSP5'<U<+2O
MY&<KQC<]#HHHJ2@HHHH **** "BBB@ HHHH **** #M7C7CYVO?B5HMF[$Q+
M>1*4)W*0WE9&*]E/2O&/&X-K\5-'GD'R27T!!^GE9JJ*3K1YMM?R8W?DE;M^
MJ.Z\9Z5;2>!KBW%O"-B1*N(AQATZ#\*SOA;=M)H=U;,3B"^>%<MT"HG '8>U
M;?C"\B@\&75RYQ'MC.<'NZ_XU@_"VW8:5?7/\$NHRRJ?9D3%*G\=2_9?>3/^
M%"W?]$>@DX&:^?8O%L-OXO-VVEIJ1-AY>TR!MO[S.<[3_DU[^[HJ$L>!UXKB
M_#%MX,U2YD?2X-/NI%0AC_9^P@97NRCU'YU,4_:<RZ+\RW9TW%]6BGX;\?Z=
MJ^I1VESI-KIT[ 8\R==V[< !@J#DYS7H2E2H*D%?45Y/\2-,L-/NM.NK"&"V
MNSJ< _<0B-B-I.-P[9 KT#PK+--X;M))]QE._.YMQ^^W>KC:=/G6EG8B7NS4
M>ZN;-<1XA^)6G>'KO[//]E+;W3Y[Q8SE2 >"/>NWKYY^*/PY\3Z_K0GTS3?.
MC^T7#D^?$O#,"/O,/2I&<;\7_%EKXK\1P7=JL(1+)(CY4XE&1(YZ@#^]TKW;
MX.?\BC=_]?[_ /HN.OEKQ!X7U?PO>+::O:?9YFC$H7S$?Y22 <J2.H-?4OP<
M_P"11N_^O]__ $7'0!Z%1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%,FD\J&20C(12V/H*\GU'XZ6>GZI>6+:1
MN-M,\);[21NVL1G'E^U=>$P&(Q;:H1YK>A,I*.YZW17C?_"_[#_H#_\ DRW_
M ,;H_P"%_P!A_P! ?_R9;_XW7;_8&9?\^G]Z_P R?:P[GK5SJ=A99^U7MM 0
M<?O957GKW--MM5TZ\.+:_M9CD#$<RMUZ=#7RMXD\6:CXAU"6X6ZNX8G96$?V
MEF PH7VJ+0?$NHZ%?1W'VR[EC65'9!<,H(4YQWKUUPI/V/,Y^_V,_;JY]=45
MXK:_'NTAMDCETHNXSEFNFR>?^N=3?\+_ +#_ * __DRW_P ;KR7P_F*?\)_>
MO\S3VL.Y[)7EGQ5\<7WA6YMHK.UN)S(BL?)N&CQDN.P/]T5G']H"Q XT;)]/
MM3?_ !NL?XMZO!<W-K>R#RXPB18Y;G,A]*XL7EN)PLH?6(\JD_(TA--2<=6D
M3#Q-XU,?F?V+KY YQNF_^)KH?!OQ"N[C6H]'U>QGM9RNW-W<D,69UP-K*#G#
M<5IQ_%SP.(,?VDN<'Y?LLW_Q%<0VH6OC#XF6UQH<:M"EU;W!F4;"438K<,%/
M7^5<L&^?EM=/\/,FR<')NS7]6.Z\<^+KC0==T6TA@ED2\G*,R3E .8QR #G[
MU=Q9RF>QMYB,%XU8@G/49KR;XGJ4\3^%48Y(NFR?^!15M^(+G7-0L-.TS2%G
MMF>,JUS#<["NT*0<9&<X(Z\9J4_<5M7=FLE\+VTNST0,"< @_C2UX;JUAXL\
M)6S:M<^(-3NXXU#O URRC+G;C.\]"<].U>E)XRM4T3^TID*Q_:?(QN)YV[O[
MO]*';D<K[;D:\RCWV.G+!1DD#ZTM>+VFG>+_ !J!J=KJ^HZ;9S@M&L=V6 *G
M81C>O4@GI5VR\5:SX2AN+778KB<P0.!<2WF\NY^8# W$<$C.>U.S7Q:/L&[]
MW4]:+ 8R0,],TM>*Q+XB\;F35[#7-0TVUX,445PS!L?*?XEQRA[=ZWO _BJZ
M37'\/ZH\\MP#Y,<LLYD+F-6W-CG&<#O^="BWH]'V%)VU6W<FN?&=S'\2(-#%
MO,8G$F7$YV_+YG\./]GUKT7(/0BOGWQF]_\ \+:@CTU9#,T<A5DE\LCYI<\_
M2MW4=#\:>&HFU636M2O8( -T+794-N.W^^>F0>E":Y(MZ>9I4C^\:CV6GWGL
MU)N&<9&?2O,M8^*MDFC)<6D;/)]H"%5D9.-I.<[?IQ60WAGQO;6IUI]=U-O*
M!E>S-V<$)SC=YF.=OIWH::;YE9+J9IJ25MV>RT5QG@+Q2VLV,MI>(\=[:E1*
M'E,A^<L5^;&.@'<UV9XHDN4$[Z=3E?&7B,:/8RPP_/=E$=(TFVN07P< <] ?
MUK4\.3SW6AVUS<"17F19,2$DC*@]37FUTS:_\6X5W$P0&:V=&.Y25\T]#]16
MM\1]<O/#6B$V1E!AMH=JPS&+^/;VZ<4E:---[R9=N>IR1Z+7U/2"P'4@?6EK
MQJ30?&VMP?:X=7U*TVMY9B2\)!P,[L[QZX_"NJ^'7BN37;"&VN4D%TL3R.9)
MC(>),#G'H1WJE%NZZKH9N:LI+9G=T4C9V''7'%>?:K8>+)-0E:T>[\DRN5VW
M@4;<\<;JB^MB[:7/0J*\P;3?&V.'O?\ P.'_ ,57<>'HK^+2T743(9\C.^3>
M?NCOD]\U26A+9KUQWC/QUI_AW37,=Q:SW1?RQ"MVJ."4)!QR>P_.NND4LN%)
M!SVKQ[QEX"6RTN;5+R\6ZDSD"2 $A@AP=Q8\_+6;;OY%K;S/0?!&MR>(?#5O
MJ,D;1M)N^5I-Y&'9>N!Z5=UKQ!I^BV$\]S>6J/'$[JDDZH6*C.!FL#X7#_BA
MK15X'SXQ_P!='JEXE\!RZJ;J[N=1+1)YLHBDBWC:>2O+=,#'2M<2K3:CHC+#
MN\$Y:L=X"\;OXKU34D$#)% Z[&^T>8K!M^".!Q\M6?$FO7>B:_&QCF:T$6YB
M9"B DL!GC'I^E<O\)+>.SU[7+>)55(Y40;5VC \T#BNV\>V N_"UZRJIDQ&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\YDSG/55'H/2NCK6LUSNQG2^&_<****R- HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH *Q;OPY:7VK)?7$*NR*5!WL#CGL..];5%'6X=+!1110 4444
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M /1<=>/?'K3-/TSQ=;1:?8VUI&=/C8I;PK&"WFR#. !S@#\J]A^#G_(HW?\
MU_O_ .BXZ /0J*** "BBB@ HHHH **** "BBB@ HHHH **** $9@JEF("@9)
M/05@77C+1+2Y\B35-/#AF4AKM 01UXS5KQ-)-%X:U-X-V\6<Q4JVT@[#CFOD
MN^N))KN]>>XD\X2L1N)8@ECGFO?R7)X8]2E.5DC*I4Y3[#L[R"_MDN+::.6-
M@"&C<,.1GJ/K3;V66*$-"K,V[& ,\<UX)\/?BA:Z!91Z?J+RL@D)WM(Y 4(
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M2W[L]3*U@W4?UIZ="I_PN"X]+'_OS+_\51_PN"X]+'_OS+_\55;_ (4SJ/\
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M\^^)WB&XTJSMX+.79,TBN<;@=N''4$=P*]!KR'Q)_P 3#Q_' _R@:6'R./\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% %#5-(M-6M'@NH1(K9(!9EYP1V/O56T\-V%
MKH[:<MNHB9&0J)&(PV<\YSWK9HJ>57O8U5:HH\JD[;F-I'AG3M(W&WM@C,02
M1(S=,XZGWK9HHII)*R)J5)U)<TW=A7BWQIM-0DU.TFL].O;M?)12;:!I,'=(
M><?A^8KVFJ]Q96]WCSX]V.GS$?RHU4E)="4U9I]3SA?B=*+4HN@>(Q)@X/\
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M8;'_ .CI*]7^#G_(HW?_ %_O_P"BXZ /0J*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ I&4,,'I2T4 <EK7PY\/ZR$,EKL=<
M?-YDAX&>,;AZUY1KGPQU+PQ,][HL]S*T)!41V1?@+N[ENXKZ$I&174JZAE/!
M!&0:];!YSBL-IS<T>SU7XD2IQ9\ZZ7\4?%'AV6*TU.TG=-XRTT:P\9R?^6?H
MU>M>&OB'I>O*%DN+*WD"*2#>(QR02>./2K^N^#=*UN,B2SLEDV,H=K57/( S
M^E>0ZW\'M<TR:6[T:\=LR,0D*K#@$\#/F>A->ISY7F*]Y*E/\+_D9^_#S1[[
M%+'-&)(I$D0\AD.0?QI]?.&F^-/$/@RZ6TU:.\F6 D,KWY((QL' W=Q7IOA[
MXM:!JT,,=Q+]FN#P4(DDZ+D\[/K7GXO(\307/!<\>ZU_(N-6+W+&K?$:#2[U
M8'@B^:,/\UR%[D?W?:NHT[7=/U*%&AO+5G;/[M)U8]<=JYKQ!X*T_P 3A)K9
M[>)TPA86H)P,G&21_>KSJY\(>*O"\S7,$MQ)!%CYDN%CXQN/ <^E?-SG6IR]
MY71]%1PF Q5)*G/DGY]?O/?.M%>.:#\3I-, M=6AF=]R@O)<LY R23]T]B*]
M%TKQAHVKA1;W67.WY?+?@MT&2HK6%:$]F<.*RS$X=^]%M=UL;U%("" 1T-+6
MIYX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/^11N_\ K_?_ -%QU\N>(KW7[V]637TN%N1& HFMQ$=F3CC XSGFOJ/X.?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO5_@Y_R*-W_U_O\ ^BXZ /0J*** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[/M7 ,/&.,<8^E<Y\1-'TO5M.BM[][Q2Q;8;<J/XE)SD'T%><WOPETW3M/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW=Q-&D+2-^Z< G?CU4^@JY9:5IG@K2P4>[ECA /S%6)R GH*Z@G KQ?4K/\
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MHW?_ %_O_P"BXZ /0J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445P?Q
M&37'LY1H]E#<-Y28$C <^9SU8=JWPU#V]54^9*_5B;LKG"_'$?\ %26?_7FG
M_H<E>Z("$ /6OF'4_#/C?5YUEN=%@1E4*!'/&!C)/=SZUZK\-(_$D=XPUK3X
M+:+[,^&C<$[MZX'#'MFOI,UPD%@:48U8MT[[-:WMY^1C"3YGIN>EUS/CK_D5
M]1_Z\KC_ - -='--';P232MMCC4NQQG  R:X3QCXJT2[T"_MH;W=,UI,BKY3
MC)*<#)&*^0JR2B[L]3 4ISKQ<8MI/L+\+O\ D#O_ ->]O_Z"U=[7EGP^\2Z/
MI>EM'>7GEOY,*X\MVY"G/05Z;:W<%[;)<6[[XG4,K8(R",CK]:FA)."5S;-:
M4XXJ<G%I-]O(=)!#,,2Q1N!_>4&L34/!?A_4MOG:7: KT*6\>>_JOO6_1753
MK5*;O"31Y;2>YY%X@^#-AY$DFD+=M..4 DB0?=/^R.^*X:[T3QQX0=!;R7T:
M+\^QKX;?EP>BN/6OI:BO:P_$&)IKEJI37F9NDGMH?/.D?%[7]-N5BU<VJQXV
M[G$DAX!]'/?%>EZ!\3]%U6*/S;Z(2'A@EO*.=N>XK9UKPA8ZRA\Z6Y4[BW[M
ME'4@GJ#Z5X3X_P# L>B:I*T7V@QE/,!DD0]7(["NM5,IQW\1>REY6M^)=*C7
MG+EIKF9]'VU_;7?^HEW\X^Z1_,59KY%TZ76K!//L[2&2-6.3(1U(Q_>'M7?Z
M)\99[57CNOL,8)+#$$I]/0UGB.'*B7-AIJ:\O^!<EU'%\LU9^9[W17+Z/X^T
M'5O+BCOU:X;^!8) .N!U'N*Z:.1)4#H<J>^*^?JT*M%\M2+7JBTT]AU%%%9#
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** $9@JY-<-XH\8Z8UI>:7)#>>8&"EE5<95
MQ_M>WI7<LH88(R*YB]^'?A74;R2[NM+\R>5BSM]HE&222> V.I-1)-Z="HM+
M7J>9_#'XBZ5I=E<Z;+;7C,TC7&Y44CHBX^\/3TK<\;_$G2KG0Y=/CMKT271-
MN&:-<#>C#/WO>NI/PO\ !IZZ/_Y,S?\ Q=*GPP\'1N&71\,#D'[3-_\ %UK.
M7.TY?,F/NMM$7PNMQ!X&LMI)#>9U_P"NKUV=5=.TVTTJS2TLHO*@3.U-Q;&2
M2>22>I-6J=22E-R1,4TM=PH/2LS6]?T[P_8M=ZA.D:#HI=06Y XR1ZBH]+\1
MV&KZ:VH0,T=LK;=\I4 \ @Y!(Q\PK/=-]BMK>9Q'@K6I[OQ7-;ND846+/D Y
MSO4>M>G5X[:>./#NE:L;K3K&^G#0>69+55E ^;.#\^,\#]*]0T?7;#7+2.YL
M9T=7!(7>I8 '!R 3WIP3=./DM13TJ2OU>AI4AZ&EHH8SQ^!(]>^)3VMWN18+
MNY5##P3P_7.?[HKT:;P[9R6'V=I)_+"J,AAGC'M[5R/Q+T;3#9)?"XL[:\1G
M9&GN"I8LRAL G!XZ\<9KQZ/5]9FOC8SWT8L0S('9%$>U<[?FV].!@]ZF/OP]
MFE9_@74^/VG3\3O_ (>:79ZA?3V+/.L0B:;((#9R@].G-:/P=46_VNWCR4.]
M\MUS^[%:=GX2LYO#YMO#MS8%_M7F.Z7+2+C9@C/S<_=KH?!_A2#PM8RPQQQJ
M\DA?,<C,,$*/XO\ =K?X7+T2]3/F4H;;N_H=+11160PHHHH *AN;A;:,.P)!
M..*FILD:R+M<9&<TG>V@U:^IP ^+.D&\6W^R7NYF"Y\M,<_\#]Z[/3]4BU#2
MEU"-76-@S88 '@D>OM5+_A$M#$@E^P_.#G/FOV_X%7FOQ3UC4].GM-'TBPU%
M[,B2.<0VOFJ58(?O')'WF]/TH<DHI=6"C>5[Z$_BSQ.?&=XWA/3HO*9I9(YI
M+A=HS&0PVE2?[AZCTKT#PAH8T#P];69DWOM5G.<C=L4'' XXKSGPQXOTGPYI
MT2P^'==2Y>&-9V6VW!F5<$_,_')/85Z7HFNKK.DF]2VNX1NV[+B,*_0'H"?7
M^=790BTM>[(<N:2OHNB+^H_\>,GX?S%>3? S_CVO?7>_\HZ[RP\2_P!HZQ+I
MK65^@6>2+?+ %0[<G(.>AQP:X+1A<?#;6G^VV-W+9S6YP;2(N/,+#J6QV0\9
M]*(2Y9-/[2T^5RYZP\TS:^*:JT&G==W]IP?3[C5UW@\$>%K('K\__H;5YU?7
MU[XW\5VBV5E>II\5W#<[KB#:NU<*WS+GG)/>O6;*V6SLXX%  7/ )/4D]Z*:
M<:+3ZNY-1WJIKHBQ7S3\6XKYM='EFVV_:;G&[=G&Y:^EJ*D9\'ZHDZ3@3^7N
MV#_5YQC)]:^KO@Y_R*-W_P!?[_\ HN.O*?VB#GQG:_\ 8-C_ /1TE>K?!S_D
M4;O_ *_W_P#1<= 'H5%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% $%[:I?6%Q:2%@D\31,5Z@,"#C\ZX.3
MX0Z+).TIO+_+8_Y:IV_X!7H=%1.G&?Q(Z:&,KX=-4I6N>=/\'M$?K>:A_P!_
M4_\ B*[C2=,BTC3(+&%G:.%%12Y!) 4#G 'I5VBE&E"#O%#KXW$8B*C5E=(*
M***T.4**** "L77_  W;:_;O'/+,FY57]VP'1L]P:VJ*4HJ2LRZ=25.2G!V:
M.:\.^#+/P];F*":=P9#)\[ \D =E'I5+7_ASIFOA/.N;M"F,;'4=,^JGUKLJ
M*VP]:IAG>B[!7J2KR<ZCNV>":Q\$;FP22ZL+Z(A>0)Y3T R>D?J*YJVU+6_!
M5[)$%T^4J5<Y#MT^;U']ZOJ"JU[%:2Q%+LH$*D?,^W@]>]>]1XCJN/)BH\Z^
MXY_8K[)XYHWQU5G6'4; \  FWA[@'/WI/7%>C:%XVL-=53!!<H2JM\Z*.H)[
M,?2L?7?AKX?UJW;[#:P>:QW,S7,A!R0>Q/H:\\UKX.:M8#S]*2U\P,=OEO+(
M0,@="I[$UK[/*,:O<;IR??;\Q?O(;ZGOZ.'0,,X(SS3J^9[>[\>^%KE8Y8KP
MPQ9SY-CN'3:.2@]*[;1_C+;J[KJWVY#@E?-ABC],?Q#WKEQ'#]>"YJ,E->0U
M5770]BHKF],\=^'=55##J5M&6!($L\8/7'9C6_!=6]RF^WGBE3^]&X8?I7C5
M*%2D[3BT:)I[$M%%%9#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "@D 9-%9NO/.FC7#6P8RC;MVMM/WA
MW^E3)V38XJ[2*U[XNT&P<)/K&FQL1D"2[13CGU/M59?'GAMF"C7-)))P +Z/
M_&O,_ /@N'7K*>?5[I+BX21D5;F 3$* I!#$^I/'UKL%^%VBI(K".Q!4@\6"
M?XUHXN+M(3:N['<65[;ZA:K<VLT4T39P\3AU.#CJ/<58JCI&FPZ3IT=G!L$:
M9QL0(.23T'UJ]2E:^@E>VIY+XT!\1>+])T*[/^ARRW2NN.NP!ATP>JCO5_Q<
MUOX.^'4]GI@6-EB@8?/DD[T4G#9["I/'N@:C'=V>NZ7%YTMHTS-&CK$3YFU?
MO$^Y[5QUS:>)?'>HVUK+82VMLD(MIBUVLH+)ELE<C.3C_&HA'GIQIKOKZ?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4445S#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS@]-LRG^1JVKJXRK CV-<;C*.Z*%HHHJ0"BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI)WHI.5QS@5%W[+GZMV7Y?F:<O[Q4_FRI=_&719G"Q:<EY$!G<[LN&],&/\
M7WKLO#%UH.IVR7VCVUM%YJ-CRK?8=H;!YVCN*YWP+X(T:#1)EO-*M9Y#<L0U
MQ#'(P&U>,XZ=:Y[X;W4]IXRO-,25_LD-DS)&6. 2T9Z=/XCV[UO&G:<J?5*]
MS"4[P51;=CV6O(_'J"7XBZ"K ,/ML8P>1R8J]<KQSXL:7XCD\0Z;J&@V:S-
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M  2/8KHSQ.V^,=]IY/V_2YMIZ%K\MS^"GT-=39_&_P .RE%F/E$\?\M&[_\
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M?'7C(^#(H88(1*\C*Y+KN&#N'9A_=J#X;>$YM-1=7NIHVFG@>)EB8E1^\&,
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M(![5UR01QN75<,3DG-255[)VW?4FU[)[(XS2?&,VJ>(IM*>%%1+F6'<JD'"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR7]^N.U94WR*TMM3:5I7:W)?^%K?]07_ ,FO_L*Z+PUXN_X2$X^P_9_W;/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,J3PI+&RLCJ&!4Y!!YZT^M3A:L%%%(&4]"#]#0 M%%% !1110 4444 %%%%
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M1J$)MR].A>HHHK<\D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(^J/+?AA_P CM=_]>1_]#CKV2O&_AA_R.UW_ ->1_P#0XZ]DKGPO\,]7/?\
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M6O2J*3U:?;0=]_,\U\/?#&:QUU-6U.ZC,R[6VVTAV[E92.&3.,+SS7I*J%4
M4M%-R;21-M;A1112&?,W[1'_ ".EM_V#H_\ T=)7J_P<_P"11N_^O]__ $7'
M7E'[1'_(Z6W_ &#H_P#T=)7J_P '/^11N_\ K_?_ -%QT >A4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!YGKWPI76=:N+_P"UE?.=GQYF,98G
M^X?6H]+^$BZ==M-]K+ QE,>9GN#_ '/:O4**Q^KT[WL>FLXQBA[/FT"BBBMC
MS HHHH **** "BBB@ HHHH **** "BBB@ I&4.,&EHH :B!,XSSZTZBB@ K@
M_$WPW@\07KW(N9$9W5B/, '"[?[IKO**F<(S5I&^'Q-7#SYZ3LS!\*>&T\,Z
M4+-)&D]26S_$Q]!_>K>HHIQBHJR(JU959N<W=L*#113,SR7Q)\2[O2]1CB^S
M0,&A#?ZLGN?]H>E58OC1(B@/9+^$7_V=>LW.F6=VP:>'>0,#YB/Y&LRX\(:/
M.A5K,$'_ *:O_C7-*G5O=2/<I8W+^11J47?U./L/B];7*YELY0<C[L0]?]^K
M&J>--,\0:->:<\-VGVJ"2#<$48WJ5S]XU>NOACH,\C.+"/<>YN)?3ZUF7'PF
ML&W>3;6Z\<9GEHA+$TY*46KHT?\ 9%3I*/W?YG!6/PHTS49UAAN[Q7;H7D4#
MIGLGM6POP!C.#_:#8/\ TV_^UUI0_":\M]2AFB-FL2EMP\V0DY&!_#7J>EV9
ML-,M[4[<QQJIVDD9  [_ $KW:/$>:._/,\O'8/!4[/#RO?\ KN6(H_+4C/?-
M8/B?6+>#2-4M&24R&UD7( QDH<=_>NAKPWXB>&KG3[Z?4U5!"\B+D%CQY?/4
M8_AKQ:\Y1C=(VRK#4Z]=1G*W;U%^'NJ06'C68RK(?-M_*7:!P2Z8SSTXKVZ*
M02QAU! /K7S+X?TZ76-;M8(@"3*C'.<8W =OK7T3X?TUM*T>&U<+O3=G:21R
MQ/?ZUCA)-IKH>EQ#1IQJ1FG[UMC4HHHKL/FPHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "LGQ+-+!H%U)#D2#9C S_&*UJA
MN[6.\MG@E&4;&1]#G^E3--Q:14&E)-GS_H/@W2M<\(O=W-LDUZM^8@PF<$1B
M,'&%..IZXK6A\%^&7\$0:Q:VD:W4'F3ES<N3A"_0;B,\"NP\.^"[C1+B2U%V
M[V3*9-AM]H\PD#.[)/0=*Y6;PKXGL[K^Q+2^NO[)8B(XTX%=C_?^;K_$W?\
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M+A0 VSS;41?W<?PC_:KO:ABO+6=RD5S#(P&=J."<5-3D[@E9A1114C"BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:);6R;8DS@9)ZDGO]:QPBDD^QZ7$52C*I%)>_P#H6:***[#YH**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *S?$/_(M:K_UYS?\ H!K2K-\0_P#(M:K_ -><W_H!
MI2V9I1_B1]4>6_##_D=KO_KR/_H<=>R5XW\+_P#D=KS_ *\C_P"AQU[)7/A?
MX9ZN>_[U\D%%%%=)XP4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% "$9&*\Z\8:UHF@:@\=TFH/.Z^;^Z"%>6([D'L:[Z]E,-
MH\@.",?S%>5^$M'M==\8ZEJE]$)98-3NH$8LRD* 2!A<#^(T0CS5+=E=E-\L
M.9^AW4/AS3[F,L)+D ''++_A7"67BG0Y?%?]AR1:B)<HJNJIMRQ7&3GI\WI7
MK@ '2N%^)6AVD_AN>^$(^TVY,ZN7;ADC;!QG'I1>TD^@H1O'EZG96,$=O:)'
M$7*#.-^,]35FN*^%=Y-=^![,SON==^3@#_EJ_I7:U=2/+-HB#NM0KS3Q1\4S
MX>UN33Q:A]F>?+ST9A_?'I7I=>5^/O%UXFL'0]+F>"XDB!#/&A3*NV3DY/1?
M2LG?F21K%*SN9S?&Y\?+8KGWB_\ ME:?PXT.ZEU)_$%U)"#=6SQ[(B>"'4="
M/]CUKDG\,>.M-7S_ .V=.^8[/E&??O'[5Z7X"\7'Q#8Q13M,]R(WD=V15! ?
M Z>Q':MZ>BDX[V_ QJ-V2>S.TKS'XC?#[5O%>K65[IEQ91M;LS$7+N 3A,?=
M4_W37IU<;XQT;5KF1;_3+FWA^SJTC>9G/ !&!M([&L)6339M!M7L>:ZA\)O&
M>H6;6DUWH"H<#*23 \$'NGM3K+X5>--/MEMXKO0&5>[23$] /[GM6K:?%*YT
MB9X=8FN;@1'RSY$$?49!].^*TS\:]$\O(MM3SC_GC'_\75=-"/)FMX \+ZYH
M#3G5Y=.<.&V_9&<]=N,[@/0_I7=YYQ7C$GQ"U;7[CR=)NY(%1=S">&/G!P>@
M/J*]!\(Z)J&DPRG49X)9&8X,1/3Y?8>AJWS27,]"=$[(Z>BBBH*"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#YF_:(_Y'2V_[!T?_HZ2O5_@Y_R*-W_U
M_O\ ^BXZ\H_:(_Y'2V_[!T?_ *.DKU?X.?\ (HW?_7^__HN.@#T*BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KR'Q%X\ULW=_I*P:?Y#Q>7N*/NPR#/.['<]J]>HK.I!S5D['9@\33H2<IPY
MOPL?//AW5=3T#6Q>P):.\P$#!PQ !93Q@CGY:]TT"^FU+1;>[N%C663=N$8(
M7AB.,_2M*BII4G3ZW-\PS".,L_9\K[W_ . %%%%;'F!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ,EC$L91AD&O'[N;4? W
MC.XO)+2[DTJ6>6ZD-M!O&9"RC+,!@YV\9Q7L=4M2TBQU>W>"^@\V)P R[V7.
M#D=".])-QES1'HX\LMCF(_BGX6D7/VU4YQAI8@?_ $.N6\3^-$\811Z)H5K?
M2^?,JO*(5:(QLI5OF4L0,L,GMS6X_P &O"#-E=/VCT\Z4_\ L]=#HG@K0?#Y
M1M.LO*=00&\UVXSN_B8]ZI*+=V*[7PC?!&BOH'A:TL)5594W[@I..78CKSWK
MHJ**<Y.4G)DQCRJPA&17CTMP/#'Q*>^U**2.V::>;SMN$"OO5<EL#K_.O8JX
MGQQ_PBDT,L>MM9O+Y:@I)>^4=N_T##OFHYG"7,O0T2YDXLO3?$+PM$@;^VK%
M^<82ZB)_]"KC?A[875SXJNM86"2.TN+1D1I$(R0R#KT_A/>N4BTGX>HY+QV+
MC&,?VDP_]GKUOP?J^CW=LEKI,<$<*1LRK'=>;@;^??J:UIZ7DM[&<V^7EZ'5
M4445F45+W3+/48_+NX?,3TW$?R/L*S!X,T -N%ASZ^=)_P#%5O44+0"&WM(+
M1"L";%)R1DG^=3444 %%%% !1110 444A(49) ^M "TC,%4LQ 4#))[57_M"
MRW;?M=OGT\P?XUS?C#Q,=.MDM;(I-<7<<D:;'!8-@!<+@Y.6Z4F[(<5=V.?\
M5?$E+'7K'3-,N9#(\DZ2^6D;C* 8SDDCO7H.DW#W>D6=S(27E@1V) &25![5
MX?X@\+KIESHNJS!VO;Q))GW(4*N54MQG'\1["O:O#^?^$<TW/_/K%_Z *TC&
MU'7>Y,W>::V:_5FE7E'C#QAXD_X2"+3?#4T^?LHG?9;)*/OLIYVL<_=KU8G
MS7SQ9ZSXF7Q0;NQT6_E?[%Y9:. MQOSC[A]JQ6M5)[69I9^SE);Z'::%>?$=
MM8MUU.XE:T+KY@^Q!>-PSSY8[9[UZC$6,0+_ 'N_%>4Z)\1M=AUZ'3]?TN>W
MCD=8O.N0(1N9ACJ@YP3QGG%>JP3)<0K+&RLC="IR/SK9KW4S+[1)117COCOX
MR77A/4_LL6F>>/.FCS]H"_<8#^X?6H*.(_:(!'C.VX_YAL?_ *.DKU?X.?\
M(HW?_7^__HN.OG#Q[X[G\=:O%?SVGV=H[=8 OF!^ S-G(5?[U?1_P<_Y%&[_
M .O]_P#T7'0!Z%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** $(R,5Y)*MSX<^)1NYK2Y:VDEFGWQ1%AA]X')P,]
M*]<JE>:38Z@X>Z@\Q@NW.]AQG/8T1;C+F7H_0>\7$\PM=87P/XF,FI6]R+26
MSVJ8XQC>7]6([*>*?X -QJ/BR[U.*WGBLYK0B-I8\<AD!&>1U![UW^M^%-'\
M0(BZC:>=L((_>.O3/]TCU-6]+T:PT:V2"Q@\J- 0!O9N"<GJ3WITGR*SZ*R%
M4;E>WVM_^ 7Z***0!1110 4444 %%%% !1110 4457O))8H@T2EFW8P!GBDW
M97&E=V+%>1?&#5+6#4-)MKEMRL9%9 1D@B/(ZY[U(/&'C7^T%B.DZAY1906^
MR\8XS_RSK3O_  _X?\5R:9=>)IH(M120[;>>8Q2$E@ -H9>2%7MW%/D<N62[
MCC)1;3[%'2/%O@^+3[&UGL+R + B&69@L8PH[F3_ #D5Z/I,UC<:?%-ISH]N
MZAE*/NZ@$<Y/;%<9XJ\!>&T\+3F*T6%HU0)*9I" -ZCNV.E,^%=W.VD7=FY+
MPVU_);Q-@ ;$1 M6FIN2ZK4S:Y(Q?1Z'?W$@A@:0]!C^=>.?"Z%/$FIW.H7Z
M^<4A: $G:1AD;HN!_$:]?OE,EG(HY)QT^HKR3X('RDO(6&'R[X/!Q^['2E22
MYY-[I:?B7/\ A6[LM^.M.@T77[#5K:+RW;4K=68$L<!<]#Q_#7I&AWGV_1X+
MK)._=R0!T8CM]*X3XGNLITZV!!<ZG -H.3RK=OQKLO"L+6_AJTB8$%=_!&#]
M]J5+6@_*7^9-7^-'_#_D;-<MK'Q!\/:%<>1?WL<<FYDP98QRIP>K#UKJ:^8O
MB_X:UN_UX266C:A<H;JY8M#:NXP67!X'>D,S?C5XFTKQ-XGM[K2YA+$MBD3$
M.K?,)')^Z3V(KVWX.?\ (HW?_7^__HN.ODV_TO4-+F$.H6-U:2E=P2XA:,D9
MQG! XR#^5?67P<_Y%&[_ .O]_P#T7'0!Z%1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF+_XN@#Z$_X7QX,_Y_O_ "%-_P#&Z/\ A?'@S_G^_P#(4W_QNOGO_A6?B_\
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M7QX,_P"?[_R%-_\ &Z^>_P#A6?B__H$?^3,7_P 71_PK/Q?_ - C_P F8O\
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M (7QX,_Y_O\ R%-_\;KY[_X5GXO_ .@1_P"3,7_Q='_"L_%__0(_\F8O_BZ
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M /H3_A?'@S_G^_\ (4W_ ,;H_P"%\>#/^?[_ ,A3?_&Z^>_^%9^+_P#H$?\
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M\F8O_BZ /H3_ (7QX,_Y_O\ R%-_\;H_X7QX,_Y_O_(4W_QNOGO_ (5GXO\
M^@1_Y,Q?_%T?\*S\7_\ 0(_\F8O_ (N@#Z$_X7QX,_Y_O_(4W_QNC_A?'@S_
M )_O_(4W_P ;KY[_ .%9^+_^@1_Y,Q?_ !='_"L_%_\ T"/_ "9B_P#BZ /H
M3_A?'@S_ )_O_(4W_P ;H_X7QX,_Y_O_ "%-_P#&Z^>G^&WBU$9VTG"J,D_:
M8NG_ 'U7,7$$EK<RV\R[98G*.N0<,#@CB@#ZL_X7QX,_Y_O_ "%-_P#&Z/\
MA?'@S_G^_P#(4W_QNOG*P\!>)=3LX[NSTWS() &5O/C&00"."V>A%6?^%9^+
M_P#H$?\ DS%_\70!]"?\+X\&?\_W_D*;_P"-T?\ "^/!G_/]_P"0IO\ XW7S
MW_PK/Q?_ - C_P F8O\ XNC_ (5GXO\ ^@1_Y,Q?_%T ?0G_  OCP9_S_?\
MD*;_ .-T?\+X\&?\_P!_Y"F_^-U\]_\ "L_%_P#T"/\ R9B_^+H_X5GXO_Z!
M'_DS%_\ %T ?0G_"^/!G_/\ ?^0IO_C='_"^/!G_ #_?^0IO_C=?/?\ PK/Q
M?_T"/_)F+_XNC_A6?B__ *!'_DS%_P#%T ?0G_"^/!G_ #_?^0IO_C='_"^/
M!G_/]_Y"F_\ C=?/?_"L_%__ $"/_)F+_P"+H_X5GXO_ .@1_P"3,7_Q= 'T
M)_POCP9_S_?^0IO_ (W1_P +X\&?\_W_ )"F_P#C=?/?_"L_%_\ T"/_ "9B
M_P#BZ/\ A6?B_P#Z!'_DS%_\70!]"?\ "^/!G_/]_P"0IO\ XW1_POCP9_S_
M '_D*;_XW7SW_P *S\7_ /0(_P#)F+_XNC_A6?B__H$?^3,7_P 70!]"?\+X
M\&?\_P!_Y"F_^-T?\+X\&?\ /]_Y"F_^-U\]_P#"L_%__0(_\F8O_BZ/^%9^
M+_\ H$?^3,7_ ,70!]"?\+X\&?\ /]_Y"F_^-T?\+X\&?\_W_D*;_P"-U\]_
M\*S\7_\ 0(_\F8O_ (NC_A6?B_\ Z!'_ ),Q?_%T ?0G_"^/!G_/]_Y"F_\
MC='_  OCP9_S_?\ D*;_ .-U\]_\*S\7_P#0(_\ )F+_ .+H_P"%9^+_ /H$
M?^3,7_Q= 'T)_P +X\&?\_W_ )"F_P#C='_"^/!G_/\ ?^0IO_C=?/?_  K/
MQ?\ ] C_ ,F8O_BZ/^%9^+_^@1_Y,Q?_ != 'T)_POCP9_S_ '_D*;_XW1_P
MOCP9_P _W_D*;_XW7SW_ ,*S\7_] C_R9B_^+H_X5GXO_P"@1_Y,Q?\ Q= '
MT)_POCP9_P _W_D*;_XW1_POCP9_S_?^0IO_ (W7SW_PK/Q?_P! C_R9B_\
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MH3_A?'@S_G^_\A3?_&Z/^%\>#/\ G^_\A3?_ !NOGO\ X5GXO_Z!'_DS%_\
M%T?\*S\7_P#0(_\ )F+_ .+H ^A/^%\>#/\ G^_\A3?_ !NC_A?'@S_G^_\
M(4W_ ,;KY[_X5GXO_P"@1_Y,Q?\ Q='_  K/Q?\ ] C_ ,F8O_BZ /H3_A?'
M@S_G^_\ (4W_ ,;J>U^-OA"\E,<5[E@N[_52_P#QOWKYT_X5GXO_ .@1_P"3
M,7_Q=:>A_#OQ9;WKN^D@ QD<W$1[C_:H ^P**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"&6TMIVW36\4C8QET!./QJ/^S;#_GRMO^_2_P"%
M6J* *O\ 9MA_SY6W_?I?\*/[-L/^?*V_[]+_ (5:HH J_P!FV'_/E;?]^E_P
MH_LVP_Y\K;_OTO\ A5JB@"K_ &;8?\^5M_WZ7_"C^S;#_GRMO^_2_P"%6J*
M*O\ 9MA_SY6W_?I?\*/[-L/^?*V_[]+_ (5:HH J_P!FV'_/E;?]^E_PH_LV
MP_Y\K;_OTO\ A5JB@"K_ &;8?\^5M_WZ7_"C^S;#_GRMO^_2_P"%6J* *O\
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MC^S;#_GRMO\ OTO^%6J* *O]FV'_ #Y6W_?I?\*/[-L/^?*V_P"_2_X5:HH
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MH_LVP_Y\K;_OTO\ A5JB@"K_ &;8?\^5M_WZ7_"C^S;#_GRMO^_2_P"%6J*
M*O\ 9MA_SY6W_?I?\*/[-L/^?*V_[]+_ (5:HH J_P!FV'_/E;?]^E_PH_LV
MP_Y\K;_OTO\ A5JB@"K_ &;8?\^5M_WZ7_"C^S;#_GRMO^_2_P"%6J* *O\
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M?[-L/^?*V_[]+_A1_9MA_P ^5M_WZ7_"K5% %7^S;#_GRMO^_2_X4?V;8?\
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MCCS@N03R2>WUH 3^S;#_ )\K;_OTO^%']FV'_/E;?]^E_P *M44 5?[-L/\
MGRMO^_2_X4?V;8?\^5M_WZ7_  JU10!5_LVP_P"?*V_[]+_A1_9MA_SY6W_?
MI?\ "K5% %7^S;#_ )\K;_OTO^%']FV'_/E;?]^E_P *M44 5?[-L/\ GRMO
M^_2_X4?V;8?\^5M_WZ7_  JU10!5_LVP_P"?*V_[]+_A1_9MA_SY6W_?I?\
M"K5% %7^S;#_ )\K;_OTO^%']FV'_/E;?]^E_P *M44 5?[-L/\ GRMO^_2_
MX4?V;8?\^5M_WZ7_  JU10!5_LVP_P"?*V_[]+_A2C3[)3E;.W!]HE_PJS10
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %>$>.8]3U?QM8Z9;7$2))<78(D&!A<$<@$]J]WKP'QW<ZA
M:>.["72XI9;H7%YM6*/>W09XP>V>U1I[:%]M?R-%?V-2V]C4;X6ZTM@EQ%=:
M>LA16R9'[X_V/>N@^%?B6_U9+FTU"5Y95+2!O+55V_(,< <\FN8F\2_$:335
MBBT[5(QL4!O[.#=,?],ZU_@_+:1BZCFV+??.WS28;R_W?\/IGO6\+MR70PE9
M1B^IZ?>:I8:>NZ\O;>W&=O[V54YQG')K(M_'7ANYN5@CU>RWL0%S<Q\D\8'S
M>]<WXRT==1OI3?ZQ%;VF]"D4B* K!,?>R">YKC/%.G>#=)TY;C1+:VBOHI0R
M3)?-)R%)'REB.H'Y5C&761JX]$>WRZG8P6OVF2\MUAVLWF&50I Z\YQQ61!X
MX\-W%SY":O9;\D#-S'@X_P"!>U>1SZIKNH^!])D433V^RY^T[( 0R;\$$@?+
MP#S4^G:5X*U&P@%LUGI>JK$FZ9[XR-O(^;Y&8 'AACMGVK3EM)KHG\R;KD3Z
MO[CW**>*:%9HI4>-@"KJP((/3FL6]\:>'K"01S:M9;B,@"YCZ?BWM6%JFI3^
M%OAU)/;WB73P1P^7*H51M)1?<=/YUYCX?D\*ZA;27'B&"UO;@.41FOC!A< @
M84C/);\_:IWD^79!M%-[L][L-8T[549K"]M[D*<'R95?'3T)]1^=>7?#F_O;
MKQ)=QW,X:/[&QQM P=R<\"L?POKXT3Q#):Z-$)+)K4R,L;[QYA=03N()Z <9
MK2^'0QXDO\?\^#_^A)5P2]Z2V<7^@-^ZXO=-?J=G:VT</BG4;DZC8E=T#-&)
MAO0!?XAVSU%;-QXMT"V21I-8L,QG#*+F/(.<<\UYRDC_ /"7^*QNX"6V!C_I
MD:PO ?A>'Q-XFUY-6<SVD=QD1;2G!,A^\I!Z@?E2@G*$;=KE5$HRDWW2_!'L
MVF^)]%U9@EEJ=I*Y8J$2=&8D#)X!/:M*:>*WC,DTJ1H.K.P 'XFO#M3TI/!/
MQ$LH-&;R;9H6F,6"WS-YB]6)/0#\JZ'XK^++O25>PMY%C22WCD+';P?,/J/]
MFHE).,7#J[?/3_,%!\[C+M?Y:_Y'8_\ "=^&?,V?VU8=,Y^U1X_]"K?AGBN(
MQ)#*DD;=&1@0?Q%>#"R\!BVVFTM#-OSYG]I-]W'3&[U[UUWPK\2ZAJ833[I&
M,4=O)()"  3Y@]%']X]ZTC'FNENM3*4K)2Z,]/HHHJ"PHHHH **** "BBB@
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M:M276=,A,0DU"U3S@3'NF4;P.>.>>M>(^)M+\&:59"72H+47<4<CI*E\S_.
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M+*>PLGBN&1G,A8%>F,#V'I6E1152DY.[)C'E5D%%%%2,**** "BBB@ HHHH
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M"9Y;>SM8G9"A:.!5)''&1VXIIJ-TNUOR'=M._=/[K_YGF"9_X3#Q9Q_!;?\
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MJ%547   P !VI0=H./5N_P""*E=R79+\22BBBI&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% %6^TVRU.'R;VUAN(\[MDL8<9QCH1Z$T6.G66F0""QM(+
M:+^[#&J#J3T ]S^=6J*%H 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53U#2K#58A%?V<%R@Z
M+-$KCMV(/H/RJY10!7L[&TT^!8+.VAMXEZ)%&$'3'0>P%6*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** (KBVAND"3Q)(H.0'4$9_&JMAHNEZ6!]AT^UMB 1F&%4."<XX [
MU?HH6FP/4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG  ]33NFM-[J_P RH0;DK[,]TCECE7=&ZN,XRIS3ZQM%GC@TYWFE2-3*0"[
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MI\O[N,WU)YTZDH+I8****DL**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "JUUJ%E8H'N[N"!2=N99 HSUQR:;
MJ%X;*!9!'O);;C..Q_PKYY\;^)O%NK@O);W=E9F560/; J&"$8W%!GN:GFO+
ME15DE=GT=%-'/$)(G5T;HRG(/XU#=:A961475W! 7SM$L@7/TR?<5A6%^^G>
M"%NXHC-)''*RHIP6(+$#H?2O&_%OB3Q-K/B'3GEM[FRLA, J/;@AE.P-ABH]
M/PS5R5JOLUW,XRO3YWV/HB.1)8UDC8,C ,K*<@@]"*=5#0CGP_II/_/K%_Z
M*OT25FT.+NDPHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*** "BBB@#"\8_\ (I:M_P!>,_\ Z+->"^#_ !%XPL#?1Z1:7LL7R F*U#C
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M2_IUO^(U=0FJF^O_  +'M4;[US[T^N:\5>++?PE;133P[UD<*/F*\D,>P/\
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M7 QM7Z]_2IO'>E/96*:V74RVMK%&R _*27P<#'3YO6I;BN5OJ[%)-MI=K_\
M /2Z*S=$U5=7LGN$0J%D*8(QV!]3ZUI4Y1<79D1DI*Z"BBBI*"BBB@ HHHH
M**** "BBB@ HHHH *BN+F*UA>:9]L:*68X)P!R>E2UYUX_T+4=?U?3[>"2U2
MU#E)2Y8/M;8#MP",\'K[4G>Z2*274Z/_ (3KPW]J%M_:7[XL%"^1)U/3G;6_
M%*DT22QG*.H93CJ#TKSB?X9:9:>%;@-=7AEBMY6&)%VDX)'\%1?">_E>;4M/
M94\NT\J)" <D ..?^^:T44^9=49.5DI=&>GUC:IXKT71I%34+WR68 @>4[9!
MSZ ^AH\4ZM_8OAZZO@FXQ;.",]7 ]1ZUY9X+\,V5U93:IJDMP'$C6ZK:LN,8
M5LG</KW]*SBG*[6R-'9)-[L]>T[5['5H5EL9_-1@2#L9> <'J!WJ:]OK;3[5
M[FZD\N% 2S;2<8&>@]@:\\\,>!I=%\4OJ=E.CV3($59G)DQE2<X4#JIQSZ4[
MQ;X=O_$?B-+9Y+9+ 7,,A(9A+@* >Q&>3C\*<MTH]?P!+>_3\3?B\3^#[_4$
M*2V\MV74*[6C;MW1?F*_2NI5@Z!EY4C(KR[Q-\.=,L/#TUQ%<WA>TMYI5#NN
M"0-PS\O3BMSX;:C+>Z*(9%0"WMX%4J#S\I'//M512DI6^S^I$FXN+?VCH;[P
MUHFI2F6\TFQGE(P7DMD9NN>I'J322RZ-X=B 6&WLE<YQ#!@$G_='M^E:I.!F
MO*=P\<>+?L[9BBBL=^1\K;A)CWX^:IAK-014M(N;Z'JL;AT##H:9<7$5K \\
MS;8T4LS8)P ,GI4@&!BN'\=Z1?:Z(+"%[9(&NX_,+E@VPJ0V, C//%*3=TEU
M'%7W-?\ X3KPW]J%M_:7[XL%"^1)U/3G;6_%*DT22QG*.H93CJ#7G%Q\,M+M
M/"MP&NKPRPV\S#$BX)P2/X*R_ FMS66E:U%L0I8B")#@Y(!9>>?;VJG9*7>.
MOJ2KMQ\W8](U/Q-H^C.4O[OR6"AL>6[<9QV![BI=-UW3=77=8W/FC<5^XR\@
M9[@=J\J\*^$X/&&MZCKM[+)%Y6HW$(2%@ORXR."#S\_K47BG18O!.NP:C9.\
MJ0P!BLQ#$EBR=@..10ERN,9[O]=@>O-R?9_0]=;5;2.[^S22XEV>9MVGIG&>
ME7J\V^)-IYMA;ZE$?G\U8-K'C&';/^37:^'M576M$M[]4*B7=P1CHQ7U/I0E
M>-^JW_0&U=-;,U****0PHHHH **** "BBB@ HHHH **** "BBB@"&YNH;.!I
MYWV1KC+8)[X[?6L6/QOX=FO#:1ZCF<,5V^3)U'7G;CM65X[\-W_B<6=G#+;1
MVX,GFEV8/_"5VX!'5><USGB7P'IND>#'<W%TUS%%$#\ZE"=R@_P@XZU*E9<T
MMKE<MVHK=GK%%<1\,=0N-0T"YDN%B5A=,!Y8(&-B>I]Z[&[61K*=8MOF&-@N
M[IG'&?:M*L>2378SIRYU<HZIXBTK12HU"Z\DL"1^[9NF,] ?44FE>(])UH,=
M/N_."D _NW7KG'4#T-<3'\/)M5\17>IZO<1JI:)HEM'(/RKAMVY3Z#&#ZUS7
MB[3H/#7C?0O[/:20SW:>9]H(.-ICQC ']XTJ:NXJ77\.I4D]>7I^)[-?ZC::
M9;-<7DOE1+U;:6[@=@?45B1>(O"NN70MQ)!=3'*!9;5CTYQEE^IKGM<\)ZAX
MLO-,:YFM8[)1(TGELPDPR@KC((Z@9K \>^$M/T#P[)=6\UR]S;P1*HD92A^<
M*<X4'H34IVLY]7;_ ((^5R=H=OZ1[( %&  /I67=>&=#OIO.N=(L)9<AB[VR
M,3@8&214?AJZEN].DDF"!A*5&P'&,#UK5N)1!;2S$9$:%B![#-54CR-WZ$4Y
M<T4UU*&-(T**-(H+>T5F\I%BAVC)YQ\H[U?AE6>)9$.5/0XKRP7C>)_B8]D5
M$<-H\-VIQAB5\L8/4?Q'_&O58T$:!1G ]:%=P4I=?R&[*7*NGYBD@#)Z5@WO
MC7P]IUVUK=:AY<RD@KY,AZ$CJ%QV-+XOL;[4O#UQ::>UNL\FW!N"P7AU/;GH
M#7+Z1\-;6#29&U.YF-S*_FO]FD&P$@9QN7/7/X5%VKM[(NRLN[/0+:[@O(S)
M ^]0=I.".?QJAJWB72-#*C4;OR2V,?NW;.<_W0?0UY?\);B>&\NK2$1F,QO(
M2^<YR@[=JU=#^'-Q<W[WFN7,081&)18N<8R",[U^OZ5<E[VFVY*T3YMT>@:9
MKFG:P@>PN/.4@L#L9> <'J!WI][JEK82PQW$H0RG"_*3GIZ?45XXEG'X?^*4
M<%@SNC3V\1,Y!.UO+)Z8YS7IWBS2UU/0KB5F*O#;S%<' )V]^/:E)I04T.*]
M_DD= CK)&KJ<JP!!]J=7%?#W7QJ=I-IQCVMIT<,);& V P]>?N^U=K5SCRNQ
M$9<R"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** ,+QAQX6U3_ *\I_P#T
M UXK!H[_ -G1ZE!%S;0BX9ADXP-V?3M7M7C#_D5=5_Z\I_\ T UQ'@ZR_M'P
M?JT&S+M8*B Y')C<=JS@G>I);JWYHJ3_ (:>S;_)FAK.OJWPRA,$VZ[:TMSM
M7:6SE,\?G7GEW8&WN[.>1-LMS;K<$G()+9R<4W0+R_U3Q4GAMXYC# \D#*T6
M%^16Q\P&?X*Z+QO;_8M;TNW5"/+TZ-2!D\@N._TKH27M(37VI+[M/UN92NJ<
MJ3^S%_?K^EBQ\8?$LMA<6EA%.8U*I-C:I&<R#J>>U8E^G@"VT9Y-,LF35(E9
MXI!<EOG )7 ,ASSMXQ6C\8-$>?6+6]ELY;BU%ND7[I6.'W2'M[>]6[S2_AE%
MI37=M]CEG(;RX8M1+RE@#@!?,Y)(X^HK&'\)/K?YFLG[Z72WR-?X;ZQ>ZMX/
MO(9#(LT,3!'EC"KEC)@\=>@S63/H.A3ZU=S^+9[*ZE)0QHET8V7"_-D KU&W
M%:WAUTM? ^IW>DV5U;9M9&C5T)8LH?& 2<\_SKCO#@L-<U*]N?%5_903HT1$
M=[.+9\8(/RC'8+^8]:N7O5FUT77Y$K2EZOI\_P ".SGT;2/'VG+X:0V\<DEP
M)AO\S< AV?>9L=35.\TV[U[XHVL.]#;S+(9%?(RW[QNH'':K5Y%H5OXYTG^Q
MK=E427(DF60O&PV?*0=QX/./7-:&B$GXGV! .,2\]ON256']Y1;UWW%4;4II
M::+8B^)7@W3_  I9V]_H-LEI))(L+GS7D)!#D\,2/X1^5>PZ!=/>Z);W$C%G
M?=DD =&([?2N$^-&?^$>M, G_2TZ?[DE=IX3_P"19M/^!_\ H;5%.3<))]&O
MU*J)*4&NJ?Z">+;DVOA35)5)!%K+@@#^XQKD?A(//TV]U!N7N/+RW3.TN.G2
MNK\9P/<>$-5C098VLV!_VS:N4^$)\K0KFS8XFAV[E/4;FD(]Z*>\WUM^J'42
M]G'_ !?HQ?'GA"YU5XKWP_-:Q:G \C;GD9CERN<+AATW=JYBTUGXA^'D$-_!
MJ%U##P3:Z<&!&-HP2@[C/TK8O?$>J^%_&7G:M]H_LF6XGPR0*%51G;EB!CEE
MQSS74M\0/"ES8!Y=5M-KJ"8S<QAAT."-W6IA>,+Q>G8)ZSM+?N1^#O&6E>)C
M+]F$T-RF<I<;5;8-O. QXRW6O'--N]=L_%C-HD5R\AL2&$%OYIQY@SQ@^@KJ
M_AO8--XIN+VPM)K>R%DT1,JGF3>AZ\]L=ZSO"/B#3]!\9RRW\ZP(^GE09'50
M29%_O$>AIV7MHO:Z?Z!+2E4BM;-?J;'_  D7Q$)_X]M4_P#!8/\ XBO0O"-W
MJUYI"R:PDRW/.1-#Y9^\W; [8JI_PL?PM_T%;7_P(B_^*K6TCQ%IFN(SZ?=1
MS*N,E)%;&<XZ$^AJT]&K$/H<?\7XC_PC2W"_>BS@^F7C%=%X%N6N?!VFLQ)*
M6\2<@#I&M<_\7Y5'A4PY^>3[H'4X>,FM[P# \'@W3@XP7@B<?0QK2IWY)+I?
M]$.IO#Y_J=+1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBL+Q3K%QHNF_:;>UO+AO[EK")&ZJ.GX_SH&E<X;XQHQT^=\':
M+>+)Q_TUKTO3W5[=BA!&[L?85QWB#2Y_&7@J1UMI8[J:.(!+E61A\RN<JN?4
MUCZ-X_N=+T][?4=&UV2Z:4N#'8C&S 'J.X/:G%\M.4'NG?UO;_(4US2A)=K&
M+X:A,WQ0U:2%24-D,$<_\\JF\!XC^+.IJ_#?8@,'CO#6]\.?#6H6L_\ :VIQ
M;)I[=XV#JR/G>,94@ <+69JNE:AX4\=3>(XK.>:RD:*)UM8FD<H%0MP1C'R'
MG/I6L9JFXPE_+;YZ?Y$-<_M)+O=?C_F=%\3VC&B;&^\]M<!1GJ=HK5\"1M'X
M6TX,"/\ 0K?_ - %<'XDU;4/'6I:;#I.F:G!:Q2%+@W=KM!5RHZKNX^5LGBO
M5-(LO[/TFSM< -%!'&<$D950.]94TXQDW]I_D54:DX)=$_Q,CQ],T'@O4)$.
M&'EXXS_RT6L?X4PK'X>N2H'_ !]OW_V$KHO%M@^I>&;RTC7<\FS Y[.I[?2N
M2^$-\L^BW4!)$@N'?:< XVQC-.CM47I^H5?AAZO]#TBO%( 8OCG=F08!\@#/
M'.(:[_6?$MWIVJ);1V&I2H81)O@M@ZYW$8SZ\=*YKQAH-YIOB5?%%G;22J+F
M%Y5@1I)#&B@M\N,?P>OI2IRY9QJ='=?D6U>,H==SK_&K(/#&HA^]E/CG_8->
M3SV\J_"S5VV-M:&S*\'IYBUNZ_XLO_%-G#IVF:1K,3RK)!,T]D OSX"DD9P.
MN:Z<^$&E^'XTAHX_M$MM;I("S@%D*D]LCH>U*-X1J2[M6^33_0FZE.FO6_E<
MG^&; ^"K0 \A4!^OEI7 >,U6X^(FFK"-S&RXQSWDK5\/^))_!"7&CZEI.KSA
M+AVC:UM-R>6 %7!8@G[I_2J?AO0]:U[Q99:SJ%K-'! 'A9;F)HF^XQ& !C&7
M'.?6M/BQ$:BV6I+?+1G#J]$;WQDA27PS:%@/^/Q._P#L25U/@V1I?"ED[G+'
MS,\?[;5QWQFNC_8MI:Q;FF^T))L49.W;(,XZ]:[KPY:-8Z#;6SKM9-V1SW8G
MO]:SIIJ$F]FU^MS2J_@7D_T-6BBB@D**** "BBB@ HHHH **** "BBB@ HHH
MH R]>U0Z3ISW*PSRE<?+ @=NH'0_6N0MOB%+/>"#^S-97DC+6:@<#US7?7%M
M#=1&.9-R'MDC^54DT#3$?>MMAO7S&_QHCI*[V"6JLMS1&#S7C?A$Y^*M[_U[
MK_.*O9:\D\*Z9J$'Q,O+F:QN8X# H$KPL%)S%WQCL?RJJ7\7Y/\ -$5?X7S7
MZGK=4-:MQ=Z->VQDCC$UO)'ND;:HRI&2>PYIVK7<ECI=Q<Q1RR/'&S!(DW,<
M*3@#N>*YFTU+4?$WAS4E2UO+6Z^SNL7VR#R_F8,!P,YY _2LI:Q?D;1T:9@^
M'_A'X>#W,VHVMK>-*5<-;W<I&3DD\$=<BN:N()/ OQ'M[/3B(-/=9)_)C_>'
MGS%'+\YPJ]^U;7ASQ;JWA>6[M/$.FZM= %8X7MK(;?DW!B"=N0<KBJ]MI6J>
M-/'$.MRV=Q#IJ&2()=PM$^W#LOW1C'SCG/K71#^*FG[O7T,I?PY<RUZ>IZS?
MZI9:7"LM[<Q0(S;09'5<GGU(]#7D&N7^O?$"Z>VTF&Z33U99XGN+;"':NT@.
MH;)RQXSZ^E,^,&HZ_>7EK9:9IFJ36XC29C%9;U#YD'4 \X(XJ_H_C1-#TZ*T
ML_"_B2,1[@ +#<,%B>[>IK"GRS7/+Y+_ #-)-P]V._?_ "/2]"T:#0]*ALH(
MU18@P 5BPY8MU//>K&J,4TF]8=1 Y'_?)JAX>UF36+..>2TO+<NK';<PB-AA
ML<BM.^B,]A<1 9+Q,H'U!%76YM;[D4N56L>4?"P>=XL\0RORPN01^)EKUZO(
M?A]G2_'FL6DP*&XNG"9& =GFD]?K7;^)O$-UH\H%O9:A<+Y:OFUMQ(,EB/SJ
MIM-0MU2':]2?K^B.@FO;2V8+/=0Q,1D!Y IQ^->=^-OAYJ/B@0[9K,B/;Q)(
MZ]-W]U?]JCXE:=XEO$M[K02005C=?*+M_&2<;3QR*1?B;(+38=#\0&X\S/\
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M=R?05S=]\*O"6HSK/<:;ND"[ ?/E'&2>S^]=K10]7S/<%[JLMC@?^%.^#?\
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M;P_7<,=F/%>A*H48'2A55?NJ!]!2T+2*CV!ZR<@HHHH **** "BBB@ HHHH
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M*::N@HHHI#"BJM_?1:?;^=*KLN<80 GH3_2EL;V/4+5;B)75&S@. #P2/Z4
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M% R3@=&JDF]B6[;G24444AA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%4M2U.#2K9IYUD951G(0 G
M"C)ZD5S/_"S-&_Y]K_\ []I_\72N@L=G17.:9XTT[5;J.W@ANE=\X,B*!P,]
MF-='5--;BNF%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%4-5U:#2+5[BX21D0 D1@$\G'<BDVEN-
M*Y?HKC/^%F:-_P ^U_\ ]^T_^+K3TGQAI^L70M[>&Z5R,YD50.H'9CZU23>Q
M+=CH****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** ,#QF,^$=7![V%P/_ "&:\@^'/PYTO74OYKFYO$($38C=1][<3U4^
ME>P>,?\ D4]6_P"O&?\ ]%FO#/!?A#Q5JYOI-*U&P@C'EL1-G.#NV_P'T-31
M^*IIT7Z#J_!#7J_R.B\:>![+P7;0:QIL]Q+-'N^6Y<,O)5>BJ#T8]Z]/\+ZB
MTO@[3[R=0#]FBR(QZHOJ?>O'M;\'>)?##1:[K5U:7=K;%BPM-Q8;\)W11U8=
M^QJ_XS\5?:_AZ@LC*%%G;*4**3N#+GUJ^:U*RU;E]U[?\.)1YJB;T5OO.GNO
MC5H-M.(S9:D05S_JD]?^NE=W8:O;ZCI@OX4E6(JS8< -A20>A]J\ETOQ(UA8
MM;Q^%_$>PR%\+8DC. .[>U,^':ZK#J=^DUK<V]B-/EV)- 4(.Y>Y'U/6J45[
MR[*]R>:Z4N[V.]U'XC:1ITUU#);7K/;+N8JB$'*[N/FJGH_Q6T;6)98X[2_5
MHRH.Z-!][/\ MGTKD= T.UU#XE:U<SQ*YCFLF7+L"/D]OI3?BWHUHOB3PYY<
M('F3L'R[<\Q>]3%:0;^U^!I)7G.$?LG4O\7]#35SIYL]0WK(Z$^4F,KG_;]J
MZV;Q!:0>'QK+QS&V*(^T*-^&QCC./XAWKB_&&B:?'\,%86^'6V@P=[?WH_>L
MBW);X*:DAY5)8D4>@!AQ4R=H2[Q?WA"/-.':1OZG\7]$TZ-6-GJ#$D#B)#Z_
M[?M71^'/%ECXGM8Y[2&XC#JS@2JHX#;>Q/>N3^%'ARPM= N6^SKO-TXR)&Z;
M$]ZY;P]"--^)>J0VH$<2V8"KG.,^4>_O6DH*,W2?];?YF/.W3]HNAV'ARXT/
M3I+R\LQJ+-#:2.PFV'*@@G&._%>8^(_$>BZ]\1DDNH[](EN(-OE*@;!" YR3
MZ<5V'PSC3^W[H$<&R<'_ +[2G7EO OQ/N#Y9PMQ:D<G^ZM$5^_A?^6_X%UVH
MPJ+^];\3KKGQ)I'@_P /6]Z8KZ6WDA0H J,VWY0,\@9^851T7XMZ+K5\EI%:
M:@LCLP4M&@' SS\Y]*Y3P[&NO?%&^BO1YD-I>7"QHWRD ^8.W7[HZUU?Q%\.
MZ>?"MU<);@2Q1Q(C&1N!YB^_N:B4N5*<];_D4H7E[./3KYG<W5W':1"20,06
MV_**\YNOC9H-O,$^Q:D05S_JD]?^NE9<<&I>-O .V.1?/BU3.9EV_*(O]D'N
MU9OAO6Y?#5A)8ZUH6M,'E,RLEH0O(  R2O/RGBJG!PG*+>WXBC)2IQE;?\#K
M?'^IV^L_#];V%95B:1F < -\J2 ]"?2N9\(?$W2/#'A2PL;BUOI''F9,<:$?
MZQCW<?WJ?K9\.S^ RFCM$ID613%Y^Y@I#@Y&XXY[^]=#\+/#NGIX%A+6X+3J
MX<B1N0))!Z^]-)J,[;70-WC"_=G8:!XCM/$5H+BTCG1?+1\2J <,,CH3Z5!'
MXNL)->_L<0W/VC<Z[BJ[,KG/.[/\)[5YUX7MQH_Q4FM;8!(;F[N RJ=W""0C
M)/(ZU'9*/^%S @<^?<_REH@HS<6MFF_NNOT"2<8SONK?B>KZQK-OHEC)=W*2
MO'& 2(P">6 [D>M8T?C_ $J6Y\A;>\W;-^2BXQG']ZL[XJE1X-U#<1]R+O\
M]-5K@O%>DG_A'8M1M8B7^UB E<L<;&;IT]*SHM-MSV32^\*B?NQCNT_PL>W:
ME?Q:7837DZNT<2,[! "2 ">,D>E<?JNN:+XBT-+N5+](/+EP%"!L=#W([<5D
M>+/$$.N>&-.LK682S7EZL$B*5)VL'7D D@<CD51U[1UT7X?V%B8PC)!=Y )/
M4Y[\]Z)1M%M]&E^)=%J4XI=4W^!W=IJFGZ)X3AOU6Z>TBMX< A3)M. O<#/(
MS6#=?%[0[>Z2#['J)++N!\I/?_;]JS-:4'X)[>WV*R_]"CJ7X7>%M+;PV;J>
MU#3/.6W"1^\:=LX[FM&KU)7V5C.-E14K:MM'HNF:A%JFFV]["KK'-&LBAP 0
M" ><$^M>4_&V)=2CL]/)*[2D^1Q_ST7^M>O11)!$L4:[44  9S@"O.?&W@)/
M%VNPS33V+1QVRKY<D[H^0S'.%'3YJC>I&RTN5&Z@W?6Q3TSX;>&VN(HX[G5?
M-C(<;I(]O7_=]Z[IK*'0?"UU!"SO'#;RL"Y!)X9NV/6N!\6?#?1]#T.35=%L
MH[:[M"9_,,\C\(K-P&)!.0.OI5[P;?7/B;X<7-K<W""=K::(R3 (OSF0 \#I
MTSQ1)N5.7+NA1CRRBWLSA?"_A#2=8UO7;_49KU0]QYJBW9!]]G)SN4^U>F^'
M?!.CZ!-_:=E/?.V VV=T(Y!'91_>/>L+0O@[HB132:E:VET\H1@\-U-C/.3P
M1UR*YV[T^;P)XGCAL]L=G>2S 1Q9D.V,':"7&>-W8TYR2?*M';3[A*+E>4M5
M?7[R\FE+XZ\>7+73F&WMKJ>S/E':Y";F!Y##J1_A47B_0XOA_>17^FN\R31B
M%A<D,026/\(7^X*UOA?,LNH:A(W#RZI</@\'E >E/^-FQM%LU(RWVA#^&V2K
MFO92I\OD$+5'-2V/3;&Y%Y9QS@$!L\'V)']*J:SKEMH< FN8YG4JS8B )PHR
M>I'K3/#*-'X>M5<88;\_]]FN3^+""31!&?X[:Y7\U%9U_<DTN_ZE89>TY>;M
M^@FH_%_0[!86:SU B3)XB3MC_;]ZO7'Q,TBWT1=4:VOC$8T?:(TW8;&/X_?U
MJGX*\.6$'@J,F!<S:=#N(D;G]V??WKC/AIHMHWQ"\0[X@5BO'"#>W S**T=/
MWG"^RO<A2O!5+=;6^=CT/PS\1M+\3SB&UMKR-VD9 944#A=W9CVK8\0^);/P
MW;1SWD4\BNX0"%03D@GN1_=->5^*[.#3_BK8M:IY9^SLQY)Y)E!ZU=U2%/$O
MQ$6WO 'A320X5SL^82D9^7V8U"7M.11TO?\ "W^8V_9N3EJE;\?^&-S3OC!H
ME^V!9Z@ORD\Q(.^/[]=GI&M6VM6J7%LDJ(X) D !X..Q-<?\3= L)?"<CB%0
M\;EP3(W41O[T[X3H(O"-@@Q@)+T_ZZM502DI>1-1RBX^9W](S!%+'H*6H[C_
M %#?A_.LI.T6S1*[L<E?_$G1]/EN8I;:^9K>5HGVQH02#@X^;I57PY\4](\1
M7,EO!:WR.B%R7C0# ('9SZUQGAC0K2^^)U_<W$*N5U.[7[[ ]']/K4WQAT^W
MLY[2XMHPDA5$)W$\9D/?Z5HDHN#E]H)*[E&/0]HHJKIS%[&-F.2<_P S5JE)
M6;1$7S13"D89&*6BD4<1K/PQTG6]2DOKBZO4D<DD1R(!R2>Z'UKRCQCX#TRZ
MUB+2-,N+L.+<7+-<NN,;F7 *K].WK7O/B/58]&T.YOI)-@BV\C&>6 [\=Z\]
M^#^DSF"[U.]3,VY[<,<J=N(VQC '7-%*-YWZ1'-VA?J]CO?#/AZ+PWITEI%(
M[J\IER[ ]0!Z#^[6U1152DY/F9$8J*L@HHHJ2@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S]6TB'5[98)W
MD55</E" <@$=P?6M"BDTFK,:;6J/*-=^%^@:-H=Y?-=:FWE0NX DC.2%)_N#
MTK$^&/@>UOM3GUZ*>81":"6)&<;LH6!W#;ZKV-;_ ,0=4.K:W9^'+=R[#4+?
MS4P,;&7!Y'(^^*[[PYI::/H=O9(@01[N 2>K$]^>]71;2=7Y+_,FJMJ;]7^A
MJT445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,S6M$M]<M&M[AY$1HWC)C(!PPP>H->;^)/AOX?\
M/Z'<:@]SJ;B/;\HDC/5@O]T>M>MUY-X]NSXCU_3= MF\P&2X25.,93:1RN2/
MNFHY;R4%O+^OR+3LG)[1,SX7^ ;?^U6\11W$NQ+N;RT9QG:T?&1MZ_/ZU[96
M;H%@NF:!8VBH%,=O&K $GD* >OTK2K>I*[2Z+0Q@MY=6%%%%9EA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5E:YH-OKUE):W,DJ)(%!,9 /#;NX/I6K12:3W&FUL>2:_P##GP[X?L$NI;G5
M'#RB/"O&>H)_NCTJC\(O ,=E<Q>(_M#D30.@3?T(E';;_L>M2_$627Q1KMOH
M]DWFB.V6Z*XR.&=<Y7)_B'M7KMG:QV5JEO$NU$S@9)ZG/?ZU=%N,'4_FT7H3
M52;5/MJ_T)Z***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% &)XNBDF\+:JD,;R2-93A4122Q*'  KQ+PAXQ\1>%C>P_\
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MFKV5X_P>^S)9SM<_8[0>2(R7R&3(QC/'-;GPUM[BV\*)'<P2P2>8/DD0J?\
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MDGEP1XW-M)QD@#@ GJ:3:6K&DV[(MT5E:'XAT_Q%:O<:=-YL:.4)VLO( /\
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MZ'P%.9_!FFDX^2WB3CVC6IIV=-KJG^&_ZE5+\ZEW7Y'24444@"BBB@ HHHH
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MZ,:LZ<DZ;C_*_P [_P"1=16E&7=/\+?YF_1110(**** "BBB@ HHHH ****
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M6,GM< <<?PFN?^$KD^&K-.,"*7_T::BGO.F^EF*HUR4YKK='HM%%%(H****
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M&J61M2"BVY6?=ZLV>/H.]<Q?>/[[Q? MA96]O$\;><3,C*, %>S'GYJ]II
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M_-N9P(UY_NC/SFHKK6K[XDW]G' EO!;6\@1_,#*Y$A .,%AGY3^E>V$9&*0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img57592461_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '\!&P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI&8(I
M9C@ 9-8 \;^'".=20'T,;\?I346]D)R2W9T%%8UGXKT34+N.UM;]99Y#\J!&
M&?S%;-#36X)I[!12 @YP0<<4M(84444 %%%% !1110 444R.:*8$Q2(X5BI*
ML#@CJ/K0 ^BBB@ HHHH **** "BDR 0,\GI2T %%12W-O \233Q1O*VV-7<
MN?09ZFI: "BBB@ HHHH **** "BH;NZALK5[FX?9$@RS8SBLK_A+=$_Y_/\
MR&W^%1.K"'Q.Q<:<Y_"KFW16=8:YI^ISM#:3^8ZKN(VD<?C]:T:<9*2O%W1,
MHN+LT%%("&&001ZBEJA!1110 4449H **** "BF":)IFA$J&50&9 PW 'H2*
M?0 44 @C(.0:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** ([C_CVE_W#_*OG5_\ 6-_O&OHR1/,B
M=,XW*1FO,C\++PL3_:4 R<\(:[<'5A3OSG'BZ4ZEN4Y_P/\ \CAI_P#O-_Z#
M7M]<#H'P^N='UNVOWOHI%B))54()XQ7?5GBJD:D[Q+PM.5.%I'D>AVFBW/B3
M5S>^%=0U"[_MJ8+?1Q;XHQOXRV_C'TKM4\37MWXFN=+L;*U,=G*L=P;BYV2D
M%0=R)M.5YQDD9P:I:=HOBW1KW4%L9M%DLKJ_DNAYZRB10YR1\O&<5/K/AK4M
M:UB&69M+AMX+A)HKJ*%A=JJD'9NSCG&">F#TKF.@S=)U77);WQA_:<%K-86K
MO^Z%P[$ 0J0BC;PI')/J3Q6C%XCNHSHFFZ7I$;O>:7]JC5YRB0A0F%)P3CYL
M9QGI4A\-ZA'J'B#R;BU^P:O&6(=6\R.7RPGT*X /K4^G>')[+4M&NFFB9;#3
M#8N #EF^3D>WR'\Z%YC?D9">.]3?29]3_L +;6%PUO?AKGYE96VL8QMPP'7)
M(X[5I^)O$]SHA5H(].:+RO-)N[WRF<<_*BA22<#J<#FH3X2N?^$5US2/M,/F
M:C=3S(^T[4#L" ?<4R]\*ZH=;O;RQNK$1WUND,AN(2TD&U2/W9'&#UP>_/-(
M91O_ !%K5_K?A*YT:.#[#J,,DWES7#)O_=[L, I^Z.1[^E3ZEX_-O<ZA]DMK
M.6WTUREP9[U8I)& !81+CG'OC)XJ=?"NIVFF>&5LKNU-[HT?E,9E8QRJR!&Z
M<YXR*A?P;=VFIWLMA%HL]O>S&=S?VF^2%V #;2/O*>N#CJ>:.K$7Y?$]U>WZ
M6F@6$=V1;1W4TMQ,8D1) 2BCY22Q SZ"J_P[D>71+]Y(3#(VJ71>-CDH?,.1
MD=:L7&@:K9ZX^I:+=62"YACAN8;F)MH* A73:>.#C;TZ<U:\*:'<Z!I<]K=7
M27,LMU-.9$7:"'8D<4^H',_$"=-7U.W\/)J45D\%N^H%VF"9E7(A&<]-V2?]
MVMJ'QC'-X2TK58+=KFZU+9%!;HP&^8Y# GH -K$GT%/M/"%G-J6J:AKEK8ZC
M<WD^8S+ KB*%5"H@W#CH2?4FJ*^!YK>"Z@L;N&UCAU :AI86+*V[E<.C+P"A
M);@$?>H O3:]K&G0V9U33+6.6YOX;1?(N3(NU^"W*@Y![=ZM7.MW(\1SZ+:6
MT3S+IQNXWED*@OOVA3@'CH<U2U#1-=UG25%[=Z?#J-O<Q7-J8(G,2LAS\VXY
M(/3C&/>GZ5H>KIXKDUW5+NU=I+$6OD6RL%0A]V03R: .?\.>+M1T_P"']CJ.
MLI#-/<R"&U;[1S,[,W,C, % P3GG@5T/AWQ2VK:G=:7=1VB7D$2S@VER)XW1
MB1UP""".01W%9,7@6]_X1J+1KBZLG&GW FT^4P%@P!;Y94/!!#$'!K?\/Z7>
M6#327EMI$#. %73K<H.^<L>3VXQ1U H:DQ'Q/T 9(!T^[R.Q^:*J,'CG4GT:
MWUR;1$CTIIO)F?[3^\7]YY>]5VX*Y]2#6_=Z++<>+]-UE98Q%:6L\#(0=Q,A
M0@C_ +YK+;PE<M\//^$<^TQ>?G/FX.W_ %WF>F>G%/H);LS9);I?BI?W-]:6
M#V5CIR2K-)(2\*;G.Y05X8D<X/;K5BP^(!NKO3WFMK..QU&18H-EZKSH6&5,
MD8' /L21D9K9D\.F?Q%J=_-(IMKZP2S,:Y##!;)S[AOTK-T+PI?:3-:021:&
M]K:85+E++;<NJ_=SV#>I%)#9<M/$&K:M=-+I6E0R:4D[0FYGN"CR[6VNR+M/
MR@@CDC.*P-"U?6[BW\9/K$%M<65K/.OEBX=B (E/EJ-OW<9YX.3TK<TS1-<T
M2<V=A>V3Z09VE47$;F:)68LR @X(R3@GIGO3(_#.H03>)8(KFV-CK DE3>K>
M9%,Z!"#V*<9]:$,1/$5TRZ=IFAZ7%)<M81W,BS3&.*WC(PJ[L$DG! X[<U'-
MXWFM]'N)Y-*;^T;2^ALKBS64'YI&4!E;'((8$9Q[U)_PC6J:?/9WVD7EJ+N.
MQBLKF*Y1O*E5.C KRI!)['@]J8WA"[ET]_M%[#+J%SJ,%]<R;"L?[ME^1!R0
M JX&:.I)9@\37T&JW.G:OIB03):->0FVF\T2HIP5Y (8'ZCD<U+X8UZ^\00B
M]>ULH["6,/"T%WYK@GG:XV@*<'IDX-2WFBW,WB>+5X)HE$5C);*K@GYV96!/
MMQ]:HZ%X:O;3Q#-K-\;"&62#R6AT^-D24[L^8^>K#&!QQD\F@9I^*/\ D6[S
MG'RC^8KR[TZ5ZUK%BVI:5/:(X1I!@,W0<UR'_"!7G_/Y!^35X&;X&MB9Q=-;
M'MY5C*.'A)5':XWP+SK%Q_UP/?\ VA7::I_R";S_ *X/_P"@FL7P[X;N-&OI
M)Y9XY%>/9A0<YR#_ $K?O(#<V5Q K!3+&R GMD8KT,NHSHX:-.:UU.#'U8U:
M[G#8\=\*1Z%<0>&D\-1RQ:^/)EO)$62,&(?ZW?NP&!Y'&>2#77ZE\0OLDVH3
M6UO926&GR-'.TMZL<TA7[QC3!R!R.2,D<5<?PE<KX:T6WM[F*/6-(6/[/<X.
MPD !E(Z[6&0:JIX-O+._NC:1:'+:W<[3L]Y9^9-"S'+;2,!QG)&<=:]!O4XE
ML7IO$^H7.NSZ7I&F13F.UAN5GGF,:;9-W!PI.?E']<5&GC5I-)@=--<ZM-=O
M8_83(,+,@);+_P!P ;LXZ'IFJ36^KCX@ZRVC2VD;)86BM'<1GRSS+@C;R,8/
M%6AX,N8=,MG@U%?[8@O'O_M#Q_NWE<$.I4'.W!P.<C -(9/%XHO;6ZNK'6-.
MBM[R.S>\A,$YDBF5>HR5!!!(ZCO7/:SXH\3WWA&UU6TTZWL(+F6T:)FO&$K!
MW7(("\ DXZYP3QVKH8_#NIWUS<7^L75J;PV<EI;QVR,(X@^-S$GDDD#TP!3[
MWPQ<7/@>ST2*ZC2[M8K?9*RDH9(BIR1UP2OZT=!.Y!JGBVYTVZM=+,%@-5D@
M\^<37?E01+G PQ7+$G.,+V.:9%XX-[IME]@L5FU2ZN9;5;8S#RT>/.]BXSE!
MQR <[AQ1JGA:_OM0MM8"Z3+J0MQ;W,%U"7@< D@H3\RD$GZ@T^X\+7_V;3+N
MRGL+;5M/>1D$<!2V=7&&0J#D=%^;KE?>@94\.SWL_P 1];;4+1+:X73[52L<
MF]&^:3E3@''/<"KWC[44M=!2P^TI;R:I.MFLC.%V*W+MD^B!OQQ4NB:%JEIX
MEU#6=2O+:9KNVBA$4"%1'L+' SU'S=?T%2:CX9CUGQ-!?:FEM=:?;6S1P6LL
M8<>:S LY!&.B@#\:&,R/"&N6>F^&=4M9[M9HM!D>,RHX?=!C?&<CJ=IQ]15]
M-?UU-,NM5O-%@@LDM)+F)1<EI1A=RAUVX&1UP3BH[KP-9MJ=V;*&UL]-O]/>
MSO+>",)N;.4D4+QD98?E5FVTG7KBQN-+UB\L)[%[9[<2PQ,LTF1M#,"=JG'I
MGF@0^Y\3/!:>')Q:JQU>>*)@7QY0>,OD<<XQBL/PYKNL0:CXMNM;^SC3K"Y<
MLRSLQCVQ(VU 5 VXYZCDU(GA3Q%,N@PWNI6!M]'N4D3R8G5ID5&4%LGAN1P.
M*O?\(I<-?>(8))K=M)UH%Y%VD31R&,(<'H1\H-/N"*^E^.GN]3T^"[M[**#4
M6*VY@O5ED1MI8"10.,@'H3@]:O\ BV[N@-+TFTG>WDU2Z\AYT.&CC"L[[?0D
M+@'MG-5]!\-ZAIUY;F[AT(PVZE1/;6>R>7C )/13W.,YK6\0:&FNV$<(N'M;
MF"59[:YC +0R+T.#U&"01W!-("OIW@W0M)OH[ZRLC'=J"#/YKEGR.=Q)^;\:
MR_\ A-Y8/$-IIUW;Z>$N[C[,BV]\)9HVYP70+@#@]"2*T["W\4/.8M6NM*-I
MM92UI%(LKY! /S,0OKWZ5@V'@K6+:/1[62]L!::7=I,IAA*R7"KGES_>Y[=3
MWH U]*\27VL:U<P6UC:K96UP]O-YESBX4KQN,>WA2>F3R*R1\2(V9+U;>S_L
MEI_)W&]7[1C=M\SRL?=SVSG'.*T'\-ZG>^)[34[M]-A6SF+I-:1,L\R8($;G
M.-O//7IVJKIG@V[TF:.UAAT*?3XY=Z33V1-R$+;MI.<$C. V?PH0&A%XEO;W
MQ1<Z58V=KY5G,L=PT]SLE(*@ETCVG*\]21T-=-7)ZOX;U+6M:@FG;3(;>VN$
MFANH8F%VJJ0=FXG !Q@GICM764 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO.!764 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!YQ=_%A(-4U"RBT.6465U):M(;A5W,AP2
M!CI47_"VW_Z%Z3_P+7_XFO.[K_D9_$G_ &&+G_T.BO4I8.G*"DSRZN+J1FTC
MT7_A;;_]"])_X%K_ /$T?\+;?_H7I/\ P+7_ .)KSJBM/J-(S^O5#T7_ (6V
M_P#T+TG_ (%K_P#$T?\ "VW_ .A>D_\  M?_ (FO.J*/J-(/KU0]%_X6V_\
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MUO\ Z\;3_P!"EKI:YK3_ /DH>M_]>-I_Z%+72T %%%% !1110 4444 %%%%
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M?TI@.HIFQO\ GJ_Y#_"C8W_/5_R'^% #Z*9L;_GJ_P"0_P *-C?\]7_(?X4
M/HIFQO\ GJ_Y#_"C8W_/5_R'^% #Z*9L;_GJ_P"0_P *-C?\]7_(?X4 /HIF
MQO\ GJ_Y#_"C8W_/5_R'^% #Z*9L;_GJ_P"0_P *-C?\]7_(?X4 /HIFQO\
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M?X4 /HIFQO\ GJ_Y#_"C8W_/5_R'^% #Z*9L;_GJ_P"0_P *-C?\]7_(?X4
M/HIFQO\ GJ_Y#_"C8W_/5_R'^% #Z*9L;_GJ_P"0_P *-C?\]7_(?X4 /HIF
MQO\ GJ_Y#_"C8W_/5_R'^% #Z*9L;_GJ_P"0_P *-C?\]7_(?X4 /HIFQO\
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M444 %%%% '-:?_R4/6_^O&T_]"EKI:YK3_\ DH>M_P#7C:?^A2UTM !1110
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MUKUBO)_BK_R,6F?]>DG_ *&M=.$_C(Y\5_"9P]%%%>V>(%%%% @HHHH */\
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MW)O\I]G+[3M^M>>^$4M_#C:1I>K^&$T_4I$,,6H*L4@FDVDL-Z_,"1GKUP:
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MEN&'[R$Q,RQA6ZJ%"#&#_.NZTJ_$N@Z==7<JQR36\;L9&"Y8J":2=P,O3_\
MDH>M_P#7C:?^A2UTM<QI<L4WQ!UMHI4<?8;094Y_BES_ $_.NGI@%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_/)/^^11Y,7_ #R3_OD4^B@!GDQ?\\D_[Y%'DQ?\\D_[Y%/HH 9Y,7_/)/\
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MB_YY)_WR*?161J,\F+_GDG_?(I1&@7:$4+Z8XIU% 'S?=?\ (S^)/^PQ<_\
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M_P!>-I_Z%+72US6G_P#)0];_ .O&T_\ 0I:Z6@ HHHH **** "BBB@ HHHH
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MM/\ T8*RQ'\*1MA_XJ/H^BBBO />"BBB@ KR?XJ_\C%IG_7I)_Z&M>L5Y/\
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M_P#7E/\ ^A1URM=5\./^1YA_Z\I__0HZY\7_  6=&%_C(]FHHHKPSW HHHH
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MYM_*OH;2(U;1-/R6_P"/:,<,1_"*^>KK_CSG_P"N;?RKZ(T;_D!Z?_U[1_\
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M$92V^(>MV\?/RKJ,B@<\_P /K7IGA:6PF\/V[Z9JEQJ=IEMEU<2F1W^8YRQ
M)P<C\*YJ;XA^$Y8)(SINHSAUP8AI4F7]L%:V_ D-]!X.LDU"%X)279(7^]%&
M78HK>X7 HZ ='1152+5+&?4IM.BNXI+R% \L*-ED!.!GTH MT5C7/BS0[34_
M[/GU"-+D.L;#:Q56/16<#:I/H2#6K//%;023SR+'%&I9W<X"@=230!)165I/
MB72-;FDAT^\$LL:[V1D9&V_W@& )7W'%1VWBS0KS4QIT&H1O<EF15VL%=EZJ
MK$;6([@'- &S16->^*]#T_4?L%WJ$<5P"H8%6*H6^Z&8#:I/;)%;- '-:?\
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M(\'$?Q9>K"BBBM3$**** "BBBF U_P#5M]#7O?A7_D4-$_Z\(/\ T6M>"/\
MZMOH:][\*_\ (H:)_P!>$'_HM:\S,/L_,]++_M?(UZ***\T](**** ,7QA_R
M).O?]@ZX_P#1;5X37NWC#_D2=>_[!UQ_Z+:O":]/+_M'FYA]D****]$\T***
M* "BBB@ I;7_ )&+P[_V&;3_ -&"DI;7_D8O#O\ V&;3_P!&"LL1_"D;8?\
MBH^CZ***\ ]X**** "O)_BK_ ,C%IG_7I)_Z&M>L5Y/\5?\ D8M,_P"O23_T
M-:Z<)_&1SXK^$SAZ***]L\0****!!1110 4?X44?X4#.Y^#7_(2\5?\ 7:V_
M]%FO5Z\H^#7_ "$O%7_7:V_]%FO5Z\"O_%EZGO4?X<?0****R-0HHHH ^;[O
M_D9_$G_88N?_ $.BB[_Y&?Q)_P!ABY_]#HKW\/\ PT>#B/XK"BBBM3$****
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M<V_E7T1HW_(#T_\ Z]H__017FYAO'YGIY?M+Y%VBBBO-/1"BBB@#S;XT,/\
MA&M('?\ MF#M_L/7G!ZUZ1\:/^19TC_L,0?^@25YO7JX#X&>5C_C04445WG
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M+_S_ %]S.H^#7_(2\5?]=K;_ -%FO5B0.I%>0>!H&\0WFL16TAL#:/$':/\
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MF!XY.#R=.@)_[^35W_V[QE_T M)_\&3_ /QJN+\3^$O&GB#7?[26QT>$&W2
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MSDYZ<UH?\*X\;_\ /OHG_@9)_P#$4?\ "N/&_P#S[Z)_X&2?_&ZT^K4_^?\
M/[S/V]3_ )\0-?P(UXNG7Z^'-K6_VYC/YG7SMJYQGV"UU>[Q@>T _P"^:P?!
M>@>,_"5A?6S:;I-R;J[:YW"_==N548_U9_NUTWV[QE_T M*_\&3_ /QJO.E@
MKR?[R7WGHQQ>B_=Q^X@_XJ\_Q0#\J3;XP//FP#_OG_"K'VWQE_T ]*_\&3__
M !JC[;XR_P"@'I7_ (,G_P#C53]1_P"GDOO']<_N1^XK^7XP/_+> ?\ ?/\
MA08_%^"/M,'Y#_"K'VWQC_T M*_\&3__ !JC[9XQ(P="TK_P8O\ _&J/J/\
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M>NLS_@3_ (TH\)7A^]K-Q^O^-3_;?&7_ $ M*_\ !D__ ,:H^V^,O^@%I/\
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M_P#0"TK_ ,&3_P#QJG]7I?RK[@]O5_F?WGC'VNX^W:FIFDPFH7"(-Q^51(P
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MS@7DGS;&SM_U?>LZN*I2@TC2EA:L9IL]M'3IBG8'I7-?;?&/_0"TK_P9/_\
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M'URCW#ZG6[&3@T8]JW8OAYXVFA21;?1=KJ&&;N3H?^V=._X5QXX_Y]]$_P#
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M5#KGAVPUW2;C3YHUB6?&9(T7<,,&XR/:M>B@!%4*H50 H& !T%+110 4444
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M[>_PB2Q-C QM4*1@D$8Y!YKH:* ,O1M$CT@7,C7,UW=W3AY[F;&YR!@#
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M:WMY(%0$;2'*DD^_RUHT44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img57592461_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )M VH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@!:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[%8IPN[RW)7Y\=^>:R?%WA?QGIFC0W6K^-CJ=DMY;>9:_8UCW_O5Q\P/8\T
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MY<C^53>%[F2\\)Z1<RG,DMG"['U)09H UJ*** "BBB@ HHHH **** "BBB@
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MB2VN;>59[:YB^]%(,X(]>I&*RM,\&W,<U_J&L:J^H:K=V_V43F-46*/GA5
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M)!N8[L <<''X50L/A[=0SZ?;7^NW%[HVF2+)9V;HH(*_<WL!E@O&,GM7=T4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !24M)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUE/2*4[6_(UO!@PRI!'J* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS[F@#R_Q[IUM;ZO;Q",/N@#.[\L[9/)-<G]EV?ZF9X_;.1^1KMOB+_R'K?\
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M]P?RI)_^/>0_[-+#_J(_]P?RH ?1110!!+_Q]V_U;^53U!+_ ,?=O]6_E4]
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MEE91V2%4+/(YW22-RSGU- %'0K-;>.ZE=O,N7G;S)B.6YZ>PK6JEIG^KN/\
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M7YM(TMA,2L:L6)8C^('TK<K)7_D;I/\ KP7_ -&-0!!_96M_]##+_P" \?\
M\31_96M_]##+_P" \?\ \36[7D?Q.\<^(_#_ (IM]-T:ZM[>$V@F<R0"0EBS
M#O\ 2IE)17,]C6A0J5ZBI4U>3.__ +*UO_H89?\ P'C_ /B:/[*UO_H89?\
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M>:HQ'T444 06WWI_^NS?TJ>H+;[T_P#UV;^E3T %0W?_ !Z2?0?S%35#=_\
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MZ$V\$R*^P D9RO!K$E&Z)Q[5LZ?)YEDA[CBN[!3U<3YCB;#_ +N-7JG;[_\
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M?#H,6:-S@,,^AX-)%_RT/JU.9$?AE!'O4$,)$>8W9,D\=1^5-6L0W-25U?\
MK^NI9J%W9+I IPS#^1I=L[<%U4>JCFFF)8W1AUS@D]33CHQ5;SC:VANBYD4
MRV[8(^]'\WZ=:;)<0RRP!) 6\S[IX/3TJ6T??;(>XX-1W<,<KP!T5AO[CVKW
M(2YHIGY;7I.E5E3?1M%JHKE]EN[>U,^S-'_J9W3_ &3\P_*JUZ\XB"2A,$_>
M4]?PJ:TN6FV=&74?;8NG3[M?YF;+UC'JU25&_P#K8A[D_I4E>&]C]/CNPHHH
MI%$6 UPP(! 4=:/(0<H2A_V3_2E3F>0_05)5-M&<8QDKM=R+$Z=UD'OP://
M_P!8K)]1Q^=2T'H:5^X^5K9_J16[!XRRD$%CT^M2U7C@C>)6*X)YR.#3_)8?
M=F<?4Y%-VN1!S45H2,H92#6K97BSQA)'43KP5)Y/O6-B<='1OJ,4([QSK)+
MC)T?!S\M=.%J^SE9O1GC9Y@?K5#GBGSQV\UU6AO6XPT__75JFJA;6_$K6\[H
MID.!U7'TJ??=1_?B64>J'!_(UZQ\ 6*AN_\ CTD^@_F*1;N$G#$QMZ.,?KTI
M;DAK.0@@C Y'/<4 2K]Q?H*6D7[B_04M !4#?\?T7^XU3U W_']%_N-0!/11
M10!$]O#*<O&I/J.#^=>W?#%0G@BU4$D!WZG)ZUXM7M7PT_Y$NV_ZZ/\ SH Z
M^L3Q:UBOANY.HK(UOQD1G#9SQC\:VZYCX@?\B?=?[\?_ *&*$<V,ERX>;\G^
M1YYI<?B1@#HXU$6W\')VX_E710Q?$+:-KX_WRG]:[#PI_P BIIG_ %[K6Q3N
M>=ALL7LXR]I)771V.<\-+XG6:?\ MYXFBVCR]NW.?^ UT=%%(]:E3]G#ENWZ
MZLI:Q)=1:->262EKI8F,0 SEL<5YQX /A!]&']I&Q?56D;S_ +?M+LV<\;NO
MX?C7I&JZC'I&EW&H2Q221VZ%W6/&[ ],D5SY\/>&/&>EP:F;!1]I42>8@"2
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M\-JT<UU?3 F*UMTW.W^%<[XG 'Q2\-L!AC&03Z_,:RW&MW'Q5U7^S);*.[2
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M@2#^HH OT57^TNG^NMW7_:7YA^E21SQ3?ZN16/H#S0!)7M7PT_Y$NV_ZZ/\
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M8+'J-.LXM\]5Z]DKWWW;Z;+2Y:HHHK<\H**** "BBB@ HHHH **** "BBB@
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M*6QQGVS5&9-D<\]*:LT3MM61&;T# FO//#;ZI9:9XR^WWCWM_%*YWHN!NV'
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M<DGUYJ*U\0O?JUO) %<C[ZGC\JEKFS:A5P]94:JLTK_>=?"M)>PG5[NWW?\
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M2_#0GJ&[_P"/23Z#^8J8$$9!!'M4-U_QZR?0?S%=9X!*OW%^@I:1?N+]!2T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9I)6C8,%#M'MSCUP?RKM: "LKQ)_R +G_@'_ *&*U:RO$G_( N?^ ?\ H8H
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M,']Z[#&]B2<?2@#M:*** .(^)ER$TG3[.1;QH+F\03"S4F0HI!(&.F>G-6O
M']B?V3<#16O0%EQ/#>L?-B?T([5?\3:AJ^EQ6EYIFGF_A27_ $JWC7,IC/=/
M<=<=ZH>#[>^GU+6==O;![ :B\8BMI!APB C<P[$YZ4 =%?ZE::9$KWDWEJQP
M#M+<_@#7$Z9=OJ=K+#8,RVYN)C)=8(X+GA,\Y]^U=^Z*ZX90WU&:Y/20!9R
M  "YFX'_ %T- %FWMX;2!88$"(O0#^=5X/\ D,7O_7./^M7:I0?\AB]_ZYQ_
MUH NUGW]S!974-S=3)#!%#(SR.< #*U/J&HVFE6$M]?3K!;Q#+.Q_0>IKYU\
M>^/[KQ==B&$-;Z;$2(X@>7]V]?I7H9?EU7&U.6&RW?;_ ()$YJ*U-'X@_$FX
M\23-IFEL\.EJV"1PTY]3[>@KU7X?Z%_8'A"TMW7;<3+YTWKD\X_#I7S[X4CL
M'\36/]JW"0V2R!I7<<8':OJ&SU"RU&(2V5W#<1GH8W!KPO$BM]4P]'+:$6H?
M%)VW>RUV[O[C?!+FDYLL55C^;4YCD_)&JX]\Y_K5K'-5;/YY;N7.0TN![  #
M^>:_)([-GHEJBBBH IZGS;1K_?FC4_0FKE4[_)DLT!ZSJ<>N*N5;^% (RJZ[
M7567T89K!U+P5H&J$M+8K'*?^6D/RM6_13IU:E)WIR:]"HRE%WB[,\JO_A?+
M_:,J:9?A@D8(2X'//;(_PKFM1\*ZYI63<Z?(4'_+2+YU_P ?TKVVWR=5OCZ+
M&!^1J[GC%>Q3SO$TVE.TEI^7D>C0S?%4M&^9>9\VDX;:>&'8\&K-CI][JDXA
ML+62X?\ V!P/J>E>[7_A[2-3.;O3X)&Z[@NT_F*N6=E:Z? (;.WC@C'\,:XK
MKGQ!'D]R'O>>QWSX@DX6C"TO70\ZT7X7.VR;6KG:.IMX/Y%O_K5)XR%MH?AB
M;1K1%BB>Y4HB_P!TC<?UKTBO)_BE<QMKEK;J?GCBRX]ST_2N; XJMC<7%57=
M+6W16.7!5:N+QL'5E>VIPM1SG$#D>E25'/\ ZDCU.*^M6Y]?4^!D@& !1112
M*"HY.98A[G^525&W-PGL"::)GM]WYDE%%%(H:T:./F4&H$B99I/+D9<   \B
MK-1Q_P"LE/\ M8_2J3=C*<(N2T_JPF^9?O1AAZH?Z4"XC[DJ?<5+1UZTKHKE
MDMG]XT2(W1U/XU#AOM$LB<[< CU&*E,,;=47\J[OP7X+TGQ!X<GFE$T-V)V4
M2HW;MP>,5AB,53PU/VD]MCBQN*6&C&55:7Z>C.&5@ZAE/%0WC21VKRQ,5DC^
M=2/45T?B'P9J_AUVG,7VBT!YFB'!'J1V-8!VS0D#E6&*VPV(IR<:M-W5RU4I
MXRA*$'>Z:^\J6WBNX3 N(4E'JO!K3'B&PN;=U+M$Y X<>]<6WR9#=1Q2 $\G
M\!7ZY6R'!5TI4;Q;UTV_$_)?:3B[2/3(I$EC4QNKC ^Z<T^O-8KB:!LQ2NA_
MV3BM:V\3WT.!+LF7_:&#^E>/B.&L33UI-27W/^OF6JT7N=I4#?\ ']%_N-65
M;>*+.7 F1X6_,5H175O=74;03)(-A^Z:\.OA:U!VJP:]4:J2>Q<HHHK 85[3
M\,O^1*MO^NC_ ,Z\6KVGX9?\B5;?]='_ )T =A7,?$#_ )$^Z_WX_P#T,5T]
M<Q\0/^1/NO\ ?C_]#%".7'?[M4]'^1?\*?\ (J:9_P!>ZUL5C>%2%\)Z820!
M]G7K6R#D9%!IA_X,/1?D%%%%!L%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+24 +1110 4444 %%
M%% !62O_ "-TG_7@O_HQJUJR5_Y&Z3_KP7_T8U &M7S=^T" WCFQ##(%@O!_
MWWKZ1KA?&GPMTKQMJT.HWMW=P2Q0B$"%@ 0"3W'O77@:\,/B(U:BNET^1,DV
MK(\J^!#-#J/B1X1AUTX,N/7<:[LPQ6OPX\(7$("RQW<#JX'.6W!C^()K>\$_
M#/2_ ]Y=W-E=7,[W40B<3$$  Y["ET[P#)9:C:";69KC1[&4S6>GM&!Y;$$#
M+9^8 ,<# ZTL;6A7Q$JM-63Z!%65F)KM];>.=&N]*\.ZC:O=0SH)O.5@H )R
M.G/(JSX=U+6[?Q%=Z!KTMO<SK +J"Z@38&0G:5(]0:T]?\-V^M:5):1R-93;
MUECN(  R2+T;WZU6\.^&;C2KZZU/4]3;4M3N%$;3F/RU6,=%5<G'//7K7*4=
M'1110 5E>)/^0!<_\ _]#%:M97B3_D 7/_ /_0Q0!II]Q?H*=34^XOT%.H R
M/$NN+X=T.;43 ]PZD+'"G61R< 5E:-K/B^[U.*+5/#$5E:,#OF%VCE?3@&K_
M (QTPZOX7N[5=0CT\D!_M4B;A%M.<XR/2N6\&:K?:MK 5/'5GJT,"GS;9+ P
MNX[$$MR/<"@#T:BBB@ HHHH #T-<CI7_ !Z2_P#7S-_Z,-=<>AKD=*_X])?^
MOF;_ -&&@"]6%J6M6'A^74=0U&<10QQ)@?Q.>>%'<U-XC\2Z=X6TMK[4),9X
MBB'WI&] /ZU\V>*_%-]XLU=[ZZ;8GW8X5/RHO;ZGWKU<LRNKC9WV@MW^B\R)
MS42[XU\<7_B^_)D)AL(S^YMP> /4^IKE:3)';- (-?H&'HTL/35*FK)'(VV[
ML6I[6]NK&42VMQ+!(.C1N5/Z5!16M2G"I%PJ)-/H]1)M;'=:1\6/$VF;5FG2
M]B7^&X&3_P!]=:]<\">+K/Q5I+.FV*]1V,T!/(R<@CU%?-)Z&I+>XFM7$D$K
MQ./XD8@U\+G_  #EV8TW]5BJ-3>Z6C\FMON.NCBYP?O:H^O>G6BOG+2/BEXG
MTK:C7@NXA_!<#=Q]:[O2?C7ITX5-5T^6V;N\)#K^1Q7Y5F/A_GF"O*-/VD>\
M'?\ #1_@=\,92EUL>C7(W:C8CT+L1_P&KE<[IGB;1->U2!]/U&&4I$3M)VMD
M\8P:Z(@CK7R&(HU*,E3JQ<9+HU9[ON=,6GJ@HHHK 93LOFN;YO\ IMC\JN52
MTWF.Y;^]</S[9J[5U/B!!1114 %5;S3;'48S'>VD,Z^DB U:HJHR<7=.PSBM
M1^&6BW66LY)K)SV0[E_(UQFM?#G6K!4:W:&\C:15&P[6_(U[15*^R;JQ7/'F
MY/X5Z>&S;%4Y).5UYZ_\$[*68XFDK1GIV>IX#=V5WI[E+VUFMV'_ #T0@?GT
MJ '(R.17T?+#%<(4FB213V=0:YK4OA]X?U LRVS6LI_C@;'YBO5HY_3>E6-O
M34]BCG_2M#[O\G_F>*U'_P O/T3^M>@:C\+=0ARVG7L5RO9)1L;\^<UQU[HF
MJ:9>2I>6$T>P#)"[AS[BO7H8W#U_X<T_S^X]2GF6&K649Z^>A4HI 0> >:6N
MD] *CAZ.3W8U)4<'^J!]2?YT^A+^)?,DHHHI% >E>P^ 8C::#I^0 +J-V^K!
MB1^E>.M]T_2O;]'@^R^$M#DQS!'$Q^C  _H:\7/)?N8P[O\ 1GSO$,O<A'S9
MT9 92K %3P0>AK@/%'PZMKDM?:.%MIB<RP@?(WN!V->@45\OAL55PT^>F[?J
M?.TJU2C+GINS/EK4/#&IP:O<0"W\PJV0R,"N#R.:?%X0U.0?.(X_]YL_RKUS
MQMI(L]8CO;<F);M</CIO ]/H*YOS)H_]9'N7^\G^%?K&#XUS"6$IQH\JLDMM
M=-.KL?&9GBJU/%3CIO?[SEHO!+'_ %UX!_N+G^=7HO!VG(!YCRR'ZX_E6^DB
M2?=8'V[TDLBPIN;/H .I/I7-6XDS:MI*LUZ:?E8\J6*KR=KF9_8>DVB@BS1V
M/"AOF)-5=8T5&TF26"-8[J/YQY8Q@?W1BMJ*)M_G2_ZPC@=E'H*FK@CF&(C6
MC5<W)Q=]6W^9*KSC).]['FUMK^H6V!YWF*.TG-;%MXLA; N8&0_WDY%8VO:?
M_9VJRQ 8C8[T^AK,K]AIY=E^98>&(A&W,KZ:?\ ^CIUVXJ2>C/0[;4[*ZQY-
MRA)_A8X/ZU[9\/+^SL?!5I]KNH(-[N5\V0+NY[9ZU\P:5I4^I3X3*1*?GD]/
MI[U]">!/!&CZGX-LGG$X=&==R2?>Y[YS7R>9X.CA*OLZ<^;OY?,VE.JZ;=-:
M^9WTGB718QEM3MC_ +L@/\JY/QGXKTC4=!FL+.Y,T[LA&$( PP/4BKDGPST@
MC]W/<J?=@?Z5SGB7P*NAZ9)?Q7QEC1E!1H\'DXZYKSE8\G&U<?[&2<%RV=]>
MAOP1Z1J_@:PTVZU:WMI%B4\3J"K#L1G]*QK?Q)J7A*:.RDNK74K''R&*4,5&
M?4<_@:L6GA3PW'X9M-6U.>XA\V,,Q$G!8CH!BN?31X-<O?L_AZQN1&OWIKB4
M$8]\#C]:9QUIUXJ$HI*=E:S;;7FK'JVD>(--UN+=9W"L_>)CAQ^%:E<CX<\"
M6NCRI=W4IN+M>1CA5_QKKJD^@PLJ\J:==)2\@KE/B)XDG\,>$I[RS=5OY'6*
MU!7=ER1V/'3)KJZ\D\6WD.O?&#1=%GN4ALM+Q=3%W&TN!N7KWZ#\:]'*Z$:N
M(O-7C%.3]%T^>WS-INR.A^&GBV]\16%[9ZS(AUBQEVS!4"@HP^4X''8Y_"NZ
MKR+4K^T\+_&.PU&RN+=['7(S#<B.0,!("/FX/7E1^=:_Q&U"_O=>T/PGIMZ]
MFVH/YEQ-']X1@XX_(UUXG *MB8RI+EA-<WDK?%]S3_ F,K+7H=%X]U>\T'P3
MJ6IZ?(L=U BF-F4,!E@.A]C6IH5U-?:%8W5PP::6%7<@8R2/2O)_B!\.X?#G
M@N^OM$U2_C145;N&XF,BSIN'Y$'!K4\5:U?67@7PUI.EW!M[W53'")1U5 !N
MQ^8JE@*57#TXT)7<IO5JS223UWVWW#F:;N>A>(;R;3_#FI7ELP6>"VDDC8C(
M#!21Q7+V.K^)]:^%$6I:4T<OB":%&C)5%4G<-W#87[N>M8'B+X8QZ-X6OK_2
M-:U&/4([9S/)+,66==OSJ5[9Y^E5;MWC_9LW(S*PMX<%3@_ZU*NAA,.Z=/V4
ME)NI%7<?P:OJGZZ^0.3N[]CLO&WB?4/"G@VVOUBC>_DDB@?=]U68?,>.O0U<
MUF7Q*[^'WT54:%[E#J1;8,0G&XC=^/3FN ^+&D6UQX$T35)#*;E&MX!ASM*L
MI)R/7CK5C7M%MO#;>!;/3Y;D0RZS%(PDF+')VY&?3VJJ.$HNC2E&W.W/>-UH
MO7IT\WY"<G=_(]<HKS3Q,[^&/BKH>LB65;/5%:RN5&=N[^#VR3C\J7XC7$NN
M^(M#\'63R"2:07=VR-C9$IP#D?\  OTKSZ>7.<J=I>[*+DW;:U[_ '6^>A;G
M:YZ517C'B;Q#9ZSX^NM U3Q ^CZ#I\01DB8HUP^!D9YQC/Y"L^75]"\':[I-
MWX2\3/>6<UPL%[823M)D-QOY' '^%=,,DJ2BM7S-72Y7;:Z3ELF_^'8O:(]W
MHI%8,H93D$9!I:\,T"BBB@ HHHH **** "BBB@ HHHH **** "DI:2@!:***
M "BBB@ HHHH *R5_Y&Z3_KP7_P!&-6M62O\ R-TG_7@O_HQJ -:BBO+_ (@>
M,/$>D^*HM+T6>U@B^R+.[31;R2688_\ ':B<XTXN4MD14J1IQ<Y.R1ZA2$@#
M).!7FWPZ\6^(-:\07^FZU/;3+%;+/&T,>S!+8P:UOB86?P_:VGV:\N(KF\1)
MH[1"7* %B..F2H&3ZTX3C.*E'9A"<:D5*.S.S#!NA!^E!('4@?6N0^'_ /8:
M6%Y#I%I=6,L<V+JTNR?,C; QG/8C'(XJKKNFQ^*_'/\ 8M]-<+IUI8_:#%#*
M4WRLV 3CT!X]ZHL[JBN8\!7US>>&$2\E:6>UE>V:5SDOM/!-=/0 5E>)/^0!
M<_\  /\ T,5JUE>)/^0!<_\  /\ T,4 ::?<7Z"G4U/N+]!3J .:\?65S?\
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M*CC*536]O4F>'JPU:*5%%%=:,1%[_6EI%Z?C2U,/A0!2'[I^E+2-]TT3TBP
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M!!'8U9T#0;7P]IWV2U:20LYDEFE;<\KGJS'U-:E%  >E<IIW_'O+_P!?$O\
MZ&:ZL]*Y33O^/>7_ *^)?_0S0!;JI#_R%+O_ '$_K5NN*\1^+(]*U*ZM+1U-
MS(B@RGE8^N>?6M*5*562A!:E1BY.R-3Q'XFCTA3;6VV2^8=.HC'JW^%>=R22
M33/--(TDLAR[L<DTT-YA,A<R,QRSDY+'U)HKZW X&&&C?>3Z_P"1Z5*BJ:\R
M%[6%SDH%;^\ORG]*;Y,\?^JGW#^[(,_KUJQ17;RHUL5_M$L?^NMVQ_>3YA^5
M1"[2]<PVTH"CAWZ$>P]Z>7:[8K&2L ^\_=_8>U2M;0,@0Q+M' &.E1[SV>@M
M1\<:Q($08 IU5_LSQ_ZF=U']UOF%'FW,?^LA$@]8SS^1J^:VZ'<L4$@ DG '
M<U +V#!W/Y>.OF#;_.F ->$,P*V^>%/\?N?:CG70+@2;W*C*VW<]Y/\ ZU)-
MIT$@38/**.&S'QT/M5L# P.E%+D3^+4+=RG/:/*I5Q%<)_=F0$_G6+=^&]-F
MR6MYK1_[T9W+734R21(D+N< ?K1R\NL78B=.$U[R."NO"D\<;2VMS#<1KSC=
M@UBSV=S:L5G@DC( )W+ZUZ9]C2\<37,0 '*)W'N?>C[#(D\KI-N5PHV2C=TS
M_C6T,7B(^:.*> A+6.AY;17H5WH5C<9,^G^6W>2W/]*Q+CPD&)^Q7J,?[DPV
M&NN&80>DU8Y)X&I';4YBD7[M7[W1]0L#B>V< ]"OS _E5!>@KIA5A.?NN^G^
M1R2A*.DE86BBBMB1&^Z:6D;H/K2U*^)_( HHHJ@$/WA2TG\?X4M3'=@7]/UK
M4])D#V%_<6Y':.0@?ETKM]*^,GB"S4)>QV]\H'5UVM^8Q7G-%>1F'#V5YC_O
M5",GWM9_>K,TA6J0^%GH&M>-I?%FIQW"0M:".$1[5?.XY)/\ZSFR_P!]W;_>
M8FLK3H'CT[[3CY?-)4_0#(K5SD9'2ORG,L#2P.*GAZ$>6$79+R]3](R+#8>>
M%C5<(N;U;LK_ 'B!,L%11O8X7CO766EN+6UCA'\(Y/J>]8>DV7VF=IF+*L7"
ME3CYJN7-U=1OY%O*)F/&2,'Z _UKZKA["_5Z#Q$UK/;T_P""<6<XKGJ^RCM'
M\RU=WHB_=Q<R$XR.<'T^M):610B:?#2]0.NW_$U3CM$1EEN_M$4PSS$YVC\O
MYUK1R1R#]W(K?0\U]#"\Y7E\D>,M7J/IDD,4H_>1JWU%/HZ#)Z5LTFK,LIMI
MZCF&5XSZ9R/UJEY=PUUN6-98XP070XR?;UJ^6:[)5"5@!PS=W]A[595510J@
M!1P *\^KEV'K:\MO-:&$J%.70RO.0'#YC;T<8J3MFM%E5QAE!'H:K-I\)YCW
M1'_8./TKSJV226M*5_4PEA']EE>O:?AE_P B5;?]='_G7B\EO/"I;>DB#^]\
MIKT_P=X@'AOPQ86VKZ;>6B3,S+,X4K@\C@'=^E>37PM6@[5%8Y*R]BKU-$>D
MUS'Q _Y$^Z_WX_\ T,5P5QXGO[F:ZUL:U<P7D<^+/3$SY)A!Q\_8EN3GMQ6S
MXD\8VWB+2WTO3K.YDED93NVCL0>@YK!(\K&8W#RH3A&:;::5M3L_"G_(J:9_
MU[K6Q69X=MI;/P[86\Z%)8X55E/8UITCOPZ:I13[+\@HHHH-0HHHH **** "
MBBB@ HHHH H:SHUEKVERZ??Q>9;R=1G!!]0?6N3/PPMI(1:SZ_K4]@#_ ,>D
MEP"A7LO3.!]:[NB@"&TM+>QM8[6UB2*"-0J(@P *FHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ I*6DH 6BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!"JDY*@_45#%<6DDS112PM*GWE1@2OU%8
M?B#4-8TV5Y8K0W.EO"5=K<$SP-S\^W^(>PYXKB/ V@7TFKZ=J-O:6<-M;>9Y
M^HV]SO>^+=G7.0<\D'I0!ZU37=8T+NP51R23@"E9E12S,% [DXKB_B38W6I^
M$[AH-2>WLHHR\Z0XS-@C"[NPZYQ[4 =?/=VUM;_:)YXXH<9\QV 7\Z?%+'/$
MLL3J\;#*LIR"/K7 ZA:P:UKOA/2+Z))K 69N)+=QE)&"87<.X!&<5H^!$%E)
MKFD0C;:65^RVZ9^XC<[1[#% '8'I7*:=_P >\O\ U\3?^AFM_4=2M],B5[@2
ME7.!Y<9<_I7DFL>+F*S:99F2VW32&1Y5,;L"Q("@\@8/6MJ%&5::A#=E0@YN
MR-;Q+XL\LOI^F29DZ2W Z+[+[^]<054@AANR<G=SF@ *  ,"EKZ_"8.GAH6C
MOU9Z=.DJ:LBN;.+=N3=&WJAHVW4?1TE'HPP?SJQ2,ZHA9R HZDUT\J7D:6*Y
MO%C!,\;P@=6/*_G3$D&H<HP^S>QY?_ZU."M=D-("L Y5.[>Y]O:I'M(7.=FU
MO[R?*?TJ+2?H+5DP 4  8 [457\JXC_U<^X?W9!G]>M'VB2/_70,!_>3YA5\
MUMQW+%-=UC0NYPH[U$;RW"%O-!QQM_BSZ8]:1(GE<2W Q@Y2/LON?>CFOI$+
M]AGD_;&$EP@\H<I&PY^I_P *?]C53F%WB/\ LGC]:L44<BZA8KYNX^H28>WR
MG^M O(P<2J\1_P!L<58J*>98E (W,W"I_>I--=0%DGCCCW[@P/0+R2:CCA9Y
M!-/C</N)V3_Z]0QZ<A?SI!MF/_/,X"_2IMEU']R191Z.,'\Q4^\]9(6O4L45
M7^U%.)H73W W#]*ECECE&8W5OH:T4DQW'U7NC$ %:(22-PJ=S^/84Z:?8PCC
M&^9NB^GN?:EA@\O+L=\K?>8_R'H*EN^B J)IS(CN)F$S*1CJH]@#51]'BFMH
MTN["&4A<%HSM8?XUMT4O913NB7"+T9QESX4M')^S7;P/_<G7/ZBLFZ\-:G:@
MMY'G)_>B.X5Z0RJXPRAAZ$9JC+$OF&*T+1R_Q,I^5/PZ9K:.(K4]G<Y:F"I2
MZ6]#RZ161PK JP/((Q17H]SI.^: 2017: N79UPQ)'<UF7?AC3I"2GGV;_[7
MS)^=;TL?9OVD;?U_74XYY?-?"SBZ*W;CPGJ$:E[<QW2>L;<_E6//;S6S[9XG
MB;T=<5W0Q%*>S..=&I#XD0_QGZ4M(/O-2UI#;YO\S,****H#O="L1<^$TC(Y
M<LRGT-9D&_9Y6T^8C>7M/KT%;VB6?E:):%)GC.S)YR.I[&L^6TGEU=IH-LH8
M9*K\N3C&X^W\Z^!SG+5C)0J+>^OFO^ ?9Y;CY8.G:VZT];&BC&&WCLK4%C_$
MW]X]_P />KUI:+;+D_-*1RWI[#VJG:PP6LWF/-.DC?>$G"GV],5J AAD$$>H
MKV:$$DO+9=D<:;D^:6XM0R6L,G)0 ^J\&IJ1W5$+N0%'))K=I/<97,4T0)CN
M/E':49 _&JWGS7./.@=;;OLYW_X"K"JUV0\@*P=50]6]S_A5JL^7FVV%:Y%%
M/ X C=>.W2I:CDABE_UD:M[D5']E:/\ U,[I[,=P_6KO)#U+%(S!%R?H .I/
MH*KF6YC95: 3%F"J(OO,3T '>NRT.RAT#2KSQ#K>GW0O+6(O!#-$1'&<X R>
M"Q)'TKCQF/AAHZ_%T1E5K*FO,UO!W@4L\6JZW$,C#V]H?X?1G]3[5V/B+0X-
M:TF> Q(UP(G%N[9^1RI /YXKDM.;7M$UG09]3U::ZGUIF6ZLW V0G;N CXXV
MYP?7%>B$XZU\E6KSK3<YO4\RK^]OSZGE&F:'/K5]I6GOX>GTV&P(?4;F8?\
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M>6\$SE4E4IM(W '&.HXJ_P"$M&N]*LKJ?4FB.HWUPUS<>4244GHH)Z@5T%%
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MB87E8QV<\D48X9\Y!]AFARE'S"[18DE>9S# >G#R?W?8>]311)#&$0<>O<U
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M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HK!\2Z]<Z2;.TT^S%YJ5Z[+!$S;5PN"S,?09'YTOAGQ&NOV]P
MDUNUIJ-G)Y-W:N<F-_4'N".0?0T 8]CXDM_&4_BCPV4$;VV^"-P>)4((W#Z'
M'YURUL?&&F>#/[29+:SL--0P-I+0#_2(5.UG+=F/45TGB32H_#,NDZ_I%KL2
MPE,-S%$.7@E(#?4AMA_"KVJ^$)];U*2:37KT:3<A3/IPQL?'8'JH/<"@#DK'
MP[KT/AX^#[;3XY-'FF$UMJ32X,4)</AEQRXZ YKU>-/+B1,YVJ!GUI54(H50
M H& !VK.\0:S#X>T&\U:X4M%:Q[V4=2,X_K0!9OM0M-,M'N[ZXCM[=.6DD.
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M'XBMRBFFT[H+V/-]0^%A7<VE:HZ^D5TN\?\ ?7_UJY"[\'>(-)=YKS3FN/\
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MD?E6-X;T&9/&%K;:JRR36,#ZG=\_*;F8@ _\!56'XT >AZ-K=CKUC]KL9&9
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MDD48W$#K5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ I*6DH 6BBB@ HHHH **** "BBB@
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M(Z>AH ](BE2>%)8SN1U#*?4'D4^H+&U%E86UHK%E@B6,$]]H _I4] !1110
M4444 %%%% !1110 445@>*M>FT>S@@L(EGU6]D\FTA;H6[LW^R._X4 ;<YD$
M#B IYQ4^6'Z9[9KRK4=66[\-ZE"-)-KXGL;R*]N+%#EKAA(,NA_B4C/TS5N&
M+Q)KLE[IE_J$5OXAT.59;6]MLK#,'4-M=">1S@U?T.RU7Q#XMMM;U[0AIDVF
M0-#&ZRY\Z1B,L,=4P#P<]: -_P ):9=6EA+?ZBY;4M1?[1.,\1Y'RH/0 8_'
M-=!110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %)2TE "T444 %%%% !1110 4444
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MZBO8I[&&2.]V?:%9<B3;]W/KBBZTN*)9;NQM8OMXMOL\3'CY1G"Y]!DUIT4
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M/7WK0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6DH 6BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "DI:2@!:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *2EI* %HHS1F@ HHS1F@ HHS1F@ HHS1F
M@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HH
MS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@
M HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS
M1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@
MHHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1
MF@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ I*7-)0!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img57592461_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )4!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYY0?]\M_C1_PDEY_SR@_[Y;_ !K&HH_M?'?\_6'U6C_*;/\ PDEY_P \H/\
MOEO\:/\ A)+S_GE!_P!\M_C6-11_:^._Y^L/JM'^4V?^$DO/^>4'_?+?XT?\
M))>?\\H/^^6_QK&HH_M?'?\ /UA]5H_RFS_PDEY_SR@_[Y;_ !H_X22\_P">
M4'_?+?XUC44?VOCO^?K#ZK1_E-G_ (22\_YY0?\ ?+?XT?\ "27G_/*#_OEO
M\:QJ*/[7QW_/UA]5H_RFS_PDEY_SR@_[Y;_&C_A)+S_GE!_WRW^-8U%']KX[
M_GZP^JT?Y39_X22\_P">4'_?+?XT?\))>?\ /*#_ +Y;_&L:BC^U\=_S]8?5
M:/\ *;/_  DEY_SR@_[Y;_&C_A)+S_GE!_WRW^-8U%']KX[_ )^L/JM'^4VE
M\2W0/S0Q'Z9']:NVWB."0A9XVB)[CD5S%%;4<]QU-WY[^3_JY$L%1DMK'H"2
M)(@9&#*>A!R#3JXS3-3>QF ))@8_,OI[BNQ1Q(@92"",@BOM,LS.GCZ?,M)+
M=?UT/(Q.'E1E9["@@D@$$@X/M2U##_K;C_KH/_05J:O3.<**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!DO^K-5ZL2_ZLU7KFK?$:0V"BBBL2@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB[WT?-;3\=/0*=6;DKO=M?=<ZVBBBO&.P**** "BBB@ HHHH **** "BBB@
MHHHH *ZC0;DR681CDHQ7\.H_K^5<O6WH)*I*>QD0?HU>YP[4E#'1BNJ:?W7_
M $.+'Q3HM]CH8?\ 6W'_ %T'_H*U-4$'^LN/^N@_]!6IZ_0SP@HHHH ****
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M<&4^@]O4_P!:Z33('"F64DR-R2:^OX;RZ<9/%5%96LO\SRLPKIKV4?F7(/\
M67'_ %T'_H*U/4,/^MN/^N@_]!6IJ^P/*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9+_JS5>K$O\
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M[;TSWQ7&2>%==A^'UAH>FZG'::C;LI>>.5T4C)) (&>X[<XKLXE98D5VWN%
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M ,777?V3;_W!1_9-O_<%']@Y?_S[_&7^8?7:_P#-^".1W6?_ #TN_P#OPO\
M\71NL_\ GI=_]^%_^+KKO[)M_P"X*/[)M_[@H_L'+_\ GW^,O\P^NU_YOP1R
M.ZS_ .>EW_WX7_XNC=9_\]+O_OPO_P 777?V3;_W!1_9-O\ W!1_8.7_ //O
M\9?YA]=K_P WX(Y'=9_\]+O_ +\+_P#%T;K/_GI=_P#?A?\ XNNN_LFW_N"C
M^R;?^X*/[!R__GW^,O\ ,/KM?^;\$<CNL_\ GI=_]^%_^+HW6?\ STN_^_"_
M_%UUW]DV_P#<%']DV_\ <%']@Y?_ ,^_QE_F'UVO_-^".1W6?_/2[_[\+_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRD,/^NN/]\?^@BIJAA_UUQ_OC_T$5-7H& 4444 %%%% !1110 4444 %%%%
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M986ZJPJCIWAO2-*G\ZRLDCEZ!RS,1]"Q./PKIO[#U'_GW_\ 'U_QH_L/4?\
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MG<****T$%%%% !1110 4444 %%%% $+?\?L7_7-_YK4U0M_Q^Q?]<W_FM34
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI_S3_P"*H^T2_P#/E/\ FG_Q5 %BBJ_VB7_GRG_-/_BJ/M$O_/E/^:?_ !5
M%BBJ_P!HE_Y\I_S3_P"*H^T2_P#/E/\ FG_Q5 %BBJ_VB7_GRG_-/_BJ/M$O
M_/E/^:?_ !5 %BBH%GD+ &TF4$]24P/_ !ZIZ "BBB@ HHHH **** "BBB@
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M;: 8HIEB=?WL>5SMP!\P&<#+8]JZ7QCX!FUBUTAM$NX[.[TD!+?S<[=HVXY
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M_GVSD,R;V7D'(Y4@U>KDM8U_7)/%0\/^'X=/\^.U^U337Y?9@G:% 3G/3DT
M=1:VT5G:0VMNFR&%!'&N2<*!@#)YJ6FQ>9Y2>:%$FT;]O3/?'M3J "BBLS3=
M<M=4U+4[&".99=.D6.4N %8L,C;@G(^N* -.BBB@ HJCK5[)IVA:A?0JC2V]
MM)*@<94E5)&<=N*C\/:A+JWAW3M0G5%FN;=)76,$*"1DXR3Q0!I4444 %%%1
MSRK!!),P)6-2Q ZX S0!)16?HVL0:[HMOJEI'*L-PI9$E #<$CG!([>M)H=S
MJEUIBRZQ8QV5X68&%)1( N>#D>U &C1110 445F:;KEKJFI:G8P1S++ITBQR
MEP K%AD;<$Y'UQ0!IT444 %%%9NE7.JW$M\-2L([5([@K;,DH?S8NS''0_YQ
M0!I4444 %%(> 36!X+URZ\1^&(-2O(X4FD>12L((7Y6('4D]O6@#H**** "B
MN?UK7;K3O%'A_3(8X6AU%YEF9P2R[%!&W!P.O<&KUK<ZK)K=]!<V$<6G1JAM
MKD2@M*2/F!7J,?A^- &E1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !65KT-S-9J+<,P#?.J]2/IWK5HK#$T%B*4J3=
MK]BZ<^22DNAGZ+%<1:<JW 8-D[5;J!6A1154*2HTHTT[V5A3ESR<NX4445J2
M>5^"_P#A,O['N?[$_L'[%]MGQ]M\[S-V[G[O&*T_"G]K?\+)UO\ MO[%]M^P
MP[OL6_R\9XQNYS70^#]#N?#^CRV=W)"\CW4LP,1)&UFR.H'-%GH=S;^.-2UM
MY(3;75K%"B@G>&7KD8QC\: ,/X7A9+#7+IN;J;59C,3UXQ@?J?S-=K>6D5_8
MSV<Z[H9XVC<>H(P:Y.Z\+:UI6N7>J^%+ZSB^W-ON;&^1C"7_ +ZE>0?;W_"M
M;0[#7H[N6^U[4X9970(EI9H5@BYR2-WS,3ZGIS0!R?A_7W\/_#O6;:Z?-YH,
MDMJ,_P 7/[L_0DX'TK<T91X+\$:=')87UW,0#.EG 99/,?+,2!V!XS]*I:QX
M%N=0\:)J4,\":5</#+?V[$[I7BSMP,8(Z9Y'>NZH \^\;:R-9^&FLRC3]0LM
MAB7;?6YA9OWB'(!ZBF^,;-[_ ,2>#+2.[FM3+YZF: X=5\M<[3V)&1GMFNF\
M9:+<^(?"E[I=H\23SA-K2DA1AU8YP">@]*@U3P_=WOB'PWJ$<D(BTPR^<&8[
MFW(%&WCGD=\4 <_)HUGX1\?>'H]$62V@U+SX[J'S7=9-J ACN)YR>O\ ]>J,
M?A#0;CXLW]G+IR-;BP6ZV;VQYI<9;K_]:NRUK0KK4?%'A_4X9(5ATYYFF5R0
MS;U &W P>G<BFP:!=1_$"ZUYI(?LLMBMLJ G>&# Y(QC'XT <#I]UIOB*YU'
M4?$.C:WJLAN9(K86]K*\-O$IP%7:0 W')ZU9?6==T_X=W5NW]H6TTFI?8;.>
M]1DF6!R"&^;G(&1G_"NCB\.^(_#]Y>_\(U=:9)87<S7'V;4%<>0[==K)G(/H
M<?U-[4?#=]XA\*SZ;K=]";R5Q*DUK$52!A@J%!.2!@\DY.>U #+'X?>'].GA
MN+:">.Y3[\PN7W39&&#Y."#GTKF?"7@[0&\7^(@VG(1I]Y%]E^=_W7R[N.>>
M?6NFTVS\9R75L-8U'2X[2 AG-E&YDN<= Q; 4="<?3I4,>@:]I?BZ_U'2KC3
MGT_4I(I+F.Z#^9'M&#LV\'(SU]O3D YF]O;37/&6LIKNF:MJ=E82+!:6UI;2
M211G'S,P7JQ[9[?A4NG:KJ.A:!XL>VM-2MM.M(UDTP:A"ZM'N!!4;^2%.#CG
M]:Z*[\.ZWIOB"\U?PU=6(^W[3=6E\K;"ZC&]67D'VQ_]:]%I&JZKHE_8^);F
MSD^V1^6([*,JD(P1D%B2QS@\],4 <G=^!-.M_ EQJB3W:ZR=/>>:^^T.6F)3
M<RL"<%3TQCI[UU_@K_D2-$_Z\HO_ $$5SW_"->,IM!?P_/J^FK8+ 8$N(HW\
M^5 ,*K9^50>A(R<5UGA[3Y=)\.Z=I\[(TUM;I$[1DE20,'&0.* .3\=VDE]X
MP\)6L5W-:&5[E3-"<.J[%W!3V)&1GMG-5]2T2S\$^(O#]YH:RV\=[>"SNX?-
M=UF##ACDGD$9S4WCVVNKOQ=X2ALKPVERTER8IPN[8P12,@]1Q@CT-7X/#FO:
MKXAL-3\2W6G^5IQ+VUM8*^UW(QO<MZ=@/\<@&?XCMO"%YKMU'J5OJ>M:@H5G
MM;833"V4@#A4PJYZ\\\^]5O"D$&O> M9TW48Y[BTLKR:*!+HL)$1 &0-W!&>
ME; T#Q'I&N:K=:%<:9);:E*)G%]YF^)\8.-O##V.*M>$O#-[HFG:M:ZG=173
MWMY+/YL0VEE< 9(P #P>!D4 9/PQ\/:5:^%M.UF&S5-0G@99)]S$L-Q[9QV'
M;M7/V&KW>C_!2&6QD>.YGNGMTDC7<R;I6R1[XSCWKLO!^B>(/#ULNDWEQIL^
ME6ZN()(PXG;+9&X'Y0.3TSVJK8>!7/P\_P"$:U*XC6<.\B3VY+"-]Y96&0"<
M=^G>@#EM0M[/3[&.Z\,>'O$MOK<,B.+A[.?,_P PWB0G(8$9ZBMK6]+&M_%6
MUM)I[B"W?1]TZ0N4,J>:<QEAR 3C./3%;,%MX]S';SW^A+"O#7:0R-,P]=AP
MH)^N*N/H5TWC^+7A)#]E33C:E,G?OW[LXQC&/>@#G])TNV\/?$>;0M.#QZ5>
M:8;B2U,C,@??M)7)XR*H>$O!V@-XO\1!M.0C3[R+[+\[_NOEW<<\\^M=>^A7
M3>/XM>$D/V5-.-J4R=^_?NSC&,8]ZH1Z!KVE^+K_ %'2KC3GT_4I(I+F.Z#^
M9'M&#LV\'(SU]O3D Y[6H-.M?%NI7/C73KNXT^9D^PWOSO! F,;2%/R'/MR>
M?>O2+#[-_9]L+)U>U\I?)97W@IC@@GKQCFN:U?3O&5Y]NL;>[T9].N@R"2XB
M?SHD;((VCY6P#QG\:K:T+[PQX8T/0=!NF.HRS1VL+LBL64 EV(.0  /PH [:
MO-=*_P"1<^(G_7[>_P#H%>E=JY"R\*WUMI/BJT>6W,FKW%Q+ 0S842+@;N.#
MZXS0!S-OX.L)_AI'K5U-=S:I%IWVBWN3.RFWVIE$0 X &/3GDU=U35;_ %7P
MWX.TYKJ2)]::,7<\3;7*!06 (Z%LUU$&A747@ :"TD/VK^SC:[P3LWE-N<XS
MC/M6;=>#+FY\):+9)=QV^K:0(Y(+A063S%&"#D E3]/\* -+2O!>B:#>B[TJ
MWEM7"%'5)W*R _W@Q.2/6O/8_P#DWVY_ZZ'_ -*!7H.DVOBJ2^6XUR]TZ.&-
M"JVVGHY61B/O,S\\<X ]?:LW3?!,R_#F7PQJ%Q$)9/,_>PY95)<LIY SCB@!
M/B-_R3"__P"N</\ Z,2J_B*)M<\1^'_#4\TB:;-;/<W4<;E3,%& A(YQGK_^
MJJ^J>%O&FO>&WTC4=4TM$1%"&W5P;@J1@R,1\HXSA1R:V_$'AJ_O+G2]5T>Z
M@M]7TY2B>>I,4J,,,K8YQZ$>_P!0 <Y?>&[/P]\0O":::TT=G+)<%;5I&=(V
MV<E<DD9R,CVK7T+_ )*;XN_ZY6O_ *+IJ^&?$=]XHT?6]6O[%C9/)NM;8,L<
M:LI'RDC+,3C)..G%:VFZ%=6?C#7=7DDA-O?I L2J3O78N#N&,?D30!Q/@7P7
MIOB'P7%<:L]Q=9:5;>,S,J6P#MR@4CDGDDY[#I3TUC4YO@M%=->SB<2B"2='
MQ*T8FVG!/);''J:[3P9H5UX=\+P:9=R0O-&\C%H22OS,2.H![^E<9JNA7&@_
M#_1]"N;A%U&354%O/ Q,<<C2,P8E@,@#/&.M %%M$\&ZUXFT.#PW8M<JLK-?
ME1+L6,+QO+=&S^/KVKV'H*X#6KGQ1X1M[;4)_$,.K1/<1PFTELDB:3<<81D/
M7OT_/I7?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!YEXVU_Q1'X^T_0- U**T^U6ZL/-B1EW9?))*L>B]J7P]XI\4:9X
MYC\*^*'M[M[A"T5S"H7'RD@\  CY2.0#FLCQ_%J4_P 6]'BT>XBM]0:U40RR
MC*J<R=>#VSV-=+X:\":G;^)3XD\3:I'?ZDJ[8A$N$3C&>@[$\ #KF@#:N/'W
MA>T6Y,^K)']FF\B4&)\A^<@#;ENAY&16-JEII%U\4=%O7UV2*^%N##8B!R)5
M^<YW]%'7(/7%<YX&T+3-7\?>+)=1LH;OR+EQ&DR!U&Z1\G!XSP*OZZJI\=/#
MRJ JBTP !@ 8EH [.[\:>';&ZO;:ZU..&:R ,ZNC#;GD <?,?9<FHHO'OA:7
M2Y-2368/LL;;&+!E8'TV$;CW[=C7"6.D:?K'QRUN+4;6.YBAA\U8Y1E=P6,9
M(Z'@G@U!X5\,Z-=?%?Q!:SZ?!):V@9H;=US&I+ ?=/!ZG Z4 >I:/X@TG7[)
MKO2[V.X@0X<@%2I]PP!'XBLA_B1X0CN_LQUN$R9QE4<I_P!]A=OXYKC?!ALM
M"\3^.U\LKI]J&8PITV N< ?3(%<UJ*RZCX%N-3L_#7A[3M'!V12L2UWD-CA\
MY)^O49H ]NU3Q!I6BV<%W?W:QV]PZQQ2*K.'8C(QM!Z@=>E9TGC[PO&EXYU5
M&2R95G9(G<*6.!@A3GD=LUYKXN9G^"OADL<GS(Q^ 5P*]#E\%:.W@ZYTNQT^
MW@>YM!'YBQC<S 94LW4D-SS0!N3:WIUOHG]LR72C3_*$WGX)&P]#@#/?IC-2
M6>I6VI:7'J%C+YMO*F^-]I7</H0#7@HUZZU'P)I_@M-W]HMJ'V=T/41@Y /_
M  (X_P" U[S:V46G:/%90#$5O (D'L%Q0!Y)X7U3XD^+K6YN=/\ $-E%'!+Y
M;"X@0'.,\8B/'->BV^KOX;T33H_%FIPOJ$\OD^=%&Q61R3M VJ,<8Y( KR;X
M>?#_ $KQ?IM]=:A<7L3PW'EJ+=U4$8!YRI]:Z'XM:=#I_A/P]IL3.T,$ZP*S
MD%BH3 S@8S^% '=6GCGPS?:L-+MM7@ENR=JJH;:Q]%?&TGZ&K.N>*-$\.+&=
M6U".V,GW%PS,1Z[5!./?%>:?$30-*T&Z\*G2[&*U<7(0O$,,P!3!8]2?<\U-
M>6MEJGQXDMM9BCE@2W46\4PRCGRP0,'@\ECCU% %_2_$4FJ?&)H[+59;C29+
M/>D:3$Q$[!SMS@'.>V<YKJ9O'WA>"WGGEU:-$@G-N^8WW;QU 7&6QZ@$5PNA
M6>FV/QUNK?2DB2V6!ODB/RH^P;@/3GMVZ57^'6DZ'J?B7Q/_ &K;6MS/'.WE
MI< -A"S[F /X<]O;- 'K&DZQI^N6"WNFW27-NQ(WKD8/H0>0?8UBW'Q%\(VU
MZ;236X/-!P2B.Z _[X!7]:\J\/3S67A7Q\NE,[6:%5A93_ 7920?]SFNJ\-^
M'_"D_P *?MES:6;L;:1I[IU7S$DYZ-U7!Q@#^M '4^-AI>K>!;IKC5A::?,$
M;[9$AF7&X8X7[P)XXI^FZOHOAOPMH<<^J&2VG2.&VN'B?,Q(XXP2OX]*\RT]
M[EO@%J0F),2W8$&>R[T)_P#'BU3^-T$GPO\ !J'HWE@X_P"N= 'IMIXY\,WV
MK#2[;5X);LG:JJ&VL?17QM)^AKF]?^)UOH_C6VTI9K?^STRM_*\,A>)^>!CK
MVZ ]:P?B)H&E:#=>%3I=C%:N+D(7B&&8 I@L>I/N>:M^+M-TT_%_P]'+96AB
MN4+3JT2[96)8988^8].OM0!W5WXR\/6.E6NIW.IQ1VETNZ!BK;I!ZA<;OTXJ
M;3_%&B:KI<^IV6H1RVEN"9I,$>6 ,G((!''M7&^-_!\FH:MIMSH/]F276GP8
M&DW 78\>3C"=,9R.<#CKQ4O@;4M(U:QUW3[G0[;29HODU*&)ML+#!4D8X7H<
MX^N30!VNCZUI^OZ>M]IER+BV9BH<*5Y'4$$ BK]9/ARRT6PT>.'P_P"0=/+,
MRM!+YJLV>3NR<^G7M6M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%9FAZ
MY:Z_:SW%K',B0W#V["4 $LAP2,$\5IT %%%87C+6KGP]X4O=4M$B>> )M64$
MJ<NJG."#T/K0!H76DV-[J%E?W$&^YLBQMWWL-A88;@'!X]<U=ID+F2"-SC+*
M"<?2GT %%9M_<ZK%JNGQ65A'/92LPNYVE"F$8^4@=3D^E:5 !117/ZUKMUIW
MBCP_ID,<+0ZB\RS,X)9=B@C;@X'7N#0!T%%%% !1110 5$UM ]RERT$;3QJ5
M24H"R@XR >H!P/RJDUSJH\1);+81G2C;EFN_-&X2YX7;UQCV_&M*@ HHHH *
M*** "BBB@ HHHH **** "JFI:98ZO9/9ZA:QW-N_5)!D9]1Z'W%6Z* .?T[P
M3X=TN\CN[731Y\0Q&\TKR^7_ +N]C@^XKH*** "BBB@ HHHH **** "BBB@
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M4HW% 2<'*D=23P!UK2TGP-HNC:#>:1:1RB*]0I<2L^9'!!'7&!@$]!BNDHH
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MA^RIIQM2F3OW[]V<8QC'O1K6A76H^*/#^IPR0K#ISS-,KDAFWJ -N!@].Y%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3^]_M>W\OK][)]* .VHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB1C_ !,S\\<X ]?:J/A_0->\/ZO=P0W&G2Z'<7<ET=X?[0F\?='\/7'/U]>
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M737LXG$H@DG1\2M&)MIP3R6QQZFNT\&:%=>'?"\&F7<D+S1O(Q:$DK\S$CJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,# Y_0>E<QX,TNSN_'GB?Q#;1[81.;6(]B_!E8?5@/S->A44 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV]O$D,,:[4CC4*JCT '2O#M!\&Z=XP\<^*(M0FNHEM[IV3[.RJ23(PYRI]*
M/3-.O]1\+^&YKOQMJUM*ZS<3P1$@*<!1A4!)SGMWJ9_'OA:/4DT]]9MQ<N0
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M [;PI?:#X5^'UO='6FNM,21@+MH'7)+D8"8+#GC]:U'\>^%H]233WUFW%RY
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M1X<^RF)Y<SFWG\WYP.A.3C'I[T ;M%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOA::?4%TID'EQSX66(;O0Y"GIGMQ3?A/X1L+V]N-9DFN1<:=>%(55U",-O\
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M.<@D=0?3I5RPL-+'P]AM?*B_LYM/#,, J04R6^O?/K7!QO/)\,_!1N-VX:O
M%W==@=POZ8H ]-UC7]*\/VZ3ZI>QVR.<(&R6<^R@$G\!3-%\2Z/XA60Z5?1W
M!B.'3!5U^JL 1^5<W:HES\8[\W:AGMM.C-F'_A4GYF7\21GWHUB-(?BWX>EM
M5 GFM9UNMH^]&%^4M^/\J -C4_'/AO2+J6VO=359H?\ 6K'$\GE^S%%(!]C5
M75?$6FZOX+O-1T[7I+"V5E0WZVKDQG<O1" 3G(&1ZUS/AVXUDZ'J]MH^A1:A
M:7UY<F*\>Y2,?,Q4F1#\QQ[=1CI5[Q9I<FB?!>7399!));00H[KT)\Q<X]J
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M*R2!G:25UX!(!.3@\FMK4M6L=(2W>^G\I;B=;>([&;=(W0< XZ=3Q7G>I?\
M)// Q["]LB3Z?*:W/B.ZBV\/(6 8ZU;D#/)QNH WM3\4:+HUT]MJ-^EO*EO]
MI975O]7NVY!Q@G/&!S[4W_A*]#_L!-<.HQKIKY"3.&7<02,!2-Q.0>,9XKG-
M0L;6^^,U@;J!)?(TDRQAN0KB0@''MDU!XO%_+\1O#D%E'9NZ032P)>,RQ&3N
M?E!^8#D4 =;I'B;1]=DDBTZ]66:(9>)D:-P/7:P!QR.<8K6KBX]#\37GC#2M
M:U$:/ EFDD<GV261GD1EX!W*.AYZ^M=I0 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]7MUDMA*SQNW.'PQ.& &,CKFN@N_!MU<^$-%L8[N*WU;21%)!<*"R>8@P0>
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MJ$ _BAB<."?KT'TKTW&!@4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVD>)M'UV22+3KU99HAEXF1HW ]=K ''(YQBN3\7_ -H3?$?PY#9QV<CI!-+
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ME[J.HRS(8FDO[DRG8>J@<*!^%93?#?2VLY+!M1U<Z:P;98F[_<QYZ8&,\'D
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M9XWF>8F4@G<QR>@'%48/!UA;:;K&GP7%Y';:H[O(BNH\HMPWE_+P#[YKH:*
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MGO#0F3X?^-89EB1X[F]4I#G8A\L9"YYQGI0!U<OQ!\*PR01R:S"K3JCI\KX
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M9X-P+1,2N"Q( ) / ([5NT %%%% !1110 4444 %%%% !1110 4444 %%%%
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MII\EUC[2EE<>6DQ'<C!P<=QBI--\&Z7I.AZEI%HUPMI?M(S@N"8]Z[2%..@
MXSG\:Z&B@#,CT*UB\,C05DF^R_93:[R1OV%=N<XQG'M5:?PGI=WX9M] N4DE
MM;=%6)RV)$*C"L& &&_"MRB@#G]'\)6FDWPO9+_4M1NE0QQRW]R93&IQD*,
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M .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .M4M*TFRT2P2QTZ#R
M;9"2J;V;!)R>22>IJ[10 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 5=1TZTU?3YK"_@$UM,-KQDD9YSU'(Y]*L1QK%$D:9VH HR
M2>![FG44 %%%% !1110 4444 4[C2K*[U*TU"> /=68<0.6/R;AAN,XS@=2*
MN444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img57592461_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )3 S\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*C^T0_\ /:/_ +Z%'VB'_GM'_P!]"@"2BH_M$/\ SVC_ .^A1]HA_P">T?\
MWT* )**C^T0_\]H_^^A1]HA_Y[1_]]"@"2BH_M$/_/:/_OH4?:(?^>T?_?0H
M DHJ/[1#_P ]H_\ OH4?:(?^>T?_ 'T* )**C^T0_P#/:/\ [Z%'VB'_ )[1
M_P#?0H DHJ/[1#_SVC_[Z%'VB'_GM'_WT* )**C^T0_\]H_^^A1]HA_Y[1_]
M]"@"2BH_M$/_ #VC_P"^A1]HA_Y[1_\ ?0H DHJ/[1#_ ,]H_P#OH4?:(?\
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M_OH4?:(?^>T?_?0H DHI%97&58,/4'-+0 4444 %%%% !1110 4444 %%%%
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M#^S/[WX?\$]#HKSS!HP:/]:_^G7_ )-_]J']F?WOP_X)Z'17GF#1@T?ZU_\
M3K_R;_[4/[,_O?A_P3T.BO/,&C!H_P!:_P#IU_Y-_P#:A_9G][\/^">AT5YY
M@UH:%_R&;?\ X%_Z":VP_$OMJT*7LK<S2^+N[=B*F7\D'+FV\O\ @G9T445]
M2>:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!+147V:#_GA'_P!\"C[-!_SPC_[X% $M%1?9H/\ GA'_ -\"C[-!_P \(_\
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M_O@4 2T4U$2,8154>@&*=0 4444 %%%% !1110 4444 %%%% !1110 4444
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M>A5]API_R^_[=_4\K,_L_/\ 0****^O/*"BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4444 <UXHMS<WNGB87L5HGF,;G3XW:=), *H* LJD%LD#L
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M(O*?_GXD_)?\*/*?_GXD_)?\*EHH B\I_P#GXD_)?\*/*?\ Y^)/R7_"I:*
M&HI48+LWN<?TIU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#SSC_[^'_"N"'2OD.*_P#ES_V]_P"VGJY9]KY?J%%%%?'GJA1110 4444
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M +^'_P")HW3_ //./_OX?_B: ):*BW3_ //./_OX?_B:-T__ #SC_P"_A_\
MB: .:\2_\A*/_KB/YFL>M?Q$7.HQ[U4'RAT.>Y]JR*_,LX_WZKZGT6%_@Q"B
MBBO-.@**** "BBB@ HHHH **** "M#0_^0S;_P# O_036?5_1=PU>#: 3\W!
M./X379EW^^4O\4?S1C7_ (4O1G9T5%NN/^>47_?P_P#Q-&ZX_P">47_?P_\
MQ-?J9\V2T5%NN/\ GE%_W\/_ ,31NN/^>47_ '\/_P 30!+146ZX_P">47_?
MP_\ Q-&ZX_YY1?\ ?P__ !- $M%-0N5^=54^BG/]!3J "BBB@ HHHH ****
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M7^-$Y:BBBOS(^B"BBB@ HHHH **** "BBB@ HHHH #TKT*O/3TKT*OL.%/\
ME]_V[^IY69_9^?Z!1117UYY04444 %%%% !1110 4444 %%%% '*^)?^0E'_
M -<1_,UCUL>)?^0E'_UQ'\S6/7YEG'^_5?4^BPO\&(4445YIT!1110 4444
M%%%% !1110 5H:'_ ,AFW_X%_P"@FL^M#0_^0S;_ / O_0379EW^^4O\4?S1
MC7_A2]&=E1117ZF?-A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#GA)^:_P"-'FO_ ,\)/S7_ !J6B@"+S7_YX2?FO^-'FO\ \\)/S7_&I:*
M(O-?_GA)^:_XT>:__/"3\U_QJ6B@"+S7_P">$GYK_C1YK_\ /"3\U_QJ6B@"
M+S7_ .>$GYK_ (T>:_\ SPD_-?\ &I:* .4\1,6U&,E"I\H<''J?2LBMCQ+_
M ,A*/_KB/YFL>OS+./\ ?JOJ?187^#$****\TZ HHHH **** "BBB@ HHHH
M*OZ*2-7@(4L?FX'^Z:H5H:'_ ,AFW_X%_P"@FNS+O]\I?XH_FC&O_"EZ,ZWS
M7_Y]Y/S7_&CS7_Y]Y/S7_&I:*_4SYLB\U_\ GWD_-?\ &CS7_P"?>3\U_P :
MEHH B\U_^?>3\U_QH\U_^?>3\U_QJ6B@!J,6&2C+['']*=110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <9XX^R+JOAV350ITE;F03AQE-^SY"WMD'
MVJ'Q9+X/;PO>8?2S(86-O]G,9DWX^7;MYZ_IG/%=A?6EI?6CVU]#%+ _#)(
M0:Y6Z\'^%]$LKO4[73('GMH7FC665W7<JDC(+'- '2:&9CH.G?:,^=]FC\S/
M7=M&:OU2T>]?4=%L;V155[B!)65>@+*"0/SJ[0 4444 %%%% !1110 4444
M%%%% !7GHZ5Z%7GHZ5\AQ7_RY_[>_P#;3U<L^U\OU"BBBOCSU0HHHH ****
M"BBB@ HHHH **** .I\-?\@Z3_KL?Y"MFL;PU_R#I/\ KL?Y"MFOTW*/]QI>
MA\[BOXT@HHHKTCG"BBB@ HHHH **** "BBB@ K&\2_\ (.C_ .NP_D:V:QO$
MO_(.C_Z[#^1KS<W_ -QJ^AT87^-$Y:BBBOS(^B"BBB@ HHHH **** "BBB@
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MPOX=TU[>-HX#:QF-&;<57:,#/?BM&JVG6:Z=IEK9(Q=;>%(@S=2% &?TJS0
M45A>(+B\AN=/6">^@MG9_M$EG:^>XPOR\;'P,^U0?;Y-0NM-T_3]6E\J:WDN
M7O%2,R.%*J%P4V@Y;GY<C;C H Z2BLO0;R>[L)%NG$EQ;SR6[R  ;]C$!L#@
M$C!..Y[5J4 %%1M/$C;7E13Z%@*3[3!_SWC_ .^Q0!+147VF#_GO'_WV*/M,
M'_/>/_OL4 2T5%]I@_Y[Q_\ ?8H^TP?\]X_^^Q0!+7GHZ5WOVF#_ )[Q_P#?
M8K@ATKY#BO\ Y<_]O?\ MIZN6?:^7ZA1117QYZH4444 %%%% !1110 4444
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M9K'K\RSC_?JOJ?187^#$****\TZ HHHH **** "BBB@ HHHH *T-#_Y#-O\
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M:*B^S0?\\(_^^!1]F@_YX1_]\"@"6BHOLT'_ #PC_P"^!1]F@_YX1_\ ? H
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M_O@4 2T4U$2,8154>@&*=0 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#S\2?DO^%2T5Z1SD7E/_S\2?DO^%'E/_S\2?DO^%2T4 1>4_\ S\2?DO\
MA1Y3_P#/Q)^2_P"%2T4 1>4__/Q)^2_X4>4__/Q)^2_X5+10!%Y3_P#/Q)^2
M_P"%'E/_ ,_$GY+_ (5+10!%Y3_\_$GY+_A61XC1ET^,F5F_?#A@/0^@K<K&
M\2_\@Z/_ *[#^1KS<W_W&KZ'1A?XT3EJ***_,CZ(**** "BBB@ HHHH ****
M "BBB@ /2N]\I_\ GXD_)?\ "N"/2O0J^PX4_P"7W_;OZGE9G]GY_H1>4_\
MS\2?DO\ A1Y3_P#/Q)^2_P"%2T5]>>41>4__ #\2?DO^%'E/_P _$GY+_A4M
M% $7E/\ \_$GY+_A1Y3_ //Q)^2_X5+10!%Y3_\ /Q)^2_X4>4__ #\2?DO^
M%2T4 1>4_P#S\2?DO^%'E/\ \_$GY+_A4M% $7E/_P _$GY+_A1Y3_\ /Q)^
M2_X5+10!RGB)2NHQ@NS?NAR<>I]*R*V/$O\ R$H_^N(_F:QZ_,LX_P!^J^I]
M%A?X,0HHHKS3H"BBB@ HHHH **** "BBB@ J_HH)U> !BOWN1_NFJ%:&A_\
M(9M_^!?^@FNS+O\ ?*7^*/YHQK_PI>C.M\I_^?B7\E_PH\E_^?B7\E_PJ6BO
MU,^;(O)?_GXE_)?\*/)?_GXE_)?\*EHH B\E_P#GXE_)?\*/)?\ Y^)?R7_"
MI:* &HI5<%V<^K8_I3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[:Z$[2Q77^H\B)Y6DXSPJ@MP.O''>J_B#7X-%AAC:6!+NZ)2#SY B CJS,>
MHSGU/0<FL:UDT[2+[1KG^TH)=-6TG@^VF1?*,Q=&.6!V@G#\9[8H ZRTNX+^
MUCN;:020R#*L 1^!!Y!'0@\@U-6-X95O[-GFVE8KB[GFA![QLY(/T/7\:V:
M"BHV,H;Y$0CU+D?TI-T__/./_OX?_B: ):*BW3_\\X_^_A_^)HW3_P#/./\
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M%&Z?_GG'_P!_#_A0!+146Z?_ )YQ_P#?P_X4;I_^><?_ '\/^% $M%1;I_\
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M34+E?G55/HIS_04Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .N(_F:QZV/$O_(2C_ZXC^9K'K\RSC_?JOJ?187^#$****\TZ HHHH ****
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MAK_D'2?]=C_(5LU^FY1_N-+T/G<5_&D%%%%>D<X4444 %%%% !1110 4444
M%8WB7_D'1_\ 78?R-;-8WB7_ )!T?_78?R->;F_^XU?0Z,+_ !HG+4445^9'
MT05E>(+^2PL8O*D\J2>=(5DV[BFX\D#N< X'K6K5#5K&6^M4$#JEQ#*LT1?.
MTLIS@X['D?C6^&<%5BZFUR*E^1\NYG"_L-/LKZ:VFO&N(+8RF.\>;) !P0LG
M;(QD"HKE)]+LK'45O+F6=I8EN!),S)('(#80G:O)R, 8Q5J32+C4KJ:?41#$
MK6KVRQ0.7X;JQ8A>>!@8IO\ 9NI7<%I9WQMOLUNZN\D;L6FV?=RI4!<D GD]
M,5Z$9TDT^:_\UW?2VR?7Y=6NUSG:D^GH27^;W7K&S'^JMP;N7ZCY4'YY/_ :
MS;'4[.]C^WZA=WJ;Y2(_+,T<$2[R%!9,(3TR6/4XK2T(B[>^U3.1=3%8C_TS
M3Y5_,[C^-56T74/[+FT96MA8R.P6<NWF+&S;L;,8)Y(SN]\=J(.G#]S-V<;*
M][-;N7?9NUEJT@:D_?6M[_\  )T0ZOJNH1RW%PD%J5AC2"9HOF*AF8E2"3R
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MH **** "BBB@ HHK&U*XN9];L]*MKJ2T$D,EQ+-&JL^%*J%&\$#);)X/3WH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@CK3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV+RZY+<R36[>06;R^JLK ?*H&2>0,>N*]DHH \QUF:;P[8^'_$UJF=VG"SG
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 4]5OCIFCWM^(_-^S0/-Y><;MJDXS@XZ>E
M95SXG-OI6@WWV,-_:L\$)3S<>5YBELYQ\V,>V:TM;LI-2T'4+&$H);FVDA0N
M<*"RD#/!XY]*YBXT#Q#<Z-H=F;?2UETFYMYE;[;(1,(U*D']UE2>/7O^(!M:
MAK\T6O1:)IMDMW?-!]ID,LQBBBCR0"6"L22>  /?BLP>.XQ82"33W754O_[.
M%B)0P:8_=P^/N$<[MOKQ4KZ1K2>(X_$-O#8?:I+4VMS9O=/Y>T-N5ED\O.?4
M%?QJ@_@B]:%M0-U;'6CJ8U, AO)! VB+/WMN/XL9]J ->#Q.T&LRZ5K=K!I\
MRVWVM)DN?,@:,'#?.RI@@]B.G.:EN/%ND_8Y)M.O['4)(V0-%;W2,0&=4S\N
M>A:L22RUQ_'MOJ&H69ABFLGL[>?39?.%J^=Q:3>@Z@$ [2,X&#FM;4M!U&?3
M)X8]8N+V5C&R1WHB2/*R*W6.(,.%([]>E &KJ&K6>E^4+EY-\Q*QQQ0O*[X&
M3A$!8@#J<<5';Z[IMV(C!=!A+"\Z_*P^1" ^<C@J2 5/(/45G36FNRZC::LM
MIIRW<"26[6YO)"CQ/M;<'\H$,&0<;2"">:JW'A:\EL+79-;B\-Q.]RQSL\J<
ML943@DXRN,XR5R<9H VX==TV=+5X[H%+JW:YB8JP!C7;N8DCY<;EZXZU!#XH
MTF>&>59YD2" W+>;;2QEHAR74,H+CW7/4>HK/7PK+,NM07-PBPW<,EM:F/),
M4;LS-D'ON?&!V0?A5'A>\FL;Z*:UACN9+":U@G;5[FZ 9U ^Y(N%4X!."3P.
MM &]_;4%UHEWJ.GEI$BB=XWDA=%<A<@C(&Y3QRO![&J]IX@5H;9KLPINTT7\
MQ7?E1@9PNTC;R?XL^QZU>FLI)-"DL0R^8UL803TR5Q^58C>&KPQ!/,M\_P!A
MG3NI_P!8<<]/N_K[4 7/^$QT,L56YG=@@D54LYF,B'/SH GSIQ]Y<KTYY%27
M7B*WMV9H]L\7V+[8IA#N[KD 854(*G/7.1Z8YI!I%P-0AN"\>Q-.:T(R<[R5
M.>G3@_X50TOPU=V:62S2P8AT5=/<H2?W@QR,@97C_P"M0!J6>OVEQX>CUF??
M:VYB$DGG1NNW(' W*"W)P"!SVJEJ?BVTM]!U.]LQ+)<V<>?(FM94<,0=I9"H
M8(?[V,<'G@TAT;4;CPA:Z?-]EBO[3R6B*2,\3O"59=QVJ0&*\X!QGO4=YH>I
MZI;:O+="TM[N\LQ:1112M(B@%B&9R@))+GC;P!WS0!HQZO'::+!>ZE.6:1@@
M,=E+&SL3@!83N?/MSTSTI]OX@TRZ5&AN2=UQ]EP8G4B7;NV$$9! ZYQ@\'GB
MF:UI]W=-I]U8^2US8W'G+'.[(D@*,C L 2.')!P>1TK!LK'4KP:C*!:'4+;6
MEN?*+LL3?N8P4W8)X5C\VWDC.!G  .DEUNPA2=C)(Y@F\ATB@>1_,VAMH502
MWRG/ /&?0U7?Q1I$=O:S&XD9;O=Y");R.[E3A@$"ELCN,9&#Z&LE]"UUK>=S
M-;B6XU W4T$%U+;J\9B5 GFJN\$,H.0/FQVS@3Z)X<O--;3#-+"WV5KPOMD=
MR?.DWK@MR<#J2<_6@"Q-XML5N-*2".XN(=0W%98[>5MH /8(><C!!P1U-5]7
M\4/9Z?/);(AG74%LE98)IU7+*"655!R QPH."< ,2<4L6AZE:)I;P?999;2\
MN9G225D!25I#PP4G<-XXQCKSWIP\/W7D7,?F0YEUA+X88\1AT8CI]["G_&@"
MP/$EM:F5+Z5=T0A7]U#+YDCR*2 (MI8'@G +$ '.,5)-XHTFWACFDGF$;#)8
M6LI\H;BO[S"_N^01\^.A]#6=?>'M0/B*76;-K5I4FAEAAF8J' C>-PS!25.'
MR" >G(JKK_A[Q!K<-PCSVX6XM3$(TO9XH[=R6R=J#$P(*CY\?=)Q@XH UAXF
M@;5-3L/L\ZM8Q"3S'AE"-PQ.6V8 ^7@\[NV<4[_A*]*BBB-Q<%6:*.65HHI)
M(H0XR"\@3"#OE]O') J*?2;\ZCJK1BU:VO[-8=S2,'1U5Q]W:05.X<Y!'H:S
MH?#>KVFFWFEP-8O;:A D<\TDK[X&\E87*KM(<80$ E>20>* -F[\4:197DMK
M/<N)8BHEVP2.L>[&TNP4A0<C!) Z^AK8KG+OP_<RV7B"WBDB_P")A&J0EV/&
M(@GS''J.V:Z(#  H 6JNHW4MG82W$,'GR)C$8W?-R!_"K']/R'-6J* .=T_Q
M'-)X2EUF]M0CQ1;Q&FX>:=H(QD8Y)P-I<?[1YQ:L_$$$NAG4;U#:-'(89H1F
M1DE#[-@P,L2<8P,G(P.:3Q!I-UK*V5M%=?9K:.X6>>1 #)\G*!0RE?O[2<CM
M6>/#E[;#58BT6K6]\8Y@M[-Y#B8?*QW11X7A4(*C.1^- &X-5M3IQOV\^. <
M8EMI$D)S@ 1LH8DG@#&3D8S4-MX@TR[>%(IW$DTK0(DD#QMYBKN*D,H*G;S@
MXR.E9YTG6?\ A&#9"]Q>&;>/])<XB\S/E>=MW_=^7?C=5&#PKJ,.E7NV2!-0
M:_2_M"]S+.L;*B+M:1QN((5E)]&Z#H #<E\1Z9%"TOFS2*LDD1$-M+*P9#A_
ME52< \%L8R1S4=UKR 2BT:"0?V<U]$Q+$L!T.-N"O_ L^W>LRY\-ZBFGZ99V
MEP'A@@:.=/M<MMOE;!\W=$,MSO\ E) .[K19^&+VWMK>-I;<F+0_[.)#'F3C
MGI]WCZ^U &@GB6SM]+L;C479))[:.>0Q6\CI'N Y8J"$7.<%B.AYX-0OXKM+
M/5]2M+^3RX[9H]CQP2.$1D4[I&4$(,DX+;1P?0UDZMX4UF^TQ;".YB:+^SDM
M5!O9H4AD"D,VQ!B4-\OWNF.AR15[4-#UB:;68;8V!L]518G>21UD@'EB-F "
MD.<9P,KT'// !H+KJPZGK*7CQ165@D+B0 YPZDG/KR!@ ?G5W3]6L]3,JVS2
MB2(@21S0/"ZYZ':X!P>QQ@X/H:P[_P +37AU<+,BI<_96@^=@=T)SAF7!&2
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MZ\]*Q[RRU[4-.A\Z+38[JWN()HXTG<H^QLMERF5SV 4XQU.>)M?T:ZU9+*2
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MY/LZ6FJ62P22+(3)"X5P<+MPP^8<Y!XZ54@\,W;6]VL]K$D[64MO#,=7N;D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
@* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img57592461_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 4Z"+@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ SB
MH4NK>2YDMDGC:>,!GC# LH/0D=NAJ4]*\N\*$_\ "[_%PR?]3#W^M 'J5%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%%  :\M\)_\EO\7_\ 7&+^M>I&O+?"?_);_%__ %QB_K0!
MZE1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !11FC- !11FB@ HHHH ****  UY;X3_ .2W^+_^N,7]:]2->6^$_P#DM_B_
M_KC%_6@#U*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*HZ?K.FZM$\NG7UO=QHVUF@D#@'T.*;'KNE3:D^FQZC:O?)DM;K*"XQZKUH
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M#U.BO+/^&@/!?]Z^_P# <T?\- >"_P"]??\ @.: /4Z*\L_X: \%_P!Z^_\
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M:_\ A0G@<\_9[W_P(_\ K5Y9\-?^2[W'_72;^8KZA% 'F/\ PH/P/_SPO?\
MP(_^M1_PH/P/_P \+W_P(_\ K5Z=10!YC_PH/P/_ ,\+W_P(_P#K4?\ "@_
M_P#SPO?_  (_^M7IU% 'F/\ PH/P/_SPO?\ P(_^M1_PH/P/_P \+W_P(_\
MK5Z=10!YC_PH/P/_ ,\+W_P(_P#K4?\ "@_ _P#SPO?_  (_^M7IU% 'F/\
MPH/P/_SPO?\ P(_^M1_PH/P/_P \+W_P(_\ K5Z=10!YC_PH/P/_ ,\+W_P(
M_P#K4?\ "@_ _P#SPO?_  (_^M7IU% 'F/\ PH/P/_SPO?\ P(_^M1_PH/P/
M_P \+W_P(_\ K5Z=10!YC_PH/P/_ ,\+W_P(_P#K4?\ "@_ _P#SPO?_  (_
M^M7IU% 'F/\ PH/P/_SPO?\ P(_^M1_PH/P/_P \+W_P(_\ K5Z=10!YC_PH
M/P/_ ,\+W_P(_P#K4?\ "@_ _P#SPO?_  (_^M7IU% 'F/\ PH/P/_SPO?\
MP(_^M1_PH/P/_P \+W_P(_\ K5Z=10!YC_PH/P/_ ,\+W_P(_P#K4?\ "@_
M_P#SPO?_  (_^M7IU% 'F/\ PH/P/_SPO?\ P(_^M1_PH/P/_P \+W_P(_\
MK5Z=10!YC_PH/P/_ ,\+W_P(_P#K4?\ "@_ _P#SPO?_  (_^M7IU% 'F/\
MPH/P/_SPO?\ P(_^M1_PH/P/_P \+W_P(_\ K5Z=10!YC_PH/P/_ ,\+W_P(
M_P#K4?\ "@_ _P#SPO?_  (_^M7IU% 'F/\ PH/P/_SPO?\ P(_^M1_PH/P/
M_P \+W_P(_\ K5Z=10!YC_PH/P/_ ,\+W_P(_P#K4?\ "@_ _P#SPO?_  (_
M^M7IU% 'F/\ PH/P/_SPO?\ P(_^M1_PH/P/_P \+W_P(_\ K5Z=10!YC_PH
M/P/_ ,\+W_P(_P#K4?\ "@_ _P#SPO?_  (_^M7IU% 'F/\ PH/P/_SPO?\
MP(_^M1_PH/P/_P \+W_P(_\ K5Z=10!YC_PH/P/_ ,\+W_P(_P#K4?\ "@_
M_P#SPO?_  (_^M7IU% 'F/\ PH/P/_SPO?\ P(_^M1_PH/P/_P \+W_P(_\
MK5Z=10!YC_PH/P/_ ,\+W_P(_P#K4?\ "A/ X_Y=[W_P(_\ K5Z=0>E 'S_H
M/AS3O"O[0=OI6EI(EJEF7 D?<<GKS^%>_CI7BTW_ "<Y%_UX_P"->U#I0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 8%%%% !1110 4444 %%%%  :\M\)_\EO\ %_\
MUQB_K7J1KRWPG_R6_P 7_P#7&+^M 'J5%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R]\-?\ DN]Q
M_P!=)OYBOJ$5\O?#7_DN]Q_UTF_F*^H10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !0>E%!Z4 >*S?\G.1?\ 7C_C
M7M0Z5XK-_P G.1?]>/\ C7M0Z4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%%  :\M\)_\EO\ %_\ UQB_K7J1KRWPG_R6_P 7_P#7&+^M 'J5
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'R]\-?\ DN]Q_P!=)OYBOJ$5\O?#7_DN]Q_UTF_F*^H1
M0 4444 %%%(: #-+FJ6I:G::1927E[,(H4&23W]AZFN*;XL:6'8)873J#PW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH #7EOA/\ Y+?XO_ZXQ?UKU(UY;X3_ .2W^+_^N,7]: /4J*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=*\5F_Y.<B_Z\?\ &O:ATH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)^?^F2T^V_9RM+>YBF_M^=O+<-CRAV.:]SHH0#(D\N)$_NJ!^5/HHH ****
M"BBB@ HHHH *#THH/2@#Q6;_ ).<B_Z\?\:]J'2O%9O^3G(O^O'_ !KVH=*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ->6^$_^2W^+_\
MKC%_6O4C7EOA/_DM_B__ *XQ?UH ]2HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#Y>^&O_)=[C_KI-_,5]0BOE[X:_\ )=[C_KI-_,5]
M0B@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,T +15:74;*!S'+=V\;C^
M%Y5!_+-3+*KH'1E=3T93D4 /HH'(HH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHH)P* "BH)KVVML>?<119Z>8X7^=/CF25 \3JZ'HRD$4
M24444 %%%% !1110 4444 %!Z44'I0!XK-_R<Y%_UX_XU[4.E>*S?\G.1?\
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M967<I!'J#2+(CYVNK8ZX.: '44WS$W[-Z[O3/-#.B??95SZG% #J*0L NXD
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MY=NP'XU\T_"_0;KQE\2!JDD1%K!<&[G?'"G.Y5^N:<=[ ]CZN'(XI:0<4M(
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M!9:YH<NC7HE-I*@1@CE6P.G/X5'X>\.6'A?1H])TU91:H20)9"[<G)YK9HH
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MW#W-\BF[D63:V1SM&.@S7=:/HEEHEC%;VL"*47!D"_,Q]SUK4'05TUJM*?\
M#AR_B?'590;M!:&3I&@6>AZ'%H]D)19QHR .Y9L'.>?QK/\ "_@;1O!\EW)I
M2W :[;=)YLQ?OGC/3K73T5@9'+OX#T63Q@OBAEN?[27&")CLZ?W:D\4^"=(\
M916R:LMP1;/OC\F4IS[XKI** ,K4=!L]4T"31+D2_8WB$)"2$-MQCK4/AOPQ
MI_A32!IFF"86P8M^]D+MD^YK;HH Y?0O >B^'-;O=7T];D7=X293),67DY.!
MVYHU7P%HNL^);37[Q;DWUKM\LI,53@Y&17444 8/BCPGIGC#35L-668P)()
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M:]J'2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME 'BLW_)SD7_ %X_XU[4.E>*S?\ )SD7_7C_ (U[4.E !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG?:+J<[3O8X:&1SEMIR"I/MBO/9=1\2R?%W6-.T&\D%W=W$MNI9B0B[N2/3
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MP\V(H[Y?LYB[-D<#';-$-[#>Q]CKTIU16^XVT1?[VP9^N*EH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/2@#Q6;_ ).<B_Z\?\:]J'2O%9O^3G(O^O'_ !KVH=* "BBB@ HHHH ****
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MQ->5.T8GMY3EL,3>I5^%?B:?Q#\;W^NZ4WEQ-;0HA!C23(8GN:XWPE*)-%V
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MENKXZ[2#0!)13/.C\SR]Z[_[N1G\J1IHX\;W5,]-Q S0!)133(JJ68A5'<G
MI%E5U#(0RGNIR* 'T5&LT;DA'5B.H5@<4IFC#A"ZAST4D9_*@!]%,:9(QF1E
M0>K'%+YBXW9&W&<YXH =13$E21=R,KCU4YI!-&S%%=2PZJ",B@"2BHVFC1E5
MW52W0%@":5I409=@H]6.!0 ^BFB16 92"I[@\4U)HY 3&ZO@X.T@XH DHJ/S
MH]^S>N_^[D9_*E>:./'F.J9X&Y@,T /HIID502Q 4=R>*19$=0R,&4]U.10
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MQE2#2":,OL#J7_NY&?RH DHJ-IHT(#NJD] S 9I6D5 2Y"@=R<"@!]%,617
M92&4]P<BD6:.3.QU?'7:P.* )**C\Z,/L+KO_NY&?RH>:.,9D=4'3YB!0!)1
M32Z@9) 7U)XI%E20;D8./53D4 /HJ-9HV9E5U9EZ@,"109HU8*SJK'H"P!-
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M^%L>!?\ H9+/_P >_P * .RHKC?^%L>!?^ADL_\ Q[_"C_A;'@7_ *&2S_\
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M-_X6QX%_Z&2S_P#'O\*/^%L>!?\ H9+/_P >_P * .RHKC?^%L>!?^ADL_\
MQ[_"C_A;'@7_ *&2S_\ 'O\ "@#LJ*XW_A;'@7_H9+/_ ,>_PH_X6QX%_P"A
MDL__ ![_  H [*BN-_X6QX%_Z&2S_P#'O\*/^%L>!?\ H9+/_P >_P * .RH
MKC?^%L>!?^ADL_\ Q[_"C_A;'@7_ *&2S_\ 'O\ "@#LJ*XW_A;'@7_H9+/_
M ,>_PH_X6QX%_P"ADL__ ![_  H [*BN-_X6QX%_Z&2S_P#'O\*/^%L>!?\
MH9+/_P >_P * .RHKC?^%L>!?^ADL_\ Q[_"C_A;'@7_ *&2S_\ 'O\ "@#L
MJ#TKC?\ A;'@7_H9+/\ \>_PI/\ A:_@7_H9+/\ \>_PH XB;_DYR+_KQ_QK
MVH=*\&TW6M.U_P#:,@O]*NX[JU:R*B6/."1U'ZU[R.E !1110 4444 %%%%
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M!>N:N^V*R:!1R9)_E'^->D>%/ -OX?NTU":ZEGO@I7Y6(C /7CO^-=ICCD4
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M#>KWNI63W;3W>?,$UPSKR<]"?UHU3P)I&K>)[77[E[P7EOC8$N&5..G ./\
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MS=F6VU6^MHB!^[P'Y]<GFJI_9LT@G_D8;[_OTE>WT4 >(?\ #-FD?]##??\
M?E*/^&;-(_Z&&^_[\I7M]% 'B'_#-FD?]##??]^4H_X9LTC_ *&&^_[\I7M]
M% 'B'_#-FD?]##??]^4H_P"&;-(_Z&&^_P"_*5[?10!XA_PS9I'_ $,-]_WY
M2C_AFS2/^AAOO^_*5[?10!XA_P ,V:1_T,-]_P!^4H_X9LTC_H8;[_ORE>WT
M4 >(?\,V:1_T,-]_WY2C_AFS2/\ H8;[_ORE>WT4 >(?\,V:1_T,-]_WY2C_
M (9LTC_H8;[_ +\I7M]% 'B'_#-FD?\ 0PWW_?E*/^&;-(_Z&&^_[\I7M]%
M'B'_  S9I'_0PWW_ 'Y2C_AFS2/^AAOO^_*5[?10!XA_PS9I'_0PWW_?E*/^
M&;-(_P"AAOO^_*5[?10!XA_PS9I'_0PWW_?E*/\ AFS2/^AAOO\ ORE>WT4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ P/2L6\\(^'M0NC<W>
MCVDLQZNT8S6U10!%!;PVT2Q01)'&HP%1< 5+110 4444 %%%%  :\M\)_P#)
M;_%__7&+^M>I&O+?"?\ R6_Q?_UQB_K0!ZE1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !3<^U)+-%#&9)9%C0=68X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,92<G=A1114B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH =13=XHW#&: '44FX8I X- #J*;N&<4%P* '44FX8I P(S0 ZBF[Q1N&<4
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M.: '44W>*-PQF@!U%)N%('!H =13=PSBC>* '44FX8I-PQF@!U%-WBC<,XH
M=132X%+N% "T4T,",T;Q0 ZBFE@"*4L!0 M%)N!I P- #J*;O&:"P% #J*0L
M!2;@: '44T,"31O% #J*:6 %+N% "T4T.#2[AG% "T4W>*-PQF@!U%)N&*0.
M#0 ZBF[AG%!<"@!U%)N&*3<,9H =13=XHW#(% #J*:7 I=PH 6BFA@11O&:
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M21AP!WXK9VBC H RM)M=6M] CM]2U".ZU-8RK72Q[5+=CMK.\*:;XGL#=_\
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M8% &3HEIJ]IH,5MJVH1WNI*A#W*Q[5)['%9OA33/%-A/>-XBUV#4XW;]PL<
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MQI?BFPNKU_$&O0:E#(V;=(X AC&>Y YXKI\"C H Y6YTSQ6_C**\@UZWCT(
M;[ P LWK\V/ZU/XLTWQ+J-M;IX;UN'2Y4DS*TL(DWKZ#(.*Z/:*,"@#+O+;5
M)/#SVUM?1Q:H80JW1CRHDQRVVJWA6RUVPTGRO$.J1:E>[R?/CB$8V^F,"MW
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MX#JCCOQ_.OI^PN4O=/M[I!\LL8<?B*I6M=$OL3TZBBD,**** "BBB@ HHHH
M**** "HKBWANK>2WGB66&12KHPR&!Z@BI:*35P,O2/#FC:")!I.F6MD)?]9Y
M$87=]<5J444P"BBB@ HHHH #7EOA/_DM_B__ *XQ?UKU(UY;X3_Y+?XO_P"N
M,7]: /4J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %&*** *=[I=AJ,1CO+."=3VD0&LD^!/"K'<= L2?^N0KHLB
MHI[F"UB,MQ-'%&.K2,%'YF@"E8:!I&F9^Q:;;09Z[(P*T<#'2N#UGXO^#]*N
MDMAJ!O)V<(4ME+ 'W/2N[C8/&K#HP!% #J*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH #7EOA/_ )+?XO\ ^N,7]:]2->6^$_\ DM_B_P#Z
MXQ?UH ]2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "JFHZE9:3927E_<Q6]O&,M)(V *M&O)OCYIVI:CX3LDT^VFG5+@
MM*L0SQ@8R/SI,$8?C'X_1H7L?"EOYTA^47<PX_X"O>N3TCX:^-_B->_VEK]S
M/;6[G)FNLY(_V4XKG/#MWXI\,2B6P\.QM<#E9I[(NX^AS76?\+4^*G:P'_@"
M?\:K1 >Q^$?A?X;\'A)+6T^T7H'-U/\ ,V?;L*[4=*^;K'XH?%&6_MXY-/4H
MTBJP^Q$9!//.:^CXB6B0L,,5!/UH8A]%%%(84444 %%%% !1110 4E+10!FZ
MZU\FAWS:8";X0MY  S\W:OFGQA<_%:XT%U\0Q7JZ;_RUQ$%7_@6!TKZ&\4>,
M](\(?8WUB5XHKJ3RUD5<A3@GG\JQ-?\ B7X.C\.7K_VO:W0D@95@0Y+DC@8I
M,:.,^ FK^&%MYM,LX9(-:=0\S3,#YP']T^@]/>O<*^4/@MI]UJ/Q+M[FVB80
M6VZ65AT52> :^KZM]&3U"FMG/%.HJ1GG&I^'OB5/J=S+8^+;."U>0F*+[+G8
MO8=:J_\ ",_%3_H<[/\ \!!7J-% 'EW_  C/Q5'_ #.5D?\ MT%<OX*TWQ7'
M\8M82?6K=YX1&;]_)XN$YP .U>\FO+?"?_);_%__ %QB_K0!U_BRP\2ZA90)
MX<U6#3IUDW2O+#OW+CH/2KT]MJ[>'C;17L*ZKY&T7)C.SS,?>VY]:U:* .?\
M*V/B&PTUXO$6IPZA=&0E98HMF%[ ^O>JND:9XMM_$]W=:GK=M<Z3)N\FU2#:
MR9/'.>PKJJ* .4U_3/%MWKEE/HVM6UGI\9'VB"2#<TG//.?2K_B:SUV^T<PZ
M!J,-A>[@?.DBWC'< 5N44 9.FVVKP:!%;W][#/J8B*M<K&54MV.W-9WA/3O%
M.GI<CQ)J]OJ+.P,)BAV%!W[UT]% '*IIGBT>,VO6UNV.A'I9>1\P&,?>SUSS
M2^*]-\5:@]H?#FL6^G*A/GB6'>7'&._UKJ:* ,C5[76+G0);?3+V*UU(H EP
M\>Y0>YVYJ/P[::W9:)'!KFH0WU^"V9XX]@()XR,UMT4 <IX;TSQ;9:G>RZ[K
M5M?6DA_T>**#84Y/?/IBEU#3/%LWBVVO+'6[:#1DQYMHT&YF]?FS7544 <YX
MLL/$FH6,4?AO58=.N%?+O+%OW+Z#TJ\UMJQ\/-;+>PKJGD;1=>6=GF8^]MSZ
MUJT4 <]X5L?$6GZ;)%XBU2'4;HR$I)%%LPOH?6JNEZ9XMM_%%U=:CK5M<:.^
M[R;5(-K)SQSGL*ZNB@#E?$.F>+;S6;&?1-;MK*PC(^T020;S)SSSGTXJ]XEL
M]=OM':'0=1AL;[<#Y\D>\8[@"MRB@#)TNVU>#0([?4+V*?4Q$5:Y6/"E\<';
MFL[PIIWBG3UN_P#A(]8M]1+OF'RH=FP?GTKIZ* .472_%H\9&].MVQT+M9>1
M\V,=-V>OO3_%>F^*=0-G_P ([K,&G!&)G$L.\N./_KUU%% &1K%MK%SH,EOI
ME]#;:F44+<O'N4-QD[<_6H_#5IK=EHT<&NZA%?7P)W3QQ[!CMD5MT4 <MX=T
MSQ99ZM?3:YK=M?64G^HAC@V%.?7--U+3/%L_BJUN[#6[:WT=,>;:-!N9O7G-
M=710!SWBNP\1:AIJ1>'-4ATZY#Y>26+?E?0>E7?LVK?V!]G^VP_VIY.W[5Y9
MV>9_>VYZ?C6I10!SOA.P\1:?I\D?B/5(=1N3)E)(HMFU?0^M5]-TSQ9!XLNK
MN_UNVGT9\^5:)!M9?3YL]17544 <KXCTSQ;>ZK93:'K5M8V<9'VB&6#>7YYY
MSTQ6AXCM-;O=$>#0M0BL;\D8GDCWC'? K:HH R-*M=8M] BM]2OHKG4Q&0UR
MD>U2W8[<UG^%=-\4V!NSXBUBWU .^8!%#L*#\^E=/10!RITSQ;_PF8O1K=M_
M87_/EY'S8_WL]?>G^*].\4:@+3_A'-8@T[8^9_-AWEQ^?2NGHH R=3MM7G\/
MR6^GWT4&IF(*MRT>Y0_<[<_6HO#5GKEEHJ0:]J$5]?!CF:*/8,=@1ZUMT4 <
MIX>TSQ;9ZQ>SZWK5M>V,A/D0QP;"G/'.>F/6EU33/%EQXIM+O3M;MK?1TQYU
MJ\&YG]><]ZZJB@#GO%=AXBU#3DB\.:I#IUT'RTDL6_*^@]*NI;ZL- %N]["=
M4\G:;GRSL\S^]MST_&M2B@#G?"=AXCT_3Y(_$>JPZC<%\H\46S:OH?6JVGZ9
MXMA\5W-W>ZW;3Z,V?*M%@PR\<?-FNKHH Y7Q+IGBV^U&RDT'6[:PM8_]?%+!
MO+\^N:T/$=IK=[HLD&AW\5E?DC;/)'O ]<"MJB@#(T6UUFVT&.WU2^ANM2",
M&N4CVJ6YP=N>W%9WA73?%6GR7A\1:S;ZBCMF!8H=A3D]_P JZBB@#E)-+\6M
MXR6]36[9="'WK(P?,1_O9Z^]2^+-.\4:A%:CPYK$&G,CYF\V'?O'YUTU% &3
MJ5MJ\WA^2WL;V*'4S"%6Y:/*A\<G;GUJ#PS9Z]8Z0(=?U&&_O=Q/G11[!CL"
M*W:* .5T#3/%MIKE]/K6MVUYI\A;[/!'!L,?/'.?3BDU?3/%MQXFM+K3=:MK
M;24V^?:O!N9^>><]Q75T4 <_XJL?$-_I:1>'M3AT^[$@+22Q;\KZ#TJW%;:L
MOAY;:6]A?5!!M-T(SL\S'WMN:U:* .;\)Z?XET^RF3Q)JL&HSL^8WBBV;5]#
MZU#8Z9XMB\77%Y>:W;3:*V?+LU@PR\<?-FNJHH Y7Q-IGBR^U"RDT#6K:PMH
MS^_CE@WF3D=\^F:T/$-IK=YH<D&B7\-EJ!QMGDCW@<\X&:VJ* ,C1;76+708
MK?5;Z*ZU(*0]PD>U2>QQGZ5F^%=-\5V$UXWB+6;?4(W(\A8H=ACZY[_2NIHH
M Y673/%K>,TO8];MET(?>LC!\Q&/[V>N>:D\6:=XHU"&W7PWJ]OISHQ,IEAW
MEQV[UTU% &3?6VKR^'I+:TO88=4,.U;DQDH'_O;<U!X8LM>L=(\G7]1AO[W>
M2)8XM@V]@1WK=HH Y30M,\6VFO7MQK&M6UYILA;R+>.#:R<\<Y]*76=,\6W/
MB2SNM*UNVM=*CV^?;20;F?!YYSW%=510!@>*;'Q!?Z6L7A[4H=/NPX+2RQ;\
MKW 'Y59M;;5T\/+;3WL+ZH(-IN1&0ADQ][;GUK6HH YOPGI_B;3[.=/$>K0:
MC,TFZ)HH=FU?0U!9Z9XMC\7S7ESK=M+HC9\NS6##+Z?-GK75T4 <MXGTSQ7?
M7MB^@:U;V%O&?](CE@WF3D=\^F:T/$%IK5WHDD&C7\-GJ)V[;B2/<H]>,ULT
M4 8^@VNLVFAQ6^KWT5WJ(4[[A(]JD]N*SO"VF>*["XO6\0ZU;ZA%(08%B@V%
M/QSTKJ:* .3N-+\7/XPCO8=;MDT,8W61@RQXY^;/7-3^+=.\3ZC;6Z^&]7@T
MV17)E:6'?N'8#TKI:* ,F^MM7ET![>TO88M4,0"W)C)0/Z[<U7\+66OV&E>3
MX@U**_O-Y/FQQ[ %[ CO6]10!RNAZ9XMM?$%[<:OK=M=Z;)GR+>.#:R<\<YI
MNM:9XNNO$5I<Z5K=M::6F//MG@W,_KSFNLHH P?%-EK]_I(A\/:E%I]YO!,L
ML6_*^@]*LVMMJT?A]+:YO8I-4$)5KD1D)OQPVW-:M% '->$]/\3:?;7"^(]6
M@U&5I,Q-%%LV+Z'UJ*VTSQ8GC&6]GUNV?0R#LLQ!AAZ?-GK[UU5% '+>)]-\
M5W]U9/X?UFWT^&-@;A)8=Y?GUSTQ6CKEKK-UH4EOI%_%::B5 6XDCW*#WXSW
MK8HH Q]!M-9M-"BM]8OXKS40"&N(X]H/IQ6=X8TWQ78WEZ_B#6K>_@D.8$B@
MV%.?7/3%=310!RMWIGBV3QC#>6VMVT>AKC?9F#+$=_FSU]ZF\6Z?XFU"U@3P
MWJT&G2J^96EBW[E[ >E=)10!E7-MJS^'WMH+V&/5#"%%R8R4W]VVYZ?C5;PM
M9:_8:3Y/B+4H=0O-Y(EBBV87T/K6]10!RFBZ9XMM?$5Y<ZKK=M=:6^?(MHX-
MK)Z<YI==TSQ;=:_97&CZW;6FFQX\^WD@W%_7G-=510!@^*;+7K_23#X>U*+3
M[S>#YLL>_*]P/2K-C;:M%H"6]W>PRZH(2IN5C(0OV.W/T[UJT4 <UX3T_P 3
MZ?;W*^(]7@U&1GS"8H=A0=P?6H8-+\6KXQDO9M;MGT(YVV0@PP';YL]?>NKH
MH Y?Q1IOBJ_N+)O#VLV^GQ1MF=98-Y?GUSTK0URUUBZT*6WTF^BM-1*@+</'
MN4'OQ6Q10!C:!::U::)'!K-_%>:@ =T\<>U?;(S5#PSIOBNQO;Z37]:M[^WD
M8FWCB@V%.?7/3%=110!ROB#3/%MYK-E/HNM6UE81D?:()(-Y?GGG/3'I5_Q+
M9ZY>Z,T&@ZA%87VX8FECWC'< 5MT4 9.FVVKP^'XK:_OHI]3$15KE8]JE\<'
M;FL[PIIWBC3UNO\ A(]8@U$N^8?*AV;!^?2NGHH Y5=,\6CQF;UM;MCH7:R\
MCYL?[V>OO3O%6F^*;]K0^'=8M]/5&S.)8=Y<?GTKJ** ,C5K;6+C0)+?3;Z*
MVU,Q@+<O'N4-W.W-,\.6FMV6B1P:[J$5]?@G=/''L&.V16U10!ROAS3/%MEJ
ME[-KNM6U]9R'_1XHH-A3GUSTQ1J.F>+9O%EM=V.MVT&BICS;1H,LWK\V>]=5
M10!SOBRP\1ZA81Q^'-4ATZX#Y=Y8M^Y?0>E7C;:M_P (_P#9Q>PC5/)V_:O+
M.SS/[VW/3\:U** .>\*6'B+3]->/Q'JD.HW)?*211;,+Z'UJKIFF>+8/%-U=
MZAK=M<:.^?*M$@VLOISG\ZZNB@#E?$6F>++S5[&;0];MK*RC_P!?#+!O+\^N
M:O\ B:SUR]T9X-!U"*QOBPQ-)'O&.X K;HH R=*MM7M]!CM]1O8;C4Q&0URD
M>U"W8[<_2L_PIIWBC3UN_P#A(M8@U'>^8/*AV%![UTU% '*?V9XM_P"$R-[_
M &W;?V%_SY>1\W_?6>OO4GBO3?%.H"T_X1S6+?3MCYF\V'>7'Y]*Z>B@#(U6
MUUB?0)+?3KZ*WU,Q +<M'N4/CD[<U%X:L]=LM'6'7M0AOK[<29XX]@QV!%;E
M% '*^'=,\6V>L7TVMZW;7MC(3]GAC@V%.>.<],<4FJ:7XNG\4VMWI^MVUOHZ
M;?.M'@W,W//.>IKJZ* .>\5V/B+4--CC\.ZI#IUR) 7DEBW[E]!Z5<6VU8>'
MA;->PG5/(VFZ\L[/,Q][;FM6B@#G/"=AXDT^PDC\2:K#J-PSY1XHMFU?0^M0
M:=IGBV'Q9<WE]K=M/HSY\JT6#:R\<<YKJJ* .4\2:9XMO=3LI="UJVL;2/\
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M_P"!K6XO1-)J%U;B;SU?&PD9  Z?G7D_AKP;J_BWQ--X5AO2EI8RR&1G.5C
M8@L%]2?YT^M@Z7/5=;_:#LQ?Q6F@:>;E6D"&>X.Q3SV'7\Z]KB;?"C'JR@UY
M[X6^#?A7PVT<[V[:A=IR);DY /LHX_.O1% "@ 8% A:***!A1110 4444 %%
M%% !1110!C>(_"VD^*]/^PZQ:B>$-N7D@J?4$=*\[_X9Y\*_:?,^T7OEYSY6
M_P#3/6O7:*+ 8OASPIHWA2R-KH]DENAY=NK.?=CR:VJ** "BBB@ HHHH #7E
MOA/_ )+?XO\ ^N,7]:]2->6^$_\ DM_B_P#ZXQ?UH ]2HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^+_^N,7]: /4J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@!*R]=\2:5X9L?MNKWB6L!.T,V>3Z#%:AZ5YK\9-&TK
M5?#-O-K.K?V=;6L^[S FYGSC@ #.>*3!'/>(/VB=(M=T6B:=->../,G(C3/M
MC)-<)/\ $/XD^-YV@TI+B*-NB6497 SW;O7I?P^^&?@&\TB'5[.VGU)7)"RW
MRE<X[[#Q^.*]4M[2VL81#:6\4$0Z)$@4#\!3L%SYU\._ OQ+J6H1ZCX@O8[7
M,@D<%C)*V#W[?K7TA&NR-5'\( KDM0^(OA[2O%$?AV_FEM[V0J$+Q,$8GI\V
M,5UP.0".E%[AU%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ ->6^$_^2W^+_\ KC%_6O4C7EOA/_DM_B__ *XQ?UH ]2HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7U3#&D,"11C"(H51["A*T;,;=WH24444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 &O+?"?\ R6_Q?_UQB_K7J1KRWPG_ ,EO\7_]<8OZT >I
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*3-&10 M%)N!HW"@!:*3(HS0 M%)D4;A0 M%)G%&X"@!:*3(HS0 M%)N%&:
M%HI-P HW4 +129%&X4 +129%&: %HI-P-&X4 +12;@*,T +129H# T +12;J
M-P% "T4F:,T +12;A1D4 +129HW"@!:*3-&X4 +12;A1F@!:*3(-&10 M%)N
M%&: %HI-PHW"@!:*3=1N% "T4F:,\4 +12;A1N% "T4FX"C(H 6BDS1N% "T
M4F11D"@!:*3-&10 M%)N%&10 M%)G%&: %HI,T;A0 M%)D"C<!0 M%)FC(H
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M$VGRGQ5:V-O=!_W8M')!7WSTJMIUQXR;Q9<IJ%EIJ:#SY,L4A,IXXR/K74A
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MJU#+K'_".K)-;VRZQY&3$'_=>;CIGTS6J5!&*-HH YSPC-XIELICXJM;&WN
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M))I,%M+JWEC;',Y$>[OSZ4SPY+KTNB(_B*WM(-2R=RVS$ICMUZ5L[10% &*
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MEZFO6.FPZ8,_9GMY"7//&?PI-8N/&:>)K1-)LM-ET7Y?/DFD(E']['Z5U>T
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M9:=! #_HS6LA8D9[Y]N]=1M [4@4#- '+7-QXR'C&*.VLM-;P]QOF:0^</7
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M2<^&K:SGORXRETY";>_UJQI\NLMX>C>^@MEU?ROGBC?]WYGIGTK5*@]11M%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH #7EOA/\ Y+?XO_ZXQ?UKU(UY;X3_ .2W^+_^N,7]
M: /4J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%%%% !1110 &O+?"?_);_%__ %QB_K7J1KRWPG_R6_Q?_P!<8OZT >I4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2 O]U.K'WP*RA"522C%7;[#9N45PW_"W/!O_ $$S_P!^S1_PMSP;_P!!,_\
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M\]J^@37EOA/_ )+?XO\ ^N,7]:VHUZM"?/2E9B:3W'?\*-T#_G^O?^^A2?\
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MKS6Y^"7AZ>[GG6YO(Q+(7V*PP,G->F44J&*K8=MT9.-^P-)[GE__  HW0/\
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M1=:;=AC!<1F-]IP<&O/!\#/#X&!>WN/]X5ZC15X?&8C#IJC-QOV!Q3W/+_\
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M"Y(]A-O-,FA2XA>&091U*L/8U)17GE'E_P#PHSP\"=EY>JI.0H8<4?\ "C=
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M110 4444 %%%% !1110 4444 %(5!&" ?K2T4 ,\J/\ N+^5*$0=% ^@IU%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX5(O_08;_OS_ /94?\*D7_H,-_WY_P#LJ/JE7L']M8+^;\&>945Z;_PJ1?\
MH,-_WY_^RH_X5(O_ $&&_P"_/_V5'U2KV#^VL%_-^#/,J*]-_P"%2+_T&&_[
M\_\ V5'_  J1?^@PW_?G_P"RH^J5>P?VU@OYOP9YE17IO_"I%_Z##?\ ?G_[
M*C_A4B_]!AO^_/\ ]E1]4J]@_MK!?S?@SS*BO3?^%2+_ -!AO^_/_P!E1_PJ
M1?\ H,-_WY_^RH^J5>P?VU@OYOP9YE17IO\ PJ1?^@PW_?G_ .RH_P"%2+_T
M&&_[\_\ V5'U2KV#^VL%_-^#/,J*]-_X5(O_ $&&_P"_/_V5'_"I%_Z##?\
M?G_[*CZI5[!_;6"_F_!GF5%>F_\ "I%_Z##?]^?_ +*C_A4B_P#08;_OS_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M***  UY;X3_Y+?XO_P"N,7]:]2->6^$_^2W^+_\ KC%_6@#U*BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ ->6^$_^2W^+_\ KC%_6O4C7EOA/_DM_B__ *XQ?UH ]2HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH #7EOA/_DM_B__ *XQ?UKU(UY;X3_Y+?XO_P"N,7]: /4J
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ****  UY;X3_Y+?XO_P"N,7]:]2->6^$_^2W^+_\ KC%_
M6@#U*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ ->6^$_^2W^+_\ KC%_6O4C7EOA/_DM_B__
M *XQ?UH ]2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %H_X61XS_Z)W>?]_P!:]2HH \M_X61XS_Z)W>?]_P!:/^%D>,_^B=WG_?\
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M .B=WG_?]:/^%D>,_P#HG=Y_W_6O4J* /+?^%D>,_P#HG=Y_W_6C_A9'C/\
MZ)W>?]_UKU*B@#RW_A9'C/\ Z)W>?]_UH_X61XS_ .B=WG_?]:]2HH \M_X6
M1XS_ .B=WG_?]:/^%D>,_P#HG=Y_W_6O4J* /+?^%D>,_P#HG=Y_W_6C_A9'
MC/\ Z)W>?]_UKU*B@#RW_A9'C/\ Z)W>?]_UH_X61XS_ .B=WG_?]:]2HH \
MM_X61XS_ .B=WG_?]:/^%D>,_P#HG=Y_W_6O4J* /+?^%D>,_P#HG=Y_W_6C
M_A9'C/\ Z)W>?]_UKU*B@#RW_A9'C/\ Z)W>?]_UH_X61XS_ .B=WG_?]:]2
MHH \M_X61XS_ .B=WG_?]:/^%D>,_P#HG=Y_W_6O4J* /+?^%D>,_P#HG=Y_
MW_6C_A9'C/\ Z)W>?]_UKU*B@#RW_A9'C/\ Z)W>?]_UH_X61XS_ .B=WG_?
M]:]2HH \M_X61XS_ .B=WG_?]:/^%D>,_P#HG=Y_W_6O4J* /+?^%D>,_P#H
MG=Y_W_6C_A9'C/\ Z)W>?]_UKU*B@#RW_A9'C/\ Z)W>?]_UH_X61XS_ .B=
MWG_?]:]2HH \M_X61XS_ .B=WG_?]:/^%D>,_P#HG=Y_W_6O4J* /+?^%D>,
M_P#HG=Y_W_6C_A9'C/\ Z)W>?]_UKU*B@#RW_A9'C/\ Z)W>?]_UH_X61XS_
M .B=WG_?]:]2HH \M_X61XS_ .B=WG_?]:/^%D>,_P#HG=Y_W_6O4J* /+?^
M%D>,_P#HG=Y_W_6C_A9'C/\ Z)W>?]_UKU*B@#RW_A9'C/\ Z)W>?]_UH_X6
M1XS_ .B=WG_?]:]2HH \M_X61XS_ .B=WG_?]:/^%D>,_P#HG=Y_W_6O4J*
M/+?^%D>,_P#HG=Y_W_6C_A9'C/\ Z)W>?]_UKU*B@#RW_A9'C/\ Z)W>?]_U
MH_X61XS_ .B=WG_?]:]2HH \M_X61XS_ .B=WG_?]:/^%D>,_P#HG=Y_W_6O
M4J* /+?^%D>,_P#HG=Y_W_6C_A9'C/\ Z)W>?]_UKU*B@#RW_A9'C/\ Z)W>
M?]_UH_X61XS_ .B=WG_?]:]2HH \M_X61XS_ .B=WG_?]:/^%D>,_P#HG=Y_
MW_6O4J* /+?^%D>,_P#HG=Y_W_6C_A9'C/\ Z)W>?]_UKU*B@#RW_A9'C/\
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M *)W>?\ ?]:]2HH \M_X61XS_P"B=WG_ '_6C_A9'C/_ *)W>?\ ?]:]2HH
M\M_X61XS_P"B=WG_ '_6C_A9'C/_ *)W>?\ ?]:]2HH \M_X61XS_P"B=WG_
M '_6C_A9'C/_ *)W>?\ ?]:]2HH \M_X61XS_P"B=WG_ '_6C_A9'C/_ *)W
M>?\ ?]:]2HH \M_X61XS_P"B=WG_ '_6C_A9'C/_ *)W>?\ ?]:]2HH \M_X
M61XS_P"B=WG_ '_6C_A9'C/_ *)W>?\ ?]:]2HH \M_X61XS_P"B=WG_ '_6
MC_A9'C/_ *)W>?\ ?]:]2HH \M_X61XS_P"B=WG_ '_6C_A9'C/_ *)W>?\
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M0GN1Z5WP.:7&:0#% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 0W7_'I-_N-_*O./@A_P B
MGJ7_ &%)_P"=>D7(S;2@<DHV!^%>=_!:WFM_"FH">%XRVISD!UQD9ZT >DT4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '/\ CK_D0M>_Z\9?_036;\*?^28:#_U[+6IXVC>7P-KD<:,[M92A549)
M.TUG?"V-XOAIH22(R.+9<JPP10!U]%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!Y=\<?^1:T3_L,V_\ )J]0%>9_
M&NWFN?#FC+!#)*5UB D(I.!AN:],% "T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 -(R>*50%7  'L*6B@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/2D1=H
MP /04ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** &;?88I]%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5FZSK=AH&G/?ZG<"WM4(#2$9QGI6E7G/QO'_%
ML+_(S^]C_P#0J3V&MR]_PMSP/_T'8O\ OEO\*GM/BCX,O9UABU^V#L<#>=H_
M,UXS\(?AMX?\:Z)>W>K+<^;#,$7R9 HQCOP:VOB+\&O#/A[P=>:OILUS#/;
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:*WA7HD:@"K7M2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXVD\$^%!/:[3J%RWE0;N=IQRWX5X_I?@CX@>+] D\4-KTZLZF2*)IF5I .X
M( I7 ^GJ*\-^"WQ#U34]2G\,ZY.9YXU)@DD^^-O53Z]#7N"BJ:$.HHHI#"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!_:6L)9YIK@ /)*>P[8'%=G0[=!(****0PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "J][9PZA936EPF^"9#'(N2,J1@CBK%% '*:#\.?"OAG4/M^D
MZ4D%UM*B0NS$#VR375 4M% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img57592461_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57592461_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *S!$D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_7Q_[P_G7N_:LU?#^CHP9=,M P.01"O!K2KGQ6(5:UEL:X>BZ5[O<XGXH_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS:E=W+)Y16,[B(L,2Q9@,<<"O3J "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** *=_IMC?F&6\M89WMF,D)D0-Y;8QN&>AQWKS?PU+-
M!^S>TMN669-)NF0J<$$&3D5WVOZ;JFIVL<6EZV^DR*V7D2V28N,=,-TK&\(>
M"KKPQI+Z1=:[)JFE>28H[66U2,("26^8<G.3UH P?$%K:)^ST8T1!%'I,,D>
M!P) %8$>^ZK7PR+SZGXLN;GF];4(XY">NU8$VCZ<M4D'PR98H-+N/$E_<>&[
M>59(])>- ,*VY4:3&YE![&K^J^"+F77+K5M!\0W6B7%ZJK>+##'*DVT85L,/
ME8 ]10!RGA70+C4].NY-,EACDT;Q1<SV2RY\ITQM9"1R!\[<@=:KQG_23;7*
M'4;+^V'EEAM@ E_J#MN\I"W'E1 9)/5E]B*]#M?"T>E^$3H&D7L]GE6'VO >
M7<QR[Y/\1R>>Q-,OO!]I+HVF6&GRFP?2I4FLI54/L901\P/WL@G/.3G.<T 7
M]!UR+7K*69();>:WG>VN()<;HI5ZKD<'J#D=0:U*RO#^B+H5E-$;A[FXN9WN
M;F=E"^9*W4X' &  !V %:M  >E5OM,O_ #Z2_F/\:LT4 5OM,O\ SZ2_F/\
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M_P ^DOYC_&C[3+_SZ2_F/\:LT4 5OM,O_/I+^8_QH^TR_P#/I+^8_P :LT4
M5OM,O_/I+^8_QH^TR_\ /I+^8_QJS10!6^TR_P#/I+^8_P :/M,O_/I+^8_Q
MJS10!6^TR_\ /I+^8_QH^TR_\^DOYC_&K-% %;[3+_SZ2_F/\:/M,O\ SZ2_
MF/\ &K-% %;[3+_SZ2_F/\:/M,O_ #Z2_F/\:LT4 5OM,G_/I+^G^-1S:@+=
M=TL$B#U)'^-7:R/$/_'C^#?RJH1YI),F3LKD2ZAI27TE\MM$+N1!&\X"[V09
M(4GK@$GCWJ?^WK7_ "R_XUP=%=WU2/<Y?K,NQWG]O6GK_P"/#_&C^WK3U_\
M'A_C7!T4?5(]P^LR['HD.HBX!,4$C@=P1_C6;J7BVQTFY%O>13I*4#@!<\'/
MO[&I?#?_ !Y?\!7^1KBOB#_R,<?_ %[+_P"A-65&A&=9P>QI5JRC3YT=+_PL
M#1O2Y_[]T?\ "P-&]+G_ +]UY?17?_9]+S./ZY4\CTNX\;^'[NVEMKF&6:"5
M"DD;PY5P>""#U%.B\=Z%;PI##%-'%&H5$2+ 4#H .U>944?V?2\P^N5/(]HL
M-834[-+JUMYFA?(4D =#@]ZL_:9/^?27]/\ &L?P1_R*=K_O2?\ H9KH:\FK
M%1FXKHST:<G*";*WVF7_ )])?S'^-'VF7_GTE_,?XU9HK,LK?:9?^?27\Q_C
M1]IE_P"?27\Q_C5FB@"M]IE_Y])?S'^-'VF7_GTE_,?XU9HH K?:9?\ GTE_
M,?XT?:9?^?27\Q_C5FB@"M]IE_Y])?S'^-!NI "?LLOZ?XU9IK_<;Z4 8UY?
MZ7=F$7EK'*89!-$)0IV..C#/0\]?>IO[>M?\LO\ C7':E_Q^M]!_*JE=ZPL6
MKW.1XB2=K'>?V]:>O_CP_P :/[>M/\L/\:X.BG]4CW%]9EV._CUJ"5PL:,[$
MX !%+?:NNG6<EW<VTRPQXW$8.,D#U]ZY7P__ ,?_ /P)?YUN^,_^13OOHG_H
M:UA*C%58P[FJJMTW(I_\+ T;TN?^_='_  L#1O2Y_P"_=>7T5Z/]GTO,XOKE
M3R/4/^%@:-Z7/_?NJ]MXR\.633M:VKPM/(99C' %\QSU9L=2<#FO-Z*/[/I>
M8?7*GD>MZ=XNL-5N_LUI'.\NTM@IC@?C[UK?:9,_\>LOZ?XUYKX!_P"1G'_7
M!_YBO4Z\[%4HTJG+$[</4=2'-(K?:9?^?27]/\:/M,O_ #Z2_F/\:LT5S&Y6
M^TR_\^DOYC_&C[3+_P ^DOYC_&K-% %;[3+_ ,^DOYC_ !H^TR_\^DOYC_&K
M-% %;[3+_P ^DOYC_&C[3+_SZ2_F/\:LT4 5OM,O_/I+^8_QH^TR_P#/I+^8
M_P :LT4 5OM,O_/I+^8_QH^TR_\ /I+^8_QJS10!6^TR_P#/I+^8_P :/M,O
M_/I+^8_QJS10!6^TR_\ /I+^8_QH^TR_\^DOYC_&K-% %;[3+_SZ2_F/\:/M
M,O\ SZ2_F/\ &K-% %;[3+_SZ2_F/\:/M,O_ #Z2_F/\:LT4 5OM,O\ SZ2_
MF/\ &C[3+_SZ2_F/\:LT4 5OM,O_ #Z2_F/\:/M,O_/I+^8_QJS10!6^TR_\
M^DOYC_&C[3+_ ,^DOYC_ !JS10!76XD9@#:R $]21Q^M6*** "BBB@ HHHH
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MS#-C>F1T;!(S^-3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9Y,74\>]8(XU!8A<C+<C /'6NLKC_'MOX<D@T^?7=9?1IX)BUE?1S"-XWQR
M2".1U!% #/#VLZU:>,+SPMKUU#?2BU6]M;V*$1;XRQ4HR@D9!'4=J-7N9]6^
M)&D:-;S2I;:="VH7OEL5#$_)$C8Z@_,<>PK!\&6T-WXYU#Q#;:K?:EI=K8?9
MO[2O6!$SEM[;, #8HQR!C)-;GP[C?4+?5/%,X/F:U=M+#GJMLGR1#VX&?QH
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M6K;_ )$)#\#KC<#46JZYIGC?Q?X5M/#]W'?I8W37]W-!EDA54(4,>Q);I[4
M>ET444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\_\ K59HH K>;=_\^R?]_/\ ZU'FW?\ S[)_W\_^M5FB@"MYMW_S[)_W\_\
MK4>;=_\ /LG_ '\_^M5FB@"MYMW_ ,^R?]_/_K4>;=_\^R?]_/\ ZU6:* *W
MFW?_ #[)_P!_/_K4>;=_\^R?]_/_ *U6:* *WFW?_/LG_?S_ .M1YMWG_CV3
M_OY_]:K-% %;S;O_ )]D_P"_G_UJ/-N_^?9/^_G_ -:K-% %;S;O_GV3_OY_
M]:CS;O\ Y]D_[^?_ %JLT4 5O-N_^?9/^_G_ -:CS;O_ )]D_P"_G_UJLT4
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M#_R,X_ZX/_,5ZG7BYA_%^1ZF#_A_,K>;=_\ /LG_ '\_^M1YMW_S[)_W\_\
MK59HKA.HK>;=_P#/LG_?S_ZU'FW?_/LG_?S_ .M5FB@"MYMW_P ^R?\ ?S_Z
MU'FW?_/LG_?S_P"M5FB@"MYMW_S[)_W\_P#K4>;=_P#/LG_?S_ZU6:* *WFW
M?_/LG_?S_P"M4<R27"[)["&5>N'8,/U%7:* .:\1E9=$N=+F#6=O<0F)FMR
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M_P!#6N.I_O$?5'3#^#+YGD=%%%>R>8%%%% '3^ ?^1G'_7!_YBO4Z\L\ _\
M(SC_ *X/_,5ZG7BYA_%^1ZF#_A_,****X3J"BBB@ HHHH **** "BBB@#F/%
M7W1]%_F:Y6NJ\5?='T7^9KE:]3#?PT<%?XPHHHK<R%3[Z_45Z)IG_'BGU/\
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M^8KU.O+/ /\ R,X_ZX/_ #%>IUXN8?Q?D>I@_P"'\PHHHKA.H**** "BBB@
MHHHH **** .8\5?='T7^9KE:ZKQ5]T?1?YFN5KU,-_#1P5_C"BBBMS(5/OK]
M17HFF?\ 'BGU/\Z\[3[Z_45Z)IG_ !XI]3_.N/%_"CIPV[/(_$/_ ",>H_\
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M6[5+2]*LM%L5L["'RH58M@L69F)R69B26)/4DYJ[0 =JK>3=?\_?_D,59HH
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M[H[R**Y,2$76!M''EBO%KS/VZXR<GS7Y_$U[A!_J(_\ ='\J\0O?^/\ N?\
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M](X@JUI__']'^/\ (U5JUI__ !_1_C_(U,OA8X[H]$A_U$?^Z/Y5X?>_\?\
M<_\ 79__ $(U[A#_ *B/_='\J\/O?^/^Y_Z[/_Z$:QR[XI&F-VB04445ZIP!
M3H_]:G^\*;3H_P#6I_O"@#WBBBBOESW@HHHH **** "BBB@ HHHH *R/$/\
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M***]<\X**** .RT&(RV0Q+(F%7[AZ]:XSQ[&8_$$:EV?_1UY8\_>:NX\-_\
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M?J?_ +Z'^%6:* *WV1O^?J?\Q_A1]D;_ )^I_P#OH?X59HH K?9&_P"?J?\
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M* "N'\1_\?O_  )OYBNXKA_$?_'[_P "?^8KIPOQF&(^$QJ***](X@JUI_\
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M$EP\:!6FEQND('+''&34] !112;E_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O\
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M0 4444 %%%% !1110 4444 %%%% !69XA;68]#N7\/QVTNJ+M,,=T2(WPPW
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MV&U_YX)Z=*L44 5_L-K_ ,\$_*C[#:_\\$_*K%% %?[#:_\ /!/3I1]AM?\
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M@EM%=XE9LGDCWK@$^^OU%>B:9_QXI]3_ #KCQ>R.G#;L\BU]0GB'4%48 N'
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M<[XC0EC\COR%4\@'H,4 >N=>E%4M(_LX:1:KI+P-IZ1A8#;L&38.!@C@U=H
M**.E0_:K?_GO%_WV* )J*A^U6_\ SWC_ .^Q2_:K?_GO'_WV* ):*A^U6_\
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M?M5O_P ]X_\ OL4?:K?_ )[Q?]]B@":BH?M5O_SWB_[[%'VJW_Y[Q?\ ?8H
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M]JM_^>\?_?8I?M5O_P ]X_\ OL4 2T5#]JM_^>\7_?8I?M5O_P ]X_\ OL4
M2T5#]JM_^>\7_?8H^U6__/>/_OL4 345#]JM_P#GO%_WV*/M5O\ \]X_^^Q0
M!SWBK[OX+_,URM=1XGD21-R.K#"\@Y[FN7KU,-_#1P5_C"BBBMS(5/OK]17H
MFF?\>*?4_P Z\[3[Z_45Z!IT\,=FJO*BG)X+ =ZX\7LCIPV[/)_$/_(QZC_U
M\/\ SK-K2\0,&\0ZBRD$&X?!'UK-KUJ?P+T/.G\3"BBBK)$/W3]*]RT[_D&6
MO_7%/Y"O#3T->VZ?<VXTVU!GC!\E/XAZ"O-S+X8_,[L%NR]14/VJW_Y[Q_\
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M3'_SS3_OD4>3'_SS3_OD4^B@!GDQ_P#/-/\ OD4>3'_SS3_OD4^B@!GDQ?\
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M.F'\&7S/(Z***]D\P**** .F\!JK>)@&4$>0_4>XKU'R8O\ GFG_ 'R*\O\
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M^7IG\>U=W;V_Q$'@(1RWFFGQ/YV?-=!Y?E[NF  ,X]JP_LOQI_Z".@?]^O\
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M $,UT-<]X(_Y%.U_WI/_ $,UT-?.XC^++U9[5'^''T"BBBL30**** "BBB@
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M?#_SK-KUJ?P+T/.G\3"BBBK)$/W3]*]RT[_D&6O_ %Q3^0KPT_=/TKW+3O\
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M4 6:*K?;[;_GH?\ OD_X4?;[;_GH?^^3_A0!9IK_ '&^AJ#[?;?\]#_WR?\
M"D:^MBC#S.W]T_X4 <'J7_'ZWT'\JJ5;U+_C];Z#^55*]F'PH\R6["BBBJ$:
MWA__ (_Q_O+_ #K=\9_\BG??1/\ T-:P= 8+>EB< %2?SK7\7WD$OA:]1'RQ
MV8&#_?6N.I_O$?5'3#^#+YGE5%%%>R>8%%%% '3^ ?\ D9Q_UP?^8KU.O*?
MTJ0^) [G"^0XSC/I7IOV^V_YZ_\ CI_PKQ<P_B_(]3!_P_F6:*K?;[;_ )Z?
M^.G_  H^WVW_ #T_\=/^%<)U%FBJWV^V_P">G_CI_P */M]M_P ]/_'3_A0!
M9HJM]OMO^>O_ (Z?\*/M]M_ST_\ '3_A0!9HJM]OMO\ GK_XZ?\ "C[?;?\
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M 4444 %%%% !1110 4444 8OBG5-4T?0Y+O1])?5;P.JK;*VTD$\G/M7"?\
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M_P!#6N.I_O$?5'3#^#+YGD=%%%>R>8%%%% '3^ ?^1G'_7!_YBO4Z\L\ _\
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M_B/_ (_?^!-_2NXKA_$?_'[_ ,";^E=.%^,PQ'P&-1117I'$%6M/_P"/Z/\
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MZN\N)YFMI0;5U!0Y.X<<5P=]_P ?TW^]7;@^IRXGH5Z***[CE"M[PQ_Q]_\
M A_(U@UN>'&*W!*H7(884=^#65;^&S2E\:+?Q!_Y%M?^OA/Y&O+Z]*\>2R/X
M>4/ T8\].20>QKS6M<!_!^9GC/X@4445VG*%=E\.?^0M>?\ 7 ?^A5QM=?\
M#YW35;LI$9#Y X! Q\U<^+_@R-L/_%1Z715;[1/_ ,^C_P#?0H^T3_\ /H__
M 'T*^?/8+-%5OM$__/H__?0H^T3_ //H_P#WT* +-%5OM$__ #Z/_P!]"C[1
M/_SZ/_WT* +-%5OM$_\ SZ/_ -]"C[1/_P ^C_\ ?0H LT56^T3_ //H_P#W
MT*/M$_\ SZ/_ -]"@"S7#^(_^/W_ ($W]*Z_[1/_ ,^C_P#?0KC_ !"2UV"5
MVDLV0>W2NG"_&88CX#'HHHKTCB"K6G_\?T?X_P C56K6G_\ ']'^/\C4R^%C
MCNCT2'_41_[H_E7A][_Q_P!S_P!=G_\ 0C7L\4\PB0"U<C:.=PKQ>\YOK@D8
M_>OQ^)K'+OBD:8W:)#1117JG %.C_P!:G^\*;3D_UB?[PH ]XHJM]HG_ .?1
M_P#OH4?:)_\ GT?_ +Z%?+GO%FBJWVB?_GT?_OH4?:)_^?1_^^A0!9HJM]HG
M_P"?1_\ OH4?:)_^?1_^^A0!9HJM]HG_ .?1_P#OH4?:)_\ GT?_ +Z% %FB
MJWVB?_GT?_OH4?:)_P#GT?\ [Z% %FLCQ#_QX_@W\JO?:)_^?1_^^A69K<DD
MEDP>%H\*W)(.>*TI?&B*GPLXJBBBO7/."BBB@#M_#?\ QY?\!7^M<5\0?^1C
MC_Z]E_\ 0FKL-!D>.R&R%I,JN<$#'YUQGCUV?Q!&7C,9^SKP3G^)JY<+_O+-
MZ_\  1R]%%%>N><%%%% 'K/@C_D4[7_>D_\ 0S70UR_@R:5/"UJ%MV<;I/F#
M#GYS6_\ :)_^?1_^^A7SN(_BR]6>U1_AQ]"S15;[1/\ \^C_ /?0H^T3_P#/
MH_\ WT*Q-"S15;[1/_SZ/_WT*/M$_P#SZ/\ ]]"@"S15;[1/_P ^C_\ ?0H^
MT3_\^C_]]"@"S15;[1/_ ,^C_P#?0H^T3_\ /H__ 'T* +--?[C?0U!]HG_Y
M]'_[Z%(UQ,4.;1QQ_>% '!ZE_P ?K?0?RJI5O4O^/YOH/Y54KV8?"CS);L**
M**H1K>'_ /C_ !]5_G6[XS_Y%.^^B?\ H:U@Z"2+TD D@K@#OS6OXOFE;PM>
MJULZ [/F+#CYUKCJ?[Q'U1TP_@R^9Y51117LGF!1110!T_@'_D9Q_P!<'_F*
M]3KRGP,[)XD!2,N?(?@''I7IOVB?_GT?_OH5XN8?Q?D>I@_X?S+-%5OM$_\
MSZ/_ -]"C[1/_P ^C_\ ?0KA.HLT56^T3_\ /H__ 'T*/M$__/H__?0H LT5
M6^T3_P#/H_\ WT*/M$__ #Z/_P!]"@"S15;[1/\ \^C_ /?0H^T3_P#/H_\
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M%/Y"O#3]T_2O<M._Y!EK_P!<4_D*\W,OAC\SNP6[+-%%%>2>@%%%% !1110
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M7I7CQKAO#R^;$BKYZ<AL]C7FM:X#^#\R,9_$"BBBNTY0KLOAS_R%KS_K@/\
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M_P#K4>9>?\\(_P#OY_\ 6H LT56\R\_YX1_]_/\ ZU'F7G_/"/\ [^?_ %J
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M%% !1110 4444 %%%% !1110 4444 %1W$(N+:6%F=!(A0LAPPR,9![&I**
M.#T[X5Z?I-O';V'B+Q-;VZ-N6&/42J9)R> O<UL^(/!>F^(;RWOI+B_LK^!#
M$EY87+0RE#R4+#J,\XKHZ* ,"V\'Z99>&9M!M&NH+:?<9I4F/G2LWWV9SDEF
M[G\L5/J'AG3M0TNTL CVD=DZ/:/:D(UNRC *<8Z9&"",&MBB@#/T;1K70[$V
MML97WR-+++,VZ261CEG8]R:T*** "BBB@ HHHH **** (;K_ (])O]QOY5YY
M??\ ']-_O5Z'=?\ 'I-_N-_*O/+[_C^F_P!ZNW!]3EQ/0KT445W'*%;WAC_C
M[_X$/Y&L&M[PQ_Q]_P# A_(UE6_ALNE\:+/Q!_Y%M?\ KX3^1KR^O4/B#_R+
M:_\ 7PG\C7E]:X#^#\R,7_$"BBBNTY0KLOAS_P A:\_ZX#_T*N-KLOAS_P A
M:\_ZX#_T*N?%_P &1MA_XJ/2****^?/8"BBB@ HHHH **** "BBB@ KB/$?_
M !^_\";^E=O7#^(_^/W_ ($W]*Z<+\9AB/A,:BBBO2.(*M:?_P ?T?X_R-5:
MM:?_ ,?T?X_R-3+X6..Z/1(?]1'_ +H_E7A][_Q_W/\ UV?_ -"->X0_ZB/_
M '1_*O#[W_C_ +G_ *[/_P"A&L<N^*1IC=HD%%%%>J< 4Z/_ %J?[PIM.C_U
MJ?[PH ]XHHHKY<]X**** "BBB@ HHHH **** "LCQ#_QX_@W\JUZR/$/_'C^
M#?RK2E\:(J?"SA:***]<\X**** .W\-_\>7_  !?ZUQ7Q!_Y&./_ *]E_P#0
MFKM?#?\ QY?\!7^M<5\0?^1CC_Z]E_\ 0FKEPO\ O+-Z_P# 1RE%%%>N><%%
M%% 'K/@C_D4[7_>D_P#0S70USW@C_D4[7_>D_P#0S70U\[B/XLO5GM4?X<?0
M****Q- HHHH **** "BBB@ IK_<;Z4ZFO]QOH: /.]2_X_6^@_E52K>I?\?K
M?0?RJI7LP^%'F2W844450C6\/_\ '^/JO\ZW?&?_ "*=]]$_]#6L+P__ ,?X
M^J_SK=\9_P#(IWWT3_T-:XZG^\1]4=,/X,OF>1T445[)Y@4444 =/X!_Y&<?
M]<'_ )BO4Z\L\ _\C./^N#_S%>IUXN8?Q?D>I@_X?S"BBBN$Z@HHHH ****
M"BBB@ HHHH YCQ5]W\%_F:Y6NJ\5?='T7^9KE:]3#?PT<%?XPHHHK<R%3[Z_
M45Z)IG_'BOU/\Z\[3[Z_45Z)IG_'BGU/\ZX\7\*.G#;L\C\0_P#(QZC_ -?#
M_P ZS:TO$/\ R,>H_P#7P_\ .LVO6I_ O0\Z?Q,****LD0_=/TKW+3O^09:_
M]<4_D*\-/W3]*]RT[_D&6O\ UQ3^0KS<R^&/S.[!;LLT445Y)Z 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC,,1\)C4445Z1Q!5K3_^/Z/\?Y&JM6M/_P"/Z/\ '^1J9?"QQW1Z)#_J(_\
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MUH\BY_Y^S_W[% %FBJWD7/\ S]G_ +]BCR+G_G[/_?L4 6:*K>1<_P#/V?\
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M^%G"T445ZYYP4444 =OX;_X\O^ K_6N*^(/_ ",<?_7LO_H35VOAO_CR_P"
MK_6N*^(/_(QQ_P#7LO\ Z$U<N%_WEF]?^ CE****]<\X**** /6?!'_(IVO^
M])_Z&:Z&N>\$?\BG:_[TG_H9KH:^=Q'\67JSVJ/\./H%%%%8F@4444 %%%%
M!1110 4U_N-]#3J:_P!QOH: /.]2_P"/UOH/Y54JWJ7_ !^M]!_*JE>S#X4>
M9+=A1115"-;P_P#\?X^J_P ZW?&?_(IWWT3_ -#6L+P__P ?X^J_SK=\9_\
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M"UY_UP'_ *%7&UV7PY_Y"UY_UP'_ *%7/B_X,C;#_P 5'I%%%%?/GL!1110
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M!9HJM]C/_/S<?]]T?9#_ ,_-Q_WW0!9HJM]D/_/S<?\ ?='V0_\ /S<?]]T
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M^%)_PCNG_P#//]!_A7='%Q2M8Y'AVW>YP=%=Y_PCNG_\\_T'^%'_  CNG_\
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M%$S@.X')VCJ<>U %BBJ>E:I9:WID&HZ=.)[2<$QR!2-P!(Z$ ]0:MDA5+,0
M.23VH 6BJ%CK>DZG-)#I^J65W+%_K$M[A)&3Z@$XJ_0 4444 %%%% !1110
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M=.U>PO&C +BWN4D*@]"=I.*FL=3LM2$_V2<2^1,\$F 1M=?O#GTS0!;HHHH
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M;>"ZWWJO))F2+:1M'7O@]NG6@#TJBFQQI#$D<:A40!5 [ 4Z@ HHHH ****
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MK;PI-8V6CVG]N:I<JEDT<0\]YV<,6W_>P.23G %>DV44L-C;Q3OYDJ1JKO\
MWF Y-><Q>'_'T'BV_P!>DMO#M]<2,8[1[BZF7[-!GA%4)@9ZD]2:]&LC=-90
M&^6%+HH/-6%B4#8YVD@$C/K0!/1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY++<BZM(XXT592(R&89W+W- 'K%A=K?Z=;7B(R+/$LH5NH# '!_.K%<-\/O
MVE^'+"VU6QGOI+B[LH]ZW%P709 ;@=N:\R\(:;X=\7WFHQ>.M6OH/%WVIT,4
MMVT!B&?E$0Z?0<^PH ^AJ*JZ;9_V=IEM9?:)KCR(EC\Z9MSO@8RQ[FK5 !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5@^+?$-QX8T7^TX-)N=35)56:*V&71#G+X[XX_.MZB@#QSQ+\7= \
M2^&;[1=%T[4M1U*^A:".T^RG()XRW7IUXS4^H^"]3L/V>&\/F-YM1AM_-:*/
MYCN\S>5'KC./PKUL* 20 ">3[TM 'G_PU\?Z3XETRQTBT6Z%_:6*?:5>$A8R
MH"D;OKTKC/#GB6W^%GC#Q3I?B.VO(X;^]:[LKB*(NLJDD@#WP1^.:]R  )(
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>26
<FILENAME>avir-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-02-28T16:23:42.5683+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.ateapharma.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:avir="http://www.ateapharma.com/20231231" xmlns:srt="http://fasb.org/srt/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails2" id="DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails2">
        <link:definition>100020 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments under Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusiness" id="Role_DisclosureNatureOfBusiness">
        <link:definition>100080 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCollaborationRevenue" id="Role_DisclosureCollaborationRevenue">
        <link:definition>100100 - Disclosure - Collaboration Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100110 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecurities" id="DisclosureMarketableSecurities">
        <link:definition>100120 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100130 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100140 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100150 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStock" id="DisclosurePreferredStock">
        <link:definition>100160 - Disclosure - Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100170 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100180 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100190 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>100200 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlan" id="Role_DisclosureBenefitPlan">
        <link:definition>100210 - Disclosure - Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100220 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100230 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100240 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100250 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
        <link:definition>100260 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100270 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100280 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100290 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>100300 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100310 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100320 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>100330 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Nature of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails">
        <link:definition>100360 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" id="DisclosureCollaborationAgreementAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Collaboration Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100380 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" id="DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
        <link:definition>100390 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" id="DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>100410 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100430 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAssetsAndLiabilitiesRecordedOnConsolidatedBalanceSheetDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfAssetsAndLiabilitiesRecordedOnConsolidatedBalanceSheetDetails">
        <link:definition>100440 - Disclosure - Commitments and Contingencies - Summary of Assets and Liabilities Recorded on Consolidated Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseCostsDetails" id="Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseCostsDetails">
        <link:definition>100450 - Disclosure - Commitments and Contingencies - Components of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfRemainingLeaseTermAndDiscountRateDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfRemainingLeaseTermAndDiscountRateDetails">
        <link:definition>100460 - Disclosure - Commitments and Contingencies - Summary of Remaining Lease Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails">
        <link:definition>100480 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments under Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails" id="DisclosurePreferredStockAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails" id="Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails">
        <link:definition>100510 - Disclosure - Common Stock - Summary of Reserved Shares of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails">
        <link:definition>100530 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails">
        <link:definition>100540 - Disclosure - Stock-based Compensation - Summary of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails" id="Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails">
        <link:definition>100550 - Disclosure - Stock-based Compensation - Summary of Assumptions Used to Estimate Fair Value of Award (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>100560 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails">
        <link:definition>100570 - Disclosure - Stock-based Compensation - Summary of Components of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" id="Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
        <link:definition>100590 - Disclosure - Income Taxes - Summary of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails">
        <link:definition>100600 - Disclosure - Income Taxes - Summary of Principal Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails">
        <link:definition>100610 - Disclosure - Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails" id="DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails">
        <link:definition>100620 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" id="DisclosureNetLossPerShareAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Net Loss Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlanAdditionalInformationDetails" id="Role_DisclosureBenefitPlanAdditionalInformationDetails">
        <link:definition>100640 - Disclosure - Benefit Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="avir-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="avir-20231231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="avir-20231231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="avir-20231231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="avir-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="avir-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="avir-20231231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusiness" xlink:href="avir-20231231.xsd#Role_DisclosureNatureOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="avir-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCollaborationRevenue" xlink:href="avir-20231231.xsd#Role_DisclosureCollaborationRevenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="avir-20231231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecurities" xlink:href="avir-20231231.xsd#DisclosureMarketableSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="avir-20231231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="avir-20231231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="avir-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStock" xlink:href="avir-20231231.xsd#DisclosurePreferredStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="avir-20231231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="avir-20231231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="avir-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="avir-20231231.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlan" xlink:href="avir-20231231.xsd#Role_DisclosureBenefitPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="avir-20231231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="avir-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="avir-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="avir-20231231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="avir-20231231.xsd#DisclosureMarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="avir-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="avir-20231231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="avir-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:href="avir-20231231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="avir-20231231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="avir-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="avir-20231231.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" xlink:href="avir-20231231.xsd#Role_DisclosureNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="avir-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails" xlink:href="avir-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:href="avir-20231231.xsd#DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="avir-20231231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:href="avir-20231231.xsd#DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="avir-20231231.xsd#DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="avir-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="avir-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="avir-20231231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAssetsAndLiabilitiesRecordedOnConsolidatedBalanceSheetDetails" xlink:href="avir-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfAssetsAndLiabilitiesRecordedOnConsolidatedBalanceSheetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseCostsDetails" xlink:href="avir-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseCostsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfRemainingLeaseTermAndDiscountRateDetails" xlink:href="avir-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfRemainingLeaseTermAndDiscountRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="avir-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails" xlink:href="avir-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails" xlink:href="avir-20231231.xsd#DisclosurePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:href="avir-20231231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails" xlink:href="avir-20231231.xsd#Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="avir-20231231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails" xlink:href="avir-20231231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" xlink:href="avir-20231231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails" xlink:href="avir-20231231.xsd#Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="avir-20231231.xsd#Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails" xlink:href="avir-20231231.xsd#Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="avir-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="avir-20231231.xsd#Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails" xlink:href="avir-20231231.xsd#Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:href="avir-20231231.xsd#DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails" xlink:href="avir-20231231.xsd#DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:href="avir-20231231.xsd#DisclosureNetLossPerShareAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlanAdditionalInformationDetails" xlink:href="avir-20231231.xsd#Role_DisclosureBenefitPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="avir-20231231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails2" xlink:href="avir-20231231.xsd#DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_IncomeTaxDisclosureLineItems" xlink:label="avir_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NatureOfBusinessLineItems" xlink:label="avir_NatureOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ResearchAndDevelopmentTaxCreditsMember" xlink:label="avir_ResearchAndDevelopmentTaxCreditsMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ConsultingServicesMember" xlink:label="avir_ConsultingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DocumentDocumentAndEntityInformationAbstract" xlink:label="avir_DocumentDocumentAndEntityInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" xlink:label="avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SeriesDOneConvertiblePreferredStockMember" xlink:label="avir_SeriesDOneConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OutstandingOptionsMember" xlink:label="avir_OutstandingOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortizationMethod" xlink:label="us-gaap_CapitalizedContractCostAmortizationMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_RocheLicenseMember" xlink:label="avir_RocheLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:label="us-gaap_AccountingStandardsUpdate201711Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccruedExpenseAndOtherCurrentLiabilitiesMember" xlink:label="avir_AccruedExpenseAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PaymentOfTerminationFeeForTerminationOfAgreement" xlink:label="avir_PaymentOfTerminationFeeForTerminationOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PerformanceBasedRestrictedStockUnitsMember" xlink:label="avir_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PriorOfficeSpaceMember" xlink:label="avir_PriorOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest" xlink:label="avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_FairValueAssetsMeasuredOnRecurringBasisAbstract" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OfficeSpaceMember" xlink:label="avir_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesMember" xlink:label="us-gaap_OtherLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NonRefundableUpfrontPaymentAccruedMember" xlink:label="avir_NonRefundableUpfrontPaymentAccruedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_MerckLicenseAgreementMember" xlink:label="avir_MerckLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_LaboratoryEquipmentMember" xlink:label="avir_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock" xlink:label="avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_RelatedPartyTransactionEntityControlledByDirectorNumber" xlink:label="avir_RelatedPartyTransactionEntityControlledByDirectorNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_MilestonePayments" xlink:label="avir_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_StockIssuanceProgramAuthorizedAmount" xlink:label="avir_StockIssuanceProgramAuthorizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DevelopmentAndRegulatoryMilestonesMember" xlink:label="avir_DevelopmentAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_RestrictedCommonStockMember" xlink:label="avir_RestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SalesBasedMember" xlink:label="avir_SalesBasedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SECFilingStatusPolicyTextBlock" xlink:label="avir_SECFilingStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_BusinessDevelopmentConsultingAgreementsMember" xlink:label="avir_BusinessDevelopmentConsultingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock" xlink:label="avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent" xlink:label="avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NovaMedicaLLCMember" xlink:label="avir_NovaMedicaLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccountingPoliciesLineItems" xlink:label="avir_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DevelopmentRegulatoryAndCommercialMember" xlink:label="avir_DevelopmentRegulatoryAndCommercialMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NatureOfBusinessTable" xlink:label="avir_NatureOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainageDeposit" xlink:label="us-gaap_RetainageDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember" xlink:label="avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_LeaseCommencementDate" xlink:label="avir_LeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OutstandingRestrictedStockUnitsMember" xlink:label="avir_OutstandingRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate" xlink:label="avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_LocationOfOfficeSpace" xlink:label="avir_LocationOfOfficeSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NonRefundableUpfrontPaymentPaidLicenseAgreement" xlink:label="avir_NonRefundableUpfrontPaymentPaidLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_FairValueAssetsMeasuredOnRecurringBasisTable" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ConsultingAgreementMember" xlink:label="avir_ConsultingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_EmployeeStockPurchasePlanMember" xlink:label="avir_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_UtilizedOperatingLossCarryforward" xlink:label="avir_UtilizedOperatingLossCarryforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_FairValueAssetsMeasuredOnRecurringBasisLineItems" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_RocheLicenseAgreementMember" xlink:label="avir_RocheLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax" xlink:label="avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DeferredTaxAssetsPrepaidExpenses" xlink:label="avir_DeferredTaxAssetsPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SeriesDConvertiblePreferredStockMember" xlink:label="avir_SeriesDConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_JefferiesLlcMember" xlink:label="avir_JefferiesLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SharesReservedUnderEmployeeStockPurchasePlanMember" xlink:label="avir_SharesReservedUnderEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_TwoThousandTwentyIncentiveAwardPlanMember" xlink:label="avir_TwoThousandTwentyIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DeferredTaxAssetsLicenseAgreement" xlink:label="avir_DeferredTaxAssetsLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock" xlink:label="avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_IncomeTaxDisclosureTable" xlink:label="avir_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NatureOfBusinessAbstract" xlink:label="avir_NatureOfBusinessAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SeriesABCDAndD1ConvertiblePreferredStockMember" xlink:label="avir_SeriesABCDAndD1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_IncrementalCostMember" xlink:label="avir_IncrementalCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_FormerChiefFinancialOfficerMember" xlink:label="avir_FormerChiefFinancialOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SeriesD1PreferredStockMember" xlink:label="avir_SeriesD1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_LeaseExpirationMonthAndYear" xlink:label="avir_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ConsultingAgreementSuccessFeePayout" xlink:label="avir_ConsultingAgreementSuccessFeePayout"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:label="avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts" xlink:label="avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OpenMarketSaleAgreementMember" xlink:label="avir_OpenMarketSaleAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccountingPoliciesTable" xlink:label="avir_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ResearchAndDevelopmentCostsAmortizationPeriod" xlink:label="avir_ResearchAndDevelopmentCostsAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_FromTwoThousandThirteenIncentivePlanMember" xlink:label="avir_FromTwoThousandThirteenIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_BankDepositRestrictedCash" xlink:label="avir_BankDepositRestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ResearchAndDevelopmentCreditAdjustment" xlink:label="avir_ResearchAndDevelopmentCreditAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_EntityControlledByDirectorMember" xlink:label="avir_EntityControlledByDirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_CommonStockTextBlock" xlink:label="avir_CommonStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_TaxCreditCarryforwardExpirationYear" xlink:label="avir_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_UpfrontPaymentReceived" xlink:label="avir_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SalesBasedMilestoneMember" xlink:label="avir_SalesBasedMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_CommissionRate" xlink:label="avir_CommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards" xlink:label="avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccruedLicenseFeesCurrent" xlink:label="avir_AccruedLicenseFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201901Member" xlink:label="us-gaap_AccountingStandardsUpdate201901Member"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OtherAssetsPolicyTextBlock" xlink:label="avir_OtherAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_CostsReimbursedAmount" xlink:label="avir_CostsReimbursedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccruedProfessionalFeesAndOtherCurrent" xlink:label="avir_AccruedProfessionalFeesAndOtherCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_MilestonePaymentReceived" xlink:label="avir_MilestonePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OperatingLossCarryforwardsExpirationYear" xlink:label="avir_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OutstandingPerformanceBasedRestrictedStockUnitsMember" xlink:label="avir_OutstandingPerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_StockIssuanceCosts" xlink:label="avir_StockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OfficeFacilityMember" xlink:label="avir_OfficeFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (years), Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Benefit Plan Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NatureOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NatureOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NatureOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ResearchAndDevelopmentTaxCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Tax Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ResearchAndDevelopmentTaxCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ResearchAndDevelopmentTaxCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ConsultingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ConsultingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ConsultingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting Services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Released</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Option Released In Period Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were released during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DocumentDocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document - Document and Entity Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DocumentDocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Document And Entity Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DocumentDocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Document Document And Entity Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Uncertain Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to uncertain tax positions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Stock-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of annual installments in which a share-based payment award vests.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Vesting Number Of Installments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of installments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SeriesDOneConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D-1 Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SeriesDOneConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D One Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SeriesDOneConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D-1 convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OutstandingOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OutstandingOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OutstandingOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortizationMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition method for costs of obtaining a contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortizationMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Amortization Method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering, net of issuance costs of $3,245</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value per option granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets and Liabilities Recorded on Consolidated Balance Sheet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Disclosure Of Balance Sheet Information Related To Leases Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of balance sheet information related to leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, capital shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accummulated Other Comprehensive Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax examination description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_RocheLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roche License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_RocheLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Roche License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_RocheLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Roche license.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201711Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2017-11 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201711Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2017-11</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccruedExpenseAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccruedExpenseAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expense And Other Current Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccruedExpenseAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected income tax benefit at the federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_PaymentOfTerminationFeeForTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for termination fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_PaymentOfTerminationFeeForTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Termination Fee For Termination Of Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_PaymentOfTerminationFeeForTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of termination fee paid by the Company during the period, upon termination of an agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance based restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_PriorOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prior office space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_PriorOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prior Office Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_PriorOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior Office Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of shares of new stock classified as temporary equity issued during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income (loss) before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase in unrecognized tax benefits resulting from accrued interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting from Accrued Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to accrued interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets measured on recurring basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NonRefundableUpfrontPaymentAccruedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable Upfront Payment Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NonRefundableUpfrontPaymentAccruedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payment Accrued [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NonRefundableUpfrontPaymentAccruedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable upfront payment accrued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_MerckLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merck License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_MerckLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Merck License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_MerckLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Merck license agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process Research and Development Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development Assets [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets, not acquired in a business combination, to be used in research and development activities. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_RelatedPartyTransactionEntityControlledByDirectorNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of company directors in control of related party entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_RelatedPartyTransactionEntityControlledByDirectorNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Entity Controlled By Director Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_RelatedPartyTransactionEntityControlledByDirectorNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of Company directors in control of a related party entity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount due upon achievement of specified milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset-Backed Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset-backed securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_StockIssuanceProgramAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of shares authorized to be issued under a stock issuance program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_StockIssuanceProgramAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Program Authorized Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_StockIssuanceProgramAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained Earnings (Accumulated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Unvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under ESPP, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Regulatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development And Regulatory Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock for exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government agency securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan recognized expense related to matching contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock into common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Remaining Lease Term and Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Remaining Lease Term And Discount Rate Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of information related to leases including, but not limited to, the remaining lease term and discount rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_RestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_RestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_RestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, capital shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 300,000,000 shares authorized; 83,435,513 and 83,287,639 shares issued and outstanding as of December 31, 2023 and 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (years), Vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income (loss) from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-12 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-12</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax benefit (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Benefit from income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SalesBasedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Based</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SalesBasedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Based [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SalesBasedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales based.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SECFilingStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEC Filing Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SECFilingStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">S E C Filing Status Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SECFilingStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy pertaining to SEC filing status.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares of common stock Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The maximum increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year, as a percentage of shares outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_BusinessDevelopmentConsultingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Development Consulting Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_BusinessDevelopmentConsultingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Development Consulting Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_BusinessDevelopmentConsultingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business development consulting agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon vesting of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon release of restricted stock units (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and restricted cash at the end of period:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and Significant Suppliers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentrations Of Credit Risk And Significant Suppliers Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for credit risk and risk associated with reliance on significant suppliers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development, including manufacturing and clinical expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research and Development Expense including Manufacturing and Clinical Expenditures Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred and payable for research and development, including, but not limited to, manufacturing and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from License Fees Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NovaMedicaLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NovaMedica LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NovaMedicaLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nova Medica L L C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NovaMedicaLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NovaMedica LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate grant date fair market value of restricted stock units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate grant date fair value of equity instruments other than options granted during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Aggregate Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series D Preferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DevelopmentRegulatoryAndCommercialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Regulatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DevelopmentRegulatoryAndCommercialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Regulatory And Commercial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DevelopmentRegulatoryAndCommercialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development, regulatory and commercial.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NatureOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NatureOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NatureOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment Estimated Useful Life Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of estimated useful lives of physical assets used in the normal conduct of business and not intended for resale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainageDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual retainer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainageDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retainage deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Payments under Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved for future grant under two thousand twenty incentive award plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Reserved for Future Grant Under Two Thousand Twenty Incentive Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for future grant under 2020 Incentive Award Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Date which lease or group of leases is set to commence, in YYYY-MM-DD format.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OutstandingRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OutstandingRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OutstandingRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (see Note 8)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation in connection with vesting of restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement, Percentage of Purchase Price Lesser of Market Price, on Offering Date or Purchase Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock purchase price, lesser of market value per share on offering or purchase date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The purchase price of common stock, as a percentage of the lessor of the fair market value per share of the common stock on the first business day of an offering period or on the purchase date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">All Award Types</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_LocationOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Location of Office Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_LocationOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Location of Office Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_LocationOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Location of office space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting service period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NonRefundableUpfrontPaymentPaidLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront payment paid license agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NonRefundableUpfrontPaymentPaidLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payment Paid License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NonRefundableUpfrontPaymentPaidLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of upfront payment paid as part of a licensing agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer matching contribution, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of held securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for exercise of stock options , shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less amount representing implied interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less amount representing implied interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets Measured On Recurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of information about assets at fair value on recurring basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unbilled accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_UtilizedOperatingLossCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Utilized operating loss tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_UtilizedOperatingLossCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Utilized Operating Loss Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_UtilizedOperatingLossCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of operating loss carryforward utilized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assumptions, method used</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Method Used</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets Measured On Recurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining weighted average period for recognize compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (years), Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable debt securities, charges for credit-related impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_RocheLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roche License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_RocheLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Roche License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_RocheLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Roche license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Additional Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of annual limit on use of net operating losses and other tax attributes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Annual Limit On Use Of Net Operating Losses And Other Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of annual limit on use of net operating losses and other tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DeferredTaxAssetsPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DeferredTaxAssetsPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Prepaid Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DeferredTaxAssetsPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from prepaid expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SeriesDConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SeriesDConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SeriesDConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Incremental cost included in general and administration costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_JefferiesLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_JefferiesLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_JefferiesLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jeffries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used to Estimate Fair Value of Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SharesReservedUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved under Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SharesReservedUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Reserved Under Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SharesReservedUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved under employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_TwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Incentive Award Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_TwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Incentive Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_TwoThousandTwentyIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty incentive award plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DeferredTaxAssetsLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DeferredTaxAssetsLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DeferredTaxAssetsLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease related to current year provision to return adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease related to current year provision to return adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement, Percentage of Discount on Purchase Price of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of discount on common stock purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The discount on the purchase price of common stock, as a percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares excluded from computation of diluted net income per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Principal Components of Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Released</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Released</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of equity-based payment instruments, excluding stock (or unit) options, that were released during the reporting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of premium and discounts on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NatureOfBusinessAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_NatureOfBusinessAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-13 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SeriesABCDAndD1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A, B, C, D and D-1 Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SeriesABCDAndD1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A B C D And D1 Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SeriesABCDAndD1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A, B, C, D and D-1 convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Return to provision adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">intangible income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_IncrementalCostMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_IncrementalCostMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Cost [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_IncrementalCostMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_FormerChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Former Chief Financial Officer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_FormerChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Former Chief Financial Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_FormerChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Former chief financial officer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SeriesD1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D-1 Preferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SeriesD1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SeriesD1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D-1 preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements and Recently Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Costs and Expenses, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment, at cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use assets obtained in exchange for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of common shares - basic and diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock converted into shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ConsultingAgreementSuccessFeePayout_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ConsultingAgreementSuccessFeePayout_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Agreement Success Fee Payout</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ConsultingAgreementSuccessFeePayout_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate amount payable by the Company, as part of a consulting agreement. The payout amount is a success fee calculated as a percentage of certain product sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of preferred stock to common stock upon closing of initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Use Of Estimates Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS) as well as the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs. Excludes costs in connection with a business combination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign derived intangible income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, FDII, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Open market sale agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Market Sale Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on available-for-sale investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at the beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at the end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ResearchAndDevelopmentCostsAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization period of costs capitalized for research and development, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ResearchAndDevelopmentCostsAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development costs amortization period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ResearchAndDevelopmentCostsAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Costs Amortization Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_FromTwoThousandThirteenIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">From Two Thousand Thirteen Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_FromTwoThousandThirteenIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">From Two Thousand Thirteen Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_FromTwoThousandThirteenIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">From 2013 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Grant Date Fair Value, Outstanding at January 1, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Unvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_BankDepositRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bank deposits, restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_BankDepositRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bank Deposit Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_BankDepositRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of a bank deposit to collateralize a letter of credit, classified as restricted cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand and Twenty Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ResearchAndDevelopmentCreditAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate credit recorded during the period to research and development expense as a result of adjustments to amounts originally reported and the close out of certain activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ResearchAndDevelopmentCreditAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Credit Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_ResearchAndDevelopmentCreditAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development net credit adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities maturing longer than one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Defined Benefit Plans Disclosures [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_EntityControlledByDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entity controlled by director.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_EntityControlledByDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Controlled by Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_EntityControlledByDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Controlled by Director</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Hardware</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_CommonStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_CommonStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_CommonStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for common stock, including, but not limited to, the number of shares issued and outstanding, voting rights, and number of shares reserved for each class of stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reserved Shares of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The year that tax credit carryforwards will begin to expire.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of upfront payment received upon entering a licensing agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SalesBasedMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales-based</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SalesBasedMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Based Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_SalesBasedMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales-based milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_CommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The commission rate the Company agreed to pay for shares sold under a Sales Agreement, as a percentage of aggregate gross sales proceeds from each sale of shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_CommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commission Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_CommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commission percentage of aggregate gross proceeds from each sale of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number Diluted Shares Outstanding Adjustment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive effect of outstanding stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Utilized research and development tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Utilized Research And Development Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of research and development tax credit carryforwards utilized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance based restricted stock units terms of award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities in unrealized loss position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccruedLicenseFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccruedLicenseFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued License Fees Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccruedLicenseFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred and payable for licensing arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (years), Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201901Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-01 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201901Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-01</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for items classified as other assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock into common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_CostsReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs reimbursed amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_CostsReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs Reimbursed Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_CostsReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate amount of costs that have been, or will be, reimbursed by the licensee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of units cancelled due to terminations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccruedProfessionalFeesAndOtherCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees and other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccruedProfessionalFeesAndOtherCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees And Other Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_AccruedProfessionalFeesAndOtherCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received, and fees classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increased number of shares available under plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_MilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Received pursuant of milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_MilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_MilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount received upon achievement of a milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses carryforwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The year that operating loss carryforwards will begin to expire.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from initial public offering ("IPO")</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from initial public offering of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and local taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OutstandingPerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding performance-based restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OutstandingPerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Performance-based Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OutstandingPerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding performance-based restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of issuance costs deducted from cash proceeds received on stock transaction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest and Other Income, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income and other, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price Per Share, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price Per Share, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Earnings Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OfficeFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OfficeFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="avir_OfficeFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office facility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current income tax expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Additions to property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering, net of issuance costs of $3,245, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and payroll related</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from sales and maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="avir_IncomeTaxDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="avir_NatureOfBusinessLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMember" xlink:to="us-gaap_OtherAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ResearchAndDevelopmentTaxCreditsMember" xlink:to="avir_ResearchAndDevelopmentTaxCreditsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ConsultingServicesMember" xlink:to="avir_ConsultingServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:to="avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="avir_DocumentDocumentAndEntityInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" xlink:to="avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments" xlink:to="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_SeriesDOneConvertiblePreferredStockMember" xlink:to="avir_SeriesDOneConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_OutstandingOptionsMember" xlink:to="avir_OutstandingOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAmortizationMethod" xlink:to="us-gaap_CapitalizedContractCostAmortizationMethod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_RocheLicenseMember" xlink:to="avir_RocheLicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201711Member" xlink:to="us-gaap_AccountingStandardsUpdate201711Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_AccruedExpenseAndOtherCurrentLiabilitiesMember" xlink:to="avir_AccruedExpenseAndOtherCurrentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_PaymentOfTerminationFeeForTerminationOfAgreement" xlink:to="avir_PaymentOfTerminationFeeForTerminationOfAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_PerformanceBasedRestrictedStockUnitsMember" xlink:to="avir_PerformanceBasedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_PriorOfficeSpaceMember" xlink:to="avir_PriorOfficeSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest" xlink:to="avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_FairValueAssetsMeasuredOnRecurringBasisAbstract" xlink:to="avir_FairValueAssetsMeasuredOnRecurringBasisAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_OfficeSpaceMember" xlink:to="avir_OfficeSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesMember" xlink:to="us-gaap_OtherLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_NonRefundableUpfrontPaymentAccruedMember" xlink:to="avir_NonRefundableUpfrontPaymentAccruedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_MerckLicenseAgreementMember" xlink:to="avir_MerckLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_LaboratoryEquipmentMember" xlink:to="avir_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock" xlink:to="avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_RelatedPartyTransactionEntityControlledByDirectorNumber" xlink:to="avir_RelatedPartyTransactionEntityControlledByDirectorNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_MilestonePayments" xlink:to="avir_MilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_StockIssuanceProgramAuthorizedAmount" xlink:to="avir_StockIssuanceProgramAuthorizedAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_DevelopmentAndRegulatoryMilestonesMember" xlink:to="avir_DevelopmentAndRegulatoryMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:to="avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_RestrictedCommonStockMember" xlink:to="avir_RestrictedCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_SalesBasedMember" xlink:to="avir_SalesBasedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_SECFilingStatusPolicyTextBlock" xlink:to="avir_SECFilingStatusPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:to="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_BusinessDevelopmentConsultingAgreementsMember" xlink:to="avir_BusinessDevelopmentConsultingAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock" xlink:to="avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent" xlink:to="avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_NovaMedicaLLCMember" xlink:to="avir_NovaMedicaLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue" xlink:to="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="avir_AccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_DevelopmentRegulatoryAndCommercialMember" xlink:to="avir_DevelopmentRegulatoryAndCommercialMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_NatureOfBusinessTable" xlink:to="avir_NatureOfBusinessTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainageDeposit" xlink:to="us-gaap_RetainageDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember" xlink:to="avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_LeaseCommencementDate" xlink:to="avir_LeaseCommencementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_OutstandingRestrictedStockUnitsMember" xlink:to="avir_OutstandingRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate" xlink:to="avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="us-gaap_AccruedIncomeTaxesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_LocationOfOfficeSpace" xlink:to="avir_LocationOfOfficeSpace_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_NonRefundableUpfrontPaymentPaidLicenseAgreement" xlink:to="avir_NonRefundableUpfrontPaymentPaidLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_FairValueAssetsMeasuredOnRecurringBasisTable" xlink:to="avir_FairValueAssetsMeasuredOnRecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ConsultingAgreementMember" xlink:to="avir_ConsultingAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_EmployeeStockPurchasePlanMember" xlink:to="avir_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_UtilizedOperatingLossCarryforward" xlink:to="avir_UtilizedOperatingLossCarryforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_FairValueAssetsMeasuredOnRecurringBasisLineItems" xlink:to="avir_FairValueAssetsMeasuredOnRecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_RocheLicenseAgreementMember" xlink:to="avir_RocheLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax" xlink:to="avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_DeferredTaxAssetsPrepaidExpenses" xlink:to="avir_DeferredTaxAssetsPrepaidExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_SeriesDConvertiblePreferredStockMember" xlink:to="avir_SeriesDConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_JefferiesLlcMember" xlink:to="avir_JefferiesLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_SharesReservedUnderEmployeeStockPurchasePlanMember" xlink:to="avir_SharesReservedUnderEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_TwoThousandTwentyIncentiveAwardPlanMember" xlink:to="avir_TwoThousandTwentyIncentiveAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_DeferredTaxAssetsLicenseAgreement" xlink:to="avir_DeferredTaxAssetsLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock" xlink:to="avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:to="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_IncomeTaxDisclosureTable" xlink:to="avir_IncomeTaxDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_NatureOfBusinessAbstract" xlink:to="avir_NatureOfBusinessAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_SeriesABCDAndD1ConvertiblePreferredStockMember" xlink:to="avir_SeriesABCDAndD1ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_IncrementalCostMember" xlink:to="avir_IncrementalCostMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_FormerChiefFinancialOfficerMember" xlink:to="avir_FormerChiefFinancialOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_SeriesD1PreferredStockMember" xlink:to="avir_SeriesD1PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_LeaseExpirationMonthAndYear" xlink:to="avir_LeaseExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ConsultingAgreementSuccessFeePayout" xlink:to="avir_ConsultingAgreementSuccessFeePayout_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:to="avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts" xlink:to="avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_OpenMarketSaleAgreementMember" xlink:to="avir_OpenMarketSaleAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_AccountingPoliciesTable" xlink:to="avir_AccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ResearchAndDevelopmentCostsAmortizationPeriod" xlink:to="avir_ResearchAndDevelopmentCostsAmortizationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_FromTwoThousandThirteenIncentivePlanMember" xlink:to="avir_FromTwoThousandThirteenIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_BankDepositRestrictedCash" xlink:to="avir_BankDepositRestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:to="avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_ResearchAndDevelopmentCreditAdjustment" xlink:to="avir_ResearchAndDevelopmentCreditAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_EntityControlledByDirectorMember" xlink:to="avir_EntityControlledByDirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_CommonStockTextBlock" xlink:to="avir_CommonStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_TaxCreditCarryforwardExpirationYear" xlink:to="avir_TaxCreditCarryforwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_UpfrontPaymentReceived" xlink:to="avir_UpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_SalesBasedMilestoneMember" xlink:to="avir_SalesBasedMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_CommissionRate" xlink:to="avir_CommissionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards" xlink:to="avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_AccruedLicenseFeesCurrent" xlink:to="avir_AccruedLicenseFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201901Member" xlink:to="us-gaap_AccountingStandardsUpdate201901Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_OtherAssetsPolicyTextBlock" xlink:to="avir_OtherAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_CostsReimbursedAmount" xlink:to="avir_CostsReimbursedAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_AccruedProfessionalFeesAndOtherCurrent" xlink:to="avir_AccruedProfessionalFeesAndOtherCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_MilestonePaymentReceived" xlink:to="avir_MilestonePaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_OperatingLossCarryforwardsExpirationYear" xlink:to="avir_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_OutstandingPerformanceBasedRestrictedStockUnitsMember" xlink:to="avir_OutstandingPerformanceBasedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_StockIssuanceCosts" xlink:to="avir_StockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avir_OfficeFacilityMember" xlink:to="avir_OfficeFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DocumentDocumentAndEntityInformationAbstract" xlink:label="avir_DocumentDocumentAndEntityInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntitySmallBusiness" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityShellCompany" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentAnnualReport" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentTransitionReport" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_AuditorFirmId" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_AuditorName" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_DocumentDocumentAndEntityInformationAbstract" xlink:to="dei_AuditorLocation" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedIncomeTaxesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SeriesDOneConvertiblePreferredStockMember" xlink:label="avir_SeriesDOneConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_21"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_22"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_23"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_24"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_SeriesDOneConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SeriesDConvertiblePreferredStockMember" xlink:label="avir_SeriesDConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_StockIssuanceCosts" xlink:label="avir_StockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SeriesDOneConvertiblePreferredStockMember" xlink:label="avir_SeriesDOneConvertiblePreferredStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_SeriesDConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="avir_StockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_SeriesDOneConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCollaborationRevenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_CommonStockTextBlock" xlink:label="avir_CommonStockTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="avir_CommonStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:label="avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock" xlink:label="avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OtherAssetsPolicyTextBlock" xlink:label="avir_OtherAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock" xlink:label="avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SECFilingStatusPolicyTextBlock" xlink:label="avir_SECFilingStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avir_OtherAssetsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avir_SECFilingStatusPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PerformanceBasedRestrictedStockUnitsMember" xlink:label="avir_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avir_PerformanceBasedRestrictedStockUnitsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NatureOfBusinessLineItems" xlink:label="avir_NatureOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_UpfrontPaymentReceived" xlink:label="avir_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SeriesABCDAndD1ConvertiblePreferredStockMember" xlink:label="avir_SeriesABCDAndD1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NatureOfBusinessTable" xlink:label="avir_NatureOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_JefferiesLlcMember" xlink:label="avir_JefferiesLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NatureOfBusinessAbstract" xlink:label="avir_NatureOfBusinessAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_RocheLicenseAgreementMember" xlink:label="avir_RocheLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_MilestonePaymentReceived" xlink:label="avir_MilestonePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OpenMarketSaleAgreementMember" xlink:label="avir_OpenMarketSaleAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_StockIssuanceProgramAuthorizedAmount" xlink:label="avir_StockIssuanceProgramAuthorizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_CommissionRate" xlink:label="avir_CommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="avir_UpfrontPaymentReceived" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_SeriesABCDAndD1ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="avir_JefferiesLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessAbstract" xlink:to="avir_NatureOfBusinessTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avir_RocheLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="avir_MilestonePaymentReceived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avir_OpenMarketSaleAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessTable" xlink:to="avir_NatureOfBusinessLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="avir_StockIssuanceProgramAuthorizedAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="avir_CommissionRate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccountingPoliciesLineItems" xlink:label="avir_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortizationMethod" xlink:label="us-gaap_CapitalizedContractCostAmortizationMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccountingPoliciesTable" xlink:label="avir_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_IncrementalCostMember" xlink:label="avir_IncrementalCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_RocheLicenseMember" xlink:label="avir_RocheLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201901Member" xlink:label="us-gaap_AccountingStandardsUpdate201901Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainageDeposit" xlink:label="us-gaap_RetainageDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:label="us-gaap_AccountingStandardsUpdate201711Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate" xlink:label="avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock" xlink:label="avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortizationMethod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avir_AccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="avir_IncrementalCostMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avir_RocheLicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201901Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_RetainageDeposit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201711Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesTable" xlink:to="avir_AccountingPoliciesLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_LaboratoryEquipmentMember" xlink:label="avir_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="avir_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DevelopmentRegulatoryAndCommercialMember" xlink:label="avir_DevelopmentRegulatoryAndCommercialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_RocheLicenseAgreementMember" xlink:label="avir_RocheLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SalesBasedMember" xlink:label="avir_SalesBasedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_CostsReimbursedAmount" xlink:label="avir_CostsReimbursedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ResearchAndDevelopmentCreditAdjustment" xlink:label="avir_ResearchAndDevelopmentCreditAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avir_DevelopmentRegulatoryAndCommercialMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avir_RocheLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avir_SalesBasedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="avir_CostsReimbursedAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="avir_ResearchAndDevelopmentCreditAdjustment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_FairValueAssetsMeasuredOnRecurringBasisAbstract" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_FairValueAssetsMeasuredOnRecurringBasisTable" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_FairValueAssetsMeasuredOnRecurringBasisLineItems" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_FairValueAssetsMeasuredOnRecurringBasisAbstract" xlink:to="avir_FairValueAssetsMeasuredOnRecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_FairValueAssetsMeasuredOnRecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_FairValueAssetsMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_FairValueAssetsMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_FairValueAssetsMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_FairValueAssetsMeasuredOnRecurringBasisTable" xlink:to="avir_FairValueAssetsMeasuredOnRecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_LaboratoryEquipmentMember" xlink:label="avir_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="avir_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent" xlink:label="avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccruedLicenseFeesCurrent" xlink:label="avir_AccruedLicenseFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccruedProfessionalFeesAndOtherCurrent" xlink:label="avir_AccruedProfessionalFeesAndOtherCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="avir_AccruedLicenseFeesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="avir_AccruedProfessionalFeesAndOtherCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAssetsAndLiabilitiesRecordedOnConsolidatedBalanceSheetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseCostsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfRemainingLeaseTermAndDiscountRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_BusinessDevelopmentConsultingAgreementsMember" xlink:label="avir_BusinessDevelopmentConsultingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_LocationOfOfficeSpace" xlink:label="avir_LocationOfOfficeSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DevelopmentAndRegulatoryMilestonesMember" xlink:label="avir_DevelopmentAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OfficeSpaceMember" xlink:label="avir_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_MerckLicenseAgreementMember" xlink:label="avir_MerckLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_LeaseCommencementDate" xlink:label="avir_LeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SalesBasedMilestoneMember" xlink:label="avir_SalesBasedMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OfficeFacilityMember" xlink:label="avir_OfficeFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NonRefundableUpfrontPaymentAccruedMember" xlink:label="avir_NonRefundableUpfrontPaymentAccruedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PriorOfficeSpaceMember" xlink:label="avir_PriorOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_LeaseExpirationMonthAndYear" xlink:label="avir_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_BankDepositRestrictedCash" xlink:label="avir_BankDepositRestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NonRefundableUpfrontPaymentPaidLicenseAgreement" xlink:label="avir_NonRefundableUpfrontPaymentPaidLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_MilestonePayments" xlink:label="avir_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ConsultingAgreementSuccessFeePayout" xlink:label="avir_ConsultingAgreementSuccessFeePayout"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="avir_BusinessDevelopmentConsultingAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="avir_LocationOfOfficeSpace" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="avir_DevelopmentAndRegulatoryMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="avir_OfficeSpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avir_MerckLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="avir_LeaseCommencementDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="avir_SalesBasedMilestoneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="avir_OfficeFacilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="avir_NonRefundableUpfrontPaymentAccruedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="avir_PriorOfficeSpaceMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="avir_LeaseExpirationMonthAndYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="avir_BankDepositRestrictedCash" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="avir_NonRefundableUpfrontPaymentPaidLicenseAgreement" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="avir_MilestonePayments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="avir_ConsultingAgreementSuccessFeePayout" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SeriesD1PreferredStockMember" xlink:label="avir_SeriesD1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_SeriesD1PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockVotingRights" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OutstandingOptionsMember" xlink:label="avir_OutstandingOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OutstandingRestrictedStockUnitsMember" xlink:label="avir_OutstandingRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OutstandingPerformanceBasedRestrictedStockUnitsMember" xlink:label="avir_OutstandingPerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember" xlink:label="avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SharesReservedUnderEmployeeStockPurchasePlanMember" xlink:label="avir_SharesReservedUnderEmployeeStockPurchasePlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_OutstandingOptionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_OutstandingRestrictedStockUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_OutstandingPerformanceBasedRestrictedStockUnitsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_SharesReservedUnderEmployeeStockPurchasePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_TwoThousandTwentyIncentiveAwardPlanMember" xlink:label="avir_TwoThousandTwentyIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_EmployeeStockPurchasePlanMember" xlink:label="avir_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PerformanceBasedRestrictedStockUnitsMember" xlink:label="avir_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_FromTwoThousandThirteenIncentivePlanMember" xlink:label="avir_FromTwoThousandThirteenIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="avir_TwoThousandTwentyIncentiveAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="avir_EmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avir_PerformanceBasedRestrictedStockUnitsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avir_FromTwoThousandThirteenIncentivePlanMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockPlans" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PerformanceBasedRestrictedStockUnitsMember" xlink:label="avir_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avir_PerformanceBasedRestrictedStockUnitsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_RestrictedCommonStockMember" xlink:label="avir_RestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_EmployeeStockPurchasePlanMember" xlink:label="avir_EmployeeStockPurchasePlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avir_RestrictedCommonStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avir_EmployeeStockPurchasePlanMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_IncomeTaxDisclosureLineItems" xlink:label="avir_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_IncomeTaxDisclosureTable" xlink:label="avir_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesMember" xlink:label="us-gaap_OtherLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ResearchAndDevelopmentTaxCreditsMember" xlink:label="avir_ResearchAndDevelopmentTaxCreditsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OperatingLossCarryforwardsExpirationYear" xlink:label="avir_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ResearchAndDevelopmentCostsAmortizationPeriod" xlink:label="avir_ResearchAndDevelopmentCostsAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_TaxCreditCarryforwardExpirationYear" xlink:label="avir_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_UtilizedOperatingLossCarryforward" xlink:label="avir_UtilizedOperatingLossCarryforward"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards" xlink:label="avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax" xlink:label="avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="avir_IncomeTaxDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureTable" xlink:to="avir_IncomeTaxDisclosureLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="avir_ResearchAndDevelopmentTaxCreditsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="avir_OperatingLossCarryforwardsExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="avir_ResearchAndDevelopmentCostsAmortizationPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="avir_TaxCreditCarryforwardExpirationYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="avir_UtilizedOperatingLossCarryforward" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" xlink:label="avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts" xlink:label="avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DeferredTaxAssetsLicenseAgreement" xlink:label="avir_DeferredTaxAssetsLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DeferredTaxAssetsPrepaidExpenses" xlink:label="avir_DeferredTaxAssetsPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="avir_DeferredTaxAssetsLicenseAgreement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="avir_DeferredTaxAssetsPrepaidExpenses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest" xlink:label="avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PerformanceBasedRestrictedStockUnitsMember" xlink:label="avir_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="avir_PerformanceBasedRestrictedStockUnitsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_RelatedPartyTransactionEntityControlledByDirectorNumber" xlink:label="avir_RelatedPartyTransactionEntityControlledByDirectorNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NovaMedicaLLCMember" xlink:label="avir_NovaMedicaLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ConsultingAgreementMember" xlink:label="avir_ConsultingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccruedExpenseAndOtherCurrentLiabilitiesMember" xlink:label="avir_AccruedExpenseAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_EntityControlledByDirectorMember" xlink:label="avir_EntityControlledByDirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainageDeposit" xlink:label="us-gaap_RetainageDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ConsultingServicesMember" xlink:label="avir_ConsultingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_FormerChiefFinancialOfficerMember" xlink:label="avir_FormerChiefFinancialOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PaymentOfTerminationFeeForTerminationOfAgreement" xlink:label="avir_PaymentOfTerminationFeeForTerminationOfAgreement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avir_RelatedPartyTransactionEntityControlledByDirectorNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avir_NovaMedicaLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="avir_ConsultingAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="avir_AccruedExpenseAndOtherCurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="avir_EntityControlledByDirectorMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RetainageDeposit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="avir_ConsultingServicesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="avir_FormerChiefFinancialOfficerMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avir_PaymentOfTerminationFeeForTerminationOfAgreement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SeriesDOneConvertiblePreferredStockMember" xlink:label="avir_SeriesDOneConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_SeriesDOneConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SeriesDConvertiblePreferredStockMember" xlink:label="avir_SeriesDConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_StockIssuanceCosts" xlink:label="avir_StockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SeriesDOneConvertiblePreferredStockMember" xlink:label="avir_SeriesDOneConvertiblePreferredStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_SeriesDConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="avir_StockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_SeriesDOneConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PerformanceBasedRestrictedStockUnitsMember" xlink:label="avir_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avir_PerformanceBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NatureOfBusinessLineItems" xlink:label="avir_NatureOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NatureOfBusinessTable" xlink:label="avir_NatureOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_UpfrontPaymentReceived" xlink:label="avir_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SeriesABCDAndD1ConvertiblePreferredStockMember" xlink:label="avir_SeriesABCDAndD1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_JefferiesLlcMember" xlink:label="avir_JefferiesLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_RocheLicenseAgreementMember" xlink:label="avir_RocheLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_MilestonePaymentReceived" xlink:label="avir_MilestonePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OpenMarketSaleAgreementMember" xlink:label="avir_OpenMarketSaleAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_StockIssuanceProgramAuthorizedAmount" xlink:label="avir_StockIssuanceProgramAuthorizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_CommissionRate" xlink:label="avir_CommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="avir_NatureOfBusinessTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="avir_UpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_SeriesABCDAndD1ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_NatureOfBusinessTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avir_JefferiesLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avir_RocheLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="avir_MilestonePaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_NatureOfBusinessTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="avir_OpenMarketSaleAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_NatureOfBusinessTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_NatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_NatureOfBusinessTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_NatureOfBusinessTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="avir_StockIssuanceProgramAuthorizedAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="avir_CommissionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_NatureOfBusinessLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccountingPoliciesLineItems" xlink:label="avir_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccountingPoliciesTable" xlink:label="avir_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortizationMethod" xlink:label="us-gaap_CapitalizedContractCostAmortizationMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_IncrementalCostMember" xlink:label="avir_IncrementalCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_RocheLicenseMember" xlink:label="avir_RocheLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201901Member" xlink:label="us-gaap_AccountingStandardsUpdate201901Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainageDeposit" xlink:label="us-gaap_RetainageDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:label="us-gaap_AccountingStandardsUpdate201711Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate" xlink:label="avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock" xlink:label="avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="avir_AccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortizationMethod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="avir_IncrementalCostMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_AccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avir_RocheLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201901Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_AccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_RetainageDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201711Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_AccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_AccountingPoliciesTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_LaboratoryEquipmentMember" xlink:label="avir_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="avir_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DevelopmentRegulatoryAndCommercialMember" xlink:label="avir_DevelopmentRegulatoryAndCommercialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_RocheLicenseAgreementMember" xlink:label="avir_RocheLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SalesBasedMember" xlink:label="avir_SalesBasedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_CostsReimbursedAmount" xlink:label="avir_CostsReimbursedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ResearchAndDevelopmentCreditAdjustment" xlink:label="avir_ResearchAndDevelopmentCreditAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avir_DevelopmentRegulatoryAndCommercialMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avir_RocheLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avir_SalesBasedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="avir_CostsReimbursedAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="avir_ResearchAndDevelopmentCreditAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_FairValueAssetsMeasuredOnRecurringBasisLineItems" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_FairValueAssetsMeasuredOnRecurringBasisTable" xlink:label="avir_FairValueAssetsMeasuredOnRecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avir_FairValueAssetsMeasuredOnRecurringBasisLineItems" xlink:to="avir_FairValueAssetsMeasuredOnRecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_FairValueAssetsMeasuredOnRecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_FairValueAssetsMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_FairValueAssetsMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_FairValueAssetsMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_LaboratoryEquipmentMember" xlink:label="avir_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="avir_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_BusinessDevelopmentConsultingAgreementsMember" xlink:label="avir_BusinessDevelopmentConsultingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_LocationOfOfficeSpace" xlink:label="avir_LocationOfOfficeSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DevelopmentAndRegulatoryMilestonesMember" xlink:label="avir_DevelopmentAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OfficeSpaceMember" xlink:label="avir_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_MerckLicenseAgreementMember" xlink:label="avir_MerckLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_LeaseCommencementDate" xlink:label="avir_LeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SalesBasedMilestoneMember" xlink:label="avir_SalesBasedMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OfficeFacilityMember" xlink:label="avir_OfficeFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NonRefundableUpfrontPaymentAccruedMember" xlink:label="avir_NonRefundableUpfrontPaymentAccruedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PriorOfficeSpaceMember" xlink:label="avir_PriorOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_LeaseExpirationMonthAndYear" xlink:label="avir_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_BankDepositRestrictedCash" xlink:label="avir_BankDepositRestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NonRefundableUpfrontPaymentPaidLicenseAgreement" xlink:label="avir_NonRefundableUpfrontPaymentPaidLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_MilestonePayments" xlink:label="avir_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ConsultingAgreementSuccessFeePayout" xlink:label="avir_ConsultingAgreementSuccessFeePayout"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="avir_BusinessDevelopmentConsultingAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="avir_LocationOfOfficeSpace" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="avir_DevelopmentAndRegulatoryMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="avir_OfficeSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="avir_MerckLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="avir_LeaseCommencementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="avir_SalesBasedMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="avir_OfficeFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="avir_NonRefundableUpfrontPaymentAccruedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="avir_PriorOfficeSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="avir_LeaseExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="avir_BankDepositRestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="avir_NonRefundableUpfrontPaymentPaidLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="avir_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="avir_ConsultingAgreementSuccessFeePayout" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SeriesD1PreferredStockMember" xlink:label="avir_SeriesD1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_SeriesD1PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OutstandingOptionsMember" xlink:label="avir_OutstandingOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OutstandingRestrictedStockUnitsMember" xlink:label="avir_OutstandingRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OutstandingPerformanceBasedRestrictedStockUnitsMember" xlink:label="avir_OutstandingPerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember" xlink:label="avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_SharesReservedUnderEmployeeStockPurchasePlanMember" xlink:label="avir_SharesReservedUnderEmployeeStockPurchasePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_OutstandingOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_OutstandingRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_OutstandingPerformanceBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avir_SharesReservedUnderEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_TwoThousandTwentyIncentiveAwardPlanMember" xlink:label="avir_TwoThousandTwentyIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_EmployeeStockPurchasePlanMember" xlink:label="avir_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PerformanceBasedRestrictedStockUnitsMember" xlink:label="avir_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_FromTwoThousandThirteenIncentivePlanMember" xlink:label="avir_FromTwoThousandThirteenIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="avir_TwoThousandTwentyIncentiveAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="avir_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avir_PerformanceBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avir_FromTwoThousandThirteenIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PerformanceBasedRestrictedStockUnitsMember" xlink:label="avir_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:label="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avir_PerformanceBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_RestrictedCommonStockMember" xlink:label="avir_RestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_EmployeeStockPurchasePlanMember" xlink:label="avir_EmployeeStockPurchasePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avir_RestrictedCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avir_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_IncomeTaxDisclosureLineItems" xlink:label="avir_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_IncomeTaxDisclosureTable" xlink:label="avir_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesMember" xlink:label="us-gaap_OtherLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ResearchAndDevelopmentTaxCreditsMember" xlink:label="avir_ResearchAndDevelopmentTaxCreditsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_OperatingLossCarryforwardsExpirationYear" xlink:label="avir_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ResearchAndDevelopmentCostsAmortizationPeriod" xlink:label="avir_ResearchAndDevelopmentCostsAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_TaxCreditCarryforwardExpirationYear" xlink:label="avir_TaxCreditCarryforwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_UtilizedOperatingLossCarryforward" xlink:label="avir_UtilizedOperatingLossCarryforward"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards" xlink:label="avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax" xlink:label="avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="avir_IncomeTaxDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avir_IncomeTaxDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="avir_ResearchAndDevelopmentTaxCreditsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="avir_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="avir_ResearchAndDevelopmentCostsAmortizationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="avir_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="avir_UtilizedOperatingLossCarryforward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avir_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PerformanceBasedRestrictedStockUnitsMember" xlink:label="avir_PerformanceBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="avir_PerformanceBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlanAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_RelatedPartyTransactionEntityControlledByDirectorNumber" xlink:label="avir_RelatedPartyTransactionEntityControlledByDirectorNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_NovaMedicaLLCMember" xlink:label="avir_NovaMedicaLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ConsultingAgreementMember" xlink:label="avir_ConsultingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccruedExpenseAndOtherCurrentLiabilitiesMember" xlink:label="avir_AccruedExpenseAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_EntityControlledByDirectorMember" xlink:label="avir_EntityControlledByDirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainageDeposit" xlink:label="us-gaap_RetainageDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_ConsultingServicesMember" xlink:label="avir_ConsultingServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_FormerChiefFinancialOfficerMember" xlink:label="avir_FormerChiefFinancialOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_PaymentOfTerminationFeeForTerminationOfAgreement" xlink:label="avir_PaymentOfTerminationFeeForTerminationOfAgreement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avir_RelatedPartyTransactionEntityControlledByDirectorNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avir_NovaMedicaLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="avir_ConsultingAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="avir_AccruedExpenseAndOtherCurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="avir_EntityControlledByDirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RetainageDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="avir_ConsultingServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="avir_FormerChiefFinancialOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avir_PaymentOfTerminationFeeForTerminationOfAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_AccruedIncomeTaxesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestAndOtherIncome" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="2" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" order="5" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="7" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="8" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="9" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="11" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="2" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="avir_AccruedLicenseFeesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="avir_AccruedProfessionalFeesAndOtherCurrent" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent" xlink:label="avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccruedLicenseFeesCurrent" xlink:label="avir_AccruedLicenseFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_AccruedProfessionalFeesAndOtherCurrent" xlink:label="avir_AccruedProfessionalFeesAndOtherCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseCostsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" order="5" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" xlink:label="avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="avir_DeferredTaxAssetsLicenseAgreement" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="avir_DeferredTaxAssetsPrepaidExpenses" order="7" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts" xlink:label="avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DeferredTaxAssetsLicenseAgreement" xlink:label="avir_DeferredTaxAssetsLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="avir-20231231.xsd#avir_DeferredTaxAssetsPrepaidExpenses" xlink:label="avir_DeferredTaxAssetsPrepaidExpenses"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="avir_AccruedProfessionalFeesAndOtherCurrent" name="AccruedProfessionalFeesAndOtherCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards" name="UtilizedResearchAndDevelopmentTaxCreditCarryforwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax" name="AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent" name="AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="avir_DeferredTaxAssetsPrepaidExpenses" name="DeferredTaxAssetsPrepaidExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest" name="UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock" name="InProcessResearchAndDevelopmentAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="avir_NatureOfBusinessAbstract" name="NatureOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" name="EffectiveIncomeTaxRateReconciliationUncertainTaxPositions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_SalesBasedMilestoneMember" name="SalesBasedMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_CommissionRate" name="CommissionRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_CommonStockTextBlock" name="CommonStockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_TwoThousandTwentyIncentiveAwardPlanMember" name="TwoThousandTwentyIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock" name="ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="avir_OutstandingOptionsMember" name="OutstandingOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_MilestonePaymentReceived" name="MilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="avir_PriorOfficeSpaceMember" name="PriorOfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_SECFilingStatusPolicyTextBlock" name="SECFilingStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_DocumentDocumentAndEntityInformationAbstract" name="DocumentDocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_StockIssuanceProgramAuthorizedAmount" name="StockIssuanceProgramAuthorizedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="avir_ResearchAndDevelopmentCostsAmortizationPeriod" name="ResearchAndDevelopmentCostsAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_OutstandingPerformanceBasedRestrictedStockUnitsMember" name="OutstandingPerformanceBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_NatureOfBusinessLineItems" name="NatureOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock" name="ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_AccruedExpenseAndOtherCurrentLiabilitiesMember" name="AccruedExpenseAndOtherCurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_ResearchAndDevelopmentCreditAdjustment" name="ResearchAndDevelopmentCreditAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock" name="SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_EntityControlledByDirectorMember" name="EntityControlledByDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_ConsultingAgreementMember" name="ConsultingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_SeriesABCDAndD1ConvertiblePreferredStockMember" name="SeriesABCDAndD1ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_CostsReimbursedAmount" name="CostsReimbursedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="avir_MerckLicenseAgreementMember" name="MerckLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_NonRefundableUpfrontPaymentPaidLicenseAgreement" name="NonRefundableUpfrontPaymentPaidLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="avir_FromTwoThousandThirteenIncentivePlanMember" name="FromTwoThousandThirteenIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="avir_SalesBasedMember" name="SalesBasedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_ConsultingAgreementSuccessFeePayout" name="ConsultingAgreementSuccessFeePayout" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="avir_ConsultingServicesMember" name="ConsultingServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_DevelopmentAndRegulatoryMilestonesMember" name="DevelopmentAndRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_BankDepositRestrictedCash" name="BankDepositRestrictedCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" name="TwoThousandAndTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_OfficeFacilityMember" name="OfficeFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_PaymentOfTerminationFeeForTerminationOfAgreement" name="PaymentOfTerminationFeeForTerminationOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="avir_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_RocheLicenseMember" name="RocheLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_FairValueAssetsMeasuredOnRecurringBasisAbstract" name="FairValueAssetsMeasuredOnRecurringBasisAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_AccruedLicenseFeesCurrent" name="AccruedLicenseFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="avir_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_StockIssuanceCosts" name="StockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="avir_UpfrontPaymentReceived" name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="avir_RocheLicenseAgreementMember" name="RocheLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_SeriesDOneConvertiblePreferredStockMember" name="SeriesDOneConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate" name="ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="avir_BusinessDevelopmentConsultingAgreementsMember" name="BusinessDevelopmentConsultingAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_DevelopmentRegulatoryAndCommercialMember" name="DevelopmentRegulatoryAndCommercialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_PerformanceBasedRestrictedStockUnitsMember" name="PerformanceBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember" name="SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_SeriesD1PreferredStockMember" name="SeriesD1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock" name="SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_LocationOfOfficeSpace" name="LocationOfOfficeSpace" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_OutstandingRestrictedStockUnitsMember" name="OutstandingRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_IncrementalCostMember" name="IncrementalCostMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_NonRefundableUpfrontPaymentAccruedMember" name="NonRefundableUpfrontPaymentAccruedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_OfficeSpaceMember" name="OfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" name="BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_RelatedPartyTransactionEntityControlledByDirectorNumber" name="RelatedPartyTransactionEntityControlledByDirectorNumber" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_OpenMarketSaleAgreementMember" name="OpenMarketSaleAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_SeriesDConvertiblePreferredStockMember" name="SeriesDConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_ResearchAndDevelopmentTaxCreditsMember" name="ResearchAndDevelopmentTaxCreditsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_RestrictedCommonStockMember" name="RestrictedCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts" name="DeferredTaxAssetsInProcessResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="avir_DeferredTaxAssetsLicenseAgreement" name="DeferredTaxAssetsLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="avir_OtherAssetsPolicyTextBlock" name="OtherAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_NovaMedicaLLCMember" name="NovaMedicaLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_AccountingPoliciesTable" name="AccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_FairValueAssetsMeasuredOnRecurringBasisLineItems" name="FairValueAssetsMeasuredOnRecurringBasisLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_UtilizedOperatingLossCarryforward" name="UtilizedOperatingLossCarryforward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="avir_JefferiesLlcMember" name="JefferiesLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_FairValueAssetsMeasuredOnRecurringBasisTable" name="FairValueAssetsMeasuredOnRecurringBasisTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_SharesReservedUnderEmployeeStockPurchasePlanMember" name="SharesReservedUnderEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="avir_FormerChiefFinancialOfficerMember" name="FormerChiefFinancialOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="avir_NatureOfBusinessTable" name="NatureOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933217381040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 25, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_DocumentDocumentAndEntityInformationAbstract', window );"><strong>Document Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ATEA PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVIR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001593899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,164,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0574869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Franklin Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">284-8891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">Portions of the registrant&#8217;s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_DocumentDocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Document Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_DocumentDocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933216880688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 143,823<span></span>
</td>
<td class="nump">$ 188,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">434,283<span></span>
</td>
<td class="nump">458,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">12,349<span></span>
</td>
<td class="nump">14,213<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">590,455<span></span>
</td>
<td class="nump">660,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,289<span></span>
</td>
<td class="nump">1,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">1,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">1,828<span></span>
</td>
<td class="nump">2,389<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">594,968<span></span>
</td>
<td class="nump">666,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,252<span></span>
</td>
<td class="nump">2,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">27,364<span></span>
</td>
<td class="nump">15,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">760<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">32,376<span></span>
</td>
<td class="nump">18,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,642<span></span>
</td>
<td class="nump">2,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Income taxes payable</a></td>
<td class="nump">5,758<span></span>
</td>
<td class="nump">5,255<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">39,776<span></span>
</td>
<td class="nump">26,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 300,000,000 shares authorized; 83,435,513 and 83,287,639 shares issued and outstanding as of December 31, 2023 and 2022</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">750,737<span></span>
</td>
<td class="nump">701,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain (loss)</a></td>
<td class="nump">207<span></span>
</td>
<td class="num">(684)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(195,835)<span></span>
</td>
<td class="num">(59,879)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">555,192<span></span>
</td>
<td class="nump">640,572<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 594,968<span></span>
</td>
<td class="nump">$ 666,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933325124896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">83,435,513<span></span>
</td>
<td class="nump">83,287,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">83,435,513<span></span>
</td>
<td class="nump">83,287,639<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933217794720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 114,243<span></span>
</td>
<td class="nump">$ 81,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">49,919<span></span>
</td>
<td class="nump">48,714<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">164,162<span></span>
</td>
<td class="nump">130,650<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(164,162)<span></span>
</td>
<td class="num">(130,650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income and other, net</a></td>
<td class="nump">29,224<span></span>
</td>
<td class="nump">11,151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(134,938)<span></span>
</td>
<td class="num">(119,499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">(1,018)<span></span>
</td>
<td class="nump">3,590<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(135,956)<span></span>
</td>
<td class="num">(115,909)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale investments</a></td>
<td class="nump">891<span></span>
</td>
<td class="num">(684)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (135,065)<span></span>
</td>
<td class="num">$ (116,593)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share attributable to common stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (1.63)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (1.63)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average number of common shares - basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">83,389,750<span></span>
</td>
<td class="nump">83,245,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">83,389,750<span></span>
</td>
<td class="nump">83,245,385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933217199008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accummulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Retained Earnings (Accumulated</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 710,077<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 653,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,102,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for exercise of stock options</a></td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for exercise of stock options , shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under ESPP</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">46,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(115,909)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115,909)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">640,572<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">701,052<span></span>
</td>
<td class="num">(684)<span></span>
</td>
<td class="num">(59,879)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,287,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under ESPP</a></td>
<td class="nump">257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">49,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(135,956)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135,956)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 555,192<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 750,737<span></span>
</td>
<td class="nump">$ 207<span></span>
</td>
<td class="num">$ (195,835)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,435,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933221847136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (135,956)<span></span>
</td>
<td class="num">$ (115,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">49,428<span></span>
</td>
<td class="nump">46,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of premium and discounts on marketable securities</a></td>
<td class="num">(15,446)<span></span>
</td>
<td class="num">(5,465)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,864<span></span>
</td>
<td class="num">(6,251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">98<span></span>
</td>
<td class="num">(1,494)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,701<span></span>
</td>
<td class="num">(1,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">12,661<span></span>
</td>
<td class="num">(37,623)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(161)<span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(85,395)<span></span>
</td>
<td class="num">(120,982)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(562,362)<span></span>
</td>
<td class="num">(545,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales and maturities of marketable securities</a></td>
<td class="nump">602,665<span></span>
</td>
<td class="nump">91,885<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">40,303<span></span>
</td>
<td class="num">(455,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock for exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under ESPP</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(44,835)<span></span>
</td>
<td class="num">(576,022)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of period</a></td>
<td class="nump">188,658<span></span>
</td>
<td class="nump">764,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of period</a></td>
<td class="nump">143,823<span></span>
</td>
<td class="nump">188,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, cash equivalents and restricted cash at the end of period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">143,823<span></span>
</td>
<td class="nump">188,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 143,823<span></span>
</td>
<td class="nump">188,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,938<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933222510224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">1. Nature of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Business Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Atea Pharmaceuticals, Inc., ("Atea" or the "Company") is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from severe viral infections.  Currently, Atea is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 ("COVID-19"). Atea is also currently conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus ("HCV").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, the Company had $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">578.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million in cash, cash equivalents and marketable securities, which the Company believes will be sufficient to fund its operations for a period through at least twelve months from the issuance date of these consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In November 2021, the Company entered into an open market sales agreement (&#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), under which the Company may from time to time offer and sell shares of its common stock for an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million, through or to Jefferies, acting as sales agent or principal. The shares will be offered and sold under the Company&#8217;s shelf registration statement on Form S-3 and a related prospectus filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on November 24, 2021, as amended. The Company has agreed to pay Jefferies a commission of </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Jefferies with customary indemnification and contribution rights. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares have been issued under the Sales Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company is subject to risks and uncertainties common to clinical-stage biopharmaceutical companies. These risks include, but are not limited to, potential failure of preclinical and clinical studies, uncertainties associated with research and development activities generally, competition from technical innovations of others, dependence upon key personnel, compliance with governmental regulations, the need to obtain marketing approval for any product candidate that the Company may develop, the need to gain broad acceptance among patients, payers and health care providers to successfully commercialize any product for which marketing approval is obtained and the need to secure and maintain adequate intellectual property protection for the Company&#8217;s proprietary technology and products. Further, the Company is currently dependent on third-party service providers for much of its preclinical research, clinical development and manufacturing activities. Product candidates currently under development will require significant amounts of additional capital, and additional research and development efforts, including further additional clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company may seek additional capital through one or more of a combination of financing through the sale of additional equity securities, debt financing, or funding in connection with any new collaborative relationships it may enter into or other arrangements. There can be no assurance that the Company will be able to obtain such additional funding, on terms acceptable to the Company, on a timely basis or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s existing stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Company is also subject to risks associated with the continued evolution of COVID-19 and its consequences, including actual and potential delays associated with certain of its ongoing and anticipated trials, and potential negative impacts on the Company&#8217;s business operations and its ability to raise</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">additional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">capital to finance its operations. Geopolitical events, including civil or political unrest and terrorism, have resulted in a significant disruption of global business and financial markets. In addition, recent or future market volatility, increased inflation and higher interest rates, if sustained, may increase our cost of financing and may restrict our access to potential sources of future liquidity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933219919808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Basis of Presentation and Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and in these accompanying notes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors and assumptions that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, which include but are not limited to estimates of accrued research and development expenses, valuation of marketable securities, valuation of stock-based awards, valuation of operating lease right-of-use assets and lease liabilities and income taxes. Changes in estimates are recorded in the period in which they become known.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The consolidated financial statements include the accounts of Atea Pharmaceuticals, Inc. and its wholly- owned subsidiary, Atea Pharmaceuticals Securities Corporation. All intercompany amounts have been eliminated in consolidation.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company considers all highly-liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company&#8217;s cash equivalents include money market funds and commercial paper, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company&#8217;s investment strategy is principally focused on capital preservation. The Company invests in financial instruments that among other things meet the credit quality standards outlined in the Company&#8217;s investment policy. Marketable securities consist of investments with maturities greater than three months. Investments not classified as cash equivalents with maturities of less than twelve months are classified as current assets on the consolidated balance sheet.  Investments with maturities greater than twelve months for which the Company has the intent and ability to hold the investment for greater than twelve months are classified as non-current on the consolidated balance sheet. Marketable securities include US treasury obligations, US agency obligations, corporate debt, commercial paper and asset-backed securities.  The Company classifies all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Unrealized gains and losses are recorded as a component of accumulated other comprehensive gain (loss) within stockholders&#8217; equity. Interest, dividends and amortization and accretion of discounts and premiums are recorded as interest income and other, net.  The Company periodically reviews its marketable securities for impairment and adjusts these investments to their fair value when a decline in market value is deemed to be other than temporary.  Declines in fair value judged to be other than temporary on marketable securities, if any, are included in interest income and other, net.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Significant Suppliers</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the US government. The Company does not believe that it is subject to any significant concentrations of credit risk from these financial instruments. The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company is dependent on third-party manufacturers for the supply of products for its research and development activities including its development programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs for preclinical and clinical development activities. The Company also currently anticipates to rely on this small number of manufacturers for commercial supply if any of the current product candidates are approved for sale. The Company's research and development programs, including any potential commercialization efforts, could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair Value Measurement,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Level 1&#8212;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Level 2&#8212;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Level 3&#8212;Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the assets and liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The carrying amounts of prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value due to short-term nature of these assets and liabilities.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the asset. </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company estimates the useful life of its assets as follows:</span></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;">
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.17%;"></td>
          <td style="width:1.66%;"></td>
          <td style="width:49.17%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Asset</span></p></td>
          <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Five years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Office furniture and fixtures</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Five years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Computer hardware</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Two years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="-sec-ix-hidden:F_3be2bd17-90cb-4ad6-9f95-d622754a93f7;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of useful life or remaining lease term</span></span></span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Maintenance and repairs that do not improve or extend the life of the respective asset are expensed to operations as incurred. Upon disposal of an asset, the related cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the consolidated statements of operations.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Other Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Other assets consist of vendor deposits related to research and development activities and a security deposit related to our facility lease.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Impairment of Long-lived Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Company reviews long-lived assets, including property and equipment and right-of-use assets ("ROU") when events or changes in circumstances indicate the carrying value of the assets may not be fully recoverable. Recoverability is measured by comparing the book value of the assets to the estimated undiscounted future net cash flows that the asset is expected to generate. If the estimated undiscounted future net cash flows are less than the book value, the asset is impaired, and the impairment loss to be recognized in income is measured as the amount by which the book value of the asset exceeds its fair value, which is measured based on the estimated discounted future net cash flows that the asset is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">expected </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">to generate. </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> impairment losses were recorded during the years ended December 31, 2023 and 2022.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company accounts for leases in accordance with ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Lease Accounting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.   At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. Leases with a term greater than one year are recognized on the consolidated balance sheet as a ROU asset and current and non-current lease liabilities, as applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense.  The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company estimates it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses consist principally of costs associated with outsourced research and development activities, including drug discovery, preclinical and clinical development, manufacturing and research conducted by contract research organizations and academic institutions, employee compensation, including stock-based compensation and consulting expenses together with related expenses, professional fees and facility and overhead costs. Facility and overhead costs primarily include the allocation of rent, utility and office-related expenses attributable to research and development personnel. In circumstances where amounts have been paid in advance or in excess of costs incurred, the Company records a prepaid expense, which is expensed as services are performed or goods are delivered.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has entered into various research and development contracts with third parties. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase of completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Costs to secure and maintain the Company&#8217;s patents are expensed as incurred and are classified as general and administrative expenses in the Company&#8217;s consolidated statements of operations.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock-based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock-based compensation expense is classified in the consolidated statement of operations and comprehensive loss in the same manner as the award recipient&#8217;s payroll costs or service payments are classified. Stock-based awards granted to employees and non-employees are measured based on the estimated fair value of the awards using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;). Stock-based compensation expense with respect to awards with service conditions is recognized using the straight-line method over the service period. Stock-based compensation with respect to awards with performance conditions is recognized when satisfaction of the performance conditions is probable. Stock-based compensation is based on awards ultimately expected to vest and, as such, it is reduced by forfeitures. The Company accounts for forfeitures as they occur.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair value of common stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The fair value of its common stock is based on the daily closing quoted market price of its common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Risk-free interest rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The risk-free interest rate is based on the US Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. Given the Company&#8217;s lack of specific history, the expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;Since the Company was privately held through October 29, 2020 and did not have any trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. During the fiscal year ended December 31, 2022 the Company began to incorporate the historical volatility of its own stock price in its calculation of its expected volatility.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected dividend yield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> &#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company uses an expected dividend yield of </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company also accounts for any modifications to share based payments in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Compensation &#8211; Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> (ASC 718).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The purchase price of the Company's common stock under the Company&#8217;s 2020 Employee Stock Purchase Plan ("ESPP") is equal to </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the lesser of (i) the fair market value per share of its common stock on the first business day of an offering period and (ii) the fair market value per share of its common stock on the purchase date. The fair value of the discounted purchases made under ESPP is calculated using the Black-Scholes valuation model. The fair value of the look-back provision plus the </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% discount is recognized as compensation expense over the 180-day purchase period.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with equity holders.  For the years ended December 31, 2023 and 2022, the only components of comprehensive loss other than net loss were unrealized gains and losses on available for sale investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Basic net income loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of shares of common stock outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding common stock equivalents except where such securities would be antidilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">In-process Research and Development Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In-process research and development assets that are acquired in a transaction that does not qualify as a business combination under GAAP and that do not have an alternative future use are expensed in the period in which the assets are acquired.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Segments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its chief executive officer, who manages and allocates resources to the operations on a total company basis. Accordingly, there is a </span><span style="font-size:10pt;font-family:Arial;"><span style="-sec-ix-hidden:F_26675b1d-cb04-4da6-8149-4bb408ad51ca;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> operating segment and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> reportable segment.</span></p></div><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Other accounting standards that have been issued or proposed by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s consolidated financial statements upon adoption.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company did not adopt any accounting pronouncements during the year ended December 31, 2023.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933214502704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Collaboration Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">3. Collaboration Agreement</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In October 2020, the Company entered into a License Agreement (&#8220;Roche License Agreement&#8221;) with F. Hoffmann-LaRoche Ltd. and Genentech, Inc. (together, &#8220;Roche&#8221;) under which the Company granted an exclusive license for certain development and commercialization rights related to bemnifosbuvir outside of the United States (other than for certain HCV uses) to Roche.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In November 2021, Roche provided the Company with a notice of termination of the Roche License Agreement which became effective in February 2022.  Upon termination, the rights and licenses granted by the Company to Roche under the Roche License Agreement were returned to the Company, resulting in the Company having all rights to continue the clinical development and future commercialization of bemnifosbuvir worldwide. Global development plan activities and related cost sharing between the parties continued through the effective date of the termination.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The activities to complete the global development plan were accounted for under ASC 808.  Expenses incurred and reimbursements made or received from Roche were accounted for pursuant to ASC 730, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  As such, the Company was expensing costs as incurred, including any reimbursements made to Roche, and recognizing reimbursement received from Roche as a reduction of research and development expense through the effective date of the termination.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For the year ended December 31, 2022, the Company recorded a net credit of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,898</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> from Roche. The credit recorded during the year ended December 31, 2022 represents a change in estimate as a result of close out activities and related reporting of amounts incurred by Roche associated with the global development plan. Included in prepaid expenses and other current assets as of December 31, 2022 is a net balance due from Roche of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,060</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  For the year ended December 31, 2023, the Company recorded a net credit of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,576</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> from Roche. The credit recorded during the year ended December 31, 2023 represents a change in estimate as a result of close out activities and related reporting of amounts incurred by Roche associated with the global development plan. Included in prepaid expenses and other current assets as of December 31, 2023 is a net balance due from Roche of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,904</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Payment for this amount due was received in February 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933217364848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">4. Fair Value Measurements</span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.331%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">143,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">143,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Marketable Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Treasury obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">155,938</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">155,938</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">178,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">178,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">39,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">39,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">60,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">60,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">143,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">434,283</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">578,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.331%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">167,584</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">167,584</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Marketable Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Treasury obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">310,433</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">310,433</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,508</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,508</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">167,584</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">458,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">625,833</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company&#8217;s assets with fair value categorized as Level 1 within the fair value hierarchy include money market accounts which invest in money market funds that are publicly traded mutual funds and are presented as cash equivalents on the consolidated balance sheets as of December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">There were no transfers among Level 1, Level 2 or Level 3 categories in the years ended December 31, 2023 and 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933220033152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">5. Marketable Securities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Arial;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.57%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.081999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.081999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.081999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.982%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Marketable Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Treasury obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">155,816</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">145</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">155,938</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">178,115</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">178,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">39,461</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">39,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">60,684</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">60,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">434,076</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">320</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">113</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">434,283</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.57%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.081999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.081999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.081999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.982%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Marketable Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Treasury obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,422</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">304</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">310,433</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">310,433</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,504</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">255</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,508</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">458,933</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">684</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">458,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023 and 2022, respectively the Company held</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ecurities, respectively that were in an unrealized loss position of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">113</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">684</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> with an aggregate fair value of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">178,003</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">143,221</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  The Company has the intent and ability to hold such securities until recovery. As a result, the Company did </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> record any charges for credit-related impairments for its marketable debt securities for the year ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">none</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> of the securities had remaining maturities longer than one year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company received proceeds of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">602,665</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">91,885</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> from sales and maturities of marketable securities during the year ended December 31, 2023 and 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933220059088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">6. Property and Equipment, net</span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Property and equipment, net, consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.84%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.04%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Office furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">396</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">396</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Computer hardware</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">102</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">102</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total property and equipment, at cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,978</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,978</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">273</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,289</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,705</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Depreciation and amortization expense was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">416</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">260</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for the years ended December 31, 2023 and 2022, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933220059088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">7. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development, including manufacturing and clinical expenditures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,999</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Payroll and payroll related</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,696</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,459</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Professional fees and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">669</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">981</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">27,364</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933373740416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">8. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Operating Lease Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In July 2021, the Company entered into a non-cancelable operating lease agreement pursuant to which the Company leased its principal office facility in </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Boston, Massachusetts at 225 Franklin Street</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> ("225 Lease"). The 225 Lease commencement date was </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">January 1, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and runs through </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">December 31, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The 225 Lease does </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">t contain any options for renewal or extension.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In connection with the 225 Lease commencement, the Company recorded a ROU asset and operating lease liability of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,938</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,873</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> as of January 1, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following assets and liabilities are recorded on the Company&#8217;s consolidated balance sheet as of December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.78%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.28%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,828</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">760</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">721</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-current operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,642</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,403</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The components of the lease expense which are allocated between the general and administrative expenses and the research and development expenses on the consolidated statement of operations for the years ended December 31, 2023 and 2022 were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.16%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.36%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">811</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">686</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">889</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The variable lease costs for the years ended December 31, 2023 and 2022 include common area maintenance and other operating charges associated with the 225 Lease. As the 225 Lease does not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company estimates it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.16%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.2%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of   December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Remaining lease term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Discount rate</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Future minimum payments under the 225 Lease, currently the Company&#8217;s only operating lease as of December 31, 2023 were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">821</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">838</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">855</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,514</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less amount representing implied interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">112</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,402</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">760</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Noncurrent portion of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,642</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Rent expense recognized was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">646</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">811</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for the years ended December 31, 2023 and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company maintains a deposit of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">198</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> with the landlord, which is included in other assets in the consolidated balance sheet as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">      </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">License Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In December 2021, the Company entered into a license agreement (&#8220;Merck License Agreement&#8221;) with MSD International GmbH, an affiliate of Merck &amp; Co, Inc. (&#8220;Merck&#8221;) for the development, manufacture and commercialization of ruzasvir. Ruzasvir is the NS5A inhibitor the Company is developing in combination with bemnifosbuvir for the treatment of HCV.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pursuant to the terms of the Merck License Agreement, the Company obtained from Merck a worldwide exclusive (subject to certain reserved rights to conduct internal research) and, sublicensable license under certain Merck patents and know-how to research, develop, manufacture, have manufactured, use, import, export, sell, offer for sale, and otherwise commercialize ruzasvir or products containing ruzasvir (each a &#8220;Product&#8221;) for all therapeutic or prophylactic uses in humans.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In addition to a non-refundable upfront payment that the Company made in February 2022, the Company will be required to pay Merck milestone payments upon its achievement of certain development, regulatory and sales-based milestones.  Additionally, the Company will pay Merck tiered royalties based on annual net sales of Products ranging from high single digits to mid-teens percentages. The Company&#8217;s royalty payment obligations will continue until the later of (i) the expiration of the last to expire valid claim of a licensed Merck patent claiming such Product and (ii) a period of years after the first commercial sale of such Product in such country. The Company may terminate the Merck License Agreement for convenience upon prior written notice. The first potential milestone in the amount of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million would be payable upon the commencement of a Phase 3 clinical trial.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Contingent Consulting Fee</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has an agreement with a consultant that requires payment of a success fee calculated as a percentage of certain product sales, subject to a cumulative maximum payout of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> million. This success payment is contingent upon the occurrence of future events and the timing and likelihood of such payment is neither probable nor estimable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Indemnification</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company enters into certain types of contracts that contingently requires the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i) the Company&#8217;s bylaws, under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship with the Company, (ii) contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship with the Company, and (iii) procurement, service or license agreements under which the Company may be required to indemnify vendors, service providers or licensees for certain claims, including claims that may be brought against them arising from the Company&#8217;s acts or omissions with respect to the Company&#8217;s products, technology, intellectual property or services.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on the Company&#8217;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount payable under these contracts since the Company has no history of prior indemnification claims and the unique facts and circumstances involved in each particular claim will be determinative.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933220033152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">9. Preferred Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023 the Company has </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of preferred stock authorized.  </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> of these shares of preferred stock have been issued.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933221585088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_CommonStockTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">10. Common Stock</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, the authorized capital of the Company included </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">300,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock, of which </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,435,513</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock were issued and outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">On all matters to be voted upon by the holders of common stock, holders of common stock are entitled to one vote per share.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> The holders of common stock are entitled to receive dividends, when declared by the board, and to share ratably in the Company&#8217;s assets legally available for distribution to the holders of the Company&#8217;s stock in the event of liquidation. The holders of common stock have no preemptive, redemption or conversion rights.</span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, the Company had the following reserved shares of common stock:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.18%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.14%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding options</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,017,319</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,337,517</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding performance-based restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">724,970</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares reserved for future grant under 2020 Incentive Award Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,510,704</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares reserved under Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,896,901</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,487,411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_CommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for common stock, including, but not limited to, the number of shares issued and outstanding, voting rights, and number of shares reserved for each class of stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_CommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933217111440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">11. Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In October 2020, the Company&#8217;s shareholders approved the Company&#8217;s 2020 Incentive Award Plan (&#8220;2020 Plan&#8221;). The 2020 Plan initially provided for the issuance of up to </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,924,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock and for the grant of incentive stock options or other incentive awards to employees, officers, directors and consultants of the Company. The number of shares of common stock that may be issued under the 2020 Plan is also subject to increase on the first day of each calendar year equal to the lesser of i) </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year or ii) such smaller number of shares as is determined by the board of directors. Through December 31, 2023, the shares available under the plan were increased by </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,450,364</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares.  As of December 31, 2023, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,510,704</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock were available for future issuance under the 2020 Plan. In January 2024, the shares of the Company's common stock available under the 2020 Plan were increased by </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,171,775</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The 2020 Plan replaced and is the successor of the Company&#8217;s 2013 Equity Incentive Plan, as amended (&#8220;2013 Plan&#8221;).  In the event of any cancellation of an outstanding option award under the 2013 Plan, the shares underlying the cancelled option award will be made available for grant under the 2020 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2023 and 2022, respectively, the Company granted </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,264,700</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">182,350</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> restricted stock units to employees with an aggregate grant date fair market value of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,384</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,302</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The restricted stock unit awards vest in </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> annual installments. In January 2023, the Company issued </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">53,935</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of common stock upon the vesting and settlement of restricted stock units. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,998</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,600</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> restricted stock units were cancelled due to employee terminations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:12pt;font-family:Arial;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.8%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.66%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding at January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">161,750</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,264,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Released</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">53,935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unvested shares at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,337,517</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.69</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Performance-based Restricted Stock Units</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> performance-based restricted stock units were granted during the year ended December 31, 2023. During the year ended December 31, 2022, the Company granted </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">742,070</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> performance-based restricted stock units to employees with an aggregate grant date fair value of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,298</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> performance-based restricted stock units were granted during the year ended December 31, 2023.  </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The performance stock unit awards provide for a performance period from February 1, 2022 through January 31, 2025 to achieve up to six defined performance metrics.  The percentage of each award eligible to vest will be determined based on the number of metrics achieved during the performance period and may range from </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">%. The Company has not recognized any compensation expense through December 31, 2023, as the minimum performance criteria had not been deemed probable. The vesting of any eligible awards will occur in equal installments on January 31, 2025 and January 31, 2026.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2023, there were </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> cancellations of performance-based restricted stock units.  During the year ended December 31, 2022, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> performance-based restricted stock units were cancelled due to employee terminations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Arial;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.8%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.66%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding at January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">724,970</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Release</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unvested shares at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">724,970</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following summarizes stock option activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.17%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.602%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.001999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.602%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price<br/>Per Share</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>($000s)</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding at January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,632,278</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,937</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,777,550</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">392,509</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.46</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,017,319</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Vested and expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,017,319</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Vested and exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,084,169</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.46</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,078</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of the options and the estimated fair value of the Company&#8217;s common stock for those options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Option grants generally vest over a service period of </span><span style="font-size:10pt;font-family:Arial;"><span style="-sec-ix-hidden:F_09624d57-9bf3-4359-9740-b83c401c942c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and have a contractual term of </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. As of December 31, 2023, total unrecognized compensation expense related to stock option awards was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">55,157</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, which amount is being recognized over a remaining weighted average period of </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">2.2</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The weighted average grant date fair value per option granted during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.09</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, respectively. </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The fair value of each award was estimated using </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Black-Scholes</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> based on the following assumptions:</span></span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.04%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.86%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected term</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.97</span></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.96</span></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">85.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">85.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In October 2020, the Company&#8217;s shareholders approved the ESPP, which became effective upon the closing of the Company&#8217;s IPO in November 2020. The Company initially reserved a total of </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,187,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares of its common stock for issuance under the ESPP. The ESPP provides that the number of shares reserved and available for issuance under the ESPP will be increased on January 1 of each calendar year by </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding December 31 or such lesser amount as specified by the board of directors. Through December 31, 2022, there was no increase in the number of shares reserved for issuance under the ESPP.  In January 2024 and 2023, the number of shares of the Company's common stock available for issuance under the ESPP was increased by </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">834,355</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">832,876</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company issued </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">93,939</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">29,036</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares for proceeds of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">257</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">140</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> during the years ended December 31, 2023 and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock-based Compensation Expense</span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock-based compensation expense is classified as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.32%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.14%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">22,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">21,870</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">26,762</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">24,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">49,428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">46,718</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The components of stock-based compensation expense were:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.32%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.14%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,679</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">352</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Performance-based restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">45,626</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">46,220</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">49,428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">46,718</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933219980800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">12.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For the year ended December 31, 2023, the Company recorded income tax expense of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,018</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  The Company recorded a net benefit for income taxes of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,590</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for the year ended December 31, 2022.  The benefit for income taxes was primarily the result of changes in estimates between the Company&#8217;s initial provision for 2021 income taxes and the actual amounts reflected in the income tax returns as filed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.62%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.4%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected income tax benefit at the federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">State and local taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Return to provision adjustments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets consisted of the following:</span></span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Deferred tax assets (liabilities)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">33,692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,305</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,385</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,590</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">License agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,043</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,884</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,215</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,826</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">695</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">893</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Deferred tax assets (liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">74,173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">41,156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">74,173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">41,156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As required by the 2017 Tax Cut and Jobs Act, effective January 1, 2022, taxpayers can no longer immediately expense qualified research and development expenditures. Taxpayers are now required to capitalize and amortize these costs over </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for research conducted in the US or </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">15 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> for research conducted abroad.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, the Company had federal net operating losses of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">31,378</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and state net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">55,305</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, which may be used to offset future tax liabilities.  The Company has federal and state credit carryforwards of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,944</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,210</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, respectively. The federal net operating losses and research and development tax credits begin to expire in </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">2034</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Management has evaluated the positive and negative evidence bearing upon the realizability of the Company&#8217;s deferred tax assets. Based on the Company&#8217;s projected net operating losses, for 2024 and beyond, the Company determined that it is more likely than not that it will not recognize the benefits of the deferred tax assets. As a result, the Company has recorded a full valuation allowance of approximately $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">74,173</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> at December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Under the provisions of Sections 382 and 383 of the Internal Revenue Code (&#8220;IRC&#8221;), net operating loss and credit carryforwards and other tax attributes may be subject to limitation if there has been a significant change in ownership of the Company, as defined by the IRC.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company performed an analysis through December 31, 2023 pursuant to Section 382 of the IRC to determine whether any limitations might exist on the utilization of net operating losses and other tax attributes. Based on this analysis, the Company has determined that there was no impact on the Company's ability to utilize net operating losses or credit carryforwards in 2023.  To the extent that the Company raises additional equity financing or other changes in the ownership interest of significant stockholders occurs, additional tax attributes may become subject to an annual limitation. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company files federal and various state income tax returns. The statute of limitations for assessment by the Internal Revenue Service (&#8220;IRS&#8221;), and state tax authorities remains open for all tax years ended since the inception of the Company. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the IRS or state tax authorities to the extent utilized in a future period. No federal or state tax audits are currently in process.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table summarizes the reconciliation of the beginning and ending amount of total unrecognized tax benefits for the year ended December 31, 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.32%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.78%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance beginning of year</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,255</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Decrease related to current year provision to return adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Increase related to accrued interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">503</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance at end of period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,758</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933219929200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">13. Net Loss Per Share</span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Basic and diluted earnings per share are calculated as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.211%;"></td>
        <td style="width:9.142%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.903%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.683%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:3.75pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="border-top:3.75pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="6" style="border-top:3.75pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
        <td style="border-top:3.75pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">135,956</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">115,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,389,750</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,245,385</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss per share - basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock options for the purchase of </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,017,319</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,337,517</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> restricted stock units, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">724,970</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> performance-based restricted stock units and </span><span style="font-size:10pt;font-family:Arial;white-space:pre-wrap;min-width:fit-content;color:#000000;">30,254</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> ESPP shares w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ere excluded from the computation of the net loss per share for the year ended December 31, 2023, due to the net loss during the periods as their effect is antidilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock options for the purchase of </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,632,278</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> shares, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">161,750</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> restricted stock units, </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">724,970</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> performance-based restricted stock units and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">24,743</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> ESPP shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">were excluded from the computation of the net loss per share for the year ended December 31, 2022, due to the net loss during the periods as their effect is antidilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933219915680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Benefit Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">14. Benefit Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2021, the Company implemented a defined contribution plan under Section 401(k) of the Internal Revenue Code (&#8220;401(k) Plan&#8221;). The 401(k) Plan covers substantially all employees who meet minimum age and service requirements.  Under the terms of the 401(k) Plan, the Company records matching contributions up to </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the participant&#8217;s eligible compensation. During the years ended December 31, 2023 and 2022, the Company recognized expense of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">708</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">541</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, respectively, relating to matching contributions to the 401(k) Plan.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933222545584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">15. Related Party Transactions</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">During the year ended December 31, 2021, the Company entered into a consulting agreement with an entity controlled by one of its directors.  The agreement provides for an annual retainer of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.  The Company recognized expense in the amount of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> in each of the years ended December 31, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In May 2022, the Company entered into a consulting agreement with one of its directors.  The Company recognized expense of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> in connection with this consulting agreement for the year ended December 31, 2022.  </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> expense related to this agreement was recognized during the year ended December 31, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933216832608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock', window );">Basis of Presentation and Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Basis of Presentation and Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and in these accompanying notes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors and assumptions that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, which include but are not limited to estimates of accrued research and development expenses, valuation of marketable securities, valuation of stock-based awards, valuation of operating lease right-of-use assets and lease liabilities and income taxes. Changes in estimates are recorded in the period in which they become known.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The consolidated financial statements include the accounts of Atea Pharmaceuticals, Inc. and its wholly- owned subsidiary, Atea Pharmaceuticals Securities Corporation. All intercompany amounts have been eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company considers all highly-liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company&#8217;s cash equivalents include money market funds and commercial paper, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company&#8217;s investment strategy is principally focused on capital preservation. The Company invests in financial instruments that among other things meet the credit quality standards outlined in the Company&#8217;s investment policy. Marketable securities consist of investments with maturities greater than three months. Investments not classified as cash equivalents with maturities of less than twelve months are classified as current assets on the consolidated balance sheet.  Investments with maturities greater than twelve months for which the Company has the intent and ability to hold the investment for greater than twelve months are classified as non-current on the consolidated balance sheet. Marketable securities include US treasury obligations, US agency obligations, corporate debt, commercial paper and asset-backed securities.  The Company classifies all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Unrealized gains and losses are recorded as a component of accumulated other comprehensive gain (loss) within stockholders&#8217; equity. Interest, dividends and amortization and accretion of discounts and premiums are recorded as interest income and other, net.  The Company periodically reviews its marketable securities for impairment and adjusts these investments to their fair value when a decline in market value is deemed to be other than temporary.  Declines in fair value judged to be other than temporary on marketable securities, if any, are included in interest income and other, net.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock', window );">Concentrations of Credit Risk and Significant Suppliers</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Significant Suppliers</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the US government. The Company does not believe that it is subject to any significant concentrations of credit risk from these financial instruments. The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company is dependent on third-party manufacturers for the supply of products for its research and development activities including its development programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs for preclinical and clinical development activities. The Company also currently anticipates to rely on this small number of manufacturers for commercial supply if any of the current product candidates are approved for sale. The Company's research and development programs, including any potential commercialization efforts, could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair Value Measurement,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Level 1&#8212;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Level 2&#8212;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Level 3&#8212;Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the assets and liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The carrying amounts of prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value due to short-term nature of these assets and liabilities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the asset. </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company estimates the useful life of its assets as follows:</span></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Arial;">
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.17%;"></td>
          <td style="width:1.66%;"></td>
          <td style="width:49.17%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Asset</span></p></td>
          <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Five years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Office furniture and fixtures</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Five years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Computer hardware</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Two years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="-sec-ix-hidden:F_3be2bd17-90cb-4ad6-9f95-d622754a93f7;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of useful life or remaining lease term</span></span></span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Maintenance and repairs that do not improve or extend the life of the respective asset are expensed to operations as incurred. Upon disposal of an asset, the related cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the consolidated statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_OtherAssetsPolicyTextBlock', window );">Other Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Other Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Other assets consist of vendor deposits related to research and development activities and a security deposit related to our facility lease.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Impairment of Long-lived Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Company reviews long-lived assets, including property and equipment and right-of-use assets ("ROU") when events or changes in circumstances indicate the carrying value of the assets may not be fully recoverable. Recoverability is measured by comparing the book value of the assets to the estimated undiscounted future net cash flows that the asset is expected to generate. If the estimated undiscounted future net cash flows are less than the book value, the asset is impaired, and the impairment loss to be recognized in income is measured as the amount by which the book value of the asset exceeds its fair value, which is measured based on the estimated discounted future net cash flows that the asset is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">expected </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">to generate. </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> impairment losses were recorded during the years ended December 31, 2023 and 2022.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company accounts for leases in accordance with ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Lease Accounting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.   At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. Leases with a term greater than one year are recognized on the consolidated balance sheet as a ROU asset and current and non-current lease liabilities, as applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense.  The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company estimates it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses consist principally of costs associated with outsourced research and development activities, including drug discovery, preclinical and clinical development, manufacturing and research conducted by contract research organizations and academic institutions, employee compensation, including stock-based compensation and consulting expenses together with related expenses, professional fees and facility and overhead costs. Facility and overhead costs primarily include the allocation of rent, utility and office-related expenses attributable to research and development personnel. In circumstances where amounts have been paid in advance or in excess of costs incurred, the Company records a prepaid expense, which is expensed as services are performed or goods are delivered.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has entered into various research and development contracts with third parties. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase of completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Patent Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Costs to secure and maintain the Company&#8217;s patents are expensed as incurred and are classified as general and administrative expenses in the Company&#8217;s consolidated statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Stock-based Compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock-based compensation expense is classified in the consolidated statement of operations and comprehensive loss in the same manner as the award recipient&#8217;s payroll costs or service payments are classified. Stock-based awards granted to employees and non-employees are measured based on the estimated fair value of the awards using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;). Stock-based compensation expense with respect to awards with service conditions is recognized using the straight-line method over the service period. Stock-based compensation with respect to awards with performance conditions is recognized when satisfaction of the performance conditions is probable. Stock-based compensation is based on awards ultimately expected to vest and, as such, it is reduced by forfeitures. The Company accounts for forfeitures as they occur.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Fair value of common stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The fair value of its common stock is based on the daily closing quoted market price of its common stock.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Risk-free interest rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The risk-free interest rate is based on the US Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. Given the Company&#8217;s lack of specific history, the expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8212;Since the Company was privately held through October 29, 2020 and did not have any trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. During the fiscal year ended December 31, 2022 the Company began to incorporate the historical volatility of its own stock price in its calculation of its expected volatility.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Expected dividend yield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> &#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company uses an expected dividend yield of </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company also accounts for any modifications to share based payments in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Compensation &#8211; Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> (ASC 718).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The purchase price of the Company's common stock under the Company&#8217;s 2020 Employee Stock Purchase Plan ("ESPP") is equal to </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% of the lesser of (i) the fair market value per share of its common stock on the first business day of an offering period and (ii) the fair market value per share of its common stock on the purchase date. The fair value of the discounted purchases made under ESPP is calculated using the Black-Scholes valuation model. The fair value of the look-back provision plus the </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">% discount is recognized as compensation expense over the 180-day purchase period.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with equity holders.  For the years ended December 31, 2023 and 2022, the only components of comprehensive loss other than net loss were unrealized gains and losses on available for sale investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Basic net income loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of shares of common stock outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding common stock equivalents except where such securities would be antidilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock', window );">In-process Research and Development Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">In-process Research and Development Assets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In-process research and development assets that are acquired in a transaction that does not qualify as a business combination under GAAP and that do not have an alternative future use are expensed in the period in which the assets are acquired.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Segments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its chief executive officer, who manages and allocates resources to the operations on a total company basis. Accordingly, there is a </span><span style="font-size:10pt;font-family:Arial;"><span style="-sec-ix-hidden:F_26675b1d-cb04-4da6-8149-4bb408ad51ca;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> operating segment and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> reportable segment.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements and Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Other accounting standards that have been issued or proposed by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s consolidated financial statements upon adoption.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company did not adopt any accounting pronouncements during the year ended December 31, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS) as well as the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk and risk associated with reliance on significant suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets, not acquired in a business combination, to be used in research and development activities. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_OtherAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for items classified as other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_OtherAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933219968880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of Estimated Useful Life</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company estimates the useful life of its assets as follows:</span>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.17%;"></td>
          <td style="width:1.66%;"></td>
          <td style="width:49.17%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Asset</span></p></td>
          <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Five years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Office furniture and fixtures</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Five years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Computer hardware</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Two years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;"><span style="-sec-ix-hidden:F_3be2bd17-90cb-4ad6-9f95-d622754a93f7;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of useful life or remaining lease term</span></span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of physical assets used in the normal conduct of business and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933219980800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.331%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">143,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">143,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Marketable Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Treasury obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">155,938</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">155,938</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">178,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">178,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">39,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">39,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">60,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">60,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">143,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">434,283</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">578,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.331%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.618%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">167,584</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">167,584</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Marketable Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Treasury obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">310,433</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">310,433</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,508</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,508</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">167,584</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">458,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">625,833</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933219926768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.57%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.081999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.081999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.081999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.982%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Marketable Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Treasury obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">155,816</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">145</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">155,938</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">178,115</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">178,160</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">39,461</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">39,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">60,684</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">60,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">434,076</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">320</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">113</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">434,283</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.57%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.081999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.081999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.081999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.982%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Marketable Securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Treasury obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,422</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">304</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">US Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">310,433</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">310,433</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,504</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">255</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">61,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Asset-backed securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,508</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">458,933</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">684</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">458,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933222540816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Property and equipment, net, consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.84%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.04%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Office furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">396</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">396</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Computer hardware</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">102</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">102</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total property and equipment, at cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,978</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,978</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">273</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,289</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,705</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933219923040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development, including manufacturing and clinical expenditures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,999</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,667</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Payroll and payroll related</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,696</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,459</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Professional fees and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">669</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">981</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">27,364</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933218240944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Summary of Assets and Liabilities Recorded on Consolidated Balance Sheet</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following assets and liabilities are recorded on the Company&#8217;s consolidated balance sheet as of December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.78%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.28%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,828</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">760</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">721</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-current operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,642</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,403</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The components of the lease expense which are allocated between the general and administrative expenses and the research and development expenses on the consolidated statement of operations for the years ended December 31, 2023 and 2022 were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.16%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.36%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">811</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">686</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">889</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock', window );">Summary of Remaining Lease Term and Discount Rate</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The variable lease costs for the years ended December 31, 2023 and 2022 include common area maintenance and other operating charges associated with the 225 Lease. As the 225 Lease does not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company estimates it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.16%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.2%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">As of   December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Remaining lease term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Discount rate</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Payments under Operating Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Future minimum payments under the 225 Lease, currently the Company&#8217;s only operating lease as of December 31, 2023 were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">821</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">838</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">855</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,514</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less amount representing implied interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">112</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,402</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">760</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Noncurrent portion of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,642</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to leases including, but not limited to, the remaining lease term and discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933219923040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Summary of Reserved Shares of Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As of December 31, 2023, the Company had the following reserved shares of common stock:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.18%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.14%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding options</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,017,319</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,337,517</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding performance-based restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">724,970</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares reserved for future grant under 2020 Incentive Award Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,510,704</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Shares reserved under Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,896,901</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,487,411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933218326144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following summarizes stock option activity:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.17%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.602%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.001999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.602%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price<br/>Per Share</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>($000s)</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding at January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,632,278</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,937</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,777,550</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">392,509</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.46</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,017,319</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Vested and expected to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,017,319</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Vested and exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,084,169</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.46</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,078</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Estimate Fair Value of Award</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The fair value of each award was estimated using </span><span style="font-size:10pt;font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Black-Scholes</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> based on the following assumptions:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.04%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:22.86%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected term</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.97</span></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.96</span></span><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">85.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">85.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Stock-based compensation expense is classified as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.32%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.14%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">22,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">21,870</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">26,762</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">24,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">49,428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">46,718</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Components of Stock-based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The components of stock-based compensation expense were:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.32%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.14%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,679</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">352</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Performance-based restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">45,626</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">46,220</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">49,428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">46,718</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Units</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.8%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.66%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding at January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">161,750</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,264,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Released</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">53,935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unvested shares at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,337,517</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.69</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avir_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Units</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.8%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.58%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.66%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Outstanding at January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">724,970</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Release</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unvested shares at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">724,970</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avir_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avir_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933214224160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.62%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.4%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Expected income tax benefit at the federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">State and local taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Return to provision adjustments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Principal Components of Deferred Tax Assets</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets consisted of the following:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Deferred tax assets (liabilities)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">33,692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,305</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,385</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,590</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">License agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,043</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,884</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,215</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,826</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">695</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">893</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Deferred tax assets (liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">74,173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">41,156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">74,173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">41,156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The following table summarizes the reconciliation of the beginning and ending amount of total unrecognized tax benefits for the year ended December 31, 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.32%;"></td>
        <td style="width:1.9%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.78%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance beginning of year</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,255</span></p></td>
        <td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Decrease related to current year provision to return adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Increase related to accrued interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">503</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Balance at end of period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,758</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933222542048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Basic and diluted earnings per share are calculated as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.211%;"></td>
        <td style="width:9.142%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.903%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.06%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.683%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="border-top:3.75pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="border-top:3.75pt solid #000000;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="6" style="border-top:3.75pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">For the Year Ended<br/>December 31,</span></p></td>
        <td style="border-top:3.75pt solid #000000;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">135,956</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">115,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,389,750</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">83,245,385</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss per share - basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(</span><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933218428112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_NatureOfBusinessLineItems', window );"><strong>Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 143,823<span></span>
</td>
<td class="nump">$ 188,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="nump">$ 578,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">83,435,513<span></span>
</td>
<td class="nump">83,287,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=avir_JefferiesLlcMember', window );">Jeffries | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_NatureOfBusinessLineItems', window );"><strong>Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_CommissionRate', window );">Commission percentage of aggregate gross proceeds from each sale of shares</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=avir_JefferiesLlcMember', window );">Jeffries | Maximum | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_NatureOfBusinessLineItems', window );"><strong>Nature of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_StockIssuanceProgramAuthorizedAmount', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_CommissionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The commission rate the Company agreed to pay for shares sold under a Sales Agreement, as a percentage of aggregate gross sales proceeds from each sale of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_CommissionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_NatureOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_NatureOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_StockIssuanceProgramAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of shares authorized to be issued under a stock issuance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_StockIssuanceProgramAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avir_JefferiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avir_JefferiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=avir_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=avir_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933218262448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Incremental cost included in general and administration costs | $</a></td>
<td class="nump">$ 49,919,000<span></span>
</td>
<td class="nump">$ 48,714,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate', window );">Percentage of common stock purchase price, lesser of market value per share on offering or purchase date</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock', window );">Percentage of discount on common stock purchase price</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount on the purchase price of common stock, as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The purchase price of common stock, as a percentage of the lessor of the fair market value per share of the common stock on the first business day of an offering period or on the purchase date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933214280592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avir_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Hardware</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Estimated useful life</a></td>
<td class="text">us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avir_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=avir_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933218415936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 114,243<span></span>
</td>
<td class="nump">$ 81,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">27,364<span></span>
</td>
<td class="nump">15,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">12,349<span></span>
</td>
<td class="nump">14,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avir_RocheLicenseAgreementMember', window );">Roche License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ResearchAndDevelopmentCreditAdjustment', window );">Research and development net credit adjustment</a></td>
<td class="nump">18,576<span></span>
</td>
<td class="nump">6,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 5,904<span></span>
</td>
<td class="nump">$ 1,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_ResearchAndDevelopmentCreditAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate credit recorded during the period to research and development expense as a result of adjustments to amounts originally reported and the close out of certain activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_ResearchAndDevelopmentCreditAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avir_RocheLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avir_RocheLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933219184656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 434,283<span></span>
</td>
<td class="nump">$ 458,249<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">578,023<span></span>
</td>
<td class="nump">625,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">143,740<span></span>
</td>
<td class="nump">167,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">434,283<span></span>
</td>
<td class="nump">458,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">155,938<span></span>
</td>
<td class="nump">59,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury obligations | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">155,938<span></span>
</td>
<td class="nump">59,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">178,160<span></span>
</td>
<td class="nump">14,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">178,160<span></span>
</td>
<td class="nump">14,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">39,448<span></span>
</td>
<td class="nump">310,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">39,448<span></span>
</td>
<td class="nump">310,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">60,737<span></span>
</td>
<td class="nump">61,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">60,737<span></span>
</td>
<td class="nump">61,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">143,740<span></span>
</td>
<td class="nump">167,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 143,740<span></span>
</td>
<td class="nump">$ 167,584<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933217739296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 434,076<span></span>
</td>
<td class="nump">$ 458,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(684)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">434,283<span></span>
</td>
<td class="nump">458,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">155,816<span></span>
</td>
<td class="nump">59,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">155,938<span></span>
</td>
<td class="nump">59,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">178,115<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">178,160<span></span>
</td>
<td class="nump">14,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">39,461<span></span>
</td>
<td class="nump">310,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">39,448<span></span>
</td>
<td class="nump">310,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">60,684<span></span>
</td>
<td class="nump">61,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 60,737<span></span>
</td>
<td class="nump">61,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933213388928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of held securities | Security</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt securities in unrealized loss position</a></td>
<td class="nump">$ 113,000<span></span>
</td>
<td class="nump">$ 684,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate fair value</a></td>
<td class="nump">178,003,000<span></span>
</td>
<td class="nump">143,221,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">434,283,000<span></span>
</td>
<td class="nump">458,249,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded', window );">Marketable debt securities, charges for credit-related impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Securities maturing longer than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">$ 602,665,000<span></span>
</td>
<td class="nump">$ 91,885,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933218283024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">$ 1,978<span></span>
</td>
<td class="nump">$ 1,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(689)<span></span>
</td>
<td class="num">(273)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,289<span></span>
</td>
<td class="nump">1,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avir_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">$ 1,475<span></span>
</td>
<td class="nump">$ 1,475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avir_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=avir_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933217246000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 416<span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933218064576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent', window );">Research and development, including manufacturing and clinical expenditures</a></td>
<td class="nump">$ 20,999<span></span>
</td>
<td class="nump">$ 7,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and payroll related</a></td>
<td class="nump">5,696<span></span>
</td>
<td class="nump">6,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_AccruedProfessionalFeesAndOtherCurrent', window );">Professional fees and other</a></td>
<td class="nump">669<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 27,364<span></span>
</td>
<td class="nump">$ 15,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_AccruedProfessionalFeesAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received, and fees classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_AccruedProfessionalFeesAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for research and development, including, but not limited to, manufacturing and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933223417680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Assets and Liabilities Recorded on Consolidated Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 1,828<span></span>
</td>
<td class="nump">$ 2,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">760<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liability</a></td>
<td class="nump">$ 1,642<span></span>
</td>
<td class="nump">$ 2,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933214698000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Components of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 646<span></span>
</td>
<td class="nump">$ 811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 686<span></span>
</td>
<td class="nump">$ 889<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933219925936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Remaining Lease Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933219132608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,828,000<span></span>
</td>
<td class="nump">$ 2,389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,000<span></span>
</td>
<td class="nump">811,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,243,000<span></span>
</td>
<td class="nump">$ 81,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avir_OfficeFacilityMember', window );">Office Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_LocationOfOfficeSpace', window );">Location of office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Boston, Massachusetts at 225 Franklin Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,938,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,873,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend', window );">Lessor, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Business Development Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ConsultingAgreementSuccessFeePayout', window );">Success fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=avir_MerckLicenseAgreementMember', window );">Merck License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_BankDepositRestrictedCash', window );">Bank deposits, restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_BankDepositRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of a bank deposit to collateralize a letter of credit, classified as restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_BankDepositRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_ConsultingAgreementSuccessFeePayout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount payable by the Company, as part of a consulting agreement. The payout amount is a success fee calculated as a percentage of certain product sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_ConsultingAgreementSuccessFeePayout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to commence, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_LocationOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Location of Office Space</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_LocationOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due upon achievement of specified milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessor has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avir_OfficeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=avir_OfficeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=avir_BusinessDevelopmentConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=avir_BusinessDevelopmentConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=avir_MerckLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=avir_MerckLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933325153776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Payments under Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amount representing implied interest</a></td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">2,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">760<span></span>
</td>
<td class="nump">$ 721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent portion of operating lease liabilities</a></td>
<td class="nump">$ 1,642<span></span>
</td>
<td class="nump">$ 2,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933222491088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Preferred Stock - Additional Information (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933220481024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">83,435,513<span></span>
</td>
<td class="nump">83,287,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">83,435,513<span></span>
</td>
<td class="nump">83,287,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights per share</a></td>
<td class="text">On all matters to be voted upon by the holders of common stock, holders of common stock are entitled to one vote per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933217226816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Summary of Reserved Shares of Common Stock (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">28,487,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avir_OutstandingOptionsMember', window );">Outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">17,017,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avir_OutstandingRestrictedStockUnitsMember', window );">Outstanding restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">2,337,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avir_OutstandingPerformanceBasedRestrictedStockUnitsMember', window );">Outstanding performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">724,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember', window );">Shares reserved for future grant under 2020 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">6,510,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avir_SharesReservedUnderEmployeeStockPurchasePlanMember', window );">Shares reserved under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">1,896,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avir_OutstandingOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avir_OutstandingOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avir_OutstandingRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avir_OutstandingRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avir_OutstandingPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avir_OutstandingPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avir_SharesReservedUnderEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avir_SharesReservedUnderEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933212707936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,487,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,487,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Gross proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per option granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="nump">$ 5.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed', window );">Fair value assumptions, method used</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Black-Scholes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage', window );">Percentage of shares of common stock Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,187,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,939<span></span>
</td>
<td class="nump">29,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Gross proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,264,700<span></span>
</td>
<td class="nump">182,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue', window );">Aggregate grant date fair market value of restricted stock units granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,384<span></span>
</td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments', window );">Number of installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of units cancelled due to terminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,998<span></span>
</td>
<td class="nump">20,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,337,517<span></span>
</td>
<td class="nump">161,750<span></span>
</td>
<td class="nump">2,337,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avir_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">742,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue', window );">Aggregate grant date fair market value of restricted stock units granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of units cancelled due to terminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Performance based restricted stock units terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The performance stock unit awards provide for a performance period from February 1, 2022 through January 31, 2025 to achieve up to six defined performance metrics.  The percentage of each award eligible to vest will be determined based on the number of metrics achieved during the performance period and may range from 0% to 200%. The Company has not recognized any compensation expense through December 31, 2023, as the minimum performance criteria had not been deemed probable. The vesting of any eligible awards will occur in equal installments on January 31, 2025 and January 31, 2026.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">724,970<span></span>
</td>
<td class="nump">724,970<span></span>
</td>
<td class="nump">724,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Vesting contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining weighted average period for recognize compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avir_TwoThousandTwentyIncentiveAwardPlanMember', window );">2020 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage', window );">Percentage of shares of common stock Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increased number of shares available under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,450,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,510,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,510,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2020 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increased number of shares available under plan</a></td>
<td class="nump">4,171,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Performance-based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Vesting service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2020 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,924,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Performance-based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Vesting service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,939<span></span>
</td>
<td class="nump">29,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increased number of shares available under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">832,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increased number of shares available under plan</a></td>
<td class="nump">834,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year, as a percentage of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate grant date fair value of equity instruments other than options granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of annual installments in which a share-based payment award vests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of method used to estimate fair value of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avir_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avir_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avir_TwoThousandTwentyIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avir_TwoThousandTwentyIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933219033568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Restricted Stock Units (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Outstanding</a></td>
<td class="nump">161,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted</a></td>
<td class="nump">2,264,700<span></span>
</td>
<td class="nump">182,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod', window );">Number of shares, Released</a></td>
<td class="num">(53,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Cancelled</a></td>
<td class="num">(34,998)<span></span>
</td>
<td class="num">(20,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested</a></td>
<td class="nump">2,337,517<span></span>
</td>
<td class="nump">161,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding</a></td>
<td class="nump">$ 7.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="nump">4.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Released</a></td>
<td class="nump">7.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Cancelled</a></td>
<td class="nump">5.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested</a></td>
<td class="nump">$ 4.69<span></span>
</td>
<td class="nump">$ 7.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avir_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Outstanding</a></td>
<td class="nump">724,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">742,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Cancelled</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested</a></td>
<td class="nump">724,970<span></span>
</td>
<td class="nump">724,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding</a></td>
<td class="nump">$ 7.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested</a></td>
<td class="nump">$ 7.14<span></span>
</td>
<td class="nump">$ 7.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were released during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were released during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avir_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avir_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933217121744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Options Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding</a></td>
<td class="nump">13,632,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Shares, Granted</a></td>
<td class="nump">3,777,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Shares, Cancelled</a></td>
<td class="num">(392,509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding</a></td>
<td class="nump">17,017,319<span></span>
</td>
<td class="nump">13,632,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Shares, Vested and expected to vest</a></td>
<td class="nump">17,017,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Shares, Vested and exercisable</a></td>
<td class="nump">11,084,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding</a></td>
<td class="nump">$ 18.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Granted</a></td>
<td class="nump">4.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Cancelled</a></td>
<td class="nump">21.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding</a></td>
<td class="nump">15.30<span></span>
</td>
<td class="nump">$ 18.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and expected to vest</a></td>
<td class="nump">15.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and exercisable</a></td>
<td class="nump">$ 16.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (years), Outstanding</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (years), Vested and expected to vest</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (years), Vested and exercisable</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 5,080<span></span>
</td>
<td class="nump">$ 10,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">5,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and exercisable</a></td>
<td class="nump">$ 5,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933220281104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Assumptions Used to Estimate Fair Value of Award (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.65%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 11 months 19 days<span></span>
</td>
<td class="text">5 years 11 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933212603440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 49,428<span></span>
</td>
<td class="nump">$ 46,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">22,666<span></span>
</td>
<td class="nump">21,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 26,762<span></span>
</td>
<td class="nump">$ 24,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933325162080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Components of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 49,428<span></span>
</td>
<td class="nump">$ 46,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,679<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">45,626<span></span>
</td>
<td class="nump">46,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avir_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avir_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avir_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933214716208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 1,018<span></span>
</td>
<td class="num">$ (3,590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 74,173<span></span>
</td>
<td class="nump">41,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax examination description</a></td>
<td class="text">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefit</a></td>
<td class="nump">$ 5,758<span></span>
</td>
<td class="nump">$ 5,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">31,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 6,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_OperatingLossCarryforwardsExpirationYear', window );">Net operating losses carryforwards expiration year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ResearchAndDevelopmentCostsAmortizationPeriod', window );">Research and development costs amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_ResearchAndDevelopmentCostsAmortizationPeriod', window );">Research and development costs amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 55,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=avir_ResearchAndDevelopmentTaxCreditsMember', window );">Research and Development Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The year that operating loss carryforwards will begin to expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_ResearchAndDevelopmentCostsAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization period of costs capitalized for research and development, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_ResearchAndDevelopmentCostsAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The year that tax credit carryforwards will begin to expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=avir_ResearchAndDevelopmentTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=avir_ResearchAndDevelopmentTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933217716352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Expected income tax benefit at the federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Return to provision adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(4.30%)<span></span>
</td>
<td class="num">(3.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(24.50%)<span></span>
</td>
<td class="num">(25.30%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933217718272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Principal Components of Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred tax assets (liabilities)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts', window );">Capitalized research and development</a></td>
<td class="nump">$ 33,692,000<span></span>
</td>
<td class="nump">$ 14,305,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">9,385,000<span></span>
</td>
<td class="nump">5,590,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_DeferredTaxAssetsLicenseAgreement', window );">License agreement</a></td>
<td class="nump">5,609,000<span></span>
</td>
<td class="nump">6,043,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">17,884,000<span></span>
</td>
<td class="nump">12,215,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">8,155,000<span></span>
</td>
<td class="nump">3,826,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">143,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_DeferredTaxAssetsPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(695,000)<span></span>
</td>
<td class="num">(893,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets (liabilities)</a></td>
<td class="nump">74,173,000<span></span>
</td>
<td class="nump">41,156,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(74,173,000)<span></span>
</td>
<td class="num">(41,156,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs. Excludes costs in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_DeferredTaxAssetsLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_DeferredTaxAssetsLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_DeferredTaxAssetsPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_DeferredTaxAssetsPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933221436368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance beginning of year</a></td>
<td class="nump">$ 5,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest', window );">Increase related to accrued interest</a></td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of period</a></td>
<td class="nump">$ 5,758<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933325156192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Basic and Diluted Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (135,956)<span></span>
</td>
<td class="num">$ (115,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">83,389,750<span></span>
</td>
<td class="nump">83,245,385<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">83,389,750<span></span>
</td>
<td class="nump">83,245,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.63)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.63)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933214259504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of shares excluded from computation of diluted net income per share</a></td>
<td class="nump">17,017,319<span></span>
</td>
<td class="nump">13,632,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of shares excluded from computation of diluted net income per share</a></td>
<td class="nump">2,337,517<span></span>
</td>
<td class="nump">161,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avir_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of shares excluded from computation of diluted net income per share</a></td>
<td class="nump">724,970<span></span>
</td>
<td class="nump">724,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of shares excluded from computation of diluted net income per share</a></td>
<td class="nump">30,254<span></span>
</td>
<td class="nump">24,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avir_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avir_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933213414544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plan - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan recognized expense related to matching contributions</a></td>
<td class="nump">$ 708<span></span>
</td>
<td class="nump">$ 541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, employer matching contribution, percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139933217717632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - Consulting Agreement - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avir_ConsultingAgreementMember', window );">Director | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Related party transaction expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avir_ConsultingAgreementMember', window );">Entity Controlled by Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainageDeposit', window );">Annual retainer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avir_ConsultingAgreementMember', window );">Entity Controlled by Director | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Related party transaction expense</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainageDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets, typically cash, provided to suppliers of goods in advance of receipt and acceptance, or services (such as research facilities, lawyers or consultants), which is held by such parties until the entity either effects full payment (including applying the retainer) or obtains release from liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainageDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avir_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avir_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=avir_EntityControlledByDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=avir_EntityControlledByDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !"(7%@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  0B%Q873FZR.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)\VJ2.CFHGA2$%Q0O(5D=C=LTX1DI-VW-ZV[740?P&-F_GSS
M#4QKHC0AX4L*$1,YS%>C[_HL35RS/5&4 -GLT>M<ET1?FMN0O*;R3#N(VAST
M#D%P?@L>25M-&B9@%1<B4ZTUTB34%-();\V"CY^IFV'6 ';HL:<,3=T 4]/$
M>!R[%BZ "4:8?/XNH%V(<_5/[-P!=DJ.V2VI81CJ837GR@X-O#\_O<[K5J[/
MI'N#Y5=VDHX1U^P\^6UU_[!Y9$IP<5UQ48F[C1"2<]G<?$RN/_PNPCY8MW7_
MV/@LJ%KX=1?J"U!+ P04    "  0B%Q8F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M !"(7%@X-"D!Q@@  "HV   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9MK;^*X'L:_BL6.5KM2*;E!Z6R+E'+9Y4PO+#"SFK,Z+TQBBM4DYMA.*=]^
M[002,C*&K,R;%D+^CY-?$N=Y8N=N0^@;6R'$P4<<)>R^L>)\_;G58L$*Q9!=
MDS5*Q"]+0F/(Q5?ZVF)KBF"8%<51R[&L3BN&.&GT[K)E$]J[(RF/<((F%+ T
MCB'=/J"(;.X;=F._8(I?5UPN:/7NUO 5S1#_NIY0\:U5J(0X1@G#) $4+>\;
MOOUYX#FR(%OC&T8;=O 9R%U9$/(FOXS#^X8EMPA%*.!2 HI_[ZB/HD@JB>WX
M_TZT4;0I"P\_[]5'V<Z+G5E AOHD^@N'?'7?Z#9 B)8PC?B4;/Y NQUJ2[V
M1"S["S;YNNU. P0IXR3>%8LMB'&2_X<?.Q '!5WK2(&S*W!^*+"](P7NKL ]
MM\#;%7@9F7Q7,@X#R&'OCI(-H')MH28_9#"S:K'[.)''?<:I^!6+.MX;D" 5
MAY$#F(1@F'#,MV"<Y.>3/"Y-\'4V +]\^A5\ C@!3SB*Q&)VU^*B<2G1"G8-
M/>0-.4<:LAWP1!*^8J*5$(55@9;8ZF+3G?VF/SA:Q0$*KH%K7P''<ES%!O7U
MY2.TN 9..ROW%.4#??E_TD2T;JE:K^R-6QP(-]-S3QV(XH.O/B)_^PO&J;A>
M_J<Z"'DCGKH1V8E\9FL8H/N&Z"48HN^HT?OY)[MC_:8":%)L8$BL M<KX'HZ
M]=X.XQ2]8LE.P'V&,5+QT^OX\Z$/)G_XTR>_/_PZ'_?]Q]D5&#_WKU7XM%IU
M\1D2J^!K%_C:VMV>4QCBY!7,MO&"1"IL^GK_VWBJ J2MJ@O(D%@%4*< U#GG
M_.J+RY;"2%RN(?H 7]!6A4JO9%F6W;YUN[>W*F#:VKK #(E5@-T4P&ZTN]E/
M*95]W BS0 #[CB"5]P4@[F'*RU*OUFS:3M.U5<2TA76)&1*K$.L6Q+KGG&(C
M'"$*^@+3*Z'*\TLO\TR2)@P"X;NHT AS/14XK4Q=<(;$*N!N"W"W9UV;)([%
MW7/&2?!V!68K*%H"+REG7#@?T;FI4&J%Z]Y,<[%V)B;=^'NOZ]D=K^VU[UKO
MA[ ,M5J!95NE'[2TN K[<7AICL1"M>?3BQUS9OJRNF>7*;4JL0,';=<B-D$4
MDU##3"\W^JXDIBVJ3<R06I684Q)SSB,VWZZ5W?V)>MMJ?E%"TI;5AF1(K0JI
MS .VUA'W?$$HS,^K""J[IQ,"2Q@Q%=V^OJXVIDL8>[MT]K;>DA?GTNZRT[F(
M4U+[0'DT4>H%:I.[A*>W2U-OZUWY[L8XBV$4@8>4B9^9NL/2ZW":JD\SH_;>
ME%H55FGP[;,<_FR%!"SA)=8P4;JO$S+'KTFCUMZ46A56:>YMO1_?P1K&B+[*
MW/B[4. K+3:]X'%L1OV]*;4JMM+AVV=9_'TVFJ(UH3S+W1SR(UY"K_@=J:KZ
M^JK:U"[A[NW2WMMG^?LY_ #C4'##2QSD3\J>TWBA##</)R2]3M-JWWC=CC*$
MZXMKT[N$W7=*N^_H'?I!K-3P.B%B67;3O>UTE E<7UL7ERFU*J[2ZSMZ<[[#
MY8>A4&=7^P_@4:P'7A*EZS@AZ3AM,*(P>1,_B"N=(L25&(T& %-J58QE '#T
M!EZ+<;XA2HQZR5F*.0*.;5E*>D:3@2FU*KTR&3AZ8_\CO;[\1BB8DTVB)*>7
M>R",$U5A7U]8F]HE@H)3!@7GK#& @IJ\J2*);4+).TX"];6KUWSRE=B,I@13
M:E5L94IPSDH)!;:).%M@!/Z+U\+/A6IH>D7+L6WU16HT,)A2JW(K X.C=_K9
M1>E3!(]CT@MTVS=*2$:#@BFU*J0R*#AZ7_](L@=F*Y)HW8=>Q.EZS6[W5FT^
MC.8#4VI56F4^<,[*!^.$(YK/EY!/.N ^,"C1_:M\H*^J3>T2^< I\X&C-_-S
MS(6W)4M@.[\L?@4S%*148%32TBM5AQ ^6=?"]X(UI. =1BD":T0!D^,*2J1&
M0X,IM>I,A3(TN'J_OV<(AA_!"B:OZ.AP^@FA9W\V\/]43CTPFAI,J55YE:G!
M/2LUC). 4)'ILW1Z8$#Z)$TXW1Z]49Q0'PR5 (WF!5-J58!E7G#/'##PDR05
M=XS\T8B2E5[HV+-*?5EM6I?(!^[!3"*]H2^'5T2L9#A[%J(A]B]'$?1UM9%=
M(ARX93APSPH'?Z$H:KXE(D>)^P1DPI:$8,Q8JO8E)S2?53&VKR^JC>T2X< M
MPX%[5CB8I(L(!V 4$:@^Q4P:^[Y1M<%.K7,P+N]TW>N;8E"^BJ;T_^Y9 P;?
M2"0Z=TAW,S>4#W%/*!TYCXSF %-J55AE#G#U%G[<'TV!GX:8B]NASSD2&3/K
MMHX-?9[0.]YI&<T#IM2JU,H\X.K=^\'$@P0F 18WQLQ39,N&E&;60D2#?(;U
MWY*E>LZHOIGC,(W&!%-J59AE3'#UYGX/DQW8--'[+^2LT242^4K]@.B4ZDO_
MZ]/P>3Z3DT1?II.7J3\?#L##=S =CH;3X7-_""9RE(<D3&84OD* %K-4?_ZI
MZ]@WOS$YD1TG.$M\:TH^MH 5QWDICC(66RUG,>_MT1-"V;B1$,S"RHI$H>A[
MKL!FA8/5#XT +/)D$C+ "5C*88 -YODZ.YN/$<MGA^_-OLQ!F&4S_^6Z.!'1
MR@(AW(KUEB*;9L5"4K-#RWRJS%9.+D)R/C@8H #)!P#%C.XK(**4V+CJP:#[
M@R$WFX )I!R,Q^.\*<RJ!A'('H30&,@)(\HINOK#5_L4OD0L\\I8YNG3U+X#
M'6&QR^.!ZG0]H6!WVRI*^JK:,YDO$<:\,HQY^KBTIW1T!KB^_,ODZ7?P^#A1
M<C*:N4RI53F5F<O31Z4])_F,3O9/2E9ZB7QDX0H\0<9@L$H9XESYP$FO4QN<
MT?C5.GBY1DYHR%Y28B"0H3U_SZ986KP(Y6>O_[3*U?.WJ)Z@G _!0(26HM2Z
MOA'>D^8O)N5?.%EGK^HL".<DSCZN$!1]MUQ!_+XDA.^_R :*U\-Z_P!02P,$
M%     @ $(A<6%2'S13&!0  '1@  !@   !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6RU66USVR@0_BN,V^FD,TX,Z#TOGFG<N;E^Z%VF:>\^$PG'3"3A LK+
M_?H#2;%L@W!RS7U(+.3=Y=D%]MG%YP]<W,D5I0H\5F4M+R8KI=:GLYG,5[0B
M\H2O::V_67)1$:6'XG8FUX*2HE6JRAF&,)Y5A-63^7G[[DK,SWFC2E;3*P%D
M4U5$/%W2DC]<3-#D^<4W=KM2YL5L?KXFM_2:JA_K*Z%'LXV5@E6TEHS70-#E
MQ>03.EW@U"BT$G\Q^B"WGH%QY8;S.S/X4EQ,H$%$2YHK8X+HCWNZH&5I+&D<
M/WNCD\V<1G'[^=GZ;ZWSVID;(NF"EW^S0JTN)ND$%'1)FE)]XP^_T]ZAR-C+
M>2G;_^"AEX43D#=2\:I7U@@J5G>?Y+$/Q)8""D<4<*^ 7ZH0] I!ZVB'K'7K
M,U%D?B[X Q!&6ELS#VUL6FWM#:O-,EXKH;]E6D_-%[R6O&0%4;0 EZ0D=4[!
MM3$GP3'X<?T9'+W_"-X#5H/O*]Y(4A?R?*;TS$9_EO>S7':SX)%9/M/\! 1H
M"C#$@4-]\7)UO*L^T_YNG,8;IW%K+QASNA&"U@H0*;6?+G<Z_="M;X[6J5R3
MG%Y,]-F15-S3R?S#.Q3#,Y=S;V1LQ]5@XVK@LSY?$+D">M% ;A[HSX;=DU+[
M[O2Z,Y6TILSYOY^C,$C-BMUO^^,02],PAANQ':3A!FGH1?J5B#NJR$U)@:1Y
M(YABU(FR,Q-M31\&(4[W43K$HA2'F1MEM$$9>5%>";HFK #T42=2264;6ZY6
M5.C3>FA7118DA(,M1!UPAU2(4>#&'6]PQU[<W[DBY0L@QM;D40;#*-K#:(O%
M,<S,X72!3#8@DP/!U?0DU%,;5+-7UYHPU!345+FP)HYPIOO1= @E,'+C3#<X
M4R_.;U0JP7*3,LVQ<F'S&GAM DEM'[+4[4*V<2'SNO!GNV7']T%F3QED\5YL
M'4)A%KJ!(3@P$O1#TWN *%;?@I)J@@;",/$Q7QXW>M A'MT2O>D=2"E.]W [
MI'"0CF0&M$6EZ 5G;#RFO?KNX0JSV()GR\5QG,"1)4<#[:&7\5[)R TK1Q,L
M>E/V>RMKNSX/_(?\!/@ISWFC^0ZLR9,A%Z?#@<T5.,+[RV)+X2A"(XLRT![R
M\YX&*!KJ991#ZV53'4Z".-S';XNA",-XQ(&!$9&?$I]WU9J+MC+G2\#WCO A
M!VS*2[;*B1Z^0PB/17^@1?0:7CR$TZ:]  ?)?EITB*$T3,:.[\".R$^/^XGQ
M$%H']<6AM:MM*1S"D6H##0R)_!3YI<YY18$BC]1_]&QNBY+(RH@.*1R-L#@:
M.!#Y2;!;_$-AM%DNR!)[T6TQ'*-@Y'3A@0VQGPT7O*J8,G50EQER7ILM0.M<
MXP5'DE+P!U<4I!^=?8S7N#OY F</\^N&=@,PL"I&7M*Z5CR_6_&RH$)^>)=B
ME)RUM:%Z.G5Z[.7H5[=N;V1MU_>M/M5+CJ;;6%*=F@H@312FX#T\@1#I R6
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M+]ZVM:FG&SP"H G:BPCMJXM[=WQCJK/BR?FLN'A\\>2>_9XD[)_(?D^.['<
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MUV7R:&*Y@55L^Q O#.NA$5JK3O+KSJR8&H)QW*]XP+T>BCSADX0!9#[<1%!
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M*$C^KRR**&LMK]A,$A-@LJ1D)!5C,2'XC;H;EMQ+/ZEU]";#\-/D,^ ?$#G
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M9IJP3UJYTK)W*H-L&V""G#;$DI[8>;(7\1+$F,VF(Y;$R6P/WFSCZ,SCS9[
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M'A\?1N&(ZU^<;OS-/M4.+[#^L<0/,S D@/NYUJY_(0.;3[WEWU!+ P04
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M*=!O1PMP?V41[_2#%/1O1"_^"U!+ P04    "  0B%Q8&<J(%4,"   C!0
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M$!=5:%9\BZ'U 3R_,H;V';] ?R_FOP%02P,$%     @ $(A<6)D5,OR] P
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M:&5E=#$W+GAM;+U968_;.!)^]Z\@/)F9!%#<NFS9.1KH7+-98))&CADL%OM
M2[3-C20ZHM2.]]?O5Z1D2;;<Z<X \]!N'61=K/KJT+.=*K[HC1 E^Y:EN7X^
MWI3E]LG%A8XW(N-ZHK8BQYN5*C)>XK987^AM(7AB-F7IA>^ZLXN,RWQ\^<P\
MNRXNGZFJ3&4NK@NFJRSCQ?Z%2-7N^=@;-P\^R/6FI <7E\^V?"T^BO+S]KK
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M2TW<5_VPY(<,C7/@]976M#5<@N%IG/T&4$L#!!0    ( !"(7%@M_#3ZX!D
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M _N#'1C2<!)#VOR:9)OX6!MZ&ALDB]#)X;!YA;Z3^-/^:]*M#CPD%I.U*4B
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M WG@.!,-*C/?34."T)<" (F.I>;L^7Y[0![F9T]YR2;O59(].ML3BWB[QU<
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MO%DHD0$O*ZV>T64QL"F4=@A2_J8031W%]2QWX\)!@:+*0W<3#LQ5HM[Y%F+
MOY?69_UNWZ66K3G_A[<M[I;I'9>&$N8$C4Z_3@/0;=MH%U95WJI;9<GX?EI0
MIT7M N@\5\KN%RY!W[N3?U!+ P04    "  0B%Q8&%'QI[@#   P"0  &0
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M:>93FI!9BK$)Q5AG2</)K:QK4(7@%6EY:PN<^7%*,9'-,D5/:X@S=%2M5-P
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MUX3_@/#B=.G/W@OMZ"3O'U?TZX2&-]#WI=9N^\(*FI^Q^7]02P,$%     @
M$(A<6,A(Z9#- @  * 8  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M?95;;]HP%,??^RFL3)HV*6NN)< @$KU,ZT,U5'9YF/9@DA,2-;%3VRGEV^_8
M#AG5@ ? E_/_^7^<G,-LR\63+ $4>6UJ)N=.J50[]3R9E=!0><E;8+A3<-%0
MA5.Q\60K@.9&U-1>Z/LCKZ$5<]*965N*=,8[55<,EH+(KFFHV%U#S;=S)W#V
M"X_5IE1ZP4MG+=W "M2/=BEPY@V4O&J R8HS(J"8.XM@>AWK>!/PLX*M/!@3
MG<F:\R<]N<_GCJ\-00V9T@2*/R]P W6M06CCN6<ZPY%:>#C>T[^8W#&7-95P
MP^M?5:[*N3-V2 X%[6KUR+=?H<_G2O,R7DOS3;8V-HX<DG52\:87HX.F8O:7
MOO;W<" 8^R<$82\(C6][D'%Y2Q5-9X)OB=#12-,#DZI1H[F*Z8>R4@)W*]2I
M](8W#5[.2O'LB7SX3M<UR(\S3R%:!WA9C[FVF/ $)@C) V>JE.2.Y9"_!7CH
M:3 6[HU=AV>)MY!=DBAP2>B'T1E>-"0:&5YT@G?WW%5J1WXOUE()?!?^'$O2
M(N+C"%T?4]G2#.8.%H $\0).^OY=,/(_GS$8#P;C<_1T9<N"\((\6GA.5B7%
M@_32X7,ZYOPL^[CSA0'C/4.S!C'<M4M4"?J\EK(=*6ENY@6OL7XKMB%B;TX.
MYC)K3FISTXMOG9**LEP'\U;7GB1!XOKXB8+)FVW4*U%E2M/,&]BQ2DD2NE&4
MN%=!\B:X!6&:$,O@DR[$_)0\"6-WDO@7_>T-AE%-BDYU LA&4*8P/,?$,6F?
MW".5Z09!%ELJ<K*L*2,C]."[B1__A[+*NZ:M^0Z@+Y]E)[(2C5EQX(XG(W?B
M!Q?AV(W'B1L' 3GVGG@'U=N V)@>)?%2.Z9L(0^K0QM<V.K_%VY[Z ,5FPJO
MNX8"I?YE<N408?N2G2C>FEZPY@H[BQF6V,I!Z #<+SA7^XD^8/AS2/\"4$L#
M!!0    ( !"(7%BT)>V]= 4   <2   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;,58;6_;-A#^[E]!N"]( =66J/<T,>"D:==A78TZ23$,^\!(9UN(
M)'HD;2?[]3M2LNPLBI)E*_K!,B7RGKOC<W<ZZFC#Q;5< "AR4^2E/.XOE%H>
M#H<R64#!Y( OH<29&1<%4W@KYD.Y%,!2(U3D0VK;P;!@6=D?'9EG$S$ZXBN5
M9R5,!)&KHF#B]@1ROCGN._WM@Z_9?*'T@^'H:,GF, 5UL9P(O!LV*&E60"DS
M7A(!L^/^V#D\<5PM8%9<9K"1>V.B7;GB_%K??$J/^[:V"')(E(9@^+>&4\AS
MC81V_%F#]AN=6G!_O$7_8)Q'9ZZ8A%.>?\M2M3CN1WV2PHRM<O65;WZ"VB%?
MXR4\E^9*-M7:,.Z39"45+VIAM*#(RNJ?W=0;L2<0V0\(T%J &KLK1<;*]TRQ
MT9'@&R+T:D33 ^.JD4;CLE*S,E4"9S.44Z.IXLGU6^U72DYY@61+9K;KX)Q=
MY2#?' T5JM&+ATD->5)!T@<@'4H^\U(M)#DK4TCO @S1OL9(NC7RA'8BOH=D
M0%S'(M2F;@>>VSCM&CSW(:<73,#;D_M.CX5@Y1PPZA2YNB7[ZR;LUCP>;YA(
MR>^_("3YI*"0?[3M4*7?:]>O,^U0+ED"QWU,)0EB#?W1ZQ=.8+_K\,YKO/.Z
MT$?3*L$(GQ'#+OFRU,Y),M89D*G;-H,[(=L-/E\ F?$<\SHKYW5:9W^!)-)H
MY<M=VJ'2P]ZOJ^(*A#;KF\D5W-1F,)[/!<R9@MZ7E9**E:G&9(K\S,J5=J8F
MGSBN%;C4HF%$7A(G&G@1"0>A'MM6[(:]CTB@!G2M, PMW[=QRL-5O;,;$$FF
MF7S](J(.?8<3]:AWRLH$ZP+.'1 WII9OQ^0-SE-GX 7_M B#$8PC;F-3:-GX
M<YU8V^$/7!MM<G#L6W9D]RY!:HL0@<#-$JL1WBA.UOCXO^,9IW2F/@#EH(AG
M.8&!"M =@I<*"K>P(]K\)MK\IT;;6&(0U+%V(2LOSZ3*L'8"^< R02Y9O@*S
M5&=16QQV*S,AIX'66R!@R8(PDY,;)@G4ZE*RDIJODYQA>9LF"XZUC%1E#H-2
MW0E=MK/[L(>UWDS_!DQ4!:QG=A(OM/<UD]=O9P* 9!AE0C,HM'/N(/#)*T('
MCDU>8:AM6091$'\0A^06T:0>!M5PMV;-<ZP].68(B?P!BM=_NQ4IYD\*R/9M
M!GE*]!+\=5 7--0%W=3A*SY=Y=!4BK;W@#:CE-#&52=Z>\W85Y/LJX%*#<DD
M27(D))ME.L9E3=.CQ* ")G0HX#ZEL,9N8VG*]187DYE:01"8K+:BT.Y]A!($
MRXT$2_'5FDF%9&*/0&A@A0$EU+,BK!SG7.$R^9CE6&=BRZ.Z+GDH[W1F5]A0
M%#XUNS0KO$2?Y'/YZE3U<(U/[BA^=!\VF!>/LZ5$9H*[>E>LR@S17V+5#D)=
MJ5R?]B8@3-.)I;E6)]K%MO5\6\VG>Z\?23S?"FB@*:'4[IU-)Q/BZ,*(A?U[
M$!LUQ$:=Q.YM067OA?:EC;5.G&>V$G%C9?R#&Z7X.WCGV+OFUWYJ>CV=D&[,
M=IM;>I_Q&LO/_/&&)W"LT+0QV -X37^#+5#@6:%=]3=^C#F5@]G_ ^*[V KY
MIH,Q,G?:&\^*X\C,^0./]B[*==5.2$VA;.\BJ.6ZV$PYH5&&O437YN^=/)S.
MS;^?X/^"@T[HY\8-W9E.?W!>U ;\SP[N#DA.YPGEF8GQC%//\Q,CQ-=S'-Y+
MC/O=?9T9G7W__;DG)<9=&UK38KAW-B] S,T7"&QR^*I4U3&]>=I\Y1A79_O=
M\NH3R6<FYAF^TG*8H:@]"+%9%M57A^I&\:4YZ5]QI7AAA@M@*0B] .=GG*OM
MC5;0?/L9_0U02P,$%     @ $(A<6/O:EFSN!   X L  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&ULG5;;;N,V$'W75PR\%R2 *^MJ.TYB(+=%%]AM
M@UQ:%$4?:&ELLRN)*DG'2;^^,Y2B.!O'6?3%EJB9,V>&9X8\6BO]S2P1+=R7
M166.>TMKZ\E@8+(EEL+XJL:*OLR5+H6E5[T8F%JCR)U360RB(!@.2B&KWO3(
MK5WJZ9%:V4)6>*G!K,I2Z(=3+-3ZN!?V'A>NY&)I>6$P/:K% J_1WM:7FMX&
M'4HN2ZR,5!5HG!_W3L+)Z9#MG<%O$M=FXQDXDYE2W_CE<W[<"Y@0%IA91A#T
M=X=G6!0,1#3^:3%[74AVW'Q^1/_D<J=<9L+@F2I^E[E='O?&/<AQ+E:%O5+K
MG['-)V6\3!7&_<*ZM0UZD*V,567K3 Q*637_XKZMPX\X1*U#Y'@W@1S+<V'%
M]$BK-6BV)C1^<*DZ;R(G*]Z4:ZOIJR0_._U<9:I$N!'W:&#O1LP*-/M' TO0
M;##(6IC3!B9Z!2:,X*NJ[-+ 195C_AQ@0)PZ8M$CL=-H)^(Y9C[$81^B((IW
MX,5=HK'#B]],%,ZER0IE5AKASY.9L9JD\=>VG!O$9#LBM\O$U"+#XQ[U@T%]
MA[WIQW?A,#C<P3?I^":[T*?739> FL,59JK*9"&%$S*M?,(<M2C@V@J[LHK,
M-M*[$A;!*KB8S]%I_ON/VU+=3>9FB=2!W[.8MRQ,QT(V@2P%TBT+2ZYGJJQ%
M]?#QW3@*1X<&L&/VO8,T( S,54'#PDP\:CP'\ <*W2C+8SFP)B+OXKXF%,PW
M0698X5Q:$-;YO63HHD2A'\"']L_C(B*(*H="961L72\D?@2I/_2NT*YTQ9G4
M6MU)-XQ$_C=U)HTF:\ E%1U"["=D:XAHMG1@.=[1R*O9"C*-N23CV"?N?D@A
M5?;M)YXF.1!WFK"FJ>H>Q8UAG_YC?PS[WFV5H;8T6UUVM3*2S:A3(? 39Q<0
MSWWO5\I6N[>05@,_]LZ6HEIP@>%.%*L&77!9!4&2993XJ0.(4H[HW2A+N3,"
MQ:7BQ(3T88>.TT['Z8_J^%+33LF:PK @5.7J1^OG.$=-%7("/3$&K=DFT9UQ
MMG<CZ[;NHF;/HFX39O[(A*LM'!/RHA/(L,Y:IT:=LEI,/!I26,ZH\C2H-I1Y
MO@5FCQIG1MUC)0U8[TS4DNHM_R4C_9IJWD,<]X<'$3V$23\.4N\7.J7I/"81
M4WB2JR%Z0NL'.IS70N<&#OKQ.(6TGQX$WA>9D:Y(V0N-Z #3_C X@&$_2.+7
M)1B.^N-Q F'4C\+T;4F/^V&:0MP?1\-6A6$2PRCP+C760N: ]XS-IPL,#QK)
MC0]8<6]6"49)/QS%D(048^A]06,FKZBYM63PQIKPN5C;-O1YC/==!S\][9#]
ML)/]\/^/[]N*A^FB<MO/HC]MQM96V>^,\[KL.Y52ZG2HM[<NBFB<B%].<UZ=
MX4)6%3OQ=F.5N\=2K6C#V<3-B-4F^XVARW.[&=<//*Z1QS5L=H@[RB?>J2C<
MKCT%(VCG\IX4&J4IMQ5=, VS+ 1W'DW?;$7[2#2<X=,HIB^ZF=!/0_EQ'STZ
M]U[@B"S3*W=H6*2"45,$<4>)C@VBS7RHR:3*':-1.MZJB,'&K:M$O7!W2YX7
M5*WF M:M=M?7D^;6]F3>W'V_"DVU,%#@G%P#?T2S3C?WR>;%JMK=X6;*THW0
M/2[I"HZ:#>C[7"G[^,(!NDO]]#]02P,$%     @ $(A<6(,ES_B? @  R 4
M !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL?511;]HP$'[G5YRR:6HE
M1D("E#*(5-I.F[1.J&RKIFD/)CE(5,?.;*=T_WYG)P2V41Z2^.R[[[[+^;OI
M5JI'G2$:>"ZXT#,O,Z:<^+Y.,BR8[LD2!9VLI2J8(5-M?%TJ9*D+*K@?!L'(
M+U@NO'CJ]A8JGLK*\%S@0H&NBH*IWW/D<COS^MYNXS[?9,9N^/&T9!M<HOE:
M+A19?HN2Y@4*G4L!"M<S[ZH_F0^LOW/XEN-6'ZS!5K*2\M$:'].9%UA"R#$Q
M%H'1YPFOD7,+1#1^-9A>F](&'JYWZ.]=[53+BFF\EOPA3TTV\\8>I+AF%3?W
M<OL!FWJ&%B^17+LW;&O? 3DGE3:R:(*)09&+^LN>F_]P$# .7@@(FX#0\:X3
M.98WS+!XJN06E/4F-+MPI;IH(I<+VY2E472:4YR)/U/?/TFM88$*EAE3"&=?
MV(JC/I_ZAA)8-S]IP.8U6/@"6#^$.RE,IN%6I)C^#> 3LY9>N*,W#T\BWF#2
M@ZC?A3 (HQ-X45MNY/"B%_!NF1*YV!R6^^-JI8VBV_'S6,$UW. XG%7,1)<L
MP9E'DM"HGM"+W[SJCX)W)\@.6K*#4^CQLA8*R#7,F<X38"*%FYQ7!E/XOY)C
M]$\GV*.F#2KN4$M"U>[_V"=A/*DXLQY,PUIRTK*>=$@78#*$[Q16M[QC^V2;
M%7;LS>+V9KV&,^A'P^[E< 3GM=4G*[B$\\Z#4XV%?4)%0P 2610D5I=: TT1
M;8@?4>I:\?W#=AQUH_%E]V(8V&4X&)(YW"?>U_#V2+ CTAM%.TZ]B @=ZYI_
MH*X"U<;-$$U,*V%JH;6[[9BZJM6Y=Z]GW!U3FUQHX+BFT*!W,?1 U7.C-HPL
MG597TI#RW3*C48O*.M#Y6DJS,VR"=GC'?P!02P,$%     @ $(A<6->UTDW9
M P  H!$  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULK5AM;ZLV&/TK
M%KN:[I6V\IJ$=@E2&G:U3FM5W>YN'Z9]<. !K +.M4W22?OQLX$2R"A**O=#
ML8W/L<_A\1/;RP-ESSP#$.BER$N^,C(A=C>FR:,,"LROZ Y*^2:AK,!"5EEJ
M\AT#'->@(C<=RYJ;!2:E$2SKMD<6+&DE<E+"(T.\*@K,_KF%G!Y6AFV\-GPA
M:294@QDL=SB%)Q!?=X],ULR.)28%E)S0$C%(5L;:O@EM5P'J'G\0./!>&2DI
M6TJ?5>4N7AF6FA'D$ E%@>5C#QO(<\4DY_&M)36Z,16P7WYE_UR+EV*VF,.&
MYG^26&0KPS=0# FN<O&%'GZ!5M!,\44TY_5_=&CZ+JX-%%5<T*(%RQD4I&R>
M^*4UH@>PYV\ G!;@G *\-P!N"W#/!7@MP*N=::34/H18X&#)Z $QU5NRJ4)M
M9HV6\DFIOON38/(MD3@1/&!1,4 T0;<5E^\X1S^B=1P3]55PCN[*)K;4-_H8
M@L DYY]DEZ]/(?KXX1/Z@$B)?L]HQ7$9\Z4IY)P4LQFUX]\VXSMOC&\[Z)Z6
M(N/HYS*&>$A@2C&=(N=5T:TSR1A"=(5<^P?D6(X[,J'-^7!G!!Y.PQ_H7L*M
M&FY/J'&[[^/6?.[YW^>OW^03W0DH^-]CAC>$WCBARB,W?(<C6!DR47!@>S""
M[[^SY]9/8V;I) LUD0V,]#HCO2GV8(-YAF2,HD@5X%M%]CB'4HS&;$.UJ*E4
MYMP'MN?Z*ISV?7-&NOF^-[>&W<+)B;U3]JR3/7N?[+I1IOIGN::W.2 .4<7D
MJH=10V;_4SI;^+9UHG0S.9=+HT43V<"V>6?;?-*VAZK8 E/+CF=8TB/">76:
MGAIK&J)9SQK?]=S9S#Z-EK&.CK^8N]<G\3(YM7<*7W3"%Y/"?X4D83((T+_H
M208*1^N4 <@?>C&F?9+KTE2CDRS41#;PT.\\]'7G;%^GD3K)0DUD R.O.R.O
MIY,7+0JY\-3>8P<LDD$HMZ+*5YS*J$RQ )0R*NW=,1H!Q!PEC!8(<)0A+J/W
MN'['/&_&MJW>@K2NK--5.SG#2\W41#8PT[:.6SU+5U)KF?K)ZC373P]VJ3.Z
MV(;6]';!]KEI[QZ_D*(JSDN T[27+ERM;*$NMJ&ESM%21W<6;!EUN:F3+=3%
M-G3S> RP)S?'P;K+>#1)@)$RE4F/1#!JH]83@%:VL&7K[R0=2_UUV:4QR.P=
M:0M@:7TUP%%$JU(TI]NNM;M^6->';O/8O;F[N,<L)25'.202:ETM9%9CS75
M4Q%T5Q^0MU3(XW9=S #'P%0'^3ZA5+Q6U #=I4SP'U!+ P04    "  0B%Q8
M[98-1;X#   (#0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6RM5VUO
MXC@0_BM6;K7:E?::%Z! %Y!*V]-5NCVA17OW8;4?C#,$JXZ=LQUHI?OQ-W8@
M!3;DVHHO$-LSCY]G/)Y,1ANE'\P*P)+'7$@S#E;6%E=A:-@*<FHN5 $25Y9*
MY]3B4&>A*330U#OE(DRBZ#+,*9?!9.3G9GHR4J457,),$U/F.=5/4Q!J,P[B
M8#?QE6<KZR;"R:B@&<S!?BMF&D=AC9+R'*3A2A(-RW%P'5_=Q(ES\!9_<=B8
MO6?BI"R4>G"#^W0<1(X1"&#605#\6\,-".&0D,<_6]"@WM,Y[C_OT'_SXE',
M@AJX4>)OGMK5.!@$)(4E+87]JC:_PU90S^$Q)8S_)9NM;1005AJK\JTS,LBY
MK/[IXS80>PZ=4P[)UB$Y<DB2$PZ=K4/'"ZV8>5FWU-+)2*L-T<X:T=R#CXWW
M1C5<NF.<6XVK'/WL9%X='U%+,N>9Y$O.J+3DFC%52LME1F9*<,;!D%_)=9IR
M%WPJR+VL4L@=Q8=;L)0+\W$46J3D@$.VW7Y:;9^<V#Y.R!<E[<J0.YE">@@0
MHI9:4+(3-$U:$6^!79!._(DD4=(AW^:WY,.[CV0.&>:>;2!X\W*X9 ?70K-3
MQ[WC<3LG<)L"_/T/-"+W%G+SHRF4%6*W&='=]RM34 ;C "^T ;V&8/+^E_@R
M^MPD^TQ@!^*[M?AN&_KD7C(-[CPPD9@REG#)1(GGCP\D PD:%ZA,"4TQY;FQ
MNDHT9VO(O^1=4W2J+?M^2U>\UI/N<!@/HR@:A>M]Y0V&@W[<W3<\4-6K5?7:
M5>4%Y=K)(D(9 R>9]GXB<$RQS>* VV7-[;*5V]UC@743 YSR-4\!0_O$0:1-
M["J@.&JAUVIRP*]?\^NW\ONSS!>@717"%Y0[;;P7IKJS+HRGK^^TPNWM48F/
MV+;N_,9,']2Z!B_4I:%0VM*%@!<*&_ROL-:MWRAL6 L;M@K#<AB1N[P0Z@F
MS*UB#V16:K;"5RJ9"2J;)+5"OK: G0GL0'T</;\VH[/7[RWDF?2?"^TP 'M]
M0]R: #/0S%7P#%QV,Y7G6*"-SX-BEP>%Y@P^$0%8#?TEP%;C 5O3-14EKN*<
M65&- !(7EZ!=-)5^]D^IA<9 Q@T%Z&+0.[H?[0K>&J'D.4+)*R*4<N,SAOCW
MV,EH-<I-FN3&/\EMI?-:N>%>3YF#SGRK;8C74'5C]6S=SE_[)O9H?NK:?-^K
M/L-4WPA?J,ZX-)@?2X2,+OI8['35=E<#JPK?N2Z4Q3[8/Z[P4P6T,\#UI5)V
M-W ;U!\_D_\ 4$L#!!0    ( !"(7%CF/Z7W^@(  !4+   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;+66;6_:,!#'OXJ52=,FK<T#A18&2'U4*[4"
ME75[,>V%22[$JAVGMM.4;[^S0P.3(-6J\@;LQ/?W[^[LW TKJ1YU!F#(B^"Y
M'GF9,<7 ]W6<@:#Z4!:0XYM4*D$-3M7"UX4"FC@CP?TH"'J^H"SWQD/W;*K&
M0UD:SG*8*J)+(:A:G@&7U<@+O=<']VR1&?O 'P\+NH 9F(=BJG#F-RH)$Y!K
M)G.B(!UYI^'@+.Q8 [?B)X-*;XR)=64NY:.=W"0C+[!$P"$V5H+BWS.< ^=6
M"3F>5J)>LZ<UW!R_JE\YY]&9.=5P+ODOEIALY)UX)(&4EMS<R^H:5@YUK5XL
MN7:_I%JM#3P2E]I(L3)& L'R^I^^K *Q8=#M[S"(5@:1XZXW<I07U-#Q4,F*
M*+L:U>S N>JL$8[E-BLSH_ M0SLSGM79(#(E,[;(6<IBFAMR&L>RS W+%V0J
M.8L9:') 9G@FDI*#77VI#<.@0$(>-*0E)[<L!?+E @QE7'\=^@;I[!Y^O"(Y
MJTFB'207$!^23OB-1$'4^=?<1Z<:SZ+&L\CI'>W0NZ5SJ:B1Z-SE4\D*/$IF
M&U6KBKT4 UW0&$8>GGH-ZAF\\>=/82_XWL+8:1@[3KVS@W&J\'HILR13[J*>
M)VM6\OL65Y,; T+_V0;>V0/X40-^U!K<=?;+.OL<L[\-LEVF2Y9 E6X!ZC9
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ME%V [U,IS>O$ME)-)SS^"U!+ P04    "  0B%Q83%2>,$,#  "S"@  &0
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M).,19SO ,VL5+;O(:Y-[JVRB-/L;IY*K7R/E)\??"'^DDLQB"J9TON&1C*@
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M%T "X-I /9\S)I\Z^MQ=_F?Q_@!02P,$%     @ $(A<6#N=TI1V @  W@4
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M5.=3Y]0A*62TYOI&K+Y ZR<P?(G@RE[)JHWU')+42HNB!:."@I7-G:[;/&P
M!J,7 'X+\%\+&+: H37:*+.V+JFF\42*%9$F&MG,P.;&HM$-*\U7O-425QGB
M='R>)+*&E'Q:8UTH4(26*?FN<Y!D5DL)I29?&9TSSC3#U0_D%NLHK3D0D9$W
M@@\O05/&U1'2W-]>DL.#(W) 6$GN<E$KQ*J)J]&34>8FK?Z+1K__@OY+2$[(
M<'!,?,\?]L!GKX?[S^$N9K)+I]^ET[=\PQ?XKNDCG?,V$S8]E"ORZWRNM,2*
M_=UGL&$<]3.:77RF*IK U,%MJD NP8G?OQN$WL<^N_^)[)GY86=^N(\]OD%&
M*I/<FD]AB2VBP@VOC_$;)[Q.6;G TBWK##-12S,S@0G2L(1R J:*4H9+T%L(
MS<LC^W+3G):Q[XW'XXF[W$S ;E04AE$7],S8J#,VVFOLJDQ$ 433=;^RO>BW
M?L&&+-@PL.'QF?R@DQ_LE8]%*07G-MM5.Y; J8:TSTVP(R (Q^%6FG>#PE'P
M@LZPTQGNURE%!LJ<#U@-&;2[2)A^TJ<SW)40;E?#;LSX=-"O,NI41GM5W@F-
M\FC;^F"S]5FIV+6;UL?_M;X^^=%N.4?#<+1E8#=J$/A>N&7!W3@ S.'[C<H%
M*Q7AD"'..XDP [(YT)J)%I4]$^9"XPECASG^ X T ;B>":&?)N:8Z?XJXK]0
M2P,$%     @ $(A<6/!!GVB> @  Q08  !D   !X;"]W;W)K<VAE971S+W-H
M965T-#,N>&ULK55=3]LP%/TK5H8FD%;RU9:.I9$@U<2D;4)T; _3'MSDIK%P
M[,YV6OCWNW9"5" @A/:2^-KW')]S[=PD.ZEN= 5@R&W-A9Y[E3&;4]_7>04U
MU<=R P)72JEJ:C!4:U]O%-#"@6KN1T$P]6O*A)<F;NY2I8EL#&<"+A7135U3
M=7<.7.[F7NC=3URQ=67LA)\F&[J&)9CKS:7"R.]9"E:#T$P*HJ"<>V?A:3:Q
M^2[A)X.=WAL3ZV0EY8T-OA1S+[""@$-N+ /%UQ8RX-P2H8R_':?7;VF!^^-[
M]L_..WI940V9Y+]88:JY-_-( 25MN+F2NPOH_#B!N>3:/<FNRPT\DC?:R+H#
MHX*:B?9-;[LZ[ '"\3. J -$KP7$'2!V1EMESM:"&IHF2NZ(LMG(9@>N-@Z-
M;IBPI[@T"E<9XDR:R;IF!H_%:$)%03(I#!-K$#D#349DV9XND24YTQJZK*^,
MKAAGQN9<02Y5 07!0T&TEIP5U&!\3CD5.9"ENXV'"S"4<7V$I-?+!3D\."('
MA GRHY*-1E*=^ 8-65E^WHD_;\5'SXA?0'Y,XO #B8(H'H!GKX='#^$^EK&O
M9=37,G)\\9MJN6 ZYU(W"LCOLY4V"F_PGR'/[2;CX4WL5WVJ-S2'N8>?K0:U
M!2]]_RZ<!I^&*O"?R![4(^[K$;_$GKJ6,)+EJ-% J+T]0W9;CA/'87O.-@UG
MT2SQM_LVGB9%\>QCG_1 WKB7-WY17M8HA6=%L",J:@^*<,"&0'AWN>^&U+:4
MDSTA)]/@D=B!G"@<UCKIM4Y>U/I=BE'^%KV3I]6=CJ-'@I\F1>,@?J38WVLR
MML%_HVK-A$81)<*"XQ-D46W3; ,C-Z[OK*3!+N:&%?YG0-D$7"^E-/>!;67]
MGRO]!U!+ P04    "  0B%Q8Y\*RF*8"   7!P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6RM55UOTS 4_2M6F- FP?+1-BLCC;2V()"8F/;% ^+!
M36X;:XX=;*<=_YYK)PU=VW4(\9+XVO>>>\Y)<I.LI'K0!8 ACR47>N05QE3G
MOJ^S DJJ3V4% D_F4I748*@6OJX4T-P5E=R/@B#V2\J$ER9N[TJEB:P-9P*N
M%-%U65+U:PQ<KD9>Z*TWKMFB,';#3Y.*+N &S%UUI3#R.Y2<E2 TDX(HF(^\
MB_!\$MM\EW#/8*4WUL0JF4GY8(//^<@++"'@D!F+0/&VA EP;H&0QL\6T^M:
MVL+-]1K]H]..6F94PT3R;RPWQ<@;>B2'.:VYN9:K3]#J&5B\3'+MKF35Y@8>
MR6IM9-D6(X.2B>9.'UL?-@K"^)F"J"V(M@OZSQ3TVH*>$]HP<[*FU- T47)%
ME,U&-+MPWKAJ5,.$?8HW1N$IPSJ33F19,H./Q6A"14XF4A@F%B R!IJ\Q;BL
MI'#'<DZ^ #J&>QK#XRD8RK@^P:R[FRDY/CHA1X0)<EO(6B.63GR##&T?/VO9
MC!LVT3-LPHA<(H%"DP\BA_PI@(_2.GW16M\X.H@XA>R4],(W) JBWAY"D[\O
MCP[0Z75V]QQ>[Y_LGC*=<:EK!>3[Q4P;A2_YCWTN-DWZ^YO8#_]<5S2#D8=?
MM@:U!"]]_2J,@_?['/A/8$_\Z'=^] ^AIU\K4-0Z0+A[M3+[:NU3W,"<.1@[
MF99IW(\3?[DI9#=G&(9=SA-^@X[?X""_>ZH8G7%XB5Z#,MAHW0^VV.VFG WW
MDXL[<O%!<K?24/X2LWC7N.&V<;LYP^&[+6[^QHPI02W<Z-78MQ:F^1R[W6ZZ
M7[BAMK4_QJG?#.D_,,TOXY*J!1,:%<T1,C@]0[-4,X:;P,C*3;*9-#@7W;+
M/Q<HFX#G<RG-.K -NG]A^AM02P,$%     @ $(A<6""@[TM0 @  "@8  !D
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M8"E(6\!\OQ)"OQS8"JJ-98O_ %!+ P04    "  0B%Q887LKT"0#  #-"@
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M;&:*VQ7VFZ#L!'R_D-(\#6Q'4W>P\1]02P,$%     @ $(A<6' 0A_LU @
MO 4  !D   !X;"]W;W)K<VAE971S+W-H965T-#@N>&ULK51=C],P$/PKEI$0
M2$?S>065)-)=*T0E$-55P /BP4TVC54G#K;3'/QZ;">-4DA/%2(/B=?>&<_8
MV8U:+@ZR %#HL625C'&A5+UP')D64!(YXS54>B7GHB1*AV+OR%H R2RH9([O
MNG.G)+3"263G-B*)>*,8K6 CD&S*DHB?]\!X&V,/GR8>Z+Y09L))HIKL80OJ
M<[T1.G(&EHR64$G**R0@C_&=MUB&)M\F?*'0RM$8&2<[S@\F6&<Q=HT@8) J
MPT#TYPA+8,P0:1D_>DX\;&F X_&)_9WUKKWLB(0E9U]IIHH8O\$H@YPT3#WP
M]CWT?FX-7\J9M&_4=KES%Z.TD8J7/5@K*&G5?<EC?PXC@!=> /@]P+\6$/2
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MG2&]7U/5LJJ#.B_+P4(C%9>RF5+Y!^,,:'ZI*?BZXQ9H/BBF?P%02P,$%
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MOQJY(W*;5U6^JC\N!9?:4PGDW^_RO'KZ117PD!>?ZM.Y^B]02P,$%     @
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MZP"U/V=,;B;Z@++/#_X"4$L#!!0    ( !"(7%@KJP]/9P,  ,D.   9
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M(;M,W?#][U 5-#9X,<^DO:)]%>LY*-Y)Q?,J63/(*2OOY+$2HI'@AR<2<)6
MCQ-&)Q*"*L$JYY;,;%E71)%H)O@>"1.MT<S :F.S=364F6U<*Z&?4IVGHK7B
M\?T'(T2"ECS7[I#$ZOL!K<N=17QCGW &3$DS.YES_6C&@-Y>@2(TD^\TRNWZ
M"KU]_0Z]1I2AKRG?2<(2.7.5)F\HN'%%=%$2Q2>(^AA]YDRE$EVS!)(V@*NK
MKDO'3Z4O<"_B%<1G*/#?(^SAH(/0\K^GXQXZ0;T3@<4+3N!=YT7&OP.@-8@'
M&NM[2@2@Q<\R7V89C\OAEPVZ@9AO&?U71ZU 4&Z"I=ZHO__0+T"?%.3RGRZY
M2S:C;C;F[W$A"Q+#W-&_!ZDI@1.]>>6'WL<NJ08":PDWJH4;]:%'7[DB&9(-
M4\9-M: T99<$)>[$XIK_W4,TFH[P^<Q]:-;6$15._$-4B_2X)CWN)7T#4@D:
M*\W6?D[HEE'5^5GTXCQWGP8":Y4<UB6'+\K@X9#"#036$FY2"S?Y108O<<<-
MZP;A9'KD[XZ@,>YV]WG-^+R7<6GI+X7AUVGJWO3G[LU 8*U*IW6ETQ=EZNF0
MP@T$UA+.]PXG#^\7V;H";EIV- YQ>&3LKK 08Z_;VW[CR.3W$K]>KU:=M'K3
MGKLY0Z&UB\2'(O&+,G9%9RCQ!D)KBW<XROF]!Y[_8^W@I].&;TZG;6-W!(W"
M(UN[C:8@![&UO9+41'9,E8?D>K7NQRYM%W*TOC!]FFTV#C!ED_>9B"UE$F6P
MT9#>V41_:J+LF\J)XH5M/>ZXTHV,'::ZUP1A O3S#>?J:6)>4'>OT0]02P,$
M%     @ $(A<6,E/@T(W!0  0!@  !D   !X;"]W;W)K<VAE971S+W-H965T
M-3<N>&ULM5E1;]LV$/XKA-<-+=#$HF3%2>88:)P5"[ .1=-N#\,>&.EL$:%(
MCZ3CI+]^1\J1+%MAX\!^B46)]]U]I^/Q$S-:*GUG"@!+'DHAS46OL'9^WN^;
MK("2F6,U!XE/IDJ7S.)0S_IFKH'EWJ@4_3B*3OHEX[(W'OE[G_5XI!96< F?
M-3&+LF3Z\1*$6E[T:._IQA<^*ZR[T1^/YFP&-V"_S3]K'/5KE)R7( U7DFB8
M7O0^T/-)G#@#/^,O#DNS=DT<E5NE[MS@.K_H12XB$)!9!\'PYQXF((1#PCC^
M6X'V:I_.</WZ"?VC)X]D;IF!B1)_\]P6%[W3'LEARA;"?E'+WV%%*'5XF1+&
M_R7+:NXPZ9%L8:PJ5\880<EE]<L>5HE8,SB-GC&(5P;QA@$=/&.0K Q\YOI5
M9)[6%;-L/-)J2;2;C6CNPN?&6R,;+MUKO+$:GW*TL^-KF:D2R%?V (8<D0]Y
MSEUZF2#7LBH2E^RW5V 9%^8=3OEV<T7>OGE'WA NR=="+0R3N1GU+4;C,/O9
MRO-EY3E^QC.-R2<E;6'(;S*'O W01QHUE_B)RV4<1+R"[)@D]#V)HSCI"&CR
M<O,X$$Y2IS;Q>,D/4TNNN,F$,@L-Y)\_<!JYME":?[N25F$.NC'=HCXW<Y;!
M10]7K0%]#[WQ+S_1D^C7+L)[ FO1']3T!R'T)_H6Z<,#=AT#Y.TM2)AR^ZZ+
M>(4V]&BN^=R/:41/1_W[=4+;DXZ2]"RJ9[4B3>M(TV"D?S&QJ.J<"6QK3&;0
M%6"ZY7LXH,-D(\)J5KHV:T!I>M(=X4D=X<G+<\FP#53AYF RS>?NNBO@,.;7
M LA$E7,F'PG<^Q1@"W NYLKX)F (=@#LU9F:27^#+ R7,\)(J30<"7X'XO'(
M%DP>265;$VV!!54HD;\GV!UPJ QL8(/@,WXK8,L)PU52 G.K)2<,0\) !=,S
M,):P4BVD)6KJP5;EA#.8)=R0&6YD%K0;2Y)&/Y,J1#?]%ESD^%SP[PB[F/L@
M@<!T"GXG(0:L%8 [E,46; MDB2X\W06&K[E]K/P4&-)T(02YDVHI()^!P\?*
M072!B41[WK3.XZYE&7PQKUR6P[J4AL'7_DVN<NW2L);$K@(:;E5\.DPWEV3'
MI#A-N^O]M [R-!CD1\A!,]$54]!PU_ZX)[ 6Q[.:X]D!MH>S?=+?$UB+/HT:
MY1$%7_*?*%)1CFI<)[C*D+^!;AD1;;74A";#S3H,>WLMFS4=1</M%-]CAAT+
MVU'&M'[$#K!D^AEA1+?6S,G98+!)*.CPM83BAE"\\^MI4W/[.M?55O0(3'=2
M#3N)HV3059EAL]=R;Y0;#2JC\1?$9#HK_.:5PSU^[<S]SI I8XW;A;3EWROF
MF"*N\D[N82>I3UI7@4S"EJ^EWR@W&I9N^(&$GS^=FB)LN6L#VA=:FV>C^VAZ
M@!9,@VIRYQ3L":V=@D98TK *W%.EAYW04*D?0@S11@W1L!RZL:@8.RD%[79^
MRWM":[-LY!0]/42A[U5K[0NMG8)&;=&@FGFYVCC;UK-I$J6;F_,AM%/<:*<X
MK)UV41LKJ-:7=4RC#4)AAZ\EU,BG."R?6GWH:JT/.:83S[2;W)Y$TBH)AY!<
M<2.YXO@ RS3>DU9:I> 0RBMNE%<<%D7/%?9+M.8/H)_3FF&S71GWU\YB2] S
M?T2-PMF=6U1'F?7=^AC\@S_\W;A_2<\GU6%V U.=K7]B>L:E(0*F"!D=#U%"
MZ.JXNAI8-?<GOK?*6E7ZRP(8?E*["?A\JI1]&C@']3\-QO\#4$L#!!0    (
M !"(7%A=H<" JP,  !X,   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM
M;*U736_C-A#]*X2*+5)@U_JTDTUM 8F31?>P:.#L;@]%#[0TLMA(I$K2=OKO
M.Z04Q78HN05ZB26*[_&](6<XF>^%?%(E@";/=<75PBNU;JY]7V4EU%1-1 ,<
MOQ1"UE3CJ]SXJI% <PNJ*S\*@IE?4\:]=&[''F0Z%UM=,0X/DJAM75/Y]RU4
M8K_P0N]E8,4VI38#?CIOZ 8>07]K'B2^^3U+SFK@B@E.)!0+[R:\7H:1 =@9
MWQGLU<$S,5;60CR9E\_YP@N,(J@@TX:"XL\.EE!5A@EU_-61>OV:!GCX_,+^
MR9I',VNJ8"FJWUBNRX5WY9$<"KJM]$KL?X'.T-3P9:)2]B_9=W,#CV1;I47=
M@5%!S7C[2Y^[0!P PMD (.H T2D@&0#$'2"V1EMEUM8=U32=2[$GTLQ&-O-@
M8V/1Z(9QLXV/6N)7ACB=?N:9J(%\I<^@R ?RV.XF$059029XQBI&;;QQY!/D
M(&E%'C756RUPVBN:K*@&H@6Y+PJP6_/FX\4=:,HJ]=/<UZC<K.]GG<K;5F4T
MH#*,R!?!=:G(/<\A/R;PT7+O.WKQ?1N-,MY!-B%Q^)Y$010[!"W_/3P:D1/W
MVQ!;OGB ;SAJQ]OPGCR S(!K\OO-6FF)6?"'*YSM:HE[-5,:KE5#,UAXF/L*
MY Z\],<?PEGPLRL4_Q/946"2/C#)&'MZ_]Q@8" GK(V+QKBL@4/!-*&:Z!)(
MT1U+U1]+B8%S1:5=*@SL6J; [=)@$H5S?W=H]]RL(Q_3WL=TU(?)&2"4YZ02
M&8K5)N%<&EN:,#Q:/4BB$Y'N:=.96^6L5SD;5;D"O97<I'$CQ8[96DWS/[$,
M8>763KVCA/_UI,V<KN+$[>JR=W5YQI4"*K/2AC^''=Y=C?%#,@DY<]NZ="N)
M3[;!/6WHL%SU@J_.'!:1/7TPMU-.\-3CE:UL]KN$CC-=)),X>.>JN,LSP'AR
M]09X9.9C;^;C*-,WGH'$PL]M[C9",6/%&?1QHHM@D@QX.0N,QKV$P>MU&8QR
M_8H51SHOL'$<:@@'Q'?(TT,4Q.Y#%!Y<[>'HFLN2\@U@Y20[6FW;:YQ6V+A1
MW!*GAW&^BRB93(=,G(-.'0?QV%?TZBL:)?LJ-*V<^L=QN =OSW0G/W+G^VDB
M^P>=5@UR8QM0A4FZY;IM/OK1OLF]L:W=R?BM:7YM!_=*TW;.7ZC<,*Y(!052
M!I-++/6R;4;;%RT:V\^MA<;NT#Z6V,"#-!/P>R&$?GDQ"_3_$J3_ %!+ P04
M    "  0B%Q8+OWJ6W #  !+"P  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6RMEFV/HS80Q[^*1:OJ3NHN& *!;1+I+E%U)_4AVO3:UUZ8)-8:3&TG
MV>NG[QA8+A&&GDY]DV S\^<W8WL\BXM4S_H(8,A+*2J]]([&U ^^K_,CE$S?
MRQHJ?+.7JF0&A^K@ZUH!*QJG4OAA$"1^R7CEK1;-W%:M%O)D!*]@JX@^E253
MG]^#D)>E1[W7B4=^.!H[X:\6-3O #LRG>JMPY/<J!2^ATEQ61,%^Z;VC#VL:
M6H?&XD\.%WWU3&PH3U(^V\''8ND%E@@$Y,9*,/P[PQJ$L$K(\7<GZO7?M([7
MSZ_J/S?!8S!/3,-:BK]X88Y++_5( 7MV$N917CY %U!L]7(I=/-++IUMX)'\
MI(TL.V<D*'G5_K.7+A%7#G0VXA!V#N'7.D2=0]0$VI(U86V88:N%DA>BK#6J
MV8<F-XTW1L,KNXP[H_ M1S^S^ECEL@3R!WL!3>[(KEU-(O=DJWB5\YH)LI9E
M+2NHC+;S&]B#4E!8'_).:\#I-QLPC O]%B4^[3;DS?=O%[Y!//L1/^]0WK<H
MX0C*!O)[$M$?21B$D<-]_?7NX:V[CTGI,Q/VF0D;O6A4KXO38)RLBU-P]L0%
M-QRT,\)6<N:6M$?R0=<LAZ6'9TZ#.H.W^N$[F@0_N>+]G\1NHH_ZZ*,I]=6:
MU=PPP?_!!%AUIO(C856!1^2,9[_&DVQ<"6A5YXVJ+2'G510E&1:58.&?KX,;
M&M)9%,37AC?@LQY\-@G^&Y8^+'**&5X=B)!:DYPI]1DKWH6I0KN@6\7XBB6+
MTGC(/+2+XRP818Y[Y'@2^1>>8UT$P@X*8"RQ\?#;29 -&8=V28")'6-,>L9D
MDG%G9/Y\9PMF0;!BX"VBF:W#+M1D@$#G:3H;LCH,PY".[X%Y#SN?A'T<V; D
MQ_/,C7,/S <L*8T=>V!H%Z5A,HJ<]LCI)/+OY@C*Q94.<W2[G"W6T&P^OC&S
M'BJ;A-HJJ!DO"+S8]09GWK+!A^^2S)$WAUV:C>]+&GRYP())R&^JTYWF3;YF
M=.Y(K,-R1FD\ON+TZNJET^<>M'X@9R9.K&UI!#95K,K!24R'"1Q#=IC^!_.7
M2Y%.WCI->2V^*>/AH. /N*=,6E[_JM.Q;>:O3!UXI8F /?H$]W,,6K6=6SLP
MLFZ:GR=IL)5J'H_8[8*R!OA^+Z5Y'=A^JN^?5_\"4$L#!!0    ( !"(7%A4
MO@P[E0(  .P%   9    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;(U446_3
M,!#^*Z<PH2'!DJ9+-XTVTKJ"V,.D:=W@ ?'@)I?$FF,'VVDW?CUGIPT%LL)+
M;)_OOON^<^ZF&Z4?385HX:D6TLR"RMKF(@Q-5F'-S(EJ4-)-H73-+!UU&9I&
M(\M]4"W".(HF8<VX#-*IM]WJ=*I:*[C$6PVFK6NFG^<HU&86C(*=X8Z7E76&
M,)TVK,0EVH?F5M,I[%%R7J,T7$G06,R"R]'%?.+\O<-GCANSMP>G9*74HSM<
MY[,@<H108&8= J-EC5<HA ,B&M^WF$&?T@7N[W?H'[UVTK)B!J^4^,)S6\V"
M\P!R+%@K[)W:?,*MGL3A94H8_X7-UC<*(&N-5?4VF!C47'8K>]K682\@CE\(
MB+<!L>?=)?(L%\RR=*K5!K3S)C2W\5)]-)'CTCW*TFJZY11GTVN9J1KAGCVA
M@7>P[-X&5 %WF"F9<<&9+Q]9'J0F6RGY#\Q=!,Q18L&M@>,%6L:%>0-'P"7<
M5ZHU3.9F&EKBZ#*%V9;/O.,3O\!G%,.-DK8R\$'FF/\.$)*X7F&\4SB/#R(N
M,#N!\>@MQ%$\AH?E HZ/WAS '?>5&WO<\3\K!PMN,J%,JQ&^7JZ,U?2O?1O2
MWB&>#B.Z_KLP#<MP%E"#&=1K#-+7KT:3Z/T!OJ<]W]-#Z.F<"28SA!667$HN
M2_>DS\CT$-$.ZLQ#N;Y>ITF<)--P/4 @Z0DD!PE0P6AL&*1>%LS2+V05-66F
M6]IR:9$DVR$N'6JRSR4:#U.9]%0F_U4+9@%E[@K1H.8J'TH_^;L49\GY'_G#
MO0ZL49=^SAC(5"MMUXR]M1]EEUT'_W+OYN -T_1 !@06%!J=G)%RW<V6[F!5
MX_MYI2Q-![^M:!RC=@YT7RAE=P>7H!_PZ4]02P,$%     @ $(A<6%0Z"3'X
M @  PP@  !D   !X;"]W;W)K<VAE971S+W-H965T-C$N>&ULK59=;]HP%/TK
M5E9-K=22+Q)"!Y$*=-JD=4)E71^F/9C$$*N)G=D&NG^_:R=DP )B4E_ '_><
MG&/?W)O!AHL7F1&BT&N1,SFT,J7*6]N6248*+#N\) QV%EP46,%4+&U9"H)3
M RIRVW.<T"XP958\,&M3$0_X2N64D:E <E446/P>D9QOAI9K;1<>Z3)3>L&.
M!R5>DAE13^54P,QN6%):$"8I9TB0Q="Z<V_'D8XW =\IV<B=,=).YIR_Z,GG
M=&@Y6A#)2:(T X:_-1F3/-=$(.-7S6DUC]3 W?&6_:/Q#E[F6)(QSY]IJK*A
M%5DH)0N\RM4CWWPBM9] \R4\E^87;>I8QT+)2BI>U&!04%!6_>/7^AQV &YX
M!.#5 .\0T#T"\&N ;XQ6RHRM"58X'@B^04)' YL>F+,Q:'!#F;[%F1*P2P&G
MXJ^0*%^XE&A*!)IE6!!T@V;5E2*^0",L:8(P2]&$YBM%4G2/!:-LN8NXG!"%
M:2ZO /LTFZ#+BRMT@6PD]:Y$E*$G1I6\AD48?\OX2@*C'-@*'&@==E*K'55J
MO2-J70\]<*8RB>Y92M)] ANL-_Z]K?^1=Y)Q0I(.\MUKY#F>WR)H?#[<.R''
M;Z[#-WS^$;Z6P_UQ-Y=*0+K_;#NOBJ[;3J=+P*TL<4*&%KSCDH@UL>+W[]S0
M^=#F]8W(]IQW&^?=4^PF$7-(Q#:3%;)GD+HLK>,;UP_Z03BPU[OZV^+<H._T
MF[@]:4$C+3@I[=G4 DA]O"8"2AM*>%% ":K3&VJC5)#/<&_7NJ30I,U#]8A@
M1UOD^U&_%S@')MH"O6[@1T&[B[!Q$;Z9B[1ZU]M\A.?Z: L\Y:/7^.B=E2BH
MA%?$B#]QZA55?R\C.J%_(+4URC^2-5&C,_IOG2?.-3I+:6O4/TKMG7Y0$+$T
M;5+"A:^8JDICL]ITXCO3@ [61]"AJX;ZEZ9J[P]8+"F3*"<+H'0Z/;AH4;7,
M:J)X:;K.G"OH86:8P5<&$3H ]A><J^U$/Z#Y;HG_ %!+ P04    "  0B%Q8
M8AW[R)8#   S$   &0   'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6S-6%UO
MHS@4_2L6*XUVI9T"AH2TFT1JTXZFTGQ$C6;F8;4/+MP$JV SMFG:?S^VH22D
MA)E*K*8O"3;W'M]S[-/Z9KKEXDZF  H]Y!F3,R=5JCAS71FGD!-YP@M@^LV:
MBYPH/10;5Q8"2&*3\LS%GC=V<T*9,Y_:N:683WFI,LI@*9 L\YR(QPO(^';F
M^,[3Q W=I,I,N/-I03:P O6E6 H]<AN4A.; ).4,"5C/G'/_;.&')L%&?*6P
ME7O/R%"YY?S.#*Z3F>.9BB"#6!D(HK_N80%99I!T'=]K4*=9TR3N/S^AO[/D
M-9E;(F'!LV\T4>G,F3@H@34I,W7#M^^A)C0R>#'/I/U$VSK6<U!<2L7S.EE7
MD%-6?9.'6HB]!']\) '7"?@P(3R2$-0)@25:569I71)%YE/!MTB8:(UF'JPV
M-ENSH<QLXTH)_9;J/#7_I$_*!RXE6H) JY0(0&_1>9)0(S+)T#6KCHJ1_,]+
M4(1F\B\=(DVHG+I*UV"0W+A>[Z):#Q]9S\?H(V<JE>B*)9"T 5Q=?,, /S&X
MP+V(EQ"?H,#_&V$/!QT%+7X]'?>4$S2"!A8O/(*W4CR^0Y\+HUBG/KWIQK5G
MLB QS!QM2PGB'ISYFS_\L?=/%[>!P%I,PX9I:-&#(TS/F:()S4KC0[2"N!3Z
MT(#>V(<X*_7>HK7@.5KPO"A5=8#X&ET1P2C;[)^W?S]H8'2M()?_=0D6#BG8
M0& MP4:-8*/>H_&IS&\U:ZU"Y1X$+:7BME)66OV.:8=2IE\"*G2V3>V2J5I[
M9-<V?[SOYW[D^5'@GT[=^WT).@*#<8!Q-&D"6_3&#;UQ+[T;D$K0V-1<F> +
MHZK3 KTX+]W1@<!:E*.&<O0J+! -*=A 8"W!)HU@D]]H@<FSDXV#(!KYT8$#
MGL?Y8S\:>=WG_[3A=MK+36^G_5_)8GAK;A8)^G5']"*_=(,' FN)X'N["X7W
M*CQ1ES&09D.AM47;NX7YO]$7]>+[!S["X6GD'?CBYW%M>GA'#_?2N\J+C#\"
MU#98EB).M4/0,B.LL^!>N!?O[4!H;?*["Z$?O Y##'JS' JM+=KN;NGWWL3^
M;T.$SPYZX.%1>.B'YV$XC,+@P [N7ON5@]C8KE3J&DNFJCZFF6TZWW/;[QW,
M7YB.V+9U.YBJG?Y(Q(8RB3)8:TCO)-(UB:I#K0:*%[;)N^5*MXSV,=5=/0@3
MH-^O.5=/ [- \SO!_ =02P,$%     @ $(A<6$#\B@;; @  Y @  !D   !X
M;"]W;W)K<VAE971S+W-H965T-C,N>&ULM59M;],P$/XK5IC0)HWFI6]CM)'6
M%<0D)E4;@P^(#VYR;:PY=K"=MN/7<W;:T(ZT8JA\2>SSW7/W/+GD,EA*]:@S
M $-6.1=ZZ&7&%)>^KY,,<JI;L@"!)S.I<FIPJ^:^+A30U 7EW(^"H.?GE DO
M'CC;1,4#61K.!$P4T66>4_4T BZ70R_T-H8[-L^,-?CQH*!SN ?S4$P4[OP:
M)64Y",VD( IF0^\JO+SN6W_G\(7!4F^MB64RE?+1;F[2H1?8@H!#8BP"Q=L"
MKH%S"X1E_%AC>G5*&[B]WJ!_<-R1RY1JN);\*TM--O0N/)+"C);<W,GE1UCS
MZ5J\1'+MKF19^?;?>B0IM9'Y.A@KR)FH[G2UUF$K(.SM"8C6 ='S@,Z>@/8Z
MH.V(5I4Y6F-J:#Q0<DF4]48TNW#:N&ADPX1]BO=&X2G#.!./0,",&3+A5) W
MY"I-F967<G(CJAZQ8I^.P5#&]1FZ/-R/R>G)&3DA3)#/F2PU%:D>^ :KL9A^
MLLX\JC)'>S*'$;F5PF2:O!<II+L /M*HN40;+J/H(.(8DA9IA^<D"J)V0T'7
M?Q\>'2BG74O;=GCMO7@SM*1D1^(QTPF7NE1 OGW"8W)C(-??F^2KT#O-Z/;M
MOM0%36#HX>NK02W BU^_"GO!NR;J1P+;$:)3"]$YA%X+D>#C5FQ:NI8JK!H*
M$CD7["<>P@H_3!K0Q*G!O9'8YB;)F)CO!#9V6I6_[_+;[]8B[@<7 W^QK<"?
M/MU.6/OL$.O6Q+H'B=W2%<O+O*FB@X$O?7A' MOAV*LY]OYK%_>.*<21P':$
MZ-="]/^MB\\)Y 673Z":._:<%* 2$ :G8I-"5=HPV.K,H!5TGK7OP>)>2MW?
M&A@YJ+F;HQJK+H6IOK>UM1[55VY"/;./<(17$_<W3#7_;ZF:,Z$)AQE"!JT^
M-K&J9FJU,;)P8VDJ#0XYM\SP-P24=<#SF91FL[$)ZA^;^!=02P,$%     @
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MA:J3@6L#]7S&F-QV] O*RCO\#U!+ P04    "  0B%Q8^=\JGS@#  #L$P
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MH*3&,"WO;*<>7 =?0$'3?ER6UF&NZ;+;NR9K0GVS229*ITRW:;ID%1H-!,O
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M;!>PVH'\_CQ04WY.%,&N8MZP)QA'D@1#H!;]-1K'R.K$\/'O#_:41%&2^!'
M_ ZB"$/@:<01S %XP) HJM^#.^^C</6>"M?_WQO]!E!+ P04    "  0B%Q8
MEXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S
M9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X
M 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO
M3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)
MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  0B%Q873FZR.X    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  0
MB%Q8F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( !"(7%@X-"D!Q@@  "HV   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  0
MB%Q85(?-%,8%   =&   &               @($)$0  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ $(A<6'B%,JW? @  X0D  !@
M         ("!!1<  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( !"(7%C&M&/KK@0  '81   8              " @1H:  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  0B%Q8.*TAH8\%  !C(P
M&               @('^'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ $(A<6-=4OVB4!@  NAT  !@              ("!PR0  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( !"(7%CY'9\6GPD
M !X7   8              " @8TK  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    "  0B%Q8]:5,]*(8  #?20  &               @(%B
M-0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ $(A<6)MG
MU#$T!0  ]@T  !@              ("!.DX  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( !"(7%AW^;HS.P0  *4*   9
M  " @:13  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M$(A<6.7^XVET!   E H  !D              ("!%E@  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    "  0B%Q8)=(]7_8"  "O!@  &0
M            @('!7   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( !"(7%AI>I23U (  'H&   9              " @>Y?  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ $(A<6 M167UT"P
M'1T  !D              ("!^6(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    "  0B%Q8&<J(%4,"   C!0  &0              @(&D
M;@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( !"(7%B9
M%3+\O0,  (T(   9              " @1YQ  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ $(A<6.*WM EV"@  &Q\  !D
M     ("!$G4  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !"(7%@M_#3ZX!D  #Y4   9              "
M@9.3  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ $(A<
M6.& 1W6K @  QP4  !D              ("!JJT  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    "  0B%Q8&%'QI[@#   P"0  &0
M        @(&,L   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( !"(7%A3!+&47P,  -('   9              " @7NT  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ $(A<6+?(9SO5 @  0@8
M !D              ("!$;@  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    "  0B%Q8=,4*A>$"  !=!@  &0              @($=NP
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( !"(7%BIW$W
M+P4  )@-   9              " @36^  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ $(A<6,A(Z9#- @  * 8  !D
M ("!F\,  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  0
MB%Q8M"7MO70%   '$@  &0              @(&?Q@  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( !"(7%C[VI9L[@0  . +   9
M          " @4K,  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#
M%     @ $(A<6(,ES_B? @  R 4  !D              ("!;]$  'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  0B%Q8U[723=D#  "@
M$0  &0              @(%%U   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;%!+ 0(4 Q0    ( !"(7%CME@U%O@,   @-   9              " @578
M  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ $(A<6.8_
MI??Z @  %0L  !D              ("!2MP  'AL+W=O<FMS:&5E=',O<VAE
M970S-2YX;6Q02P$"% ,4    "  0B%Q83%2>,$,#  "S"@  &0
M    @(%[WP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M !"(7%B97G:IM 4  /(I   9              " @?7B  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ $(A<6 GY$$@W!0  9QX  !D
M             ("!X.@  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    "  0B%Q8'0"W?G@#  !%"@  &0              @(%.[@  >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( !"(7%AF-KI7G@,
M ',1   9              " @?WQ  !X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ $(A<6#N=TI1V @  W@4  !D              ("!
MTO4  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  0B%Q8
M1Y)1M@$#  !A"   &0              @(%_^   >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( !"(7%CP09]HG@(  ,4&   9
M      " @;?[  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ $(A<6.?"LIBF @  %P<  !D              ("!C/X  'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  0B%Q8(*#O2U "   *!@
M&0              @(%I 0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( !"(7%BFI !RM 4  &0F   9              " @? # 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ $(A<6&%[*] D
M P  S0H  !D              ("!VPD! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    "  0B%Q8<!"'^S4"  "\!0  &0
M@($V#0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( !"(
M7%A$Z_JHWP(  %P(   9              " @:(/ 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ $(A<6.W_8PU2 P  J0X  !D
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M=#4T+GAM;%!+ 0(4 Q0    ( !"(7%A=:<::+0,  /,+   9
M  " @?TP 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
M$(A<6"NK#T]G P  R0X  !D              ("!830! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    "  0B%Q8R4^#0C<%  ! &   &0
M            @('_-P$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    ( !"(7%A=H<" JP,  !X,   9              " @6T] 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ $(A<6"[]ZEMP P
M2PL  !D              ("!3T$! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4    "  0B%Q85+X,.Y4"  #L!0  &0              @('V
M1 $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( !"(7%A4
M.@DQ^ (  ,,(   9              " @<)' 0!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L! A0#%     @ $(A<6&(=^\B6 P  ,Q   !D
M     ("!\4H! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
M"  0B%Q80/R*!ML"  #D"   &0              @(&^3@$ >&PO=V]R:W-H
M965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( !"(7%A;=>4(/0,  (4/   9
M              " @=!1 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L!
M A0#%     @ $(A<6/G?*I\X P  [!,   T              ( !1%4! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  0B%Q8EXJ[',     3 @  "P
M        @ &G6 $ 7W)E;',O+G)E;'-02P$"% ,4    "  0B%Q8*<129O$$
M  "7*@  #P              @ &060$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ $(A<6-))O&T1 @  %R8  !H              ( !KEX! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ $(A<6,"(;73I 0
M?B4  !,              ( !]V ! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $@ 2 "O$P  $6,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>131</ContextCount>
  <ElementCount>291</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Collaboration Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCollaborationRevenue</Role>
      <ShortName>Collaboration Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStock</Role>
      <ShortName>Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlan</Role>
      <ShortName>Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStock</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Nature of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Nature of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Collaboration Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails</Role>
      <ShortName>Collaboration Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Commitments and Contingencies - Summary of Assets and Liabilities Recorded on Consolidated Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAssetsAndLiabilitiesRecordedOnConsolidatedBalanceSheetDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Assets and Liabilities Recorded on Consolidated Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Commitments and Contingencies - Components of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Components of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Commitments and Contingencies - Summary of Remaining Lease Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfRemainingLeaseTermAndDiscountRateDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Remaining Lease Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Payments under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Common Stock - Summary of Reserved Shares of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails</Role>
      <ShortName>Common Stock - Summary of Reserved Shares of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Stock-based Compensation - Summary of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Stock-based Compensation - Summary of Assumptions Used to Estimate Fair Value of Award (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Assumptions Used to Estimate Fair Value of Award (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Stock-based Compensation - Summary of Components of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Components of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Income Taxes - Summary of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Income Taxes - Summary of Principal Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Principal Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Net Loss Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Benefit Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlanAdditionalInformationDetails</Role>
      <ShortName>Benefit Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="avir-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="avir-20231231.htm">avir-20231231.htm</File>
    <File>avir-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img57592461_0.jpg</File>
    <File>img57592461_1.jpg</File>
    <File>img57592461_10.jpg</File>
    <File>img57592461_11.jpg</File>
    <File>img57592461_12.jpg</File>
    <File>img57592461_13.jpg</File>
    <File>img57592461_14.jpg</File>
    <File>img57592461_2.jpg</File>
    <File>img57592461_3.jpg</File>
    <File>img57592461_4.jpg</File>
    <File>img57592461_5.jpg</File>
    <File>img57592461_6.jpg</File>
    <File>img57592461_7.jpg</File>
    <File>img57592461_8.jpg</File>
    <File>img57592461_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="524">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "avir-20231231.htm": {
   "nsprefix": "avir",
   "nsuri": "http://www.ateapharma.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "avir-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "avir-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 258,
   "keyCustom": 33,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 19,
   "hidden": {
    "total": 10,
    "http://fasb.org/us-gaap/2023": 7,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 131,
   "entityCount": 1,
   "segmentCount": 52,
   "elementCount": 556,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 524,
    "http://xbrl.sec.gov/dei/2023": 40
   },
   "report": {
    "R1": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss",
     "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_7f911c61-390f-464f-b142-8191cfb56974",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7f911c61-390f-464f-b142-8191cfb56974",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusiness",
     "longName": "100080 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "100090 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCollaborationRevenue",
     "longName": "100100 - Disclosure - Collaboration Revenue",
     "shortName": "Collaboration Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "100110 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecurities",
     "longName": "100120 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "longName": "100130 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "100140 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "100150 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStock",
     "longName": "100160 - Disclosure - Preferred Stock",
     "shortName": "Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStock",
     "longName": "100170 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "avir:CommonStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "avir:CommonStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "100180 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "100190 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShare",
     "longName": "100200 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlan",
     "longName": "100210 - Disclosure - Benefit Plan",
     "shortName": "Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "longName": "100220 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "100230 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "avir:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "avir:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "100240 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "avir:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "avir:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "100250 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesTables",
     "longName": "100260 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "longName": "100270 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "100280 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "longName": "100290 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "avir:SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "avir:SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables",
     "longName": "100300 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "avir:CommonStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "avir:CommonStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "100310 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "100320 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "100330 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
     "longName": "100340 - Disclosure - Nature of Business - Additional Information (Details)",
     "shortName": "Nature of Business - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails",
     "longName": "100360 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_7d2d29de-6d0b-4b53-b56c-521ea942b78d",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d2d29de-6d0b-4b53-b56c-521ea942b78d",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
     "longName": "100370 - Disclosure - Collaboration Agreement - Additional Information (Details)",
     "shortName": "Collaboration Agreement - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2379ff73-5bee-4de8-86f9-afedc9100f71",
      "name": "avir:ResearchAndDevelopmentCreditAdjustment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "100380 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails",
     "longName": "100390 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)",
     "shortName": "Marketable Securities - Schedule of Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
     "longName": "100400 - Disclosure - Marketable Securities - Additional Information (Details)",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "U_Security",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "U_Security",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
     "longName": "100410 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "100420 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "100430 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "avir:AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "avir:AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAssetsAndLiabilitiesRecordedOnConsolidatedBalanceSheetDetails",
     "longName": "100440 - Disclosure - Commitments and Contingencies - Summary of Assets and Liabilities Recorded on Consolidated Balance Sheet (Details)",
     "shortName": "Commitments and Contingencies - Summary of Assets and Liabilities Recorded on Consolidated Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseCostsDetails",
     "longName": "100450 - Disclosure - Commitments and Contingencies - Components of Lease Costs (Details)",
     "shortName": "Commitments and Contingencies - Components of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfRemainingLeaseTermAndDiscountRateDetails",
     "longName": "100460 - Disclosure - Commitments and Contingencies - Summary of Remaining Lease Term and Discount Rate (Details)",
     "shortName": "Commitments and Contingencies - Summary of Remaining Lease Term and Discount Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "avir:SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "avir:SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails",
     "longName": "100480 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments under Operating Leases (Details)",
     "shortName": "Commitments and Contingencies - Summary of Future Minimum Payments under Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
     "longName": "100490 - Disclosure - Preferred Stock - Additional Information (Details)",
     "shortName": "Preferred Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
     "longName": "100500 - Disclosure - Common Stock - Additional Information (Details)",
     "shortName": "Common Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "avir:CommonStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails",
     "longName": "100510 - Disclosure - Common Stock - Summary of Reserved Shares of Common Stock (Details)",
     "shortName": "Common Stock - Summary of Reserved Shares of Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "avir:CommonStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_be3c9676-01ad-494a-ba2a-56772d6be054",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "avir:CommonStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "longName": "100520 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "avir:CommonStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails",
     "longName": "100530 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Units (Details)",
     "shortName": "Stock-based Compensation - Summary of Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_c43a7923-c261-4651-bc39-5f0700559de8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20a4f8c4-8263-4c93-becf-4246d8ff6c21",
      "name": "avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails",
     "longName": "100540 - Disclosure - Stock-based Compensation - Summary of Stock Options Activity (Details)",
     "shortName": "Stock-based Compensation - Summary of Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_c897b11b-eb38-4bd1-97cb-ac70cc675214",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails",
     "longName": "100550 - Disclosure - Stock-based Compensation - Summary of Assumptions Used to Estimate Fair Value of Award (Details)",
     "shortName": "Stock-based Compensation - Summary of Assumptions Used to Estimate Fair Value of Award (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
     "longName": "100560 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2e76c0f9-bba5-44a0-93ae-345a4101d6c8",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails",
     "longName": "100570 - Disclosure - Stock-based Compensation - Summary of Components of Stock-based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation - Summary of Components of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20a4f8c4-8263-4c93-becf-4246d8ff6c21",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "100580 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:IncomeTaxExaminationDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails",
     "longName": "100590 - Disclosure - Income Taxes - Summary of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Summary of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails",
     "longName": "100600 - Disclosure - Income Taxes - Summary of Principal Components of Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Summary of Principal Components of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "avir:DeferredTaxAssetsInProcessResearchAndDevelopmentCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24",
      "name": "avir:DeferredTaxAssetsInProcessResearchAndDevelopmentCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails",
     "longName": "100610 - Disclosure - Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_c897b11b-eb38-4bd1-97cb-ac70cc675214",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "avir:UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails",
     "longName": "100620 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Earnings Per Share (Details)",
     "shortName": "Net Loss Per Share - Summary of Basic and Diluted Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
     "longName": "100630 - Disclosure - Net Loss Per Share - Additional Information (Details)",
     "shortName": "Net Loss Per Share - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_eea6202c-efed-4922-944f-49a05b0bd392",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eea6202c-efed-4922-944f-49a05b0bd392",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlanAdditionalInformationDetails",
     "longName": "100640 - Disclosure - Benefit Plan - Additional Information (Details)",
     "shortName": "Benefit Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_504aa066-1c9a-4526-b64e-13d9e2393363",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "100650 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_b64973ad-fef2-423f-96bd-ad36857f2986",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b64973ad-fef2-423f-96bd-ad36857f2986",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avir-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avir_AccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "AccountingPoliciesLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Line Items]",
        "label": "Accounting Policies [Line Items]",
        "documentation": "Accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "avir_AccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "AccountingPoliciesTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Table]",
        "label": "Accounting Policies [Table]",
        "documentation": "Accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02",
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201613Member",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "ASU 2016-13",
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_AccountingStandardsUpdate201711Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201711Member",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2017-11 [Member]",
        "terseLabel": "ASU 2017-11",
        "documentation": "Accounting Standards Update 2017-11 Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_AccountingStandardsUpdate201901Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201901Member",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2019-01 [Member]",
        "terseLabel": "ASU 2019-01",
        "documentation": "Accounting Standards Update 2019-01 Leases (Topic 842): Codification Improvements."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201912Member",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2019-12 [Member]",
        "terseLabel": "ASU 2019-12",
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436",
      "r437",
      "r438"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r761"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of premium and discounts on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "avir_AccruedExpenseAndOtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "AccruedExpenseAndOtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accrued Expense And Other Current Liabilities [Member]",
        "documentation": "Accrued expenses and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r121"
     ]
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Income taxes payable",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r121"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses and other current liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "avir_AccruedLicenseFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "AccruedLicenseFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fee",
        "label": "Accrued License Fees Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for licensing arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "avir_AccruedProfessionalFeesAndOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "AccruedProfessionalFeesAndOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees and other",
        "label": "Accrued Professional Fees And Other Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received, and fees classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "avir_AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development, including manufacturing and clinical expenditures",
        "label": "Accrued Research and Development Expense including Manufacturing and Clinical Expenditures Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for research and development, including, but not limited to, manufacturing and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r159",
      "r599"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive gain (loss)",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r86",
      "r165",
      "r595",
      "r623",
      "r627"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accummulated Other Comprehensive Gain (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r11",
      "r27",
      "r465",
      "r468",
      "r525",
      "r618",
      "r619",
      "r803",
      "r804",
      "r805",
      "r811",
      "r812",
      "r813"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "totalLabel": "Additional Paid in Capital, Total",
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r761",
      "r906"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r640",
      "r811",
      "r812",
      "r813",
      "r883",
      "r907"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r195",
      "r196",
      "r197",
      "r198",
      "r208",
      "r247",
      "r248",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r314",
      "r406",
      "r407",
      "r408",
      "r435",
      "r436",
      "r437",
      "r438",
      "r448",
      "r449",
      "r450",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r488",
      "r489",
      "r492",
      "r493",
      "r494",
      "r495",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r568",
      "r569",
      "r570",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation in connection with vesting of restricted stock",
        "label": "APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r369"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r414"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "avir_AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "AmountOfAnnualLimitOnUseOfNetOperatingLossesAndOtherTax",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of annual limit on use of net operating losses and other tax attributes",
        "label": "Amount Of Annual Limit On Use Of Net Operating Losses And Other Tax",
        "documentation": "Amount of annual limit on use of net operating losses and other tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares excluded from computation of diluted net income per share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed securities",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r825",
      "r830",
      "r831"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r161",
      "r185",
      "r226",
      "r238",
      "r242",
      "r284",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r453",
      "r457",
      "r490",
      "r590",
      "r674",
      "r761",
      "r774",
      "r844",
      "r845",
      "r891"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r166",
      "r185",
      "r284",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r453",
      "r457",
      "r490",
      "r761",
      "r844",
      "r845",
      "r891"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r780",
      "r781"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r780",
      "r781"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r780",
      "r781"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r303",
      "r589"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "verboseLabel": "Fair Value",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r303",
      "r583",
      "r818"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r303"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Securities maturing longer than one year",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r251",
      "r303"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68"
     ]
    },
    "avir_BankDepositRestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "BankDepositRestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank deposits, restricted cash",
        "label": "Bank Deposit Restricted Cash",
        "documentation": "The value of a bank deposit to collateralize a letter of credit, classified as restricted cash."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "avir_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "BasisOfPresentationAndUseOfEstimatesPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Use of Estimates",
        "label": "Basis Of Presentation And Use Of Estimates Policy [Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS) as well as the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": []
    },
    "avir_BusinessDevelopmentConsultingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "BusinessDevelopmentConsultingAgreementsMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Development Consulting Agreements",
        "label": "Business Development Consulting Agreements [Member]",
        "documentation": "Business development consulting agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostAmortizationMethod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostAmortizationMethod",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition method for costs of obtaining a contract",
        "label": "Capitalized Contract Cost, Amortization Method",
        "documentation": "Description of method used for amortizing cost capitalized in obtaining or fulfilling contract with customer."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r156",
      "r726"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash and cash equivalents and marketable securities",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r92",
      "r184"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and restricted cash at the end of period:",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r92"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r142",
      "r148",
      "r149",
      "r194",
      "r247",
      "r248",
      "r286",
      "r287",
      "r288",
      "r294",
      "r295",
      "r314",
      "r435",
      "r448",
      "r449",
      "r459",
      "r460",
      "r461",
      "r472",
      "r473",
      "r483",
      "r488",
      "r489",
      "r491",
      "r492",
      "r493",
      "r504",
      "r507",
      "r508",
      "r509",
      "r521",
      "r568",
      "r569",
      "r616",
      "r617"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r142",
      "r148",
      "r149",
      "r247",
      "r248",
      "r286",
      "r287",
      "r288",
      "r294",
      "r295",
      "r296",
      "r314",
      "r435",
      "r448",
      "r449",
      "r450",
      "r459",
      "r460",
      "r461",
      "r462",
      "r472",
      "r473",
      "r474",
      "r477",
      "r483",
      "r488",
      "r489",
      "r491",
      "r492",
      "r493",
      "r504",
      "r507",
      "r508",
      "r509",
      "r521",
      "r568",
      "r569",
      "r616",
      "r617",
      "r787"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r195",
      "r207",
      "r291",
      "r439"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r162",
      "r163",
      "r164",
      "r185",
      "r212",
      "r213",
      "r215",
      "r217",
      "r224",
      "r225",
      "r284",
      "r324",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r337",
      "r338",
      "r340",
      "r341",
      "r344",
      "r490",
      "r630",
      "r631",
      "r632",
      "r633",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r662",
      "r683",
      "r705",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r786",
      "r808",
      "r814"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r224",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r630",
      "r631",
      "r632",
      "r633",
      "r741",
      "r786",
      "r808"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r768",
      "r769",
      "r770",
      "r771"
     ]
    },
    "avir_CommissionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "CommissionRate",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The commission rate the Company agreed to pay for shares sold under a Sales Agreement, as a percentage of aggregate gross sales proceeds from each sale of shares.",
        "label": "Commission Rate",
        "terseLabel": "Commission percentage of aggregate gross proceeds from each sale of shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (see Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r73",
      "r591",
      "r661"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r316",
      "r317",
      "r721",
      "r839"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, capital shares reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r765",
      "r766",
      "r768",
      "r769",
      "r770",
      "r771",
      "r811",
      "r812",
      "r883",
      "r904",
      "r907"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r662"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Number of shares issued",
        "verboseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r80",
      "r662",
      "r680",
      "r907",
      "r908"
     ]
    },
    "avir_CommonStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "CommonStockTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Text Block]",
        "documentation": "The entire disclosure for common stock, including, but not limited to, the number of shares issued and outstanding, voting rights, and number of shares reserved for each class of stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; 300,000,000 shares authorized; 83,435,513 and 83,287,639 shares issued and outstanding as of December 31, 2023 and 2022",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r593",
      "r761"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock voting rights per share",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefit Plan",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets (liabilities)",
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive income (loss)",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r171",
      "r173",
      "r179",
      "r585",
      "r606"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Hardware",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "avir_ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk and Significant Suppliers",
        "label": "Concentrations Of Credit Risk And Significant Suppliers Policy [Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk and risk associated with reliance on significant suppliers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r730"
     ]
    },
    "avir_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting Agreement",
        "label": "Consulting Agreement [Member]",
        "documentation": "Consulting agreement."
       }
      }
     },
     "auth_ref": []
    },
    "avir_ConsultingAgreementSuccessFeePayout": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ConsultingAgreementSuccessFeePayout",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success fee",
        "label": "Consulting Agreement Success Fee Payout",
        "documentation": "The aggregate amount payable by the Company, as part of a consulting agreement. The payout amount is a success fee calculated as a percentage of certain product sales."
       }
      }
     },
     "auth_ref": []
    },
    "avir_ConsultingServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ConsultingServicesMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting Services",
        "label": "Consulting Services [Member]",
        "documentation": "Consulting Services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion of preferred stock to common stock upon closing of initial public offering",
        "terseLabel": "Conversion of preferred stock into common stock",
        "label": "Conversion of Stock, Amount Converted",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock into common stock, shares",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r340",
      "r768",
      "r769",
      "r770",
      "r771"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock converted into shares",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r46",
      "r79",
      "r106",
      "r342"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "avir_CostsReimbursedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "CostsReimbursedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs reimbursed amount",
        "label": "Costs Reimbursed Amount",
        "documentation": "The aggregate amount of costs that have been, or will be, reimbursed by the licensee."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r333",
      "r339",
      "r532",
      "r727",
      "r729"
     ]
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current Income Tax Expense (Benefit), Total",
        "terseLabel": "Provision for income taxes",
        "label": "Current Income Tax Expense (Benefit)",
        "verboseLabel": "Current income tax expense (benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r434",
      "r443",
      "r810"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded",
        "terseLabel": "Marketable debt securities, charges for credit-related impairments",
        "documentation": "Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r832"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Aggregate fair value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r305",
      "r738"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "terseLabel": "Debt securities in unrealized loss position",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r306"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of held securities",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r307"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total",
        "terseLabel": "Deferred income tax expense (benefit)",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r117",
      "r137",
      "r442",
      "r443",
      "r810"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets (liabilities)",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "avir_DeferredTaxAssetsInProcessResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development",
        "label": "Deferred Tax Assets In Process Research And Development Costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs. Excludes costs in connection with a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "avir_DeferredTaxAssetsLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "DeferredTaxAssetsLicenseAgreement",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement",
        "label": "Deferred Tax Assets License Agreement",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets (liabilities)",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r881"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r881"
     ]
    },
    "avir_DeferredTaxAssetsPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "DeferredTaxAssetsPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Deferred Tax Assets Prepaid Expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r881"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r881"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "negatedLabel": "Less: valuation allowance",
        "verboseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan recognized expense related to matching contributions",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, employer matching contribution, percentage",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r40"
     ]
    },
    "avir_DevelopmentAndRegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "DevelopmentAndRegulatoryMilestonesMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and Regulatory",
        "label": "Development And Regulatory Milestones [Member]",
        "documentation": "Development and regulatory milestones."
       }
      }
     },
     "auth_ref": []
    },
    "avir_DevelopmentRegulatoryAndCommercialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "DevelopmentRegulatoryAndCommercialMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and Regulatory",
        "label": "Development Regulatory And Commercial [Member]",
        "documentation": "Development, regulatory and commercial."
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r905"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation Of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation Of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r371",
      "r402",
      "r403",
      "r405",
      "r753"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r780",
      "r781"
     ]
    },
    "avir_DocumentDocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "DocumentDocumentAndEntityInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document - Document and Entity Information [Abstract]",
        "label": "Document Document And Entity Information [Abstract]",
        "documentation": "Document Document And Entity Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r780",
      "r781",
      "r783"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to common stockholders",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share, basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "terseLabel": "Basic",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r210",
      "r212",
      "r215",
      "r216",
      "r217",
      "r221",
      "r481",
      "r482",
      "r586",
      "r607",
      "r733"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share, diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "terseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r212",
      "r215",
      "r216",
      "r217",
      "r221",
      "r481",
      "r482",
      "r586",
      "r607",
      "r733"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r218",
      "r219",
      "r220"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected income tax benefit at the federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r423",
      "r444"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r882"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign derived intangible income",
        "label": "Effective Income Tax Rate Reconciliation, FDII, Percent",
        "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r882"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r882"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Return to provision adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r882"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local taxes",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r882"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "intangible income",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r882"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r882"
     ]
    },
    "avir_EffectiveIncomeTaxRateReconciliationUncertainTaxPositions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationUncertainTaxPositions",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax positions",
        "label": "Effective Income Tax Rate Reconciliation Uncertain Tax Positions",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to uncertain tax positions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "terseLabel": "Payroll and payroll related",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Additional Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining weighted average period for recognize compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "avir_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP",
        "verboseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "avir_EntityControlledByDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "EntityControlledByDirectorMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity controlled by director.",
        "label": "Entity Controlled by Director [Member]",
        "terseLabel": "Entity Controlled by Director"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r150",
      "r175",
      "r176",
      "r177",
      "r191",
      "r192",
      "r193",
      "r196",
      "r204",
      "r206",
      "r223",
      "r290",
      "r297",
      "r345",
      "r406",
      "r407",
      "r408",
      "r437",
      "r438",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r480",
      "r496",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r525",
      "r618",
      "r619",
      "r620",
      "r640",
      "r705"
     ]
    },
    "avir_FairValueAssetsMeasuredOnRecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assets Measured On Recurring Basis [Abstract]",
        "documentation": "Fair value assets measured on recurring basis."
       }
      }
     },
     "auth_ref": []
    },
    "avir_FairValueAssetsMeasuredOnRecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets Measured On Recurring Basis [Line Items]",
        "label": "Fair Value Assets Measured On Recurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "avir_FairValueAssetsMeasuredOnRecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets Measured On Recurring Basis [Table]",
        "label": "Fair Value Assets Measured On Recurring Basis [Table]",
        "documentation": "Disclosure of information about assets at fair value on recurring basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r118"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r485",
      "r538",
      "r539",
      "r540",
      "r739",
      "r740",
      "r749",
      "r750",
      "r751"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r358",
      "r363",
      "r485",
      "r538",
      "r749",
      "r750",
      "r751"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r358",
      "r363",
      "r485",
      "r539",
      "r739",
      "r740",
      "r749",
      "r750",
      "r751"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r485",
      "r540",
      "r739",
      "r740",
      "r749",
      "r750",
      "r751"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r538",
      "r539",
      "r540",
      "r739",
      "r740",
      "r749",
      "r750",
      "r751"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r308",
      "r309",
      "r336",
      "r343",
      "r471",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r605",
      "r738",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r832",
      "r833",
      "r834",
      "r835"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "avir_FormerChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "FormerChiefFinancialOfficerMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Chief Financial Officer",
        "label": "Former Chief Financial Officer [Member]",
        "documentation": "Former chief financial officer."
       }
      }
     },
     "auth_ref": []
    },
    "avir_FromTwoThousandThirteenIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "FromTwoThousandThirteenIncentivePlanMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "From Two Thousand Thirteen Incentive Plan [Member]",
        "label": "From Two Thousand Thirteen Incentive Plan [Member]",
        "terseLabel": "From 2013 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Incremental cost included in general and administration costs",
        "totalLabel": "General and Administrative Expense, Total",
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r685"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Costs",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "IPO",
        "terseLabel": "Initial Public Offering",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r780",
      "r781"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "terseLabel": "Impairment losses",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r39",
      "r100"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r101"
     ]
    },
    "avir_InProcessResearchAndDevelopmentAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "InProcessResearchAndDevelopmentAssetsPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process Research and Development Assets",
        "label": "In Process Research and Development Assets [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets, not acquired in a business combination, to be used in research and development activities. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income (loss) before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r87",
      "r123",
      "r226",
      "r237",
      "r241",
      "r243",
      "r587",
      "r601",
      "r735"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r315",
      "r690"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r690"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avir_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Line Items]",
        "label": "Income Tax Disclosure [Line Items]",
        "documentation": "Income tax disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "avir_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Table]",
        "label": "Income Tax Disclosure [Table]",
        "documentation": "Income tax disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r418",
      "r424",
      "r426",
      "r432",
      "r440",
      "r445",
      "r446",
      "r447",
      "r635"
     ]
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationDescription",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax examination description",
        "label": "Income Tax Examination, Description",
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense (benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision for income taxes",
        "negatedLabel": "Income tax benefit (expense)",
        "negatedTerseLabel": "Benefit from income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r143",
      "r205",
      "r206",
      "r229",
      "r422",
      "r441",
      "r608"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r420",
      "r421",
      "r426",
      "r427",
      "r431",
      "r433",
      "r629"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unbilled accounts receivable",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r806"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r806"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total",
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "avir_IncrementalCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "IncrementalCostMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental Cost",
        "label": "Incremental Cost [Member]",
        "documentation": "Incremental cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r97"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest and Other Income, Total",
        "terseLabel": "Interest income and other, net",
        "label": "Interest and Other Income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r125",
      "r126",
      "r147",
      "r249",
      "r252",
      "r486",
      "r487"
     ]
    },
    "avir_JefferiesLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "JefferiesLlcMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies LLC.",
        "label": "Jefferies LLC [Member]",
        "terseLabel": "Jeffries"
       }
      }
     },
     "auth_ref": []
    },
    "avir_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory equipment."
       }
      }
     },
     "auth_ref": []
    },
    "avir_LeaseCommencementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "LeaseCommencementDate",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to commence, in YYYY-MM-DD format.",
        "label": "Lease Commencement Date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease costs",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r760"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Lease Costs",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "avir_LeaseExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "LeaseExpirationMonthAndYear",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Expiration Month And Year",
        "label": "Lease Expiration Month And Year",
        "terseLabel": "Lease expiration month and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfRemainingLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Future Minimum Payments under Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less amount representing implied interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less amount representing implied interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfRemainingLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term (in years)",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_LessorOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessor has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r185",
      "r284",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r454",
      "r457",
      "r458",
      "r490",
      "r660",
      "r734",
      "r774",
      "r844",
      "r891",
      "r892"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r122",
      "r597",
      "r761",
      "r809",
      "r836",
      "r884"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r155",
      "r185",
      "r284",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r454",
      "r457",
      "r458",
      "r490",
      "r761",
      "r844",
      "r891",
      "r892"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement",
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r417",
      "r877"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "avir_LocationOfOfficeSpace": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "LocationOfOfficeSpace",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of Office Space",
        "label": "Location of Office Space",
        "terseLabel": "Location of office space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r323",
      "r840",
      "r841"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r323",
      "r840",
      "r841"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlanAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum",
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r366",
      "r565",
      "r615",
      "r652",
      "r653",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r722",
      "r723",
      "r737",
      "r741",
      "r752",
      "r763",
      "r846",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "avir_MerckLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "MerckLicenseAgreementMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merck License Agreement",
        "label": "Merck License Agreement [Member]",
        "documentation": "Merck license agreement member."
       }
      }
     },
     "auth_ref": []
    },
    "avir_MilestonePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "MilestonePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Received pursuant of milestone",
        "label": "Milestone Payment Received",
        "documentation": "The amount received upon achievement of a milestone."
       }
      }
     },
     "auth_ref": []
    },
    "avir_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "MilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments",
        "label": "Milestone Payments",
        "documentation": "The amount due upon achievement of specified milestones."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlanAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Minimum",
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r366",
      "r565",
      "r615",
      "r652",
      "r653",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r722",
      "r723",
      "r737",
      "r741",
      "r752",
      "r763",
      "r846",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "avir_NatureOfBusinessAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "NatureOfBusinessAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature Of Business [Abstract]",
        "documentation": "Nature of business."
       }
      }
     },
     "auth_ref": []
    },
    "avir_NatureOfBusinessLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "NatureOfBusinessLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business [Line Items]",
        "label": "Nature Of Business [Line Items]",
        "documentation": "Nature of business."
       }
      }
     },
     "auth_ref": []
    },
    "avir_NatureOfBusinessTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "NatureOfBusinessTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature Of Business [Table]",
        "label": "Nature Of Business [Table]",
        "documentation": "Nature of business."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r144"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r94",
      "r124",
      "r153",
      "r169",
      "r172",
      "r177",
      "r185",
      "r195",
      "r199",
      "r200",
      "r201",
      "r202",
      "r205",
      "r206",
      "r214",
      "r226",
      "r237",
      "r241",
      "r243",
      "r284",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r482",
      "r490",
      "r603",
      "r682",
      "r703",
      "r704",
      "r735",
      "r772",
      "r844"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements and Recently Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "avir_NonRefundableUpfrontPaymentAccruedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "NonRefundableUpfrontPaymentAccruedMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable Upfront Payment Accrued",
        "label": "Non Refundable Upfront Payment Accrued [Member]",
        "documentation": "Non-refundable upfront payment accrued."
       }
      }
     },
     "auth_ref": []
    },
    "avir_NonRefundableUpfrontPaymentPaidLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "NonRefundableUpfrontPaymentPaidLicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable upfront payment paid license agreement",
        "label": "Non Refundable Upfront Payment Paid License Agreement",
        "documentation": "The amount of upfront payment paid as part of a licensing agreement."
       }
      }
     },
     "auth_ref": []
    },
    "avir_NovaMedicaLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "NovaMedicaLLCMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NovaMedica LLC",
        "label": "Nova Medica L L C [Member]",
        "documentation": "NovaMedica LLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "avir_OfficeFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "OfficeFacilityMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Facility",
        "label": "Office Facility [Member]",
        "documentation": "Office facility."
       }
      }
     },
     "auth_ref": []
    },
    "avir_OfficeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "OfficeSpaceMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space.",
        "label": "Office Space [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "auth_ref": []
    },
    "avir_OpenMarketSaleAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "OpenMarketSaleAgreementMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open market sale agreement.",
        "label": "Open Market Sale Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transaction expense",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Operating Costs and Expenses, Total",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "terseLabel": "Income (loss) from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r237",
      "r241",
      "r243",
      "r735"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r760"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "totalLabel": "Total lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAssetsAndLiabilitiesRecordedOnConsolidatedBalanceSheetDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current operating lease liability",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAssetsAndLiabilitiesRecordedOnConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAssetsAndLiabilitiesRecordedOnConsolidatedBalanceSheetDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderOperatingLeasesDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current operating lease liability",
        "terseLabel": "Operating lease liabilities",
        "label": "Noncurrent portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAssetsAndLiabilitiesRecordedOnConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAssetsAndLiabilitiesRecordedOnConsolidatedBalanceSheetDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfAssetsAndLiabilitiesRecordedOnConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss Carryforwards, Total",
        "terseLabel": "Net operating losses",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "avir_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses carryforwards expiration year",
        "label": "Operating Loss Carryforwards Expiration Year",
        "documentation": "The year that operating loss carryforwards will begin to expire."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets",
        "label": "Other Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other assets."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Noncurrent, Total",
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "avir_OtherAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "OtherAssetsPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets",
        "label": "Other Assets Policy [Text Block]",
        "documentation": "Disclosure of accounting policy for items classified as other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r16",
      "r170",
      "r173",
      "r178",
      "r496",
      "r497",
      "r502",
      "r584",
      "r604",
      "r803",
      "r804"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on available-for-sale investments",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r283"
     ]
    },
    "us-gaap_OtherLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Liabilities",
        "label": "Other Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other liabilities."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69"
     ]
    },
    "avir_OutstandingOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "OutstandingOptionsMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding options",
        "label": "Outstanding Options [Member]",
        "documentation": "Outstanding options."
       }
      }
     },
     "auth_ref": []
    },
    "avir_OutstandingPerformanceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "OutstandingPerformanceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding performance-based restricted stock units.",
        "label": "Outstanding Performance-based Restricted Stock Units [Member]",
        "terseLabel": "Outstanding performance-based restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "avir_OutstandingRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "OutstandingRestrictedStockUnitsMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Restricted Stock Units [Member]",
        "documentation": "Outstanding restricted stock units.",
        "terseLabel": "Outstanding restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avir_PaymentOfTerminationFeeForTerminationOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "PaymentOfTerminationFeeForTerminationOfAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for termination fee",
        "label": "Payment Of Termination Fee For Termination Of Agreement",
        "documentation": "The amount of termination fee paid by the Company during the period, upon termination of an agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "terseLabel": "Purchases of marketable securities",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r181",
      "r250"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Additions to property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "avir_PerformanceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance based restricted stock units.",
        "label": "Performance Based Restricted Stock Units [Member]",
        "terseLabel": "Performance-based Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r337"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r662"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r337"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r662",
      "r680",
      "r907",
      "r908"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Preferred Stock",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r592",
      "r761"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "avir_PriorOfficeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "PriorOfficeSpaceMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior office space.",
        "label": "Prior Office Space [Member]",
        "terseLabel": "Prior Office Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net proceeds from initial public offering (\"IPO\")",
        "terseLabel": "Net proceeds from initial public offering of common stock",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net proceeds from issuance of preferred stock",
        "terseLabel": "Net proceeds from issuance of convertible preferred stock",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLicenseFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fee received",
        "label": "Proceeds from License Fees Received",
        "documentation": "Cash received from licensees for license fees during the current period."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales and maturities of marketable securities",
        "verboseLabel": "Proceeds from sales and maturities of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock for exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r15"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under ESPP",
        "verboseLabel": "Gross proceeds from issuance of common stock",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r244",
      "r567",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r725",
      "r742",
      "r762",
      "r789",
      "r842",
      "r843",
      "r848",
      "r903"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r244",
      "r567",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r725",
      "r742",
      "r762",
      "r789",
      "r842",
      "r843",
      "r848",
      "r903"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "terseLabel": "Net income (loss)",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r169",
      "r172",
      "r182",
      "r185",
      "r195",
      "r205",
      "r206",
      "r226",
      "r237",
      "r241",
      "r243",
      "r284",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r452",
      "r455",
      "r456",
      "r482",
      "r490",
      "r587",
      "r602",
      "r639",
      "r682",
      "r703",
      "r704",
      "r735",
      "r757",
      "r758",
      "r773",
      "r805",
      "r844"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r133",
      "r135",
      "r136"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "terseLabel": "Total property and equipment, at cost",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r158",
      "r600"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "totalLabel": "Property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r588",
      "r600",
      "r761"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r133",
      "r135",
      "r598"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life",
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlanAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r357",
      "r366",
      "r397",
      "r398",
      "r399",
      "r541",
      "r565",
      "r615",
      "r652",
      "r653",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r722",
      "r723",
      "r737",
      "r741",
      "r752",
      "r763",
      "r766",
      "r838",
      "r846",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlanAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r357",
      "r366",
      "r397",
      "r398",
      "r399",
      "r541",
      "r565",
      "r615",
      "r652",
      "r653",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r722",
      "r723",
      "r737",
      "r741",
      "r752",
      "r763",
      "r766",
      "r838",
      "r846",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r529",
      "r530",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r679",
      "r681",
      "r710"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r529",
      "r530",
      "r531",
      "r532",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r679",
      "r681",
      "r710"
     ]
    },
    "avir_RelatedPartyTransactionEntityControlledByDirectorNumber": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "RelatedPartyTransactionEntityControlledByDirectorNumber",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of company directors in control of related party entity",
        "label": "Related Party Transaction Entity Controlled By Director Number",
        "documentation": "The number of Company directors in control of a related party entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r687",
      "r690"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r529",
      "r530",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r679",
      "r681",
      "r710",
      "r890"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r527",
      "r528",
      "r530",
      "r533",
      "r636",
      "r637",
      "r638",
      "r688",
      "r689",
      "r690",
      "r708",
      "r709"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r333",
      "r339",
      "r532",
      "r728",
      "r729"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r877"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r877"
     ]
    },
    "avir_ResearchAndDevelopmentCostsAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ResearchAndDevelopmentCostsAmortizationPeriod",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period of costs capitalized for research and development, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "terseLabel": "Research and development costs amortization period",
        "label": "Research and Development Costs Amortization Period"
       }
      }
     },
     "auth_ref": []
    },
    "avir_ResearchAndDevelopmentCreditAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ResearchAndDevelopmentCreditAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate credit recorded during the period to research and development expense as a result of adjustments to amounts originally reported and the close out of certain activities.",
        "label": "Research and Development Credit Adjustment",
        "terseLabel": "Research and development net credit adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r416",
      "r899"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "avir_ResearchAndDevelopmentTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ResearchAndDevelopmentTaxCreditsMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Tax Credits",
        "label": "Research And Development Tax Credits [Member]",
        "documentation": "Research and development tax credits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash, Total",
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r798",
      "r807",
      "r900",
      "r902"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r799",
      "r807"
     ]
    },
    "avir_RestrictedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "RestrictedCommonStockMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Common Stock",
        "label": "Restricted Common Stock [Member]",
        "documentation": "Restricted common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainageDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainageDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual retainer",
        "label": "Retainage deposit",
        "documentation": "The amount of assets, typically cash, provided to suppliers of goods in advance of receipt and acceptance, or services (such as research facilities, lawyers or consultants), which is held by such parties until the entity either effects full payment (including applying the retainer) or obtains release from liability."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r108",
      "r596",
      "r622",
      "r627",
      "r634",
      "r663",
      "r761"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings (Accumulated",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r191",
      "r192",
      "r193",
      "r196",
      "r204",
      "r206",
      "r290",
      "r297",
      "r406",
      "r407",
      "r408",
      "r437",
      "r438",
      "r463",
      "r466",
      "r467",
      "r470",
      "r480",
      "r618",
      "r620",
      "r640",
      "r907"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "terseLabel": "Collaboration revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228",
      "r236",
      "r239",
      "r240",
      "r244",
      "r245",
      "r246",
      "r354",
      "r355",
      "r567"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCollaborationRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r356"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r724",
      "r731"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r760"
     ]
    },
    "avir_RocheLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "RocheLicenseAgreementMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Roche License Agreement",
        "label": "Roche License Agreement [Member]",
        "documentation": "Roche license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "avir_RocheLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "RocheLicenseMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Roche License",
        "label": "Roche License [Member]",
        "documentation": "Roche license."
       }
      }
     },
     "auth_ref": []
    },
    "avir_SECFilingStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "SECFilingStatusPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Filing Status",
        "label": "S E C Filing Status Policy [Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to SEC filing status."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "avir_SalesBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "SalesBasedMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Based",
        "label": "Sales Based [Member]",
        "documentation": "Sales based."
       }
      }
     },
     "auth_ref": []
    },
    "avir_SalesBasedMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "SalesBasedMilestoneMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-based",
        "label": "Sales Based Milestone [Member]",
        "documentation": "Sales-based milestone."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Components of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Principal Components of Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Defined Benefit Plans Disclosures [Table]",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50",
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Basic and Diluted Earnings Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "avir_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Life",
        "label": "Schedule Of Property Plant And Equipment Estimated Useful Life Table [Text Block]",
        "documentation": "Tabular disclosure of estimated useful lives of physical assets used in the normal conduct of business and not intended for resale."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r686",
      "r687",
      "r690"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r370",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Units",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Options Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r56"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assumptions Used to Estimate Fair Value of Award",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r105",
      "r107",
      "r108",
      "r162",
      "r163",
      "r164",
      "r224",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r630",
      "r631",
      "r632",
      "r633",
      "r741",
      "r786",
      "r808"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Reserved Shares of Common Stock",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r42",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r79",
      "r80",
      "r105",
      "r107",
      "r108"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r879"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r245",
      "r736"
     ]
    },
    "avir_SeriesABCDAndD1ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "SeriesABCDAndD1ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A, B, C, D and D-1 Convertible Preferred Stock",
        "label": "Series A B C D And D1 Convertible Preferred Stock [Member]",
        "documentation": "Series A, B, C, D and D-1 convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "avir_SeriesD1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "SeriesD1PreferredStockMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D-1 Preferred",
        "label": "Series D1 Preferred Stock [Member]",
        "documentation": "Series D-1 preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "avir_SeriesDConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "SeriesDConvertiblePreferredStockMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D Convertible Preferred Stock",
        "label": "Series D Convertible Preferred Stock [Member]",
        "documentation": "Series D convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "avir_SeriesDOneConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "SeriesDOneConvertiblePreferredStockMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D-1 Convertible Preferred Stock",
        "label": "Series D One Convertible Preferred Stock [Member]",
        "documentation": "Series D-1 convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series D Preferred",
        "terseLabel": "Series D Convertible Preferred Stock",
        "label": "Series D Preferred Stock [Member]",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r800",
      "r801",
      "r847"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of shares of common stock Outstanding",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Annual Increase Percentage",
        "documentation": "The maximum increase in the number of shares that may be issued under a share-based payment arrangement on the first day of each fiscal year, as a percentage of shares outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting service period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Number of units cancelled due to terminations",
        "verboseLabel": "Number of shares, Cancelled",
        "negatedLabel": "Number of shares, Cancelled",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Cancelled",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate grant date fair market value of restricted stock units granted",
        "documentation": "The aggregate grant date fair value of equity instruments other than options granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Aggregate Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of units granted",
        "verboseLabel": "Number of shares, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Number of shares, Outstanding",
        "periodEndLabel": "Number of shares, Unvested",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Outstanding",
        "label": "Weighted Average Grant Date Fair Value, Outstanding at January 1, 2022",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Unvested",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385"
     ]
    },
    "avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, Released",
        "terseLabel": "Number of shares, Released",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were released during the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value assumptions, method used",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Method Used",
        "documentation": "Description of method used to estimate fair value of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r370",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increased number of shares available under plan",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Number of shares authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, capital shares reserved for future issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "negatedLabel": "Number of Shares, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total",
        "terseLabel": "Number of Shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value per option granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Outstanding",
        "periodEndLabel": "Number of Shares, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Per Share, Outstanding",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and exercisable",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Number of Shares, Vested and exercisable",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and exercisable",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Shares, Vested and expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "terseLabel": "Performance based restricted stock units terms of award",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "avir_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of annual installments in which a share-based payment award vests.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Vesting Number Of Installments",
        "terseLabel": "Number of installments"
       }
      }
     },
     "auth_ref": []
    },
    "avir_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value, Released",
        "label": "Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Option Released In Period Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were released during the period."
       }
      }
     },
     "auth_ref": []
    },
    "avir_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement, Percentage of Discount on Purchase Price of Common Stock",
        "terseLabel": "Percentage of discount on common stock purchase price",
        "documentation": "The discount on the purchase price of common stock, as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "avir_ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement, Percentage of Purchase Price Lesser of Market Price, on Offering Date or Purchase Date",
        "terseLabel": "Percentage of common stock purchase price, lesser of market value per share on offering or purchase date",
        "documentation": "The purchase price of common stock, as a percentage of the lessor of the fair market value per share of the common stock on the first business day of an offering period or on the purchase date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfComponentsOfStockBasedCompensationExpenseDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r375",
      "r394",
      "r395",
      "r396",
      "r397",
      "r400",
      "r409",
      "r410",
      "r411",
      "r412"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToEstimateFairValueOfAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Vested and exercisable",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share price",
        "terseLabel": "Preferred stock purchase price",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "avir_SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares reserved for future grant under two thousand twenty incentive award plan.",
        "label": "Shares Reserved for Future Grant Under Two Thousand Twenty Incentive Award Plan [Member]",
        "terseLabel": "Shares reserved for future grant under 2020 Incentive Award Plan"
       }
      }
     },
     "auth_ref": []
    },
    "avir_SharesReservedUnderEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "SharesReservedUnderEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserved under Employee Stock Purchase Plan",
        "label": "Shares Reserved Under Employee Stock Purchase Plan [Member]",
        "documentation": "Shares reserved under employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r162",
      "r163",
      "r164",
      "r185",
      "r212",
      "r213",
      "r215",
      "r217",
      "r224",
      "r225",
      "r284",
      "r324",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r337",
      "r338",
      "r340",
      "r341",
      "r344",
      "r490",
      "r630",
      "r631",
      "r632",
      "r633",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r662",
      "r683",
      "r705",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r786",
      "r808",
      "r814"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings (Accumulated Deficit)",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r25",
      "r150",
      "r175",
      "r176",
      "r177",
      "r191",
      "r192",
      "r193",
      "r196",
      "r204",
      "r206",
      "r223",
      "r290",
      "r297",
      "r345",
      "r406",
      "r407",
      "r408",
      "r437",
      "r438",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r480",
      "r496",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r525",
      "r618",
      "r619",
      "r620",
      "r640",
      "r705"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r223",
      "r567",
      "r628",
      "r651",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r662",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r681",
      "r684",
      "r685",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r705",
      "r767"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r223",
      "r567",
      "r628",
      "r651",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r662",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r681",
      "r684",
      "r685",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r705",
      "r767"
     ]
    },
    "avir_StockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "StockIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance costs",
        "label": "Stock Issuance Costs",
        "documentation": "The amount of issuance costs deducted from cash proceeds received on stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "avir_StockIssuanceProgramAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "StockIssuanceProgramAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of shares authorized to be issued under a stock issuance program.",
        "label": "Stock Issuance Program Authorized Amount",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock into common stock, shares",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r24",
      "r46",
      "r108",
      "r335"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under ESPP, shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r80",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued",
        "terseLabel": "Initial public offering, net of issuance costs of $3,245, shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r80",
      "r108",
      "r630",
      "r705",
      "r717"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock upon vesting of restricted stock units",
        "terseLabel": "Issuance of common stock upon release of restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionsActivityDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for exercise of stock options , shares",
        "negatedLabel": "Number of Shares, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r80",
      "r108",
      "r381"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock into common stock",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r25",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under ESPP",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r80",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial public offering, net of issuance costs of $3,245",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r80",
      "r108",
      "r640",
      "r705",
      "r717",
      "r773"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r25",
      "r108"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r83",
      "r84",
      "r96",
      "r664",
      "r680",
      "r706",
      "r707",
      "r761",
      "r774",
      "r809",
      "r836",
      "r884",
      "r907"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r534"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r534"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r534"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "avir_SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Remaining Lease Term and Discount Rate",
        "label": "Summary Of Remaining Lease Term And Discount Rate Table [Text Block]",
        "documentation": "Tabular disclosure of information related to leases including, but not limited to, the remaining lease term and discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash financing activities:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avir_SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assets and Liabilities Recorded on Consolidated Balance Sheet",
        "label": "Supplemental Disclosure Of Balance Sheet Information Related To Leases Table [Text Block]",
        "documentation": "Tabular disclosure of balance sheet information related to leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "avir_TaxCreditCarryforwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "TaxCreditCarryforwardExpirationYear",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards expiration year",
        "label": "Tax Credit Carryforward Expiration Year",
        "documentation": "The year that tax credit carryforwards will begin to expire."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r413",
      "r594"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares outstanding",
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "avir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of convertible preferred stock, net of issuance costs, shares",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "documentation": "The number of shares of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of convertible preferred stock, net of issuance costs",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r889"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r336",
      "r343",
      "r471",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r605",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r832",
      "r833",
      "r834",
      "r835"
     ]
    },
    "avir_TwoThousandAndTwentyEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "TwoThousandAndTwentyEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Employee Stock Purchase Plan",
        "label": "Two Thousand and Twenty Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand and twenty employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "avir_TwoThousandTwentyIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "TwoThousandTwentyIncentiveAwardPlanMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Incentive Award Plan",
        "label": "Two Thousand Twenty Incentive Award Plan [Member]",
        "documentation": "Two thousand twenty incentive award plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r195",
      "r196",
      "r197",
      "r198",
      "r208",
      "r247",
      "r248",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r314",
      "r406",
      "r407",
      "r408",
      "r435",
      "r436",
      "r437",
      "r438",
      "r448",
      "r449",
      "r450",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r488",
      "r489",
      "r492",
      "r493",
      "r494",
      "r495",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r568",
      "r569",
      "r570",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government agency securities",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r749",
      "r901"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury obligations",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r749",
      "r751",
      "r901"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefit",
        "label": "Unrecognized Tax Benefits",
        "periodStartLabel": "Balance beginning of year",
        "periodEndLabel": "Balance at end of period",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r425"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "terseLabel": "Decrease related to current year provision to return adjustment",
        "negatedLabel": "Decrease related to current year provision to return adjustment",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "avir_UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from accrued interest.",
        "label": "Unrecognized Tax Benefits Increases Resulting from Accrued Interest",
        "terseLabel": "Increase related to accrued interest"
       }
      }
     },
     "auth_ref": []
    },
    "avir_UpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "UpfrontPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable upfront payment received",
        "label": "Upfront Payment Received",
        "documentation": "The amount of upfront payment received upon entering a licensing agreement."
       }
      }
     },
     "auth_ref": []
    },
    "avir_UtilizedOperatingLossCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "UtilizedOperatingLossCarryforward",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Utilized operating loss tax credit carryforwards",
        "label": "Utilized Operating Loss Carryforward",
        "documentation": "The amount of operating loss carryforward utilized."
       }
      }
     },
     "auth_ref": []
    },
    "avir_UtilizedResearchAndDevelopmentTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ateapharma.com/20231231",
     "localname": "UtilizedResearchAndDevelopmentTaxCreditCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Utilized research and development tax credit carryforwards",
        "label": "Utilized Research And Development Tax Credit Carryforwards",
        "documentation": "The amount of research and development tax credit carryforwards utilized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r760"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment, Total",
        "terseLabel": "Dilutive effect of outstanding stock options",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted average common shares outstanding, diluted",
        "terseLabel": "Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r217"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of common shares - basic and diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.ateapharma.com/20231231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.ateapharma.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted average common shares outstanding, basic",
        "terseLabel": "Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r217"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "340",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482586/260-10-65-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0000950170-24-022226-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-022226-xbrl.zip
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M&5Q_^N55!9OU1C'X&WSJF_JQ/[-<S(RRFJ7REU=C6IPGV5N#3JO\_TO&D[P
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M]:MU-XHP(]]VA0<4P6)@2P<.R2AP3<)"A[MP/$:NS9=G>@+82+Z'!0;I,I[
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M*13.?#]K__P'/)$6?#3[0U[(='$WVXL.L\FT*M45UKH$PCXM1ZB%P#\H$BZ
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MP?VTHMKH\Y$669*=ER"$M.H_6_V EP8D8]NRS1A!@60V06,E"6D4$A:' FC
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M^EY@AD[O<'Q?8Q-[ )?N5M*@G]MYIT#&YF)57V&4I^)P/"GR"T4&6Y-=Q%Q
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M0TC&(WE^N>\Z'OKZ'0]. %^:A(7,)PZ7@624!JR_-9][U0IJ0]T=+!D'L1>
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MZP4*K>>GW$7TK.Y)6NI 8K&Y^+[]>B!*ZGQI!S/(FD'6O$!9\_RRQB-VEA>
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MOVU-7 LTC,.E4&<AIE EM%+)/&3&(+I0AS36K\^0I>AM=I#N;NSGRN)?K[P
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M&J1J]?>F)]$]I0;;W<E5=_^?=)R>AG=)*]PXMF=+D4%+>R/6NT?\9^F :[I
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M3;%$B=>Q#'!7T_="8VG-P[GYF=\+MPVUWWAYF68DNGURY>Y/C>&:YJ=-X/Y
M G=1QD74%:.KL?9. R=JZ5QNFKWFBW8LE:E78#()/OR]D5Q.H/6NN.1[17F]
M8&-5T>#%8$TQ&57LU0UMG4CQ\K'09.XT737HZ!1+PW4OMX^XCXRD1'D0,^XK
M9]3]GE>11.,W#7JQ/%"VK(X=_;W'E0*O+(NXGM>OYMUJ>J-.D 1_#7;Z1QM&
M[C[7M=K'+B51^^1E]9-!?[LG*;=-Z90H\2 DEA5UH93A1%U/D9M>/6$5)MN<
MA-&^7RH +'^&?!>RP4EGYC_F@0F7RRS]QDRV.I5,(\XFN4U5"L[6R9JM_'K0
MNL'""X"]L&CCZM8K$]IR\8HKV'1/PC21Y"1J/:K97S_U,JW-.OD^CSF,5'!P
MY("5KXW*:<(VNBIBXF,]C9[!V!Q^"K:60M*@V]B6(Y-?UG0'1JD%R5\/CNQ5
MR5]I-[.:V_!@J^C.>[1?];/QR2^/\+1=_]D'=P!?V$9F[GUD9K>-S-R1R,QU
MI;@.-X1*#K^;XNI?EN"H37'=F137^6&0BK%I,8M-E?>V/DL(:E?!\6N^]?!P
M+9W 1QBZ:6^ S7OGL<-Q[>QL^/8:'JOG%P2@I[+BFF)&\5?J E"%[]'=KH'@
M. 8#[B(N;+7!GED63L#M2L[&L!>\">E$AZ$-=D>09VP]>?/VR;:-%-G+.,W'
M#5W3Q8)1YZ8N =]Y$6R8IZ/@X(+3=+1Y1M?FJ.,9WVA28!R]!$"\\-DI.77,
M*REX+_P4)0Y">EY=!$WF>@))/_.'%GRPZ;T;%ISK4R3& &8FVE3< 8V6LE:P
M8DG/R2T>)<PV(-POU1(8T^^T$KO;E)N\=2OKEH,][WE[?!(^XWLS&9=1G)\N
M0?#LDW0PFT<RGJ=A?*I2U*_&X2DJZ[>>O#S^#5WRA%F!(T++6$G,F;<9,Z*%
M8\T*H)OT0C\%BS#/@U$8<V9;WX ;O# PV]%+\T@MU7K.G;B_V[= F&<KO8$[
M.AUM&=6:8DN@2A-@N(U7Z2XZIHV-OXLK8?HF'NS[L\<NA>WV63$PN20,6L4V
MS,5W&_?@U%6ZNJ'@.HPX.E5::7'A4IG,<G(LEW0$T&<((9 4D'Q.XS*:;'<J
M<:2<WK2Q>213:?W"]':6;/U<<=4%UT8"^0 R>&+W3F(^V/ 3<.W-M^7NTD4D
M_7O2<>0Z5S8G1^Z\Z%R3>C::RM")O\)LXA^I<M6S^1C4]S&XBR*II#&S8H2S
MLJFN4OY\_8\L8II#X0MI#)L6B5*H^H$.'*?=]2!1;7/C 1A++EL?G) G__5A
MYYB1486N5!(^\=K7<I5HUB;_JU/HBKC\QJI\KF#/CTE%%^%737C'-FH&B#T_
M)LJ9BB;Y<[70=*(+59!5A2JRG ZC!,T7.'/)A*AJ$CDJ.5!BQLS[E3NZNY\;
M%LAS$)]6W,*VQ)E*'T/[?=7=NVJS8*UOA/3&633">M-?9EY(UNOPHXM";SO#
MVL:VKB.VM=?&MAY.;.NFI&;='EXWOXP65[8B*4HFZIO61=#-K$QW@ZU%- G_
M)%=@06;7A^XL7HU3%(4J,ORV)M$L_1:!(GB%<G;2>%P6-0ZS4;@(_R3[+5%T
M&004804X "@/1,=L=@;,C:!"TVP62FMV;NO@-"B=8_%JJ99%A*#&RT&PE:5Y
M>1HR!U^RW0M>AEQ(G_!1Z X]<\#X9V+'[S6Q[A"P66EOP&E?_\ASD]6DHX4Z
M695T#GC:/*5M2:]#IX)TVI!0C9\RD[R-H:@]+6-$N@!?7>=3%!JBL$XY>_'>
M&/?'UOSYL*'U\,Z+':[Y<0%85M9:NF=U!\CB:R[0/"Y$+GN,/<#/'&L*%Q@?
M]>C6F[<V+&<[M9Z*-:*S>Q) DB@8[QL3">O4(D36FZTPYGF!K.:W/\[][]@Y
MK,T<)$Z\9$BW8-<P+=ZEW)"VZC=+56\LP 9;0:O9GQVE>95ZXL8,FON#&;OD
MH>#5$&LE9#S=\QN >5W#0J<>05P?GJ:BJC[\7<QGB;F0#IJ"K7/*76RKT!!F
M(@"72CUZ\+>09H)/+1-&,$PZPKVBB0H .#3D/QN;& ,L$V:3*!QS")ML;D.P
MYCU0H$5.]"5*Z+WL^;,"+*0H[HJ"WE*]6:]38WDP[H'T:T8,/EHLPRB#H[$M
MQX3T1+MU,_[N"OV5-!RJGA!8CH_EGV'N][?Z[/>W^O7DRXV!%Q_9$ET\/D2+
MX&)#VLP!^]9I1"^$-3R1EA?!)\/'")8CVE7W9N(NA=6B64&H(QC%:3JA(64P
MO2WO-8(6]'N>VR*HCHZ81FQH<H 42HXTK&TJSF'87F!O;8C&A/V"OC2>9RF,
M=/ZBM3FY43C_1<SV.#3L&CF])^H(3R,]3MVB@*FJ.J07 8!T/,$3CC7%\%RB
M\==<%]6IX!^?$*3ZIP04Q*C'@,+Q."WQ*.S=*KAL7PK*$"!+:/7&H0[WT*OU
M2(C"69("G"1_P<N"M-O6_>NAJKRH9$<69/^,)8*#C[21#R8PJSVD^HQ?[E\E
MP*^PV%Q/ P.*LM XLDW3A>GL@(X+B$RYB_ *B0MGPY5)K26H;_'F,TW4KWS"
M%,!;T5DXYGN:Q?(_8P:6IS#<#O=DAL8E0E.8'],OE,W5<J0;H*HL2M$'/F=Q
M$0,8>,DT&.[3^:R^WG[LZ4%N;",) @X63R[!8@=;;SYW!U96Z9<#P?#M'\#L
M*,A7-DN)6_&71TKGRM$.)!IIV\QU?#J0[8+ORU:)S,;S =7FENR HIK8&^-H
MI57 M$Q,5@74X"_8S"1EQ'[#.,JR.>^\+?EV3G8:R!RW-=NEX;^UJ W>8Y.4
M(<0K54CB4*PG-:D]DML@(2FIFI\YT;YZOHE"S#G,M7=QYMK#]J"/2:-FAEL2
M O#'K^_9@05V9,'3N7<(MS46W9 B!VP[[/#:6*T#,3:*RZ@6IB8<]/;L+:"<
M[;=R:<+%Y)ZD=YC;W>#DT0=4C25?N"Q'<93/:3 GKT[X07E)/B_=DJ-*@EHQ
ME/VAZ5\E&!'QPR'?E0%6)/ZSO+CWTJ+I*R?,\'F_TP<.7R9A(ALU&/8'ST5+
MXO[&F:^<EV9W,MXF_&>:Z0XWFNO4*Z)RHFN3#*G-(M#.&4=T>H2M_KUR6M#S
MY(HUWV6%2QLY9]H5=">[9)74MS$90&QRE9G*A5-P)50 HQ""8"4G*;DO$<F-
M16E9*T<.=1F#>;!3]ES<@V<8<C6266F8Q]W,MP;#YT_MR_BD@U)NR);A&8*Q
MLW!98=#=."3-R.CV$_]9EQJ"J>LTFI3<G'V>:O/%5<#88P?@+GJ?,@G/PLQU
M"ESQ>62_/M)-7>0L2X)9RB4+A7Q*YF(4Z]Y6.@1K0Z8X?&RS$/;7C8&+:!=?
M:$TO%^-C2Q C((V%[C!ZYX*L,EO0';2IV>.XHOI7R2JLHR<&UY6)H__-ORJI
M@QD7)> *-J@+E I'#5E.1$6-RHP.34PWUV3(75@0H40T:>G97$DMAV0ZT3/^
M&QV-].HL8%LTUVDVBB8>E&R<LMV[9M%OFS:1F@-/1)9U73@Y#9GXOME!T.>W
M V;R<<';VZ LM+RLO6F;9KR!-.-^FV9\W&G&*PE4O94C QKHK9_EJ)Q#MQ].
MNWWKY6Y4 UQ7M<;S#=4:SYM:5SP?>*TK]O?::HU[6*WQ*2TSNA&,YEX@-N07
MCDRYP-,'Z[%]4LO"=M0<W@?7I>5.N3W1>@5*=')E_(();6N*4V6-UI&B,2>Z
M#H0<FAWCKHC7P-%L>B_5$6-9DN0=/IO6<1;U8 "Y3_Q%9YQ&4D\T+JRYSV3E
MTJ24W92\4"$Z0QBB<S*T,3KI5Q?F: &%W^5P=*?E-%=%7O.FX"^Z@!BG\R?7
ML',N:N%<&Z?(1L.BX/FN16,$C1D*5D=B4 &)[E=5<' 3$UN!Y$@G]F]17MAH
M/?U7Y4IQ"GM:PB/2E-_L/*:+A<HXP:MO6UMTO= L5KW@HW%A]% 2NB G:3%.
M/7WR[SN]?C#2D2\6T^&.%PLB*6-.#=#SL!/(T3)-C:<17;CA?5":]RS>TV[P
MA[7!D9WJ[_4Y8#%2JS31[2PV[FO>Q/SUZ]KA;C>'A>QQ5CLZSDXG3;NKKY>'
MZMBVB;?ZO]B ];C7,W).-S731)LWB9L&J#V NB3AC#U"TKEN44EN#!2N$L8T
MF-4B2Z5O K:/;IT./"\*3RS]4V6G2O5?FN9<Z?SEHPXETEY@;0J^?^[_ZV='
MC'XT!Z9=NDF9A;99&GN27+TWE.1T,%$<[J37*)=IHM&<,UHF2<FO&W^B*0ST
M08X%O* .\Y+Z&)GNQ_)20(,Y;B9I16QSBU+>R^@!A3[N4;[0(7J+"O"F)BB@
M:HK\1?#NT\ZSW6-!2$M.81Z-(FF7_N[3WG'E#[@+_?$E'2GC6*7Y5K&-^#R
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MCWM=10!'K)AK;EQX!,> <.CXN%=;X4 @!B[F=3WZ0QD2YDUMV'&WX\_=O<%
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M]ESB*OPUJZI#[T+/WB:A7SD]>.[>H5^'@6M_EFJW<+6,'"[C<4_T[@0+^6&
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M\E!@%(B(.W-SK@5;NWIPJLRH\*'X/E?^NZ+DJGD42H KSYA -R_--_T#Q]2
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MHB$&UB-,G#>2'!U0<IIR*.G8$>X+ZNP5N*^XL)10^<BSDI]VJ@F-8])S1S#
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MW__Y8/_G%T?)'0'5AMYLK$=R*9_R2=506SI,G9"->G#P-.'(=)W-\VIO@"A
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M:&6]LT_HP\IF^4:&  86MZ8: VFP*S9<]\&J9IB*0"P0>!B?6F)EA@NX3+T
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MA(E/DPU.4RW=F4$4F&6+$M9-_A&9(=MEHP1JU%N26]41FZKON( %!-P60KP
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M_,*=^:Y3Y,U^:>KO/;XQ"3RO0S/JB4*Q[Y(6!.!T4='/CR?_M*&GT,1!8.R
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M3,'@TS?@[ZFUC 5W4V-V@EO0HQX_OYF?S])62HC--(86+"E $W%<$EJ"881
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M>(P\Y%?WJNR:(UWIEY]]G3&A_:IT]0&M>>Q!Z.\FU_]]P<H]02X(%QJ[_)/
MW'S-4X92.3,)RP!LO*CY/2>P1TF.D<\FO^;%S2!(<D@#$*1W7(-(ELLZPM,O
MM!\<V(94(")\]J<3+X!#KNF^+A1M3BM$7!G;U+!^1CMVU1;T*$J>;U@"4DH7
M_O_7J_HREP?>V[XEQY#G_/*"SEEOBRS8FTUL,!8>9JR#.R-F451C<-'X244I
MA(]L/P &6?YO;K:_AV;[_;G9/C?;WZ*/&>W*FB2XIH&#0Y1H,"YUA^:U?!,E
M 15%_E"J&G$E)X+G>RW7D7I\Y* W<9UTV'&+SW8=L#'=%'6[Q^6%BQI ]13
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ML8CZG\7:&'9C#RQ66;0MA$8";^\Z<'6.6^>D91J\?;;0.V^AFL3S',*>$\5
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M4;2OVL4+I5)4@WH2E,^>Q/P./T6>'*_XL?WC9]<*@N'90(;B17 FCP)K!>?
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M5 Z"Y!_ T\Q A/?PF+^X-P,1[C80X=W&KPD%4#;)(QW!>&/_;3Z8SM3*+A!
MG![GN&Q=<RE.<Q#F"AT0)Y HR3%Z^89E$@,,J\A&(-7V%VT.,RI/[KI#P';B
MM"\?O7AY1N<X>["@LW5MIA?3M<+>2:NIU[TX"50[B5Z].;GGFZ!"Y%GK!C":
MOV[\_,]$K(+[D!Q8;4!WJB'MA=UC3]@T+@I-G2G3E)AS81YHZBKFHVHZWE-9
M=#6.M=,(V^^5?C_4.NCP#[CTD&=;2SH$ >&593UL[@@$UZ:61C"[F@OUX+Y_
M$-OQ:2??MX1<^?EB/%,.#( 1J[Z2&IKDR37,^CS/[JKMX8+23^FNDE_(.%7$
M%;3=3OJJ3*^&I<.A75(63@A-2OHF60Q_QL^8G\:/G!@3,0\\PC0R)A8XBDAJ
MD1KPI.R,3?I@^[/YX3T&$ X''\S'Y,V2(C#]V:Z6G:+E^OUHJ290_V%/KKM#
M5.<<Z4[%W.@\JG)J512[/914QB@P66)<)HWBO$1-W)\N4G]YLP79[[G04CSN
ML=]"D2M_Y5H10I?"]::&@%%4I-ZA+]*O%]O0E\RD1B*^54>/'V/K(S+I7,,^
M[I53FS(1(V*M:#<J#YZ):F3/+:K+NK2\C[=3*4W(N*-M/%CYDNM-3D[9@-*\
MX[QK3HN(5L1O)G4)XB8NSFY]:<BZ&60)TA]CN?G$NNAMY9$P 7QTLA1XHE!&
MNM<!>+6J0;XY,= '/HO[7W[=C@>;0GI-E]C0FE":W=:T88.4GDVX"AA+.,_8
M,!?H7ZY+I37!Y4%K%;=&U];K@(2:KZ$#XC@QKEE+W+@J>,Q>1]4T>./)KB ]
M-IOSNS9G;@NS.02U7"8(L#H570KE4,4*=*V5I@!7CO>DJ&C&-*^T09&S0K\P
M4TVX,APGM(.CUB]7LY9U3ZLQ02!Q-A=E<0"$MS*7V0..6"R^XZ!?+37A4!N7
MV/WVET<6#_:CP:F=QDJ(/9-/]X!O?Q%("DK(<.E6H -@QNBW<],?7C&_3!95
M:]=VC9(WC3SAZ&3CB*V,<3CN-8J3W"F!?G0"&3EQU+3:2'^JZJNX3%I%F"%Z
MY('1Q0P&7D-_!,.2IM"MBR](.\WT9NN&S@IGLCY69+MT)XPT@RJUJW1'9"<D
MP\.%O0MX,?4I]M9ZK_K-WIQ1=0A<"@Z)7@$[:CIDWO!G0C$\>?0V%8IGE8 K
MQ*BTC$#+=N.8B63"11\N4)<;&3[W,#'),-,Y VVL]>[=2\1NN"\A<[\)=J.-
MTW25; S-]0C[%]UH>%I)X8*LBRO]O+%\!\GFGYM\]6H!J-RVTL9U *BK%,,F
MPE\)<4F.T/3ICT_ &Z4E*1#V,EM\&[V&0Z2!V_;7:\CP?+!I (,4N]*K4N#-
M>01"?SE-W?B\+;W+NWLQOG;9'\2X!P ,&V=TXTE48?[<PA1:<XA!F"T4SL<*
M1!98&'^##,R']A(O?)&5C_@Y-['-B-T-8"D1GT06UG%??Q)]["CQ8<Q ->J]
M(F(35[5=XY*,*>#^QKXZ=Y??>58>P:"7FI8K')2,(PMPS_'2*SF:;#PYYZF;
M7=>&89GKL$ZP?>XN<J%<JDU"*+62IO:H36J3=O2 ?2W*-Y:0I NXZ.B=M:=T
M+"=VZ- $]WW<M!8F,83?L;3 =D#62Y%A6_"GA02L\EPJGKAJFN%]K).LU"T8
M3XS&C%)R%[Y,GDB:+M:=8Y4'_>3ITITVU'EDD<YX"NPCJ@S5<8R*!7R;,$[C
MI-/7X(L>?Y_NR,X""I^L@(+%R*FR]S55-=X5BS;?-LZ%'IZ$=!G*?257S?PN
MRIT;NM:#AWS&/9*NZ=?69B6<V2;?RB:5:2H*UDXT,;%_V>XE2"#:HRL@^G3D
M#L(['B1$%\/[.]*1MI!+HM_-0A_O$<YR?X:SO \XR^QEQ[SL94%Q)(-__WY1
MK->N>G._^V=UN(*M8/*Z6)<;>I6O*;T55$43Z-B@=N<:1,]6C.4LHEN+H,')
MSF&D:5(K07*,X^C:/M=AD'A]_Y64.?JXF]%'@'-K468]P&OIF'3,C!RJ010Y
M+)LZ7PL=\AX\QAP.7TJYJ>5:38">84!'DFF?1J(?$"XB='>OG*2>MI[F4/E.
M&^N8UD]2IZD7;Q5-ZUC@#5K)H46W=)7;%")KRL >GNA6P\:,\IS7W6UCY2(!
MBN=0]!2& >X.]I$UTT7$46<K S'"I"P\+<M=P>/_2@.;#.3'?VVN@=,%4!2F
M-<K67:'5/5OQG;?BMZI.6 '78"PR%#2J09TQ*Y[\>\W#UAPCR-B95HRYH4#?
M14I2&$BC:-9GP!$D8XF-E_36",)K>C,[US7ZW;/*[FSR21M5D6T2VT;8MLW;
MA1I#V(+"VX!Z@QE7W,$$"L#D+%.PW&0;=E*&]]/J/#+3DJ+.!]WN+.;MP/N)
MX+"JA#F0/1@,WDBWW-1E\ ;@RQAN<7+_3.<X3TD8B&?B/E<*,$] Z#TAG6AP
MG=%G0^!P=LKH ISP5-^203+N2D98>7 T"-:M??>.1TBO!,1,GEL>F<<]A\&8
M6//*<KT:=[E95'G3U%?Q40'5:BIAIH-9+UY\^^QE3&7$Q#\1JX5!MLX7$W )
MBY_B+8@E1W#M4@-BX-D%<X)M F]]&U0FE,42_Z $N#J$URW@T&W$A;UW#6XO
M5WJ95=UB?=-3.9R%TM#8G%?R?D;@S+R?@;MLZ4J% QH20CG'^/S\=SE'7NS:
M"%<+DCI?QS<04,KPY\'T>6A1<ZEK2"4820F3A6R%TW7EZ)46M?5O3]GUC!5Z
MSQ,BGO\_(8@)S?*(F0R$#<:M-3:56+"68#3LXUTQ+28/5C-_+%B.'/1NBK-,
MX4L"B)90K#UX=;"I-=+3Y/( NB9 14:^;LLS .4\(9",>!X 2)TG>][W3OZ-
MX%QN/'D3%>5O'&YY7Z?:T:=4A1+(40P4ZC-_L91B.\1?MW\8-W0>I#J4*!P+
M;G*T3MF3O<9D!!8E-\UA2Z=J2A&/<O^B,?[,VH FA<0X^&A&1R(KIJ'1L,J.
M3.OU^>I0*P7C_2&]E5$]ZM:;4CUJ2 !F+4&$]]E%[!.F[_/L^?,?7S[_\?O>
M+<A85=T=5BHB.*5DQ3#_,[F]_E.(_(N&C-P'W\1;)?Y9L@CJD&"3XU*M3B9#
M)H>F\P-GO;'G 6Q]DA@V@:4/"8EN1HV-R-,IO2^ Y%T,1F-LMHQYZ<05 P"\
M:&1^4 N0N8*%&OA8B-!&NB1\A7PDZ31XV'AMG"E"TW=PAGL;1_BU@3K[?/&,
M/E>S1.6^IW23Y$I9[T6P!%->'EL1;J)E54(NMXYL4B7KHD]QTH5L[-(*>&:G
MM/"V3=WM>VN#O^#]UK/G+WY\^N/W+__[?]@2CS(\YVL3_&0:*(1Q*"HS(^HY
MKB59EGU3^:*G1NO?@'UXD#VEMP)RU3/$!/4%BH^Z5X.>;EQ_RRSKQOQWF8RG
M;\A&0)W%(Q*ZU6/(BKUA@JUJ;0I+Y<KRRE?SE?.7]1,9;E^,YCL:LJ,5; !-
MVCI*;DW=5 ]/@;"5H[-@6".BN3U)>"H7!:[?.21^QS6">N&9DT:H]V$N<..Z
M$R#O*R[K0R+E(:]V8X2RTQOV;YZ<:=OER!"=&[#?[4O4=;@_6E>2+_7/9%!?
M\P!K&W@5<45:D-%!PJV@9;NZ<.NN='$LBZMB6K? &\5-6+ZP?L?@:#C>IS\^
MB?/M>#A J2>M*#*(R,8P]Z)9'A&)Y39P;)K P^A)=.*Y%A8(YRIX^NCF@OMW
M0<D2LPUR&#X&,I6VL]I' [8+OGG.3C_T:IOQ<K>!EWLPX^5F^J<WM1J9S)["
M!=3C K,<[@U2@'>1<)DZE!&23'C*I#-L5;R/(8AXI\9_VQK)L>2ZH?BBHBE,
M0O8HW;2URY[*I?1?G15L,:!BV.PPI/+W#_T.YQ;G76AQDAL+S+Z>%2EJ+":S
MFXR+I:O9'K,0\=V6H=Z\.DI1XB7%[>]]Q=1_FIL_-.__[KDFT,,@]?T?ER3R
M"0\X XKNM.L))#@-9G:-Y+]J,=/=&B7/:#BF^.2CSM[QK%UO^FZ3PI9GBYLM
MSBRN;N*VQ;BN!0H4W+XW@CENY5.<OD,.D/<,:[:KV:YZG@PSPCN%A C/AC2K
M*754W[9O:N8;2]J'&)G(&_"C1Q(G[>(O__;XQ?/VW_XZQH33%I[B5HY.OD]9
MR^CV.3'T?<'0L*S<MK:M.B$PZU'I,)T93CYYZMGX9^-GXX=4'FZ#ZQ:4-C1=
M<?":F8TZV99^*31I9DHBV5-LX7EG8YJ-28PIWI:5LPH\Y<6A4P(7981;UE"7
M_ O?U[VOG[[XAG^Z__5?>7;A<(&&.C9P\-*D5(N>.P\"7>P&#TH>,W1RLUG.
M9JD;O+FU; '&+5>9AQ/HG&0QWLFIO*R *2!5J,ACCZRC/5F@"<5>Z8AG7I#9
M^E+KT_BM#:JZXV:RB*=:.#0#! 0QGO%1#E-B1*&'FJY>Y*OK_5Z 12K&,&<W
ML_D%YY=,;66A1]6XTN4M_TA[*_ 0)IV^8U'-:ON?[K7^%->66W&2J8;%B7D$
M-.B&4&2C34Y*V>O:8!<).GTVY3MMRLG(%!-TY6N*+J7E =T5_)+^;0-"XPQY
MIG MBB;Q=,6TD68R>6$K*:%,""JQ6<0R\B]=0SRTZ".+T<')$&\D@XUS\#";
M_/_A8:S":N*THSOX9!T%@HY&7F$Q>*.YJ"&7=SP%H\\MK&5"NP'A(D-J+#V3
M273%DW'QU.20D-71;J'#BPS=[Y'0^H]_S?@Q0YWQ;8":6 'U&XR.,06R$/*T
M'%AWE5P:+PL>&$,EMQ?[6.1-7_A:1LTJMQ6^$CLJQTTYD&A2K L"T7V,:] \
MJAMM3\SUL7D!1BAL&4!2Z(]'="Z/B4;IAN>+2T9^'MSJHN)^NUAWDQ>@L57
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M:"P)-^)1&0M-3Z-#%V99*D2##:YK[X@*P8"9GWM7/GGT1*I-MY>'$TK)6K-
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MKLR"G=FB4*N:+2:$R0*/(1W#"1,+066;WC=/265<%C2)-ZL?^UN/LD)#KZJ
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M<R\"7-S.=T@</3 OAW(KXR0=R$6E'N\I#+2-R0ZJXLFI"_PL[5,@%\=(14Q
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M@Y,#VF=4$196@]^NBU%6@S-\ ]QZHUI+Q";L\VTA@F1L3?YX20EW<#$YDFB
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M*UZ3+G7=E-N,:[@Y7S+8PZ: )UTUZTI1)U0K(M)"S'R>6\;Q&+$H@EP5T"1
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MAFVYN4&)KK;FF@TC #;%IUTD?B$ 2@VM=5*RJ"^#M2&Z<37D+HK44J<G8T.
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M-+(/_$V8>"I9 Q-&$2JQKM2HPH:JBYOJ.$VL.5IUEA W9G6\&R7;/?;D73<
M-Y83R[7'CN5X_'"27B(-=4!E9;MPQ,8T;12=068S-6./$.>6F_8R)$?_4(J>
M*.$Y\2I3JF<N8V:NA7GZU^3?$C8>_]-4X]E0P"[Y=;&5<??.*9\=\J-4(UVZ
M-.O!I,GCFJ4\+^3>D+P^-$W]!=;'D7=ULTE2N"W)IW92^*0;VI/D@^<\7T<>
MOIRFV_RK7<[D!_8ID\)ZTK.#$M 552?J2^X\0,2$!A4O!40QPC8D6U,$&X15
M#6#U$Z7\MM@-/-*ODV%GG!9^UHH<7*5/B*<Z%H^A4G[(W*_SBKZ%DZS<X.,8
MUC/-8NH1SH)+,)7IQ@:_[^D?#DW'JH2<7D\?29L373F:VDWX*CNN%M.X7M1.
MK*GU Z%RL!O(4\?MH;K%H]N5Z\=63XB7.]+5%-&4K4$CT%C2?[1T7OB]4F]X
M9N ELPB'&(^T7>(7(D'GT'IP/ +2J3V)"UOIT&UWMJLSD8Z6H9SE;(M:R!FN
MF[>%C(9Z:P&9-O-_@CRBMNM2B<4\H9@V^/O#5D7Q5IZ+HZ:D/VW1GI58^J99
M56'%P3R(!V+JCK"9*E; 221VV@):C9*!L "G#BF>>O;OQ^ZV%%6D6$5M$XME
M>U*N\&(K-STN_QK&Z=XGO'+?CRYD56!6BP(0YIA,'_F'GWG4Q<L_L"R]BMS-
MA2!NHEF.:N;Y<.?X.%JAR_V ,*/E3_-_E%LK=A+T@:K6M4-$M2%GY^8TU?>Y
M)CP7#-+^FW7JXBY4Q"PY&;8<MMA=R8VLRM&1!LY:9GUJM@6'(.0I_;-SN#:S
M E: T(F^DV>4T=RH0Y%>LHG9U4T(WDL"&?-GCP))/'_JV1P\PWP8AS9SIEKW
M"*O2 K27W?GJ82?*Z+M/-@C#0V$TGW%T5-/_&'7=F'!2?D9?M(D!,0*.G'%/
MY_.86I]+V1W]DGZ8JS_TXI6QF-VJA@FQ9Y V'$G[.)B='9A#E.^8)RV K@@_
M6E?0%$%?T(0=#L'PKB!^B]!;R)!OSU?L=(,*\Y8C@DY8ENB(@Y>,.CV[LNUZ
MC/"S;LP;ZN.?C)=X,<@YV#2$C]+=.5;6=?@S*YH%(Y2CF8D1 .:,24*,.&;5
M,DG$@A82;L N,V(I8GF:,6\@DU%RW]<O$L-;@V%%,<5TP)1H>Z[H39+FRR8"
M81/12KZ*FGU7G+@)]"O*M^'%>EWCL(:D:,XLF,$X08-YPVQ?D\67G);3+;(-
M$H 6,L_$]N>WV'+>?1 $EE=ZRD;"89ZS.]@#%[BJ5)$T$J^DAP XI81/UV?V
M4E>;(Y*.=NII"1.F%7)YN/W@#B0&+/L2.]8\^3<_NY_[^]"6W59%AKC(3;\V
M!H,?!EAW)THMQHNEOG;H\LLS;A$L<LC:-A2QMZ60XFFL'+[(M0:?]J6TQ]=Y
M>[3$45<N?(LV;-GMD09Q76BWLC<D]8[NV-&0BR*K[1X($! .[-@>!X_NKW(F
MB^BXQO+C&PR97U@4I0SD X=O2L0S!3E%S"Q1ZDL'Q48&$"49HO_1]8VV$#5B
M6+_+Y4"SV@.W)T$O5/]4W*52X#0CPY\F0Z>O&IE;N?_,LW1>;_WG-Q;OK[F\
M2#EE*:&;%8ICXE I[DWX"1GV)J!%K/'B]]Z/FI5W-$*4.5>:.Q<X<F3#F#&R
MROS 638HQ%QTP+H7D; 2L4%2GF3B?,K^0:B:G)!<RP@Q=7  ']L8%MC ^X -
M_&F!#2RP@?M:S?30.M&E(B>2<3KO,M"CHZ>]9G"3YHN6JP5_=UM4/L)P(D=C
M=O*0;0VFK!E\)0V\2 RHQV,X/57X5EQKA+XZ$5$2ZJ-0H#/6.<=$CO*'%I65
M'!? ]&,=EG&3"%V+J)-58HPKCNZHJ,,W<9O62T'YV>9B4 Q!W9RP7LE=Z-(-
MM88PA:<,XK"+0,_792OLLIN(K<L%T<R=28NB+U8OY7E6VT';;W6,DE@^<R<5
MI\NV$+ BQU*\NAQ)Q185_2=17^8W(=4DA?KPN)AULILS6=6B+PC7ZDF2Y=6F
MA$;=(=Q'T\K%PKEES^9C],E-.7MP(+_PB[]@<O0./V643D+3FY1ABE\/>GC6
M Z2+P]/3M\I:U:VT8; N;%2)L %EK[!-NJH2"E='O7FY:;;OE!H*B<#,DG[:
MV-S(=RDJF<*C9 @/2:]FM0S M)I7YRI/6\[4.*L2 '^33 K54<@YYR)6> F9
M'UR3SI8;\U4RQ%+R-S=R+2E<3U"K\,NT5017NW5A73;.5X-E!9.0N[NM(2U5
M,7-RIKI]75BJQ.Z:+@W'YS\B\G%C-6^:LF'SK]FU?O_C"R[Z;D/2AP?QR>XD
M1@V+(<G^""--WS)'.%=X1B]S:"\UD_2",>.)R0Q3W3*%(R2HHQII4H^^"N'+
M:IVWP:Y:E== W-[:<!AJY#4-C#-<8YF]?6]]DG@<K(-!UK40WOV Z9=G7SS[
M(M,C7[04$U )7GQA=98]J'.'\-6P<>&C=?YU-%Z:3)YNR_RR#@8KQ_OJU:9O
MR,7S[ A=^D7:IZ53]@W]1[CCS>IU6R!O!Z#Q_X;0Y?GJQP)G"VJG'!8<7>SR
MFFEDO^,]_89;]O!?X<&_^^Z-RLQL87HDH( -WPWABGVOFW-^1>QY?_+MX*_I
MWLLU:&K#_>*@XXUL5S>0.K8['>8R%!V_&)Y@_D=I@PZMSCG[LU]F(4 9)-_[
MD:83JM5K1C$<TQNU>W/;5U=.;S5;O<Y_K2A"PMO[[["^UVW94!>_E"((DBYY
M! ?_E[,VK/+?PLWO]1W3\YK+:RH?9LX\K#3CX$P0U!9M,FD].:W#[4IHP!BC
MK2V+7)W:/ .6W&(0;?O%V-):?FVA: >K.DK(8,NR"\$;>A-<V-*?"\_ZIQ 1
M_=7OL_!O?\C&-!?AP>/DQC@O./6<VGV!&W8%2=)\T&.)5TMCZ1$E2':JP2G+
M%VY]!?V98"GE 9W#L!)_%T%6ZI?$W>D;GA/ %#<L1J68HG4H-IQ?O].8+*^.
M5#=F!I 00+3 -"B^3ABQE+%C%7YJ6V"SZ'BN<9T40D\ML_EY_P0Z)X?FD,C.
M&5AZ-W>3"!T0",DKB@'CR5?C9G%$^97"W"<1L,C549,WH\!40N9ML4=LX:9Y
MAD-/BB7>NZ8_Z %Q_S+GUWN"R,9)OJ'6@G/$P,P.725.-^1RG'!!(XU);P7&
M085WYMQVLV8Q$BXI/*.HJYC@3]+QPZE,[O%T_#P>JZ^W)[ M40XWSA8L6.:/
MF%6A:Z6XI'2:3_\UG4^V5O[$2LG#CB*#V.ZA"]9)ZH9JD79[Y@QN:F?L",D-
MT\770UEMXTPB8_@A/(5SLDZ2(2Z__+HI+ #H^B<6WM3"?+1M6+AJB>@?].E>
M*B<&7(X[JQ.WI][+CV;Z-^A&L2?2X"G1=^Y\GXY_VJE$UB*EG7->+ 06XP;V
MY-Y;BHNI8I;\WN3VSOY^EXA#);]/@8U06T16$6DSI\A *=SY<6**1,#MQBN"
M+[A[E$-#\@L47_W#KKP/7R?'%*0_PF9KE& #J%G_T\9_MNRBAY\\06??C9X8
MYQO*ME"9*FN2X-.>L;E)W5_W"R_&&LQN%"4$$P0T*AAE2O%@1-:"_X8*12'X
M"SL@SIR75BDG514-!UP3&[<'H3AFS$O[!2%Q$,1B(Y],F2GL".,CQR>P7%XC
M^'%!"=7ABNI(I+A6=O2M8CM[P;Y YEDS_PZ*6B(UJ@[)T\!)A*1JE?<-Y;@>
MS%?OHV[JBKDM,RGH*?.,JW3?8T9OY.52)OMR-TZ/^:?/E$XI'I!AST))!X Y
MKOB/FQ&?@5N,Y-DIB6(%5ZQP4S"J&@K($P(?0JW'T=*PM_8Y!2>,Z!MJ'?\O
MV0R9"]'8,$<KI3N(HHO2 !@,@.0E'V'#C2>HHDB$8?X"8I/-@!;]H>F8# Z\
M@^=L]:,[RJ7G_CYZ[G]>>NY+S_W>S)/*5ZIT0V5]5:YEAMC)[=YI,,35!)3P
ME'!W2B&D&5[?+&HD"T?WA] /P$'J0DB+%XRA*(9ZW%-'7AYI \^>HXM4P*.V
M+NZ5.R0*&TNL:KF9."N/1[)+X)/"9X?<)QS."MU',?J"=O6:G:\4QJ,>P6*)
MC]@2)WZ.YH0.AH('D&%DF\PM:WY.N7*2_'OZ_7!]2J"%TN2JJ# 3MU\1/ACP
MNFBR$24Q.U04)X.<?KS17VL6M)CY8N:IPZWRS5L5LHTT?)$V"D02F*5G%.;(
M[A,UVA":#ICJSA,=VO" )D7+/"/E=:$00IX]P>YA7CV;&;+B"6$Z%DM]U)8Z
M<<B.^$Q" E>"M-DTFCD:ZHW-3^@X:Y,R2(*U6L2J\D6'Z'&;VE#3F%I' #0&
M/#)3CU;INZ[9E(!AL]XV(1:Y,$RE<; TQ2IXFN?X;M@_(V+TH 6?I9_S3^ <
MF0$NA' MS4'B($.3AZ!7]25W*VYO+=IA&[S8S54C!"3*]&7%9\\#)E.H_MJ&
M >H,Q(@V1M$9"[:>J S$W5S-?_]N9&7N>A^]_/V)V=4,N A-P+0#*+T9:JQP
M,NQ-C>(GCK3"R7<54A=%?<PVFF[!!L4V,GYRR^>O];A,?^$^1)-Q"!)8%!6/
MBM;>M+[K9@<T'@2V>X+:A[9>)2A%08CS+H,+WY;,T4^SSD.*KI_IQ\=?;0AJ
M6%W+:LQRM;LKJ?; &:+VGB@@@#V(37BA:P>($'3M8%= L\IW[2>DX_.*Z+A(
M9-5G,G1PZT?=#NN$A1Q2\M+XLH4<8RM(B;(._TE<=]2TP J>-9M4( 2C1P".
MTC,&P][EUTT;5R+3B\4E$Z#$+62SF09[P(02LMCT7$ HL8#[W[]SBJUAJ[K=
M%Z/P3V$@>3O>!01Y)_ZMD?"+_16-Z 2[X6=SF@XMZ%\*QZ^D$E><W0KHAS->
M7Q9BT8 1 ^#L)U_OPBO#PB1PI(E61?BW%^OU_Y3@B<*<$]I1V%(QP>;M7E5/
M!*@^DMUD-QQYG%>_A,=HJ/VDHBH&DR"0Q4IQA9IC>:"S\$N$BX&J:>Z7+%'+
M9G%+JI"0A"3Y94Y$/P(-X/K!K.["X@3>VX1/$;D2MP_B"R2RO&P%U"G39E'O
M$T-WW80W2&<)>08W@R%2V'I%-B+LS%6P^W"%R)PR)T*9&8[G&B2#F*S3$&+3
MZW8P@58G<9/>H; R@<,OO,*Z<$@; 08Z0&+3IE@<[?(>9!3I?GCOTZ?R(FWU
MT6'IKV(I_K)M;OHKX>"D"#73U"_3X] E9.$#!=([X](1TIHL9IX6U+EY'7=2
M.<$HGFKQK04&((+4R"BQ_UG_N4#[WU'^,#9KL%'9".YH*'>"EY3UV(Q2#Q11
MR_.XZ=NBLXO;$-"N,O+N">K,8^"'(0Y)XUZYC5=&%@%-)>\)OIS]K;\I&)NS
M<:5G7O&$%Y;%EI2G_/2Y041_H*&V7H:4E>X /[YO9-+F]/T(]^","IS1/DRE
M[\I.M1:W?+CU5X5O&_JK"06[H&7S?O3X62PFS=V#XCY//P .-.+RE/3M8O63
MY=2SVG8XZY3#;$S551I?Y,<^TQ9(YGM8Y#]_L4 R%TCF?:TFBLE)'JE2P/40
M_'XS<,"C'(O.Z4@%C$MMZDZC\XF0"YZGVQ7]4:<6A"7^I-N+W-#0\YQ-0E(Y
M/6%9M*:EI%6>B'(\OG>JH"MUOA%QJ^03D?TUX<?4XJJ6.]TI<^81B9MDS^,D
M[QB19'<):>>C5E\Y(=CL IE=VLD?!;FP"?<?4NZVDQZ;#]0MU+DCO^ATARS0
MF$=O8"DT1N7N'27O%.FB:562L*V& R5RO@)%N5YPH(N1/6HCHP G<J!P#&6=
M#88._LH!"I4\04<F3LHK$_?YK]!LIPA*8Y8J!%%5$FDMIO:H38T5,^@4C*3C
MY+:TL<6':7(0.DYS!F #,H"^.C%5"/K%L?<M)O:H38RU=%B<"O^K"M95=YS]
M+8YHL1(+K"2LRK2Y[8:3&$,<*]C4N6RTZ7AZGI/5>BHN%*#S_Z3;$+GI&CH6
MP5=5S<9H[18;?-PV6#7U9=&"30-V(_BWJ_)P0/@5 6:H<8$@V@S(V*=/%VD6
M\WK<YA6"]8%P@<:<BYY8L;G2RJ-2K2M/=B%ZI?;-\)&Z$Z#I8DV/VII4\R:X
MF5[XNVGJ-H<L8<08$&JL(HCNP#30AX+:I (K5=6R26B_V-:CMBT6N(3NGZKL
M1@):1:!#*:DJ:-0P(5D]9W&+73UJNY( 2XI2BHL "H*">W%C"+T62WG4EF(G
M$H!,&["1,KZ3\7@5\:MJ'+1,D3YR:V$ND[YH#T2+H[&0B@_).71==IA,9B
MS]>KF57YC<G($<2Z9^EUO0)8#P>BU'WW.=)_(0C'M[(J,I2P2_BG$\SB&)_
M4&ZH]=  EI$O<J68UQPO:Q_Y_G:IQI\*56:0F.Z-PL/8X2$VK)4BHL8O4@$F
M:XR($&G>EKO=,I3PX)-)M\!$NRA\EHH4&)?_&<QKAZE"9B*5$;L9Q*N#<)[
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MM^TUN5O"/_)6ICVS%>@X4647TD\ATM/9CS/*](2=?T/1J&/C3V3&SLEUIL^
ME)#/S0B3QT:@F;O@W?37=(30/T8*S!]G$4N^OT'P48D$4C[N,*3[ANU$050P
MX;O=W,S1&*:(,7VFU+2PA 0:)UP_G1^U6)^) ^8'R8/[YJLGCEU].L/O*+31
M,)1!L&76T"6%!O3?X[,)R$V/]=+$,<,=ZOR[AO\2+N"Q/%6ZKMUR!D@E-; S
M$^Q1=]["<E,,W[.POXBT]#0S^%M*[T4D"[ZGSIX0S1(Q-Z8BZCF.)C"<%JVX
MU^;M"!0U3L <8'D>[E/O5O71R"5Z@&NYWRB9>['BW%MD]..JCA!V#JFC"XO^
MZ!R-XU,T/:-/'9/7K.6V?CU!T\[0JA-%;](+(#K7,^9\]9PD$+C:8'@.5WW(
M*^X9GO'>VA8V$Y]O,<_5AV4A=':(CU3EK"5LE#^6=W3<T5_\/,@OPF%9W]:D
MU="$:<9$<GA'C5=A#S>]> TI[Z(I%8? L-Y4I.#25;?M1AS<OJK_'=Y(<"O@
M&?'$R^E"(:-((1_K%Y#0WDB<OJL)X0 ?FS;T47O^L,-\&T7ZX2>1QQ9/GEV]
M&!1N0&YEZBTP =PYX86EK>P]-9<\/[>=QB#GY"SKP[H,_WB3V92SC:QIPY&Q
M.XM;?)K,.Y#U$ !F3%*+<YHTQH:E6FHB91H/?[\;^1_T;?Y[%N<;RI!P)\@9
M=8SYI91_7NX],883^44Q$9[IR>C/82!?*:D%%O48HZ4=U:=[]H-VW4UXX*1J
MNJ'UO9-.NK.V,PITN-T []MK@]C^,(!RYF3I!JN#XR-R76C>U1(5]N]%V+^Q
M$4HXW0MM^!MWX]QG"Q[NXKRA-: 'N,BP,(6!J4[+V#DY?KY\3)S67!VNFUWX
M?O5Z+^WAWM=3ER9M]-J7P0_@:#6<]N0&53-FAUNC-(%J7W@\"'(CV:,B9VG^
M;!X=JY>KEPPL%VJH*+IB:6/B_B'N3$8EMJ*1(]V:[JI"W$!)&XQWD9!R>G?P
M(1@09H+@M:*=,2HCD"XN9$82XYYQ%O&K8C-K'FLJ*Y4UTR2:8+19VR9VUA2>
M#\"%0-K6^F!3E(CL^&VR^#<?H W<!YH'VG\WE!65/8+2.Y:2Y3=W6I6Y:1O$
MU$//N<6Y-=: &D';,>5VUL;-IF03^QQ9HTWSH><[''5SW%7,\K('O"7^0.]3
MK""R0WM6<K^67)@61DOY+CFIE%G6,\Z2C,IDLD9F\K_ FUHP!^\"<_#Y@CGX
MN&FLWM'NO==O9LE[6$#U\*M?;BQK:BUWG*9TUKU.XA!_C%-4L,2%'[CD\:M.
M[(E@)"E.KESA]'*UE%'S,NKJISF6&OD$,]P3G+.7SQ%';9Q@F8/M.M=C@_GT
M]S[CYX^"\S,M]"F=4NJ-.>XSE(G$O\\+ 1JP1E%?#AE=,0;D8_Q)W.,L8BWR
M6H7<@8#RJU=5=<.YW%01=R8 <8-63%#=\%<7E99[BT#G9P7Z[NXIM%CV!9"H
MHGY=;:&ZG5<#.;W-KQ+G)NPVR>FO3W[5Q(?FF7PJ<DYG\T?SGH)8]RU#M AR
M!36M'$3%RVN)S=[JV_U($MW#85UUMH.]X7+&^DR&J%<V"=4*9M$^"G9JRN21
M\2)P$%J"^[K3G5]N6%O;2A7(>O@RF.L9IJ ?2H^959+H!KG!^U,'EJ0.0]50
M#'M&=;Z].([F70!2:7JA.:)7N&JR9$MJIL-U=VWW2HTMEW>3GGK>#'JKG?LM
M9)*[^NI*:JR6.XD,DM[^COAJN/;8FRV4"FVW6G?U]@H6@Z^\7*5J[6\8^Q8S
M]#Z)B0!3:#QPJF/-/9*>+>$W0:CSFS863WK 3(P!G^V\00O&E>5BY@Q;754-
MG4*.>LD?@P!:'$*8#HY3KUH-C@[ERXC)WIUHGF--QC.+!8HFS\H\,>ZS*WUR
M]/J!Y05I.:Y0"V"3EX]K-C/C*P!U])V0]KUV?BSF>E0Q(;N:)()I%U4QE5PF
M=BQ%R8W2LP2E2ZPNHXNS,&U=.3#&\1I:N^$YWQ.$)>S$K9+VX9X5Y_Q]6CS.
MVF[HN 6'9H_000;E8$,YLV9&P!XNE7CC[?U2,8=D\,,[W,49%4K&\!;#C:Q<
M-R4^J?<RV._--2T<Q5NCI-G<MGN<35'&B&74X+;08?B*#!8."WWGDM]6\Y,X
M!CUX/#5C7$RA<L%O&S<W55*(YWGT"^[D& 17@SO4P1J"A>,J4  UOM],JZ)G
MSB9;SP9&;S^K\=L^OMXQ'>V(.=)5O_D3/HA"ED'*.Q="Y2W9>M,IYO"D%_O;
MIR\T+LJ+K4+J2N;%G439HNZKZA5VRCWKLUO-%LD6',:'S;?E>.#Y)6K>NL,;
MTX=\ 6;/SU8O__']#]^]_/KBLVS-%>ZJQSFA:!76R%!:5VQ8)FO'_)0F[!#>
M6([NW(ZA?U.5OTGZY?LX7=UK*W'[Q(VF'C]OC\/1K[#>O9<)0,)2=%'1JB[1
M#[EBS7:JB4$N/N%24OCF9&,? B"%][GN797L;2G@??K#<ZU:-^1&0/LYLT/Y
MJ]:-6(V(_4XN([6(-BQ3S<9,HI/ADH6QTP"*=%0.K9Q^!2K!95YGUT(;2Q8+
MCQFA(H$<KV*@Z+X2N51A(&#P;]%QI/2Q9?#I3M2L0.URY9%Z1Z[K?173OS'#
M>47IO$:7J6,/GH"E.KZ5^)65&K-N=ON!6=L%\%PC?8PN*";QHVF^# 8C_'OX
MYWT()PKU:"B;&SY<+<G(546:!CPJ$D@@!B&-B/./V.M\B;Q"]D4EQM <FWY3
M3N-55WG81?,*\ Y]F)@'+6S[I>2B55QX4Q_:,-38 M@3^A[)<I*7-USY3U$=
MC>_?16Q)GD0,9UVR(#60X-^D&<6KH=ZRJQQF.,SSAE4D/+K^8?!PM0A2JIA'
M0TVS3_\P?4<9DRQU'.(:.Y'"21L,0A)ATJZ M<7\85D&)[<AZ??]Q%:4:VM?
M[4\J<)AK"IGCA?!'SB"P:9!%ZI#0CI.8_1A!%MFZ_=#.ZH(4>!=(@3\L2(&/
M&RGP)JO&X)+!?F]#;(\3QO":KG?GX::9BT6<YF'A'>/1G4B&RTFZKNBN$N%H
M'W*2IM0$)I]0T@J&%J1J=6H'/JR1)XI6F@,YX@Z>[C,2+9_)%B3T;FTKYK(4
MRDE?C1V3"4SI('!_7]7[X]*.Q2RY.'5;S:U&-P,WTO-.VF'IRQ'B N75<><=
MGU>2E--6.]<6E!\Q2685/QY_TRZ$-^4(8)XV/7&DFY75+8B50LJ2.GF[F?_F
ME/F!KAHULW G(S[1^T)LY]H8Z1956"KMJ>*XL("$V VSKI(;R#_/!&=X?4[1
M;,;F<1TQ''/9X%=#,#KAW=P&Q ^F(AY+2Z?O+QOYMCVZMG$K&)KPKQ0:KOV\
MJ-WJ+?P8I%KIH-:)H%"F8B+^&\#7'!Y#6;;<[KGOK=Q>"Q!U)OBC8@W]>"8
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M(Z5?7,ZW71MV@='$T3[E&MFBF6L20P*%K&^;2@8(>#%B(-+[$G+M0<UI'C0
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MF"'J'MX85W[C$/)8V5B0NQX6C_FM^PJ/OOCB3X6'3V 3M^&08C((;L;9ACL
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MV]>OA+?9'8_(7T 52=7ZN,VD)L#P4=@O!$,K(^(.:4^F&^MZ88"@[Z.V3$E
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M)_+W$QWX^J"L-$Y0;MR(Y',ZV4<>*].BLX6HLI%6&K/)Q0"G2!1^T*-2-\S
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MA]146KI-PI*1E@B-&4/X /MJ'$880\&O]GNGY>'N@CUNF$Y;RB_45U&&0&>
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MO6MSVU;6)OKY_ M4)CUC5T%LD9)\B6<^*$[<[7>2V,=RDC-UZI0+!#9%Q"#
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M1$?*18\5212/%T0?\2#G2_D4*G-<F5>0%.F8FL.0"TW7>-]:8M.."YLZVOX
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M.+74\]PV&]R2=8P?67.PSQKL?MH9/\774N9M<.:X;4WABP >I C@N2\"\$4
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MMWQ1YFD42N0*,7$5P>'2M2)='5PU6LPE=6EP(#DZT@86)\!_Y,62*+N97LO
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M'?')\8@$[O3X5-<47T3E. (M<?3N2Z86P7E<:P'1#%=.KX1PQX%IX,B>A8T
MRPQUN:800*GYNP&C097"LP,2V9CS862?:I:C7/_6>9^6==;-2TE4<XA6G3^Z
M4EKD9X0^[O!;67Q\2QLQ@6,*3UFHJ$3H<) #:E[ZKPB&!S?C, Q&QZ-3GA"&
M-O&@NKO#%BM/"11V)<1>=C+KZP_IC1)2&KB<U5SE"2_-)>*PXRNY\,$M[YVD
M< 70OMSY6WBG]JU/9XX\,5UIOE9Z>_4LYTU9-1'+E\@JB>A7[,D@>'?GJ>,T
M:<$)YYTV2U-T&&IAD412IYC0H)[O:Q5]SIF'C>2+K9$6H]B=%H1Y\O!%.-]
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M';3LV:H2<&>IPN6^U25>C Y8C+I514O%Y297%27PC)3T%N$4Z_(CJD[R,G3
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MJ.#=A^LN 'SXB>. K&.5#0(RL%8\T<QF+0.O[3?CQT&-@_N# XNG47Y)9F6
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M(57#J>'N5A9B3M,F1V!GC6'X'/S(V9>$M^F\>5%>1GGZ'[Y#X:M5,Y\7)4P
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M>[*Z(19B-I?%\*X,<%>^H5A K_CT-"O$77Y[>=)7*1<NXLIPETF7)6@LPK
MBM1# L'BCH]#&OPI2^ZU#U?!(!&1D%'"^+!<0A72D,?5Q.,\1EE$,X78K'FA
M9?%<W3$M%/-)*8%*RT$N=B1/]EI<<_T8G-[#IX8\O@$2$K<"_]1(2>K5E,O(
M*]PH ,'E,3V+(/#S,KKBF)[BK2/E;:Z5!%(!FN_RN,'<1+E-A(H0IT-4)8GU
MLWI P@KU6M+0PKMJKYZ_!3Z01MF?)$P%24G;#\P!<59%52\GGV"1H*Y84/L5
MW/DM@1LTK1#L^P[ 8G)_*\E]"Y/[G4SN[U5C4U"9N2_U7)2N\I/X,.-WTIR4
M$A,TS&F>V/\AK5:A*S^+.*FFDG])51;%TI.0N@R^$_!4*ITRW55J'!!=(E:U
MH -R?9/[9J*PNY3F4OF04NT4>E)(4W&#U$)"UE6QJ0=2>5'=":F\4MW58]5Y
MHOZQ _F$[!7'6?6$85R%,C'3M6NC6QXT*;U=\<,YV!^ 9;[1L6X=XN'_\*IH
M4EK4PCT<SL!*A?VSXIC7FA4MK-(RQ% <ESJ3M:H4J'=4U*B6%\K4CS2::L>Z
M]G*V%68(F#.3@8QN#.61 -(CEZ<I\CD"\JC3P[]6J7YX!Y^51IVHS\P>%*.#
M<PNV:VE:"D<XWZ52[%+<+;U;,-(3(5S SHZD902[J<S+.BS$.VJI==F9(1I5
M\@=SGUPN1QA<67&,NES4PTW(-TWRK/Y$1J6J=8[!SK\OW.>ZR7KT[O'7^<F\
M5]7)O)T!RJ99G3G]26=RPF^DAQ8FP;0(KP9T+" G0FG"L<MS%Z(*)7\T/[<9
MGIT6D1H1%AIQ7B0<<]K]"Y2Q8%T9UQ(N+ZBXR5"F:*(\CUI;ATS)S$1:9]51
MR57/3K@L1VI'+=^(S@WIQ-!X02H\]MZ2[W^_DET?V32=U6OV>N("F*MQ\.#/
M09*"C2'<'<;]R4H9(:$5#,&* (] RL-"QX]6KD34X=S22'9 $;!3B*BZZ<OB
MB2*JVBL"I@^%QSSR.:E9%'WE]QAV-)1A@QN0ID6Z-\FR%1%3*D,>(/SR:J$B
M5@I_2OF Q[*Y D"5C/*JA*CP&\'J$6%+Z7P['Z0LF@ *3T<B:%AT[<B2@0 H
MHHRLBYQ_$0N5'6U\%$U'RRNJG,K\NT<OJ#X+S/Y;VHI?):'R#<^)[9"H^CRW
MCR.1X0VE["@B3WG,(B^K* M @8!X="O;\Y*XJED5-7,BW"][6D1>0,3)P;3.
M0GFH;)ED$75[DSL1D"XT9!['CL94$JN0;Q7<931;U#]<G2FNKO:4;9G8KR60
MWLYM?^!9D&%1-A!B)A?")$\U"4SF0F$0\52$[6>%7S97) 6,EX29B)7.GXJR
MQ42@Q*8L4PEFN8X83_/\@0PZ5M]]0 QSS-,J3?@0R47QK]0E<AM9T5A8$6/>
M")OM^[3;;2+UB\2?5@PVN7@$NGEL'98!UH2 T5_31-BBDE$SY>TTSG,[G+W+
MT<Y$5:VLS,B3<36,Y+HY/_"<%_RX22ZG8Q#67P#ATG19A+)L#8S@@S1]K,IK
M":YYEKODF3+!E_C2\!-F2ID'6&:<GE+4V.:Q4]%0+?BY_*V7KV?J"Q-PDB=&
M9>A\*KH-:X=TSR,]<V%P^.@V7LA0T[B&%)E/JM55%4_78DHU47;TYM.9B/>)
M,HY2#YSE/LH/<*HE*+^'(2EK*ZY$;86\U!FP;61>K6"Z0@!4+0_ L&5P8EHV
M3\\!*;5F&>(0D 0I!!N,ZE,6PA6!BBJH\< +$DZ+B!ZM] UEUF\(LFU252/D
M]^3^I*S^KSE4_FPQ^-*K!9E 0H$B E]/S(0?]^K?FLS&.6]%6385D1Y^+XJN
MB^$0<\=17&7B(X+I1)6VR)[%DM>$XU?4BBR,NBAF$M3[*.+9 @\_#=Q:2>TJ
M>5GK$HF3U7?D#G-2(W591B1?W\LA* V:%)BPE@>N1HGTRA!W_2_EI)+RL0%G
MLH.NGC<_4/GS>/LXDY,E *L27%4#UV'[:XLC>,JPC^"V!6@\K/C*B\T8$&PZ
M6S&@IZ\\F!CQH&A,RH7R&\#<(BH!;)".9!A8QA\$^//"WFCDR_?GM0#%NOCB
MX)TB1I)-9047RTV:HFV@8/B'C\[J=1]Y[U:<YY++6/=,."FRT$+$0D0$:3R3
MPP1Z9;MFQ4@B]#$4Q>M3&8 3(WXFPMX+118H]TSRWD]_EK^X&ATTR[]6)'_$
MCF7+*@\&L;0B"F=F;GAE?!D[\Z)-<+-J<X!X.N9R2?*;(@X_[Q?E]R :ZS7;
MU5OR3U8]8E4KW;S5LNCRJJ85W F!4SGT\U(5V8OR>.5@WK-7IMIDA]=<'O);
M7D-B7K I$W,A%]8QO<NF4>Z!@(4[&?(<P%E5:E@1WN/0ZBNGF4Q=B.*YWN*<
MHQ5U/HOSC&#U1>"_.Y+R->7"LM%2[E_"MN)>J?ES[T$TS<BZS1" S=.<-<M<
M;=$2*%BFZAC,1+)CR(O&HOP5\H[\!0!CJ:SN0,/)6B5A$A2- H+,BJAVWM!,
M8;\REOESL(SSHL0J$!H_$Y'=?>=7L9!E*X4L-A:R8"'+2\E&*.M(YE%J;<MU
M(54KYBBE5)% R6K2JOI345:Y137ZM $@E&I1$C/OI9O?\@',K3NA77M51WLE
M>VO26S@ATU1Z'%)LBD[SHE6,365/@JBFOQ_GO:"RA%"J\+(/562&;F6T7A:D
MEZ'<6;GKTB$4X7VI]NNZ][&"F^>W+WV@HH=$U/W /<)A7;&9-BGPG?$PZIZM
MZ1X'=<^AZ!XE8K^^@9V-'+K7F 2L0'%.^\K_"E<ZFN0M0T+4_J^LTX#?%^S8
M<M77#KW^J_;(]5_E[?!ST< /^WJ%"=S(]F OGZII IER*KO?\Z*/;D5RMQ0
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MQT^E\_@MN<UK4(UEYQ&)M\T"'PM)$>U82(JX?XV=@F@_.K0;[PU5N'7(\IW
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MH')9Q_2&YQXIH2&L[H0.[^@L^_#F_4.L+!Y[L +>KP'KCMAW-0R7/K<^7Y<
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M%NCO/BCB$*<4)L/L3W1V4:^@L]L:6"$IH;-[2-JFKFGRN3=(X,C_"!X$3UO
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MX:GEK;E&SS2LGJ6MFBNS'[H5\:0]$:H>AKKOF&!G6Q1\>MUR".6>2M0@])W
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MC('9>QBCD1DOR5(*'ET)5&>HSK:?(6"A906611S3!=7D448\3CEQ;.KKFF>
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M+IV^8:_UZ!.91_?)*MG7#%$K>%,(J96^[[.E&*6$6B$%W8:$X&I+?2>!R<W
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M!2VL+4&R-!HI4V)CBC*GY+ :]5#E"4),BERDL.%XY"Q!\QA)-&J6.1EHYGF
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M\J.;55<Q&0Z#H*K+    N]%&";^#!#E8RN'NX27C92-83R^OZG"5^%2SZ<=
M6YC5&*0W]M\T2^_C'3)?5Y=9$^X2>+N]TG3N6R.Y.<NRE\NZ#M^874^R2(;P
M5H$P=FEBF#^2)1CF;/6BV0)(F;F/:K9L4P':7<ZGOFKT,EP^I@G@D1;!6EN
MTH#'>EG5U5R%/R\;>/N8.Z"8R$#=EV_^Z_7/B,CO?CA;/4 @?Y69_L'V/0_]
MPO/ W0,9==!?,>H0[K_YB+$W:?F_JKGQ>2\<$'(1'N5EUC[U]]_]Z^5_A6=\
M;,LX>QY2]T 8].OTW\NIG2ZNXYF]5%?P^>P/UU3+VKAG@L_W0J0HS3\[XRYU
ML#,8F01YH6P26;6#H.Q"V>P_]C'D5V][\)B>8J(@%D8Z:^F"T6$Q$J)0J,!4
M>UN0')?Z@3J)SN?VW455+]Z[^O+U/.!@E.*;2]*+C1!>_M7-FN*,W!C">S04
M")^916I_<>]\8."_7(R8!< /^!D3LY,L/(NYV. <[693!RKC4[AN^"FJBZD!
MU0&JQ2_#Q::0"%[9@Q$G53<+.%RKKI8?XOA@2 2'+WURLZ"++L,37S2MRH'[
M39MF&9P(EX%+<<\PSY%)]NMY]GM0VU&L@TB339&.L9Z8> _'$!XH',"\.]:L
M"2<=SOE#[2*1LN\AYT?QC^_B[\_[W\??DA]_"&>[N,C^7Q?M@/"!7W]]N?K*
MZK?]AR=!6FQXHEU6N537W7D&F@)SQ/]6\/W(<XT+'!3]H A9P#5@PU1 S,K\
MU?+-/#QV>+X/+1=TALE5\',B4RROX+HC03+#-<.8!,_)*>B))!3IX&4AZGBI
M"NPX9WP;R:3S6ANB$2Z%1MR+$DE>:E0&5"QL::VCOD<RL()>O /2O.Z$XVU=
M?:C5Y?DR>)MU>%5['OW) P$8Q?CLYAE:CPU@DQ5T@-E5K=ES$DM!P<)K5HP>
MC;$:^"3@PY6:G6405.YXK4>NR$Y!8B(O!O.C8^0!"\?4>/ECN.Z%F_DLL.&T
M6;2PMH8<L,M_"73,WB$6KZ7"!V<1H(*9W5P%@SE8@7XZ"[^(@@4W>+<"V?B5
M/J\$-[X,T <W6 GIJY<KP:R&$, G'0R$%P\,$A[>MN^YUO*=T%L@V%40Q[5,
MJRAKW:V")(U#A+3(N=-$(DQ,$"&L<UC)4R*6<^H\YR67=%N$"&?82%(@HL+_
M\)PII*'A+>>E$,[EB@N\(4)K&L-:[0UAN0IN_$I:$!V*R]<R=FP$LO*W3E$.
M,/-#8,$&&-$$-NCTJU,!J4%4X..M4$P"STXO];*&TJSPS5GF7<>;P>N*O[]<
M&0O@/4ZM&W!3Y.O@I08=J>KKH(-L=)N"EQ4/MW5/Y\'?TLOXBYA #C[DC<;J
M.-B1EJ;0F!"D:<Y1@'?H=U<.6,N;TE).R*YM*JDNL;.(,241%\X@231'N?;<
MT5(K)>V.;1K57H3V=_$X ."=W6#-]IR&'/GZ]U\V>!(%RPWX$BH7&S?_[A_S
MZLDYLL?<"Q5L/.V"23*-KS; VBTCY)D8< _DMOXQ;?YJA>S/H-]KJ#O8+I$<
M+TWNPR!#?36%X)/^GZ P05_5*U(LAZ3H;<3PB5M&T,*7HEX,T-9>,Q@%LZ5U
MDRR@44PKSZO@C4POIXNH*2?9505/!XZ%5]-9%]H-[[J*'$5 ZW]H%DL;[9#-
MYU1-4P7G9-&K_2 &3M6FG=K>Q>ZB_;#N9,F"X1+<IAF$U.#9'422PKNV5K0S
M%^T-I_-Y];%SKL*#51#?:R >> 5& #A-RZOPK;_<-7A=336?NUE[P=DT^E3Q
M>3Y (''>M=L$;;&<M9=LW8IY9S6T!;V=(Q&MK"N ?R!--,^O01M C"WXE7,;
M';/P_6XYS- 3Z-YX\^H?X-JZKI2%C+^[6L3'4^%\/ZP"DA.P7,)K1+I=.#4#
M50.GUJFA.L8TFV7X?M/XY2R&_=:A4+?QD/#0K:>RYXVF@_IEN-GP2:-7[#I?
M.9PP/+BRP8V&%X::A-D,##VH2ZC!]UW$>R[::.DJ5+AM5\)G@P)=@-*,YQLD
M[<-UKV3AB0/K_K*LX80WW3T(MJ["G/W)1UMT<3&M+8+JB.OPU/5'<)76I((G
MN5R&]^\\KB%7]QPZ6?/V!I_&=Y\O?6#89;W9@W66O=UF@^$#MF@_O%@TPFL(
M0P2J-@%YHK4 =VE38O!\D) '\L5943& -VD-[/7O;Q2J8)I4-3!/*^PQG-W2
M<>.RJU"P:Q9](+V3A2J<2<\:$W E6K]CR%M18,ZR5Q]!K_GM\XG1%&#R*-2!
M3>KP?/.E&T0Y>B.L/8EM D[@HNTC.!M^6$1! K#2+CQ&/-: IG"?L^SUYOT!
MN*)@['P4'*/P=,MY_WQ-L-N G?N/Q#HVX"0539OI?!EC]:J9MM@P[Y\D^%#K
MJW0?==O1GP %5S,U!YF:P?FT<JQC5X!I92LX84NS_<44+W\8)0L'USCWUQ[I
M6GO8\\@EEU6K^=1V4F3=A=E_8\C,@PN#?$<86H<4K=.+]04F<!\(&L+%($0)
MRJK%S*BDX(GG@:2!.C.E*^"-CZ[UKX%)+J973<^-,0#6AK^@WZ05];H&M[J-
M#((-$%XHR!>PW[P"#;VLH\;9T5A]C*#G[DX--H"<@_?KGGP2<=?5ETVOQKJO
M#2XY:24*8F !$*,TP7.&^P9]W_KM[16 @B# *QK#RRD;E'4#WU3>1P,I?/XB
M&)_A TV?86R]JMX'W-8U[O.TQ;@878/OABL>0,KVER6<J)0]-F@-U0VD/G?M
MYRTKM$UQME!M,_>QFBU[J>[SJ1&@VVCLO D2#!;EAB)5K:$3K925I6R#3%[O
MWJ^SB'LE%PR[JM>SD*"&Z%RTNN$MF\G6-><0PP"!GX:W-/'K>UE;]P4'0[W3
MO42OSX B:MJX)U4KP1MWGZ/S\8]4@'H<!:CEOGK)[+8UJ*D ]18%J#&*M9*;
MXU(: V/BL3EW9?55G;&Q8X)G_W35505=NB86RK3N^%H1F.#]S6*B9?6AY1QF
M][;NLZOK*FBARTD;_@M_6,X6;6^PVO#Y M+5RZM>#WV853I<:07J<*UUJK?U
MV\.SO9ZO+#&(7ILNY^.7L1:ORWP&_1;>!11 ?.X:ZH?@ ?QL'9F^" +66HXN
M/GN]\KTZSPB<+S#"^@MDU;(.RK%9;-K"K7]\O1I>'#^F8E@BYE]6:JVK08G?
M;I]VUE>K/*W7\_>-2M*[E7\?6.8.^Y9[FVCV5]GNO_ -5;:<"%YH2#L9KQ'G
M6"%%;?A7KLI",$N5.DB5[4_@+KSQ;R'<,5]$UH7BE;4(G1L#89/ AF^#*)K@
M:;T/=_QI%BS]4ZO'I6?9N^5ES$,% 1O0*%L3*>NI-.3^ _ #4X)[:G-$E,"!
M'[A&$K,<V<(;7%*3:YQ_"S_$_.5^9OBS<6_\JV  7@)\Q?>[/GH>N$--<NMP
M^VQ(MC;1TL2HQ8ITQ^V@AJM<J7H[DK-10M7%82"S"(Y3=./^>7[^M@_7-A %
M5FU4!13;I?K+9:XG7^O:-<WR\JIUQ&)L91"UZ .\X4&JNC,'.J_TRZ5=K4LW
M[RK!=CL$-XL?=%#4331HUH\6WOEBVBR"41+MF<]0DP;>[23[:UY]FD,E[]RV
M]VGC1ZT5@:"( T!D'5BJW<Q]!$R!8'A5W_#6T\6Z7BZ&8C.P'ZHV9KK.@)II
M;9:734Q^A+=X,X_U6YVGW,5=!R3O"I:WWZZOUNNR6S<DMX;4\$#$&N( -X?1
M XWF#5R\JY)NV>:&<L&-S\0P$]+1X%*?5&VW/[ ]$B:&KU#ET6">##S/SL"8
MCA%B7'NA/@/-7L;RF<BZ TZL@> &7*45EW5EB.&G5<':=1\CCTQP]E6#Z""&
M \XI+[% FKL2:L7"OTK/D7=,&X>MS)DZA.&P[LL*1$]*80L0W[;U8;-6&#9H
M==Q:X.M8VZ/(HFO&[G-R-S>\K")NGRZJV>P:94&8PM6;I6Z":Q/,L<G>+P]+
MX5Y6]555=UFU\]FL]<GZ/IA><:QK21S@VEQU2L0,S^]QQ%C2,G<T%X@I$JQ^
M92QTV6ED*<Y+QH6CNCB(&.]=GIKD>3L:#J7M;;]'^,> 4L<MS;W) P+09OE5
MD!T(:P0Q;$,+03Y6_0U]9BU8,]/P&C&F @E]B)'$4OW:08E#FWIJ_Y!UZ;&N
M@CN[6@9C(6CE29MLJMVJ@#]<8-8%/+3;Z378,-%6X?N=CH0>?,(UW74?RH%<
M6[/5Z99=!7ZO>\L']'W[UEU I0WO %PTBQIJ2DSM[#1&>"!OUE<%#6D#UQ@D
M40+9H=JN_^*Z5:)-KYQE*Y;;;:N *RTB. 7J0;AH]9R0TO_<&2E]H K6'S\.
M:.G2$%%BA[#@/ !089'V'J,\)\X+B;$A.QN?[P-:OZV,Q#7$MY"5D&I-FX'^
M.PF46DG]6NJR6%3O/L0TYJIF?[;1^=H'JZ_ 5:D_=C;"1O5@O%YT =86S70>
MKKUL1;MU1&-M6>O$+2YB]OS2N1;=.B'_]U+%C"$X9!;\EJQ:+F;]5,M]^<?!
MJUQ%!C_+?MOG(;4(W<:-=P"YP]I8!@@=I?$!U7P#7B'JO?X:>'9F%CREX)L"
MRNQ!TNTKAQNW\!ROO-%Z!7BU=;6V?FLUVW./GZ[5+"8.FHM Q+-LX_&^_%:;
M;5_5O@8BZ%^(O6"1C5H7>YW-A0J&[L\KZL-UOG";W5>,@\6[U[S%^^T_U5Y=
M_?DN]@(W2P@]ZB!H?4%E^ /TI)BM7YO.W'6Q*&:RH]?ZH();()A;"\;TZJ:!
MUANJOW^K5O=WV?:];GIL%_FHIC/X/0H40U"X<Q:CHS6D=:#Z=+%7,:Z<:06!
MCVG=::WLSWEX;:BUM+&BLW/;JZ;9=L)5UWAR%11[VR\=?(OEY;)MEVFE$OY<
MNPL7)"6<7*P0_1ZNU;:E3><;]2N="':%1B >;1)GD@5%&6RAWF0(8E\ONH*]
M]A<F2'L?B8AM]<MU>X.[G"XO=Q]]E2'J8@^K.-$DFT?N'YY(&V@ %V<&*2$8
M@]!\X5" <Z'*85JO:BV5A81^L^<LVLHB:$%?'4(0'P=I-1O+.>'C&Y8%(*N%
M GO;668] H*,N$M@PSJ0#UHQX.LMBJXO_C]+^^&+7P7AN2$H-(WU3)-(S4Y2
M(I!^A9J/8PIIPRW.)>+2Y>%_2HQT234J3"$<9SP7Y<X:PSO'ZU]6<TA.=DG5
M-_YE5#-0Z;^9PXG[#Z:!J9-?MU/E-*1@C-6TJAJ(&!EGF.99T?%X[:E?;C9P
M5FGF #LK1V: 2VVI[A8Y>[\(R!D,L/"FT]GUT%JY?=,X: ,(;$\7>^RBS1KV
M&)5N5G&=]M,M.,1"RP$\ZNM-WVTR\%FG<QMP,F 0#':_F@SONKB^:H$E=AW5
MJUE,@+9#!=[V)(6;P.,%;;WNC=BT,6WEFJX .X;U5V'^S=85^.BPON'+!.^K
MP0/([S5<=YLZY]4-)FXTN2KOT8;=$F\SZ8I7HZH)8CJ8SQY;\Z"^+KCS;17&
M\#=]RJ/_VH6S'V*YP["V-A6Y'761F[BAR"V5N:4RM_NT^=W8L+3N+^J;E6)G
M 6CTZ[8)K^V*:NWEF$7^>E?=NF -OC'\T%4[0*&M)H,GF)K@BVRU6M6 ]:W&
M@W2H:0WP5;]+;&"9=0TSS26X7_-E;&>.B=+A^\1FF_@JTT6+U>TKQ+1ZB^#]
M*\?'=]E60V-X!U <*PT,.?K.>;+U\D.SFCS0>@B-&[SA^XV?P_,O9[$/9[NU
MH%6$FP5ZT5;O2_2Z(,CZ4.[YK#Y.:+BAJ7+_46ZJPJUA7^MZ\F9X*(&]FJ^<
M"SS)P/GNSZAMQ.C:*?HHP6Z;5CN9N&O3:DV+Z% /'O7__@*C]B>R46$/#N2J
M7G"GY6S=W?;DI_@X?AJ1A<@9$<B4BB!N<X(DLQCA7%#.I<ZI_::ZJCYD_4MP
M>?\+/-[?8A@GRF3KC26?;-L(@>A I%4V(-8Q^USK<$C48+[M$VY#E.U$HN@-
M?.I%$FJ2IP )L1M[U1TW;T-ZL6Q:35NH#I9T$\<BK<I<H"AE\<FM9SBUVBG
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M7)VL7\U7ZN%YCX^TC<JCM0N^<77</31-QP)J,!7SMFS0IXBR_^QRQ.V-.XK
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M)=_IVLF%UL03CPPM@EVOB40ZIPYY)J6PN%!"/75/<X$G)2L?UJY/DO5,:))
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M<4<@V;DO\DQ'R++5KR?:EL)6]XWWTXU<Q6J# !L%2.+\^GNR"B!!@A2W E
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M5 _9+3\80NREQ_K3J#/(K.JACB\J-"LT&ZR<#B.';+NS$EYO&+S[Y-AA4'R
MDQ6V-!IJR%"R7;Y_D'ET0-0J0V@&!JQE1%2O-E(A4Y'.,B)J2&PWJ +;08=H
M'D[Q=O\/31-:Y)RZ'.'NJW+FF$,WCRW]V#N7//SIRZ22)^[PJA2 ;UA$T>=B
M*&LYLI$D)&W27#!#A8I]5*WN8O^>C#2]>__^4$5BVQ!0D/ KRSX4?;D')%P^
M^HM!0I&"<$)I)(,$5!,.(Q-T1,PK1;%D'NRQ/@I$=Y/)Q/2V.I3M3R2&$5HL
M%OEM%%^V=+H[9_'PU5*O]'I07+68)<5 %YPKCD$9)1QS6QDF$)C9$4QU%2T
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MHC(W'J_/\N%FG*CIPD0KJ)Q?G'>V>?Y)ELVF@^(K81A?7.'RNB< )ZF75+P
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M1FK#8Y#KZ%AHQ##=.P?=,:=@VU&%6\%TM=_Y*;;#Z@:BD9VVGDD3D/$*[+8
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M5 4ZA*$'?VU=KSLF'+1?_@@K]?;_;^]+>]M(LFR_OU^1,+KPN@$%*_;%KBG
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MX',ZPP"D/6SUN10LQ4$BIG1 /$6+G'<169D84U(&JX>7Z\^J_P8T_^U"\?\
MO;^VN7<^7]F_0_3;>"_82(JC(Y=ZZ-&E[PJ>%CPM>'IO/!6!L<221HSFDG/#
M''(&0-5+ZHS7BHCU7F%[+9W8/Y[2$3D^LKZMX^F@$IS'$!_\>MFS)C9G#P]>
MC])@W3O],53<OJ5RQ6KJ&0%O-FI!$9?8@B.+%6"JXYPY+EED!^6+V(2^EP>"
M]\3_($9&[:!6Y1MD\_K1D&]6R6$(Y8%SN067#B\"]\:EP$A*.FID$D 2MTPA
M< 89(I&"OZB=]NN'*Q[L%3YA7)(%EX:-2R6+O2LO]=-T#,J:B_-*QJ5D7$K&
MY=X9%QTP9LX1Q$A,B.-\8#\PCY(24NE@)#-KO)X'SV OU?X_+[7^6W(N=YUV
MU6)4,BXE@UWPM.#I S+8BBEAI<WMU7DF5)/($ !5S9-@ )SPOS4\/7@&N^#I
MX?%T< W8A\E'MYOP(=2?ZA GH;JHXS@4UM+"6CH4PUG(2E>H>5Q*6":/L.(^
M[T\(9 P5B&GBA=/$R3C<6.67!<1\Z^[PCSNVG</4NJ&$*\.<G8+=!;N?&'93
M N!->4"<&?@G<L#A@#GR-A*LJ#="K?4B&$Q<5+![,*'1->[H5<Z$@;)'LR?&
M'GUDPWGPP9Z'<(<LR?FJCEVG>C=O_"G 3/5N;"?'RQKW=E+][F?3?)";8HI/
M-A)D=QT43V%V8]-6]OR\F7Z*/9_WK^_?O5L2.[KH <RKF%+/OE3-SQ=$+'X\
M[8AZ;N'??OON]ZJ>5+_!7<^6+S*J/EQ="9_6L[HCJVYBIJC.#'<+]M*'4D%N
MW48J8K'"2:.$@\]\N1QI$Q/*;7RL)81;)V[:R"AM9"QZ%*UCB%-+<H\?CJA)
MRDL=.*;JIHW\N6,K[X3T9WM>PQQT)K']8S$S;Z;-F_D,3-M;,(5V<J,MVH.:
M89X0K4Y@F@Y.[M5+8D=G6\\V,,37BR'#B$-L+B6T%Z;\4Y5E%[R!!7U\OF#2
M=0S-MUS<_$K$)IE(T=;CCLKF*_>O/M?C,<@_R*EOXI*"Z#\L&+?FHB*7%%;9
MTY@$VW-*5^YB*)*;@L.81F2HARB;L A.6A (4^X%$\FIM$::FRBA.%F*='04
MY:8B2%NCD4LZ>"-YH.R2_M1^JIM'\(1/8!K';Q<S^RXVV=6V'^_MRMW%6D<.
M+M7?+8%Q312O ^;_O2'Q61H78CJ]:C^_9+^JS\YBJ,'G!=2$=P1G/'^X0MN1
M&>?;.8CE.+9M)M[MB7DMX#TXSG6JX=X@H_E>;IJYU^!M0@UWFDV;-JM4,YU_
M/%VC"*6=#6EB1]4VF5[J1(;XK^O;5S6X>GNE4? 4OB0B92</F;I[JC6,X$JE
M!Z.O-+/Y,QE15%)"9*49,L0S,#Q"ZH0)"4ZMM?T)GDHP0@B,$T1PP3"(QI)$
MB06NE;>,\\W,[ ]1V;X)\^_I=0@=%?'21+V>STZG328L?K1-THR?,''[6;6]
M6:0LAL,0"T^(3CP:Q)BGN1B$(">H10#J JN@G<=V+4AW5@JO&-*"<OA.E @\
M$@&6P ;/;;#<N:<E%O1$J]N[M^[94;E!1GJ\8<0U9[TW2\-0"BTTTTY2)%GV
M;2072/O D1=6RZ"U-&GMC*_$FH88+=*))?#DA0 G7@=PTADQ1#HN55I3BFQ6
MWG8C_Z6CTNYY>7L!O^1]SQ<M \L<5[:/%GC#3@P[/.ON@& 0EI0IHA(\)F9+
MERQRA$?$4N(L<:W)>N,;KPBV%F0C.,!/GA2'%<<2$2>=L@DP4JSG*@^TXM2<
M8#88A.O\)PBJ?(RA<[H&0N,=O);*"(($H6 ,(9@&'PEK1+7#TLJ(C7+;T/MW
MBZ&_::9G_6*O+?+#.W?0 ;3M&!(WN]#@X#H!:R,(@+DC&,)/%A!F.C=I4=:M
M'R5YB&KO=%$)'T >Y9O;/7S%DX&QQ"]^/ _Q.G/R.'Y!?;P(0\RLN_.SR:M0
MM^=C>_$R?_KJW(8<E*ZP(]63[IV795/PZS_G[:Q.%\N7[[Z(X&U?N>F7//9,
M'WRYD_+EGCLFA#[<M=I,-+C+U7J#]BT?Q%S;S<E;,_T.S@^GEZ5MY_9C[*O6
M()*$&7EIQY_M19M)@E?%8+G&W>; I@5^S#KN<_-D;0K7'G?_W>ENK^O[5<49
M^F"?Y591?T%^P,N<9Z_]K1/060G4L\^O1L75KWT+M<>QRV]H6!5%XA"V6W!E
MP! J@YQ3X*XD(HF1Q@NQMM?PN$84]VI=]7H\GOKNI]_3S>94N6U5>UM/BF,+
MAU?%86-'O=Q9=VS;ML^RVG;1JV"E.\'P=H]+8X#\6"%&["ZZ?3IZ+"$_T2-R
M9_N! ;[%OIA<-OEC3X86_["4"F5*KJ9DCZT"CH\8=^"- 8Y.8@?%DE7: )0V
M (5HO+0!&!9$%E4LJE@X_P>ABH4M:=N<_[$%1SLW0IV$*L1/<3P]SZ4URYQ2
MH?HX"JJ/AYZ_^<N6UW\8$+6'3647%?>):11([@) N<IGVRA2)$HN$DU*IK6R
MN:BDQREGW:U G%N,#+,1,2YLKH4.TNN;N?1%<CR&S;GSQ4;!MBH'Z(F4MQ>)
M/%7EV#48%$P<Y+(73-PS)A(9C3#2HDP;C;A7%)".>V2I5U@J@1U>JYHTRGA#
M7$ B!@>8"-^QB7G$K15.>\6T72NTV2\FDA.MCH_+:!CIQ>*PKTWWO\=);.RX
M/T86X*JZG34V%U 5L[1K#HN!)'8.[*\\E43$'BP:)<IJ)BRB0H)U<M0@$RQ#
M8,JH%\X8L7XZ-RBON%4<$9? RS?1(4,909%&H:+QT9L#6S1YHB3=)TM%T:O!
MSDF!Y.,0G6<#R<Q8ZSFQB%BE$(\N'TE5&B7*)8^18B'7@@S*.3,&0HL@\W>T
M]TAK"%$TUQG"B>/<'Q:2^0F\2X'DX]DW> HT38_$_@\=DTI[1]%J(><;@!4=
MRCP-)2576/JN#*HU$:= $_))XARO<&1$,"B$)$6":$72K?0SWJM!Y>:$T[T:
MU*&HV* \U:%,2L'G@L]/%9\3IS'QR!#16N<SS!@Y:@7RS)FDH[2<\&VPJ.X7
MG^6)(@6?MQ3Q7"-(O=8$<(CTJ(\\$;:-DY"66J:8U8AB)U$NOT!6)H-DPB':
MP#4/V^EZ>WD2<E65\J'&-]-FG>[HB@RI73T4N5DANZ.1/UUDDH$/>?4?=4KR
M(%'F0RF#<I@YG>19ZIC;[CHU^3DVL9R0+"<DRPG)AY[B&>3AOX/Z^65&+F=D
MCZ<AA^'S/^OSD<-8@@&>02@G)O>)OT]HBZL<TQH8PI83DT45BRH.117+B<DC
MJWP8<,+IOB<F9TW=M8CM6?]SPKLMQ=?E3% Y$_2 ,T%>".]T0,DEB[CB&.G<
M Y!8*D*BD::X1KY+L>5)>XXT[<X1&89<]"F?LI1!IR0])0?=O6(G4MW.GOY4
M=>/ E0,%$@LD/@M(U)(9+3IDTWGSD6GDA&?(4DM"\C8)ND8R;[WD3&"%&!/P
M'1DQ<MI)Q'Q4T5FKG#CLT7$F=GRBY D#8CDCN647_5UL.F&<^+C8^&V*TWZ\
M%NK CLDP#--6%:AKHDJ+8!0\*,M>\*#@0<FI[E:^^N;HT_,<%A2OK*#PT:#P
M'M(%E--$E6 H.6X0-R(@2YE%B5%G,/'>8[K&00%_=CYG7>%CQ&.2R%&FD&-8
M8D6Q)6FM;^]^Z__%B:2%::Y 88'" H7W[^0H1=(2$"W2R $* T"ABQ810WE@
M7)GHUS*G082@!15(VY@0EXHBDYQ&A!J7+.62JL-R/W!Y0FDAF"O)TSWYXK^^
M?_>NV)W"6U1XB_9JNSPSAF?*(ANH0YP9EVE2"6*"^VB(8PRO$4:'P)40B8+M
M2ACE/N3(@:E#$FP7T4Z($-=:2^_5=I%<25M(BX:F5 6/ASI-@Q>=9X/'+CJM
MC Y(&)8YX81#&O-<I^:UX-'CI/!:5WC#%<09"7D'803@-D>61HJ$#U@YI:P2
M[K!XS'><4SEJI1I<VG^8#!:%1.YYFM"AS--0"A8+2=&5-8TB:AF20XP:#Y;1
M)62"P,AYKK2*SEN\1E)42.0&JV*#<E.',BD%GPL^/U5\-DQSYQU'U-* ., K
M,I(+9!D.A@K#Z?HF<B&1&ZR*[2+BN8-$;N-?X:L#@N&-;%IK3[OO1.6Q=2/?
M1" 7(TD4!XI4C*!/RFBD-0E($DR8"IAS1K;A[[R=0#@4/]@OO]2M'T_;>?,$
M>=[6SH8_A/B-T-%R<0[V#E6_'!6L1[Q6QG:/F;]3+H?#L;>D(+K(%$0Q4Q!5
MJ_1#52;0..FNR-AN)Q=5$WW&R5#5_03-[)=+^KUIJOZR:>7N?+T=M([@."0,
MH0G'H(#$!*1IX"@:)@6GA$<<MJJT"W/W4YQ$>+]MY?A.\%>,WKYD9%15'S8)
M@*TF<5:Y?L1Y("LB$=LA"0,L.-'4H90(R65U!FD"OI&20A%'N1-B_6#R SRB
M1PM#"Q  /]UY)%F8VXM(]B45W8+? 1UT(3JWRLAGVU;G#0RK@0=V=VMB.Q_/
MLO#XT\R0VL(7P/C-X)H9_.+B['.,DU5$Z@K:U:M\83V#-X8;3C,C)2Q_?AZ\
M!KG^T-QN+W\?)FZ>N^^=3>>97[2):1R[8V5U?_\5@&OB;-Y,X*MME>IQ#(^R
M3P^:[6K+M+@8Y)MZPQ&A%"/.HP"H#"(WRTE),D43M=NEQ?TU)9C>^E.\5),_
M8$G_ #29^'I<=T'#X]EMGY#M_=")^^KPL]BG&+JFD.W,SN:S:7-Q30YAQJK9
M=*/XQ^7\KGVA[@5W"@';Y[;0XPZ='E>:D;R3=G9$]6.9:?&(R<?>8V2&\!IT
MQ N%[H"SG&5&+F?DDC5.%PK=PU+H%N[7X^5^?2:S5"@H"QOLTV.#?2[35+2S
M$,06[1S@- VN^'/ &WKW.V?VY7R9.;W,/"USOG;6.>CK::V<0ME6&<B!)G%X
M94)/N$"AG(B^8Q=+2<%9Y$C9X!!77B++74"16:.B542:K32RNT^>_O7L3:_/
M[Y?J?.WB:SM>Y_,F7FYY(;JZYW77_B<EHW):^BCU9:OFY[LB$D<@$GN 4.X<
M)BPY1(,1B&/J $(#S>@H+2$VF;A&*O&00H "H45?C@1""R?'UOGQ\I9\KD')
MY=/COB:EQ$$E#CH*4-I''*2%",I&A)U5B >=D-'PD[*4:9>L(6GM-/>NXJ!.
MF5]/PM^S*E]>%]MM66\^*E3[1ZDG!3&+).P-,8643N,D$9-=*Q*BD7%2(\\8
M=<Q:P,PU/J)=A3V[1DPQ*E2C1ZDG94?H*44Y?W0%\[E4^:H:WX9_SMO9&5Q0
MXIUBO8\#E4IKAB(8Q<$ODG!8!U_I8"UU&E$GP%EW02&+A4&8*28="S&(O3GX
M[YIZVN1R[!TX]VS$BW-_C#HR0.>^;&%\K6TZZ+<_[78Q0OP4Q]/S[-97OHEA
MB[T8BW=?8.GH37>R6+*8$$F2(\Z412Z8@"0V COOK-%;(:JXW^GK+S_W&KS4
M\&\PW/?D+ACMF$6\J,H16O B"4]($O:QH2$<MIG=AS$7$+>.(R=B1(DR00E-
MTCB_KWAG#Z!)1Z2 YC&JR@##GK*G\?7.IAN8RTNX4RSW4<#15K7EK[=RO^VX
M/,QYHBP1R'BM4&ZJA(R1&ADM@\78FJ#6?(-=!52_33,CQ1PN<^.X((7;S);[
M\[2=;=UOX$<8;#V4<?IO1ZFQ!;L+=A\1=@OJ>.[ZBBAS,9,2YJ9+DL!3E394
M>.WTWO:Q#HS=;+1CMO."W<>,W67/:\N0^.?$PZ!LIH:U7ZKS:5MGE2Q;7<5_
M. XT.@K_@6B<L L2><\8XB;[#\*R_$]P(3FLU:-:4]E/=7,OY^$2+>#3=TNL
MV+J/@(^P'*;X" 6?"SX?*3YCKAFCF"%%(\F-T172CEDDC+)<YE*'N%;L\"WQ
MW>#P^?A.;Q9\'G@,5S;P;IWNWV>GL2D16_$(C@)[CL(C<-A@1JE"%LP\XKEC
MI5&,@K&'X"L9$4C:&ZE=!P^OKPXI[L ?.+XZGN(/%'0NZ'R81K]*1JVQ151'
M!M&4" @"*,!!08U6*5KLM]+6;L?8>0=D'E\)0]&/849.9??KUNG^N>O%F!LC
M?K+C>=^KSN9V<G;B"XGWMFWVW23]SP^UGDKC@J.(RJ*R$%!Q@6)D G%J<6Z8
M:Y%5"@N3A$MJC2=W5U%9#SUO)[_$%)LF!KCH==O&6?N?2R1ZO02B[1^\X".Q
M6_=CD*H^E)CNJ>A\L2#%@A0+<OU8<R#6>9-0(((C+HE'FD>*B(8'R!"HCVN5
M&+N*30]J0<2N ]A!JGJQ( .R((/;1[R^*AM[WAY<9A^Y(A^F,SO>9F \S#D;
MNN<SE'D:E.NS<5*&@8-'X?L0$Y6AF"-*I$$\>(Z,X E9X@C\14@BQ.ZBYY_A
MOO5D7D\^_GX>&[NKRJ8=GTX9IAH/TZUY+OJ\W39?PY2P8B@&L[TJM>( R1"$
M>N\0MQI"6*P$,MH'P14\1:O=A;"/A/$[SA;NN ZEZ-93UJW]-Q:#GZT;QQ^7
M4OG;_"PVM8??0_UI2%'-U;._^KA[BQ4,-W[QXWF L<-0+\<YCE]0J)O8Z>9+
M6)#YV>15J-OSL;UXF3]]=6Y# '!826W4_8.743W\FJLQZG2Q?(/NBRA. HCB
MESP4^/[+2ZG\<D]9(_2NT=\^V5="_1!YVSSY7Q>_-VA3$+#+)U)\3>*S /=2
M_L/I9>;EW'Z,?5(%S /,R$L[_FPOVE<OOK\F!LLU[@1\TP(_9AV?J,;TB/#]
MJN(,-5'T$.E9YJA7.JG#JS815-?WC=0G<5;%SF5HJVFJ9O'L?-K8YJ(*-?RU
MB1,/7W!Q]CG&2?<%;YOF D2DLF?3^:3_ENWRWWT7PMJZ>ES/:O@:> U5JB=V
MXN$=X:EPYUG^)O@:Y],V]E_(]US>:IZYL/*W5AJ_+R\>5;?&WU^;F4MW;&$$
MEL5N#!O,N4*8DX0X"1!4$Q%0,L(I(6P2>"M!]7M_&L-\'']/:]L%N6O1U61]
MR!;K SSLI_'4_^M%%<$5.X<;S9KYHNH.W+<87L_N^_;_3?8H9Q]@$<\;6+7Z
M'%8ZLYE-)W$A''F!,[^%G5QT'2G4JQ:<RX5<YA5>2 _<K:W;&?QQ\:4TS?LH
M&8TN-?:F/;]2Y%5S=S^96,RI72V!O.^\#@P0Y3<MUAH*+MVFSFM:/G+QAOEM
M7MKY;+IT./-+Y#6!=\Z7(W AIG-P!NHO,;SJ'T<P'N'OEE\ N1O;\S:^;..Y
MA= C+@??>8O]O5]LVE#(?7XZ];AXN;S';3L%W6.E'!G#OLMF[_:+R$C2NRZY
MZW,ZTOK.YPSR/1Y7R;A)"+]E0V<A$%D[-L8K@RFIW=L^1)F1RQD!6<N?_ML+
M^>)QL_-4-FGO:X\_][KIIN/P39Z?CV<N-A4C)[N3Q*<RUP/<$-\6J&YA898*
MO\MEV1RK[PUHGU"QRQZAEK[8HA0=+9123-DN96P8<SAX57PNTU2T\UNUDQ:Q
M.V!%WY8=F&,XW_;+AO367U<RH_<JX'B.L=]=D/<,E/%N$2B34/2@B,"SF(2]
MG3SO1EE/0M[7)QSN^I 3UJM;!MU-5N^*;^XN/0E+_K,]KV?PK/\%8][<TJ=T
MRX4]1XELWUKR=7 /\/ZC_\M1$FKLH2+2*<*%(P%1GB+BCBCD'/4(!RFQ%M1Z
MO4;6Q0DF%"N,K$X$<<P9,I'#+9RG05G+/+U.W[FV[?YV\JZ9^MA>]M=[/0F_
M7"ES[KYPO3+RS_>_7!9&LM6Z2'1G820[D>;X.#L/7/A8\+'@X[/ 1TE5LDY'
M%# UB%,3D96,(24H3I@8I]@:(9?71CE"'(J.:<#40)!1WB'K%?9>PE?)</"1
M\!.&=\R(\83Q<6\';8OSOWEY?HNS:MH?EYA\K,;3MNVK'T&H/]LF;*U;2S%L
M1Z&OQ9[=00/E*/944"1B;J?BF$1&.XNDU=0R3J5)]C'^_K+F=LVD_;[4X;^#
M"O^\JL%;,F3FA.EBQPH<%C@L<'C_[B4V<L>=1\I9@;@W$KFD-:"*D4DH1[U=
MZRS\+>[]X>!0G B#"QR6G/XPW?J_USYW7ZWLQR;&DL OAJL8KF\R7)0P1P,5
MR#!&$3<X(DT,&"[X%SY1Q$JS_;S]0FM?+Y5V:[9*8E-L54' @H % >^+@(PQ
M&Y(BR'NN$(\2?#*%.=)&"XP]I?#9]C/S.T) >0)H7!"P).&'Z:V_GTW]OY"S
MF1H@'RP'%>B.;!>354Q6,5GW-EF))<IXQ$A@9Q 7DB(3M$64:9^PHD*9M)/D
M._RP_-NO7[+VQI]7M/CU)/P4)Q%&T+X_M4W\*>OYZ@5YOWE;V\WJ1.OC:W%>
M?/T"G 4X=P:</'$JDB!(FN 1MP0CS61"FAL=I10L^+76 UM)TP\(..D))65_
MLR3T!QHB_'%+87[E07= 08K%*Q:O6+S[APHB.:JB0,$PB3B5"ED5."*:*^$2
M)ERN6;QMA0H_=QI[;5-ZJ=U;,F;ZA(ABRPHD%D@LD'C_+4_+?=0AH.  XSC%
M$IE@-0I$)4.BM]BOT85N*PC8/22R$TUE@<2R S!,][YK!E\,5C%8Q6#=O[C4
M1:Z\]BCD5E%<!(^<"!;%P */QH(3O]9M9#NU]EE9MW8^K.Q+%]PKN%=P[_YG
MC&+ B46-O&* >X$0I"/GB!M %:/!Y[:/JLS9"^ZI4CQ?<NT#=<;?-?'<UJ&*
M_994R:WOO.GL0&B)#VS!G@I1YU&TG#564ZJT1L1R@;CT AD?,:)<6X(]TU[)
M[5?X+Z!EL=G]#8?1[M=D5IH=I_T'J;;#[#$[D,DIT%^@OT#_=>C'E#DJ<P@4
M&>+""@#T2!%QQ#FL/<%T!Z1#.X9^;7:<2!JDVFX=^O>V$_*06.LI!E-;X0DO
MT=6SR7Z4[-]=#$-29TY1%*3SB!,2D2-2HQ"<D9[)X/0:I<96=CW^O9FVVV+/
M4/R$J++Q4:"O0%^!OOL?2<::4FDP"M0"C-E<M.D!^@#$DA:"F.AWPR:T3>CC
MY(2(4HET\,V/Y^)__SVV[<OJDQTOND#;W'#:3GPLQJ>DMDIJZ\A26RHP%[4%
M$VEH[NZN4^XW8)!(@49"DJ+^4?T&;C61_[D$F-=+?'E"H<(@U;;L:A3H+]!?
MH/^^T.^M,T9KCY)0$.E(99!Q2B)AG;!&Z$#4&F7=5J*CG4'_/D*E0:KM\>]J
M7)]V.J(#G/<M=%8(>][\&.:T#MU8#V6>AM)]Z!ZS,PR[O0>K&I0GTG"'N#80
M4($A1<9P@HB+EB2/ V9KQ=9;":@ /M;-Z)7QQ-=M9ZJ_Q(#^-S;3K"^:$OIJ
MGW9S*!HT*']W*)-2X+? [U.%7T&]BL9:Y+7RB"<=D3:YGXZ2VB4;@K9Z)T%-
M@=^!; +!S]:-XX_=?.8;U),^VH2_A/K3D."T>[:$1S]F'K8\'+D\D?/XJ.?J
M7>X_OM=MU<3_F=<Y!G(7U>PT5A0358&>53_/9QV;U7],75N]]K.3*J8405D^
MQ>H_+*QR<U&1$[B>TI,<0)W;B]CD]G23:C*MQM/)Q]A4]=E9#+6=Q?'%\KQ.
M]3]S&&RJO]+.NK\TU+,Y7#'*;[.XN6TBW/SSU4O/IO# 97_L[C;V; H:";_
M8.!A/C>+K*:@IM6MB9^OS=PE\OTV/XM-[9=L',Y03UA V.3..9)H9!,1*'(6
MK4C.!+.6S8F:NNB)0<2F &!).7B@A"$1#0XD26FHN%:C^I7VEZ_[47::]@[>
M:QJN(1YJHW\9YDU.!;1QLD>)2ED\+N"UKXYE79N_'S>MPBY?*$_+E:#!W\/<
MST!RZDDG[G^^KZ;;%0T1I24A05#!<UR"F0'12!X9S&60/$6PF#=%@RC'35 :
M!1L[<0H(K"I%VF/AK8S,W2A??HJB0<23$ SKFJD-H[V_SE%;F6FJ?HD^GCG
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M&>=1[&W ]W,?T77"KKPU[;^?6I%OV%?[)K%.^TH- 5JG@R!B% 2&\;;%#H)
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MS\=+5QB$2_7WPXF-9P%-,_3T4P-RH<!0LF?8U4W[#$>$\3/E9P]F5)W@Y8Z
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M+2-(FQ^?G^@B#7[H+$F+<PWDX"YT,H6R*B&_;+=!Y+"](BGM%)F#2$TS0Z*
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M7H*[IR")'-^]>^%G,!0AY__P'8/"-9S1-7',YJC/3QFJ$N@-$C9=8D*(A5S
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MJ2M@F#?;1&40[94ZKL.Y,4-[1#PV>(]U8(1Z&-3J]B->@/6UO_J7_#*H_#2
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ML"]*6X_GQBD@_#0%652WGY\-0*K37 I84R_&DFZ^EFD050"ZV.MW5"@7< E
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MYR8. _L]@D+!"_'D;>\"<2,*?((^>PF[@KV3=39CSE@E4X-C.=0ZYD6HEX$
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MP_D*Z1-G+8WZ_$+CY;IG1GR.+(&0R!DQPLIXD-&Z[Z#"VK=PJ:-(@QG\QX6
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M13TSWS4OG:Q J#HB2RBA)[LBV)<M%*F!62^<$#@%B"LBG41DHZ8 *^&I*7B
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M'1+5(YY>6I\#YT598SMURI#K=AS;#.NS-@N%'9[9(A$/(0,1V0K6 50#\P/
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M^5,;N=D/%#^-PDPB>5O,BAEE'FX.+IT56^4QQP+P/MQ;L6A0)&=A2?$8C>+
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MR86"6#J-XX# BJ[%9$0XF'F!050 2#JOPT!L"KJ_W1DJ.>7L06S:F?Q+'TK
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M+&51J6GIJL2PZC_N&UJMP1! X**B0@%+\/VP6@LYDA,6M2I*$4' )K[D^'0
M-ZI44F%&)/M5R+0\;!96P$HJ'/(%#GEB+FVIRL+7#YL]=<GN'57X O5NJ^P
MSGF5(MQNZKB0<<SF.?D3>([%3#\(<Q V2]2'Z^\T78I<59B7.25IM;YV$\C5
M3'F=;BHQC%IO#[%OTR?/*[].MQF>*OX-4-L"6DULMO3L15C%+BWQVR*VR76%
M69=59O$9E$7/SQPZB\E-,$26@XC+0I@; 2EA+EE[="I"D0 2%EH,.%LT,+%.
M083F6!Z767(E>\^ZL-(1FQR,,%\\0D--.X]\;A7$AW:2Z S\>$5>L,6K Y=
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MP5-ZV+/W #?%BJCO[O9Y':KX/#I?(.0TU-=H?^D.)20WW,Y.95O.A*A8Q)-
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M;TZ"PQ9:9[.67A,H:*S^TZ?AV?T.65V/R(LC+P@#(E%6X.2+=L/B\TLP^9"
MR6<PX"$1RQ5)_DG^]H+S K[J5#][YM3A]<OVX(-_H*4R9JL0Q0HV@9@Y)C*]
M@* A?&%)>/K)*!9WNYSLR??[ T][(>_(T+4K1F//TIPJQDB45 .B*N3,4I,#
M5GVU+@K$%7B5P\2%,NVS4GV.CSZCS$ *NH%_!*7<'(&OTJ?@+0K6@0?.DK+0
M&IRN (T$1Y-O-E"!$$2F\F.. .' /W=(' BY;16JZ,7@)"L_2FNSZGDQ(])
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MW%3?LH*1@]"RI6K-D &7O[,$CR4(K%PU;MQ6BG;+$Z 1.RN8AO(<LTZ]K=C
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M\C6=)HT20%;O<-OH>MA6=U!+B+[/\GM??)A,CG"C_6(D/"-\C21NLJ.[VS3
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MT0N5?6SF^S\*)IL$"]30*SKOZZ-@9/]@!9&]HO?_F-EF$$E08ULWU_PQ\];
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M1F!MIDQBC?SSK.BWBAZ1AWF'%24L\0?I$M%C"@^*B*@E3+X^8X7/OM<0(_N
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M0SV-8!$@2R\)"$S_10$UY&DY1CQIUE@-NA51HR7,]9@U;NJWIEI%"_IY)8M
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MS2 G?0YXP8YK?+8 X1MYD.%0N4.FRA,R(W%&. AN1XCL-- (J%6]D/DR6FG
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M&D1XK2[* 2OB^+\W:20/Y4;O(U-(_RT@Y8QLKX+6,P8 JF.0^LXI595J)GU
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M\R, 2504(D_]#[3W_M__!U!+ P04    "  1B%Q8P*O,Y1$?   @\0  $
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M^LX9[NOD(J1TYJ4M3: YQUGD!SQ[KF*YH:>*Q@E'2U0 .2@AT @NZ%5-#L=
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M;P&7-<@0HS]@,$289H9-5@(>BULV$$G?;N&1.V$P"B:5,6WME49WD:,ZX3"
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M=U>Q,AUO=O( M>T949T[7VEDG8LZ($&W0+EP5I5,T7E>4@RF3GZ2ZKN+(S*
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MJ2NWG4<#V\(^VXL&KOG]"U!+ P04    "  1B%Q8^T73M;$"  #/#P  #P
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MCMO T7^RX/@5'2WH^1<S=E7JJ0(QAD[ B G@$!H#6:D=HU%<EHR7,U:7SM2
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M%Z/>J&5G">*N5>:&MCN4/P;E)\\6Y9]7(/&3:Q#<E'D4"$V>2_P88'+)N(4
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M#+!'$[(,:Q!JFB;T383S$PUDD25VU2?JK"'(#^_:[8V(Z[H<'!XN=KB!"U]
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MC@L5GL3;I<$3T&:ZFO7*\LZ_^CR(-SC<$L@[P6/:W#ZY;H.N._SSJ11ZP<6
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M9:SA#_E9C$CG"F7:0).Y1L/II?J\8E%TQ3T,;^TP8 _OK$V@$@RGB%8]/JR
M$JO<*!A]K6NQS?TDS#SEH:)!&<H3"6(E%'V,8 1P?>D99.VEX0F-XWZO1<HN
MAUL0O J97:;U8H(NQNC&LIO=C/ 63M OZ+0JWGBX^WS\-?H[NN.';U?WH>MV
MEAX!!:QQE83K]';\[Q0L4,\2?HM+H$E:"$QB[63L#_X->Y,8E3_\:-4*)L2(
MDP>M6=E@?"*WUU5C>RFKS0Y+Q%/C1@M,U2*67[:0T5]&.Q@-G7_"9!>*Y5S
MY0!E3C(1LOW\.1_C6G&87Z6I#R_*S92<T"0%-YLR+MS(,1D6W8=F'!\V$TDG
MO._P::H-9"CG9+HTF-57?NRTP*$)<B&>"680?3K ML5[+J0;C5O!PS9<(K[7
ME"M^>RXCF:4KN0I,9+DW(<4ZI9493(&-74%7T\%T)"-2QXR2<)!BCD[894RA
M%J)9_FJ3R2DTXG6*$D2VAB/)^&::J]&[RT3BEDO>632'#.AXL9TD[X6=:,""
MSL,I\G6E=;^QWB:@\)_B;?;=ORO6SL!0QZ,]G#-H;A8^.Z^](4;O>O>>.G!6
MU:8D#QC4#;2\BS?GJP]D"I>3B-6-NGE-:XF)Y;V427^ILYR6=?I  N/8HW)M
MQOG$XD<4YY<4W5VS#<>UW:,G6]CK2IK4K8=>1D8G;M'6OQQPSYD:&\U:J0K1
M5=LMQ;6:_:V#H0 O)^IN+T9JR4#&CJ.EE$+ QF@@16:T0P0;-2HU?GU&W2,)
MDO*#^-P)]I>W9;">25XW;V0[8EHT&0_1<BZWO8H P'J2[W&(E 7IK<<P[_18
M%5AZT]3'0QZ+'\?1&C1AHH%-%WTYK.1R5C2C+*>-M#_)E6B/:6IRALM^V0!H
MXU7[BUD?'>P]&,P!KT64MSFLQ1L_)\X0Y7HQOW#ORYSEEM8@RHAXIB6:^I!Q
MU;.L6N5F!J.EPP>GDINUNXY=*A%2(51W8E?I8)'Y.);X<Q]-(I%)?NX67P$X
M:"B$,6,CLKEX'A][H]O]@$]XBM%_Z<% >L(MT1%;AZ@N>C0BEC"TD2T3M.U4
ME/5U3CX1J0<A+>Q905VWY:C#'4N9\"DBE(3"'*6KY5/BT7NH<-S*AFKB2<)-
M'T>&)<XQT05:W=J7%V6M.1T'E74X.M<RO:9,;Z:[&X'K2DV-GUP67"A6*@8E
M?O[XL412TS95GJ!AVGL*6"KN,6/@<5K@N&+XE(MWQD?7:Z6-Z%Q,@IL$,SH)
M=4D!KP)7NX<80R@,AITB)PJJ8398#/1+_D)JI&0)&G&>-!/LKL+%F*;<O^6F
MO9MQF_#<2SQ8D:Y>4\R>&IU*)WF%&?;>EO*AF$=2JBEAY)0OVZ24$4=9C=,
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M4^6<9W<X]Y.N*H&3"K+9\A_N[BUNR=<YM@K!>%$:UWQN5>^P)5,G6I3J6D9
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M Y-I<J@[$-\!<=[I%CQ1A45@2(#=72%0@W?EN?H2\QWLS2RY#&O%)A0 +0*
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MO=OZ/[;ONY#L],YF@T[(KY\GC*+;3\_(0U;3.LPH2#IK,K((P+N^[.6O=CM
M/;=AB%W]ZZ8$>!,KBUWZ>]MWC:E^4R#@_"?C\+ZYZN!WSQ6[1-)U!%^=[6ST
M:&EYL_M>V,[L1O#'DL3P>]0A,UZ$!9,?9D]9+?<YKTB8.YMV][D]8>QAGG]%
M()_J.)(#9?5;&]1,_.RE6UH_#-T84908*+21*!,PM'GV42LIM8S.6RUYJ8+O
M9L8.]V*3OH+$]E#SB4^<BW7AYO""F/(+%'4&-@4/E[EDBTK:  E[4CBH^E0A
MQSKWR,,3)U1?<)^9(79&MR?8<01MGBE<L$WT91?9+%XK--\R-LZ'KG)@H]S"
M0(XUME)S#[MP\5CL8\1]CVW['OPOKFJ: 58"AR<' 3.L-_IM]^_B% 3'1ZVI
M8\C%:=HOE,Y(-U+YM8F'CQ8.K\WROI/<!2OBZTTL>YA./ZINT VX1"&-]XZG
MTR^RVU*/0"R],N?(KZ$5)VUTA=/^"M=E#M'^9U^D47 CZ>('4;FE%,#1_5[:
M[C/@(E)]CB=\FZ]I*WCT]1E7DZ79B(T5V2!L]EUD:)\M"E44*?.[9M7E:%;2
MQ]H<H(MS/0047B:VG0,TJU0$=!(BC7+C=,6M)_>MBCN6;'&?FHULAFON'^38
MW:5D[;8^,V1+:!^Z6587W!-$IWQ*-EZ*@1:%T97BY2MJTSB'"76:NKJ#MQ7\
M6'1:-/1F$O@ZP[AP=$&\'W4B2@P ZU%RE&A<9D&FG&L-7QB.$TK_YC*]Z$Z_
MR*@NFBC2CB.1B90\&S*[8C@_.$D K/_""HDJSCR+AM/S=.$B(VO*O_;>BW1-
MS?DB<P.X+M*U6X87F=NO7:N<["0KO]R*<U].C."7?O["7\W7SI,R#3^/;HQR
M>!G+7#7<9\WSB;8:%-OZ5HWA2;'RDRAK)_8VH0[>8B>W'H;/,#Z\_9[1V*N)
M-B]OG;B^J3-P?3MD7*4X^X!P[4E_ZO!6U-)Z*^E$C<#.YQ0$H.Y.GM@QD*5!
M,!<ZT"60<5HAE#=3E476E\1UAX*/I';-GB)2=%%:=173HWF(S^[Q;.#-XP6Q
M;BDC*=D!?^G'O.T/N@GOX]>7CRK28,=,/#S_7%"Q>, =<UGR<GF!!YE%OHNF
MK0>EV?T73@_V;2%9>H4?G1E4A'=&XV4Y.#XA@U'OBPL1LW].VL7P_RS>?4O^
MA;[7 KEHK,T) F>,HC3U_3Y]!Y!RJ=*NT09;^B4*BI4U/7C,%[GV<EV<#==F
M[M7IT;XR%WL<M0KI#QP#29F;LS4ZS&C=3CT!D%'*LJMC5K&/6JG\6,9[,MXS
M5DXFU;L?UP?E0N6F4;R+Q'=(7Y]GE9X^W-LP,(],88JY:U^S>%KG(#1BIIU0
M7V6=(?+4L8VWQ% /6G8+"SU6<'X^'*"X&>/;.>1%=Y[S9G*5SF:WOB^C(^O8
M1V&C)OCN7J4YQ<K) 'LMQ8&[%QL"L)T\?X(;:=+1EE)]._YTFH,K>3\OSRU.
MJI]/CH;_9-^XMM[ZW<Y+D]IY_%0C!_MN5MK#6=<GL+65]<+R"([9*<EPM5/>
M-C":/_=5S!197E1VGD;#T6$?F@IX_QZHN/!FBFMDQ%V?3='#SN>3[BOJG*)4
M/<*'!\-PALIWO?LXT8[..=!JHG5I-O2JCU\3;A>[58WH%9E\"8XU@:<*)=8,
M7',N]F&PC;!ACM Y!(#K%J1,2FF0<Q :E=7D3L2$5L26JIQ*,5;QX9C/VF5J
M5=YR1,%?:R'DDTZ:6X@)RDT0=Q$-9IUJS9&YL^/-G"L[O#N68UEK^@8Z-_)G
MWAN]%[\:(VR4?&:O?RDH_(PK;PTTRJ_3S&,P[QL"#63(U6  ^Z /4:6$&."6
MUB0,>YN;]M9(73^/-0G$1#>]*=272K*?$E2Z2IF=YFA<U).C:Z6Q9NO^.'85
M;J0^5OG01SF\<JU'>("O(;#CC<4)S;,A@REY[NGU(F[Q:&&)^R5SKA1M>:W@
MG)*1#<[RFLF;O/$<[ SA*OIBVH2MXIR"#,7MU,-9I&BQ@V?D<2?E7>NN_NBO
MI;QO/;RR9&3RXGB")_Q5VYRN$&G\>6CJ9\MDUZ0#:5(Z'IO)<4F>L$0?YS2)
MV]@[1>$-:S#.0W,$,,HZ"FZM%T( 1;T-DTBO,TVC_MSSI?-DU1V/.3.+1.II
M&[;./;E[;,[('C%1"_&J18Z2'/4M"?HLXN8[*B'W9)FO$JOFI2?=8U-6(.Y3
M("9BSL&VR,&^_##$F5<UEU''+GL@ +U8@CF3.-U?:_6GWHSLK4O,J>(!%ST_
M_"SBE^GQ# 'L]%FIL=^ &76492[^_AVO&=PEN'3T^E3(/L< =,+X_+3"! Z-
M@(&6ZCRLW4@\0/["B@>Y([)UT8?+(+MUGY.(&=&Y8[4R;UK%5V.?/8KZX"GS
M+H/*$C*PM(O0^;5J+=> 2L#S+%!@OPCAYGK@*Z,?&6I"M!S[WBTH]H9T#4VU
MJ580C>M)CA"&D]UA$[D-UCE84MA-8.U(_>Q1\+;0Y>.X/'R41T>/(M6/\M']
MG(4V!46='?ONS)1B&^ZP>A4#'Q>8"*[PP[BR4GGO3U%2(4W])(/!595H3G97
M#U'@._EMS0(FSZ*PXDK>F)"$\DW$Q1$I-)>VC]Y9]*->RN1..4(I0G7+KR@G
M[3\S+)B&Z1.HW-$:/TQH^##_O'F8ONH:'X[6*&3IC0F88">O\,U\BE*(7&BY
MIR#&0N);@#,5QM?U-E(49M.@?KT<%B\ZGC6M)=@3F^QEBJR):,"R?&;ZIT(?
MMYS[-\#FDZ Z0I60[*H9I*Y$<U>H]/LW(DUDGEPBQZ&,UMS( 3\[^X#3G),:
M[0_!'^I>AJ;I7H*4M]UH.\RBLH=A5*O%"DJ:1.IYY'5Y<V!#=0H2'"(R(9I%
M7]S)0^R?E*GNFRRGA\#PE?Y/ O'7WPL96JAT9Q7]^Q\<N]>8T50\:V6M>*/O
M^6%.N[J_,*.2])#2N;=2:O=P4^]*QZ )0T,YX&X83*6[(YHU*R\EUSNV.S79
M/SQV;*.,U_!B_'.^ 'LLK-!_3R-"?\?V U3E.O]$F]T\VJ%N)U70%P<0-@P,
MII)C=;0%@]&O$,F$,S<5*AI@4@_>7JY6;QBM?<[]D;-D\U2TG<0K:=KS$69G
M\M&:[ <N/A%-#0'*F*2#9^R\?!4O^0MM^K9K"+H64*JKZ'"M1L8X@V&*^&-N
MZ6W-.FK#FV_H_8C'6#C48N][!WT"#\6+W]( \LCI#_-==/CCLLN>&V>/CL5#
MALGIU:;W&Q?]:-UM"RQ$67;>Q;/7P9/,LI=+>%TBXS/"=:M>HV'%M]]KO3,/
M.QC: 7,&>VEFN4F(>II>1P J%'.=JKO(!-N].!)6&,6)[>8PY91,@R8;;O%9
M2#K6/E"#VA^+FK*!YGFF0+2!!!A5_P$0:Q:&^0+?[W5>6QW@P$$HROMA@9IG
MV7K1;P#5@/7=&UU%@E (R2HEK )5V\8X?(KYK*Y>EI/1G$F02:3 ZM77_,9M
MI,UP_X3LM!0!K,>LE\\9TD!&E@TW>Q! B5+X8_-MLW-GX<"7*BHA&4TFWX*%
MT$7O>[RY$4Z<_D(EY.&W '4YY-9@GT)J[/>01*P:P*MZ$7Z$$FX-$K'?4;5L
M\M=*?ZF"K8P,;S_U[+*(_5\J76NZZ(D%J83(*C^(;(I]H=+[/?(1L7^-ANQ_
M3^D@>I4YF0?%F-FXU%Q_=(X6]A&FB.YFTO';4)'J81B/39CH,GSG4"2/W]EH
MN[1Y2"FHZT#HG'<RB7]B.H!,%S.!+-MJB%B-SI/D8Q0RT/D%Z(2>JPSI7*1J
MJ9A_=LBG1J;X^&VD@ZHQG'0)%.21G L6F![U4.].?7M<A&W*632WHJP\QAZG
MP*&JK%M*NB976LVT[L'8G')L8=AA.)+2'ZI/H.HK, IO,:]S*0;:FSV(K%J?
M%ZP*:.0H#5(IRH,^3M=C,N;!!&%0^]S1LN+?.$RFV0P<<,_GX8?]M4=&R_*G
M\BDQ&<?@HZ1]5LT<#Y>Z.L,S@L960WQ#PKTU(J8RY0"ZM"P$\%1'?$2SAFD-
M 8Q J?0]9>O<B<;@%)1\;#.ZJ32*=:JU.^@*[Y8>U)2\+-O)3#9)J1Y=B9B]
MLZ*V_>JWHH:NAD'9;/;.V.'C&R>$D"8>NP9'G6HZ P@4)]VJE_3VJK),I;7H
M8X;(97FKMC>6 X9\+UU?U'U<XBHP#7/.UEVKUI\<+:]H\)=IE6RQ41P8+EAU
MLRW90"8_H#V&\8<>!?M'&M/V/2D$\E2!*7*!9C0^78(/X!CE,%C_AOY];;[$
MNMIY>@0PK4^PI+F/61/>JEERY;4O=[W]-9&]"*NF[<6ZW#6R0R6]>U8'O6%4
MH0ZRI#"*-65<=A82HO"M:L4=#;.]H2)954_V?4BTD$_&]1"Q-$EB0.02NX=4
MXM?MY:>S'PN4P3_9@GZN2YT!8MJ72AY*F*^/(+,WLW)7A";B#F+?3NF,R;N;
M+12@)_"RY= 7"^)7WF'P9WW3=R8#AM $E#>W5R>U)L9M83-88]E=QHP,2S01
M+*2<:SR9/J/G!X.M\@K'J'+/HEEFM1Z9XV;YC??%!"JBJ[?U"2MFKHYQ9.58
MWIXJ60[.UOOM4([LQ1=_K617 %*3'!B;(11\YCA38(V-9V6M?%6QTB%2VL2K
M"OW)T]9-+)$"T8$6O%RW RQVSGY](FOBJ4(2,?;%C<G*L/ [[X4]'E5Y"S3Y
MW.R%%>$8BF>)>WIG\O5W&8VP!#Q]8[=ZS-JXM'-6MK1=7U6PQM/C:(Z17.%#
M%]N1<!E%.MM=[E*CH#!U%,;E+L!I3.KYF4"1E6+.2L(;33+IR[M-)9MHA?UB
M>$>/XC$CO#@=H0C Y,,;L</Q W24=[$P@N>9IVAZ=$^]R(JTUZK-#\H#"XNU
M6I?CN,%<\NCN]QL8[PI<$OQB'LZCHG4DU[R196E 7-6W853\MH&,O8#]8\6K
M_)9Z+?BV2:)IGPO&>4[S!H]ZG&YI<2QYX9N,*#GS)#.+!;4'I6^QL'W=&*(\
M-5Y."?65U=')O=8:LC:N;G@GH_I1!IN+WJN1,$8O&<<$QA?!$3J+Y0RBT&G)
MRAP6:B9@)+N_0!PL#$W#IG47.4+-;9F9)EH>&1,Y3WZ.D;HD'O&@*E#W9<3Z
M)E<L4U+G*IG@HB]?+==<J)LHK>7)4@C?;S),[E<^FBRT1_JB*#DVTERR6+W:
M,\>)FPDGW"'2L8F&BY*RC_NN/J55@HGP'(]<XO05EJ,+$.:;;['CA%54$8WK
M&-ZH?179@1NUFQ%F_GFV)B*HFGTX-$,?NI&T >UJ&7BPXNX5I]"<_WR\3VR)
MAD!8"5/1C'A;ZSW)4,^8#1&?MOGGJY^,!*TS_**[+RE*$#>3_!CF-4N&+)&A
M -(HM<=+H9&S03_CJ7=,^E)SN$RUZL-YTOG6!_CE7:.LHC>YZ;/P+OCA# )
M/Q9]J3D$4[:'/()X;B, ?Z_T6T/[9L1ZAJ.0Z3/0EQ26$&5#M3Z)EO.X<P1P
M,;\QBV2?CU@/5-+0< 1Y+ZI#O'H2'L+!N9ZR!:?;5HR3N*,Y2(R$,X5 OL(U
MWFJJ3PTZM\B$U$^K(F$BOL'L8>5H#J@AQYD@@&\#NQ1(8'5(NI^GO]+E1=*5
MO: ;^GV"V1W-?E[DA(>0@9Z+OEL6"<S[8CP$MO<58/Z6A#>%Q-W04QQXL@^2
ME20)YJ)TBXQ7H+<-*TM?19U]J=D[J/R)<YWNQ/V"=T_B<ICXM]LX@@'G?@A
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M7^^([PBER #:KW%ON_YY-#SH7TOX7U(>NK@3ZSC] W6P56LWCIS%K!]VIE$
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M+0W='CYRC^F'[*@U;#\]\H0CL8\I%>$LH?&U05?/^DZGCVG%)3P.SZX9T"*
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MN4F!UL;I(PT4#9'0J(QG/12]J([Q.'$_ DHDNH&[Q<*+5IN,)7_SN7_X#K#
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ML5QWL?HI)D[&>0^$$*X(@>,[0 [5,["+LB)2]^SZ RQKN"3\8,;@*0%]O*D
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M=X]7;G9Y <?!%7H\^7.Q.U+J3N#FO;FRE2'9/P25G7O/\(,Q/XY6ZM[&RBK
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M<E1:FHB^L]X 7AJ@9.O]%JN"X>TUZ$;BO!T^];Z9?DU03ZHA^:[3I&F:8V'
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M!=Q4%EL^U01<A,'EAW1^\)UY/@4<:#6V@3$TY"8=MI+/OA<=9(*8DMU78*?
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MR9*YD6MDE^-I@\+-_.5KC-*<@JEEAIJQ$"R]^OF&F8LTH2N0^1)E?>#"H9Q
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MK"=:H+LX@C')_%C5KJALJCBX_.UEAJ,A#VJ&;L)AHW<!:4%.']@ZH"[+YKU
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M659/!-+W+TV%+K96U=9[N*'I2CFQ9&!N5$#;?46,-S:BV:/E&$*F#JG\:.M
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M=#=<;IHZV3A2\K*Z$8( 8ZV<P=8%0D/%]=GM6+5:,HROAV*85%C!*&*2IGL
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MFW];0.H2SN\FJ$G^NJ826Z"F'+IN4#&;QNVW77@+O/(5WNO-[REVGA\:W>@
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M\YP/WU3B"T#U#Q;XZ]-XNKZPX_0STY8[)2?-_+W7JZXJ.;N+Z0XKOX51.5[
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M+F?>AS-O &%?<'Y$V\.K7RM0*+#G,B_+>SLG%V02VY0GDQJP*:4*T3=S$*"
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MV9+HKO#E(T!,4Y#OUXV7%=-*<7Y*V".@RM$)N']NU+N1N3Z?VJ<;T F0[>U
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M+?TF:\H+Y$KMR T]UB,/&%D5'^CEKN@<6-3AQ]K80!MW;O"G;X7^>8N6"5C
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M@LG^;W?B_W7\8Y)D'F?^!U!+ P04    "  1B%Q8;3#(FZG'  #'WP  $@
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M)?,.98N;7VQ*$;F^HW9RZBL<SN0*=*8GO,P=.]F Z^35DD<W=P6,),3JDXI
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MHI-KCT!K7,+HD, P#Q(PES^Q[G8[ $S/BG$0-!+WTH+?A</;IPUF:*#Y]R9
M\,VF1%;TL.8C@\NIP)QL2/2,''^UZ_2[UV6;; 1H#=B6ZV>%<6WW5,<[BG*[
M"H>>V90EG@]= 'T/4SWV9D6=#/9)0#US[GBXSB6Z]QQ/%*5/-0$#_5@<'Y4
M/&S\4 )O=JKI%9?3A?F.XLLRE8GJ)'-"VN3/0)?/MJ,0@U;VJ#B=5]&LY=Q6
M5\F#^5^5"Y;*38O%YF)&[AVF&4-OV7,JCPYGX&&.2& ?LZU&X.-W)*!5(S#5
MZ5HNQ1<C@\=1N>85T&[MF1CG*PB]U!J3R$(-NU7E'*Q1V<4/KDS;OQ^GJ<HM
MH]0?IP0HN&3 R"X:FZ>%PS/8Y!Q<8< 53X &.O!.RTX*\$ "$5M5U9/5<DQM
M,;(MF%VMA>UO>%+R>/J:0KEW4G]KROBG]G<O=PMWG><_<]Y-(+V?(8073_!@
MO<S:$>C)\0P;S&E9?T+]W33Q^:2!X],28XMSO\F23(&U;"_IY7Y?(:. :]91
M$5Q3LJE[ CLG2,"]B(<][1*7M&[5!HV+>%O-LK+_*-[,.58XJPA+[;"7M!A0
M!BC0?3$Y ?NI):R)9<-QEQ*M3MZEQ=GB*)N3V =9@* R%B&M5=^1V$=<)( S
M/:]W9PP%6PQ?#]Z!Y?=8T^\_.?PQ75)LM& Y=S8EX/F=WO83H^8'!J)8$]Z&
M82O7F-\2V?/NKO3[6%%\,LD%9I11^EMI.:[?7"C2"46/6@+3\C^^.:;_XGRE
MZJ5&X]H^<B#Y!.2==XJ]E(H$[A_J"HPI?;$E#-)5>5IA,5&W=*_*@[IV_3Y\
M46]> D(?;T?\^G/<G#\Z2T&!!7ITTQ%GRU[B5H(;AV7!E91(66PZ3[X&&Q1/
MD?ZG\&?=,ZJAEA*Q/!<(M9252&R8Z;UV%@M*P=5&&"J+.Q&T(9V)SO;47SE+
M;39T]DM-;D9EG_N)>D8%]X^+4#O13%\'5A2V9A0NSM]]>VNJKIVU%: ,T$0K
MNIPI8]D%G97M@0DMK[42S6Z8\ F_2[]X9\H_8/A1.-JKJ<G+^X.7-]XUM-K
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M==RZEQ9O/'??CTCT[07Z*5_F;+OZ94D%V66'UD#?QW^;7WY)" J6HJ"-;%8
M&WX$/ X)'"(!^=3T>B2@8X=  F?IN+W#6-G5#0WE,;\J&U(G[XPC\[;":VA)
M0-.6;<0?)8T#ZBWLLFAS#$JN(G8-/L0?F\HT.I'>/I_M;7Y.NM1P'1Z[7H,!
M/CYV@). SE+3BBWG"NTJ6OQ^NQ'5,WG+6#49\>;/K,K.1O5(2_JQ9XQ_=%@5
M?6Z5<U4?ZE"Y;K<V<YY.Z)'9/*UT66?GRV\@+.LP)4OM>6=O#RD?%]%+AVV7
MF!?\Z S==RI'R)" :J1(E$'_'4U.04X<_S]](=+^7=V]"\P2OMIYXMZ*8=>7
M9KYLJ26'\[OB9'!%$YT\FY<*QIOA+/6P\@@)V*3,7I3.3DP/G1RK0A--59VC
M4HEV76W@$&8@!B[5.5PL;RDD[?(LZ:Y#_%XE$HCTKKMS--K0Q%91UH7V?*.'
M#T)CQ72RZK[F)OR43JZBFP#I]L4RU+N]*ZQLX/ $)19C) [A8X<H80>(\"&V
M1J$I6N,9,>K$BO9XL[@)6;ZAY$*PM6O-?< CHI-4_1BS,3- Q2H=X,;^-=G;
MK-(OYJQY';R+^"=(PH16?K\*-(^828Z8BDJ%\=D<9V=A?Q,$Q^K\)1'%23D.
M5F[XY#N[YV7N\VB!,-X_D*F1L"T\=\ "PK+\9:W7L'G(OB"!<GLP&U"AK \M
MKD,"T&M5DP.QT!A"A^J)YXL@)CIK.R+"B=#PU$Q?+A5%&3DL4S,'6!X?#&##
M@:ZMKMVMJ$T\0 (]73TW/WU94(L530@)K"TI75@^EN+NE*6<$3H<GXJ#7E[$
MW,UI0R=D$+\1ZJ"R//=XO3&E:[H\0:,#V8]=X%1%ESFWKI#>\L;4%)J.O 3;
M+J5I;*$RT4Q?T9XWE_XK@XI3_*UDIR]D#["Z6>8:+3;"->Y1%Q6LDPJ5?6=1
MGA98\67<_'W'+MVC.L%7NYBWK*\'K:*.S(.UW .\'TFY+R4=2^I5_USJP(2Y
M65M#QX-WSY:_7M_;)-X>,'NZSTO<=C&RZOM2EZTEYR[GUM L9>(%[MUV,O<=
M6Q= HB+U?Z=]J_X&5/]G+O Y0/67./ ^9BY:CI@B48[B,>L CR"@1>]5,%QJ
MU&41/&KYMGC^4\>0>D2?QZT%VN1YUI/Z?9OW^W2IV<5UZ(%)DVKS$Q,OHF0P
M/ZN\_L0H9XJ75;[ !BO,9'L<($6!EP7@%>6CYK40.HVBM+-'XF0W$UK@XYT7
M-X$YAQK\+_.+SZZRO\7$/E*1UAE.)P&8.S43]9^_F5>6SEI($W^9&(AO:9>G
M4+0^\\7I7JLC^5TN'-R?D#O;QZ=Y$5]O^=JT_XOW3"!8[5 WZ_^(Q+:^(@.K
M++>ARDA@NA );"OJI[A B=Y_<0_'/"6'SL8SBL#Y^Y5!?T';N*C6->][@-3?
MD39P&B'Z& DXJT\ ZN0T?;:$%T@@1^GO.:X,G$<VV<[6M#7G8<4,-$3<Z;?W
M9/M?3Z+RMVW.$ P?X8TX9/D%[DZRX5/5U[>.>BN[EE&DH6*S&K>Z]O%=2D=4
M^^TV2J$9[9W((')=T6_*3@F/LP;K(^[>@WHNLL!CODQI"-%U). :1P\G0@+U
MX%@)Y@DN@F!ZB,U-27O!"A)0H;_QOU)&W\X,!OR,+F_JKNM."F"XT+6#9=AR
M?UXZ6GBUBCB1M@)G]:F"'5]D[Q-K/FN)?0/7I&/"3ET?,H7/+:%T,66#2,";
M\*A4;/Y0"0D8)%VKGX%@UVY=80+ZSW+,1;/<G#N_7AU!Y?=0@_K DJHPL'*"
M(4D4L*;O/34247\>%B42%1T-ZLB8ZTA3$:=7&C5$SW7OZ1163?=7\3 %? Y^
MV]&G&4TUW7NY.L7=F/M=IKBVAQ%Q)8*H!NU,:&+%KRFB:SWBK,&94AM[^G;J
M-LP.BX WFPC&"K) !<7Z7]2>/K7\CU^0C3WDBPV#QU:4Z5<LG>^_\<SV]UO3
MK"[(>3'"H+S>P 'DVT-]B&?,@#=E^-*#,CMKI3=;FU"U_3G?)XF6-5<8\3C'
MEOU.M$WV'\[,Z5+]OM9/<?SXC9.-@&A9?4,")Y2HC"U5A?*GX]>HJ:#(7AW5
M1=F][5<E4YH-[IS[JX',Q 9R'#[Z.DC PK&G/!V_+KYBMM O5RY;,)QY(QD)
M!+5HZ#W%4#-8XNUS-F4P/>@$-[:MJ<WI>/#R=QYN+O:*>;PD-#LCY1^^]51$
MK*1C5*.^A16\FX@$V))=2#'S;CTDD(#^])7Z&FH5Z3K\<KIYNP;//[!C3G2M
M+&<8 D_U2VL2W>G-%>@,\\\VUE3:!#^C47 $!Z6&P*"QUGIZ4I9H'7C[4K?#
M#>F$7,<'*39V1?.=C(2-P-#AP,OW)XJ.4+-91*YYQ+P0?53I_"K7;5 )$MB=
M@3[7#P.TEEWHE\*8Z?+MH;IBL_=Q'$=IG"--X3N:3TLS(@.!4+=T+-U32R*:
ML*PHU4EV+T'$,+6TX9,Y(<G@>'*',XM-NJ -<!H?R.0?,BC[1K>@<[2/",[(
M>)8=]SIJOU^X;GCF1ADS\<\3/W[TEY>H4]W5X7^1.HBC=-P_BR=PDR]Z21Q&
M87/ QEJ"UDX9*/-EGP8]:GPL[W]=@8!4(TRL,(90Y23M*(<\"OWKB]?0>0KZ
M-/G42%]I' RO$0SB!],"&[+&IX[WO32"L_BSC2"^N=LS<1OW7ZK/VV;=5#)E
MC783;HF3L:+@"(+CP*=$W\H+ED]@#I?XYF*7D8Y3TGJ&0J_9-A30Z'GOH$:J
M"BJ?ZHL7O(40?7\-U8W+;$#-GXY8VI0ODU%CFX2";)N+CU^<+U5O*7<_S@6I
M:T<GU5"4"[&VE1:1C-_'ROE()/!#B50UP^[R-N1N*IU0<MR'W4KS1DNU,GS'
MJYD%XF/ 7C8NQNCNIO*SS]F&&=QNGR-S!Q^'ESW,9J!+IR\!O#DQ.U_PX+Y+
M%#(5I1,@(%QED[^J'#LY5(K_5=F4NGAGZL@^<49(FY,7R&$^M>11RF()N(_0
M!# X]<+3@V,?R8N<NLJDJ^A_@Q)5DPL^61&=XT'PYYFM#A+?_93(EVE& OAF
M2KM2H<:A'8-SSXT\:J08&'PE,.A6X_RS_UO7/#M^9^J3"'&R41DS!ZBW<Z<$
MQ)9W".L%_3M>L/!B\:"RI#T2, T\9U=4U3;:&]O7C,*F#O:?KH7B 7TQ/9KH
M'9&P"KV% 8YQ[\27S$9+">USICWYHKN2':V/@CH%''MK3W47VA\%K\X9!WWM
M,47P;R4R0+R-7H^7!O=Q!E:YD$P#**;L+$[R3WOEY@PO;>OH4@J_U31% EI)
M[QS&7:<& 1<40DS8G W8";N*I.2'#+QT!=SX$C]-O)9WWJ@Q'QX\#WS'LU]-
MM5FL"IE-4YF@?-^T=%Q8*O^:).KS\'B9+A!K4C_Q3/-&%1#>ZJO#9L>Y@-MY
M:D/7G[HA5J&Z=1J/4&HT9_GFZYT%VJ)J&D)2  KO5]JL<:UPP2]@FN8LX=!1
M[ T6/_ @(BAC69[S?;9DQ.<8HO":>(E[:/S"E'[)[NA08Z-"04&Q:TYG/?$Y
MT_!DJ\,5H563I3EMLI1RG.O+[*C6T[J"7"OP,2P-/@>^PU'&;/R3UD^0@/U$
M"XP]$S-Y/1((C5:R A24+D_\$0T1&^I+EBY"NO@?+/9!G?'XDTA@5@EFU5(0
MHUWU2>NCKKLXQ=H],"UV)HKU9\.(^=7#7F4>D=P'TO&H1%3:;?A4&%[K+ !B
M-1GJU<-P-WKX$1(8*AW!3OPHA8H5WG;G1;@)B2IM^ALF+?P%DTB"#M)R.!_=
MY.V($\VAYJ38Z" X+O./$=-&&3%.@+9"O;3$V/+=(X$*GX+VG7TMJW_X,4")
M;14,=\*F7XR$JLC,&8"GQ=?NLJ\"M#-]&</=<VZBGXHE;"80WG[4AS8_/='K
M>G'=.QE1*E08.=\;,[P^U ^B ?\"ZP)M4EJGMHPH2 ,<=BD1@<GQ]CSMWF';
M:Y9W%J!QU"TUIQV,=2 RP1?8)]E_$ J\][=N.O:H% D(H^WXP@YNMZ$V08PZ
M>[%MLBU621SSU7EY0Y\X82&*S!.#@2P[DFWSD]Q>XKH!AN%=->],;91$$I]!
MG$&Y;PML_@Y"XD0R#@1YN PL-WE^K'^@QQ(%/7&R)O%W[ZV6531*.1-?HJ[B
M0G&3?4#KO8VV>C=YC:=;7*G?G?61_?%O)\KVVS AV]\L! @]3\%YE-[Q#&A;
M.^&ZT,V%\0I[3G B 7J4U)H \9.HB&-Z$7:$O-1KPYR_RYVCK!UXLLR#;IHZ
M6T979G%IC 0>J]/#IY2VQ!,5=5(P$K&B6#LLIV;.0PDW]"/"/G)E:UL\--+5
MQ3&7$<>K:!\ C20>[GZ__(3ZF/?TS3&*4$T2!1TFGHJ(++,U*F5DK'PP/ZI-
M_-7U_4<#$[S$L^<H[S8XT?S.J\1:51BUSMN#,F_]@EG39_Y[T*<4W".<%^(\
M\TZ,:LRD1?,=DQ,#0?+9_ *]X<2@P&F/;F#3!W[:)\,*XUD<X]5N[,_E>OKK
M]X<]@;U=\DXQBHIC*KVDA&<,];4F(PMS?97:IQ/H_NUK)W]*ODEVZ!8]'069
MA6\BLU,=ARI-C)\Y;=HBSCV*KK&#BIN%3,ZG/N@0A+^/LUQVCFZ :5_P%TD!
MV!FE:HI_6 :\NVIT1S"MZ4FUP;=\"8]!M#(C@9%!0*\0Q2J]JH=WG8@:V_(I
M'7Y1S1-\.3P]3(VX%<_4-C8D$ ;HI1Y &N;&VBNJ5R'A?7NM);<%!9![J3EF
M)/@U'PMPX2SL??P^.(]K/QD'H$FCG$()^#;0&K4(OZ4-6J#MJTY"UP;!N\U&
MUQ1%-2DE S14%G&:<R%\K],N*=+Q3WHCN\?D5XBD=2(D=!YF)W951\M3B8H\
M>DJYDB-6LBU:Z/X[7C7*ELN4YT<>C][#Z;L\N-BDZU^A9@0-Y;3#VO+BVOKS
M:*4D+%%J7QDZS8_0$(2QHH4G($K7$*WT5Q/Q*)F5>8"YX?1EU:AYZU84%DJ>
M.2>4%2:R6\ "??; 0P0NYK]4,CM+H;^@+YBXW_/K<D7F0FM$&3OA\GSI;-=>
MSL%9\T,=MHEW)Z6(US1G(PS<_)45KN9_I65S3(Z0G$*MKSUP0JFT+X->[]>.
M@[ 6&I/<WO?,LHRTX19F!-P_B+:EK:I']#JH9=^?8%_XO_,Q8$73,[J$A]R-
MHJ20L7-<!>G[6-=0+ IPBL)Y>=IN9C27(XJI_I4'5R]X+/N<NHA0V8K]'P"5
M^J?\F1Z$$'L&7B(5E?@7*&)%\X1DRG+#*+R"74A ;[VD9)FX>X]O6T"K<4\:
MPW%."MCV:<74_C=JZ#47X] L>N=2.)O+NPZV]J"*00PL"@:B;2NRJA A<5,[
M=<$[8640UZWW_)W>E3K\E49#.&S9.H1KZ8>#__@$2NM"9A&-Y!'+U$%_%%%N
M#X=C:#>L8V8\'PW?K@5\YVJWHS9!MHRR=GO+8R@_\W?MDY-OBP36QI32$2:^
MS']DD.3C^@Y6L,JKNRX4_ !EYWQJWQ-6P7N)7ULG:1>,'(U1HK<26F*0KX<
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M^@,BEBFRA[4CLVY%G/ ?Z)IPKAEQ]WHH;2_MN[J6DF-<)?;7]Q3TO#1TK=]
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M>(DYR!?BCG=?8RZ,HL.-N0GR(LZOMZ(+%XOIHZ\$#DUD)#^A[5N:D[@EA0N
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M[7WCAJ45_[I,H7A&;Y[]HC#P2Z#G1(!8LOMHKRR;\'ZE?IQ[&=>=ZXF S!M
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MDRP/94A9 (_NYK L;YG@5Z<CDH)C^CAP<Q-!Q?Y]@UE];7V]&5E;RJ#0W12
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MH_1[4X_8#^W'-S4L^6@XEEJ&MZAZKA=I_-N-)EVFQ9%\XT-0^/O9 G:!"[T
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M*T5IUW+OU(MH<:>J'57D/M)=>Z51+0WZ%/,./>Z/JA0_ZD;FE3 PO.R%)<I
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MC8[#/E)E0/6)K9/62*CU->SH:+.U)IH?'L$KD"_R&_6-XPQ0>K^)MT@(NCJ
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M7:UBJ2?+X9\T'^;TJL-<_3-6%TIG"=NZI^'S<[ZP(9B=A/^390[;Z7:^,_-
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MN<XQD8GMRM)*Y>,O"!8,Z+OP9'=OGQ-V%7N+W<]K^6K$L#;JD$5?/%SN!ZW
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M9]Z+"ELAJ%J<S4H3/E_$%.3&H;Y@'V@B/SQO'.JWY%@)ZS)QN0.<FY9N-I'
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M><=N!0I(3P*=+(%.ZP2O\]M!I>:+_>9+(_>%'P(H8)889#Z# IQT:!!X)BA
M @60@SZ53MJA ,'%:#GWC,NC>A30C(T"VH?K!I$^1BA@(1@%+&^7(+NKD8M9
M%XP+%X$Q.Y3-2'\D#PIX= X#K5\2=OW7>*I=!25=US5WF*S3&)5>+@0*4TV
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M>_7"NZJB0;+NF;7UR[K+Z*PVBA0;"JKQ+68;NN<$U"EAWP:AAF<C[B8[-XM
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MJ$4$Y\-+6(?<,ANU)-I<=ZE-\D#6,LM>*?MLXH)#871C@B9-?).J<,ET>(Y
MPOOB&*:R$4<(33@UD[VD=L:SVE 6/77NA^\?=YF+48OX4-O5[)<&/]AOAPR>
M/TM*2G+QKA949\:0/?>@C!\[4'8CUO@P,T3\RC6=;?\SG$[74#H (3A!=/9>
MI3P,V/!6E_7! A=Y\=AK\<U435A&&)09,GZA9!6$EFR<FY62[_I,ZLDP" 1V
MK54Z8C:FU[CW&V@E:8VU!1BZ5"H1=31U"0TR'?*7EVR.;ITS7$>,/A/J*BEB
MQ\KMLMXK=/E=V_.5UMFK,S4[3B*2KR^E/NM>Q3R#!\ZTU-2JY3Q58*IE").,
M,AD3(W%!/H@W'(;\<.O=7"&<%?PQ89X$X,#H 2_J1K;2S*)TG>L_=-NDW_@*
M*1M_.<:9.\;IKA91_PY-83OJL__LW?2KPK<T>"54[*^.50EF36P$.*FQN2J*
M_44P7BB\G#DSK>]AAKYWR<H8$^.Z]D:D-LDG,^E<91W=JZQ.9X-^\,G15.W#
MDB.+ 1YNE<R<JDZS) G\P4#:?>A,\SB)I/6!S[+RM0_S7)JH/&Z\?_%B<V&3
M6G5JSZSN(J4:-M@[9B:\K5^IUM=N[CJ=$;*;.]$,.8K2J]SN?D@P^!%]N"<K
M5S,V4%PJ)ZDU25#[7'W>=M#5V<RGVI'W>U8_G20SUF.UP6;%#>:\ON]=4 @(
MSW#>[ODVA7'AM/_!$_NYR!OF<6+06PJ4T"8;/DELD/G<5L6L+=$6IOJ/]4]#
M&%WJ^'21E/L &:6.C SEP 0V700U9C.%8?(C.$?7<,]7&8<':@\+-L",+CWX
MKW"B><,G4EJ-W:.#[!$-( MEXOJ&YN-ZXA+NC"3A$_ 6,_2EN05C5'4[CUU
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M"8U<Q 'VXE3$7_>[N3U/46PM[\&_8RO ,YL;MDS.SEY";Z,_!]-VY/AX.6]
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M)?$_"9B_A5"E/[\KPI8;\]U*_'LX,SCL[U]5Y>;"W4.\GUF'3<]X6)'UG&N
M1E' )A0%4(,]4$#,5/-V"@K@+\B_B7TEB4P'P;<D_UH_S?P'\@_D_RPR+08V
M_VH!#C\)"3CY7/#[V/3Z?0W"(#T'75VG'2MCH#P4,#J(%#>H_!>0F+R^Q(,.
M@TYQ"5+O=:G9B.I A+.O*J,![]BO 4$HH#2\O6R4J1GTWC[2W74(%.5G[)5.
M1Y$_'+6:I(("]@FW7USUB(WX$!?V1YH:O$[!KN+YC#/1"'WGT48QW"M$600B
M'2D'K_JR3:U:L XW/XCV;W?RUR^Y>?>.*5W.9++E_ A_ 02SH!Z9A@)4)4^/
M:391P-'A]<337J3]\$@8W9Q"_PH/&O+R+P++_5F#\7H9P'74/\OZL&'6*NH,
M"6$(J[EKBI?1GIX193MGX)__,/%[4/RV>B?1DS>$C]4>X__':Q28@.S%4>Z9
MPN;Y!#]+K6AF%AO)1A&UND] I?<U;LR7G&0@_$@KAD5<4E\L^^C*&L&#YZ:3
M6?RS<GB-*6];KOR]:V8CB5F/JNK$;ZW$(X/2?B4QO&-.N5$JHWL0/WJ<]5LK
MLP=0&1_6S@_I&>#?6OF28XJP#6O_1OZW5E-=PL/&X>6_D?^M58?4'T+\"T(P
M_PPQE D+4]_TBT#R2$DLGZ;]] #H?Q^0/%F 7_SYWOXOQ?\@AM&\:SA"/R99
M,:I9;C?7'C# 2= =.V8_X/J8=..O\5QA;I8=8QYGZM?U7>9$G1B;);+W>,[1
MGX=N%?[F=PJK1*)*<BB_ZBNMLZLW<'K$OM,(H8SN>,WQ6[BA>013']2N]MZQ
M/#13T&>TSW':<I)[X%GTX?>(1/.N=J"RAS(M74)>^)Q5[+?[!-RTFJE0YQ9Q
M$:SF/T=Z6@K\;/(0>;?)%%)7V9%.ZM&> B!UA:K3!ZB6T6YNKAK986IJB.^I
M>H/==:%D?[,)0UD9IT",L/^N0[0,3AY9%]W#US2_Q3>/JZN^2O.5S\K1._&R
MYPK@EB?MW8Q>&04+JHYQN!M)W-]F\9NQF71SK"Q9.GI  53\9S<-'Z& DAH4
MX ?:>)B;_Q(%&#DC3U' D(SRWX2IY/&;(/LQG!.F$_D;V2^.SY'\F:'EGY\^
M+\0 ;@(:^<4L+PM&/N20%$,<"UP*6.C3NU@3D)]NG?NMO'KM_&!+LJ-D6$<[
MDDWJ>V:=:62JT7(/@EOI5J8T]ZVL^RZB;T:/BHC55%*)'WRNPU+979(AU@K]
M=]_Z_M^$X%_V=GXM_],_A$,=?U@N<'VHQS,?$,!Q'WRE$P>>:]GO2,@TUL]I
M"DF2OVO\]$5T84ML( E.9-N;ALM:^D!7XW)?&Y*KJ/;4Q8]649E.>'@39&)(
M_O[F8'[LM'OB6'NZX<H,6F86T7W9>Q17XSR.;%,WGN!<6";?%3S6K(]7J#>2
M<&3<_S[_-$7:WL^Y!9W:+J8&[KZ3*$'9 $FX)VRJE/;4'O/$(DZ >LJ*"0G8
MU6MA?=%\@?::+;%B_YG L-US_A]QN%+40F8'<(2YI><#U\&^5<0&\XU<\'($
M3+A!(9\NC(,/!3!.S!-]PO!HL12Z'WI_S$P\FN7<HRB_M41W)@)LH%:91FFD
MX)G#7_,FP1-#^^#]B_>R>*HJ_FX<ETQH^Y".")#+"8?;'D=[#U?B()T ;-$U
M$(][<C>\/N_'-D$#:)JBDI2[HZ9-($!#WCFREG/!Y .7Q.QS3'+\\&,#&,V%
MPX"]NL&[#PWZYOI*E;@$]O5B+>0,H>B[^)&(3A)&2(E2MA?BV-X4U]?7PL[Q
ME<69J9Q5/"Z=Q\W1 C%\APC5?>27[*>OW&#&0I4MM-;+OD:'3[-7"[N;'7A4
M!&D[G =8)I'$E>/\'(K+QVU5)Q/.TY7W'^G8<>/<%W>9=6XA1I,V;AKGHY)4
M-  K;DP'+OQ_[+UE4)U!MR[X$@@$#R2X)FB")+AK$B0$38*[PV;CLG$+D.!.
M<'<V[N[N&]AAX^ZP<8?)]]69,S-5]]RI>\ZI>V_-G!_KSUOOLZJK>W6O9ZWN
MU8W0+"$NF)0.&$SUU?@NNR:D %"-@K(G\[3".#%5;H3.3*ZMC5 )<9!>NEQ[
MH3A;ON-*0?)PMNH]F=?P5]&0ESG1\QI'A!$K]!@JI"BAAQT#_3LA@G@1U $Y
MGPPHH1PJHR?O4=VKB(U\V\F84&M>)<J[%.Q1,T]5[\E_.KOUY&7NX) *GQRB
MG>>S^7KB@X&*MGZJ_1!69$EN%I@3S&5SG^U>)F?.@/"H=HX\M,U97WXBS@03
M*"U=DVS4L?;\^F6*<%*N()XE-GYI!+?NL/)NJ,:'WB$*%OXV5!<S6 3S;'.*
MR37@5$_"^9MKU%"3?<QL"_Z7];.\5T=.!>9>])/[I3QO:K#EY89_>F;Q3Z]&
MO2RG[2W"BHJ4P""E/"]J)9\YM*F1JITZUV [-S'CLN#2*F*6'ZGN=@XT\,$[
M&.9(0Y?BR9Q@SYN&GK-I/K D0HGB9]G^?N]5-TCQ.]2H:-\"S,(=E!E]/>V*
M+2Z3\@J))G<V$$^#X8.FICI-.>!N:J[. #(1(24,,;M5$1./5PS[?.;OQ&KE
MLX2Z<S]ZN8KG )P<?66MKM""TAJV=SWQFN#1;(;[EO/J2J\+^@\OH^)NFUYZ
MY/!]B&G?@G+<4;1)"IK-':?*'3R8Q3P"\AXCOQ>NS,0"+)9V&#WM^]0T,$',
MIA* KC$[R555W\+9D3BEQTUO@T,FPO)X+T9SQ*F(K; B^)G,Q]//+W7ZM2"H
M=O0W2):&J;5F,/4.JS6.2ZO<,Y.W^?CAF&A&936NU@D75"P204HP)])'8(5!
M4G(G$+&0O]2&3OR$@^^+WUQ0F0(+/++B$VN3>KB4@_\'--L$:O:6Z+ZNA/C*
MK#Y668>"L(R'_4JIKCF<]4>@'==FIS%@>NL7#Q3FFZ_AZKR=+"4\TK10%7IF
M0F774:3JA1F(8+-$;^*4**#KP_'2%1T.'5W'<[U.25MXJC;E&++ TO'5@G=2
MWKW DNOW9F,XH4#<@RLIS@&*PX!( /"M<MH4=O<&"FG_6*F]^\*F3KK_R?M.
M9HF+![J'2\NE-P7FSB3D81=E/#<2EB<C.)&]V?:A&UC,M+92>(?9:0)U[AE_
MEB"NU0+/<Q,##)1IGCY9LZ#^H4]P5@"NAGZ6<ZZ9/N=_!]9$Q98FRH\UZ>]@
MEZM5X+IT/N=&\7?Q+MUY( SI(=P-E"7F;DCK&@@5-[(R>7FP^ RW@]65,I3R
M>U_3M!,-V<)._$VRICK##RY_2F83O.&N#=8<?=]1B6V.<'E^B,*A/#L5X9':
MB^T)L![+_IQ9-(_ -U<^_7" 7UR&ZI-E1_:U*$/C#-KUZ4%VW8FSD76O4<I6
MZ^'O W'*6+>VG\9(ZTRH7%'1O 68D]5.*V\HG>$GXQ<_J7U'R?JQ#=X<N%M$
MA+ (0VI[-==.C-! .==KPA\'8Q2-]A+4O;4DG4T>+$7FZ>"_U'JKWD9H\#8-
M].+2891KE^M UF'%=4D%QH.M\V5NWN(B<)8+_=S>>;U\GK/^:SOM"9X4,RK[
MD?:TXX%03[PB!*9CH=KI#NH+0^5L).1C1I%5R7$$0NU4;7AP-=>Z$>R)X +/
M).P6D<W4^)>F_2R#Z_K4[GX"PH[%;"N,Z9]G5AJFA(?N#; 4[5\A?O+&*176
M+Z/L=L>D62Z/<Y3M(/(1WFNC$P<>;>^.#N=.S80]%W^+F#_)"_,N&+S93!8Y
M$48XKM U)S%LD*'Z[39)T-$;Z]OR[VG<>+4T]91;\*8QZ!C.'$Y*L>>AN[L^
M#WUNI/1>8KO]I$U9[>B..@$)\7OSCDRJ=*)^CO1^XI.28/IO$PFZ</[+0GWD
M^1[$KT^];6HE24XF)^"5'VPP H0RQMXG[!8% _374>DZXNMXD2 X#2+!_MDY
M2\U)ZFO$/OX2O[C#&:V[LE'9;MV-6 !8=9WAL.R%K,A2?%.4L@O']]Z%/EH<
M/XQ,Z(B01#W,NH8A^(:WHB5)SA^[W:,[JGV4QAEK_458PQ;T6T0GC=DDMQSD
MW87>]EZ(>QG3VUD*=4ZS.+IR?3<'<8(P.:7)FCTH]>K]D8J\R!%;?CRW!MU;
MY\K:'BQI6O_0<PQA5?G:BC*)Y06F[CK!BM1U<^$]O:K>"D$A-!'TY4> UYX4
M)Z(I>(<6>5?FZN1=L)@[<C?3.TW-[%&_$GHBF6DJP!0M1[GL6$#1Z=Y,9K%R
M5/L(]-7_<'U06SR9YUL8(^L5',>0_?12A?3?ER#[]XDXK)_4UX(+<//[_3<V
M9$(P/ +I;QZ!O\Y_M>!)#Y'> >$C,!;[""1Y'W_SS-*[/DD_57QXZ\.J_/UA
MXMW=M>+UWZB12/J_8/\%^R_8?Q2&,O((T%1XP_D>0%^_VXC*=[1V\8JW"_R%
M)?S?M:$8!I==_/+>&O0>$;LJ$OV_M(D3,Q<] N8)#Q[Y=[!'(#C[OU#_A?K_
M,PK8_E<W^=U V">:U13M?$/@K]LM]/K?L+7_^:@"8E=L ,RHI*CR%?41H"[<
M_N^<L%P7MED+1'HT>BCO@+T9=O2+JJQHP^I1-ZQB&GT$;UC&SFQ^[3F5=N2
M-(DVPYQL);NV""68?%.*HF+:^7FV_Q(4C9O%"IL,<[A@[N1GI%:!F;H/J[WX
M&CW>0XWZKAKYV \ME?$IZ,A(8?2$&?"\VZ-A/;SU*@,WB>5%I_?<$C*BZQ'
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MSC1ZEVSSUB;L(FY>] >J+A;/'E2Z/<G;#^9R$6))8^8H\E%_'?41>,+_"/C
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MB9*]'8IZBG:.-=2E16)+.@^=8]_\,-J@=1(0C<L5?_I230P*JM-T"186R_M
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M+E<U6%+G90$K43*]&;U9+:C8$VNGV9NXF3YHOS"?0B51Z/)H(<6(M*^%?";
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M3W=2$O95><9I*>BRCE>3-\XLLZ4D@"[)E/-:GY#L.XEE&B>ZVSCZ9;B'!4F
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MW)VAF!. LK_P>)$M_7H];%#J6?]6KOPG0,+$Q"9?O<,$1)-@\^39VI>8&FG
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M8XB[S0:!IUZ"DEK;E73UB\0VC__Q)$&Z9O9PK_TITEB/IG;)Q*K "#(Z6N(
M;& GBU'>3,SJ*9 0B%9W"IHT$3A$.+,'*4^B.!18X1\U6*H'2BJGN]+(Y\-\
MN;%2/9FY^9V8*#XE=/"1B$)]KO2H2W?U:(AZ;AEEFQKE9RQG-8W&@:1T+OQ1
M7>'FO(!QJ@-I,J/72$<8 DQ(1+  &RXOG]]ZW4+QJM6):[(6?751]7Z7 SI7
MZ:NU3NL#E@UXW%/V^I*X&\Q2HY2F-D"E(#??H3%>X'F&L4W3EQ+,724 N&CN
MAQ5SQK TUAOL7/-ER09UL,.],?:"-4WM*46S.[&:6I*VLC_D*>UP+MH\PKWL
M)&_YAZ/?A]3-ER07"HFZ*$3O7*:GC]P#3#HJE\XN#J2I_5\@VRI#UEE1]&T_
M%@_F5G0ZX$1B3BX&,I@VCDMTYH3!#$W9 VD4J<4'_I3-S75Z:1>GPFS@4:&!
M!C&(P RZ5K9YWI?6-0\^],A8);ZT+O_3;P/E(4#6 $P.$4NX:C\G:K$W_UB^
MV*X!UYDH"S=Z.(K<P07C(@??C'I/UU P<GV$7A+C80W(8\L",XY7/ZOUO(SG
M'M ;B:@+OP3#%DTVIL<CJ^[$;O97JG-!WA>)^2R;:=YFAOL\RQJ;*<2'VDLO
M99C78AI/I@I056'<XC+O[:^L>G6O,C,0("\K9O;#SCC<31^/'$+'I0"0/GJC
MMUQ9.2=M>'YZ.!J'V<_H]SLU1Q$KM,U:XUI&%]_RS](W6&\<M+XOG,3 X$80
MNW+?!ROT#9";#4ND5]C3-U%%G#YKU:RUE3<L 5(AK4(%^7/=?KS;*P9?:\'O
MJ9[6WS2Q9?$^!,@4H\VZ36FG]%>-5[H(1H=VXMV?^_P$F ,?BC@<,X<,[.FG
MB=G!-7HEGJW*3+NK\4Y=B>0U!1T_9U)6J=RR(IJ)"LC(N#!],<$MX#'MY+;X
M^4/'=-&O7"/H&VU+\] !IGT. 5\)A-$)Q>[52H5[X>=#WPEPA=RZ'"L&?@^G
MLO@. ,"S J64O@<D9"-6KW;L[@'?#CS[S$[9#Z3.-X3NH/;U?_>]&J1J6).H
M-0'#HS*@,(JT>R:[\PCO.5#XZ ? JZ\CN)P-;<< <Q=8@N<;>L*YCM\<%J[:
M6Q$#A $6TUEJ3L:F=FEA4#>C#E*S<;*W Z2B/4QEQDW&#D\EK<=< _<,D;9Z
M6A" +1>SE/W=F&!+EYC0E\6,#>%QF)4Q6DY;DA&YZ9&B6U*ZVT(M_J,?%\<D
MGPY_8P(!%;FEKSMB0S#$.^7L-1>FVOG132YU>9+%YQ?HN=2$[2M(C:F[5[BA
M869T:$3W^^N62"/;\7H+)@&[?]A),+<?C_9'^@VWJYGCTGW. C^\8X/\*[0\
MI.KS,5<[R;AC[SW 'EYK]Q3C=^O2H;'/T9,[LA_> E,LR-5/] *X=74P.^ZG
MWZ/35*.<8U,R6VK4)?R3JH2@QY:HW=GD;>(\6/?*D(/RBB.Y$B:^!;7(&,BB
M-XN^>::J7,"/]5A,3;?S>W2![.1@U"NMSAV&VZ8;@$CT8Z[8:/XMY$5XA=V5
M2;=2RJ0Q?(3N:= 6G>,:793'+6BJ#*@2VQ?K6P,2HGGM44QT[*"M8(=+_Q,5
MQ0 A[_B_,I'[*\B/N8_ )MI>2=3-1+^FRA_@#&[J"I9\&_+Q8(W0T93&IVV8
M@GV+DGND0"C+;IQMOY&K1_QBEDF;(N+GI4"&>2XE9976F9:\!S4=5HH?PHQ*
MK7C%[NI,5*VB8GI1WJ'>3DQPR7?,*#Y;)F*?>391=F*]"<5RGD\26&] ^I2^
MZ3KG%$+/06F % 8=1-OT7$5=*92QC6VSCO()W?++==T##G8PY]S#8K+N 3TT
M+$MP';VTON5IHR["M?#MES)Q/-BV X7>"*BH'VT?G/+S2^:&:8&':9!YU]>#
MD_42TN:X]*+>\[B5D%J-V1N'*[?VIS-G1R_AJX %SOB6)<<NS!!FJ$2UWG%,
MO20;Y(.)(;THFUO3:T%ML63-U!X*K8FS@9(*/(W?G,UAMT&D]P Y,HSJ8DB#
MS(2U*NVMQNU3)OQAXJV/C8Q\AV\;YC/>!9!"A@<4D&7V%RF:ZM-/KVD?VC'%
MW^*:9E[%&U<%CH>;KNHU39M/9F[/6%_++8^PIT"DW-8U &Y7LV71>)H3DM3H
M;P0R%9[JT\:*]&4\2K/0WPIK8CLP@*-=QV-^VC:B:UG0<M8;9]IO7 5XM%)T
M5E[4@X/C<\VTMRKCJM,%,]QLQ(:]+2MO2 !7A!KK!L1[\:!LHK5I2R:KL4P:
MK(/@[^9WV%B-(3/Y**$P7[[U\-J+5,<HT2";>/J.%>R#D!PBG2#;8_!&UC-#
M$3+1!)Q!)J;@P9+G@$>YTIU P"/#_W01Y'\8E1I]*T*QW0V"WR.Q6WF?)[LD
M@$^?X5-ZK>TD3D?L:[].)D\6Q(_*30J3)5(!^)%W<4?#6-$F0N&C%-E@Q1=,
M"RMF5\N90C9%'8;'N:[,Q$W]!C+"5YK W?_E/[7\$B[S9K LQ)Q(_--&'P\2
M**ZE,+-YUM]HVZ7VAE8Q5987WB'EGH(GL\S4U.<,84OOFMF!V=.MI.O++T_%
M6DSXO5#X"K]43G\'')]8!!]SY/Q']=#!7S<14CU@X3P9ANK*O@\_L?K%-C;C
MO"NG^&+[84XWC/FF>Q1I]HHL&1YO&.94]7XRXXN5N0Z=9.Q4&:Y\@XKX: #U
MC4 >WJ,I5TDKN?9F#O-OPUY2>QPQ40$LX[!$V$0JA,_P]&_4!%MKU"Y*P'VU
M3YG,-5WC>#+N!,KD :Y"=]C?FV>*.NHZ9LY:(H/30Z>/?:N?GYO+4%]25=":
M$2X8V=;NJ>TL+2YAD<)&?S"--)HG].X(G_793TI393$@9TSIPA'!6C.5WUZ4
MT'EZ,GSHSA/&>?5*Y!:[P)4!?^KP^,8+$?!X4;&>6 3V^8*[*REL%GKSPYO\
M/\4ZYM\5NKIM!*-S]EP]KPA^E9XS[:W ;,MY^"F>?2D1 EV\S/C-G-],?<6I
M1VPWW( 1;'FDN__05DO^W2.5:/9I]0M=LJUQMI?K\N1O=2*.P:S''%C1+U=8
M]0UE9<N(H<J +,FD$K;4'D0LOME!.WNVX<Q&E#&PR*A$P4$Z[V$@(#8U7"K$
MK8- (&FVE1I?08NYGA-LT.]OWN$>ZM6ES>':(RIU@1UZR%^CV4J,P<2FX#I"
MG*VMIO5]@MOM'D!KWYROW7.;7MP=@EB2*Q_FB>.)(LYRS;(%!L;>J5WLW#4S
MWK*3']1W_ W_9"R*9M,V"YF&F(_;7<R[=*L=;=T#*E;G';U]W"OWR7BZ:.BL
M=("Q!0 OCP+G]998*M D>LPZZ:FE*K-'7/]G31(R-L4AZG$)'FVT!^DZ8\A5
M?378BJ5B)DCY&=_SE;?.Q!1O=PG]DP1#BO:;LV (U3:B7J("^#W 3I2?&T2W
MM:DIQ+,<E),57,FA)]?8C))(^>PK43%$ (</7>BV-J@%:8YD94"'_23:1  ;
M=T-%'6'^TUB1"$\4DRR+R1O#\;:B?M=&QI8LGFG&3 =(J-BRS5LDC8F:ZWLO
M5[(5'P5!E4^]+9UW>^*Q#G-]R:D;%;Q3]+RKFI-LL)#7SLL:9-_,H>96&' E
MJI/S"@(-Z?9V%';H.5&=[$&A5^'Z5W([O"?&I5!%376^/H#KJ>V</S'J,BQO
MDD+55H!;4JS8=]X]T?X!U3%;1E;'K;>1B2 1':3*1/1G@@\!KS,(;,UL%?58
MTD9,:8CMYJPRUG"B$L9(!@EX&ZJD2R^R;9<TA+\X@]$ Q"YRX9 \Z6D^3D=P
M+/_%4:9U)RC<G[K59SVG(BS/"#XZO^C$<DPL["I"#^@@0=1L$\=N*%?ZNAH^
M+ZE7NG\6,8$NVFG=A/BH2@#KNYR[4[&Q'%G(PI',:6#41J[ --JSIZ'>.W.[
MH<)$SK7,Y%M_][)*'[[%-U8O\5/E>\#Y#/(NL H2H-<21!LM:D*(.%;-:Y6"
MDT*N\]#>&]E550!J2=K9@'4RY&4X?TO>+UOMEFZJV]WL[=A?;.?ET1J*3=/^
M#&AKH%A/@'M9ES/SHLL09WK,1^_X^-_O_LQ&VP!XP.,Z'U4O9'.4M/UC(D0H
M&R'NU1FCR@PZ%T\C?_>[(H?L>%EGY#-W63F 8F,._BHYQ'&D"^[ P#3%L"VA
M -^6DK3)7*Y,^HI%E" SYO-(@]2>V-Y?#,SQMG;FQ"U=3.?+SX7.8^:D&#GE
MAH0<MW'J&Y#V3H\DZWQ1#0Q%F%LDF6+'.[IJ&3UG5&B:WK6N6"G50WE>1;@?
M@(QC^RPNY0DFN ?$7WBMMRCPJ*<.#IG*,.0MH@ ]R,;F!A37;59TD7T]#?\<
M"T+UVHM$V!%C8*0CY\D.<!I>##&D?S!\-SS?F^8WFQV!^9-2+Y;MZDWJ6C[T
MZ/V$1>[>#P^X>T>$I6KR;)7;@LDWRR Q*H,DJC.7,1?GO2A=@7\;)@IL^#_@
M+?S_&L#L&?$_B5O[2G4Q4]BO4":<.<+@&??=1?^?.:"G-LWI%LE<.WWTH;Y!
M/9QFS6;F*MOUA]'_^GS''LW0"5+4/Y6:'I543#.)(17II.[<F=#>-U2+J4S>
M\\-.J_]5T2OG\_(G9>Y:U/DNI*SN_P$"T'_%OR>P'VXXT>R+^E?;K7<0+N9?
M]4U@UD9][MH+G!8G'0=X[T2IO=5&IZQ=:Y7N>WK[%WTHQYSLASI@;F0\RT(/
M_E LUJ"(19W2EOVFX/#YK)C"'/:H*2IG\QY0AW,#*D5GEQC\1)/</=^2X9K"
M69?U<FUDP/Z^#>7SU4*)T@MU7WGD%5#17/S6U6EHC%[ W!1Z(3WX/@:&'7EC
M@U6&W#[0G' 7T844AK D$"!K>)[$X78-3#7Y^2BK:@2)<LY35$=VL7,P*0B5
MBHEA9.4\ENESZWC,Z7;-&,)V+3D%7V8!>3K5]A?39;@XSQ](TZ8)Q?I*D">G
M%*T<:-'+''TC<>)<%='*'(_.V:G4,-R#_84:J0']^!?4B/#*3LD9L$2RNS6@
M7Y)VBG_UTY7$<L$GGN7JD+0U[A.J9I*?CODV#3+P3-0#H_#S59Q%98>&.%H=
M]X;D]S1J3_ME+#K'*#L"O %G1Z3]#(PHLG'"I!)%\5)>BQ>#"^<84&:_YPWM
M_,B+3$\OD%<),Y]!:=W^9,<P(4^,I,7@FN5\1F58!1&]K6@$VGJ@9S\1T_GA
MYA.5-B0T*K.E^8'2E0[*CD)T8 "LS24+%_OZ#:K"%.>HW?48/[AK'\*/L5\O
M- =/BJ*L3_!*_I4#6<5TQ&XG$MB\2!N(;55$5+CT*,QS@;]5-[KCB3^'M@P"
MB&E)I]N\M]I:!9-1BXN]<3TT1TH;FJ5Y$QA3K6(R2,?,#2(Z]#<N65!Q\LK>
M3\FQX?Q$)D*7HBFH!)]ZQXPO]WI3Y0VXS$CE0(BTB_C)\TZM$&GE,1_/DNR!
M=HI8;36)\W1GETW JSX9B4@+6\G>>8Z-(\+%GFQ<(Y5:KRP<&[4*GH<QEIPN
MTL"2LW(B*K23TK0_Z>ZE1_+C 8]^"A"TH_7#KJI5<WS6,K8]X+S-QG3J1LKV
M)<QHX>@;VR,CYNJS1[P::QSC[MP4+TM03#UL\G,L*>J9SIS.*L-1+DNBSF,\
M,S8%-I 2\P[43C"7NX-@UD4\Z39CTM?$./]\=OY;D/J4VWC4%::A#L7%=7T=
M2AKPSBF=D7U=G6=@8P4J07C0G\50DW6%EZDNG%\-?TD^&3JU#-C8EAQ)@WV#
M1"JAZ%O&\U<*AA4\VC%TWQZ78S F>?V99':B*?W++O2ZM%Z=VA-]P@\-D-G=
M$(LH%/JB%$ZXS(U@BYR6UKJP=;"QG>)NI@,_(<JS? 0X VL,K%!.GAB.7>J%
MOR1;CR?>A/OA:DI+]I?;>Z99P]9N96UA D:XX'P"3XS5[V 18;H$"='YA\@&
M.>1VT3I>687LU-3Q[BAB_5C+((]J _-V,L:%9W6JYH:T29QRHSC'!6[/G&TC
M,LAF\6>)KCYE!]8C"RZ"U\W"YBX5#4$5/,SF+^'8Q@F;YJQXA)!;D-:-S[KM
M.?/TJD$#Y4MI(+X.Z4*]8/"AFM>7CE.GC_> ^?F[60&V*%^A?+L.W#.?%E4<
MBQ8+/(%.LQ4>-Y::9:5QQV 8P'U%&/VYG6KVD/]:K\&+1MI)US;C*T*XYSGF
M ^=LTTR.7#-JB%?=TXH N]YF+U>JI-D45\*<Y[3A%WU>)[VJJKSBM*Y<K5C*
MF]&.+&[4\=+J5)=T6; )R$'7=WNX?[I-GG*1_M*BRNGB3]%212G9!<U7&NH#
M51*VP,))\7>YZ"@5MPJ9E_AR+UL,J!4KJ8"QWBGR*(I$!-5.HDJK45+@31..
MKDD1"LBT6N!L"IPYN@>LL[9/GK2*V.0?.!O%\O^$5BM!@X-*/Q*-$KJX'DTU
MC^/OM=--5QPKADD.?_!R%6G(_O&[<U==G6?O1)JV[C_(B_3OAP'\N,EJ??D9
M6%730__981[GH3<[0R&4W[9*8NJ.Q6S?,.1;0/?3$OFB997BE")G8QX SV^>
MF( VPW8NU%9#J!/7V2XGVPQ,+&29OIR.SF.H2WQM#>"MB6TD[]Q.B@XD^GPN
M<E;6)NC'_?8SA> O$A=L4R5,!F]B(\D7\V&AOF*N9;1.=;]I ]P[K ^_FS8*
M'^S])9:7HH@*@N0U-,_<L/G9%8TIC.0^M7*Z=(F@_57U!M84>C%%6^9)(L.+
MR^1\HZ(@<U/\P)"]7(H 4CK0IVFB:D'>"P+SA/3NYR3W0[K$-;&VR$<A3G<D
MXT?+%M<^PW=COX@6/ ZO6V(D3X3[)2\%IB?^>VI[CP[NTY6DS=8(/>4( _UN
M_1KU(A\8)^D0/\!4"'*!/N)(:D=E+]SX6*P'?'>ZUC&U@?L>@M=C!(]VCJ\N
M*TO_5OSDG.4\B-AHQ4",G)#+E+2=":)@%0-?LF2_8UJT*V\WFQ@=K2Y<9O],
M]U_=;/AYN4&+.CW?J*H &'^K%F>[;;L'X-Q((1/ =U-+BQ>'>UE\M5MC$AR.
M?[Y;*=>7_9C3E\>3(IN^'!Y:Q/Z0R_PH*U7\U > FT/8'K$A+K21_L-&WX1/
M&SE[E\C_>9Q4([.<LFKEG50RJ/9/FX91+XL$H]<KY+0;7GM5Y-H16V*6,,UC
M.FM"I P:4=@A#NZJ=>%LF?HUO3A:H4Q1"3[>$UA;_W)AJNO?4&ZT2R,P5N*6
MT$JQ3SWW!(\N3G@(V%$!L-72.<M4H;=1ALU4S,F';O,\XX1B :[6XJ]FA_\I
M%SB]*,9/=0%DB_G>F=6>L9+&@XLF?+L!N8.5GF_0,NM^HD>.](XG'AF?C_.U
M4R\?Y4G)]7G6:6)9-^4L0,*4$M]T1*5[=M$23N6[/;GH<YWP?35Q="/DGIM_
MN6K3G&2=(/?L=ZKI5S'GV.X6E3]E[^P-8Q'(E+I^PM&JR<C(F4HQ^HO4X"M>
M):8BF)@ATC\60<"ZJC'SU([DIVP/.[B&C6J0:1[(1'6!:"C.(>3NN0?@W4BM
M+ZM+*"Q7L35]WA9L_/(XC&KP$9;WY0^0$42]>[YOWI1%V5'M:-3?*(_WM_E[
M12#U^+#8W#D90"][GQ'[1J+$7D]OVF0?Q-);P5&JRC"AO[G!KBY2)?T-*KS@
M3[,[ ='=Z"ES]0>S-5+B;[_^!<1W^]/X+QX57&9=5QZP]70PUK91$JR!^!/D
MI]Q-,) Y2-1'3T8>X.K_!"D9BU#CG1K^;<UHJ?E]G!3C611 X:/,&+;]^+0_
M)=I'N6VZBDMR)G&AZ>.V])O1@([3BP& N7OE5 0 ]=57H B=A^B(X+]59CZ]
M:=M%U<\K_'XELS=QB>EJ&KL>@+7'0-*0+"$H0J-<O:W&Y^@)S%D#8$M *Z[8
M@8$SDH\AIG?GE3JFAL?@'^2M.4]%SJR$KQYP%#0@ZY-LUIO.:(4)VKY,MCIM
M96<<4W$E9F2[&O%K8K]8P9A*[RI;=Y7864BZZ6(]_\77XFG2>'"D"PO WH//
MAX+K:%,==>>6%(@WK(A.\?$3</:.3!Z288P?K!!.M2KF&=FE=#N]7&30J6XD
M;*0ZB'*1*&,-"&EG:)S@<@L#K;Z87=[XJB+>:49;>WJT VRP/_HSBJ >!LQ)
M7U96$&::<J%)+/\Q]?#51P!P]X43'EI.#1DEI&4W_A&Q+7UL\['7(H<*&*/1
M\1<BY3]W#Y<'D&]ETS)_L8-SLK<D'1M$5/]6!I@SCLZ7S ML!. J;A#@&WBM
MR/>JLP1I\P+=NA@^T0#689D^ W>/DD<TYYSXKRLD[5Y;PS&-V?L]=FR?K-'1
MQ>NZ[1AEQS94L8F!,2(]G9:+-#JS1V>J?<51DC OR_:7\SDMTX>#ED$ 95\/
M"YB?:$96>U.%!@6$5KL#1=#PN56DN,^B]'4Z[0^S^% <[-P=;*HGP0-O7#!B
MRS 8!XZ8>U^-@Z]_M-TI8TM!R2=NWMT#$CQ+_#[< R8C-=$:732AF57C".['
M^UJK^U.%?3R5Q-BR,IV'/% LD?.*;)I=3TDF9,%*B@WS<_$^P;K>$"IS]8^X
M1WO2##H-6:PHC<"S$[P%B"E"[&-U;,.P4O2L%SZN)O:V_3T@HB[SP=2!^N2Y
MB9E!:S)\F%U/?9H)7R=P)'.56_+K.!#>IMKC;0D7"CT[$ER/WZX/M/"(2LB/
M?1-H'-JQ%O"8D4H5(86_?S&70DG\>=LH9 P+(/Q;G^Z(7OIJ EL N;\$ O:V
M4Z3YR;@5RFP-2%+HAY[(Q145^CBKH376:?$6%Z.ME2OE^S,AVN1ZFE&"]X#'
M_1JFO7HF:[&8^^VT\^=J<MHS3]JN/Q"ME( /?XY08)J[9NT@2U?HD8KAX@((
M ],1@WH:LGDL.W..5#K7P.$,AN"G82J $:3$^G<48VR58,HILY?'U9$=H93*
M^EK+Q/F!3X5&[\K3&5)#3XL'?=26L==ML=2'.'W>.R$WU)[YH"SFYAF&.9")
MKJP6DS6;G0VSH/0 P4):;P.2+5I<U*H..1 .SINF'RGW5,)C]2_N05&-Y^3@
MX[597QJ@*3E3IEIK>B#?O2I=QG(#J27&A6]>5/UIIVL^1%45Y0/2JP61U+TQ
MKB<'/G_"YAP8.,_0W0;41SK6EMQ(@@E-#+@%V+ZJS NQ!&5G>PAC0K&!L</9
MB !L>YI5J ,_A]=1PO&"7-.F-8['2T(<S+LO&'TW*A-'50+<A/8)0T)P@;=D
M?"%/7D1QO^#I^AUK/%\*<>V9RZ*:G'Y3D^#U1,&&0.S!3S:V'.!9I4\_PZ,V
M%%9(?H^5%WE[;F&2I>=8MRS4"\@4AR-<&=:3#/]1&!-_,#]I:G;,LA4N6RF&
M$<(X#!6F=[I3W0Z_!YC^V=IE$IHUPM..5@+7?A95>\1LVU$\3/(N=%%F" -$
M7<_I1;:2(R0T^CU6GDPX'8*M@AY&T[AX8OVN[>_'?-\RL[=.1'+0S)!7".G1
M@S49> CD)U='=1]D5-.22H1*\$U!Q0NWP=AOIBO.U4A[O1/1X2JM+1,A'_R1
MV/1M0V,2!Q.^KN[Y^VG^(2\;2NU?^7V;4;U-+6+=2?WZ?%P<WT6$;B?FG%^2
M!!T55YGA:P)FR"K;*H\O.@F*P1;#&+\A0E404:"9]&9@%6+&$S"EBG,.X==B
ME0IR&-GIPH[^%EU84!'&,$JSGQV/'?G+@*7R!2..8URPAWA/G@ 3\J+.-SWX
M5Q^AO0,^>\+K.P+*S8R6>D14%0*1'R04)P"*@)B;>:WU<2 D6!W5B"*L+ETT
MJXOC'>UQJ4>\ M ZUP$D)).TI<),6:8$TD_0BN(R!*%)OK^35*Q?TR'S''GY
MNO +H;QW- <?(3;=*\]F3N8,+()0F%DJ0:,:(W&XP)+SRE -ACU_;F35Y]SI
MBI,/(#])15?1%U'D3RSPO2JX 1#)D^[']A^--? GEXR=0N+#P5!SQT&Z6X[<
M>0>667X"V6X*^>3M982"BVS0L/28F"9V[+#&#=^2^#U@9/QN3L"H-XNF:4J<
MI0#=!BO["0LW9'UI]"CP2QQI8V?G0>Q[DW0T4,<I)'P]ML[@MLGZE_B/HZV-
M4:YY1V]&E0F45#",P*E3D(:\]6+(T^'ITBD?IA@E-N:# !59T2-)FZ9IL$TB
M[68(??6^-&MK6?>CE_Z"D""CKF;$4Z'$EN^$I3SW (R-7="L@SG(1!*^/,A-
MIA*E5R@-C$"(OT->'-\#>O$0W$3V%AJS"D(G8P-/+$2H!^B(@XAVDOE@,R=8
MF06FIO&-1IVG&_/VB;<<@ZT\:WDH/)7T7IJ+:N]Y[>$#G/!Y!\C%$U16#]VC
M0WYN(D@7C%0HPAW-S25>% 4WJB21[F$4)/?V(WB_>".%2@F[N?Y312>LT O:
M<.JZ]U1"-C8=G9>(IZ"\;EQ&FHUHSPWZ9W<(U<3",F97$>:U3?#0X:--/Q"+
M.(,5VC"+-?U=BY!@CWOYB]66<,ROG2<9FYO$\[E5"M_1?K=):R9OY>N;#:K.
M,9UXMS7?&0QN%"H!4>*)&K%=\* ;3DE*NZ/VQ2VR7T"AE&P^3V.;(AC Y>X9
M2J%RE<B7&_QPH\^G[&&,45POS[O.Z^4:I:&KJUDI"LAC"*E\K-FD>^1Y6X0.
M26UCS^8Y%;##(HNCHAWM :^"UK61;.\+NQ.( ^E[I6M"=Y@RZ!@D1![4;"&Q
MHP1^/<P.OU'&A%N^I!UI,,M$#4@]^Q6SF:&)Y=E+.]*F:P9<7AP$OSRA=&FD
MZQW?.I5,+6-XB78OM,W":$\6&]DK:$@\DBEP%\NL+QD?F>ZH:G-KYT2"5V"E
M:!<_B:/W]5,%^'M,K\1D9!^L,8RLDD^@8Q5I[@%A56ZUW$D7GR_"^CVR<C;V
M'P*<_8%(^2^2!#YEH);&8_=T0$*UN2ZOS)8TX/(85(H,"_USQ"2;(%6]!BT?
MQ6>/6BY@:4@W"3/&&L\1A?KR(([89-NGN=U;K&,/*PBS-X._ZN_@&]F*.Q]$
MK"!#4\KV:!X8@KQC%T\PH_K->+(?:0!= 1H;!S$S&&W_A,O ASZ1UT9Z.EE6
M"H[!-V=E@"!>$?+H4ML:T^7P;TEDCX%81V<5MGF/N^.#XR(HV>"-N^]Z56!*
M,R'?ZOU^V%"QR_<=S/@)=%E:Z;[H?4SE(5FWS_%]<,L7KV)EO]E]J[+L2>+;
MZ<HL^'I]R&KP:3T X#RP+CT+PSOY[++GD4++?X#WZE+Z6>94QQ(U$Q,P"V?/
MH(%/?CTV@L#U*;'^@>Z;,6\,?B:1>T![P%L]2489SF:NE0:7$$>!R)3FI\V?
M?WUB?(,?6P%0RP7I&GH&2\&<8+\%.%['-YA)U#[=NMBPQONH+G4U6_ >D4FJ
M,ULT=>B.L]/:H#WUC,,<("TE^.JCTB[HA\4](-&O^1Y0&7T/*'C0PD@*+XQ%
M-E\1O"!^T&<%>VT15T0;XWTVQ(;*P7/YWW(GW[5Z^3F#;7*5;=PY9<&&R]2Y
M<95G(H/,[MC3!<9_CS[9U?]K"#G>I;#AL5[62>EI$KC$O1<!.%NV,)MJE7),
MW$^I7F3*>.*0['J80Q* \6;25S4/'6(I^N[,$XLI[ VY^U490''+>+F49;Q?
M[)=';M:B>M3/L#MRMFVK&V7JRSS]Z*?HAO4]L [N-BS3L3ZVC<KL2\/&33'0
MXBUJ//0LL@1<Y2Y@D'L/,*SN/?7R']52PEZ8-='K-72L6FOYH:@^G_^]7E='
MZ,!^L]^3^_43THS ^ /C\3!'@<3<_0NX9 A%KIV?E\N'5I\O4;ZC.JF/;P88
MEA5$WYU0V+G89C_<FK:*4V:I>YS7?,8V:KP!AXK1WMIH3)P5GPBHGD4\SO&J
MP:<F%&/?3!SJ)*>(1/C1]G*]V/,<$>L+?D9F:87=/@?86&G*5'2X!Y"*<SNY
MAP9RYB=C.H8:NU]!,2IW+)_M^"_<G'Y=#FPLELKBM07&H!,1N>LG1*T4\V"G
MXJ4UV1%:NI=K5,%1#["\?ZE-BLNM5^ I@$K$-0(\,:>.=&<R5]2&L62?:_:Z
M$ %B[/Q?W ,&$^X!Y^=$=Z$<<L9S*],FTW5M8F^"?NEEL4%6[#!!F!8E7$%>
M3#ET""B_FQG)[MTS92.5=M58=H0\?'#D7!<0._Q=?C.X9X4[F< ;M/<$%-?1
MS$.KH"/U+ N]$=]GL]L!#T<Y;ESK<E!5LDP)O:JQMC1G!I#H [-6W^C0Z-U$
M9A-+'5Q<W@.D<PACY>;!AZW4.<;[#;';IHKX',R!F?E)\U ES,VU4Q!(>[;<
M[5.#S]Y-06,F&"%&W:"TC W8*'K;Y[52< ]@_M4Y\+VMAOG*M[!!DJDYTHGH
MJ3G5@>XF_JES,U0()D5FVRPPO6@OM.?TPNBV(&FV8_9X,<XYR+4?6W)F%:UR
M)G6(.4^81[-7%9<H;+4DPX2AM*0NLT&-:/HAVS]WO2$0V!S(<LJ?R/F^Z1%"
M%F.@7DT&@0K@[G4BE+&B3V_^BT6YP?LW%J4(&<;<'@/KY/E/YDCU-@/KSU8(
M2]LE(I-RC &FC ^PLLA8.93 3A1_!4B+1AS7.D&1[2=+?-9KJS7Z85$&[ZMY
MN_]K;-@_/<@'LJGW]2Y3[-;O 00C)7"XBGGR5N44P-C]$955]4&?VY7[HMD>
M<EFB;J[BV6:/Z/K$%;$TA>VW)BX+LWEFE";R3\Y8G[Y!'_G/\L]O79AGYDJK
MNTXG2M.#R19:QY^+3WQ3R_-?23V)M2\IV_^X"U>;*_A8PR\XF4IO :@&3C,3
MS4%?3FK^7"HX^D+I'$H\3C.8VPSM89+*_)]-Z/6D$#\\#F2"57WTUUW=BWOL
M[VS9<'X/43%EL?]E5S Z[3YB\E9[YM \QBI%/=[B2R.&_O?!Q2 7R<8< E'V
M?/$'MABVE0%=WEOSGV]XL J\Z)[SQSY+^O2X@^.Q:(*/][S,W_X3!E4SAW ;
M-Z,80Y_,5#&%L,9O:G\/HMSZ@*VMX60(V&7_NYX5Y6UZIFW?491A_%NAC]/B
MOQACC?"222]HX]!K?+0%YGVK!3NZ&PBT[+YT8(I4C]9<- Z7L5-F?,4Q8X&\
ML?NW$4S_Y,#7($4;]O2E^7IXGHB#Z+(^B..3=W51#6$'$8",%OM =N1U'/7L
M<0J1NX#.$ML<0EL(FYH9MO)ZH,3J0F8DM5!5ZN7E^6),^S)'#L@VOTZPYML0
M'EORX,;3%*HG,3<Z=9K8-)*T=JK4]2:J!B;\]>H9W$K0V.,-VFKTW$K1>@N!
M]KA&70 O#N=+IBS,X$<8ZN1>V%L[.17>[$ \$V1A=I6QC"=GBF[*W(:#7K++
M;Y?2*QMLIGVQ;$,UVNYZ0[)+RNH13[_BT1;#XRLG7NTVV1TJX*Y47,4^.[#?
M[;,X?O);H8@UP>9?:DQ+W=JVJ;@6T(BO5/T\,; YB(],T[P_XX\"4&P ?5OO
MJ#E)PY6L-!TO%B>1N"<]1_,W* ^L ]_NZKR@58@54@ 3JS@&;_[D9YLU0N:]
M1LY6AO//X[G[^'B]>G0I5)O*_$+DD2@ 2T/&B%\3R^PS/ZT9B9V-1FN"Y:?!
M&L=/T)]OXV=H@HV0;5D-SB"W>4H/S_HF8A.#D1KIHM+-(!Q)1/UN#J&K$M(Z
M.P\$+I=W]9,XC*-B2=AV>C62C.WJ/ \5[NS<>[N(UNV'CQC4*3OB>[?6C(AP
M-KU]TK4X )P6J1AF!Q)N=*=9K89\0QX-#W%]T>*T'5UP;LBSQ!A?-\A;7TD>
M!W/-WI7YN()Y5<G[9L>_[I)M/AGLU)8>P]*H<)_1Q+*PU:U 6,Y')?J5<*D5
MOXE.%W(<X\G864FO1'MJH A:M5;*(Y!2J9C(06VE]%E]W0HRC, "B#H![V\G
MEEEW/UE+3 6GRM%(!@5",H"H=[#1V7_R1F8%FECZ8?UMB0^P*EJE+9EYH!O1
M0RKSX;E*HD?'A[WQ!!75W.QO?<X4&64?J0359QUS=$/(WFGF%T]%\Y]8O5<W
M/G4Y)M.2MU?N5,Z'Q'9YZOV9*TH"$L^\#!%JHMJZ^D/7*T9N4K&;&@).FO.^
M0@@I'(-][Z3EV?IL_I8W.,>Q'*>%STBW'7V(I.TL:]&?F7STS]4>*:6_X&:@
MIOA(Y)>W.;ZGJ;I&[<"O1D-/<2S58*>'M<ZPR_C2TZFMQ8EID7I PQO0.[FH
M/N7_=(_BBC"]U"XY9?('_2BELS*-RCM/#G;_?(N;S2T46DZF$5T;8/,R(]J1
MD^+ ^F(@S=CJ3X5W7N;^#W'6=6L3+_/0@>Y5_'&WR4;D]3J8)_A4=/_B#4*(
MK=$\[2OO6KPO^702UJ8KY\JLV[TRIQ>Z\J\J8"7'G%8S[90@)L/:-C:U-.OI
MK%L3%N(U,C9A-D#\F"+#[%3?^BHQVO_T\HZXK()7%:\I;>,0'M1X2M]\9#DF
M<R9\5V0(9M2:]>7R*P0)?9>8W70,5;6-R#>@ ^ . 7XE>.40?H10JJ:LSTSL
M>:@2;&U%::<0]K:6YJ:4;&3<N9OISUNBV'J.2(97WIB"$A3MGM+KV=WN71$4
M_:HLZY[S?S)]2#%NF*B>( 9)X/"H6VT*BK*Z=,[ F%YI(L+=-4.YG*>2! BI
M317$+;+9;G]]L.:'I;@ES9#DA.E1/VG4RT.G1*R8 WS0R$V\")']9=(<J]TP
M<UXA(UL+7\0MI!B6IGOQ7D_":R?;^XQF0R$0(<%D/.M8QQ'-JPI6T>*+/.'S
MU8BB Z^'5?<!/J =3XUB0TW9&CP;;<OAQRL8KMD\%L1;[P(WB3,L8+H-2/=/
M?Y(MTUQE84NZ3J3ZM7S;4.:7Q:,WWYY@ _"]78<J(Q60R45%:+->0_#L5EO?
M7(% ;_P8AJ9O[R,\?-\B\3C>AW9=N2;R:Q@Y=7&W9=?"\!/,PY6WCJY1&Y(S
M&*/[S4EW%>M../H"2W'M=2B6)11]I2;K-N""M03=T"UJ$Z8>+!C'"@L\]W%/
M6% 9IVT0]N41-L?B%=UNQNO 6C9&R\E7QQQS^!DI$RL_[ X:VG[2A0U5R2XJ
MHB\M+%C/IC@XM9NV;PY-95RH>I9A9(A-_/UM\H=17*XHJ##=>0[AL=*</ER(
M6O&AOG>PJ=4Z-[8M >(>0(PU'1<M><I=<W-R797B2?=KO,+;SX7X'YJ!X+?\
MF_BZDALQ4HCG0,H=#2Q-=VJESXEK/4'V3F:YKC3!-=:^R7-]V5,-17Y<M5Y6
M1M <.NUNYU].ZAV%K:LN<W%U_6$UK%7,QZ;$],#[QXR0* S!:3.H72U'M1N>
MI2&>$'!K3B<06N69=T,6:D3-()9ZG+7,'.W)ZYA4H]C.%^NM]H\<)$J^(SFR
MP[*1T?9ZQ.7K*Z^SEI*)VT^'>YZ0QMR*S19SM?I\/=KIF$@F7Z^<HJ:Q9F@A
M)",]_S-]0%=*\^W/X08:SOP44[;7E1;A]:EO1Z5:F%TPA,?$\#U+W*,IN[P=
MYIK59H0NK865&Z; *W;UE0C5P[<9FUGZ%Q>5X6<<A:@;0V0"8TUA!EC%\F2U
MP\,YRH+A7%5SPGW$C'R\<O>MOIB)43E?EZ\Q1D/><\V %X!AM/O'ZGW_9U,5
M%FW!ZK $MOKZ5EV]3Z()>@2#U'0!YP?<G:9X4^?W &PYU[+TR!S+)/.HT<%D
MM&M"KM)FEK+((4<9<B#,'<QM/'?.I7L*WU9[+2L3J'+T(I^X+@8P"$Q0HA:?
MDPQ;#Z"!@.2-Z(7>3EF24-BH)L5]IJK>Y@6,*1!2N>?@@UH6R[*#O8\*EDZ<
M6;,A#KUC+F,E+\P35X-CNYLE NX4S8!^CE)GVM/'K00O?$6:D,M)4ZI>8KC,
M38TLKQ,H\4>=$T0M.NRG9L6E/'T0C 3[Q$,XD6]X?W=]/08/DH$WLA1]-;$4
MTJV<BF]D49F92[)&7CDPY<<)0D!&=0ZI]8X0-\7ZUAF:+H+9]EQG?&U*"QCV
M,!9?S*=YO4);/5U3WGF!<.9/BZOY>"0E8OU]74L\L8-IN>NW0%/D794GIA"-
M6S-]WU**(B2@CA5UJ8@\'Y R,P7P^@J5W@.ZGZ^?D-AY*FY/%'A^XKF>E/K!
MN*UQ8$(4R%_"GXWSLZ"+=7^-MF3HH%WCZ\Y>G-2CK5;PGT.LW8WLY!'73O<^
M#T:QM%0$588PV\&$'\>T<V#@/RUY_H<Q3F"5!Z([85;(K=G;42XPYSW :D:7
MC,' ^KH2EQ9*EP5CK5W[.#]/,QYV3GT6K:N1.:KVU=KIRC8L^!XP/X9;ZC']
M T6T;M75%$)QJK2LT'6:JGF3[VT9^#L-L'>C41:-W:-WE2P-^< J?NG:'3L:
ML26@^N>8;;2W0E)S-P\R4=1*M%JZ!UA'?V;QM+"CVBBB*L4KRZ8Q@$BI#KGR
M^95I,@01XCA9.]^4Z2'PA81HQD.>UK4(IA#Y=K$1ARUXG,,A4M$ X3\9$CD>
M?I8II3/+-'L(4[1-EK/_/H0'Y;F$,*4=@WY4@+GY5\.3>=!9O\_ULK#O1EK8
MGRDM^9V?SI@+2D5*9H?E3V +!6R<X.VEQ(+<R_I9HXX^QK<&$CJ'OL#!EJR#
ME/75IQ&%TNH$0?*]\GZD+DPI<E@PL?CX;/J!7BX:S+I?B_U:OZ55C54E5255
M]N(QJV.(Z2)6YW6=^:7?;,3G"\AV'J*H+;["I8&*:>!#RC10 FFP\CNK46<F
M8_:0R7=?73#>#PY*X)9ZUU<7VV5)38(-/[I5*#Q_=EK//<)[2NO!-_C$0K@B
MFRC.5Z@@SD5RB/(.RI&-3@2SW3 ]+S4J%J)Y-^H9OA@B_/XWXQ3T^8TBRK1H
M?8]_H2[!=Q3V8^)1Q?6G)X]=A#&S\K(X7/N\45.^E%YE!H/XH<07-D IOK7G
M _XY<^09CR$]O7=/FI<81NWVBKI[XJ_[5GI]3F%A!2O*57M9CY&'O_F,3$5:
M%20H%H6Q#Y)R"*],7!9[FEF"T6%:\LV02?IZJX)$H,>,3.+0X8N5^"H[[S/N
MEZF0Q,]C/\D>E(?=%CPAGFZL9#W;_^5KW"SJ9NB;0G'EXO7L2E&SV&C;$DXD
M(BS@34_;FWQU5X2@G2Q4&"\4EWSW)8''B_*+19.B1,<+P,\VU$#HV?5OSDIW
MI3G(9P/!O)I^#2IK0&EV"7GV1J:"K0,_]2$W/<F&;L-;9I(XYNC:?IDM#8;^
M[^+$V.&62(%R;_?Z0*ZD;A&/QC0S7EG]T-5/3!**ZUH@;\&\'#1I]Y5)[\6)
M#U;UH[S*G2BKC"IC$BS% H W)WPNVZG<:(_7F*AAZ2ED7<=:3%'[XZN\)405
MW9&8<X9SVKH_0YVJ5[E<"1,1:?GF:ET1R[S44XTKFRAS(B?[XUU@T!P"-9=>
ML'1@AHQ;<*R/&KWR]9 ;?M$:Q\P6H%&T;F(=7'(/<-BE$$V-'19ZQ1G"EYD?
M(^]R]ZPMO0_^J9UT<BG2TES :(*W^F7 [//C';HK?TCM!FO+Y T35FKNPHKH
M\)"M6@:K8A"=[RC@)#!P.G$.RK.%\JCUVZ#_4_6%1/9<4A8.D3VK;F+']<17
MD-T)#![CF.(8/(_VF(-?=PM>^#/,@RO.KA-(GI<;&$I34DEKC"[_\&YK7;6K
MCW"FB__]F=&R#);"),Q4?9&#+]9!AW;L8P5E:I$.-8)LS+A&O"(OH9J\TH.;
M^#YS]>FE^@<4SWV*E@:<'6[IB79]@@]!T>@ D+7[*H7);RW:R=(1:O]*4A'@
M@HV4L8\N_JDRJ,A728WSJ%Y9SREE4C]*-5;]# ,^A,+KCC=-5YS+)<%>T.?X
MVG6V&MU1X6!O.):9M^#7?'?,SA6.89QQS):C*6)QR/&BNT>5D>@][/3;W1A8
MG __03[9D%.5[]4\1\ZN=U8+<J='3[>!IZ?$;JKN8M5.>[(1OTO.XB]&QA14
MC,.,8C>EGC+ENRF?C'5N$2LN>1Q#F)W)0.XN!U$WX^-#7QDFN/$/FE6)T?@N
M.MW3$-N!%\I/H$KCVI)))>OC)";VWB$7B:5[B &=&IRI%TH,(N3-O-D:%M-2
MQC:^ B*3[M(X@[.. 5]S"(<5]?/LZ-9U*-BHU_3POOF^F1:@][@;1JQ3$(O*
MFUO4I[CEAHDU"N_$>,S-1D)&]XD#;!5S(KE66P5/>!(9?E*-JXPA QF17]&#
M-MFPOH$;P 16?=X&-]$>GTE/0 DSB2$9*1-3 EY4,8 H/08R)C8SW\X^Z78D
M.*_9W*%T5-D-:X+W%6 ^$"RFC=5:;',UY(HNOP=0W*AY<N+\6NQS>.:Q8[W;
M[WS2N7.C]K;U;BX1L3Q_X6#HEKBX5[+)]:NY-%>*1ZW4:VC@3Y^!V<RFSA>8
MT]5:8]RC$#)!?ZUO<YQ=[XCA@,]9I*K5#N[%GL>XK4Q??]VA:0,,"XKV#&=3
M(IQ\52OH>6E=S3^DB0G%-QR)!3\>%L6/':X14%,T^'.\6UGZ:0M_EQ5Z44,6
M8_=U9 NJ9*5C4@H9I#Z0IET10>6;DD_GVIJRMJ;.]"?T'D:ETL;H 9_XW+GG
M4D:Y4=<99;[G-CJD&",Q,,2EM!,&;G$D7H;)&,>&6W(C?13B%YDKXIGO 9T@
M5T2 %"',+#_@BL?VP15ZM4>M[&5R<RO64;:Y)JV=T_%)_]*UC0@BF8@&[7B@
M3Z-#4\=KRN?P3G/1H VX82?9.2^&PE.K:4!;T-<)3C*_:NM(+FW\F0S86 KR
MNA3@[A6C!3$^7(A4TL:P\G($=^-[!0@*W^P"JV8%0 04?57N',5'%?-!Q][9
MTJ*)AR*E<,7P.C\/Y6?35;H&WZ@AJ31"P'D0P'EPAZI2H^\> "?U541N"CK_
M'-S#G.I,J1PA3FSZ+?,;"HAH8PA#@,:I[ SGOO%#2'XPQVC4J#*)?Q[I%/OB
M)GY^GD/ T4$/L>^S%A(MMWV?>;0LWL!)[X]\A*5$O8\EL>_306[W"FUW/EAE
MD3#N-/2"29AKX7$>4U9[)LKX'@#E/.JH]]7SV2R"JU?PFSI*@E.Q'?UX7;70
M(KH<1-2RP0Y:^YXRC]VT&K[G$' _1"/&^R@H)H=>$.CT3JGA:RH5-SI\'.79
M6YJ-9=A/V/,G;A'LO2W=K"BG.F@;6Y$,9D,6M]/&^3/LHD5NIP-VP3KMS!:#
MR..;WP&+NM?M&1/ \^N?-RRYNX:L,>]#025Y-3&(]TF?+5*8FBXN*[CXWJ D
MDK:Y6^4(\VQWNR(-RGD5%M8J5W#&*VP/O!FR$5P\9[<J&)SX<H0?AWORGA^"
M8F&)NDB;2+<*"A-MD[?*,R/YSPZVTQ[D2?F@PY@6]V*D!6[^K1<DE;2VV\M>
M _X6@_J]9K\<'QA.D6_5I1ZSI;EK%ST'[[9M*P]*IM+R&0>]_5#JN#3K)QNI
MR_%]^Y.>!984Q>:Y8\V*_FJWR]="6@P?@_<"X\]S\&.)LJD@D6^:9MZC]!LL
MFY+9U_PD68V9S!\L8*>M(!L^"S"20"2JDFDA, %>.=BEE\*[-0:1Q>FBMH]7
M%/$(GW%L^T3;YNO%(GBEX$^69BOD4B#WBK9/0*+)#G1KVAIIG<V:A!WOJ'D<
M5;]M@/'[U"?SYS94Y(38&#W>[>TU7S@/%L"#Y)M)]ARJDH1\P!Y>2Q;/N@=4
MJ9RTSS]:\*O1(Y9^]LL@8^W%!G-V=Z//CA2Q@-7TD>L] &<YJJNRTKEOJ6R*
M_USK3]UV'EZ+>N!3&*D^]6':G2-:<%MV?OP]4*F;9> 8O=>(FOE( -"<\-6H
MW,\2KONU=>KF)[MB< 3&!S4JM'+46H@XJO,MZ19]5IIL=<TYP$M2G8*#^XFP
M/7\PWDFD[;P4UR!&1^<M#>0<."L21,5]INDM_T3:]6[\A5C6;!OJ3Z7:6Z:P
M>%>W?W&GOW-B>:6)#?ZGD1:<=_J]DVZWX)" 'I=]C_J$KRQ-H#HH);UL*+6#
M-\I$,M-C_LI72 ,L4*;4]&JLT4WRD^;#M+_0G"^2JTIZ\NR$#).Z!R<6%2S=
MHQ[T$KV)DS+,&MOB=LAIB7H5 YF3)YC!HJ:^V7U@GU>X>T$CN\05Q: '9[7;
M8OD9V>+.G*!F6KYXG:G+I:<1,=PM<EA@3>E:E_N&B?$YL&3H+(?@Q;]*WF6C
MK%O<<[H*VLH_-C7/O(<%\)-^\MV,(AXGG]#\RW>X?&F_?M*(_D6WV(!/B$'2
M%FX--\+1._Y.'F#WW]F5KE=_/N"SP>6JF" LWQ8D/<D;W'IBG#D@? /-^9M&
M&X= I;L6@KG>"&?L"WA$8#5-"->U^^@@RN=_LA5^2)RW0&![P*!XY14V^$NU
MNMM&&"A,=_6H[7]+Z73UO*K8;!>>=E-]?M,XA=W:)B:SE H/']S@&J=#2=.S
MD ^;09K/8645'#(3^;,VM7@714(<#Q3T+=DY"3>4BR'#8&Z%NIFJ,Z-('9]J
ML%NB$@:4-/;58QSW2ZH? /<O;TUFF>RHH?*TX8</G9TV?@>L$VH\[LM+,:B\
M&W?":();:O?)'2_V*XG_=<<&C]A([_>.2?<!47YN%6--![NSAW)\/9Y:!V8%
M?L<PJS!!29;Y?-NGX4*H4ZHG'!PVQ)-AB_43_YHQCYV#BJK\RTB4_R RALT?
MV33"8BR5'!F6/^4\,"#$I6*+ $S_>_A3>15DFMA4]P"".D0TIG=_"WFD)2W5
M26R"S'Z+TI@4S7XY)Y=;"Y5#>8X^.->DA.8,>'-9QJ^)+?4-+:8ZX5XAIU/+
MEWJBS%GSBH.*J_$3 /^!G_*>GKL$X>*[CFDGM@2K1(VO/Q[+ JR9& 5E-O8B
MIK]!>=U7B0Q!>W87X6RAJLIS"&IS<WI]GSC(>84]>PZAU@U&8>JQ>-F1-AY'
M*GZBOIQK/3;;B:7%$X8U8D-#IU#^([X>1F0L>[+/@UA:W*\45B[*F% )-8=_
MR#^V-S64"["2R.S^5UOCK A 'W(@E%.<K: ^NZANG%3)RB8U\$,OQ@+&!.$L
M5LK:#PXE%,M="WC'K_*7V.P"V9LX]0DL!:5C-3=^32S6IG6PE&D67HEE$ZRM
M 5/>TXXG1@>[>%Q6,N>NKEDH=&VR*&%M=5_O\F4+_OP\JS:E2"<=@._(2$<3
MFXT-RDF"L.._U="?0J2.)A@MK%!M6$NHXPC?\!A2^I--5YXMBW:V#<N]=TGA
M :>X\I6P;7,ER#!O-[#GX/N,$_Q<@02-&Y%H/#PO_;**!V"1NR'$$6%, JED
M.6@P;)L,Z[ED$&=MK&3* S[.!>!SGNV^$91D1K'4R4>2!:&?;9X+X\XU_V!3
MNQN:SJN]!F]M=VMD>G&G,EGN)'?^,/D&Y1/X-X;OOY3L_DO)[O\G)3L%(FQ]
M([OF_NR'?9L>\+R6P8A]\6]+0BFG2*)V4.XWJ'"Z4VC]A>Z>$P@10-KU )_3
MV2SDW16@D7S^I^%M1#^>F:3733[N]MAUOJ^GQ=+US)DFEB6<ON[N&6P.KASR
MHX[KP1.F][HB(E1C 30[-Z\[%B5%D7=QV;P&%#.5WNNR-]5W++4FF?\/:!B0
MZ>9G8*8I?KZA=/?S7#\+?CO%EE3)/%W 8A65W;;5((>^>_WKW8U:)1P=VV-*
M-<O94ZY]H+N6%\7[BA-'*MI>V0;U6.&B>C^-+%Y0QU2<EW.-X5IQ*'LJ(0#
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MM[(3H\7&1@D<IU:FR$CY\_)@NI54J*))Q4]BX67A%:J@ 8Y(6>D%6X^.P51
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MZO\!!,._]"_]2__2WT5U]OU_ %!+ P04    "  1B%Q8F&50Y_=+  "#?@
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M'0;2")!#^42 ^>D#_/*!@86#1T!$0D9!18,N*+T&P,+ P<'"PR$@P,-#CWI
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MXOD\<Z&]<O%0^5C.'O0O)ODV$2]K;FH_G!Q?*><.YZ_.)]!'I2"F?+@3XGK
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MJ2EHEQ *T+Q RS>+5\&!;T^K4=L)2$?A38[EG!Y/;[VJ:R+O)!@&X]00CO[
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MN\\LP)Q_@C\MH,F].CD. @23?9_^C#^AL[TMNL6Z.:EOLY\ Y5>R'-]FG)>
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M%$RU;ITZZX"N;EON0Y5^64,28_&% &H)&I^5"/>#^2'C5'M;T$R HVQ\P)O
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MNR!ASD TZ'(_178$Z#>E#2N.ACVO30(G00T6%3TL;..*JI=@7L =*V?,@,M
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M<^^Y_5Z_U_\_^O88/2S'-QP%>^^UUESSFW/N3=7EY.4\Z(:RO)(\" ,3!,(
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MJF^P&0ZM='U.=QJC]T\7'X9J=$EENF4[N*K4PBU&\^%<%LUQ6T;5F>+^.(;
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M329U>'7WJ!.717HOG.G^$KO,^MT&W;#\=1^?27!B# )1Q*Q V=:[H;>>B>_
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M:L9YW/4:&FK%8XB?I30K;9@VRPE\HTE-BO+#SO?:4%4Q6AQ6OSY#T$[TGNB
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MTYXY!>;3F!& ^06T9PA&&VB%1IZ1TG]=K"]JP3%1^.-1OI:^Q!Z._9*XI^,
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ML00>KAXTF!8OE?0U5/8D&"5]A6[S30.RRP"6"JQ.:&5LWK:?D4VCT'X.K;W
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M^=6KBHEC.D?+:+J*F.=85O9$9F<%_)PKX4+M;I+C'-]?U*!JGY7CO<]HG%H
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M3SC6[@$KS$J_-(I0ZHIR9UD8=$?^V$B3#^,3#949;Z-MX8CA6HQNB)72U!_
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MO%*&X.M98EIX$4YTIQWR.&"]NV<T;:XG!J@=D-[\MN(\+%O?LC?JB/C]P(
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MRNI/517H"Q2X0:B&F8J/[2(**8<Q\,*+@N/7CS<#R_3BMFF+>/Y/?I#Y_\/
M^'?/(O^W>R#^DP,).PF[\C_V*.>?[&D6DM[K<((%OZ]A%:0^ZC$NH:L'04".
MSN1XR7-"'1Y2D?WQ3:2HR*#9E1WTWBR-3T[@HFC,DO2S>=Z M<Q?D=UUP_X9
M1)#]^!7NJKVWLY[5)ZG]EH%DY$AA(*\X)B?DSY,N2."A]-4F49F'Q305]:_9
MK)SG<S!L&48MB63'CVD:;L;'K7;#?CF[0A#2FY-Q*N#-5+%"0%KT6$[6.8$9
M5!0%S-S9>PE+1U"\ZU-:1*._Y8_CEJHY[^%._;.?96R0M.!;$$I#UP#)PQ==
M82\VRJ1!)])TD6SB=='QR&^^(\;U9EGWSH5M\"L@%>0Q%C[[\<)N.Y_<E^/]
M+YR);]M982$@3QPB6<(7:DYJ @AO'^6:*V)7?%,],0*^QQXECT=]2._:RZ^L
M9K8VG+ -VZGT%\94?'.4?<3?M--R64=P54AHMMI]IC(LVXDZ<B].^<WOQBA]
MK3F:JA-L3WZX%_9F(8\J%H_6/2?1B/BL0:R4G(W^I#Y( #LZ\X</F1AKGF3W
M.V.1[1[L9L-59_%Y4QYX63$KE12>/5OMB7**",?[KC^O,R8D/"^<0'5!I498
M ]%<2P5>,SL9<1\D&&(6K?% Z7'&,E16*CL*BZAH>7GO&=B'\DOV4?92A=O!
MS;ZX-[UZ"C=TG3?/A2@)=01I,R\91X116'$^@P[WM1-J&(&\$P\VZ-!.JE9%
MEE],)UC]4;^!;Y?+4K"'9Y'^-E9;ODZJ)6W:5PX==A^WC<4TY;@)W-VM#@/3
M3S:)GW=F [/-\[6J)M>V4!DFT\"UNA+@TLPGQM_*$U;:9@EN5"^FDW06=?6E
MQW7G^_EJ*'MG"J2#=!S+!%VZALWV'#9MSU&Q;507;NZ=G55LJQ_I+O"XYAAV
M;OAF=(RH<#,^PE^M=LW+D">..(9]C@&K!C[,D,)?)D>-U24(0#%,%T_UG^3\
M>?)B/(RVH(@Z^/WNOA-*3G5EP'KZS3;MM5?\HEDF2NFO=.HI9ESNB<!# QZF
M$\[/RV2/AK/GFW._YM@.D^_ZO;2KD_ 2D'6C28KV&VI3^6#DJS'2WCT_/@^I
M8%STV$]'SK<-H0ID)38K"&U5Q4=,]T^Y%_*#0/(/NUCB(]$G<8ZRT\T?%I 8
M&^??O!IF<3OH=EXS/<PQSPY#VR_,2/U$D/6(-B\9F\Y06'%("AQM+*'0VQ9W
M=M<[)5LSVYD^HEA" 1]N&^H/ASX/BS&RF2$<*Q.JA)F(JY 6V\DT20Z)+]8-
MP\N8@^DE&[*-[;9S"$4XC'\@*ZU^]6,3>OS;-AZB;^<<H[::Q.>\5OI](\#Y
M4\H90"J!RO.D=(4<]J;]3AZVSM^X@<LIN-H\VUULN 4U )88OQ[Q C6B,-:W
MUC<%L/MQ\@)&R<=\L5WD/R+@S2[^-.(*MJ(BMA.0G]@#LTF_B@*C42D"#@0J
M[)YX"MVA-N0B8J4#G;_RM=%>=J*B2%6>+%D">]^)6L"&;U1 %_0O4SB>\7V-
M'6%'2%&+5I3A>9Q=QXT-NJ#S$S-&S6'+6%Y38ASM2X\HBVB0A%]GGNOHP>%9
MZ2UH_P]$D2B^FN:![X.DQ#@ UZ:\C\1#$R(63_**XH$^,-?OZ\115S.8>' O
M1)G#XD?8-D$]W3,L (JDL1PCYKOK#,8.;PUO<L@ ,E)ES'=1)B_5";I5_"6I
MPYI;M_7A;EV */VW%ZJ N48+N#5P_C>:.*W&S^/.D,FC32+>[#IY.,VV_N%L
M&-_J?SL;J=DJ0?0DLGR2+T 7LLQ9[Z+P)@!74XFR%D<74%E30-HLF#*;25:=
M3';S:8T62>%\6[Q=[(;8B@5G%U<ESOG=IYX:X,0!)2[$QR>]?\+Y2$(=J70\
MA7^S/PX]MX?/GOT<?J)9LW&B!64!KB?LTF/TA2;/53[0(,*9Y9V:PH]7=/OH
M8N2#1#%/)S]M8_O#.<0T'=\V8()G$WZ3KMEA)A* A0D#MR5[A(T:@W@RY)*C
MJ20V'T;BJ;(.G$6<.CSI:WT%>M:+WESS;#554U63S4<@N(UT_[GHCQ7)HZ-$
M]!5<LI 5WP#\8\*ECA09YR^U(:[_UFGI>AY8=<!&NE,XNL]4^UKGA0?1R+,8
M.^DCUI:!J\]C#%G&N0,S((6+DJ((9SD 8"Y@WG'Q,)P%U4AA#=2QRH(0S9_T
M$;NVM(!3O Y1>?&L<.,95+)"@MJ9MYEW[^YX]J'( <!*KDRM ?3%X7/]+27_
M8<R?H_WI]O/)X1-4B*]]=#+D#7AK)Y+R8@6EP $P9OBRPT,'.P4]AAIW[F+M
MD/B2#E08_4M23$YH_4MUTJ\B.5CB0XJZ,NA?\=\IW(M3L>(P4]6=E'&\YYNB
M%O]4AN^^XL*?C(R8@R/0!DZ)E7A&S:7>UC8KT@68K,2&1(O)R6]4^$>[$:(G
MV6R!E8-;"1N]W\!O1E:QBWO;O_WG9>[^B"CNGWB C$V0K7;'#I3OX+=%JA+^
M@0^XS&=*YZ'A,T1V:1OP=A:=R90$X9,]7]-&J,/JA+=UG!0 /'Y'N"<DDU*;
M!#Z##-*?<M/]"O9[X%;"(5G\.<XOOY8'>S*%A_U7_6\\*;\D;TBLN[I/>Y\!
M1J;$,=J-G+2=O 4GAY@0\VC1A+_V.N4%.3'@CL--PG]^Y04LY8ED+KMXZ=/T
M5QDADGUP?S%78DV\"W%?Q"C^$N*HI?!8RVNWXI^-/<IF5N!-)%%Y&@W[ U+A
M#ZHT688/S+7$A&6BOO+%_C6/$8=8R!(G'R[H$Y/D$,./]W)T/[71O04M] [_
M>C5(_): !.X,M,!*YHDI2#UC*>178BQ8M7]A?/)O?&LLH6:\C83X;S0F@PJ_
M,:,?T:4;?XG%?Q!N*(<]:O?VZJ2<&9:X3I83,V^!P5WD!BST([*3DMN#9P#?
MJA"E^Y45<F,C'&'\[>\[M"X,&N.50F'36H'Y'TBJOO2_8*M;QA3G56_&""6]
M=POZ'#-\"R*]!3T&[6Z6<MW@]OAZ;[ZKN 7UM+1'PK1)[__-$07_.N)?1_S?
M<H0 0_@M*.#[LOX% >,M"'H R0$^EOWE8Q8Z^5\_2X=8<6F-5]V"9ME0KNGW
M^8K4RNFI(KDIG<A*W'O_!S=</=^1D1(F?7XIL7&)++F\=RDU?'UHF0:1:(N'
M1@:45+E?VYM-*;Q^TOW9#R2Y(20WN=5"<,7J -9'ZJU6)+ N7L/*L9STN?=$
MB/\&YU<FAA>K-HRE0_;+MI;'$3]Z-V:0.<%V,4:SN81)X 5V,^GBMAXRK#*#
MC MU1*"M.AGAG$B B+3JA);S2+V#"4\96M;9QZ_]X?VH9@]K6J_ZX\$K^OPF
M3X8(BWJ&V,F?6J)U')5*!/ F!2VHVV[Q7<>'%J3O]]]YZ#:S>1.6 (O WIYY
M-*YX"VJMN041'O^@11KH:5UZC)3)KO3'=[_X<98]J:=722LLB1;.W30BM+V7
MJJ5X+GOX(TO^-\T*].@ASLG@2VXK)^HZC978 7URD\A,#Z<==9.1$FK(^:AF
M_B6=?V]O7-!<F.=^5;X8R,!%O]W-^V/EU/?QE)4OIFQDO$H;-.,"O*JZ-*UN
MXN%@[2:WF0.T7T-[-\8=;(?V+C2S\-+(I&F/1SFP(*V*21M2B([6$Z.G.FPL
MR!0^GA8'P?RL!N!TRJUZ?[EGC$1G;'$\I#E.\'>SL<B.6'$T/18@7<A_^;W;
MZ/XO1IC0GE,Q  *,1@;BIY.7<O:&&9_]_*@R78!=EPH;88#%Y_@CU-\E36!C
M;ECQ-'!FG.P#=S>?<J/RLB=#UZ#%;.@"735E?C2?.$^/CN==P525)^*PUDCN
M&'.*G17Y/<.8> ^,T_K3/!?W#F=!@M%8F>_F@_68$JETSANQ??"7+2*SKBPA
MF@OB3Y2Q%)/N]G^X^29K.]0DM2G?1!CD<QPNTZ5V0YY^<'\7?Q9S)9Y[Z] _
MXF1\5!B?E![BE0J^Q"_AI*[56/7<67NC#(!<%/E92VKEZ$N%_.DKY"CYE ][
MW8)G.E/IV C^*]Z/S!>?CN>4CZ<L=U$D8Z33P0O"BLPSD,8X,K$6+$\/7&R8
M/]A@V ZDI67&I:G+BX$<"&]!OAR1F):X6NE'"Z&AHOPM]"O1+CS$2'<%::ED
M6%MH>?J58,2V"M1<(HI\"OBK10G<3'Q-<\U8-T_W>*HDPX0;<S/O&1V06@JU
M+SX::WQ6\TK6,OLT8?[&8X_FB'-,49BX'88AJ8]/AA74>.FZ]P?$/57PMA!C
MC3I6Z#G3PK/?S:Z29Y"MLWXC?&*%.*PQDC.ZKV7W?K- 6EH5PAJ9Y##[!7(0
MQ.C!DDV=_'8\Z4G" TV9&L&-W/?C;H]!AS9/S%-,?>Y/S'(DZL_R5JN]XM][
MIK)O*Z_G4B8 *NQ^N)K',"K(H-F;$A^^/S92CDV9@7#/;D^5Y7WC\V+ST<6N
MPEN0R2)^3^K3\_)6A[;UAD62=FP[[.S!>F_V^?Z=]G : L_29K.5B37E9)_6
M?3<,K9^0J<#ZF_IJX5XF81-7!0._4_Z+Z=(M/>01Q\+7HYK!5$@(ZWPMQ*0,
MW5W&#MG*\4U"9,G;DT-;2N'%\RU(?97#]W=2&O9"^K(4^V*\X[S#W20"^)%L
M5BXK)ZCK$]R7<[W4R%]@Z/'=<,X:18B!U.(*Z2WZ,H5"!W8,U1G*]?37'?2>
M0YCCP;IRPPHM,;NR9A()SVO?$1,?(Y\4W9!#)B.#*TW'#F;MK#NQ[JK"(JJ^
MB[UW[=:+S]+<O,!V$ZB0LS(*ZT;YH0EQN^I)&8:T^#F6/2*JR!<8)\J#+]VS
M*X0;)_CBM4&HHSS>\LOI'>VMULP2F5X?I1G-Y4J!(^]M>3'C9BNZYUZR[\N3
M.P,,H"XA!C+>UD++*,KJRY[G $^"GV("WH&>^6+]"V0IL!A8NE+XTN&$>ET
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MR3_9[N6LNGRBE^EZCC%H2O2C]VZK!H)(043P9?V5,K:CBQ.WRS#JV]JT'/5
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M=6-<,Y<NVS64]%'W;WRQ9'M]^0<!B< 9]F@^ZV4O:91L"%6R:+:;+^L=_%6
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MV]D$W \E0/?U\/'?\4O\BW9!+$X7S2":O:@6D$ZSF?:/=PAA,Y#W3^O]AW)
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M[N'62$OUGM2G%](.-A#;[1M$/,^S,O9I6Q^?@]X^G*T\):TPQUQJ.-'TBJ+
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M.:/>3)I !P6K3&'T1] C44F#"%:TST&E'\L;,/'7A2?0*J+/SCO6:Z9:O9R
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M$?-8S(^D)B$1AA5][&YO ,"D// AS.G2^30^9SIYWXL5#K!+K8OL9PPBW38
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M A#VTXU6!;!,DY%-!)\'R;#PLCWZ<.#NWHO)X$<Q<6/2;PCN2@#91:,Z,23
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MP-2H>Q8P!B.,7^_YUFS, R1<_1<)>_&74KP!/)[#\A\<# Q+76?+3Q[@8 N
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MX.SNE5/\06$$"&;2?-NIWULD:7O(5QFC]:'WOAS=^F/HG<?;?U+P5OK%^\V
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MDU\5PX1E3IWP%W-&#E?D/%F 6$D_U^OT6UUSTTW4Q&8:",:2HF^)[Y:DD2V
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MLN:CS?O*+:X^B<T-Y^WTB^W<WG&GI-R0YR/:[*3,?_#NIUT+8)PCJFY%_QA
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M<((&4$O5TWT#;QT[K@-#C^3(#IN13-23%]?+FO?/+\\=C08!C\B;T(#F792
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MSXB_6!A'XX-8 $@6LAB>8@!RU>CUE&Y)H,.G #[_DN98N3MO*=K%'^[O!NI
M$8TT&-I\LN.EW4256HBXGE%O.,F]@ NFJMM_^U%_3*+$02?(TF(3OM)9IEAN
M'63C['0\9YSWIHG69IXD>M80^TLCXPTOK[O>K+O&D:QK-24?EK;;8[/GFO9[
ME''I1.'=AAR.9AEM:(!$R;IBUI<-[#50/0*<"39%\+4-)][F\_KL9YB^ C(X
M?3CB=B>[KG&4TX'K]AV+A+O?>/= <GIV 3< NVK5?'QMCVY>!XDW"]$T'?<X
M<FJ>](+T<7'Y2)]+WG1&$2'\\CSYUM9 '&&A28O7'076 =YZ0#GGMBI%F=&P
MX;WZB.P!Z2YZ(M<%JEE#=3\G)_R6'(I>D1Z)0V,::M^GMDIY;([,# >?U46Z
MV/<->-5TMI3Q4M+"+*?<]6H[$>K0KD3H3370.4?R!XMXO.>Z/8"4,3H6A&$V
M(L_ 7FUM:XLJ]>JGB"\BI7N087,GO+QJ+=\9(Z/""8E\).X03NL8=SGJV%L^
M,:\SQ[9ZXE:%@"[\C>:<(ID'56:\KZ6OK')Q2LDLJ>;4=4Y2/9$V".O'J_\?
M 9A,0*BC5,!A:,!V.'"B4?'GZP!)Y7_"0_[E:/!8BD_YA(C%K];EZ2<<-Q\B
MGFZ$?#YNQ%*'7\_[7H53\U%4DQ O_2F(?>PBFT;MVPTVLZ+""!O?PX&'W:1;
M1Q,(!?+#U:V#:X. SKBHTLO?7B@V'U$ZGA^B =_UDH^5&Z.*]2>(?C3?\(HG
MVVR&%5"@ F^B ?[@<W9IJ";WQ8T[*"0:<*+MIUEFBIIN!0LO#O)E-@JCR!C0
M@"&SYOU!-,!2 <DNAY'"=O!".JHWJE!GAW[F&?<:DFI-6^_R[.ELX!F!\,4/
M-& G_Z>G:V >'G@.NHY<")3HA1PM(+0QD9()QDBD]$4\_1];(E6@]PEL;]J<
M#+/^H&&2C ;@Q8 W>!9.U]& SUD_-V6<_81HMYCBT)_@D)UC%/S'+H#_V)*S
M')/6BZK7*,?6-$LY;\>?>O!S0[2+IJ2K/P'[$?S?\LM4?^[!SRW9BO?!/IG
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M&V<W@X,L3PQQ&KY\G>TX>':6!.U>>V>GX;JY]3W>][$E-F62RDA"- &!YN1
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M2V$'!3<);MQ6-OW*3:_3G>5"A_+QHP0'<[=4O:EPL+**8>#T>C%HGG_(EU=
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MP9%A""#8YYF#O65U*E8[^SM72;PTG.+4VZTH>MC*@6K6YLOO7]EWW</3%)9
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M*@_W22=HN+BX!/@$%(2$%-P7:"YP_Y<_R/< ,0YZ :8L!AH]@$Z,AD&,AFP
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M#XYVK:KR2DXJ:+.Q(E6Y-3)_5YS ?]E#@7T@NFA'7VVL4K4Y:BU8D@#!@]8
M>XFXT3J#<,^NB50[OMKTB/;=YNZ348N]5NAP4];C_$]XW%S"0\H7DPN+8^^&
MX Q/F!E<?D7V?O'*[;[Z839K6I[,BX8?Z+%F=N).2]8G+#2*\8<VK&&^,Q_L
M?FTE4ON4R0ZW.941P;O(XQM_F\436,1B!TB5I?ZG_#]9U-9LLCDK-_)U&\&A
M%WP-V.OOVP[<$B)>$C_W(Z9GCDUH:S+:.-F3XK.]/$M)P[%@[7NU/U8.R),B
M54+[:2'3R\T^>\Q&-7_!B?'>;<_2\0^G\=&&*!DB_WC/D&, G].=M+APHP?
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M7LLY'T&=$.::(X.=)D@KD2W7NHEX7D[VJH?:IZRT+'K=VM0$?UYN[!8V< ?
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M!E3TJ76=YWR9<W6WG_@RQYV>J(=\#DX:S%KZ?HY<T4!V5VL.230LIVI@6TC
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MAIN)[>&KJ&,@GFH<A.*Z4 3JW! :@\;"?9TFKB.![L%WE6 D )HYGD,X5LR
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M3-.>(W2Z733 YFBND'=%^SG5N%5R!,4ENRCB+MX>6/F05.5FXRS=^2"I%.Y
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M*P)_"R>@@;-_1/RY.B106>"*(J$REW\G=NG.W)='Z@:3.?@XEKCX, *C!I'
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M]!K;%7D+\V18KZU[J4L!KQ@=*6=\.S?7GUI-08A&EM2%9P.PP"+/;,)>,!:
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MQ[._G ^$>KI-66T \U_8UR;EEPKV T?W=R"0[)K: $8+M9<_11U/VL=T[N[
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M!>U$V0!>*0NSPSFXRS<  DJO89!V";8B5_!M+X DD!.$47'AS7(3),/5OQ@
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M/C'#)Q3[:)PG7HW623+T^8;I*8GF;,G/;7K$T_MCRK0.C2D+@=WMP;71:J>
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MJ#/O^.6;^?M/W>Q@=\VJY:H3B#&[G[ULI?Q0M4?"K^A11373 XYCU',"'>T
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M-X!'?K 8)"X%$?+19K4U2;C2!M!U?O+CXSBVT:<'C'T=T#*Z:%">#(,NUVP
MF.D&42HJ D*Q]S!T7/5AQZF"[JI3D#[KP>MI"2:4"PV\%T>@/AFY, O2%(?F
M)=E5&U#E*)ZH%_#ZBWO]E^\=2/UF6!?L@?99:FGBM5CU<J^0M;^%QAE)1,<S
M9_ _-5>2C&S6'$70Y4,1\^L8</D-X-@T*"H);@"B2(+VQ9HE/F0*VRC&+A4O
M8-\^JE'PJ.*N':GBQG(7P_[C-N*<H(9:ENO;*:'Z8X>(7I<: 10S7M1X4&GN
M2.Z 1?A.JJ:<2N>C3QA&*A)K7-;/[NI)7-!42%X2=/)<G(%?SC1=F?=#KE -
M2(+'PK-S+*F-4\16>CQM<3USI-O\0 M4BXX%^VP PN"V]M$ASD$'\)J?U&3(
MK@U#7:C 8ZM>/&?-/9;8=P<R/[^]\Z L .&A6NZUQ8C>C,1^"AY@_=;^X2 0
MX%99; 5N7_P^B6KGN2VU\E/C]I3=A[92@W]^-:"Z5S(E;7?RU9!KOI;=+!G\
MJQ=1UYE>L:F>O1K4[L<?7="XMZL@X/5"D+9(9P1SSH3_Y,-U-<T&[%ULB=S#
MEJW)X PJI9"'[(?X0188,S]%:;ZM8V(G9T999RKJ=+-8&[^<8V8[AY+)^9R!
M,IR9B:N-*=^'5"%Z5-:?DNO/D$#9=,E;X&+(MQO3MB<))OI@[F,E\Z-4ZW.;
M'W390GOGM,!)YU>?%?@?=*Y(=%]Q:CCJ]/FKYYD&7#) +S1D!Q$Z0VYHS#_4
ME+V$^]733[?^%QCR#7,SPKEV Y EVCJ/#2#>RV]MVO$?NKOMZ=Z]X:P7N6*[
M^7)0_&A#*37<L15;IT6IU'2'G^!Y4PV_ 2T3B =/#M($=;&6),)/N>T_T&V=
M5WHHPN"#M*ML-;,@K/&7895)_OK!3[G'G.GL4C$6WIAPYIKTZ[/1!ZN\G*%[
M2ST?>:5,,3 AWM@G1CJ!=UGPRD](H+:'!!O )A90;6$!<V?) &YSR6@#9 O@
M81[Z?3O' D[2 8&?U^^ 84&5NYB\-?GU?(KNW)TJGFI'L_&6U/4="-4@#OV0
MN1(@P'C38NA#W29MH5I9V=RGL350EHI\"6Y=7KW7@?LDW^]O[7P-='23?<1,
MNB$?FT!F\K>BUG>>]-M]:-.>M3-%^/LS^^P+:9=>2CL-ZUH'R"Z[0UI>@83;
M6G8#B(!&@31V(L[=F^Z>K^$S\CC[, J"+_L.B6J;332";$+-X:&0^^91T.Z&
MM]_\!@U7HJ1L+6T, 3$G25HW/;4MPE+^$\]F>$6:JH(TO=&50.>VN1\=73HA
M95U7YPK?=3/7C)I?!*2%XSWU#IQ&S<@I^2L?1X*QK^68U^BG:6WR&8E=/H,/
MLH@8Z Z'2 //Y,[Z%<U&ZA^UC@P(>(S0[\=H<,;=AP#/MEWA%M"#HI&;?-6(
M/N#36'F3Q4OCX(1?T1LS"G&0.NT0L /4:<(HR]DAVMPYC+"__?#R60><G0'B
MY$G94NW5&N?KA3T! _%S;Q,^>QM7$\<QQ5D]Y1XB!O^*=B0C-\!#\R' MU D
MQO_V*T&+Z3B[L6Z!:XO,\QLC#ZH8U40H14IL$A=Y9WR?H0@1:*E/\)K29 9/
M'YO60ZL\(85:@Z&9U#;4Y9&6PCI-FQ/ZC7CT^6G\J_T"3VJ[^,/LY8YZ,D4$
M):H:V=TA]0WGC6AY</7A4;H':+Y_H+:19DLILE0 ?/1+44>C$U0F[*['<SX=
M7XT+ZDF')LO8_^$?^ V%-VGA-RJ9).>LNBC]_ =_,=(06_I;B8E\](%-<FC/
M%-!7FU0<"GM%6! E/%/HHE\GJZQ-QKW-(YZQ3B5]/M&>YY*":1MA\Q3_L_=T
M;ROQC,CI9E684;YF0QQEI*D]>2>'ND,*H>!;?6OC+\0/)!PF+CEB,IVHZ]84
M;I\V-=')SI$M8FE!$U\-?/^&)I39_8;^'6E:?S&ZF"/).)>.?6-$6?B=+4I)
M<]G#@H)MN-N0],M+ U[@>2I; '?IV ,I+I-6N7<E&43!UL'+A/'TLEB)8V:=
M(QCDNB"FJF8+4S=;"KCFO.W@7,OK#/8]\<S?K0TU].Z,!P+RNI<K92GOM5H/
M&X^X4(_^D!#'\7K L%FU"^K.::S::S&E538; ^3FY$EC.C>%QPZ^3F^;S**!
M?&; 6SDMB'<+-ZMS!MOAH@CAV.]@+6$T@DR%TM[C!J.<R>:6Q[0%MB14#K+B
MV3,4N:FV#F?Z.!6.6[C@1SB^Y45WY$R(O:=P:;)4 2O@.D 0;C9(@=?1<*+.
MY[:L:\?0^M4YC>C8R.ET7H@+8""O>)^+^>2-OL;6-.,TF@;!.ELE\<;7HK0>
MBP(GU&M8IME37N6#A.@F5D!B8>3T&S[P&;4_:S^Y]4LT)$T-CRW+,%1>RC:[
M\-[^13 70RN+..ZW?(NT^_Y]706]YXPL59^]<!Q^-CJ"VN7(VBS7JZ7VJ>),
M09[K%XY2U \#*+H/T&4?&OIL'AC'<+?VA)UQW'O@>7R!U"?4IOZP)O0X_)HX
M7YM@E5A5.K,@"SXT.V=Y-6W5OF0?/<NC994TGF)83\IXO\53'%N(.H&O>)RK
MEY95W&*<2QV_^+9+MM$?>*<G\^JU_[H>])?U)5F/XTOHL&4/7(XNI5BG2QC"
M5TL*'MMC*R )>CMD/1;NSN*X<K'2N%,9Y>BWI;_'DL28KP1LW;Q'7R"I:P=M
M8DTS;+2,!*Q1IX.>!YY#$+3D)[0900A-IR_FGSQ]584((S8# =)2<D7$.*<L
MJE8U;%ZIV3)O:K1M\29G"$>%M)_]R3=.(KPH-W,,"_HA6(9:E+#U-KOZ"B+2
MHLEZUHJW 0J(5_A'1!@P8W+,1<BMR[5/?2-U<[/ P=%'/\IM9ML5UY:4>\E5
M@I9+P[L >QU )'6P)QMG,9-,IM'B=5]W.>,=Z'JSC5PYPH *9]$'50:V.!(N
M%&LW'>;Z9<KZK=-<3]X9DNQ1:O(WU>@%O3J6#,VIG9+Z1#?TW7.,G!YE/:[H
M/_UD(0I'N,W"F!U)V.@Z5<BC8VQ@_CHVAS2PZW)ZXJ4/!+A+3P*J>2E?<(TO
MC@KC-!4:#53Z?E&GPJG)^'BFC?UQYT59@=/S?!\ V:A^S 7#/\49)K("_;3[
MHUGAJ.6"QF1OR ETG"!T-^5%*"\:FPGV'1N">7N7P;[%E$_W8O?Q!%?'!Y]D
MZM-00] 6P1+SD,U>\LCW?@QH;H&8T)G/9_,M8*QSCVZ8GCKACNZM/J4E<GN$
M+(W]0Z_W;3+SOC1#2=B9>82\YB-9$T[-P:FI=]993=Y59,15Y\W#%O%1_%*-
M"(6/P7WN?U&7HH5]4U/M=D*]1A/&1,WP).RA/6#4S'FT ]W_M-$[]>RH%5O"
MW@?^H]'8MM57EY-/FI>>&*0B[-'23N8PL"853;_;<SF)X64AQ^P3WZA1/@KF
MVV4=H0V1T6=\\\Q.ME<6$ _E^7A<E!">X*762>],NSH:"@P@S)AL2M9,FOBS
M?:*ZK[0BRHF(BE69(J5*T3: 3,DXJR]8M[X<:WHKN@%X/*+ 6;](X#:(XU),
MU'Y_D4^GV1@]WB* X^-DO^U';.+^U?F6; 350 $4$WZO\:K3L5?^=#?-ON(I
M?NU"/<\0(;44=;+K-[YPP9<*'#A>:C,A P2SN-R$>4KZDH'+*^LS:3EQFK/W
M=1<?40R\;FT(T4GLO:CUJ3)+1$%SA/:F-Z'@4"HS*">(SQK[^6:QFHNZ242<
MZ-;78;87=/]PN[>!X!B272TK&6ZJ,LOF%B]KRQ41/L@J/#3%/:].&$R@XY\Y
M#03=_<:(RC (<;'0%"@ELBL.>?UY?-7U&>&WCL$. H^@I[X<47=P_9TGI&>Y
MR\J6!ZXG)=6_[EHOFHR!"KVZ21N@#$\/C=@ RI%<LW>.Q\%]C4GKI/24\C6%
M8@-D@C $./J/8J *73.UZ1/)G25ZDL6*5_K*U_[Y93,2CV/GW\^),$0M1!T;
MA:5&F@](3RZLLU]Q,JJ[(\&A=M*G"5'ZX#J_K]U@7A\*'.<&#%E@F=!WE8'R
M_NRK_+H/IX*Z9M\^)% G=[K8&KH@H]]%IJ+[\ 3M47J[)S>:?A=3B$$Q2R76
MQM6(T_TZ\GY(BK$UQ<=L#N'*?''!*NFA^2'/BG3GLL<76KAZ*:LODY[-X(H,
MM+S+FI 3)!!#0'[^I/?YI=1.;=E39#9W8 O91RP>WO%<4;^3Y/LR)(AZ/HRT
MLDF0+P7B.3(+<1]^*]/WSHO7.)D'7VK9Y$RX(XOTTOLH;*NA2AZUR-*DRQ)T
MJFU7]#_B*(:_K'OHP(OUI6V&4EUES%H8+<N8S5CB0XLM+>'3;H\(\5.G +%2
M(9R!T)9W,(JIG K;1>O<'.,3#?9CK!+6<:U1DO=O$U<-=;Y):3RESV,7[X[@
M2E O9,9^8<Z2X:9+G"2A8/Q^>'BY$C"+P,QOA0PPS/)XWI]T=8GN[F8MJHQ-
M>%L[\EHUUL:MYSTOR42@:B=WRQ=X2%D$<YNC3*^L$N75JY*K7 D>'PTFKUOS
MY"VE=LV4UIL-&77/4V1VL:7<8LUB-B!Q%O1\+ %@47+@T*9GI3D74^26- ^W
M<AHQ&O?G]]FET;\(8(TUIK#O7QKO<!1B\KQO%GN!WBQ!081 9/(H_Y\CQE!5
MOF9]CG<R0MIL8&D6VY_@54Y ^RF9,P6$C<_]<T[Z5Y-W6.6QN8!*E$G@X,QQ
M<5)U_7S'?/U7UU[B-M0VO5F+/UDSY3FYF#XDE448*,K/6ODRZ@C9$+TQ&78L
M!VHNU55,M_+'V,B/L*7XVV_J"=JK4EA:OZP89 NU8!'(C_MI9:*(57#$NQ>:
M#X03$N*I=3LG]^ V)2+2<2J?A]DK7TPU5+O^8E:@HM4029K?\8J0.WZ9\,1#
M6A3M,QG+HHM+2ZGQ Z/.BQ"L<ENV'.NCO0M. C9Q[H%>-B&X;VK(YZ13A" B
M^=FS'7DI5YJRXM:S"N6CZ-]><#V9>YMXQ0UD1!N 8R'/4HEK68/1"^/DK./#
M^:[,S+XZ3[H?N/,N3?C=8#)U";9:=<CQ9)FB54GI[YR^[<LUEG@$8*IRCK+Q
M*LMG2XH?=[X><<%NWL##[&)B+-M#>5@>&IZ9]^*4(N)T-+Q:K"T+-U$TVL%+
MKCAT52D[-RA6\H&P(I8C;G4*< ]Q#3;CEE)XCLLGV,]@/2]1(U&5TPQ':%0/
M2QWZY?UP8!B*5N!=_+>?NBL%5@)B#4&=\LLM/J[1"S;0ZB:;[ U *Z"[/*<3
M[X)O\S3;:^T,T0A<A;/H=H%MH0M&=!8=<F1?7=@\<;AT=.6X^;JDT+Q7F]!^
M*ZG^[_<?]2/P&)S!4X=+EBUW]7Z\=SE;Y/*M_@(\ @G[._[JEFY#."=%!V<P
M^_1#\(B#OZ)_!AJJT#@B'XM$81-VWH"7)(S#)JPZNHZ(<1R_W1K&/>?F']RH
M8>\Y:;D!$/*X"N(]$GTS/G?\MB]W: </6M(%P#N"]VSA2'F5,#M<T]3TM4V=
MM-$4(;DX89*^-8&6(T\:92Y$+6OVI6S+(TG8L$UBUS?;1PE/NXGC:'F4S99#
M\J)P5%K3B.1;64W]20@'"9XQ6Z(X\D+"55-Q!CJ?9*;A?%+]MF3>5U39_DRG
MP]YIC .5G-W$Z'1_<HN,V1 N?>J I5O5" -Y*+!HQUQG_/4ILL5:_@79K:8J
M(D&'KU.J.1T\5*>+STV0LB)?69I&Z4MY&J?$?KKG[W;#@1<20J&/:C1X-N.-
MP1=A&$5XT,+24F=(<@ZNQ#!+4OX%5XIJAOFT*VG +,,?7V%^%7U'U$03>S7'
M.;2GLW+R':;N=P?:G&Q[L_) P!R^D-^682,VE!J2D-ER\F+%>3)5_&S%NQHH
MU2965)4)J!T)::SP)X)?J.%^ Z;'U.II)7PMR698W5>(IIT7R\VFF=LHN0*X
M?5SEG]P02D!I<^/EG>CF^DIU+#Y2K..13+]7K6;?M?R+ZA?#@CWRJ>H,$(:R
MZ+7LGL*L\) *"4EN-7UD?99<WSF=Y08(3H>C /NQ>,\;'<M(O#?&]&$].9^+
M/YY'T\R8Z<AGFDMSSM H?C(8+&%P5E-MJ [;O $=8U3#S<D">@)>Q1PTJY25
M(#9$]V""J=ZFJ?8T^LKE6S![LWK GL'[=,5,]),!/M;;;8_::_-(-,,W ,IG
M$2RSEVP$RMY-*&?/F ]/*OOBH= _Y6V\WTDS&T?_%JY.?L[\(J<R]_A(!F+&
MN2U2BQDRY.8VQ2YX)'_X78]7DM20#\%=6@X25VMV<Q'*=!VKG%7+K$$ZVD:\
M#P3YCN_)J1J2E4_"UMYW:;NQL&:ID\S$YA:\\[/KT2 2?4KVI#MTGOV803'%
MK,-(#)%OEM&8H.92O!A^CC&*N]Y77.Q(T<:W43BO$A+SC2.7K%X8WUWR2!5T
M#X;PW^N9>>*=/FW8_F]'T_\S<N \V'>JQ^:V.++563JOK?V,8BBS3LAEOKJA
M8E[$A)TG,-N(A]!L$I09>#E%)-Z:Q2IYH]@ERK=U,IXZ@J/7SG*(2SBFO^AZ
M^9*-*<[S+\829%"N:+\1@<+ZKY*I%_W*BNXSHCT%& )G9$0HH;#.ZE59#XLZ
M"MIF$Y?U.$^'."T\0HZH<V3%1<S>L%$/8R2A37DEO[;[5!J=*W(Q=3*5UCW_
M0VP L%Q*Y6O4XP@$ &AS#N,/<$#%AWE Z,JR.GQ9.,4RKC&^TCPF/=O3S(.4
M>HS@N14#VF#PA +D!)+%R.YUBL&#+LI"#]K><LH!<J]/2+UY@BG.4\=*2?!1
M^HOI9UF0['"??N-+K5?RG27<Y'&[>S7.5N4^E$L_T<8(W%H>*6CT)L7/;W0<
MS<W"F.JZX^5@HO 0T[)Z(/)#P;=106N#Y&^46&WW+? EVMANS]U\]/)($OF%
MQE9.E/)'5#R4YSHL9RC[*M_)5*O+W!6<\L'7HPKP7G76RE-YC U;M5$OXS?Q
M?BFC?@G-Q>YBA J213KE S"K[45$%'%L]G7DT#7NL^:6!JS>WV*<UF2#98><
M-P"4U.X!/3?U<BC.PIKM,Z\"E[5K53-%12NERZBHL-063V#.](_3M3H#)00]
M7@;W]+/4/0@9JU1A&">^&47,CGH)8@QI8@XR6B3ES,JDUJETU 9_/3-)XB8G
MQ/$X:$;AI<34)[)T[Z$P.0P?A'1V6PH2;=QJ]95UVVTC\4C(15.*APY&"?"8
M.$TC*DS3J>0!6SV5V\\DG%FZI>A1%NJM,^4P(N"H@V>#!D]BGR C9J<O>=O:
M/$TS)X42),)$ED=O-J&AYX/0ZZ<BAC^>/K[P,F-0#->WX_2=.HO 6U-DCE_%
M+$G&NXJ:@./4*(&!,Q+-!5;HD[=Y1_%1&N"8G0KO8&?]C)-#D$V^/<<ON[$(
MH2RC'LGG_R>;//[W^]_OG_##V?C\_P!02P,$%     @ $8A<6#4G!KS_W0
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M;6TM<\PABIECT<O,)8P8$"AEO1Q@SW-4YPX)\G[\N/:7C/U.A_VV_"_JG^C
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MG6PQB=23,2=7!6& ENH;QC,)JQDLXSW^FY8H_&U)BZLU7@6F_J-"J_-IW"I
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MMMA(=P]Q?,7XCENM>R!CF'4<B.$/<//2T0*0<ZC*4@>=M#QEXM6WVR,=?/G
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MRJ3YR96*ND=O:U.:%:+D.[XL!O&>/"W=3(H;@KVO8V*PX?*K=/H^&!@AM,D
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M.Q2$E1&C'L2(]NC3S1W7S!>:V9L)V#U'',JFJ&HPE\8D( %HD)YQ.EYCF=X
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M\;M,(^Z4%V$X.RPTZ"-*[>2!MEM)QM;Q$G-Y!Q^D8GJ>'BA]#D"(+"AD<AI
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M#<!/C7Z[A5YU7RTWC%WSH]/VI_J&#XWTX"]/C)4F8E,JCSYNN<DL#)!_:;2
MMG;> ![@Y9\T6_1>3]BRD_KL.K[PX$K@7)X17Q*4ERWHUL>9E'8FVTX)Z92L
M!;'1ZWU.M0-"P[S<VYL/9+&FR Q\/I2*-XW5^!)HA]+N&,DQ64FL.FDQ49O1
M*4DJWY>F;C@G<C%RTHP4'Z=J\:2Y%"]L&4-K1BVJ=#XO<Z"%)*'''1?I0H':
MT*[O[1=> 9GM! (!44!4&4\MCAL *K3C,ZD^HVC2*CZ9M<G@H>PIX.*X]Z0L
MH?/%LJ;H=2&G=)=/I[_]#0#^V?NR1O\)A3/QS!M 1FW=#2  *?L:R])W@_%N
MF:A]VR4DPESM1R4Y6/@([VX5P?#(MX,1\PJQINV20-#FLR3[C_+I/WMLW #>
M:).?HP)]SU@\YK(BS.]JS)^.W@!&=71N .T!GW\6==PD3C)X5UO]T_"Y!BB=
M];Y=7W6V;],<J;1?[6+[&(>6/S#:WXL>0^%2[OAN7''RMR5Y\9I94\ZN,=AX
MJGK2P6(2(D;0D-F6II".X:4#%R@:\ACO"<*S^M0'Y4Y#YAV[-P!YH +,S&W7
MW$KI36PEF^1'7A(;?>] Y::F^M3HMO_:0)7!GKL*]S^/D/],0#I@I<&.'R7F
M?]HLO(CW]MI_YNLU&EF=979BX/^J\WZ)'>^'N_+]G_25_%D:!(;CR')70(\7
M\+O"<<WT&,LW@$?>MN57]\CJ^,?3O]W.A]DKM C(_YF4AO_.,+Z+>*_14@U^
M')KTE,-_V:8!9,:R3J!["R1PEK#+'UV8',$O*5U$5Q0CJ(MR>%2H&SXG/#UD
MH?/52GJID+FDC%%#(4"&W"KMF0&ML/M[-$F 7],&7=Q,?6H9XW!RUO1L:<U4
M""<R$S&Q<8(Z78\@#[7 1,Q&HRFW_8SL$J,\?Z+0"G-1A<LYDX-U_COJR)<M
M+9,E-;+<S;3(?$Z5V> N[TE]5_CV^D^*^X+%7<Z:H%WPI@TG89:9W\&4_<!!
MH!K@B*"7FF"M\!FLD#&YC@\]+HEBI!1H228>;._[A.K# @!1[C8Z)7\&NG&:
M6G]OQ<;7Q6;%9$-7#.I;:BQJ[Q6)D>$L6V<^I3_09R7L])2-#0;=[D$J*-0
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M.\GY+73RO<A- RN\KS837@=IAI$7,GI0Q_ O<^,"*FT?-+W2B-FM&G.SYUB
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MOI&-UH[Z/GEFEHERV(R:L,7P^7#:( L1-'<!IIC"H+P5TUR% 6W.*K8KP*'
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M==F")XAH+;W:L:IRG[5(JS]'F/XK5)T3.W--=)ND)S0B^@SBX:#Z1F/9E;C
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M"5.3HJ"MF]4I-O5G&.O%E^8<I,O0GCQQ>ON*9J@@TI!5NEM 2?]Y!?@C9 ;
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MW84YFMJ@X4(L29"A(E@IO*%ZP$U$OJ*2;&;NKY91(3_,%<TXS;S_1R"_)WL
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M_Y+Y\F"?$*"%]V!47_]&WEZKCE>)7WAT%%$ZI'.JVV. B*IZ _@>U,<L(TL
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MA H%T4Z;+[!GM,5L$;THV(OH M4R5/#W35RX"WL]?66XXC?GFJH84M=]/>!
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M>#6/B2W<QI^1,/*MOCKYZ]I_\NR_SK&P_R[/_A_'_E^_8  <%"1$\% ( )*
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M:"^#=(9X:4+P#5?9G5NTUK$3;*Y4H)-*=3\;?=A7](GO.UL7\K/6SW:-KV+
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MI JSG2< )H?S1QL@L.! LS03 Y#>O]5<0 "DB"B(O7]E[^PV@+:?R/$<*0:
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M!>Y20V/I;U&N'[7U.3Q>KU&2GO!E \XD8,F!A??M' NA,S/9T]4LXRO3?$^
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M?\NT_L6"'/9K@2#9?6H]GW=66P)IQOF"7;OGNT_"=A/W"XDL=YN7/CF)ZD^
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MQ1(_NE)T/1Y$9I3K[\1+C%Z\^I*JQ$M3DC8@L04:?XOF1L. 2)J]SN4CM2=
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M=]_'5!_0O_KB=D-,_@G ,!/1OE2 "&%56Q,^P1.@_V+5^0I1D6-V*-5%L2R
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M87%N:-ED@%XI')8TR]XVQ?$NZ(,BR"H)>U*2B^AOCZ%)+J\^N39%0.)[2)^
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M.@$6TZ300P+]UIR=*I:5N]>:;_&:+>3KV35*]*-GI_Y8?QA!T4>PO8@W,O>
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MS/>SW[QP/KE2P02PUHAZZP+<"@_QI(RI#Z) CYMK&B8*9U;B3S8'V7V(RO$
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M!!=++H%)HKJJ5L,4^=)R[*,W@XIK)+7S%22(@_BBE_Z964Q@LFJ^1A0]>X]
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M% =AYKE2.?,[5>R+O6%LLW)?M6A%V#/71M#\B!.OX2$T28SIUQ#?GUT;?+7
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MF\!2!9<F8+1$IOF6Z-*)^7$?6MI?WY.T%0IW7Y1\(NCL/92(0O+2685TI.+
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MI*OE?/E2D'.^!9 Z<)6@=K,#O0U3O0%SZ+,:=:,GY ;CO+HVW^1?>79N%[4
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MJ?9M'\>7-2$!U8%?U 6"/N*!SKP/@G_0,G0O>:!'.'4Y8[8HO+/518M)-V%
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M )_% 0 1    :6UG-3<U.3(T-C%?-"YJ<&?LNW54'.VW+EBX2PCN"1HTN--
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M7'0=N;J_L-VT-*!PRZ?=NB@B^*):'J4V:<]]'_)JN?.\@D+,4 JL#5R0X1!
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M@U[4JJ@H0R)\.4*$0<D'<>ZZV%^\HJ0M1Z)I%*)GXM<2ZWL6;H!&E=A ,6'
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M'*$+'S4G5/"9&#OSB8&7JE5>L[[*7#,MC #A>\;CMUW5$=BSG($$V=ZOD8C
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MB "]N"7:H'BE)7CFZ[ V"O:)&BD_<' JFF>$-B1_[T./JS]]O_<D)D-#4.?
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M/NKTDX$=_%9\Z;-'E/WL<=5.N]4-=DM-':R=+,U=S@=?_9:QM+"D920#)HR
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MT4!DBQ5?\)>R5U(UK"8<HB@8"G!4=Q7.<H\-U3KA[(D/;7M!^$(QM@_?CT9
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M=Q'>5'>I-+AD\=YHA$:LDRP1%5%1(%G*]XE.)G88]K-'KA[A4(E5S"LI*]H
MF5Q&Z4K?Z<A:?'E#:V+RC2>32Z^14@_2VL;\%*D.&[> ]1M*'3%8_N)\*!SR
MZ%!S0>^5H>QPS4^U@:QY%\311?"Q'A\2:^#D)?S1<JCX<3G8_W=K8C 6^9&I
MKVL>K0Y>,_S)8F$!)HSE9F&!!XB%)CH^SH^6+,@YBW [CN!"I6;4O"A5_62M
M#+W"E.J:X\?R4NU_M'/+V3NP=<2("7C;+;@N" ZS>(4I&#+QJ4"SJSTU"!E9
M$;G:41&979Q=P9X]%H]BR,UO*<]Q+XN/&>(W,PN,N0)'VP#^Q%DX"=2EI5X+
M"FJEMJ#-2TK@,+5N:_.;^_&FRG(/@9OI>4OP#"S^!V1-[5P(:=4/]5UNI&9U
MYMD1_:^4C1!'<@S.3GYG;VIX=%UW@,W@>@9A5R/OHX'!B.SOUDA'?V?_,CQ_
MOCK<QY]LYL\=S@&[+JI#I&P]&VP$.O3UI*3H]N_X%X>M>9W/G='C8AG)CY4<
M@\A>H=&>H_U=.R 9\:YA?I80[9"CCWWE@LRNL7Y5&H_D96^3@W@KZB"'*=HZ
M8'Y7E8<Z%\*W1!M;O3P1A,?H&=15Y;:IR%GS=8I]1]ELM23]K'ZOP FW&%7>
M ?:%<V);FWO8C5@U#>W7]PE[DS,,9SB] P&H^WH5<Q?NUQI1P#AY"ZG55<0;
M%=%37//QVF;U_.5]/8?O26CQH^;>Q"NQP[ 1]/3?#-^\-T0MU)LFL2FP754F
MRRV@00I::W@BTJ($4@\J%$&-0;)>?>NU]I&-C0U-9S=ANI<':>]TCH/1\\ U
M[Z8.P5V.'E?TF5/SGS,ZD/\S__S_E(NB_<\8.^WI4E=T-69]IRNE%X AS0M
MBH\/X%W>MK9[O,+^@:>H<SA(&J?C[!$N;L35:[2GW1@@@,<9(_JQC5M@+(SX
M6%N+:[$8"]ED.$<)L49??B^S29GGJB!ERYP[0B?<M? OX<C>F-0NZL]3'K[0
MFVNX\A7\]6QIFS5[_@(830Q[!G2] +HGMD5'#S&R1F*X<EI$'JB-[\[_$HYV
MLH#;5/&JK1= %@ON(T+8"R \]Y?Q++%X!K6YC(_GM6C;Q9;I"^ ;YPO@C#?
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M?FRI7F'=L->0J#34B)G# SR@VW)[_*+/Q8GA%)$!JZO#FL17GTP&TOH%A^N
M&F]C(T_KRQZ>KO=X+X#O(#[W!\]Y\5IKV[:I+^<7F>_/1HWM]G;S>.!?U=>T
M3@N_U3ZQ*H(\"?;-UNUW39D=DLG8:@D7&L3'\\;<F;;.,I-Q0T0ER^WU? F?
M?L\'6D?SW5>#*7&5ZW?B66:*"D$ZC#D1TO]E,:'\HH!!<?B]YOR_=M1\R:=N
MR64CF#-+BQ=V[PU[L]V;^@,%."63WG_#57-FX0$WR+CN&+?5U%<]3XWGUM6U
MQ$I35AEZ0RBC;K1D&.M'Z6DK1ZDN/E>$NU.4+NDMJ(S%FQ<,5BWKM[%9W$D#
MZF5%&G8EJ(2.%%,P=I1D7&/6^W:@8VG*4$*ETE)>=!!'? FQ)_\V0J6O"6+"
MT;!NR_0Q&T'GK [*%(=NO(BY(!K_^:$QZB9B^E%_WYWDKB'R< E+W!3?PUTM
M#9Y^?IE'8WY($_FK)?XI65D6H",A\-09S4A.=;KND>]]-BA;M[](!J-)DEQ;
M,?1G'T9,2G5I\-'H=.0^*=]NF9]^]V?;9"9+;,CP<RY=J**^S@U5WBI/U9VJ
M:Z_"XP&A3D+WA9?RL7W]^U&7BTXSV 2U7*H@K'QUJ#FIUQ4&QJ# S,@@'MUU
MW844*2$G3N=>]X!Y]%=&W=M,Q;WDA/8R!1".,NW5-2>/+OW8-SXW+FVVI_VB
M':210"T6)#KFWB+NLA>XS^@M7/L^Z99?>\&'%/>:)49(>_-K[F-IZ$XE?? H
M,0QB[Y,49^_JS_L]J7/2,3'UD#5?\BX%CPD)890U;_54<&";>'B?A1K;^^T9
MVG@J52E;SI*^2AN=Y0B9.25^W.(.7_I7,YST&UOSQ 35Y]$:-OZI%)C#\C!L
MTR#T:N\D@CUH1UU&JSKI6 >]I4[1._$'"V6K&?YLJ0FEG\0F]2Q#U)@3']E7
MF?7ZRR,^]A2G#^ )E<W"^[K.8HQN&!4G:@OV++NGF[9P*VOHB<KX]H1#5,]T
MGHZD$S!(K"E@FO0+)7('*N "C&,76K..+66,ZQ6TQ&9>-WE(^^XS[$-)[IM_
M>5]>;[RIY/2$8@T.;<I%%!J,<7?G+<M>L_W4O@^="J)0\-=U_I;RUN4;&&LG
M5(PK?3J_M4UX>6GO/BI"WZC+T3%7I_#"/)6KXTU$,1(U&LLBM:L<I\%23D,D
M#<F@0)ARFV]!I))@>S7#R<W0H3,GH0T9<)5J\=291\OA:F'V2E&$2E\I8OA$
M-:I)VG4'>T" 6Z"O7G '_'<?<J5M:)&1<168.[),<SQAP]P0'$&Q)_TP4X=M
M_5'ID\VS86UE6,C[<:QR./G=QQ#,&22H/#F<]YC'/Z*K;H:#U#A&?O+P#33)
MZ[4-$-; 0W]$RYV>@R<KN2MYM5Y#=Y9X."^S#*'^\;[+DC5<2$!"2,.,/->P
MC1\P0E8AZCJ=S$T\TAK1W3*3X71X^<0]Q<%^;"I T_RSAQ*$NVZ% 0?& @ W
M>SK"_+5)I/X<4^X4MI#OA-V68:%??OPT!77T[WJ-R'W\^TB/;<J_'MQ<>Y*(
MSS=J>$!AU6CF22P5?+EQK?M]^:3DFQ8DY!NM=J1G_-ELVU4.IKFL1_GU..=+
MWO:,C!28YPE-Z29@M[N&'LH^=K=);>96+H^)P[J PUXEZGWY#4(%3D+VBUJ!
M) 0*3SR>)C%EL2]PMOJS@H*D:<RG'"B^4+WW+#J"U?QWDQ! 3#."Z&5N"O)(
M:,3.(=^1U(Y1T_@Q[Z#S="6ZI:]^#?NT4V,6K^T%?L+,W7AKBY]UR:S>OIZ%
MUJEQWY@TJ[:1.4M@/4MY.P(M3:..A?N)S!^#E9P&;)P'_;1>O4M"&<?ILT$
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M!,X=E ;\>ED]LW9P:[]4,VH(;I]UL0V!FU63R9_4C,O/M_FX4E&X9MYRWZK
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M1#$>/2_L.*"%MENV2>KV$F3IA@GNLOO67?S&YSVIS $EB1O2A*XTYB\CXLP
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MZPH+PAZ>)[K2O->_JH"9=D9%,1=U79A]Q,QM>+'%$Z(G63ANN*+H_VS)]E\
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M?NK-,C>OQU3_0!'3R/FJ(X8(\)'D5U8JT]@\?R4GOH(5@E2_<&-I/^2@N#F
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M-I;^RY1'<L!ED&W2Q[ORG.:TFV[6X&'M$7"Y_ CH\&%24GV8?7Y)]PAHQ7[
M]ZQA/5!X!'A1WM$_Z2;0VR_WMO.^_14-+DO]Q?,7SU\\?_'\Q?,7SU\\_XI'
MD7G.LOWM4*3M#Q;@9G#*___'.?Y?3)E%.S4W%"'N!?-?,9N3F#G]V&(9,ND
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MQ^YYP\0+7W2RS1<O!=,VR3"6/D6!*,B/(%_\O,CUS-QB3A;,E^DB5TQ"!BE
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MQ)3<TXP57DJ$@$C/5T+VF ZQN/V9QT%-Q9E><^?1WH3NAD3$Q2.DYC">A+A
M^,[P@AT\LJM'(Z8B@"R&CYP=H=MA<:9&6+5*SZ#F9%\:['@2A_/M#1J&1Y:[
M2B5(S&:,<U2*YMWM*HM/M%4\\9:KX*_>NV<7-6?1@C_@LQM6O$.#<05JUB2+
M8-Z2I+)HD*5G)F+DDS.R)-OX'&E'B$ [H5NA9T;/!JJ6ZO<#F751P6J/^P-V
M&[>(E*E%'7-^R/ZDNKJ;9W9WE\;)>BR!\P<R*!X[WT:L#J-\2I?&D#[X9=J:
MZ%$^U#ZU09*^CLPZF%,(2V2/'K+'!)4MZL6/^*RFT8G,]'VK0'Y<W3<JR5[=
MNJCHP .BG[DP^];A^]E&Y/C0-Q1=Q3;*J$R"#Y]P>V0(QAX!AMNI,XN_7K!4
M_4= JO4+CY+ZV[I>73?'#$_*#PT580.K\E6QXTRN-C)/JLQ]?0-H$)_X\&(J
MX<U*'D^%!CZ7J0UXRM;[4$(<',5 IW]'F[>$YPEV5CZ:*C^ZKTY)LERJ3]!8
M=VP@)O&G9U(VO$P5C'05_!4>%.;\?)5ZGQ*K-FBD4CKS^3U-^UIH7<_K:2="
MYXM%DZ8JOY7%\'DY(L?57& P"^$;#YZ"[='MN(&+V!M^35VNIF/4=E]*J*45
M $@#9:4]3FEPVS^[4*,"F7-81,E_D+4F5OW8+B+ @]9D2"<DVLN%>?F%Z6"?
MJ8@ZC%2'?V'9U%W# *T"\M+OV =YCVTUR1T6<)%HF-]1MC@#FN\JKGO9)4OM
MO^O'?RIMRI-^Y7KF7:N[V&^:._,CS&AB;[Z[RL*MDI!WO@HC1H7<[3B(M<CP
M:#A[^<I!(*3J]$"B4:-Y,DKR"#+X1MVPU@1A8)6X?5>'H/1+E>QSYZJQLUMG
M!_HA@HH7QD)B;6N4[R-[)<:K:ITGS@8%I&P#P2Z$[)VC2Q@3N -;SHKF*23'
M_/-]>;"X6@CWJG_@R^@'*J@;[/(SLTG%D5<$Q";;)&S\S<Z\RCZ9%SG#?D]H
M]OQ"K[M]SLR0,P6W BW:<!T?D0'[&XO]%_\4P_SO2<5^A+RZ*>K'K,%7V48W
M +L<0$;"X,J[F\3Y*Z&]X2:CJ*ACC(V-O=\;!3(2>#XT.F;E#,]\QR^8$;&'
MYS+!R>]5>1W8-64'I:E;U8!@3947 V5+P2(]\4R=&>*:9_[ ]44R2CE*N39E
M*->:G[?K?Q'WED%Q]-'7X""!X!#<;9!@"<[@$F2"NQ,(.I#!9= @@1!< @0;
MW!DL#.[N.MC@'B"XA"2$;)[]]E;M[G]K/[S;5?VU^]:5<\[]5?>]Z=^K :!X
M ^B[Y)$I5;-6KQU8]>''4TG7(J+B^6H\V&5YHA<#8<VYH(*T73DM>SU.J+A3
MM50>N1)QLUCBD\C;]1M=X"#+JUZC::G,\#C;5D;8Y(L'#C.W!_9=4TX;,C=N
M1?T?I9:K08CNS?7ALJ#=+,!J8<O!$E?[Y5FBG4UWO9Q#BS_"D067QA+QV4'E
M46 O(<#H0]<+I)JKP'9==^L\8JUX:::0)A72GT2 :]VQ5YG<.^0ASTA$&1N\
MXR(E=4(/C#HX#KRW<K%Q#?L0YNZ1(D^+"Y)@\%0VC!TR^D&V%AO,JY]U,)GI
M>FHD0H(C W8O8T^B_)(\WPGP_FPL%5QI8B7WT76GLXO,R@+K'?2-L_IG!TP=
M?]Y0V$F.07,7AV1( =3%H^@87\#U28=05&A5ZAH&YVD+=EY&V.)_GJ"?IEA%
M3\+8ZKK;P\=CJV*]%9-R[!(S(P2Q4AO%A$\&-?UWI,S]^0J04<&*.[>$=?TN
MC?5QA!D<F08O6.S@X-W_MO)X=I$OV"WX=).UIAR.)AP $VC[L?"NAO;1 4$K
M1[TGTV;'Y8#"^O,@):*:8G1P9]K^'Y2'_SQ'9<&5#IR RG[O.I*6BY&7O-\*
M&"Y'M.G<O.0UCH<J2R#:SE+!T6#C@7N-8 0&ZN Z*MNB86&<J'FM]KJ.^;.2
MN%%\B^B1+R2=R.1E.X\D->EYXX$[[>WQ3G=ECSOS-^(!4,O#\;>(L!P?7(89
MG 7*(6?T]W2XQ"PF_:AU6UU:RAQ3T-)8VLB(COPTGSS#M?Y)" LUG/B2 !U;
M1?^;!FC*EO0AG6HU#:2GRIZD(&)"W! S&.S!MS-_:H0^_O5K!X,E?.TY-)^P
M7;BAG+9G;R]UR/D@M<K\A"I>F@!H#W0JB3'L'SA9,/$:N0,&Z#PYYDU<$OW4
M>,Y\1(KEQZ>_,D$UAZF=S6G,\(R:Q3&=A417S^5_?/^AW@'Y#A'5<P$D2>/X
MV[-Z8,2(N]A>R['Y 8V<6:2TESW'YQ^S1^A44_/7LQ9K3S_S29E#@%3C&$M[
M1&%+N#& 8^YJA))5<T,KLC$*[[SF[/,H96=-WRI@?]3!D&#FOW"*IFW+&&D:
MFU_29PH$?3E[J[:=\_)E'I^K95G9)#R'J>,VG[@RAI=>_Y*C)K/*')+X9&(I
M0U<D214?JQL"J $#F+Q2PT(]E0'O9BW@S3L8_EOGI)WE;?7=]>'**<^?@FV@
MK?II0$\0-KG9)MISU=2,+R#X]&$:O_TI9ARASPMVGD.9K_#[81$,A+)-6<S-
M\,75"7 BZ>M/1:K$'QNNIUU&F^=GN\PUH(H,JP1>\ZIXE:%KS805[ 170Q-*
MT.]2,6MM9C_0T3!;J&AYM?D+LF&O]T_2IO*"RR:]:%/6+"LQN!F2Q(2M0[VB
M>O^X9%],QS)M*G5EG1%I_>1W<WTR.19Z@HE'+-P:\9)@BE3L"1565V&#F[2"
M"Y2_FNIR,MC'CS:=AM\WW6E(Z.?;2NKD47;0KJA 6G5O57#!L^>(,ZC=U1E_
M#04>NXR*NQI+@@)V.#>62LST@D]L,(?U,^!7;2^N-#>WISA@\QH<-0!&"IB%
MQ*SV133B5&3%391 O?V%@ )UJHAU>[NMDV9DQ"&+NW;0+DZH&'=UH#8I$)T%
M6?*ES@I&U6>RJB?3DF/\:&J0(DP0PL/-FM9F6 ';R]P$^!8O&LTU&HMC<A 0
M+Z+!3QIZ?'YB6?OT[H1*QO!^7NQ0*#>]_ZK\]6M#6TMC2X*CSX?^Q^1(/;$,
M=Y6UO4-7KR'GFPWN*!G[F^C&DY/8FT^<3H4F]RK3')E]<;:X\&);$8QVY;<6
ML'21UG]0H=6%,IN.376JWQ$;\GTX:\]FS)#XM1A25<U_.ASIVK@Z2E2R?X<7
M'_.)?,PKBEEWY@<%QL*L14U&%8&FZJ ?7>1:^-S4J6!G[-.E,:5(9OT9'\Y&
MO@Y5QLD'*F/)X+L\T0D'=0_?<NQ\3_GER7",*7K<VWRB2MZX2^K80C<B%Z'E
MWO*G; DFY'J1JND<^*IC2FX]KN+05?B?D_*Y]>(YOMSEKXU/3;_LI39Z.F&N
M_W\Z!S34-!38FW-=['/CO!C8>)6M! WRZ,5F^O<X?112788-9;&IN:]H9](/
MY;\6[*$!_*A1T:;:7%/?/LE6#)_=3H!J^NXE"GYX+>GQ<0WV>"JELX0T;%@0
M)0A$I)]4*3B^ZS++84G6TQ\YY#,)87B;&^G54FDD64S]P_CNDB_L>RGIB DA
M%0]B6.9E_UQK5$/+^YB&AF,_C\3OC:G.U2:KA\SK5Q_WS_^<!<SS\=W2YSH.
MJLP;!5*J]^B/1M+&_B2[&NPGZI0 ,'7,X+HIOW4ROKZ/Z*/RJV4WM[ T#Y]^
M:E'DS:&$*9FPM<2U?7ZJ*;YM8):64. !K!L^K"9A4%8$?FBK(9<3.JS@FJ>(
M"I"A',DCLP+O2CEM)]._@BWBL+[?;R](,Y<X:L188A8U:%SR"580R?9I?]GU
MU<-#Q.OG:S,"@WU#!1H^E0T3!KO;G=@G4P<Q!RPH44;A@89OUY.R5?0K]".T
MZ< OE-8(9@S2B"0%B?/4N?QYT4X5;0KG6=GX2IJ_@-F>^)+0:*$R8*(XP^U/
M3U@^<5O%AG-Z0/!@,;6^OZ>5^KY\.WCC?DJ"P5UJ\4V<#_T?<=5P2S&[F /U
M$58B-C<+X5 %IIR[WANV I2K*"/;>?]=-]K+XD_-P[!TJBJ- -R<L<@Y%,>
M^4T X*@R*J]*H<)BLQ=?#6$KE\SJ#N!O%%,AT7AY4^,O&K@LK<G?A7CO5?:Q
MG6SEU>+88H9@<L^U[YZ:.TP -(3QS:/Z5FIV9]WE57W&=[V-8XV_ -=DPS3%
M05KNT#V1#[[L +OK./VZF@".R0&C](:UJ6W62,*$P\)R6JZKRC:M4A\78/MO
MHLEJ3\#LG_Q22[41:[)L+/B][$+NKIK=>VSGL6:A(;TY%0>=5G>*/8;PEX&[
MN#,QY0U-F=N=0L]O?[>@?32KTRM$^X-"O\<;/F7Q 18Q.":C6',M*7L&=U9_
M0^G?L)D*E#2TQA"8UO+'"02MMP<-H+N]FZV%<'?-)!\S*A2V^6VGE\[.C+\_
MH]K$YO%[ MRJ!%#$A3_E*J7QX\,U5_: ^ <7P>1>16W<@6N0U$U-42Z?%?G[
M\T<Q#/T &#V@0UJ@X4$KROO-,XB1L+.PLUA;1B;M;T656H+"C"<:3OGA&-BD
M@=;_Z",K9O=!W*?6V4QSHTR@X'"<H5G0W.SIKMJF2]T;P::S*7D&TI<XGIX:
M&Y0+]FTYJV^<C>/+H[$SJ*@7JPB&O.)GTPP),[$=7SQ()VPQZK(0IH8I&Z'8
M&S.T6A,>AOC0G*83\4A?LBEMFX3;@6_BY*KE_;@?:E[4WKSLM:.N3X7B1S1&
M.[QEV!( 8"PECYS(,T*GNDM,CQ?1!C]F^?^,#ACM\@W'7>&N,_A(3,KI++[S
M;F5-.  3SCN.1]%806B(B]DPEQFG7@K)N. .-#5=P"+Z/?NQ=4?%*MJ,7P%&
M7@E@O)7,\9A4V!$._@O 2XN%O1]/-4V8'*A?J_TET<Q';!I&2--P&7>8L^6E
MH6I8=BR6A2A<-]5JZ /3 L*+?;"9%!A[>RE6-?6F'H^OT&CHM>D(>ZYO<GWT
M""T[7(:7H,>U3*4-;&2 BMQ#E ^SA35MUTU08\=WQ)'Z4ZKJ+-U*B$S3:3).
MK8BL !IES?+X_-4V<JZT+?[# (\,X9.[MJEXR!]DAW,%2[;8:#1^^;L!P9Q=
M%C<!T.C4R[<=BTBHE-*EG<K]I$^)]>JZM!-#E/RN.SY%<HXW[4V)S=H9=XW0
M07#(DNDL0JZI.=X02.ZP(HAA2/0E2CC'CFA_& 0:(C3.6D24.87P16_2UGA7
MTP>6Q6,EC3"X8BBF""?D_-*U;EW3M;BKK]@P6[^'LF8[;UA&'](K;'3IBX$8
M/'%?EQ!F+5:5WX=SWY9]C1K;'6\F71V:(/D<?TVEA[]W V#2GIP!$+?%[)P^
M@,N=?[V/8@E7;FQ;V/7G:GE%M%_MDKY,SP[<I<7&@!.!O6K>P+STN[^VMP:_
M?GHS*OK4+DT7J/<!1ZG>4 V$S6#GM13#AVNC[$4UYYP5\O%/^_LJ=5^JR3/'
MQBM;D\>S"W96)4+OG[%V@5?"9^?(2?$^W7NXIFE9LJUZ9G70ET7,^+C"I"YK
M%G'L^CW/E__T?"?EF.@4H@+6KS=OO6 U-46@QOF&AP8M?]I=8*TBL4<:0$@V
MY0F]101WL$)VP$A1@:_%VDY);(,\_EVZ?&I\#(>^"@!WP;5T GB$LN>U9M6;
M^ZEKC0@#%RD:*.N7GSI%ZJV9PV,33P&GM",R.(*3=FOWL>:Q\JT)4N7=C7RW
M7V[^ AJEY:LK+=U-50# E[BN4KL4WW&#E3U_10Z5V/L7.^DZI\H,Y5])9\P-
M,MWOQBNP4G!;I,AC1R0$7&K21165G#2;O?I1&Y!8)O.=FIR-+[DAJ41KT) ]
M297V).=2C;@R&_B)4)OOX],8T\1\RL-+YRYV;1*8GY%D']BC0IWPF1)'I3^+
M6C%.3_\9 _DU0-N:UW/N7+?ADKBHQ.+-:""="6)-:)*.MX#C<\5RY=.?GA+3
MB[FAZ_.W!);&VE&_QMZ(H7W6Z4]Y6X*?XE0OP95VB*PTJ96[42]>(!I_-OX%
M2.X\CBUPL+EV=UC&(\42"@+@:@@B[0%]6:1MJ5*YA:KK(MN5^:38R)K(BI0!
M"P&+H72*FDRHB(FQE&2!1Y4"M'KER#6%]FPW16T9HQ%[R&OJ?;1OC<G]1Q-+
M2FM.D[,S4>7YTUJ!=VA.IV5,#L$ZYI?T'^6+$[[LY/$C3LL&+(D$?*@[H]'K
M-&BG63O]#R,<F!6,@E<12ZG*H:=.-9Z_SG[]!0RZ%*+?@&T(Q<*/(3:O($"^
M04.56VM +U?<37E)ZP+GTFF0=%OVP*QI=E7V\K:VT)N\M^6$M-2MM@F!&&J.
MNLH>U%D'56601YX&EV[)D]=-U%1+\70?K8\'<'4P4TK41@!D"9(+%6>WP;PZ
M,Z4MJ$E40-Q?@"-\<^15/ &K]>R6*PWO@\8*3FCKHC"VXG ^[3_52 '),**S
M7$E1,S: IE>P,4ZLY3"V8A6<QXPWMRP@5WQBLZ$&:&5'S[NFNQ-\25!<T"0K
MN\>H1%_#%HG9V,5CD9_]MANV$G;[LS,W'H]&QO$&E6'V!/DCK3X93/ S&K@I
M,1G%5V9Y'B(Y'>2"][U;=<DUM,QRMFNN_>-,J$OB+,+U[65>S %=R<J5&16W
M'G^# T/H)B?L-%S2*\N<\;T!2B01'\V_E!98I3@W#6/7&RLOR';>==U- F$3
MP_[U.SLQ^]O=*)%-LNDB"ZO.&ST3T3WRB>@&%</P-"E*@P0%!L<:KT$[U<J3
MQ4>2N2"P1Q4M7,G5$4EU6:V5,%;6M/47(.9)0YC8ADM1+97[AW*XM#80]U-)
M\T+MF??%C[=2W%DK9G,'0A),KFN?B$F>#$OTR)#8_#]K0M%9COBB9"5V3%H3
M.[)O$)0.3DA:P5$;FUJ;3Z$\!\@3#_@(3$UTGBF, 7-7L;Q>?>(5 FI(U;DX
M7AU^]T.JYG1\H#YC[)-!DVJI<)[S$7<I+@=5>A!HE]YW[AV=#*]>?%%K#%IN
M74F(L#A;%9_&'GR4)&RQ48>^^UH8?;9D I6W&IHW4;:F0HN8?N1EU6CIP=WW
MU/**PTK4+<P=M,VL1[9H1V=USBOPK([:NGYZKDCVA7H$MX"=K>Y]PRWEC-4V
M7PV=NASI:)#ULM(X:=)>N5Q@1')"RT[GLQ@!*A N?-?P<C'1#R<O(/WEZAIK
M2Q9N-)5U!]2:-L"'Q3''D5)=(^5:]<+[D3%;HRM#/]XAG)6RO5'_G!_YL/9.
MQ\_NS%J%V*6C,"S'(:_(\BCK+R!RRR[%H&&N)-QT 2S_%]!.,_UN:U<VS4L5
MV1*K?VD^ZL;#]X.UD.\#'FY*$>_)"'O,T;=B7#C$#'H3PGP!U+;W;#"W.,LU
MX\1AW1\1ZF=^ ?2Y13RM51Z./W/SH9=18&]@MIM'0>;;4CP.U%MU:KGPB0.P
M3BQS*<YXF0)=BE<A2VV3-?4N-7)H-V!+Y/?B-B>'!"WW5US.=2!<=\8$#S-^
MR)^P'4NQ1RF"^I*_ (?@CW:"(N>NAA'<]IH3*D+_+AQ-7Q%=CQR'U$"Q3(^=
M=3?=^3,$M+FDC[=\[5L]L:K$-*-P[]:U)31W;,-4P;M^E&Z2;N290I2.BKNJ
MK4;W_*F/E(V;/W4V\:WGAR0\/1I'1A7YK0OG21:0B'^C',WQ#_V5#6UH^2!!
M+T<CD1@C1852(V.GPI,ZD/1MM9K(I&F'9+.J9JXKO\\/%-/$GQ]QH!&K"7=/
MP=YAQJK9;V4>)OM<U](*._%T!W/H*UY-T9(L2 UT@VAB1%?7L,?A'_[1 'Q&
MJ^DCN[]>R+9OW\SYX)VCU0MH$M8[FN.7ZWQ2Z;6)?BBL)\<9%\\J#WF(Q_K9
M[ZSC_P7\ECUS,1%98<_=CFY-Y) B!O\%V-GM K%B*H)M RL@72*HG;I6Y6ZD
M"3\KS-3^LTJ<N+^=*RU7J(H:(^^,4^%.?9\SG;["CCJ1WAV1YG>[>:-9=._A
M,R6VW'[//J4TEN0U3- @%)*EW#I?\CB:83B7[A(A/,HUR3<,H&)S_X[1<XRQ
M.U^KI,R:XU!$>9:]J\EVF]^-XL^OSP*=&9%.B$MN)<5@R'TOG\)@83"D/Z%?
M5]>\+"VCC!SC_U/9"R'H&^<K%+%I'V=W'Y7&%)(_LHI0E@H;^Y-R^/CL+X!D
M^LX_J+QQ)04LQE@^/-[#5;]U>6J:3A=\'"2RA*";VG:U=]D4("?'#9Y8=6\9
MG8+=UMS%"+#'F=2()))"S*KO,CS-9%.:/'^22B,(0Z-HE9_4^=-BE=,6@3NS
M-5HN79O+CWX8-:W.;5.B7+U-/K+G."9D;EWXUTQ5O3FZ:\NM:^Z(G?P8T*JH
MAEU!*)Q0Q.(.$P'\EDKK: @_LDT1S1)- D80YL=M)0RU$@5<+ >IS3K^%KG.
MK\M18]'\'ML: BU*'V8 :-?7+'[=GST]6$(@H_R5!SM>8'*SVQBQY,0Y2A/?
M1'DL+8JWI?_SFQ8OP6?SWX;A<]21Z::OG/K]TE6V4V#8=F%SC4CZ22/TM3;R
M1;GI4?=;POEET^!"_9<]R_VVIS2@WQTYUX,^-_HMB<(-<Z).'<\I)FU]?U"9
MG6S^*U@,OMF/(!:2STW$*AMX#+Z(OX!G>$&FV\&*_9K(SF>1\:@UQ;L^%6.B
M.C=\K\B3.$]03=-_T"+#N:3:CJJN*:Q;ZEH .!JAF$Z@K;P1CZU-J5.REIL9
MHO$EVL%E,'6#N?U9'ZJ.5OB>67[3VY2?"3U4[VQP05(CN\E9-V;<6-'(^9H.
MX6H(M=?JM(<C4U)64"V47&-6K5C,MYS/X$H(UR:KM12RE!6%1!R?<!QD$VV%
M\_I>+=CSTH \4YZC\8" ?@G:GI&:FA@E$*-5WV^M!6]^PY+.!=:&=/L63@Z(
MH9U.0;A*5<MS1LS4<$B0X@^ZJ5S'P+)E*\DC] =C?HJZ+W!OB[/EQ*B1:5HL
MH ><%U$8"@(_3)/"BE1:&YLZ8N8U(0Y9+ME^$5Y"% :&[K2)P!0< *.GBUB_
M=J=V5-9MD>D:_P0B<+_OK?5Y:[8K-2UHF@FY,:NUY=$\:V'J+/L,9=?8%ABH
MQA&S.QJV#UO9T1&*(;#E4=62J/KE39[(>/S# <]HPUS*AB&>%G^ >@3[!RTM
MXU=+1HK0W9NJ3QWB?@CS39--];O8(X'38B32_\/8_4_/_$AK%=FW4DQIBO.*
M*._?S'B]HAWQ(F:?,Z@):#98B!N:\!BL7;%DA"W__ >=P15.DE%E]KN\3OQ[
MI@(O6-/79&W)L=5&\8>7(+2W",M_H>Q 59^]_;\+Y:*N<M]P3GYWW7U@^;W+
M;Y['X-<2-:R628()K]X.J &'YON#9_S(AWC;YV:+YOB245753VE-K",:W9W7
M*:+^W^PY_;^ZO2YA4AI1TT9(HY:K6[8-!Q,'OO1W7 PVF5\<I;,R'P3M?CWI
M2K!ON6))YGCF2K^>UK^?\-*SGROAL 2J*T_K9P;THT-)-AK[B37K#NZU?K1Y
M-MSNNTB(&/(:Z=V[UC>#O#2U<"97N:+JRICZ+$B#^[9L?%B#^R2K4QF@.R?2
M(F+)MJK9#&&B]UY&L#Z)_M&#=5,N$H_#2#>G+N%:P]$ [9."-%%$/P/C*T:Q
MY^UP(IWRB2'29*7#V\.SSW8NWPI5%WJP_2P?#VV1<G])\4(KK<!_^[=4E3HW
M64E3(&;I'.PI"3'.AM!3EEIL4@7<$N=9>=HLWT^4D7L_YBS6K#8U"L5:6WE;
M6+[%4!H:.'*%C4H?( ;MW9[L#ZYYG,*WN-.:R=N=^BYG?&1X!BDPE(SFK!?Y
M"\.W]PQC8(?ZM( S%4)<ELMDE8+BWO)U$PN-*][EZ<,!TE "*&]$\CQAP-O:
M67F:#":ZA+-C\384$N_4MH7ZN2-[09P$B.%T0UXZU)P!8^9MIM<VH]@QHR*(
M;M=G?Z;]FK('Q@%XXC0EJR>6T'J^&K-1&/I\$S)[+"G]"SK0T.C58Y.B$+I'
M%AY@*Q<E4YE[^!%ZEJ'E=.8*K1&YY77SPK,\QC]EB=(K)L7578TS^F=W!/,'
M[VV7BEX/CLD95 QR?)K3I"$4"Q. AN$FX.  & RCO?D4I*G1N7=%%#-?\"T:
M *07L'ACX*^</ V[0[,80#\333,4SSL[>W7\2Q&W=;IB+/")8%T16RU+J +H
MQ\A.:>.,'A%8E*#]I%/Q6$2P[X>L"6G%[U5#2A5M6B!Y6-P.LCR?<)R(>%5K
MSF$^/VM+F7=L_V&RIE2%SWT\SAK.D_K-<[ESJC)#O*VF/!WQI*X%ENHDO?7.
M0#<%!SRZ>_V-.Y\PFXC-I$.0*BW8GP-5NCF6M:.A-C7@&>*N<#(3+E/!.EO[
M-D5,E@VU3AJQW^C;:T(\3!J16$!9JPRP<8;308T>"5I%$2KDT!>YV!Y\]&^A
M)9[B*N M>/%MV=J]#U=G^*.,RMVJ3@+)UTZ4K-51*JB_BE6KXZ*H]K\DIQ#)
M9=M4:TZ7,#-E@IA!#M+"_.UD3+8PEMT!6(P\N<.1U:Y09#F3>6A6NVM.E$7M
M&/7^;@*%SR3T7[+-?UO\01>5'7#.G:I-S :($]M'^WD<'<4@_+=C>9=]ONRE
M;PE44V@C/XXC%>,[/'K.L]"%H<)ELX@S42*QVPU=3CC#*PP:Z'CCV>[\/,70
MQ9^XQ"K:B+&L<LP=,;<,##$;CY&M@%O$:VXL>&S?2_ZA7)FIB@K+KIQM1,=/
M<GRQM%[\4''<BG&/I1KO4Y$O?#6B>$7^!&_4#U_3Q&'5Z^_OEOZSTZHP]*5^
MGZ^@TR_?/,(?NF(Y?F;K["^R:0]EC"$C0%*#<)+7\-7^IGJPG^C:_#$UM8?_
MLTF_QE3JAVL,0X,7P L<\*'H/T?;FL#\W^FR0K4>#Z8D)CS04R.VANPT'#K"
MUN[BY#^W%F /K,YU"HZ<!>]E,[&B$OJ,E4CQ/2O5Y+]7>H1.J&*!:J)B  7$
MJ=AT"QN5M:SP8^X='R 40SB.T%%.\-P@HV_Q^39RYD,SL[WQ,]RU]BO@M>0N
M8W";T3X%QNAHD87E_=7C)5=7 ^80=L(!0*QYDG._OXK]/=[>,XFCK.Z_@*>E
M>7]2J?(.+-ZIEW3XJT< &SX2FXXR["6XXS;Q^L8 IA>\8:*ZKM/ &0MS\,'J
MFKP\+)M&8H0E_!]V_'- ^%+_A0+_^L /8_&,#%W_%U[NQK#$AG)#0]T4;:P4
M_TF7?X5>U"^F!)YKW!3;'9T'QJB9NZ\-R;6WQS$'81BMJC4'6T'5.KJ\FPH7
M,MB=Y <;)*8\ASO?_"/!O8LLA9+>,C,7NA)$AU'?<K4;[4:1=.Z(O*LV;[-T
M *$F5Q3?PKOX#TMTWHLZ?^"TB$QU?Y/?<0PO;6:N\+#MF)#-R@ [B_N C=]@
M,>H,8Z_Z) T!,WD.,,98V]83O:<T (S3T0FC1]HH&>=-XY;NKO:N</%XN]P9
M3$2"6&5EG&TY(.<:+MBJ#+!WIJ/P:_M@]D$\PTB\?NCM]6F3_2Z7E(ED0S)<
ME9:2XI$AQJ@Q]\5Y05>32IQ54='KX[6&.GL>!0F)U2&<EQ*(2FXL\D<R%\XY
M'UY:A]:T6Y:^XZ.5H".AEZ"AV; > $!&<J%JG6[C3^-!VCY.GP^<O]BS]W7H
MFG>OC*"9B X.0Q=U<^!X:T%75U/4;82EN0);],$[ZYPTON(X3-T,"0KS>Z,^
M]+@*,L$\\04X=2(TW:(>/7[M,=+/] 4QQHT%_$8F4.]5H>3G0V!9B)AX7C<L
ML,"#-Y:.C;6<$)[/1-&@R:Q9%Q/X)5MS>$4@.6,R+BS<W[*,G26\F#3 Z)0"
M(\T^O]_%P\M'=')R?W_@+5=K"V^'BB1;I*$A+? "Q)6#TH,YC&D3F3MQFB<V
MK$:'2]AT_'R'O[?+W"<\^ \D_F>8;_KV/_U57-I>K-N8\M) 1UV8 2"C"9",
MF9Y#3HJ;@^FUVL$#JL0 EL2>4(]S,XI4/6/YW#M\[FIM2N=F,]D8@7<?.'U;
MHBB%6>WI]_#!@'"//#-KZ*S%:0VB8A56*D.NYZ*>)[M0PY:U2!7KL B(,O(]
M20XGJ:6$=.@7E6PWN92.3>Z)%.(1LFF?T?I^)YH2;*]E=,)Z&S/>?DF581]R
M1VX!ZE!;U'>C> &,!+.05A;7;1W2#@<9NMUK-&*Y4?8Y8YSNX6O,#GQ/CI)@
MLL6(_OGX*,G\&K!>^%64A!028+DFEN$G)<"I!-3E>W?*@HW5R"V5*(,KNV;H
M,NDZ=]UO%GF;4/YN\8E/RCXB$[Z24?/M"\[(XQ'C(,!5U\*J>8=V>]$[F)/W
MY%[/R<H\MLH25)RBP7.Z3.C:PM'@3BS!8'2Z&7TS*;BQL;/C;Q_^<OX+M/C+
MD&#.Z'X%7O*TQ$,YEE7,5.N2]ZJZB\O'UFOVMK^ 1 _7>&'-H1!E>75"KR1)
M(\[N'?N&EHO;">IQHLCU58Y^28RTIYO/"86*7PY)@';1H9)CO&+35O.UD=.I
M?#%W_=ZSFEB#;)A">*HZR^P%0\3/S2WG]<'-"V:'5,8X@A3M] <;\E:"R2FJ
MNO)T(H;JFEI3OW;."/R;QR%<:9)I/+IU)![3V)X2U550UU6#1>\C/M$<]#3A
M(#1DS$-V"-\"1$NO37.>!?C&75W%_ P2D+NT\KTLQ>])6HSYB"%^RE.'5:26
MP87:-,TQKU$H/B^EM''AJ+0N8O4T2YOG^<2SI\ 0F.GK[USA./2IPV;I)P-9
MEO!\=-#7D:48BB]LS2G&_8[83_34?FIINPK'Q0 6"C.!GRBT>7/8GCM(?'MB
MV[OSA_CP^P']W.4:I<D!Z>@^E4U2J6:[8?<*D$E^$ "=-2$]SL ::DN+FZ]<
M7EU6DC#"QQ1T)!QLN]%%[<9\==NQY#G1B1GD2G/,$5;D:$X1_?("6"04&4(<
MH@<[+ &XZ)H:PX%SWP5*FN#^A$GED(YL?P[2B!$AH>=XPW*"#%YSN>]W&,4U
M<ZWA$#I;VHSQYG#PBO[O"78CGJY#P Q.+N48+&*@PE;NHRL"^315L[.5#1*B
MUZ"ZGP*2 0UK!1H=Y"%,CE,T*1M3\/*'LREF.H2XI<-U>R1D6P8!;PKK]0<#
M^%('Z=:[5HJO"G-Z6<)5#R,_U_3!6&Q:I7T0E0#N&M]QJZ]ULZ5=J-O!UE K
M:69(H!=IW#F:-%3R^:[';I>+8K_5/)*W&=F<I2VC\YH]'3>ZP9$^(R!^''Z2
M/')+@5&B[!'P,89S-HC+IUPUQ,=T\;(03!1;R<F!KQM.+!87.A _S.AB=6*H
M_JDQ(T(7/LC9)OA3>%D2.461^\7GB21Y.V,YEF_,2.>E;'*9VHF7%UNUZS-P
M^H9JC!@7C3_EZ^>C#,\$D[.*JF'ED!"NN9M-3L?P;0Y()M]!6I?A$U\*;'']
M'*R$^WSB])CQSDNJ[+*Q9&V^(8?8J:N"IG1C@\=KGN<\,LO$CY]_Q_MI-,W;
MH)A.S18]JPA>$4;I;7JSE7-\N@' NSYC%"E[T;V)?H\,<O1SA'I;C?%2)/7-
M?H?M;_2<$6(][V%@K@$A$*I&7^<6V7W8HS*;E!D\1!K4/%*1I%026%Q8,8!V
M94=P#>1RI=_;P1?<P*ZV[9<6?8QM33UR)I@<D?,VDSKZIJ(Q&Z$KD+C"3Q ;
MY91KQM8-$R)K(3N*F\$IH8R6?I/_LS*^G >/=)0B1>6(H5(PCW\$_X\J/K@J
M*P1I4RER!.7]F;Z']S:+.NK5R @' PX@X2.-A.QGC)"88>2E2J*_#V4'M8:9
M@WV42KARS-M.134#]ALY;WA:F9=[>M.<-MO(6 10E5YM,[P<^(@9RE'8LBX\
MZ(: ,4$5S3-%QDN:_8%M5,^^%/:R>Y[1!&',D)NGNOSRS>([/7=KMEA3.GB%
MS6<6G&]760Z2CFCT^B:13^3,2_!(SOATM7'<C_V# #!!"F*FUI0C=M]W)B]C
M0KR!##@QFZ_^;M.9?J1!GD;Z)2QIPOSL@R%VO<P_+>Z$^8=276OA'=)D+Q!D
MVE%VM:<:7P1;G4T.M9?3U>I"(;SW5%K\U@[Q&/[1A%P-2L=DMZ)G2^=)&Z_0
MYH"DX52F1WG)#@+Q54AKKDKEK?UQ=376\SMVZ40S>+\!$M7_)V>"3MH5O 6S
MP)HY=2<FD9#H[;T1P?",Z>M N19>-F64%;<@X7/^P$2GGYFOH: A%2%G]3Q*
MI\6OKU/699?MR-2%S$<N!E:P2+CU8A380>R,E_+T(H8$?QR&-4@),K.#]J)M
MHSC3P2^%? LQ!S!088,J00JEL=QG'^:$U"8^T2FPOYXH(Y3.;[^2BO/8I, H
M4_8*:([>R>[-&JHHLF26G'LN[Q!=I<Q#')<@]/2&+5O@JP])](V+7\Z?]&!)
MET\H%3P'RR_2A#^D2<P 1^752Y<XZ5E/E^B^OW<4PL->I=DC#[O:!8T."6;-
M0,C8A-JQXP1V)GNP4/\01S)FM/E2(,VG7/EMZMC7*=J"9ZNC=!/4*;J9BMVX
M<L^EO>;*FA<;3Q!BP8J\25#H1+BQO?VROM35TVD:F?)_08D5C[F!08V^34OU
MS7P:5X+PP<W(DJ8HP?*J<F(2TR4"!2&)8K$<375-%^M:8CSR'-3..G4ZF_T]
M4^?.@)7"UG5>TZ1C*W:ZR#E^1/P<T+ZO/%[#R0/^D+JT6+M\'Z&%<H./X7&J
M%\>]MFEI2L%]GN.*J:RG AO))Y+DC;TXC^?/5L^]C3WP+^S($D^&KJ13/*/4
M%DSVS1\"O7-$N%@>&S_?U>3I>_YQ18"?*VV&6^K_#-[[Z!N9;W7T*",I6)FJ
M>O^[)<VT[!'(JV<TK_+6A$Z7Z7-L_:PD%P?_U_. 9X#1+5V=];^ X9R_@-O)
M[C2 8UE,D RP4&2IL2DY 1.Q9Y=Z%+>(A)%$34>J]IV:'!=I2\*/9*?;W=#"
M2%_H(Y_K@^3O)4V7G6#;WDW"()#GW8GTU^G]+X?8S2E^E 3A+WW#X@[C/.29
M4JM=S$+"RI!W9>XL34;X;VS%N?+[PIW7R%6]W!@NZF#%.M_Z6]A9EG).X*R7
M1-VA;DAF,MA[#5/EB;<$YA^N;9U&&1K.Y%X^R*;Y65RF5Q0[6S'4S3>>F">>
M\@;]!#V/ZD%3'.+GP[<NN+$Z"SL.Y&CNNYC)1[>K$%SJ&;HI@OP==6,G^+6^
M07M)H*.(9#,XY:555<6QV5!\U?)J:469UV/,@"JWC& [T'?OUPU-/O%8S-4?
MVQW<Z$8.:K^(?FV:)#R1;R]HSV:8!@YI&4=PC\RZ7EP.%15L.GE ?,FLB+3$
M[#]%N/%'+F/@8J4?1MSKX/HI^Z]OQ@5I%S!B:I-"%L5F-M9$J .%--Z(CRD0
MR^_"O6864;*<G1WWL;)A+HSM)F9FGUSM>?P^RE P[+:<GLC3+_WJRBSY_CB#
M@O)+3WS__>J$Z;O/D-JTKF;]8B-"=UWDC];4Z8Q]^H9/4OFM!!?EX7M**^X'
M]6UQ^.PYF^E:9X,*$**R-Q8I!\M[?2PMYU5*SZ]XK7G1^(NO;G@:[7W;)'2A
M-K39@<.-55G8T30]'/(2%<3VR-HT=Y,,=6E9H_9;Y\;-XU?XZ2YYQB5396MT
M'WX!<U3NG'^78JEJRI,^H_;3P!5CE&8*#ZO9"H6!VCA!.^15FD*:C64M]X_8
M-F3B_'9K6:Q#)!!T5XQF4/]'SGL]_A#T&&AVN;A):PB$<4,TPM[E H-U#V0\
M"BP&R14O0\[NXDJ?GQ%4JK0<AN#Q@5D @'-YIC!E=TGQ :-@<HL\\T:U%XU&
M*QX,V*=)*0;0*8]TFN- NC*YN =[^WSE'1<$+UA2.MNBER'Q+C(^&A\L]\)C
MM?LUX/0\2*'D"(V 9_KYLG=T2(3SQ_E=)^1;AP"-<MW-NC]99P_"R:C0P9$#
MDBG^G[P\<(X*]</%&![*%K/_ O#</M4^F"*<))6CLD[MQFSA^[F&U SG@)2!
M0RR:X0# ^;=:H=1!L^9/74SWD9J(M*XBVP,%6/6$3NE\2_XQ?3@ F""YD!AU
M[3)S3\8)^^[P-0&MTI# ?^#@/ME_&.<8%@.X,>.E[LM*J*C\U])=F];_ICQ)
M)R$>T@"HX;IX"LFX./_O&W&4 &-O;4[!R_#6JU!]HZ/RWP( PC<D]V^T+M!3
M?$$'D!&!N28M''<<P&ZJN8&N/DUYE;(3,&7VB6<>&:%M7V;F0TO7"K3SQW>T
M],+HFF!BK?/QMTK:'O2?4!BZ[PWA)O(^BY8-!?QM;EFM&ZIA-S(Q2/P8"_??
MC5NT2H38BT?^!6PS+SZH!T.\:V;6(*'R0/YN]^52=G:<$6L%T+39+<_S-2.0
M"U#W4EA?XDF&1C, WK+)=8_?&TDI2P4K<HZ<6-K;LI63(OG&._NM<,N#-&A#
M_*+75?M.Y"/7T@\?)8.=_IV7C&+/A[M7%COI8@2H)'Z^WW._*/L#LWC_31!E
MQEEELWVR'K)IUAHS=J"IJ/[EX0#MRF8M1C&]N07M&1T9]&W4$9X\%?G&U\%?
MQ*ANY$9R[(X<6!2>H'SU^KMV^O:C_E7#PX>(848BL;\ 8_CC4B^ZM HZTIVB
M<K7]3HBG:T61(>DEUF]BE[GRPIWZ06"]RZ-P1\=<B7FV26-ZX[]&U5N;5VQ?
MOC]<?F^W]+@WVZ3A_<< I@R&R/,"^!QO-(7]Z0J'SH;U([$*CD>*"B_J6^&V
M;<2EX407TY* P"G%)]$JN88AW, 2Z_K4<^3TGTNCHOF=N0[[;80L1O3I37OT
MTB:.;$@9PM= UQWD!F"K_<C!DT_5U<8G?QRT2"L7RIP&=7'7]LD_%KOKOKSD
M;_Q$+?$S)DG.K%N9%>[E7[Y\+$>T/<-GJE5S=VDN )=;&N1)P_7TD2\!\[GC
M"!^9!UA8!RDOFO9 J+61EO>'58?7/0]5585AE#XO?C[Y1S!+U'\!,YK^:5TE
M-L$7Z>,*C=8^YM%%4;RBE@T9:_03!$MN3YIO=A$!:1-R3L@LHM6@ ;LIX;@X
M0QE<]<>!F7>-TU)3O_G4J3.;7;_[#6G)25I;^U^9P4XLX!)6.R;>,,NWVIVL
M1*SX,M.O>[.MLBU0#UP@U,U)Z-(H^^J*XF]$K,JR*;,_[?%+0W#O;H15KC+
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M9O&]&93N')RP:*X&I&IFVP>2@_A4QV3/A"27O)0!;^_U?_L]DIV\OU>[^PN
M['=,M@?8[4K)6NS.-97__S$OM5J.\L@OJRF504R%R^F,/4O=?[G:C[N,4XR%
MB60F 0>63] VA<#Y6#)>;E&<2&B/008P/[ NJF <J;H],#N\LRJX^*&C/,M>
MUU+?'@/B9S1<1.M=GI$E7T6R=G^D'1W96]*M4LB'S*Y '%7,$QNELH/%T)1X
MK  J!T4CX01B\VXM2-C<K)71F>U%8B)?46/*V.+Z:-3LV.-ND/,$SJ(]("<'
M*RP+W38/%7'IQK=:5F1M@Q]9M^0\L_*&?:E+;NOF(0'U8L;B'[J?UM/6YV"Z
MR,DO=#>+T,MHCUS)SC/]!;P(.>VXF<)YS[-_<RHY;)D]T(QNP&T/OU.'E3GT
MHP?IPN'F/EHE#8(I_I,*!=HEB5@PY[%?0Y:O7:*S1QKD:=2;T_EH/K 0,M3O
M-HM@?!,Q3OOZY8%C=YS[%-B ;/:T:?0L&]FD^XJ!S)3GX@)L.33=GHK-J\^(
MK*J;/'RYY3V!B>(M88)G/_%W_LH=#O=Z4(E],I5U8O);/-K[E'=D_6ZD)'5R
M,SY;[#+.*W>CLTJKY9-(KM3K^^1"@;QGYGSI&1R('2G;-VWBV S/9488=M'(
M!X] C[)[<=U69-KV9[;:K!PA'.N2L--0\+0SCC=E+ [2)W"'?E)R;HBSN=YI
M;F?'/#R^-<.7#)-Q&=N'=[$..<FE??%S]D6CN0GB#/U([WD1BO"@SY%L97[/
MXCHZS2[R%T#X[9>=K. EL!ZR^(FC<T*1VH2"YH>B.%1B%P0:MIAA;RQL3:2?
M."D[6H2[#+H%EO=#/4<&M3\/[-EYXP)"1!VNAOL?Z>=J72<KE]%"W)GO^E7;
M<_XIU:"!)B&0-*:'FL,M90]DAY<YVNR=KR1%%I^QKSY> >\SOM77:5)O?6EI
MI7.8G)E)5OKMM];-+:/6.19871;#(13"RLB]O@(Y;T=@&"I5JT^&JK"M-69J
MSJ4B^YU.D=KIMWR[)8PBV'O=K'E%5+7W'YY%]UD+[7*.DXX?@G4387\!WN)4
MHQ)\\A(W-;'#\6PP<C/!X/.&.CFMOX!2)YI5.?*1+.(TGW*SK\YT>6)W1I7B
M=2!K60> S4LPD+BK#PE%*J>C_<].744N7?$^6T9B&-.NMX+U!+]I2>U\]6$F
M*:TO@WPULU*W"78(0P@4ZFQ8&6-3NM*J#:G6U;P9H"NM]=M^3^&4%:[$<9!'
MH2<S6&/H$)G-Q1-R M5/SO$:Q)1,O%=G%WN/)B@Z1I3:^JUB@YL=?]Q17_O^
M^)TY+#'XIGVI\41&@%_Y\)K_$,URI>";F7U6B3%.;O3JKE^#_#S.[*G?V:[K
MA*.<AG&VD^ZHF]O%GS,_ GW^J<E=#/4J&M4_USWYQ+\V#=K:DO.AG'=##O%9
M7*TF&T*J%?&KC*K8<7??W.$,"]EF,Z?G',H)NP<)L"4),%E,'>TA+>X%PFP_
MZ)G6.1G+<'K;9(\&P^Y9ZJ]4-4?#_WUS1_4-X"Y0GF,7&-QT3DRP\/G;R00)
MIAM\/5TM[8+1R1U-L/1K3G*2[[J!=\_:<3=71Z>$ES:1SAMK4W#)N=-%?RK<
MIN2LEWN\9#G/).D.M3_XI%]$Q_[6;/K^6W6Y:T3</R^0_FO[/\VC&QRX(X/S
M*U J^M+N! 3[@AU$%I$\I"D\5";YVT#;F+JVIDKEYK':\@(Z\<-,<WQ-&S@E
ML*\S!WH+&,*5J5(W6!)9I]4YIH80_P6TO33)Z\%TR9L1 9]Y/T><_2/40^JY
M$4)B&U_<,MV14DNTI9,59R-*=OQ]I5E)V<J/_.M2HU&07)Z5Y(P;_@)D>[<,
M:M4==;"^%..MSLV2%7B#)WD65_G5E:D%@)K<(>(7649B^98N&C]-X:D?9UK&
M8FN%VB!!;GSK[T3--66VW-8A^7B&XTPT"1$%#R%(+7YZO7^"C5@MI-_C[HO;
MQ(9Z8NYGVS)F<91/X8 ZO:466.7.>.6\+.]-JM2**+T)\ND[)@N+B<A9,;C\
ML5><H;G<,PCUCU-;EV"&9BPYGHB(A!:)W@<B&V69LZI=1MF'(^JFQ0HW-M<6
MS>(<IJ+[@$LX4ETE_)'(&;W1UZ_;7$]X*FT\&\$ 3*B7TQ^5D7P4,9G=Y0'5
M&!;YKFR@ _P"'G$UN6(:)9 D=5U%I"U$C7&,^;^HAN3,I/5%FAYINK/PK)X;
M25<54;+L>;.UJ ?C'TA!1"85YP>$7ML#.1IC[XP/HX#AN$M99QV:4& 716=S
M<P+8[F6D@8YI(GO=B8+()665;L44HC1[T['L]@?ES0MRB)_[BLE[)[Z, ^RU
M,@^^504Y01JNRRKC1^Y9[_':AO7-8B\_^>KE7UL,(:(? \NT6"XR4AU97/S9
MKWU?>='T'?KB,MQ.*F%9?C/.0@E_\\N8#!0&4\PH=UIJ*]LN>SU\HUYTZ9-N
M:-9\=XJ\ZQ[W*NNXQ$FU<21:G[Q1QUX;&D_?O,$"SG)%BY0C$#5VG?'6K=-I
MK+@NUG;7"7(,QFS>_C>;)!"RM95C33^,Y#FH!"Z,-L$W[>SIR<V/<E%.E+[&
MQ:JSF,)9Y+8MP%"?94I%55Z3BJ)^H3#[,[0P4.:%R^;YO/:5%,%[4@@:F;9Z
ME#';F#0TD!(GYM';2\M^4?WF7D,?/'M3U@67.HDMRD@7=4)Q[A"$?<WQ'L(0
MI41T;I35'F>U'36+N=-3A>G![L"\NS6;_<QIAGG:W=HX]\'I0SO@=V=&IM8F
MTU\HA-^3O'G]%,Y.QMVJZ@UO\O5U,7]3/[\&JWW5V-P,#]PW.:,.>M/^UC38
M'4=UUW2#:V'Q/6%_8,F&V'!K_*NZ5CT5=]7:;0/DT:U4I^*4#W*Q8'ZO>6J5
M@D B58;Y=U'9STG'P9)CO"U;YT5QQ2UGA8>&R#Q756EBU>[7F$T\C3^/5M5E
MWBVYB7<K54CFI#\"N\WC%5_4K:+Q-%L^-0_/\VEMJ%IAR+W.ZA\T$R@3'H0$
M,<X2QG]9E]=%[87R@M*/IP=_->4WZ8_3+;_(:!#^1&.[C]M:?8KO<L2&*DU5
M1^$T^Y WYWJX-;"&70V5)&KED$V'?*:K5E9#[9_MSW:2SZ'_C&PV7?I&^(.B
MB!3HY FLBPA#A3R2I[465#4N<^$-S76*.QL'@JP?W1T)8R2\KBYO3BS6X^%E
MLE6%DZ)-3>>$)W=1[6_66?\";#QZ=FNUTNJ+./933WYYHWVV(/MPIP.R TYL
M=W$_KAE=6SI8AS*8]QORV^W<24U45QZBWV4[VU+)"%60"@/EZI1[I<8)8$@'
M^E;Y,K',(24<TJ<N.4P,&B,@A$5+V ZME/.UIXV)A!MBN3)]RQG"Z \_A[2Q
MG^\E/U+Z;A!TZENB?"+G7=]MB?&[5DA"4QQ.<KL/\PN'/E\:9O!!9[W]T*>;
MHT>_L@5AW?)9.S3LJ"((YU OLGY:7NLE23V"2$F_80[1-1OLGC288]\*_ 4
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M^Z L?^H#XUMYUZJCF1G_Q5QSCQ>,79UF"V<)MQ/&\,*ZQ/;[?.6HP;HS@=@
M]DG]58:XEVF.)%^'1!(2QM<S?N3=3BO/[C1&IIMXI@_9,WR-]4(HJ+[:^XNC
MFIQI(O-@Y=2HP8:YRS8O3K#K/?(\]#7,7M;@+%Z>]EL9 J\]YT9*VHU>P<6!
MOHN^AB&QN$G<\TU0/P&FDBSG_JK6EL/D_V@4_Y_7/174P;2RXA\)BOI *=\E
MJP"PBJ()5))Q\2<^<S5B!GV'Q=E?;SMC':-1;6;A>HKI*&A@]CGM0+J5^%V)
MU31/+@?X\7-\TVRV=VFM6E)QV]M!G-X>9>3.41>CI'O[1A@A/76P_  G(G@&
MXTPQ6]TH,\B.6Z/!JXNZ>3?C@--7CJ0CBMU5#<7)C<#%D7+[0SAK04 ]P?U?
M!0@ 3QK,Y'#)?Y]Y*Z NTN7+=V\1>S[/DX6-'4C\G,&*Z3@)J6TRS_5Z#EP_
M"E()GSV>C*V'W;PU=U=+_9#\'@J10Z/QV@@49*Y >NA$2T_:-PA/%L@34T=W
MF<H#S"^W(#[:VO  :%5H@TUL2EM;CWOE/H/@R-"KS[]38,\1W%E@U.+1>0 U
M/\D0R.XN/'/=D.="M2Y<+AMJHD&])"J49'MBJFIRD>5R!?6)-1LX8TQ-V+*_
MUR0<W3GI6PF3Y8:XM,PW &S5#)@BQ&0\2F\%]9OKISYEJ(5;$ZZIW,]ULIJ?
M#VU:'EVT")'WV_Z:;*@PUMM+ OVVJ%^HI,OT__@=0&5&1=#O$F^-FI=76\]A
M?AB_LLP(3W$@F8G_\/81X?RCRZFS<TS./T4Y@, PEW!Y3UM$-^>OO,H=30S@
MY(!F';_6#>GL0QGS,>-#F9@TF+KMPSO2:4F<4O-."S"Q8S 9O8[9-+%_+CQV
M++1+739"L;TE,@I++[<Y76Q;Y(:E(K9&($,\ \X16C4#:R'C8JK/MTD&EF[[
M[BX46V:0]>)S,'7%-/1C6!V:*68$6/2/6H[B12<3U/;#!K.]6[;$$$*2AW+I
M;2O$[_:WM %.X\D_BP%6,W"(Y(]#TF+=]DT/G#\!ZC8\/1S&T[^%6)%MGIAU
M*"Z!8F5%L?BFC]XTOD6S]#KV3:9R16/CECRE,NNP!<SG-7+AWZ8^ 51O SCS
MB[O!3 ISE G7>56H%4,594/%CDPQ6XXN2/W%BDUD.\V?^:DU.W@'&V8P\M=G
M<(S'KNGQFAF:609@?Z_2K^'^OJ7\MMZ0DZV^Q@6[2GPRQ#?0O.PSI=  6G8^
MTUG9].T4KT7>\H+-^4J [:>) HL>!TJ ,Z68HV;(.%6.-SYN451G2$\<25^Q
M7=DO++M,+"?W;H0&SR !1@JCYA8)7;"XL' Y!4VY7]G2!S?QT'<@@_=UT@PZ
M1@X864*+C4+T1>M=NT52?Z-@VW,_RXVN58/ZX+F]3^OJI /<(><YQ4E7#^7J
M_Y[[ :5E] H%B#<L5M94K"6#3#9K6LW,Q&D\UA?[]='AIPY?D7]WJ9"'<;%^
M\C<3*^:75+(UUS$[Q1M@<^.9+'3K_5G%G5Z4,"P^[ ZEI<BN*B][C"0P6+O#
MH0MT);:C6U75R@5>;[S$:K1/2#&RBF!G"TE<OT]Z5-%'U%>G^_JY.'&TU+\9
M5+.R'IM:ML(H\IY7DWE%]8Z50Y!M<06F ]_QZK9NCK[52_C":/:\Q$J@,M-W
MH/^[N(R=S#74H]<;_."MM1+;EBB9SCCC#Q*F1Y$ZENRYK.R+XOSTCB V,37#
MGR(_:C+Q?/#J400L<LIW/L[G\N*"Z)D094O2'FORHM;\ ULFEFMU)M).R#WF
MO4?<MW-9WNDV;Q)B@P#5Z#BV--GV&Y?QJVR><SQB(R,E&M@<G+M$;BIS9PV@
M];50;"^.V(@\F$/B9 "RC_B8A8EMJXMOC(HZU[+(W-A1]V.4R>\),"HYL=FJ
MSB^);!0H*GW,W2)H :*.\%CET_PL-#'0-_CE*YI(66YCFG8O)V'P$RVN*@#J
M':8ZQQ?M9SN@;]!:2N;FVR<E3*MJW406@YJ9M<D&R\DIYD?S$.F/KC]LF.)D
MIZN)3-7)$6^)1$,W<)0:=]#0@RU^V=^X//UM?)NVM$(M+>O-*43[*4LG'Q?=
M2G_O^CJC8:>@5HFQ=^(EXC,:,_6SL\XGP$M.X37[C1./4?<'*'PMQB%"\IS]
M<65UG^#L<+ L0<:MXK9.I3E.L6EZHR8L5>%MG/V&-(H.%3YOG_AAT7_\5MO;
M-347A75JQ6-G_Y.6B[HO%^6>)T=B_%[KO_FP!JO>6CUSC2'+^AML[^+V1#33
M$H;S#_]00H!Z7.:PVM?Y$<]-I819\=0E"[UQK,8+0,MV LWYK7D^YN8R:&"Z
M7>%-\4?KIN1J'!GF83M&6*3HP]A[ZC?W:M,/0'<8X>)C!XU,:W3-V'16PD+N
MCDTW^(-Z[L_(Q^@ -'>--Z,,DVO/ %2X+9[W_22(29GA/^.*<TD72X9>[?I9
M'U.;Z[EO2X^@A43#(F1 IE6C;9>NC;(][33HQA(E'#X7\^:53IH:^>N:B0 W
MKTUQNPGKO/4K]%%R%W'J)P#I$T#C7WM:QO[\]:)<N .E<L[Z%V Z\KWO)E,P
M\;G\WY6_I&!N_/.]R<L+MG2B<B'WR@$=45IY(-+]WQ)S<,UL@4%>M['5BPDM
M\G_YEXR5N5$,3=\C%2K96W4N;$SSK!FGK>L>=N,DOZHL=U5\()"X[+DKUT0Z
MSM@L=5^PH,C2U:<B9>>A5AVB.;U3VX36RX,$%R?LR37R,T(;&^K#5PR7/P:A
M"J-'H%)MMJ&/8^]J#1[]-AYCW[YL$U6ER(V86]F:7K0+M;:R%F0Y3$19>P)<
M'2H/?YJG:X6 .O ?R]"9?"5-/Z[TWP0-0)M9#)H]=:4YC'+ ;NV#"_]_G 6;
MY>T>$ZKE77+#^LLKX1+ZYCDQXV*CMTDNGW%"/]6VGB&7Y>E8-X,QX*45;)@[
M ;@'BZX4_*,S:1Z<I7QJX5+.$F=(2#[_ 7V0WIUR@D,^:!BG96B8'<K"@Z^L
M8A3HU/L*<XUA"\IQXE&LF8J(V.6XC,X,(++&XF\!4D._IIX?,9)TBM^A[BMG
MK5CG<'7,6$Q5GGQOB25EX<B_('_W7!/R,V[;,);88.E #;CB[M%\#_U-X]ML
M\6!$U 8'<XS<0=>MH=VII.LUX:82Q]P/)?#IJHI6_JJ]*;UEH"-9JP<6$8$S
MK@B-LU]'Y_SW29F1O_C[(U]]WR&I[0D@FN6K_0JC5P1MW(8EBEK2KD76/1\I
M1@3!40]1;#0DZK7]PD@X[L24+);4+#,FBQ"F^?9/*2A09^_5R6TY%6X^#93V
M^I,EM=Z7U%Z2CCH=PDBGR3A5$;>2-Y-7I+<N?E;7;$%NUWD;3+2B@"%GR;:)
MRT.C:)E7K[<GG<&#!QGWLQ BX_ ;'=@4/]F7!OD\F*7>CQ@O#ZP)>[7Q'R7Y
M4^GU..YV=N+FHRZ$S'\F?@)9,&J#<L25[2:8\S93C<F51H>U.X &:P\*U&,)
MQ=9WV[7$C? @\(Y&U^)@4.Z//V[3MQXJ?X9.KPIK-';8?0JH;VA4#FR50'+P
M.=(53O-O<FAYJA%2N')2OS#>U%MS0B@36\M<:^$'3P TKRW]L-G5"-S2"FOO
MD6#4:%%/**9\_PU$?C@@]Y,;W@8&1>%*LCOA$!B)/J:Z'4T3":<BNH(V5SE8
M.-CQ]U3WD *_KK*9)_:3G2"7"E%4</Z"AOC*$JQC#A&QP2<Z' *5*"[?6^S)
M"!W=[I/Y<0Z=. M*^IWE?;_%;:O_D>(XB2;)P]%AVQV6P;!"0V6VX[#^%U3%
M#SORHN.K26.;KN9!G"W+ZZ;3#F*\Y3;SW=T;YR35I--86HB#WV-.^R :PIIF
M.+R]M37L>\;==C&!H*;&!*U_PZ2:S"B+R::RK<(>S*BL'\?#\XO$:X0!CH3/
M!/L,"5SJN*F?SN-R<Z[L0_&ANP1Q(M!.8<TN\^_ :V$N[&JTQY#^H!/# F^9
M5N^MQ6HO_TGV]V_599>Q7<G&/*^@+SE-JSF5E=4;EJ$.O&&GO;&+MR&JV<@K
MF7 [I9KAD@MZJJ!@']?]?55=&=_V9QV3!5,GB0?$]OI$L$_MCE]O._X!KB:U
M3N:^(4.&CE/Z\08_SM]<]>6;I&7@J=[7 4>;D?DF(F;3.39IWGPA71>%A9 B
M?9_MY'Y7U*&?,35:5!Z'1I$RKXB&39:S;QZU(*;G0VJ;V6\V*'7P&>OR!Q*R
MR[LZ&1PE4C[(1>U,'-Z!YQ*\F!M3;5*"-X2)XYII9^YUP#*O^#WY1T=RM?]<
MINTY^9,";QL<.#BJIA6CGI6Y,:>81^P>Y[NQ]4]!;_&)"HW&'XA6%??\Y%#O
M=!2<7C3!4I\=!W]DUL-],= GU_:AR&;"1L150&"IM20<Q2S1:Y!I]6UT$O#E
M_IC("ML?@>D)N RQNFCP_Z'MY@N."N27A,2Y13(2R$8-G:I*%8DXL6I*(+/X
M7Y(E7(6WI\$4%!Y=VKLM5LKG7+2V@#NZ3.7ZIH:]GL//E:FUM7X5"E+Y,B&W
MRW6B3H)U4Q?4XMJ>ZY-Q^9*Y47>3]J=(L"=0 4) :9NJ8U,R2-E.J@?DE<]L
ML?(!>#N*:LW7=\R+R12N&NR?[U\WVR1*P0EEIX#TG!. V&_HJ R)+EE.B&9;
MYF=%Q:W[TZRZT-//#<CT9*\H93+?51:A<0S )8-;I<JGT]F-_3^OZ^ -2<#I
M*A-NO85QH:0A=VW$K;9)%- 5[7(,W?U2%8/2I=BV.2Z8@T.RC@$^PW<-2_B<
MH3N0GL<JKZU-AQJ,(H3,TMP'EQ_0\%?/,DWC%(:2)GV(M)!-%B61?*=-CT%E
MDO-5:*.YF1DUB$*YS6JM_ F M63C[Q*:P<RYZ$H@!DX46FF5'(W!?RZ'Z*7A
M"[X GB+BRO4"FXNR:]'>^]]DY.@9NR06GU;>E1G;I'HGP 03O#HLTZTB'$Q0
MJ]Y+B6VNOLGN->7 ^Z1$^;YV.BG!X>4/2<07YP"BI-MYKNO,)>/(NXI4&(X/
M>36<4(XXJA;7&-TCOL!M3/YZ7/&8M< ;7*!?<)?X(;II4[<@R>EWBDM0S&83
M4M[J]1/@15_%G7 ;R\N#8AV*Z@8>WU:G;=+]%@?R_5Q[.S4DU]4X@8W'O(AO
MLU]EAGD\1T]"?>+ <#V WA)%:I A:Y?*HS(CBA,CX];9T%(%\R"55-\X]SJS
MI62MB>A-@4^!Q5NI'D%RIFV<A#T[IWK0RE]"(=526^_WGHWR>76&4#;)6=CK
M>1]F>I9@WAPY_;W+1X%I19B=#[-O289L\C^)#ZJ:K9R"V68/$@C^GO=*7^0F
M<6-M+&>#K"4L2C@E!!5?E<<II _7D3?+:=1PYJC!Q<^$8E6U>9IPW RT?Q.\
M,N<H-S+:AL7)\XXL!I+-5ID7#>G/[5H'Z_J*S_*EPF7:$\^!$?EVL>N=R4*4
MXTQT9APAAU%+,\BJ*Y\./,/*;/[&AG:><:HIN6:^\Q67\QJ,1!%"K\K4*!W4
MY.H0[5/D')18Q* YYI6'@X<# Z]L)O!*0; V(5BDQ!ZOBD01[Z7QPH=U:RUU
M][JVU)WSCR8D6.5),6OQ6"8>)U''S'EK+E6? U[%.%S)0[5U09_D35?H5,\Q
MS.JOZ$MVR79*/0-D,L9[ZA!Z-AK6B^;QM *3.^]KQ^1_EM'S5)(XY?#FI,Q/
M2I%[8]_U]H:T-]F@0R?2NPLX&LFZ?JMH#-[]T2J5(0:H_;O,@(]&LGW6WGY)
M^G2TK[AX<< L<=\^D4?^L &/XT#XH1P6KB+R8GMAO^W#%Z=P TBH]P3J7EX4
M@/E_6*52JYJWQ%NF\![M)X"9@+^77_'(RKCO)FV86_)_'\7,L]SX"1!J]1,N
M O_5/KU%\CB?7N>NB]LHT9Z,4B?CK,\5Z0LL&[9B:,>_YP\;T+G7N4YV:'@Q
M /Z&]L@&_8MG;)EG\Q'VK=SK7@VBS.N)K@GX[)TI6VNG+R2A -=D+1_RQ4,5
M6*,CZC!A"_I^(LI&Q3]7.),V@+'V2W)>8I)6Z(COU.][13\K[B;=I/V>>-Y
M0E+^Z3J^88A56>U35/%K$%70[4P]0$VWF3;RR.T>J3PU)QJ:I)PY^&WH^S-G
M61VT+=_B2K9_XW/;_V!E-_"Y9G!!FD<2^SLFA/O-&IZS"@!7":";5RL7Z9I[
MU'1%VF0.@SM1]<D;4I/% Y@UWS$Y(A&5P!+]K@"P&4.HP7)YJT)]5EC?ACP9
MV< AI![%-JHKKB^')G6#S&PF)<>*X =!^\16/$DFF;I3)X/56:D;'JEUAN'(
MW+Q'"U/HLS,&Y2,4\C%B0EEA!D>A,5XI2CYMB_D(UTP.$<0?NQG2&Z%S<A07
M3EG9654@E?NS_*\]=_Q]20*EU.>9\I3FE6HALK]0L0OL,1@<90!VDP:P\LU1
MSGZ%5W/!H)7I"@+6#ZP5,8J[.-7![WZAF0M*9TRD:46=7?ZP\;_N.U _I$J-
M;7:5 G*2/<N&R-^Y?<?)8&._C5:DH+=[?H2%SOBIA;($_&TI]M=*'[?23"NP
M8)^7K(HSW5SS@MHL;(N[^";71%2NJ?,[CBU+ I#JM&"B>9 XBIQ:^0/J1(B>
M]A_62<XK[N(NWUH#7AY.>G#,$(^6,:4"3>!NB!0EL3;J[=+/4L<)@8*6T!S5
MST3)5@.46L%(LZ0)(FU[,6"!_D' K]J57-BQUKDZD_NPJQAJ/SW3]X&_"T0Q
MHRV^&E4/HH3!&MM>[ATDOHM=%/IVB;M&\F'@OL<-^L_9\?-U6H=E,(>7TECX
M1?52T=D[5BQT)X4$]IB[:%]V$.R+C([ KE^9ZN6I'A4)?"H5PFX)7&ZBEI4!
MV$[J!IQ^L\90!=$BB2\RC!E!9K\M58Z]OOUJ61(NMI7@F+@LCX2>< 6KO'@N
MG\KD#HC9?8E)AZM A<L;\T\3GW2W#>JWP\KPCHPK]+8QL7 I@^&$A 9-PG[J
MP+)7[?Q3' ^";E#0)_N\$&<O.\KP"\!]C,"V1(70*,!54X=\@Y80*_>YG >8
M;X[08%D:=6!]_=UV<CM6F!!6R\X^Z,XXHAYJAI3\W(( .^UBQ.8SOQA@>$=%
M,.:M^KR0),%L(Y96K0T(!(U.#17FK1#E#6&HQW2R;3XFVIB><29(E+D.V(^D
M!<O&YLMG(2T.&X/"J*@('1V=IOYI1X-Q!O^JOOX=K."!*?:]FXEY/%Z@''VQ
MG^G[VZ(9,;T\&P]>D"'B* <?JR=!M!K-2DA5@6PKH7/S[X=_F=3DN(**'!]@
MV?D4)NHA_\SBJSJ>F>-T;E++;T*!%B6+ML_7](=W_#(L@S7J RL;!P:I-L5+
MGLV2C.W#:XUNBT'I._'ZNNSNI61F=>XKQPO'_A:T05>E)F>0$%<Z3Z[HG[RL
M!1N88MFCDY\RW<N=)=2E!_O^GI-Z;:WQB,L6)87Z7TP)55I:L:VJ"O3(+^O5
M9<Y"6Y=45N0D^M1&6"S\2YDK9N.PVF2'N*->_P$!5#B=Q5U(CO=&H&!)A>0M
M\)*+]W-[E\4JP;L!M$TZ_[V4GM9X@%+/EBET\;#98COF)F$%/7PE2ME2-C+O
M\PQ/([J*<GX;P'I2+U7D3W:)4::0D6L3P>]@MF@]$TN#33KY\H1<Q3(QLQ^M
M.H3];NP)( S>0>J*RAHPPSM3XC Q&CP&D\LW@8+692X',.WND6$A6G"\C$,8
MQPXW6HR):R<34Q3X3Y55L8B<Z*>I1D;38,RWOKC%MBQ_Z999@M2KDHJZ#:77
MKJZS&7?\U1Z8N^_HV$B7P@>&+KK&N%>)811_,DN-^ M;I_Q^F%U\=.YBD$D2
M6FZ9L3>X(:>*TP=,Y]52]MR]-V3 <:);Y4I,HO022_7/_-CB3I0C<6,D,F>>
MT3C]8%4QZ.7&LW^]:$[$XSM6>M&^\Y)W##"(V@!PT]02O@*Q?;:TR,*##;R!
M=Z=>D 7+OA,Q(4KJE;;9P!&X.SF:NY ?T4LQZ'K3_]KH!P,K2437NL*>'P[
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M@\]-W:2W.?=%F-%ULQ>N1[V%R<DP:!4+"VP<K9LU*?Q:!L[>X]*H8W$S)"H
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MED;E"6-*>I"Y'1SZWKOF!8, :P20YWV[P@4UB;M<4$R\_/AFQO$_NQD$F7/
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M@3F&\?,#,0]D3*6K$+H'(E!(-;A00#O:.VE)=O)KW X:B>47?,V+')?%IB<
MH>'A?#L.O+T%A%>[,@I^'<QHD8ANHY;&J1N)^PYOJ,U9Q*3EY6[>K)X;I2X_
MI0\FXY*;8^79VRD/]+YCIZ 82 .P1[]^42F&U@(BS,5Y3#BWK.@8M'SUQ240
M18@JR[3:XL^,2D0&A:V*#3,I7%88NFE]T6U.S+[07[F9=4FVC8VTKA+[OX'9
MGMNCJ9^$-%QWXG*6.S7"%JWNDW_FM#65LZ"5>,V@B0AKQ<WUY &W+E]C<X9
M"I'-MF:@LE/<!FVVDWX1O,QV43#T2ESB0)3 S^?E($V?;PU.U^MY9T=_HP=G
M;IT&Z=(X2NM2^^M8=]?[((:Q&'KC#/9J*07)XV-J[S/E;M&7;%&-9_:%9F8E
M_2XD3<W5[1"$7<FZ"[:32#@1W^=H$]1@0;>3J/UZGU(NUZOL$W8'XAI,%_,
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M-9M:?2(LQ=Z('XJLGYD57@(65D2SUN4JS)WNJ-G.UVX#?A W=>RT7V(5AJY
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M7<A(UW&GM./&DY00[7NAO:8(=BR#:FBE( _6FX(-3W&YQ6LHQ#]B:,FXEBN
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MF1)I$UT%4U ^4,[ J"E2CGHS5CH+2,/\[1R+H9>D/:2 P(1N6@!TB[_/?$Z
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M74*K'8.];I#T>]1<Q,.U8[X83$!N,N[7<)-^WG\U_0J&;"6F=[LQ(>J+D<D
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MS46T=B]LYVH]\1@2$.4H:5JC"MB("!OEI#1J?2BBMM&('R791N;)<Q4,)1S
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M8H:4'#8[GF(;:03B>?5F919G'(3%2E ^!TQ+0SCC(XAX2DC%DAY[D(-(LYR
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M#.83NCA^+!'*I[<Z%TRG9(RS4V;]0K\DX_;$(DY_4L0L+4H+?"%.(AS""(*
MI5@&%,/LO" ELG)-9$.,9V#_)MI\H$\KF-L(#,3B7BA"<3-D#H*]?#";,#A0
M&^G/^=4H;:$BZ:PI)$K16KG%IU48O1F"CR'BB .D71P'@)EM.FXDE%=LH8N
MHJH  Q' N$?HE6GE&9$E*'$Y*%%*Z(/<!I?(3[A)6S; .'6W!DPQH%H&,]@;
MA,1<:QBUX7I2KQ5Y,>U3L)0C> F13QAS,.-;D@)CP.XP^#2T$ )U/$T6U^C\
M4B69B)JPK%J.:ME*P(P#()ZRLNTJ7&J*B4G^K_?R@3[? #(J!^1\ -<GSC'(
M2N4(,CY6[!>:8V9,Z.$P(B6,J$$0#BNRF1@_1I$43#,1R!*FP*33&;8",K-.
M\E2&RIP=I0P94 E%R"0NPGT.GH5P2V"^+Q>)F/TY@]8>4KI N81!\$S&&_3S
M8-+OEJAI?YI4^GD4A=$*-.R*@/DL0&"@#&9,YO&ZF&PU7H%EHA*1B D^,<1M
M%(DX;@["YH:HA 5W2R Y Q%A+AKQA7+V>-J."TUN&"248,@L 9&GEF(5HDP\
MATU<1,QU.C4<;MS "SN8,)E(!,Q<@."8N?I</!-%42P:BVK53.X!HW8&EH@=
M0:M'F'5XXCP)CNGXZ;S'YCAS+A*RQQ1N0=+F"TG3DF"FO! 2MQADFX(*QLW*
MF44K%XTV!8-NGBN;\IJ-1JT6,1+2G")').Q27S9*@WDX)Y5C4H?>[8W9M4P6
M!=O4;A^ ">/!6(S)(&"+)&-*<(5RKR@8=&3C*IU3;0ZRDSZCF>L1.#B*-.%
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M:>8HX!"(QYGRD$ZURTRF1&8V:0\2.4Z0L@ $ ":MI(N")(@V#4!QSM,-296
M(IE0&@'<5IXU;E7RA!(#$,S$\V.KI1ZA@QU)"P-,?@>D20^>T?)$03H P;]-
M"9!9 =]O)\3RQ[_^=.H-R!][^\,A.>#/I^3R1^Z>>ZRN%\GTML8).!E XGUB
M4,#B* :1>*+\B"F7WYW7G5O<69Y$,;B8QU.*)%V*;4DH3N>*K4JU@L!I)$/W
M G['XAG6<*!'('_.\#GG^!P(]5?G^/HHB1B*HX%B60S)_K-9_IY'+^"Y Y8_
M!HW2&/)O'B;,Q+ >&(2'>K?-E,!($$IB=-L^,J>*RQ$(BTT6NUEGUC )>+$U
M#"608GYQ@D["V6*22-!(O#A0+AN<+DYQNO.*>28H7GY0^-]9L.<\=/E$GIX5
MK% (($(BH8J>?SI!V*OB=&P/)1%(EI^BU2G[,#>ZPRC<0R"6\'GBH*2$R^?R
M2P02'J]$XD<X)0*!1 QQN'Z!R"^H4)??D_^)M0Y/T! >0)ZR1AG64AXG@(@X
M_A*A*"!D6,-(B106BDKXD$2,B$0"*9^+_,+Z&?(_L;;$T1"*0]ASGMXO0@)!
M7A NX0I%HA*!6"@LD0J#O!(I%_&+_6*^),#A_C+$<]C\:2@MFF"4)?OOJ>>_
M=\RTXK1Q#RA0?FB[3P)*(7 OX'?W_IH(_;.,_S4!_(G\K\=(AQ&\_)@NOX3#
M_/"<7%$/OK0'5^+[A4M%A[^F3Q!!.@W%$5F($?'SCQ_S?G_\^'ET?\T_$&9,
M$('[ +\0_G+C7_.&_Y%58XPYA<3I?V/EF'&@&,(X@D2?8)R(%4,DB:$!J)P*
M*/<0^6/\Q33QNY84#C\]0([^)L%?QGR&Y=]3_WOJ?T_][ZG_AZ?^?QV<_C4
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MQ_V>C=+\;ZO_Y/FZWL)-PK5W=P_4SHF[+G^RO=.P5<O+%B9+]PL/LZHH!G4
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M80+QN=D&3C1ZJ5'Y,+Y3E((R-L2V7D4FJBGV68>K[83UEFB]9@4YLQ-ND%Z
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MC]F-=CW3,%:W<"4R:.J;=,Q_Z-WE+<^,*?](2G2;60=-GHCQ+DDJ\0?29,-
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M%,<6E;Y%KQ7NF#Z)M!-ZBSRQ\.0P!A+3.;H#YC,M1I%TQMFZ;9 (G@!9^XF
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M3#9/Q?+9KHN&@S9@/L'X%"BC7H?+<HV.=5O+BN>):Q=!X0X+&GT,H45)E2G
MT['^'_M:K^>_KM/_()5$?YHV]"Z)MT[C'XX"=>?GV-EK"SJM+WR8@OO(19G)
MH<EH"=*VZ9,D24F4WJ,8\R#.#.>T<21]KMW3CLO7:TY&=DC3S@N&Q/PTAX"?
M$:K+4E:[:E,3UA_D=\.QL"0+A$,34.D:][3G \WD#=/H8 -XF3IWUDBNW\?_
MQ:?Y_]J&NB,!]5]A>W% '?&ZB(M)W(L#(T&6ZRD!^?'(:#F[W;WK+\0O573@
M1)DG:KFOYMXG>%T^^V!W=1O2ZG14'PMC KW9(F%&KN_^KPO[;XQKY &>EX*G
MP;/?A3Z>? KX?&QTU-PD<_,H-"!],4<;WRY\!Y70I_H?,\F!VZ"%^ [SP$SR
MDXOOJC3;='X3-JR5+4Z,)?N;U$<CE<"7N%N? ==BV2+@A_-[+3M1ZI=(QH^4
MGN+4BW##L^DYLXY\P/[+YRVE5X!'XJK",KZ[95J0\0^KCZ/V-WW@%HG:$RB7
M*P#9^#@KGW#"GY,-LB**J0+'"GFQ[NX27T.$>\J=!CO$J-,26.C>D!S/F88
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MZ1D:G?'!RHN+(WS-MUS]X/_BA&C4+^WX_K[<DVD9?_.8M??6FW.>BY5,H2L
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M'DF<.\1$B$0N7(SP< )X22+0>Z-I@Y)HP-GALF3OF>FTY57"NX'^YU\M,[H
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M$/ADNY8].2J1PI.V RV(:QX45YY>$+H@E>DW'Y-A&%Y-"_0/V=Y.PK-8@C"
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M(!HI@Y[BZJ?U0@<Z]IJ# 0N::^3T"K:#TG/ ! ]?9-3!UW3.<9,8ZKL5=8-
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MNGYY*SN:H6C6&K/B"BL7YM[3(H(IMW4>GQ986 #",C=".S^W=B)IG>G,/P5
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M@D/BDY4(3]/0?CFNRV!P;J1&YT_Y4J5;<.M!MYY.U@\J\R=,F;/USQO'0Z7
M]G<S-LR9V13>A3?>$40JB"RD?>-FB;6B:9&C?-/_#O?%JI$B\YNBOD'!7L5V
M.$+=R0GSJJ;R?X._B7<"C+%^FRJ#66R]<F0=U_+._)T%NH-@5&P?->!8F\'C
MQ05W[_*LV.1IQ^E7L+=40,M;B->ZM:F9M56A1-LAB-\0K5J8M;@&O1,@EFF.
MO@2B6^(V67H.O5.XQ9,FA\8F9=:9,]5IQB2_Z&8;47:"^27B9SIX[*32;-MI
M'UP(&Z.-1 ]*E69FZ75\\_[D1,>/6>0G3W:SO\3F%'$]7EIBA[G!0M,7WO[V
M]^#50O.9JW ;7^Z^[_Q]UJ667 ^%]L]/*]&/FT^B:Y#E$6K&M*Y'Y;^C+%29
M"AMM<\9HO55=J!_%M"ZDT[D8^)>E?*R6(OYJLVB9.6@:C51K:_>X3P("*&PW
MG?#//2]=^!-1IG:ODP[VTKT*H54SFLT>\?@@&O)U[7$\2'T#1TTK($$OVO1.
M!Z #8$VO=%+G]N+V\4XD'+WJ)REEVIN'.DM/6<^- OO@<:)]/L.9&DLCLGN;
M2,N9UN8>\(EQ)%_N%G\NLKO'V@73.KC.X/TBU[ 9D%7/_L70F.[^'XM.K_'1
M;W/CI$P##0MP/XNZG3#G&+]Z*<&05P0%T]J4^C?C6N[#'FDL<4Z7#Q^CD1:&
M_&G"J'VR'60ON5F9>DJ+9"]<XEO&M\S89>5?<YE<R_,LO16 +5-=H'B[$(XT
M2KCS#VC06XC: TV7:Z2W7"+4@=&T<39Y$?(V1._%"5*3Y^N(OMO\JDZ+Y$*'
M:O=\<:;XT!EYQ9E4CR:J2#(->70MA'#O;7Y=Y5O:<+WOO,,I($;EOPEV* QB
MYLUP*A* 93;%>^I\F3GT<* 'EH"I/G?.BPCDT@9JMB!B-5O(63T8X6+)W#$[
MT01FNLU#.1\00T^LJ1/6BDUK9!"K]$%2+$P#^0:UMM7<5VZ@OV, 4WKZX,O&
MP:+K8@YSG4L#)@ _]1Z;O,H)BEEN3%;YMIT_G3@) /D9$CC'T?'G6X.8&-O:
M]W4ZXK7:Z[J)+JOC/)QCS^C-@C+O-.]6A)BQ2I&%*+3O9]_>:R96FN :GK6A
MHP98R4*'%\V:#YQ^)7],=)C9%COHK8Y)8R]]\,[O@.[8/&%XRJ4YQ. 11LHH
M_R3VVT*Y+>>RX5IMFGX@/*5+PO9[WWR9J=_\\G*A'0<7+6^PG:%RD1,'/-65
M5"ILA.>+.-(-'S&"80UUY,ZG^^T(38G8B3:!2U ]/!DW5IY!G[H,=N9#N+45
MNCU:P!+<O=G'NH@"V4U6 _HKM>D<SWNLO'C&E'YSR(HL=**Z7MV9,-9_V0GX
M6.Y8^PWNFCSD+=K"6*8NZQB<9&RUC6G1<>"BU+J@K]*T$2QP1OX6X\+O+=;A
MTSJ&56[%;F?+;5:8N_3&%9O4('=9W6CX<^@EQ!%ZX",^+J =6<TCZMN]5ED^
M\1_7RJ'\'@#=6*9&W7I3$B*OSC\#>_0>[KT.8(K/YZZTR[U<"$,1J2IZ)YQQ
M#]9)?Z>/SZNLOW_[X3"X8V5/0T3$@R']Y)7L-Q 3S@Y9V+_I\[S4Q3A$^%2D
MD1"_U:KOO)/C9WH^N&7^>DFO6<_P=3-@]6DP+GV<6XHAZX6HT^Q;_N$C=9(8
M=B>,C_^V39%W\G$9\(MGBUG6ZYH8KC]ZCY<%*OM,K9K9,O1FQ5GBU+I19OE=
M+J$_9]\TSVD"RF>EY]'HLLM<)C*7\_"S(;W^.^4%-T0^^AUW6L3F&0EF(]@'
MYEX>@=*./K'BUN.I:]$33\"C>],9$< GB>9<@L,BC1M>Z5I<%7N7GQ/V^-GR
M,NL\N'G&IDP%8,K9KJS4P9D;B'%MEG9]M.NY^Y_5EMOQT98N<<&_9NX)9>F4
M27.\-="VMWH_)B/$+;,1+5N&L=G8\Y_>+(4?->W\&L%T&?WJD<COZ4,WHZ-K
M3=ACG]:;O]NGH'90X"S;KG]'L%\;V6='[)]QN%0?OXD=:']I=BW'#G?B<'1F
MK/<#1R UMWZABD)]BFVU)UT+O]7-RLA[;\?Z;3)\<7KETHCF.5G9=ZZ]]Y&4
MBSA=31>.\5.5[27J9V5J-1\PC1A/:=[!84#'QA3I_[1ME26V7!  E1E#TX]3
M (&J+ORMK6=)(WGN$$2W^[W_@[WWCFJRV_9&45Y%14!%0+J"@$B3&B 4 >D"
MTD('*:&'T'M1$)'>0NA%BM2 E 0(!)1>!*2%$HKT$@B]M_N^>W]WC#N^O>^Y
MYW[[O'N/,\[^/?^MYX]GSKGFG&NM9\WR:(IQ<J>)?1ERM_IQ-T>:1&Q2HBH_
MQ-_(>H>PX9FNE_RLA$EVDIMI8LBHV)1B%!JFO\+%?Y=WVHQ]17A ^-*CI.)'
MW( I?B.;(A/4=;QR(OZ(P*9\HXJ;\5QBLZ;, ?HX U$TW#/(QYNC_.YAS@YR
M<^H!X*.QXL]^QD[.:D%>]8I:\W&MY755H>_"7TH&MJ?BIP^UUM%VC$_B()]*
M>1!V]DZZ$"^P4PF-EQRVD3I%2CEV_^>,3Q0RQDAF@]S"6MU% ?]E3BBSJ@.I
MGO<>EF&CRZF %_$0BM@H]0UH[E68A8QN5L%J.#-'\TA<OL<T3L6G9[V+;Z*D
M7"XSX[3(_:G0QB48YOAZB"+^+MW+$F27H F2=K'VJ\HZY^*0"6E"$QZJIF)(
M?QW_XXJ(?/*8G++&8W'O;NGU\7$X,&/.0,BPQA3PN%V@[F-BW7DOE=W$K!W;
MPQ.VQ(IBT\W]S8+G)./OXVH_/0\@?WNPO0BG+$2 !3F */=D6I=16M/(4O"A
MB& P/D!::+!]!U7A6F[@:!VS4 JUCS1R<'!$<'HTJ?\<<Q6.X'?YP4H_5;"J
M*&#?3HI%U/*X\MQ30WMQ>< YP#TF%NZ(T0+4$/+RCO8QT>7/?_VES9^,C[PH
MLSA)S:VF[*\_<NX,_65,W"_4C#Y0S&_[[>Q -!'ZC\N'KNQVS3,7'\AQ0\<5
MT6B>UGLANNKO@IO)91[]':<_,*3X*R+B-D&H7.#'P(1]C?*R0"FOP:SX"RY]
MG[\F<B;LSL@P<TUM^0"!?C44C6=W@S9?71$)0,^,KTTVNFP;.@N:O/XVX J(
M\]M*\'K%/JK,+4MUUT_!8:/@H*A!^2*1Y_'#'R*"2KH$ [9[LD#.MYLW[I_5
M.A@$=+^'\'#DN5\1T2-C.+X(B=2V"8N4?5](C&S?]F>AS7_*8.D7N.9%)8.
M%UV"E-N=G _VTN&^%T,1HJXEI9R^R3>LSZV8JT1(5KR^!(1!<B1LOLN< >KY
M]J9[+J_M/Z,V7J&1J/L^7*J@LDN1Y'<?11(BY&?%\)N?=>3K9;%+TZ7TSL$4
M!>+(ZBNB,"L#H71/4DY53ITTI%-"C"GO1"X7;XJ67CP3(/K=O(6O='CCX];/
MO^[+]_I;\BXJ?$OK9G]J;&9!(PC/&C,<E="%"?",E*"XF&8Y@URQ0[A-WR0'
MG=7[$.2Y*2-8Q"PS+Q1\2BSW_$1I4J@\=_#>L(/BU%CW)%KS$*H,&;.?24%/
MGOB*(ONPV-.3.WE'0CDR9@*>-@)'3+]JP7NYEEY6]-F<[>:CYH*8>0%1B?A+
ML@<$;>;0!L:H+LM<;<@G$7AXG,SS%T[IS[N>[C:51M0AY.PDP9(<$=MR9N![
MQ<\:^P%M45J^;+_9&<$-U9G57\2]30!-IHT9Y\:D3ZC:J?(A',Q^56Q?2SX*
MI:$+[3X=WR'(>OQF)M[NS'A%E-3BL_2LUC,P+8PK1&T)5>IE$8.KS'(M2 8E
MFX#W<V$;Z$D36P=G(J)'\\?O%]U>X\NE11$QLKYF0FX-VS\4J2SO1AY-4(Z)
M7J+'O#TIZ7\;#?;J%HO'9&@_?90_@TM";W'8NR/\,)]7F<_=Q\Z"FH]SWTD?
MKU4<7A$%[<@3+4,F6IK0QO NBRJ"H@M?*=]C@2Y1(_ZNU]F>MH%O-XT_,C.I
M[74+_;+X4MT(\E61HN[FI"%_-DKE*!M9G@NKQ02,%MFW#N;13C[24+DDF0-F
M/_BQ+9G\86> N-75D<M\(=$[QBYB-D) FSGB?1=_1G2&_R+K>)?H<K=F ^R!
M5MMF+<%._9M@\_;^_%<?Q4][%%HN$="UR UU\)+F;3Y5J QMUP:)$S+&/U</
MYU'"R>P>VIMGIE5<IR;,:6@")AKM(J*][>[ML&DWS[]P?I-"GL6RDF#M5$;-
MTV#H98][:) UVFK:J?5I,K/&\0OODO6Z%JP@2V7]<+AA_=KS+ #M!("A;PXE
MA%@'T;%&&?R&)^7"+4(2NU#E\LP\ =ENT[O)R/8)+4(/%@/'X51\,S^[Q83J
MCXAP#AX5NAM3"HU7>73P!"241X XP+4_EB%Z/P0XDG(].2 Z<5T<)J)-R$)?
M_"C"Z??'X0W\'A=P?JK3G/V4#U+/">HJOR*Z-Y5&PM*A"PH''6H[>9)RJ[7"
M1[5P%;EC"SZO@H412:@M=L1,A1=&Y0/XF'EI";LP)OD85)+U/GIJTM=4)*GA
MA$ZU;X[6B!,] ;4I*C!8V+E8OR+RS)P]?V>J_P]Y/>)MUXP\QA;^J%BAWN6\
MRD:->^^3>P2B(LR'''/?NHS?.GHP[*852XTHJHF)C+8MP9<&V-G;<7B,'CR[
MZ<EPMI.^2^YFN2@:I$&F6>[,(W^#]U"*%>KD'V@D/$%_.X]&E67L:62K ^>U
M2/RXV(<@6)643,V/V(1=KZ)J75Y-Y'OJ60<*1'(/L\D%DU#%@1#)9"L>O!LV
M%J08S76A=NWPZ^F$_^>#V<$%E2LB[9?#P"\*V^.-\+7-5J>7D&[KQ 9IYYT5
M@PV&77"4CCNEF$0>6R=M5Z\$A.+>=+Z5!1?:$(^0_ZU,I<?WCW(#Z+_R^P17
M#E#M8 35"2:MCBO&WP.VWDB6L]]9X4PO^20O,/&&?XA;TE&C"0HA&,R?G-]-
M+"J,U!HMLRK9G-6E(MA8Z-VT9Z!;YQNQ:<5W9WXN!XWU[Q0Z64VV0K.XH2D^
MV#K4JV6JED\*2W$]\DJ==9%=/#'U4-G%'7*3#F4!$V$GE%IR/.KSVXS"3L:O
MT_.D52V^+G,IAP%N[&O(;M<L]7YKT6 !D0DPH[@92?C@./<P7)53M22->I'3
M- E9\+PJJ=#WL]D4O9F'R,ZSO>6UM<('8OUZS_,E0 Y5NA\"*'*.FXOCO-<\
MXS=_0ET'ZSJ #R/ZL=%A:AY?7&_3P[5J@=[5A<)D%M[*;1#S[TQ<=J8<]K_Q
M?J'\\G6Y;E<@$BF3'Z,7)^Z\;,/?SQX']5B=$$L'5VF &7&0,0,+ J&JYX@'
M!;LSXITOSKPRM=^ZHVZW Z TXEE<AK7!6E'4%:'0V2Z :;;%H:S3\W/Y7!&O
M+YX@3"+,QPTDF>4F_&A'H6O:#^Y()WH'L5^V\]Q-HP!$":6MEG0CZ2:[%MK=
MA>P\4.A,21U+I]&6WM\D5'';W!LGF]LEN??50=+@"!Z>_ &&C%SBP=2F&UAL
M3I%XN5%VA/9<C)5R>*Q0BW:&NK ^[F&E^9@X.=2@I>B[DK('"!=7QEVXX2J$
MI80C%Y.J]A$R>X>4.@X0*LQ3A(LK*8IB9OOKOBG.+SL^)4R;H#E7'8=6!4D;
MB2^<&NPIKO5!,WLN8W0^3&H6*>.4;]^E-P&:GKBSP] CBU5  ]T"@J/C%5'W
MQX1?ORO5C7N-+D$),YG9L>>QA\#"=_5;E(%<#+8GS6L5(67.Y._^(0O]_X:8
MD:5;8EA:B)>YO^.D!'Q8E/QRG%!Y4Y\IJZ>Z[ADD-%EB8 76O@W_^:BWTZZ[
MFR?)RLZX.[IXPL-8#%4\@?,J(M'Y4TG\/PQ_(=/W_G_V8SGZ?5TL ?Q'D2/7
MSJW\SBQL,*]WR,CXGE[P@'-J1!YNW>ET*NA6,$O8%&9:G"C_W9#03:Z7!M5*
M=:,/#WB0HG[<J$E0A(FWH5E>V,NFI$> .W7MZ-U,DA(QOYI:IO2Q!BCWY%D)
M;=9X>_Z2)SEU!JY(0MMD22=A[-YX$[_GZP9V.(AU"# SP393DM?VH)[HJ]/M
M7._A3B4PFS \?3"-B[EM)[EL-/Z[\#)QF7EEF7"PIU*7L.:,]/V;/?2T5HFD
M>H8]4^DZF[+)TRI:/:#W"1J?>M/0D9D8'2\%[,]A2-6T:JAEG12\S0U%JM^H
M'F#B05U"RZ076Y+F^66!UB>YNXOUT7H[M8J"))I/NRF\KJJ7V."2OS:RZSBY
M$Q6CK:!"[1>#SFSX -VL;_Q@_*7FG;(.H0!8JTNC1H/@.J<B3-U4F7HXH8[F
M.AAH-2;DS[8O-%HN9O4,-KBT?.+SLJ[JF5Q*"[01K<R],ZBLWR'Z10NNWA$^
M5<"H/TTZO)N)MW-V%(M=O$?K^!N[;D1?F]5XD]I]^CA+'W;IISW6Q(_?I5I%
MP22FGK;9]UL6Y++E97QIL'GV+)<KMZ!VP@,[K3(BEIZ1@<9F4,[#-Y>D1N%1
M,9W"(F0 27IZEHN&&]7</5%PU=MCVTW.54Q><=8GDIMY::S@:7R2RTP%&#[M
M\?G- -FL,5.)I)(/O)G9AQ18@G)*_;9?;O35\V/+EYS(UKT.@F56QTOS,<&4
ML5W1F/O,@I))BVH(7?J<,7GOY1C;2'<8JESK%O6.CLL5D? "GT% *)K%2/+]
MNT4I8 G@LJHKM=:PH\M*'\MW[=TRM7 <"(?CD:3/_D6JPIO$912GHH8<,U+5
M5:^]F8 1.MDK%H_?(='>=0"IMP/]XA<J*\]4*6S7,-;"\/$8JV"Q)HHX^?&U
MX:Z"1Z\-<\MXS:H'YN&..[R[7!,><IAO)212C0;&;WX="0A><BG8GM?&QXFC
M640 8KBT4JOY-<$H7'(#:"/9H+(3;"Y)PQM#2^/*V:7")C:K .UGA=J -ZE,
M/]M(\E2G$3 RI;64#*J"WU(@:D&?-I3.^2R^AD4,5'IO]-R(D6VA%(QXE]']
M>7[7]M"5FOV@VH?$$^ "Z3Y1+878WY3$2/N$QVQS(;[<[F$8[?F!/"3MB:Z]
M494- +M'Q*>M6#?W'P1" 8Z^H*FYS7&"6$I='/*IG>O1#!:FGFPVC?I<=9,'
MMF#0(1R[[&TM0PJWH+7BME:,7'JTF"Y6%L32N9R:QWH?<)N/H?KC@WBM* ;V
M:J];Q;ZJ; &U1AYVACKDPNO2_1CMX?1/0"\84,N)/QG!X*295=?!)%8IQIB(
MLF*9';LV%L?C-^)\<"DC,#/+I[.)CEH8<MXT72<;;?K9-]OROG.J-R'3LC)@
MA]_RQ%L=8&[DX+O!$#II?U)Z7@OLM$8&<G?C1QPKN6S8!"!1->A;1V4E:ZWU
M#56+PUH_V54[UCHR$A29YZ1YYRQA7E'S6YXB[\<I!FWG5-HPW9C[F7C@E)@R
MVSWEQ-/OB\6@4N-D#U\V2.9IJ:'^@[ YJ74:Q E@N/3VO-_Y%S$FN>TY6/F3
M>',HC4S^""$G"-;=[>!X>2VT9]3 V)-=W([!X[1K:+TJL/UY/?*YE(UNR_!;
M3;\.\ C H'/UPFPX\D9WG@!9?=(&MYN'T_AXTD2WG^G;1U'&?2D*@,29Q,B*
MCSV"C7"[VR $%\2$@^;^$ASYU$P0\\UC*\0R)I6Z>"WS*\!:I5M!.G_EB8!_
M\MW<\&>99OAI.]+[B/&>(QCAJ'%!(J)K" 7'&=DG^O$5C'F=\9"Z_F.N_J5-
M^+##XFER;O*+60M>D#E7IM H^O-4!+E$]&9E=&3MBR@_$8AKH+R&N$+07>=+
MGE=GW8?LI_BS48(7[YT-[U=H59=$W[7-ZH$L5?L-5D_UKSB^FH[$ED,A!FOS
M,/-B\W$"#PS<<,U?'4PR?IZE)L@!1UHR5;<]-.011<)DX5/K$6_XTH95UNH.
MNP3,BST2V2':2.H^NK?>U=9]@U69\*?!M]KU$Y1Q&K_^* M#?!I0Y &H#VRX
M#+4T"R'R>[,.=;WPNKC3T7SSVA&W/G^D]:0X?[K2ZJ'2EXET:IY!V[X\=T1!
M^..)4C]*F=^T49GP"7 -"G9YY]K%V[_R+V:6Z,\T=T4DF&OYN5Z[8U,:D]Z"
M,WILYLC]G,F&I9,2XRMFP.# 58_V41"-+$!LFG;PT8]CN(QT"K#8FB(%*?XY
MV*I+N'KGHJ;Q_?=>3Q[E1J"@B5ODZM9?5:9*[J#0"8^:P.B5RE3WU;11! IH
MBX1SJD)1L":<4\[KP*PA.H=8?2'/JI^GA29K"*\'N9&=<W3-9)W;CB;5!</R
M''R(#QWCBB^:Y)>B-W8)3E5+8XB:DN1I,QT*3:+?/'8'\K/5^EV[Q;O$Y%HO
MY*I<C_J*!B^_V]%R5'CZAS@P5OI&/*"7TU>92[^]"X''HCX-&@#/(U3*$P)&
MINHJWVRK4<T=KN(Z&2KOSAHX W7Y$FK\F)]^7Q[*F##:R3>.,G2]W=G\Z>.L
M6'_/AT^^V!,N+!+4E]#<K^6$<=!-0VG>2ZG1E$=S IP2;!\'>[+\KR;+H*&V
M(64@)R3\2R9\"(Y3^?U4!WQ&\D?5]_]I37OD:(SXNIB*CF8UQJW?W+#[RQBC
M9$M%=#,#YO@%=*7CG8GM[T/@]GGMM9,!M4VL((Q>6LDY-MDOT7#QGOB-1XQA
M)743]9Y,9"(U *:##]PMFK36K*&]WY0YJ029&A1%<N=/<Y9N/&AN"$@V>CDT
M%KVCY6SL]?-KHLO W++Y?A,B(OE3DO6\E/IS=6F28-M+<?F0FD'/]C,:VYF$
MKE)PR=,")&I=JP9!=/B.B*AL*V)/#LHKO]\0.G;N/PPT\[,)=TW4MKHS)PXU
M63J3YE6_#G@XT9=O/=*QG>+3G<[R2#1.1CACE(XE"5\(&=.JQ:F$)7K+B:YU
M\0IMD\:E0%G=08L_:?W'7K@ZIM%33:=UBHP:/$6)-,&'XI6L[L?YC##<S3L6
M+F#)%*F<5#8-[47IBIO-JI^^D8AMI_A9"MW;30$('7O%%*;MTNN9A^,1F86#
M/LPT_$CA#U89-01)8 COY:'C4Y&;]RY=UAT4ZTS;K5G@E2+)HSCVC=D;;#5F
MVE*5& YZX,])O-LN:63\)F^JUC1KO<<'B1I3T>KZ4:UL-^+2$ZJ*JH^/_)"N
M2C:WT2#)$&'_W4Z0F1=,LYV/O-XF\SA&?-V$L12;M21R@!5C<2E?,BZ(DMG9
MBSQJYRZ@K8;W+;O<M=%=L_N(U9_0Q>6L#)@!2SVV;(/Q^@5$%X$%,W3J3MMJ
MO,(*=ILN#6+-@&KA?F6>>@[OX3P1A9Y6CZ8?G;M&E$8/K;)8HW]8E;D@*WVZ
M)CN[^D5B#.UZO7IRIKDT-:N=AQ+S9_0J!0CI#)PNM<(?NX;356D79C#8= I3
M2!DE)[9^D?=W+QN/I1Q@<][H?T[S)!*<H&0!Z%&<*O5S=&,XN)& WH=5G07_
M)J$@Q2C6]%D+[Z88NBI3O33B)-5";[T^$?YHRI4R_H7^5$ 4?_&S*+BF]9MQ
M NY=I'V4A8H*[P>=&@NU!(-AK@DCOYP"5.-*A?%E]&:F[2HBNOORV4N%9GA(
M+!98K=MA=?S4L@$+YF+=](O>VB 1:F4=#)A6GH?R[V_(#Y';S[%!E:>/2ICW
M=P+K,OVJ-V1YG0@JNSLE#VJGKY^T4?HS1]>1'E"[T++&UVF1T]]:(! =]NKJ
M-B3/J)6.)FKTK;DF5;45T<FYOUB="W,/6=#I9V63O/_UA+7>K-4*=T5D+2?L
M.D/66L=>\:;=8YEJ9165T'SS.W>R'XC ^#2RF&8@$ZCYE%N7.CIDPW=X_\/H
MA:EH![PF%0Y^!XVV6#;B7$#-NG;;("HELM2J7UGO&!>7:AR[;7IEUT8YSFBU
M ?OIN"=*%QU-%-P=ZZQ3DW:"$+6RF-XD\*-E0#>3&,:JN\<5EZ=:*)CR^Z;4
MPL)%RG.-Q,W D9(68P)_6>V(,,/1)CQQ6$TKMBA/%711[Y7;WS-%9WJ*(<BW
M%'&]:GO9.*GO\U 7)DE[3%"YF\&GT K[J$CPHNALZ7;CVH9<!*B-@4T/ -!D
M*U<XLT_K,?!^S2<[2YK\6 2.&SO/79=#L+EG,V\KZS<.TR[T>V+'+Y#HE5QC
MP83@J/%'<ODC00AD@L8PPII6[<M0H$K' =CA-R/TWGZKREL!XWF ')/^+K[8
M,ZCHY$D;P70U@+&&[<2QT>MQ-:\X04+:U-S'7E]]J&M_QO2*B*N+WU;"5(6L
MH]7F_OB@8C?'BX@9^P28IOM6CG^34:._C!1S:G@_<-B></&D-(\]_XESO3*#
M'/5THTUWNH1OPPC;?DW_['?!J>M/)#YV]6;KYKMJ)JQJ'=@>_&XUSBE,Q,2E
MXMB#O:E'/T8:I.1</X/-ZN1C^OLFQ-KJ<"7C?6IHB,A%V=!]_>6D,4V8']UZ
MR=</3HECL&C=FU%3)9,C/&1"O@+[B:.9K**UUOD=BVDVP#R+ALC>D_NU"=:E
MXC:T>=2JJ*@/G;CZ*Z*/+\;JZ&T(="TH/73!@?/:.HI];AUKR%C]HY_%KMS+
MI=!^QRB@!<&/.&R2UD_&=Q9%^IS;@Q-A;"Y1PU3^<R1*G4N//LIVUX10095U
M[*L>5EJ-RAYH-0KT+,?*]9=AF $- 95YYD?4WUI<Q-:E1XUKYRU?=[?ER]GT
M5Y@SP%TH0W7[(24V&;EKU-#X(/ VE,9K.=JL&:DR]'EEW3L,O>.H]$%(QTM(
MY$?IR=.?[71RYH9NK^4WQYPL&RCS1,3*:8LL#R].J)X/U9BXYV-8D'9!25KK
MV,N?>-,4*3JGP .JR1U<:9IS@T;TN4]V1H/ .)##O9!E+ Z7MN(*^'T'&CJ7
M6H"WN=V[Y%&15*Z=@)0%]$UKXLU4IC5$W@@SCDP6FJYB+-^M(30B%<S%A_4M
MWNA+D86W%KBZ_!3M%V/Z8/7:ETIKB<9T,:VVMH<;L<Z+1M;+0S&J!/3GU9?_
MT)+)0#-*$B:T<D5$5"_7]LK*\-4/ IF;G[&(NERS4@<]#7GFQW'?P1%D]^^Z
M:"4+)'X07=I05@!%(OD0->B:@N</<=NU'@_;T7[6C;%K7 ,KGCN1DK7N2C;H
M)>R\?Q87)55UEN7X)6OV>M1')Q.K7Y4-7UAW'J4ZNK3W0R)3,*WH'&0/VD;1
M/"?1AF<&(+,@/.@^.,0I9K]6A>*=[O780.K0R+B7U[/%&W 5>R3C#'$>R ([
MTV_2XW^/E7_Q+R;!5GSHV1B&6W);W"ZPCI+(UOM/_=S]LQ'I"",*^&3G[9:#
MMGX:4L[H%<\EB@SK(<'XRO5.7.R/ME'JB.^6]:RA3#YMT<E>4&4@$(;&7$YJ
M)=WZ>)I4KW8I;4NQIMY^V?,M0&7JRQ41<PW)?J'%%1'XK52!DW90["3QJ79E
M4-579JU:SN;.S6L7G./-$_H4Q4:PV87#=Y>P#;.-,I(11 ]TY^QED(HGWR&(
MI'('G]_)*BRR.W(FR-HGE#?.0"G1*1#N&9?*Y+YL\L-?(H&"(8\N9-.%KL\F
M.3_3-K.D3J%G^AR T] AO?LG"NL:\[3.G!A%PCYAJ8:"$C3>5_^$JY@M=6WI
M@$F&,\(QOYK-3%$S^MA3F92-@I.,[U5CH8>[R1,/N%<3 ;9)S OI',2U479E
MH*;.XB3,ECWW^\NB[&Y;V]7M)=,#>:IH0WM-.]BG8D4&K)=YHL!^H<\3?7D6
M$Q%'()S=3(5MT!?&P;TVQO+Y-9**X^X^;FKJ9*\UBC";F,H4M!DN8'I=L67E
M1YH683=9K[8>A_,(VAVA0)R6-RHS+4A<$9UO+9I-OJ$HP;?%$P0'KHCZ+^4O
M"JX5#JA.\3DYE&=F\'T'+'IJ4J(K><7QCQCS:-.E##5X+=,5+1UQ ZBN13W/
M"YNJ->FJ4UY$;ZG1UF:%;W,+R=_1S/]A)X5_ JZM ,V<[:/O!_=M7(Q5.4-4
MRRMK_!L)+I55*<9 ZHBJ&G3QY*Y3 /[6/MP4!1I)W,W2-+I<[G5"U^3<$ZL^
MU[F@0M;,;]\]X4C:6.%Y6$)AYD#&A61_BZN ]&KM_\S*[. O"O^PF>LYO92'
M]9Q9YX)ZJ):JKKT-,D7LJ._K3@R__L7@ZO48J[%(7>JI"N$11.ZL&F$W:QL4
M4X5,.:6C97,+DM#KW!<X'<XI!&\3KA1<^QO!O@]9"HBAN%WMWM'Y'=6/[M:L
M[Y#.=(@JIQ!J^Z*E?OH%:5EUUV,_RJ@AO13BJ(6C0G1SJOS1P)'KI>2MOR."
M_UDYK/\$4(A-T9O=&*3+LR)@LD5B .5(7C+8AN.\1V#/!%6D^<\*F^49PTRG
MJM(RF-\-B3306%-))HYG$[W^YF[Z4?GBNN:\[\KB1]KBQS9L+X[UW"C3*C2Z
MK'3"A_UM1N"2EF3&S< T-4PEO%\*:=V4G%+?4*RLB!\L?0A5P98-W]X;RB(Y
M]QV_.2!&.Z"<M!O&7:R7<@@;_F'X4K;KY-69(R1EQ<!H@B$UZ0'JB@C==(?E
M=#I :AE6A=D^[UOZ%01UI#R:LEM)Z[7J8@T8]$;MCH@ @A-=%+ G0MDKX^1O
MUF7)Z#-QIKOA"ZX P\S]C:I:@_,<&;Z'/IPCVJV" XL>_?OMKL>,0?RL#X^\
M5AU6N-C* .5E_B>V[JB/5?%5!Y6U]4+V_+W3-^*$D0 E<?LR!\*\GI3-&VSL
MM7X7M<_!<WY\Q*EV\;_.*!]T"F8(/C'W&.//:A<8]W0[WN@%EJ-PY7:<]Q]'
MK&%K"APL8 =$IW^;2/LOKJ#$))CDTAMK,-/2>3@#_;S?#T96"N=,6>" ST>/
M%>2^5A8^:DL:%ATZOK3CN[GW]*,14TI3^?C41(^7D)MA29)C$^:79,J?3.*?
M#KW6=HYT*WV-5S%&>O0F"@[@!''@;;AOJ [2G7\JQ!=?RO%&_8Q+E4?=/,0A
M#[LUA)J:GH0/5^$1".((";HT.5-S1@&WOK%;$R&(^$8?JC3A 0X>F0(V0QG\
MK2()OULMR>ZA3F[^5M+Y5@4_U9PVL3Q2F)%"5SS7F]H71)S(!?6AM#V6M9,<
MKZE(T0X_17W70&*B]A68_?!0@JA3_QCNCB)/:[R71U=C"5?/+Q=7^ 2D!P=F
MU;E4/5%->LWFUFJ>I>$8^*F1M,L50",6%]."^GAS6K6\X !%HKNU65G&;[V/
MX*ZNPJ9T/.Y[KET]4@ KA/@![2D3_E80_^KB+O_]H7BDR\L,7&G6D +M"+!9
M1^\&5)<Q& 1S/BXH4O0#SPF^.6/6YV!?/M!$9EC@2.]%5?8<(&R#:8P+/0E;
MGI^S.L/<$+ @)9[LNF-PWRKWV,.%WQ?WC*;,N/VGC1_5.J978L>S:),ENYRM
MN[C$C^B[]%N$;40CGS(H5[J13[^BYYEQ@<@I;@+[8QZY4C"#87:\()<M&]EF
MJ*(RWR?(#SH#G)_TD5#^O&;Z?J/@"-?1\UK/8/+[#01HU>3INZ";FRNSM[QG
M8R5[ (4\HGME+"FYN:/5G#A];;&P ^4[8J5*$A"QT"J)&#6%@ZTO0Y)YR2HX
MLSKU7X+V.]<]HHT0&H]KH _JU,*7ZT5"OPLN+@@GZKU1MW23>K7E.-I>YZB@
MR1C>0%"66=BTG,5*,]J>=@SI&;%LMBZF3V&B#3_&7(AZ(TSO;VM$3.DZ+]%4
MBUNJS7MC34\06-/NRV_NV+7-B$MQE.?P8*Q;L0^5D1:R:1W0U&/B<5#@5.19
M]S<3\:_>)]P1\?!?87YQ0!$N5\A!+^S%5BM"G.,I OE&;;"<U>[6O0KQ2Q8<
M.)'GC%SNJ[IKGEZ3]W2PI[(-874ZJHV.H3=ZM;59.W)]]^V?3.:?CANVIZW>
MMM[U(RL<&;.3"QS:4<;5,*O,ZOJ-IW<$)U<<&BQ"/WUU0;YP-Y$7:V#9<W=T
M6#ON5)+:E9QL4%#LRLE\KQ&=^>L23QRB(FH3)K<SYM:I3QA)Z_WE5UQ&%5FC
M%0.MG-Q E=U$>TXN0A1Z0>HP$*H(6:->,J$Z4B/=K.TMB4;;5&W2K72Y#"BT
M3BWCS7J7SX*G/GMN4NYZF38\P^C&KM1*N2)K35YI:5ICIP,P$<^2D 6_C(/R
MFC^>14QS?YEP.L]F=>D.-.1@6((%CG>[+!\?LI;%P>P<[#PG$XE+3WI:>QID
MY TK)$X6ZN73S'PAJ]]IR(U*J(7_CC3^U0[VGUR,X,_'-6TII^-J[X46<KTM
M7@[PN?IT:KEJGION=KUC!?V/%PK.;C'WW[8HC WV@9^G'Z[.1(76("*&,:K%
M9J":#83L=__R97) .Q/5)KF]E:C[LD&D_>:;,4>EN3<#XP+9B5&N'XPB<U.E
M R"6B8%IKNX;]>IM!'1__Z06IN;.EX#:0/;S<)_[%V+8YK,1$IS7/+0K.9YY
M.-/AB@CS\C]^6ZMX[X26I'>&;]7TS8+^8OF3V"V$R:?-1XZF'KV ZA?\$^Y:
M#Q 6B]-?KXC>B_H.LJW9)[,=4:&S"HM(%/[*N6NSB-C[(F^:]HOZGNFYQ]6O
MB;46O'KK8LS=S-27$@>,/U-%F#]J(<<Z3?<KIUA!TU_80([&DR+XEJC0;8Z:
MJG)<INH'=GA2[' \E_V%#&?#8&C/3)=1A6A0.TEJ^ET+^@<R[9R6&<L;ZL=K
M/,'Y0.$RD-G3[HI\/R."KE5B%-C(B(59X*SU9"PQ^B=LYHV_V+1^XJ=G2[.U
MJ4-^;CI+?KHA !=UXP9UX-TAG.43G)1KC4?$TVKKG5'3VFF%HXDE*!(8;").
M?YPEQE?D%4/25I[O=]/-U8YAY5G$F*91ITV]IEK[YUTOPL_WD5[9RP)"*MJ2
MWP($/;@SS!YCVA;!#S%+S*:1?A//Z;2NZ0;=+S0[R4JNK&NFK:O!T68N,_UL
MY_OQM,H_.DWLIF2.Q]Y8C,5G <6422P6P#I.:]G!QT7!=(B?J)+)-&UV1),*
MR8QK6MY<"#*^1)%*#LSM$(SV:.@\))#A*_0<4H:D2B+9'V5]A@9%RS5058T
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M64O0L:TO-J[A+LTECW)FSC4M9K2*Z^^Z-9%-+=]U2I6X"%FLP,FPOQP!\T3
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MW!J_L8.QGJ/?]*P="@F@BU"NV9)4F(=TZD/6IFR22XSZQL>3BP:GQB=0XE^
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M75P1DJ,,)1S#7@0M0>#QW4?5%'+<*.;6^/7>_G- +Z7ZZ8?G1P/!6ERK$^>
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MH:-H$M039:T0H[WP5@2>VO8]=Z3&M:8_6[#62?J'YI["SLYA/2FG3^JGSA?
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MKGCI\B^=!>\,+>OOB[X\AB,;=X$/2$W<?:(2K:KQ)TJCH$V<QH)B=F/93M^
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M^ 0M":01;036BZ.K*4;N_945_FRN]U\:?ZR0Z-=!$6^EPM1;CLJ=R^N#SN>
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M[_!W:,U6VK1E1KA&6[P;3K-O -L3Q0U&&>9X'P9)11<]*D<VJ;N6"!C.1::
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M1GN/QKQ_,#[VRH?/NP'*F_+[=C]:[^Q;KB.&_IUM^$+A@MP.N[D'"2J$NG/
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MR.;;HQU:]T+?$O?W;&T7=+/45[U9PMNV.'',N4TGZ1*VSO3X#. *9LA^+-.
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M =*\ K^9@GL.A>JW7\'(S:*CJ)M,) =C'GQ:J"0))1YQD*: >577@L2T@[M
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M!IB!RT T,&^NPLJ;HUB6&:=WJ!)ANV0;'KNV!X]^$I[JG[?YGA52D:=2?^F
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M^8R&7MDP[S\^Z@P,G_0B':D$G#OW#Z[.FTB[_A!Q[07;F?NI%!&7L'6<-&'
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M@V7B"&]E/R1UD?^QX(1VLZH,[)%<L,5W?+QT O@C/H/"^&AZ#!D0O,,4/!9
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M]GYZ>L1:*;2-(Q11S_$U<Z+N5"NK6U1CWI G%E/K/2%,*Y.M=SGU=*]RD%O
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M_,\;@AYY([AW-C45(/^X^UNADI>KE]IYK.^(WRFEZSIA#[L6<BQUW'E:Y,!
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M?[L%?IK#_U9EK!"T[N$7C]N#FIW$%;]P:?G3QZ6(5ML?F_2;4RV;0BFOX4W
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M3:F7>[6P?']YT6WT@[*?KJ;SNF:-+*#T>J"A_8B[K21JF(.^HC.OAL5UCLB
M6 W7?I6S;5"DO0N/B3D2 YX#C5PI=PP7VK1YXHRH?9W=[5_ZJF9(B;OVUH^O
M!L:T?$?3+-W0?6O51^LKS!(S=P=K@>9"][<DSV[M9N$=80Y-]D/=>BA=50HI
M(SA4@T> \*V+%$UFM!8R).UI)R?M'*%MLTD0INA<;@"L&'2,MD+6>O#"8.+L
M[2--+8J+QQ8/V9?5#8J\>14X-+]W-:,'G=; *:/)CWL/<A?OQD\SDQ[F-QJL
M&\NF]TDY4C7MT)0>N,VFK9)!BM.''=D$SNEG&6TI[UP3(]3!]?AQV#VOQVM_
MX=M^D:]2>; AQ_;ZMH<Z<V3U4']"K<O%,]JBD,M?:^!0WDG:&/.N0I750HK>
MPXGZ5D&W[\.]>-Y0?V ;B\6'L1Q>K*M]AK>F_\I2STKT$1NO@KY+@[;G?$P<
M^!(E99F1;1+=U_[V8Y#*88L:OI89%97DQ8K=SQ@7P_.Y!!H,O_69+\9*O:M[
M_6M#_N7(/E=(5Q)_D"C^1SA\TJ/[U_^KQ,W@6H5TB>3+!"'W0LGKCIH*+48K
M[;+ZY%$:;9!UW 'M KOGDDDH6FE]HIV?,&KF3RZP7;@_U,I:XKIA4*-1)/K0
M/',:^[ZVH81V40*HK-QBX;YKPKY=H-RF*/IJV;K]<@LAR3?Z+DIF>GQ%  XE
MX,V-QXW[6::NCL[XD1UN%1X>#\55]^IG;NGVW,C;&M.Q_AI\JV3XE.#6QVS:
M;R*$:[7V .IU@AB$K:VI2JF 6ECZ^)PA5J:L<)A"-FZCI6]@V]NW"7Y,*207
M$M;.OO>0!OURDF"&IBTOD/2M3LS5N#B^$9OCH#]/^S!N:,03SPY/Q?WBMD<Y
M+2W'ODA[BKNUK*2LYR!MA6ZNX<:BY[;R6ZHB=;3H/+>_]A4V(;&>T1TF7 #>
M C-MZ9.#C[""7V D%W6D7)W,2*/#A2#Y^-3*\-X$TM%FR5<A*Q_7VQ<C7UIE
MQ]!0VA4%;PZ?R](2R.5-I:.!/T@D-;_&EI6"^FX.(N?-5:^+O=1P:(@P7->]
M/+KH'+*X):5&GAJHU5[A88F-:1.2I#ZA5NH70-F'X#J'5C7GED< (Y":;UNU
MKDX&JD;9R=O=09JWT5?U#-6MW%?U8D;4G2<D.?>'3S .EKW! @)4Z]RF7KJ1
M83H_2!Z.RW.-:V!!G''35S+^-. 73@[S#K7#?I T;_X@Z>)[7=OR6U&AF]ZK
M/UN90#(=,HK4F5Q]+2+S.W(57ONQ1D_"M(\&)) *"P$W*LQ%9*:H3!F#Z&'U
M+G#(I3N5B.\Y 5.(&NCY8>$DOA">:V[2=B-Z( =MQ@X?!#E9#W0S?4J)6J[L
MIPF7/G&:[94Z>:ZTEB)'%GJ<7_, V5!2Q"*;&"[20A.<[#Z0Y= LG!H7]+3R
M03T0-#^!4ZW)Q]OW%.J16ORT%RX ZJA^D!CP%MYN?B"ELSGX%.;EZS FY<(Y
M_R[MIG]@W[V=I\I3O1YC3015(+79]+M:NS<ESI)1*+68;#/JP9]FBEI4;$%8
M0[<WQ0\2&K2GUX[=QDLZ0QKD[\^K_TEVQ#D7'>?W]YI6\^F8D#";5* '"^O2
M9?6D+$!OG'X[GONGBM.+S9$>,@5X9CS&2WG+CG-[9MCJT@_QO&DIX2N5VO^P
M0/0+D=P7#@78P,)Z54'(CID<P1I_-/NV?<:\=(I*/H5#0^SZ3S'7:=?)^;B2
M*G%\S75Q*2#:O-25OZ)5V*</>),U:8-O,?)1][[Z W#3LH@OD;+(]:9 P$MR
M55%3/5/I@/<1WFN8-G$C+^+XW.OU=><M+?I%FCOX.DJAU;!SYH@-&;H)ZA/N
MD)"7HNSA9EF#.NHV"8VM$\D<X;/9;-'ZTHXU4KTK=B!'S++.\B^&F\R9Q6HW
M0PSPXV)SSIINUZ*Z+1SF\KCW;U+2"5R+7F7HNV^+[D&\9WOW I*F+&$D.F S
M>@3.6J\DHT J%;C5NSB9G%P:E8AE\BO:45>SF$J45DN?]4"31S7,#R.?-C4.
M@EU:9&*8/5AN\/8.\?5K%H@;J7'FQ(.(1(C=X^/_4@@N:)A3QQND8AL@'D45
M\DVA&"VS-:CR=)_1Q,C((PIH6+LS(XM#X9@2&W/#@R240RA#;5M+YKRV"V>8
MME/GNZ>?\+4%TI5*7T!IL1/4X< ]EM[#9O:=L[H@9WD%V\%:%W2.[6:B3V)9
MV0>E6-\1AGH.$[$6)TZ<A&MV%4C;9NGT1%F _F \<T1IPB$KXZ VPXPBW&!+
M7LV:V!#N_:;Q*.@VNA3O8>/XAJUPSG6P;Y?AJ0X%C*-"3-S7J_S%#CACYM[P
M^D)LG/7#[4GN&"4T@V&P)FEE-6OJ2[%<#0QP"=[BW64NW6SEM#16%I3X4.6L
M ZWXH>J+)8/F@J<%QA%H.O>> 4W;V?_UGL'X"+E*/"0&U3DFIIKQZC_00/]A
M/Y&=&U55KLW,3LWTS#Z0SI?9\!7E5=;4Q60WN491'.VHIK[Q1QJ&6<Z.^8\O
M>OP>8+&E!'$!16I"*E('2]H+DH1N$2CHT"&YX5&J[08:<:6(=5"Q=4$&@3P'
MWLH;W&JJ5E0[.DA$H7@ ^Q?.XR<M$":9\2 +! A^,.GS4Z_FQ<415M"$Y5XB
M!#>*&,3N<3V6<01LBT>8Q/@GMAXNU8ITG35MC126=OBS]%8I7!EU<C*Z$4I4
M,2<5YO/7U"P)3<+Z?S4HU.\O]61%Q1]XX4'&@6479BO<6"5^D)2**7GE[IWO
M]%4.3@SX=#N<Z0<ZC/%PC-R;;1.PU#OSG=J,<<1XR]?.@W3SLN_AUW260:>B
M.3\U>AD,N<>23)Z=39(TW9A4&=NXYX00OZ.%W2&??Y#:&N^U>\[57BU&#GWF
MS>T5[8*O6M]'=^K;3^\\N^.4'(O67$'IM/7+JE.0C*>4SC3?\[E[K P#19SZ
M[2ZZ?$L;3XXQM2]6]]"2V?8-WCN(^GRL4/=]D3%-N8XX1[5ZOKW^^:3&%(\5
MV_R:9'ML\ I<4_=67K>EM!.. (<Y7%==GG 86(RVBYJ!P;ZMZ^V(?RH<+P47
MS@UB-C8<<5B*AG'O@&\FX$;+';3BQ@WY#*=$AS=H#IJ$]9KX@.5JH!JW#R//
MH^9[$2TN^9\X Q-)6SYP=$5;)0U):I>)#N#:AH/CC1F^[)6Z8GZ0&-F2R"4R
MP,][7OLXF/+6#1I]ILA59O0K?R'E^ (F$$%((KW4ALO=Z_/LIAFEC'3O*FL5
MN]Q5[]1R(RC::C4VNFGKE-J2+24LO#U/B'8.;1JBLL? OT8/]@2:0WB>R_[E
MJ=7?._XBPSFW3GR*&#]>4'#/#$E]7N_57:;49=PN!YT1S:()O_7$YA%B\N&>
M:+:NTFAF*MX8Q3.F$Z>)_W;5M9V0R9>\FOHDZ[#Q0UZ!*&LRC[FEUD,?>CI*
M69YPGKC&4N=+X9^?]7[WYF!T'P&A"$'ZR@7L(#M(IU^LYN9I.'XR5I;\,#'!
M3T[QPG7#FY+JS5+U6_<&U.QBYQ,6)$%1J'+@J*:Z<"A*![6+BM5)@Q^(%N<3
M3^]K%ANO9D:Z#S%B&?@X&YAQI\7LSG=&L:I)0,O0%\[5P*\]^'7IT"2 "H>M
MXP%R?-GORMWSBTTR'W).^K*9JH=U#3P56+\XGX&E8N:Y/-=356<E[WAFVBVW
M3Y[F,$B%^JZYT7CBQO(<#Z1Y'J.=2'A-65$B?DIBV+<;)?'#M-YP="H'G-)T
M.]E6!K"4'*_-K8/7.152!.+\W%HXK./.K[TQO<6KWZO8F P.80CX=G2O''[)
MX6N*:5!%3OM1+'_O5P8E6?MH R#2>$3\V[K)" 2;XXU9-B4"!N,N5H4G\[;V
M(:$.!=![_&76?3]-7UVC2_RJ()Z?.UX.I+;M&\6?@VO_5_=-V@)%!K>.+,NJ
MU6O$\(.X63)6,>JP+R[AZ3=W?+K]ETQCD/;>DFB:MB"30$&7. =#!GN%6\W)
M,T[7C(\U#QQO8_VE/V'V2J5ZIP3^1@['/\N4V;K^H:M[3%=XYI& S)%M@DT5
M&Z-/R$HH@CSL&T+W6OV0.<EKNQL&R:3"H3'.\?/.T<'LGN4OZ5W)8HH1 P:P
M5$?-S:+ 8#?S*4)>@0!@S;&H9-76'+S*H;*TZD;Q4\Q55AWO-MVW]!"(OU_/
M=/DR2Y7*<,7"!Z*:@RK5*F;4S^G&SUY?9//\MJ<]-,Y1 8^&>H",K.CSI';3
M+C6=P6IV:RNA72[4!2V=ZGC,"36>]/-MG59)K)W>:28PLU64%[978W^W=PG?
MV_YBV0R9JGZ<MX,X*FI/&1N<ZA9PH4V\OKY<U8:=R.MV?6\;P\7%_7:)0R4L
M"&]0H#4Y D'FW[T*EECAM?/9YD-3+&W*GYI5+FW\-%/?6;\P,_S[3/N5_@W]
ML?_V /^O40PNW))]0IAR N?R]S;"F7G'UWG-V;H>?2WK4-*E': T\N6*?#S.
MPW)E>_@T6+ [<9SG-CLC/()N<LQIM/&YS@EG\CO'ZOLT!?B@B)QT/BD$;#%L
MU$5D3$=:WMF>+E3\FK5D'NP*9R"E8UHS[UL8Y<V4L0E9?(PCW#ZG'\4U_(O[
MH8/4TB99KOAE!"Y@'JB-^2A&#6J_O@AM$&F 9W=9T^;2R7X2 =(Q3'NHS,<H
MDAUTO1 2&YLHWS!.19J;ZQQ?>,F,'>K)&B?U.G^Y'5'[V@==&\;TG7YRAR+6
M9_>2^JGZ&5BB;$ ?R@]>YVQ8M35,"W0K@SGDR0U+S-"^%=X!W0B_WB1&0_.&
MH''::?P$USBFOQ*?+[H=4FS]P0B&,$%-NPG<>,:O3]I#]J;(A2HEB[^6!?<P
M<7@Y+A/;")-3@(P%7@).$'F+DP7> 90G(O)'YJ#X@>+-?HZ_,'%L%&?5>X^Z
M!/NEGVXH]Q0[#I[8AI08V@A'FB2EO33IUK<]ZCU*$XJN&<T#?V@QV;ZQ-[C?
MB]?1ZL\;&\PP4\[<X':-X#VV<Z80[-5UXJ>;\F33MSO=N!YD5. (]VT<.&2X
M21\[%?VME<?ED]5LNL)8D2VR5$#V@WYA.6J;)\\X$+HM'^7I%T30>KE-Z;W@
M;,B$'I1868UXD!J'Z,&V#0_0HVVO7O?'WZ@1B+&BD Z=I66'F\AY8E[E "9]
M."\#)^A0X#A'7X*G\(N5:J,Q)KJB](VPZ:0<2G# [":C[X&9K6&V"#C^598%
MXI%;W&+))O"G=<IA7^L!0!B<C+['_\J!?] 3[YK'G)%.*DQJCYCU?7DL),]6
MZ4CLZ!Q^\^URY=<# 0%MWWUR)MS_1=Y[1S7U;?OB451$%$00I*LT$0@B2%<L
M% $!:8$0($IO 2FA%[& TDL@=!0(/90  4)3D!::E 1""$@70I'>X?F];]QS
M[KGGG.^[X_S>&&^,\YO_[;W7VF/MN>:<ZS/7FGM.S[:=4C;1 =I[X8$]84!]
M0UR_;!HE$3J3*UY&'W)*/Y-)Z/E1I_QRM=IX9LD0<M9S?W@/".U\ULSPJ OB
MO=/F[0\>!\=_5I+A"D^9&JBCO60U:51(T4RO;%M9N?E^)==2_).WT!O(%%N7
M>#KE!$!C\IT^U,G_@)T@OZ$X*E>TJOH21[Z(EUS":F*Z&G@C)K^[8(3G*006
M=?F]' .W0D\S>.5!)JCR^/+MHDGY81*P>ZA^9=&^8I3LV3,_#W0'5T+EG5)*
M%D)?NE6X]PY%Q:(^Y+ZS[(G'"!F/$S"W/L-N7-X2T;RB!=@R+PF\Z<T#=!I[
M^]K_-"$Y^K9O]#.E)V<L(YLGV2^V,1=4T-546G/<7!%C5>]9+I[-49@QE_GP
M7MWX74' <,?3/'?#I-N7VR>%O.IYMO07W^0)6N<)R5V>.)46.7[%AS];KJ"=
M$\07*!/66QR+B#3KAE2ES#B-\6FF0-WE3=+%GNQQ@!\"N_J.CC+7'-^G(6=8
M"X;964=)N&I]JSV>IN'=1AD%I+KVG#GLZ:&KVIUK@W3">35+HA4SF=WF86:1
M4R:U8,T!+05"V:W@@?"6K\E;"2V2C5E'NG(W.NQ(6GT8+(L'%X]0X+U+U6X%
MHGP""2UN2]DB'=(\?$G-D\]?U8Z)ON,*E!KDT6A[JCR>8F@W'MG_R6=5I":U
MZO V16W7I[ZFJ.-2,&:WIS,BQ8)7:-C'K3AEEMV&_O7,B(=G)\'O?HATA#9W
M>JT.*ZEX?-I]H;6L 4$8%DWE%W>$]9[>O/]<'OH36(RCOSR==W/]Z.O[25GS
M'Z\IKFXI>D'T[7?SV$%R[Y<N7HWP?[M$A2YYOW?=LI!6F+VJ+BTL5XM_:N:P
M37+X6'CYR?9M7[!?H_L)8".O';II>+KDFHXJ4,P]O.BP[Q3.:5[Q7<94[UO=
M=?^\6>W)CJUMSQ2Z*>;;;7.E]]R2>(J&KZUKH6P6G&4B=&<QADFQY?::(C]S
M#- T3QF\/'X1%$D+!^6R? _B8->MX!X@\4(W>[]2[P/H_.B^0!4N7JYVZOS>
M8J'E8+\6,"9+"K-WGDJY5[<G(T-^'@5E,'K>\['K 7!^S'QF8]A^ Y(W[K8:
M=="?MM&59@WF!TKO0[A:).W)8R45PWNG@1(^U^CR9,:RH@1NN'A7#=5N88,M
M7OQ5*?]92 U/7?MJ5V_<#H4XWOWY86+O?T6'S/6OP*QC(=][N4 (YY!Y0I>X
MR6\\Q*0I^[;!A)BP):(]6[4%2&BL_E#JW-WO2($[D$S9A%0X%5R6JCSNGD/6
MX!*)&=H)#3)T>E4H/T=*GDN!AN<[GF!+X]0!^WX!2(80R7I$BI!H@O9'KI=Z
MM6R.%&B? +RJJZP'&_N.=8:6EI<_7<4#SH;)Z9C4+]#D)%H'65QRO4^CYE'=
M !//8EJ:)F(6P1ID+ZM((K%A!>]))A_M6 -*:E@9?[I:;X;,I"1@%X4\,@HP
M9"K,#PFU-'L+WR9[V7I6@QT2B97'''J+0;.?+HNE%+^-Z!)[123#'!JU%"L<
MG7!(DL,%?%T#)^P/[VXYRTL?4[DE\O"!U7\RC;<I+.C]M8G#(,;#J1'ZI7]F
M"/\!T<BOLDXL^RX4K1H6*8&[ZR^Q/#RU*Z>M?C5DFIT'*H^)_+%FS.X?9^VA
MJXOO4'G47A,?"Q;\278K8=%*A:Q@N^PAI6@%8>W18*0_HSX#$UR#RD]-O6\L
M8Y$B&:+HJ?5FS'S:J;=V], ZU[R%,W5]UUD@7MFAQZ]L*EDZ.>'Q8:8L^$A8
MW>CV#8;QV>FEZN[F?M.Y-;Y-R)BIX!Q/UC!7SU9KV78FJ\_9DCN*09N>LQYJ
M>>Z*TWJS([WBEQ;L*6QLM&P+ZIW*ES="HR"53YHFP :#6.K/JYN_2K=L%_8&
MWVJM3[#,!1YOIV22R#(0*UD%1H>&X;(C&<93X59,F-Y#J@'5?Q;ADG+?/R%#
M:RJ2H-] MJZ&:!"#<[!R,2VS-9L,1M$*F^_.:=&SQ7QMVO#24MSFL0^[HAMU
M2%B_E('=2-1V:NHL3G$@C2\UDIU1]@^/8OZ4W?\VAT2GA?>K-F.^!YAMAK#G
M[_ ?JY3F;96X.,-*MG-9VP2VP>'Y>Y$6F/H ?D%]W?AZKSM158SW7;P\D7(O
M>GR-ZL='#6Y+#HDTR[6/\[PJBAU+^R*GU>@)M,V]UW78Q?4UYY>_()%=.=4H
MPN3SE:FR?(H(Q7T>OK3.4IB 0RRA@EXS2/QTG2PGWM>732VKI:F7 :U^!]OP
M=D14:*M-?O=^H 2*,]Y60L.!3H,">K7N!E;ULS.)S9[$!KP/ U7!3V1\-5B2
MUX+O8Y-8B7+0HZK2X_53VS=E4]='9]0V.4U. *O7[\=K[ )Q7B^2(QYH5<OD
M">P@I!3V'Q@!3'3.#QOGJJ; 76:RUKV\V^[.2^K=75DD@&+C^K5=T)T[($PB
MU.&KRT4=EK:R9T8<7W]UR'9;,K:X[CKIL[1]YA#@O11M:;SD;O?AEFSBI>7R
M<[JQ$DX#SA1.84UF=0482ECC.>.GOW+YZO8:\VIO L=T2*'C@]P8EVW#NE/D
M!3/F@JVJI:49YHAMNK>)'^;WF\W@,4^@?)$080/>WHZ)IV&?%N=$LHY+"KAF
M[AY/NYEV!.$J[($)98HK8?ZDY:UP^[:%@+P$Y_RTERUR0Q:B/1AMN6G9N-X,
M7"A6I\'-=9F3P('#=#EC",XU2M!DC\4@QR650)08[@W.+J[?HUUO#A+U^*Y_
M!6=B9D.%D\KQ@>W->($T?D0#1_X;>I+U)AS.W)B(ACUY5'IA>WZ!_D;VW2.U
MK]X7VTW7DY]V*.;%R6Z? .*"D\?)=+*( HYAH?:[/Z77=K?!!1*=0HLY_0B%
MI^0;R !#J-JGJ<=1YF>Q#T\]7?GLLQH>)IDR%OGRZ[9<5MHSQW(>5)9+-/'P
M7**UYR55IBU[T+J")*M/AJ).W^TF"E[$K_ $X-F0_MHU#PN-DCP!6'K2SJ7F
MVFY)T?ZWZ_-*5'T$?*K#-4H)3-3"*D]P.-XO6_E>E?9-MC8"[#%5OIL@?993
MN-W[*3(:F'UFRF\H ;T UL9_UC S]'MBU/L_J5K$H#,?M>_5VLB\/AA;7IWM
M1(R?+IDD&5.B1*N4N:R],VCEQ#YB=!56,%W+07$R#M'6CAI&>,]3IJOGYE)A
M89ND4?**EG7.1L93MR!91&JF-Z;7*G,:-\?(V_J9HZ/>?<)M;Q0,*7X_2S5'
M;34N7-@^(@#1CRWVF^&/AH]N[T8JX69)4MU>@E8K1T%M1VJ&K+7;':,#,.H<
MCQLAW?\$0/2\'H:(2P'+Y\$A0I;*B.SV2-'G?&JHOF>PX&\9%S=DDOW;X$))
M</9YZ7AR'5\,NZ"1 Q!SWS&J[V4M@SIC[BBND3RF6N<\:<!C)?:]01K[]!/I
MC3WA?$BA*=?['XF[[]>[YKV"OA K3S\]U$W+R>/ /73Y(-N^7=DC=T_\XUKF
M%1698:SW0HGW'CCR0]RERRC3CIOSAE,;,!;MT9'TVRM]PA!T:=QS_@K4*BMZ
M$JIC?L,UTH8G,IV >W+9/JUB29OL-,HNZ;AA5H).1&E ')RQ(/7;Z,IEW"(D
M0&'8S M&8+0BCCV>%OQ,/K",D9]7?R%+7!_7V]%:AN$B[I=N RWFYKI-=..[
M&\%J&Q'EF_V13VI9^FW6/HZGBU<UB*.=\_6-6H(/?'U_^DVY"6WA.QXV?&%"
M$D)CTZ:FQ=DL*YPS_-U>=AZK6W%"&9IO;,V,7TV>OS84*";$&:]ES6ZCT7>^
MNXSV^UILI 254_!HJ$)5O<&;(D+U#>=/GWR4KZVQQ%U%I(\^X/PVH:ULE\N1
M"V+0CY;O)'Z$O7$=O^F@)&)W%)'[?*&[R&AS0'JV#&:(1(9:)Q8H3DI]CXN%
M7>O=/Y7O3KMD?:TB/L)[0%5:)=MK;?TBU\VU\&UQIO(6M0A*=8/J2HJ\,ZHZ
M%X4TL]XVTT2C[4T,+FQ[)^%B.C=W%SH35*D^!Y_V3N%#5S=5"_Q[C,X_L[RL
M%TLOCI46U5M>#"N>F$IR&+?Z.NHH6,=>D,C@A!K76'S^H+H%.:@MF:>DW>-'
M33DE>ZSB9B-/X[U*HKV4C_CF5S!21Z&B+5:H=5V?R$8O!XA8<)5+@]2\N49Q
MNKUC%/[,;K#JV 70"I,W7IJ!,:)FTZ9^?J[0=YH_#+5H@B<5MVM6CVH^+0SU
M8:7B\<Y'=^8VC5;,L]2[B]-%#K,2\LV?_A<%>_V@-G/3[ 20V+>7?1KPU\6-
MMF3M8'TCIV$'7EUQZ[E !7IGEO'QL: -;U_LP\>F+"WUOFX<@0^PH\<,(/F7
MD<.##=8ET]Q96U7.U0?8?BNQY;SCAZ*2!$=:OPX&N9^-FH[>\_HCVY(<&]>3
M<@(R/)=#&#$W7!>LYB9NOO&: 'EOC"C'><%%-*J*4E<;1\$6R-RK\\'!J7B;
MK+5N9\''GH&P#>^1#]ZYX0_BXF(\4072-IW9?BS@EO<(' )+MC<9HK_@COE6
M0QZTU%D;,,2KS[$_-A:\)\1! 2WJJEW#158L34YY":*V92,CNRX[1"=H5WN5
M>D0&O5DD!IL]!QA/J[35S9:J1X3K6;*"^3)?7K1:LUE+O!6FS=7W@F3)'1IV
M!Z9R7[DTM;W$!M^UND+R'2[0F( )PV$7%I1>[(MM='1*.T_G9*?7O+S!<X3K
MGKCCW^-(KK-9RPYG?D4@&]%1+#Y.P*I) 5781;U*-*"\]-3:@K/ +QGX:OJ[
MGG'@"4 8)IDZW3USI0H1_L&[.^":6=#AV]1X0UJPJMZ6)MBX2C2K0.Z19N D
MQ#D?]->@3*4@EA/ !8FFW6/>O=8R-M+?FDZ:>:CU;IIIQ5-VT6SNJ/0@=\=K
MS8VID?:BZSM%AG4*)FJR;JGM; JN.H()HI@JO1- ;36V\1.O\I^@FW^ >?^_
M',NLE9DE?_*!%L[FW9/N)W(>Z-AHW56\K28V!&'CZ?O5Z4%PJI36.C-Q=W@C
M3E0TD,3F=7.*N++D-DIM"NDZN'U&Z@C)\Y[W1N9&\ASO_J-378ISO\8\((/U
MOP$P99CK[E9=V9;M;P!<_DOQ[>;'68^F3Q6*O'JS)&EQR9_)E 5A6N&?M1V5
M;!M>D6E2T-HQL  SCGK[#P"\F;2P-Q3T&P"+S 4&;\]F$A5D()8C"B< F-9P
MZ7TZ1J5PJRMZ/8K#!DL1[ AD>H-%PK'NE/-5G3J2-9%L,O#Y-P*.?C)EO,D@
M'"VUZ7].DIXM^E'91JCV(9[G:AA3>:3BPOJ*>>V&C59Q!5XT*VR"LMQ(+4$[
M/O__"P(& ,[[SS.: Y%'#];G?0<#W.3EG\#:A1WT.9#Z7[26GTUSZ5=4*4N>
M60-%E2_=5!$!8DX $LDQ+XZ4$>7*WQOD=_*9XK<[Y%5/ $N,OW5'4M9KNY)F
M.<8C\@0PPF-V;/-J==F.EGQ]@?,$4*98=]@].3'ZG55SVOP$\-7'\)/'"8 ?
M_D:_P[&'4KK6$!_"AU"K_M@1W^Z6-&,U+9H2:;>O5<'.(6T^<3LABA7;U: !
MA4[2D%__9>SGE .T,>F1A/AO0AD_2:8)2_Z!:CWGM2]0K9&X+;ZJE<HO6)04
M/M[5B8MXD(HQ'+0W10^P8 MO;S]JM<L,W!=X2("$'1KUFP+[C=FX=N>#E1TI
M9J46'&TJK6WWG%+W0A>PC^@4J\7B'YWALB*5/)MDE$,@W,<]M@C#T(")KQJT
M63"85O%.;EW7/>#T5XF 9+1D?N@=.4^FY):*]';;K'3R2+9M?U^<(6>)]KY)
ME@:98GBVN$JYI%Q3#!<<ZW*K[##\DXN9#]G#?ZC0N(]#)H.S?&LXP2,GG-1P
MMN+Z9_>K5=\VWIOFS#EV.2KVC(L(8JH_%;4R&?HYI+M@]L]]_;TD!O87S87Y
M@$HAUY<Q#5V#ZY%C*(>.@C$0F:6B,7VSU'H(-;2\9:\1? 3X5^-I3]^1)TSI
MRU6K:V?=N7P)X2-L+K@B7)ER,RX<.-DH''8?G\/D'&90:YA6P'T!S8P9!5%+
MEU#")D/G^W]%SJS%4]COI>F?Y32GTE$.5J^E5%T8*,P67)7<FHMS$=8!#=\+
MZ4J!:A@1UF7 T!]+I^_AMCUFJ.Z=P,+1S$1_YL%%IW2?=K$@=)K=Q>CK(X=:
M)6*OG4:&U_7W#'+,\V<$/0?NC_74<IO(-U!WA5B+*U21@JAQFXF.4."R$G9U
MV;*\H4))\+AL_03@Q$NZ<7S&=R)F:_B8\01 73WZM==^;'T"H#\!S"GAO1Y&
M1S/H#)>>  H;2W0^K"YXH4\ FM$?YT\ /WE&FI#08_JF.%Z!XXLG@,/20YGZ
ML^'[?<1>;SCIY]&@"M+3]NS@^JK<^R:+?'S4E.''<'^JN"9/9V+CXLCX\(AV
MHD<SV5%3F)3(IV'F&RX$^^P* .CR_BT2JS9Z'F@[;7:_YGV-7%"R8_V\_=0H
M/$3VV)%QV/!MM8!GB%:2Y:Z^+;$@1KT5X\)T]49LUM0C/P<,.EFPD)B%8D8#
M-A@2CM3AMH8\ I;^V<281@Q772?F4$:>$.T&\M%60;OYV\"G0:[L%^-E1SP2
MW&,LD.U:GR$0L#6G.M@:V(@U@S^^J&CMP_/:?E#M5)O[SK6LNG%H3))3-.]T
MVJWW)#R=JFHWN3+W9:QJ D+GLB:SNR/84'REW9":3S9$F_DD -* D6L'-\51
M.CI83H=. _?<,=U!SPZ9]/7-%$=FSQM<N?R]8!F#[&_\X,F=,G4K)(I-15/$
M H':ICR\'4QXF9#^O%Y74>0'5XK=C+QM6/>=O .>"UVW%H5;/U@:N:6^JDX&
M0U@=4N0"K[)%6SJ+HA1NH1/YR"HKZ%ML"X"S5^4"P\A*;2[-W2YLZC(N6QDE
M7UGQA:-=B$U?V?$4BA]X'X,4TNC');0+<?0K_)90?XST">#2]L!GW_\:G_A/
M=O-XX448SVO:W<,^:87B7"I3<D2^^,X;/"FWF\S>G3GT+_IFG#/;HKJHJ%NG
MB=8@7-7 3YCH49?S8';<G4-0Y/X@T@=4D4;\[M/-]TR2-R,,H2,;\3KR5=U'
M=58=SO'F#JY4 74#)_6JH<9"\X0A7.42RG[Q.]\[.M7):'W%IH@1U#UGES"S
MBJVW<!XT@"1GHFKEC<PTS0[5[5_AKO)OUN?U6#\8VKB'5ITQ,--<@M2.1#ZI
M&%A,^-H36)\+R9<MD&0O,]_#(Y\*E-YCJ#'7M34PW[F'Z);P*8YSGI '.]:C
MQNVFJGTTBTQ C:BOC&E9LZRMLYZM=??[G.V^%IU+"/NV)EN(_FEJPM9EVF B
M5;AC6M&^REJ'5_#,6X]B^:WL%B#^N)='_BHDG*V>L_%AES]UU8GB.W[!)[S>
MB)@KDN+C([,,TQ";_[0AM%86MI>RB1[7F[7+"FJQ%GG.A?O="[8"OMCUQ''5
M4<QWZL+9\&=_]'J_1R=]R5E#=_[3K^'UYQ]]IK90XWH$AZS,E@#AYTI!'TS;
M1](>=<\(27A&NOEK\JL7.771(+SKKNU](T$#EJ#E,8^$9%ITVONMG1X-Q[A:
M,YL<&*AH@,9_:E S\L>8\5:<MLGM5_/X/=\(FT%LN:A:"H@.:;.L*&&.5*<Y
MZ(VH#O^$*XT)Z&-'Z^>UF@NPZH%T:K/27NF0COQLMFK2,W,EYSH"TX PWHA+
M6QLS"):*-S^*X+_KH\DIX0+J7H ;/'I#Y\,"JFO,BA(OYQP\/_<76?J_&(-^
M_N6BP/>6CP'/:KFS]^XW;//>+%<\>&3YZ]HX-U/!78H]S0=UB7;)6K$WK:8)
M(9;Y&Z2\*$(*0E? V?%Z;U?*']$S!&'#V\R*M'1;UQ;6<N73UE(LP^JH@J3=
MQ(;4+E?1SK'>K)36Z^Y2,[^&%Y^V?AI7DVS>^*EP#8A)R YWCFK01&^)-N+W
M/\F[;^X.<DO4]#"VFM''.QU6FS=;USI;#=@Z]UC$DU+B?.(W9ZPON_*%O/2^
MR+UT&2ROVX!M-T9A]Y$3 0'/%<H81<=]PSEGSL6/R7/>]9-C_^!, 9?!60T%
M(FI?]/%'MVUK"XB']-YO']=HZVZM3+-GNUL8R>+6,TI7"D/>"L/J84V9M@::
MLD\ '+[*+^O<::>=7>LWO--[XBU]S)]/>UO5,*C?;%9C#8OY$*UZRI0>3 7U
M@$5'-0X2JYJ!I;A]",0%@T!7T?T?#KG_G4(1(P(Q:>TI/W2>K8#7O9@\P\7>
MACH2=XEE;J6IM[/%D)5N3^]#WVE56\P=.,777<WLZD<:-EEO-E3Z5N%&2; ?
M-K^-Y.>Y=:I9F?3<MXYM:H,^JFK[X7B=CK?5G=5MH'W:4GV5"H9-MNT>[PT9
M1O7#SUU7Q6.3$4%\(VW1G+>RG W@L-<FM7EO]-\0I1^W'];,QB,3\V!<)?V7
M%#LQ17J97KZ76+_P7W5.)QS3.YN9#)X XO)Y![<%:MC6,;,3QZNY314/>2T@
MP4$BP-_>\LJ^XX'4Z>%Z[>D2B6_.4G:]=R;=XTG20I^W$H6+UL;>WBH.<!/^
MD*8A=C[7C=GPHRTOYP+;K<^:">OG^9&^3>XPX<53W_\ZES37,U"BDB6)@3<B
M2VO-IM>!PJ5[+4P]BL+A*0(6[+F-(YPW2K9A5UGW(,A'W>ZY\8S76:!-ADRO
M"(XLN'8Z*.62J6PMOH&F^TCBP^J*M%.]BYVC8NM;VV>S/_A-:GWHKV>#5C*F
M2$XFFK<.6+M?+,X-Y=P<'XEO"P_HV=8?0C\9W-;N&L:YG\9O)P[WN*;#2^X8
M&_FP6J;.Z8NZ'EIROK.$ =T%Q"7X*SR=R&"RICUD!>722'7Z(R+._GD[-3W5
M3;-$"*(8!WG4W+7/B>!L-U[0DJ)X$S@T4"7E2<508^5Y2=?>1+W=<%-+[_4]
MJ?0H<6S'3())&*B+J0['>:W,ZIT[J^MR 9SSCATEWA?J%;A_G<!Y60,)A8*H
M^>F(Y=(=!]JMU_]RY7/&KWC7I&>#USI^+26$N27-@6G$(V:8BD"+?'QT]WFF
M@(9A51@L19E2YI'EY0E*6*JYX.IM/]3IZ[=A5!"D8M9X/.?.L6.I'[M_UEX@
M0;5V^^)6&JNP3+SR6)W-,@\ZEIKPRM[Q^>-*DU&3@RKY_L*MIT!/VI05?VD=
MBX7ETM+/;"^(M@K$6B+GY3E#H_.JTO&=:S[&JO0=Q?U%\W9E*F0JT&0F%JRI
MCW*$(8<QH^^N>WOA=-WX<I#LU8'),X&VJ W3;&L7"-:#^4@@UI:=B^;IA1_7
M0D3FXGHK&N#HG.?(S8C3PWM2)B71L3C\GOF6,^;[/L-UC]H9!AQ5I,^\@"NA
M:XM!A[O.]1Q'>'A2(QUB7NZ!9K!#QTY2L=G5GNSU2/A[RY$,9>H5XJN&N5^]
M<TSE8PA4AGM M6%+648, %21TZ3&H_5+H2!:#VBSO$15MO)M2@*;$]*(K^0G
MA$:N["UQ/IL/PB\;(S;RZS.-7^YN6B;N;E"9W)_NJ2LX^6F0K/$"(U6/6U+%
M(2]2H\UM.5+M+-; V!J2;,XV4]H4\X>Q*3[^UKMVPTS,,0-T8%^'O8K=>0<A
M2'%CJ^BJ5S&.7*"9SV)/YF%V]G"M=IYC[U,[SKF+8Z;O-:VNZI5)64Y?^+31
M<5Y$/ &L:*%IY[K"?%O?5NV)K'F?A.Z2@1Y"?0!;I)F@6E3/Z#S9]&['8H:\
M>FUFU;C7HF,#<K>-Y<44KBK1Z+=HGWM1R17?_ES7CQ?N'*1J2S(_1R388;[?
M>J(J. LO55<SPF9U*M"CL\+$^M7K/'Z[9\SE+)=5N_YW]8@_2A=I.FE)+?U'
MWFD$2ICT4$2GA2=2,77 S%,NFB )M\7Q"0PIE'*38TV\.)HQ9L%\6(D=GT"=
M8M)+>/>/^:VH^Q_:L.&$W9RW0L@[&3&X]C ^"U!^PN*M&/ KQA\)B,BW$;$I
MR?X#P)O<;SO5P3+47$*$AY,?G+O1?PT_;!SO&<F1[18F#+>')4),B V(T\@,
MWFY!QWP9P^-<;F>WI_.51&:?1O7V\;L/XM5;X#86<4^NOH.)QMVN</1*>^DK
M<J'-\BJN(=''OG5PJ? #%')Z\>%?->C_T0]O_R/Z-PH$ YQF4'PJSWQ[1DTU
MRL;"6-$_ FL4.BT+FHD*B]0H80MBR_-4Y2MS5UZQ2Z&O]9JY<U[.<$"+9S'A
M55P@&H8BFC-I_B@?VS_@6UANJC1P'&FK4S):CPM2P/_0>S4Q$/UJ^7/I/>I%
M&0FW\:%8\_Q&Q!?4U +<O]HS5GJ[0 -JX7FVX^'?C.:1%R0J%.=5=%S\VA6\
MG1*.,"EX.S<:ZK$ON* *O$&Y73%O,FBE)MW -GCM(B*E6O:1@7C1B%&A^6Q5
MX4@1UH7F?O%TU@D &ICJQZH'?6[_P$A-(VOV'-.!7S"[LU?JL."+J?B+HTTO
MYA]U#-JHJIFG:"\W""?5M&O%F8^6O ')JQ;1_N(;U/]F-*3GR\E,WK?-3^S#
M +7ESNGY4_!8(F^XI9<@$=Y\%VU=JQO[4*(\1Y_-[>IJ^QX<UD#I$+#NY1$,
M^^J]\F:<VU\$!5N18VIT<W)QW5#@;R>^<12+NN>96]>?=%CA%YO9OM52ZQEA
MC;D8?_V11G5\!]<]RX#N W"54Y@,SO 7>.P/7OR+J3E/G:,\VS>#I>_@'_!N
ML?SH-2RZYR6[BTJJB$STJ;):[X:8K0:<XE.7WC,OZ,.8,C/V861G"]AD!#O#
M<R;'@[[,9?#G>58Z99V2S2<XQFK,LPK&;6GC2U)NC^&$T1![0U%UOWX7WTY2
M$$P,5T""%"P2R4%O@H]?_U6@I'PK7/N0APV3)>ZMX]Q.W(8%=\V6MA7,EBF?
M*_(D;PU?RWB;6M@)8[ES/DWI0I=+YX8BYDI&Z(90R8T4,XXCBMW>V?J$[5#5
M5W4?]E/?I+T8/#08<,UX^7J12[>>V2B</\4M69F:D(CH<O=_,U,$8>VH,$W?
MJ)6IAD"%'%9*RN5-$K!@._CE_\*0_S<I!'ST.,E/Y<BKLKMD-X<\SG4EEFJ%
MH)S+(]YA=0%1C+[+$'"R(K&@BY*,;15WVSNSP.<G B9N%5?C/2=@MWD*:1-M
M#OK4J:+MIHX]L35PF\:^':[472V5MS8'M%=:);D+)-F,]]6_42-L?,W>$5V%
MN,$VC6;U%@P):KUZJV0=85L[WR1>[C)IP::A$9LGY=NY[J&.6GX?[Q27&&4X
M74QAN]0B\:'+4)T^QXTKF\^/D_9",R$1@R^>]8A'#9.UQT>_,P*Z]ZA?TUU#
M'&'197N9WPX9S5=LF/5P08K=>VSY$OZ2CJJ6#FV?8Y]2G;+<)2QIT^\$F]BG
M1X/"S09@SIZ15]%5H-Y?/J'$UH&N(^LTP+Z5Z_"!*LWFRWV41T>'==:/Z_(1
MKU3=/-U4$(JBHDK W2,A,0DQP5E!W7Y7UV[LE3Y^?BL>,8NGUQ.0A875OYTX
MXN+ :Z]77-ZESX\!,GU 0OA&:JC=$I5G0'K9K52PLM!G%B,CE7U@;/8!F@J)
M,=F>D]%U$  =[:/,3P"V7@2:LB_KJ!UL#*R:M+;6.T/0VID)$?;T;'DJ7K;&
M@CU8XFFE2#?=M44;(*LEW<.,9\,6B*IM1I*HGQ,NB&7,XO/[!G\F-_].7M/T
MRB>NSR[-O=?<9!+$[TTI6.?&$#%[16BG>;X*)I?D:J<BD.97\3B1R-D%Y:PU
MH2K4(N7:]OBR"$P/E[!%<R-_)4_?WV&>1Z7[&.F[P_^#V2EC&![;3QB5J*.:
MF8S:]_#,C#C K.$VN.B (G[SK/B0YWI,JZ4A;NG5&$]DK+WJYQ<7V=H(/4DU
MTDO;XDRRK<E]62GJ13+A7<L7+Z7B\F"P!O@D=,:GSQ5_A,"M\L]*%7CYU5EC
MB8FCO+;;XWLRZ]?Z>=,HP;MW:,E^,Q,=ELJ![IZT/[Z(!WP95^U>WPGALIAE
M?1+9]G(P=57S1ZJ&T=7WWHN/A7@#D(^E$UVO\NQM?:SW[$^G[HCJ:MH'_%'?
M\Z'\T-]SZ?]Z)O+KC"6V1VQ!LQ7'=E]>W_G+;8172O6YJ<SSY'DR,T,K)N.1
M6X$(V-%NK/G<S< C*%K?Q;*:Y&'J1&:S+^N$JCY0/3 7H+@1P*SFVEC3M^$N
MC'.31D*R+U%;5L=B'8WW#YQL^C;VP+OUX:.9!O.!UN'R[:[&<\\;D;UY4ZA4
MG\I*_=E#DM0*S#9M9QE7G8^ZQ1T2JH@SDS=C17L_*T("#;7.+7^?]N)A-8,3
M&S_FA D+)9EF%1:BAK!D&,H1[DC2,6 TF*<&\CF4B,J:IWD2][N<G,_SFSC6
MP\3TBS]M/Y!=+VQK2(Q%>$7<W+O%"RE.S')&.&TYC$YZ?,<N4@((E2*F82*R
M8,'E 5WXL-ZWYX\X@8;6B:#%_Z@K#FQ086E<_*.N.+&JU!J01MDSO_MKWOI7
MJKF3F/B[V>Y7W% YQ&K=S7LE=/<3Y@?E6)G$WD\[: WX_AQ9F$F96QY7]V%;
M32AD'0DK.!I]NO=POVEP'I7947$X5K-\Y$I3ZL&C_J7WX0^?WL'0*89+KQVU
M L-1N1OH]"RI"-8'#9;)$WQWTDS*HC%&+L#?'FJA/"Y_)"$#U"76."L"N769
MS?GLJ:X,&Z46*2>19T)T)+\KJC5=JF6BGT<L:B19"'Y\XLX*S,K&=[0B+KJM
M+-E:ZV,+04-U1(J7-YWO"#NM9B.]DLYS*WEK+*4WJ2*L3GBCF)%EE*1PELTF
M>\[E+ATL] 93=$MCG-,*H=26S<TPRR$;WK.DTPD*GN6*FII@\>%KBZA ^$M'
M.$;UO*A$(/$2'Z2C/T]G5(26RSTKN:!SR16^7/YQ5];(,'"P?R&7T,S:KP#3
MO:=K>#U<^Z:3&*QTQUDF<*;YU=*\X6R&_H5>]KG+3)+J7[Y9R>0,C.&XA^*-
M&%Y8K2$3M B]I+'X)JERJ\%&<BEJB'%Y3H=CQKNZ;KYJ)\'\"5.,NF*F69^8
MB3 XXJZAX0+O[)A@BAU:X KN @8.@6')Q,>%$!BS7N_WV;^DN @\%CYFL0Q:
M.U3:"'\ACOE;O3CG'?"JR7<'%=I(JR4^?/K%)<9_ID&T7%N .5#3P@F@A;+<
M!8N>,7OB("H\4PQ4S*XDB:?,ZVGPT97^ HE R?"H]<,VE7A>85@U :=IWD D
M?BM9.A_TZX?K6XL;[0V10QN(7@.\3^S0CF#N*A[CPS_63Y3+JL_"+D0(GJHC
MCQ'9V&-#2G.3JQW0D &F(06-0<P]#A/N6$(>6IQE7_G'Y2M^Z1=+E<8@'+?A
MQVG]20IG!Y)[[Y_ULW%!V6P(+0.__3)]+*VG4JC#(Z?[[;V3"36IO<,\K,"$
M18=H&CF_(^*O'" IT_1<5.CFT!YH<"2EZ'Z_O*>YQ/:]JR6[.Q*)\TRREHJ.
M5Y"@A5WOA8_^GBJ47FM];0T+ZL_C?<.ZD"H:O1^WZZ:&*7NBX@"X$L,]3)'L
MJ/_.3&/5X/>1 \=!=9]N?>;DZ&YKSMPJ44,*%EU>_(U=V$%ZH)#_F"J.PX)F
M$ABJYH1"PT/\?TXWG=FEUKKWK+ZUY#HW-&!2!!;_E'>OD=E&=?A&Z]8#N3C-
MV1[)'FC5[05J*YQ9R-Z4HHKW:6GWJFGH683XON34;[SH''^MGJM7*\Y-,_V[
M[(K"53X%)06)ZETR-S,]_>4>>SJPO3JM/UB]Z-K/.;$A,!R!&QK0Z"KYCS0@
M(@7]U!R>T$4A@OC='MET@:87./M?@Y86<D'8MGE$ZYQGU(^.-?5<C+&-$/.-
M""K:+^H1NGSV!@O2+"^;Q>=4!$236T1M)07THUPG;#C&=#+1NI4AW52Y53H-
MJ-3]+.LNC2/LF06C8%CK7:2/9U"D \7V\_@RJ^O5M\$O8^?D+D6Y"7HJJ0\L
MLT8^:FVTV#(P"XV>SJ!C$!Q4RV-+W*"/O>"F;L=27P*/4J8:>/A[ZOC"2J&=
MB\F**O[;-F<QE6 1!7=I!C8L5@0J8&(:^6A2=V98$![*5SO<WQ=#BJ<D7&U1
MJXU/ATE5%NV-+ ?.Z\/>>21V?EU3M]<L#7"NRTB,BXQ[$[7TZ-IHUO;, +:D
M%/LE;I7I!'!-^N:AW_!]'5G,[#-(,O<=C,/*H9%0I%:/F96O"%[ >;[9EHQI
MJ+(I3_KIX&L_[:71W_"2HUL*I<"?B/IZAUMI+Z%T__6K'>5ULJD/:QG9ZX*M
MR+UHP669HDGPD$/X8Z>+5]>)GF9^]4\DHGS;\6:PW\Z>M#BLLASB]Z3\]9^L
M8/\^T0*T:<L]:F@O8E6WQ_9D2Y;TN?(1I@L/;9),]QW0]+'-Q86::$[^L N?
MLM!7=>E%X)6-Z2N]^/WTRM.2QY]YHI06-Z>;-MW4?M4PYJME1^\WR*X><<4>
M FD6F7Y.'Y=J*YP U/B#Z%_OO_.5/0$4#4:= /H[>9M_J(^7$F7/)0Y[VZ (
MQL6@2^BM<07VCR^O^5\Q^GPITO)53[$]VZ5K86$BOL^2L-ID9FRUF0E$9Y)F
MY>^_]U_<MOQ-WDJW?"Z]7Q./JBN*AW!(WDKYLJE=C<>&F#&_PWR,[<IY(7&^
M:G8F>3I"R&:MQM:='NL"SQ=<.)!R;JQ$+9)T<)\,J<M%'I@=FOD3P%Q%5-."
M <W_X^LS;S<'UJZ]BB\,O9FQAHQ.J4/L>GJW0&;(C^QAG>\6G_DQX6BN(MIO
M\K/GG@#H* <,-A7T<IWDL3#X2V5G3*N(&Q:42/;6^=OBI?\L$PHW]S>S9V1O
M-WT=1^$S_G.<U[M&:SM2]RLWTJ!<SO-"G2D["[!Q[?E7=WJO8!<'*K'4!9/@
MP08C3ZV]:K&\-5"87M)Q3EMY\07N[,!%I^?FY9TS\48R3IEP?D-M;=\Y)#%Q
MH*HJ/?$$X&>-^*3ZZ<KD0&;4[C$D9=8TF=3H0 ;_/&.88#&G@=23>T9Y>Z&7
M<F=Q$1Q0+?GEY97-,,06L&I@::BZ05,<^_G;8?6,T\XM+T]]S,RJY_BYV2+Z
MX"\U>M7@J$G7PB*G)YSZJ^8I+N;$@_$&=!6Z^KX;&K9440>CH7K3%0E7USKF
MKE6+^:_P\/%7R':(X;#]%Y1__"R(\Q$R*(4-8V-CHYU[J;\!H5>:7@9*P?E3
M4/L#Z73/WQZX#/#9V[":#V&=A*]K^P.+IN]OWC&(;Q,U0]F;;%<A_#CJR'^4
MOBHI,L=[[MCQ,.5NV:C4>48Q%KIJ@-7'I@)R1&POD'PCIU,G)ER%[ZQ\.P$D
MU$;PZ\,II9J!U([/7K8P/P#R02X$RMF_3S7[Q:=1X ^2"'O8TK6$XA0?63XJ
M-//(X3K3NJ"K8!0@=QU-NI@'J\SJ @Y0_<0*$T_-!["MS0WX9W3G<:%4@&T>
M2_O=0+38\F-5(^&6Z5M556C*RFC;[04EO='!<AU0Y9;P\ZA>56M&=[,CG%O!
MV<*ZY(;L]/NH"2^*5A6)/\P)(J B#-O^U!-FGY4.1(DH+Z%$%H-%*5?YBT3$
M.I9APK ^B?KHRZU6&>U%< +,)&<N\.P1ECR1%X=3>;<L"L(.8@_T*K!-KG:7
MWXLVE[MA7)%0%6!4C'?SK-CR4B.:*W^\>A";.(Q9S",?LIQV\&'DB;[I:_(3
MMC(W*M\K!<F]9GJ8U1#6I,^CZH#KG_8*'R GO)I2(1NS7Y@(("RM"IL<#2 -
MSJO^Q>;]'_Y-?I4XO8#\&OC0S1'BSOO*=8.[IU8LG]>1).92!;7RF:9S F\7
MXA-ZM@Y"RB^33)WOK"RY")OO?-3MNKH,VM\!97T\^L(]^L^LCO"]:1Y2,M"6
M=M KV+B^H;_3S2A&/SE09Z84-$Y-TS*5-'8\L+KR2-/9[UIEQBSBCZQ+!T!7
MKKAT1(."R,/:-IIWEBE]9YNW&KF:1^K5H!;&<TSAJF"(HY6G7-B3BN"W+V$P
M;)>CX],V.B%MO-X?"G06L+8<_@UX%[9,*-YCKI)*I"FOED[^$/N.P-X&8W1^
MMFJ.38B# ;=6!-CN9-><-WVS=^[CA%6AF%B\:N(.LZMU KKJ@L.6Q=&*-L)\
MQ]]NUV+F!5O-Z?3#=%3Z(T60O_)W=%V%;S6J-\RU@^NHPJO2_YWY@)]5(/P2
MGZ8(#-RN\$2R"QZF*00K%(=*-&$/G%&5#X'7SSY2-#G<[+V7QWN/5JM$"7AT
MO#U?\I#(>3NTO<0\66#?OD2%\W3[Y:@&!;(AFU^I!<[EDHM%M?$B4%XWA>@C
M(Y7/W#>0_?J:FA8#PT*4J,6'=MF.'S?B\%Z"8!ZD.YG&RUITI'8DV2V, BMA
MLP:?6VA7Z7=>1_^83I9&#_MP@#[??&W@AX;>/WR8TN*Y0E$8] N)CT_S:"Y;
MXOBP#KD\W6N+V6[I3KW53-*R]B!N=UJM[WJ^:.&"QV1-X%4G,6'E@:U6!$AC
MV,((%V&2L=>;;T:.FZO%>EDQNA XY)G[$G].8?]LE$2L^A-EJ[MN5_(7#@8Z
M[R+ES)78DJSP1?%-,:_Z;@:)N6GSM%4ZI6K"Z'/F1U3E*NZ8#D+F1,40WSP9
M!&(GV9]9;V$3GTXGFRITL+>Q@:@NV,2ZB,!"^#+*GN3UR^""Y:ZLIXUFR*.M
MFS] NN(>8:8.,RP\T @?"*&N?E[42)+(>7ID$ZE'35;E$\K-HNC2PS!=ID\+
M\ZQ=]/:'@/A_OC(":!2!G,?[#PYVOL[2+LY*GPO]]">-_XQD:8K8EC"+X W
MG-HBM?QU">,;Z!0]?C7](#HXTO1LW\/_WN&?EFG^A\3J]Q.]!NYK. &L9[Y%
M@\XTOOX'C6P'B:FMT.IALH_.Y7V]IYCPJ-<91C1X.=5VGN@>S'(PDM#Z:^#:
M/.\/%'MW\[UVI\ J,.I!$9N;GO/R>OD#A\C(<<4++>Y*EZA:(2^25OGD%D\
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M_"S]' SWABOAB3 NPS%Z%:2$X1I1;?VTH5KD7D?KKH>(7FK'X+W7 S1&^TQ
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MMO>/9T;WOS1DEBT#485+CPB,?I!VL/;&EN:T?PZI;.52MJ8FROK53A#J4D#
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M2[91#A>4BN0)*-^.C&2Q,DWF1#ZZ4_E2ETULF%$)&E>?4C(!A9(NHD-F]'1
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M<B@,P<'&+..[B3^F/@*&@U^#5YKC$7MNYJ-'GT.$![%#&5RD1@D%T8G= ?(
M0VO,B[1]+O,IW1FI^W<6-G7.'^Q<.@[<;QL3YD0@.S+1>0D+<["4T+<:2NDM
MJ(-J'](V?66Q\,:!BT;:)JJ64*$Y;EI 'PT?/'+R>VAM..HN"#X4D*[&!1OM
M3RC7X]WA,0]D"05+C1Z=)N_@F)057.\ZL%'%>>B\=*$S*N\ZE^CDO^ZL^KN%
M-[ KR'6%*2]L;S-=U2J2W'CZ4&CI(+G.)QM+F9Z1[%?FE JYQW5.T]:5X$$N
M ZU90W#D/==KBV&Q%O9'<BN)_0RMY]449PP-/=L^0QS9PN%G5C\="WNE+"P7
M*DN:7U <-UW>-9_G[1E4"7-&7%#L!5Q;073JI>1'G0[]L$'6OK/WW+Q!%=_>
M]6E^2.S] R\J&AOZFY2?JRRT[1CV#3K)\_.9Q6^D=7ZIS4OGR4N? #W4-'@9
MEOE7??C'B'2XI"@3J:E[:?MIVG%UKD+1D^.=18;4]_AD--;IQ'DCSA^//5/.
M%"YP2SMSL,UAN&FE?4S$LEIM8N[=V>@*;='XH1)2=5_=^_9O*S5PJYCIPKR_
MH(@+F/DHI)W[Y8("5;:]Z_ A'\EQ^@[O,5<58GC[VY?9L3_<;7D#N-*S17A]
M@![GZ%_7TO;X%!ZG$#GJM$ZBWK62V.,'[D: J_[CP+9K8=]CDS.-Z^KL5_K)
MF)P&4K/8ZG7WSWYD=DVYMEJ6HE$WILPN\03PMAII73>]&)5SOS+62*-V'VB.
M+$%=NVV?M*4O=VO!GG7'HI1!R?QQJIIF3VZNC\8A?B!--:XMX*C4:YALD 1R
M@ XQ\G&A?5LQH?7HM-\X8OZ%_<8\S="=(U8ZB_-'8[1OWJ<G.HFE--OQ\XQQ
MQ'FN<A5HB[)0#CRQ/$M:AS=:WY^@9S#!$)'3DZ\(I],+I31U%;#=L"C FH7O
MD.F)K+:4B3NQ$]W'6]XC76N6FL/;/Z&T'<,-,GP"?Z_1;P08/B X#(!KOWY[
M\*]C]S?*AJ+)J!X1;[%39ETUAP6;*]..;XP3(2Z:I6NG\CKO#B8(IS* %!QL
M3[D1HF7A<1*X.X_S&ZG@SI$)^NR F(K*7O^VA= _@N9*]?+875"  .HEXLL#
MX;+>R]D6:?HX! +HUZ(Y/6F"@P$EK3KC-GZL5:LA%D&],X1F9OC+LF$[<,T8
MF$B (P!!DB9,'<?A^R.*S/ZK41EB;;-'X"=?K(PO,W0OW]_:=^O6TWCZ1:/G
MX]L7.)9<=*C(5@J T%GG/MU;7EAIZ9!NIDDT'TY=%^@W:E_)BA=O/Q1*D>O[
M/E:3Y4=+'_7%ICQ[TP2,ZUU!J(I]@6+2#+5'5"5',%( ,1J6.GDV>FCCY]YX
MSH1YTPCX%&U .G^T,%>3B.RP(),_E6O='3V'XM04&^ZK6TR$J9;WQAL[:[)H
MK!LHW9A JTMP,;'%]617EFEC>=;"9OR:R\T<&;EQ0AOGU+R? 1:3-3H8>O,1
M;S3<1&K($EI(QEE"='.:Y**&Z%9*LVUY9$*;NXX.1NX-\N]H/Z%FGT:_7@;A
M>VR9 %!OZ?E&SNODUP_18P)%'5X]*W*:BC6%8Q5N_)K&T2:-6G"#WNE<)<$.
M0PGI1>)9X0PVJ!.B7^TVL7&3.F+RMH:4R@Q*[ZK@ELQ*X1[=0!;4?1KAT]F!
M+BU'A/'P38U(^813G30%K[;UA6D*:IDMLCQ9D,R_M(/%R9QU/>--%-GGK1NM
M,:Z5*\K("-\P,69!U=7V^N&:3[1U&)JO$PNPI\I:C.[*:OU!U:264=*0AW1_
MJ7@3F[FO26%YK 2@97?$2N"'GAKD&9DJE3Q??J)A7.Y-Z_FDPM^N1UC&C >/
MKR\1?<(IU0G$E"B$FA.UE@RJ'90;)\/LYO=]!\^F:Y]N['6:H>JK-G\R.I_>
M4&\KV^EH L2XGLFXG(GPKG%TLY4U-LHUV$BXQ]B2@9;N36W7OWR/S4.KLW?9
M/5B=T 85M=\+QDL6D[.IP);S6'+C%Z@P4.%<K7VDMH692&=>ZA(_$2^AE',9
MDC&IAG(;P.TT70V-;MU1,\N>\VRP$*4LKW.<9E['TN$84/Q;J/M9T,6>:'@%
MU&76\WZV2XIN3,Y3X0FO8$(\@5)UPZGRSN>[S3%O"KSG-.I9?=$)-=JQS F5
M:725SC?&NU8/LH9;'@N^1R_ :J$PX+K7J*J$SJ2_X/"ZDSX5: !2>:-*000/
M1(E-%C%!Z(&(H IXCI%%]L>#*OTO6=\F,."&$=>')1(J_33:8]8W!^55O&28
M>OV0$T0#E-HBM>3M9_/,>-E3V $GW8ZLP83"O/AJQHK8^\+K[2C'@FRK6"?&
MPL6@1N0@'Y'9>B^N64P%&#] !S[6E1I%V649>\"9!EKL>/ BYW!;:,W+.F]?
M8"6]DCAH#CQ&9U(HW"$VMY0MF.U6W=FA*&BD:EV!1JOOH,+<R1AW\D-8EYE0
MD6BJ_DG^DF7=NL/=@5[]ZPU\J72CO19X]MMRDI,(790EI();\X<%A2?!]>/:
M"(5\I0(_E+OR&F:LI?2AC70L+)/HC7>?-Q99&B>,6)J+R9Y3H>V\B95><K[?
M0>:%_"APGH28CEBI(TSBX?*@[N4-=@-77>D7/^P!+OS''6:_>R.WL@;LQ%+5
M.UO,0ISH(FI7N#]XDM^-%)>OW7"K-+F.J$Y!]^[[X4D@5-L<'\(2 * MA!^<
MP]LAT6NK<(+%:+\QC@CL<# 6:V2+*6\UYED_YH,[=K*/!E0@(IH!^E\01B=!
MH T=A6Q'6P$]7O9Z[=2WP-CDYG:W92_2=/S85#Q)PK,( M8DD75/DM&[)* ;
M$ 1S.94L^TY+(V^GI7.W22I $3#%/1'=Z+IHI-WEHR,A.1 O1END#7:)VDU9
M_D N+E/1?8)(T<R0LDM;0'W<3BL11E?5POS%^X'!X>C<?C=SPQ.4N;K%5)=A
MT0_SR[AC/U#;]O@-23C7PJ7.@RG,>>2"PI'SBE_6!<7-YL%!R@N*.\+_JH)]
MK:E;I*<LCCI61=\VV9<%?W,[J%L3]VL_GT"HGQ0('NZ]V]%5VGWT?_ZLE;]"
MN$)7/.>D?-C9B*/07:3E_%@UHT:=&HB%VWO 4MX;@;]/K/-U1Y]LMJP!'>IA
M;N8&+TUXT_(%X.]/@=AE3VF@A+VW$U\GET%TGE;LN*2C5SPJ'#B&&/;*893"
M2G768UG43=,RA)88'%5AK@@D3V',.-HYLM-KOJ-UZ((BV#[>*ZY :#K$"7+O
M?JZ]>]F]/?O@6Z!ATA#EKYBJQ.=+P1$<[ GZ#M"\@9*T%T3*,@C)*MLRQDBH
M*,8A$^X?_W@I0$DK<<DT3._NL =S[Y9&)CF6N=NF^ ZB[8:SW'BDZ/W%(O8/
MH:*J;1 C#2U!30+$Q>JKTC\IV'^,IT;_'E=XT'FGP8W4AUWQ)Y?:>_I$3X+"
M1=7,F4@V%Q3=EH[G ET=#S9NB;#Y_V$M:2UQ!6P-HL&P5Z?3H_6=I]<.VQI"
MU<*F/_YH]+RR05KK,\>U3W^S<Q"OV 5MAQGOBC8/:)"SOQB*'M '@9Z?S5Y0
MX,TQNPX7%#-?KFI<Q7SZYU_+[[P*MH&G+D['#1;GF??2W^I0]/G5%\;O3?5;
MG2.UYX1Z@HOYR-'U_3J$SP_I1-6BWJQI7%]"*1NCZ)!=L>L;E%,U@INQJ%IC
MGX2$F]8 .IJNR*[4!%5L&+K1JYJZI0&.RDLW;P=/L8EAJ'W7B%7YI &0NYG"
MY-1;I?ZX3FE6RF9L><[;F:?2;W+1,<8(Y)Y+ZB<EV&B9 PAY$NRR-HPH>U/]
MSI9S*+[S,2D'FK'GY&&6+P+ER;WMYMHIWK<RE0G'2<,WCB5ZA8A9FRJ=2V27
M@_.TD/91YLV[$XJ !<.5PU ;)/LSI>AN)URCD%D=.?D&4C#=3DZ+ -_VK*'=
M$B)8Q6+74HQ[2Q'&!H."H-VRV#I+0T;828-]6+D":!1FUNMC^1XDOXAA+LL=
ML_3;M,J[&^36ZIJK=+_S?LMBI3]L1&7$VS''%\ H"S%LBRDJXI9G78N6&91P
MMTN#<^Y)D>33/-RJQ"__"LA7FG" +G5(<[IO\%P)$M<1K&I<M%W7[2TSGRZH
M,*<KXK!0O^J\?UX ^Y!2$_H(HL 85:W4"_E2&90C!?#.9V#H7RWMEU 4EIWT
M\B,/7KUO"]:)BAJ2D#RP,AQ4TMX:T_9*EWAYJI[ED:JBWZ8E+6W'Q#4)>1=G
MUG<\GY3HE5JGRA/(;I-J7UY8MY?E)^Z(4Y@@:('0\82SV75+^"9?<Z-2Y.*T
MYWD-B_%$>B&Y=,Q$)\ZZC/'UK.'=*1WT*D9%7V>&PY+>EC^J])SG[+"T$F=^
MEH;Q[8^*BM[R:V$ISW/[$!#X1>G7#Y,#ED(..I]KBLK?F4$C5(XPV5PYJ7"8
M1856;0@RK'=($TCP41"!U:-3$<I5,NNB%LTK+D,<Z3N)>]DC=;!H5X8.X1-M
M=QM>\<ZAHC=B06C7(7IU= %A3BQ)49@%N9H5+T:C[>]YDE1K83QSJ#3KW-]7
MI:VY45A[R!/#E1(]I>35W.<XCFH,&H^WEM$EL=67')CF64EIM4*$-AEE8*H$
M'_6BE2!P'5G/Y1#V'L0A.N8F:1)\S1$*FP,9BM'Z4_G),CK'*^3*QC,*KV8F
MLH 3Z#KD#;N0 ?<ZE(KEN$\CY\?NC=LRW;8BII"W140H9<1TU/N9N7K4?0($
MLMCO)<_*F2.G)A-#9LT+YS&VHT];FBT$.=3N;S K6O;ZMOL_I![!E'Q<]U[;
MJ3FO-RM>EW!$]WM<R9IW*6VRQ/B5M[>/Z8AIX_QOR'P?^]X0O9\O$VERM9G&
M CAKD9-VSC5:S1*DYOPP+=HM+QGKXHVR?X 4J)P(":TE.V05GTN+&^NQQP4*
M.MZ,MKW-C@[(D0$# N\?(#B$2I 'D^?MEIT6T5!)LT3LJ?XAV1$;E$$F2?4@
M["11.>N1DJBYW?:A>;Y&;1-51A$S%*#[B\UWG(GW@GFC=R4*?J++IL\J*$7Z
M+ ->QL&*S=R$,75[(W*1_,WI+J^=)JSN3^K/\4\EBRP\[UHL&@Y:Y(+#D.4P
MD1;"#X77_#;>>*6::$B[VF8^V5R-WH-*P\=QVB1IK) U7*!1EY8IJLW0NSR>
M!N#EN$ACJ<^2).62&=\U'9:IB#S2WQ;=(=3^\/"ZEJ/KVLN"6&//W0DR6HB"
M"XI)NR:TUW$E.+0-OGOM5BGD?&S"5++3,+$%R)/65E=5Q)3<G5Y'^8EH6D5:
M,5/3+<$A1CI22P9$#>KU@1OG+'"8^X-4?4#O7'ETU&;7<D8X>H:$Q[@.#$@Q
MLE4&=KIES'L%N"Z=]4F+G,5L:MMXIJD0X;A>@49% 6BECH_Q.D#/SP'(G6[6
MV]O@"86SR@)4,RP=1 $.Z<;'TU!H92BX6=6H90U/^OWN6C5(0QH&MX"O0RPQ
M1CCOBJRLK)'?\U])*-3]_B+JZ2[X6\GYNHYDHY^TV&5MBWOE/UF/QUO:E;S@
MVG[G%YE_).5B&[_NEBCVRK'U.QZ%)I/)Z.:DW; Q%D#X8MD%A=XQDK.:L77^
M=E$C>_E<N%,^2>E^#DZ_2-70<?&HZWN];G0"5?:#=-*N[]305%XW#1<SZ5_4
MQ=\O7>2_1V%&G!U4! @3ZX>,*&LY)&X=G-C=*<4MWGK+4IG=[%\UK8F)&@LJ
M,5E?!1C89&(?/^L9D$*H  !OI&_P+S*U6DI=?B6O>*C%L<.H\BVW?%F7.%A?
MVD P/1%J!:RN/QIC>>JN^RVEJNF 8="[:4SR+58L5[CT68^*=5='V0VAQ3Z[
MU#1+/TVBD3"UYYK#MVFG<E^X2:.\+SBT$NG-%OS#_KR?^Y6E0U':27K AM/\
M_IHN>N;A9R]8Z&VX"?L;)TK4._\;!$'0?N&;]JG2;+W+<XIL;+K>IUI!"\WB
M^Q'ZG&(PO]';.C6RWP8 ZQODS\@P%O83@<&/W3?99)%57E,'UUWNB1?Y8GKN
M\=[TCN8&;1+Y/9W_*=I5_V87XY'PZL3A#Q/D@L(.'7 S?TMFKJ8S,><\^U"^
MB^+?!_%+E,EQ]D7]X4C?Y/6EN:#XN5'XL*,J/$?"0.+!@=&Q(4DZ[0 2SH.O
MGOO(41%CRI?@_I[BYY_V^BXH"C=/D>']=W^Y^H>U4L]T*'^)\SA7CCSW<K^R
M_^C?4LM1AE:UK/BY02N16[ZGHR/9ZP5L_DMF;==#W['(O7R0C66M)9Z^31IC
M(M:8:0ZD0.X6Q3D@D-)H@LB.0VMJ&2CTD?#POZWQ_SUCC4+G=F^6>L$459</
M,FTWDOL0R+'2_[:MV74G"YYK">43S>1)-D*,G-@-Q8'W>E$'*Q-^R3)^P&4-
M_(F 7<H<3\%Y6NA@_\/E($@9F[KI!OS0TJ;N1 ?JREW-&%>$\:=/[Q>CC8Y*
M!%E?$A[R0Y?I7<($9 VQR^<]:+)""_US$W["-3V8+VK1WLP%7O4)Y?QN&C23
MM>X>_R75C2/!+02DDF^O._UL!O@\P4!#A,2 Y3<WS<DPM@[?]ILQUV_U[P!F
MM_9/)>ID2C/6L1",)]EI338&8W D9B^S=T?Y5 P/C'D$F@& @45:"V>$JF$C
M_50IM+D*(+8:JAJHV96"6>T]A.!1H\PM2MDG1EU(73P9\"[>(/W9 FBR3(OV
MR532MF0SI0%!!"EW-9H($M$M&V >BT&M-T]M8-/V<B87XZM =S!9[#$007Y$
M]_8Q?SR=#I17U7^U5(:S:XS9>2HZ5M*LU)8GRU/.D_3;/_?X[YB>[]_AJDJH
MF4?X( ?-]-1H[6"NO,O'QK:RAF#69+?IR:2:N_OJ+[WFEO0/@*!SA\EMN2\'
MU@ZMOHL.]#!!R![LJ<5X><.X;/>*J:/P_;E[XQ*Q,7$O7H-,N]2Z4#I%#$($
M3E"TC/,05+HTVV\X?<*AOH1_XI%RTZV(QKL3*%V/.YU:O.],"2R=>[SZ4Z)V
M79U%#G?BX\98E!4[D4()0FGI,UK)[U _#:;'(U-;,B;QK3,&:WY?I19_;_8_
M2+X3I\BQFP?50:;!WWR'SSQY_BJY/*4.1.'PP)MC*Y%E_TIT2J;U_NZY55R]
M!/Y'=>_1_:> Q!B;J;L6\AM_U(B?!$.9E!0\K0Z EX^:*USB#ZFW(CV/X\Z:
M;<YC.\-*!,/>]^/^*-;F?XJ_6;[Q_PG^[[DU8Z]5O%[<%6/^T$Q^:AUP/+)<
MZ\8?>D (2B1XS_"FJ':,\4+28/@6-9R@WB88IB"H23 ?_@#_2B%^=TM2-$39
M6LFA.=[!&\ZDZ^6H@>&1A-Y4"/6@;=C]86H9W3$X5@C:1E2'$41:%CU@Q#1T
M2[G;  6EVMZMU?4Y[TE6_ +XTQRU2)T%1]R1<7LP?^D6W[F5UHN^WSSW[JJ7
M3L2&J%(>\=&1_9+' F^&:OICPM'7F$--E!Z(9HA\/O;YL3+N7L/YS%\Z\B9S
ME"G.;+U\,XU0-"1)=)+=$N''E1XA*3YV1^Y+':!2FMP9#QEYT]T^A5N/+7#&
MZU;6TR\-=%+C0 (EJ3!6_=N]^+Q>O[=MK@-9T\),_79PGKUEJ9WQIDMVE]NY
M'SBW!]9),*3Z<=Q+[%+H-"UA A''%R:?5+WV^Z"GSPR<.O_&$;AG<?BIQ0)S
M;750YO0%!V P[N8B]F-8[DYXYT__."0Y+?)*0$+S\%9XB4%X4%JCZKD4D/QP
MXL#FC*Z[,:_@YQ-Y=LYJWR;K5:."Z:)4ZWE BU_H>+BJN(B3TV>E@<@H$E&4
M\1C >U"^R'B(\\@K\.,8TH[-FOBN5_=A3OY J^,\3>-L3>[W6I>=B)&[AO>7
M_$)H_Y)E@GYXO/'1GPS_9/@GP[\!0ZO&*C1/0(4D^LXZ0H;77HH0N&=6+9UP
MKZ_L?70OC,/N[3CTN)._1)VQOF:R7A?E=^!<0BSX$F+BC3Z;ZFLLA;HRE+@*
M8_81,H*?%M-K)+2)<5)08=6>0H$8GI:?U2E=8J!#98VEP9OZQ_"0%]8BEF]V
MEW/.Q;XOEOT;(?YO!3SU@PDVVE,CPINOTY,A!4GC[*A0SA51RQ!LH-1*@=91
M8O%IVZ"A27_3!<50_&FU?UWK@OOZ^?[+P,B)Q2WNDZI'H8*PD_%K?Q;^ZQ2H
M]YZVC<WIN]>*L*R/2YJ H6Z_UH9\+(GAJC49WAW579,N ;5@UTM<S,.O.%_3
M/OL#<^"/3(7_FK3;QN/3;!XTY]/$!FNN_83!SKKU,[BE+;7GP[8T;WA/WKNH
MID^\J;T/,F3/=;=J:[UB;1N940_MO#6!QAM@:+J?Y=HKG/+_'<;$WY9T.5^"
M_648C^6[Y-XELX'U!*QX8X>^E=V]_,7F;?%AMU]Q5Y]!]TBIHI;!P\X3DNLP
M7+5#ND'!YR<E,O 15F;7S B)@7V)VGB'?@^G[,^5C6H2LNT 6K\]LA1ZPT1,
MVY 6 #"4D* ;H>LL>'*?0V+?5U'=:C6@=;A"N5D/_KLT/A:LVV@[YD_R45"Z
M\9=4=;[6SLH0\LG'\QA[BX'!UZ%YU#1C:"O17:C>IGZOZ!9T1D&)K%R8Q2A1
M]ZW Z6D[9",C]DP@Y634._;4%34PB*%>*57M(Q_R3GS=8@LNF;N@T"P^WV,M
MO*!@ANW\R?)/EG^R_#_"\@04_M6I?0OJS56[[M;R]7.MK[F\;>J^&!97R&WH
M>(QU#\!WQ=/HN#WW<:@OV=_?M]0,*NLW 8^Q,D.SWN[#R!F.Y@59G1#HQ&V3
MC*71(0!-4"<[$9.D$YQF^*7TOB^ ;7S7:O,OQ9=MSKV"_UBV*>G)K)S-#4S(
MDIJTE!<W=#+GJ7&NF''6R.QM[R3==-M%F;A1RQPH7TP&TC<>:F8^LN&!3"NK
M?*0H0]X^3#[#_ZJ4AC\C7_ZS\%^T<.V1'1M7"/#0Z&<KP6@?4=$NL09I9&WD
MF\@E<N7=;GPZ$;*/=!RZ/<?'"3K UR,G#?(0EP]:*@ON,F(S7IS)+5U0Q%U>
M:]QZ%=+H1SV2[W'X2>E/VM^)=BV!W!(QS<_6=RRNY[8M!XJ\1SGD2"/JO6';
MF./#V@-IFG6LP@4EHWY]73G2"D'N&Z""RHB,(OJ-*GU/WY*,^Q&7K;P8:H+F
M4Q:/\GDZ:%71-=+.& !=WVJV2W:AK\H N3U(5/(O/<"RF=]E6VC'/Z*8_I/E
MGRS_WV IBGOU_2 @=2NPVSV'E?#U?=9M!6$VA2L2+%@.R:2HK*B N+<6.=<T
M9!#&@Z9*'K85_" 72(R9Y@CNPY',IK9S=IG*.63)\B,Q89'I7=R8$"XWO=/A
M7;,JP<3YRV0IQA^$HR<TJNKK9KL6-L149!*CHS)]N_[2$8W1AOZ1FWI^PRJU
M1?1&=R.?68*[TQU]VEOLJKWJBLMT7\@+G,4LY4,[O,[\YN-U3CKIC5)"Z+02
M/-'<Z+;GB6(+5RLDBKH$TAI,\6?AOVCA)W+009%)S('A$W275($0K^<SQMI8
M'4Q4QU')/6KV)4NLFK9)LEF=@J'F0:Q$/#BMUSAO;3P^]?RF\S7B_UOW;_Z(
M=F/R2T,2OE/Y0]CT?*E.-VO:C%%6?S03?[4,_>GKL UO46KUX+73)!*=/YO;
MLI=+!71VF0E &93!,_?#K/B$>%3WUYO&NLL\@%8/#HN62LLJW16M%/"\;!,&
M,I:A\4E.;\@).D_= :*ZL W79*J'#DL/*PC6#0B!8<(JI'G-2 I/<57ES/6"
MXI@K1%WAA"[F@@*OY1@"GX<G/.9J36YT8?7_9?C8S%AZBE![8J1S2M^-)X5M
MH( $:_3Z9<O?'WU>BK*2;>WQT!WL.E<_81OY9'$0W4J?(!DRLSOV&2][[3_Q
M9/)/_"5N-9V^"%'M";B@&"VC6=P7P9&M.+!LX7&Z)2DJD]M*AWD3Q44?/+63
MLJG-S;.%[%TBN^:VHX2RD;)FV S& Q=O$\$ 2^JB:\#;4GO*\_L8VV7[.=,,
M,:\^S=N,?BM-,>82'-B%';[R43-[IB7DZX!9^CJVX)16#Y]=0-P.IE#8+T=]
M6B/(;/%ID7PFQ&V.6JM?+F69T&9GYQW\6#;2WTU)\9&]&%AZ:; '[J1J:Y=I
MQP==,KC,""45^<:=X/?5.I$&A,J@6.A$W<N!HK:9(FD/P]N-IIL\2$YNGKLD
M4&7N3EV(??G]Q;N=C;@CE73@:Z0K8HUHZ^%P$$)V[9^T@AFUR*5@UDOV90P_
M2OW3 >__F_$2?^)_A5FE0J*B[,[H?#P3!U,CXR]GSQBK"8MWU9P2H6\L!DW<
M93O%A7[=Z7LXGVHAB=1YHV$BG &>Y39OL5WU(YD!Z=9_<]+O];@V Z!ZF*;%
MV>5XG).126]OH,><V>''P%_N4S)G4@G5QP,C-ERFM)A?)3D9XX]\.;?EBBOM
MWD*3>RT7JQXI*23FTRA5$^QX7=A0GB"-CBKS">EN[ *!U_-;U@[AON"4_FZ$
M<L)*5O.'$,RN/@S_&X[44,GHI0D,6N$VKW9V]AC.*9%AE]?:FEOG+=X(3W=H
MM-LWXUDA,G'RQ-51U62*.U>J@8EUSI7IAQO<"2COV@?OHZK08N5PV %T<3XC
MD?5M_DN*_Z^',/^)_Q"'BLO&;FSYJ=XL@A8O@JFN0UAA=Q)\HNR.7/5=FQ L
M[(*LN:>^[^*,(':^*R4]!I,S*NLEQ.9)OVN3DLZX-\9]IDAP3RS/2KUC?R$_
MTG6HTGY=%>/8/X1L?PY^+6V %:I-11)<- U22RC.7_Z]^_HG_E.XW.6W>5_V
M@J)K):<,A=\90:M1=N*;6MS Y"E!H,KD\$%_D1#$-\%!AG( /Z:AJ-HL"CN;
MA,.B]P_@R#1JRC9TFN_RN$_4_-UKRK+ZN0MP?<_%EH>1WF6J"R,)+'6:E0J6
M=S,MUDE[^J[QB&:M=5WD!$@!#..[YE)8*T*CT08QM+PR4F//J'8"4+4'(#-*
MH9IFP"K]WWT4Y)IQ/4R0\$CYKT]J^\<$9?1A6R!V_?(G5N5HT]2#3+*2X]+^
MQ^ZL.F##&14CU*)]4:X6*A"? ?^L&"GEDZ!F0("K)=^B>Z^6IJ_ :GJ%'2V^
MP\BW&C@Z$X\I>HA4IQH[DH%9R/@B4C;$P!<4B:QOWG8YZ/=. X*'=9R= RHR
M+7I*0DK2*WUMZ6$NFL1'TAZU)W2U.%HT8:2%\..S2 G>VF'TAZ<(PN.1/][&
MD&EE%>8_75 \ K!T/C[A?!'F'^0T[C=YN3.$CJ,N./F"XN%4]3>.)Z_ZIF4+
M>F3TJ$-T54Z81W_3[GIGO<_FQ;L5F\Q1U3)YJ9V"XB=+T3N,)L%H6\\-\E/]
M01YL1FZNA\([%XBY0$RR_""3<ZROQ/HXQA7?HC'P8$"#Y[F286V,7O/C(-/9
MJZ)W+O<T"1-%B=\Q$:[;!=YJ#<#4D&\.-VIK&5/P BWJ[U8STJWE8!\/$HKY
MB@MI)RQK8^SKSDY& ":B60C?@O2XDH.? 8<+%Q2?E;);XRQJSD'S'VD>SCJ1
M;GI<.1+U_P4%!ZR<"W@7\22X,/$*H%W:UJB.CSL],P?LZQ"C-;)-A@_!;P(T
M.D36-:ZX)P:4=/^&PXU%E+V@&/BQAFB/S%9G-_V["^S1J3?% QS#;<9^5F;T
M-R&)-G[*^_3C$E^"GG/JMNX\%+7S"I/P<D%**/0]_!!CG:EA?\0BZ7TK^!%I
MN9JUXXE]HA@"5@56_RC>%6=ES/YP?:S._HU\<]B$+X/SFX^%G52=YXUG[@S!
M!6WS4Z@E$<FU0#?: 6G=D'J&]R#E6V]W2@J]+ I #@'@]"B?1-/9M;#$:$L6
MN[105SH-;O;B[,_GP<IE,A;L2?HD#_Y^_9YIH<<2!K?-?=Q7XBLY%.+:IE[O
MB'W7E6@:2PB^)OSZE0Z]!0:<EZ+[2^VD<B&@1#@HK_)*RZGL-.?I9E8@6>_G
MQD6QJP>AW>UR)D\WWV9WSF> I7[+A.[K6;E?S]PU>XR:T%"1 DS9QW+EW)..
MA3PW8^$2TM#X!?V)Z=MAS*D&9I\EQ'W@JN_Q^.8> P>4HX>TOMXM= \7M^]G
M4FMG834H^ 429CODM@"95G[57>(;W!. S=:3SP3/2K*BG.,%=G\5I%G1&I/)
M.(Q1C"JC025\2NPNNA,V)DC,4;>TP=#^&@%BSVE8CA>+7Z_; GT0N[LDIR62
MJ"]-6;RN "MRK2!H&BEMQA MCC&[I@N64GY3^=,BOWYL]--&AO\B]^Q$..GE
M^\ZFI30KLDA?;ZT!\YZ+GP8NH.H-2PM>%+0M2-2X"MC6C("S:BUL5"_YLTB.
M\4OVQ22;ST-F:;)2K^4.*=C;&EM!:PHZ2D?4%FF>WF^K5=.[;Y]2>S*B<<)=
MA23!2D3*#4\ZV/8ZPM)/@XX;6FHW?[A]0P,SUM8?1%?523?'-I&.7@12W23O
M!87+IN4YJFGP@D+Q@B+B*"/I@F+1\I,@VX^9IQ...KF@B.&[?$&1D'U!X7%P
M04'W_/8S NL9R>R#A N;2]-1-8Y#BQP0,33(C3@?7X@4@N!!#,.6R>+Z(L5>
MVFWBD7GVDP9RO6"6:2C#))H2&)J&)E281Q2TL',? 7B'_>./U,7%V7K2P2&S
MH,C<X\69P B=7/>>_O!TI[H=Y@%S<P_QC.R>,R;.MXV.3:ZB],@3SE0UI)FK
MB=DD?<T6BU>1YV[%&NT']-SW)/0X5IL@%YLPDY2$[QZ[:^@I[0PUN.$8QPD#
M$]F"N\\">IQ[WL+T%=(RG-?'TFK(KRF?BV1\!CNZZO[&"A@Y_3@\&%+*@?!*
MW];]]F-FKGE<QF;AJR2$ U-P"&$=Q=B;W3D-MG,D4*$N7QK\%]@Z7E6K#?;I
M/R^'?WI&32L:Y>3FI?"BQ_?P6PL 3-^0:?=]."1RQBM=RC^)Y.9=>EWGB2O1
MPR2JP84FN[5C6OI]6O:V)NSNL"I:2%3M2:Q(GZ!@!S7UH&E^A3XL4'&3=5=$
M%$7G(HM];_%E,D7?AX4?NLZ7$M(2;R$Q>&"E<:G>QW':1:1>BKQ@#HWO,_9.
M0TUE^MT&?>M;P\9\DLMZ/=@ K"U^CB88=#S(:ZV_J]=<XFZP-CTQT#ED>E78
M 4ET$*Y.3]9L)JU.:(XT Y^^\9611K<>!C>RCSQWZ"&?O>AB#'=/MVQO[CL:
MT/N 9)>Z=W_=A5]1CN=.W=U09EWERM@DK&?D_E1E.QP)G^)UBSB(@%I<7EHJ
M7N-L/]/"/A0+3A^'8R,,CK1M-=K\:<=ON]R>?5:%O=0-!A$U5RUL(;7E@6Z@
M&IGXTY3BB@43703UZO(F/WZ6\58@&Y;GT""8:2 *;V@VK\WF0JIY*V[B+@(F
M5KE%G]QW,HIU+XKTFRI$UENMF8%<M(+=-+\*WIN%KA'ZIJ%-/<NW[7JF9B-A
MMYX:N$E!(C(^VX6"UIJ=IZWE>DZW/[[?LUPH7I@O3JKM6%RRTM LSZM7BQV?
M;/^J+6+Q/RZG(F=J*X.N6G [:.;-Z=M;'2$<RL@["DO]F N*&<^O4C;_^L-;
MT<>&8=OI>4<''N%G$FZOX+_/F9\6"#M,.?V^QJMM7NE6*3WB1)V:FMPPA0%S
MB=VW4_L<$O1WL(-<K)(O1@9F,#K*?.B*PH+@YM!]@B;^E<H%!=6,"KALZMJ:
M&C;,>S N'\><QL94_WU1?! <]G#9<BJ1RY 9S:#PU7S,W5%..&0_B10NK 9Y
MK+2\G4$@>#@[W_F]7?8WAV8.H@-(.WV$@DT66:JPE[]_2R>^I;S',9F;N\#P
M<<7AR[5J)PFJR)QO#RP2O!*4&A6\FTB2X7>0J*\#Q9,'539Q\](//9(<2-8S
MCQ4V')-[.=U#8@2N-!Y[>%I;[,[-PC/FK!IVG%;=IORZF#JM<A28,.,8M:#Z
MU'$STHF"P%Q^?G>Z25^2F6JJ#5V*L9'! L'LN<+_R.#$QS\7N'75YLZX6N"(
MWINC43^K94&=#5[L0T*,DAMO7$TG?!O&*\ES0[I?-4='LW\&]+QW@<7:1ZVJ
MO!B0486)Q-?>WOAN=(X5/MJYH)@,KZRF?X1:H5"D35$L^'HJ/\(4^:L<9ZT7
MT0SZ,<)$+K-'G-%($YXW8YNA/G]XZFIDH,7=N\R@6=[54:/A/V@"$U)5@%_^
M=1K)!O2C-F$WJ:Z?_IC4YBM2"Q*,V,(8=_--'HS#[QX15)?$0_*7-.$]H%<?
MISM1@8+> @*Q]N^=/TL9:Z3%0EFD7UY*9>=.I+D],AOQ"?A*D;';KB9T98;-
M1K2;:F:)QK 6#<NWO#.MQSR6?127ESA_U_V&-O@QO]P-=9TT-']L9ZJ#IJ+Q
M\JW7A4%%Q8,6[.4-(U;J=L>"2:RQ7<NTS;OLQ)F3V+N=8WVF?1CO,Y=<!:Z%
MEH'V18DH,R9**+1ZKCIH2)T>C:J<@04_W85LBAP/[W).FV[<3-;;OOQ4X8W[
MY^V0$")IP"'HYHLY#?V?/9 L="DI*6-UWV6*)KM&9.M2I]4K7:-^.\*\K49^
M&JTKJ7Y.],)=CC ?29L\>M= 6"45BSW\4+T1NLIK/N)N>_Y#/$3*ABX <21-
MGJVJ5+?8*AWUY]O"#/J2J08+5=33:\#/5#ZCB1$*!=$$&IYXCP&O/7L(WG2N
M0P#91,C<=GM&BENOA8WH+Y9_69 NLW_-]V,1_8)!FICT-+:D4:8$6,HGNP_(
M@L^ROF[FP.V]<N>M' -'PUGIL=,"V>,##C%*@6&=\Y,B!?A!T9M22W!O;4T2
M"$'OMOIS"D#+2NV#LS77_TIL=[:5SJP?S!V<<SUHI;K]:4*1@EVB>R86?WB0
M-<G^A9>BI_K+_ GD4.+<4+EB^=>7^,@P.XE > Q1%BR.'0[D 58@I242NP*Q
M:F'O<_+;EFP+S0(7WD3$,0<2#ES*%AD!DH:;_M4M!!?SKWP%LYB5^-&3EV?/
M)CP&S+92)HL,BHJD\UE+S=8'NYI(F*2%&#N3)UU!-\W7X[JXJ_.''WHLE@^4
M\TZ=&YP$@]:I+CWZ7=Q,-H&M61.83B=JK=_)?1*Q^9JQ_W!W\ZCN1<&F[LOT
M?]XMPS2P$_OA&@#6-L:AM,30.-<*%Y'K]Y$P 07T1Z_/=EU/E/LDUO?FYU )
M99*:OT>GT[.C'%,GF4!H4OI#PYY]TW@<NM>"6>R?:KJT=^5LH;_Q@B(Z_<KW
MFG>OJO_)L;J$MN(2@1_XML\2QR.*\G4R1.5DI_TIA]?J ?1<D'SQ(885)T*-
M'PX6DI)KDYNL_5M(F0-=0=#KW9HOMZRXKJ4$ -'6F%G_6[A%I85X3Q3?T:=>
M6@=[4=XJ0$CBS1%1H18?H,TFVS-]#17>6HP#78_3R4$I%&XMX;JJ+,RDM7'S
MZ;]HW7,WH5A?@.>LT=?'/V^:0? MHTFJ=##8F@ T T^@U5$0AH'1B!)^3;_1
M6T/H;X>%@3>:]SNM.\-R% 1_'3X-:O.^EEG7?%95G*\".CMX\!E2E(>=94JU
MC>YS.W.M.PFV@4<V5XT6&INN.KD4S\717,_X''1Y;VQ1T2V4/!B)R>&$I 2)
MK06"-PCFE:9D,R!S1Y?9S5^7.,- [J)VY1--3W12G&<=ZW5'DQ&2&V0]C+-O
M ;U\%^3]2GCW==ACK#1P3 S?3ZQ+[F] 81D#%<;T:O@91QNG'Y?X,9BY]RTQ
MU(XBB'V6;?+!L0UA4"CFQ9ZY,?+J;Q:JBWZ92P>L>TY\OE?521DFZW$0N6[
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MKV@L^Y94(+\'= !)K#>XW%6*^?@ZIG(^=*AJ7&NM-DP_)J&ZJD&IZ38!&_?
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MD;#(QM(>&+>HJ*G02>,@>QJ=?KL08%%P7B:]2?TW0=MVLSI%/:)BH=7J=+F
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MEI%N[+2_>1V4FB5Z9W.(J8*;2S'7?37(%>I=MB^+A74\*M6BG4A+AH8&@YB
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M%8%LQS/_2W@Q9F4U%'X-Y%Q&V4(,/&W<UPNRG9L\FY7CJ@='F0^@&KRM.KI
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MAWSA<,><%=#;J]2HUUB=C,* 5RX7!8S/NRY'M+FH;UJ/YF)&<6??>N&FE2W
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MQ&"J2M*+AS:Q?,O.@\FH;C/ZN-KG*950_W#R?WPCJR&PF1]TW*MU&IG]1!O
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MX2_&*CG78P8T7-?5C-.]646O:7E'Z:I?).R5S3-H589N<ZGJ?%1_1./WVG,
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MDOAZDJ'2V1419D/\O@ B(5<?[8\WWW_F^E74:=,EB$17OB'VM>XMEDIO72;
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MKL^P["8-UW<%;\D,FW;Y,4(7;XFXY+>6DC8L%&M_MH?F<7=Z0^)[&1'X$2\
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M3?%WNW;^ZQ3^+R___Z\4/PG^ %!+ P04    "  1B%Q8/>2[[!%$  #;6
M$0   &EM9S4W-3DR-#8Q7S8N:G!G[+P%5%Q=FBY\"@@NP=V"!H($=PT6@@<)
M'B!!*D#PP@*!X!8@0'!W"G<-$C2XA<+=H8K@>OGZSG1_?:?[3O=,=\_ZUW]/
MK6>MDE-G[W>?UYYWOU5W/^^6@(?/Y97D 1 2 (#N'\#=+" +H*.BHJ$^0$=#
M0\/ 0,?$)L+!QL+")B<@Q".BIJ"EH::@HJ)CY&2A>_2$@8J*5?#Q$^ZG?'Q\
MM"S"XD(\8IR\?#R_702$@8&!C85-AH-#QD-/1<_S=Q]WWP!\="0 J1(9] A
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MK39_L>&9GQBW%_4RNSCZ@G?Y+#E>^OK>?*.\7:+0U<]=6"/%WYD!_1Z\RW=
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M,@8^1I;['-S<W)3T B+\G,)L7-R<-YW H:&A86)@$F%A$7%2DU%S_H<_T,_
M;51X. 1E!+B[ /QM.(3;<-!6@!(V3R2X[Q_@IP\</ (B$C(**AHZ!NR!BEL
M[$<(\(@(2$B(B+"[GK#[ .)M)%QJ#@ED/.5G*'?M\#F](]-0:1Z4?"%0&=JC
MY3)ZY8.&3GB'B)B$[AX] R,3-P\O'[^ H.1#*6D96;E'JD_5U#4TM;2-39Z_
M,#4SM[!W<'1R=G%U\WWCYQ\0&!0<%?TN)C;N?7Q">D9FUL?LG-R\TK+RBLJJ
MZIK:YI;6MO:.SJ[NX9'1,?#XQ-?)A<6EY975M?6-S?V#PZ/CD].S\XL;N>
M!+@?GS^4ZS9,+GA$1 1$E!NYX."=;QZXC8A$S8&,*Z&,\LP.[RZG-RK^@\BT
MDB]H-%PJ>P1&KX;0"6FY%^CV;T3[+MG?$\SG?TNRGP7[1:Y) !,!#K9Y"+<!
M,>#T@B'="_W?[7]VDS8,U@K#QXQR5QD6#)"6)L:\;X;0(RRTY"FCMX_USK=5
MVTK.G@MY*-,K5[94O'5*<0,;;BKR P3_6J:M\>Y4H4MP_PG^</G;?3.'0_BJ
MY+08K9 DB7-_#BBP91WG6R^!:P:AB&K^RCW#KG(G/Z_@<WDP4?&3%!>.F9"C
M>;=7V_+-^G?;*Q:FA!A,AAW?[KM,>B<]_9P5$__(D9X)Z#A>+*=7'1D"RXZ-
MKFC"XY1DJQI+!?.$(A.(/Q'Q8R3UQP8A!$?YI6<<:(Q!@=U**$ B'',,NMQN
M:O>B_??5?U_]]]7_]JOO2_(^^,R]Q5-*A0]F^,.&;:FQ?QK@P/I A_7!CN;:
M6]+/59%>G8BOD 5OJZR_YAFLE_&DBXUWI"WKH'S?/2CX[!6*"K##U!1NC340
MD!'C2"I_I[PN>(5D_Z2%AGJ!<N+"S5LS&:?!T[1=@Z1PIS!3S@E\%[%\A-84
MB>! KVL' Q!M'&UUO @(9.%.G-@^1HZ:%  8[>_>AC.2G31(3Q9:^D009%QD
M647!?$D;F_WMGOFM\!+9O$B@C0XO=F*JN!YN;F)HL6V?)2Z?(JJL(5_"3W/)
M.S*+KO3>(;:3L>W,Z4FA/"566Y9^!V^\HTA6D5SL%\5U4JKK,:MSCXC7*BCD
M# @VP0R9]].#&8#_2QI"XGY1C&V>.6^AL[TU4E;2-S[5Q(S 61[^YU;[G2(7
M'["/^UW@VTA;G:LNK%>C+IZJ0X'GLM_D<.@'WKD^#2.UD7:_7*S%(5^O<IL-
M@->2(!^M'+?3O8Z51J]"SUSE5");:R)3=_;G+GP$(M)S\=F5#'_H5Q [9AVE
M]B*FRJ3.>LD+6/M@E"+A*"24F.C.3^*>N^A#T+Y!]S*/JX,6K%Z2/Z>Y2>)9
M&/KFCO]6+QO%/K4A/L(!XTK76C9"2 2VM%)K(6<S%/ARRF5QQYFW1'M18="^
M+H(WIA,K.L0DA(QDK1S5@50L\(DV0N'TM/@+?_#FQ;S<[7=4G$PA+Q]4G2]Z
MB4C_'[^?94J!Y5(-EWB6)"ZU<ROGR!M\N_V\V_WVR1RJ<OGF@W-9;VK]\O3E
MNG7*NVEMT]?N>;$IR_;F9+WW>\(IQP^HZ9"K*HW1N')?;EF62U8DS#Z/8#SB
MI\>'L_F3$_V[$TYI,-A(H;_E?(=D>?+5ID)5/Y[%O7L+XL1Z2V3&%5I[E:'S
MUF)/7>MY6-_JOW]4['/5.ZLO_5IE+<1OC0 GW+J0U=JZR+I<Y.[NTZ8&_[X7
M#>5: &L$!IG)$J#.[F5#:T H9VIOF_I%; *S>H1EC,AC08L\@"J7TKE1XB--
M];Y49;SS0M(#\A>JA!^,>H<9OXAC2Y!12" @H-"7%,DT<[JH[^P^XG46?!.G
M/J(7J'_D<=C=[:]A'*8()NH7NE ?;Q7JH\!!G9FRY,.5PNKVDR#$]/.%1_>1
M_D:&RS5(LN3!;/E18BD1.:XUMV!&B:>OE]$4/4^&.77VX-;T<PT +N1">1!'
M+SV8$9.A2(620D?/$M?\I/9>U4N:.MYP1ZQ4,X(6PZB%:H1<_@VIW59RDA:M
M:*589K#L<TW3!EDN6\30(;W#+U=BA80(^?_M>O0'+9,>B)Z,#0;V"]FW:_$K
M+U;ST]?Y3MS\"[[6/"C3DZ&I:6$.*8+3G<>U3P[(\GP$GEUJUN<&KP5A%]H6
M$O@O+_6&L$3ZH<^( \DIPW67!@&"=!]SR1?E/ :E.*K]OZSUE:N 7%7)0211
MIPN0<%!!5XX\ZV;F<,'(5]JSJF2I]?[WRT>[4UMQ=IJY^VRKBV+^<<-LQE$/
M@TR >:_^M(!-*=41%FL'V^"AKQOJ0U.3?>DH"?SB:M.TGXU0/ Q-YV9K$\.Q
M)F=%/[*SL;-95^!KSH*U@H*ID,6<FIJ55'?5KD3F+W&PI^7M"?J.MT<#2UQ/
MRUS#2L("LQ$PML7)D?"599])X3^!^Q<-A6,IL>%!CVQ9BF)I\O'P!6$L*NO#
M;T,^FGL24X//2B+L1@HE%Y+D%1O!1295>['967H#Q%&6^75PJ!'+)K8#M-$I
M'GC*9Y7=_>VS2T\:QX6E3*WMA'4FFYVFK"N(3(#,/,K%K>C*S+VPI(]!!LHC
M'EIY6QSOKRK#-J\4@SZ0Q7QFFG8^YF[5WO<\]3,J">MIP]-!?6'815;#(KO#
M>R#:%.#F6#'@9\7#C&JEJA!V<(U6><DB5S-B;K4B@^&W-0A&"5R-?GP6CIS-
MZYN[Z63P51KN1$B27X,3UVU/5-=W+L6M]\RH>.,NAE *QM83BRJDUO%3PH</
M\SC5G$NZ0].D.<;W4G%4,P6^=&AK,V+NDW-NBC Z]#1@M,8=;FH(E@0O/4I!
M)^(B7TE#JDQ.X56:=V/+L$>J>G-EGJ[$A*6^I,V*579[599$MCM&=]D';D._
M.4$QB3#UXHV;9YY^$];+XIS(QL*0X:XL\Q&##A"K7_ZL]/TX+/1X?'=>3L&4
M_J0V(W='A\H@$^O^6\BBV60C4_Q"XO2#'U2&9$W</T*!9#LH,&=ZQ3##=W48
M#KD46U!1%K^]DPAQ[8 "GBE[&0YSA_UBE]^@@)^<%"!3:WN^1GE] FH.'0$-
M\,/03AF$@ X?CF*C:>T#Z/0K%$#G4X "PDM0H''@[.F[)XC_'N+?0_Q[B+\<
M@CFH\2S8J@(C43(+Y?ZCH=A+1:[R)?ZOVWIC+C8-4("&,!L*&+R" NLOBM!$
M.A,MC4M@@R:#UG&@0+3!M1_E7AD4V+SY(G;MYWI,X!$8YN2&<\4"!2Y\H<#R
M !1X)G/%<@@%Q$%7"5#@&_- 3D8DBI (J$6?(;H59#%E5.Q*:A]?93.3<B)S
M:@GZ1;"7!IABJ\Q0P ITXG9$TO^H=YAM/?R7VZ2_B,#TB.D1S<\K)?V+U%'!
M@%&\O$>GEUL _87J^I^'8;@<>ZRU=[JHAW87BY,R27=HWSQ2NV]?H82X1N[^
MHO1*:#Z4KV7RS45"CP@X^V6F@CTSW(<(6?14!D0O-[Q=A?V=;,\L%]=[I?';
M,3M&P:O;-+/6:<;^'H:7..TUX?ZB=&,\B9W;'VN3#V:9D2WCGZ^90-RW2</M
MB<E,4T^R!V4D\^;FY/9)989CKPL*8K_N!.J"LOBM&[4&# 6NK@/EMZ:V*(,2
M] KN[(I\3+-E3S&9N#O7HUO@6SVM*')^TL9.H:NSJ1WS*6"D15*G_E;%ZHC=
MLBL#-B>9?90T1^14H=X><OS"W#=9G@;2QY<L<9&+TE&2M%Z^_GJ]<NT:E5Q>
M=N+DGG_3D_ZW-'W23Z#.MEPH,#[==$'\Z=4GK''8MJ,19H>?7\9! 4F>E]-!
MWTR'I AR(Y2E\.'6Q3 YDC3&3\4N1=RP7$];<,Z#H< 4Y75R W))\NK0!$-Z
M<)3/OT+,JHO(A:Z99K?D3#VQWBHXX^/J=N?-ZEHI+A(T[E,DQQ_U22X(%Z4.
M08%F.]-";[1[8-0%O6R:M7,TT;E0]7W]#);HF0D%S_DJV96@^:JQ9;IW5D(]
MN<*\C[9I2@1RZO&@ '4-:%D&"H0[08$(G LH4-\ FC@^;1/UV;2P3"88X\'!
M[2C<T*>"]"19BW;*3( ]>^I++ON\N\CKGE(0[KVN6LBPM(4M@M*D0S5&M.EU
M<E"=D]+<M*9'AUB6^KY_O'..2Y6<SGL>N2.-P+90T0<?27VF9<_$'-A?3UQA
M,11<*9DN?<+1,@C:=;CDJ^;8E*3OE0Y?T2KY;"C-Z;;LW >X2?T/TXBF9:-1
M*+"U8W"-.=9B+Q!_I"QE\0)?60IPP_FU!M1?+@1<M8&VPR$#^KZ: _9FWV#/
MR$G\*P!)M\0]5+YETAC74NN4E:NO*V,))"/V=$ZSK5%] ,3$^0M @&6"31K(
MELP-.3Y[=L#P])X.OYJHLI"TJO<'CSRW<<DEN?*%+&TM"Z<'.Z27Z]8$?.\F
M>^= -)%>:$L;LS4&_H<;L1?78TFQ@97R]E;CO..49N;ZLNHJ[P4N:PR5*#_A
M7V#DCF^]IO-$/N&PSS10R.9^EG#R57@(SV19,.R!MV]=<@-3MD_F\/+;IRF*
M8,-1]8L3^9D<WG+J_8,8>AJB'93A0A<? USB5FUY<["Z/.'Y,48[B_%64@Y_
M)T!6TB$Z-G F+[O7MQMH J89;ZH\GO!FYUT@TD>/U1Q'(%LZ"[CK)0(?S$CL
MD_N""N"4VY8U&M)_?!$#;MAG;]%N7.3.I:_Q;^84/4CW&(8"GX.NWJF_R$6K
M'_9073RG^V I^*)P6:N7]MF*=%@P/IM=" ?,*>B.%!>Y/R<@PR6V7HK(55DG
M1<GIS"Y!1Q-8&GP1T9:><3@RK'1Y,K<@DYP<!9JKA-ER("HX?$!)3FQW"N1'
MX>8F!P5>3UTQP#]B$A,1H84"3=80?->-#?KK2]N]5#2&G*NCHVC(==69\EIV
M9LKI=E/S38CLW[W^N]?_.;W"S!H(9M;VH8#8=_S54/>C/Y>P6OM%\L?S4*!C
MN@$T!_. _>[$?V;R#A<2WT!&.VT\BH*53J^9FWY,]<;\6<E)R?P8,/S'O CH
M<)65SW^:6\:/,0$Y*8[GZE; ^>D#L2S1/T52 NR!95J? JBKZH;CGEK656_/
M5W(1E3&;FD\+.IQL:8FBCYI4[Y,YC0MB?8QA<5,)A)\F)OM,"6!_AE=\Y6Q*
MT+#D?N9P30&6&0&5LU&<X)>_:?Q,/_/.:,:+9G]CMKB>&G[B;.F)[Y-!XQ*P
M:06?OL<=5A9;4KE# &?ZO"G.9C>U-HDOQ.%MJ'NS=EB\V0(;?8@5[3PNJA7>
M;LAKGEZS"^E\T&(?C7+U7B\))HDNKG2[0&3(2IS9$[PS&5K3T;$47#TIV_T[
M#P4K+K4VE*?J*Y>[C4-W)(VQW3Q'VNW&R?>5*XX+!]H4>!5P5._H>Q9DJ(0Q
MUG?&\B#T"./"38/Z%<6%-L-<C&NJHM T'%XQRN@N487<5E&6-442:U;"(E=I
M7AV>^S:H4\:]9QMY!4&>>]^H@9(L.%H%!;#]=K*<5#43L"@N%FP^<:_XR<:*
MOWIYWNTC3FM\85R=GM1FV([\=R,>_V=Y8T%_&+[4CO?#5Q:G\-UK@1@UG<!8
MC.DGB4^B9\^@ (?!I3$4*!M/!7--3Y+"1%1Y L-QP%\TN.ZM6:2J?:3ELNFM
MA&5E6;7&'J0)S:=%]Q\0\ L UZZY#NS(.NN"]9,)FQ<-VZV#Y^PG6Y%4-%3A
M"R@T5<(F%V.4Y&>)E[Q?K!UF7C5W0X%M#KHOKC3F5$'A["LE79O8'(/1NRHN
MVG*D*HX@\LFMN1J!RB!J)$69@0/<EX)N]H]EE-R?F>;J)+IOR;*ET8OJ[@?H
M7LR?%K"C;$2;&VL$6XN"^[ NK^,-@[EG (1GUDE*]+OVFHU<T3HE^PJQ6:8?
MYRP(][4Z8TNFX+O(ITQ0(B4NZY2T>_?6WNR6B]TQ4T$MTC[?7JT&%_5$D_D=
M5G!](,04<MP:,,11^1[&3 \&_JM:SSYRHFO>Q@OP@&JBXHN7)@E(O7XH:JJ1
MY2G:2QZD]_+SS28A\105GH@E_;A?*Y#FW"TR'2/('+<'/F4Y)M,/'[.J*H:8
MDT1/S$DP]9':&$89GU&2/SW=TB2<Q09G5X[;LA\[5( K#%C0'!8W(U#;\1GY
MC2/'KQ*,F,_NND_9WK$4%)Y,SA"IOYTK6V%ZS]GPI8G2A8F[_;1&ZCAUJHNS
MKL'MRJ9%H3I&=MQ!K1;RJ,J^Q"I"HPFAH %%YD]IH3>'Y5^&Q^OY]#JN:+63
MQ=9NE'6\1L-_:^Z PP)T?,H.\;=8J,&;&$@/9E:ENLFS#+XF O5J0"9@+/9X
MG6=M[M?TM-T]4<8P/9CIT;]*^//C4)J/KYXTKSW:JTS,K2]+K4F0-UN.]%HR
M)E3UHZ'DLU(+1S<7+*>@23C9:JE5?/N"U2,K;.@NVXXFV:X:"A$Y6H=2,TZ@
M/ND0[? .#T9BH@YQ=DVP5E8M)Z<NM]EFX(-B&I_7N\(./'%[W9-@$2-7ZKVF
MB<XJ*HN(+KME10SV[GP^D;+D>M5UMFS)12QY_=I]#PJ*(7;K;[(EEE_I8RGO
M5PV44Y'7=(A!\@H7R.U;&UDMR14UM[]QYTC@^I$F'XBC)S7-B,^%R;P>/)N<
MDA*EKJJ)4]E'U.XJ/UBL&$([-'GK*K"@1"S22>:N3MG21ZIF[;Y-J!%WDL 6
M;\=:/NFYLA^9H) M=C<O=<5;Q!6ED!PA=^N=LA3UC7% ^J]H]G-['USL(3YB
MY_!*D'NU).<G>1PUG#'A,$/T9JTEY>BVV.DB[$;XF:*P !20H+SRIH<">/HB
M4@9W:9*26V"<JR- ;)T&1MM@SG+1[+>_JG<+%KAE7S9;8%M8P<R_LTU[2!4M
MI&.N.Q_A0B,BD4\P<$8)>7B)<VD.!3)(:M'[=LPJ83H1T?R3-J*[%7VHK8RS
M,SR]0[@A^,V<=9K9>P[1=SQ[21^T0(HRZ&%<M,'[A)PG8:2WM"19/4&@V"FH
MQ[==D;/!531FQO*"KBJP7">)[5MM&^?2*S+.R$Z:_8(4G#/II<=C*>ICCO&.
MUI*=A$./]@)C^;W[X7U>V<^^#\%!U9[3]E 87QK]U#CE9+5@3H=6\>JE4\XW
M% G]<$VGU^27]&^/R4';.I"OF':N%/J\U@A)7]?XCPAJ)$ENYO[SPOYSM*BA
M&W:VH$#D6]6.J^L>*)"64&WS\(1K/3UXM//&MAQ1^E,>$D"!RO\,4<=D)S0_
M)?D8QLKJT" *D8GPJ%H.3"<2$Z/D=;<;X(F9WT6><WFU(Y^8I)5,_];(O)@[
MY877LDG1J9&;(_^FI5);,I4M]M<)7;A;\F_/K#.C5-\$$5WU*DKSHR3[%-=3
M+C:8:NQCZ%B@P977E5E>*K&BFF7@OA_EV(W@>RWFQT$J2CU\Q9.WR:N>D!-H
M86^B+6RC8E=.V%UZ "P?MEO&[EF=$(HR5X]PBQ%B2<]J929L@@]PGYM.^3LD
M @*=%!-=:X569V7-D^"LPGNY:7/:7X2^BH0TF6-=EAM'[<?T4U;P*>X)F=<.
M!-0'W25Q"K5E(Z5L2';E)$O^8N=[\03%4@H_#$T:?4J.C,P4W]]U>(N"8:3>
M\>-&W&1#TG1<T0!;$B:<"JI 2T$F?(?OP?'2M)J(?%LCS=>;FJ$+U*/"NU?:
MY,*?LP>>=!>T*Z9>M1!!@>.I1)G]L K/K(W)OHHRB6R+NWN;6W<1.!GIU(SU
MG\XO)?-?*>C)-.O?%!XY]7??&79TWW=Q1!#,]99GYGRWJ=3-$2:6<7MCO[.T
M-8JQN]0?96(D-^<MF47P_3P 84*EU%^7;&EB\8;?'>"!E2[/YI9D(I)+07/M
M4(#D!B]W*FF)[2Z!0BD>N'5! 1#IE=D-7J86,8'ATE (MRO:%OWUE>W^=[S\
MYC@: N$[&UJF+T@YW?^I!.+?O?Z/Z?53BN5<_4^7Q[W [WHW869$F_@[2FR9
M!YWC?1/;SH:$6*Q;)NX]?C1[JT3 +H4K(Q(*L)+.UN+\&(7'=WKFAL3\Z#?\
MY^']__ J'-VK.- M[GSFK]LFE0V<DC32;<KW'WVP.W374/KQ=+V,'M$^=J8(
M6]86Y#PO^'$\;[@$%/"+SH " X50X'HOY4J/<J_4 71^T@0%&O&@0/ GMO1/
MD;?[!Y3_^+GCGYY["WLN["'9MU,L')W*\6_)FV"!2%Q)8EPO;'&4$N%7S(^J
M!P(X\L_<YJ/F]H]FB,+GE1YM_5@ZL+56 KW#?TC4WYGDNA];!B.0'(ODLFYZ
M\N/7AQI8O:O?XZ?O?XJ?_@K7' [XVP5 1KMLSY\/!4*@0)8SY,=N6Q+O6),'
M_<'>9J;_B1I\9'F43=6TN P%M#V!&Z;Z1\T.=(MVO)>7=U(_%#G+E&7CY%VD
MV@'<90'1+?SCN2O^[#-S#PF^0/TUY1$6[A[$4DT:GUG992/)YR^[.?'A7>;M
M%<[BK5GG_ O3P]HO+L2J'H[H:+7K9868E'YXA2QTL;2E5D]@O7#F&"166D]=
M:(YWCDCZ=LOYX?/NJQI3X62<>?.C.ZHY^Q15E $>8J[Y\K=CK =O$UG9&HDC
MB-30)*Q<"2WUS$AJ^CX>8S'T6;3LR==]L/SM?CJ?P%92+U>'A)Y2H+@U\K;.
M8VL%8MZ&]%N8P;(HQ#O(2@NZ(-^[>R*5Y1J/*ZI+P,&1)WH/9<NH1%Z217[
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MXJ2<6"VE0+]GGLY<H#:/?]F]%!:-0C+. J[93.(J'\D?U6P827K_%6S;X])
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ME_:["=\:O\!\FG"3JLP$*V@M;M/BD8">T., !:UN.981)?I$[N$(O2G W@N
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M)-L=Z<,IL*&B+$ZDD8PUR'ZDHT>QVMK@E]9[__P *QO1$2MZ])B^4.C!7EC
M0NZ+:-F22ZY>^$Z/<0_OD5V.X\+:/WSC##XL)F/"+/;%B*)OEU>=K(8[7Z\K
M/8M<5M6PE;6C?-\C(MY9?42\KH:P/5^,+_Q$%%YJD__]_S>ZB+AIN9+^VEOL
MI-"9^PE*@+X$ 3A%I+Z;@M'#HG/3/9>(YB _P=\[BRUC'\<FR2+WN?GM2JE
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MT;?DT$"?S.%S 5<?7!S-_B4+&HE]8(.'P'3+M2<48AUJB,SZ-]/ K5*<?<%
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M(PEY;J+?PUQ26V& C8,&.3>;EO+1*>C>4N@BG5.S+97\Q\ $_\CTUQD7$2A
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M!@"<2%7GP.S(/2YP%P3OT,U D4@Y+5OQLQ>]71# +%M:?43)G4=;U5&U[O1
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M5VRMUL%$DO)U5WRWNE"=%_C^@X"+XBKU_".BIEWUXEQ+W!P^&=; FLK9C?\
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MAW(AO0':N:5H-<XC$UWV<A-LTJA2=V#H-I@7YNN1/Z??_Y&]I/P=^R]V]_+
MWL1>P\CUM5N;UU3>3K\:]G8> -C6S$P3%S'FE>?"2X]]Q4>S1AE>N8/I0C9"
MV4X8R76JCTK,?'GKD_L[:[P_.*3(L<W&.0K2CZ1[/P#PCXP<(FZ5%PD"F=B+
M_4=.N)P)3%@!(53?;JK2CI?:!!!F43KJY*!DS+#1ZC)JP>Z!I\//6+-?JA<(
MW:48;+KTL:M'FG0&G$Z<A;]S? K-+K/,BY[/0L)CJ.4FR>]PIS97^2(C[:GY
MA4A$[2CW2@*"FXE]N/%FO!!/CH2-%^?V!#H7<2>UK_@"\-87V.)[D+_[T;B=
M,3EK73%:3/3;;D =0AK[4M(-.M2<J7Q?ARFO+[OAWA"0DC0K<,\@2< [=>%Y
M #9C>KMNW5C'HNN3!=A;0FS^=1/_]JDFR]H8 $IXJ[U =/K$JP97[Y$%1C5E
MWM$347,JUIJ20C'8X4""LE*GGON_Z/W]*;Q1BU$?_1A_NCRY.%]LOZ*V:9(&
MF 6TL68_ (:3[J4#D"7D!N2V3*(1GA>RJ6M.P.$=;:;,9W'6U;'SI&O?[* 1
MQ/,JC'!ORYR<&9N> C_,Y$))-!].T6O\79MS0C&/Y]]Y[\C:%52KM>]5 5].
M*QR5?1(6X:/2.//RNG]^_HGOX/^')#G]_=^CB/^W[F/_J*&H0507Z^6XWCYV
M^J=VYC;IQH3*3_4*[QZAX\?ZD*GK://F:,P.*D^7K5QS=E"Z2+=P[<;)'6]]
M)"ALOY2D=/=>;=)XAU0*J7GVO;9:3X&59&I%-U!&KKN:I27TEOPC#/%=CMTT
MB>XJ<%8W7HYQ?/P<SCHI^FH5[]E\TT%J!8E'-;8ZFR$(+2>@RC"I2-9/[4RT
M%KO3ISI/HT;VFFK:(U?7!I 2ZON[/2,MQ&O8S%"[[#B@O3Z!ELY8D0E-)-<N
M.F#NLC@&YU8E?/13Z:2Z-.2IML?/7%$.$>9#/._SY^P*XZKJ4^57GRE>5L9L
MBG5ZZW[HJQ*SFK#=]*P=J(>1:1=1BIR)4FN@](JLGIWN>-3P>!EFR^8E#I/7
M'XIUJE8B6Z)\V=075Q>/^M )Z*IT3Q[U[J:?GWT!1+[ NBP42.;XZ9]K9#WE
M0H#U1)<(F9$/=T\/.'C%\38Y^4SG-D9HK*9MW\L_!EG":!Y]W<44Q@1=;]3:
MFU@SA4N-W>KDVA2*EKSKJ%-UIQ_C7@==Z]##?%^/GS-P@NFA!>0]NOLZJ6?4
MGJXP3%64QFH39?J:4F/&I[)-4F(.GB\/ ':Q/9V0/F[;2XT+Y_VCZ_!SVOJZ
M,Q:Y>"9S-U-O(J$\G<$+8S:D2;!![\3KIMH79>C-T DS!V6?\$->>-0U6V&_
M!VEPN5Q_P[K3#O54+9+T"0O5.?U00Q%P JK-Z8>GFUW&NT1LA2B0KFI8/!CU
MK:%$SC]#H'/U[!CS*6C\.N =/^55XK;*#O_R3VL$B#)*;"ZNJ9+XLUR="!4&
M%GR8[7]?$+7&1"V2T-XYW(MP/@#(88WB:"]#8_A(A#C?&&;7@'ZI&3Z!(%W:
M$<U0!S,'#HMT\V!Q/2%+04I5#[ZEB4]<5:6#,I6&!H=\='^Y=-9U_1=-##:$
M=W](7G7%(P/WI7]CP\PZ+ZJ2T@\7JOPY]O&[B$M70*BF)DI/%049?GI\#UF%
MOTAJ'H%Q[!]H<)6WNKYX14*WYGP:*.)>@KJE1#ZUE &;:;*0$.!<.MQ<&0Y_
M;::Q$2<A0+ 1V]I=)7&2)S0>4+<M1NP8N0:0@+S4N,U.N:AWZ1\ 9(A1)6>[
M#_"!JQC9XTGH7>(W=++OY8JN#36-,4TQ W);C&64>\;EOD)%_#79[;YS/ Q'
MM5@4W)17!_H3>?X@O]ZHDJQ!5'NG-RC$M8+OFFWN?I\-EQH[\X3P;!['J5Z@
MT^_I.=.R'S&.J(+>E.Z<$ZWUZ]*RZ-KN$I'.6(:2-3!QV[%7=0G]C-7<ID8P
MNCE%=*9&8\!*%+7*L>ATM3OQQ:6JY./<LG>A[9?A>#2@6"40J7.K9I*.0USQ
MBI</7Q/\5)CS%2JIK9[72;&D$RS"_2S;]A,*TXGB0#RDR).U8SJ=[L?P73*8
M+9W8"NE,8<YE"/[=[9*J0[GL@+'@68ZP72(:]!%(/"!TZG4LS_RMCDON >1Q
M,6XQ^Z6[4UJLK1UKD!T(".?[\-C9&T]_+F%V03&@ISLEC<.DL<;0(^+\P$R^
M-MAUX?615HT]JV?IVB.G"9>)>ZV9::(U4KX&@WR8'1O[(3C!I0]$$ZSZYXZ(
M/0!8NE3,=%.7;AG%68Y6Y/'*)A-NF8$K?$@:D6]!CDN+]Q,QP&L<XW%Q&I2]
M#K<-ZT?LWL^[B<J.\^NN8IUVU*2>= Q'PM-YMU? /Z5:<S)4>;T9=]K-SPA*
MEA@_)2G9:EN5 O08\<GHJ[\^?0X/$_9U#JVD+A--\1"\X0WKEMHY,)+]:C%]
M^"91R1[_Y1.6+/-Y[I,U5$R33@<,$BM&"7,]4Y.6^V?$5W=$@&I7/NXK7. '
MQ>EV4Y%OT:!%!M. :).W;>.0F($'YW?V8]<[,%+V=5Q:W&8]:@Y)=5S)N9[K
ML0KPZR+6ZD\/@+;)> R]HTKJ"CVNGMH;RWL\J4H&KY[;O;K1<Q\CAP\AUZ.7
MLF\*MF6>JCKU4&77 4.UZQF2EB.^T*<5F[/9DMX(,GZ3\,9E]B?.76O'/C3H
M\PD<"9SWLN2=^S+CH]59X,(*GOC)\-UB_K H$"G;,2,J5BB;UY[G5P[ZJBR;
M:M:6:''XU8VZQ"-WV;+9W8'(NN0/R:XRAI:TWF F8G0VR&$>\2RUZ \] !K5
M=@K<[^:AX&)OF00DPZGZQ$IE0ONB1!SD0P88)S)6&'P)NQ<XI<6)!%5YP8,;
M02M-&EK1HR65/7 L\O?\;'GNRZ]2?<+/JN8JP3OZ?.:1XXW!V>''?[A0"_'Y
MT;/=;$37\R=2HLC[*SI&K-^XT6(V"D(."!K\-1&[!\ (__])WST%1OK:%GA.
M:R@>R+./:7Y]A_[L-QA[\/:#5S_9M=D_:-KB/QPAFU//:R,]7G2S7,M]^;:G
MH28Q;KU !5K-" $Z)-J6\*V$R*S3:>\V)M*=UKKS#:+\'5ZBO$_D8&9U/XW?
M_B8? =!%SXI##HFTSN9>^0V"[ U(>L.\_;6&V80W-Z,CSW= 1$2,,N7J)F$6
MRIID^L)J1IC1A-/OXQ3JBYAW2<PU\C.QC63;KI6SH^G&]VOXWP[:17IO-FZ9
MH-B2#'#37-#IS,2UDF%_ &ZU6-$,$^R6'Q3>+C*6L?LAB]3>=P$8V.BTXA4U
M\.I5@BRQ^ &BNWL1V.7'<IB 5-$<L2=;TJVICX-\CZ-'^N+F98J%P@.2IQ97
M% ;1G9EW*1\-;QG>0Y>!N#;!"##'I-'W0.1<%]X'-Q;;F6@OV1=U3I4)I_K
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M"N/K@8K/0]B9?8M9?!X] ,0PH=X>@>*O6]?>H/.?2/_0-TE[?.;8].-Z6JC
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M+XW$A1E5'PQYB)\.H,+'9R!5+'O($GC]H+;41PXZ=U$V:B9EJD._4^:3$U#
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M^  D:1S6M!_)'ID-#>]X\NHFS?7[>CO"5 Y[+2'.1N\W2#_61C4-(?4J];@
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M;O] ';8/ULWQQ,O>9]U/=%"U#7AQL]:&YB-NG>,2_^U>T+@$UB#!Y*_O Q3
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MFXL6P'9B.((E+LP_(=.C-4X1+O#K]S85+&_-E ADJ;1#;*J'A@"(E&IVP3G
MQ*(401D:*]([0X5G@<J9K+]BK1.D<=@Z:6LYZQXSVB;*X=C)JP@PGR("4#DK
MDNG"\/'T1FRRN"E/[H,UYT+H,?RMX'YTB+->H^ZS%123LG07C8D.9>58[N,7
MLKQ.5&6"!YF9P?8Q/Y(36"/HR[\;J$9(VPBP0M^=5--EA\_EIEKS6^$PG"CW
M6V"UCC0'UZ6103K><;#UEE0G#6[EOZ,Y^>%T<H'!OYV5T*$U.#;.9+ ^..DA
M?%HE07IGUGW3\W+_#>2"?L.+XK>V%JSP0$V-.GQB?3SJU2<J:C:L9M#WZU(%
M1MJU?5YF\I!0?>#\9]"5VV4KVOZMX-(OC3W6=K)WI&S%SCI6J'#/V\29U/CH
MY1Y[Z_CXC&EY48($4>DEME'YB,'&@"&P3!>$ZI"!Q87] V:=FOW!CB0"T*UR
MB<\(\%^>0/_$\,1"P4Y,$N[(^3\KF/Y!OON14&.7 !BI6)3?=SU%IDZ=UKT3
M'G1:J5[8F1P";FBMA I\=C@PJ/[UCK-[T4XLB8P0TYL(W3<F;D^R\76W]N^=
M>V4HS7O' W+VS_61?6>RT3>FI*'IQ".25,UN6#$VUVZB*4/?X^-0G*B1HI4H
MIM?@E*<->_%\3$4L3LU-DF\]^^2*8A46C8%=[B^NRK!WX+C#W*#S R*X-X-$
MSY3C\N;PLFE)XH-ZCH[\!C:Q2PS\Y;.J%4P9(:\!6L^X?KJ[P[R48OMK\^F@
MMF$/J'$Q+,%#SNK00?-&]U!'W625L>=^XQAHUFVN3%N=D)-6^2/NECS7SQ5*
M7AWB.'5,8RY\L(U=\73#9E1([>@O95*$K$\0 /=6@BT^VBY+)W(W<I#NQ$YM
MN+A:TT'D:]($?[[T'11HJJU.$4J_[8M!4@8J!WH[$-]<F2,[<Y6D*,%&"S^L
MWW%-$'Q889KJ<IX; 3)!OR;&/@9J^(13706BN(PL1-SX]_X+#JW%!GH2O@.=
M*2.XOTHS-CF: ;1\\4)F-WZM>C=] ?E[*WO^SR2O][I=:G*R:6:[:BRMY"PU
M)"O(H#<#BFP$&[2A5[W$96:T3YJXNU3F(X);7C?'-@X_89!&2S!E_K&AS^](
M6U9PD4ETE<BP]\#6TA5^ 0-W/ Y:I%,\ N"SA0"\F!OG2*&2!4&9:JM#-AGN
MDKX"2?IW!<T#09B.S+?8L)A'SR0-)YB":7:J\E$9N3]([5Q;I.TYOY$MQO*J
MEC\H2 XO#*8KH/MGU:_-B\P"'^4'<.;ZBO 53#F-. Z/(^A F/?"S )KZPS#
MZ3Y$M#6@O1R] R#6_5>F"LPAHEK%8JS2[R-%??,N0\EV#(NF+(+O2ABM?$ZV
M/18V9+A[""OWBO(E7>/./=*O,Z#>];U#MO/-,6N'&K&MWTNP\B?BZ/TPHD]N
M!*I[[7OLNTU@OATU0F_B)J1K$F1J'E+5Y:\K_G(8LT;<%>N":?F<F)HXOOFK
MY-"U#\@WBJ&)V;.:P?*R\H?Q^WV3*I6)*O[OG >*E7(G>,E=W]3K/G>9%)VQ
M-O3!%$(G]0NMQRV5E%-R?,:?-E%=]0BAR-=BR7ST(V'A<\EWX>J^8NC(;<2[
M[-T&YB L"RM:Z10F]R6N+YE<\)%8RL5ZVF1F@8TSBA\UIA>UZXK3'+6[7^^E
MFRJ:F\LGCVK(/Y@Y;:X]^QK+<Q/8ZWBB?>)GN5-]NI3-S7NNZG68G-;26S91
M_X"]MI63FI[H]S"3X6E79WVQ%_V%F(7>Z]@.T&,_T>BH+/JBD$#\"ZLRJ7 :
MK;.=X8F,]*_RZAYS! #+8=CK8+1.6GAA"0%P-?I%5H%R!JYV<E *O:'=P/8K
MOF=>EV!D1'G]JI]&2.G)ZQBJ<-^]F>;)/TG-?Q@Q(NVUA\5U]AJ=2$P>E5*)
M6AE]G6H,3VK?%74?E3J#X+MTJC=#^7?Y!+@ ]^,G3:IW?4-@^B66EA0SQQT9
MJQ!=C)C?_4!<#R.T>Y^JUOY6V)83_#F4L+JXA9-?6DT\>O@NTBT  ,$]TK',
MWH>S3T^'/D\OG?BX_)8B]?OMK/7I_-7M?4"SINWK;X.NKRNZO#&,YVMRRR B
MKX)ZQ1<O$NDR*]__R]7M%?<BZ_Q@S#G.Z45["1_N&%PZVF=L;E$'DE6QOR<L
MYTCQ56.Q(RC(!=]S@N_.@0@ 69GP&&<C!,=4WHRPGUZ4$N6]-_* _R&X1#FE
M5&;ZT'1<U"Z5 7J<M(:'TUS;&-D?ZDJ75WJB ESB9,RIE^2NF![7BO 7HMQ+
M?9?PM;*V*2R8:*@O_0N+SI"G>6FAK;F=(OC+7]J3W23]ZX>%E]']J_7"N\AC
M^?\)#B3[>Q%A-E8=2?I%F/VZ?&/BQ%9)=ISI=3?NUX!E-%ID0899^MCM&/U\
M'O=\@1[T6O[?MLE7'*)U@PENH(\G1'A#C(Y^IZ"@T,38YKZJN%&SGQO$R[K3
M@8=YP1!OS)ZL]<%F60;7]<K$L<!Y-6B? 8IQU!3%Y<J!%_[X_8? AK"\E'(?
MD,O!)&B):FJZF5FL?+PD&IU8('\,!_7*ZGG_/MC-(>U-Y6ZQGWR]SHHY!/;T
MEBXS\I^O'RB[]],$4XZ_,UH*14I]QVUHF^.LU^U*U(.I,(,I(EE3;SG0(VJ
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M_ZQ4_5\2AAT$@$2\\ "(3SM1<JRGEFIN0_CQFT\@-B7>O?+%4Q?/Z_MX9 1
ME[!U@#Z6@'X,/%0UG\/5Z)73"Y,OZ?&7L'J/$OQ<<5O"E1SDDW,Z&U@->FZ>
MU;E,F?)SD(-5\^>&7(#MX)=R!:_;V_5F#X<R EAQ?JK0Z5"0[[LF%&_7/I:-
MX(FD:E&BRLE3(RN!,<^9O-+E@U=.219,S-:61QM?(R<&\K'!BL<,]$!R%S/7
M^]B9]\XO'RF QP;\J=9LX$4^I[0,]YVQ0C##:U(B?SD<+N%5JSXJE!=K39IY
M+B#)\:TD<9\YYHU/<WRZ' DT;?I5%62A#^SJYS3%-?5F C/2]DNEU0RDQ-]K
M56U$2"PSLJ.4\/:B/0O5F+[4>X-1Q@?QC+%"261Y!(+/&]U-[[^N(5_5&D7S
MPY]]/J6Z((9#\SUPUYTCVMDZ^=-39P;6[>NG945828@W2DSIYD8$]6](Q*3D
MOL_."Z+?Z<IR]_3I:I)FA';N,$&3];=&W"-&2NH82>GV/Q)L>KT(MH3TUKY:
M'.HAH<3ZJ56Z:3+K3XQVG'BY+\L5W'*DU5CJ%"^#S333\FK?+2Y'<,A>'27:
M.-(ZJKV3+#Q$QWJ=&<N<4&/=])7A='&\)<6'[PDL;35KUY(C^-#@6^RNAO)Q
M#H:0HP$,=]MZGW UK+P#+2+OBV^EYMQ";YLP##7W9H _OFW]VOSB@P3DW<$O
MH!FUBIJ% _:Y,H:G=R,^CK_/*__E4DI",N3W3>=GVQ5%;(XH@4),3.-;UBV5
MC_^KG>3_?6'H\- NUC0!X7(<W-4LO-#2,5A-S2+_)BA1YE0LJ-CA)E1&&7TN
M6Y'0;H3)6<B+<KD9#BNH5*;BG+P/;K#Y 52,#MF@]=/_%20SLZTDISH87PI:
M+&8.("1R2PLJY32L)HP;-)KYK:KR]#K+J7W7D]^Q]-!#\/0Q<OZ4C8^X/0UO
M0"?G&I4)BYZ8>480+N%/Z7UQ<?MB@O&=_25[M!7%:,::#E=#0T0O7_#^=>7\
MGK?X%J$]_4VJA@T.!2@D#5H$9YAN>@WR3\4D9. ?+*X=>3_T/LO<8\[P4.)$
MIZ08IBD]4U__J](5'969YE<]#_&)4K$'>I;&V]F*\O@M>GNCE.%/JG7IMUYO
MH[T0 #Z!C8Z&A3V*9Q7G%UOUU0SOZC#I7@225T;YUN& D2<*8:D(0/NK5/\)
MDUK"N,0L/UNR5^Y4!K_B2*^^M2V-0GJ:HSQX<QA]U<.$^H25X[_4:J>3[83J
M-^MIWO.-IS>=#Y?XOI7$?0AB84^ESSF1/?QY5RYI7=!OVH!:4NQ!VU 9M1FM
MKL-,V4]I.1Y!Y\.VB(5-$+LFH]IVI<*V //IE:VI9XO_<"5D^\X/.58D7,3V
M2&?6VO1I2:%F)X;I2SJYP&^JW\)]][2V<U;)@7*Q!IK\Q!)R3>H9H[IY)5C@
M1!4-5NIZ!?>LJ-.MJ[ 2<P7(5Y,9O27+D3V],/T;7XS2%[YCOHE9ISN@TZ@5
M!&#6%P'8E=3)RG9QEQF7GYD8F7C3%3VN6>QIVPO\"*X<J[I[GJKISJ^6$IEA
MLJI,;=LC;O4N-\NA4?.,?$'V8?*N#&[\\RUDC05J#&RW1  RP]1@X+2C$YP=
MN#OM>5PSU1T>F(@([R%\82B9+JHI=G#UB\'U>ERG6,6D8:*FM+2+CF(\JW"^
MVOE4>+,,_M8@J:N:(Y ]YGCRKMA5M^N->)<[7L2-/0(PEU/42M#$[NS)?94M
M5WPJ8DEF26H)2&.Y3;L*,+LP'\8&MS1I%H7PJQLISU-($/S$<NG?J2^*)QQ;
M$AX'X]OU_![HR_BV(XAI2%S7K>FP<-_:ET>]XQ5&<X, )&P.KJ?YRUAN<Z;&
ME;5:C1YVN/1JW3A.N"!].LW9=%/BDI?$\SL;2(T(M4'+-6N'V6:2.'M&@-%K
M284Z?HZ6.#K5.%W)%:N,B;Y@LJE(EV.S'U/ISW&>3N"L4A5V>R3)?[4W21DJ
MK 2"E0 EDFBH6Z<[CA83N)#'%40J<RW6UNV8EZUE&_3,F].2J.\$6T3CMI&#
MQ[R4JA5"X\%G)CE6ZJ*7N@5]HM"8CG'U3T]G=I3D:P=_."$ =O4_#T]:7L/6
M5]2"D2GB,M8P)M P $Z*59&NRTWZP1<?3Z\[VQ" /MK/O7F_]4N.^"4K)E;5
M+!D95Y6/,*1\>7H_7A2%2&F=.%8D@>.C+$8I8&'VU#KTM=H*QYHR_(=22M$&
MBDS7<*05*]>K;I#NC  Y4Q2&ADQS7 ;?$#HDXV?X(I>LNJ $<9G"S#U[[D%A
MFGE5=51D*$?-P>NV4;('&?GR4ZX(@W3.L- Z%(.Y])/$P;B+YJ2]V?H\SD+[
MK"B8IP4G,.!M^X_GU)7U,MD&3[2]KTZT\(L\#=<W3]/%SU1<OE)+/-'3SKY/
M 87DNI:939\XE*'L#MO4E(L2HW)*9/UF^VCAD;Z18[N,7ZY+""L\[UJ?H#N:
M-S=];?1B\Y!4]GD[65Z.56*!;M)A3EGA I1MRV&7<^;6 P%8U;I8HA]2,^5R
M2J<[^R(Q@BJT_TVZX/W15[J:I1W;6G-+03'76^4&OAG[IK)M+<$%"L4U<.#X
M7A!C68B.)LGO!"JV@6OJL@$T^CPR__OF [P>9ZB'Q%1&[>GN^0RQ2-.*C0_Z
MDSJ;UA7%Q(LE_78-V=+=[9$!;CG4#9-0VU'R9K.>D#5M]D_+EH='! N\+D>Q
M6%@\&WO*S]T'[)90JF3$"TK,<?V7J/2CV4<W%.5%WQX?4Q<7^P339;/\-3-[
M%.2=DT"W'Z_ W>::C3&!6;5ZO3'3.<CI@L/.OSR,3S/#F:XA"[SB\'YML:(U
M0:!:W9WH<9*^0*/32>(TM85!:K9[XB@"X.>Z=GRK\A-RU,$GU^#CNZMTHW4S
M:]!R\#B3VG9GW.)#[UT:-C2)'2Y-CO67Z/O0Q>1MD"A].^V# WJYN5E<-HSR
M[!EK@IG2;T(2\(Z9UK8B+)>:/<WG+*H6!/EHPA^C _X30#!E,E[JM+3ZZ7)*
M2<>@O:G9L>S1F691LO<'@4DG68&03W0U-\FUQM&P$.73[XDH8Z8X<_MX#ZE?
MMSU#.^0#;R066V=#5456CP0=1Y\,YT4V)LZ,$1ABX(<_(EQ44'[*%&:(E_7[
MMTQCJ<68VX.G:<-,238,3X;](9$XJ@WI3<27UQ+ CKS<?5+Y[Y-WG^9E;<P/
M4YDH;B%$X-6CB,U^@<+G\>\"KW'/'!" .*\F+X(+"QR:!GQ1992=%ZPZZJO-
MQ <MM#'=8A-T:^;U\VS"%73[$KRK$:V3! <$65KEH6['#Y!LV>C\^86,IQ,#
MXTB$SE:'MMVN$0%PZLZ<D1D*.E.+[6#V^NS8X^=Z'^7/"N!XLX(5.D5:RR6K
M)53*L3GN#/BQ/U]NCQ,G8^AS1C=8EN:&#ZNGVJZC=\.^K3^P7G">'QY:R37=
M+'3^V#$_$K"PUHD]C)-+,D=W>=X?3"/LY?UB>%R /<\D,K:VJAI+@F:C5HG:
M1V)O+W&NJ$%.+HCI6&N([O\[Q?*OR..,6??4FQ6&M3)>'EA^HZVA*0>+AEZA
M7*"V>!>3@SM><9787!.Y67Z?J$=IJ@D\E" FB]I3+$PV:B!,W/RAJV1W DWK
M6&??TKJ)_G*D'1V:VLG/D%Q;V00+V*!SW$T_*WY__"6.;80: W7L-]I3U]"K
M[<8MF.?:I:/U80J[;QH,&EY[\< T*%V+,S>OV=;<Q4J/W"^(-C43664X.FUA
MR%!W5IH7"LMU]NU1D3^HM=/80^<<\-D<\OMP W&J/ZD-M4TSB^AV*_N^<YK2
M71-F:0RQ4V"I1 ?3_"*W8QO<?7ZPW&RO>=J35/J)<'UBK"%:I-^J]",UWNPL
M@6QOVSQG]EON\O(?>*D68T[%]=;@J(M[&;(2(0?C>W;'^,YX<@1@8@$!^"!U
MMH+7Z;J& !#VYPJ7;"Y+$D3TK1&]+-S9(A>O=;M^>X?F?VA/QM*)UW^M%_'E
MO7@Z\' V=N&S@.O&[S++XLE#VV',B8$N+H]?P2Y?GNV 8BUYW37NQQ?*,E+H
MZ!UX#<\N!9';$BDG!/A-BO-IT-]$XR /?;]$;2@,?Q;W3(43@/0;XT5TT&"B
M3'"RJU[4#I!X)])%2^.3IF-OEOYQDU$#"$G](:(]42\26=(2/\P;53+,/DVQ
MVWS_E7)J?GZMTYAL0?+S3.S0C=E=^B$<<4MK,MPWV;;YRDI: $ ;P"D'S83G
MT@H!\*%7M=..OI?\/[:<OR,AL*Y:8)0%OKV:(0T\;S2H""#IX</=E2'D<XQ+
M /CT3*";M#9BF/D6" *N02D:F7[I_Z8'*DYQ%&&JO"9X2":BXWL_SA"^%"CD
M>U;T0^ZI.S^IC-!3GY%Y4I?X3%'BCY/D:.4$>G]#Z[-_09XPA)A815)#J8.Q
M/CBB&$,+:UXQQ>=\NR(7FOGM+?;53VXU><.;?_J63L,"6^[?\)P_Y4_Y4_Z4
M_YT\X<T-7B:*,WW),R[-W@@ D$5+'JF5;%BC%Q$(44Z<83V[L]"";$RUL-)X
MO"O"L?'J!,&]S?L$D$Y/I*#T*V O;K; 9$_HH!5M%K:47%-RX^OA_![&X[E#
M%3CSZ=%4!QWG,)<DMJAF7;_@+6K1]:L<OYS6>29FR_4 $VO6+64MB@#J#=2F
M^.X5+(Z3%RY>&QH3;^\$IVN62JJ3^%/D'K:ILBBFDPK-N1/S.M_IK%U+8MAT
MM@(,4".2 8(R_+E5R_L( %L&ZF99I> $KWZLL]C^!L] \N0!J6@J#\>.:X[$
MU, 'IC:,555>5ZA0Q_QF-[[*9,^SH1"7NAY>06RI@AR2N@1%*SE%_@$&T@]0
MFKA6 RO&[=J!A\MP1\^F2/:('&.7@%ZN5YA]M4N6 K]YP=7TY:LXK+ZSG&S7
MV@G2VN&%P=OW@AL,F%Z*+R0MR5:QEQ@'&@U\)'K10I53G+NN7N$S32YJN@9G
M? ?;Y$LPAB, $5N?FI<ZA*YZECXZNEH:$D?ONV0(._E'=?AXLGG%]N^NX'(\
M*!B'KVJJQRIT#C4JIJ:FN\%_I+W\B0!T\%KI6]^XZXB#VBXY2;^[AN00*)BA
M:5LZ6[N^&+84L/\T-P^M^V)C.^4^-;V9^A)Z&1>[IDFLICFTK\5ZIU"*Y,1+
MA4:PZX8=6%Q]P%RE.6PE<7= MG_G2FD,E)J1KW2:(Z%=_)U9+^C<F^@5]C\X
M>ZNPN*(M6[@(27 (!'>">W"G" 0/[A2NP=VJL$ "P8,'=W<IW(*[:^'N;H7?
MG'._7_J[]W2?[H?Y6K77GK+F6'N.L>@324!Z0XUQO?5RA'B4KG]N'XM'OVV2
M ?4U-))G&1="[SYLZS3HI?.+ML=_]CE64;WU$!3\QU0=4V1),6@?W^+@0";G
M)RE^@IB_HY+:5;GFY89%DGUT:V-MD]2HKM!,Y^82XNF=BM/"B0>NINB/#2$R
M7[*;FL6:[U)FH6Z_RM<4,46#ZAAKIVIHN6]0&;)_=?Z/-!V8T\_=FSVR]BUL
M2 38"H!NU(>W<:Y_CI2V99LQF),G#YJ\^<1AH$.S!NH/=/$2V&.VNU6/Q<O>
MA^8E-K",[A*=:Q5NY&<K;7-_*I0Z<0$8"I$(9*,UJI><NF6<-=N&&85MRP-0
M:OD+V=YW_XHB33V1A9I^.NXN?Z.)).8@X=V7#PDW"S3,S:9RF9OY3NGQ]FV>
M4U"E=P?DS):SW><F?6BDLQM<M[U8R^3Y;<$%0P\-(]?T:8(Q ?M&V:%,\O^C
MF<8RMT(=[4Q(<P.EJON.SJOPZSZZE$(#$@;\3^07('NNR+Y'YMT,$GA*3U,#
M.VWK<GQ2O [BXJNL .R(GK>0Y'2;H7@\L_B%*U<U:6%QF31]DAS&?F"$Q-\?
MU<$CT'(4,Q3Z7/UF;(I^21/OQ\/^"C*H(9M+EM2Y.CL5G[(*,>NJ@N3<(418
MH10>K.AE=V);^KV#2:2!*NX((XA)!(@^,Z!;4:,_O,D\M>L3E4T=31MA%A%(
M#1@<=$8602[0P$#>[;JW^M]*34Q/.)IVF&S['_^A(_'?/W-M'",XK$_FC:5)
MP'?66ZJZF##="E#_Y128+K:1K[I-K,5+.WU$U0BR8K>;=*?ZK, 41'-%. H)
MK3<4V0>7MQ=[BT$SM'766+WLZH@RD;7BD>!2+OXV,&^-DKK@]9(T<6&'GW2<
M8@<'K7^N2Y*W<_/O5R^KWGE?Z_-LP[-M5M]_!;OND(P8=*)(J\=L_\6^XQG*
MULL)>::%61#F?C8\190@#6^*CH?0BPHL3_&Y/C^K66BVN463FV07VSO_#G.Y
MW43AC43)QHP_HG0^7&-85JQ)#5V%4;ML!$4#>VVUFR0#XH;OY^F9)4=LZT7
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M*#Y[Q%I6NRRU,O@V<82OKI>'*D@-O?$D/:=>]\!;GP;,UY50S?*Z<G$Q4U)
M6!"3:V!?YV_=T*QMHUMN5^J>S7@8UH4-O@#\[HA64>AC%-X:]0'WHQ:?D_+
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MA$,W<Y'FIP53,Z XAX&3$>U91@1;678$#/9LX_HZ(DL,0*[H<CL&OH*5.17
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MH/NV,5^W+TUTI^7$)7B0M?1DW&4XZ4?U#M?7U8B]L\Q([=;90!9[/#P[+\.
M[WR8X^E63[N9JF=WB*;AT$P_([]__B<52%D2.M%<EK,-R!:[J2F"V/?:ED(Z
MC22E#3RWA)%^UV;LT8#C^*0GSP.<,"[4=Z?6V-8VS60$LH,XL[I&)=8-Z<!4
MCO=JJ)5>[WX'#MA;MS;SI$*SU&A7P_,S>;$,85S\BHS3ZUJQQ<3^G0I 4/1?
MC IRW%@E&7&U .-KF?(I,T>GZ5N;RC#E%IW7&.%6M.N\H1P E'[G8WJN-*E_
MIO0>ITKL_HIGOX_%ULUG%=FZ&2A0.\.*RK"2%!;A_\D=Q<_\[@/MR, ;F.OU
M;!?-GE>;<#MA8V'QM,K<B.VD/ ZXH5[,X7P9;1I9HVG[R0LQ^<)9JTCHI_>(
M,O+E_OM5.SS@IJE2>-7<IFS!C[XN[OG\O=4JZZR$EX:&-S<+3:G76?OID33K
M)[2@MI/(A[$;@I4PA\WZ%BZ^QA#:_,OQ-2,$T:S-1">-H9DBNOINBB6A*.$.
MD*A$KEQNW8P"FTMZC<*$@TC,5#GYAEU*_4-<D9/B:%Y/.R<#3I89=F_AMP]I
MA-\?]*GP]2_&;TT;BP,6E*^LW?2R?1>@:T#7.[E\F3)EBM0IIV&GE5@!7F,B
ME87L9W@ ?N\*:L+$3-84\F1R\V];[WEUV2 ;AAY"'RSA\;V?0;H^-F%<SA^1
M<P5<<WHD??"<::X$FJ<<,MT8\1%%J-Z/ =[<4C K5W#<M[-/-K";<9ECSAFS
MP2;=;VG$Z,G=/D,W>L^\D-H][(S*3DFH,4,<HH<AN0P1CD-#Z!;/CA6$DSM,
M)K5\)Q0X:EB1&5@$*C=DZ2_.6O<_DE#:=?$-6=8A\.H7UXMT_ 4/AZ6C/[V-
M]6%,FJ#OB>[R6943!ZTHVSMJ&N?&(2EZX<L/\E7;ELME6&EL+/%8.N1S3[ Q
MW 4%Y[[;00I^^G^@N**G[JC_T9@+9G:EE:<")[T" B[()[Q5U1]^395$6K#N
MC7P,8>@IZIIJ-GVU2>FN^PCPMO[AY"]G 2K[ I#YVK_CV,W XYK[]4!>9#B;
M NY%>[]=,O5JH3!F=,YCB0"S_X1W^VS=./;(8@SGD,C<WDC5M1@QD$;>O[=*
MYB]0;L+2(=+JY2%/_R$[791.JYV$0U#V?: L&A9=G+8:)S2ZLXE!WA7>U;=*
ML#M_8@/VB4Y,[!U."<7!*B29T47$K:L)F$8-?73=!FQ);1"^P6JAB\,1KHZX
MG[<&:>K_D6+^T=D!DG>LQ[X;;6';&J3:BR]M8G=O =)]_=^3OD\&J'JEKMG5
M=TUMJ^XQ5"DCKMTP-[X[.2B>GB7!HDF6NZ8\@$S';VE!\%:QK34@L51$&&=
MB0XZ^G[R3K44U.F\P';^5EN0^XQ_+=4R_LUE@?UAR&[UJ"^G@ $2,R?_38J]
MP+72(1E=['*BQNGG75!6/:IJS6\1E^5$?N6APLSLZI7I^0^LPG8Q3CH1S4Y4
M+]@/;.66/OPBR=)6_P7G5M!SP#]L13T-G].9\=G;Z/,@8N-G#Z[:VG"22//
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M?6K>=:?FT4EU>CWA8+A2PUL-OM,#X]"4 ]]<W3_U<?X3V3>E>*?=YGQ_9_8
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M0/N(]U.H'%>@[P_A+<KA9/ @Y4:,<YP_V]H1;X\(!3%<SDZ2G?3[A&S,(R!
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M79?TWK-7J[E+@E-G77?/ACI?VSG2%X$JG.G-4M-OP6-@)AN(Q@ $BN2-?*8
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M(.:R"-<,&2 R!<VM<TV&+HZW0&9:=E-VCX6DRMTET7L08C/^W$6*D-ZGW[/
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M/.644T%EE.]1FS2&"<\YU/;5;6U\4I]%KT]0N:)^]9>'&QVX2@CG6=#T&C;
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MGL!]E,B9DW;/[4TF7=*[2,< S[M[A::I';VNAD[ZDY00JWH;H:"\VHV@QK?
MU<R+$57LM+$KJF09%(\W,L0O)64M$U5.6$&L(XR<GF"I/==P4)%^8$&UK,&
MOT*T0L^X8\?M6Y_7<B=$>Y<IX3/V'J<?88%JMKN3%[>R?(55NGE1'WZ8'X%N
MC8I">1M$G.+Y9/339(G^2:44340=KNT]A\'#Z4)?<W/;?%,:ASK7CTR1 ]DS
M]B3C2T%Z6'L+89]VE2JK=UZTRG"P:2C5K3B(Y:@^*H1,DPT)1I4T+EB+:+9'
ME:Q?6</"'-?D]>9\0V=WL-.RTJ3@8_>TS>X"-S/-[:@OT2V$!O3P745S&B1
M9*-S//FHT,5RZH0@ R_6P]F W_YT8NTRCN_2G-?Q[>.$J([JSK0#91LQV[TA
M=@>+ZCN9T7[HCY0C'3?#DSE<MPJSK5Z[FS\H7+^U$<'PK,7<E/9-&U&%<S(_
M!\66[9?7V5[<C_2X#@[?48U/CMK'4-Q%M67:9%\-C,Q.%']+,;\M-;!^K&=)
M3O0EVI:NOW?\ILEU)12VC'GFMZC2 7EPB>CY'MX)Q9O\PKDN1L)B;-Z-T=&#
M^0:6U 7)[X_CPUS- A8HIS\$+UP:Q3E'UF<U&QA1+>ZL7<6>-KY$;7!0KJ/D
MS%6NJ6(F-XKEQNRHFD/;U83=I]._#I=,?*:MBEZY@CYZ]T6<TP6JKELCK*>C
MHR$M?!W3W)Q: 5\*[4JYHV7MPC&.(J^=\P2$W[)V:ZY+7K 0SGIC33U?$)GA
M["%MRE]7>#'H-@?CN.B2TOZE'*C_0GG "B[->UO3$#7JX'ARKH+*N,8,7B"-
MY3V:SPI0+5R=;]4]\DKS9FFD?A+,EJ+M S_/T%0Y!X'L^D2!P>I#IB;GI;+X
M'LG/V33O)W1Q DX.@D0Q(T.$E-5ZA+Y8**E[/<QNS!D;;W:VOOND_4:;\ZZ=
M&./>+.5A]K(>?6$R9ZSA ,^Z8>9;\AJYXJ+;%P[-2#ZF$D :DWGZ79! R(%X
M9/'3#JGV !KM$P4!"0%GILLH5^K%%OT-"4.\-4;+LEVSOBA8)CR]_B[0RHDU
MHN<)G0,68Z0L7;-9\Y3^)$P^O:>0)_^EU>$Y6VE-E+MUY$?FU^K1^# QRN$R
M61-W!'N-]*W."_B1N:PZ!=8XM<:.A:OWXU#'$FW+7*%BI)/>9'I[E/[FLONB
MA@_UI$'2=<6]UTD?7R#Z3II/%Q.J=>QP%OL#]0\]N<KI>?M<X^+YR++RM_C/
M/R2Y<!4+"=38<%>Q.$T2RDS3GMPT\G5>F%I' H8+GA;9I,?8=NTC+!7&H0F'
M(H/QA.:FV<QY@C'$6Z\7)9Z133^AG3I8U>:29J3)JY9:*'L7V:H>;1)HOE*U
M=,?\9K1_G713='3B2&SC:PB1]<-=Q=>CQ_5<[39/&]&+G3=H]O*_X#8DC-X<
M?*I$'GQ0]OSV!V7N<IZ\0^=AD5S2IR-.?4W4904NO<MZM_FME"2NVEF\9]M9
MMRULJU3]A,44(Q!:UUWJ8S<SV:*:+VOK:&XCN3H?%F("/%&-S[#_TN(Q-;=7
MT"%P?4A0J>-5T'KL,H9;G%R3W?TGNF'\YPBP/HJROO;J8]KJ3$.;8 G@3#(U
MS<=FN;4R8:8ICL9XP-[B8WF-2%+.Y7.V52)] FD"]SVZ]C#!%M&"62:<RB(E
M5C0""6?UCEF/@CVO)W.]22?RO<<TG&%"SQ@2Y=6H]&D#*(E>>O6G;$58)WH?
M/!R5F\^IC&SAY'Q>J%Z5JR5^F?/34Z4U=ZG<B&G<#RZ')W)K_"L4XN$40_P/
M.!DV1GROTSX]5XAAN:)TGY#$6/;-^/)HS?.G-^,C/+#+DCJ(TU^2S9VC9,B9
M<]: F1K5;*-=W%]_D%$4?WFKA,+7)L!C=-82Q\'3;*J_/)&[?8(U3"? \IF<
M*4MQ7H"OF_E=U7(&O8PT=^N#OB8!&Y&6!BJSP(^6+K 18LU*:=/%/+R[CBVJ
ME_P3?=F00+3=[DOOC*/0G4V5N%6]YC!KO=L'CZ>I9?TZNIT-0N",.BF[1YAS
M U/W8=3#+YK[].DGM,(S0A[%*=A$;/&*-[>>.D@A@5&R4>N4'>PJ)%!(B 12
M$YNW-H,W!&V66>/=YW2B[I/2+C(B@1N357[C(P97\DD_TS"RELES=G_.Z8RD
M%EPH[9]J'8C0VW 8WI[$44@SD)W.W.IW:H9&7=+_2&063AER_.6DB))>@6HN
MT- W:QMW+=::1%]_1.E>=EM/9^]$OK.BSB9E'R:CDQ@3LZ,.0X,.YW0!^<3$
M MM^Q 73$ZE.@H8K*,\B*^^84;])QJ]Z5ULA'&WI-/JEL^_=A.Y1[-5VIS'%
M.L>7T2]=H;+5*BQO/>U)P(U:.S:*?BTG%CE($Y?L$6Y5=FN<EEWL2&&_63Y9
MR$KP.9W@D'C)D+WI 0EC0[M?_&<DX(!2*;KD>3]7J*90FG&5.T/9BH8E*+WD
M(5$*URX/UEA;"R&9I3O_ AW_R%2_SHD);FOMR;76D_*X>H(LV<YQ6@*GR_@7
M8IMGPL;T\_+H3%5")W8D1*H>U8O%L,=YAL>AG5=<D1B2RH=E-!U.$)4.V JN
M>F'QF)=8OH!2WJC_XH2%6\<\6^B@2I>7%M58\6J_HQGQUM7:'O]E?/SV&!/6
M#&%$N])<S)6].M*323P# QA]U_70%<'*TM!)L_S,M)B+V<RN]9S'/=TJ<]39
M878N8WF&7/5WA709=Q=)#(_4KG^H:R3[3.P<SFN::&8D*E)AFS#,I6VKL;*@
MKU4F0,A-+[EI,BLFV\I(NT&K_L9=#W&B5C9X;IE_Y>JX_GB]*[8[[3E%-M7V
M3&+?U+X-26[(@2W_QB<O7%M]50\J- ?2,E?'X*NI<R[&284Z$_YQDA)2:Z!!
MW2_KYR8>G78YT>*D3>JIL1+3]'/L<N XC"HE+>W6:%QGM[^4*SZ2'S[MQNFT
M'KOD7TM[N^)2T!L]]P2U05?.SU:)&Z-LU]4NJ-,WM*)**70,[9%=RIA^OI]"
M(NN3FU4ZF&+[H*?>ANM>:V([KAB::;J?##5E>Q263;RG?;"KLN[&H&4)%;T
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MP-0><VA?4?GVM4Z3@<*2#*O29Z69&ES0IU=D!,[75!]KXX<$E(99[GGI\CY
M?YW@%LL>3%QLP+&8(#.Q6*XYX2>T!R4VMJ$>:"<?%,XSMW4XV/5($'VO467'
MMSZMM!S;EA^]?5'8K%K?2V8M/N7CN+W..N67\O:=MX?.8V*MH@686Q/97C->
MMU36]X:U.TV6A3)OOFM_SBB_*#K6)>7I]J;"(M!N[T5&:3 =CH^TV,/,OA$2
MI_-EZYF+:.%3PA"<\]1$[O$'A\T4XEH1KZ!Q%ORM#GWC:\\"4A,4#UY"I93H
M\%T&/JX@:/I+"ZRQLVWY:;QL'B72Y)C\1K&?U&%2LKZ6T-&]@DZJ_G]=(^(N
MP79D:6BD[KH8Y''.KQW# 7OERD?XBAY;ZKG0O]O_C!;IR%?^5+_$1KAO_@5I
M'/X8XWE%N,U3PVO-!S7,O7N?DPJ(IRV^L#346W$(.D GO%]@83*SS>9YJ6%:
MR#D<TG,.T:C6##U8?Y"D\.Y%WZ>G,BF"CF5##G7K=)3^@7TYA2$&0R1*6VN)
MF8Y'36^P3#M%*I_FR! W!!76[0DM%:K@0W3ZA-SSJZZ4<=-UY,<V"B6*HUG6
MW9?':Y6D#>#KWN+(EV8?G V\.<AKF]^GT'\_DB4(U:.;*^+QER31!S$?*"F[
MJ%()1M/>5Y27J V)$%W-G**B96/=+I1>;:9>*QM]7?!Z=+@L(5OI(N5K@OOO
MB9! /D?=M <>P+A(EY=M8RMB5%26N- YL8&I%<\GJ<Q(1=76MGKUX;GFTO6"
M*5,;9[P3W\,XQ@<^CGNYJ[$]7 5<DEZ%U\QMT$N,34IMG[:<MW"IFOJ_5/?_
MM#D;T45LNE8[WTD61M^0;K6C4VSB<VSQHN""<"Q;IA(**%D4;Q5F3,V:NQWG
M%ZNBOS\OIF0:/9Q?N5W"AA\;VX+_ !9PJ=];ZF'F\M9GH87(@QA^]!F-(.;1
MFLP<>%MA9UI +Z[.B^DGZMFQ[4\C\X=16;?.!:5*J5R:@T:X>CG?HVMR*RM+
MP.7JJ]LFY+\]?-X.B.%7:D4E4V=-TNUV,<;SB=S@OCJA;U_VA-'\CC:Y]OUQ
M^5X:RQ;LSFFCJ"M3KAVX5R3'#3HREA*'@LW>5OC(S]A$W\_%Y5=Y)\!?!K<%
M[.H_4HX9/HQ^L^Q)D&*5-39JH(JF1'*:?C_"(2\\G+WK8EE.9IS?K+?H\;-D
M\<'.7/02$0:3TB/;.0O#RJQ69@+/(7.#P10DP$)B@ 2@-*JG.'K+5G[J<J3
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M+/!6:'-3 G;VQ,<=VFEJ[C>JJ5SRA*6:%8FX72')E&6EKE;SR?5WU?OY%8-
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M1T&(-;YH/[8U(KB'AU):V)XG[,N OR[-G4'YC3Q,X@RWI+4<$EXX9]FE-=L
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M<"K?1HZ3HH<#QZA"L]Z_RVK&-0JMVCH..CT,A01V8I0"+._OJ6[G,/?[K=,
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MNMMW':*S5OOR#;.8J$0"A!"Q,MTWAJML--PD[$:L/CH 82W*:L_O*C8F7AI
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M00>\BI0 5(C4/B>>6/[G'CUD4W]OHW@?!=T#>*JJ8Z@7"/@S0EC2@:!,P_P
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M+FAT;5!+ 0(4 Q0    ( !&(7%C#)9H$)5<! ,V$%  1              "
M 95O! !A=FER+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( !&(7%C J\SE$1\
M "#Q   0              "  >G&!0!A=FER+65X,3!?,3,N:'1M4$L! A0#
M%     @ $8A<6#/IY@IE'@  TNX  !               ( !*.8% &%V:7(M
M97@Q,%\Q-"YH=&U02P$"% ,4    "  1B%Q8\+S'ZS@#   #%P  #P
M        @ &[! 8 879I<BUE>#(Q7S$N:'1M4$L! A0#%     @ $8A<6/M%
MT[6Q @  SP\   \              ( !( @& &%V:7(M97@R,U\Q+FAT;5!+
M 0(4 Q0    ( !&(7%AX:M@QA @  -@^   /              "  ?X*!@!A
M=FER+65X,S%?,2YH=&U02P$"% ,4    "  1B%Q8D968[H<(  !9/@  #P
M            @ &O$P8 879I<BUE>#,Q7S(N:'1M4$L! A0#%     @ $8A<
M6&$]W2B-!0  ^R0   \              ( !8QP& &%V:7(M97@S,E\Q+FAT
M;5!+ 0(4 Q0    ( !&(7%@-3"P=AP4  #TF   /              "  1TB
M!@!A=FER+65X,S)?,BYH=&U02P$"% ,4    "  1B%Q80_EL2@D3   WA@
M#P              @ '1)P8 879I<BUE>#DW7S$N:'1M4$L! A0#%     @
M$8A<6)2>OB,NH0  6^0  !$              ( !!SL& &EM9S4W-3DR-#8Q
M7S N:G!G4$L! A0#%     @ $8A<6%,H##C$IP  O[P  !$
M ( !9-P& &EM9S4W-3DR-#8Q7S$N:G!G4$L! A0#%     @ $8A<6&TPR)NI
MQP  Q]\  !(              ( !5X0' &EM9S4W-3DR-#8Q7S$P+FIP9U!+
M 0(4 Q0    ( !&(7%B+PAUFVMT  & ; 0 2              "  3!," !I
M;6<U-S4Y,C0V,5\Q,2YJ<&=02P$"% ,4    "  1B%Q8F&50Y_=+  "#?@
M$@              @ $Z*@D :6UG-3<U.3(T-C%?,3(N:G!G4$L! A0#%
M  @ $8A<6&_<L)0@7 $ 1R$" !(              ( !878) &EM9S4W-3DR
M-#8Q7S$S+FIP9U!+ 0(4 Q0    ( !&(7%@!7$NAN8   ,/:   2
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M.3(T-C%?-2YJ<&=02P$"% ,4    "  1B%Q8/>2[[!%$  #;6   $0
M        @ %J:A$ :6UG-3<U.3(T-C%?-BYJ<&=02P$"% ,4    "  1B%Q8
MH>74(7Y-   ?=P  $0              @ &JKA$ :6UG-3<U.3(T-C%?-RYJ
M<&=02P$"% ,4    "  1B%Q84 [*+1!\ 0!?RP$ $0              @ %7
M_!$ :6UG-3<U.3(T-C%?."YJ<&=02P$"% ,4    "  1B%Q81 ^"2PAK  "[
MF0  $0              @ &6>!, :6UG-3<U.3(T-C%?.2YJ<&=02P4&
/ !H &@!;!@  S>,3

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>avir-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avir="http://www.ateapharma.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avir-20231231.xsd" xlink:type="simple"/>
    <context id="C_e6ae33ec-eab3-42a1-9844-29f7c68d4027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_ec7ec460-3701-487b-868d-61c2b3b9856f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_6082deea-8f3f-4b55-a38d-ea31916b467f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e263b72f-5f38-4b91-b56a-46d57583ec9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_17b49d78-dae5-461d-9aa2-8c05ca6e3b14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_90c6d8d7-56c9-490c-bdcc-72c602e51c09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0bf67e90-3bf5-437f-9149-e6de45de31f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
        </entity>
        <period>
            <instant>2024-02-25</instant>
        </period>
    </context>
    <context id="C_ff6f76c6-f05a-4d88-acf9-a3905001881d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avir:OfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_99cf4023-d6e5-48bb-8b91-c16c96320d2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f2120fa2-8eb2-4101-8a98-bf8dc964d235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_2df95855-8dda-4f54-99a2-64899a2d8236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_741e6762-6491-44e9-9d3f-00660692cfff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c7289ade-105d-4563-a9d4-f2ae3de82763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avir:OfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_c897b11b-eb38-4bd1-97cb-ac70cc675214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0c0e66ec-bf40-4f31-a93c-62669833f34d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_648185c1-cde8-40e2-9c2e-3faf51913ced">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_5a0ce532-9b29-4fdb-8d7c-26fffea11b48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">avir:ResearchAndDevelopmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4dc26114-0dcd-4d93-aff6-f3d487ca3445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="C_7cf00f8c-9982-454f-9f70-f11345935575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_134ce635-cd15-4e3a-bce0-502a40422357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b18b1fcf-b3ac-4d66-bbfb-5bd569b10abc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avir:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3e7810ba-ac14-4633-950d-17f455aae7a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cb12c3db-f2bf-4359-9b84-6e55943ac2cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_95e99b78-705a-4c5a-8427-757b8ec386de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f6e3b279-caec-40bb-8720-9d81118a4e31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avir:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avir:EntityControlledByDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_839b2d04-8e9a-4f78-802e-358d03925bc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9efbbc1b-078b-4f87-947b-73866d7dde2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avir:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avir:JefferiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_c22f1db1-902d-4c7a-b09a-45671bb979be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f773dd53-698b-4d30-a6b5-df061f6a5858">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_159d6d12-6162-484a-9282-0ea77a622978">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_641d1e37-afd3-4641-8d1a-05bebb533e59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a5182e60-9be2-448b-a355-f35129b377d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6c968b4c-959e-4b16-a465-e034a657083f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bb842308-4e24-47f1-9016-a28f5d33ba86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b4858b4b-fada-48fa-9ad8-39d05a6e7b50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6399a783-fb32-4189-8185-57a59a53f325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7f911c61-390f-464f-b142-8191cfb56974">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4121b4df-602e-41a1-a327-97cd041787d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avir:SharesReservedUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bdd23298-c96b-461d-b614-f7ff7d9f6a55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avir:RocheLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_08a2ebd0-8a41-4aeb-aeaf-b254fd869fe7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c947d34f-cb72-4ce4-a2e2-5cd07b77a75b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_76b14b33-56a4-4cf1-80df-723f41684b40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6ee4d578-76e6-43b0-9c50-08cb7a6fb76d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avir:MerckLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2d9ddc2b-fdf7-4243-aa54-0ba461e33dd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d1ccbc8d-fccc-4ef6-b237-b3060720a1f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_53e1a418-db9d-4b78-8fda-8cf250f5882f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c9b4d51c-a9e8-4986-afd4-c57dce1daa35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avir:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_8ba33c50-6a8d-4f09-b491-7da8f49a8f50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avir:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_790b7edc-c301-4076-b9d2-20c39e9f87b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_78f030a1-a021-4e69-b8c8-b89c33ca2f1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5c1df01c-45d9-4b82-b0a8-9c4a4df04fae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_34dd0c12-849b-4618-af9e-a655ab282d18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_975884e8-2fb7-4e8c-a0e2-9c732451f66c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d7c74a74-1bf5-49eb-9231-e2e57e9cec94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b416c72d-54aa-4b09-b126-d3012f0dd986">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_677d6563-424e-4877-8d04-062f7a6292c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_be71de03-d103-4906-b856-69607d3bce32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avir:RocheLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2b6262d6-cb17-47e6-a290-98609c2cd44a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_be3c9676-01ad-494a-ba2a-56772d6be054">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avir:OutstandingOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6b14283c-1b14-4a23-bceb-fe0448f96bd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_29ced885-cd6c-4728-afb5-8721d3d3a564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_38c339a5-7c33-4fe4-88f1-30dc3c9078f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avir:OfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_bdc446e2-c3c8-45df-b44f-251b2b84015d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avir:OutstandingRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a00419f3-633d-4353-a505-f066bdea810a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e51f2865-c244-4aee-985f-6b147207f1c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avir:OutstandingPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9ac4181a-51cc-4958-ac53-7166a997b2a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avir:RocheLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_24439972-d677-48cc-8863-848995b1b44c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e97f5628-4e13-4a16-80cb-1a647ed32f3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_14ac9cbe-603c-4063-874a-18ef17519699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dd4755f2-8af0-43f4-b924-629b18b55def">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_492b70ed-33a9-48ec-91b4-5bf4e27baa9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avir:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avir:JefferiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2e76c0f9-bba5-44a0-93ae-345a4101d6c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7d2d29de-6d0b-4b53-b56c-521ea942b78d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avir:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1430c916-1a16-453a-bad9-54788ee5a480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avir:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avir:JefferiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_74f3bf0b-5c43-436d-86d9-f0ad7bbfae47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b7a5ba3b-2c98-40aa-a0e2-a6986cac7344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avir:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="C_2f732af4-d836-404e-a933-0b892aefa2ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">avir:BusinessDevelopmentConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9feada43-9600-4ad4-8a75-de79be8486b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avir:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avir:EntityControlledByDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ac643507-3356-46e0-b8b6-3ce7ebaa7b58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_81ef7f57-de18-4346-8a86-4f826a99b8fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avir:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5d94cdb2-afb4-4c89-bda1-0c555813396a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_62b17805-037e-4608-865a-45eafd3e8444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2fc9ee26-6947-4538-b0a8-2c3589305d62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_04aa3fcc-acfa-4ce1-806a-36590f240e92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avir:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_aa0a55b5-ae8d-454b-abaa-c3998b787bed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avir:TwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8d744964-680d-40b2-ba6f-5c4572c15939">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c710aa45-dbe9-4f74-a306-1b6b7afa6554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0ced1b9b-cadf-4b52-b730-507c4215184a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b71efb31-3b73-4d78-88bd-0522c7021985">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_31dd3b4f-faf9-41d7-b2d8-342548a15e74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_24dbddef-dc7c-4756-ab44-6dbdef0b512c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avir:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_13f35122-e303-4b3d-a59e-14c0c552587f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2379ff73-5bee-4de8-86f9-afedc9100f71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">avir:RocheLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20998f02-abbf-48fb-8f95-9b2494effbb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_504aa066-1c9a-4526-b64e-13d9e2393363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_43bf2db5-6e41-408f-92b7-55c92bcb1e87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2ae7bd15-ab3e-4d2d-98a8-359e5079ac8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e35146f5-20fa-4ec8-a345-92d23314956f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2be2f376-615a-4108-a6a0-9913d287e512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c7618177-dbbf-4f5e-963a-5fa2381e45b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_302fd01a-656a-4ecd-a50f-578a8254ff85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e82bec19-1afd-4f24-a813-5e90d1f66925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_436595f0-3519-4a55-81e8-9e4c814063e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2ba65c73-8524-40e6-ae35-92adc4ada4bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_c43a7923-c261-4651-bc39-5f0700559de8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_aa816b49-5422-4e75-80e8-d75787e65427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bfb5c27a-df03-47f9-a4cd-6d0ff368feee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f28b0360-b9b7-4972-a2a7-9ed9288fa68a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avir:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avir:EntityControlledByDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_35620468-f729-48e1-8999-2b9f79ad7f7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_be5035eb-e660-4560-be97-44cb8c0f9a0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_154ac387-b035-4286-8b39-36a8ea30d163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_979c91bd-5edb-4472-af3c-4aa5b8c738a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_86685938-2c65-4dd3-9449-fcecbd25ce2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b64973ad-fef2-423f-96bd-ad36857f2986">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avir:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a68f75ab-379f-4790-b7da-2cc14623e5e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e3c8ea54-34b8-4665-bdf3-a8dcf0a0cfef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d5dd8525-8aef-4672-9fb8-129bfa24627c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1c5aa2e0-6ee2-47c4-83c0-bcebcd1b5028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_79bea9f4-f71d-40b2-9f73-0182a669f7ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avir:SharesReservedForFutureGrantUnderTwoThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_da444999-94ef-4fbd-9372-2cec9051adf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1d0f79dd-b812-4c0e-ae93-dd31e490b53c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e6cc6cbb-fa79-4362-b951-fdcabe1d05f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f787167a-61d9-4235-9630-d8d7035b8ce9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8e5a6e9b-41ce-4bde-b88a-39f1e3b103e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_101c9929-49f6-4ecd-b591-e27524e394d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c6080656-f365-4660-9a2e-1abe8d881a2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avir:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eea6202c-efed-4922-944f-49a05b0bd392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_58bb1f1f-c269-4b19-b52e-f3998d06a8a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_74e7c620-e2ac-4ca1-a2bd-90153b3ef496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001593899</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Security">
        <measure>avir:Security</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>avir:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Installment">
        <measure>avir:Installment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_af2fe959-cc5a-41f6-8bc5-501c3a9350e7">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_06d6cb9f-bf12-44b5-ac0d-66e699fd1470">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_fdbd8ee8-add0-48b3-9606-fbe2d8518a2b">0001593899</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      id="F_8825678c-5618-4fdf-86f5-25beefdc3d5d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      id="F_f13f86af-3f04-4fdb-a9a7-d85157377ef3"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      id="F_6a58375c-3c73-45b9-96be-2164642efd86"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      id="F_3f67c47a-74e2-4ce2-b416-6f7418743d08"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_bb842308-4e24-47f1-9016-a28f5d33ba86"
      id="F_3be2bd17-90cb-4ad6-9f95-d622754a93f7">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="INF"
      id="F_26675b1d-cb04-4da6-8149-4bb408ad51ca"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_74f3bf0b-5c43-436d-86d9-f0ad7bbfae47"
      id="F_09624d57-9bf3-4359-9740-b83c401c942c">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <dei:DocumentType
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_7e76f69d-733c-4ce0-8dbd-9efb5743f2cd">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_9e6a0c89-7c16-4364-8096-fbcacc1de314">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_010cedad-5907-4995-8ed1-f00b32a2572a">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_02165538-e213-4989-9c45-27ab64888c80">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_1d40a94c-5fc5-473b-869f-41e2c06479be">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_4d3a8dd2-dcd1-4c7d-a74d-bdbbca40f74a">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_6dba3b0e-bf8e-4ebc-8108-c627991a72b1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_b692983c-38de-4f75-9684-8d7f8e793523">001-39661</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_2f94d124-8623-4489-a694-11c2598f8b72">ATEA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_db6e71c0-2ccf-4428-8033-9eeca0fd090e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_234fb03e-f4ae-4494-a4b0-b0f42222751f">46-0574869</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_7de1cef4-ab0f-4571-aa38-b47e1d2cb03a">225 Franklin Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_270a5e85-fefb-4191-853b-332d0bd280a7">Suite 2100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_1c445d20-9904-44b7-974e-75b841246f66">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_bc0144ef-16ff-41b0-b2c5-3d93a722e453">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_b8d1ed41-e605-4f94-9aed-d58065e34061">02110</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_527f7923-5728-4380-92c9-d168d966eaf6">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_c9f04e2b-8978-434d-8baa-33737ba619fe">284-8891</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_70cafdd2-0e22-4eb1-b780-9daa709c32b6">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_f3ca983b-41c1-4c86-a4d3-6c4fab64ff0a">AVIR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_d675e656-86d6-44f4-821b-9376e7a48a25">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_e152c967-a513-4f1b-9826-306f9931f9e1">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_ebf0c9e0-f12b-4a69-a594-67227fa65634">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_6d792ec6-a488-43ee-bc48-0703cae62b01">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_d1f7a1ea-8c13-4a43-b36b-c1fc0785655e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_17dd4ce6-8ec9-420b-8429-48dd2ad06661">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_4ae1f6d6-4a92-4686-bb02-dbeda0d52dc6">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_8e005d9a-0684-405b-b6b7-570ab25b3343">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_755c4a59-1f09-4cce-a56d-8d2945761673">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_7a9e17d2-1d8b-4299-8ae9-df1d84af304a">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_1857773f-6e3c-4449-b4be-08b5b0d6607a">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_648185c1-cde8-40e2-9c2e-3faf51913ced"
      decimals="-5"
      id="F_6b76fe62-ccf3-48d1-92a0-8beca8e85e10"
      unitRef="U_USD">283700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0bf67e90-3bf5-437f-9149-e6de45de31f3"
      decimals="INF"
      id="F_fe0c9ba6-3eb5-4cb8-9b1f-a84dd50d79bc"
      unitRef="U_shares">84164545</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_6676b9ec-316b-4729-a5b2-f19eea26a2bf">&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the registrant intends to file with the Securities and Exchange Commission within 120 days after the end of the registrant&#x2019;s fiscal year ended December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_cee3200d-27fa-4986-b569-c947750402c3">185</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_ea180156-234c-4532-9c9f-6c7daf2c461f">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_5328b805-d278-4521-b2ee-a89a29f81b00">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_493d5898-a6cc-414e-8cfd-51d796082465"
      unitRef="U_USD">143823000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_15b271e7-7ae2-4368-9a85-3ec03d5f07ec"
      unitRef="U_USD">188460000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_8cd49ddb-d4d9-49c2-828b-8755f9bfbec0"
      unitRef="U_USD">434283000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_3b64ca75-bc14-43b2-9da4-42820325fc1e"
      unitRef="U_USD">458249000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_bbbd58dc-d724-476f-b222-c5f5ec27ed51"
      unitRef="U_USD">12349000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_01a7fada-a0cc-4ae5-a88d-a46a609a967e"
      unitRef="U_USD">14213000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_b7f22d16-c598-4f76-a14a-e0281c99448b"
      unitRef="U_USD">590455000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_fac0ecd1-a551-4a7e-ba83-59dee3df63e4"
      unitRef="U_USD">660922000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_21867c07-8f26-495a-939e-856908ea5781"
      unitRef="U_USD">1289000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_10483874-5b55-4a1f-ad2a-343ec0dd7ffb"
      unitRef="U_USD">1705000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_cc057eb1-4aa8-4868-b730-882ddc02d607"
      unitRef="U_USD">198000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_fe5641e5-f5d8-4c4e-845b-42b201ee9bf7"
      unitRef="U_USD">1396000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_45a9bea3-6e3d-4bcd-abf0-fb084cc72ac3"
      unitRef="U_USD">1494000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_383813e3-46ca-471b-b514-031830af9b88"
      unitRef="U_USD">1828000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_74144d64-1645-49f8-9d95-e41b80483305"
      unitRef="U_USD">2389000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_a57788fc-fb7b-4644-aa2a-7c1b67165bbb"
      unitRef="U_USD">594968000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_fb9d2932-fa36-4522-8cc2-d9f2e8f15f03"
      unitRef="U_USD">666708000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_f2cb9782-5b83-467c-9494-2d9661e5aa28"
      unitRef="U_USD">4252000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_e6147103-aaf1-46c4-a0fa-3dcde5316b95"
      unitRef="U_USD">2551000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_d5b204ce-00a0-4eb4-b78b-29c57b53c14c"
      unitRef="U_USD">27364000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_57f8ac48-1ad3-4de9-9d78-a6309715870f"
      unitRef="U_USD">15206000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_1b220e97-34a1-43d8-9ae0-bd58f12a5500"
      unitRef="U_USD">760000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_c8dc579e-4d13-4d63-b397-79b825514e3c"
      unitRef="U_USD">721000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_f394fdda-43c7-4687-875a-c22da7c3d88e"
      unitRef="U_USD">32376000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_7a868df0-ef0d-4e99-b4b4-5fab67c03778"
      unitRef="U_USD">18478000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_0cdc1ffd-42fb-4598-958c-20941ada85c3"
      unitRef="U_USD">1642000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_4b213c86-6c9f-4b56-be22-96f1b8bb757c"
      unitRef="U_USD">2403000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_b42b52b0-d597-4fe7-a75d-ca136b12b87e"
      unitRef="U_USD">5758000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_9437567a-1e82-4a1d-8c40-244f1f34cba2"
      unitRef="U_USD">5255000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_5815bc31-34bd-4eea-9dc3-f538c5cccd45"
      unitRef="U_USD">39776000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_6aad8978-7bdd-4c3a-bb52-4e4da61071bb"
      unitRef="U_USD">26136000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_b975b12f-de89-41a5-961d-cbc2a73e71e4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="INF"
      id="F_0c08feb2-dd9e-4f22-aae3-df8cd75e49b5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_ae46d2f0-57ba-481c-aedb-41de21add9aa"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="INF"
      id="F_da3cdf45-217a-4632-83dd-ef137dd8dae6"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_bf205be5-b98d-49d9-9483-b691eaa51b97"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="INF"
      id="F_0fbc097a-f012-416c-bbb6-21428349d163"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_fa0d4975-e7c2-46fe-8db8-24eefa52ffde"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="INF"
      id="F_17c35954-4cf5-426a-8bc5-29a2a46a6a5b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_d5ad8dbe-c964-4020-9461-f9f0898be8cc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="INF"
      id="F_55d54fc2-f912-4b98-af2c-1b9508e9a82d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_f76b4c1e-3515-44cc-82c0-ec07fbac0607"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="INF"
      id="F_ace7fab3-d416-4d02-9515-5c2dc755bb6c"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_3d41bdfc-682d-4c14-b861-d304feb14197"
      unitRef="U_shares">83435513</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_4b1ae773-daa2-4514-8cff-29537551dbf1"
      unitRef="U_shares">83435513</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="INF"
      id="F_2ff2b742-b5a3-4257-ae90-0cfb7c7debc6"
      unitRef="U_shares">83287639</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="INF"
      id="F_05ab1ff7-6d6c-4638-870c-109785d35441"
      unitRef="U_shares">83287639</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_242d6043-9f12-4b30-8894-01e5d1579592"
      unitRef="U_USD">83000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_a6476e01-fa2a-4af6-a914-59840a86d84d"
      unitRef="U_USD">83000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_ac03d363-19d1-4512-9366-affb7dcbb67f"
      unitRef="U_USD">750737000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_02c74ec3-55b3-4684-98f4-12619ab73ba0"
      unitRef="U_USD">701052000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_7ca3e754-d252-4db2-b34d-df7905692997"
      unitRef="U_USD">207000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_4abc1cbe-9829-4639-ad32-8058bff4a92d"
      unitRef="U_USD">-684000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_87db8f52-03a7-4964-a102-810b5392f24d"
      unitRef="U_USD">-195835000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_e4535a14-f4e5-4c5f-b969-a663a4da71b9"
      unitRef="U_USD">-59879000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_ffc63291-9adf-4f6c-9203-946ad2a43727"
      unitRef="U_USD">555192000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_3f9e3018-4537-4155-9425-7b6bc72ee653"
      unitRef="U_USD">640572000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_77dc6a4d-5812-4a5a-abe8-9bfcedcdd44a"
      unitRef="U_USD">594968000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_e1b2110d-c778-4eb9-81bf-2c838f2eae62"
      unitRef="U_USD">666708000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_9b8c53c0-bb0e-40e5-ae3f-07d1453d706a"
      unitRef="U_USD">114243000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_35e05a89-30e0-4f45-b40c-ab18775e732a"
      unitRef="U_USD">81936000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_ef338337-a717-4e12-a091-14a8b5a6e3bf"
      unitRef="U_USD">49919000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_c2276ef3-6209-4dfb-9b3e-ab8733fb6aff"
      unitRef="U_USD">48714000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_9df55c55-748c-49ad-9eae-76ab2193c9aa"
      unitRef="U_USD">164162000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_c9dd9b75-ac71-4df8-84a9-440a552e0e5e"
      unitRef="U_USD">130650000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_0d7dbd3d-1512-46ff-bc62-cc8f9936b13c"
      unitRef="U_USD">-164162000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_0a5ce441-91d5-42b8-b22b-e7d584615973"
      unitRef="U_USD">-130650000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_c033f947-c6a2-4add-ab6b-c95d4a69e0aa"
      unitRef="U_USD">29224000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_a5638fad-2cf1-41eb-88b5-6fc152944f4b"
      unitRef="U_USD">11151000</us-gaap:InterestAndOtherIncome>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_542bfef9-8c20-43ed-b75e-a3605a7978fb"
      unitRef="U_USD">-134938000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_371474a9-0211-434a-b03b-73472a8d1701"
      unitRef="U_USD">-119499000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_05afaf18-52bb-4fac-b8ff-b6f88baa7ac3"
      unitRef="U_USD">1018000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_5e3c5964-18fe-4d34-8b46-14467ecbf04d"
      unitRef="U_USD">-3590000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_41e85c9e-d0be-4230-99da-31960b99ed4a"
      unitRef="U_USD">-135956000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_5cbb88ed-3b97-4678-bd4f-e95bf25c18f5"
      unitRef="U_USD">-115909000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_06740dcf-af38-44fd-86ca-53888df9d8cb"
      unitRef="U_USD">891000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_bf22d0f6-d7c9-4ad5-a9bf-1b8abe8d74be"
      unitRef="U_USD">-684000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_e2be1ac0-d5be-42d4-8636-2266fcfa2ac5"
      unitRef="U_USD">-135065000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_f763d6b4-c0d9-48a9-beac-2240b5d2c854"
      unitRef="U_USD">-116593000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="2"
      id="F_f3a8eb4c-9c6b-4c23-af5e-626c5e5f6a82"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="2"
      id="F_f5df8c41-bb12-41c9-8f80-f666a5f4e2fb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="2"
      id="F_e6a7fec8-ddd2-4819-b0c6-ca259d5707b9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="2"
      id="F_1c6677b3-6da2-4749-911e-c6138529f7f7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="0"
      id="F_0cfeefbb-acdc-4644-9c2e-4c5b9d1081f4"
      unitRef="U_shares">83389750</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="0"
      id="F_0b9e9f31-aba3-47e3-98bf-af281de02f47"
      unitRef="U_shares">83389750</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="0"
      id="F_a9f11904-5c98-45cc-a83b-50e74ad9e1b8"
      unitRef="U_shares">83245385</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="0"
      id="F_12b109ec-aa3e-4866-bb88-c6b2aa9bc554"
      unitRef="U_shares">83245385</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_7cf00f8c-9982-454f-9f70-f11345935575"
      decimals="INF"
      id="F_9c50e140-8a46-4b51-bdba-57b1b0cd90cf"
      unitRef="U_shares">83102730</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_7cf00f8c-9982-454f-9f70-f11345935575"
      decimals="-3"
      id="F_5a0b9dc9-e1e0-46a3-8aaf-7b42b5221537"
      unitRef="U_USD">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_741e6762-6491-44e9-9d3f-00660692cfff"
      decimals="-3"
      id="F_7387203e-186b-4545-a4d0-88c936a768b6"
      unitRef="U_USD">653964000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_14ac9cbe-603c-4063-874a-18ef17519699"
      decimals="-3"
      id="F_378d654e-4829-40de-8732-a3623ff9be3a"
      unitRef="U_USD">56030000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7f911c61-390f-464f-b142-8191cfb56974"
      decimals="-3"
      id="F_f7f27968-1a22-4a60-9869-83903f40af8c"
      unitRef="U_USD">710077000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_839b2d04-8e9a-4f78-802e-358d03925bc9"
      decimals="INF"
      id="F_418e7bd1-a460-491c-989f-bdb5aea259ca"
      unitRef="U_shares">155873</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6c968b4c-959e-4b16-a465-e034a657083f"
      decimals="-3"
      id="F_32b0e8dd-e127-4e16-88c8-2fd23c5d2ffa"
      unitRef="U_USD">230000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_aaff2ac5-6bb7-4684-aa85-df78d76e42a3"
      unitRef="U_USD">230000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_839b2d04-8e9a-4f78-802e-358d03925bc9"
      decimals="INF"
      id="F_d4b36534-c861-463e-9de7-156e57a5e05c"
      unitRef="U_shares">29036</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_6c968b4c-959e-4b16-a465-e034a657083f"
      decimals="-3"
      id="F_d240cfc8-6395-43b1-ae3a-595e0f720cf5"
      unitRef="U_USD">140000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_feb999ea-75ec-4ae6-adf9-22074f266574"
      unitRef="U_USD">140000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6c968b4c-959e-4b16-a465-e034a657083f"
      decimals="-3"
      id="F_8c1ab249-b3a8-40c4-82f9-0202851a9cc9"
      unitRef="U_USD">46718000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_093e06ab-f721-4715-9fcd-b793ab0e577b"
      unitRef="U_USD">46718000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_be5035eb-e660-4560-be97-44cb8c0f9a0e"
      decimals="-3"
      id="F_020834b9-21e2-4e70-b6f4-c2190a244774"
      unitRef="U_USD">-684000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_e275dea4-a6bd-4ff1-98f2-106c03b3ff16"
      unitRef="U_USD">-684000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_e97f5628-4e13-4a16-80cb-1a647ed32f3f"
      decimals="-3"
      id="F_831724cb-8973-4555-98fe-9ce7a0ed61f7"
      unitRef="U_USD">-115909000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_f016fb28-598d-4a52-882d-c07dead1e2c4"
      unitRef="U_USD">-115909000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_1c5aa2e0-6ee2-47c4-83c0-bcebcd1b5028"
      decimals="INF"
      id="F_5ab08175-e730-48b5-bd52-bbd13a528241"
      unitRef="U_shares">83287639</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_1c5aa2e0-6ee2-47c4-83c0-bcebcd1b5028"
      decimals="-3"
      id="F_6cd49f1f-9402-4b50-af0a-ff956f49ffe5"
      unitRef="U_USD">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b416c72d-54aa-4b09-b126-d3012f0dd986"
      decimals="-3"
      id="F_35f441bb-cd3d-4167-9532-fafba8f39724"
      unitRef="U_USD">701052000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_53e1a418-db9d-4b78-8fda-8cf250f5882f"
      decimals="-3"
      id="F_5563abf2-4080-4eb8-b7fc-ad94e87df78f"
      unitRef="U_USD">-684000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a00419f3-633d-4353-a505-f066bdea810a"
      decimals="-3"
      id="F_159346e0-aa56-4dbe-bea4-6a762683fb85"
      unitRef="U_USD">-59879000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_1b15e495-4ff1-4973-8568-e6a175ec8582"
      unitRef="U_USD">640572000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_2df95855-8dda-4f54-99a2-64899a2d8236"
      decimals="0"
      id="F_95f5b781-b662-43ba-a1b9-b69874c6902f"
      unitRef="U_shares">53935</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_2df95855-8dda-4f54-99a2-64899a2d8236"
      decimals="INF"
      id="F_4ca1652c-c1e8-411d-9a09-77b2663679d1"
      unitRef="U_shares">93939</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_35620468-f729-48e1-8999-2b9f79ad7f7e"
      decimals="-3"
      id="F_d2f4ed2b-8c38-4a7e-8139-6b6a70c750f3"
      unitRef="U_USD">257000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_fbf82f17-afb5-4de5-944e-5bec7ddea3ac"
      unitRef="U_USD">257000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_35620468-f729-48e1-8999-2b9f79ad7f7e"
      decimals="-3"
      id="F_1d6f88ed-8d6d-4e04-8a06-baf27cf3311f"
      unitRef="U_USD">49428000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_892d5baf-b854-4ac5-b93e-cb861ee6cb74"
      unitRef="U_USD">49428000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_b71efb31-3b73-4d78-88bd-0522c7021985"
      decimals="-3"
      id="F_54616155-a900-4705-8a7b-878f2445d979"
      unitRef="U_USD">891000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_b0b9fbf0-8c0a-4a61-b94e-0e40ea9cbd40"
      unitRef="U_USD">891000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_e35146f5-20fa-4ec8-a345-92d23314956f"
      decimals="-3"
      id="F_6e0eea35-c377-4bbd-a70c-d84ea2a8dfa2"
      unitRef="U_USD">-135956000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_353d0383-a39f-4d7e-835d-f169c289da41"
      unitRef="U_USD">-135956000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_2d9ddc2b-fdf7-4243-aa54-0ba461e33dd8"
      decimals="INF"
      id="F_bb1e376a-7a87-4d96-8139-b3de4e145852"
      unitRef="U_shares">83435513</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_2d9ddc2b-fdf7-4243-aa54-0ba461e33dd8"
      decimals="-3"
      id="F_dbcda4b7-d4ae-4f1b-8dd8-f9e684be4c2d"
      unitRef="U_USD">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_677d6563-424e-4877-8d04-062f7a6292c3"
      decimals="-3"
      id="F_bea33680-8adc-401a-9373-919df0a0e3c8"
      unitRef="U_USD">750737000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cb12c3db-f2bf-4359-9b84-6e55943ac2cb"
      decimals="-3"
      id="F_5f4a2257-9692-4245-9f93-0e898591113e"
      unitRef="U_USD">207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2be2f376-615a-4108-a6a0-9913d287e512"
      decimals="-3"
      id="F_19d114d3-09f2-437d-b316-206917a87ca9"
      unitRef="U_USD">-195835000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_7fb959ff-c1dc-4e9b-99f5-cc11fd1976e3"
      unitRef="U_USD">555192000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_47eba798-1c1f-4243-b9e6-0681d08c36d0"
      unitRef="U_USD">-135956000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_84302aa6-f2f4-4bac-9652-19d17b04084f"
      unitRef="U_USD">-115909000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_4bfbc2fd-cc4c-477b-82fe-7d4e32374fad"
      unitRef="U_USD">49428000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_62845f9c-52f2-4a5b-b2a9-7bf5ae3b6993"
      unitRef="U_USD">46718000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_4c373a56-4f7d-4710-be76-ae1eb82efa3f"
      unitRef="U_USD">416000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_58be84c1-fe09-47f2-a4d7-8d062e542807"
      unitRef="U_USD">260000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_34203c09-3cb4-43b7-b42b-fc6ab6a4558a"
      unitRef="U_USD">15446000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_866d6a0e-878d-4a23-89b9-86e3e47fe307"
      unitRef="U_USD">5465000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_f780722c-2a63-436c-8110-79f84ead86c1"
      unitRef="U_USD">-1864000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_e1a5319e-e6a7-4972-b0f4-73027840887a"
      unitRef="U_USD">6251000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_c0c0e3af-9603-4421-ba0a-d5daf7765126"
      unitRef="U_USD">-98000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_6497342a-191a-456a-937a-a05708b5da1b"
      unitRef="U_USD">1494000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_91c49669-1c5c-4614-8034-5af8e341bbf1"
      unitRef="U_USD">1701000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_8dd7d299-53f2-4885-8778-904351781f49"
      unitRef="U_USD">-1983000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_d782fa82-4046-4992-a1af-a096f264649e"
      unitRef="U_USD">12661000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_169479cc-d910-45b0-8665-7b6feb085929"
      unitRef="U_USD">-37623000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_a3314d59-844d-49d6-a074-46215caa7a6c"
      unitRef="U_USD">-161000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_50df42fa-dd67-4c65-9999-089e79895355"
      unitRef="U_USD">765000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_d006ca88-f5ef-4913-b8d4-73698b9c968e"
      unitRef="U_USD">-85395000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_3473c2e4-0b53-4575-af45-73d131e7d232"
      unitRef="U_USD">-120982000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_28c4d06a-f76d-413f-a040-db4f5b4752f7"
      unitRef="U_USD">1943000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_2f681871-788e-4242-a0dc-3987ef3a0656"
      unitRef="U_USD">562362000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_692cbf98-faa3-4f02-aad5-0821f0692e8a"
      unitRef="U_USD">545352000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_48cd7418-cb47-4ab3-934f-036e13e59baa"
      unitRef="U_USD">602665000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_c3120846-1400-42fc-9e53-90a6507db653"
      unitRef="U_USD">91885000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_771b2417-de0e-427e-8970-e2a05c356edd"
      unitRef="U_USD">40303000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_1087b577-c830-4124-83a9-8a0340c0736b"
      unitRef="U_USD">-455410000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_861e118e-945c-4056-aef9-bcfa47108f98"
      unitRef="U_USD">230000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_aa9718f6-e7ba-4140-ac62-93948a0af173"
      unitRef="U_USD">257000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_36bc7799-ed39-4bbd-adb0-5c7943bc1844"
      unitRef="U_USD">140000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_3605a064-83ac-4b73-970a-da240f5c4479"
      unitRef="U_USD">257000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_4424b719-71c5-4e3e-bacc-d01ce0e77877"
      unitRef="U_USD">370000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_f4fe1fc4-ef72-427b-9af0-10328f1434e9"
      unitRef="U_USD">-44835000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_c4aced5e-a648-490b-8006-771279e4d928"
      unitRef="U_USD">-576022000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_f9b032aa-f5ad-4fbc-a90d-b52bc3c04b4a"
      unitRef="U_USD">188658000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7f911c61-390f-464f-b142-8191cfb56974"
      decimals="-3"
      id="F_454bd732-b280-4c0b-b6c0-e236b10fc62c"
      unitRef="U_USD">764680000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_40df466a-24ed-4a36-b7d8-55bb9b30ca2a"
      unitRef="U_USD">143823000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_5f75e0c7-e1c1-4ca6-8490-e1ac4f00571f"
      unitRef="U_USD">188658000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_5c48dca6-986e-413e-888c-874af992ddd3"
      unitRef="U_USD">143823000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_cb93d1f6-b262-46c4-8990-b0af42e30f23"
      unitRef="U_USD">188460000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_5451e91a-ebe4-41a0-9e25-3346dff49b31"
      unitRef="U_USD">198000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_6d38594e-a9df-4229-8a28-e93bbf24d0d9"
      unitRef="U_USD">143823000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_0cd981e9-2ad9-4ff2-8339-1e23dc8c10bf"
      unitRef="U_USD">188658000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_27722673-de92-42f2-a24a-e75781e67917"
      unitRef="U_USD">2938000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_e8917e00-4cf9-4d16-839a-bf8e9f3f29fd">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;1. Nature of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Business Overview&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Atea Pharmaceuticals, Inc., ("Atea" or the "Company") is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from severe viral infections.  Currently, Atea is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 ("COVID-19"). Atea is also currently conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus ("HCV").&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2023, the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;578.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million in cash, cash equivalents and marketable securities, which the Company believes will be sufficient to fund its operations for a period through at least twelve months from the issuance date of these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In November 2021, the Company entered into an open market sales agreement (&#x201c;Sales Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;), under which the Company may from time to time offer and sell shares of its common stock for an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million, through or to Jefferies, acting as sales agent or principal. The shares will be offered and sold under the Company&#x2019;s shelf registration statement on Form S-3 and a related prospectus filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on November 24, 2021, as amended. The Company has agreed to pay Jefferies a commission of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Jefferies with customary indemnification and contribution rights. As of December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares have been issued under the Sales Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company is subject to risks and uncertainties common to clinical-stage biopharmaceutical companies. These risks include, but are not limited to, potential failure of preclinical and clinical studies, uncertainties associated with research and development activities generally, competition from technical innovations of others, dependence upon key personnel, compliance with governmental regulations, the need to obtain marketing approval for any product candidate that the Company may develop, the need to gain broad acceptance among patients, payers and health care providers to successfully commercialize any product for which marketing approval is obtained and the need to secure and maintain adequate intellectual property protection for the Company&#x2019;s proprietary technology and products. Further, the Company is currently dependent on third-party service providers for much of its preclinical research, clinical development and manufacturing activities. Product candidates currently under development will require significant amounts of additional capital, and additional research and development efforts, including further additional clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company may seek additional capital through one or more of a combination of financing through the sale of additional equity securities, debt financing, or funding in connection with any new collaborative relationships it may enter into or other arrangements. There can be no assurance that the Company will be able to obtain such additional funding, on terms acceptable to the Company, on a timely basis or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s existing stockholders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Company is also subject to risks associated with the continued evolution of COVID-19 and its consequences, including actual and potential delays associated with certain of its ongoing and anticipated trials, and potential negative impacts on the Company&#x2019;s business operations and its ability to raise&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;additional &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;capital to finance its operations. Geopolitical events, including civil or political unrest and terrorism, have resulted in a significant disruption of global business and financial markets. In addition, recent or future market volatility, increased inflation and higher interest rates, if sustained, may increase our cost of financing and may restrict our access to potential sources of future liquidity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-5"
      id="F_a3861d90-eb9e-45d0-886a-602bfd61507b"
      unitRef="U_USD">578100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <avir:StockIssuanceProgramAuthorizedAmount
      contextRef="C_9efbbc1b-078b-4f87-947b-73866d7dde2f"
      decimals="-5"
      id="F_c4b3001a-4eaf-4212-b9fd-2e47a60e4434"
      unitRef="U_USD">200000000</avir:StockIssuanceProgramAuthorizedAmount>
    <avir:CommissionRate
      contextRef="C_1430c916-1a16-453a-bad9-54788ee5a480"
      decimals="3"
      id="F_b854eb19-01cf-40b5-b7d7-3542ef447492"
      unitRef="U_pure">0.03</avir:CommissionRate>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_492b70ed-33a9-48ec-91b4-5bf4e27baa9d"
      decimals="INF"
      id="F_27c6b011-b254-4b3e-a9ae-547fc7d2411b"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_41846b16-4cfb-440a-a2db-45a7683d2aad">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and in these accompanying notes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors and assumptions that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, which include but are not limited to estimates of accrued research and development expenses, valuation of marketable securities, valuation of stock-based awards, valuation of operating lease right-of-use assets and lease liabilities and income taxes. Changes in estimates are recorded in the period in which they become known.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Atea Pharmaceuticals, Inc. and its wholly- owned subsidiary, Atea Pharmaceuticals Securities Corporation. All intercompany amounts have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company considers all highly-liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company&#x2019;s cash equivalents include money market funds and commercial paper, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company&#x2019;s investment strategy is principally focused on capital preservation. The Company invests in financial instruments that among other things meet the credit quality standards outlined in the Company&#x2019;s investment policy. Marketable securities consist of investments with maturities greater than three months. Investments not classified as cash equivalents with maturities of less than twelve months are classified as current assets on the consolidated balance sheet.  Investments with maturities greater than twelve months for which the Company has the intent and ability to hold the investment for greater than twelve months are classified as non-current on the consolidated balance sheet. Marketable securities include US treasury obligations, US agency obligations, corporate debt, commercial paper and asset-backed securities.  The Company classifies all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Unrealized gains and losses are recorded as a component of accumulated other comprehensive gain (loss) within stockholders&#x2019; equity. Interest, dividends and amortization and accretion of discounts and premiums are recorded as interest income and other, net.  The Company periodically reviews its marketable securities for impairment and adjusts these investments to their fair value when a decline in market value is deemed to be other than temporary.  Declines in fair value judged to be other than temporary on marketable securities, if any, are included in interest income and other, net.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and Significant Suppliers&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the US government. The Company does not believe that it is subject to any significant concentrations of credit risk from these financial instruments. The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company is dependent on third-party manufacturers for the supply of products for its research and development activities including its development programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs for preclinical and clinical development activities. The Company also currently anticipates to rely on this small number of manufacturers for commercial supply if any of the current product candidates are approved for sale. The Company's research and development programs, including any potential commercialization efforts, could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurement,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Level 1&#x2014;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Level 2&#x2014;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Level 3&#x2014;Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the assets and liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The carrying amounts of prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value due to short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the asset. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company estimates the useful life of its assets as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.17%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:49.17%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Five years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Five years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Computer hardware&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Two years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_3be2bd17-90cb-4ad6-9f95-d622754a93f7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Maintenance and repairs that do not improve or extend the life of the respective asset are expensed to operations as incurred. Upon disposal of an asset, the related cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Other Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Other assets consist of vendor deposits related to research and development activities and a security deposit related to our facility lease.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Company reviews long-lived assets, including property and equipment and right-of-use assets ("ROU") when events or changes in circumstances indicate the carrying value of the assets may not be fully recoverable. Recoverability is measured by comparing the book value of the assets to the estimated undiscounted future net cash flows that the asset is expected to generate. If the estimated undiscounted future net cash flows are less than the book value, the asset is impaired, and the impairment loss to be recognized in income is measured as the amount by which the book value of the asset exceeds its fair value, which is measured based on the estimated discounted future net cash flows that the asset is&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;expected &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;to generate. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; impairment losses were recorded during the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company accounts for leases in accordance with ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Lease Accounting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;.   At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. Leases with a term greater than one year are recognized on the consolidated balance sheet as a ROU asset and current and non-current lease liabilities, as applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense.  The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company estimates it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist principally of costs associated with outsourced research and development activities, including drug discovery, preclinical and clinical development, manufacturing and research conducted by contract research organizations and academic institutions, employee compensation, including stock-based compensation and consulting expenses together with related expenses, professional fees and facility and overhead costs. Facility and overhead costs primarily include the allocation of rent, utility and office-related expenses attributable to research and development personnel. In circumstances where amounts have been paid in advance or in excess of costs incurred, the Company records a prepaid expense, which is expensed as services are performed or goods are delivered.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company has entered into various research and development contracts with third parties. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase of completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Costs to secure and maintain the Company&#x2019;s patents are expensed as incurred and are classified as general and administrative expenses in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Stock-based compensation expense is classified in the consolidated statement of operations and comprehensive loss in the same manner as the award recipient&#x2019;s payroll costs or service payments are classified. Stock-based awards granted to employees and non-employees are measured based on the estimated fair value of the awards using the Black-Scholes option pricing model (&#x201c;Black-Scholes&#x201d;). Stock-based compensation expense with respect to awards with service conditions is recognized using the straight-line method over the service period. Stock-based compensation with respect to awards with performance conditions is recognized when satisfaction of the performance conditions is probable. Stock-based compensation is based on awards ultimately expected to vest and, as such, it is reduced by forfeitures. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Fair value of common stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;The fair value of its common stock is based on the daily closing quoted market price of its common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;The risk-free interest rate is based on the US Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;The expected term represents the period that stock-based awards are expected to be outstanding. Given the Company&#x2019;s lack of specific history, the expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;Since the Company was privately held through October 29, 2020 and did not have any trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. During the fiscal year ended December 31, 2022 the Company began to incorporate the historical volatility of its own stock price in its calculation of its expected volatility.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company uses an expected dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company also accounts for any modifications to share based payments in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; (ASC 718).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The purchase price of the Company's common stock under the Company&#x2019;s 2020 Employee Stock Purchase Plan ("ESPP") is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;% of the lesser of (i) the fair market value per share of its common stock on the first business day of an offering period and (ii) the fair market value per share of its common stock on the purchase date. The fair value of the discounted purchases made under ESPP is calculated using the Black-Scholes valuation model. The fair value of the look-back provision plus the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;% discount is recognized as compensation expense over the 180-day purchase period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with equity holders.  For the years ended December 31, 2023 and 2022, the only components of comprehensive loss other than net loss were unrealized gains and losses on available for sale investments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Basic net income loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of shares of common stock outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding common stock equivalents except where such securities would be antidilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;In-process Research and Development Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In-process research and development assets that are acquired in a transaction that does not qualify as a business combination under GAAP and that do not have an alternative future use are expensed in the period in which the assets are acquired.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#x201c;CODM&#x201d;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its chief executive officer, who manages and allocates resources to the operations on a total company basis. Accordingly, there is a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_26675b1d-cb04-4da6-8149-4bb408ad51ca;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; operating segment and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; reportable segment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Other accounting standards that have been issued or proposed by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company did not adopt any accounting pronouncements during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <avir:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_3a84f2d5-1a80-444b-9035-d6fc072c5b05">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and in these accompanying notes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors and assumptions that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, which include but are not limited to estimates of accrued research and development expenses, valuation of marketable securities, valuation of stock-based awards, valuation of operating lease right-of-use assets and lease liabilities and income taxes. Changes in estimates are recorded in the period in which they become known.&lt;/span&gt;&lt;/p&gt;</avir:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_40524708-b4e7-4218-b7f4-fe3bce0d953a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Atea Pharmaceuticals, Inc. and its wholly- owned subsidiary, Atea Pharmaceuticals Securities Corporation. All intercompany amounts have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_9275e258-3a1b-4acd-839b-d2057348e2b6">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company considers all highly-liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company&#x2019;s cash equivalents include money market funds and commercial paper, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_b7c1870e-0844-456d-bff0-551ef8900c13">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company&#x2019;s investment strategy is principally focused on capital preservation. The Company invests in financial instruments that among other things meet the credit quality standards outlined in the Company&#x2019;s investment policy. Marketable securities consist of investments with maturities greater than three months. Investments not classified as cash equivalents with maturities of less than twelve months are classified as current assets on the consolidated balance sheet.  Investments with maturities greater than twelve months for which the Company has the intent and ability to hold the investment for greater than twelve months are classified as non-current on the consolidated balance sheet. Marketable securities include US treasury obligations, US agency obligations, corporate debt, commercial paper and asset-backed securities.  The Company classifies all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Unrealized gains and losses are recorded as a component of accumulated other comprehensive gain (loss) within stockholders&#x2019; equity. Interest, dividends and amortization and accretion of discounts and premiums are recorded as interest income and other, net.  The Company periodically reviews its marketable securities for impairment and adjusts these investments to their fair value when a decline in market value is deemed to be other than temporary.  Declines in fair value judged to be other than temporary on marketable securities, if any, are included in interest income and other, net.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <avir:ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_bbc4d059-49e5-4970-b72b-6c68e4345879">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and Significant Suppliers&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the US government. The Company does not believe that it is subject to any significant concentrations of credit risk from these financial instruments. The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company is dependent on third-party manufacturers for the supply of products for its research and development activities including its development programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs for preclinical and clinical development activities. The Company also currently anticipates to rely on this small number of manufacturers for commercial supply if any of the current product candidates are approved for sale. The Company's research and development programs, including any potential commercialization efforts, could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.&lt;/span&gt;&lt;/p&gt;</avir:ConcentrationsOfCreditRiskAndSignificantSuppliersPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_19685318-c7a1-4d51-93d0-0582449b52d5">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurement,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Level 1&#x2014;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Level 2&#x2014;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Level 3&#x2014;Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the assets and liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The carrying amounts of prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value due to short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_868e0ae3-4f9c-4dec-b568-1e83896e96bd">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the asset. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company estimates the useful life of its assets as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.17%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:49.17%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Five years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Five years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Computer hardware&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Two years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_3be2bd17-90cb-4ad6-9f95-d622754a93f7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Maintenance and repairs that do not improve or extend the life of the respective asset are expensed to operations as incurred. Upon disposal of an asset, the related cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <avir:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_db694ea3-8c60-4991-a698-671a647dc97d">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company estimates the useful life of its assets as follows:&lt;/span&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.17%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:49.17%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Five years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Five years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Computer hardware&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Two years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_3be2bd17-90cb-4ad6-9f95-d622754a93f7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</avir:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_7d2d29de-6d0b-4b53-b56c-521ea942b78d"
      id="F_9f019bb8-31ed-40da-920c-870389ee1c09">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_6399a783-fb32-4189-8185-57a59a53f325"
      id="F_13b4648e-cde4-467b-8bca-8a1d2cd4be0f">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_c7618177-dbbf-4f5e-963a-5fa2381e45b8"
      id="F_66a82b5e-07cf-48dc-ad56-e885692aab8a">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <avir:OtherAssetsPolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_2d62b0a1-fd30-4b55-8c38-c6121730ce6d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Other Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Other assets consist of vendor deposits related to research and development activities and a security deposit related to our facility lease.&lt;/span&gt;&lt;/p&gt;</avir:OtherAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_afa1035c-5c7a-4ea1-9eb6-08afd613cae3">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Company reviews long-lived assets, including property and equipment and right-of-use assets ("ROU") when events or changes in circumstances indicate the carrying value of the assets may not be fully recoverable. Recoverability is measured by comparing the book value of the assets to the estimated undiscounted future net cash flows that the asset is expected to generate. If the estimated undiscounted future net cash flows are less than the book value, the asset is impaired, and the impairment loss to be recognized in income is measured as the amount by which the book value of the asset exceeds its fair value, which is measured based on the estimated discounted future net cash flows that the asset is&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;expected &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;to generate. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; impairment losses were recorded during the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="INF"
      id="F_01b7dfe1-ba91-4334-a880-00f6f90d5a1b"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="INF"
      id="F_c1598cc6-957e-4790-a0d9-7406d28b67a1"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_1779adb0-43ae-4c8f-8555-ceadec631298">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company accounts for leases in accordance with ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Lease Accounting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;.   At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. Leases with a term greater than one year are recognized on the consolidated balance sheet as a ROU asset and current and non-current lease liabilities, as applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense.  The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company estimates it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_db496878-b06c-49c0-85ce-7b2b774124b3">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist principally of costs associated with outsourced research and development activities, including drug discovery, preclinical and clinical development, manufacturing and research conducted by contract research organizations and academic institutions, employee compensation, including stock-based compensation and consulting expenses together with related expenses, professional fees and facility and overhead costs. Facility and overhead costs primarily include the allocation of rent, utility and office-related expenses attributable to research and development personnel. In circumstances where amounts have been paid in advance or in excess of costs incurred, the Company records a prepaid expense, which is expensed as services are performed or goods are delivered.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company has entered into various research and development contracts with third parties. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase of completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_93a34553-46ad-45a4-ab3f-d6cca5774206">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Costs to secure and maintain the Company&#x2019;s patents are expensed as incurred and are classified as general and administrative expenses in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_bdbd4410-ddde-43ad-80d8-d4339d1b1016">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Stock-based compensation expense is classified in the consolidated statement of operations and comprehensive loss in the same manner as the award recipient&#x2019;s payroll costs or service payments are classified. Stock-based awards granted to employees and non-employees are measured based on the estimated fair value of the awards using the Black-Scholes option pricing model (&#x201c;Black-Scholes&#x201d;). Stock-based compensation expense with respect to awards with service conditions is recognized using the straight-line method over the service period. Stock-based compensation with respect to awards with performance conditions is recognized when satisfaction of the performance conditions is probable. Stock-based compensation is based on awards ultimately expected to vest and, as such, it is reduced by forfeitures. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Fair value of common stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;The fair value of its common stock is based on the daily closing quoted market price of its common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;The risk-free interest rate is based on the US Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;The expected term represents the period that stock-based awards are expected to be outstanding. Given the Company&#x2019;s lack of specific history, the expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#x2014;Since the Company was privately held through October 29, 2020 and did not have any trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. During the fiscal year ended December 31, 2022 the Company began to incorporate the historical volatility of its own stock price in its calculation of its expected volatility.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company uses an expected dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company also accounts for any modifications to share based payments in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; (ASC 718).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The purchase price of the Company's common stock under the Company&#x2019;s 2020 Employee Stock Purchase Plan ("ESPP") is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;% of the lesser of (i) the fair market value per share of its common stock on the first business day of an offering period and (ii) the fair market value per share of its common stock on the purchase date. The fair value of the discounted purchases made under ESPP is calculated using the Black-Scholes valuation model. The fair value of the look-back provision plus the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;% discount is recognized as compensation expense over the 180-day purchase period.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="INF"
      id="F_8cf8aea2-c382-419f-bbbb-4a9a77e45caf"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <avir:ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate
      contextRef="C_b18b1fcf-b3ac-4d66-bbfb-5bd569b10abc"
      decimals="2"
      id="F_a727901d-c3dd-47d1-b30b-adc7a9794ca2"
      unitRef="U_pure">0.85</avir:ShareBasedCompensationArrangementPercentageOfPurchasePriceLesserOfMarketPriceOnOfferingDateOrPurchaseDate>
    <avir:ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock
      contextRef="C_b18b1fcf-b3ac-4d66-bbfb-5bd569b10abc"
      decimals="2"
      id="F_97a14069-3f8f-4eee-8540-4c28dcf700bb"
      unitRef="U_pure">0.15</avir:ShareBasedCompensationArrangementPercentageOfDiscountOnPurchasePriceOfCommonStock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_a04dd871-cdfc-4c02-822a-097137132445">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_853d48f4-49ba-4afb-8c38-23a3a3036177">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with equity holders.  For the years ended December 31, 2023 and 2022, the only components of comprehensive loss other than net loss were unrealized gains and losses on available for sale investments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_c80eddcf-5d17-49a1-85bd-7351ac6143d1">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Basic net income loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of shares of common stock outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding common stock equivalents except where such securities would be antidilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <avir:InProcessResearchAndDevelopmentAssetsPolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_3ebf7fa3-6484-4bb3-9911-53f524cc6971">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;In-process Research and Development Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In-process research and development assets that are acquired in a transaction that does not qualify as a business combination under GAAP and that do not have an alternative future use are expensed in the period in which the assets are acquired.&lt;/span&gt;&lt;/p&gt;</avir:InProcessResearchAndDevelopmentAssetsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_aff6a027-bfc0-4cea-9338-c384cca7d978">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#x201c;CODM&#x201d;), in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its chief executive officer, who manages and allocates resources to the operations on a total company basis. Accordingly, there is a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_26675b1d-cb04-4da6-8149-4bb408ad51ca;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; operating segment and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; reportable segment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="INF"
      id="F_e7897746-16f1-48bf-b7d0-edb4c1a0aa9f"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_6e23ad47-7204-4135-b8f6-348c9b32576e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Other accounting standards that have been issued or proposed by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company did not adopt any accounting pronouncements during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_9825d672-5418-4394-a99a-ddcf2e7c49d6">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;3. Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In October 2020, the Company entered into a License Agreement (&#x201c;Roche License Agreement&#x201d;) with F. Hoffmann-LaRoche Ltd. and Genentech, Inc. (together, &#x201c;Roche&#x201d;) under which the Company granted an exclusive license for certain development and commercialization rights related to bemnifosbuvir outside of the United States (other than for certain HCV uses) to Roche.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In November 2021, Roche provided the Company with a notice of termination of the Roche License Agreement which became effective in February 2022.  Upon termination, the rights and licenses granted by the Company to Roche under the Roche License Agreement were returned to the Company, resulting in the Company having all rights to continue the clinical development and future commercialization of bemnifosbuvir worldwide. Global development plan activities and related cost sharing between the parties continued through the effective date of the termination.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The activities to complete the global development plan were accounted for under ASC 808.  Expenses incurred and reimbursements made or received from Roche were accounted for pursuant to ASC 730, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;.  As such, the Company was expensing costs as incurred, including any reimbursements made to Roche, and recognizing reimbursement received from Roche as a reduction of research and development expense through the effective date of the termination.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;For the year ended December 31, 2022, the Company recorded a net credit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,898&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; from Roche. The credit recorded during the year ended December 31, 2022 represents a change in estimate as a result of close out activities and related reporting of amounts incurred by Roche associated with the global development plan. Included in prepaid expenses and other current assets as of December 31, 2022 is a net balance due from Roche of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,060&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;.  For the year ended December 31, 2023, the Company recorded a net credit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,576&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; from Roche. The credit recorded during the year ended December 31, 2023 represents a change in estimate as a result of close out activities and related reporting of amounts incurred by Roche associated with the global development plan. Included in prepaid expenses and other current assets as of December 31, 2023 is a net balance due from Roche of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,904&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. Payment for this amount due was received in February 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <avir:ResearchAndDevelopmentCreditAdjustment
      contextRef="C_9ac4181a-51cc-4958-ac53-7166a997b2a6"
      decimals="-3"
      id="F_2d44c40f-0b40-4997-922e-db1f69c323e9"
      unitRef="U_USD">6898000</avir:ResearchAndDevelopmentCreditAdjustment>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_be71de03-d103-4906-b856-69607d3bce32"
      decimals="-3"
      id="F_df0c6607-ebfb-4973-b313-327e9f8c2af6"
      unitRef="U_USD">1060000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <avir:ResearchAndDevelopmentCreditAdjustment
      contextRef="C_2379ff73-5bee-4de8-86f9-afedc9100f71"
      decimals="-3"
      id="F_67d05e87-825b-4001-afef-4655fad4fee6"
      unitRef="U_USD">18576000</avir:ResearchAndDevelopmentCreditAdjustment>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_bdd23298-c96b-461d-b614-f7ff7d9f6a55"
      decimals="-3"
      id="F_1668040d-46fe-4839-ab3c-1ab6f34ef11c"
      unitRef="U_USD">5904000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_45dbd4a4-09e7-4e0f-9034-5d75eecce2b6">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;4. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.331%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Treasury obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;434,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;578,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.331%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Treasury obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;458,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;625,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company&#x2019;s assets with fair value categorized as Level 1 within the fair value hierarchy include money market accounts which invest in money market funds that are publicly traded mutual funds and are presented as cash equivalents on the consolidated balance sheets as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;There were no transfers among Level 1, Level 2 or Level 3 categories in the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_d4c25d84-4ed0-4425-a953-6b3aacb0e4bf">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.331%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Treasury obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;434,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;578,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.331%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.618%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Treasury obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;458,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;625,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e263b72f-5f38-4b91-b56a-46d57583ec9d"
      decimals="-3"
      id="F_a19d7ae5-c2d4-4775-9c8b-9fa2276596be"
      unitRef="U_USD">143740000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5d94cdb2-afb4-4c89-bda1-0c555813396a"
      decimals="-3"
      id="F_51583379-27c2-40b9-8296-569c00512902"
      unitRef="U_USD">143740000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_74e7c620-e2ac-4ca1-a2bd-90153b3ef496"
      decimals="-3"
      id="F_48900372-e880-4bbd-abf4-ef07f299a8b1"
      unitRef="U_USD">155938000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1d0f79dd-b812-4c0e-ae93-dd31e490b53c"
      decimals="-3"
      id="F_055d5be7-57f1-4357-a47d-6d525d58f257"
      unitRef="U_USD">155938000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_76b14b33-56a4-4cf1-80df-723f41684b40"
      decimals="-3"
      id="F_fb3e9615-ac7d-420f-bfe9-5439fe86c672"
      unitRef="U_USD">178160000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_154ac387-b035-4286-8b39-36a8ea30d163"
      decimals="-3"
      id="F_68024c13-b568-4e13-a658-a323b111bd61"
      unitRef="U_USD">178160000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f787167a-61d9-4235-9630-d8d7035b8ce9"
      decimals="-3"
      id="F_90fa081f-6313-4faf-9ee3-f0757ab8611c"
      unitRef="U_USD">39448000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_31dd3b4f-faf9-41d7-b2d8-342548a15e74"
      decimals="-3"
      id="F_0d4b757b-5dd5-4028-87e4-84b546e81055"
      unitRef="U_USD">39448000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_58bb1f1f-c269-4b19-b52e-f3998d06a8a6"
      decimals="-3"
      id="F_c11b37a7-a19b-4b73-b8cc-f63264214947"
      unitRef="U_USD">60737000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_43bf2db5-6e41-408f-92b7-55c92bcb1e87"
      decimals="-3"
      id="F_0678ebf7-9f2b-4ca2-a8ed-8e01d4344a6e"
      unitRef="U_USD">60737000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_975884e8-2fb7-4e8c-a0e2-9c732451f66c"
      decimals="-3"
      id="F_7c9b011a-d240-4e33-8126-c8e94621152e"
      unitRef="U_USD">143740000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_78f030a1-a021-4e69-b8c8-b89c33ca2f1e"
      decimals="-3"
      id="F_1422ee9f-59b8-495f-8f4d-15562a5466a3"
      unitRef="U_USD">434283000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_c9aa6794-69f4-438f-bc33-fbf3172a097f"
      unitRef="U_USD">578023000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_134ce635-cd15-4e3a-bce0-502a40422357"
      decimals="-3"
      id="F_d582f54a-671e-4f10-b003-7c0ba2385ecc"
      unitRef="U_USD">167584000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f773dd53-698b-4d30-a6b5-df061f6a5858"
      decimals="-3"
      id="F_cee30605-3e16-45f7-818f-b4b6ca651a32"
      unitRef="U_USD">167584000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3e7810ba-ac14-4633-950d-17f455aae7a6"
      decimals="-3"
      id="F_6c7acdb1-cf35-4841-b1b1-8886bbe1dcf9"
      unitRef="U_USD">59118000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_13f35122-e303-4b3d-a59e-14c0c552587f"
      decimals="-3"
      id="F_1c50b786-25c2-4d6d-9907-7de9b2114193"
      unitRef="U_USD">59118000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6b14283c-1b14-4a23-bceb-fe0448f96bd1"
      decimals="-3"
      id="F_9635793e-fd07-44ca-8c5b-578c42cf83eb"
      unitRef="U_USD">14941000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_302fd01a-656a-4ecd-a50f-578a8254ff85"
      decimals="-3"
      id="F_63f20b88-e50a-4799-a2c5-1f35ec982ad7"
      unitRef="U_USD">14941000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5c1df01c-45d9-4b82-b0a8-9c4a4df04fae"
      decimals="-3"
      id="F_cef563cd-fb5c-439b-b34b-50242a62343a"
      unitRef="U_USD">310433000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_aa816b49-5422-4e75-80e8-d75787e65427"
      decimals="-3"
      id="F_f8d77b20-3ee8-4520-b479-9ffd314dc2ce"
      unitRef="U_USD">310433000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0ced1b9b-cadf-4b52-b730-507c4215184a"
      decimals="-3"
      id="F_796a3ad6-7f6f-4664-94f4-c7cffa16c818"
      unitRef="U_USD">61249000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_641d1e37-afd3-4641-8d1a-05bebb533e59"
      decimals="-3"
      id="F_abad9b16-8132-4aa7-9bb5-90e11aceeb8b"
      unitRef="U_USD">61249000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_101c9929-49f6-4ecd-b591-e27524e394d7"
      decimals="-3"
      id="F_6f6524ac-168c-43c9-803d-5f7af846c03a"
      unitRef="U_USD">12508000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_20998f02-abbf-48fb-8f95-9b2494effbb9"
      decimals="-3"
      id="F_40b9e9a5-8359-47b3-8b0b-230a5387089a"
      unitRef="U_USD">12508000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_790b7edc-c301-4076-b9d2-20c39e9f87b1"
      decimals="-3"
      id="F_f82e5da3-8ed5-4825-8601-a878ad1baf73"
      unitRef="U_USD">167584000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_08a2ebd0-8a41-4aeb-aeaf-b254fd869fe7"
      decimals="-3"
      id="F_49e33220-f7ca-47df-9be9-87977ffcdd07"
      unitRef="U_USD">458249000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_d5f5fe23-e7f7-492a-a9ae-904c0fd9f12c"
      unitRef="U_USD">625833000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_80bd91a1-3741-48c1-a663-1849567cd2b0">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;5. Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.57%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.081999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.081999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.081999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.982%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Treasury obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;434,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;434,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.57%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.081999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.081999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.081999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.982%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Treasury obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;458,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;458,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, respectively the Company held&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; s&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;ecurities, respectively that were in an unrealized loss position of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; with an aggregate fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,003&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,221&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;.  The Company has the intent and ability to hold such securities until recovery. As a result, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;t&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; record any charges for credit-related impairments for its marketable debt securities for the year ended December 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;none&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; of the securities had remaining maturities longer than one year.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company received proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;602,665&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,885&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; from sales and maturities of marketable securities during the year ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_9c6670ca-ed92-425e-82c8-e7d9d9fc2c9b">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.57%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.081999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.081999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.081999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.982%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Treasury obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;434,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;434,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.57%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.081999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.081999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.081999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.982%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Treasury obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;US Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;61,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:28pt;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="margin-left:28pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;458,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;458,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1d0f79dd-b812-4c0e-ae93-dd31e490b53c"
      decimals="-3"
      id="F_29440dee-35a4-4e07-963b-1098b21baffd"
      unitRef="U_USD">155816000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_1d0f79dd-b812-4c0e-ae93-dd31e490b53c"
      decimals="-3"
      id="F_372a3e09-777c-4456-be38-2d85968e8588"
      unitRef="U_USD">145000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1d0f79dd-b812-4c0e-ae93-dd31e490b53c"
      decimals="-3"
      id="F_8062e00a-f0bb-4a6a-9aec-d7b04059b1bf"
      unitRef="U_USD">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1d0f79dd-b812-4c0e-ae93-dd31e490b53c"
      decimals="-3"
      id="F_741d333e-5a8c-452f-8215-ecb98177dc14"
      unitRef="U_USD">155938000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_154ac387-b035-4286-8b39-36a8ea30d163"
      decimals="-3"
      id="F_c0cfd4e7-f886-43d3-b7e1-7069a608f877"
      unitRef="U_USD">178115000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_154ac387-b035-4286-8b39-36a8ea30d163"
      decimals="-3"
      id="F_8b5bab4b-41fe-466e-ba47-f9e30ce36a27"
      unitRef="U_USD">96000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_154ac387-b035-4286-8b39-36a8ea30d163"
      decimals="-3"
      id="F_23ae1d7c-77f3-4ecd-aada-c6d78f7cf21b"
      unitRef="U_USD">51000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_154ac387-b035-4286-8b39-36a8ea30d163"
      decimals="-3"
      id="F_784438ff-a456-42b0-a655-72ffb2ed0f74"
      unitRef="U_USD">178160000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_31dd3b4f-faf9-41d7-b2d8-342548a15e74"
      decimals="-3"
      id="F_01592796-b6dd-4e9a-9dc0-e38753cec242"
      unitRef="U_USD">39461000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_31dd3b4f-faf9-41d7-b2d8-342548a15e74"
      decimals="-3"
      id="F_28d85787-715f-44d3-ad0f-13fd2b560732"
      unitRef="U_USD">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_31dd3b4f-faf9-41d7-b2d8-342548a15e74"
      decimals="-3"
      id="F_189c7b2e-bf48-4cbb-abd1-aa0c18e36511"
      unitRef="U_USD">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_31dd3b4f-faf9-41d7-b2d8-342548a15e74"
      decimals="-3"
      id="F_089620e8-9bb6-4cc5-a9ca-dca117d3a11f"
      unitRef="U_USD">39448000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_43bf2db5-6e41-408f-92b7-55c92bcb1e87"
      decimals="-3"
      id="F_1e06bd5b-5303-401f-9b43-5209c4b21e1c"
      unitRef="U_USD">60684000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_43bf2db5-6e41-408f-92b7-55c92bcb1e87"
      decimals="-3"
      id="F_3a75d11a-6ed4-4fff-b5fb-db8263fe7f93"
      unitRef="U_USD">65000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_43bf2db5-6e41-408f-92b7-55c92bcb1e87"
      decimals="-3"
      id="F_957dee73-40fb-4918-884d-fe4c7d4918c7"
      unitRef="U_USD">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_43bf2db5-6e41-408f-92b7-55c92bcb1e87"
      decimals="-3"
      id="F_b86a5644-19a3-4015-9169-6b77fc11b011"
      unitRef="U_USD">60737000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_7f10212a-59e7-4cc1-b7ca-64e915bcad67"
      unitRef="U_USD">434076000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_2e361cae-5b54-40d9-8c37-23d347381554"
      unitRef="U_USD">320000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_e06aafcf-a610-4e1d-a433-f55ec967f569"
      unitRef="U_USD">113000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_ccdc3607-8726-4ca4-8ee8-cce56d351c02"
      unitRef="U_USD">434283000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_13f35122-e303-4b3d-a59e-14c0c552587f"
      decimals="-3"
      id="F_4c4e3306-f9a4-4537-bed9-453fcf923ef8"
      unitRef="U_USD">59422000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_13f35122-e303-4b3d-a59e-14c0c552587f"
      decimals="-3"
      id="F_09bf4e85-01d4-425b-b9ad-fe9d86866c1f"
      unitRef="U_USD">304000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_13f35122-e303-4b3d-a59e-14c0c552587f"
      decimals="-3"
      id="F_f391b32e-8ce8-433e-8241-32850c0ecd44"
      unitRef="U_USD">59118000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_302fd01a-656a-4ecd-a50f-578a8254ff85"
      decimals="-3"
      id="F_ac5d4c53-9a0c-44f2-bf53-2ea58a20d35d"
      unitRef="U_USD">15000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_302fd01a-656a-4ecd-a50f-578a8254ff85"
      decimals="-3"
      id="F_28ace0ac-d43a-42ba-9db1-35c5d78dd2de"
      unitRef="U_USD">59000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_302fd01a-656a-4ecd-a50f-578a8254ff85"
      decimals="-3"
      id="F_b877bc69-aede-45c7-8a7f-22510a3001ea"
      unitRef="U_USD">14941000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_aa816b49-5422-4e75-80e8-d75787e65427"
      decimals="-3"
      id="F_2cd4cba0-7d2f-4e20-8e7b-653703fd5381"
      unitRef="U_USD">310433000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_aa816b49-5422-4e75-80e8-d75787e65427"
      decimals="-3"
      id="F_ce868b20-3ab3-4784-9f0b-9f7b8bb1fc2a"
      unitRef="U_USD">310433000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_641d1e37-afd3-4641-8d1a-05bebb533e59"
      decimals="-3"
      id="F_ab8ae984-d521-4d3c-9bc0-aa70fef4755c"
      unitRef="U_USD">61504000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_641d1e37-afd3-4641-8d1a-05bebb533e59"
      decimals="-3"
      id="F_16ed42be-d641-48aa-90dd-307b69581901"
      unitRef="U_USD">255000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_641d1e37-afd3-4641-8d1a-05bebb533e59"
      decimals="-3"
      id="F_e28cf1b0-b1b2-4309-b5c2-937d0ac12825"
      unitRef="U_USD">61249000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_20998f02-abbf-48fb-8f95-9b2494effbb9"
      decimals="-3"
      id="F_a9cd0d34-f3c8-49b6-96af-fe0e2ba44103"
      unitRef="U_USD">12574000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_20998f02-abbf-48fb-8f95-9b2494effbb9"
      decimals="-3"
      id="F_cd62fb67-47ac-4053-aa67-e2a388823133"
      unitRef="U_USD">66000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_20998f02-abbf-48fb-8f95-9b2494effbb9"
      decimals="-3"
      id="F_ec7e05d3-9bfb-47b1-810c-37ce1fdfb06e"
      unitRef="U_USD">12508000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_7e15687f-8d95-4287-89b6-a9cb2799f7ec"
      unitRef="U_USD">458933000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_5e82c3a9-fbc3-4fdf-89d6-81dc3aface3c"
      unitRef="U_USD">684000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_f2e6f1b7-6254-4fa4-a538-ee9afaf09f72"
      unitRef="U_USD">458249000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_337147ef-fee3-403c-9751-283f6725a803"
      unitRef="U_Security">26</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="INF"
      id="F_c646730d-0309-4dfb-b2a8-078a313648a9"
      unitRef="U_Security">15</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_36d211b0-d4fc-4edd-8c41-5fdbe4951613"
      unitRef="U_USD">113000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_6a670b0e-1de6-4f20-bd40-82b8040d56b2"
      unitRef="U_USD">684000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_c1978598-3d36-4886-8730-4641a8f2357a"
      unitRef="U_USD">178003000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_9802e92f-057f-4432-b606-6329d1f6ceed"
      unitRef="U_USD">143221000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="INF"
      id="F_6547aab6-b7d0-4f22-94d8-fa5ee2f05107"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="INF"
      id="F_49c904b4-53c7-416d-821f-c6af0c805c88"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_788c52eb-af13-447a-b9f1-cad197d4870d"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="INF"
      id="F_c28a0383-01b3-4753-903b-0b9465245dbe"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_ea4b506b-f26c-43a3-bce7-e85e235d703d"
      unitRef="U_USD">602665000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_b32b84a0-ea1c-46f2-9018-34075803e316"
      unitRef="U_USD">91885000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_0aa81bf8-6c1d-48a6-9923-0dcdbb9218d1">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;6. Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Property and equipment, net, consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Computer hardware&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total property and equipment, at cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Depreciation and amortization expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;416&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;260&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_e7218537-a89a-454c-8599-1f1e2097f0e0">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Property and equipment, net, consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Computer hardware&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total property and equipment, at cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7d2d29de-6d0b-4b53-b56c-521ea942b78d"
      decimals="-3"
      id="F_645dc7f3-c85a-47b7-b69c-007299a6f8f5"
      unitRef="U_USD">5000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_24dbddef-dc7c-4756-ab44-6dbdef0b512c"
      decimals="-3"
      id="F_81e41b3d-a0d5-4a67-9a8c-89d12b723975"
      unitRef="U_USD">5000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6399a783-fb32-4189-8185-57a59a53f325"
      decimals="-3"
      id="F_332c40e9-3597-40b8-b139-57db2e7a8e72"
      unitRef="U_USD">396000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e3c8ea54-34b8-4665-bdf3-a8dcf0a0cfef"
      decimals="-3"
      id="F_4a810d70-7588-4da4-9cb4-d182a0b7902c"
      unitRef="U_USD">396000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c7618177-dbbf-4f5e-963a-5fa2381e45b8"
      decimals="-3"
      id="F_01c4747c-84b2-410d-83fb-7e208dc233d6"
      unitRef="U_USD">102000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_436595f0-3519-4a55-81e8-9e4c814063e3"
      decimals="-3"
      id="F_5e14d9c9-f177-4abb-a0fd-8346f28a6a92"
      unitRef="U_USD">102000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bb842308-4e24-47f1-9016-a28f5d33ba86"
      decimals="-3"
      id="F_41edcc89-3e1d-46f0-8da3-2df89bd2a8df"
      unitRef="U_USD">1475000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_34dd0c12-849b-4618-af9e-a655ab282d18"
      decimals="-3"
      id="F_889d67a0-09a6-454e-b228-5bbb70bf5277"
      unitRef="U_USD">1475000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_fdd08849-d96f-4c65-a29f-59ad66aca71f"
      unitRef="U_USD">1978000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_528cba5a-35ce-4c0b-a688-9b0ac014eae3"
      unitRef="U_USD">1978000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_0d32d811-8405-49eb-9294-ca013a20b046"
      unitRef="U_USD">689000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_6e8639b5-e065-4b55-97d9-1c19d85b34b2"
      unitRef="U_USD">273000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_373d3c98-bd91-4e1c-a721-98840319d260"
      unitRef="U_USD">1289000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_435f0b0c-0d49-41ae-bdc7-2d10fc34065e"
      unitRef="U_USD">1705000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_8d7325de-2290-4c9b-a393-a9b1edd564d0"
      unitRef="U_USD">416000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_f49397e1-fcbf-4ee5-935e-101e40ebbf49"
      unitRef="U_USD">260000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_a8834a68-0c1c-4680-8fba-916445061516">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;7. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Research and development, including manufacturing and clinical expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Payroll and payroll related&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Professional fees and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_31da7853-9221-4700-804e-2f51524c499d">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Research and development, including manufacturing and clinical expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Payroll and payroll related&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Professional fees and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <avir:AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_b1f79f1e-8268-416f-a123-03b569da9eaa"
      unitRef="U_USD">20999000</avir:AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent>
    <avir:AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_424c8a1c-1453-4a03-8011-b9d43c1538b6"
      unitRef="U_USD">7667000</avir:AccruedResearchAndDevelopmentExpenseIncludingManufacturingAndClinicalExpendituresCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_500d9147-8504-4b95-8588-355a7ba3c0a5"
      unitRef="U_USD">99000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_f9212bb2-4085-497b-8674-145087e75b36"
      unitRef="U_USD">5696000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_5b440ab4-c7d6-4207-ac41-7c34adb7b3f2"
      unitRef="U_USD">6459000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <avir:AccruedProfessionalFeesAndOtherCurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_132a72f7-19f4-4baf-8eb1-f1f57b960f3a"
      unitRef="U_USD">669000</avir:AccruedProfessionalFeesAndOtherCurrent>
    <avir:AccruedProfessionalFeesAndOtherCurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_b03825e3-eb74-4a53-8dfc-6550c5bd19c6"
      unitRef="U_USD">981000</avir:AccruedProfessionalFeesAndOtherCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_090b69a2-4654-4783-896b-d240cabc2aa8"
      unitRef="U_USD">27364000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_0eb74c8e-97b6-4ae9-ab2d-46b530fdf0d7"
      unitRef="U_USD">15206000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_97315cdd-a20d-420e-ac7b-29b5e8f97cc6">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;8. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Operating Lease Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In July 2021, the Company entered into a non-cancelable operating lease agreement pursuant to which the Company leased its principal office facility in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Boston, Massachusetts at 225 Franklin Street&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; ("225 Lease"). The 225 Lease commencement date was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and runs through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;December 31, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. The 225 Lease does &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;t contain any options for renewal or extension.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In connection with the 225 Lease commencement, the Company recorded a ROU asset and operating lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,938&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,873&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; as of January 1, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The following assets and liabilities are recorded on the Company&#x2019;s consolidated balance sheet as of December 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Current operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Non-current operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The components of the lease expense which are allocated between the general and administrative expenses and the research and development expenses on the consolidated statement of operations for the years ended December 31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The variable lease costs for the years ended December 31, 2023 and 2022 include common area maintenance and other operating charges associated with the 225 Lease. As the 225 Lease does not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company estimates it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;As of   December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Future minimum payments under the 225 Lease, currently the Company&#x2019;s only operating lease as of December 31, 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Less amount representing implied interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Noncurrent portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Rent expense recognized was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;811&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company maintains a deposit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; with the landlord, which is included in other assets in the consolidated balance sheet as of December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;      &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In December 2021, the Company entered into a license agreement (&#x201c;Merck License Agreement&#x201d;) with MSD International GmbH, an affiliate of Merck &amp;amp; Co, Inc. (&#x201c;Merck&#x201d;) for the development, manufacture and commercialization of ruzasvir. Ruzasvir is the NS5A inhibitor the Company is developing in combination with bemnifosbuvir for the treatment of HCV.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Pursuant to the terms of the Merck License Agreement, the Company obtained from Merck a worldwide exclusive (subject to certain reserved rights to conduct internal research) and, sublicensable license under certain Merck patents and know-how to research, develop, manufacture, have manufactured, use, import, export, sell, offer for sale, and otherwise commercialize ruzasvir or products containing ruzasvir (each a &#x201c;Product&#x201d;) for all therapeutic or prophylactic uses in humans.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In addition to a non-refundable upfront payment that the Company made in February 2022, the Company will be required to pay Merck milestone payments upon its achievement of certain development, regulatory and sales-based milestones.  Additionally, the Company will pay Merck tiered royalties based on annual net sales of Products ranging from high single digits to mid-teens percentages. The Company&#x2019;s royalty payment obligations will continue until the later of (i) the expiration of the last to expire valid claim of a licensed Merck patent claiming such Product and (ii) a period of years after the first commercial sale of such Product in such country. The Company may terminate the Merck License Agreement for convenience upon prior written notice. The first potential milestone in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million would be payable upon the commencement of a Phase 3 clinical trial.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Contingent Consulting Fee&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company has an agreement with a consultant that requires payment of a success fee calculated as a percentage of certain product sales, subject to a cumulative maximum payout of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; million. This success payment is contingent upon the occurrence of future events and the timing and likelihood of such payment is neither probable nor estimable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Indemnification&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company enters into certain types of contracts that contingently requires the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i) the Company&#x2019;s bylaws, under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship with the Company, (ii) contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship with the Company, and (iii) procurement, service or license agreements under which the Company may be required to indemnify vendors, service providers or licensees for certain claims, including claims that may be brought against them arising from the Company&#x2019;s acts or omissions with respect to the Company&#x2019;s products, technology, intellectual property or services.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on the Company&#x2019;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount payable under these contracts since the Company has no history of prior indemnification claims and the unique facts and circumstances involved in each particular claim will be determinative.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <avir:LocationOfOfficeSpace
      contextRef="C_ff6f76c6-f05a-4d88-acf9-a3905001881d"
      id="F_c83a68e4-3b60-43f3-8b2a-e562c48315f9">Boston, Massachusetts at 225 Franklin Street</avir:LocationOfOfficeSpace>
    <avir:LeaseCommencementDate
      contextRef="C_38c339a5-7c33-4fe4-88f1-30dc3c9078f4"
      id="F_cd22c577-a2f7-4c31-8f8c-918a0978e9d8">2022-01-01</avir:LeaseCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_38c339a5-7c33-4fe4-88f1-30dc3c9078f4"
      id="F_7a0aa768-5dac-481b-8e09-fc1dc731f62c">2026-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LessorOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_ff6f76c6-f05a-4d88-acf9-a3905001881d"
      id="F_7ff9d6db-140f-430b-8c09-864e90dd9fd1">false</us-gaap:LessorOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c7289ade-105d-4563-a9d4-f2ae3de82763"
      decimals="-3"
      id="F_b9655c65-409b-4a39-9ba4-4c93f6cb224f"
      unitRef="U_USD">2938000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_c7289ade-105d-4563-a9d4-f2ae3de82763"
      decimals="-3"
      id="F_9ba12abf-38b9-464f-b08e-196d559a8476"
      unitRef="U_USD">2873000</us-gaap:OperatingLeaseLiability>
    <avir:SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_ee02be4a-5c7c-4ef2-b546-0837ad4e8194">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The following assets and liabilities are recorded on the Company&#x2019;s consolidated balance sheet as of December 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Current operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Non-current operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</avir:SupplementalDisclosureOfBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_7fd1603e-ec2d-4aa4-ae1f-6af84539257e"
      unitRef="U_USD">1828000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_5fd5b578-6d61-45b0-9d8e-3c772063c0fc"
      unitRef="U_USD">2389000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_544740b0-f0e4-4735-bc2e-4a7eadec589d"
      unitRef="U_USD">760000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_d4c7fa78-dc01-437a-9c7d-3e7b791564b5"
      unitRef="U_USD">721000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_30170752-252e-40a8-91e9-65db8e57bc68"
      unitRef="U_USD">1642000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_8ee54d4a-a05b-4324-8d54-65b65bb21139"
      unitRef="U_USD">2403000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_d98fffe2-7c36-4d95-82ee-40d8e37fff97">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The components of the lease expense which are allocated between the general and administrative expenses and the research and development expenses on the consolidated statement of operations for the years ended December 31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_235a16e6-c916-45aa-bd8d-dd8c7e303793"
      unitRef="U_USD">646000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_c7f9256f-8f7e-4b59-a418-bca17db769ae"
      unitRef="U_USD">811000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_635a4c6b-7ba6-470c-9a57-7accbb47fa6c"
      unitRef="U_USD">40000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_a7fe933a-3a08-42e6-9f4f-7f8aff5b000a"
      unitRef="U_USD">78000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_1e07d2dd-3b14-4f5b-82b0-7d8ccf585e2a"
      unitRef="U_USD">686000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_51b4b68e-a679-44f7-b7bc-1437f7c6c340"
      unitRef="U_USD">889000</us-gaap:LeaseCost>
    <avir:SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_17e24753-680b-4bee-9f53-29edbc6682c2">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The variable lease costs for the years ended December 31, 2023 and 2022 include common area maintenance and other operating charges associated with the 225 Lease. As the 225 Lease does not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company estimates it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;As of   December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</avir:SummaryOfRemainingLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      id="F_891ea9ad-03c6-4043-b4df-1107880165cc">P3Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      id="F_63a0d799-75d8-4d6c-826e-da6d48cb3340">P4Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="3"
      id="F_c3608b87-d906-47e2-aac9-5bce7f03f071"
      unitRef="U_pure">0.031</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="3"
      id="F_f203e1df-7dd6-4ce7-b819-ade617ac524a"
      unitRef="U_pure">0.031</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_f9a332a5-c22b-4ff8-8edf-d482850b49f4">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Future minimum payments under the 225 Lease, currently the Company&#x2019;s only operating lease as of December 31, 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Less amount representing implied interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Noncurrent portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_bc5bf564-b256-4c97-a1b0-4de2c3954baa"
      unitRef="U_USD">821000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_b5ef9423-d6f0-4b88-a93b-b2f32d13a626"
      unitRef="U_USD">838000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_0b959a39-8490-4539-b8c0-b59eb193819e"
      unitRef="U_USD">855000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_e9ff65ee-d2c6-4194-850b-17a3f33190ea"
      unitRef="U_USD">2514000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_14ba5738-a687-4a3a-b1a9-b696b630fb0d"
      unitRef="U_USD">112000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_d6fa84ca-ef27-44de-858c-656c5e7da4ae"
      unitRef="U_USD">2402000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_ea9aa31e-9ac9-4719-ba99-ee07e976f907"
      unitRef="U_USD">760000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_8335e7f8-83f4-421a-920b-6dfbfb9b95e2"
      unitRef="U_USD">1642000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_8d62d8e6-9014-4556-b47f-a4c2f4ec9842"
      unitRef="U_USD">646000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_eddbb8a5-9d18-4e69-b14a-3c7ee730fac5"
      unitRef="U_USD">811000</us-gaap:OperatingLeaseExpense>
    <avir:BankDepositRestrictedCash
      contextRef="C_8e5a6e9b-41ce-4bde-b88a-39f1e3b103e8"
      decimals="-3"
      id="F_15fa4d4f-a6f8-489f-99f7-620121534ff9"
      unitRef="U_USD">198000</avir:BankDepositRestrictedCash>
    <avir:MilestonePayments
      contextRef="C_6ee4d578-76e6-43b0-9c50-08cb7a6fb76d"
      decimals="-5"
      id="F_7cb00ab7-6a19-4afe-92e4-618ff9ff5cba"
      unitRef="U_USD">5000000</avir:MilestonePayments>
    <avir:ConsultingAgreementSuccessFeePayout
      contextRef="C_2f732af4-d836-404e-a933-0b892aefa2ad"
      decimals="INF"
      id="F_1b906fc6-1eb9-4d4d-b4c3-dbde60fd6f51"
      unitRef="U_USD">5000000</avir:ConsultingAgreementSuccessFeePayout>
    <us-gaap:PreferredStockTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_21923dfc-2fdf-4758-9ee0-4976251b679b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;9. Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2023 the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares of preferred stock authorized.  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; of these shares of preferred stock have been issued.&lt;/span&gt;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_71731f46-27a7-41f9-9f5d-2c744f784c8c"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_aa2cb6f8-0676-4a58-9cbb-a39373701cdf"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <avir:CommonStockTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_3a5f30d2-b49c-4305-be05-4f4e706ccf56">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;10. Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2023, the authorized capital of the Company included &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares of common stock, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,435,513&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares of common stock were issued and outstanding.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;On all matters to be voted upon by the holders of common stock, holders of common stock are entitled to one vote per share.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; The holders of common stock are entitled to receive dividends, when declared by the board, and to share ratably in the Company&#x2019;s assets legally available for distribution to the holders of the Company&#x2019;s stock in the event of liquidation. The holders of common stock have no preemptive, redemption or conversion rights.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2023, the Company had the following reserved shares of common stock:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Outstanding options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,017,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Outstanding restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,337,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Outstanding performance-based restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;724,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Shares reserved for future grant under 2020 Incentive Award Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,510,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Shares reserved under Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,896,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,487,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</avir:CommonStockTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_347f12f0-4b0e-4db3-9162-75389acf18ab"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="0"
      id="F_1e5999c8-cc4b-4a38-a8a9-827ecd483250"
      unitRef="U_shares">83435513</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="0"
      id="F_c1ee40bf-7900-401f-ae3e-ac829b39006d"
      unitRef="U_shares">83435513</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_41fc8f81-3942-4553-9c91-e88b6e38bd5d">On all matters to be voted upon by the holders of common stock, holders of common stock are entitled to one vote per share.</us-gaap:CommonStockVotingRights>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_cdce23d6-bff9-4a90-af02-9f1a8958e198">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2023, the Company had the following reserved shares of common stock:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Outstanding options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,017,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Outstanding restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,337,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Outstanding performance-based restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;724,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Shares reserved for future grant under 2020 Incentive Award Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,510,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Shares reserved under Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,896,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,487,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_be3c9676-01ad-494a-ba2a-56772d6be054"
      decimals="INF"
      id="F_016a7eff-ebae-495a-900a-29b7e353d06b"
      unitRef="U_shares">17017319</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_bdc446e2-c3c8-45df-b44f-251b2b84015d"
      decimals="INF"
      id="F_9b5c03a3-fae7-4265-87e8-6dc1eb31e9ae"
      unitRef="U_shares">2337517</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e51f2865-c244-4aee-985f-6b147207f1c6"
      decimals="INF"
      id="F_89943ec7-a8ed-4d1b-93d3-77e6cafeb1bb"
      unitRef="U_shares">724970</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_79bea9f4-f71d-40b2-9f73-0182a669f7ed"
      decimals="INF"
      id="F_f350e034-c7ba-4293-a07c-c635b7223435"
      unitRef="U_shares">6510704</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4121b4df-602e-41a1-a327-97cd041787d0"
      decimals="INF"
      id="F_81fdf336-08a5-4c27-aae5-c3b175c22e6e"
      unitRef="U_shares">1896901</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_3da47908-6c12-4700-80e0-5e8662a1252b"
      unitRef="U_shares">28487411</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_5daed8b8-9947-48e7-b930-5c6ded755ed4">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;11. Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In October 2020, the Company&#x2019;s shareholders approved the Company&#x2019;s 2020 Incentive Award Plan (&#x201c;2020 Plan&#x201d;). The 2020 Plan initially provided for the issuance of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,924,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares of common stock and for the grant of incentive stock options or other incentive awards to employees, officers, directors and consultants of the Company. The number of shares of common stock that may be issued under the 2020 Plan is also subject to increase on the first day of each calendar year equal to the lesser of i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year or ii) such smaller number of shares as is determined by the board of directors. Through December 31, 2023, the shares available under the plan were increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,450,364&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares.  As of December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,510,704&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares of common stock were available for future issuance under the 2020 Plan. In January 2024, the shares of the Company's common stock available under the 2020 Plan were increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,171,775&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The 2020 Plan replaced and is the successor of the Company&#x2019;s 2013 Equity Incentive Plan, as amended (&#x201c;2013 Plan&#x201d;).  In the event of any cancellation of an outstanding option award under the 2013 Plan, the shares underlying the cancelled option award will be made available for grant under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;During the year ended December 31, 2023 and 2022, respectively, the Company granted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,264,700&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;182,350&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; restricted stock units to employees with an aggregate grant date fair market value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,384&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,302&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The restricted stock unit awards vest in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; annual installments. In January 2023, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,935&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares of common stock upon the vesting and settlement of restricted stock units. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;During the year ended December 31, 2023 and 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,998&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,600&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; restricted stock units were cancelled due to employee terminations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Arial;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,264,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Unvested shares at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,337,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Performance-based Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; performance-based restricted stock units were granted during the year ended December 31, 2023. During the year ended December 31, 2022, the Company granted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;742,070&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; performance-based restricted stock units to employees with an aggregate grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,298&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;.  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; performance-based restricted stock units were granted during the year ended December 31, 2023.  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The performance stock unit awards provide for a performance period from February 1, 2022 through January 31, 2025 to achieve up to six defined performance metrics.  The percentage of each award eligible to vest will be determined based on the number of metrics achieved during the performance period and may range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;%. The Company has not recognized any compensation expense through December 31, 2023, as the minimum performance criteria had not been deemed probable. The vesting of any eligible awards will occur in equal installments on January 31, 2025 and January 31, 2026.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;During the year ended December 31, 2023, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; cancellations of performance-based restricted stock units.  During the year ended December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; performance-based restricted stock units were cancelled due to employee terminations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;724,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Release&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Unvested shares at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;724,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The following summarizes stock option activity:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.602%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.001999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.602%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;($000s)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,632,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,777,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;392,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,017,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,017,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Vested and exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,084,169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of the options and the estimated fair value of the Company&#x2019;s common stock for those options that had exercise prices lower than the fair value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Option grants generally vest over a service period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="-sec-ix-hidden:F_09624d57-9bf3-4359-9740-b83c401c942c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and have a contractual term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;. As of December 31, 2023, total unrecognized compensation expense related to stock option awards was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,157&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, which amount is being recognized over a remaining weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The weighted average grant date fair value per option granted during the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.09&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, respectively. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The fair value of each award was estimated using &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Black-Scholes&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; based on the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;For the Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.97&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.96&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:3pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In October 2020, the Company&#x2019;s shareholders approved the ESPP, which became effective upon the closing of the Company&#x2019;s IPO in November 2020. The Company initially reserved a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,187,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares of its common stock for issuance under the ESPP. The ESPP provides that the number of shares reserved and available for issuance under the ESPP will be increased on January 1 of each calendar year by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding December 31 or such lesser amount as specified by the board of directors. Through December 31, 2022, there was no increase in the number of shares reserved for issuance under the ESPP.  In January 2024 and 2023, the number of shares of the Company's common stock available for issuance under the ESPP was increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;834,355&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;832,876&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,939&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,036&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares for proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;257&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Stock-based compensation expense is classified as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;For the Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The components of stock-based compensation expense were:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;For the Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_8ba33c50-6a8d-4f09-b491-7da8f49a8f50"
      decimals="INF"
      id="F_ef6f1b7d-d27b-4ce6-badf-2dca06f20e4c"
      unitRef="U_shares">7924000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage
      contextRef="C_c9b4d51c-a9e8-4986-afd4-c57dce1daa35"
      decimals="2"
      id="F_21c08040-e926-452f-936d-444a3afa433e"
      unitRef="U_pure">0.05</avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_81ef7f57-de18-4346-8a86-4f826a99b8fb"
      decimals="INF"
      id="F_2d5aaff5-9488-4fd5-b6a8-27433101ad1f"
      unitRef="U_shares">12450364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_aa0a55b5-ae8d-454b-abaa-c3998b787bed"
      decimals="INF"
      id="F_52c6614a-7ec4-4b52-bc1e-0cdf562e5bf2"
      unitRef="U_shares">6510704</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_b7a5ba3b-2c98-40aa-a0e2-a6986cac7344"
      decimals="INF"
      id="F_a57c7a47-3bde-418a-9e56-9d8b7dd94107"
      unitRef="U_shares">4171775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21"
      decimals="INF"
      id="F_c1169695-8488-4773-bd08-b802bd5736c3"
      unitRef="U_shares">2264700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_ac643507-3356-46e0-b8b6-3ce7ebaa7b58"
      decimals="INF"
      id="F_c40f25c4-1f95-40ef-8475-1c7b37e67555"
      unitRef="U_shares">182350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue
      contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21"
      decimals="-3"
      id="F_084e27f3-7af4-4123-9e79-5e3e2938ca13"
      unitRef="U_USD">10384000</avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue>
    <avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue
      contextRef="C_ac643507-3356-46e0-b8b6-3ce7ebaa7b58"
      decimals="-3"
      id="F_9d5241a8-714c-45e6-95f7-df576425a4b4"
      unitRef="U_USD">1302000</avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue>
    <avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments
      contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21"
      decimals="INF"
      id="F_b8ac369d-9c78-4d9d-baf2-04bb3a3e042b"
      unitRef="U_Installment">3</avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfInstallments>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_ec7ec460-3701-487b-868d-61c2b3b9856f"
      decimals="INF"
      id="F_888dc4b7-dd80-4c66-a9d3-2ccf85af7636"
      unitRef="U_shares">53935</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21"
      decimals="INF"
      id="F_0a976076-baf7-441c-a2be-667ad4c0e1a8"
      unitRef="U_shares">34998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_ac643507-3356-46e0-b8b6-3ce7ebaa7b58"
      decimals="INF"
      id="F_f98af60e-c30b-4f2f-9097-2132ea40c233"
      unitRef="U_shares">20600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21"
      id="F_5d705137-b457-4b58-ac6d-10633dc7e6a3">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,264,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Unvested shares at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,337,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_c43a7923-c261-4651-bc39-5f0700559de8"
      decimals="INF"
      id="F_f6135a72-103d-4b23-bd73-5484ae055e40"
      unitRef="U_shares">161750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_c43a7923-c261-4651-bc39-5f0700559de8"
      decimals="2"
      id="F_ec361541-4dc3-43df-bb9c-756aa6ee4102"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21"
      decimals="INF"
      id="F_987f43ec-a5ad-4e9d-b3f4-5b8f263e4a5a"
      unitRef="U_shares">2264700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21"
      decimals="2"
      id="F_449da4b3-9705-47ff-8821-9717466ed52b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod
      contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21"
      decimals="INF"
      id="F_a15d298a-16c8-4429-8eee-1ba0379dcbce"
      unitRef="U_shares">53935</avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod>
    <avir:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21"
      decimals="2"
      id="F_0fd96214-874d-431f-9364-eef539989241"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.14</avir:ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionReleasedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21"
      decimals="INF"
      id="F_7b5badcd-139a-47cf-9c70-fa4fc1f1af25"
      unitRef="U_shares">34998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21"
      decimals="2"
      id="F_bbf4b843-ac78-4598-8c3f-1ed4b4872f34"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_bfb5c27a-df03-47f9-a4cd-6d0ff368feee"
      decimals="INF"
      id="F_67f96eca-4ac6-4c88-8845-1114350ab643"
      unitRef="U_shares">2337517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_bfb5c27a-df03-47f9-a4cd-6d0ff368feee"
      decimals="2"
      id="F_0f47007d-6830-4381-8697-8c7ad546d7e9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_8d744964-680d-40b2-ba6f-5c4572c15939"
      decimals="INF"
      id="F_568ca551-8c37-4561-867b-2cab028342e7"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_2b6262d6-cb17-47e6-a290-98609c2cd44a"
      decimals="INF"
      id="F_281b87f3-3da2-4641-8920-6a1ed8a85915"
      unitRef="U_shares">742070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue
      contextRef="C_2b6262d6-cb17-47e6-a290-98609c2cd44a"
      decimals="-3"
      id="F_5250af10-5001-4948-8f5e-ca9a148bec67"
      unitRef="U_USD">5298000</avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodAggregateGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_8d744964-680d-40b2-ba6f-5c4572c15939"
      decimals="INF"
      id="F_0b19c8d4-da9f-486b-8fce-797f92fc3a7c"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="C_8d744964-680d-40b2-ba6f-5c4572c15939"
      id="F_0a641f7e-3594-4fd7-b674-b21de84760f3">The performance stock unit awards provide for a performance period from February 1, 2022 through January 31, 2025 to achieve up to six defined performance metrics.  The percentage of each award eligible to vest will be determined based on the number of metrics achieved during the performance period and may range from 0% to 200%. The Company has not recognized any compensation expense through December 31, 2023, as the minimum performance criteria had not been deemed probable. The vesting of any eligible awards will occur in equal installments on January 31, 2025 and January 31, 2026.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_86685938-2c65-4dd3-9449-fcecbd25ce2f"
      decimals="INF"
      id="F_480535c5-3aba-469a-8b35-82db724f90c2"
      unitRef="U_pure">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_c6080656-f365-4660-9a2e-1abe8d881a2c"
      decimals="INF"
      id="F_b97190e4-ae89-4822-ad40-ff636079eac9"
      unitRef="U_pure">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_8d744964-680d-40b2-ba6f-5c4572c15939"
      decimals="INF"
      id="F_6d43ac76-ce91-4bb1-9c66-e94277b8838a"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_2b6262d6-cb17-47e6-a290-98609c2cd44a"
      decimals="INF"
      id="F_766884b5-87ab-4741-b5ec-a6abe40ade10"
      unitRef="U_shares">17100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_8d744964-680d-40b2-ba6f-5c4572c15939"
      id="F_742a15a0-5e57-4e84-9c0a-2a11425fd180">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.66%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;724,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Release&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Unvested shares at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;724,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_95e99b78-705a-4c5a-8427-757b8ec386de"
      decimals="INF"
      id="F_9ddb148c-9be0-4228-9d2f-728bb5176be8"
      unitRef="U_shares">724970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_95e99b78-705a-4c5a-8427-757b8ec386de"
      decimals="INF"
      id="F_f14f87ca-f4be-4cbb-9127-fcd578f335b1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_90c6d8d7-56c9-490c-bdcc-72c602e51c09"
      decimals="INF"
      id="F_b432a0eb-4ca1-4389-b62c-eba4e40272cc"
      unitRef="U_shares">724970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_90c6d8d7-56c9-490c-bdcc-72c602e51c09"
      decimals="2"
      id="F_988f0267-b9c2-48a3-828d-c706fa9b4041"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_4eb9567f-d765-4fd4-9005-cb96787e2c20">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The following summarizes stock option activity:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.17%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.602%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.001999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.602%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;($000s)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,632,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,777,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;392,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,017,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,017,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Vested and exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,084,169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="INF"
      id="F_268703fe-f553-4a87-a963-4f1fe07c6126"
      unitRef="U_shares">13632278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="2"
      id="F_f409b425-9099-4294-8e06-64f4e5e75f8a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      id="F_55b60e90-e45b-4dab-ab14-34ef029a7d7e">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_7496ff91-b19a-4aa3-9c0f-3b6e555d7b41"
      unitRef="U_USD">10937000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="INF"
      id="F_32a63067-9fa3-46b9-b2f0-e1d0b72ad5d2"
      unitRef="U_shares">3777550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="2"
      id="F_c38d44cc-4f1f-4bea-842d-9fe685dc91c9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="INF"
      id="F_a83172f1-aad0-4d38-bbc3-a8afd84aca0f"
      unitRef="U_shares">392509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="2"
      id="F_34f2c0cb-adba-4508-8cf8-4b5edb851115"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_802e455b-7e2c-4628-8437-adafb1b95bcb"
      unitRef="U_shares">17017319</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="2"
      id="F_c322908d-8153-495c-84b4-a189afacf78a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_416123cc-9df7-4e05-9030-0efdee8812e8">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_4b8c845b-c560-4ede-b1bf-043b810fee51"
      unitRef="U_USD">5080000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_0fa1b95b-39a3-43e3-8558-90edbf53c1ce"
      unitRef="U_shares">17017319</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="2"
      id="F_4bf32d73-c9c5-461a-ac96-6acc85b28e25"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_2af66fce-fb59-4734-bbd4-8c2dae1c83f9">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_1dce0a29-385e-41ec-ab61-a845f3a010a8"
      unitRef="U_USD">5080000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="INF"
      id="F_1cb5c913-aeaa-4026-9c67-5df13ab747ae"
      unitRef="U_shares">11084169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="2"
      id="F_a1ad1562-bc15-4df6-ad3f-c78212fe1eb6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_4a322891-fa7c-47a0-9842-44a090116781">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_98383de0-0728-4d69-8ba2-5f79226bed19"
      unitRef="U_USD">5078000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_a5182e60-9be2-448b-a355-f35129b377d3"
      id="F_34609155-c74e-425f-bba2-fc88069fb58c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_d1ccbc8d-fccc-4ef6-b237-b3060720a1f5"
      id="F_5e7556cc-1c26-4baf-b054-4a8d09d02a28">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_2fc9ee26-6947-4538-b0a8-2c3589305d62"
      decimals="-3"
      id="F_0cb3e5f8-1568-45ff-88b0-811477648230"
      unitRef="U_USD">55157000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_d1ccbc8d-fccc-4ef6-b237-b3060720a1f5"
      id="F_faa5a7da-0886-4fd0-956d-9f583ca2926e">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="2"
      id="F_ffc9e753-b480-42d2-83b4-26cd409d27d2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="2"
      id="F_64cd1ffe-0a6c-4ff3-a378-1a599df777ce"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_19741941-6264-4419-bc82-ec30daefac84">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The fair value of each award was estimated using &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Black-Scholes&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; based on the following assumptions:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;For the Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.97&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.96&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_9cb157ed-0ee3-4b3d-8506-b2ecf7705be9">Black-Scholes</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="INF"
      id="F_bfda20d6-378d-4fea-bcbe-a6f33766da89"
      unitRef="U_pure">0.0365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="INF"
      id="F_5d33f3f8-324e-493b-b9ea-c62b9c8715e8"
      unitRef="U_pure">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_a82c31d6-e852-460a-a607-47b443b463e3">P5Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      id="F_d31ff8e8-9f0a-4a37-9c83-1e2d338b8c6e">P5Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="3"
      id="F_8d003bb1-31ef-408b-ad3c-f75678d96396"
      unitRef="U_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="3"
      id="F_57375a6a-0434-4d66-918b-84f535040406"
      unitRef="U_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="INF"
      id="F_0bff06fc-074c-4605-9925-381c5b81b6e6"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="INF"
      id="F_21bff24d-439d-4e46-bd04-cae1072c9571"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e6ae33ec-eab3-42a1-9844-29f7c68d4027"
      decimals="INF"
      id="F_71a070f8-f0dc-4ba4-89ef-a322aa114ab5"
      unitRef="U_shares">1187000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage
      contextRef="C_f2120fa2-8eb2-4101-8a98-bf8dc964d235"
      decimals="2"
      id="F_7fdb002e-92ca-413e-87d5-024c535fb7f0"
      unitRef="U_pure">0.01</avir:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_4dc26114-0dcd-4d93-aff6-f3d487ca3445"
      decimals="INF"
      id="F_2425f36e-e766-4783-91c3-f0568f011db7"
      unitRef="U_shares">834355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_2ba65c73-8524-40e6-ae35-92adc4ada4bb"
      decimals="INF"
      id="F_c118f4e9-33c2-4081-b52a-2ca507d8bc0a"
      unitRef="U_shares">832876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_6082deea-8f3f-4b55-a38d-ea31916b467f"
      decimals="INF"
      id="F_85838b62-63ca-4645-8cd4-c5a86d8869f9"
      unitRef="U_shares">93939</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_c710aa45-dbe9-4f74-a306-1b6b7afa6554"
      decimals="INF"
      id="F_8693717f-faed-4dfa-b14e-3ff43f48818c"
      unitRef="U_shares">29036</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_6082deea-8f3f-4b55-a38d-ea31916b467f"
      decimals="-3"
      id="F_dc867951-5122-4c68-9108-28b06a6e097b"
      unitRef="U_USD">257000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_c710aa45-dbe9-4f74-a306-1b6b7afa6554"
      decimals="-3"
      id="F_58568b5f-451a-4b10-8e3d-0385d627ab6e"
      unitRef="U_USD">140000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_fae5f473-aa6e-4b79-bb75-af161969c555">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Stock-based compensation expense is classified as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;For the Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2e76c0f9-bba5-44a0-93ae-345a4101d6c8"
      decimals="-3"
      id="F_be74cf38-d18d-4247-bd02-71e645f2f76f"
      unitRef="U_USD">22666000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_979c91bd-5edb-4472-af3c-4aa5b8c738a4"
      decimals="-3"
      id="F_16e9596a-b463-4c72-bb4c-a2c706750b09"
      unitRef="U_USD">21870000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d7c74a74-1bf5-49eb-9231-e2e57e9cec94"
      decimals="-3"
      id="F_217a835a-256b-4b29-9da3-50b2c5b995b5"
      unitRef="U_USD">26762000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_24439972-d677-48cc-8863-848995b1b44c"
      decimals="-3"
      id="F_39aac41a-1a77-4eb3-af78-f2464ee20569"
      unitRef="U_USD">24848000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_a9e0fd2f-cf60-49e4-95d9-ddf65fec9629"
      unitRef="U_USD">49428000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_f42ef4e3-1888-4510-b2a5-c3b9f8e6a414"
      unitRef="U_USD">46718000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_a2a373a8-20b6-45a4-a6f9-6f0dead484d3">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The components of stock-based compensation expense were:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;For the Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20a4f8c4-8263-4c93-becf-4246d8ff6c21"
      decimals="-3"
      id="F_1c55cb8d-fbfa-4740-8d04-1a25df2e2fee"
      unitRef="U_USD">3679000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ac643507-3356-46e0-b8b6-3ce7ebaa7b58"
      decimals="-3"
      id="F_86398563-4c86-4538-b5c3-a2a1dfcaf52b"
      unitRef="U_USD">352000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d1ccbc8d-fccc-4ef6-b237-b3060720a1f5"
      decimals="-3"
      id="F_242f2753-fb49-495d-a23a-f32b901ccc02"
      unitRef="U_USD">45626000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d5dd8525-8aef-4672-9fb8-129bfa24627c"
      decimals="-3"
      id="F_565f86cc-e2e4-49dd-abea-1924d3479ecb"
      unitRef="U_USD">46220000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dd4755f2-8af0-43f4-b924-629b18b55def"
      decimals="-3"
      id="F_c3994a77-ad2b-439b-b461-354ce91b330f"
      unitRef="U_USD">123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c947d34f-cb72-4ce4-a2e2-5cd07b77a75b"
      decimals="-3"
      id="F_beb8798d-5937-485b-804d-fbc854ec0f70"
      unitRef="U_USD">146000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_e5e86dfb-329c-4cbf-9d50-bc4787ebca04"
      unitRef="U_USD">49428000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_9384bcb4-2a2d-4e23-9645-a30d92594202"
      unitRef="U_USD">46718000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_ee1f20d2-7eed-4798-881d-610137d04431">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;12.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;For the year ended December 31, 2023, the Company recorded income tax expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,018&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;.  The Company recorded a net benefit for income taxes of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,590&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; for the year ended December 31, 2022.  The benefit for income taxes was primarily the result of changes in estimates between the Company&#x2019;s initial provision for 2021 income taxes and the actual amounts reflected in the income tax returns as filed.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The reconciliation of federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.4%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;For the Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected income tax benefit at the federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;State and local taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Return to provision adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The principal components of the Company&#x2019;s deferred tax assets consisted of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;License agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;As required by the 2017 Tax Cut and Jobs Act, effective January 1, 2022, taxpayers can no longer immediately expense qualified research and development expenditures. Taxpayers are now required to capitalize and amortize these costs over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; for research conducted in the US or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; for research conducted abroad.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;As of December 31, 2023, the Company had federal net operating losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,378&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and state net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,305&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, which may be used to offset future tax liabilities.  The Company has federal and state credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,944&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,210&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, respectively. The federal net operating losses and research and development tax credits begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Management has evaluated the positive and negative evidence bearing upon the realizability of the Company&#x2019;s deferred tax assets. Based on the Company&#x2019;s projected net operating losses, for 2024 and beyond, the Company determined that it is more likely than not that it will not recognize the benefits of the deferred tax assets. As a result, the Company has recorded a full valuation allowance of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,173&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; at December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Under the provisions of Sections 382 and 383 of the Internal Revenue Code (&#x201c;IRC&#x201d;), net operating loss and credit carryforwards and other tax attributes may be subject to limitation if there has been a significant change in ownership of the Company, as defined by the IRC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company performed an analysis through December 31, 2023 pursuant to Section 382 of the IRC to determine whether any limitations might exist on the utilization of net operating losses and other tax attributes. Based on this analysis, the Company has determined that there was no impact on the Company's ability to utilize net operating losses or credit carryforwards in 2023.  To the extent that the Company raises additional equity financing or other changes in the ownership interest of significant stockholders occurs, additional tax attributes may become subject to an annual limitation. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company files federal and various state income tax returns. The statute of limitations for assessment by the Internal Revenue Service (&#x201c;IRS&#x201d;), and state tax authorities remains open for all tax years ended since the inception of the Company. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the IRS or state tax authorities to the extent utilized in a future period. No federal or state tax audits are currently in process.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Arial;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The following table summarizes the reconciliation of the beginning and ending amount of total unrecognized tax benefits for the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Balance beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Decrease related to current year provision to return adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Increase related to accrued interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Balance at end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_3940df0f-940a-419d-82d4-e93654214e0d"
      unitRef="U_USD">1018000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_3421182b-ff11-4959-812d-76571b24b55e"
      unitRef="U_USD">-3590000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_09ce2c94-1220-44e5-94d5-886ff6372f2a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The reconciliation of federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.4%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;For the Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Expected income tax benefit at the federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;State and local taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Return to provision adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="3"
      id="F_376543e4-7adb-47c6-a4bd-e3a97ea71693"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="3"
      id="F_4bb013fb-2d95-402b-a4d2-1c96a11af9eb"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="3"
      id="F_3855d7ae-0ba7-4d8f-98a7-7a238bfa91f0"
      unitRef="U_pure">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="3"
      id="F_566b80f6-3663-4c18-9b68-c332b3aafa9f"
      unitRef="U_pure">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="3"
      id="F_78daa2b8-2b5c-4bd7-a059-03736b3ded5f"
      unitRef="U_pure">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="3"
      id="F_7fa063ef-1f64-437a-bd9d-60950bcba98d"
      unitRef="U_pure">-0.033</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="3"
      id="F_55b0af0f-33bd-4ab4-b5ee-f235212f69bc"
      unitRef="U_pure">-0.021</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="3"
      id="F_3bc17a15-9c87-4755-9968-986da00a9d7c"
      unitRef="U_pure">-0.043</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="3"
      id="F_52b4f86c-23be-44e4-a261-fa78925c8b8f"
      unitRef="U_pure">-0.038</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <avir:EffectiveIncomeTaxRateReconciliationUncertainTaxPositions
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="3"
      id="F_180f0bd6-cc33-49e4-a5a3-a5adbdfb0874"
      unitRef="U_pure">-0.004</avir:EffectiveIncomeTaxRateReconciliationUncertainTaxPositions>
    <avir:EffectiveIncomeTaxRateReconciliationUncertainTaxPositions
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="3"
      id="F_04833203-72e1-4397-8b3a-597a46a98ded"
      unitRef="U_pure">-0.002</avir:EffectiveIncomeTaxRateReconciliationUncertainTaxPositions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="3"
      id="F_b0903227-a9ce-4a2d-9732-cd9e2f95d1f3"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="3"
      id="F_976e880a-28e3-435d-8dee-152987fea0ce"
      unitRef="U_pure">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="3"
      id="F_e7a64e45-ee35-42a0-812a-a77059f5bf7b"
      unitRef="U_pure">-0.245</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="3"
      id="F_7d1abc9f-d154-461c-84e2-180006dd2ce4"
      unitRef="U_pure">-0.253</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="3"
      id="F_19e79204-2169-4dc4-954f-a1b116956155"
      unitRef="U_pure">-0.008</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="3"
      id="F_6874a068-accb-4a8c-8075-98cd54700087"
      unitRef="U_pure">0.031</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_93090447-041f-41d4-915d-f95b755af505">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The principal components of the Company&#x2019;s deferred tax assets consisted of the following:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;License agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:14pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <avir:DeferredTaxAssetsInProcessResearchAndDevelopmentCosts
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_b7145b1d-24fe-4b17-bb2c-0d660852ac83"
      unitRef="U_USD">33692000</avir:DeferredTaxAssetsInProcessResearchAndDevelopmentCosts>
    <avir:DeferredTaxAssetsInProcessResearchAndDevelopmentCosts
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_627fab8e-d029-429e-a633-7520f019b73e"
      unitRef="U_USD">14305000</avir:DeferredTaxAssetsInProcessResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_eb20c252-5e33-4b36-98ba-6a82a34269fa"
      unitRef="U_USD">9385000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_0ae4b4bc-7ba5-4c96-bf88-de96f57b2cac"
      unitRef="U_USD">5590000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <avir:DeferredTaxAssetsLicenseAgreement
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_213b2d25-9332-490e-8198-d8193b271a69"
      unitRef="U_USD">5609000</avir:DeferredTaxAssetsLicenseAgreement>
    <avir:DeferredTaxAssetsLicenseAgreement
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_333adf71-cc47-4e6d-b704-898500c22f71"
      unitRef="U_USD">6043000</avir:DeferredTaxAssetsLicenseAgreement>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_f3f234e0-50b9-4562-9d8a-238cf072579f"
      unitRef="U_USD">17884000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_4f425f51-69dc-4a10-836f-8498e6653dc4"
      unitRef="U_USD">12215000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_f5fb27e5-d936-4267-a7d4-18475bf01464"
      unitRef="U_USD">8155000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_2a4ce8dd-db70-4206-9da8-d17f91eca0c5"
      unitRef="U_USD">3826000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_0be47c8c-d54f-45dc-b5da-ed3d4e9a0147"
      unitRef="U_USD">143000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_eed0f3e8-c73f-4d11-8e44-49dec98521a1"
      unitRef="U_USD">70000</us-gaap:DeferredTaxAssetsOther>
    <avir:DeferredTaxAssetsPrepaidExpenses
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_9a822788-1a45-46c5-9ce0-248a10c38c76"
      unitRef="U_USD">-695000</avir:DeferredTaxAssetsPrepaidExpenses>
    <avir:DeferredTaxAssetsPrepaidExpenses
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_9023b261-97e3-45a5-a8e2-1b1bb08c102e"
      unitRef="U_USD">-893000</avir:DeferredTaxAssetsPrepaidExpenses>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_eb68145b-d6bc-411e-b168-ddb96c36db8c"
      unitRef="U_USD">74173000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_30822690-d2a1-4a67-ac68-c2df85519ecc"
      unitRef="U_USD">41156000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_7d3be8a0-d92f-418f-bb29-5fd2e11f72c3"
      unitRef="U_USD">74173000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_cab9988c-f578-4679-9b76-5ab5a958d179"
      unitRef="U_USD">41156000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="0"
      id="F_d7c1694b-489f-4a95-9941-1bea1fc0d031"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="0"
      id="F_52c7e9aa-c87c-4f8e-89ba-6768bfadd8a8"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <avir:ResearchAndDevelopmentCostsAmortizationPeriod
      contextRef="C_e82bec19-1afd-4f24-a813-5e90d1f66925"
      id="F_2b92c13d-09a5-4618-af15-e43ea5fb9d99">P5Y</avir:ResearchAndDevelopmentCostsAmortizationPeriod>
    <avir:ResearchAndDevelopmentCostsAmortizationPeriod
      contextRef="C_17b49d78-dae5-461d-9aa2-8c05ca6e3b14"
      id="F_5e6a1df3-944b-4039-affc-9046d64fe7e9">P15Y</avir:ResearchAndDevelopmentCostsAmortizationPeriod>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_2ae7bd15-ab3e-4d2d-98a8-359e5079ac8a"
      decimals="-3"
      id="F_ecc946f6-24a6-4664-9b58-3f3f6d4eab66"
      unitRef="U_USD">31378000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_b4858b4b-fada-48fa-9ad8-39d05a6e7b50"
      decimals="-3"
      id="F_16fd84cb-e37d-468a-a20b-c03bc882f5d5"
      unitRef="U_USD">55305000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_2ae7bd15-ab3e-4d2d-98a8-359e5079ac8a"
      decimals="-3"
      id="F_b464e4e8-2193-4506-9fd1-2900a854145d"
      unitRef="U_USD">6944000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_b4858b4b-fada-48fa-9ad8-39d05a6e7b50"
      decimals="-3"
      id="F_a434d586-19b6-4373-b5f2-059856ad387e"
      unitRef="U_USD">1210000</us-gaap:TaxCreditCarryforwardAmount>
    <avir:TaxCreditCarryforwardExpirationYear
      contextRef="C_5a0ce532-9b29-4fdb-8d7c-26fffea11b48"
      id="F_f92c64e9-95ac-424b-bbfc-0558be7af7c7">2034</avir:TaxCreditCarryforwardExpirationYear>
    <avir:OperatingLossCarryforwardsExpirationYear
      contextRef="C_e82bec19-1afd-4f24-a813-5e90d1f66925"
      id="F_40828361-7420-4212-a89b-4aaaa77039aa">2034</avir:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_9c6b93b2-e7cf-45e3-a33d-78e3b76dc689"
      unitRef="U_USD">74173000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExaminationDescription
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_6b06a1d6-89c4-425f-80a0-fc7b959ffd4d">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_9e40e273-13af-4a7e-887f-621d18521d07">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;The following table summarizes the reconciliation of the beginning and ending amount of total unrecognized tax benefits for the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.9%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Balance beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Decrease related to current year provision to return adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Increase related to accrued interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Balance at end of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_c897b11b-eb38-4bd1-97cb-ac70cc675214"
      decimals="-3"
      id="F_87b757f6-a6e4-4f3b-898c-909c75ec5e0c"
      unitRef="U_USD">5255000</us-gaap:UnrecognizedTaxBenefits>
    <avir:UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_e242e3d4-ba62-4a8b-a07e-b811c548dd0d"
      unitRef="U_USD">503000</avir:UnrecognizedTaxBenefitsIncreasesResultingFromAccruedInterest>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_41012070-a8f1-4043-9e4d-2bc2d7aa3c24"
      decimals="-3"
      id="F_29fd9259-f41c-4a36-a63c-eead8d1284a6"
      unitRef="U_USD">5758000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_37b5af23-e531-4cbe-8a71-ced5fc3eae2b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;13. Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.142%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.903%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.683%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:3.75pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:3.75pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:3.75pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;For the Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:3.75pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;135,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Weighted average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,389,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,245,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Stock options for the purchase of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,017,319&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,337,517&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; restricted stock units, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;724,970&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; performance-based restricted stock units and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;30,254&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; ESPP shares w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;ere excluded from the computation of the net loss per share for the year ended December 31, 2023, due to the net loss during the periods as their effect is antidilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Stock options for the purchase of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,632,278&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; shares, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161,750&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; restricted stock units, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;724,970&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; performance-based restricted stock units and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,743&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; ESPP shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;were excluded from the computation of the net loss per share for the year ended December 31, 2022, due to the net loss during the periods as their effect is antidilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_0ca38a2a-02ad-417d-be01-466e174fcb95">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.142%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.903%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.683%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="border-top:3.75pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:3.75pt solid #000000;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:3.75pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;For the Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:3.75pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;135,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Weighted average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,389,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,245,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-family:Arial;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_b93362f7-449d-48a0-b897-60ff64396c8f"
      unitRef="U_USD">-135956000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_fc6dd83f-aaef-4b74-b9ae-91d8399ef2a0"
      unitRef="U_USD">-115909000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="0"
      id="F_ebf84c7c-3c11-461c-a21c-6694d05a43fe"
      unitRef="U_shares">83389750</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="0"
      id="F_8a86520c-aec6-4ac3-b728-e046c42f12d0"
      unitRef="U_shares">83389750</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="0"
      id="F_87265ac5-5805-44b3-9a2d-1626732fc9c1"
      unitRef="U_shares">83245385</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="0"
      id="F_3c3841e6-d656-4b28-8ac3-ad5596e72c60"
      unitRef="U_shares">83245385</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="2"
      id="F_602f2bea-d10f-4d2a-b820-82bcacfebdb8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="2"
      id="F_64eedcda-0f95-4f59-877c-459c83cf92c2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="2"
      id="F_d7811c10-3c2c-48be-9eff-73292a3d97bb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="2"
      id="F_555ca420-de14-4153-b63b-265f43477fac"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_eea6202c-efed-4922-944f-49a05b0bd392"
      decimals="INF"
      id="F_20298725-1df6-4b49-a855-1f60cf36c266"
      unitRef="U_shares">17017319</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0c0e66ec-bf40-4f31-a93c-62669833f34d"
      decimals="INF"
      id="F_278e311e-e083-4a42-a3f4-5edac0a3fe92"
      unitRef="U_shares">2337517</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_159d6d12-6162-484a-9282-0ea77a622978"
      decimals="INF"
      id="F_382f8c7a-7458-45c7-9f82-60372138a1c0"
      unitRef="U_shares">724970</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_99cf4023-d6e5-48bb-8b91-c16c96320d2f"
      decimals="INF"
      id="F_d65e820f-eff2-4c8c-86b0-6a0e7dac813a"
      unitRef="U_shares">30254</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a68f75ab-379f-4790-b7da-2cc14623e5e5"
      decimals="INF"
      id="F_745cba9c-80b3-4dee-ae2c-0ae75ccbd035"
      unitRef="U_shares">13632278</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c22f1db1-902d-4c7a-b09a-45671bb979be"
      decimals="INF"
      id="F_7f1a1ac4-e868-452d-bb7e-8865e905ebde"
      unitRef="U_shares">161750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_da444999-94ef-4fbd-9372-2cec9051adf7"
      decimals="INF"
      id="F_0baee6e6-04dd-4683-976c-d5e85976eb03"
      unitRef="U_shares">724970</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_62b17805-037e-4608-865a-45eafd3e8444"
      decimals="INF"
      id="F_689262df-e175-41f8-9f43-a1f7cf77cd8f"
      unitRef="U_shares">24743</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_1212487c-303c-4387-b044-817f640bb927">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;14. Benefit Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;During the year ended December 31, 2021, the Company implemented a defined contribution plan under Section 401(k) of the Internal Revenue Code (&#x201c;401(k) Plan&#x201d;). The 401(k) Plan covers substantially all employees who meet minimum age and service requirements.  Under the terms of the 401(k) Plan, the Company records matching contributions up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;% of the participant&#x2019;s eligible compensation. During the years ended December 31, 2023 and 2022, the Company recognized expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;708&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;541&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;, respectively, relating to matching contributions to the 401(k) Plan.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_e6cc6cbb-fa79-4362-b951-fdcabe1d05f1"
      decimals="INF"
      id="F_1213abbc-71cd-443e-92e7-ec74105658a6"
      unitRef="U_pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      decimals="-3"
      id="F_c82edaa5-9b30-4688-83b3-a3312eb471aa"
      unitRef="U_USD">708000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_29ced885-cd6c-4728-afb5-8721d3d3a564"
      decimals="-3"
      id="F_726261e8-f954-4e16-8e59-3daa496c47cc"
      unitRef="U_USD">541000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_504aa066-1c9a-4526-b64e-13d9e2393363"
      id="F_c22067b4-06c6-40af-ba1f-213ba26ea3a3">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;15. Related Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;During the year ended December 31, 2021, the Company entered into a consulting agreement with an entity controlled by one of its directors.  The agreement provides for an annual retainer of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;.  The Company recognized expense in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; in each of the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;In May 2022, the Company entered into a consulting agreement with one of its directors.  The Company recognized expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; in connection with this consulting agreement for the year ended December 31, 2022.  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt; expense related to this agreement was recognized during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RetainageDeposit
      contextRef="C_f28b0360-b9b7-4972-a2a7-9ed9288fa68a"
      decimals="-3"
      id="F_90306642-a3fb-40ec-b6bf-6f03de4a4dc3"
      unitRef="U_USD">110000</us-gaap:RetainageDeposit>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_9feada43-9600-4ad4-8a75-de79be8486b3"
      decimals="-3"
      id="F_d0f0e6b3-15db-4305-802e-2687af0056a7"
      unitRef="U_USD">110000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_f6e3b279-caec-40bb-8720-9d81118a4e31"
      decimals="-3"
      id="F_8637fb82-4a69-40db-9291-754df0abce90"
      unitRef="U_USD">110000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_04aa3fcc-acfa-4ce1-806a-36590f240e92"
      decimals="-3"
      id="F_5e7b2626-0381-431a-b504-d141f425dee4"
      unitRef="U_USD">1000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_b64973ad-fef2-423f-96bd-ad36857f2986"
      decimals="INF"
      id="F_52474e67-8d77-4ccc-b09a-b5ded834f032"
      unitRef="U_USD">0</us-gaap:OperatingCostsAndExpenses>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
